0001144204-14-019623.txt : 20140331 0001144204-14-019623.hdr.sgml : 20140331 20140331172939 ACCESSION NUMBER: 0001144204-14-019623 CONFORMED SUBMISSION TYPE: 10-K PUBLIC DOCUMENT COUNT: 13 CONFORMED PERIOD OF REPORT: 20131231 FILED AS OF DATE: 20140331 DATE AS OF CHANGE: 20140331 FILER: COMPANY DATA: COMPANY CONFORMED NAME: POSITRON CORP CENTRAL INDEX KEY: 0000844985 STANDARD INDUSTRIAL CLASSIFICATION: ELECTROMEDICAL & ELECTROTHERAPEUTIC APPARATUS [3845] IRS NUMBER: 760083622 STATE OF INCORPORATION: TX FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-K SEC ACT: 1934 Act SEC FILE NUMBER: 000-24092 FILM NUMBER: 14731466 BUSINESS ADDRESS: STREET 1: 1304 LANGHAM CREEK DRIVE, SUITE 310 CITY: HOUSTON STATE: TX ZIP: 77048 BUSINESS PHONE: 2814927100 MAIL ADDRESS: STREET 1: 1304 LANGHAM CREEK DRIVE, SUITE 310 CITY: HOUSTON STATE: TX ZIP: 77048 10-K 1 v372432_10k.htm 10-K

 

 

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 10-K

 

x ANNUAL REPORT PURSUANT TO SECTION 13 or 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934.

 

FOR THE YEAR ENDED December 31, 2013

Commission file number 000-29449

 

 

POSITRON CORPORATION

 

(Exact Name of Registrant as specified in its charter)

 

Texas   76-0083622
(State or Other Jurisdiction of Incorporation or   (IRS Employer Identification No.)
Organization)    

 

530 Oakmont Lane, Westmont, Illinois   60559
(Address of Principal Executive Offices)   (Zip Code)

 

Registrant’s Telephone Number, Including Area Code: (317) 576-0183

 

Securities registered under Section 12(b) of the Exchange Act: None

 

Securities registered under Section 12(g) of the Exchange Act: Common Stock, $0.01 par value.

 

Indicate by a check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Yes ¨ No x

 

Indicate by a check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act. ¨

 

Indicate by check mark whether the issuer (1) filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes x No ¨

 

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes x No ¨

 

Indicate by check mark if disclosure of delinquent filers pursuant to Item 405 of Regulation S-K is not contained herein, and will not be contained, to the best of registrant’s knowledge, in definitive proxy or information statements incorporated by reference in Part III of this Form 10-K or any amendment to this Form 10-K. ¨

 

 
 

 

Indicate by check mark whether the registrant is a larger accelerated filer, an accelerated filer, a non-accelerated or a smaller reporting company filer. See the definition of “large accelerated filer, accelerated filer and smaller reporting company" in Rule 12b-2 of the Exchange Act. (Check one)

 

Large accelerated filer   ¨ Accelerated filer             ¨
Non-accelerated filer  ¨ Smaller reporting company  x

 

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ¨ No x

 

The aggregate market value of voting common stock held by non-affiliates of the registrant (assuming, for purposes of this calculation, without conceding, that all executive officers and directors are “affiliates”) was $10,995,744.90 as of June 30, 2013, based on the closing sale price of such common stock as reported on the OTC Bulletin Board.

 

There were 1,452,548,262 shares of the registrant’s common stock, par value $0.01 per share, outstanding as of March 31, 2014.

 
 

 

INDEX   Page
     
PART I Business 1
     
Item 1A. Risk Factors 11
     
Item 1B. Unresolved Staff Comments 14
     
Item 2. Properties 15
     
Item 3. Legal Proceedings 15
     
Item 4. Mine Safety Disclosures 15
     
PART II    
     
Item 5. Market for the Registrant’s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities 15
     
Item 6. Selected Financial Data 21
     
Item 7. Management’s Discussion and Analysis of Financial Condition and Results of Operations 21
     
Item 7A. Quantitative and Qualitative Disclosure About Market Risk 28
     
Item 8. Financial Statements and Supplementary Data 28
     
Item 9. Changes in Disagreements with Accountants on Accounting and Financial Disclosures 29
     
Item 9A. Control and Procedures 29
     
Item 9B. Other Information 30
     
PART III    
     
Item 10. Directors, Executive Officers, and Corporate Governance 30
     
Item 11. Executive Compensation 32
     
Item 12. Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters 36
     
Item 13. Certain Relationships and Related Transactions and Director Independence 38
     
Item 14. Principal Accountant Fees and Services 39
     
PART IV   39
     
Item 15. Exhibits and Financial Statement Schedules 39
   
  SIGNATURES 48

 

 

 
 

PART I

 

Forward-Looking Statements

 

This report contains various forward-looking statements regarding our business, financial condition, results of operations and future plans and projects. Forward-looking statements discuss matters that are not historical facts and can be identified by the use of words such as “believes,” “expects,” “anticipates,” “intends,” “estimates,” “projects,” “can,” “could,” “may,” “will,” “would” or similar expressions. In this report, for example, we make forward-looking statements regarding, among other things, our expectations about the rate of revenue growth in specific business segments and the reasons for that growth and our profitability, our expectations regarding an increase in sales, strategic traction and sales and marketing spending, uncertainties relating to our ability to compete, uncertainties relating to our ability to increase our market share, changes in coverage and reimbursement policies of third-party payers and the effect on our ability to sell our products and services, the existence and likelihood of strategic acquisitions and our ability to timely develop new products or services that will be accepted by the market.

 

Although these forward-looking statements reflect the good faith judgment of our management, such statements can only be based upon facts and factors currently known to us. Forward-looking statements are inherently subject to risks and uncertainties, many of which are beyond our control. As a result, our actual results could differ materially from those anticipated in these forward-looking statements as a result of various factors, including those set forth below under the caption “Risk Factors.” For these statements, we claim the protection of the safe harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995. You should not unduly rely on these forward-looking statements, which speak only as of the date on which they were made. They give our expectations regarding the future but are not guarantees. We undertake no obligation to update publicly or revise any forward-looking statements, whether as a result of new information, future events or otherwise, unless required by law.

 

Item 1. Business

 

Organization

 

Positron Corporation (the "Company" or “Positron”), unless the context requires otherwise, in this report the terms “we,” “us” and “our” refer to Positron Corporation.

 

Nature of Business

 

Positron Corporation is a nuclear medicine healthcare company specializing in the field of cardiac Positron Emission Tomography (PET) imaging. Cardiac PET is the superior method in diagnostic nuclear imaging for the detection of coronary artery disease (CAD).

 

Positron’s products and services enable healthcare providers to more accurately diagnose disease and improve patient outcomes, while practicing cost effective medicine. Positron is the only company that will provide an economical, end-to-end solution for PET myocardial perfusion imaging through complementary product integration of PET imaging systems, radiopharmaceuticals and radioisotopes.

 

The Company believes that our unique proprietary products, market position and vertically integrated strategy will lead to accelerated adoption and growth of the cardiac PET modality in the U.S. and emerging markets. Through leadership within our field, Positron intends to gain a dominant market position with strong earnings potential, ultimately becoming a sustained, long-term value creator for industry participants and our shareholders.

 

Our mission is to facilitate the stabilization, security and growth of the cardiac PET industry by providing cardiologists with: an economical, high-quality, PET imaging system; a reliable supply of radiopharmaceuticals for imaging procedures; and a comprehensive clinical, technical, support and service program.

 

 
 

 

Corporate History

 

Positron Corporation was incorporated as a Texas corporation in 1983 with offices in Westmont, Illinois, Fishers, Indiana, Lubbock, Texas and Niagara, New York.

 

On June 30, 2005, the Company entered into a Joint Venture Contract with Neusoft Medical Systems Co., Inc. of Shenyang, in the People's Republic of China ("Neusoft"). Pursuant to the Joint Venture Contract, the parties formed a jointly-owned company, Neusoft Positron Medical Systems Co., Ltd. (the “JV Company”), to engage in the manufacturing of PET and PET/CT medical imaging equipment. The JV Company received its business license and was organized in September 2005.

 

On November 18, 2008, Solaris Opportunity Fund, L.P. (“Solaris”) became the Company’s controlling shareholder, having acquired approximately 60% of the Company’s voting capital stock at that time. Soloris exchanged its rights title and interest in two notes receivable in the aggregate amount of $2,181,000 due from the Company (the “Notes”) and 100,000,000 shares of the Company’s common stock, par value $0.01 per share (the “Common Stock”) pledged to Solaris (the “Pledged Shares”) and retired advances made to the Company in the aggregate amount of $1,155,000, for the issuance of 100,000 shares of the Company’s Series S Preferred Stock.

 

On January 4, 2012, the Company increased the number of the Company’s authorized shares of capital stock from 810,000,000 shares to 3,020,000,000 of which 3,000,000,000 shares will be common stock par value $0.01 per share (“Common Stock”) and 20,000,000 shares will be preferred stock par value $1.00 per share (“Preferred Stock”).

 

On January 17, 2012, the Company acquired all of the membership interests and retained all employees of Manhattan Isotope Technology, LLC (“MIT”) based in Lubbock, Texas. In exchange, MIT’s previous owners shall receive cash advances, shares of Positron Common Stock, the assumption of certain indebtedness and earnout consideration of up to $3,500,000 based on 20 percent of the net income from sales relating to radioisotope and radiopharmaceutical operations of MIT through December 31, 2018. MIT is the only commercial resource in the United States with practical knowledge and experience in all stages of strontium-82 (Sr-82) production and spent generator lifecycle management. Positron will focus on increasing Sr-82 supply through the processing of proton irradiated target material from domestic and foreign suppliers and recycling Sr-82 from spent generators. MIT has become the first supplier to provide Active Pharmaceutical Ingredient (API) grade Sr-82 in the U.S. besides the United States Department of Energy. In an effort to expand Positron’s radioisotope product offerings, MIT possesses the unique and specialized expertise in the production of additional radioisotopes that are currently only supplied by the U.S. Government.

 

On July 9, 2012, the Company received approval of a Pledge Resolution for $15 Million in Tax Increment Financing (TIF) Bonds, from the City of Gary Redevelopment Commission, of Indiana towards the development of Positron’s 70 MeV cyclotron project. In addition to the TIF incentives, the City of Gary will assist in sourcing the appropriate allocation of New Market Tax Credits (NMTC) that could cover approximately $15 Million, or 33%, of the estimated total development costs for the project. Positron seeks to raise approximately $65 million, in total, for this project through a combination of debt, equity and incentives.

 

On June 27, 2011, the Company formed Positron Isotope Corporation, a wholly-owned subsidiary, for the purpose of developing its cyclotron project in a wholly owned subsidiary.

 

The Company

 

Positron, a pioneer in cardiac PET, is well-branded in the field of nuclear cardiology. Positron has gained significant traction in the industry based on its imaging technology and strong commitment towards advancing cardiac care. Originally a research and development company, Positron has expanded from a medical imaging device manufacturing to a company which is integrating the key components of the cardiac PET supply chain and will be able to offer an end-to-end solution for the nuclear cardiology market. Led by an experienced management team, Positron is moving towards becoming a true business enterprise with strong recurring revenue generating business model scalable to the global marketplace.

 

2
 

The Company believes that its unique products, market position and vertical integration strategy will stabilize and secure the supply chain, significantly reducing costs and industry uncertainties; a substantial advantage, leading to further adoption and growth of the cardiac PET modality.

 

Positron is the only commercial resource in the U.S. with practical knowledge and experience in all stages of Strontium-82 (Sr-82) production and spent generator lifecycle management. Positron seeks to secure both the short and long-term supply of radioisotopes used in cardiac PET imaging. Currently, the Company is producing Active Pharmaceutical Ingredient (API) grade Sr-82 at its Lubbock, Texas, facility from Sr-82 received from foreign irradiated source suppliers. The Company intends to further supplement strontium resources by pursuing additional supply agreements with all available domestic and foreign irradiated source suppliers and through recycling expired generators. Positron seeks to secure a long-term North America supply of medical radioisotopes for cardiac PET imaging by building and operating the world’s largest commercial high energy/high current cyclotron (70MeV) within the U.S. This 70 MeV cyclotron will be at the heart of providing a reliable, dependable, and indigenous supply of radioisotopes, stabilizing and building confidence in the PET market and nuclear medicine community overall. Securing a reliable supply of radioisotopes should also increase the demand for Positron’s complementary products: pharmaceuticals, imaging equipment and services.

 

Positron’s business strategy is to gain a dominant market share in the nuclear cardiac industry through the vertical integration of such key components as: imaging technologies, clinical services, radiopharmaceutical and radioisotope processing, production, supply and distribution. Positron intends to maximize market share by offering cost-effective, value added solutions to end-users that meet the current and future market demands of nuclear cardiology.

 

Our Products and Key Components

 

The Company offers a range of products and services for nuclear imaging community which are discussed below.

 

PET Imaging Systems: Support and Service

 

Attrius® is the only FDA approved dedicated PET scanner optimized for cardiac imaging. Attrius® was named the “Most Innovative Device of 2010” by the renowned business research and consulting firm Frost & Sullivan. The Attrius® provides a robust, cardiac specific imaging software package designed to ensure effortless interpretation for today’s most challenging clinical cases for nuclear cardiologists. Heart disease specific software includes the ability to monitor therapy, coronary artery overlay display, and open architecture for new protocol development and customization and motion correction software. The Attrius® is targeted for cardiac clinics and is designed to meet the performance, budget and space needs of the most demanding cardiologists.

 

Positron has further advanced its product portfolio with the addition of Coronary Flow Reserve (CFR) software. The University of Texas Health Science Center at Houston has received FDA approval for the CFR quantification software, to be used with Positron’s Attrius PET scanner. Positron is licensed to distribute and support this software, a clear differentiator in patient diagnosis.

 

Positron offers a comprehensive world-class clinical, technical, and service customer care plan, through its PosiStar® customer care services. PosiStar® includes: 24/7 clinical and service support; uptime guarantees; remote access diagnostic/maintenance; physician interpretation training; billing training; nurse training; post-install physician over-reads; ICANL approval assistance; 6 months evaluation/assessment; industry luminary collaboration, etc. PosiStar® is a fee-based service, typically for three to five years.

 

Radiopharmaceuticals: Manufacturing, Processing & Distribution

 

Positron intends to couple an Sr-82/Rb-82 generator with Attrius sales and utilize Positron’s current nuclear cardiology network. Initial efforts will be focused on North America. This product is a key element of Positron’s strategy to vertically integrate the production and delivery of a complete cardiac imaging solution: isotope (Sr-82), generator (Rb-82), and imaging system (Attrius®).

 

3
 

PosiRx® is a radiopharmaceutical system that automates the elution, preparation and dispensing processes for radiopharmaceutical agents used in molecular imaging. It was created to simplify and control the procedures associated with compounding radiopharmaceuticals. PosiRx® integrates features that increase productivity while decreasing exposure and costs. Additionally, the PosiRx® assists in compliance with all current USP-797 and ALARA exposure control requirements for the production of unit dose radiopharmaceuticals.

 

PosiRx® is the first system of its kind to offer a complete and comprehensive automated solution, creating a more efficient and economical alternative to the current pharmacy per dose model. PosiRx® is targeted for clinics and hospitals with average to high SPECT imaging and pharmaceutical compounding volumes, in the U.S. and abroad. With PosiRx®, Positron intends to exploit possibilities existing in the SPECT imaging and pharmaceutical markets for both cardiology and oncology.

 

Radioisotopes: Production & Distribution

 

Positron, through MIT, has registered its Drug Master File (DMF) for API grade Sr-82 with the FDA. This marks Positron’s entrance into the radioisotope market with a high demand product as a precursor for PET radiopharmaceuticals. Positron is the only commercial resource in the U.S. that possesses the practical experience and knowledge in all stages of Sr-82 production and spent generator lifecycle management. Currently, Positron produces API grade strontium-82 from target material received from its foreign collaborators.

 

Positron plans to build and operate the world’s largest commercial high energy/high current cyclotron (70MeV) within the U.S. The proposed facility will be unique in that it will be capable of producing isotopes that are either not available or have very limited availability from other commercial sources in the United States and the world. Positron seeks to secure the supply of radioisotopes used in cardiac PET imaging therefore stabilizing and building confidence in the market. Securing a reliable supply of radioisotopes will increase demand for Positron’s pharmaceuticals, imaging equipment and services provided to nuclear medicine practices.

 

The primary isotope to be produced is Sr-82, which is currently in short supply world-wide and is only produced in the U.S. by the Department of Energy (“DOE”) National Laboratories.

 

FINANCIAL SOLUTIONS

 

Positron intends to provide customers with a variety of innovative risk mitigating financing programs, which are designed to minimize any barriers of entry, thus accelerating the expansion of cardiac PET and further securing Positron’s position in the market.

 

Major developments and milestones achieved by Positron Corporation during 2013 include:

 

  · Executed a Know-How and License Agreement with the Institute of Nuclear Research (INR) of Troitsk, Russia, for the rubidium metal and "loop" technologies for Sr-82 production. Such technologies improve quality, significantly increase yield and decrease waste. Positron has exclusive rights to implement these technologies in North America.

 

  · Positron and iThemba LABS (South Africa) entered into radioisotope supply agreement.

 

  · Positron began processing Sr-82 from third party irradiators iThemba Labs, U.S.DOE and Arronax.

 

  · Positron has been approved as a qualified supplier of API grade Sr-82 for Jubilant DraxImage.

 

  · Positron introduced next generation PosiRx Pharmacy Automation System.

 

  · Positron Radioiotope Facility received ISO 9001.

 

4
 

 

Market Opportunity

 

Molecular Imaging Devices for Cardiology

 

Cardiovascular disease (CVD) is the leading cause of death in the United States and constitutes 17% of overall national health expenditures (Forecasting the Future of Cardiovascular Disease in the United States, American Heart Association, 2011). Direct CVD costs are projected to increase from $273 billion in 2010 to $818 billion in 2030, indirect costs (due to lost productivity) – from $172 billion in 2010 to $276 billion in 2030.

 

Diagnostic imaging facilitates the early diagnosis of diseases and disorders, potentially minimizing the scope, cost and amount of care required, and potentially reducing the need for more invasive procedures. Nuclear imaging uses very low-level radioactive material, called radiopharmaceuticals, injected into a patient. The radiopharmaceuticals are specially formulated to concentrate temporarily in the specific part of the body to be studied. The radiation signals emitted by the materials are then converted into an image of the body part or organ. Nuclear imaging, in contrast to other diagnostic imaging modalities, shows not only the anatomy or structure of an organ or body part, but also its function—including blood flow, organ function, metabolic activity and biochemical activity. In cardiology, nuclear medicine provides the most accurate non-invasive tests for identifying narrowed coronary arteries, mild cholesterol build-up or diffuse coronary vascular disease that are responsible for most heart attacks. Management of coronary disease (CAD) currently utilizes noninvasive diagnostic testing as a ‘‘gatekeeper’’ and invasive coronary arteriography, when results are abnormal, to provide a definitive diagnosis of CAD. There are two major modalities in nuclear medicine imaging, gamma cameras and Positron Emission Tomography (PET), both of which are used for cardiovascular procedures. The most widely used imaging acquisition technology utilizing gamma cameras is single photon emission computed tomography, or SPECT.

 

Though PET tests are much more accurate and has been shown to reduce long-term costs, the nuclear cardiology imaging has been dominated by SPECT. This imbalance is a result of lower prices of SPECT cameras and decades long preferable reimbursement rates for cardiac SPECT procedures. The Company believes that recent dynamic market changes, including the dramatic increase of reimbursement rates for cardiac PET procedures, SPECT reimbursement cuts and the world shortage of the molybdenum-99 isotope used in cardiac SPECT, will significantly improve the economics of cardiac PET imaging and make PET technology much more competitive and appealing to cardiologists.

 

In myocardial perfusion imaging, PET has been proven to be superior in sensitivity and specificity when compared to SPECT, the more commonly utilized modality. Cardiac PET scans, with Rubidium-82 Chloride (Rb-82) or Nitrogen- 13 Ammonia (N-13), result in a lower patient radiation exposure and is capable of performing superior quantitative measurements such as coronary flow reserve. Cardiac PET imaging has been shown to provide a 50% reduction in invasive coronary arteriography and coronary artery bypass grafting, leading to a 30% costs savings and improved clinical outcomes, when compared to SPECT (M.E. Merhige, M.D., et al., Journal Nuclear Medicine 2007; 48: 1069-1076).

 

SPECT IMAGING MODALITY

 

SPECT is a comparatively old technology in a market that is mature if not oversaturated, with more than 85% of cameras purchased as replacements (Nuclear Medicine Market Outlook Report, IMV, 2011). 31% of all SPECT and SPECT/CT cameras in the U.S., or approximately 4,100, are dedicated cardiac cameras.

 

According to market research company BIO-TECH Systems, Inc. (The U.S. Market for SPECT and PET Radiopharmaceuticals, Report #360), in 2012, total sales of SPECT radiopharmaceuticals were $719 million, among which, per our estimate, sales of major cardiac SPECT radiopharmaceuticals, Cardiolite, Myoview and sestamibi, were approximately $575 million. BIO-TECH expects that sales of SPECT radiopharmaceuticals will be $1.7 billion by 2021, due primarily to new products for imaging cancer entering the market. We expect cardiac SPECT radiopharmaceuticals may rise to $620-650 million and be effectively flat thereafter.

 

Positron intends to enter this large SPECT radiopharmaceutical market with PosiRx® - a radiopharmaceutical system that automates the elution, preparation and dispensing processes for radiopharmaceutical agents used in molecular imaging. It was created to simplify and control the procedures associated with compounding radiopharmaceuticals. PosiRx® integrates features that increase productivity while decreasing exposure and costs. Additionally, the PosiRx® assists in compliance with all current USP-797 and ALARA exposure control requirements for the production of unit dose radiopharmaceuticals. Currently, the PosiRx® has been developed for use specific to SPECT agents.

 

5
 

PET IMAGING MODALITY

 

PET is a younger and more advanced technology than SPECT. In cardiology perfusion imaging, PET scanners, in particular Positron’s Attrius®, have superior sensitivity and specificity compared to SPECT cameras, provide less radiation exposure and are capable of performing quantitative measurements. Cardiac PET imaging has been shown to provide a 50% reduction in invasive coronary arteriography and coronary artery bypass grafting, a 30% costs savings, and excellent clinical outcomes compared with SPECT (M.E. Merhige, et al., J Nucl Med 2007; 48: 1069-1076).

 

The cardiac PET equipment market is much smaller than SPECT but has seen significant (25-30%) annual growth during the last decade and is expected to continue its expansion at 20% average annual growth during the next five years. According to Bracco Diagnostics, there were approximately 170 dedicated cardiac PET/PET/CT scanners in the U.S. in 2012.

 

For many years, a major constraint for the cardiac PET market has been a high cost of PET and PET/CT. Positron Corporation has managed to reduce the buyers’ barrier to entry by bringing to the market the Attrius® - the only cardiac dedicated PET system in the world. All other manufacturers (GE, Philips, Siemens) offer PET/CT systems at a 200% - 300% higher price but comparable performance of cardiac studies. In 2010 and 2011, Positron’s share in sales of dedicated cardiac PET scanners was 14% and 17%, respectively. While we expect this share to grow significantly in the next several years, Positron’s sales since 2011 have been negatively impacted by the shortage of Rb-82 and Sr-82. This impact was a result of an unscheduled maintenance of the United States Department of Energy (DOE) accelerator producing Sr-82, a pre-cursor to Rb-82, and by a voluntary recall of Sr-82/Rb-82 generators by Bracco Diagnostics for additional testing. Though delivery of Bracco's generators to existing clients was restored in 2013, generators for new clients were not available, which made sales of Attrius® impossible. We believe that situation may change rapidly in 2014 upon market entry of the DraxImage generator, once FDA approved.

 

Another issue is that the increasing demand for Sr-82 which is used as a parent isotope for production of Rb-82 in Sr-82/Rb-82 generators is beginning to outpace supply. Until recently, the U.S. Department of Energy had been the only entity in the United States capable of providing this material. Positron has registered its DMF with the FDA and has begun production of API grade strontium-82 through its subsidiary, MIT.

 

Positron has been working to secure the supply of Sr-82 and to enter the fast growing market of PET radiopharmaceuticals. Positron seeks to build, own and operate a 70 MeV high-energy cyclotron that can produce enough Sr-82 to supply Sr-82/Rb-82 generators to current and future Positron customers, optimally, customers with the Attrius® PET scanners. The cyclotron project is an expensive and lengthy project; however, if completed, it may eliminate a potential limiting factor in cardiac PET market growth.

 

Positron’s acquisition of MIT has additional advantages that we believe will help to resolve a potentially significant problem of limited waste facilities for spent generators. Currently, waste management for spent generators is provided by DOE but capacity of its waste facilities will reach their limits in the very near future. MIT has technologies and facilities to replace DOE in this role and is currently pursuing this opportunity.

 

Competitive Strengths

 

We believe that our Company has the following competitive strengths:

 

  · Well Known Name Among Cardiologists. The high count-rate capability and sensitivity of Positron’s PET systems result in excellent diagnostic accuracy, faster imaging and ability to use short half-life radiopharmaceuticals, which made Positron’s PET systems a system of choice for certain cardiac applications.

 

6
 

 

  · The Only PET System on the Market. All major PET manufacturers have discontinued manufacturing of stand-alone PET systems, offering very expensive PET combined with Computerized Tomography (PET/CT) instead. In cardiac applications, the Positron’s Attrius® provides image quality comparable to PET/CT at significantly lower price. It also significantly reduces radiation exposure compared to PET/CT and even SPECT. A small footprint and affordable price makes it ideal for imaging clinics and hospitals.

 

  · Cardiac Specific Software. The Attrius® provides a robust, cardiac specific imaging software package designed to ensure effortless interpretation for today’s most challenging clinical cases for nuclear cardiologists. Heart disease specific software includes the ability to monitor therapy, coronary artery overlay display, and open architecture for new protocol development and customization and motion correction software.

 

  · Unique Automated Radiopharmaceutical System. Positron’s PosiRx® is a radiopharmaceutical system that automates the elution, preparation and dispensing processes for radiopharmaceutical agents used in molecular imaging. The PosiRx® system provides unprecedented “unit dose” flexibility to imaging providers at the touch of a button, 24/7. It was created to simplify and control the procedures associated with compounding radiopharmaceuticals. PosiRx® integrates features that increase productivity while decreasing exposure and costs.

 

·The only commercial entity in the U.S. with a registered Drug Master File (DMF) for producing Active Pharmaceutical Ingredient (API) grade Sr-82.

 

  · Unique Knowledge and Expertise in Sr-82 Production. The Company, through its wholly owned subsidiary MIT, is the only commercial resource in the United States with practical knowledge and experience in all stages of Sr-82 production.

 

  · The Only Commercial Facility for refurbishment of Sr-82/Rb-82 generators in the U.S. MIT’s current facility in Lubbock, Texas has the capacity to provide critical services necessary for the refurbishment of spent Sr-82/Rb-82 generators.

 

  · Currently, the Only Commercial Source of Sr-82 in the U.S. Using patented methods; MIT can recycle Sr-82 from spent Sr-82/Rb-82 generators at its facility in Lubbock, Texas, and process Sr-82 from foreign sources.

 

  · Value-Added Offering of Complimentary Products to Customers. The addition of complementary products, such as PET imaging systems, clinical and support services, radiopharmaceutical dispensing systems, radiopharmaceuticals and radioisotopes enhances the value of the offering to Positron’s customers, providing them a total solution in nuclear cardiology.

 

Sales and Marketing

 

To market its equipment and services, Positron employs an internal sales and marketing team dedicated to promote, educate and sell Positron products. Positron is also able to rely on referrals from users of its existing base of installed scanners and cameras, trade show exhibits, trade journal advertisements, clinical presentations at professional and industry conferences, and published articles in trade journals. The Company’s sales personnel vary in geographic location and/or market expertise.

 

Positron sells and/or distributes its products and services directly to end-users.

 

Customer Care, Service and Warranty

 

Positron has implemented PosiStar®, a complete customer care plan that offers full clinical support from Positron’s experienced clinical and technical staff and industry luminaries that consult for the Company or are affiliated through Positron’s customer network. PosiStar® Customer Care provides: physician interpretation training; nurse training; billing and prior-authorization training; physician over reads; post install, 24/7 clinical and service support; priority response with afterhours maintenance/service available; uptime guarantees and software upgrades; and remote access diagnostic/maintenance capabilities.

 

7
 

The Company has field service engineers who have primary responsibility for supporting and maintaining the Company’s installed equipment base. In addition, the Company has field engineers involved in site planning, customer training, sales of hardware upgrades, sales and administration of service contracts, telephone technical support and customer service.

 

The Company services customers of our systems remotely through Internet access that facilitates real time system diagnosis without the need for a field service visit. When physical repair is required, our modular part replacement capability allows our field service engineers to perform field repairs that minimize customer downtime.

 

The Company typically provides a one-year parts and labor warranty to purchasers of our equipment. Following the warranty period, the Company offers purchasers a comprehensive service contract under which the Company provides all parts and labor, system software upgrades and unlimited service calls.

 

The Company’s service goal is to maintain maximum system uptime. Success of a clinical site is largely dependent on patient volume during normal working hours and, therefore, equipment uptime and reliability are key factors in this success. Records compiled by the Company show an average uptime of more than 98% for all installed PET scanners.

 

Due to the Company’s expertise and access to parts, we expect to service all the PET scanners we sell.

 

Competition

 

The Company faces no direct competition from other manufacturers of PET scanners as it offers the only commercial standalone PET scanner, Attrius®. However, the Company has experienced competition from used PET/CT scanners although the remaining supply of used PET/CT systems is believed to be extremely low. The Company does not believe that MRI and CT scan imaging represent significant competing technologies, but potentially complementary technologies to PET, since PET, MRI and CT scans each provide information not available from the other modalities. Computed tomography angiography (“CTA”) was once seen by some cardiologists to be competitive with PET myocardial perfusion imaging; however, there is an increasing public concern about a high radiation exposure of CT and, currently, there is no substantial movement into this modality.

 

In 2001-2002, GE, Siemens and Philips introduced PET/CT systems that combine CT scanning and PET in one unit. Since then production of standalone PET scanners have been discontinued and replaced by high priced PET/CT systems with costs much greater than Positron’s Attrius® PET system. PET/CT integrates functional (PET) and structural (CT) information into a single scanning session, allowing fusion of the PET and CT images and thus improving lesion localization and interpretation accuracy. The CT scan is also used for attenuation correction, ultimately leading to high patient throughput. These combined advantages have rendered PET/CT a preferred imaging modality over standalone PET except in the imaging of cardiac studies. All major PET manufacturers, except Positron, pursue the similar strategies of developing more and more sophisticated and expensive whole-body PET/CT scanners. A hospital or medical imaging clinic with a whole-body PET/CT device has flexibility of using the scanner for oncology, cardiology or neurology purposes. However, the redundancy of functions, as well as the high price and large size, has negative impact on usage of PET scanners by specialty physicians (cardiologists, neurologists, urologists, etc.).

 

Though PET/CT has been commercially accepted, the need for the CT technology in myocardial perfusion imaging can be debated, due to the potential of increased radiation exposure to the patient. PET/CT, compared to PET, only has a larger capital acquisition cost, more room required and more expensive ongoing service expense. Significant limitations of cardiac PET/CT are respiratory motion and metallic artifacts, which can result in artifactual PET defects in up to 40% of patients scanned, and these defects are moderate to severe in 23%. (J Nucl Med. 2007 Jul;48(7):1112-21) Interest in PET by cardiologists has increased significantly since 2009 boosted by preferable reimbursement rates and shortage of Tc-99m, a major cardiac SPECT radiopharmaceutical. Positron Corporation has been exploiting this rise of the demand by cardiologists and the lack of the supply of affordable PET systems on the market by offering its cardiac specific, standalone Attrius® PET.

 

8
 

Currently radiopharmaceutical delivery is dominated by Cardinal Health (160 nuclear pharmacies and 26 cyclotron-based PET radiopharmaceutical manufacturing facilities), PETnet Solutions, a fully owned subsidiary of Siemens Medical Solutions USA (52 radiopharmacies and distribution centers), Triad Isotopes (63 radiopharmacies after acquiring a Covidien’s network and 6 cyclotrons), and GE healthcare (31 radiopharmacies). There are also approximately 73 independent radiopharmacies and 70 institutional radiopharmacies (affiliated with major medical schools).

 

Radiopharmaceuticals for cardiac applications are prepared in radiopharmaceutical generators, Tc-99m generators for SPECT (manufactured by Covidien and Lantheus) and Rb-82 generators for PET (Bracco Diagnostics). Rb-82 has a half-life of 75 seconds, and Rb-82 generators are delivered by Bracco directly to end users typically 13 times per year.

 

Tc-99m has a half-life of 6 hours, and centralized radiopharmacies use Tc-99m generators to deliver unit doses of Tc-99m based radiopharmaceuticals to customers. Centralized radiopharmacies incur very high fixed costs (approximately greater than $1.0 million per year) and freight costs (two-three times-a-day deliveries to each client) and are affected by geographical factors: clients have to be in a 75 miles proximity to the pharmacy due to a short half-life of Tc-99m. Positron Corporation’s PosiRx® does not have these limitations, as the radiopharmaceutical unit dose drawing devices can be placed directly into physicians’ offices with once-a-week deliveries.

 

The Department of Energy is the only entity in the U.S. that produces Sr-82 and refurbishes spent Sr-82/Rb-82 generators; according to current policies, DOE should not compete with commercial companies.

 

Many of our competitors enjoy competitive advantages over us, including: greater name recognition; greater financial, technical and service resources; established relationships with healthcare professionals; established distribution networks; additional lines of products and the ability to offer rebates or bundle products to offer discounts or incentives; and greater resources for product development and sales and marketing. See “Item 1. Description of Business—Risk Associated with Business Activities—Substantial Competition and Effects of Technological Change”.

 

Third party Reimbursement

 

Our customers typically rely on the Medicare and Medicaid programs and private payers for reimbursement. As a result, demand for our products is dependent in part on the coverage and reimbursement policies of these payers. Third party coverage and reimbursement is subject to extensive federal, state, local, and foreign regulation, and private payer rules and policies. In many instances, the applicable regulations, policies and rules have not been definitively interpreted by the regulatory authorities or the courts, and are open to a variety of interpretations and are subject to change without notice.

 

The scopes of coverage and payment policies vary among third-party private payers. For example, some payers will not reimburse a provider unless the provider has a contract with the payer, and in many instances such payers will not enter into such contracts. Other payers prohibit reimbursement unless physicians own or lease our scanners and cameras on a full-time basis, or meet certain accreditation or privileging standards. Such requirements and limitations can significantly restrict the types of business models we can successfully utilize.

 

Medicare reimbursement rules impose many standards and policies on the payment of services that our customers provide. For instance, the Medicare prohibition on the “mark-up” of diagnostic tests can restrict what a physician may charge Medicare for diagnostic tests. Medicare also imposes medical necessity and other standards on physician and facilities that bill Medicare for services.

 

Any limitation of Medicare, Medicaid or private payer coverage for PET or SPECT procedures using will likely have a material adverse effect on the Company’s business, financial condition, results of operations and cash flows.

 

9
 

Centers for Medicare & Medicaid Services (CMS) released their 2014 Medicare Physician Fee Schedule, which outlines the payment rates for medical services paid to private physicians in the outpatient office setting. This fee schedule stated that Myocardial PET perfusion imaging was increased to $1,310.60 per study. The Medicare Physician Fee Schedule also states that Cardiovascular SPECT reimbursement for outpatient cardiology practices billing under CPT codes has been increased to $1,153.62.

 

Manufacturing

 

Our manufacturing strategy combines our internal design expertise and proprietary process technology with strategic outsourcing to achieve cost efficiencies. All of the Company’s PET scanners are manufactured through our joint venture, Neusoft Positron Medical Systems, at its development and manufacturing facility in Shenyang, China. The manufacturing of the PosiRx® line takes place in Fishers, Indiana. The refurbishment of spent Sr-82/Rb-82 generators, production, recycling and processing of Sr-82 from foreign vendors are performed at MIT’s facility in Lubbock, Texas.

 

The Company expects to continue outsourcing additional components and processes to gain efficiencies and cost savings. The Company expects to perform subassembly and final system performance tests, packaging and labeling at our facility. The Company provides connectivity solutions which include consulting and configured computers. The Company also sells accessories which are outsourced and include printers, equipment for handling and measuring radioactive materials, and software for the cameras and systems.

 

The Company and its third-party manufacturers are subject to the FDA’s Quality System Regulation, state regulations, and regulations promulgated by the European Union.

 

Joint Venture with Neusoft Medical Systems Co., Ltd.

 

On June 30, 2005, the Company entered into a Joint Venture Contract with Neusoft Medical Systems Co., Inc. of Shenyang, in the People's Republic of China ("Neusoft"). Pursuant to the Joint Venture Contract the parties formed a jointly-owned company, Neusoft Positron Medical Systems Co., Ltd. (the “JV Company”), to engage in the manufacturing of PET and CT/PET medical imaging equipment. Neusoft's aggregate contribution to the capital of the JV Company was 67.5% of the total registered capital of the Company, or US$1,350,000, and the Company's aggregate contribution consisted of cash in the amount of $250,000 and a technology license valued at $400,000. Positron has transferred to the JV Company certain of its PET technology. During 2008-2009, as a result of additional capital contributions by Neusoft, the Company’s share in JV Company decreased to 1%.

 

Under its Joint Venture Contract with Neusoft, the Company has the exclusive right to sell PET system products developed by the JV Company in the U.S, Canada, and Mexico under its registered trademarks. Neusoft has the exclusive right to sell products developed by the JV Company in China under its registered trademarks. Each of Neusoft and the Company has the right to sell products developed by the JV Company in the countries and regions worldwide with the exception of China, the U.S., Canada and Mexico, where select exclusive rights apply.

 

The joint venture obtained the FDA 510k regulatory approval of Attrius® Cardiac PET in April 2009.

 

Research and Development

 

The Company’s research and development expenses were approximately $564,000 and $940,000 for the years 2013 and 2012, respectively. The research and development activities have been focused on development of radiopharmaceutical delivery systems and regulatory and quality systems compliance required to offer radiopharmaceuticals, radiochemicals and radioisotopes into the marketplace. We continue to improve and/or customize our radiopharmaceutical equipment to fit it to new products and meet unique user requirements. There have been significant resources allocated in the initial start up, preparation, licensure and regulatory compliance of the Company’s radiopharmaceutical manufacturing and radioisotope production facilities. We are also developing additional software and hardware for our PET and PET/CT scanner for additional functions that enhance performance and diagnostic efficacy and also in preparation for new cardiac radiopharmaceuticals that are in a pipeline of a major radiopharmaceutical manufacturer. These research and development activities are costly and critical to the Company’s ability to maintain, develop and improve its “state of the art” products. The Company’s inability to conduct such activities in the future may have a material adverse effect on the Company’s business as a whole.

 

10
 

Patent, Trademarks and Royalty Arrangements

 

The Company has three (3) patents covering the solid-state quantum photodetector technology and configuration of imaging apparatus and systems, one (1) U.S. patents pertaining to gamma cameras, and one (1) patent for PET radiopharmaceuticals infusion and shielding device. The Company has one (1) patent and one (1) patent pending pertaining to specific features of the Company’s automated radiopharmaceutical system.

 

As of December 31, 2013, we hold trademark registrations in the United States for the following marks: Positron®, Attrius®, PosiRx®, PosiStar®, Tech-Assist® and Pulse CDC™."

 

The Company seeks to protect its trade secrets and proprietary know-how through confidentiality agreements with its employees and consultants. The Company requires our employees, consultants and advisors to enter into a confidentiality agreement containing provisions prohibiting the disclosure of confidential information to anyone outside the Company, and requiring disclosure to the Company of any ideas, developments, discoveries or investigations conceived during service and the assignment to the Company of patents and proprietary rights to such matters related to the business and technology of the Company. Despite any measures taken to protect our intellectual property, unauthorized parties may attempt to copy aspects of our products or to obtain and use information that we regard as proprietary.

 

Product Liability and Insurance

 

Medical device companies are subject to a risk of product liability and other liability claims in the event that the use of their products results in personal injury claims. The Company carries the appropriate commercial and business insurances coverage to mitigate this risk. The Company has not experienced any product liability claims to date.

 

Employees

 

As of December 31, 2013, the Company employed twenty-two (22) full-time employees. None of the Company’s employees are represented by a union.

 

Available Information

 

Positron Corporation is required to file annual, quarterly and special reports, proxy statements and other information with the Securities and Exchange Commission (“SEC”). Investors may read and copy any document that Positron Corporation files, including this Annual Report on Form 10-K, at the SEC’s Public Reference Room at 450 F Street, N.W., Washington, DC 20549. Investors may obtain information on the operation of the Public Reference Room by calling the SEC at 1-800-SEC-0330. In addition, the SEC maintains an Internet site at http://www.sec.gov that contains reports, proxy and information statements and other information regarding issuers that file electronically with the SEC, from which investors can electronically access Positron’s SEC filings.

 

Item 1A. Risk Factors

 

Risk Associated with Business Activities

 

History of Losses. To date, the Company has been unable to sell its products in quantities sufficient to be operationally profitable. Consequently, the Company has sustained substantial losses. During the year ended December 31, 2013, the Company had a net loss of approximately $7,104,000 compared to a net loss of approximately $7,955,000 during 2012. At December 31, 2013, the Company had an accumulated deficit of approximately $123,432,000. There can be no assurances that the Company will ever achieve the level of revenues needed to be operationally profitable in the future and if profitability is achieved, that it will be sustained. Due to the limited number of products that have been sold in each fiscal period, the Company’s revenues have fluctuated, and may likely continue to fluctuate significantly from quarter to quarter and from year to year. The opinion of the Company’s independent auditors for the year ended December 31, 2013 expressed doubt as to the Company’s ability to continue as a going concern. The Company will need to obtain additional capital and increase product sales to become profitable.

 

11
 

Recruiting and Retention of Qualified Personnel. The Company’s success is dependent to a significant degree upon the efforts of its executive officers and key employees. The loss or unavailability of the services of any of its key personnel could have a material adverse effect on the Company. The Company’s success is also dependent upon its ability to attract and retain qualified personnel in all areas of its business, particularly management, research and development, sales and marketing and engineering. There can be no assurance that the Company will be able to continue to hire and retain a sufficient number of qualified personnel. If the Company is unable to retain and attract such qualified personnel, its business, operating results and cash flows could be adversely affected.

 

Working Capital. The Company had cash and cash equivalents of approximately $1,744,000 at December 31, 2013. The Company utilized $2,520,000 proceeds from issuance of convertible debt and securities, and $2,285,000 proceeds from non-interest bearing advances to fund operating activities during the year ended December 31, 2013. The Company had accounts payable and accrued liabilities of approximately $1,401,000 and a negative working capital of approximately $12,084,000. The Company believes that it may continue to experience operating losses and accumulate deficits in the foreseeable future. If we are unable to obtain financing to meet our cash needs we may have to severely limit or cease our business activities or may seek protection from our creditors under the bankruptcy laws.

 

Penny Stock Rules. If the shares of the Registrant's common stock are listed on The Nasdaq Stock Market or certain other national securities exchanges and the price thereof is below $5.00, then subsequent purchases of such securities will be subject to the requirements of the penny stock rules absent the availability of another exemption. The SEC has adopted rules that regulate broker-dealer practices in connection with transactions in "penny stocks." Penny stocks generally are equity securities with a price of less than $5.00 (other than securities registered on certain national securities exchanges or quoted on The Nasdaq Stock Market). The penny stock rules require a broker-dealer to deliver a standardized risk disclosure document required by the SEC, to provide the customer with current bid and offer quotations for the penny stock, the compensation of the broker-dealer and its salesperson in the transaction, monthly account statements showing the market value of each penny stock held in the customer's account, to make a special written determination that the penny stock is a suitable investment for the purchaser and receive the purchaser's written agreement to the transaction. These disclosure requirements may have the effect of reducing the level of trading activity in the secondary market for a stock that becomes subject to the penny stock rules.

 

A Small Number of Large Stockholders and Thinly Traded Market. A small number of our current stockholders hold a substantial number of shares of our common stock that they may sell in the public market. In addition, our common stock is thinly traded and any significant sales of our common stock may cause volatility in our common stock price. Sales by our current stockholders of a substantial number of shares, or the expectation that such sale may occur, could significantly reduce the market price of our common stock. We have also registered all shares of common stock that we may issue under our employee benefit plans. Accordingly, these shares can be freely sold in the public market upon issuance, subject to restrictions under the securities laws. If any of these stockholders cause a large number of securities to be sold in the public market, the sales could reduce the trading price of our common stock. These sales also could impede our ability to raise capital in the future.

 

In addition, these stockholders, acting together, will be able to significantly influence all matters requiring approval by our stockholders, including the election of directors and the approval of mergers or other business combination transactions. The interests of this group of stockholders may not always coincide with our interests or the interests of other stockholders, and they may act in a manner that advances their best interests and not necessarily those of other stockholders. As a result of their actions, or inaction our stock price may decline.

 

Substantial Competition and Effects of Technological Change. The industry in which the Company is engaged is subject to rapid and significant technological change. There can be no assurance that Company’s systems can be upgraded to meet future innovations in the industry or that new technologies will not emerge, or existing technologies will not be improved, which would render the Company’s products obsolete or non-competitive. Many of our competitors enjoy significant competitive advantages over us, including: greater name recognition; greater financial, technical and service resources; established relationships with healthcare professionals; established distribution networks; additional lines of products and the ability to offer rebates or bundle products to offer discounts or incentives; and greater resources for product development and sales and marketing. In addition, there can be no assurance that other established medical imaging companies, any of which would likely have greater resources than the Company, will not enter the market. There can be no assurance that the Company will be able to compete successfully against any of its competitors.

 

12
 

The downturn in the U.S. economy. Our revenues may be significantly impacted by the downturn in the U.S. economy. The slowing economy may also drive greater pricing pressures from our competition, increase the rate at which we lose business, or lead to disruptions in our supply chain, any of which would impede our ability to become profitable. Further, we cannot assure you that an improvement in economic conditions will result in an immediate, if at all positive, improvement in our operating results or cash flows.

 

Dependence upon third-party suppliers and the availability of certain radiopharmaceuticals. We rely on a limited number of third parties to manufacture and supply certain key components of our products. Alternative sources of production and supply may not be readily available. We have also outsourced production of PET systems to a single contract manufacturer. If a disruption in the availability of parts, or in the operations of these suppliers were to occur, our business could be materially affected. For this reason, we have backup plans in place that are designed to prevent delays in production. If these plans are unsuccessful, delays in the production of systems for an extended period of time could cause the loss of revenue, which could significantly harm our business and results of operations. Our equipment leasing service will involve the use of certain radiopharmaceuticals. If we experience disruptions in the supply of these radiopharmaceuticals, that will cause us to cancel services that would otherwise be provided. If we are unable to obtain an adequate supply of the necessary radiopharmaceuticals, we may be unable to lease our equipment, and our business may be harmed.

 

No Assurance of Market Acceptance. The Company’s systems involve new technology that competes with more established technologies. The purchase and installation of our system involves a significant capital expenditure on the part of the purchaser. A potential purchaser of our system must have an available patient base that is large enough to provide the utilization rate needed to justify such capital expenditure. There can be no assurance that the Company’s systems will be accepted by the target markets, or that the Company’s sales of systems will increase or that the Company will be profitable.

 

Patents and Proprietary Technology. The Company holds certain patent and trade secret rights relating to various aspects of its technologies, which are of material importance to the Company and its future prospects. Our pending U.S. and foreign patent applications, which include claims to material aspects of our products and procedures that are not currently protected by issued patents, may not issue as patents in a form that will be advantageous to us. Any patents we have obtained or do obtain may be challenged by re-examination or otherwise invalidated or eventually found unenforceable. Both the patent application process and the process of managing patent disputes can be time consuming and expensive. Competitors may attempt to challenge or invalidate our patents, or may be able to design alternative techniques or devices that avoid infringement of our patents, or develop products with functionalities that are comparable to ours. In the event a competitor infringes upon our patent or other intellectual property rights, litigation to enforce our intellectual property rights or to defend our patents against challenge, even if successful, could be expensive and time consuming and could require significant time and attention from our management. Furthermore, there can be no assurance that the Company’s products will not infringe on any patents of others. We may not have sufficient resources to enforce our intellectual property rights or to defend our patents against challenges from others.

 

In addition, the Company requires each of its consultants to enter into a confidentiality agreement designed to assist in protecting the Company’s proprietary rights. There can be no assurance that these agreements will provide meaningful protection or adequate remedies for the Company’s trade secrets or proprietary know-how in the event of unauthorized use or disclosure of such information, or that others will not independently develop substantially equivalent proprietary information and techniques or otherwise gain access to the Company’s trade secrets and proprietary know-how.

13
 

 

We Use Products that are Highly Regulated. In July 2011, Bracco Diagnostics Inc. voluntarily recalled its CardioGen-82 generator after the U.S. Food and Drug Administration (“FDA”) found that certain patients who had undergone PET imaging scans with rubidium chloride injected from CardioGen-82 generator, the radioactive drug injected into a patient to evaluate the functions of the heart, received excessive yet non-harmful amounts of the radiopharmaceutical. The recall was lifted in or about January 2012 and adversely affected the Company’s operations. There can be no assurance that another, similar incident or a voluntary recall will not occur which would adversely affect the Company’s business, financial conditions results of operations and cash flows.

 

Government Regulation. We are directly, or indirectly through our clients, subject to extensive regulation by both the federal government and the states in which we conduct our business including: the federal Medicare and Medicaid anti-kickback laws, other Medicare laws, regulations, rules, manual provisions, and policies that prescribe the requirements for coverage and payment for services performed by us and our DIS customers; the federal False Claims statutes; the federal Health Insurance Portability and Accountability Act of 1996, or HIPAA; the Stark Law; the Federal Food, Drug and Cosmetic Act; federal and state radioactive materials laws; state food and drug and pharmacy laws and regulations; state laws that prohibit the practice of medicine by non-physicians and fee-splitting arrangements between physicians and non-physicians; state scope-of-practice laws; and federal rules prohibiting the mark-up of diagnostic tests to Medicare under certain circumstances. If our customers are unable or unwilling to comply with these statutes, regulations, rules and policies, utilization rates of our services and products will decline and our business will be harmed.

 

We maintain a compliance program to identify and correct any compliance issues and remain in compliance with all applicable laws, to train employees, to audit and monitor our operations, and to achieve other compliance goals. Like most companies with compliance programs, we occasionally discover compliance concerns. In such cases, we take responsive action including corrective measures when necessary. There can be no assurance that our responsive actions will insulate us from liability associated with any detected compliance concerns.

 

If our past or present operations are found to be in violation of any of the laws, regulations, rules or policies described above or the other laws or regulations to which we or our customers are subject, we may be subject to civil and criminal penalties, damages, fines, exclusion from federal or state health care programs, or the curtailment or restructuring of our operations. Similarly, if our customers are found to be non-compliant with applicable laws, they may be subject to sanctions, which could have a negative impact on us. If we are excluded from federal or state health care programs, our customers who participate in those programs could not do business with us. Any penalties, damages, fines, curtailment or restructuring of our operations would adversely affect our ability to operate our business and our financial results. Any action against us for violation of these laws, even if we successfully defend against it, could cause us to incur significant legal expenses, divert our management’s attention from the operation of our business, and damage our reputation.

 

All laws and regulations, including those specifically applicable to the Company, are subject to change. The Company cannot predict what effect changes in laws and regulations might have on its business. Failure to comply with applicable laws and regulatory requirements could have material adverse effect on the Company’s business, financial conditions, results of operations and cash flows.

 

Further, sales of medical devices outside the country may be subject to foreign regulatory requirements. These requirements vary widely from country to country. There is no assurance that the time and effort required to meet those varying requirements may not adversely affect Positron’s ability to distribute its systems in some countries.

 

No Dividends. The Company has never paid cash dividends on its common stock and does not intend to pay cash dividends on its common stock in the foreseeable future.

 

Item 1B. Unresolved Staff Comments

 

None.

 

14
 

Item 2. Properties

 

In January 2012, the Company purchased approximately 2,000 square feet of office space in Westmont, Illinois from a related party in which it uses for corporate and administrative offices.

 

On April 19, 2010, the Company entered into a lease agreement (the “Lease”) for PET parts and service and Clinical and Technical Cardiovascular PET Training Institute. The amount of leased space at this location in Niagara, New York is approximately 3,125 square feet at a monthly rental of $1,600.

 

The Company has a month to month operating lease for its remaining Houston operations where the Company maintains inventory at times. Monthly rent for the facility is $1,000.

 

On July 7, 2011, the Company entered into an operating lease with a third party for space for medical device assembly and warehousing at a building in Fishers, Indiana. The Company will be required to make payments of $5,083 each month from December 1, 2011 through November 13, 2013, and $5,287 from December 1, 2013 through November 30, 2016. The amount of leased space at this location is approximately 9,761 square feet.

 

On December 5, 2011, MIT entered into an operating lease with a third party for space for warehousing at a building in Lubbock, Texas. The Company was required to make payments of $1,475 each month from December 1, 2011 through December 1, 2012. The lease continues on a month to month basis.

 

Item 3. Legal Proceedings

 

On June 8, 2012, the owner of the radiopharmaceutical manufacturing facility the Company formerly leased in Crown Point, Indiana commenced an action to recover the use of the premises and the remaining rent due under the lease. On November 14, 2012, the owner was awarded a judgment against the Company in the amount of $85,525.98 plus interest at the rate of 8%. The Company and the owner agreed to monthly payments in the minimum amount of $5,000 until the judgment is paid in its entirety.

 

In May, 2013, the Company was served with a First Amended Complaint in an action commenced against its CEO and principal shareholder. The plaintiff in the action is seeking to enforce a judgment against the CEO and principal shareholder and is seeking to have the Company’s Westmont, Illinois offices, which it purchased from the CEO, reconveyed. The related party defendants have disputed the basis of the judgment and the Company has denied the allegations in the Complaint and is defending the action. The action is currently in the discovery stage.

 

From time to time, we are a party to legal proceedings arising in the ordinary course of business. We are not currently a party to any other legal proceedings that we believe could have a material adverse effect on financial condition or results of operations.

 

Item 4. Mine Safety Disclosure

 

Not applicable.

 

Item 5. Market for Common Equity and Related Stockholder Matters

 

Market Information

 

The Company’s common stock is currently traded and quoted on the NASDAQ OTC Bulletin Board under the symbol POSC.

 

The following range of the high and low reported closing sales prices for the Company’s common stock for each quarter in 2013 and 2012, all as reported on the NASDAQ OTC Bulletin Board. These quotations reflect interdealer prices, without retail mark-up, mark-down or commission and may not represent actual transactions.

 

    2013     2012  
    High     Low     High     Low  
First Quarter   $ 0.01     $ 0.01     $ 0.02     $ 0.01  
Second Quarter   $ 0.01     $ 0.01     $ 0.02     $ 0.01  
Third Quarter   $ 0.01     $ 0.01     $ 0.01     $ 0.01  
Fourth Quarter   $ 0.01     $ 0.01     $ 0.01     $ 0.01  

 

15
 

 

Holders

 

There were approximately 4,059 shareholders of common stock as of March 31, 2014.

 

Dividends

 

Dividends payable to common shareholders, if any, will be contingent upon our revenues and earnings, capital requirements and financial conditions. The payment of dividends, if any, will be within the discretion of our Board of Directors. We presently intend to retain all earnings, if any, for use in our business operations.

 

Description of Securities

 

Number of Authorized and Outstanding Shares. The Company's Certificate of Formation, as amended, authorizes the issuance of 3,000,000,000 shares of common stock, $0.01 par value per share (the “Common Stock”), of which 1,452,548,262 shares were outstanding on December 31, 2013. All of the outstanding shares of Common Stock are fully paid and non-assessable.

 

Voting Rights. Holders of shares of Common Stock are entitled to one vote for each share held of record on all matters to be voted on by the shareholders. Accordingly, the holders of in excess of 50% of the aggregate number of shares of Common Stock outstanding will be able to elect all of the directors of the Company and to approve or disapprove any other matter submitted to a vote of all shareholders. The holders of our Common Stock are entitled to receive ratably such dividends, if any, as may be declared by the Board of Directors out of funds legally available. We have not paid any dividends since our inception, and we presently anticipate that all earnings, if any, will be retained for development of our business. Any future disposition of dividends will be at the discretion of our Board of Directors and will depend upon, among other things, our future earnings, operating and financial condition, capital requirements, and other factors.

 

Other. Holders of Common Stock have no cumulative voting rights. Holders of Common Stock have no preemptive rights to purchase the Company's Common Stock. There are no conversion rights or redemption or sinking fund provisions with respect to the Common Stock.

 

Transfer Agent. Shares of Common Stock are registered at the transfer agent and are transferable at such office by the registered holder (or duly authorized attorney) upon surrender of the Common Stock certificate, properly endorsed. No transfer shall be registered unless the Company is satisfied that such transfer will not result in a violation of any applicable federal or state security laws. The Company’s transfer agent for its Common Stock is Continental Stock Transfer & Trust Company, 17 Battery Place, 8th Floor, New York, NY 10004, (212) 509-4000.

 

Description of Preferred Stock

 

The Company’s Certificate of Formation, as amended, authorizes the issuance of 20,000,000 shares of preferred stock from time to time in one or more series. The Board of Directors is authorized to determine, prior to issuing any such series of preferred stock and without any vote or action by the shareholders, the rights, preferences, privileges and restrictions of the shares of such series, including dividend rights, voting rights, terms of redemption, the provisions of any purchase, retirement or sinking fund to be provided for the shares of any series, conversion and exchange rights, the preferences upon any distribution of the assets of the Company, including in the event of voluntary or involuntary liquidation, dissolution or winding up of the Company, and the preferences and relative rights among each series of preferred stock. The Board of Directors has designated the following series of preferred stock:

 

(i) 7,900,000 shares of Series A 8% Convertible Redeemable Preferred Stock (“Series A”), of which 447,652 shares are outstanding. Holders of the Series A have no voting rights but may vote on a converted basis on any matter requiring shareholder vote. The Series A is senior to the Company’s Common Stock in liquidation. While the Series A is outstanding or any dividends thereon remain unpaid, no Common Stock dividends may be paid or declared by the Company. The Series A may be redeemed in whole or in part, at the option of the Company, at any time subsequent to March 1998 at a price of $1.46 per share plus any undeclared and/or unpaid dividends to the date of redemption. Redemption requires at least 30 days advanced notice and notice may only be given if the Company’s Common Stock has closed above $2.00 per share for the twenty consecutive trading days prior to the notice.

 

16
 

(ii) 9,000,000 shares of Series B Preferred Stock (“Series B”), of which 3,056,487 shares are outstanding. Holders of the Series B are entitled to 1 votes per share on all matters requiring shareholder vote. Each share of Series B, $1.00 par value, is convertible into 1 shares of the Company’s Common Stock. The Series B is senior to the Company’s Common Stock and junior in priority to the Company’s Series A in liquidation. While the Series B is outstanding, no Common Stock dividends may be paid or declared by the Company. The Series B may be redeemed in whole or in part, at the option of the Company, at any time at a price of $1.00 per share.

 

(iii) 100,000 shares of Series S Convertible Preferred Stock (“Series S”), of which 100,000 shares are outstanding. Holders of the Series S are entitled to 10,000 votes per share on all matters requiring shareholder vote. Each share of Series S, $1.00 par value per share, is convertible into 100 shares of the Company’s Common Stock, subject to adjustment. The Series S is senior to the Company’s Common Stock and junior in priority to the Company’s Series A and Series B in liquidation. While Series S is outstanding, no Common Stock dividends may be paid or declared by the Company.

 

(iv) 15,000,000 shares of Series H Junior Convertible Preferred Stock (“Series H”), of which 12,500,000 are outstanding. Holders of the Series Have entitled to 200 votes per share and all matter holders of Common Stock at the rate of the number of Series H shares being converted multiplied by $0.10 and divided by seventy percent (70%) of the daily weighted average of three trading days prior to such conversion. The Series H rank junior as to dividends and the distribution of assets of the Company to the Common Stock, the Series A, the Series B and the Series S.

 

Penny Stock Rules

 

The Securities and Exchange Commission has also adopted rules that regulate broker-dealer practices in connection with transactions in penny stocks. Penny stocks are generally equity securities with a price of less than $5.00 (other than securities registered on certain national securities exchanges or quoted on the NASDAQ system, provided that current price and volume information with respect to transactions in such securities is provided by the exchange or system).

 

Our shares are considered penny stock under the Securities and Exchange Act. The shares will remain penny stocks for the foreseeable future. The classification of penny stock makes it more difficult for a broker-dealer to sell the stock into a secondary market, which makes it more difficult for a purchaser to liquidate his/her investment. Any broker-dealer engaged by the purchaser for the purpose of selling his or her shares in us will be subject to Rules 15g-1 through 15g-10 of the Securities and Exchange Act. Rather than creating a need to comply with those rules, some broker-dealers will refuse to attempt to sell penny stock.

 

The penny stock rules require a broker-dealer, prior to a transaction in a penny stock not otherwise exempt from those rules, to deliver a standardized risk disclosure document, which:

 

  · Contains a description of the nature and level of risk in the market for penny stock in both public offerings and secondary trading.

 

  · Contains a description of the broker's or dealer's duties to the customer and of the rights and remedies available to the customer with respect to a violation of such duties or other requirements of the Securities Act of 1934, as amended.

 

  · Contains a brief, clear, narrative description of a dealer market, including "bid" and "ask" price for the penny stock and the significance of the spread between the bid and ask price.

 

  · Contains a toll-free telephone number for inquiries on disciplinary actions.

 

17
 

  · Defines significant terms in the disclosure document or in the conduct of trading penny stocks.

 

  · Contains such other information and is in such form (including language, type, size and format) as the Securities and Exchange Commission shall require by rule or regulation.

 

The broker-dealer also must provide, prior to effecting any transaction in a penny stock, to the customer:

 

  · The bid and offer quotations for the penny stock.

 

  · The compensation of the broker-dealer and its salesperson in the transaction.

 

  · The number of shares to which such bid and ask prices apply, or other comparable information relating to the depth and liquidity of the market for such stock.

 

  · Monthly account statements showing the market value of each penny stock held in the customer's account.

 

In addition, the penny stock rules require that prior to a transaction in a penny stock not otherwise exempt from those rules; the broker-dealer must make a special written determination that the penny stock is a suitable investment for the purchaser and receive the purchaser's written acknowledgment of the receipt of a risk disclosure statement, a written agreement to transactions involving penny stocks, and a signed and dated copy of a written suitability statement. These disclosure requirements will have the effect of reducing the trading activity in the secondary market for our stock because it will be subject to these penny stock rules. Therefore, stockholders may have difficulty selling their securities.

 

Recent Sales of Unregistered Securities

 

During the fiscal years ended December 31, 2013, 2012 and 2011, the Company issued the following securities exempt from the registration requirements of the Securities Act pursuant to Section 4(2) of the Securities Act. No underwriting or other compensation was paid in connection with these transactions:

 

2013

 

On December 6, 2013, the Company issued a Convertible Debenture in the amount of $2,500,000, due on December 31, 2014, without interest and convertible into shares of the Company’s Common Stock at the rate of the daily weighted volume average price of the three trading days prior to a conversion, multiplied by 0.55.

 

On November 7, 2013, Patrick Rooney, the Company’s Chairman and Chief Executive Officer, converted previously made advances in the amount of $500,000 into 5,000,000 shares of Series H Junior Convertible Preferred Stock (the “Series H Preferred Stock”).

 

On April 11, 2013, the Company accepted subscriptions from Patrick Rooney, its Chairman and Chief Executive Officer, and Corey N. Conn, its Chief Financial Officer in the amounts of $500,000 and $250,000 respectively for an aggregate investment of $750,000. In consideration of these subscriptions, the Company issued 7,500,000 shares of its newly created Series H Junior Convertible Preferred Stock, par value $0.01 per share (the “Series H Preferred Stock”).

 

On April 12, 2013, the Company issued 621,000 shares of common stock for consulting services. On the date of the issuance, the common stock had a fair market value of $0.008 per share.

 

2012

 

On October 31, 2012, the Company issued two convertible debentures to Patrick Rooney, its Chairman and Chief Executive Officer and Corey Conn Chief Financial Officer, in the amount of $1,600,000. In Connection with this subscription, on November 13, 2012, the Company issued Mr. Rooney warrants to purchase 37,500,000 shares of common stock and Mr. Conn warrants to purchase 10,500,000 shares of common stock all at the exercise price of $0.01 per share.

 

18
 

On September 10, 2012, the Company converted obligations totaling $35,605 into 10,000,000 shares of Common Stock. Of these shares, 6,666,667 shares were payable as of September 30, 2012 and were issued in October 2012.

 

On August 31, 2012, the Company converted 1,888,836 shares of Series B Convertible Preferred Stock into 118,883,629 shares of Common Stock. Also on August 31, the Company issued 2,000,000 shares to an investor who had purchased shares during the three months ended June 30, 2012 and which were included in stock payable as of June 30, 2012.

 

On August 21, 2012, the Company issued 1,000,000 shares of Common Stock to a vendor for services.

 

On July 17, 2012, the Company issued 1,000,000 shares of Common Stock to vendors for services rendered. The Company issued and additional 1,000,000 shares of Common Stock to a vendor for services rendered on July 18, 2012. Both issuances were valued at $10,000.

 

On June 19, 2012, the Company converted 16,667 shares of Series A Convertible Preferred Stock into 16,667 shares of Common Stock, converted 118,149 shares of Series B Convertible Preferred Stock into 11,814,878 shares of Common Stock, and converted 18,200 shares of Series G Convertible Preferred Stock into 2,020,000 shares of Common Stock. In addition, the Company issued 3,970,786 shares of Common Stock to a vendor for settlement of accounts payable.

 

On June 7, 2012, the Company issued 4,000,000 warrants in connection with a Convertible Debt issuance to a lender to purchase Common Stock of the Company, which will expire on December 31, 2013.

 

On May 29, 2012, the Company converted 231,190 shares of Series B Convertible Preferred Stock into 23,119,000 shares of Common Stock. The Company issued 18,181,181 , shares of Common Stock for repayment of related party convertible debt.

 

On May 21, 2012, the Company converted 73,226 shares of Series B Convertible Preferred Stock into 7,322,636 shares of Common Stock. The Company also accepted subscriptions in the amount of $130,000 and issued 15,000,000 shares of Common Stock. In connection with these issuances, the Company issued 13,000,000 warrants to investors to purchase Common Stock of the Company, which will expire on December 31, 2014. In addition, the Company issued 175,000 shares of Common Stock to a vendor on May 21, 2012 for services rendered valued at $2,000.

 

On May 20, 2012, the Company issued 2,000,000 warrants to an investor to purchase Common Stock of the Company, which will expire on December 31, 2013.

 

On May 7, 2012, the Company issued 4,000,000 warrants in connection with a Convertible Debt issuance to a Lender to purchase Common Stock of the Company, which will expire on December 31, 2013.

 

On April 5, 2012, the Company converted 634,000 shares of Series B Convertible Preferred Stock into 63,400,000 shares of Common Stock. The Company also accepted subscriptions in the amount of $28,000 and issued 2,800,000 shares of Common Stock. In connection with these Common Stock issuances, the Company also issued 3,100,000 warrants to purchase Common Stock of the Company, which will expire on December 31, 2013. Also on April 5, 2012, the Company issued 39,682,539 shares of Common Stock for repayment of convertible debt, and issued 2,208,750 shares of Common Stock to a vendor for settlement of accounts payable. The Company recorded $26,456 loss on the settlement.

 

On March 14, 2012, the Company accepted subscriptions in the amount of $35,000 and issued 3,500,000 shares of Common Stock. In connection with these issuances, the Company also issued 3,500,000 warrants to investors to purchase Common Stock of the Company, which will expire on December 31, 2013, and extended the expiration date of 750,000 warrants which had expired to December 31, 2013. Also on March 14, 2012, the Company issued 1,200,000 shares of Common Stock to an employee for services valued at $20,000, and 600,000 shares of Common Stock to a vendor for services rendered valued $10,000.

 

19
 

On March 1, 2012, the Company converted 603,711 shares of Series B Convertible Preferred Stock into 60,371,100 shares of Common Stock. Also on March 1, 2012, the Company issued 3,000,000 shares of Common Stock to a vendor for services rendered valued at $51,000.

 

On January 20, 2012, the Company accepted subscriptions in the amount of $50,000 and issued 5,000,000 shares of Common Stock. In connection with these Common Stock issuances, the Company also issued 5,000,000 warrants to purchase Common Stock of the Company, which will expire on December 31, 2013, and extended the expiration date of 7,500,000 warrants which had expired to December 31, 2013.

 

On January 19, 2012, the Company converted 1,923,223 shares of Series B Convertible Preferred Stock into 192,322,258 shares of Common Stock. Also on January 19, 2012, the Company accepted subscriptions in the amount of $100,000 and issued 27,000,000 shares of Common Stock. Additionally, the Company issued 10,000,000 warrants to investors to purchase Common Stock of the Company, which will expire on December 31, 2014, and extended the expiration dates of 30,000,000 warrants which had expired to December 31, 2014. Furthermore, on January 19, 2012, the Company issued 5,000,000 shares in connection with the acquisition of MIT and 76,261 shares of Common Stock were issued for royalties. On January 19, 2012, the Company issued 25,000,000 shares of Common Stock and a convertible debenture due on December 31, 2014, with interest at the rate of 8%, to a related party as the purchase price for the office space previously leased by the Company. In addition, the Company issued 35,000,000 warrants, which entitle the related party to purchase shares of the Company’s common stock of the Company, which will expire on December 31, 2014.

 

On January 9, 2012, the Company issued 1,400,000 shares to a vendor for services.

 

2011

 

In October 2011, the Company issued 500,000 shares of common stock for consulting services.

 

In October 2011, the Company issued 113,636 shares of its Series B Convertible Preferred Stock in exchange for the conversion of a promissory note in the aggregate principal amount of $100,000.

 

In November 2011, the Company issued 100,000 shares of its Series B Convertible Preferred Stock for consulting services valued at $130,000.

 

During the quarter ending September 30, 2011, investors exercised warrants on preferred stock for which the Company received $270,000 in cash proceeds and issued 270,000 shares of Series B preferred stock. In addition, the Company received $250,000 in cash proceeds for warrants and issued 125,000 shares of Series B preferred stock, which were exercised at December 31, 2010, and recorded as receivable from warrants exercise at December 31, 2010.

 

On August 2, 2011, the Company issued 3,000 shares of Series B stock to an unrelated party for consulting services valued at $9,000.

 

On July 15, 2011, the Company issued 500,000 shares of common stock to an unrelated party for consulting services valued at $17,000.

 

During the quarter ending June 30, 2011, the Company issued 10,000,000 shares of common stock to an unrelated third party for consulting services valued at $290,000.

 

During the quarter ending June 30, 2011, warrant holders exercised warrants on preferred stock for which the Company received $325,000 in cash proceeds and issued 130,000 shares of Series B preferred stock.

 

On June 21, 2011, the Company issued 11,500 shares of Series Preferred B stock to two unrelated parties for consulting services valued at $33,000.

 

On April 6, 2011 and May 27, 2011, the Company issued 300,000 and 2,300,000 shares of common stock, respectively, to two, unrelated parties for consulting services valued at $12,000 and $67,000, respectively.

 

20
 

 

On May 26, 2011, the Company issued 424,242 Series B Convertible Preferred Stock upon the conversion of certain convertible debentures in the aggregate amount of $700,000.

 

During the quarter ending March 31, 2011, investors converted 20,000 shares of Series B Preferred Stock into 2,000,000 shares of common stock.

 

During the quarter ending March 31, 2011, we received $575,000 for the exercise of warrants and issued 255,000 shares of Series B Preferred Stock in connection with the exercise of these warrants.

 

On February 15, 2011, the Company issued 3,000 shares of Series B Preferred Stock to an unrelated party for consulting services. On the date of issuance, the common stock had a fair market value of $0.04 per share. The Company recorded consulting fee expense of $12,000 for the issuance of the shares.

 

Unless noted above, the sales of the securities identified above were made pursuant to privately negotiated transactions that did not involve a public offering of securities and, accordingly, we believe that these transactions were exempt from the registration requirements of the Securities Act pursuant to Section 4(2) thereof and rules promulgated there under. Each of the above-referenced investors in our stock represented to us in connection with their investment that they were “accredited investors” (as defined by Rule 501 under the Securities Act) and were acquiring the shares for investment and not distribution, that they could bear the risks of the investment and could hold the securities for an indefinite period of time. The investors received written disclosures that the securities had not been registered under the Securities Act and that any resale must be made pursuant to a registration or an available exemption from such registration. All of the foregoing securities are deemed restricted securities for purposes of the Securities Act.

 

Item 6. Selected Financial Data

 

Not applicable for smaller reporting companies.

 

Item 7. Management’s Discussion and Analysis or Plan of Operation

 

The following discussion and analysis of our financial condition and results of operations should be read in conjunction with our selected financial data and our financial statements and the accompanying notes included in this annual report. The following discussion may contain forward-looking statements that reflect our plans, estimates and beliefs and involve risks, uncertainties and assumptions. Our actual results could differ materially from those discussed in these forward-looking statements. Factors that could cause or contribute to these differences include those discussed below and under the headings “Risk Factors” and “Forward-Looking Statements.”

 

Overview

 

Positron Corporation is a nuclear medicine healthcare company specializing in the field of cardiac Positron Emission Tomography (PET) imaging. Cardiac PET is the superior method in diagnostic nuclear imaging for the detection of coronary artery disease (CAD)

 

Positron’s products and services enable healthcare providers to more accurately diagnose disease and improve patient outcomes, while practicing cost effective medicine. Positron is the only company that will provide an economical, end-to-end solution for PET myocardial perfusion imaging through complementary product integration of PET imaging systems, radiopharmaceuticals, and radioisotopes.

 

The Company believes its unique proprietary products, market position and vertically integrated strategy will lead to accelerated adoption and growth of the cardiac PET modality in the U.S. and emerging markets. Through leadership within our field, Positron intends to gain a dominant market position with strong earnings potential, ultimately becoming a sustained, long-term value creator for industry participants and our shareholders.

 

21
 

The Company

 

Positron, a pioneer in cardiac PET, is well branded in the field of nuclear cardiology. Founded in 1983, Positron has gained significant traction in the industry based on its imaging technology and strong commitment towards advancing cardiac care. Originally a research & development company, Positron’s business strategy has evolved and grown over the past several years. Positron has expanded from a medical imaging device manufacturer to a nuclear healthcare company integrating the key components of the cardiac PET supply chain to provide an end-to-end solution for the market. Led by an experienced management team, Positron has become a true business enterprise with strong recurring revenue generating business model scalable to the global marketplace.

 

The Company believes that our unique products, market position and vertical integration strategy will stabilize and secure the supply chain, significantly reducing costs and industry uncertainties, a substantial advantage, leading to further adoption and growth of the cardiac PET modality.

 

Positron is the only commercial resource in the U.S. with practical knowledge and experience in all stages of Sr-82 production and generator lifecycle management. Positron seeks to secure both short and long-term supply of radioisotopes used in cardiac PET imaging. Currently, the Company is producing Active Pharmaceutical Ingredient (API) grade Sr-82 at its Lubbock, Texas, facility from strontium received from foreign irradiated source suppliers. The Company intends to further supplement strontium resources by pursuing additional supply agreements with all domestic and foreign irradiated source suppliers, requesting increases in production schedules from third party suppliers, and by recycling expired generators. Positron seeks to secure a long-term North America supply of medical radioisotopes for cardiac PET imaging by building and operating the world’s largest commercial high-energy/high-current cyclotron (70MeV) within the U.S. This 70 MeV cyclotron will be at the heart of providing a reliable, dependable, and indigenous supply of radioisotopes, stabilizing and building confidence in the PET market and nuclear medicine community overall. Securing and delivering a reliable supply of radioisotopes should also increase the demand for Positron’s complementary products.

 

Positron’s business strategy is to gain a dominant market share through the vertical integration of such key components: imaging technologies, clinical services, radiopharmaceutical and radioisotope processing, production, and distribution. Positron creates market efficiencies by integrating these critical components. Positron intends to maximize market share by offering cost-effective, value added solutions to end-users that meet the current and future nuclear cardiology market demands.

 

PET vs. SPECT

 

There are two main imaging modalities utilized in nuclear cardiology: Single Photon Emission Computed Tomography, or SPECT, and Positron Emission Tomography, or PET.

 

In myocardial perfusion imaging, PET has been proven to be superior in sensitivity and specificity when compared to SPECT, the more commonly utilized modality. Cardiac PET scans, with Rb-82 Chloride or Nitrogen-13 Ammonia (N-13), result in a lower patient radiation exposure and is capable of performing superior quantitative measurements such as coronary flow reserve. Cardiac PET imaging has been shown to provide a 50% reduction in invasive coronary arteriography and coronary artery bypass grafting, leading to a 30% costs savings and improved clinical outcomes, when compared to SPECT (M.E. Merhige, M.D., et al. Journal Nuclear Medicine 2007; 48:1069-1076).

 

The cardiac PET equipment market is much smaller than SPECT, but has seen significant annual growth of 30% during the last decade. According to Bracco Diagnostics, there were approximately 160 dedicated cardiac PET & PET/CT scanners performing nuclear cardiology within the U.S. in 2012, a tenfold increase since 2006.

 

Barriers to entry

 

For many years, one of the major constraints for adoption of this modality had been the high cost of PET and PET/CT scanners. Many practices and hospitals could not justify the cost of a new system for cardiac studies. In 2010, Positron received FDA clearance to market and distribute its dedicated PET system, which is optimized for nuclear cardiology. The Attrius is the only new, cost effective, dedicated PET system available on the market. Other system manufacturers (GE, Philips, Siemens) offer PET/CT cameras, which have a 200%-300% higher purchase price; PET/CT systems also possess attributes that may affect the accuracy of a perfusion study, leading to false positives.

 

22
 

 

Another more recent issue that has slowed the growth of nuclear cardiology is the shortage of the key drugs utilized in both SPECT (Mo-99/Tc-99m) and PET imaging (Sr-82/Rb-82).

 

The Sr-82 isotope decays to produce the Rb-82 tracer utilized in cardiac PET studies. Rb-82 is the most commonly used cardiac PET tracer in the United States. The FDA approved Rb-82 in 1989 for use in the detection of coronary artery disease and the Health Care Financing Administration approved reimbursement for Rb-82, PET MPI, in 1995 as a first line test in symptomatic patients. Rubidium is uniformly available through generator production in the U.S. and is used in conjunction with an automatic infusion system.

 

Over the past five years the explosive growth of cardiac PET imaging has driven a significant increase in the use of Sr-82/Rb-82 generators. The increasing demand for Sr-82 is beginning to outpace supply. Until recently, the U.S. Department of Energy had been the only entity in the United States capable of providing this material. In August of 2012, MIT submitted its DMF with the FDA and has begun production of API grade strontium-82.

 

Due to the growing demand and limited supply, the industry suffered a Sr-82 shortage in January 2011, effecting supply of Rb-82 generators. The same year Bracco Diagnostics Inc., the sole market supplier of the Rb-82 generator, underwent a voluntary recall of generators, further stunting industry sales and growth.

 

Positron is acutely focused on production of Sr-82. Positron possesses certain resources and technical advantages, unique to MIT, which will increase current and future strontium supply. Positron anticipates the cardiac PET market to rebound in Q2 2013, beginning with Bracco’s ability to now accept new generator customers, and with accelerated expansion upon market entry of the DraxImage’s generator, once FDA approved.

 

70 MeV Cyclotron Project

 

Pursuing a strategy of complementary product integration, Positron seeks to build and operate a high-energy cyclotron facility used primarily for the production of medical diagnostic imaging and radiotherapy isotopes. The proposed 70MeV cyclotron is unique and capable of producing isotopes that are not available, or have very limited availability, from other commercial sources in the United States.

 

The major isotope to be produced is Sr-82, which is currently in short supply worldwide and is produced in the U.S. only by the U.S. Department of Energy (DOE) National Laboratories in Los Alamos, New Mexico and Brookhaven, New York. Sr-82 is the parent isotope used in the production of Rb-82 generators for PET myocardial perfusion imaging. Positron will have an access to a Rb-82 generator through a proprietary relationship with a major manufacturer or its own Rb-82 generator and intends to utilize all Sr-82 produced by the facility to supply its cardiac PET client base. This allows Positron to have a complete, integrated, supply chain. Positron’s captive customer base of Attrius® owners and the existing robust PET users require a constant supply of radiopharmaceuticals manufactured from the Sr-82 radioisotope, giving us a significant advantage against any potential commercial competition.

 

A key point in determining the competitive landscape of U.S. Sr-82 production is the policy of the DOE to not compete with the private sector. While the DOE produces a majority of Sr-82 in the world, once Sr-82 is reasonably available commercially, the DOE can be compelled to withdraw from the market.

 

With the recent growth of cardiac PET imaging, the supply of isotopes is quickly moving towards capacity within the next one-three years. Annual demand for medical imaging products, produced by a high-energy cyclotron, are currently estimated at over $20 million and is expected to reach $30-35 million over the next few years, with continued growth estimated at 25-30% per year thereafter.

 

The DOE lists many isotopes for medical treatment or diagnostics that are in short supply, some of which can be produced in a high-energy commercial accelerator. Moving from R&D to clinical trials and then to commercial use, these isotopes will further expand the market. Additionally, using secondary targets, a high-energy cyclotron can also produce low-energy isotopes, in conjunction with, the production of high-energy isotopes, generating additional revenue. Positron Corporation can be a key market maker in all these segments and can enter the market, essentially, without competition. The revenue potential and diversity inherent in this project is considerable.

 

23
 

Our Market

 

According to the U.S. Department of Health and Human Services, there are more than 22,000 cardiovascular diseases specialists in the U.S., and their number will increase to 31,000 by 2020. This is the target market for our products and services, as well as hospitals in the United States that performs or could perform nuclear cardiac procedures and want to automate the delivery of radiopharmaceuticals. By adding complimentary products, we are able to offer customers value added solutions which include low cost molecular imaging devices, maintenance service, disease specific software, radiopharmaceutical unit doses drawing devices, and, potentially, radiopharmaceuticals agents for Cardiac Nuclear Medicine.

 

Cardiac Nuclear medicine helps in the diagnosis, management and prevention of cardiovascular disease (CVD) in patients. Radiopharmaceuticals are injected into a patient to provide the most accurate, non-invasive test for identifying narrowed coronary arteries, mild cholesterol build-up or diffuse coronary vascular disease, conditions that are responsible for almost all heart attacks.

 

Cardiovascular disease is the leading cause of death in the United States and constitutes 17% of overall national health expenditures (Forecasting the Future of Cardiovascular Disease in the United States, American Heart Association, 2011). Direct CVD costs are projected to increase from $273 Billion, in 2010, to $818 Billion, in 2030; with indirect costs, due to lost productivity, expected to rise from $172 Billion to $276 Billion by 2030.

 

Market Potential

 

The cardiac PET industry has an indisputable need for a stable, efficient and economical environment. Through Positron’s leadership and vision to integrate each key segment of the cardiac PET supply chain, the Company will stimulate growth and increase capacity to meet the needs of the global cardiac PET market. Positron intends to become the premier product, services, and solutions provider in the nuclear cardiology industry.

 

Although the cardiac PET industry experienced its most challenging year ever, it enabled the Company to aggressively pursue its strategy toward aggregating and integrating the key components critical in securing the cardiac value chain. Positron is dedicated to lowering the barriers that have been constricting, or could later constrict, the progress of medical advancements in cardiac PET. Through our efforts to supplement the supply of key radioisotopes and our ability to offer innovative products and services, management has methodically positioned Positron to become the industry’s only end-to-end solutions provider. PET is the future of nuclear cardiology.

 

We believe that Positron is the only company with the critical components to vertically integrate the fragmented “single source supplier environment” that exists in the cardiac PET market today and that these initiatives are intended to drive the Company towards consistent profitability and cash flow.

 

Results of Operations

 

Consolidated results of operations for the years ending December 31, 2013 and 2012 include Positron and its wholly-owned subsidiaries: Positron Isotope Corporation (“PIC”) and Manhattan Isotope Technology LLC (“MIT”), since its acquisition on January 17, 2012.

 

Revenues - Revenues for the year ended December 31, 2013 were approximately $1,630,000 as compared to $2,801,000 for the year ended December 31, 2012. There were no PET systems sold during the year ended December 31, 2013 as compared to $1,142,000 in 2012, which accounted for the significant decrease in revenues. Sales of PET systems during 2013 have been negatively impacted by the shortage of Sr-82/Rb-82 generators supplied to cardiac imaging facilities by Bracco Diagnostics due to the voluntary recall of their Rb-82 generator and limited production capacity or supply of the parent isotope Sr-82.

 

24
 

Costs of Sales - Costs of sales for the year ended December 31, 2013 were approximately $1,206,000 compared to $1,972,000 for the year ended December 31, 2012. Costs were lower in 2012 principally due to the lower sales of the PET systems.

 

Operating Expenses - The Company’s operating expenses were approximately $3,762,000 for the year ended December 31, 2013 compared to $5,551,000 for the year ended December 31, 2012.

 

General and administrative expenses during the year ended December 31, 2013 were $2,779,000 as compared to $4,326,000 for the year ended December 31, 2012. The company recorded $1,494,000 in stock based compensation in 2012, compared to $656,000 in 2013.

 

Research and development costs for the year ended December 31, 2013 were approximately $564,000 compared to $940,000 for the year ended December 31, 2012. Research and development costs included mostly payroll, contract labor and consulting fees for Attrius® software and the PosiRx® development. In addition, the Company has incurred research and development costs related to its planned radiopharmaceutical facility in preparation for regulatory approvals and production. The Company intends to continue to support research and development in software, radiopharmaceutical products and automated devices.Sales and marketing expense for the years ended December 31, 2013 and 2012 were $419,000 and $285,000, respectively and were lower in 2012 due to the Company’s efforts to limit expenditures during the recall period of the Bracco Diagnostics rubidium generator.

 

Other Expenses – During the years ended December 31, 2013 and 2012, the Company recorded other expenses of approximately $3,766,000 and $3,233,000, respectively. Other expenses include interest expense, derivative expenses, debt modification expense and other gains and losses.

 

Interest expense was $2,137,000 and $1,753,000 for the years ended December 31, 2013 and 2012, respectively. $1,910,000 and $1,380,000 of the total interest expense for the years ended December 31, 2013 and 2012, respectively, was related to the accretion of debt discount associated with convertible debt.

 

Company recorded derivate loss of $665,000 and $726,000, for the years ended December 31, 2013 and 2012, respectively, in connection with the embedded conversion derivative liabilities related to convertible debt and warrant extensions.

 

During the years ended December 31, 2013 and 2012, the Company recognized expense of $821,000 and $432,000, respectively, on the modification of the terms of the convertible debentures.

 

During the year ended December 31, 2012, the Company also recorded $18,000 loss on the disposal of property and equipment, $282,000 loss on settlement and other expenses of $22,000. The Company recorded other expenses of $143,000 in 2013 related to foreign exchange adjustments.

 

Net Loss - For the year ended December 31, 2013, the Company had a net loss approximately of $7,104,000, or $0.00 per share, compared to a net loss of $7,955,000, or $0.01 per share, for the year ended December 31, 2012.

 

Liquidity and Capital Resources

 

Since inception, the Company has expended substantial resources on research and development. The Company has sustained substantial losses due to the limited number of systems sold or placed into service each year. Revenues have also fluctuated significantly from year to year. The Company had an accumulated deficit of approximately $123,432,000 at December 31, 2013. The Company will need to increase sales of systems, services, radiopharmaceuticals and radioisotopes and apply the research and development advancements to achieve profitability in the future. Prior to the voluntary recall of Sr-82/Rb-82 generators by Bracco Diagnostics, the Company had experienced an increase in sales with the launch of Attrius® PET system and expected additional increase in revenue through sales of automated radiopharmaceutical systems and recurring revenue from the sale of radiopharmaceuticals and radioisotopes. With an increase in sales, all systems material cost of goods and labor costs will be significantly lower. The Company expects that these developments will have a positive impact on the sales & service volumes and increased net margins. However, there is no assurance that the Company will be successful in selling new systems.

 

25
 

The Company's ability to achieve its objectives is dependent on its ability to sustain and enhance its revenue stream and to continue to raise capital until such time as the Company achieves profitability. To date, management has been successful in raising capital as needed for the continued operations of the Company. There is no guarantee that management will be able to continue to raise needed capital in this fashion.

 

The Company’s current financial condition raises doubt as to its ability to continue as a going concern. The report of the Company’s independent registered public accountants, which accompanied the financial statements for the year ended December 31, 2013, is qualified with respect to that risk. If the Company is unable to obtain debt or equity financing to meet its cash needs, it may have to severely limit or cease business activities or may seek protection from creditors under the bankruptcy laws.

 

At December 31, 2013, the Company had current assets of $2,573,000 and total assets of $3,882,000 compared to December 31, 2012, when current assets were $1,104,000 and total assets were $2,685,000. The Increase in current assets is attributable primarily to the sales of convertible securities of approximately $2,520,000 during December 2013.

 

Current liabilities at December 31, 2013 were $14,657,000 compared to $8,110,000 at December 31, 2012. At December 31, 2013 and 2012, current liabilities was largely comprised of accounts payable and accrued liabilities, customer deposits, unearned revenue, current portion of notes payable, convertible debt and embedded conversion derivative liabilities. The increase in current liabilities as of December 31, 2013 is largely due to the $2,987,000 increase in the embedded derivative liability associated with the convertible debentures, and increase in the current portion of notes payable of $1,159,000.

 

Net cash used in operating activities during the year ended December 31, 2013 was $3,046,000 compared to $2,240,000 used in operating activities during the year ended December 31, 2012. The increase is primarily due to an increase in prepaid expenses and other assets caused by a $200,000 deposit to Neusoft to construct Attrius Systems placed during 2013, as well as increased non-cash changes which decreased net loss in 2013.

 

Net cash used in investing activities was $16,000 for the year ended December 31, 2013 compared to $72,000 for the year ended December 31, 2012, was related primarily to purchases of property and equipment.

 

Net cash provided by financing activities was $4,563,000 and $2,554,000 for the years ended December 31, 2013 and 2012, respectively. During the year ended December 31, 2013, cash from financing activities was comprised of $2,520,000 proceeds from the issuance of convertible debt, $2,245,000 proceeds from non-interest bearing advances, which were partially offset by repayments of notes payable of $100,000, repayments of convertible debt of $100,000 and repayment of capital lease borrowings of $2,000. During the year ended December 31, 2012, cash from financing activities was comprised of $2,210,000 proceeds from the issuance of convertible securities, $305,000 proceeds from borrowing under notes payable, $65,000 proceeds from non-interest bearing advances, $383,000 proceeds from issuance of common stock, which got partially offset by repayments of notes payable of $324,000 and repayments of non-interest bearing advances of $85,000.

 

OFF-BALANCE SHEET ARRANGEMENTS

 

We have not entered into any transactions with unconsolidated entities whereby we have financial guarantees, subordinated retained interests, derivative instruments or other contingent arrangements that expose us to material continuing risks, contingent liabilities, or any other obligations under a variable interest in an unconsolidated entity that provides us with financing, liquidity, market risk or credit risk support.

 

Recently Issued Accounting Standards

 

Pronouncements issued by the FASB or other authoritative accounting standards group with future effective dates are either not applicable or not significant to the consolidated financial statements of the Company.

 

26
 

Critical Accounting Policies

 

The discussion and analysis of our financial condition and results of operations is based upon our consolidated financial statements, which have been prepared in accordance with U.S. generally accepted accounting principles. The preparation of these financial statements requires us to make estimates and judgments that affect the reported amount of assets and liabilities and related disclosure of contingent assets and liabilities at the date of our financial statements and the reported amounts of revenues and expenses during the applicable period. Actual results may differ from these estimates under different assumptions or conditions.

 

We define critical accounting policies as those that are reflective of significant judgments and uncertainties and which may potentially result in materially different results under different assumptions and conditions. In applying these critical accounting policies, our management uses its judgment to determine the appropriate assumptions to be used in making certain estimates. These estimates are subject to an inherent degree of uncertainty. Our critical accounting policies include the following:

 

Revenue Recognition

 

The Company’s revenues are currently derived from the sale of medical equipment products, maintenance contracts, service revenues and radioisotope sales. Revenues from maintenance contracts are recognized over the term of the contract. Service revenues are recognized upon performance of the services. The Company recognizes revenues from the sale of medical equipment and radioisotope products when earned. Specifically, revenue is recognized when persuasive evidence of an arrangement exists, delivery has occurred (or services have been rendered), the price is fixed or determinable, and collectability is reasonably assured. The Company obtains a signed customer acceptance after installation is complete for the sale of its Attrius® PET systems.

 

For multiple-element arrangements, revenue is allocated to each element based on their relative selling prices. Relative selling prices are based first on vendor specific objective evidence (VSOE), then on third-party evidence of selling price (TPE) when VSOE does not exist, and then on estimated selling price (ESP) when VSOE and TPE do not exist.

 

Because the Company has neither VSOE nor TPE for its products, the allocation of revenue has been based on the Company’s ESPs. The objective of ESP is to determine the price at which the Company would transact a sale if the product was sold on a stand-alone basis. The Company determines ESP by considering the facts and circumstances of the product being sold.

 

Stock Compensation

 

We have granted stock options to employees, directors and consultants, as well as warrants to other third parties. The value of each option award is estimated on the date of grant using the Black-Scholes option-pricing model. The Black-Scholes model takes into account volatility in the price of our stock, the risk-free interest rate, the estimated life of the option, the closing market price of our stock and the exercise price. We base our estimates of our stock price volatility on the historical volatility of our common stock and our assessment of future volatility; however, these estimates are neither predictive nor indicative of the future performance of our stock. For purposes of the calculation, we assumed that no dividends would be paid during the life of the options and warrants. The estimates utilized in the Black-Scholes calculation involve inherent uncertainties and the application of management judgment. In addition, we are required to estimate the expected forfeiture rate and only recognize expense for those equity awards expected to vest. As a result, if other assumptions had been used, our recorded stock-based compensation expense could have been materially different from that reported.

 

Embedded conversion derivative liabilities

 

Embedded conversion derivative liabilities are recorded as liabilities at their estimated fair value at the date of issuance, with subsequent changes in estimated fair value recorded in other income (expense) in the Company’s statement of operations in each subsequent period. The embedded conversion derivative liabilities are measured at estimated fair value using the Black Scholes model. Inherent in this model are assumptions related to expected stock-price volatility, expected life, risk-free interest rate and dividend yield. We estimate volatility at the date of issuance, and at each subsequent reporting period, based on historical volatility that matches the expected remaining life of the embedded conversion derivative liabilities. The risk-free interest rate is based on the U.S. Treasury zero-coupon yield curve. The expected life of the embedded conversion derivative liabilities is assumed to be equivalent to their remaining contractual term. The dividend rate is based on our historical rate, which we anticipate to remain at zero. The assumptions used in calculating the estimated fair value of the embedded conversion derivative liabilities represent our best estimates, however these estimates involve inherent uncertainties and the application of management judgment. As a result, if factors change and different assumptions are used, the embedded conversion derivative liabilities and the change in estimated fair value could be materially different.

 

27
 

Allowance for doubtful accounts

 

Our allowance for doubtful accounts reflects reserves for customer and other receivables to reduce receivables to amounts expected to be collected. Management uses significant judgment in estimating uncollectible amounts. In estimating uncollectible accounts, management considers factors such as current overall economic conditions, industry-specific economic conditions, historical customer performance and anticipated customer performance. While we believe these processes effectively address our exposure for doubtful accounts and credit losses have historically been within expectations, changes in the economy, industry, or specific customer conditions may require adjustments to the allowance for doubtful accounts. As of December 31, 2013 and 2012, the allowance for doubtful accounts was $140,800 and $50,000, respectively.

 

Inventory

 

Inventories are stated at the lower of cost or market. Cost is determined using the first-in, first-out (FIFO) method of inventory valuation.

 

Management assesses the recoverability of the various inventory components on a quarterly basis and is based on the estimated net realizable values of respective finished and in process inventories.

 

Information Regarding and Factors Affecting Forward Looking Statements

 

The Company is including the following cautionary statement in this Annual Report on Form 10-K to make applicable and take advantage of the safe harbor provision of the Private Securities Litigation Reform Act of 1995 for any forward looking statements made by, or on behalf of the Company. Forward looking statements include statements concerning plans, objectives, goals, strategies, future events or performance and underlying assumptions and other statements which are other than statements of historical facts. Certain statements contained herein are forward looking statements and, accordingly, involve risks and uncertainties which could cause actual results or outcomes to differ materially from those expressed in the forward looking statements.

 

The Company’s expectations, beliefs and projections are expressed in good faith and are believed by the Company to have a reasonable basis, including without limitations, management’s examination of historical operating trends, data contained in the Company’s records and other data available from third parties, but there can be no assurance that management’s expectations, beliefs or projections will result or be achieved or accomplished. In addition to other factors and matters discussed elsewhere herein, the following are important factors that, in the view of the Company, could cause actual results to differ materially from those discussed in the forward looking statements: the ability of the Company to attain widespread market acceptance of its systems; the ability of the Company to obtain acceptable forms and amounts of financing to fund future operations; demand for the Company’s services; and competitive factors. The Company disclaims any obligation to update any forward looking statements to reflect events or circumstances after the date hereof.

 

Item 7A. Quantitative and Qualitative Disclosures About Market Risk

 

Not required for smaller reporting companies.

 

Item 8. Financial Statements

 

The required Financial Statements and the notes thereto are contained in a separate section of this report beginning with the page following the signature page.

 

28
 

Item 9. Changes in and Disagreements with Accountants on Accounting and Financial Disclosure

 

None.

 

Item 9A. Controls and Procedures

 

  (a) Evaluation of Disclosure Controls and Procedures

 

Our principal executive officer and principal financial officer, after evaluating the effectiveness of our disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) as of December 31, 2013, have concluded that, based on such evaluation, our disclosure controls and procedures were effective to ensure that information required to be disclosed by us in the reports that we file or submit under the Exchange Act is recorded, processed, summarized and reported, within the time periods specified in the SEC’s rules and forms, and is accumulated and communicated to our management, including our principal executive and principal financial officers, or persons performing similar functions, as appropriate to allow timely decisions regarding required disclosure.

 

Notwithstanding the foregoing, we have identified the following material weakness in our disclosure procedures:

 

Audit Committee and Financial Expert - The Company does not have a formal audit committee with a financial expert, and thus the Company lacks the board oversight role within the financial reporting process.

 

There can be no assurance that the Company’s disclosure controls and procedures will detect or uncover all failures of persons within the Company to disclose material information otherwise required to be set forth in the Company’s periodic reports. There are inherent limitations to the effectiveness of any system of disclosure controls and procedures, including the possibility of human error and the circumvention or overriding of the controls and procedures. Accordingly, even effective disclosure controls and procedures can only provide reasonable, not absolute, assurance of achieving their control objectives.

 

  (b) Management’s Report on Internal Control over Financial Reporting

 

Our management is responsible for establishing and maintaining adequate internal control over financial reporting. Internal control over financial reporting is defined in Rule 13a-15(f) and 15d-15(f) under the Exchange Act as a process designed by, or under the supervision of, our principal executive and principal financial officers, management and other personnel, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles, and includes those policies and procedures that:

 

  · Pertain to the maintenance of records that in reasonable detail accurately and fairly reflect the transactions and dispositions of our assets;

 

  · Provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that our receipts and expenditures are being made only in accordance with authorization of our management; and

 

  · Provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use or disposition of our assets that could have a material effect on the financial statements.

 

Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies and procedures may deteriorate.

 

29
 

Our management assessed the effectiveness of our internal control over financial reporting as of December 31, 2013. In making this assessment, management used the criteria set forth by the Internal Control — Integrated Framework issued by the Committee of Sponsoring Organizations of the Treadway Commission, or the COSO criteria. Based on this assessment, management believes that, as of December 31, 2013, our internal control over financial reporting was effective at a reasonable assurance level based on these criteria.

 

This annual report does not include an attestation report of the Company's registered public accounting firm regarding internal control over financial reporting. Management's report was not subject to attestation by the Company's independent registered public accounting firm pursuant to rules of the Securities and Exchange Commission that permit the Company to provide only management's report in this annual report.

 

  (c) Changes in Internal Control over Financial Reporting

 

There have been no changes in the Company’s internal control over financial reporting during the most recent fiscal quarter that have materially affected, or are reasonably likely to materially affect, the Company’s internal control over financial reporting.

 

Item 9B. Other Information

 

None.

 

Item 10. Directors, Executive, and Corporate Governance

 

The following table sets forth: (1) names and ages of all persons who presently are and who have been selected as directors and executive officers of the Registrant; (2) all positions and offices with the Registrant held by each such person; (3) any period during which he or she has served as such:

 

Name   Age   Position with the Company
Patrick Rooney   51   Chief Executive Officer and Chairman of the Board
Joseph Oliverio   44   President and Director
Jason Kitten   41   Executive Director of Radioisotopes
Corey Conn   51   Chief Financial Officer, Director
Sachio Okamura   63   Director
Dr. Anthony Nicholls   66   Director

 

Directors are elected annually and serve until the next annual meeting and until his successor has been elected and qualified, or until his earlier death, resignation or removal.

 

Patrick Rooney. Mr. Rooney has served as Chairman of the Company since July 26, 2004 and has served as Chief Executive Officer since 2009. Mr. Rooney serves on the Board of Directors of Neusoft Positron Medical Systems Co., Ltd., a joint venture with Neusoft Medical Systems of China that manufactures the Company's PET products. Since March 2003, Mr. Rooney has been the Managing Director of Solaris Management LLC. (“Solaris Management”). On November 18, 2011, the U.S. Securities and Exchange Commission commenced a civil action against Mr. Rooney and Solaris Management, LLC, the General Partner of Solaris Opportunity Fund L.P.(“Solaris”). The action alleges, among other things, Solaris’ investment concentration in Positron was a misuse of Solaris’ funds and that Rooney failed to sufficiently disclose his role in Positron to Solaris’ investors. On December 19, 2013, without admitting or denying the allegations in the complaint, Mr. Rooney entered into a Settlement Consent Judgment in the action and consented to an injunction from future violations certain provisions of the Investment Advisers Act of 1940, the Securities Act of 1933 and the Securities Exchange Act of 1934. Hearings on monetary damages, if any, and/or an officer or director and investment adviser bar are pending. Through 1985-2000, Patrick Rooney and/or Rooney Trading were members of The Chicago Board of Options Exchange, The Chicago Board of Trade and The Chicago Mercantile Exchange. The Company’s Officers and Directors concluded Mr. Rooney’s extensive experience in financing and background in early stage companies make him an ideal candidate to serve on the Board of Directors.

 

30
 

Joseph Oliverio. Mr. Oliverio joined Positron as President and member of the Board of Directors in 2005 and has served as Chief Technical Officer since 2009. Mr. Oliverio was reappointed to serve as Positron’s President in November of 2013. Mr. Oliverio served on the Board of Directors of Neusoft Positron Medical Systems Co., Ltd., a joint venture with Neusoft Medical Systems of China that manufactures the Company's PET products. Prior to joining Positron, Mr. Oliverio was the Chief Operating Officer of Michael E. Merhige, M.D., LLC, a renowned coronary disease reversal and prevention center. Mr. Oliverio earned an MBA from the University of Phoenix and a BS in Nuclear Medicine Technology from State University of New York at Buffalo, and is a certified nuclear medicine technologist. Mr. Oliverio has performed more than 13,000 combined heart and cancer PET scans using Positron devices and brings to the Company a valuable combination of business, clinical and technical skill sets. The Company’s Officers and Directors concluded Mr. Oliverio’s extensive clinical and technical PET experience and industry background make him an ideal candidate to serve on the Board of Directors.

 

Jason Kitten. Jason Kitten is the founder and President of Manhattan Isotope Technology, LLC (MIT), which he founded in 2009 and was acquired by Positron in January of 2012. Mr. Kitten was appointed by the Board of Directors to serve as the Company’s Executive Director of Radioisotopes. Prior thereto, Mr. Kitten worked at the Los Alamos National Laboratory from 1995 to 2010. Mr. Kitten holds a Master of Science degree in Radiopharmaceutical Science and has led projects in production of radioisotopes for medical, industrial, power, and military applications as well as Initiatives for Proliferation Prevention radioisotope projects abroad. The Company’s Officers and Board of Directors concluded Mr. Kitten’s experience and distinguished achievements in the radiopharmaceutical industry made him an ideal candidate to serve as Executive Director of Radioisotopes.

 

Corey Conn. Mr. Conn was appointed by the Board of Directors to serve as Chief Financial Officer in 2005 and was elected as a Director on January 2, 2008. Mr. Conn was Vice President of Business Development at iXL, an e-business and e-transformations services provider from June 1996 to September 1999 and also served as Managing Director of Virtual Partnerships, LLC, a business development and business strategy consulting firm from 1999 to 2004. Mr. Conn received a Bachelor’s Degree in Business Administration from Bradley University. The Company’s Officers and Directors concluded Mr. Conn’s extensive experience in financial compliance and operations in early stage companies make him an ideal candidate to serve on the Board of Directors.

 

Sachio Okamura. Mr. Okamura has served as a director since his appointment to the Board of the Company on April 1, 2001. Mr. Okamura has performed bio-medical consulting services for Okamura Associates, Inc. from 1993 through the present date. These consulting services have included regulatory, distribution, licensing, joint venture, investment, merger and acquisition activities involving businesses in the United States and Japan. Mr. Okamura was in charge of bio-medical business development for various offices of Mitsubishi Corporation from 1978 through 1993. Mr. Okamura received a BS in Biochemistry in 1975 from the University of California, Davis and a Master of International Business from the American Graduate School of International Management in 1978. The Company’s Officers and Directors concluded Mr. Okamura’s extensive experience within the medical industry makes him an ideal candidate to serve on the Board of Directors.

 

Dr. Anthony Nicholls. Dr. Nicholls has served as a director since 2005. Dr. Nicholls is an independent consultant with over 30 years’ experience in medical devices and diagnostics research. He has lectured in 45 countries of the world on subjects varying from the rapid diagnosis of Sepsis, Tuberculosis and Aids to vaccine production, environmental responsibility and entrepreneurship. He co-founded FAS Medical Ltd. in 1992, and as CEO, raised (CDN) $6 million, achieved a listing on CDNX and established sales of the company's products in 21 countries. He was employed as CEO of FAS Medical Ltd. from 1992 to 2003. Previously he was CEO of Trinity Biotech PLC and oversaw a successful IPO on NASDAQ. Earlier, Dr. Nicholls held senior management posts with Cambridge Biotech Corp. (Exec. VP), Biotech Research Labs Inc. (Pres. & COO), Fisher Scientific (Senior VP. & Gen. Manager), Ciba Corning Medical (Director, New Technology Development) and Flow General (International Scientific Director). Dr. Nicholls' academic career included seven years as Head of Microbiology and Immunology at the Midhurst Medical Research Institute in Sussex, England, where he published numerous papers on tuberculosis, pneumonia and sepsis. Dr. Nicholls is a graduate of the University of Birmingham School of Medical Sciences and has a Ph.D. in Immunology. The Company’s Officers and Directors concluded Mr. Nicholls extensive experience within the medical industry as a businessman and physician make him an ideal candidate to serve on the Board of Directors.

 

31
 

AUDIT COMMITTEE

 

Our Board of Directors has not established a separate audit committee within the meaning of Section 3(a)(58)(A) of the Securities Exchange Act of 1934, as amended (the “Exchange Act”). Instead the board of directors acts as the audit committee within the meaning of Section 3(a)(58)(B) of the Exchange Act. The Company intends on establishing an Audit Committee composed of independent directors of the Company. The audit committee's duties would be to recommend to the Company's board of directors the engagement of independent auditors to audit the Company's financial statements and to review its accounting and auditing principles. The audit committee would review the scope, timing and fees for the annual audit and the results of audit examinations performed by the internal auditors and independent public accountants, including their recommendations to improve the system of accounting and internal controls. The audit committee would at all times be composed exclusively of directors who are, in the opinion of the Company's board of directors, free from any relationship which would interfere with the exercise of independent judgment as a committee member and who possess an understanding of financial statements and generally accepted accounting principles.

 

COMPENSATION COMMITTEE

 

Our board of directors does not have a separate compensation committee responsible for determining executive and director compensation. Instead, the board of directors fulfills this function, and each member of the Board participates in the determination. Given the small size of the Company and its Board, plus the Company's limited resources, locating, obtaining and retaining additional independent directors is extremely difficult. In the absence of independent directors, the Board does not believe that creating a separate compensation committee would result in any improvement in the compensation determination process. Accordingly, the board of directors has concluded that the Company and its stockholders would be best served by having the entire board of director’s act in place of a compensation committee. When acting in this capacity, the Board does not have a charter.

 

CODE OF ETHICS

 

We have adopted a code of ethics meeting the requirements of Section 406 of the Sarbanes-Oxley Act of 2002. We believe our code of ethics is reasonably designed to deter wrongdoing and promote honest and ethical conduct; provide full, fair, accurate, timely and understandable disclosure in public reports; comply with applicable laws; ensure prompt internal reporting of violations; and provide accountability for adherence to the provisions of the code of ethic. Our code of ethics is filed as an exhibit to this Form 10-K.

 

Item 11. Executive Compensation

 

Summary Compensation Table

 

The following Summary Compensation Table shows certain compensation information for each of the Named Executive Officers. Compensation data is shown for the years ended December 31, 2013 and 2012. This information includes the dollar value of base salaries, bonus awards, the number of stock options granted, and certain other compensation, if any, whether paid or deferred.

 

Name and Principal Position  Year   Salary (a)   Bonus   Restricted
Stock Awards		   Option
Awards (b)		   Nonequity
incentive plan		   All other
compensation		   Total 
                                 
Patrick Rooney,   2013   $150,000   $-   $-   $191,931   $-   $-   $341,931 
Chief Executive Officer   2012   $138,640   $-   $-   $161,084   $-   $-   $299,724 
                                         
Joseph Oliverio,   2013   $156,000   $-   $-   $150,803   $-   $-   $306,803 
President   2012   $147,200   $-   $-   $161,084   $-   $-   $308,284 
                                         
Corey Conn,   2013   $150,000   $-   $-   $150,803   $-   $-   $300,803 
Chief Financial Officer   2012   $141,295   $-   $-   $161,084   $-   $-   $302,379 

 

32
 

 

                                         
Timothy Gabel, Vice                                        
President Engineering                                        
and Service (a)   2012   $36,801   $-   $-   $-   $-   $-   $36,801 
                                         
Scott Stiffler,                                        
General Manager of   2013   $58,000   $-   $-   $-   $-   $-   $58,000 
Pharmaceutical Automation (b)   2012   $117,031   $-   $-   $201,355   $-   $-   $318,386 
                                         
Charles Conroy                                        
Business Development   2013   $147,000   $-   $-   $-   $-   $-   $147,000 
    2012   $20,192   $-   $-   $98,057   $-   $-   $118,249 
                                         
Jason Kitten   2013   $148,000   $-   $-   $-   $-   $-   $148,000 
Executive Director of Radioisotopes   2012   $117,788   $-   $50,000   $20,136   $-   $27,500   $215,424 

 

(a) Mr. Gabel resigned effective December 31, 2012;

 

(b) Mr. Stiffler resigned effective June 6, 2013;

 

(c) Mr. Conroy resigned as COO effective November 12, 2013 and has continued with the Company in a Business Development capacity;

 

(d) For the year ending December 31, 2012, the Company granted employees options to purchase 177,600,000 shares of common stock at an exercise price of $0.01 per share. Fifty percent of the options vested immediately and the remaining fifty percent vested on January 17, 2013. The options expire on January 17, 2015. The Company granted 20,000,000 stock options to Joseph G. Oliverio, 20,000,000 stock options to Patrick Rooney, 20,000,000 stock options to Corey N. Conn, and 25,000,000 stock options to Scott Stiffler. For the year ending December 31, 2013 stock option awards relate to the extension of options to purchase Series B Preferred Shares. The options were originally scheduled to expire in December 2013 but were extended through December 2014 for current employees.

 

The following table sets forth for each named executive officer certain information concerning the outstanding equity awards as of December 31, 2013.

 

   Option awards   Stock awards 
Name and
Principal
Position		  Number of
Securities
Underlying
Unexercised
Options
Exercisable		   Number
of Securities
Underlying
Unexercised
Options
Unexercisable		   Option
Exercise
Price ($)		   Option
Expiration
Date		  Number
of Shares
or Units
of Stock
that Have
Not
Vested		   Market
Value of
Shares or
Units of
Stock
that Have
Not
Vested		   Equity
Incentive Plan
Awards:
Number of
Unearned
Shares, Units
or Other
Rights that
Have Not
Vested		   Equity Incentive
Plan Awards:
Market or Payout
Value of
Unearned Shares,
Units or Other
Rights that Have
Not Vested		 
Joseph Oliverio   550,000(1)   -   $1.00   12/31/14   -    -    -    - 
Joseph Oliverio   20,000,000    -   $0.01   01/17/15   -    -    -    - 
Patrick Rooney   700,000(1)   -   $1.00   12/31/14   -    -    -    - 
Patrick Rooney   20,000,000    -   $0.01   01/17/15   -    -    -    - 
Corey Conn   550,000(1)   -   $1.00   12/31/14   -    -    -    - 
Corey Conn   20,000,000    -   $0.01   01/17/15   -    -    -    - 
Scott Stiffler   25,000,000    -   $0.01   01/17/15   -    -    -    - 
Charles Conroy   20,000,000    -   $0.01   01/17/15   -    -    -    - 
Jason Kitten   2,500,000    -   $0.01   01/17/15   -    -    -    - 

 

  (1) - Options were granted for Series B preferred shares.

 

33
 

 

Equity Compensation Plan Information

 

The following table summarizes share and exercise information about the Company's equity compensation plans as of December 31, 2013.

 

Plan Category  Number of
Securities to be
Issued Upon
Exercise of
Outstanding
Options, Warrants
and Rights		   Weighted-Average
Exercise Price of
Outstanding Options,
Warrants and Rights		   Number of Securities
Remaining Available for
Future Issuance Under
Equity Compensation
Plans (excluding
securities included in
column 1)		 
             
Series B Preferred Stock Options   2,070,000   $1.00    - 
Common Stock   188,100,000    0.01    9,400,000 

 

 

SUMMARY OF EQUITY COMPENSATION PLANS

 

Equity-Based Compensation

 

Key Employee Incentive Compensation

 

The Company has an incentive compensation plan for certain key employees. The incentive compensation plan provides for annual bonus payments based upon achievement of certain corporate objectives as determined by the Company's Board of Directors. During 2013, the Company did not pay any bonus pursuant to the incentive compensation plan.

 

2009 Stock Incentive Plan

 

Positron's Board of Directors (the “Board”) administers the 2009 Stock Incentive Plan ("2009 Plan"), which was adopted by the Board effective September 22, 2009. The purpose of the 2009 Plan is to advance the interests of the Company’s stockholders by enhancing the Company’s ability to attract, retain and motivate persons who are expected to make important contributions to the Company and by providing such persons with equity ownership opportunities and performance-based incentives that are intended to better align their interests with those of the Company’s stockholders. The 2009 Plan provides for the direct issuance of Awards including stock options, restricted stock awards and unrestricted stock awards. All of the Company’s employees, officers and directors (including persons who have entered into an agreement with the Company under which they will be employed by the Company in the future), as well as all of the Company’s consultants and advisors that are natural persons, are eligible to the awards under the 2009 Plan. The administrator is authorized to determine the terms of each award granted under the plan, including the number of shares, exercise price, term and exercisability. Stock and options may be granted for services rendered or to be rendered. A total of 100,000 shares of Common Stock have been authorized for issuance under the 2009 Plan. During 2012, 86,000 shares total had been issued under the 2009 Plan. As of December 31, 2013, no shares had been issued under the 2009 Plan.

 

2010 Equity Incentive Plan

 

Positron's Board of Directors (the “Board”) administers the 2010 Equity Incentive Plan ("2010 Plan"), which was adopted by the Board effective March 25, 2010. The purpose of the 2010 Plan is to advance the interests of the Company’s stockholders by enhancing the Company’s ability to attract, retain and motivate persons who are expected to make important contributions to the Company and by providing such persons with equity ownership opportunities and performance-based incentives that are intended to better align their interests with those of the Company’s stockholders. The 2010 Plan provides for the direct issuance of Awards including stock options, restricted stock awards and unrestricted stock awards. All of the Company’s employees, officers and directors (including persons who have entered into an agreement with the Company under which they will be employed by the Company in the future), as well as all of the Company’s consultants and advisors that are natural persons, are eligible to the awards under the 2010 Plan. The administrator is authorized to determine the terms of each award granted under the plan, including the number of shares, exercise price, term and exercisability. Stock and options may be granted for services rendered or to be rendered. A total of 500,000 shares of Common Stock have been authorized for issuance under the 2010 Plan. As of December 31, 2012, 400,000 shares in total had been issued under the 2010 Plan.

 

34
 

2012 Equity Incentive Plan

 

On January 17, 2012, Positron's Board of Directors (the “Board”) adopted the 2012 Equity Incentive Plan ("2012 Plan"). The plan authorizes issuance a total of 2,000,000 options to purchase common stock shares. The purpose of the 2012 Plan is to advance the interests of the Company’s stockholders by enhancing the Company’s ability to attract, retain and motivate persons who are expected to make important contributions to the Company and by providing such persons with equity ownership opportunities and performance-based incentives that are intended to better align their interests with those of the Company’s stockholders. The 2012 Plan provides for the direct issuance of Awards including stock options, restricted stock awards and unrestricted stock awards. All of the Company’s employees, officers and directors (including persons who have entered into an agreement with the Company under which they will be employed by the Company in the future), as well as all of the Company’s consultants and advisors that are natural persons, are eligible to the awards under the 2012 Plan. The administrator is authorized to determine the terms of each award granted under the plan, including the number of shares, exercise price, term and exercisability. Stock and options may be granted for services rendered or to be rendered. A total of 200,000,000 shares of Common Stock have been authorized for issuance under the 2012 Plan. On January 17, 2012, the Company granted certain employees options to purchase 177,600,000 shares of common stock under the 2012 Plan at an exercise price of $0.01 per share. During 2012, 7,000,000 of these options were forfeited. On November 5, 2012, the Company granted additional options to purchase 2,000,000 shares of common stock to a new employee at an exercise price of $0.01 per share. Fifty percent of the January and November 2012 option grants vested immediately on the grant date and the remaining fifty percent vested on January 17, 2013. All the options issued under the plan expire on January 17, 2015. As of December 31, 2013, the Company had a total of 188,100,000 options outstanding.

 

401(k) Savings Plan

 

The Company has a 401(k) Retirement Plan and Trust (the "401(k) Plan") which became effective as of January 1, 1989. Employees of the Company who have completed one-quarter year of service and have attained age 21 are eligible to participate in the 401(k) Plan. Subject to certain statutory limitations, a participant may elect to have his or her compensation reduced by up to 20% and have the Company contribute such amounts to the 401(k) Plan on his or her behalf ("Deferral Contributions"). The Company may make discretionary contributions in an amount up to 25% of the participant's Deferral Contributions up to 6% of his/her compensation ("Employer Contributions"). Additionally, the Company may make such additional contributions, as it shall determine each year in its discretion. All Deferral and Employer Contributions made on behalf of a participant are allocated to his/her individual accounts and such participant is permitted to direct the investment of such accounts.

 

A participant is fully vested in the current value of that portion of his/her accounts attributable to Deferral Contributions. A participant's interest in that portion of his/her accounts attributable to Employer Contributions is generally fully vested after five years of employment. Distributions under the 401(k) Plan are made upon termination of employment, retirement, disability and death. In addition, participants may make withdrawals in the event of severe hardship or after the participant attains age fifty-nine and one-half. The 401(k) Plan is intended to qualify under Section 401 of the Internal Revenue Code of 1986, so that contributions made under the 401(k) Plan, and income earned on contributions, are not taxable to participants until withdrawal from the 401(k) Plan.

 

Policy with Respect to $1 Million Deduction Limit

 

It is the Company's policy, where practical, to avail itself of all proper deductions under the Internal Revenue Code. Amendments to the Internal Revenue in 1993, limit, in certain circumstances, the deductibility of compensation in excess of $1 million paid to each of the five highest paid executives in one year. The total compensation of the executive officers did not exceed this deduction limitation in 2012 or 2011.

 

35
 

Compensation of Directors

 

Directors who are also employees of the Company receive no fees for services provided in that capacity, but are reimbursed for out-of-pocket expenses incurred in connection with attendance at meetings of the Board of Directors and its committees.

 

Non-Employee Director Compensation

 

During the year ended December 31, 2013 and 2012, our Non-Employee Directors received no compensation from the Company. Non-Employee Directors continue to be reimbursed for their reasonable expenses associated with attending board and committee meetings.

 

Item 12. Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters

 

The following table sets forth certain information, as of December 31, 2013 with respect to any person (including any "group", as that term is used in Section 13(d)(3) of the Securities Exchange Act of 1934, as amended (the "Exchange Act") who is known to the Company to be the beneficial owner of more than five percent of any class of the Company's voting securities, and as to those shares of the Company's equity securities beneficially owned by each its directors, the executive officers of the Company and all of its directors and executive officers of the Company and all of its directors and executive officers as a group. Unless otherwise specified in the table below, such information, other than information with respect to the directors and officers of the Company, is based on a review of statements filed, with the Securities and Exchange commission (the "Commission") pursuant to Sections 13 (d), 13 (f), and 13 (g) of the Exchange Act with respect to the Company's Common Stock.

 

Name of Beneficial Owner       Title of Class      Beneficial
Ownership (a)		   Number of Shares
Subject to Options,
Warrants and
Convertible Preferred
Stock Exercisable		     Percent of
Class (b)		  
Solaris Opportunity Fund, L.P.   (c)   Common     3,300,000   0           40.9 %  
        Series S Preferred     100,000   1,000,000,000                
Imagin Diagnostic Centres, Inc.   (d)   Common     750,000   0           15.3 %  
        Series B Preferred     2,622,502   262,250,200                
Joseph Oliverio   (e)   Common     0   75,000,000           4.9 %  
Patrick Rooney   (f)   Common     48,181,818   1,213,981,818           47.9 %  
        Series H Preferred     10,000,000   187,500,000                
Corey Conn   (g)   Common     0   85,500,000           7.7 %  
        Series H Preferred     2,500,000   62,500,000                
Sachio Okamura   (h)   Common     0   2,500,000           *    
Dr. Anthony Nicholls   (i)   Common     0   1,500,000           *    
Jason Kitten   (j)   Common     5,000,000   7,500,000           *    
All Directors and Executive Officers as a Group       Common     60,681,818   1,740,663,636           56.5 %  
                                       

 

* Does not exceed 1% of the referenced class of securities.

36
 

 

 

(a) Security ownership is direct unless indicated otherwise. Security ownership information for beneficial owners is taken from statements filed with the Securities and Exchange Commission pursuant to Sections 13(d), 13(g) and 16(a) and/or information made known to the Company.

 

(b) For each shareholder, the calculation of beneficial ownership is based upon 1,451,927,262 shares of Common Stock outstanding as of September 19, 2013 and shares of Common Stock subject to options, warrants and/or conversion rights held by the shareholder that are currently exercisable or exercisable within 60 days, which are deemed to be outstanding and to be beneficially owned by the shareholder holding such options, warrants, or conversion rights. Each share of Series A Preferred Stock converts into one fully paid and non-assessable shares of Common Stock. Each share of Series B Convertible Preferred Stock converts into one hundred (100) shares of Common Stock. Each share of Series H Junior Convertible Preferred Stock Converts into a number of shares of Common Stock equal to the number of shares of Series H Preferred Stock being converted multiplied by $0.10 and divided by the volume weighted average price for the three trading days prior to conversion multiplied by .70. Each share of the Series S Convertible Preferred Stock converts into the number of Series S Preferred shares converted multiplied by Ten Thousand (10,000).

 

(c) Includes 3,300,000 Common shares owned directly and 1,000,000,000 shares issuable upon full conversion of 100,000 shares of Series S Preferred Stock. The address for Solaris Opportunity Fund, L.P. is 3801 N. Washington St. Oak Brook, Illinois 60523. Patrick Rooney holds voting and dispositive power for Solaris Opportunity Fund, L.P.

 

(d) Includes 750,000 shares owned directly, and 262,250,200 shares issuable upon full conversion of 2,622,502 shares of Series B Preferred Stock. The address for Imagin Diagnostic Centres, Inc. (“IDC”) is 3014 - 610 Granville St., Vancouver, British Columbia, V6C 3T3, Canada. The Company believes Gregory Pappas, Chief Executive Officer, holds voting and dispositive power for IDC.

 

(e) Includes 55,000,000 shares of Common Stock issuable upon full conversion of 550,000 Series B shares that may be acquired by Mr. Oliverio pursuant to stock options that are exercisable until December 31, 2013 and 20,000,000 shares of Common Stock options pursuant to 2012 Equity Incentive Plan that are exercisable until January 17, 2015.

 

(f) Includes 70,000,000 shares of Common Stock issuable upon full conversion of 700,000 Series B shares that may be acquired by Mr. Rooney pursuant to options that are exercisable until December 31, 2013, warrants to purchase 72,500,000 shares of Common Stock at the exercise price of $.01 which expire on December 31, 2013, and 20,000,000 shares of Common Stock options pursuant to 2012 Equity Incentive Plan that are exercisable until January 17, 2015. Also assumes conversion of 10,000,000 shares of Series H Preferred Stock held by Mr. Rooney at the conversion price of $.004 per share. Also includes 1,003,300,000 shares of Common Stock held by or convertible to by Solaris Opportunity fund, L.P. (“Solaris”), over which Mr. Rooney holds voting and dispositive power. Mr. Rooney disavows beneficial ownership over any securities held by Solaris.

 

(g) Includes 55,000,000 shares of Common Stock issuable upon full conversion of 550,000 Series B shares that may be acquired by Mr. Conn pursuant to stock options that are exercisable until December 31, 2013, warrants to purchase 10,500,000 shares of Common Stock at the exercise price of $.01 which expire on December 31, 2013, and 20,000,000 shares of Common Stock options pursuant to 2012 Equity Incentive Plan that are exercisable until January 17, 2015. Also assumes the conversion of 2,500,000 shares of Series H Preferred Stock held by Mr. Conn at the conversion price of $.004 per share.

 

(h) Includes 2,500,000 shares of Common Stock issuable upon full conversion of 25,000 Series B shares that may be acquired by Mr. Okamura pursuant to stock options that are exercisable until December 31, 2013.

 

(i) Includes 1,500,000 shares of Common Stock issuable upon full conversion of 15,000 Series B shares that may be acquired by Dr. Nicholls pursuant to stock options that are exercisable until December 31, 2013.

 

(j) Includes 2,500,000 shares of Common Stock that may be acquired by Mr. Kitten pursuant to stock options that are exercisable until January 17, 2015.

 

The address for all officers and directors of the Company is 530 Oakmont Lane, Westmont, IL 60559.

 

37
 

SECTION 16(a) BENEFICIAL OWNERSHIP REPORTING COMPLIANCE

 

Section 16(a) of the Exchange Act requires the Company’s officers and directors, and persons who own more than ten percent of a registered class of the Company’s equity securities, to file reports of securities ownership and changes in such ownership with the SEC. Officers, directors and greater than ten percent shareholders also are required by rules promulgated by the SEC to furnish the Company with copies of all Section 16(a) forms they file.

 

Imagin Diagnostic Centres, Inc., a ten percent shareholder of the Company, has failed to file reports on Form 3 and Form 4 covering the acquisition and status to it for the periods of January 1, 2004 through the filing of this report.

 

The address for all officers and directors of the Company is 530 Oakmont Lane, Westmont, IL 60559.

 

Item 13. Certain Relationships and Related Transactions and Director Independence

 

During the fiscal year ending December 31, 2013, the Company accepted the following advances, without interest from related parties: on January 31, 2013 the Company accepted a $250,000 advance from its CEO; on February 27, 2013 the Company accepted a $250,000 advance from its CFO; on March 25, 2013 the Company accepted a $100,000 advance from its CEO; in June 2013 the Company accepted a $185,000 advance from its CEO; on April 4, 2013 the Company accepted a $150,000 advance from its CFO; on May 22, 2013 the Company accepted a $150,000 advance from its CFO; on June 21, 2013 the Company accepted a $100,000 advance from its CFO; on August 16, 2013 the Company accepted a $250,000 advance from its CFO; on August 26, 2013 the Company accepted a $250,000 advance from its CEO and on November 2, 2013 the Company accepted a $100,000 advance from its CEO.

 

On April 11, 2013, the Company converted certain advances from its CEO and CFO in the amounts of $500,000 and $ 250,000, respectively, into 5,000,000 and 2,500,000 shares of the Company’s Series H Preferred Stock, respectively.

 

On November 7, 2013, the Company converted certain advances from its CEO in the amount of $500,000, into 5,000,000 shares of the Company’s Series H Preferred Stock.

 

During 2013, the Company paid $201,000 in deposits to its joint venture partner, Neusoft, for Attrius® Systems.

  

During the years ended December 31, 2013 and 2012, the Company recognized cost of revenues of approximately $0 and $623,000, respectively, related to the purchase of Attrius® PET systems from Neusoft Positron Medical Systems (“Neusoft”) – the Company’s joint venture partner located in Shenyang, China.

 

During the twelve months ended December 31, 2012, the Company borrowed from the CEO additional $40,000. All the advances, totaling $60,000, were repaid during 2012 and as of December 31, 2012, the Company did not have an amount due to the Chief Executive Officer.

 

On January 12, 2012, the Company acquired a building in Westmont, Illinois, which the Company previously leased from its Chief Executive Officer, Patrick Rooney (CEO or Lender) for corporate and administrative offices since 2010. The Company issued the Chief Executive Officer 250,000 shares of common stock, which were valued at approximately $250,000 and a convertible debenture of $25,000,000, which shall be due on December 31, 2013 and bear interest at 8% per year payable quarterly in cash. In addition, the Company issued 35,000,000 warrants, which entitle the Lender to purchase shares of the Company’s common stock, par value $0.01 per share, at an exercise price of $0.01 per share and expiring on December 31, 2013. The Lender is entitled to convert the accrued interest and principal of the convertible debentures into common stock of the Company at a conversion price equal to 55% of the lowest daily volume weighted average price for the three trading days preceding conversion. During the twelve months ended December 31, 2012, the Company converted $100,000 of the principal amount of these Convertible Debentures into 18,181,818 shares of Common Stock.

 

During the year ended December 31, 2012, the Company issued additional convertible debt to its Chief Executive Officer in the amount of $1,320,000. The debt is noninterest bearing and matures on December 31, 2013. In connection with the this debt, the Company issued warrants to purchase 37,500,000 shares of the Company’s Common Stock, at an exercise price of $0.01 per share expiring on December 31, 2013. The lender is entitled to convert the accrued interest and principal of the convertible debentures into common stock of the Company at a conversion price equal to 55% of the lowest daily volume weighted average price for the three trading days preceding conversion.

 

In September and December 2012, the Company issued two non-interest bearing convertible debentures totaling $380,000 to Corey Conn, the Company’s Chief Financial Officer (CFO or Lender). In connection with the this debt, the Company issued warrants (“Warrants”) to purchase 10,500,000 shares of the Company’s Common Stock, at an exercise price of $0.01 per share expiring on December 31, 2013. The Lender is entitled to convert the accrued interest and principal of the Convertible Debentures into common stock of the Company at a conversion price equal to 55% of the lowest daily volume weighted average price for the three trading days preceding conversion. These debentures are noninterest bearing.

 

Director Independence

 

We currently use NASDAQ’s general definition for determining director independence, which states that “independent director” means a person other than an officer or employee of the company or its subsidiaries or any other individual having a relationship, that, in the opinion of the company’s Board of Directors, would interfere with the exercise of independent judgment in carrying out the responsibilities of the director.

 

The Board has determined that two of our five current directors, Sachio Okamura and Dr. Anthony C. Nicholls meet this definition of independence.

 

38
 

Item 14. Principal Accountant Fees and Services

 

The following table shows the fees billed to the Company for the audits and other services provided by Sassetti LLC, its independent registered public accounting firm for the year ended December 31:

 

   2013   2012 
         
Audit fees (1)  $79,835   $78,945 
Audit-related fees (2)   -    5,200 
Tax fees (3)   13,685    10,940 
All other fees (4)   -    - 
           
   $93,520   $95,085 

 

  (1) Audit fees consist of fees billed for professional services rendered for the audit of the Registrant's annual financial statements and review of the interim consolidated financial statements included in quarterly reports and services that are normally provided in connection with statutory and regulatory filings or engagements.

 

  (2) Audit-Related fees in 2012 consist of fees billed for due diligence and audit procedures related to the acquisition of MIT, including testing of beginning balances.

 

  (3) Tax fees consist of fees billed for professional services rendered for tax compliance, tax advice and tax planning (domestic and international). These services include assistance regarding federal, state and international tax compliance, acquisitions and tax planning.

 

  (4) Other fees consist of review of regulatory compliance.

 

The Board of Directors has considered the role of Sassetti LLC in providing certain tax services to Positron and has concluded that such services are compatible with Sassetti LLC’s independence as our auditors. In addition, the Board of Directors has approved providing certain tax services since the effective date of the SEC rules. The rule states that an auditor is not independent of an audit client if the services it provides to the client are not appropriately approved. The Board of Directors will continue to pre-approve all audit and permissible non-audit services provided by the independent auditors until an audit committee is formed which will then be responsible for approving audit fees. We are looking for new board members that would be qualified to serve on an audit committee.

 

The Board of Directors has adopted a policy for the pre-approval of services provided by the independent auditors, pursuant to which it may pre-approve any service consistent with applicable law, rules and regulations. Under the policy, the Board of Directors may also delegate authority to pre-approve certain specified audit or permissible non-audit services to one or more of its members, including the Chairman. A member to whom pre-approval authority has been delegated must report its preapproval decisions, if any, to the Board of Directors at its next meeting, and any such pre-approvals must specify clearly in writing the services and fees approved.

Unless the Board of Directors determines otherwise, the term for any service pre-approved by a member to whom pre-approval authority has been delegated is twelve months.

 

Item 15. Exhibits

 

2.1 Securities Exchange Agreement with Solaris Opportunity Fund, L.P. and Imagin Molecular Corporation, dated November 17, 2008 (incorporated herein by reference to Exhibit 2.1 of the Company’s Quarterly Report on Form 10-Q for the quarter ending September 30, 2008 filed on November 19, 2008 (File No. 000-24092).

 

39
 

 

3.1 Articles of Incorporation of the Registrant (incorporated herein by reference to Exhibit 3.1 to the Company’s Registration Statement on Form SB-2 (File No.33-68722)).

 

3.2 By-laws of the Registrant, as amended (incorporated herein by reference to Exhibit 3.2 to the Company’s Registration Statement on Form SB-2 (File No. 33-68722)).

 

4.1 Specimen Stock Certificate (incorporated herein by reference to Exhibit 4.1 of the Company’s Annual Report on Form 10-KSB for the year ended December 31, 1994).

 

4.2 Statement of Designation Establishing Series A 8% Cumulative Convertible Redeemable Preferred Stock of Positron Corporation, dated February 28, 1996 (incorporated herein by reference to Exhibit 4.3 of the Company’s Annual Report on Form 10-KSB for the year ended December 31, 1995).

 

4.3 Warrant Agreement dated as of June 15, 1999 between Positron Corporation and Gary Brooks (incorporated herein by reference to Exhibit 4.9 to the Company's Registration Statement on Form SB-2 (File No. 333-30316)).

  

4.4 Stock Purchase Warrant dated as of June 15, 1999 issued by Positron Corporation to Gary H. Brooks (incorporated herein by reference to Exhibit 4.10 to the Company's Registration Statement on Form SB-2 (File No. 333-30316)).

 

4.5 Warrant Agreement dated as of June 15, 1999 between Positron Corporation and S. Lewis Meyer (incorporated herein by reference to Exhibit 4.11 to the Company's Registration Statement on Form SB-2 (File No. 333-30316)).

 

4.6 Stock Purchase Warrant dated as of June 15, 1999 issued by Positron Corporation to S. Lewis Meyer (incorporated herein by reference to Exhibit 4.12 to the Company's Registration Statement on Form SB-2 (File No. 333-30316)).

 

4.7 Statement of Designation Establishing Series B Preferred Stock of Positron Corporation dated September 30, 2006 (incorporated by reference to Exhibit 4.7 to the Company’s Annual Report on Form 10-K/A filed on March 4, 2012).

 

4.8 Statement of Designation Establishing Series C Preferred Stock of Positron Corporation dated May 21, 2004 (incorporated by reference to Exhibit 4.1 to the Company's Report on Form 8-K dated May 21, 2004).

 

4.9 Statement of Designation Establishing Series D Preferred Stock of Positron Corporation dated May 21, 2004 (incorporated by reference to Exhibit 4.2 to the Company's Report on Form 8-K dated May 21, 2004).

 

4.10 Statement of Designation Establishing Series E Preferred Stock of Positron Corporation dated February 28, 2005 (incorporated by reference to Exhibit 4.18 to the Company's Annual Report on Form 10-KSB dated April 19, 2005).

 

4.11 Statement of Designation Establishing Series F Preferred Stock of Positron Corporation (incorporated herein by reference to Exhibit 4.1 to the Company’s Current Report on Form 8-K dated June 27, 2005).

 

4.12 Statement of Designation Establishing Series S Convertible Redeemable Preferred Stock of Positron Corporation, dated November 7, 2008 (incorporated herein by reference to Exhibit 2.1 of the Company’s Quarterly Report on Form 10-Q for the quarter ending September 30, 2008 filed on November 19, 2008 (File No. 000-24092)).

 

4.13 2007 Omnibus Securities and Incentive Plan (incorporated by reference to Exhibit 4.13 to the Company’s Annual Report on Form 10-K/A filed on March 4, 2012).

 

40
 

 

4.14 Amended to the Statement of Designation Establishing Series H Junior Convertible Preferred Stock (incorporated herein by reference to Exhibit 4.01 to the Company’s Current Report on Form 8-K filed December 27, 2013).

 

10.1 Lease Agreement dated as of July 1, 1991, by and between Lincoln National Pension Insurance Company and Positron Corporation (incorporated herein by reference to Exhibit 10.1 to the Company’s Registration Statement on Form SB-2 (File No. 33-68722)).

 

10.2 Agreement dated as of March 1, 1993, by and between Positron Corporation and Oxford Instruments (UK) Limited (incorporated herein by reference to Exhibit 10.2 to the Company’s Registration Statement on Form SB-2 (File No. 33-68722)).

 

10.3 International Distribution Agreement dated as of November 1, 1992, by and between Positron Corporation and Batec International, Inc. (incorporated herein by reference to Exhibit 10.3 to the Company’s Registration Statement on Form SB-2 (File No. 33-68722)).

 

10.4† 1994 Incentive and Nonstatutory Option Plan (incorporated herein by reference to Exhibit A to Company’s Proxy Statement dated May 2, 1994).†

 

10.5 Amended and Restated 1987 Stock Option Plan (incorporated herein by reference to Exhibit 10.5 to the Company’s Registration Statement on Form SB-2 (File No. 33-68722)).†

 

10.6 Retirement Plan and Trust (incorporated herein by reference to Exhibit 10.6 to the Company’s Registration Statement on Form SB-2 (File No. 33-68722)).†

 

10.7 Amended and Restated License Agreement dated as of June 30, 1987, by and among The Clayton Foundation for Research, Positron Corporation, K. Lance Gould, M.D., and Nizar A. Mullani (incorporated herein by reference to Exhibit 10.7 to the Company’s Registration Statement on Form SB-2 (File No. 33-68722)).

 

10.8 Clarification Agreement to Exhibit 10.7 (incorporated herein by reference to Exhibit 10.8 to the Company’s Registration Statement on Form SB-2 (File No. 33-68722)).

 

10.9 Royalty Assignment dated as of December 22, 1988, by and between K. Lance Gould and Positron Corporation (incorporated herein by reference to Exhibit 10.10 to the Company’s Registration Statement on Form SB-2 (File No. 33-68722)).

 

10.10 Royalty Assignment dated as of December 22, 1988, by and between Nizar A. Mullani and Positron Corporation (incorporated herein by reference to Exhibit 10.11 to the Company’s Registration Statement on Form SB-2 (File No. 33-68722)).

  

10.11 Royalty Assignment dated as of December 22, 1988, by and between The Clayton Foundation and Positron Corporation (incorporated herein by reference to Exhibit 10.12 to the Company’s Registration Statement on Form SB-2 (File No. 33-68722)).

 

10.12 Consulting Agreement dated as of January 15, 1993, by and between Positron Corporation and K. Lance Gould, M.D. (incorporated herein by reference to Exhibit 10.24 to the Company’s Registration Statement on Form SB-2 (File No. 33-68722)).

 

10.13 Consulting Agreement dated February 23, 1995, effective December 15, 1994, by and between Positron Corporation and F. David Rollo, M.D. Ph.D., FACNP.

 

10.14 Consulting Agreement dated as of January 15, 1993, by and between Positron Corporation and Nizar A. Mullani (incorporated herein by reference to Exhibit 10.31 to the Company’s Registration Statement on Form SB-2 (File No. 33-68722)).

 

10.15 Consulting Agreement dated as of November 12, 1993, by and between Positron Corporation and OmniMed Corporation (incorporated herein by reference to Exhibit 10.35 to the Company’s Registration Statement on Form SB-2 (File No. 33-68722)).

 

41
 

 

10.16 Contract No. 1318 dated as of December 30, 1991, by and between Positron Corporation and The University of Texas Health Science Center at Houston (incorporated herein by reference to Exhibit 10.39 to the Company’s Registration Statement on Form SB-2 (File No. 33-68722)).

 

10.17 Letter Agreement dated July 30, 1993 between Positron Corporation and Howard Baker (incorporated herein by reference to Exhibit 10.52 to the Company’s Registration Statement on Form SB-2 (File No. 33-68722)).

 

10.18 Technology Transfer Agreement dated as of September 17, 1990, by and between Positron Corporation and Clayton Foundation for Research (incorporated herein by reference to Exhibit 10.54 to the Company’s Registration Statement on Form SB-2 (File No. 33-68722)).

 

10.19 Form of Amended and Restated Registration Rights Agreement dated as of November 3, 1993, by and among Positron and the other signatories thereto (1993 Private Placement) (incorporated herein by reference to Exhibit 10.73 to the Company’s Registration Statement on Form SB-2 (File No. 33-68722).

 

10.20 Registration Rights Agreement dated as of July 31, 1993, by and among Positron and the other signatories thereto (other than the 1993 Private Placement) (incorporated herein by reference to Exhibit 10.74 to the Company’s Registration Statement on Form SB-2 (File No. 33-68722)).

 

10.21 Software Licenses dated as of March 1, 1993, by and between Positron Corporation and Oxford Instruments (UK) Limited (incorporated herein by reference to Exhibit 10.81 to the Company’s Registration Statement on Form SB-2 (File No. 33-68722)).

 

10.22 Distribution Agreement dated as of June 1, 1993, by and between Positron Corporation and Elscint, Ltd. (incorporated herein by reference to Exhibit 10.82 to the Company’s Registration Statement on Form SB-2 (File No. 33-68722)).

 

10.23 First Amendment to Amended and Restated Registration Rights Agreement, dated as of November 19, 1993, by and among Positron Corporation and the other signatories thereto (incorporated herein by reference to Exhibit 10.91 to the Company’s Registration Statement on Form SB-2 (File No. 33-68722)).

 

10.24 Agreement made and entered into as of October 31, 1993, by and between Positron Corporation and Nizar A. Mullani (incorporated herein by reference to Exhibit 10.97 to the Company’s Registration Statement on Form SB-2 (File No. 33-68722)).

 

10.25 Agreement made and entered into as of October 31, 1993, by and between Positron Corporation and K. Lance Gould (incorporated herein by reference to Exhibit 10.98 to the Company’s Registration Statement on Form SB-2 (File No. 33-68722)).

 

10.26 Agreement made and entered into as of November 15, 1993, by and between Positron Corporation and Nizar A. Mullani (incorporated herein by reference to Exhibit 10.100 to the Company’s Registration Statement on Form SB-2 (File No. 33-68722)).

 

10.27 Agreement made and entered into as of November 15, 1993, by and between Positron Corporation and K. Lance Gould (incorporated herein by reference to Exhibit 10.101 to the Company’s Registration Statement on Form SB-2 (File No. 33-68722)).

 

10.28 First Amendment made and entered as of January 25, 1994, by and between Emory University d/b/a Crawford Long Hospital and Positron Corporation (incorporated herein by reference to Exhibit 10.102 of the Company’s Annual Report on Form 10-KSB for the year ended December 31, 1993).

 

10.29 Acquisition Agreement between General Electric Company and Positron Corporation dated July 15, 1996 (incorporated by reference to Exhibit 10.56 to the Company’s Report on Form 10-KSB for the year ended December 31, 1996).

 

42
 

 

10.30 Sales and Marketing Agreement With Beijing Chang Feng Medical (incorporated by reference to Exhibit 10.58 to the Company’s Report on Form 10-KSB/A for the year ended December 31, 1996).

 

 

10.31 Stock Purchase Agreement between Positron Corporation and Imatron, Inc. (incorporated hereby by reference to Annex A to the Company’s Proxy Statement dated December 18, 1998).

 

10.32 Agreement and Release dated as of November 30, 1999 by and among Positron Corporation, K. Lance Gould and University of Texas Medical Center (incorporated herein by reference to Exhibit 10.62 to the Company's Registration Statement on Form SB-2 (File No. 333-30316)).

 

10.33 1999 Stock Option Plan (incorporated herein by reference to Exhibit 10.63 to the Company's Registration Statement on Form SB-2 (File No. 333-30316)).†

 

  10.34 1999 Non-Employee Directors' Stock Option Plan (incorporated herein by reference to Exhibit 10.64 to the Company's Registration Statement on Form SB-2 (File No. 333-30316)).†

 

10.35 1999 Stock Bonus Incentive Plan (incorporated herein by reference to Exhibit 10.65 to the Company's Registration Statement on Form SB-2 (File No. 333-30316)).†

 

  10.36 1999 Employee Stock Purchase Plan (incorporated herein by reference to Exhibit 10.66 to the Company's Registration Statement on Form SB-2 (File No. 333-30316)).†

 

10.37 Stock Purchase Warrant dated September 1, 1999 issued by Positron to S. Okamura and Associates, Inc. (incorporated herein by reference to Exhibit 10.67 to the Company's Registration Statement on Form SB-2 (File No. 333-30316)).

 

10.38 Stock Purchase Warrant dated August 18, 1999 issued by Positron to Morris Holdings Ltd. (incorporated herein by reference to Exhibit 10.68 to the Company's Registration Statement on Form SB-2 (File No. 333-30316)).

 

10.39 Stock Purchase Warrant dated January 20, 2000 issued by Positron to Vistula Finance Limited (incorporated herein by reference to Exhibit 10.69 to the Company's Registration Statement on Form SB-2 (File No. 333-30316)).

 

10.40 Loan Agreement with Imatron Inc dated June 29, 2001 (incorporation herein by reference to the Company’s Report on Form 8-K dated July 12, 2001).

 

10.41 Technology Purchase Agreement, dated as of June 29, 2003, by and between General Electric Company and Positron Corporation (incorporated by reference to Exhibit 10.1 to the Company's Current Report on Form 8-K filed on July 14, 2003).

 

10.42 Software License Agreement, dated as of June 29, 2003, by and between General Electric Company and Positron Corporation (incorporated by reference to Exhibit 10.2 to the Company's Current Report on Form 8-K filed on July 14, 2003).

 

10.43 Agreement for Services, dated as of June 29, 2003, by and between General Electric Company and Positron Corporation (incorporated by reference to Exhibit 10.3 to the Company's Current Report on Form 8-K filed on July 14, 2003).

 

10.44 Note Purchase Agreement dated May 21, 2004 between Positron and IMAGIN Diagnostic Centres, Inc. (incorporated by reference to Exhibit 10.1 to the Company's Report on Form 8-K dated May 21, 2004).

 

43
 

10.45 Secured Convertible Promissory Note dated May 21, 2004 in the principal amount of $400,000 (incorporated by reference to Exhibit 10.2 to the Company's Report on Form 8-K dated May 21, 2004).

 

10.46 Form Secured Convertible Promissory Note in the principal amount of $300,000 (incorporated by reference to Exhibit 10.3 to the Company's Report on Form 8-K dated May 21, 2004).

 

10.47 Security Agreement dated May 21, 2004 between Positron and IMAGIN Diagnostic Centres, Inc. (entered into in connection with Note Purchase Agreement) (incorporated by reference to Exhibit 10.4 to the Company's Report on Form 8-K dated May 21, 2004).

 

10.48 Loan Agreement dated May 21, 2004 between Positron and IMAGIN Diagnostic Centres, Inc. (incorporated by reference to Exhibit 10.5 to the Company's Report on Form 8-K dated May 21, 2004).

 

10.49 Security Agreement dated May 21, 2004 between Positron and IMAGIN Diagnostic Centres, Inc. (entered into in connection with Loan Agreement) (incorporated by reference to Exhibit 10.7 to the Company's Report on Form 8-K dated May 21, 2004).

 

10.50 Voting Agreement dated May 21, 2004 between Positron and IMAGIN Diagnostic Centres, Inc. (incorporated by reference to Exhibit 10.8 to the Company's Report on Form 8-K dated May 21, 2004).

 

10.51 Registration Rights Agreement dated May 21, 2004 between Positron and IMAGIN Diagnostic Centres, Inc. (incorporated by reference to Exhibit 10.9 to the Company's Report on Form 8-K dated May 21, 2004).

 

10.52 Note Purchase Agreement dated February 28, 2005 between Positron and Solaris Opportunity Fund, L.P. (incorporated by reference to Exhibit 10.83 to the Company's Annual Report on Form 10-KSB/A for the fiscal year ended December 31, 2005).

 

10.53 Secured Convertible Promissory Note dated March 7, 2005 in the principal amount of $200,000 in favor of Solaris Opportunity Fund, L.P. (incorporated by reference to Exhibit 10.84 to the Company's Annual Report on Form 10-KSB/A for the fiscal year ended December 31, 2005).

 

10.54 Security Agreement dated February 28, 2005 between Positron and Solaris Opportunity Fund, L.P. (incorporated by reference to Exhibit 10.85 to the Company's Annual Report on Form 10-KSB/A for the fiscal year ended December 31, 2005).

 

10.55 Registration Rights Agreement dated February 28, 2005 between Positron and Solaris Opportunity Fund, L.P. (incorporated by reference to Exhibit 10.86 to the Company's Annual Report on Form 10-KSB/A for the fiscal year ended December 31, 2005).

 

10.56 Warrant Purchase Agreement by and among Positron Corporation, Carlos Sao Paulo, Sofia Salema Garcao, Maria Madalena Pimental and José Maria Salema Garçăo dated May 12, 2005 (incorporated by reference to Exhibit 10.1 to the Company's Report on Form 8-K dated May 12, 2005).

 

10.57 Note Purchase Agreement dated June 27, 2005 between Positron and Solaris Opportunity Fund, L.P. (incorporated by reference to Exhibit 10.1 to the Company's Report on Form 8-K dated June 27, 2005).

 

10.58 Form Secured Convertible Promissory Note (incorporated by reference to Exhibit 10.2 to the Company's Report on Form 8-K dated June 27, 2005).

 

10.59 Security Agreement dated June 27, 2005 between Positron and Solaris Opportunity Fund, L.P. (incorporated by reference to Exhibit 10.3 to the Company's Report on Form 8-K dated June 27, 2005).

 

10.60 Registration Rights Agreement dated June 27, 2005 between Positron and Solaris Opportunity Fund, L.P. (incorporated by reference to Exhibit 10.4 to the Company's Report on Form 8-K dated June 27, 2005).

 

10.61 Note Purchase Agreement dated August 8, 2005 between Positron and IMAGIN Diagnostic Centres, Inc. (incorporated by reference to Exhibit 10.1 to the Company's Report on Form 8-K dated August 8, 2005).

 

44
 

 

10.62 Form Secured Convertible Promissory Note (incorporated by reference to Exhibit 10.2 to the Company's Report on Form 8-K dated August 8, 2005).

 

10.63 Registration Rights Agreement dated August 8, 2005 between Positron and IMAGIN Diagnostic Centres, Inc. (incorporated by reference to Exhibit 10.3 to the Company's Report on Form 8-K dated August 8, 2005).

 

10.64 Agreement between Gary H. Brooks and Positron Corporation dated September 29, 2005 (incorporated by reference to Exhibit 10.1 of the Company's Report on Form 8-K dated September 29, 2005).

 

10.65 Note Purchase Agreement dated October 31, 2005 between Positron and IMAGIN Diagnostic Centres, Inc. (incorporated by reference to Exhibit 10.1 of the Company's Report on Form 8-K dated October 31, 2005).

 

10.66 Form Secured Convertible Promissory Note (incorporated by reference to Exhibit 10.2 of the Company's Report on Form 8-K dated October 31, 2005).

 

10.67 Registration Rights Agreement dated October 31, 2005 between Positron and IMAGIN Diagnostic Centres, Inc. (incorporated by reference to Exhibit 10.3 of the Company's Report on Form 8-K dated October 31, 2005).

 

10.68 Joint Venture Contract dated July 30, 2005 between Positron Corporation and Neusoft Medical Systems Co., Ltd. (incorporated by reference to Exhibit 10.1 of the Company's Quarterly Report on Form 10-QSB for the quarter ended September 30, 2005).

 

10.69 Technologies Contribution Agreement dated July 30, 2005 between Positron Corporation and Neusoft Positron Medical Systems Co., Ltd. (incorporated by reference to Exhibit 10.2 of the Company's Quarterly Report on Form 10-QSB for the quarter ended September 30, 2005).

 

10.70 Software Sub-License Agreement dated September 6, 2005 between Positron Corporation and Neusoft Positron Medical Systems Co., Ltd. (incorporated by reference to Exhibit 10.3 of the Company's Quarterly Report on Form 10-QSB for the quarter ended September 30, 2005).

 

10.71 Trademark License Agreement dated July 30, 2005 between Positron Corporation and Neusoft Positron Medical Systems Co., Ltd. (incorporated by reference to Exhibit 10.4 of the Company's Quarterly Report on Form 10-QSB for the quarter ended September 30, 2005).

 

10.72 Corporate Name License Agreement dated July 30, 2005 between Positron Corporation and Neusoft Positron Medical Systems Co., Ltd. (incorporated by reference to Exhibit 10.5 of the Company's Quarterly Report on Form 10-QSB for the quarter ended September 30, 2005).

 

10.73 Employment Agreement dated December 27, 2005 between Positron Corporation and Joseph G. Oliverio (incorporated by reference to Exhibit 10.1 of the Company's Current Report on Form 8-K filed on March 9, 2006).†

 

10.74 Joseph G. Oliverio Stock Option Agreement (incorporated by reference to Exhibit 10.2 of the Company's Current Report on Form 8-K filed on March 9, 2006).†

 

10.75 Joseph G. Oliverio Notice of Grant of Stock Option (incorporated by reference to Exhibit 10.3 of the Company's Current Report on Form 8-K filed on March 9, 2006).†

 

10.76 Amended and Restated 2005 Stock Incentive Plan (incorporated by reference to Exhibit 10.4 of the Company's Current Report on Form 8-K filed on March 9, 2006).†

 

10.77 2005 Stock Incentive Plan - Form Notice of Grant of Stock Option (incorporated by reference to Exhibit 10.5 of the Company's Current Report on Form 8-K filed on March 9, 2006).†

 

45
 

 

10.78 2005 Stock Incentive Plan - Form Stock Option Agreement (incorporated by reference to Exhibit 10.6 of the Company's Current Report on Form 8-K filed on March 9, 2006).†

 

10.79 Memorandum of Understanding between Quantum Molecular Pharmaceutical, Inc., Imagin Diagnostic Centres, Inc. and Positron Corporation dated December 28, 2005 (incorporated by reference to Exhibit 10.79 of the Company’s Annual Report on Form 10-K filed April 5, 2006.

 

10.80 2006 Stock Incentive Plan (incorporated by reference to the Company's Current Report on Form 8-K filed on , 2006).

 

10.81 Statement of Designation Establishing Series G Preferred Stock of Positron Corporation (incorporated by reference to the Company's Current Report on Form 8-K filed on March 9, 2006).

 

10.82 Form of Series G Unit Subscription Agreement (incorporated by reference to the Company's Current Report on Form 8-K filed on March 9, 2006).

 

10.83 Form of Common Stock Purchase Warrant (incorporated by reference to the Company's Current Report on Form 8-K filed on March 9, 2006).

 

10.84 Securities Purchase Agreement dated May 23, 2006 (incorporated by reference to Exhibit 10.6 of the Company's Current Report on Form 8-K filed on June 1, 2006).

 

10.85 Callable Secured Convertible Note in favor of AJW Offshore, Ltd dated May 23, 2006 (incorporated by reference to the Company's Current Report on Form 8-K filed on June 1, 2006).

 

10.86 Callable Secured Convertible Note in favor of AJW Partners, LLC dated May 23, 2006 (incorporated by reference to the Company's Current Report on Form 8-K filed on June 1, 2006).

 

10.87 Stock Purchase Warrant in favor of AJW Qualified Partners, LLC (incorporated by reference to the Company's Current Report on Form 8-K filed on June 1, 2006).

 

10.88 Stock Purchase Warrant in favor of AJW Offshore, Ltd. (incorporated by reference to the Company's Current Report on Form 8-K filed on June 1, 2006).

 

10.89 Stock Purchase Warrant in favor of New Millennium Capital Partners, II (incorporated by reference to the Company's Current Report on Form 8-K filed on June 1, 2006).

 

10.90 Registration Rights Agreement dated May 23, 2006 (incorporated by reference to the Company's Current Report on Form 8-K filed on June 1, 2006).

 

10.91 Security Agreement dated May 23, 2006 (incorporated by reference to the Company's Current Report on Form 8-K filed on June 1, 2006).

 

10.92 Intellectual property Security Agreement.( incorporated by reference to the Company's Current Report on Form 8-K filed on June 1, 2006).

 

10.93 Securities Purchase Agreement dated January 26, 2007 (incorporated by reference to the Company's Current Report on Form 8-K filed on January 31, 2006).

 

10.94 Purchase Agreement dated January 26, 2007 (incorporated by reference to the Company's Current Report on Form 8-K filed on January 31, 2006.

 

10.95 Non-Negotiable Promissory Note dated January 26, 2007 (incorporated by reference to the Company's Current Report on Form 8-K filed on January 31, 2006).

 

46
 

 

10.96 Collateral Pledge Agreement dated January 26, 2007 (incorporated by reference to the Company's Current Report on Form 8-K filed on January 31, 2006).

 

10.97 Promissory Note in favor of Imagin Molecular Corporation, dated April 10, 2008 (incorporated by reference to the Company's Annual Report on Form 10-K filed on April 14, 2008).

 

10.98 Stock Pledge Agreement with Imagin Molecular Corporation dated April 10, 2008. (incorporated by reference to the Company's Annual Report on Form 10-K filed on April 14, 2008).

 

10.99 Stock Purchase Agreement with Positron Pharmaceutical Company, Dos Shield Corporation, Nukemed, Inc., Michael Thomas, and John Zehner, dated June 11, 2008 incorporated by reference to the Company's Current Report on Form 8-K filed on June 11, 2008).

 

10.100 Employment Agreement with John Zehner, dated June 6, 2008 (incorporated by reference to the Company's Current Report on Form 8-K filed on June 11, 2008).

 

10.101 2008 Stock Incentive Plan (incorporated herein by reference to Exhibit 10.1 to the Company's Registration Statement on Form S-8(File No. 333-152616)).†

 

10.102 Promissory Note in favor of Imagin Molecular Corporation, dated August 18, 2008 (incorporated by reference to the Company's Quarterly Report on Form 10-Q filed on August 19, 2008).

 

10.103 Addendum to the Stock Pledge Agreement with Imagin Molecular Corporation, dated August 18, 2008 (incorporated by reference to the Company's Quarterly Report on Form 10-Q filed on August 19, 2008).

 

10.104 2009 Stock Incentive Plan (incorporated herein by reference to Exhibit 10.1 to the Company's Registration Statement on Form S-8(File No. 333-162204)).† 2009 Equity Incentive Plan (incorporated herein by reference to Exhibit 99.1 to the Company's Registration Statement on Form S-8(File No. 333-165724)).†

 

10.105 Settlement Agreement and Mutual Release with New Millennium Capital Partners II, LLC, AJW Offshore, Ltd., AJW Qualified Partners, LLC and AJW Partners, LLC, dated July 28, 2011 (incorporated herein by reference to Exhibit 10.1 to the Company's Current Form 8-K (File No. 000-24092)).

 

14.1 Code of Conduct and Ethics.

 

21* List of Subsidiaries.

 

31.1* Chairman of the Board Certification of Periodic Financial Report Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002

 

31.2* Chief Financial Officer Certification of Periodic Financial Report Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002

 

32.1# Chairman of the Board Certification Pursuant to 18 U.S.C. Section 1350, as adopted pursuant to section 906 of the Sarbanes-Oxley Act of 2002

 

32.2# Chief Financial Officer Certification Pursuant to 18 U.S.C. Section 1350, as adopted pursuant to section 906 of the Sarbanes-Oxley Act of 2002

 

101.INS   XBRL Instance Document
     
101.SCH   XBRL Taxonomy Extension Schema Document
     
101.CAL   XBRL Taxonomy Extension Calculation Linkbase Document
     
101.DEF   XBRL Taxonomy Extension Definition Linkbase Document
     
101.LAB   XBRL Taxonomy Extension Label Linkbase Document
     
101.PRE   XBRL Taxonomy Extension Presentation Linkbase Document

 

† Management contract or compensatory plan or arrangement identified pursuant to Item 13(a).

 

* Filed herewith

 

# Furnished herewith

 

(b) Reports on Form 8-K

 

None.

 

47
 

 

SIGNATURES

 

In accordance with Section 13 or 15(d) of the Exchange Act, the Registrant caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

    POSITRON CORPORATION
     
Date: March 31, 2014 By: /s/ Patrick Rooney
    Patrick Rooney
    Chief Executive Officer and Chairman of the Board (Principal Executive Officer)
     
  By: /s/ Corey Conn
    Corey Conn
    Chief Financial Officer (Principal Financial Officer)
     
  By: /s/ Joseph Oliverio
    Joseph Oliverio
    President and Director

 

Pursuant to the requirements of the Securities Exchange Act of 1934, this Report has been signed below by the following persons on behalf of the Registrant and in the capacities and on the dates indicated.

 

Signature   Title   Date
         
/s/ PATRICK ROONEY   Chairman and Chief Executive   March 31, 2014
Patrick Rooney   (Principal Executive Officer)    
         
/s/COREY CONN   Chief Financial Officer and Director   March 31, 2014
Corey Conn   (Principal Financial Officer)    
         
/s/JOSEPH OLIVERIO   President and Director   March 31, 2014
Joseph Oliverio        
         
/s/JASON KITTEN   Executive Director of Radioisotopes   March 31, 2014
Jason Kitten        
         
/s/SACHIO OKAMURA   Director   March 31, 2014
Sachio Okamura        
         
/s/ANTHONY C. NICHOLLS   Director   March 31, 2014
Dr. Anthony Nicholls        

 

48
 

 

POSITRON CORPORATION AND SUBSIDIARIES

FINANCIAL STATEMENTS

WITH REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

for the years ended December 31, 2013 and 2012

 

FINANCIAL STATEMENTS

TABLE OF CONTENTS

 

  Page
   
Report of Independent Registered Public Accounting Firm 43
   
Consolidated Balance Sheets at December 31, 2013 and 2012 44
   
Consolidated Statements of Operations and Comprehensive Loss for the years ended December 31, 2013 and 2012 45
   
Consolidated Statements of Stockholders’ Equity (Deficit) for the years ended December 31, 2013 and 2012 46
   
Consolidated Statements of Cash Flows for the years ended December 31, 2013 and 2012 48
   
Notes to Consolidated Financial Statements 49

 

49
 

 

Sassetti LLC

Certified Public Accountants

 

The Board of Directors

Positron Corporation

 

REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

 

We have audited the accompanying consolidated balance sheets of Positron Corporation and Subsidiaries as of December 31, 2013 and 2012 and the related consolidated statements of operations and comprehensive loss, stockholders' equity, and cash flows for the years then ended.  These financial statements are the responsibility of the Company's management.  Our responsibility is to express an opinion on these financial statements based on our audits.

 

We conducted our audits in accordance with the standards of the Public Company Accounting Oversight Board (United States).  Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement.  An audit includes examining, on a test basis, evidence supporting the amounts and disclosures in the financial statements.  An audit also includes assessing the accounting principles used and significant estimates made by management, as well as evaluating the overall financial statement presentation.  We believe that our audits provide a reasonable basis for our opinion.

 

In our opinion, the consolidated financial statements referred to above present fairly, in all material respects, the financial position of Positron Corporation and Subsidiaries as of December 31, 2013 and 2012, and the results of their operations and cash flows for the years then ended, in conformity with accounting principles generally accepted in the United States of America.

 

The accompanying consolidated financial statements have been prepared assuming that the Company will continue as a going concern.  As discussed in Note 2 to the financial statements, the Company has a significant accumulated deficit which raises substantial doubt about the Company's ability to continue as a going concern.  Management's plans in regard to these matters are also described in Note 2.  The financial statements do not include any adjustments that might result from the outcome of this uncertainly.

 

/s/ Sassetti LLC

 

Oak Park, Illinois

 

March 31, 2014

 

6611 W. North Avenue * Oak Park, Illinois 60302 * Phone (708) 386-1433 * Fax (708) 386-0139

 

50
 

 

POSITRON CORPORATION AND SUBSIDIARIES

CONSOLIDATED BALANCE SHEETS

(In thousands, except share data)

 

   December 31, 
   2013   2012 
ASSETS          
           
Current assets:          
Cash and cash equivalents  $1,744   $243 
Accounts receivable, less allowance for doubtful accounts of $141 and $50   247    273 
Inventories, less reserve of $444 and $457   547    551 
Prepaid expenses   35    37 
Total current assets   2,573    1,104 
           
Property and equipment, less accumulated depreciation of $504 and $346   1,044    1,170 
Intangible assets, less accumulated amortization of $4 and $2   10    358 
Other assets   255    53 
Total assets  $3,882   $2,685 
           
LIABILITIES AND STOCKHOLDERS’ DEFICIT          
           
Current liabilities:          
Accounts payable, trade and accrued liabilities  $1,401   $1,634 
Customer deposits   658    746 
Unearned revenue   45    58 
Advances from related parties   1,035    - 
Notes payable – current portion   95    129 
Capital lease – current portion   3    - 
Convertible debentures, less debt discount of $1,328 and $1,798   4,452    1,562 
Embedded conversion derivative liabilities   6,968    3,981 
Total current liabilities   14,657    8,110 
           
Notes payable – noncurrent portion   455    560 
Capital lease – noncurrent portion   11    - 
Contingent earnout payable   -    205 
Total liabilities   15,123    8,875 
           
Stockholders’ deficit:          
Series A preferred stock:  $1.00 par value; 8% cumulative, convertible, redeemable; 7,900,000 shares authorized; 447,652 shares issued and outstanding.   448    448 
Series B preferred stock: $1.00 par value; convertible, redeemable; 9,000,000 shares authorized; 3,056,487 shares issued and outstanding   2,750    2,750 
Series S preferred stock:  $1.00 par value; convertible, redeemable; 100,000 shares authorized;  100,000 shares issued and outstanding   100    100 
Series H preferred stock: $0.01 par value; convertible, redeemable; 15,000,000 shares authorized; 12,500,000 shares issued and outstanding in 2013   125    - 
Common stock:  $0.01 par value; 3,000,000,000 shares authorized; 1,452,548,262 and 1,451,927,262 shares issued and outstanding   14,208    14,203 
Additional paid-in capital   94,575    92,795 
Other comprehensive income   -    (143)
Accumulated deficit   (123,432)   (116,328)
Treasury stock: 60,156 shares at cost   (15)   (15)
Total stockholders’ deficit   (11,241)   (6,190)
Total liabilities and stockholders’ deficit  $3,882   $2,685 

 

See accompanying notes to consolidated financial statements

 

51
 

 

POSITRON CORPORATION AND SUBSIDIARIES

CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME

(In thousands, except per share data)

 

   Year Ended
December 31,		 
   2013   2012 
         
Sales:  $1,630   $2,801 
           
Costs of sales:   1,206    1,972 
           
Gross profit   424    829 
           
Operating expenses:          
General and administrative   2,779    4,326 
Research and development   564    940 
Selling and marketing   419    285 
           
Total operating expenses   3,762    5,551 
           
Loss from operations   (3,338)   (4,722)
           
Other income (expense)          
Interest expense   (2,137)   (1,753)
Derivative loss   (665)   (726)
Debt modification expense   (821)   (432)
Loss on settlement of accounts payable   -    (282)
Other expense   (143)   (22)
Loss on disposal of property and equipment   -    (18)
           
Total other income (expense)   (3,766)   (3,233)
           
Loss before income taxes   (7,104)   (7,955)
           
Income taxes   -    - 
           
Net loss   (7,104)   (7,955)
           
Other comprehensive loss          
Foreign currency translation adjustments   143   - 
           
Other comprehensive loss  $(6,961)  $(7,955)
           
Basic and diluted net loss per common share  $(0.00)  $(0.01)
           
Basic and diluted weighted average shares outstanding   1,452,364    1,265,270 

 

See accompanying notes to consolidated financial statements

 

52
 

 

POSITRON CORPORATION AND SUBSIDIARIES

CONSOLIDATED STATEMENT OF STOCKHOLDERS’ EQUITY (DEFICIT)

(In thousands, except share data)

 

   Series A
Preferred Stock		   Series B
Preferred Stock		   Series S
Preferred Stock		   Series G
Preferred Stock		   Series H
Preferred Stock		 
   Shares   Amount   Shares   Amount   Shares   Amount   Shares   Amount   Shares   Amount 
                                         
Balance December 31, 2011   457,599   $457    7,828,822   $7,521    100,000   $100    19,200   $19    -   $- 
                                                   
Net loss   -    -    -    -    -    -    -    -    -      
                                                   
Conversion of Series A to common stock and adjust   (9,947)   (9)   -    -    -    -    -    -    -    - 
                                                   
Conversion of Series B to common stock   -    -    (4,772,335)   (4,771)   -    -    -    -    -    - 
                                                   
Conversion of Series  G to common stock   -    -    -    -    -    -    (19,200)   (19)   -    - 
                                                   
Issuance of common  stock for cash   -    -    -    -    -    -    -    -    -    - 
                                                   
Issuance of common stock for services   -    -    -    -    -    -    -    -    -    - 
                                                   
Issuance of common  stock for investment   -    -    -    -    -    -    -    -    -    - 
                                                   
Allocation of convertible debenture to fair value of warrants   -    -    -    -    -    -    -    -    -    - 
                                                   
Conversion of convertible debenture to Series B   -    -    -    -    -    -    -    -    -    - 
                                                   
Reclassification of embedded conversion derivative liability to APIC upon conversion of convertible debenture   -    -    -    -    -    -    -    -    -    - 
                                                   
Issuance of stock payable   -    -    -    -    -    -    -    -    -    - 
                                                   
Shares issued for note payable   -    -    -    -    -    -    -    -    -    - 
                                                   
Receivable from warrants exercise   -    -    -    -    -    -    -    -    -    - 
                                                   
Net Loss   -    -    -    -    -    -    -    -    -    - 
                                                   
Balance December 31, 2012   447,652   $448    3,056,487   $2,750    100,000   $100    -   $-    -   $- 
                                                   
Issuance of Series H preferred stock   -    -    -    -    -    -    -    -    12,500,000    125 
                                                   
Issuance of common stock for services   -    -    -    -    -    -    -    -    -    - 
                                                   
Close other comprehensive income   -    -    -    -    -    -    -    -    -    - 
                                                   
Stock based compensation - stock options   -    -    -    -    -    -    -    -    -    - 
                                                   
Net Loss   -    -    -    -    -    -    -    -    -    - 
                                                   
Balance December   31, 2013   447,652   $448    3,056,487   $2,750    100,000   $100    -   $-    12,500,000   $125 

 

See accompanying notes to consolidated financial statements

 

53
 

 

POSITRON CORPORATION AND SUBSIDIARIES

CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ DEFICIT

(In thousands, except share data)

(Continued)

 

   Common Stock   Additional Paid-
In Capital		   Other
Comprehensive
Income		   Accumulated
Deficit		   Treasury Stock
Shares		   Total 
   Shares   Amount               Shares   Amount     
                                 
Balance December 31, 2011   788,327,497   $7,567   $89,999   $(143)  $(108,373)   602   $(15)  $(2,868)
                                         
Conversion of Series A to common stock and adjust   16,667    -    9    -    -    -    -    - 
                                         
Conversion of Series B to common stock   477,233,501    4,772    (1)   -    -    -    -    - 
                                         
Conversion of Series  G to common stock   2,020,000    20    (1)   -    -    -    -    - 
                                         
Issuance of common  stock for cash   38,300,000    383    -    -    -    -    -    383 
                                         
Issuance of common stock for services   41,165,240    412    30    -    -    -    -    442 
                                         
Issuance of common  stock for investment   30,000,000    300    -    -    -    -    -    300 
                                         
Allocation of convertible debenture to fair value of warrants   -    -    331    -    -    -    -    331 
                                         
Reclassification of embedded conversion derivative liability to APIC upon conversion of convertible debenture   -    -    545    -    -    -    -    545 
                                         
Issuance of stock payable   17,000,000    170    99    -    -    -    -    269 
                                         
Shares issued for note payable   57,864,357    579    -    -    -    -    -    579 
                                         
Stock based compensation - stock options   -    -    1,784    -    -    -    -    1,784 
                                         
Net Loss   -    -    -    -    (7,955)   -    -    (7,955)
                                         
Balance December 31, 2012   1,451,927,262    14,203    92,795   $(143)  $(116,328)   602   $(15)  $(6,190)
                                         
Issuance of Series H preferred stock   -    -    1,125    -    -    -    -    1,250 
                                         
Issuance of common stock for services   621,000    5    -    -    -    -    -    5 
                                         
Close other comprehensive income   -    -    -    143    -   -    -    143 
                                         
Stock based compensation - stock options   -    -    655    -    -    -    -    655 
                                         
Net Loss   -    -    -    -    (7,104)   -    -    (7,104)
                                         
Balance December   31, 2013   1,452,548,262   $14,208   $94,575   $-   $(123,432)   -    (15)   (11,241)

 

See accompanying notes to consolidated financial statements

 

54
 

 

POSITRON CORPORATION AND SUBSIDIARIES

CONSOLIDATED STATEMENTS OF CASH FLOWS

(In thousands)

 

   Year Ended
December 31,		 
   2013   2012 
Cash flows from operating activities:          
Net loss  $(7,104)  $(7,955)
Adjustment to reconcile net loss to net cash used in operating activities          
Allowance for doubtful accounts   91    - 
Depreciation and amortization   160    226 
Loss on disposal of property and equipment   -    18 
Impairment of intangible asset   346    - 
Loss on settlement   -    282 
Stock based compensation   656    1,784 
Derivative losses   665    726 
Debt modification expense   821    432 
Common stock issued for services   6    442 
Contingent earnout   (205)   - 
Deferred rent   -    77 
Accretion of debt discount   1,970   1,628 
Inventory reserve   (13)   - 
Other  143    - 
Changes in operating assets and liabilities:          
Accounts receivable   (65)   339 
Inventories   17    190 
Prepaid expenses and other assets   (200)   603 
Accounts payable, trade and accrued liabilities   (233)   (146)
Customer deposits   (88)   (656)
Unearned revenue   (13)   (230)
           
Net cash used in operating activities   (3,046)   (2,240)
           
Cash flows from investing activities:          
Purchase of property and equipment   (16)   (73)
Purchase of MIT, net of cash acquired   -    1 
           
Net cash used in investing activities   (16)   (72)
           
Cash flows from financing activities:          
Borrowings under note payable   -    305 
Payments on note payable   (100)   (324)
Noninterest bearing advances   2,245    65 
Payment of noninterest bearing advances   -   (85)
Payments on capital lease   (2)     
Common stock issued   -    383 
Proceeds from convertible debt   2,520    2,210 
Payments on convertible debt   (100)   - 
           
Net cash provided by financing activities   4,563    2,554 
           
Net increase (decrease) in cash and cash equivalents   1,501    242 
           
Cash and cash equivalents, beginning of period   243    1 
           
Cash and cash equivalents, end of period  $1,744   $243 
           
Supplemental cash flow information:          
Interest paid  $39   $32 
Income taxes paid  $-   $- 
Non-cash disclosures          
Conversion of Series A preferred stock to common stock  $-   $16 
Conversion of Series B preferred stock to common stock  $-   $4,771 
Conversion of Series G preferred stock to common stock  $-   $19 
Issuance of 17,000,000 common stock owed  $-   $269 
Allocation of Convertible Debentures to warrants and embedded conversion derivative liability  $3,695   $2,460 
Issuance of common stock, warrants, and convertible debentures for purchase of building from related party  $-   $500 
Conversion of Convertible Debenture to common stock  $-  $578 
Conversion of embedded derivative liability to paid - in capital  $-   $545 
Property and equipment additions financed  $-   $50 
Equipment under capital lease  $16   $- 
Noncash consideration for MIT acquisition (see Note 4)  $-   $255 
Conversion of advances to series H preferred stock  $1,125   $- 

 

See accompanying notes to consolidated financial statements

 

55
 

 

POSITRON CORPORATION AND SUBSIDIARIES

SELECTED NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

 

1.DESCRIPTION OF BUSINESS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

 

Description of Business

 

Positron Corporation (the “Company”) was incorporated on December 20, 1983 in the state of Texas and commenced commercial operations in 1986. Positron Corporation is a nuclear medicine healthcare company. The Company offers positron emission tomography molecular imaging systems, clinical and support services, automated radiopharmaceutical systems, radiopharmaceuticals and radioisotope processing and production.

 

The molecular imaging systems portion of the business provides Positron Emission Tomography (PET) scanners. The automated radiopharmaceutical system portion of the business offers the world’s first robotic system for the preparation and dispensing of radiopharmaceuticals that provides unit dose radiopharmaceutical agents used in molecular imaging. The radioisotope manufacturing portion of the business enables the Company to process and produce radioisotope(s) that are critical components required in nuclear imaging.

 

The Company’s objective is to generate revenue by offering inexpensive molecular imaging systems and support services, disease specific software, automated radiopharmaceutical dose preparation and dispensing system, radiopharmaceutical(s) and radioisotope(s) for nuclear medicine primarily in the field of cardiac nuclear medicine.

 

On January 17, 2012, the Company acquired all of the issued and outstanding membership interest of Manhattan Isotope Technology LLC (“MIT”). See Note 3.

 

MIT possesses the unique and specialized expertise in all stages of strontium-82 (Sr-82) production and spent generator lifecycle management. Currently, MIT produces API grade strontium-82 from target material received from its foreign collaborators.

 

Positron Isotopes Corporation (PIC) was formed to investigate the possibility of building a cyclotron.

 

Principles of Consolidation

 

For the years ended December 31, 2013 and 2012, the financial statements include the transactions of Positron Corporation and its wholly-owned subsidiaries, MIT, Positron Pharmaceuticals Company and PIC. All intercompany transactions have been eliminated.

 

Basis of Presentation and Use of Estimates

 

These financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America (GAAP). Such principles require management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.

 

Affiliated Entities

 

Affiliated entities and their affiliation, as defined by FASB Codification Topic 850 are as follows:

 

Solaris Opportunity Fund owns or controls common and preferred shares of the Company and its managing member is the CEO of the Company.

 

The Company has a 1% ownership interest in the joint venture Neusoft Positron Medical Systems ("Neusoft"). Both the Company and the joint venture's other partner, Neusoft Medical Systems purchase PET systems at a wholesale transfer price from Neusoft. The Company maintains one of five board seats on Neusoft's board. The Company currently accounts for its investment in Neusoft on the cost method and has no recorded value as of December 31, 2013 and 2012 based on prior losses of Neusoft.

 

56
 

 

Concentrations of Credit Risk

 

The Company maintains its cash in institutions insured by the Federal Deposit Insurance Corporation (FDIC) and at times, balances may exceed government insured limits. The Company has never experienced any losses related to these balances.

 

During the twelve months ended December 31, 2013, no one customer accounted for more than 10% of sales and a separate customer accounted for 80% of accounts receivable. During the twelve months ended December 31, 2012, one customer accounted for 26% of sales and a separate customer accounted for 70% of accounts receivable.

 

Cash Equivalents and Short-term Investments

 

For the purposes of reporting cash flows, the Company considers highly liquid, temporary cash investments with an original maturity period of three months or less to be cash equivalents.

 

Accounts Receivable

 

Accounts receivable consist of amounts due from customers. The Company records a provision for doubtful accounts to allow for any amounts which may be unrecoverable, which is based upon an analysis of the Company’s prior collection experience, customer creditworthiness and current economic trends.

 

Goodwill and Other Intangible Assets

 

Accounting Standard Codification (“ASC”) 350 “Goodwill and Other Intangible Assets” requires that assets with indefinite lives no longer be amortized, but instead be subject to annual impairment tests. The Company follows this guidance.

 

The Company tests goodwill that is not subject to amortization for impairment annually or more frequently if events or circumstances indicate that impairment is possible. Goodwill was tested as of December 31, 2013 at which time the Company determined that the carrying value of goodwill was impaired. Impairment loss of $346,000 was recognized during the year ended December 31, 2013.

 

The impairment tests performed at December 31, 2013 and 2012 were based on a discounted cash flow model using management’s business plan projection for expected cash flows. As noted above, it was determined goodwill was fully impaired at December 31, 2013. As of December 31, 2012, no impairment was indicated. Goodwill as of December 31, 2013 and 2012 was $0 and $346,000, respectively.

 

Definite lived intangible assets are being amortized over their useful lives.

 

Inventory

 

Inventories are stated at the lower of cost or market. Cost is determined using the first-in, first-out (FIFO) method of inventory valuation. Management assesses the recoverability and establishes reserves of the various inventory components on a quarterly basis and is based on the estimated net realizable values of respective finished, in process and raw material inventories.

 

Property and Equipment

 

Property and equipment are recorded at cost and depreciated for financial statement purposes using the straight-line over estimated useful lives below:

 

   Estimated life,
years
Buildings  39
Furniture and fixtures  5-7
Leasehold improvements  1-3
Computer equipment  3-5
Research equipment  7
Machinery and equipment  3-5

 

Gains or losses on dispositions are included in the statement of operations in the period incurred. Maintenance and repairs are charged to expense as incurred.

 

Impairment of Long-Lived Assets

 

Periodically, the Company evaluates the carrying value of its long-lived assets, by comparing the anticipated future net cash flows associated with those assets to the related net book value. If impairment is indicated as a result of such reviews, the Company would record the impairment based on the fair market value of the assets, using techniques such as projected future discounted cash flows or third party valuations.

 

57
 

 

Fair Value of Financial Instruments

 

The carrying value of cash and cash equivalents, accounts receivable, accounts payable and accrued liabilities and unearned revenue, approximate their fair values because of the short-term nature of these instruments. Management believes the Company is not exposed to significant interest or credit risks arising from these financial instruments.

 

Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date.

 

Valuation techniques used to measure fair value maximize the use of observable inputs and minimize the use of unobservable inputs. The Company utilizes a fair value hierarchy based on three levels of inputs, of which the first two are considered observable and the last unobservable.

 

·Level 1 — Quoted prices in active markets for identical assets or liabilities. These are typically obtained from real-time quotes for transactions in active exchange markets involving identical assets.

 

·Level 2 — Quoted prices for similar assets and liabilities in active markets; quoted prices included for identical or similar assets and liabilities that are not active; and model-derived valuations in which all significant inputs and significant value drivers are observable in active markets. These are typically obtained from readily-available pricing sources for comparable instruments.

 

·Level 3 — Unobservable inputs, where there is little or no market activity for the asset or liability. These inputs reflect the reporting entity’s own beliefs about the assumptions that market participants would use in pricing the asset or liability, based on the best information available in the circumstances.

 

The following table presents the embedded conversion derivative liabilities, the Company’s only financial liabilities measured and recorded at fair value on the Company’s consolidated balance sheets on a recurring basis and their level within the fair value hierarchy as of December 31, 2013 and 2013 and 2012 (in thousands):

 

   Level 1   Level 2   Level 3 
             
Embedded conversion derivative liability:               
December 31, 2013  $-   $-   $6,968 
                
December 31, 2012  $-   $-   $3,981 

 

The following table reconciles, for the year ended December 31, 2013 and 2012, the beginning and ending balances for financial instruments that are recognized at fair value in the consolidated financial statements (in thousands):

 

Balance of embedded conversion derivative liability as of December 31, 2011  $1,238 
Fair value of embedded conversion derivative liabilities at issuance   2,129 
Reductions in fair value due to conversion of Convertible Debentures into common stock   (544)
Debt modification expense   432 
Loss on fair value adjustments to embedded conversion derivative liabilities   726 
Balance of embedded conversion derivative liability as of December 31, 2012  $3,981 
Fair value of embedded conversion derivative liabilities at issuance   1,501 
Debt modification expense   821 
Loss on fair value adjustments to embedded conversion derivative liabilities   665
Balance of embedded conversion derivative liabilities at December 31, 2013  $6,968 

 

58
 

 

 

The fair value of the conversion features are calculated at the time of issuance and the Company records a derivative liability for the calculated value using a Black-Scholes option-pricing model. Changes in the fair value of the derivative liability are recorded in other income (expense) in the consolidated statement of operations. Upon conversion of the convertible debt to stock, the Company reclassifies the related embedded conversion derivative liability to paid-in capital. Since the fair value of the embedded conversion derivative liability exceeded the carrying value of the convertible debentures on the issuance date, the convertible debentures were recorded at a full discount. The Company recognizes expense for accretion of the convertible debentures discount over the term of the notes. The Company has considered the provisions of ASC 480, Distinguishing Liabilities from Equity, as the conversion feature embedded in each debenture could result in the note principal being converted to a variable number of the Company’s common shares.

 

The derivatives were valued using the Black-Scholes option pricing model with the following assumptions:

 

   December 31,
2013		   December 31,
2012		 
Market value of stock on measurement date  $0.0048   $0.0085 
Risk-free interest rate   0.11%   0.15%
Dividend yield   0%   0%
Volatility factor   200%   141%
Term   1 year    1 year 

 

Debt discount

 

Costs incurred with parties who are providing long-term financing, which generally include the value of warrants or the fair value of an embedded derivative conversion feature, are reflected as a debt discount and are amortized over the life of the related debt. When the debt is repaid, the related debt discount is recorded as additional interest expenses and the related derivative liability is relieved into additional paid in capital.

 

The Company valued the embedded derivative conversion using Black-Scholes method. The debt discount attributable to the warrants issued with convertible debentures during the years December 31, 2013 and 2012 was $0 and $331,000, respectively. The debt discount attributable to the embedded conversion derivative liability at issuance during the years ended December 31, 2013 and 2012 was $1,500,000 and $2,129,000, respectively.

 

At December 31, 2013, convertible notes totaled $5,780,000 of which $1,328,000 was attributable to the discount on debt. These notes originally were set to mature on December 31, 2013 but were extended under existing terms through December 31, 2014 or were presented for conversion subsequent to year end.

 

Income Taxes

 

Income taxes are accounted for under the liability method. Deferred income taxes are provided for temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and amounts used for income tax purposes. Deferred taxes are reduced by a valuation allowance when, in the opinion of management, it is more likely than not that some portion or the entire deferred tax asset will not be realized. Deferred tax assets and liabilities are adjusted for the effects of changes in tax laws and rates on the date of the enactment. We recognize tax benefits when we believe the benefit is more likely than not to be sustained upon review from the relevant authorities. We recognize penalties and interest expense related to unrecognized tax benefits in income tax expense.

 

The Company’s federal and state tax forms for the years ending December 31, 2010, 2011 and 2012 are subject to examination by the IRS or other taxing authorities, generally for three years after they are filed.

 

Accumulated Other Comprehensive Income

 

Accumulated other comprehensive income relates to foreign currency translation adjustments associated with transactions denominated in foreign currency. The balance of accumulated other comprehensive income as of December 31, 2012 was $143,000. During the year ended December 31, 2013 the entire balance was reclassified to net income.

 

59
 

 

Revenue Recognition

 

The Company’s revenues are currently derived from the sale of medical equipment products, maintenance contracts, service revenues and radioisotope sales. Revenues from maintenance contracts are recognized over the term of the contract. Service revenues are recognized upon performance of the services. The Company recognizes revenues from the sale of medical equipment and radioisotope products when earned. Specifically, revenue is recognized when persuasive evidence of an arrangement exists, delivery has occurred (or services have been rendered), the price is fixed or determinable, and collectability is reasonably assured. The Company obtains a signed customer acceptance after installation is complete for the sale of its Attrius® PET systems.

 

For multiple-element arrangements, revenue is allocated to each element based on their relative selling prices. Relative selling prices are based first on vendor specific objective evidence (VSOE), then on third-party evidence of selling price (TPE) when VSOE does not exist, and then on estimated selling price (ESP) when VSOE and TPE do not exist.

 

Because the Company has neither VSOE nor TPE for its products, the allocation of revenue has been based on the Company’s ESPs. The objective of ESP is to determine the price at which the Company would transact a sale if the product was sold on a stand-alone basis. The Company determines ESP by considering the facts and circumstances of the product being sold.

 

The Company typically provides a one-year parts and labor warranty to purchasers of equipment. A portion of revenue recorded upon the sale of a new machine is allocated to the warranty provided. At the time of sale, the Company records deferred revenue in the amount of revenue allocated to the warranty which is amortized over a one-year period.

 

Research and Development Expenses

 

All costs related to research and development costs are charged to expense as incurred and include salaries and benefits, supplies and consulting expenses.

 

Stock Based Compensation

 

We recognize compensation expense for share-based awards using the fair value of the option at the time of the grant and amortizing the fair value over the estimated service period on the straight-line attribute method.

 

Loss Per Common Share

 

Basic loss per common share is calculated by dividing net loss by the weighted average common shares outstanding during the period. Stock options, warrants and other dilutive securities are not included in the computation of the weighted average number of shares outstanding for dilutive net loss per common share during each of the periods presented in the Statement of Operations and Comprehensive Income, as the effect would be antidilutive.

 

Recent Accounting Pronouncements

 

The Company has implemented all new accounting pronouncements that are in effect and that may impact its financial statements and does not believe that there are any other new accounting pronouncements that have been issued that might have a material impact on its financial position or results of operations.

 

2.GOING CONCERN

 

Since inception, the Company has expended substantial resources on research and development. Consequently, we have sustained substantial losses. Due to the limited number of products sold each year, revenues have fluctuated significantly from year to year and has not sold quantities that are sufficient to be operationally profitable. The Company had an accumulated deficit of $123,432,000 and a stockholders’ deficit of $11,241,000 at December 31, 2013. The Company will need to resume and increase sales of PET and radiopharmaceutical systems, services, radiopharmaceuticals and radioisotope sales and apply the research and development advancements to achieve profitability in the future. There can be no assurance that the Company will continue to be successful in selling products.

 

The Company utilized $2,520,000 proceeds from issuance of convertible debt, $2,285,000 proceeds from non-interest bearing advances, and proceeds from borrowings under capital lease to fund operating activities during the year ended December 31, 2013. The Company had cash and cash equivalents of $1,744,000 at December 31, 2013, accounts payable and accrued liabilities of $1,401,000 and a negative working capital of $12,084,000. Working capital requirements for the upcoming year will reach beyond our current cash balances. The Company plans to continue to raise funds as required through equity and debt financing to sustain business operations. These factors raise substantial doubt about the Company’s ability to continue as a going concern.

 

There can be no assurance that the Company will be successful in implementing its business plan and ultimately achieving operational profitability. The Company’s long-term viability as a going concern is dependent on its ability to 1) achieve adequate profitability and cash flows from operations to sustain its operations, 2) control costs and expand revenues from existing or new business 3) meet current commitments and fund the continuation of its business operation in the near future and 4) raise additional funds through debt and/or equity financings.

 

60
 

 

3.ACQUISITION OF MIT

 

On January 17, 2012, the Company acquired Manhattan Isotope Technology LLC (“MIT”) upon consummation of a Membership Interest Purchase Agreement (the “Agreement”) with MIT and the interest-holders of MIT, whereby the Company acquired all of the issued and outstanding membership interests from the holders in exchange for: (i) the assumption of the liabilities of MIT; (ii) cash advances; (iii) earn-out payments equal to twenty percent (20%) of “Net Income” as defined in the Agreement; (iv) 5,000,000 common shares of Positron stock; and (v) entry into employment agreements with MIT’s employees.

 

In accordance with the transaction, the Company acquired the assets related to MIT’s business of refurbishing spent strontium-82/rubidium-82 and other radioisotope generators, recycling strontium-82 and other radioisotopes from generators, processing of strontium-82 and other radioisotopes, providing expertise in production of radioisotopes and radioisotopes services, including cash, equipment, leasehold improvements, patent, certain supply and distribution and other vendor contracts, goodwill and assumed liabilities including trade payables, accruals and a note payable with a commercial bank. The parties made customary representations, warranties and indemnities in the Agreement that are typical and consistent for a transaction of this size and scope.

 

The Company has included the financial results of MIT in the consolidated financial statements from the date of acquisition. MIT is included in the Radiopharmaceuticals operating segment.

 

The Company incurred acquisition costs of approximately $12,000 in 2012.

 

The following table summarizes the consideration transferred to acquire MIT at the acquisition date:

 

Fair Value of Consideration Transferred:

 

Common stock of Company  $50,000 
Contingent consideration   205,297 
Total  $255,297 

 

The total purchase price for the MIT acquisition was allocated to the net tangible and intangible assets based upon their fair values as of January 17, 2012 as set forth below. The excess of the purchase price over the net assets was recorded as goodwill. The following table summarizes the fair values of the assets and liabilities assumed at the acquisition date.

 

Cash  $829 
Equipment and leasehold improvements   653,567 
Patent   14,000 
Trade and other payables   (59,282)
Note payable   (700,000)
Net liabilities assumed  $(90,886)
      
Goodwill  $346,183 

 

The Company identified intangible assets associated with patents and assigned the fair value of $14,000. The useful life associated with patents was 6 years.

 

The acquisition of MIT includes a contingent consideration arrangement that requires cash payments to the previous members equal to 20% of “Net Income” as defined in the Agreement through December 31, 2018. The range of the undiscounted amounts the Company could owe under this arrangement is between $0 and $3,000,000. The fair value of the contingent consideration on the acquisition date of approximately $205,000 was estimated based on the present value of projected payments which were based on projected net income through 2018. These calculations and projections are based on significant inputs not observable in the market, which ASC 820 refers to as Level 3 inputs. Key assumptions include a discount rate of 25 percent as well as an increasing level of revenues and expenses based on probability factors at the acquisition date.

 

At December 31, 2013, the Company evaluated the cashflow projections included in the contingent consideration and determined that there was a decrease in the fair value of the contingent consideration and impairment of goodwill. The net effect of the adjustment is a decrease in general and administrative expenses of $141,000.

 

61
 

 

4.OTHER ASSETS

 

Other assets at December 31, 2013, consisted of $201,000 in deposits paid to our joint venture partner, Neusoft for Attrius® systems and $54,000 in operating lease deposits. Other assets at December 31, 2012, consisted of $53,000 in operating lease deposits.

   
5.INVENTORIES

 

Inventories at December 31, 2013 and 2012 consisted of the following (in thousands):

 

   December 31, 
   2013   2012 
Finished systems  $24   $310 
Raw materials and service parts   927    698 
Work in progress   40    - 
    991    1,008 
Less: Reserve for obsolete inventory   (444)   (457)
   $547   $551 

 

Inventories are stated at the lower of cost or market.  Cost is determined using the first-in, first-out (FIFO) method of inventory valuation.  The Company evaluated the reserve as of December 31, 2013 and December 31, 2012.

 

6.PROPERTY AND EQUIPMENT

 

Property and equipment at December 31, 2013 and 2012 consisted of the following (in thousands):

 

   December 31, 
   2013   2012 
Buildings  $500   $500 
Furniture and fixtures   88    75 
Leasehold improvements   72    72 
Computer equipment   62    60 
Research equipment   667    667 
Machinery and equipment   158    142 
    1,547    1,516 
Less: Accumulated depreciation   (503)   (346)
   $1,044   $1,170 

 

7.ACCOUNTS PAYABLE AND ACCRUED LIABILITIES

 

Accounts payable and accrued liabilities at December 31, 2013 and, 2012 consisted of the following (in thousands):

 

   December 31, 
   2013   2012 
Trade accounts payable  $849   $1,127 
Accrued royalties   87    87 
Accrued interest   278    154 
Sales taxes payable   89    78 
Accrued compensation   70    80 
Other accrued expenses   28    108 
           
 Total  $1,401   $1,634 

 

62
 

 

8.CUSTOMER DEPOSITS

 

Customer deposits represent amounts paid to the Company by customers for devices in advance of manufacturing completion and/or shipment of the device to the customer.  Deposit amounts may vary depending on the contract. Customer deposits at December 31, 2013 and 2012, were $658,000 and $746,000, respectively. Included in customer deposits at December 31, 2013 and 2012 were deposits of approximately $658,000 and $669,000 from a customer that had placed an order in 2007 for five Nuclear Pharm-Assist™ systems.  As of the date of this report, there can be no assurance that this customer will fulfill its order for these devices.

 

Also, included in customer deposits at December 31, 2012 are $77,000 deposits on two Attrius® systems.

 

Our customer sales contracts require our customers to pay the Company 30% upon signing the contract, 60% upon notification to ship, and the remaining 10% after customer acceptance.

 

9.CONVERTIBLE DEBENTURES

 

Convertible Debentures 2012

 

On January 12, 2012, the Company acquired a building in Westmont, Illinois, which the Company previously leased from a related party for corporate and administrative offices (see Note 17). As a part of the price consideration, the Company issued the related party a convertible debenture in the principal amount of $250,000, which shall be due on December 31, 2013 and bears interest at 8% per year payable quarterly in cash. In addition, the Company issued warrants (“Warrants”) to the related party to purchase 25,000,000 shares of the Company’s common stock, par value $0.01 per share (the “Common Stock”), at an exercise price of $0.01 per share and expiring on December 31, 2013. The related party is entitled to convert the accrued interest and principal of the convertible debentures into common stock of the Company at a conversion price equal to 55% of the lowest daily volume weighted average price for the three trading days preceding conversion. During the period ended December 31, 2012, the Company has converted $100,000 of the principal amount of the debt into 18,181,818 shares of common stock and recorded loss on debt settlement of $44,661.

 

During the twelve months ended December 31, 2012, the Company issued additional of $2,210,000 of convertible debt with maturity date December 31, 2013, of which $460,000 bears 8% interest and $1,750,000 is non-interest bearing. $510,000 of the convertible debt was issued to unrelated parties, and $1,700,000 to related parties. In connection with the issuances the Company issued warrants (“Warrants”) to purchase 68,500,000 shares of the Company’s Common Stock, at an exercise price of $0.01 per share and expiring on December 31, 2013. The lender is entitled to convert the accrued interest and principal of the Convertible Debentures into common stock of the Company at a conversion price equal to 55% of the lowest daily volume weighted average price for the three trading days preceding conversion.

 

Initial Accounting

 

Under the initial accounting, the Company separated the Convertible Debentures instrument into component parts of the Convertible Debt, the $0.01 Warrants and the embedded conversion derivative liability. The Company estimated the fair value of each component as of the date of the issuance. The fair value of the embedded conversion derivative liability exceeded the value of the Convertible Debt less the allocation of the liability to the $0.01 Warrants, which resulted in a debt discount of $2,460,000. The discount is accreted to interest expense over the life of the Convertible Debt.

 

The following is a summary of Convertible Debt and the initial accounting of the issuances (in thousands):

 

Convertible debt issuance  $2,460 
      
Allocation of debt to warrants   (331)
      
Allocation of debt to embedded conversion derivative liability   (2,129)

 

63
 

 

Convertible Debentures 2013

 

In December 2013, the Company issued $2,520,000 of convertible debentures “(Convertible Debentures”) to certain investors (“Investors”). The Convertible Debentures do not accrue interest. The debentures mature on December 31, 2014. The Investors are entitled to convert the accrued interest and principal of the Convertible Debentures into common stock of the Company at a conversion price equal to 55% of the lowest daily volume weighted average price for the three trading days preceding conversion. On December 9, 2013, one of the Investors agreed to convert $1,000,000 of his outstanding debt, pending authorization and/or issuance of additional shares of common stock. As of December 9, 2013, there were not enough shares available to convert.

 

Initial Accounting

 

Under the initial accounting, the Company separated the Convertible Debentures instrument into debt and the embedded conversion derivative liability. The Company allocated the proceeds to the embedded conversion derivative liability. The fair value of the embedded conversion derivative liability exceeded the proceeds from the Convertible Debentures, which resulted in a debt discount of $1,500,000. The debt is accreted to interest expense over the life of the Convertible Debentures.

 

The following is a summary of the proceeds from the issuance of the Convertible Debentures and the initial accounting of the issuance (in thousands):

 

Proceeds from convertible debt issuance  $2,520 
      
Allocation of proceeds to embedded conversion derivative liability   (1,500)

 

Convertible debentures as of December 31, 2013

 

As of December 31, 2013, the holders of the convertible debentures issued in 2012 agreed to extend those issuances through December 31, 2014. The related Warrants were also extended through December 31, 2014. Approximately $821,000 in expense was recorded for the year ended December 31, 2013 related to modification of the Warrants.

 

As of December 31, 2013, convertible debt totaled $5,780,000, of which $1,328,000 was attributable to the discount on debt. These notes originally were set to mature on December 31, 2013 but were extended under existing terms through December 31, 2014 or were presented for conversion subsequent to year end.

 

During the years ended December 31, 2013 and 2012, the Company recognized interest expense related to Convertible Debentures of $1,970,000 and $1,628,000, respectively. As of December 31, 2013 and December 31, 2012, accrued interest on Convertible Debentures was $277,542 and $148,741 respectively. Convertible Debentures outstanding as of December 31, 2013 and 2012 were as follows (in thousands):

 

December 31, 2013  Unrelated
parties		   Related parties   Total 
             
Convertible debentures- face value  $4,030   $1,750   $5,780 
Debt discount   (1,328)   0   (1,328)
Total convertible debentures   2702    1,750   $4,452 
Less current portion   (2702)   (1,750)   (4,452)
Long term portion  $-   $-   $- 

 

December 31, 2012  Unrelated
parties		   Related parties   Total 
             
Convertible debentures- face value  $1,510   $1,850   $3,360 
Debt discount   (350)   (1,448)   (1,798)
Total current convertible debentures  $1,160   $402   $1,562 

 

Subsequent to year end, various holders of debt issued in 2012 and 2013 agreed to convert their convertible debt pending authorization of additional common stock at a specific price based on the weighted average close price of the three days prior to the conversion. A total of $2,220,000 have been presented for conversion effective January 2014. Of the $2,220,000, $1,120,000 was debt held by unrelated parties and $1,100,000 was debt held by related parties.

 

64
 

 

10.NOTES PAYABLE AND ADVANCES FROM RELATED PARTIES

 

On January 17, 2012, the Company assumed from MIT a note payable with Los Alamos National Bank (“LANB”) in the amount of $700,000. On February 10, 2012, MIT refinanced with LANB the principal and accrued interest of this note payable with a promissory note of $708,000, with an extended maturity of April 2015. The note renews annually. The monthly payment to LANB on the promissory note is $10,000, with the interest rate of 5.5% at December 31, 2013 and 2012. The promissory note is guaranteed by the Company and secured by all assets of the Company. Total interest expense related to the promissory note recorded during the years ended December 31, 2013 and 2012 was $35,000. The outstanding principal amount and accrued interest as of December 31, 2013, was approximately, $550,000 and $3,000, respectively. The outstanding principal and accrued interest as of December 31, 2012 was approximately $649,000 and $3,000, respectively.

 

During the twelve months ended December 31, 2013, the Company received $2,285,000 in short term notes from their CEO and CFO to help fund operations. The notes are unsecured and non-interest bearing. As of December 31, 2013, $1,250,000 of the notes/advances were converted to preferred shares (see note 17). The total outstanding notes/advances at December 31, 2013 were $1,035,000.

 

From time to time, the company receives advances from unrelated parties. These advances are unsecured, bear interest at 8% and there are no specific repayment terms. During the twelve months ended December 31, 2012, the Company received advances and made repayments of these advances in the amounts of $305,000 and $265,000, respectively. During the year ended December 31, 2012, the Company recorded interest expense related to the advances of $1,600. As of December 31, 2013, and 2012 the amounts due to the unrelated parties were $0 and $40,000, respectively.

 

Future maturities of the advances and notes payable are as follows:

 

Debt maturities as of    December 31, 
2014  $1,130,000 
      
2015   455,000 

 

11.NOTES PAYABLE – CAPITAL LEASE

 

The Company has entered into a capital leases for equipment at interest rates of 7.25%, payable through 2018. The assets and liabilities under the capital leases are recorded at the present value of the minimum lease payments and are depreciated over their estimated useful lives. The gross amount of assets held under capital leases for the nine months December 31, 2013 and December 31, 2012 was $16,300 and $0, respectively, with accumulated depreciation of $1,165 and $0, respectively. Depreciation expense for this equipment for the years ended December 31, 2013 and December 31, 2012 was $1,165 and $0, respectively.

 

Future minimum lease payments and the present value of the payments are as follows:

 

Debt maturities as of   December 31, 
2014  $4,000 
2015   4,000 
2016   4,000 
2017   4,000 
2018 and thereafter   1,000 
    17,000 
Less: amounts representing interest   (3,000)
Present value   14,000 
Less: current portion   (3,000)
Note payable Capital Lease – noncurrent portion  $11,000 

 

65
 

 

12.STOCKHOLDERS’ EQUITY

 

2013

 

On April 12, 2013, the Company issued 621,000 shares of common stock for consulting services. On the date of the issuance, the common stock had a fair market value of $0.008 per share. The Company recorded consulting fee expense of $5,000 for the issuance of the shares.

 

On April 11, 2013, the Company accepted subscriptions from Patrick Rooney, its Chairman and Chief Executive Officer, and Corey Conn, its Chief Financial Officer and converted certain advances (see note 17) in the amounts of $500,000 and $250,000 respectively for an aggregate investment of $750,000. In consideration of these subscriptions, the Company issued 7,500,000 shares of its newly created Series H Junior Convertible Preferred Stock, par value $0.01 per share (the “Series H Preferred Stock”). In November 2013, the Company accepted a subscription from Patrick G Rooney, Chairman and CEO to convert additional advances in the amount of $500,000 for 5,000,000 shares of Series H Preferred Stock. The Series H Preferred Stock ranks junior to dividends and distributions of the Company’s assets upon liquidation to all previously-issued shares of the Company’s capital stock and is not entitled to receive interest or dividends. The Series H Preferred Stock is convertible into shares of the Company’s Common Stock at a rate equal to the number of shares of Series H Preferred Stock being converted multiplied by the Original Issuance Price of $0.10 and divided by seventy percent (70%) of the daily weighted volume average price for the three trading days prior to conversion. The Series H Preferred Stock shall be entitled to two hundred (200) votes per share of Series H Preferred Stock on all matters which holders of Common Stock are entitled to vote.

 

In May 2013 the Board of Directors, subject to the approval of the shareholders of the Company, authorized an amendment to the Company's Certificate of Incorporation in order to effect a reverse split of the Company's common stock in a ratio of 1 for 100 (the "Reverse Split"), reduce the number of shares of capital stock from 3,020,000,000 to 520,000,000 of which 500,000,000 shares will be common stock and 20,000,000 shares will be preferred stock, each par value $0.0001 per share. The shareholders also approved the conversion of the Company to a Delaware corporation. These actions are not effective.

  

2012

 

On January 4, 2012, the Company increased the number of the Company’s authorized shares of capital stock from 810,000,000 shares to 3,020,000,000 of which 3,000,000,000 shares were classified as common stock par value $0.01 per share (“Common Stock”) and 20,000,000 shares were classified as preferred stock par value $1.00 per share (“Preferred Stock”). Additionally on January 4, 2012, the Company accepted subscriptions in the amount of $150,000 and issued 15,000,000 shares of Common Stock. In connection with these Common Stock issuances, the Company also issued 15,000,000 warrants to purchase Common Stock of the Company, which will expire on December 31, 2013 and extended the expiration date of 20,000,000 warrants which had expired to December 31, 2013.

 

On January 4, 2012, the Company issued 400,000 shares to a vendor for services rendered valued at $4,000.

 

On January 9, 2012, the Company issued 1,400,000 shares to a vendor for services rendered valued at $14,000.

 

On January 19, 2012, the Company converted 1,923,223 shares of Series B Convertible Preferred Stock into 192,322,258 shares of common stock and accepted subscriptions in the amount of $100,000 and issued 27,000,000 shares of Common Stock. Additionally, the Company issued 10,000,000 warrants to investors to purchase Common Stock of the Company, which will expire on December 31, 2013 and extended the expiration dates of 30,000,000 warrants which had expired to December 31, 2013.

 

On January 19, 2012, the Company issued 5,000,000 shares in connection with the acquisition of MIT and 76,261 shares of Common Stock were issued for royalties.

 

 

66
 

 

On January 19, 2012, the Company issued 25,000,000 shares of Common Stock and a convertible debenture due on December 31, 2013, with interest at the rate of 8%, to a related party as the purchase price for the office space previously leased by the Company. In addition, the Company issued 35,000,000 warrants, which entitle the related party to purchase shares of the Company’s common stock of the Company, which will expire on December 31, 2013.

 

On January 20, 2012, the Company accepted subscriptions in the amount of $50,000 and issued 5,000,000 shares of Common Stock. In connection with these Common Stock issuances, the Company also issued 5,000,000 warrants to purchase Common Stock of the Company, which will expire on December 31, 2013, and extended the expiration date of 7,500,000 warrants which had expired to December 31, 2013.

 

On March 1, 2012, the Company converted 603,711 shares of Series B Convertible Preferred Stock into 60,371,100 shares of Common Stock and issued 3,000,000 shares of Common Stock to a vendor for services rendered valued at $51,000.

 

On March 14, 2012, the Company accepted subscriptions in the amount of $35,000 and issued 3,500,000 shares of Common Stock. In connection with these issuances, the Company also issued 3,500,000 warrants to investors to purchase Common Stock of the Company, which will expire on December 31, 2013, and extended the expiration date of 750,000 warrants which had expired to December 31, 2013. Also on March 14, 2012, the Company issued 1,200,000 shares of Common Stock to an employee for services valued at $20,000, and 600,000 shares of Common Stock to a vendor for services rendered valued at $10,000.

 

On April 5, 2012, the Company converted 634,000 shares of Series B Convertible Preferred Stock into 63,400,000 shares of Common Stock. The Company also accepted subscriptions in the amount of $28,000 and issued 2,800,000 shares of Common Stock. In connection with these Common Stock issuances, the Company also issued 3,100,000 warrants to purchase Common Stock of the Company, which will expire on December 31, 2013. Also on April 5, 2012, the Company issued 39,682,539 shares of Common Stock for repayment of convertible debt, and issued 2,208,750 shares of Common Stock to a vendor for settlement of accounts payable. The Company recorded $26,456 loss on the settlement.

 

On May 7, 2012, the Company issued 4,000,000 warrants in connection with a Convertible Debt issuance to a Lender to purchase Common Stock of the Company, which will expire on December 31, 2013.

 

On May 20, 2012, the Company issued 2,000,000 warrants to an investor to purchase Common Stock of the Company, which will expire on December 31, 2013.

 

On May 21, 2012, the Company converted 73,226 shares of Series B Convertible Preferred Stock into 7,322,636 shares of Common Stock. The Company also accepted subscriptions in the amount of $130,000 and issued 15,000,000 shares of Common Stock. In connection with these issuances, the Company issued 13,000,000 warrants to investors to purchase Common Stock of the Company, which will expire on December 31, 2013. In addition, the Company issued 175,000 shares of Common Stock to a vendor on May 21, 2012 for services rendered valued at $2,000.

 

On May 29, 2012, the Company converted 231,190 shares of Series B Convertible Preferred Stock into 23,119,000 shares of Common Stock. The Company issued 18,181,818 shares of Common Stock for repayment of related party convertible debt.

 

On June 7, 2012, the Company issued 4,000,000 warrants in connection with a Convertible Debt issuance to a lender to purchase Common Stock of the Company, which will expire on December 31, 2013.

 

On June 19, 2012, the Company converted 16,667 shares of Series A Convertible Preferred Stock into 16,667 shares of Common Stock, converted 118,149 shares of Series B Convertible Preferred Stock into 11,814,878 shares of Common Stock, and converted 18,200 shares of Series G Convertible Preferred Stock into 2,020,000 shares of Common Stock. In addition, the Company issued 3,970,786 shares of Common Stock to a vendor for settlement of accounts payable. 

 

67
 

 

On July 17, 2012, the Company issued 1,000,000 shares of Common Stock to vendors for services rendered. The Company issued and additional 1,000,000 shares of Common Stock to a vendor for services rendered on July 18, 2012. Both were valued at $10,000.

 

On August 21, 2012 the Company issued 1,000,000 shares of Common Stock to a vendor for services rendered valued at $10,000.

 

On August 31, 2012, the Company converted 1,188,836 shares of Series B Convertible Preferred Stock into 118,883,629 shares of Common Stock. Also on August 31, the Company issued 2,000,000 shares to an investor who had purchased shares during the three months ended June 30, 2012 and which were included in stock payable as of June 30, 2012.

 

On September 10, 2012, the Company converted obligations totaling $35,605 into 10,000,000 shares of Common Stock. Of these shares, 6,666,667 shares were payable as of September 30, 2012 and were issued in October 2012. In connection with this issuance the Company recorded a loss on settlement of $54,395.

 

In November 2012, the Company issued warrants to purchase a total of 10,500,000 shares of the Company’s Common Stock, at an exercise price of $0.01 per share expiring on December 31, 2013, to its Chief Financial Officer. The warrants were issued in connection with the issuance of two non-interest bearing convertible debentures totaling $380,000 to the CFO.

 

In November 2012, the Company issued warrants to purchase a total of 37,500,000 shares of the Company’s Common Stock, at an exercise price of $0.01 per share to its Chief Executive Officer. The warrants expire on December 31, 2013. The warrants were issued in connection with the issuance of two non-interest bearing convertible debentures totaling $1,320,000 to the CEO.

 

In December 2012, the Company issued a convertible debenture in the amount of $50,000 to a third party. In connection with the debt, the Company also issued to the third party warrants to purchase 1,500,000 shares of the Company’s Common Stock, at an exercise price of $0.01 per share expiring on December 31, 2013.

 

Options

For all of the Company’s stock-based compensation plans, the fair value of each grant was estimated at the date of grant using the Black-Scholes option-pricing model. Black-Scholes utilizes assumptions related to volatility, the risk-free interest rate, the dividend yield (which is assumed to be zero, as the Company has not paid cash dividends to date and does not currently expect to pay cash dividends) and the expected term of the option. Expected volatilities utilized in the model are based mainly on the historical volatility of the Company’s stock price over a period commensurate with the expected life of the share option as well as other factors. The risk-free interest rate is derived from the zero-coupon U.S. government issues with a remaining term equal to the expected life at the time of grant.

 

For all of the Company’s stock-based compensation plans, the fair value of each grant was estimated at the date of grant using the Black-Scholes option-pricing model. Black-Scholes utilizes assumptions related to volatility, the risk-free interest rate, the dividend yield (which is assumed to be zero, as the Company has not paid cash dividends to date and does not currently expect to pay cash dividends) and the expected term of the option. Expected volatilities utilized in the model are based mainly on the historical volatility of the Company’s stock price over a period commensurate with the expected life of the share option as well as other factors. The risk-free interest rate is derived from the zero-coupon U.S. government issues with a remaining term equal to the expected life at the time of grant.

 

68
 

 

In January 2010 the Company granted certain employees options to purchase 2,500,000 shares of Series B Preferred stock at an exercise price of $1.00 per share (the “Preferred Options”.) The options vest immediately and have a term of three years. Accordingly, in January 2010 the Company recorded compensation expense of $2,500,000 for the Preferred Option grants. At December 31, 2013, 430,000 of these options expired and 2,070,000 were extended for one year. The Company recorded compensation expense of $567,567 for the extended Preferred Option grants. Fair market value using the Black-Scholes option-pricing model was determined using the following assumptions:

 

Expected life (years)   1 
Risk free rate of return   11%
Dividend yield   0 
Expected volatility   200%

 

A summary of Series B Preferred stock option activity is as follows:

 

   Shares Issuable
Under
Outstanding
Options		   Weighted
Average
Exercise
Price		 
         
Balance at December 31, 2012   2,500,000   $1.00 
Issued   -   - 
Expired/forfeited   (430,000)   1.00 
Exercised   -    - 
Balance at December 31, 2013   2,070,000   $1.00 
Exercisable, December 31, 2013   2,070,000   $1.00 

 

On January 17, 2012, Positron's Board of Directors (the “Board”) adopted the 2012 Equity Incentive Plan ("2012 Plan"), authorizing issuance of 200,000,000 stock options to purchase shares of the Company’s common stock.

 

On January 17, 2012, the Company granted certain employees options to purchase 177,600,000 shares of common stock under the plan at an exercise price of $0.01 per share (“January Issuance”). Fifty (50) percent of the options vested immediately on the grant date with the remaining fifty (50) percent vesting on January 17, 2013. The Company recorded a total expense of approximately $1,735,000 related to these options during the year ended December 31, 2012 and recorded an additional $39,000 for these stock options in the first quarter of 2013. During the year ended December 31, 2012, options to purchase 7,000,000 shares of stock were forfeited and a total of 170,600,000 options from the January issuance were outstanding as of December 31, 2012. At December 31, 2012, the remaining weighted average contractual term of these options was 2.05 years. The intrinsic value of these options on the grant date was $187,600 as the closing stock price on the grant date was $0.011. Fair market value using the Black-Scholes option-pricing model was determined using the following assumptions:

 

Expected life (years)   1.75 
Risk free rate of return   0.75%
Dividend yield   0 
Expected volatility   218%

 

In November 2012, the Company granted additional options to purchase 20,000,000 shares of common stock under the 2012 Plan to a new employee at an exercise price of $0.01 per share. Fifty (50) percent of the options vested immediately on the grant date with the remaining fifty (50) percent vesting on January 17, 2013 The Company recognized an expense of approximately $49,000 related to these options during the year ended December 31, 2012 and will recognize an additional expense of $49,000 during the first quarter of 2013. At December 31, 2012, the remaining weighted average contractual term of these options was 2.05 years. The intrinsic value of the options on the grant date was $0, as the closing stock price on the grant date was $0.008. Fair market value using the Black-Scholes option-pricing model was determined using the following assumptions:

 

Expected life (years)   2.25 
Risk free rate of return   0.27%
Dividend yield   0 
Expected volatility   125%

 

69
 

 

As of December 31, 2012, the Company had a total of 190,600,000 options outstanding with 9,400,000 options available for issuance under the 2012 Plan. Fifty (50) percent of the outstanding options were fully and the remaining fifty (50) percent vest on January 17, 2013. All the options issued under the 2012 Plan expire on January 17, 2015.

 

A summary of common stock option activity is as follows:

 

   Shares Issuable
Under
Outstanding
Options		   Weighted
Average
Exercise
Price		 
Issued in 2012    197,600,000  $ 0.01 
Forfeited    (7,000,000)    0.01 
Balance at December 31, 2012   190,600,000   $0.01 
Forfeited   (2,500,000)  $0.01 
Exercised   -    - 
Balance at December 31, 2013   188,100,000   $0.01 
Exercisable, December 31, 2013   188,100,000   $0.01 

 

Warrants

 

A summary of warrant activity based on common stock equivalents is as follows:

 

   Number of Shares   Exercise
Price		   Weighted
Average
Exercise
Price		 
Balance at December 31, 2011   183,583,338   $0.01-0.15   $0.05 
Warrants exercised   -    -    - 
Warrants expired   (134,583,338)  $0.01-0.03   $0.03 
Warrants issued with common and Series B Preferred stock in private placement   114,850,000   $0.01   $0.01 
Warrants issued with convertible debentures and notes payable   103,500,000   $0.01   $0.01 
Balance at December 31, 2012   267,350,000   $0.01-0.15   $0.03 
Warrants exercised   -    -    - 
Warrants expired   (144,850,000)  $0.01-0.15   $0.02 
Warrants issued with convertible debentures and notes payable   -   $-   $- 
Balance at December 31, 2013   122,500,000   $0.01-0.02   $0.01 

 

All outstanding warrants are currently exercisable.  A summary of outstanding common stock warrants at December 31, 2013 follows:

 

Number of
Common Stock
Equivalents		   Expiration Date  Remaining
Contractual Life
(Years)		   Exercise
Price		 
 4,000,000   (a)   -   $0.02 
 118,500,000   (b)   1.00   $0.01 

 

(a) Warrants expire six months after the date on which a registration statement is filed and accepted by the Securities Exchange Commission permitting a sale of the shares issuable upon exercise of the warrant.

 

(b) Warrants were originally set to expire on December 31, 2013, but were extended by the Company through December 31, 2014.

 

70
 

 

 

13.PREFERRED STOCK

 

The Company’s Certificate of Formation, as amended, authorizes the issuance of 20,000,000 shares of preferred stock from time to time in one or more series. The Board of Directors is authorized to determine, prior to issuing any such series of preferred stock and without any vote or action by the shareholders, the rights, preferences, privileges and restrictions of the shares of such series, including dividend rights, voting rights, terms of redemption, the provisions of any purchase, retirement or sinking fund to be provided for the shares of any series, conversion and exchange rights, the preferences upon any distribution of the assets of the Company, including in the event of voluntary or involuntary liquidation, dissolution or winding up of the Company, and the preferences and relative rights among each series of preferred stock. The Board of Directors has designated the following series of preferred stock

 

Series A Preferred Stock

 

The Company had 7,900,000 shares of Series A Preferred Stock authorized for issuance. Subject to adjustment based on issuance of shares at less than fair market value, each share of the Series A Preferred Stock was initially convertible into one share of common stock. Each Redeemable common stock Purchase Warrant is exercisable at a price of $2.00 per share of common stock. Eight percent (8%) dividends on the Series A Preferred Stock may be paid in cash or in Series A Preferred Stock at the discretion of the Company. The Series A Preferred Stock is senior to the Company’s common stock in liquidation. Holders of the Series A Preferred stock may vote on an as if converted basis on any matter requiring shareholder vote. While the Series A Preferred Stock is outstanding or any dividends thereon remain unpaid, no common stock dividends may be paid or declared by the Company. The Series A Preferred Stock may be redeemed in whole or in part, at the option of the Company, at any time subsequent to March 1998 at a price of $1.46 per share plus any undeclared and/or unpaid dividends to the date of redemption. Redemption requires at least 30 days advanced notice and notice may only be given if the Company’s common stock has closed above $2.00 per share for the twenty consecutive trading days prior to the notice.

 

As of December 31, 2013 and 2012, there were 447,652 shares of Series A Preferred Stock outstanding, respectively.

 

Series B Preferred Stock

 

As of December 31, 2012, the Company has 9,000,000 shares of Series B Preferred Stock authorized for issuance. Each share of Series B Preferred Stock $1.00 par value is convertible into 100 shares of the Company’s Common Stock. The Series B Preferred Stock is senior to the Company’s Common Stock and junior in priority to the Company’s A and G Preferred Stock in liquidation. Holders of the Series B Preferred Stock are entitled to 100 votes per share on all matters requiring shareholder vote. While Series B Preferred Stock is outstanding no Common Stock dividends may be paid or declared by the Company. The Series B Preferred Stock may be redeemed in whole or in part, at the option of the Company, at any time at a price of $1.00 per share.

 

As of December 31, 2013 and 2012, 3,056,487 shares of Series B Preferred Stock were outstanding, respectively.

 

Series G Preferred Stock

 

The Company has designated 3,000,000 shares of preferred stock as Series G Preferred Stock $1.00 par value. Each share of Series G Preferred Stock is convertible into 100 shares of common stock. The Series G Preferred Stock is senior to the Company's common stock and junior in priority to the Registrant's Series A, C, D, E and F Preferred Stock in liquidation. Except as required by law and in the case of various actions affecting the rights of the Series G Preferred Stock, holders of the Series G Preferred Stock are not entitled to vote on matters requiring shareholder vote. While the Series G Preferred Stock is outstanding or any dividends thereon remain unpaid, no common stock dividends may be paid or declared by the Company. The Series G Preferred Stock may be redeemed in whole or in part, at the option of the Company, at any time at a price of $5.00 per share plus any undeclared and/or unpaid dividends to the date of redemption.

 

As of December 31, 2013 and 2012, there are no shares of Series G Preferred Stock outstanding.

 

Series S Preferred Stock

 

As of December 31, 2012, the Company has 10,000 shares of Series S Preferred Stock authorized for issuance. Each share of Series S Convertible Preferred Stock, $1.00 par value per share, is convertible into 10,000 shares of the Company’s Common Stock, subject to adjustment The Series S Preferred Stock is senior to the Company’s Common Stock and junior in priority to the Company’s A, B and G Preferred Stock in liquidation. Holders of the Series S Preferred Stock are entitled to 10,000 votes per share on all matters requiring shareholder vote. While Series S Preferred Stock is outstanding no Common Stock dividends may be paid or declared by the Company.

 

As of December 31, 2013 and 2012, 100,000 shares of Series S Convertible Preferred Stock were outstanding.

 

71
 

 

Series H Preferred Stock

 

As of December 31, 2013, the Company has 15,000,000 shares of Series H Preferred Stock authorized for issuance at par value of $0.01 per share. The Series H Preferred Stock rank junior to dividends and distributions of the Company’s assets upon liquidation to all previously-issued shares of capital stock of the Company and is not entitled to receive interest or dividends. The Series H Preferred Stock is convertible into shares of the Company’s Common Stock at a rate equal to the number of shares of Series H Preferred Stock being converted multiplied by the Original Issuance Price of $0.10 and divided by seventy percent (70%) of the daily weighted volume average price for the three trading days prior to conversion. The Series H Preferred Stock is entitled to two hundred (200) votes per share of Series H Preferred Stock on all matters which holders of Common Stock are entitled to vote.

 

As of December 31, 2013 and 2012, 12,500,000 and 0 shares of Series H Preferred Stock were outstanding, respectively.

 

14.OTHER EXPENSES

 

During the years ended December 31, 2013 and 2012, the Company recorded other expenses of approximately $3,766,000 and $3,233,000, respectively. Other expenses include interest expense, derivative expenses and other gains and losses.

 

Interest expense was $2,137,000 and $1,753,000 for the years ended December 31, 2013 and 2012, respectively. $1,910,000 and $1,628,000 of the total interest expense for the years ended December 31, 2013 and 2012, respectively, was related to the accretion of debt discount associated with convertible debt.

 

For the years ended December 31, 2013 and 2012, the Company recorded losses of approximately $665,000 and $726,000, respectively, on fair value adjustments to embedded conversion derivative liability associated with the convertible debt. Debt modification expense was $821,000 and $432,000 for the years ended December 31, 2013 and 2012, respectively.

 

During the year ended December 31, 2012, the Company also recorded $18,000 loss on the disposal of property and equipment, $282,000 loss on settlement and other expenses of $22,000. During the year ended December 31, 2013 the Company recorded other expenses of $143,000, which is made up of foreign currency translation losses reclassified out of accumulated other comprehensive income.

 

72
 

 

15.LOSS PER SHARE

 

Basic loss per common share is based on the weighted average number of common shares outstanding in each period and earnings adjusted for preferred stock dividend requirements. Diluted earnings per common share assumes that any dilutive convertible preferred shares outstanding at the beginning of each period were converted at those dates, with related interest, preferred stock dividend requirements and outstanding common shares adjusted accordingly. It also assumes that outstanding common shares were increased by shares issuable upon exercise of those stock options and warrants for which market price exceeds exercise price, less shares which could have been purchased by the Company with related proceeds. The convertible preferred stock and outstanding stock options and warrants were not included in the computation of diluted earnings per common share for the twelve months ended December 31, 2013 and 2012, respectively since it would have resulted in an antidilutive effect.

 

The following table sets forth the computation of basic and diluted loss per share (in thousands, except per share data):

 

   Year Ended December 31, 
   2013   2012 
Numerator          
Basic and diluted loss  $(7,104)  $(7,955)
           
Denominator          
Basic and diluted earnings per share - weighted average shares outstanding   1,452,364    1,265,270 
           
Basic and diluted loss per common share  $(0.00)  $(0.01)

 

Anti-dilutive securities (based on conversions to common shares) not included in net loss per share calculation (in thousands):

 

   Year Ended December 31, 
   2013   2012 
Convertible Series A preferred stock   448    448 
Convertible Series B preferred stock   305,648    305,648 
Convertible Series G preferred stock   -    100 
Convertible Series S preferred stock   1,000,000    1,000,000 
Convertible Series H preferred stock   482,625    - 
Stock warrants   122,500    267,350 
Convertible debt   2,693,553    722,910 
Common stock options   188,100    190,600 
Series B preferred stock options   207,000    250,000 

 

73
 

 

16.INCOME TAXES

 

The Company has incurred losses since its inception and, therefore, has not been subject to federal income taxes. As of December 31, 2013, the Company had domestic net operating loss (“NOL”) carryforwards for income tax purposes of approximately $55,340,000 which expire in 2013 through 2033. Under the provisions of Section 382 of the Internal Revenue Code greater than 50% ownership changes that occurred in the Company may significantly limit the Company’s ability to utilize its NOL carry forwards to reduce future taxable income and related tax liabilities.

 

Section 382 allows an owner shift any time there is a transfer of stock by a person who directly, or indirectly, owns more than 5% of the corporation and the percentage of stock of the corporation owned by one or more five percent shareholders has increased, in the aggregate, by more than 50 percentage points over the lowest percentage of stock owned by such shareholders at any time during the "testing period." The "testing period" is generally a three-year period ending on the date of any owner or equity structure shift.

 

The amount of post-change income that may be offset by pre-change losses is limited each year by the "Section 382 Limitation." Generally, the Section 382 Limitation is an amount equal to the value of the old loss corporation multiplied by a long-term interest rate established monthly by the Internal Revenue Service. The Company has not yet determined the qualifying events and resulting limitation that may impact utilization of net operating losses against future periods.

 

The composition of deferred tax assets and the related tax effects at December 31, 2013 and 2012 are as follows (in thousands):

 

   2013   2012 
Deferred tax assets:          
           
Domestic net operating losses  $18,816   $19,529 
Stock option compensation   223    606 
Book/tax differences in fixed assets   27    32 
Accrued liabilities and reserves   327    272 
    19,393    20,439 
Valuation allowance   (19,393)   (20,439)
   $-   $-

 

The difference between the income tax benefit in the accompanying statement of operations and the amount that would result if the U.S. Federal statutory rate of 34% were applied to pre-tax loss is as follows (amounts in thousands):

 

   2013   2012 
   Amount   %   Amount   % 
Benefit for income taxes at federal statutory rate  $2,415    34%  $2,704    34%
Derivative losses   (226)   (3)  (596)   (7)
Discount amortization and other   (949)   (13)   (565)   (7)
Change in rates and other   (2,286)   (32)   21    - 
Change in valuation allowance   1,046   14    (1,564)   (20)
   $-    -%  $-    - %

 

17.401(k) PLAN

 

The Positron Corporation 401(k) Plan and Trust (the “Plan”) covers all of the Company’s employees who are United States citizens, at least 21 years of age and have completed at least one quarter of service with the Company. Pursuant to the Plan, employees may elect to reduce their current compensation by up to the statutorily prescribed annual limit and have the amount of such reduction contributed to the Plan. The Plan allows for the Company to make discretionary contributions in an amount equal to 25 percent of the participant’s deferral contributions, up to 6 percent of the employee’s compensation, as defined in the Plan agreement. The Company made no contributions in 2013 and 2012. The Board of Directors of the Company may authorize additional discretionary contributions; however, no such contributions were made by the Company in 2013 or 2012.

 

74
 

 

18.RELATED PARTY TRANSACTIONS

 

2013

 

On January 31, 2013 the Company accepted a non-interest bearing $250,000 advance from its CEO.  At the time, the Company issued no shares or warrants in connection with this transaction.

 

On February 27, 2013 the Company accepted a non-interest bearing $250,000 advance from its CFO.  At the time, the Company issued no shares or warrants in connection with this transaction.

 

On March 25, 2013 the Company accepted a non-interest bearing $100,000 advance from its CEO.  At the time, the Company issued no shares or warrants in connection with this transaction.

 

During June 2013 the Company accepted a non-interest bearing $185,000 advance from its CEO.  At the time, the Company issued no shares or warrants in connection with this transaction.

 

On April 4, 2013 the Company accepted a non-interest bearing $150,000 advance from its CFO.  At the time, the Company issued no shares or warrants in connection with this transaction.

 

On April 11, 2013, the Company converted certain advances from its CEO and CFO in the amounts of $ 500,000 and $ 250,000, respectively, into Series H preferred shares (see note 15).

 

On May 22, 2013 the Company accepted a non-interest bearing $150,000 advance from its CFO.  At the time, the Company issued no shares or warrants in connection with this transaction.

 

On June 21, 2013 the Company accepted a non-interest bearing $100,000 advance from its CFO.  At the time, the Company issued no shares or warrants in connection with this transaction.

 

On August 16, 2013 the Company accepted a non-interest bearing $250,000 advance from its CFO.  At the time, the Company issued no shares or warrants in connection with this transaction.

 

On August 26, 2013 the Company accepted a non-interest bearing $250,000 advance from its CEO.  At the time, the Company issued no shares or warrants in connection with this transaction.

 

On November 2, 2013 the Company accepted a non-interest bearing $100,000 advance from its CEO.  At the time, the Company issued no shares or warrants in connection with this transaction.

 

On November 7, 2013, the Company converted certain advances from its CEO in the amount of $500,000, into Series H preferred shares (see note 15).

  

During 2013, the Company paid $201,000 in deposits to the joint venture partner, Neusoft, for Attrius® Systems.

 

On January 3, 2014 the related party debt holders agreed to convert certain convertible debt issued in 2012. The CEO and CFO agreed to convert a portion of their outstanding debt in the amount of $1,000,000 and $300,000, respectively, pending reverse split authorization and/or approval of additional authorized shares. Remaining convertible debt originally due December 31, 2013 due to the CEO and CFO in the amount of $400,000 and $50,000, respectively, was extended through December 31, 2014. Warrants associated with this debt issued in 2012 were also extended through December 31, 2014. 

 

2012

 

On January 12, 2012, the Company acquired a building in Westmont, Illinois, which the Company previously leased from its Chief Executive Officer (Lender or Related Party) for corporate and administrative offices since 2010. The Company issued the Chief Executive Officer 25,000,000 shares of common stock, which were valued at approximately $250,000 and a convertible debenture of $250,000, which shall be due on December 31, 2013 and bear interest at 8% per year payable quarterly in cash. In addition, the Company issued 35,000,000 warrants (“Warrants”), which entitle the Related Party to purchase shares of the Company’s common stock, par value $0.01 per share, at an exercise price of $0.01 per share and expiring on December 31, 2013. The Lender is entitled to convert the accrued interest and principal of the Convertible Debentures into common stock of the Company at a conversion price equal to 55% of the lowest daily volume weighted average price for the three trading days preceding conversion. During the twelve months ended December 31, 2012, the Company issued 18,181,818 shares of Common Stock for repayment of $100,000 of these Convertible Debentures. During the year ended December 31, 2012, the Company expensed $77,000 of deferred rent.

 

75
 

 

During the year ended December 31, 2012, the Company recognized cost of revenues of approximately $623,000 related to the purchase of Attrius® PET Systems from Neusoft, the joint venture partner.

 

During the year ended December 31, 2012 the Company issued additional convertible debt to its Chief Executive Officer (“Lender”) in the amount of $1,320,000. The debt is non-interest bearing and matures on December 31, 2013. In connection with the this debt, the Company issued warrants (“Warrants”) to purchase 37,500,000 shares of the Company’s Common Stock, at an exercise price of $0.01 per share expiring on December 31, 2013. The lender is entitled to convert the accrued interest and principal of the Convertible Debentures into common stock of the Company at a conversion price equal to 55% of the lowest daily volume weighted average price for the three trading days preceding conversion.

 

During September and December 2012, the Company issued two non-interest bearing convertible debentures totaling $380,000 to it Chief Financial Officer (“Lender” or “CFO”). In connection with this debt, the Company issued to the CFO warrants to purchase 10,500,000 shares of the Company’s Common Stock, at an exercise price of $0.01 per share expiring on December 31, 2013. The Lender is entitled to convert the accrued interest and principal of the Convertible Debentures into common stock of the Company at a conversion price equal to 55% of the lowest daily volume weighted average price for the three trading days preceding conversion. These debentures are noninterest bearing. As of December 31, 2012, the Company all of the $380,000 debt was outstanding.

 

In September of 2012, the Company received an unsecured advance of $25,000 from a related party, which accrues interest at 8% per annum. This note was fully repaid as of December 31, 2012.

 

19.COMMITMENTS AND CONTINGENCIES

 

Lease Agreements

 

On April 19, 2010, the Company entered into an operating lease agreement with a third party for warehousing and office space in Niagara, New York. The lease expires in May 2014, with an option to renew for an additional three years. Monthly rent is $1,800. The Company is currently negotiating an extension.

 

On July 7, 2011, the Company entered into an operating lease with a third party for space for medical device assembly and warehousing at a building in Fishers, Indiana. The Company is required to make payments of $5,083 each month from December 1, 2011 through November 13, 2013, and $5,287 from December 1, 2013 through November 30, 2016. The amount of leased space at this location is approximately 9,761 square feet.

 

On December 5, 2011, MIT entered into an operating lease with a third party for space for warehousing at a building in Lubbock, Texas. The Company will be required to make payments of $1,475 each month from month to month.

 

Total rent expense for the years ended December 31, 2013 and 2012 was $84,011 and $69,512, respectively.

 

Future minimum rental commitments under non-cancellable facilities operating leases as of December 31, 2013 are as follows:

 

Year Ending December 31,    
2014  $72,444 
2015   63,444 
2016   58,157 

 

Litigation

 

On June 8, 2012, the owner of the radiopharmaceutical manufacturing facility the Company formerly leased in Crown Point, Indiana commenced an action to recover the use of the premises and the remaining rent due under the lease. On November 14, 2012, the owner was awarded a judgment against the Company in the amount of $85,525.98 plus interest at the rate of 8%. The Company and the owner agreed to monthly payments in the minimum amount of $5,000 until the judgment is paid in its entirety.

 

In May, 2013, the Company was served with a First Amended Complaint in an action commenced against related its CEO and principal shareholder. The plaintiff in the action is seeking to enforce a judgment against the CEO and principal shareholder and is seeking to have the Company’s Westmont, Illinois offices, which it purchased from the CEO, reconveyed. The CEO and the principal shareholder have disputed the basis of the judgment and the Company has denied the allegations in the Complaint and is defending the action. The action is currently in the discovery stage.

  

20.SELECTED QUARTERLY FINANCIAL DATA (UNAUDITED) (in thousands)

 

   Quarter ended 
   March 31,
2013		   June 30,
2013		   September 30,
2013		   December 31,
2013		 
                 
Net Sales  $371   $432   $351   $476 
Gross profit (loss)   125    14    121    164 
Net loss   (1,201)   (1,088)   (1,390)   (3,425)
Net (loss) per share - basic and diluted  $(0.00)  $(0.00)  $(0.00)  $(0.00)
Weighted average basic and diluted shares   1,451,927    1,452,425    1,452,548    1,452,548 

 

   Quarter ended 
   March 31,
2012		   June 30,
2012		   September 30,
2012		   December 31,
2012		 
                 
Net Sales  $829   $1,224   $370   $378 
Gross profit (loss)   359    331    106    33 
Net loss   (2,962)   (1,235)   (1,568)   (2,190)
Net (loss) per share - basic and diluted  $(0.00)  $(0.00)  $(0.00)  $(0.00)
Weighted average basic and diluted shares   970,887    1,256,915    1,360,107    1,451,140 

 

76
 

 

21.SEGMENTS

 

We have aggregated our operations into two reportable segments based upon product lines, manufacturing processes, marketing and management of our businesses: medical equipment and radiopharmaceuticals.  Our business segments operate in the nuclear medicine industry. The Company’s medical equipment segment is currently generating all revenues and the majority of all expenses as the radiopharmaceuticals segment is still in the development and regulatory approval phase.

 

We evaluate a segment’s performance based primarily upon operating income before corporate expenses.

 

Corporate assets consist primarily of cash but also include plant and equipment associated with our headquarters. These items (and income and expenses related to these items) are allocated to the segments. Unallocated income/expenses include interest income, interest expense, debt extinguishment and refinancing costs and other (expense) income and certain expenses which are not considered related to either segment, but are instead considered general corporate expenses.

 

The following table represents sales, operating loss and total assets attributable to these business segments for the periods indicated (in thousands):

 

   Year Ended December 31, 
   2013   2012 
Total Sales:          
Medical equipment  $1,630   $2,789 
Radiopharmaceuticals   -    12 
Total sales  $1,630   $2,801 
           
           
Operating loss:          
Medical equipment  $(2,486)  $(3,690)
Radiopharmaceuticals   (862)   (1,026)
Unallocated   -    (6)
Total operating loss  $(3,338)  $(4,722)
           
Total Assets:          
Medical equipment  $3,373   $1,739 
Radiopharmaceuticals   509    945 
Unallocated   -    1 
Total assets  $3,882   $2,685 

 

21.SUBSEQUENT EVENTS

 

Management has evaluated all events that occurred after the balance sheet date through the date when these financial statements were issued to determine if they must be reported. The management of the Company has determined the following:

 

The Company issued an aggregate of $320,000 of convertible notes to unrelated parties in February and March 2014. As with the Company’s other, recent sales of convertible notes, the notes are convertible into shares of the Company’s Common Stock at a rate equal to the daily volume weighted average price of the three trading days prior to a conversion, mulitiplied by 0.55.

 

77

 EX-21 2 v372432_ex21.htm EXHIBIT 21

 

EXHIBIT 21

 

SUBSIDIARIES OF THE REGISTRANT

 

 

Imaging PET Technologies, Inc., a Canadian company

Positron Pharmaceuticals Company, a Nevada corporation

Manhattan Isotope Technology LLC, a Texas limited liability company

Positron Isotope Corporation, an Indiana corporation

 

 

 

 EX-31.1 3 v372432_ex31-1.htm EXHIBIT 31.1

 

EXHIBIT 31.1

 

Certification

Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002

 

I, Patrick Rooney, certify that:

 

1.  I have reviewed this annual report on Form 10-K of Positron Corporation;

 

2.  Based on my knowledge, this annual report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

 

3.  Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

 

4.  The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

 

  a)  Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

 

  b)  Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

 

  c)  Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

 

  d)  Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

 

5.  The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

 

  a)  All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

 

  b)  Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

 

Dated March 31, 2014 /s/ Patrick Rooney
  Patrick Rooney
  Chairman of the Board and Chief Executive Officer
  (Principal Executive Officer)

 

 

 

 EX-31.2 4 v372432_ex31-2.htm EXHIBIT 31.2

 

EXHIBIT 31.2

 

Certification

Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002

 

I, Corey Conn, certify that:

 

1.  I have reviewed this annual report on Form 10-K of Positron Corporation;

 

2.  Based on my knowledge, this annual report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

 

3.  Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

 

4.  The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

 

  a)  Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

 

  b)  Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

 

  c)  Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

 

  d)  Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

 

5.  The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

 

  a)  All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

 

  b)  Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

 

Dated: March 31, 2014 /s/ Corey Conn
  Corey Conn
  Chief Financial Officer
  (Principal Financial Officer)

 

 

 

 EX-32.1 5 v372432_ex32-1.htm EXHIBIT 32.1

 

EXHIBIT 32.1

 

Certification Pursuant to 18 U.S.C. Section 1350,

 

As Adopted Pursuant to

 

Section 906 of the Sarbanes-Oxley Act of 2002

 

In connection with the Annual Report of Positron Corporation (the “Company”) on Form 10-K for the year ended December 31, 2013 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), Patrick Rooney, as Chairman and Chief Executive Officer of the Company, hereby certifies, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 that:

 

(1) The Report fully complies with the requirements of section 13 (a) or 15 (d), as applicable of the Securities Exchange Act of 1934: and

 

(2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

 

Dated: March 31, 2014 /s/ Patrick Rooney
  Patrick Rooney
  Chairman of the Board and Chief Executive Officer
  (Principal Executive Officer)

 

A signed original of this written statement required by Section 906 has been provided to Positron Corporation and will be retained by Positron Corporation and furnished to the Securities and Exchange Commission or its staff upon request.

 

 

 

 EX-32.2 6 v372432_ex32-2.htm EXHIBIT 32.2

 

EXHIBIT 32.2

 

Certification Pursuant to 18 U.S.C. Section 1350,

 

As Adopted Pursuant to

 

Section 906 of the Sarbanes-Oxley Act of 2002

 

In connection with the Annual Report of Positron Corporation (the “Company”) on Form 10-K for the year ended December 31, 2013 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), Corey Conn, as Chief Financial Officer of the Company, hereby certifies, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 that:

 

(1) The Report fully complies with the requirements of section 13 (a) or 15 (d), as applicable of the Securities Exchange Act of 1934: and

 

(2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

 

Dated: March 31, 2014 /s/ Corey Conn
  Corey Conn
  Chief Financial Officer
  (Principal Financial Officer)

 

A signed original of this written statement required by Section 906 has been provided to Positron Corporation and will be retained by Positron Corporation and furnished to the Securities and Exchange Commission or its staff upon request.

 

 

 

 GRAPHIC 7 image_002.jpg GRAPHIC begin 644 image_002.jpg M_]C_X``02D9)1@`!`@``9`!D``#_[``11'5C:WD``0`$````9```_^X`#D%D M;V)E`&3``````?_;`(0``0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$! M`0$!`0$!`0$!`0$!`0("`@("`@("`@("`P,#`P,#`P,#`P$!`0$!`0$"`0$" M`@(!`@(#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,# M`P,#`P,#`P,#_\``$0@`+`#Y`P$1``(1`0,1`?_$`(\```("`@,!`0`````` M``````@)``AX4)2)"49\'&1 M8G*2,T14-74G-[&"HE,T9*1E-D<1`0````````````````````#_V@`,`P$` M`A$#$0`_`'8:A\K*4F$-(-)P4-`1#S,*B6*4G(':+&!W+2\VDQ1D9,R2P*N0 M2,-]Q;A&ZP$,S\GA,X`:0S3@RJAL.#&CES$`/R2$,XE2G`A.SML'SRGD_/&I M2NZ;S,IAQ(-_:HDEJ3=MR**)]Y(G,-9)<4^_^5@&ZP:+&C4NDVMX.DM5&3]# MUAEU-N"LHVLX^%0,JS2%0I%'3*7:<,CP&I"@HLU=%(O@[Q1&ZP-_C=.>G&78 M,92.RMH=W'R3-L_9.D8TADG+5TB5=!=,04&\BB1P$/HL'V_+%I]#?E+1?NPO MKV#/RPZ??NEHSW67U[!/EAT^_=)1GNL/7L$^6'3[]TM&>["^O8)\L.GW[I:, M]V%]>P8^6+3[]TM%[[O[L+O]'])OL&?EBT^C_P#DM&>ZR^O8)\L.G[[I*,]U ME]>P3Y8M/H;1REHP`_PPOKV#(:9-/UVS*:C+O\++Z?Y?IL`A:GO+WIK-Z4RZ M-^W;8*`T]1VF/4,PK20@^[^["[]_Y]@S\L.G MW[I:,]V%]>P8#3%I]'=E+1GNLOKV#/RPZ??NDHSW6'KV#'RQ:?+[OA+1=X=G M3"W_`,&.^P9^6'3[]TM&>["^O8,?+%I]V_Y2T9LW_JLOKV"?+%I]'=E+1?NP MOKV#/RPZ??NEHSW87U[!S+IFR!(8IB93T:4Q1`Q3%C"@8!`;P,`@>_8-@N+H M\7_86_\`,"P(/S2-CS(T!I@/LPI&C37#L"\U6D`!W;RV#T!6"6`,]?-+P]1Z M7#CH.#IF`!VE&P=YH>EGTQI8R?= M2)SJ+ITX9D1101$YVS!\[:M3")MHARZ10#Z`L'W:J-3--Z9J%)4,Z1*41[3%N^BP:Q":IM4>E>KX:E=5D">J:( ME')&B=9M$D5WC6=. MDX>EX(511ZK-.2F,DFLJ4IC)M6Z9!45,`7@0-FT0L"^X"CO,/U(QZ%7R68[# M):E9P@/8J*;BXBW'3W)"J(&;Q\>FK)`CPS`*:CE0BB@;1*%]@V0-#.K(GMT] M8,X#H"[`,XJ8R>,-UYA>#LO^BP:I42?F$:56*E9258Q.=E`PX@O/(K`O(K(, M`.7CKK(+I(2[0I$RB''3%0B8_:+=ML#+LA,YZ>S\RR@LQZ=1.S1DRG;246LH M11:(EVABE?1ZJI;@5!,Y@,0X`&-,Q1NVV`>-;&?68V1ZN2P4`\BVI:XKLL!/ M!)QB4B"D<*\23`UXAR`\EW*[A5-XDDFT7$01:7%'O` M`[K`^*E6LVQIJ`95+(HR]0M(A@WFY1!/A(2,HBV33?/44[B\--PX`QP+^2`W M6"B]2^I6C]-5%)5%/)*S,],+*,:3I1HH0CZ;D"$`QSF.(&Y:/:8RBLJ(#A`; MB@(C=8``95MYF>>"9)^E("(RQIJ0(+J(*[1C84>56Q"V$1F3.9AWW1"\QTDR MCO`+K`V6A&U3LZ+I5K6;E-[5K:!BT:E=H'(HBYFDVB022R1R%(0Y%'0&$!`` M"[=8!6U>:NH_3K&Q5/T]%DJO-*K2B%.T\;B&:L&XJ`W)+3!6X\P=%1T8$T$" M>T74W;`$;`+4-DCK_P`\V2%45YG:.4+*3*+IK3,8+EJ^:M5B@HB"D?#"1)I> M`A>FJL*I0W[;!RD-&^MFELJ9S..T2BHBQDY.>C^,J'>`H"[,_9;3?G@` M>FP8ROUCYW9*YBQ&4.L"",V1F7*+&)KL&Z"2C8RIP;H/WKID/3)N&66,'$71 M`BB`&`3EWV!NZ*J:R::J1RJ)J)D434(8#$.FH7$0Y3!L,4Q1O`>T+!2V?>>5 M':?J`?U[6"BJB::I&,/#-1)U"?EU0$6T:R*>\H8L(F44-W4TRB8;`L:,SB\Q M#4BAXERLIEAE_0SQ0_27($81A5T`.(IJDDYX1>R(8!`IE$DBI&$+RWA8.P7: M>:7E\FI/'>Q]:-611<+Q?-4[/F511O,J7D2$8/%<9"CL34$X=@#8"OTE:R8[ M/Y:3H>L(0M$9N4ZDJI*4Z85B-91!H<$7;J,3=87:"[10?;ME`XB8"!MI=M@. M>P>?W-5Y%168.@J7G'2,?$1U#4R]D9!T;"T9MVU3\11=901*!4TP"\1[+`Y@ MFH[(8Y1.7-V@A+Z1J..*`7;!NQ+!VA8.KF-4VG>!;'=R6<-"IHE*8]R$TW>+ M&`I<0@F@S%=501#=<&^P+@U":B)G6B\9:=M-4/+2M/RDHS5K.N7;)9E&@P9K M@<1`RV`6T6U/[4QU0`RQB`4I;`V++*A8S+++^D:`A[SL*3@F$0DJ8"@=<[=( M`I M+)F[@%?R"R)#@`7F*6X=E@<:1(B8%*0I2$(4"$(0H$*4I0`I2E*6X``I0``# M<`!8.8@([AN^J^P43J0RLA\YQ.*3-%?F62`".X MCMHB3B70-TBG8G:O M#(E6*B8N$ATA,F8MP@-@(EM*1;TM[*18O"B&P6KQNX`0]("DJ8!L$D6#638O M(UZB1PS?LW#)R@J0IDU4'*1DEDS`<#`)3IFW#LV6`?\`3?IRA--U.U+3-/5+ M,S\5453.*E2;RJ35,D.HY2*B9FP*V*7]'X:1`$3WF'`%@$+S+?\`K-,@8 M(B(':*'#?^_8&I#M`0L"AZBBVFH+S(6E/SA>I4CDM3B;].,.!7#`\G'IH/!, MX14O3#C2[U,#A=WP2`!V!8&YE3*`!AN*6X`PE``+<6X"W!=L``"X.RZP?IA# M]W[M]@33E!"AG]YA>;%9U&0LI`Y/K."P;5>Y9HB^C54X6#O2/>4Q6RAG#@FS MNJ#?OVV!R@%`0O`1O&[O"([1`?1Z-E@Y7;+OHN_!8`GU\92Q.9.G:LI%1HB: MHZ"8GJVG)`$BBZ;J1H@I(,RJFO'E9!EC*H4=@W`/98-XT95RZS"TUY6U`_." MCY*`)"NU,1C"HK!*J1A5#F/M,=1)N4PCZ1L`1ZJV09Z:X%_P!-X?3?8$^:UH)')#4Y MD+J#I5,(MU4<^A"U9RI"((2!VJJ"#E5T5,"XU'\.[.FH8;Q'A@([@L#$J2B(2%EFY#F2.NP>U$1)PF58ABG3$Z1A` M!`0NOL#%?V;.D[LHJ7``O`"^)Y82A>.(?M*F$;Q'ML':Q/EWZ4(AR1R7+I20 M.0Y3E)*3LLZ2[HX@`Q"N4L9;Q^R81`;`6%(4%1=`QI8>BJ6@Z6C0#O-(2.;, M$U!_.6,@F11<_P#&.)AL&V=G^S^#T]E@4[E,5./\SC.UN^*4KF1I,SF-,8;C M&1/'1"QA(`@&*]%,V[=<-@;'8)8-3KN3;PU%5?+/%"IM(VF)UZN5>W7^#M?29B&*VEEYQRP,XG&Z@'(=)*)>&$[Y(PE$!`I!ON&P!Y7W MEQ::JU=N)*/@YBA9%PC=0>8T*D;[`R:I%"H4O/J7W`C`RI[^T`3CUS7W?58%E^5/@-EC MFJYOO,OF.;%MV"4(\IB&P]@CQ1O]-U@:G8%/Z8TL?F!ZJ5AVBA'B4H^CBR3& M\/K`GX+`V"P2P*;T'D0C]2>KZ+MOS',!1VF*4RI-H;- MM@;&&[:-_P!-@S8![U7S+:"TXYR2#HY2$"A9IL3$(=]=\W%F@0`$0Q"=58-G M;8*=\N9DZ9Z4:#YHG#YE]43MN!1$2F;'EER)J%$?R%>&(AV7#8*#A4`<^:G. M'4*"HM,N%UDA.%XHCX>;(@8@]G=-A^NP-BL$&P*Q\TYJ4^7^3SNX>(VS0;IE M->("4KAB)37"':(!8#NL"=LU2CXS\NPX;,4!3Q!+==?=4S>Z[M$0OL#Z;!+! M+!+`H[6_3M99'YY9=ZOZ#C%))E&D;P->M4BGX7+H#RR8O3I@(H,I*,4,@*IN MZ14"B.^P''D_JJR3SHAFTE35:Q#"2.F4KVFIY\VBIN.=;.(W4;O%4BN@*;[* MB(G(<-H#8+X4FX=%(SA68BTVX%$XK*/VA$BE#M%0RP$`MW;?8%>ZZ-6U-NZ5 M>9!9022=:5]7JB,!+FIPP/VT='/%RMW$4DZ;E53<2LJ:Y'`F)N$F83&$+`8N MDW)YSD=D515#21"$GDVBDS492&`P)SDN8'3IIC#8<&!#$;@/:"86`/O,9IN< MI&?R2U*TW'"[7RLJ5%O.*))AB0CEGB;IJ=PL!3&;MEC`JB)]Q>(%^RP&WE)J M.RBSFI^.G*6K"&*[JT=,7*J:IQ35O`IR`8IPN$!N& MP70,M%`&,9*/PA>(G%XUPE#M$3"J```!8*:S7U$90Y14])S=5UI!<9JS64:0 M+"0:/YN4<<(_!:LXYHJJY,=(C=8`1\KZGIQTCG?FF]C5(N#KZK M6YH)(Q.&BMP5I%^^Y80`"K)-%9`J0G"\HF`0#=8-E\QJX9W2J!OL_&5H`@-U MPWNX(.VZP,GGVIGT'-,B`(F=Q$DT(7TF<,UD@`+MNT3V!2_E;U3"04?G)ES* MR3*-J!G619!M&O7*+==PV0YJ+>G0*L`A]-@5MI>0,;7;JW7P"!4D69!,(!O4D$!N#MW6!IE@E@3- MJ`7J71SJZ;ZB8R$<2V6>:+;D*O2:8P+S:HHEE6HJB'+M7Q!1(Z:X[BJB!B@- MXA8&8Y:Z@\G,UXEM*477U/O^.F0ZD:YD&\?,LE%`Q"V>1;TZ#M)=(=A@PB%X M;QL%G/*C@(YL=X^G89FT3(90[EW),FS1"PUB]G*A8EJJ9B,:\EEO\U[6[C[^!MP M[MM@=V%^V_=V>FP9L$L$L&OU-X;\/3/B_I7ACD'?7NN_%]6VP>>S/C]GQXD=_#?XF=0XZ]_@#E_"/&O[_2?$'M,.Z_@=RZZZP46U M^#.%'KOS,>'\?M>'TK!P[^]CXOZ/AP_BL#5]$/R-=11^$W'^*.`^#XF7>,KL M($O"TYXYZ/X0Z:X\0==Y?H_2\` M\QSW,^PX&#T[?1ML'GMSG_9_>(WGPO\`BYS_`!%?]/>!X=XN+9T[K_M^7NOP MX-F'[-@I0GPON]I\S?3.]?@Y*[!_O>SNN^JP7QDO^SRZ_'?$GXK]3Y@.%\1> M!X?Q<4O#ZCX<]OPL7VN)W+K[]E]@]`=&>$?"L-X"Z+X2Z>CT'P[RW1^1P^RY M'E/88/3=MOW[;`!6OCPOX@TQ>)_$E_Q;:=)\.])X?/ M_=?=8&-?E;?3VW[MEUUVR[=O[;[!Y_=6_P`H7Q=JCP=\4/'W4UO%7PSY'P_U MRX>H\OSO?YZ_#Q^4[F/?WK`X32MP/EZRIY;KW`\+H<+Q1_\`0W4_7?B?@=)X%_RP,""[#W=W9^/MOOWV!;]*>$OVCE?\#Q'XO\`ABTYCB=+\,\IRC+!P\'Z MTYSAW7W]VP,AL$L"\_,>\+?"2C/%GB#E/B73_)^&^G<[SERO"XG4_8<*Z^^[ -;8"P_1_^\_\`%L'_V3\_ ` end EX-101.INS 8 posc-20131231.xml XBRL INSTANCE DOCUMENT 0000844985 2010-01-01 2010-01-31 0000844985 2012-01-01 2012-01-04 0000844985 2012-01-01 2012-01-09 0000844985 2012-01-01 2012-01-12 0000844985 2012-01-01 2012-01-19 0000844985 2012-01-01 2012-01-20 0000844985 2012-01-01 2012-03-31 0000844985 2012-01-01 2012-12-31 0000844985 2013-01-01 2013-03-31 0000844985 2013-01-01 2013-12-31 0000844985 2012-01-04 0000844985 2012-01-12 0000844985 2012-01-15 2012-01-17 0000844985 2012-01-17 0000844985 2012-01-19 0000844985 2012-01-20 0000844985 2012-02-03 2012-03-02 0000844985 2012-02-10 0000844985 2012-02-15 2012-03-14 0000844985 1998-03-01 1998-03-31 0000844985 2012-03-06 2012-04-05 0000844985 2013-03-11 2013-04-12 0000844985 2012-03-14 0000844985 2014-03-31 0000844985 2010-04-01 2010-04-19 0000844985 2012-04-01 2012-06-30 0000844985 2013-04-01 2013-06-30 0000844985 2012-04-05 0000844985 2013-04-11 0000844985 2013-04-12 0000844985 2012-05-01 2012-05-21 0000844985 2012-05-01 2012-05-29 0000844985 2013-05-01 2013-05-31 0000844985 2012-05-21 0000844985 2013-05-31 0000844985 2012-06-01 2012-06-19 0000844985 2013-06-30 0000844985 2011-07-01 2011-07-07 0000844985 2012-07-01 2012-07-17 0000844985 2012-07-01 2012-07-18 0000844985 2012-07-01 2012-09-30 0000844985 2013-07-01 2013-09-30 0000844985 2012-08-01 2012-08-21 0000844985 2012-08-11 2012-09-10 0000844985 2012-09-10 0000844985 2012-09-30 0000844985 2012-10-01 2012-12-31 0000844985 2013-10-01 2013-12-31 0000844985 2012-11-01 2012-11-30 0000844985 2012-11-30 0000844985 2011-12-16 2012-01-17 0000844985 2012-12-31 0000844985 2013-12-31 0000844985 2011-12-31 0000844985 us-gaap:SeriesAPreferredStockMember 2013-12-31 0000844985 us-gaap:SeriesAPreferredStockMember 2012-12-31 0000844985 us-gaap:SeriesBPreferredStockMember 2013-12-31 0000844985 us-gaap:SeriesBPreferredStockMember 2012-12-31 0000844985 posc:SeriesSPreferredStockMember 2013-12-31 0000844985 posc:SeriesSPreferredStockMember 2012-12-31 0000844985 us-gaap:SeriesHPreferredStockMember 2013-12-31 0000844985 us-gaap:SeriesHPreferredStockMember 2012-12-31 0000844985 posc:MedicalDevicesMember 2013-01-01 2013-12-31 0000844985 posc:MedicalDevicesMember 2012-01-01 2012-12-31 0000844985 posc:RadiopharmaceuticalsMember 2012-01-01 2012-12-31 0000844985 posc:RadiopharmaceuticalsMember 2013-01-01 2013-12-31 0000844985 posc:UnallocatedMember 2012-01-01 2012-12-31 0000844985 posc:UnallocatedMember 2013-01-01 2013-12-31 0000844985 posc:MedicalDevicesMember 2013-12-31 0000844985 posc:MedicalDevicesMember 2012-12-31 0000844985 posc:RadiopharmaceuticalsMember 2012-12-31 0000844985 posc:RadiopharmaceuticalsMember 2013-12-31 0000844985 posc:UnallocatedMember 2013-12-31 0000844985 posc:UnallocatedMember 2012-12-31 0000844985 posc:ManhattanIsotopeTechnologyLlcMember 2012-01-15 2012-01-17 0000844985 posc:ManhattanIsotopeTechnologyLlcMember 2012-01-17 0000844985 posc:MedicalDeviceAssemblyMember 2011-07-07 0000844985 posc:WarehousingMember 2011-07-07 0000844985 posc:MitMember 2011-12-05 0000844985 posc:MedicalDeviceAssemblyMember 2011-07-01 2011-07-07 0000844985 posc:WarehousingMember 2011-07-01 2011-07-07 0000844985 us-gaap:BuildingMember 2013-12-31 0000844985 us-gaap:FurnitureAndFixturesMember 2013-12-31 0000844985 us-gaap:LeaseholdImprovementsMember 2013-12-31 0000844985 us-gaap:ComputerEquipmentMember 2013-12-31 0000844985 posc:ResearchEquipmentAndFacilitiesMember 2013-12-31 0000844985 us-gaap:MachineryAndEquipmentMember 2013-12-31 0000844985 us-gaap:BuildingMember 2012-12-31 0000844985 us-gaap:FurnitureAndFixturesMember 2012-12-31 0000844985 us-gaap:LeaseholdImprovementsMember 2012-12-31 0000844985 us-gaap:ComputerEquipmentMember 2012-12-31 0000844985 posc:ResearchEquipmentAndFacilitiesMember 2012-12-31 0000844985 us-gaap:MachineryAndEquipmentMember 2012-12-31 0000844985 posc:RelatedPartyMember us-gaap:CommonStockMember 2012-01-01 2012-01-12 0000844985 posc:RelatedPartyMember 2012-01-12 0000844985 posc:RelatedPartyMember us-gaap:ConvertibleDebtMember 2012-01-12 0000844985 posc:RelatedPartyMember 2012-01-01 2012-01-12 0000844985 posc:RelatedPartyMember 2012-01-01 2012-12-31 0000844985 posc:RelatedPartyMember 2012-12-31 0000844985 posc:RelatedPartyMember us-gaap:CommonStockMember 2012-01-01 2012-12-31 0000844985 posc:AttriusPetSystemsMember 2012-12-31 0000844985 posc:ManhattanIsotopeTechnologyLlcMember 2012-01-17 0000844985 posc:ManhattanIsotopeTechnologyLlcMember posc:PromissoryNotesMember 2013-01-01 2013-12-31 0000844985 posc:ManhattanIsotopeTechnologyLlcMember posc:PromissoryNotesMember 2013-12-31 0000844985 posc:ManhattanIsotopeTechnologyLlcMember posc:PromissoryNotesMember 2012-12-31 0000844985 posc:ChiefExecutiveOfficerAndChiefFinancialOfficerMember 2013-12-31 0000844985 us-gaap:ConvertibleDebtMember 2013-12-31 0000844985 us-gaap:SubsequentEventMember 2012-01-01 2012-12-31 0000844985 us-gaap:SeriesAPreferredStockMember 2013-01-01 2013-12-31 0000844985 us-gaap:SeriesBPreferredStockMember 2013-01-01 2013-12-31 0000844985 us-gaap:SeriesGPreferredStockMember 2013-01-01 2013-12-31 0000844985 posc:SeriesSPreferredStockMember 2013-01-01 2013-12-31 0000844985 us-gaap:SeriesHPreferredStockMember 2013-01-01 2013-12-31 0000844985 us-gaap:WarrantMember 2013-01-01 2013-12-31 0000844985 us-gaap:ConvertibleDebtSecuritiesMember 2013-01-01 2013-12-31 0000844985 us-gaap:EmployeeStockOptionMember 2013-01-01 2013-12-31 0000844985 posc:SeriesBPreferredStockOptionsMember 2013-01-01 2013-12-31 0000844985 us-gaap:SeriesAPreferredStockMember 2012-01-01 2012-12-31 0000844985 posc:SeriesBPreferredStockOptionsMember 2012-01-01 2012-12-31 0000844985 us-gaap:SeriesBPreferredStockMember 2012-01-01 2012-12-31 0000844985 us-gaap:SeriesGPreferredStockMember 2012-01-01 2012-12-31 0000844985 posc:SeriesSPreferredStockMember 2012-01-01 2012-12-31 0000844985 us-gaap:SeriesHPreferredStockMember 2012-01-01 2012-12-31 0000844985 us-gaap:WarrantMember 2012-01-01 2012-12-31 0000844985 us-gaap:ConvertibleDebtSecuritiesMember 2012-01-01 2012-12-31 0000844985 us-gaap:EmployeeStockOptionMember 2012-01-01 2012-12-31 0000844985 us-gaap:SeriesAPreferredStockMember 2013-01-01 2013-12-31 0000844985 us-gaap:SeriesAPreferredStockMember 2012-01-01 2012-12-31 0000844985 us-gaap:SeriesBPreferredStockMember 2013-01-01 2013-12-31 0000844985 us-gaap:SeriesBPreferredStockMember 2012-01-01 2012-12-31 0000844985 us-gaap:SeriesGPreferredStockMember 2012-01-01 2012-12-31 0000844985 us-gaap:SeriesGPreferredStockMember 2013-01-01 2013-12-31 0000844985 posc:InitialAccountingOneMember 2013-01-01 2013-12-31 0000844985 us-gaap:WarrantMember posc:InitialAccountingOneMember 2013-01-01 2013-12-31 0000844985 us-gaap:EmbeddedDerivativeFinancialInstrumentsMember posc:InitialAccountingOneMember 2013-01-01 2013-12-31 0000844985 posc:InitialAccountingTwoMember 2013-01-01 2013-12-31 0000844985 us-gaap:EmbeddedDerivativeFinancialInstrumentsMember posc:InitialAccountingTwoMember 2013-01-01 2013-12-31 0000844985 posc:NonRelatedPartyMember 2013-12-31 0000844985 posc:RelatedPartyMember 2013-12-31 0000844985 posc:NonRelatedPartyMember 2012-12-31 0000844985 us-gaap:CommonStockMember posc:ConversionOfSeriesStockMember 2012-01-01 2012-12-31 0000844985 us-gaap:CommonStockMember posc:ConversionOfSeriesBStockMember 2012-01-01 2012-12-31 0000844985 us-gaap:CommonStockMember posc:ConversionOfSeriesGStockMember 2012-01-01 2012-12-31 0000844985 us-gaap:AdditionalPaidInCapitalMember posc:ConversionOfSeriesStockMember 2012-01-01 2012-12-31 0000844985 us-gaap:AdditionalPaidInCapitalMember posc:ConversionOfSeriesBStockMember 2012-01-01 2012-12-31 0000844985 us-gaap:AdditionalPaidInCapitalMember posc:ConversionOfSeriesGStockMember 2012-01-01 2012-12-31 0000844985 us-gaap:CommonStockMember 2012-01-01 2012-12-31 0000844985 us-gaap:AdditionalPaidInCapitalMember 2012-01-01 2012-12-31 0000844985 us-gaap:CommonStockMember posc:StockPayableMember 2012-01-01 2012-12-31 0000844985 us-gaap:AdditionalPaidInCapitalMember posc:StockPayableMember 2012-01-01 2012-12-31 0000844985 us-gaap:CommonStockMember us-gaap:NotesPayableOtherPayablesMember 2012-01-01 2012-12-31 0000844985 us-gaap:NotesPayableOtherPayablesMember 2012-01-01 2012-12-31 0000844985 posc:StockPayableMember 2012-01-01 2012-12-31 0000844985 posc:ConvertibleDebentures2012Member 2012-01-12 0000844985 posc:ConvertibleDebentures2012Member 2013-01-01 2013-12-31 0000844985 us-gaap:AccumulatedDeficitDuringDevelopmentStageMember 2012-01-01 2012-12-31 0000844985 posc:ConvertibleDebentures2013Member 2012-01-01 2012-12-31 0000844985 posc:ConvertibleDebenturesEightPercentageMember 2013-01-01 2013-12-31 0000844985 posc:ConvertibleDebentures2013Member 2013-12-31 0000844985 posc:ConvertibleDebentures2013Member 2012-12-31 0000844985 us-gaap:CommonStockMember 2013-01-01 2013-12-31 0000844985 us-gaap:TreasuryStockMember 2013-01-01 2013-12-31 0000844985 us-gaap:AdditionalPaidInCapitalMember 2013-01-01 2013-12-31 0000844985 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2013-01-01 2013-12-31 0000844985 us-gaap:AccumulatedDeficitDuringDevelopmentStageMember 2013-01-01 2013-12-31 0000844985 posc:ConvertibleDebentures2013Member 2013-01-01 2013-12-31 0000844985 us-gaap:CommonStockMember 2012-12-31 0000844985 us-gaap:AdditionalPaidInCapitalMember us-gaap:SeriesHPreferredStockMember 2013-01-01 2013-12-31 0000844985 us-gaap:FairValueInputsLevel1Member 2012-12-31 0000844985 us-gaap:FairValueInputsLevel2Member 2012-12-31 0000844985 us-gaap:FairValueInputsLevel3Member 2012-12-31 0000844985 us-gaap:FairValueInputsLevel1Member 2013-12-31 0000844985 us-gaap:FairValueInputsLevel2Member 2013-12-31 0000844985 us-gaap:FairValueInputsLevel3Member 2013-12-31 0000844985 us-gaap:AdditionalPaidInCapitalMember 2012-12-31 0000844985 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2012-12-31 0000844985 us-gaap:AccumulatedDeficitDuringDevelopmentStageMember 2012-12-31 0000844985 us-gaap:TreasuryStockMember 2012-12-31 0000844985 us-gaap:CommonStockMember 2013-12-31 0000844985 us-gaap:AdditionalPaidInCapitalMember 2013-12-31 0000844985 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2013-12-31 0000844985 us-gaap:AccumulatedDeficitDuringDevelopmentStageMember 2013-12-31 0000844985 us-gaap:TreasuryStockMember 2013-12-31 0000844985 us-gaap:CommonStockMember 2011-12-31 0000844985 us-gaap:TreasuryStockMember 2011-12-31 0000844985 us-gaap:AdditionalPaidInCapitalMember 2011-12-31 0000844985 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2011-12-31 0000844985 us-gaap:AccumulatedDeficitDuringDevelopmentStageMember 2011-12-31 0000844985 us-gaap:SeriesAPreferredStockMember 2011-12-31 0000844985 us-gaap:SeriesBPreferredStockMember 2011-12-31 0000844985 posc:SeriesSPreferredStockMember 2011-12-31 0000844985 us-gaap:SeriesGPreferredStockMember 2011-12-31 0000844985 us-gaap:SeriesAPreferredStockMember posc:ConversionOfSeriesStockMember 2012-01-01 2012-12-31 0000844985 us-gaap:SeriesBPreferredStockMember posc:ConversionOfSeriesBStockMember 2012-01-01 2012-12-31 0000844985 us-gaap:SeriesGPreferredStockMember posc:ConversionOfSeriesGStockMember 2012-01-01 2012-12-31 0000844985 posc:SeriesSPreferredStockMember 2012-01-01 2012-12-31 0000844985 us-gaap:SeriesAPreferredStockMember 2012-01-01 2012-12-31 0000844985 us-gaap:SeriesHPreferredStockMember 2012-01-01 2012-12-31 0000844985 posc:SeriesSPreferredStockMember 2012-12-31 0000844985 us-gaap:SeriesGPreferredStockMember 2012-12-31 0000844985 us-gaap:SeriesAPreferredStockMember 2012-12-31 0000844985 us-gaap:SeriesAPreferredStockMember 2013-12-31 0000844985 posc:SeriesSPreferredStockMember 2013-12-31 0000844985 us-gaap:SeriesGPreferredStockMember 2013-12-31 0000844985 us-gaap:SeriesAPreferredStockMember 2013-12-01 2013-12-31 0000844985 posc:SeriesSPreferredStockMember 2013-01-01 2013-12-31 0000844985 us-gaap:SeriesHPreferredStockMember 2013-01-01 2013-12-31 0000844985 us-gaap:BuildingMember 2013-01-01 2013-12-31 0000844985 posc:ResearchEquipmentMember 2013-01-01 2013-12-31 0000844985 us-gaap:MinimumMember us-gaap:FurnitureAndFixturesMember 2013-01-01 2013-12-31 0000844985 us-gaap:MaximumMember us-gaap:FurnitureAndFixturesMember 2013-01-01 2013-12-31 0000844985 us-gaap:MinimumMember us-gaap:LeaseholdImprovementsMember 2013-01-01 2013-12-31 0000844985 us-gaap:MaximumMember us-gaap:LeaseholdImprovementsMember 2013-01-01 2013-12-31 0000844985 us-gaap:ComputerEquipmentMember us-gaap:MinimumMember 2013-01-01 2013-12-31 0000844985 us-gaap:MaximumMember us-gaap:ComputerEquipmentMember 2013-01-01 2013-12-31 0000844985 us-gaap:MinimumMember us-gaap:MachineryAndEquipmentMember 2013-01-01 2013-12-31 0000844985 us-gaap:MaximumMember us-gaap:MachineryAndEquipmentMember 2013-01-01 2013-12-31 0000844985 posc:WarrantOneMember 2013-12-31 0000844985 posc:WarrantTwoMember 2013-12-31 0000844985 posc:WarrantOneMember 2013-01-01 2013-12-31 0000844985 posc:WarrantTwoMember 2013-01-01 2013-12-31 0000844985 posc:NeusoftPositronMedicalSystemsCompanyLtdMember 2013-12-31 0000844985 posc:CustomerOneMember 2013-01-01 2013-12-31 0000844985 us-gaap:EmbeddedDerivativeFinancialInstrumentsMember 2013-12-31 0000844985 us-gaap:EmbeddedDerivativeFinancialInstrumentsMember 2012-12-31 0000844985 us-gaap:WarrantMember 2011-12-31 0000844985 us-gaap:WarrantMember 2012-01-01 2012-12-31 0000844985 us-gaap:WarrantMember 2012-12-31 0000844985 us-gaap:WarrantMember 2013-01-01 2013-12-31 0000844985 us-gaap:WarrantMember 2013-12-31 0000844985 us-gaap:WarrantMember us-gaap:MinimumMember 2011-12-31 0000844985 us-gaap:WarrantMember us-gaap:MaximumMember 2011-12-31 0000844985 us-gaap:WarrantMember us-gaap:MinimumMember 2012-01-01 2012-12-31 0000844985 us-gaap:WarrantMember us-gaap:MaximumMember 2012-01-01 2012-12-31 0000844985 us-gaap:WarrantMember us-gaap:MinimumMember 2012-12-31 0000844985 us-gaap:WarrantMember us-gaap:MaximumMember 2012-12-31 0000844985 us-gaap:WarrantMember us-gaap:MinimumMember 2013-12-31 0000844985 us-gaap:WarrantMember us-gaap:MaximumMember 2013-12-31 0000844985 us-gaap:ChiefExecutiveOfficerMember 2013-04-11 0000844985 us-gaap:ChiefFinancialOfficerMember 2013-04-11 0000844985 posc:SeriesHJuniorConvertiblePreferredStockMember 2013-04-11 0000844985 posc:SeriesHJuniorConvertiblePreferredStockMember 2013-03-10 2013-04-11 0000844985 posc:BeforeAmendmentMember 2013-05-31 0000844985 posc:AfterAmendmentMember 2013-05-31 0000844985 posc:BeforeAmendmentMember 2012-01-04 0000844985 posc:AfterAmendmentMember 2012-01-04 0000844985 posc:ExtendedExpirationMember 2012-01-01 2012-01-04 0000844985 us-gaap:InvestorMember 2012-01-01 2012-01-19 0000844985 us-gaap:InvestorMember posc:ExtendedExpirationMember 2012-01-01 2012-01-19 0000844985 posc:ManhattanIsotopeTechnologyLlcMember 2012-01-19 0000844985 posc:RoyaltiesMember 2012-01-19 0000844985 posc:RelatedPartyMember us-gaap:ConvertibleDebtMember 2012-01-19 0000844985 posc:RelatedPartyMember us-gaap:ConvertibleDebtMember 2012-01-01 2012-01-19 0000844985 posc:RelatedPartyMember 2012-01-01 2012-01-19 0000844985 posc:ExtendedExpirationMember 2012-01-01 2012-01-20 0000844985 us-gaap:SeriesBPreferredStockMember 2012-02-03 2012-03-02 0000844985 us-gaap:InvestorMember 2012-02-15 2012-03-14 0000844985 posc:ExtendedExpirationMember 2012-02-15 2012-03-14 0000844985 posc:VendorMember 2012-02-15 2012-03-14 0000844985 us-gaap:SeriesBPreferredStockMember 2012-03-06 2012-04-05 0000844985 us-gaap:ConvertibleDebtMember 2012-04-05 0000844985 posc:VendorMember 2012-04-05 0000844985 us-gaap:ConvertibleDebtMember posc:LendersMember 2012-04-08 2012-05-07 0000844985 us-gaap:InvestorMember 2012-05-01 2012-05-20 0000844985 us-gaap:SeriesBPreferredStockMember 2012-05-01 2012-05-21 0000844985 us-gaap:SeriesBPreferredStockMember 2012-05-01 2012-05-29 0000844985 posc:RelatedPartyMember us-gaap:ConvertibleDebtMember 2012-05-29 0000844985 us-gaap:ConvertibleDebtMember posc:LendersMember 2012-05-08 2012-06-07 0000844985 us-gaap:SeriesAPreferredStockMember 2012-06-01 2012-06-19 0000844985 us-gaap:SeriesBPreferredStockMember 2012-06-01 2012-06-19 0000844985 us-gaap:SeriesGPreferredStockMember 2012-06-01 2012-06-19 0000844985 us-gaap:CorporateJointVentureMember 2013-12-31 0000844985 us-gaap:SeriesBPreferredStockMember 2012-08-01 2012-08-31 0000844985 us-gaap:InvestorMember 2012-06-30 0000844985 us-gaap:ChiefFinancialOfficerMember 2012-11-01 2012-11-30 0000844985 us-gaap:ChiefExecutiveOfficerMember 2012-12-31 0000844985 us-gaap:ChiefOperatingOfficerMember 2012-12-31 0000844985 us-gaap:ChiefExecutiveOfficerMember 2013-12-31 0000844985 us-gaap:ChiefFinancialOfficerMember 2013-12-31 0000844985 posc:NeusoftMember 2012-01-01 2012-12-31 0000844985 us-gaap:SeriesBPreferredStockMember 2010-01-01 2010-01-31 0000844985 us-gaap:SeriesBPreferredStockMember 2013-01-01 2013-12-31 0000844985 us-gaap:SeriesBPreferredStockMember 2013-12-31 0000844985 posc:TwoZeroOneTwoPlanMember 2012-01-17 0000844985 posc:JanuaryIssuanceMember 2012-01-15 2012-01-17 0000844985 posc:JanuaryIssuanceMember 2012-01-01 2012-12-31 0000844985 posc:JanuaryIssuanceMember 2013-01-01 2013-03-31 0000844985 posc:JanuaryIssuanceMember 2012-12-31 0000844985 posc:JanuaryIssuanceAdditionalIssuesMember 2012-11-01 2012-11-30 0000844985 posc:JanuaryIssuanceAdditionalIssuesMember 2012-01-01 2012-12-31 0000844985 posc:JanuaryIssuanceAdditionalIssuesMember 2013-01-01 2013-03-31 0000844985 posc:JanuaryIssuanceAdditionalIssuesMember 2012-12-31 0000844985 posc:TwoZeroOneTwoPlanMember 2012-12-31 0000844985 us-gaap:ConvertibleDebtMember 2013-12-31 0000844985 us-gaap:ConvertibleDebtMember 2013-01-01 2013-12-31 0000844985 us-gaap:ChiefExecutiveOfficerMember 2012-11-30 0000844985 us-gaap:ChiefExecutiveOfficerMember 2012-11-01 2012-11-30 0000844985 us-gaap:ConvertibleDebtMember 2012-12-01 2012-12-31 0000844985 us-gaap:ConvertibleDebtMember 2012-12-31 0000844985 us-gaap:SeriesHPreferredStockMember 2011-12-31 0000844985 posc:RelatedPartyMember us-gaap:ConvertibleDebtMember 2012-01-01 2012-01-12 0000844985 us-gaap:ChiefExecutiveOfficerMember 2012-01-01 2012-12-31 0000844985 us-gaap:ChiefExecutiveOfficerMember us-gaap:CommonStockMember 2012-01-01 2012-12-31 0000844985 us-gaap:ChiefFinancialOfficerMember 2012-01-01 2012-12-31 0000844985 us-gaap:ChiefFinancialOfficerMember us-gaap:CommonStockMember 2012-01-01 2012-12-31 0000844985 us-gaap:ChiefFinancialOfficerMember 2012-12-31 0000844985 posc:UnrelatedPartiesMember 2012-01-01 2012-12-31 0000844985 posc:InitialAccountingOneMember 2013-12-31 0000844985 posc:UnrelatedPartiesMember 2013-01-01 2013-12-31 0000844985 posc:RelatedPartiesMember 2013-01-01 2013-12-31 0000844985 posc:RelatedPartiesMember posc:ConvertibleDebentures2013Member 2013-01-01 2013-12-31 0000844985 posc:NuclearPharmAssistSystemsMember 2013-12-31 0000844985 posc:NuclearPharmAssistSystemsMember 2012-12-31 0000844985 us-gaap:ChiefExecutiveOfficerMember 2013-01-31 0000844985 us-gaap:ChiefFinancialOfficerMember 2013-02-27 0000844985 us-gaap:ChiefExecutiveOfficerMember 2013-03-25 0000844985 us-gaap:ChiefExecutiveOfficerMember 2013-06-30 0000844985 us-gaap:ChiefFinancialOfficerMember 2013-04-04 0000844985 us-gaap:ChiefExecutiveOfficerMember us-gaap:SeriesHPreferredStockMember 2013-03-10 2013-04-11 0000844985 us-gaap:ChiefFinancialOfficerMember us-gaap:SeriesHPreferredStockMember 2013-03-10 2013-04-11 0000844985 us-gaap:ChiefFinancialOfficerMember 2013-05-22 0000844985 us-gaap:ChiefFinancialOfficerMember 2013-06-21 0000844985 us-gaap:ChiefFinancialOfficerMember 2013-08-16 0000844985 us-gaap:ChiefExecutiveOfficerMember 2013-08-26 0000844985 us-gaap:ChiefExecutiveOfficerMember 2013-11-02 0000844985 us-gaap:ChiefExecutiveOfficerMember us-gaap:SeriesHPreferredStockMember 2013-11-07 0000844985 posc:PromissoryNotesMember 2013-01-01 2013-12-31 0000844985 us-gaap:SubsequentEventMember 2014-03-31 0000844985 us-gaap:MinimumMember 2013-01-01 2013-12-31 0000844985 us-gaap:MaximumMember 2013-01-01 2013-12-31 0000844985 us-gaap:PendingLitigationMember 2012-06-01 2012-06-08 0000844985 us-gaap:PendingLitigationMember 2012-06-08 0000844985 posc:UnrelatedPartiesMember posc:ConvertibleDebentures2013Member 2013-01-01 2013-12-31 0000844985 posc:PromissoryNotesMember 2012-01-01 2012-12-31 xbrli:shares iso4217:USD iso4217:USD xbrli:shares iso4217:USD posc:Warrant xbrli:pure 10-K false 2013-12-31 2013 FY POSC 1452548262 POSITRON CORP 0000844985 --12-31 No No Yes Smaller Reporting Company 10995744.90 1744000 243000 247000 273000 547000 551000 35000 37000 2573000 1104000 1044000 1170000 10000 358000 255000 53000 3882000 2685000 1401000 1634000 658000 746000 45000 58000 95000 129000 3000 0 4452000 1562000 6968000 3981000 14657000 8110000 455000 560000 11000 0 0 205000 15123000 8875000 448000 448000 2750000 2750000 100000 100000 125000 0 14208000 14203000 94575000 92795000 0 -143000 -123432000 -116328000 15000 15000 -11241000 -6190000 3882000 2685000 141000 50000 444000 457000 504000 346000 4000 2000 1328000 1798000 0.01 0.01 3000000000 3000000000 1452548262 1451927262 1452548262 1451927262 60156 60156 1.00 1.00 0.08 0.08 7900000 7900000 447652 447652 447652 447652 1.00 1.00 9000000 9000000 3056487 3056487 3056487 3056487 1.00 1.00 100000 100000 100000 100000 100000 100000 0.01 15000000 12500000 12500000 1630000 2801000 1206000 1972000 424000 829000 2779000 4326000 564000 940000 419000 285000 3762000 5551000 -3338000 -4722000 2137000 1753000 -665000 -726000 821000 432000 0 -282000 -143000 -22000 0 -18000 -3766000 -3233000 -7104000 -7955000 0 0 1452364 1265270 -0.00 -0.01 -7104000 -7955000 -6961000 -7955000 91000 0 160000 226000 <div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <table style="MARGIN-TOP: 0pt; FONT: 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0pt" cellspacing="0" cellpadding="0" width="100%"> <tr style="VERTICAL-ALIGN: top"> <td style="WIDTH: 0.25in"> <div><strong>21.</strong></div> </td> <td style="TEXT-ALIGN: justify"> <div><strong>SEGMENTS</strong></div> </td> </tr> </table> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: -0.25in; MARGIN: 0pt 0px 0pt 0.25in; FONT: 10pt Times New Roman, Times, Serif" align="justify"><strong>&#160;</strong></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">We have aggregated our operations into two reportable segments based upon product lines, manufacturing processes, marketing and management of our businesses: medical equipment and radiopharmaceuticals.&#160;&#160;Our business segments operate in the nuclear medicine industry. The Company&#8217;s medical equipment segment is currently generating all revenues and the majority of all expenses as the radiopharmaceuticals segment is still in the development and regulatory approval phase.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">We evaluate a segment&#8217;s performance based primarily upon operating income before corporate expenses.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">Corporate assets consist primarily of cash but also include&#160;plant and equipment associated with our headquarters. These items (and income and expenses related to these items) are allocated to the segments. Unallocated income/expenses include interest income, interest expense, debt extinguishment and refinancing costs and other (expense)&#160;income and certain expenses which are not considered related to either segment, but are instead considered general corporate expenses.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font>The following table represents sales, operating loss and total assets attributable to these business segments for the periods indicated (in thousands):</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN-TOP: 0pt; FONT: 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0pt" align="left">&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"> <table style="BORDER-BOTTOM: #9eb6ce 0px solid; BORDER-LEFT: #9eb6ce 0px solid; MARGIN: 0in; WIDTH: 100%; BORDER-COLLAPSE: collapse; OVERFLOW: visible; BORDER-TOP: #9eb6ce 0px solid; BORDER-RIGHT: #9eb6ce 0px solid" cellspacing="0" cellpadding="0" align="left"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="71%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="27%" colspan="5"> <div>Year&#160;Ended&#160;December&#160;31,</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="71%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="13%" colspan="2"> <div>2013</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="13%" colspan="2"> <div>2012</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="71%"> <div>Total Sales:</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="71%"> <div>Medical equipment</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>1,630</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>2,789</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="71%"> <div>Radiopharmaceuticals</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>12</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="71%"> <div>Total sales</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"> <div>1,630</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"> <div>2,801</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="71%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="12%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="12%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="71%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="71%"> <div>Operating loss:</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="71%"> <div>Medical equipment</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>(2,486)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>(3,690)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="71%"> <div>Radiopharmaceuticals</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>(862)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>(1,026)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="71%"> <div>Unallocated</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>(6)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="71%"> <div>Total operating loss</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"> <div>(3,338)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"> <div>(4,722)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="71%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="12%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="12%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="71%"> <div>Total Assets:</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="71%"> <div>Medical equipment</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>3,373</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>1,739</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="71%"> <div>Radiopharmaceuticals</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>509</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>945</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="71%"> <div>Unallocated</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>1</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="71%"> <div>Total assets</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"> <div>3,882</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"> <div>2,685</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> </table> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"></div> </div> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table> <div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">The following table represents sales, operating loss and total assets attributable to these business segments for the periods indicated (in thousands):</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN-TOP: 0pt; FONT: 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0pt" align="left">&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"> <table style="BORDER-BOTTOM: #9eb6ce 0px solid; BORDER-LEFT: #9eb6ce 0px solid; MARGIN: 0in; WIDTH: 100%; BORDER-COLLAPSE: collapse; OVERFLOW: visible; BORDER-TOP: #9eb6ce 0px solid; BORDER-RIGHT: #9eb6ce 0px solid" cellspacing="0" cellpadding="0" align="left"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="71%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="27%" colspan="5"> <div>Year&#160;Ended&#160;December&#160;31,</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="71%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="13%" colspan="2"> <div>2013</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="13%" colspan="2"> <div>2012</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="71%"> <div>Total Sales:</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="71%"> <div>Medical equipment</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>1,630</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>2,789</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="71%"> <div>Radiopharmaceuticals</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>12</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="71%"> <div>Total sales</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"> <div>1,630</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"> <div>2,801</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="71%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="12%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="12%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="71%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="71%"> <div>Operating loss:</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="71%"> <div>Medical equipment</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>(2,486)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>(3,690)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="71%"> <div>Radiopharmaceuticals</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>(862)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>(1,026)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="71%"> <div>Unallocated</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>(6)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="71%"> <div>Total operating loss</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"> <div>(3,338)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"> <div>(4,722)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="71%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="12%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="12%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="71%"> <div>Total Assets:</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="71%"> <div>Medical equipment</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>3,373</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>1,739</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="71%"> <div>Radiopharmaceuticals</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>509</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>945</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="71%"> <div>Unallocated</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>1</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="71%"> <div>Total assets</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"> <div>3,882</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"> <div>2,685</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> </table> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"></div> </div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table> 1630000 2789000 12000 0 -2486000 -3690000 -1026000 -6000 0 -862000 3373000 1739000 945000 509000 0 1000 <div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <table style="MARGIN-TOP: 0pt; FONT: 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0pt" cellspacing="0" cellpadding="0" width="100%"> <tr style="VERTICAL-ALIGN: top"> <td style="WIDTH: 0.25in"> <div><strong>20.</strong></div> </td> <td style="TEXT-ALIGN: justify"> <div><strong>SELECTED QUARTERLY FINANCIAL DATA (UNAUDITED) (in thousands)</strong></div> </td> </tr> </table> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"><strong><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font>&#160;</strong></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"> <table style="BORDER-BOTTOM: #9eb6ce 0px solid; BORDER-LEFT: #9eb6ce 0px solid; MARGIN: 0in; WIDTH: 100%; BORDER-COLLAPSE: collapse; OVERFLOW: visible; BORDER-TOP: #9eb6ce 0px solid; BORDER-RIGHT: #9eb6ce 0px solid" cellspacing="0" cellpadding="0" align="left"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="51%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="47%" colspan="11"> <div>Quarter&#160;ended</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="51%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>March&#160;31,<br/> 2013</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>June&#160;30,<br/> 2013</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>September&#160;30,<br/> 2013</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>December&#160;31,<br/> 2013</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="51%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="51%"> <div>Net Sales</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>371</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>432</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>351</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>476</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="51%"> <div>Gross profit (loss)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>125</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>14</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>121</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>164</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="51%"> <div>Net loss</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>(1,201)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>(1,088)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>(1,390)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>(3,425)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="51%"> <div>Net (loss) per share - basic and diluted</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>(0.00)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>(0.00)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>(0.00)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>(0.00)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="51%"> <div>Weighted average basic and diluted shares</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>1,451,927</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>1,452,425</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>1,452,548</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>1,452,548</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> </table> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"></div> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"><strong>&#160;</strong></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"> <table style="BORDER-BOTTOM: #9eb6ce 0px solid; BORDER-LEFT: #9eb6ce 0px solid; MARGIN: 0in; WIDTH: 100%; BORDER-COLLAPSE: collapse; OVERFLOW: visible; BORDER-TOP: #9eb6ce 0px solid; BORDER-RIGHT: #9eb6ce 0px solid" cellspacing="0" cellpadding="0" align="left"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="51%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="47%" colspan="11"> <div>Quarter&#160;ended</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="51%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>March&#160;31,<br/> 2012</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>June&#160;30,<br/> 2012</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>September&#160;30,<br/> 2012</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>December&#160;31,<br/> 2012</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="51%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="51%"> <div>Net Sales</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>829</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>1,224</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>370</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>378</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="51%"> <div>Gross profit (loss)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>359</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>331</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>106</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>33</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="51%"> <div>Net loss</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>(2,962)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>(1,235)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>(1,568)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>(2,190)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="51%"> <div>Net (loss) per share - basic and diluted</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>(0.00)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>(0.00)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>(0.00)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>(0.00)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="51%"> <div>Weighted average basic and diluted shares</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>970,887</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>1,256,915</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>1,360,107</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>1,451,140</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> </table> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"></div> </div> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table> <div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <table style="MARGIN-TOP: 0pt; FONT: 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0pt" cellspacing="0" cellpadding="0" width="100%"> <tr style="VERTICAL-ALIGN: top"> <td style="WIDTH: 0.25in"> <div><b>2.</b></div> </td> <td style="TEXT-ALIGN: justify"> <div><b>GOING CONCERN</b></div> </td> </tr> </table> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: -0.25in; MARGIN: 0pt 0px 0pt 0.25in; FONT: 10pt Times New Roman, Times, Serif" align="justify"><b>&#160;</b></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">Since inception, the Company has expended substantial resources on research and development. Consequently, we have sustained substantial losses. Due to the limited number of products sold each year, revenues have fluctuated significantly from year to year and has not sold quantities that are sufficient to be operationally profitable. The Company had an accumulated deficit of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">123,432,000</font> and a stockholders&#8217; deficit of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">11,241,000</font> at December 31, 2013. The Company will need to resume and increase sales of PET and radiopharmaceutical systems, services, radiopharmaceuticals and radioisotope sales and apply the research and development advancements to achieve profitability in the future. There can be no assurance that the Company will continue to be successful in selling products.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">The Company utilized $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">2,520,000</font> proceeds from issuance of convertible debt, $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">2,285,000</font> proceeds from non-interest bearing advances, and proceeds from borrowings under capital lease to fund operating activities during the year ended December 31, 2013. The Company had cash and cash equivalents of&#160;$<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">1,744,000</font> at December 31, 2013, accounts payable and accrued liabilities of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">1,401,000</font> and a negative working capital of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">12,084,000</font>. Working capital requirements for the upcoming year will reach beyond our current cash balances. The Company plans to continue to raise funds as required through equity and debt financing to sustain business operations. These factors raise substantial doubt about the Company&#8217;s ability to continue as a going concern.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">There can be no assurance that the Company will be successful in implementing its business plan and ultimately achieving operational profitability. The Company&#8217;s long-term viability as a going concern is dependent on its ability to 1) achieve adequate profitability and cash flows from operations to sustain its operations, 2) control costs and expand revenues from existing or new business 3) meet current commitments and fund the continuation of its business operation in the near future and 4) raise additional funds through debt and/or equity financings.</div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table> 371000 432000 351000 476000 125000 14000 121000 164000 1201000 1088000 1390000 3425000 -0.00 -0.00 -0.00 -0.00 1451927000 1452425000 1452548000 1452548000 829000 1224000 370000 378000 359000 331000 106000 33000 2962000 1235000 1568000 2190000 -0.00 -0.00 -0.00 -0.00 970887000 1256915000 1360107000 1451140000 <div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <table style="MARGIN-TOP: 0pt; FONT: 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0pt" cellspacing="0" cellpadding="0" width="100%"> <tr style="VERTICAL-ALIGN: top"> <td style="WIDTH: 0.25in"> <div><strong>3.</strong></div> </td> <td style="TEXT-ALIGN: justify"> <div><strong>ACQUISITION OF MIT</strong></div> </td> </tr> </table> &#160; <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">On January 17, 2012, the Company acquired Manhattan Isotope Technology LLC (&#8220;MIT&#8221;) upon consummation of a Membership Interest Purchase Agreement (the &#8220;Agreement&#8221;) with MIT and the interest-holders of MIT, whereby the Company acquired all of the issued and outstanding membership interests from the holders in exchange for: (i) the assumption of the liabilities of MIT; (ii) cash advances; (iii) earn-out payments equal to twenty percent (<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">20</font>%) of &#8220;Net Income&#8221; as defined in the Agreement; (iv) <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 5,000,000</font> common shares of Positron stock; and (v) entry into employment agreements with MIT&#8217;s employees.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">In accordance with the transaction, the Company acquired the assets related to MIT&#8217;s business of refurbishing spent strontium-82/rubidium-82 and other radioisotope generators, recycling strontium-82 and other radioisotopes from generators, processing of strontium-82 and other radioisotopes, providing expertise in production of radioisotopes and radioisotopes services, including cash, equipment, leasehold improvements, patent, certain supply and distribution and other vendor contracts, goodwill and assumed liabilities including trade payables, accruals and a note payable with a commercial bank. The parties made customary representations, warranties and indemnities in the Agreement that are typical and consistent for a transaction of this size and scope.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">The Company has included the financial results of MIT in the consolidated financial statements from the date of acquisition. MIT is included in the Radiopharmaceuticals operating segment.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">The Company incurred acquisition costs of approximately $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">12,000</font> in 2012.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">The following table summarizes the consideration transferred to acquire MIT at the acquisition date:</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font>Fair Value of Consideration Transferred:</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px 0pt 0.25in; FONT: 10pt Times New Roman, Times, Serif" align="justify">&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"> <table style="MARGIN: 0in; WIDTH: 95%; BORDER-COLLAPSE: collapse; OVERFLOW: visible" cellspacing="0" cellpadding="0" align="left"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="77%"> <div>Common stock of Company</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="15%"> <div>50,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="77%"> <div>Contingent consideration</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="15%"> <div>205,297</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="77%"> <div>Total</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="15%"> <div>255,297</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160; <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font></div> </td> </tr> </table> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px 0pt 0.25in; FONT: 10pt Times New Roman, Times, Serif" align="justify">&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">The total purchase price for the MIT acquisition was allocated to the net tangible and intangible assets based upon their fair values as of January 17, 2012 as set forth below. The excess of the purchase price over the net assets was recorded as goodwill. <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font>The following table summarizes the fair values of the assets and liabilities assumed at the acquisition date.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN-TOP: 0pt; FONT: 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0pt" align="left">&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt; TEXT-INDENT: 0in; WIDTH: 100%"> <table style="BORDER-BOTTOM: #9eb6ce 0px solid; BORDER-LEFT: #9eb6ce 0px solid; WIDTH: 95%; BORDER-COLLAPSE: collapse; OVERFLOW: visible; BORDER-TOP: #9eb6ce 0px solid; BORDER-RIGHT: #9eb6ce 0px solid" cellspacing="0" cellpadding="0"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="77%"> <div>Cash</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="15%"> <div>829</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="77%"> <div>Equipment and leasehold improvements</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="15%"> <div>653,567</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="77%"> <div>Patent</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="15%"> <div>14,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="77%"> <div>Trade and other payables</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="15%"> <div>(59,282)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="77%"> <div>Note payable</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="15%"> <div>(700,000)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="77%"> <div>Net liabilities assumed</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="15%"> <div>(90,886)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="77%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="15%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="77%"> <div>Goodwill</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="15%"> <div>346,183</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> </table> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"></div> </div> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px 0pt 0.25in; FONT: 10pt Times New Roman, Times, Serif" align="justify">&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">The Company identified intangible assets associated with patents and assigned the fair value of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">14,000</font>. The useful life associated with patents was <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">6</font> years.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">The acquisition of MIT includes a contingent consideration arrangement that requires cash payments to the previous members equal to <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 20</font>% of &#8220;Net Income&#8221; as defined in the Agreement through <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">December 31, 2018</font>. The range of the undiscounted amounts the Company could owe under this arrangement is between $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">0</font> and $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">3,000,000</font>. The fair value of the contingent consideration on the acquisition date of approximately $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">205,000</font> was estimated based on the present value of projected payments which were based on projected net income through 2018. These calculations and projections are based on significant inputs not observable in the market, which ASC 820 refers to as Level 3 inputs. Key assumptions include a discount rate of <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">25</font> percent as well as an increasing level of revenues and expenses based on probability factors at the acquisition date.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">At December 31, 2013, the Company evaluated the cashflow projections included in the contingent consideration and determined that there was a decrease in the fair value of the contingent consideration and impairment of goodwill. The net effect of the adjustment is a decrease in general and administrative expenses of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">141,000</font>.</div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table> <div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">Fair Value of Consideration Transferred:</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px 0pt 0.25in; FONT: 10pt Times New Roman, Times, Serif" align="justify">&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"> <table style="MARGIN: 0in; WIDTH: 95%; BORDER-COLLAPSE: collapse; OVERFLOW: visible" cellspacing="0" cellpadding="0" align="left"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="77%"> <div>Common stock of Company</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="15%"> <div>50,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="77%"> <div>Contingent consideration</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="15%"> <div>205,297</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="77%"> <div>Total</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="15%"> <div>255,297</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> </table> </div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table> <div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">The following table summarizes the fair values of the assets and liabilities assumed at the acquisition date.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN-TOP: 0pt; FONT: 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0pt" align="left">&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt; TEXT-INDENT: 0in; WIDTH: 100%"> <table style="BORDER-BOTTOM: #9eb6ce 0px solid; BORDER-LEFT: #9eb6ce 0px solid; WIDTH: 95%; BORDER-COLLAPSE: collapse; OVERFLOW: visible; BORDER-TOP: #9eb6ce 0px solid; BORDER-RIGHT: #9eb6ce 0px solid" cellspacing="0" cellpadding="0"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="77%"> <div>Cash</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="15%"> <div>829</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="77%"> <div>Equipment and leasehold improvements</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="15%"> <div>653,567</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="77%"> <div>Patent</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="15%"> <div>14,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="77%"> <div>Trade and other payables</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="15%"> <div>(59,282)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="77%"> <div>Note payable</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="15%"> <div>(700,000)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="77%"> <div>Net liabilities assumed</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="15%"> <div>(90,886)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="77%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="15%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="77%"> <div>Goodwill</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="15%"> <div>346,183</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> </table> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"></div> </div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table> 0.2 5000000 12000 14000 P6Y 0.2 0 3000000 205000 50000 205297 255297 829 653567 14000 59282 700000 -90886 346183 <div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <table style="MARGIN-TOP: 0pt; FONT: 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0pt" cellspacing="0" cellpadding="0" width="100%"> <tr style="VERTICAL-ALIGN: top"> <td style="WIDTH: 0.25in"> <div><strong>5.</strong></div> </td> <td style="TEXT-ALIGN: justify"> <div><strong>INVENTORIES</strong></div> </td> </tr> </table> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: -0.25in; MARGIN: 0pt 0px 0pt 0.25in; FONT: 10pt Times New Roman, Times, Serif" align="justify"><strong>&#160;</strong></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font>Inventories at December 31, 2013 and 2012 consisted of the following (in thousands):</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> &#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:center; TEXT-INDENT: 0in; WIDTH: 100%" align="center"> <table style="BORDER-BOTTOM: #9eb6ce 0px solid; BORDER-LEFT: #9eb6ce 0px solid; MARGIN: 0px:auto; WIDTH: 85%; BORDER-COLLAPSE: collapse; OVERFLOW: visible; BORDER-TOP: #9eb6ce 0px solid; BORDER-RIGHT: #9eb6ce 0px solid" cellspacing="0" cellpadding="0" align="center"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="58%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="25%" colspan="5"> <div>December&#160;31,</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="58%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="12%" colspan="2"> <div>2013</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="12%" colspan="2"> <div>2012</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="58%"> <div>Finished systems</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="11%"> <div>24</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="11%"> <div>310</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="58%"> <div>Raw materials and service parts</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%"> <div>927</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%"> <div>698</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="58%"> <div>Work in progress</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%"> <div>40</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="58%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="11%"> <div>991</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="11%"> <div>1,008</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="58%"> <div>Less: Reserve for obsolete inventory</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%"> <div>(444)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%"> <div>(457)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="58%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="11%"> <div>547</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="11%"> <div>551</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> </table> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"></div> </div> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> &#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">Inventories are stated at the lower of cost or market.&#160;&#160;Cost is determined using the first-in, first-out (FIFO) method of inventory valuation.&#160;&#160;The Company evaluated the reserve as of December 31, 2013 and December 31, 2012.</div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table> <div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">Inventories at December 31, 2013 and 2012 consisted of the following (in thousands):</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> &#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:center; TEXT-INDENT: 0in; WIDTH: 100%" align="center"> <table style="BORDER-BOTTOM: #9eb6ce 0px solid; BORDER-LEFT: #9eb6ce 0px solid; MARGIN: 0px:auto; WIDTH: 85%; BORDER-COLLAPSE: collapse; OVERFLOW: visible; BORDER-TOP: #9eb6ce 0px solid; BORDER-RIGHT: #9eb6ce 0px solid" cellspacing="0" cellpadding="0" align="center"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="58%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="25%" colspan="5"> <div>December&#160;31,</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="58%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="12%" colspan="2"> <div>2013</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="12%" colspan="2"> <div>2012</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="58%"> <div>Finished systems</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="11%"> <div>24</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="11%"> <div>310</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="58%"> <div>Raw materials and service parts</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%"> <div>927</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%"> <div>698</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="58%"> <div>Work in progress</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%"> <div>40</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="58%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="11%"> <div>991</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="11%"> <div>1,008</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="58%"> <div>Less: Reserve for obsolete inventory</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%"> <div>(444)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%"> <div>(457)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="58%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="11%"> <div>547</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="11%"> <div>551</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> </table> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"></div> </div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table> 24000 310000 927000 698000 40000 0 991000 1008000 444000 457000 1800 5083 5287 1475 2011-12-01 2013-11-13 2013-12-01 2016-11-30 2014 <div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <table style="MARGIN-TOP: 0pt; FONT: 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0pt" cellspacing="0" cellpadding="0" width="100%"> <tr style="VERTICAL-ALIGN: top"> <td style="WIDTH: 0.25in"> <div><strong>6.</strong></div> </td> <td style="TEXT-ALIGN: justify"> <div><strong>PROPERTY AND EQUIPMENT</strong></div> </td> </tr> </table> &#160; <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font>Property and equipment at December 31, 2013 and 2012 consisted of the following (in thousands):</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> &#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:center; TEXT-INDENT: 0in; WIDTH: 100%" align="center"> <table style="MARGIN: 0px:auto; WIDTH: 85%; BORDER-COLLAPSE: collapse; OVERFLOW: visible" cellspacing="0" cellpadding="0" align="center"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="58%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="25%" colspan="5"> <div>December&#160;31,</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="58%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="12%" colspan="2"> <div>2013</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="12%" colspan="2"> <div>2012</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="58%"> <div>Buildings</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="11%"> <div>500</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="11%"> <div>500</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="58%"> <div>Furniture and fixtures</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%"> <div>88</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%"> <div>75</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="58%"> <div>Leasehold improvements</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%"> <div>72</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%"> <div>72</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="58%"> <div>Computer equipment</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%"> <div>62</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%"> <div>60</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="58%"> <div>Research equipment</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%"> <div>667</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%"> <div>667</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="58%"> <div>Machinery and equipment</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%"> <div>158</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%"> <div>142</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="58%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="11%"> <div>1,547</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="11%"> <div>1,516</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="58%"> <div>Less: Accumulated depreciation</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%"> <div>(503)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%"> <div>(346)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="58%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="11%"> <div>1,044</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="11%"> <div>1,170</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> </table> </div> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table> <div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">Property and equipment at December 31, 2013 and 2012 consisted of the following (in thousands):</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> &#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:center; TEXT-INDENT: 0in; WIDTH: 100%" align="center"> <table style="MARGIN: 0px:auto; WIDTH: 85%; BORDER-COLLAPSE: collapse; OVERFLOW: visible" cellspacing="0" cellpadding="0" align="center"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="58%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="25%" colspan="5"> <div>December&#160;31,</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="58%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="12%" colspan="2"> <div>2013</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="12%" colspan="2"> <div>2012</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="58%"> <div>Buildings</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="11%"> <div>500</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="11%"> <div>500</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="58%"> <div>Furniture and fixtures</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%"> <div>88</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%"> <div>75</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="58%"> <div>Leasehold improvements</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%"> <div>72</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%"> <div>72</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="58%"> <div>Computer equipment</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%"> <div>62</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%"> <div>60</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="58%"> <div>Research equipment</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%"> <div>667</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%"> <div>667</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="58%"> <div>Machinery and equipment</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%"> <div>158</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%"> <div>142</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="58%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="11%"> <div>1,547</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="11%"> <div>1,516</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="58%"> <div>Less: Accumulated depreciation</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%"> <div>(503)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%"> <div>(346)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="58%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="11%"> <div>1,044</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="11%"> <div>1,170</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> </table> </div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table> 500000 88000 72000 62000 667000 158000 500000 75000 72000 60000 667000 142000 1547000 1516000 <div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <table style="clear:both;MARGIN-TOP: 0pt; FONT: 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0pt" cellspacing="0" cellpadding="0" width="100%"> <tr style="VERTICAL-ALIGN: top"> <td style="WIDTH: 0.25in"> <div><b>18.</b></div> </td> <td style="TEXT-ALIGN: justify"> <div><b>RELATED PARTY TRANSACTIONS</b></div> <div>&#160;</div> </td> </tr> </table> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: -0.25in; MARGIN: 0pt 0px 0pt 0.25in; FONT: 10pt Times New Roman, Times, Serif" align="justify"> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN: justify; TEXT-INDENT: 0in; MARGIN: 0in 0px 0in -0.25in; FONT: 10pt Times New Roman, Times, Serif"> <b><u>2013</u></b></div> <b>&#160;</b></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">On January 31, 2013 the Company accepted a non-interest bearing $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">250,000</font> advance from its CEO.&#160; At the time, the Company issued no shares or warrants in connection with this transaction.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">On February 27, 2013 the Company accepted a non-interest bearing $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">250,000</font> advance from its CFO.&#160; At the time, the Company issued no shares or warrants in connection with this transaction.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">On March 25, 2013 the Company accepted a non-interest bearing $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">100,000</font> advance from its CEO.&#160; At the time, the Company issued no shares or warrants in connection with this transaction.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">During June 2013 the Company accepted a non-interest bearing $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">185,000</font> advance from its CEO.&#160; At the time, the Company issued no shares or warrants in connection with this transaction.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">On April 4, 2013 the Company accepted a non-interest bearing $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">150,000</font> advance from its CFO.&#160; At the time, the Company issued no shares or warrants in connection with this transaction.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> On April 11, 2013, the Company converted certain advances from its CEO and CFO in the amounts of $ <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 500,000</font> and $ <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 250,000</font>, respectively, into Series H preferred shares (see note 15).</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> &#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">On May 22, 2013 the Company accepted a non-interest bearing $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">150,000</font> advance from its CFO.&#160; At the time, the Company issued no shares or warrants in connection with this transaction.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">On June 21, 2013 the Company accepted a non-interest bearing $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">100,000</font> advance from its CFO.&#160; At the time, the Company issued no shares or warrants in connection with this transaction.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">On August 16, 2013 the Company accepted a non-interest bearing $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">250,000</font> advance from its CFO.&#160; At the time, the Company issued no shares or warrants in connection with this transaction.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">On August 26, 2013 the Company accepted a non-interest bearing $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">250,000</font> advance from its CEO.&#160; At the time, the Company issued no shares or warrants in connection with this transaction.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">On November 2, 2013 the Company accepted a non-interest bearing $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">100,000</font> advance from its CEO.&#160; At the time, the Company issued no shares or warrants in connection with this transaction.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> On November 7, 2013, the Company converted certain advances from its CEO in the amount of $ <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 500,000</font>, into Series H preferred shares (see note 15).</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> &#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> During 2013, the Company paid $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">201,000</font> in deposits to the joint venture partner, Neusoft, for Attrius<sup>&#174;</sup> Systems.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> &#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">On January 3, 2014 the related party debt holders agreed to convert certain convertible debt issued in 2012. The CEO and&#160;CFO agreed to convert a portion of their outstanding debt in the amount of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">1,000,000</font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 12pt"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">&#160;</font></font> and $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">300,000</font>, respectively, pending reverse split authorization and/or approval of additional authorized shares. Remaining convertible debt originally due December 31, 2013 due to the CEO and CFO in the amount of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">400,000</font> and $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">50,000</font>, respectively, was extended through December 31, 2014. Warrants associated with this debt issued in 2012 were also extended through December 31, 2014.&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> <b>&#160;</b></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"><b>2012</b></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"><b>&#160;</b></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">On January 12, 2012, the Company acquired a building in Westmont, Illinois, which the Company previously leased from its Chief Executive Officer (Lender or Related Party) for corporate and administrative offices since 2010. The Company issued the Chief Executive Officer <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 25,000,000</font> shares of common stock, which were valued at approximately $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">250,000</font> and a convertible debenture of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">250,000</font>, which shall be due on <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">December 31, 2013</font> and bear interest at <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">8</font>% per year payable quarterly in cash. In addition, the Company issued <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 35,000,000</font> warrants (&#8220;Warrants&#8221;), which entitle the Related Party to purchase shares of the Company&#8217;s common stock, par value $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">0.01</font> per share, at an exercise price of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">0.01</font> per share and expiring on <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">December 31, 2013</font>. The Lender is entitled to convert the accrued interest and principal of the Convertible Debentures into common stock of the Company at a conversion price equal to <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 55</font>% of the lowest daily volume weighted average price for the three trading days preceding conversion. During the twelve months ended December 31, 2012, the Company issued <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 18,181,818</font> shares of Common Stock for repayment of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">100,000</font> of these Convertible Debentures. During the year ended&#160;December 31, 2012, the Company expensed $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">77,000</font> of deferred rent.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">During the year ended December 31, 2012, the Company recognized cost of revenues of approximately $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">623,000</font> related to the purchase of Attrius<sup>&#174;</sup> PET Systems from Neusoft, the joint venture partner.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">&#160;&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">During the year ended December 31, 2012 the Company issued additional convertible debt to its Chief Executive Officer (&#8220;Lender&#8221;) in the amount of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">1,320,000</font>. The debt is non-interest bearing and matures on <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">December 31, 2013</font>. In connection with the this debt, the Company issued warrants (&#8220;Warrants&#8221;) to purchase <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 37,500,000</font> shares of the Company&#8217;s Common Stock, at an exercise price of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">0.01</font> per share expiring on December 31, 2013. The lender is entitled to convert the accrued interest and principal of the Convertible Debentures into common stock of the Company at a conversion price equal to 55% of the lowest daily volume weighted average price for the three trading days preceding conversion.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">During September and December 2012, the Company issued two non-interest bearing convertible debentures totaling $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">380,000</font> to it Chief Financial Officer (&#8220;Lender&#8221; or &#8220;CFO&#8221;). In connection with this debt, the Company issued to the CFO warrants to purchase <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 10,500,000</font> shares of the Company&#8217;s Common Stock, at an exercise price of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">0.01</font> per share expiring on <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">December 31, 2013</font>. The Lender is entitled to convert the accrued interest and principal of the Convertible Debentures into common stock of the Company at a conversion price equal to 55% of the lowest daily volume weighted average price for the three trading days preceding conversion. These debentures are noninterest bearing. As of December 31, 2012, the Company all of the $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">380,000</font> debt was outstanding.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">In September of 2012, the Company received an unsecured advance of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">25,000</font> from a related party, which accrues interest at <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">8</font>% per annum. This note was fully repaid as of December 31, 2012.</div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table> <div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <table style="MARGIN-TOP: 0pt; FONT: 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0pt" cellspacing="0" cellpadding="0" width="100%"> <tr style="VERTICAL-ALIGN: top"> <td style="WIDTH: 0.25in"> <div><strong>7.</strong></div> </td> <td> <div><strong>ACCOUNTS PAYABLE AND ACCRUED LIABILITIES</strong></div> </td> </tr> </table> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: -0.25in; MARGIN: 0pt 0px 0pt 0.25in; FONT: 10pt Times New Roman, Times, Serif"> <strong>&#160;</strong></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font>Accounts payable and accrued liabilities at December 31, 2013 and, 2012 consisted of the following (in thousands):</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> &#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:center; TEXT-INDENT: 0in; WIDTH: 100%" align="center"> <table style="MARGIN: 0px:auto; WIDTH: 85%; BORDER-COLLAPSE: collapse; OVERFLOW: visible" cellspacing="0" cellpadding="0" align="center"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="58%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="25%" colspan="5"> <div>December&#160;31,</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="58%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="12%" colspan="2"> <div>2013</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="12%" colspan="2"> <div>2012</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="58%"> <div>Trade accounts payable</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="11%"> <div>849</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="11%"> <div>1,127</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="58%"> <div>Accrued royalties</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%"> <div>87</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%"> <div>87</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="58%"> <div>Accrued interest</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%"> <div>278</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%"> <div>154</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="58%"> <div>Sales taxes payable</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%"> <div>89</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%"> <div>78</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="58%"> <div>Accrued compensation</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%"> <div>70</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%"> <div>80</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="58%"> <div>Other accrued expenses</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%"> <div>28</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%"> <div>108</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="58%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="11%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="11%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="58%"> <div>Total</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%"> <div>1,401</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%"> <div>1,634</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> </table> </div> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table> <div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> Accounts payable and accrued liabilities at December 31, 2013 and, 2012 consisted of the following (in thousands):</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> &#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:center; TEXT-INDENT: 0in; WIDTH: 100%" align="center"> <table style="MARGIN: 0px:auto; WIDTH: 85%; BORDER-COLLAPSE: collapse; OVERFLOW: visible" cellspacing="0" cellpadding="0" align="center"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="58%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="25%" colspan="5"> <div>December&#160;31,</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="58%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="12%" colspan="2"> <div>2013</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="12%" colspan="2"> <div>2012</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="58%"> <div>Trade accounts payable</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="11%"> <div>849</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="11%"> <div>1,127</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="58%"> <div>Accrued royalties</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%"> <div>87</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%"> <div>87</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="58%"> <div>Accrued interest</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%"> <div>278</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%"> <div>154</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="58%"> <div>Sales taxes payable</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%"> <div>89</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%"> <div>78</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="58%"> <div>Accrued compensation</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%"> <div>70</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%"> <div>80</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="58%"> <div>Other accrued expenses</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%"> <div>28</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%"> <div>108</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="58%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="11%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="11%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="58%"> <div>Total</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%"> <div>1,401</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%"> <div>1,634</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> </table> </div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table> 849000 1127000 87000 87000 278000 154000 89000 78000 70000 80000 28000 108000 <div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <table style="MARGIN-TOP: 0pt; FONT: 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0pt" cellspacing="0" cellpadding="0" width="100%"> <tr style="VERTICAL-ALIGN: top"> <td style="WIDTH: 0.25in"> <div><b>8.</b></div> </td> <td style="TEXT-ALIGN: justify"> <div><b>CUSTOMER DEPOSITS</b></div> </td> </tr> </table> &#160; <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">Customer deposits represent amounts paid to the Company by customers for devices in advance of manufacturing completion and/or shipment of the device to the customer.&#160;&#160;Deposit amounts may vary depending on the contract.&#160;Customer deposits at December 31, 2013 and 2012, were $658,000 and $746,000, respectively. Included in customer deposits at December 31, 2013 and 2012 were deposits of approximately $658,000 and $669,000 from a customer that had placed an order in 2007 for five Nuclear Pharm-Assist&#153; systems.&#160;&#160;As of the date of this report, there can be no assurance that this customer will fulfill its order for these devices.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">Also, included in customer deposits at December 31, 2012&#160;are $77,000 deposits on two Attrius&#174; systems.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> Our customer sales contracts require our customers to pay the Company 30% upon signing the contract, 60% upon notification to ship, and the remaining <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 10</font>% after customer acceptance.</div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table> 25000000 250000 250000 0.08 35000000 0.01 0.01 100000 77000 18181818 <div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <table style="MARGIN-TOP: 0pt; FONT: 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0pt" cellspacing="0" cellpadding="0" width="100%"> <tr style="VERTICAL-ALIGN: top"> <td style="WIDTH: 0.25in"> <div><b>17.</b></div> </td> <td style="TEXT-ALIGN: justify"> <div><b>401(k) PLAN</b></div> </td> </tr> </table> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: -0.25in; MARGIN: 0pt 0px 0pt 0.25in; FONT: 10pt Times New Roman, Times, Serif" align="justify"><b>&#160;</b></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">The Positron Corporation 401(k) Plan and Trust (the &#8220;Plan&#8221;) covers all of the Company&#8217;s employees who are United States citizens, at least 21 years of age and have completed at least one quarter of service with the Company. Pursuant to the Plan, employees may elect to reduce their current compensation by up to the statutorily prescribed annual limit and have the amount of such reduction contributed to the Plan. The Plan allows for the Company to make discretionary contributions in an amount equal to <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">25</font> percent of the participant&#8217;s deferral contributions, up to <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">6</font> percent of the employee&#8217;s compensation, as defined in the Plan agreement. The Company made no contributions in 2013 and 2012. The Board of Directors of the Company may authorize additional discretionary contributions; however, no such contributions were made by the Company in 2013 or 2012.</div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table> 0.25 <div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <table style="MARGIN-TOP: 0pt; FONT: 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0pt" cellspacing="0" cellpadding="0" width="100%"> <tr style="VERTICAL-ALIGN: top"> <td style="WIDTH: 0.25in"> <div><strong>16.</strong></div> </td> <td> <div><strong>INCOME TAXES</strong></div> </td> </tr> </table> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: -0.25in; MARGIN: 0pt 0px 0pt 0.25in; FONT: 10pt Times New Roman, Times, Serif"> <strong>&#160;</strong></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">The Company has incurred losses since its inception and, therefore, has not been subject to federal income taxes. As of December 31, 2013, the Company had domestic net operating loss (&#8220;NOL&#8221;) carryforwards for income tax purposes of approximately $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">55,340,000</font> which expire in 2013 through <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 2033</font>. Under the provisions of Section 382 of the Internal Revenue Code greater than 50% ownership changes that occurred in the Company may significantly limit the Company&#8217;s ability to utilize its NOL carry forwards to reduce future taxable income and related tax liabilities.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">Section 382 allows an owner shift any time there is a transfer of stock by a person who directly, or indirectly, owns more than <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">5</font>% of the corporation and the percentage of stock of the corporation owned by one or more five percent shareholders has increased, in the aggregate, by more than 50 percentage points over the lowest percentage of stock owned by such shareholders at any time during the "testing period." The "testing period" is generally a three-year period ending on the date of any owner or equity structure shift.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">The amount of post-change income that may be offset by pre-change losses is limited each year by the "Section 382 Limitation." Generally, the Section 382 Limitation is an amount equal to the value of the old loss corporation multiplied by a long-term interest rate established monthly by the Internal Revenue Service. The Company has not yet determined the qualifying events and resulting limitation that may impact utilization of net operating losses against future periods.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font>The composition of deferred tax assets and the related tax effects at December 31, 2013 and 2012 are as follows (in thousands):</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"> <table style="BORDER-BOTTOM: #9eb6ce 0px solid; BORDER-LEFT: #9eb6ce 0px solid; MARGIN: 0in; WIDTH: 80%; BORDER-COLLAPSE: collapse; OVERFLOW: visible; BORDER-TOP: #9eb6ce 0px solid; BORDER-RIGHT: #9eb6ce 0px solid" cellspacing="0" cellpadding="0" align="left"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="55%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>2013</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>2012</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="55%"> <div>Deferred tax assets:</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="55%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 13px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="55%"> <div>Domestic net operating losses</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>18,816</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>19,529</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 13px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="55%"> <div>Stock option compensation</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>223</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>606</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 13px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="55%"> <div>Book/tax differences in fixed assets</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>27</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>32</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 13px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="55%"> <div>Accrued liabilities and reserves</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>327</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>272</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 13px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="55%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>19,393</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>20,439</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 13px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="55%"> <div>Valuation allowance</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>(19,393)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>(20,439)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="55%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 3px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> </table> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"></div> </div> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font>The difference between the income tax benefit in the accompanying statement of operations and the amount that would result if the U.S. Federal statutory rate of <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">34</font></font>% were applied to pre-tax loss is as follows (amounts in thousands):</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> &#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"> <table style="MARGIN: 0in; WIDTH: 95%; BORDER-COLLAPSE: collapse; OVERFLOW: visible" cellspacing="0" cellpadding="0" align="left"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="46%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="23%" colspan="5"> <div>2013</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="23%" colspan="5"> <div>2012</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="46%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>Amount</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>%</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>Amount</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>%</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="46%"> <div>Benefit for income taxes at federal statutory rate</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 3px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>2,415</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>34</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>%</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 3px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>2,704</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 2px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>34</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>%</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="46%"> <div>Derivative losses</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 1px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>(226)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>(3)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>(596)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>(7)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="46%"> <div>Discount amortization and other</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>(949)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>(13)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>(565)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>(7)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="46%"> <div>Change in rates and other</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>(2,286)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>(32)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 2px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>21</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 2px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 2px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 2px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 2px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="46%"> <div>Change in valuation allowance</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 3px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>1,046</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 3px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>14</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>(1,564)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>(20)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="46%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>%</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 3px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>%</div> </td> </tr> </table> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"></div> </div> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table> <div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">The composition of deferred tax assets and the related tax effects at December 31, 2013 and 2012 are as follows (in thousands):</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"> <table style="BORDER-BOTTOM: #9eb6ce 0px solid; BORDER-LEFT: #9eb6ce 0px solid; MARGIN: 0in; WIDTH: 80%; BORDER-COLLAPSE: collapse; OVERFLOW: visible; BORDER-TOP: #9eb6ce 0px solid; BORDER-RIGHT: #9eb6ce 0px solid" cellspacing="0" cellpadding="0" align="left"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="55%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>2013</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>2012</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="55%"> <div>Deferred tax assets:</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="55%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 13px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="55%"> <div>Domestic net operating losses</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>18,816</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>19,529</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 13px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="55%"> <div>Stock option compensation</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>223</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>606</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 13px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="55%"> <div>Book/tax differences in fixed assets</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>27</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>32</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 13px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="55%"> <div>Accrued liabilities and reserves</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>327</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>272</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 13px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="55%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>19,393</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>20,439</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 13px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="55%"> <div>Valuation allowance</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>(19,393)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>(20,439)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="55%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 3px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> </table> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"></div> </div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table> <div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> The difference between the income tax benefit in the accompanying statement of operations and the amount that would result if the U.S. Federal statutory rate of <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 34</font></font>% were applied to pre-tax loss is as follows (amounts in thousands):</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> &#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"> <table style="MARGIN: 0in; WIDTH: 95%; BORDER-COLLAPSE: collapse; OVERFLOW: visible" cellspacing="0" cellpadding="0" align="left"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="46%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="23%" colspan="5"> <div>2013</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="23%" colspan="5"> <div>2012</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="46%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>Amount</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>%</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>Amount</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>%</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="46%"> <div>Benefit for income taxes at federal statutory rate</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 3px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>2,415</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>34</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>%</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 3px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>2,704</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 2px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>34</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>%</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="46%"> <div>Derivative losses</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 1px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>(226)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>(3)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>(596)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>(7)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="46%"> <div>Discount amortization and other</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>(949)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>(13)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>(565)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>(7)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="46%"> <div>Change in rates and other</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>(2,286)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>(32)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 2px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>21</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 2px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 2px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 2px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 2px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="46%"> <div>Change in valuation allowance</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 3px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>1,046</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 3px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>14</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>(1,564)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>(20)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="46%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>%</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 3px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>%</div> </td> </tr> </table> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"></div> </div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table> <div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <table style="MARGIN-TOP: 0pt; FONT: 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0pt" cellspacing="0" cellpadding="0" width="100%"> <tr style="VERTICAL-ALIGN: top"> <td style="WIDTH: 0.25in"> <div><strong>10.&#160;&#160;&#160;</strong></div> </td> <td> <div><strong>NOTES PAYABLE&#160;AND ADVANCES FROM RELATED PARTIES</strong></div> </td> </tr> </table> &#160; <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">On January 17, 2012, the Company assumed from MIT a note payable with Los Alamos National Bank (&#8220;LANB&#8221;) in the amount of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">700,000</font>. On February 10, 2012, MIT refinanced with LANB the principal and accrued interest of this note payable with a promissory note of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">708,000</font>, with an extended maturity of April 2015. <font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">The note renews annually</font>. The monthly payment to LANB on the promissory note is $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">10,000</font>, with the interest rate of <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 5.5</font>% at December 31, 2013 and 2012. The promissory note is guaranteed by the Company and secured by all assets of the Company. Total interest expense related to the promissory note recorded during the years ended December 31, 2013 and 2012 was $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">35,000</font></font>. The outstanding principal amount and accrued interest as of December 31, 2013, was approximately, <font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">$<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">550,000</font> and $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">3,000</font>, respectively. The outstanding principal and accrued interest as of December 31, 2012 was approximately</font>&#160;$<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">649,000</font> and $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">3,000</font>, respectively.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> During the twelve months ended December 31, 2013, the Company received $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">2,285,000</font> in short term notes from their CEO and CFO to help fund operations. The notes are unsecured and non-interest bearing. As of December 31, 2013, $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">1,250,000</font> of the notes/advances were converted to preferred shares (see note 17). The total outstanding notes/advances at December 31, 2013 were $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">1,035,000</font>.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> &#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">From time to time, the company receives advances from unrelated parties. These advances are unsecured, bear interest at <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">8</font>% and there are no specific repayment terms. During the twelve months ended December 31, 2012, the Company received advances and made repayments of these advances in the amounts of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">305,000</font> and $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">265,000</font>, respectively. During the year ended December 31, 2012, the Company recorded interest expense related to the advances of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">1,600</font>.&#160; As of December 31, 2013, and 2012 the amounts due to the unrelated parties were $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">0</font> and $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">40,000</font>, respectively.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">&#160;</div> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> Future maturities of the advances and notes payable are as follows:</div> &#160; <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:center; TEXT-INDENT: 0in; WIDTH: 100%" align="center"> <table style="BORDER-BOTTOM: #9eb6ce 0px solid; BORDER-LEFT: #9eb6ce 0px solid; MARGIN: 0px:auto; WIDTH: 60%; BORDER-COLLAPSE: collapse; OVERFLOW: visible; BORDER-TOP: #9eb6ce 0px solid; BORDER-RIGHT: #9eb6ce 0px solid" cellspacing="0" cellpadding="0" align="center"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="43%"> <div>Debt&#160;maturities&#160;as&#160;of</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="15%" colspan="2"> <div>December&#160;31,</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="43%"> <div>2014</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="14%"> <div>1,130,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="43%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="14%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="43%"> <div>2015</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="14%"> <div>455,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> </table> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"></div> </div> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table> <div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> Future maturities of the advances and notes payable are as follows:</div> &#160; <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:center; TEXT-INDENT: 0in; WIDTH: 100%" align="center"> <table style="BORDER-BOTTOM: #9eb6ce 0px solid; BORDER-LEFT: #9eb6ce 0px solid; MARGIN: 0px:auto; WIDTH: 60%; BORDER-COLLAPSE: collapse; OVERFLOW: visible; BORDER-TOP: #9eb6ce 0px solid; BORDER-RIGHT: #9eb6ce 0px solid" cellspacing="0" cellpadding="0" align="center"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="43%"> <div>Debt&#160;maturities&#160;as&#160;of</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="15%" colspan="2"> <div>December&#160;31,</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="43%"> <div>2014</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="14%"> <div>1,130,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="43%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="14%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="43%"> <div>2015</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="14%"> <div>455,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> </table> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"></div> </div> </div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table> 1130000 455000 5 2 18816000 19529000 223000 606000 27000 32000 327000 272000 19393000 20439000 19393000 20439000 -2415000 -2704000 -226000 -596000 1046000 -1564000 949000 565000 -2286000 21000 0 0 0.34 0.34 -0.07 -0.03 -0.07 -0.13 0 -0.32 -0.2 0.14 -700000 10000 0.055 3000 0 0 55340000 0.05 -2285000 -1250000 1035000 than 50% ownership changes that occurred in the Company may significantly limit the Company&#8217;s ability to utilize its NOL carry forwards to reduce future taxable income and related tax liabilities 0.08 1600 0 40000 305000 265000 <div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <table style="MARGIN-TOP: 0pt; FONT: 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0pt" cellspacing="0" cellpadding="0" width="100%"> <tr style="VERTICAL-ALIGN: top"> <td style="WIDTH: 0.25in"> <div><strong>15.</strong></div> </td> <td style="TEXT-ALIGN: justify"> <div><strong>LOSS PER SHARE</strong></div> </td> </tr> </table> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: -0.25in; MARGIN: 0pt 0px 0pt 0.25in; FONT: 10pt Times New Roman, Times, Serif" align="justify"><strong>&#160;</strong></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">Basic loss per common share is based on the weighted average number of common shares outstanding in each period and earnings adjusted for preferred stock dividend requirements. Diluted earnings per common share assumes that any dilutive convertible preferred shares outstanding at the beginning of each period were converted at those dates, with related interest, preferred stock dividend requirements and outstanding common shares adjusted accordingly. It also assumes that outstanding common shares were increased by shares issuable upon exercise of those stock options and warrants for which market price exceeds exercise price, less shares which could have been purchased by the Company with related proceeds. The convertible preferred stock and outstanding stock options and warrants were not included in the computation of diluted earnings per common share for the twelve months ended December 31, 2013 and 2012, respectively since it would have resulted in an antidilutive effect.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font>The following table sets forth the computation of basic and diluted loss per share (in thousands, except per share data):</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px 0pt 0.55in; FONT: 10pt Times New Roman, Times, Serif" align="justify">&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"> <table style="MARGIN: 0in 0in 0in 0.25in; WIDTH: 80%; BORDER-COLLAPSE: collapse; OVERFLOW: visible" cellspacing="0" cellpadding="0" align="left"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="51%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="27%" colspan="5"> <div>Year&#160;Ended&#160;December&#160;31,</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="51%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="13%" colspan="2"> <div>2013</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="13%" colspan="2"> <div>2012</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="51%"> <div>Numerator</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 11px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="51%"> <div>Basic and diluted loss</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>(7,104)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>(7,955)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="51%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="51%"> <div>Denominator</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 11px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="51%"> <div>Basic and diluted earnings per share - weighted average shares outstanding</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>1,452,364</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>1,265,270</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="51%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="51%"> <div>Basic and diluted loss per common share</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>(0.00)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>(0.01)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> </table> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"></div> </div> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px 0pt 0.25in; FONT: 10pt Times New Roman, Times, Serif"> &#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN-TOP: 0pt; FONT: 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0pt; MARGIN-LEFT: 0.25in" align="justify"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font>Anti-dilutive securities (based on conversions to common shares) not included in net loss per share calculation (in thousands):</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px 0pt 0.25in; FONT: 10pt Times New Roman, Times, Serif"> &#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"> <table style="MARGIN: 0in 0in 0in 0.25in; WIDTH: 70%; BORDER-COLLAPSE: collapse; OVERFLOW: visible" cellspacing="0" cellpadding="0" align="left"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="41%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="27%" colspan="5"> <div>Year&#160;Ended&#160;December&#160;31,</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="41%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="13%" colspan="2"> <div>2013</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="13%" colspan="2"> <div>2012</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="41%"> <div>Convertible Series A preferred stock</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"> <div>448</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"> <div>448</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="41%"> <div>Convertible Series B preferred stock</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>305,648</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>305,648</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="41%"> <div>Convertible Series G preferred stock</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>100</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="41%"> <div>Convertible Series S preferred stock</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>1,000,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>1,000,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="41%"> <div>Convertible Series H preferred stock</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>482,625</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="41%"> <div>Stock warrants</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>122,500</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>267,350</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="41%"> <div>Convertible debt</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>2,693,553</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>722,910</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="41%"> <div>Common stock options</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>188,100</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>190,600</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="41%"> <div>Series B preferred stock options</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>207,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>250,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> </table> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"></div> </div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table> <div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">The following table sets forth the computation of basic and diluted loss per share (in thousands, except per share data):</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px 0pt 0.55in; FONT: 10pt Times New Roman, Times, Serif" align="justify">&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"> <table style="MARGIN: 0in 0in 0in 0.25in; WIDTH: 80%; BORDER-COLLAPSE: collapse; OVERFLOW: visible" cellspacing="0" cellpadding="0" align="left"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="51%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="27%" colspan="5"> <div>Year&#160;Ended&#160;December&#160;31,</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="51%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="13%" colspan="2"> <div>2013</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="13%" colspan="2"> <div>2012</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="51%"> <div>Numerator</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 11px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="51%"> <div>Basic and diluted loss</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>(7,104)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>(7,955)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="51%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="51%"> <div>Denominator</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 11px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="51%"> <div>Basic and diluted earnings per share - weighted average shares outstanding</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>1,452,364</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>1,265,270</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="51%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="51%"> <div>Basic and diluted loss per common share</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>(0.00)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>(0.01)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> </table> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"></div> </div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table> 708000 1265270000 1452364000 448 305648 0 1000000 482625 122500 2693553 188100 207000 448 250000 305648 100 1000000 0 267350 722910 190600 <div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <table style="MARGIN-TOP: 0pt; FONT: 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0pt" cellspacing="0" cellpadding="0" width="100%"> <tr style="VERTICAL-ALIGN: top"> <td style="WIDTH: 0.25in"> <div><b>14.</b></div> </td> <td> <div><b>OTHER EXPENSES</b></div> </td> </tr> </table> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: -0.25in; MARGIN: 0pt 0px 0pt 0.25in; FONT: 10pt Times New Roman, Times, Serif"> <b>&#160;</b></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">During the years ended December 31, 2013 and 2012, the Company recorded other expenses of approximately $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">3,766,000</font> and $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">3,233,000</font>, respectively. Other expenses include interest expense, derivative expenses and other gains and losses.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">Interest expense was $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">2,137,000</font> and $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">1,753,000</font> for the years ended December 31, 2013 and 2012, respectively. $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">1,910,000</font> and $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">1,628,000</font> of the total interest expense for the years ended December 31, 2013 and 2012, respectively, was related to the accretion of debt discount associated with convertible debt.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">For the years ended December 31, 2013 and 2012, the Company recorded losses of approximately $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">665,000</font> and&#160;$<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">726,000</font>, respectively, on fair value adjustments to embedded conversion derivative liability associated with the convertible debt. Debt modification expense was $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">821,000</font> and $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">432,000</font> for the years ended December 31, 2013 and 2012, respectively.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">During the year ended December 31, 2012, the Company also recorded $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">18,000</font> loss on the disposal of property and equipment, $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">282,000</font> loss on settlement and other expenses of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">22,000</font>. <font style="FONT-SIZE: 10pt">During the year ended December 31, 2013 the Company recorded other expenses of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">143,000</font>, which is made up of foreign currency translation losses reclassified out of accumulated other comprehensive income.</font></div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table> 656000 1784000 6000 442000 0 -77000 1970000 1628000 65000 -339000 -17000 -190000 200000 -603000 -233000 -146000 -88000 -656000 -13000 -230000 -3046000 -2240000 16000 73000 0 -1000 -16000 -72000 0 305000 0 383000 2520000 2210000 4563000 2554000 1501000 242000 1000 39000 32000 0 0 1125000 0 0 255000 16000 0 0 50000 0 545000 578000 0 500000 3695000 2460000 0 269000 0 16000 0 4771000 19000 0 -821000 -432000 0 -282000 <div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">Convertible Debentures outstanding as of December 31, 2013 and 2012 were as follows (in thousands):</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"><i>&#160;</i></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"> <table style="MARGIN: 0in; WIDTH: 100%; BORDER-COLLAPSE: collapse; OVERFLOW: visible" cellspacing="0" cellpadding="0" align="left"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="55%"> <div>December&#160;31,&#160;2013</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="14%" colspan="2"> <div>Unrelated<br/> parties</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="14%" colspan="2"> <div>Related&#160;parties</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="13%" colspan="2"> <div>Total</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="55%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="13%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="13%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="12%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="55%"> <div>Convertible debentures- face value</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 3px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="13%"> <div>4,030</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="13%"> <div>1,750</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>5,780</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="55%"> <div>Debt discount</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 1px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="13%"> <div>(1,328)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="13%"> <div>0</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>(1,328)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="55%"> <div>Total convertible debentures</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 3px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="13%"> <div>2,702</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="13%"> <div>1,750</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"> <div>4,452</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 13px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="55%"> <div>Less current portion</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 1px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="13%"> <div>(2,702)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="13%"> <div>(1,750)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>(4,452)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 13px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="55%"> <div>Long term portion</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="13%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="13%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> </table> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"></div> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"> <table style="MARGIN: 0in; WIDTH: 100%; BORDER-COLLAPSE: collapse; FONT-SIZE: 10pt; OVERFLOW: visible" cellspacing="0" cellpadding="0" align="left"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="55%"> <div>December&#160;31,&#160;2012</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="14%" colspan="2"> <div>Unrelated<br/> parties</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="14%" colspan="2"> <div>Related&#160;parties</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="13%" colspan="2"> <div>Total</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="55%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="13%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="13%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="55%"> <div>Convertible debentures- face value</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="13%"> <div>1,510</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="13%"> <div>1,850</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>3,360</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="55%"> <div>Debt discount</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="13%"> <div>(350)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="13%"> <div>(1,448)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>(1,798)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="55%"> <div>Total current convertible debentures</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="13%"> <div>1,160</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="13%"> <div>402</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"> <div>1,562</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> </table> </div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table> <div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> <table style="FONT-FAMILY: Times New Roman; TABLE-LAYOUT: fixed; FONT-SIZE: 10pt; dtth: tableHanging" cellspacing="0" cellpadding="0" width="100%"> <tr style="VERTICAL-ALIGN: top"> <td style="WIDTH: 0.25in; WORD-WRAP: break-word"> <div><strong>11.</strong></div> </td> <td style="WIDTH: auto; WORD-WRAP: break-word; VERTICAL-ALIGN: top"> <div><strong>NOTES PAYABLE &#150; CAPITAL LEASE</strong></div> </td> </tr> </table> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0in; MARGIN: 0in; FONT: 10pt Times New Roman, Times, Serif"> &#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">The Company has entered into a capital leases for equipment at interest rates of <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 7.25</font>%, payable through 2018. The assets and liabilities under the capital leases are recorded at the present value of the minimum lease payments and are depreciated over their estimated useful lives. The gross amount of assets held under capital leases for the nine months December 31, 2013 and December 31, 2012 was $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">16,300</font> and $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">0</font>, respectively, with accumulated depreciation of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">1,165</font> and $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">0</font>, respectively. Depreciation expense for this equipment for the years ended December 31, 2013 and December 31, 2012 was $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">1,165</font> and $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">0</font>, respectively.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font>Future minimum lease payments and the present value of the payments are as follows:</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> &#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:center; TEXT-INDENT: 0in; WIDTH: 100%" align="center"> <table style="MARGIN: 0px:auto; WIDTH: 60%; BORDER-COLLAPSE: collapse; FONT-SIZE: 10pt; OVERFLOW: visible" cellspacing="0" cellpadding="0" align="center"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="43%"> <div>Debt&#160;maturities&#160;as&#160;of</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="15%" colspan="2"> <div>December&#160;31,</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="43%"> <div>2014</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="14%"> <div>4,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="43%"> <div>2015</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="14%"> <div>4,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="43%"> <div>2016</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="14%"> <div>4,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="43%"> <div>2017</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="14%"> <div>4,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="43%"> <div>2018 and thereafter</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="14%"> <div>1,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="43%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="14%"> <div>17,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="43%"> <div>Less: amounts representing interest</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="14%"> <div>(3,000)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="43%"> <div>Present value</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="14%"> <div>14,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="43%"> <div>Less: current portion</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="14%"> <div>(3,000)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="43%"> <div>Note payable Capital Lease &#150; noncurrent portion</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="14%"> <div>11,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> </table> </div> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table> <div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">Future minimum lease payments and the present value of the payments are as follows:</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> &#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:center; TEXT-INDENT: 0in; WIDTH: 100%" align="center"> <table style="MARGIN: 0px:auto; WIDTH: 60%; BORDER-COLLAPSE: collapse; FONT-SIZE: 10pt; OVERFLOW: visible" cellspacing="0" cellpadding="0" align="center"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="43%"> <div>Debt&#160;maturities&#160;as&#160;of</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="15%" colspan="2"> <div>December&#160;31,</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="43%"> <div>2014</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="14%"> <div>4,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="43%"> <div>2015</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="14%"> <div>4,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="43%"> <div>2016</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="14%"> <div>4,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="43%"> <div>2017</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="14%"> <div>4,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="43%"> <div>2018 and thereafter</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="14%"> <div>1,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="43%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="14%"> <div>17,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="43%"> <div>Less: amounts representing interest</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="14%"> <div>(3,000)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="43%"> <div>Present value</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="14%"> <div>14,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="43%"> <div>Less: current portion</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="14%"> <div>(3,000)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="43%"> <div>Note payable Capital Lease &#150; noncurrent portion</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="14%"> <div>11,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> </table> </div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table> 4000 4000 4000 4000 1000 3000 14000 17000 0.0725 16300 0 1165 0 1165 0 <div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> The following is a summary of Convertible Debt and the initial accounting of the issuances (in thousands): <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px 0pt 0.25in; FONT: 10pt Times New Roman, Times, Serif" align="justify">&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"> <table style="MARGIN: 0in; WIDTH: 95%; BORDER-COLLAPSE: collapse; FONT-SIZE: 10pt; OVERFLOW: visible" cellspacing="0" cellpadding="0" align="left"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="82%"> <div>Convertible debt issuance</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>2,460</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="82%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="82%"> <div>Allocation of debt to warrants</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>(331)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="82%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="82%"> <div>Allocation of debt to embedded conversion derivative liability</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>(2,129)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> </table> </div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table> 2460000 -331000 -2129000 2520000 -1500000 5780000 4030000 1750000 1328000 1328000 0 4452000 2702000 1750000 -2702000 -1750000 0 0 0 3360000 1510000 1850000 1798000 350000 1448000 1562000 1160000 402000 -16667 -477233501 -2020000 4772000 20000 9000 -1000 -1000 38300000 383000 383000 -41165240 442000 412000 30000 30000000 300000 300000 331000 331000 545000 545000 17000000 170000 99000 579000 579000 57864357 269000 0.08 25000000 0.01 0.01 2013-12-31 250000 0.55 100000 18181818 44661000 1784000 1784000 -7955000 -7955000 2210000 460000 0.08 1750000 1700000 68500000 0.01 0.55 2520000 -621000 5000 5000 0 0 655000 0 655000 0 0 0 -7104000 0 0 0 -7104000 0 1970000 1628000 277542 148741 14203000 1125000 1250000 143000 0 <div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: -0.25in; MARGIN: 0pt 0px 0pt 0.25in; FONT: 10pt Times New Roman, Times, Serif"> <strong>&#160;</strong></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> <strong>Description of Business</strong></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> <strong>&#160;</strong></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">Positron Corporation (the &#8220;Company&#8221;) was incorporated on December 20, 1983 in the state of Texas and commenced commercial operations in 1986. Positron Corporation is a nuclear medicine healthcare company. The Company offers positron emission tomography molecular imaging systems, clinical and support services, automated radiopharmaceutical systems, radiopharmaceuticals and radioisotope processing and production.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">The molecular imaging systems portion of the business provides Positron Emission Tomography (PET) scanners. The automated radiopharmaceutical system portion of the business offers the world&#8217;s first robotic system for the preparation and dispensing of radiopharmaceuticals that provides unit dose radiopharmaceutical agents used in molecular imaging. The radioisotope manufacturing portion of the business enables the Company to process and produce radioisotope(s) that are critical components required in nuclear imaging.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">The Company&#8217;s objective is to generate revenue by offering inexpensive molecular imaging systems and support services, disease specific software, automated radiopharmaceutical dose preparation and dispensing system, radiopharmaceutical(s) and radioisotope(s) for nuclear medicine primarily in the field of cardiac nuclear medicine.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">On January 17, 2012, the Company acquired all of the issued and outstanding membership interest of Manhattan Isotope Technology LLC (&#8220;MIT&#8221;). See Note 3.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">MIT possesses the unique and specialized expertise in all stages of strontium-82 (Sr-82) production and spent generator lifecycle management. Currently, MIT produces&#160;API grade strontium-82 from target material received from its foreign collaborators.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">Positron Isotopes Corporation (PIC) was formed to investigate the possibility of building a cyclotron.</font></div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table> <div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <b><font style="FONT-SIZE: 10pt">12.</font></b><font style="FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">&#160;&#160;&#160;&#160;</font> <strong>STOCKHOLDERS&#8217; EQUITY</strong></font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: -0.25in; MARGIN: 0in 0.5in 0pt 0.25in"> <strong><font style="FONT-SIZE: 10pt">&#160;</font></strong></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: -0.25in; MARGIN: 0in 0.5in 0pt 0.25in"> <strong><u><font style="FONT-SIZE: 10pt"> 2013</font></u></strong></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: -0.25in; MARGIN: 0in 0.5in 0pt 0.25in"> <strong><u><font style="FONT-SIZE: 10pt"> </font></u></strong>&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">On April 12, 2013, the Company issued <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 621,000</font> shares of common stock for consulting services. On the date of the issuance, the common stock had a fair market value of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">0.008</font> per share. The Company recorded consulting fee expense of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">5,000</font> for the issuance of the shares.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">On April 11, 2013, the Company accepted subscriptions from Patrick Rooney, its Chairman and Chief Executive Officer, and Corey Conn, its Chief Financial Officer and converted certain advances (see note 17) in the amounts of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">500,000</font> and $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">250,000</font> respectively for an aggregate investment of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">750,000</font>. In consideration of these subscriptions, the Company issued <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 7,500,000</font> shares of its newly created Series H Junior Convertible Preferred Stock, par value $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">0.01</font> per share (the &#8220;Series H Preferred Stock&#8221;). <font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">In November 2013, the Company accepted a subscription from Patrick G Rooney, Chairman and CEO to convert additional advances in the amount of $500,000 for 5,000,000 shares of Series H Preferred Stock.</font>&#160;The Series H Preferred Stock ranks junior to dividends and distributions of the Company&#8217;s assets upon liquidation to all previously-issued shares of the Company&#8217;s capital stock and is not entitled to receive interest or dividends. The Series H Preferred Stock is convertible into shares of the Company&#8217;s Common Stock at a rate equal to the number of shares of Series H Preferred Stock being converted multiplied by the <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">Original Issuance Price of $0.10 and divided by seventy percent (70%) of the daily weighted volume average price for the three trading days prior to conversion.</font> The Series H Preferred Stock shall be entitled to <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">two hundred (200) votes per share</font> of Series H Preferred Stock on all matters which holders of Common Stock are entitled to vote.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">In May 2013 the Board of Directors, subject to the approval of the shareholders of the Company, authorized an amendment to the Company's Certificate of Incorporation in order to effect a reverse split of the Company's common stock in a <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">ratio of 1 for 100</font> (the "Reverse Split"), reduce the number of shares of capital stock from <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 3,020,000,000</font> to <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 520,000,000</font> of which <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 500,000,000</font> shares will be common stock and <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 20,000,000</font> shares will be preferred stock, each par value $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">0.0001</font> per share. The shareholders also approved the conversion of the Company to a Delaware corporation. These actions are not effective.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <strong><u><font style="FONT-SIZE: 10pt"> 2012</font></u></strong></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">On January 4, 2012, the Company increased the number of the Company&#8217;s authorized shares of capital stock from <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 810,000,000</font> shares to <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 3,020,000,000</font> of which <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 3,000,000,000</font> shares were classified as common stock par value $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">0.01</font> per share (&#8220;Common Stock&#8221;) and <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 20,000,000</font> shares were classified as preferred stock par value $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">1.00</font> per share (&#8220;Preferred Stock&#8221;). Additionally on January 4, 2012, the Company accepted subscriptions in the amount of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">150,000</font> and issued <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 15,000,000</font> shares of Common Stock. In connection with these Common Stock issuances, the Company also issued <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 15,000,000</font> warrants to purchase Common Stock of the Company, which will expire on December 31, 2013 and extended the expiration date of <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 20,000,000</font> warrants which had expired to December 31, 2013.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">On January 4, 2012, the Company issued <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 400,000</font> shares to a vendor for services rendered valued at $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">4,000</font>.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">On January 9, 2012, the Company issued <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 1,400,000</font> shares to a vendor for services rendered valued at $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">14,000</font>.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">On January 19, 2012, the Company converted <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 1,923,223</font> shares of Series B Convertible Preferred Stock into <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 192,322,258</font> shares of common stock and accepted subscriptions in the amount of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">100,000</font> and issued <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 27,000,000</font> shares of Common Stock. Additionally, the Company issued <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 10,000,000</font> warrants to investors to purchase Common Stock of the Company, which will expire on December 31, 2013 and extended the expiration dates of <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 30,000,000</font> warrants which had expired to December 31, 2013.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">On January 19, 2012, the Company issued <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 5,000,000</font> shares in connection with the acquisition of MIT and <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 76,261</font> shares of Common Stock were issued for royalties.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">On January 19, 2012, the Company issued <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 25,000,000</font> shares of Common Stock and a convertible debenture due on <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">December 31, 2013</font>, with interest at the rate of <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 8</font>%, to a related party as the purchase price for the office space previously leased by the Company. In addition, the Company issued <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 35,000,000</font> warrants, which entitle the related party to purchase shares of the Company&#8217;s common stock of the Company, which will expire on <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">December 31, 2013</font>.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">On January 20, 2012, the Company accepted subscriptions in the amount of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">50,000</font> and issued <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 5,000,000</font> shares of Common Stock. In connection with these Common Stock issuances, the Company also issued <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 5,000,000</font> warrants to purchase Common Stock of the Company, which will expire on <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">December 31, 2013</font>, and extended the expiration date of <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 7,500,000</font> warrants which had expired to <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">December 31, 2013</font>.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">On March 1, 2012, the Company converted <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 603,711</font> shares of Series B Convertible Preferred Stock into <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 60,371,100</font> shares of Common Stock and issued <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 3,000,000</font> shares of Common Stock to a vendor for services rendered valued at $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">51,000</font>.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">On March 14, 2012, the Company accepted subscriptions in the amount of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">35,000</font> and issued <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 3,500,000</font> shares of Common Stock. In connection with these issuances, the Company also issued <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 3,500,000</font> warrants to investors to purchase Common Stock of the Company, which will expire on <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">December 31, 2013</font>, and extended the expiration date of <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 750,000</font> warrants which had expired to <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">December 31, 2013</font>. Also on March 14, 2012, the Company issued <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 1,200,000</font> shares of Common Stock to an employee for services valued at $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">20,000</font>, and <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 600,000</font> shares of Common Stock to a vendor for services rendered valued at $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">10,000</font>.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">On April 5, 2012, the Company converted <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 634,000</font> shares of Series B Convertible Preferred Stock into <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 63,400,000</font> shares of Common Stock. The Company also accepted subscriptions in the amount of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">28,000</font> and issued <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 2,800,000</font> shares of Common Stock. In connection with these Common Stock issuances, the Company also issued <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 3,100,000</font> warrants to purchase Common Stock of the Company, which will expire on <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">December 31, 2013</font>. Also on April 5, 2012, the Company issued <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 39,682,539</font> shares of Common Stock for repayment of convertible debt, and issued <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 2,208,750</font> shares of Common Stock to a vendor for settlement of accounts payable. The Company recorded $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">26,456</font> loss on the settlement.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">On May 7, 2012, the Company issued <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 4,000,000</font> warrants in connection with a Convertible Debt issuance to a Lender to purchase Common Stock of the Company, which will expire on <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">December 31, 2013</font>.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">On May 20, 2012, the Company issued <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 2,000,000</font> warrants to an investor to purchase Common Stock of the Company, which will expire on <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">December 31, 2013</font>.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">On May 21, 2012, the Company converted <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 73,226</font> shares of Series B Convertible Preferred Stock into <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 7,322,636</font> shares of Common Stock. The Company also accepted subscriptions in the amount of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">130,000</font> and issued <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 15,000,000</font> shares of Common Stock. In connection with these issuances, the Company issued <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 13,000,000</font> warrants to investors to purchase Common Stock of the Company, which will expire on <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">December 31, 2013</font>. In addition, the Company issued <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 175,000</font> shares of Common Stock to a vendor on May 21, 2012 for services rendered valued at $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">2,000</font>.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">On May 29, 2012, the Company converted <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 231,190</font> shares of Series B Convertible Preferred Stock into <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 23,119,000</font> shares of Common Stock. The Company issued <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 18,181,818</font> shares of Common Stock for repayment of related party convertible debt.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">On June 7, 2012, the Company issued <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 4,000,000</font> warrants in connection with a Convertible Debt issuance to a lender to purchase Common Stock of the Company, which will expire on <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">December 31, 2013</font>.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">On June 19, 2012, the Company converted <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 16,667</font> shares of Series A Convertible Preferred Stock into <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 16,667</font> shares of Common Stock, converted <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 118,149</font> shares of Series B Convertible Preferred Stock into <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 11,814,878</font> shares of Common Stock, and converted <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 18,200</font> shares of Series G Convertible Preferred Stock into <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 2,020,000</font> shares of Common Stock. In addition, the Company issued <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 3,970,786</font> shares of Common Stock to a vendor for settlement of accounts payable.&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">On July 17, 2012, the Company issued <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 1,000,000</font> shares of Common Stock to vendors for services rendered. The Company issued and additional <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 1,000,000</font> shares of Common Stock to a vendor for services rendered on July 18, 2012. Both were valued at $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">10,000</font>.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">On August 21, 2012 the Company issued <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 1,000,000</font> shares of Common Stock to a vendor for services rendered valued at $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">10,000</font>.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">On August 31, 2012, the Company converted <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 1,188,836</font> shares of Series B Convertible Preferred Stock into <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 118,883,629</font> shares of Common Stock. Also on August 31, the Company issued <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 2,000,000</font> shares to an investor who had purchased shares during the three months ended June 30, 2012 and which were included in stock payable as of June 30, 2012.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">On September 10, 2012, the Company converted obligations totaling $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">35,605</font> into <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 10,000,000</font> shares of Common Stock. Of these shares, <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 6,666,667</font> shares were payable as of September 30, 2012 and were issued in October 2012. In connection with this issuance the Company recorded a loss on settlement of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">54,395</font>.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">In November 2012, the Company issued warrants to purchase a total of <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 10,500,000</font> shares of the Company&#8217;s Common Stock, at an exercise price of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">0.01</font> per share expiring on December 31, 2013, to its Chief Financial Officer. The warrants were issued in connection with the issuance of two non-interest bearing convertible debentures totaling $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">380,000</font> to the CFO.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">In November 2012, the Company issued warrants to purchase a total of <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 37,500,000</font> shares of the Company&#8217;s Common Stock, at an exercise price of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">0.01</font> per share to its Chief Executive Officer. The warrants expire on December 31, 2013. The warrants were issued in connection with the issuance of two non-interest bearing convertible debentures totaling $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">1,320,000</font> to the CEO.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">In December 2012, the Company issued a convertible debenture in the amount of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">50,000</font> to a third party. In connection with the debt, the Company also issued to the third party warrants to purchase <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 1,500,000</font> shares of the Company&#8217;s Common Stock, at an exercise price of $0.01 per share expiring on December 31, 2013.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt"></font>&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> <strong>Options</strong></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">For all of the Company&#8217;s stock-based compensation plans, the fair value of each grant was estimated at the date of grant using the Black-Scholes option-pricing model. Black-Scholes utilizes assumptions related to volatility, the risk-free interest rate, the dividend yield (which is assumed to be zero, as the Company has not paid cash dividends to date and does not currently expect to pay cash dividends) and the expected term of the option. Expected volatilities utilized in the model are based mainly on the historical volatility of the Company&#8217;s stock price over a period commensurate with the expected life of the share option as well as other factors. The risk-free interest rate is derived from the zero-coupon U.S. government issues with a remaining term equal to the expected life at the time of grant.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">For all of the Company&#8217;s stock-based compensation plans, the fair value of each grant was estimated at the date of grant using the Black-Scholes option-pricing model. Black-Scholes utilizes assumptions related to volatility, the risk-free interest rate, the dividend yield (which is assumed to be zero, as the Company has not paid cash dividends to date and does not currently expect to pay cash dividends) and the expected term of the option. Expected volatilities utilized in the model are based mainly on the historical volatility of the Company&#8217;s stock price over a period commensurate with the expected life of the share option as well as other factors. The risk-free interest rate is derived from the zero-coupon U.S. government issues with a remaining term equal to the expected life at the time of grant.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> In January 2010 the Company granted certain employees options to purchase <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 2,500,000</font> shares of Series B Preferred stock at an exercise price of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">1.00</font> per share (the &#8220;Preferred Options&#8221;.) The options vest immediately and have a term of <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> three</font> years. Accordingly, in January 2010 the Company recorded compensation expense of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">2,500,000</font> for the Preferred Option grants. At December 31, 2013, <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 430,000</font> of these options expired and <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 2,070,000</font> were extended for one year. The Company recorded compensation expense of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">567,567</font> for the extended Preferred Option grants. <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font>Fair market value using the Black-Scholes option-pricing model was determined using the following assumptions:</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> &#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:center; TEXT-INDENT: 0in; WIDTH: 100%" align="center"> <table style="MARGIN: 0px:auto; WIDTH: 80%; BORDER-COLLAPSE: collapse; FONT-SIZE: 10pt; OVERFLOW: visible" cellspacing="0" cellpadding="0" align="center"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="66%"> <div>Expected life (years)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>1</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="66%"> <div>Risk free rate of return</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>11</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>%</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="66%"> <div>Dividend yield</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>0</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="66%"> <div>Expected volatility</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>200</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>%</div> </td> </tr> </table> </div> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font>A summary of Series B Preferred stock option activity is as follows:</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"> <table style="BORDER-BOTTOM: #9eb6ce 0px solid; BORDER-LEFT: #9eb6ce 0px solid; MARGIN: 0in; WIDTH: 100%; BORDER-COLLAPSE: collapse; OVERFLOW: visible; BORDER-TOP: #9eb6ce 0px solid; BORDER-RIGHT: #9eb6ce 0px solid" cellspacing="0" cellpadding="0" align="left"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="71%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="13%" colspan="2"> <div>Shares&#160;Issuable<br/> Under<br/> Outstanding<br/> Options</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="13%" colspan="2"> <div>Weighted<br/> Average<br/> Exercise<br/> Price</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="71%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="12%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="12%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="71%"> <div>Balance at December 31, 2012</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>2,500,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>1.00</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="71%"> <div>Issued</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="71%"> <div>Expired/forfeited</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>(430,000)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>1.00</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="71%"> <div>Exercised</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="71%"> <div>Balance at December 31, 2013</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"> <div>2,070,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"> <div>1.00</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="71%"> <div>Exercisable, December 31, 2013</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="12%"> <div>2,070,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="12%"> <div>1.00</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> </table> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"></div> </div> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">On January 17, 2012, Positron's Board of Directors (the &#8220;Board&#8221;) adopted the 2012 Equity Incentive Plan ("2012 Plan"), authorizing issuance of <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 200,000,000</font> stock options to purchase shares of the Company&#8217;s common stock.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">On January 17, 2012, the Company granted certain employees options to purchase <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 177,600,000</font> shares of common stock under the plan at an exercise price of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">0.01</font> per share (&#8220;January Issuance&#8221;). Fifty (50) percent of the options vested immediately on the grant date with the remaining fifty (50) percent vesting on January 17, 2013. The Company recorded a total expense of approximately $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">1,735,000</font> related to these options during the year ended December 31, 2012 and recorded an&#160;additional $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">39,000</font> for these stock options in the first quarter of 2013. During the year ended December 31, 2012, options to purchase <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 7,000,000</font> shares of stock were forfeited and a total of <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 170,600,000</font> options from the January issuance were outstanding as of December 31, 2012. At December 31, 2012, the remaining weighted average contractual term of these options was <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 2.05</font> years. The intrinsic value of these options on the grant date was $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">187,600</font> as the closing stock price on the grant date was $0.011. <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font>Fair market value using the Black-Scholes option-pricing model was determined using the following assumptions:</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:center; TEXT-INDENT: 0in; WIDTH: 100%" align="center"> <table style="MARGIN: 0px:auto; WIDTH: 80%; BORDER-COLLAPSE: collapse; FONT-SIZE: 10pt; OVERFLOW: visible" cellspacing="0" cellpadding="0" align="center"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="66%"> <div>Expected life (years)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>1.75</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="66%"> <div>Risk free rate of return</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>0.75</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>%</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="66%"> <div>Dividend yield</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>0</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="66%"> <div>Expected volatility</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>218</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>%</div> </td> </tr> </table> </div> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">In November 2012, the Company granted additional options to purchase <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 20,000,000</font> shares of common stock under the 2012 Plan to a new employee at an exercise price of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">0.01</font> per share. Fifty (50) percent of the options vested immediately on the grant date with the remaining fifty (50) percent vesting on January 17, 2013 The Company recognized an expense of approximately $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">49,000</font> related to these options during the year ended December 31, 2012 and will recognize an additional expense of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">49,000</font> during the first quarter of 2013. At December 31, 2012, the remaining weighted average contractual term of these options was <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 2.05</font> years. The intrinsic value of the options on the grant date was $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">0</font>, as the closing stock price on the grant date was $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">0.008</font>. Fair market value using the Black-Scholes option-pricing model was determined using the following assumptions:</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:center; TEXT-INDENT: 0in; WIDTH: 100%" align="center"> <table style="MARGIN: 0px:auto; WIDTH: 80%; BORDER-COLLAPSE: collapse; FONT-SIZE: 10pt; OVERFLOW: visible" cellspacing="0" cellpadding="0" align="center"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="66%"> <div>Expected life (years)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>2.25</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="66%"> <div>Risk free rate of return</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>0.27</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>%</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="66%"> <div>Dividend yield</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>0</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="66%"> <div>Expected volatility</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>125</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>%</div> </td> </tr> </table> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">&#160;&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">As of December 31, 2012, the Company had a total of <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 190,600,000</font> options outstanding with <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 9,400,000</font> options available for issuance under the 2012 Plan. Fifty (50) percent of the outstanding options were fully and the remaining fifty (50) percent vest on January 17, 2013. All the options issued under the 2012 Plan expire on January 17, 2015.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font>A summary of common stock option activity is as follows:</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> &#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"> <table style="BORDER-BOTTOM: #9eb6ce 0px solid; BORDER-LEFT: #9eb6ce 0px solid; MARGIN: 0in; WIDTH: 100%; BORDER-COLLAPSE: collapse; FONT-SIZE: 10pt; OVERFLOW: visible; BORDER-TOP: #9eb6ce 0px solid; BORDER-RIGHT: #9eb6ce 0px solid" cellspacing="0" cellpadding="0" align="left"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="71%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="13%" colspan="2"> <div>Shares Issuable<br/> Under<br/> Outstanding<br/> Options</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="13%" colspan="2"> <div>Weighted<br/> Average<br/> Exercise<br/> Price</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="71%"> <div>Issued in 2012</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>197,600,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>0.01</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="71%"> <div>Forfeited</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; BACKGROUND: #ffffff; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 2px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>(7,000,000)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>0.01</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="71%"> <div>Balance at December 31, 2012</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; BACKGROUND: #ccffcc; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>190,600,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>0.01</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="71%"> <div>Forfeited</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 1px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>(2,500,000)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>0.01</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="71%"> <div>Exercised</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 6px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="71%"> <div>Balance at December 31, 2013</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"> <div>188,100,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"> <div>0.01</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="71%"> <div>Exercisable, December 31, 2013</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="12%"> <div>188,100,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="12%"> <div>0.01</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160; <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font></div> </td> </tr> </table> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"></div> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> &#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> <strong>Warrants</strong></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> &#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font>A summary of warrant activity based on common stock equivalents is as follows:</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> &#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt; TEXT-INDENT: 0in; WIDTH: 100%"> <table style="WIDTH: 100%; BORDER-COLLAPSE: collapse; OVERFLOW: visible" cellspacing="0" cellpadding="0"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="58%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="12%"> <div>Number of Shares</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="13%" colspan="2"> <div>Exercise<br/> Price</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="13%" colspan="2"> <div>Weighted<br/> Average<br/> Exercise<br/> Price</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="58%"> <div>Balance at December 31, 2011</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"> <div>183,583,338</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 2px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"> <div>0.01-0.15</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"> <div>0.05</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="58%"> <div>Warrants exercised</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 2px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="58%"> <div>Warrants expired</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>(134,583,338)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 2px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>0.01-0.03</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>0.03</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="58%"> <div>Warrants issued with common and Series B Preferred stock in private placement</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>114,850,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 2px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>0.01</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>0.01</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="58%"> <div>Warrants issued with convertible debentures and notes payable</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>103,500,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 2px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>0.01</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>0.01</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="58%"> <div>Balance at December 31, 2012</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"> <div>267,350,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 2px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>0.01-0.15</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>0.03</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="58%"> <div>Warrants exercised</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 2px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="58%"> <div>Warrants expired</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>(144,850,000)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 2px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>0.01-0.15</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>0.02</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="58%"> <div>Warrants issued with convertible debentures and notes payable</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 2px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="58%"> <div>Balance at December 31, 2013</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"> <div>122,500,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 2px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>0.01-0.02</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>0.01</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> </table> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"></div> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"></div> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> &#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> All outstanding warrants are currently exercisable.&#160;<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font>&#160;A summary of outstanding common stock warrants at December 31, 2013 follows:</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> <strong>&#160;</strong></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:center; TEXT-INDENT: 0in; WIDTH: 100%" align="center"> <table style="BORDER-BOTTOM: #9eb6ce 0px solid; BORDER-LEFT: #9eb6ce 0px solid; MARGIN: 0px:auto; WIDTH: 85%; BORDER-COLLAPSE: collapse; FONT-SIZE: 10pt; OVERFLOW: visible; BORDER-TOP: #9eb6ce 0px solid; BORDER-RIGHT: #9eb6ce 0px solid" cellspacing="0" cellpadding="0" align="center"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="14%" colspan="3"> <div>Number&#160;of<br/> Common&#160;Stock<br/> Equivalents</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="41%"> <div>Expiration&#160;Date</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="13%" colspan="2"> <div>Remaining<br/> Contractual&#160;Life<br/> (Years)</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="13%" colspan="2"> <div>Exercise<br/> Price</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>4,000,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="41%"> <div>(a)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>0.02</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>118,500,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="41%"> <div>(b)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>1.00</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>0.01</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> </table> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"></div> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> <strong>&#160;</strong> <strong>&#160;</strong></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px 0pt 49.5pt; FONT: 10pt Times New Roman, Times, Serif"> (a) Warrants expire six months after the date on which a registration statement is filed and accepted by the Securities Exchange Commission permitting a sale of the shares issuable upon exercise of the warrant.<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font></div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table><div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif ">&#160;</div><div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.7in; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">(b) Warrants were originally set to expire on December 31, 2013, but were extended by the Company through December 31, 2014.</font></div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table> <div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"><strong>Affiliated Entities</strong></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"><strong>&#160;</strong></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">Affiliated entities and their affiliation, as defined by FASB Codification Topic 850 are as follows:</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">Solaris Opportunity Fund owns or controls common and preferred shares of the Company and its managing member is the CEO of the Company.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">The Company has a <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">1</font>% ownership interest in the joint venture Neusoft Positron Medical Systems ("Neusoft"). Both the Company and the joint venture's other partner, Neusoft Medical Systems purchase PET systems at a wholesale transfer price from Neusoft. The Company maintains one of five board seats on Neusoft's board. The Company currently accounts for its investment in Neusoft on the cost method and has no recorded value as of December 31, 2013 and 2012 based on prior losses of Neusoft.</div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table> <div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"><strong>Inventory</strong></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"><strong>&#160;</strong></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">Inventories are stated at the lower of cost or market. Cost is determined using the first-in, first-out (FIFO) method of inventory valuation. Management assesses the recoverability and establishes reserves of the various inventory components on a quarterly basis and is based on the estimated net realizable values of respective finished, in process and raw material inventories.</div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table> <div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"><strong>Property and Equipment</strong></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"><strong>&#160;</strong></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font>Property and equipment are recorded at cost and depreciated for financial statement purposes using the straight-line over estimated useful lives below:</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:center; TEXT-INDENT: 0in; WIDTH: 100%" align="center"> <table style="MARGIN: 0px:auto; WIDTH: 80%; BORDER-COLLAPSE: collapse; FONT-SIZE: 10pt; OVERFLOW: visible" cellspacing="0" cellpadding="0" align="center"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="66%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>Estimated&#160;life,<br/> years</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="66%"> <div>Buildings</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"> <div>39</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="66%"> <div>Furniture and fixtures</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>5-7</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="66%"> <div>Leasehold improvements</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>1-3</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="66%"> <div>Computer equipment</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>3-5</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="66%"> <div>Research equipment</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>7</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="66%"> <div>Machinery and equipment</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>3-5</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160; <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font></div> </td> </tr> </table> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">Gains or losses on dispositions are included in the statement of operations in the period incurred. Maintenance and repairs are charged to expense as incurred.</div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table> <div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"><strong>Impairment of Long-Lived Assets</strong></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"><strong>&#160;</strong></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">Periodically, the Company evaluates the carrying value of its long-lived assets, by comparing the anticipated future net cash flows associated with those assets to the related net book value. If impairment is indicated as a result of such reviews, the Company would record the impairment based on the fair market value of the assets, using techniques such as projected future discounted cash flows or third party valuations.</div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table> <div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"><strong>Income Taxes</strong></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"><strong>&#160;</strong></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">Income taxes are accounted for under the liability method. Deferred income taxes are provided for temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and amounts used for income tax purposes. Deferred taxes are reduced by a valuation allowance when, in the opinion of management, it is more likely than not that some portion or the entire deferred tax asset will not be realized. Deferred tax assets and liabilities are adjusted for the effects of changes in tax laws and rates on the date of the enactment. We recognize tax benefits when we believe the benefit is more likely than not to be sustained upon review from the relevant authorities. We recognize penalties and interest expense related to unrecognized tax benefits in income tax expense.</div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table><div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif ">&#160;</div><div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">The Company&#8217;s federal and state tax forms for the years ending December 31, 2010, 2011 and 2012 are subject to examination by the IRS or other taxing authorities, generally for three years after they are filed.</div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table> <div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> Fair market value using the Black-Scholes option-pricing model was determined using the following assumptions:</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> &#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:center; TEXT-INDENT: 0in; WIDTH: 100%" align="center"> <table style="MARGIN: 0px:auto; WIDTH: 80%; BORDER-COLLAPSE: collapse; FONT-SIZE: 10pt; OVERFLOW: visible" cellspacing="0" cellpadding="0" align="center"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="66%"> <div>Expected life (years)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>1</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="66%"> <div>Risk free rate of return</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>11</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>%</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="66%"> <div>Dividend yield</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>0</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="66%"> <div>Expected volatility</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>200</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>%</div> </td> </tr> </table> </div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table> <div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">Fair market value using the Black-Scholes option-pricing model was determined using the following assumptions:</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:center; TEXT-INDENT: 0in; WIDTH: 100%" align="center"> <table style="MARGIN: 0px:auto; WIDTH: 80%; BORDER-COLLAPSE: collapse; FONT-SIZE: 10pt; OVERFLOW: visible" cellspacing="0" cellpadding="0" align="center"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="66%"> <div>Expected life (years)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>1.75</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="66%"> <div>Risk free rate of return</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>0.75</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>%</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="66%"> <div>Dividend yield</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>0</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="66%"> <div>Expected volatility</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>218</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>%</div> </td> </tr> </table> </div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table> <div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">Fair market value using the Black-Scholes option-pricing model was determined using the following assumptions:</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:center; TEXT-INDENT: 0in; WIDTH: 100%" align="center"> <table style="MARGIN: 0px:auto; WIDTH: 80%; BORDER-COLLAPSE: collapse; FONT-SIZE: 10pt; OVERFLOW: visible" cellspacing="0" cellpadding="0" align="center"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="66%"> <div>Expected life (years)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>2.25</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="66%"> <div>Risk free rate of return</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>0.27</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>%</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="66%"> <div>Dividend yield</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>0</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="66%"> <div>Expected volatility</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>125</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>%</div> </td> </tr> </table> </div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table> <div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"><strong>Loss Per Common Share</strong></div> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"><strong><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font>&#160;</strong></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">Basic loss per common share is calculated by dividing net loss by the weighted average common shares outstanding during the period. Stock options, warrants and other dilutive securities are not included in the computation of the weighted average number of shares outstanding for dilutive net loss per common share during each of the periods presented in the Statement of Operations and Comprehensive Income, as the effect would be antidilutive.</font></div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table> <div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"><strong>Recent Accounting Pronouncements</strong></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"><strong>&#160;</strong></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">The Company has implemented all new accounting pronouncements that are in effect and that may impact its financial statements and does not believe that there are any other new accounting pronouncements that have been issued that might have a material impact on its financial position or results of operations.<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font></div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table> <div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"><strong>Stock Based Compensation</strong></div> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font>&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">We recognize compensation expense for share-based awards using the fair value of the option at the time of the grant and amortizing the fair value over the estimated service period on the straight-line attribute method.</div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table> <div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> The derivatives were valued using the Black-Scholes option pricing model with the following assumptions:</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> &#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"> <table style="MARGIN: 0in; WIDTH: 85%; BORDER-COLLAPSE: collapse; FONT-SIZE: 10pt; OVERFLOW: visible" cellspacing="0" cellpadding="0" align="left"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="55%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="13%" colspan="2"> <div>December&#160;31,<br/> 2013</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="13%" colspan="2"> <div>December&#160;31,<br/> 2012</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="55%"> <div>Market value of stock on measurement date</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 3px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"> <div>0.0048</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"> <div>0.0085</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="55%"> <div>Risk-free interest rate</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 3px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>0.11</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>%</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>0.15</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>%</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="55%"> <div>Dividend yield</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 3px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>0</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>%</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>0</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>%</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="55%"> <div>Volatility factor</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 3px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>200</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>%</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>141</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>%</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="55%"> <div>Term</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 3px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>1 year</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>1 year</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> </table> </div> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table> <div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">Property and equipment are recorded at cost and depreciated for financial statement purposes using the straight-line over estimated useful lives below:</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:center; TEXT-INDENT: 0in; WIDTH: 100%" align="center"> <table style="MARGIN: 0px:auto; WIDTH: 80%; BORDER-COLLAPSE: collapse; FONT-SIZE: 10pt; OVERFLOW: visible" cellspacing="0" cellpadding="0" align="center"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="66%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>Estimated&#160;life,<br/> years</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="66%"> <div>Buildings</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"> <div>39</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="66%"> <div>Furniture and fixtures</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>5-7</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="66%"> <div>Leasehold improvements</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>1-3</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="66%"> <div>Computer equipment</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>3-5</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="66%"> <div>Research equipment</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>7</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="66%"> <div>Machinery and equipment</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>3-5</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> </table> </div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table> 0 0 3981000 0 0 6968000 1238000 3981000 6968000 544000 2129000 1501000 92795000 -6190000 -143000 -116328000 -15000 -11241000 14208000 94575000 0 -123432000 -15000 788327497 602 7567000 -2868000 89999000 -143000 -108373000 -15000 1451927262 602 1452548262 0 457599 7828822 100000 19200 457000 7521000 100000 19000 9947 4772335 19200 -9000 -4771000 -19000 0 0 0 0 0 0 0 0 0 0 0 0 447652 3056487 100000 0 0 448000 2750000 100000 0 0 12500000 447652 3056487 100000 0 448000 2750000 100000 0 2.00 0.08 Redemption requires at least 30 days advanced notice and notice may only be given if the Companys common stock has closed above $2.00 per share for the twenty consecutive trading days prior to the notice 1.46 Each share of Series B Preferred Stock $1.00 par value is convertible into 100 shares of the Companys Common Stock 100 votes per share 1.00 convertible into 100 shares of common stock convertible into 10,000 shares of the Companys Common Stock convertible into 15.58 shares of the Companys Common Stock 5.00 0 10,000 votes per share 0 0 <div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"><strong>Principles of Consolidation</strong></div> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"><strong>&#160;</strong></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">For the years ended December 31, 2013 and 2012, the financial statements include the transactions of Positron Corporation and its wholly-owned subsidiaries, MIT, Positron Pharmaceuticals Company and PIC. All intercompany transactions have been eliminated.</div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table> 0.11 0 2 P1Y P1Y9M 0.0075 0 2.18 P2Y3M 0.0027 0 1.25 <div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"><strong>Basis of Presentation and Use of Estimates</strong></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"><strong>&#160;</strong></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">These financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America (GAAP). Such principles require management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font></div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table> <div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"><strong>Concentrations of Credit Risk</strong></div> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"><strong>&#160;</strong></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">The Company maintains its cash in institutions insured by the Federal Deposit Insurance Corporation (FDIC) and at times, balances may exceed government insured limits. The Company has never experienced any losses related to these balances.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">During the twelve months ended December 31, 2013, no one customer accounted for more than <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 10</font>% of sales and a separate customer accounted for <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 80</font>% of accounts receivable. During the twelve months ended December 31, 2012, one customer accounted for <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 26</font>% of sales and a separate customer accounted for <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 70</font>% of accounts receivable.</div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table> <div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"><strong>Cash Equivalents and Short-term Investments</strong></div> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"><strong>&#160;</strong></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">For the purposes of reporting cash flows, the Company considers highly liquid, temporary cash investments with an original maturity period of three months or less to be cash equivalents.</div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table> <div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"><strong>Accounts Receivable</strong></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"><strong>&#160;</strong></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">Accounts receivable consist of amounts due from customers. The Company records a provision for doubtful accounts to allow for any amounts which may be unrecoverable, which is based upon an analysis of the Company&#8217;s prior collection experience, customer creditworthiness and current economic trends.<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font></div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table> <div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"><strong>Goodwill and Other Intangible Assets</strong></div> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"><strong>&#160;</strong></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">Accounting Standard Codification (&#8220;ASC&#8221;) 350 &#8220;Goodwill and Other Intangible Assets&#8221; requires that assets with indefinite lives no longer be amortized, but instead be subject to annual impairment tests. The Company follows this guidance.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">The Company tests goodwill that is not subject to amortization for impairment annually or more frequently if events or circumstances indicate that impairment is possible. Goodwill was tested as of December 31, 2013&#160;at which time the&#160;Company determined that the carrying value of goodwill was impaired. Impairment loss of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">346,000</font> was recognized during the year ended December 31, 2013.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">The impairment tests performed at December 31, 2013 and 2012 were based on a discounted cash flow model using management&#8217;s business plan projection for expected cash flows. As noted above, it was determined goodwill was fully impaired at December 31, 2013. As of December 31, 2012, no impairment was indicated. Goodwill as of December 31, 2013 and 2012 was $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">0</font> and $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">346,000</font>, respectively.</div> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">Definite lived intangible assets are being amortized over their useful lives.</div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table> <div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"><strong>Fair Value of Financial Instruments</strong></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"><strong>&#160;</strong></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">The carrying value of cash and cash equivalents, accounts receivable, accounts payable and accrued liabilities and unearned revenue, approximate their fair values because of the short-term nature of these instruments. Management believes the Company is not exposed to significant interest or credit risks arising from these financial instruments.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">Valuation techniques used to measure fair value maximize the use of observable inputs and minimize the use of unobservable inputs. The Company utilizes a fair value hierarchy based on three levels of inputs, of which the first two are considered observable and the last unobservable.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">&#160;</div> <table style="MARGIN-TOP: 0pt; FONT: 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0pt" cellspacing="0" cellpadding="0" width="100%"> <tr style="VERTICAL-ALIGN: top"> <td style="WIDTH: 0.25in"></td> <td style="WIDTH: 0.25in"> <div><font style="FONT-FAMILY:Symbol">&#8901;</font></div> </td> <td style="TEXT-ALIGN: justify"> <div>Level 1 &#151; Quoted prices in active markets for identical assets or liabilities. These are typically obtained from real-time quotes for transactions in active exchange markets involving identical assets.</div> </td> </tr> </table> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: -0.25in; MARGIN: 0pt 0px 0pt 0.5in; FONT: 10pt Times New Roman, Times, Serif" align="justify">&#160;</div> <table style="MARGIN-TOP: 0pt; FONT: 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0pt" cellspacing="0" cellpadding="0" width="100%"> <tr style="VERTICAL-ALIGN: top"> <td style="WIDTH: 0.25in"></td> <td style="WIDTH: 0.25in"> <div><font style="FONT-FAMILY:Symbol">&#8901;</font></div> </td> <td style="TEXT-ALIGN: justify"> <div>Level 2 &#151; Quoted prices for similar assets and liabilities in active markets; quoted prices included for identical or similar assets and liabilities that are not active; and model-derived valuations in which all significant inputs and significant value drivers are observable in active markets. These are typically obtained from readily-available pricing sources for comparable instruments.</div> </td> </tr> </table> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: -0.25in; MARGIN: 0pt 0px 0pt 0.5in; FONT: 10pt Times New Roman, Times, Serif" align="justify">&#160;</div> <table style="MARGIN-TOP: 0pt; FONT: 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0pt" cellspacing="0" cellpadding="0" width="100%"> <tr style="VERTICAL-ALIGN: top"> <td style="WIDTH: 0.25in"></td> <td style="WIDTH: 0.25in"> <div><font style="FONT-FAMILY:Symbol">&#8901;</font></div> </td> <td style="TEXT-ALIGN: justify"> <div>Level 3 &#151; Unobservable inputs, where there is little or no market activity for the asset or liability. These inputs reflect the reporting entity&#8217;s own beliefs about the assumptions that market participants would use in pricing the asset or liability, based on the best information available in the circumstances.</div> </td> </tr> </table> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: -0.25in; MARGIN: 0pt 0px 0pt 0.5in; FONT: 10pt Times New Roman, Times, Serif" align="justify">&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font>The following table presents the embedded conversion derivative liabilities, the Company&#8217;s only financial liabilities measured and recorded at fair value on the Company&#8217;s consolidated balance sheets on a recurring basis and their level within the fair value hierarchy as of December 31, 2013 and 2013 and 2012 (in thousands):</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"> <table style="BORDER-BOTTOM: #9eb6ce 0px solid; BORDER-LEFT: #9eb6ce 0px solid; MARGIN: 0in 0in 0in 0.5in; WIDTH: 80%; BORDER-COLLAPSE: collapse; FONT-SIZE: 10pt; OVERFLOW: visible; BORDER-TOP: #9eb6ce 0px solid; BORDER-RIGHT: #9eb6ce 0px solid" cellspacing="0" cellpadding="0" align="left"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="37%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="13%" colspan="2"> <div>Level&#160;1</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="13%" colspan="2"> <div>Level&#160;2</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="13%" colspan="2"> <div>Level&#160;3</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="37%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="12%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="12%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="12%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="37%"> <div>Embedded conversion derivative liability:</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 26px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="37%"> <div>December 31, 2013</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>6,968</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 26px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="37%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 26px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="37%"> <div>December 31, 2012</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>3,981</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> </table> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"></div> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font>The following table reconciles, for the year ended December 31, 2013 and 2012, the beginning and ending balances for financial instruments that are recognized at fair value in the consolidated financial statements (in thousands):</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"> <table style="BORDER-BOTTOM: #9eb6ce 0px solid; BORDER-LEFT: #9eb6ce 0px solid; MARGIN: 0in; WIDTH: 95%; BORDER-COLLAPSE: collapse; FONT-SIZE: 10pt; OVERFLOW: visible; BORDER-TOP: #9eb6ce 0px solid; BORDER-RIGHT: #9eb6ce 0px solid" cellspacing="0" cellpadding="0" align="left"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="80%"> <div>Balance of embedded conversion derivative liability as of December 31, 2011</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>1,238</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="80%"> <div>Fair value of embedded conversion derivative liabilities at issuance</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>2,129</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="80%"> <div>Reductions in fair value due to conversion of Convertible Debentures into common stock</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>(544)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="80%"> <div>Debt modification expense</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>432</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="80%"> <div>Loss on fair value adjustments to embedded conversion derivative liabilities</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>726</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="80%"> <div>Balance of embedded conversion derivative liability as of December 31, 2012</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"> <div>3,981</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="80%"> <div>Fair value of embedded conversion derivative liabilities at issuance</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"> <div>1,501</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="80%"> <div>Debt modification expense</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>821</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="80%"> <div>Loss on fair value adjustments to embedded conversion derivative liabilities</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>665</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="80%"> <div>Balance of embedded conversion derivative liabilities at December 31, 2013</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"> <div>6,968</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font>&#160;</div> </td> </tr> </table> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"></div> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> &#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">The fair value of the conversion features are calculated at the time of issuance and the Company records a derivative liability for the calculated value using a Black-Scholes option-pricing model. Changes in the fair value of the derivative liability are recorded in other income (expense) in the consolidated statement of operations. Upon conversion of the convertible debt to stock, the Company reclassifies the related embedded conversion derivative liability to paid-in capital. Since the fair value of the embedded conversion derivative liability exceeded the carrying value of the convertible debentures on the issuance date, the convertible debentures were recorded at a full discount. The Company recognizes expense for accretion of the convertible debentures discount over the term of the notes. The Company has considered the provisions of ASC 480, <i>Distinguishing Liabilities from Equity</i>, as the conversion feature embedded in each debenture could result in the note principal being converted to a variable number of the Company&#8217;s common shares.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font>The derivatives were valued using the Black-Scholes option pricing model with the following assumptions:</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> &#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"> <table style="MARGIN: 0in; WIDTH: 85%; BORDER-COLLAPSE: collapse; FONT-SIZE: 10pt; OVERFLOW: visible" cellspacing="0" cellpadding="0" align="left"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="55%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="13%" colspan="2"> <div>December&#160;31,<br/> 2013</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="13%" colspan="2"> <div>December&#160;31,<br/> 2012</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="55%"> <div>Market value of stock on measurement date</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 3px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"> <div>0.0048</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"> <div>0.0085</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="55%"> <div>Risk-free interest rate</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 3px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>0.11</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>%</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>0.15</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>%</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="55%"> <div>Dividend yield</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 3px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>0</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>%</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>0</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>%</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="55%"> <div>Volatility factor</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 3px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>200</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>%</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>141</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>%</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="55%"> <div>Term</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 3px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>1 year</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>1 year</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> </table> </div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table> <div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"><strong>Revenue Recognition</strong></div> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"><strong>&#160;</strong></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">The Company&#8217;s revenues are currently derived from the sale of medical equipment products, maintenance contracts, service revenues and radioisotope sales. Revenues from maintenance contracts are recognized over the term of the contract. Service revenues are recognized upon performance of the services. The Company recognizes revenues from the sale of medical equipment and radioisotope products when earned. Specifically, revenue is recognized when persuasive evidence of an arrangement exists, delivery has occurred (or services have been rendered), the price is fixed or determinable, and collectability is reasonably assured. The Company obtains a signed customer acceptance after installation is complete for the sale of its Attrius&#174; PET systems.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">For multiple-element arrangements, revenue is allocated to each element based on their relative selling prices. Relative selling prices are based first on vendor specific objective evidence (VSOE), then on third-party evidence of selling price (TPE) when VSOE does not exist, and then on estimated selling price (ESP) when VSOE and TPE do not exist.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">Because the Company has neither VSOE nor TPE for its products, the allocation of revenue has been based on the Company&#8217;s ESPs. The objective of ESP is to determine the price at which the Company would transact a sale if the product was sold on a stand-alone basis. The Company determines ESP by considering the facts and circumstances of the product being sold.</div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table><div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif ">&#160;</div><div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">The Company typically provides a one-year parts and labor warranty to purchasers of equipment. A portion of revenue recorded upon the sale of a new machine is allocated to the warranty provided. At the time of sale, the Company records deferred revenue in the amount of revenue allocated to the warranty which is amortized over a one-year period.</div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table> <div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"><strong> &#160;</strong></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"><strong><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font>The Company typically provides a one-year parts and labor warranty to purchasers of equipment. A portion of revenue recorded upon the sale of a new machine is allocated to the warranty provided. At the time of sale, the Company records deferred revenue in the amount of revenue allocated to the warranty which is amortized over a one-year period.</strong></div> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"><strong>Research and Development Expenses</strong></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"><strong>&#160;</strong></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">All costs related to research and development costs are charged to expense as incurred and include salaries and benefits, supplies and consulting expenses.</div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table> 2500000 0 430000 0 2070000 2070000 1.00 0 1.00 0 1.00 1.00 P39Y P7Y 197600000 7000000 190600000 P5Y -2500000 0 188100000 188100000 0.01 0.01 0 0.01 0.01 P7Y P1Y P3Y P3Y P5Y P3Y P5Y 4000000 118500000 P0Y P1Y 0.02 0.01 (b) 0.01 0.1 0.8 0.26 0.7 1500000 2129000 0.0048 0.0085 0.0011 0 2 0.0015 0 1.41 P1Y P1Y 183583338 0 134583338 114850000 103500000 267350000 0 144850000 0 122500000 0 0.01 0.01 0 0 0.05 0 0.03 0.01 0.01 0.03 0 0.02 0 0.01 0.01 0.15 0.01 0.03 0.01 0.15 0.01 0.015 621000 0.008 5000 750000 500000 250000 7500000 0.01 Original Issuance Price of $0.10 and divided by seventy percent (70%) of the daily weighted volume average price for the three trading days prior to conversion. two hundred (200) votes per share ratio of 1 for 100 500000000 20000000 0.0001 3020000000 520000000 346000 0 -13000 0 -143000 0 2000 3000000000 0.01 20000000 1.00 810000000 3020000000 150000 15000000 15000000 20000000 400000 4000 1400000 14000 1923223 192322258 100000 27000000 10000000 30000000 5000000 76261 25000000 2013-12-31 0.08 35000000 2013-12-31 50000 5000000 5000000 2013-12-31 2013-12-31 7500000 60371100 3000000 51000 603711 346000 0 346000 35000 3500000 2013-12-31 1200000 20000 3500000 750000 2013-12-31 600000 10000 63400000 28000 2800000 3100000 2013-12-31 26456 634000 39682539 2208750 143000 141000 7322636 130000 15000000 13000000 2013-12-31 175000 2000 4000000 2013-12-31 2000000 2013-12-31 73226 <div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <table style="MARGIN-TOP: 0pt; FONT: 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0pt" cellspacing="0" cellpadding="0" width="100%"> <tr style="VERTICAL-ALIGN: top"> <td style="WIDTH: 0.25in"> <div><b>4.</b></div> </td> <td style="TEXT-ALIGN: justify"> <div><b>OTHER ASSETS</b></div> </td> </tr> </table> &#160; <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">Other assets at December 31, 2013, consisted of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">201,000</font> in deposits paid to our joint venture partner, Neusoft for Attrius&#174; systems and $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">54,000</font> in operating lease deposits. Other assets at December 31, 2012, consisted of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">53,000</font> in operating lease deposits.</div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table> 23119000 3970786 231190 18181818 4000000 2013-12-31 16667 16667 118149 11814878 18200 2020000 54000 53000 201000 1000000 1000000 10000 1000000 10000 726000 1188836 118883629 2000000 35605 10000000 6666667 54395 10500000 0.01 380000 201000 1000000 300000 400000 50000 623000 205000 0 2500000 1.00 2500000 P3Y 430000 2070000 567567 200000000 177600000 0.01 1735000 39000 7000000 170600000 P2Y18D 187600 0.011 0 331000 20000000 49000 49000 P2Y18D 0 0.008 190600000 9400000 5780000 2013-12-31 37500000 0.01 1320000 50000 1500000 0.01 726000 665000 <div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <table style="clear:both;MARGIN-TOP: 0pt; FONT: 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0pt" cellspacing="0" cellpadding="0" width="100%"> <tr style="VERTICAL-ALIGN: top"> <td style="WIDTH: 0.25in"> <div><b>13.</b></div> </td> <td> <div><b>PREFERRED STOCK</b></div> </td> </tr> </table> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">The Company&#8217;s Certificate of Formation, as amended, authorizes the issuance of <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 20,000,000</font> shares of preferred stock from time to time in one or more series. The Board of Directors is authorized to determine, prior to issuing any such series of preferred stock and without any vote or action by the shareholders, the rights, preferences, privileges and restrictions of the shares of such series, including dividend rights, voting rights, terms of redemption, the provisions of any purchase, retirement or sinking fund to be provided for the shares of any series, conversion and exchange rights, the preferences upon any distribution of the assets of the Company, including in the event of voluntary or involuntary liquidation, dissolution or winding up of the Company, and the preferences and relative rights among each series of preferred stock. The Board of Directors has designated the following series of preferred stock</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> <b>Series A Preferred Stock</b></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> &#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">The Company had <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 7,900,000</font></font></font></font></font> shares of Series A Preferred Stock authorized for issuance. Subject to adjustment based on issuance of shares at less than fair market value, each share of the Series A Preferred Stock was initially convertible into one share of common stock. Each Redeemable common stock Purchase Warrant is exercisable at a price of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">2.00</font> per share of common stock. Eight percent (<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">8</font>%) dividends on the Series A Preferred Stock may be paid in cash or in Series A Preferred Stock at the discretion of the Company. The Series A Preferred Stock is senior to the Company&#8217;s common stock in liquidation. Holders of the Series A Preferred stock may vote on an as if converted basis on any matter requiring shareholder vote. While the Series A Preferred Stock is outstanding or any dividends thereon remain unpaid, no common stock dividends may be paid or declared by the Company. The Series A Preferred Stock may be redeemed in whole or in part, at the option of the Company, at any time subsequent to March 1998 at a price of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">1.46</font> per share plus any undeclared and/or unpaid dividends to the date of redemption. <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> Redemption requires at least 30 days advanced notice and notice may only be given if the Company&#8217;s common stock has closed above $2.00 per share for the twenty consecutive trading days prior to the notice</font>.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">As of December 31, 2013 and 2012, there were <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 447,652</font></font> shares of Series A Preferred Stock outstanding, respectively.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"><b>Series B Preferred Stock</b></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"><b>&#160;</b></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">As of December 31, 2012, the Company has <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 9,000,000</font></font></font></font></font> shares of Series B Preferred Stock authorized for issuance. <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">Each share of Series B Preferred Stock $1.00 par value is convertible into 100 shares of the Company&#8217;s Common Stock</font>. The Series B Preferred Stock is senior to the Company&#8217;s Common Stock and junior in priority to the Company&#8217;s A and G Preferred Stock in liquidation. Holders of the Series B Preferred Stock are entitled to <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">100 votes per share</font> on all matters requiring shareholder vote. While Series B Preferred Stock is outstanding no Common Stock dividends may be paid or declared by the Company. The Series B Preferred Stock may be redeemed in whole or in part, at the option of the Company, at any time at a price of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">1.00</font> per share.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">As of December 31, 2013 and 2012, <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 3,056,487</font></font> shares of Series B Preferred Stock were outstanding, respectively.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"><b>Series G Preferred Stock</b></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"><b>&#160;</b></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">The Company has designated <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 3,000,000</font></font></font></font></font> shares of preferred stock as Series G Preferred Stock $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">1.00</font> par value. Each share of Series G Preferred Stock is <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> convertible into 100 shares of common stock</font>. The Series G Preferred Stock is senior to the Company's common stock and junior in priority to the Registrant's Series A, C, D, E and F Preferred Stock in liquidation. Except as required by law and in the case of various actions affecting the rights of the Series G Preferred Stock, holders of the Series G Preferred Stock are not entitled to vote on matters requiring shareholder vote. While the Series G Preferred Stock is outstanding or any dividends thereon remain unpaid, no common stock dividends may be paid or declared by the Company. The Series G Preferred Stock may be redeemed in whole or in part, at the option of the Company, at any time at a price of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">5.00</font> per share plus any undeclared and/or unpaid dividends to the date of redemption.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">As of December 31, 2013 and 2012, there are no shares of Series G Preferred Stock outstanding.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"><b>Series S Preferred Stock</b></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"><b>&#160;</b></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">As of December 31, 2012, the Company has <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 10,000</font></font></font></font></font> shares of Series S Preferred Stock authorized for issuance. Each share of Series S Convertible Preferred Stock, $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">1.00</font> par value per share, is <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> convertible into 10,000 shares of the Company&#8217;s Common Stock</font>, subject to adjustment The Series S Preferred Stock is senior to the Company&#8217;s Common Stock and junior in priority to the Company&#8217;s A, B and G Preferred Stock in liquidation. Holders of the Series S Preferred Stock are entitled to <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 10,000 votes per share</font> on all matters requiring shareholder vote. While Series S Preferred Stock is outstanding no Common Stock dividends may be paid or declared by the Company.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">As of December 31, 2013 and 2012, <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 100,000</font></font> shares of Series S Convertible Preferred Stock were outstanding.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">&#160;<b>&#160;</b></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"><b>Series H Preferred Stock</b></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"><b>&#160;</b></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">As of December 31, 2013, the Company has <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 15,000,000</font></font></font></font></font> shares of Series H Preferred Stock authorized for issuance&#160;at par value&#160;of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">0.01</font> per share. <font style="FONT-SIZE: 10pt">The Series H Preferred Stock rank junior to dividends and distributions of the Company&#8217;s assets upon liquidation to all previously-issued shares&#160;of capital stock of the Company and is not entitled to receive interest or dividends. The Series H Preferred Stock is convertible into shares of the Company&#8217;s Common Stock at a rate equal to the number of shares of Series H Preferred Stock being converted multiplied by the Original Issuance Price of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">0.10</font> and divided by seventy percent (<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">70</font>%) of the daily weighted volume average price for the three trading days prior to conversion. The Series H Preferred Stock is entitled to two hundred (200) votes per share of Series H Preferred Stock on all matters which holders of Common Stock are entitled to vote.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> As of December 31, 2013 and 2012, <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 12,500,000</font> and <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">0</font> shares of Series H Preferred Stock were outstanding, respectively.</div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table> 0.25 2018-12-31 0.55 2018 100000 324000 2245000 65000 0 85000 17000000 17000000 2013-12-31 0 0 3000000 2013-12-31 P3D 1320000 2013-12-31 37500000 0.01 Conversion price equal to 55% of the lowest daily volume weighted average price for the three trading days preceding conversion. 2033 380000 10500000 0.01 2013-12-31 510000 0.0001 0.01 4270000 1100000 1370000 Conversion price equal to 55% of the lowest daily volume weighted average price for the three trading days preceding conversion. 2220000 1100000 25000 0.08 9,761 square feet 2013-12-31 2520000 2285000 2013-12-31 2013-12-31 649000 0.06 All of the Company&#8217;s employees who are United States citizens, at least 21 years of age and have completed at least one quarter of service with the Company. 658000 669000 77000 250000 250000 100000 185000 150000 500000 250000 150000 100000 250000 250000 100000 500000 35000 <div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"><strong>&#160;</strong></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"> <table style="BORDER-BOTTOM: #9eb6ce 0px solid; BORDER-LEFT: #9eb6ce 0px solid; MARGIN: 0in; WIDTH: 100%; BORDER-COLLAPSE: collapse; OVERFLOW: visible; BORDER-TOP: #9eb6ce 0px solid; BORDER-RIGHT: #9eb6ce 0px solid" cellspacing="0" cellpadding="0" align="left"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="51%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="47%" colspan="11"> <div>Quarter&#160;ended</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="51%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>March&#160;31,<br/> 2013</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>June&#160;30,<br/> 2013</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>September&#160;30,<br/> 2013</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>December&#160;31,<br/> 2013</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="51%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="51%"> <div>Net Sales</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>371</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>432</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>351</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>476</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="51%"> <div>Gross profit (loss)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>125</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>14</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>121</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>164</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="51%"> <div>Net loss</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>(1,201)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>(1,088)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>(1,390)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>(3,425)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="51%"> <div>Net (loss) per share - basic and diluted</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>(0.00)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>(0.00)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>(0.00)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>(0.00)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="51%"> <div>Weighted average basic and diluted shares</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>1,451,927</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>1,452,425</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>1,452,548</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>1,452,548</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> </table> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"></div> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"><strong>&#160;</strong></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"> <table style="BORDER-BOTTOM: #9eb6ce 0px solid; BORDER-LEFT: #9eb6ce 0px solid; MARGIN: 0in; WIDTH: 100%; BORDER-COLLAPSE: collapse; OVERFLOW: visible; BORDER-TOP: #9eb6ce 0px solid; BORDER-RIGHT: #9eb6ce 0px solid" cellspacing="0" cellpadding="0" align="left"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="51%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="47%" colspan="11"> <div>Quarter&#160;ended</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="51%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>March&#160;31,<br/> 2012</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>June&#160;30,<br/> 2012</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>September&#160;30,<br/> 2012</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>December&#160;31,<br/> 2012</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="51%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="51%"> <div>Net Sales</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>829</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>1,224</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>370</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>378</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="51%"> <div>Gross profit (loss)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>359</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>331</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>106</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>33</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="51%"> <div>Net loss</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>(2,962)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>(1,235)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>(1,568)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>(2,190)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="51%"> <div>Net (loss) per share - basic and diluted</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>(0.00)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>(0.00)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>(0.00)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>(0.00)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="51%"> <div>Weighted average basic and diluted shares</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>970,887</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>1,256,915</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>1,360,107</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>1,451,140</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> </table> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"></div> </div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table> 0.1 0.6 0.3 125000 125000 -12500000 0 <div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">The following table presents the embedded conversion derivative liabilities, the Company&#8217;s only financial liabilities measured and recorded at fair value on the Company&#8217;s consolidated balance sheets on a recurring basis and their level within the fair value hierarchy as of December 31, 2013 and 2013 and 2012 (in thousands):</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"> <table style="BORDER-BOTTOM: #9eb6ce 0px solid; BORDER-LEFT: #9eb6ce 0px solid; MARGIN: 0in 0in 0in 0.5in; WIDTH: 80%; BORDER-COLLAPSE: collapse; FONT-SIZE: 10pt; OVERFLOW: visible; BORDER-TOP: #9eb6ce 0px solid; BORDER-RIGHT: #9eb6ce 0px solid" cellspacing="0" cellpadding="0" align="left"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="37%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="13%" colspan="2"> <div>Level&#160;1</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="13%" colspan="2"> <div>Level&#160;2</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="13%" colspan="2"> <div>Level&#160;3</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="37%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="12%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="12%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="12%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="37%"> <div>Embedded conversion derivative liability:</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 26px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="37%"> <div>December 31, 2013</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>6,968</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 26px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="37%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 26px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="37%"> <div>December 31, 2012</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>3,981</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> </table> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"></div> </div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table> <div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> The following table reconciles, for the year ended December 31, 2013 and 2012, the beginning and ending balances for financial instruments that are recognized at fair value in the consolidated financial statements (in thousands):</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"> <table style="BORDER-BOTTOM: #9eb6ce 0px solid; BORDER-LEFT: #9eb6ce 0px solid; MARGIN: 0in; WIDTH: 95%; BORDER-COLLAPSE: collapse; FONT-SIZE: 10pt; OVERFLOW: visible; BORDER-TOP: #9eb6ce 0px solid; BORDER-RIGHT: #9eb6ce 0px solid" cellspacing="0" cellpadding="0" align="left"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="80%"> <div>Balance of embedded conversion derivative liability as of December 31, 2011</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>1,238</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="80%"> <div>Fair value of embedded conversion derivative liabilities at issuance</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>2,129</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="80%"> <div>Reductions in fair value due to conversion of Convertible Debentures into common stock</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>(544)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="80%"> <div>Debt modification expense</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>432</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="80%"> <div>Loss on fair value adjustments to embedded conversion derivative liabilities</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>726</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="80%"> <div>Balance of embedded conversion derivative liability as of December 31, 2012</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"> <div>3,981</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="80%"> <div>Fair value of embedded conversion derivative liabilities at issuance</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"> <div>1,501</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="80%"> <div>Debt modification expense</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>821</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="80%"> <div>Loss on fair value adjustments to embedded conversion derivative liabilities</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>665</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="80%"> <div>Balance of embedded conversion derivative liabilities at December 31, 2013</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"> <div>6,968</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"></td> </tr> </table> </div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table> <div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">Future minimum rental commitments under non-cancellable facilities operating leases as of December 31, 2013 are as follows:</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt" align="left"> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"> <table style="MARGIN: 0in; WIDTH: 100%; BORDER-COLLAPSE: collapse; FONT-SIZE: 10pt; OVERFLOW: visible" cellspacing="0" cellpadding="0" align="left"> <tr style="HEIGHT: 12px"> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="85%"> <div>Year&#160;Ending&#160;December&#160;31,</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="12%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="85%"> <div>2014</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>72,444</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="85%"> <div>2015</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>63,444</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="85%"> <div>2016</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>58,157</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> </table> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"></div> </div> </div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table> 72444 63444 58157 <div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> The following is a summary of the proceeds from the issuance of the Convertible Debentures and the initial accounting of the issuance (in thousands): <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> &#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt; TEXT-INDENT: 0in; WIDTH: 100%"> <table style="BORDER-BOTTOM: #9eb6ce 0px solid; BORDER-LEFT: #9eb6ce 0px solid; WIDTH: 100%; BORDER-COLLAPSE: collapse; FONT-SIZE: 10pt; OVERFLOW: visible; BORDER-TOP: #9eb6ce 0px solid; BORDER-RIGHT: #9eb6ce 0px solid" cellspacing="0" cellpadding="0"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="85%"> <div>Proceeds from convertible debt issuance</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>2,520</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="85%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="85%"> <div>Allocation of proceeds to embedded conversion derivative liability</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>(1,500)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> </table> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"></div> </div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table> 69512 84011 <div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> &#160;A summary of outstanding common stock warrants at December 31, 2013 follows: <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> <strong>&#160;</strong></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:center; TEXT-INDENT: 0in; WIDTH: 100%" align="center"> <table style="BORDER-BOTTOM: #9eb6ce 0px solid; BORDER-LEFT: #9eb6ce 0px solid; MARGIN: 0px:auto; WIDTH: 85%; BORDER-COLLAPSE: collapse; FONT-SIZE: 10pt; OVERFLOW: visible; BORDER-TOP: #9eb6ce 0px solid; BORDER-RIGHT: #9eb6ce 0px solid" cellspacing="0" cellpadding="0" align="center"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="14%" colspan="3"> <div>Number&#160;of<br/> Common&#160;Stock<br/> Equivalents</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="41%"> <div>Expiration&#160;Date</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="13%" colspan="2"> <div>Remaining<br/> Contractual&#160;Life<br/> (Years)</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="13%" colspan="2"> <div>Exercise<br/> Price</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>4,000,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="41%"> <div>(a)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>0.02</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>118,500,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="41%"> <div>(b)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>1.00</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>0.01</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> </table> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"></div> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> <strong>&#160;</strong> <strong>&#160;</strong></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px 0pt 49.5pt; FONT: 10pt Times New Roman, Times, Serif"> (a) Warrants expire six months after the date on which a registration statement is filed and accepted by the Securities Exchange Commission permitting a sale of the shares issuable upon exercise of the warrant.<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"></div> <font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt"><font style="FONT-SIZE: 10pt"></font></font> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.7in; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt"></font>&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.7in; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font>(b) Warrants were originally set to expire on December 31, 2013, but were extended by the Company through December 31, 2014.<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font></font></div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table> 0 0 <div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> A summary of common stock option activity is as follows:</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> &#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"> <table style="BORDER-BOTTOM: #9eb6ce 0px solid; BORDER-LEFT: #9eb6ce 0px solid; MARGIN: 0in; WIDTH: 100%; BORDER-COLLAPSE: collapse; FONT-SIZE: 10pt; OVERFLOW: visible; BORDER-TOP: #9eb6ce 0px solid; BORDER-RIGHT: #9eb6ce 0px solid" cellspacing="0" cellpadding="0" align="left"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="71%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="13%" colspan="2"> <div>Shares Issuable<br/> Under<br/> Outstanding<br/> Options</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="13%" colspan="2"> <div>Weighted<br/> Average<br/> Exercise<br/> Price</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="71%"> <div>Issued in 2012</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>197,600,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>0.01</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="71%"> <div>Forfeited</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; BACKGROUND: #ffffff; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 2px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>(7,000,000)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>0.01</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="71%"> <div>Balance at December 31, 2012</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; BACKGROUND: #ccffcc; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>190,600,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>0.01</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="71%"> <div>Forfeited</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 1px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>(2,500,000)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>0.01</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="71%"> <div>Exercised</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 6px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="71%"> <div>Balance at December 31, 2013</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"> <div>188,100,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"> <div>0.01</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="71%"> <div>Exercisable, December 31, 2013</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="12%"> <div>188,100,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="12%"> <div>0.01</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> </table> </div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table> <div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN-TOP: 0pt; FONT: 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0pt; MARGIN-LEFT: 0.25in" align="justify">Anti-dilutive securities (based on conversions to common shares) not included in net loss per share calculation (in thousands):</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px 0pt 0.25in; FONT: 10pt Times New Roman, Times, Serif"> &#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"> <table style="BORDER-BOTTOM: #9eb6ce 0px solid; BORDER-LEFT: #9eb6ce 0px solid; MARGIN: 0in 0in 0in 0.25in; WIDTH: 75%; BORDER-COLLAPSE: collapse; OVERFLOW: visible; BORDER-TOP: #9eb6ce 0px solid; BORDER-RIGHT: #9eb6ce 0px solid" cellspacing="0" cellpadding="0" align="left"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="46%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="27%" colspan="5"> <div>Year&#160;Ended&#160;December&#160;31,</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="46%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="13%" colspan="2"> <div>2013</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="13%" colspan="2"> <div>2012</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="46%"> <div>Convertible Series A preferred stock</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"> <div>448</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"> <div>448</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="46%"> <div>Convertible Series B preferred stock</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>305,648</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>305,648</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="46%"> <div>Convertible Series G preferred stock</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>100</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="46%"> <div>Convertible Series S preferred stock</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>1,000,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>1,000,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="46%"> <div>Convertible Series H preferred stock</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>482,625</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="46%"> <div>Stock warrants</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>122,500</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>267,350</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="46%"> <div>Convertible debt</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>2,693,553</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>722,910</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="46%"> <div>Common stock options</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>188,100</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>190,600</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="46%"> <div>Series B preferred stock options</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>207,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>250,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> </table> </div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table> 665000 -1035000 0 <div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"><strong>Debt discount</strong></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"><strong>&#160;</strong></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">Costs incurred with parties who are providing long-term financing, which generally include the value of warrants or the fair value of an embedded derivative conversion feature, are reflected as a debt discount and are amortized over the life of the related debt. When the debt is repaid, the related debt discount is recorded as additional interest expenses and the related derivative liability is relieved into additional paid in capital.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">The Company valued the embedded derivative conversion using Black-Scholes method. The debt discount attributable to the warrants issued with convertible debentures during the years December 31, 2013 and 2012 was $0 and $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">331,000</font>, respectively. The debt discount attributable to the embedded conversion derivative liability at issuance during the years ended December 31, 2013 and 2012 was $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">1,500,000</font> and $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">2,129,000</font>, respectively.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">At December 31, 2013, convertible notes totaled $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">5,780,000</font> of which $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">1,328,000</font> was attributable to the discount on debt. These notes originally were set to mature on <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">December 31, 2013&#160;</font> but were extended under existing terms through December 31, 2014&#160;or were presented for conversion subsequent to year end.</div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table> 100000 550000 3000 <div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> A summary of Series B Preferred stock option activity is as follows:</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"> <table style="BORDER-BOTTOM: #9eb6ce 0px solid; BORDER-LEFT: #9eb6ce 0px solid; MARGIN: 0in; WIDTH: 100%; BORDER-COLLAPSE: collapse; OVERFLOW: visible; BORDER-TOP: #9eb6ce 0px solid; BORDER-RIGHT: #9eb6ce 0px solid" cellspacing="0" cellpadding="0" align="left"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="71%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="13%" colspan="2"> <div>Shares&#160;Issuable<br/> Under<br/> Outstanding<br/> Options</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="13%" colspan="2"> <div>Weighted<br/> Average<br/> Exercise<br/> Price</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="71%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="12%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="12%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="71%"> <div>Balance at December 31, 2012</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>2,500,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>1.00</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="71%"> <div>Issued</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="71%"> <div>Expired/forfeited</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>(430,000)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>1.00</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="71%"> <div>Exercised</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="71%"> <div>Balance at December 31, 2013</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"> <div>2,070,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"> <div>1.00</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="71%"> <div>Exercisable, December 31, 2013</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="12%"> <div>2,070,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="12%"> <div>1.00</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> </table> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"></div> </div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table> <div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> A summary of warrant activity based on common stock equivalents is as follows:</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> &#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt; TEXT-INDENT: 0in; WIDTH: 100%"> <table style="WIDTH: 100%; BORDER-COLLAPSE: collapse; OVERFLOW: visible" cellspacing="0" cellpadding="0"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="58%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="12%"> <div>Number of Shares</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="13%" colspan="2"> <div>Exercise<br/> Price</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="13%" colspan="2"> <div>Weighted<br/> Average<br/> Exercise<br/> Price</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="58%"> <div>Balance at December 31, 2011</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"> <div>183,583,338</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 2px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"> <div>0.01-0.15</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"> <div>0.05</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="58%"> <div>Warrants exercised</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 2px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="58%"> <div>Warrants expired</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>(134,583,338)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 2px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>0.01-0.03</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>0.03</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="58%"> <div>Warrants issued with common and Series B Preferred stock in private placement</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>114,850,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 2px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>0.01</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>0.01</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="58%"> <div>Warrants issued with convertible debentures and notes payable</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>103,500,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 2px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>0.01</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>0.01</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="58%"> <div>Balance at December 31, 2012</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"> <div>267,350,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 2px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>0.01-0.15</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>0.03</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="58%"> <div>Warrants exercised</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 2px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="58%"> <div>Warrants expired</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>(144,850,000)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 2px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>0.01-0.15</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>0.02</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="58%"> <div>Warrants issued with convertible debentures and notes payable</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 2px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="58%"> <div>Balance at December 31, 2013</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"> <div>122,500,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 2px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>0.01-0.02</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>0.01</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> </table> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"></div> </div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table> 0.01 0.01 0.01 320000 0.01 0.15 <div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <table style="MARGIN-TOP: 0pt; FONT: 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0pt" cellspacing="0" cellpadding="0" width="100%"> <tr style="VERTICAL-ALIGN: top"> <td style="WIDTH: 0.25in"> <div><strong>19.</strong></div> </td> <td style="TEXT-ALIGN: justify"> <div><strong>COMMITMENTS AND CONTINGENCIES</strong></div> </td> </tr> </table> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: -0.25in; MARGIN: 0pt 0px 0pt 0.25in; FONT: 10pt Times New Roman, Times, Serif" align="justify"><strong>&#160;</strong></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> <i>Lease Agreements</i></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> &#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> On April 19, 2010, the Company entered into an operating lease agreement with a third party for warehousing and office space in Niagara, New York. The lease expires in May <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 2014</font>, with an option to renew for an additional three years. Monthly rent is $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">1,800</font>. The Company is currently negotiating an extension.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> &#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">On July 7, 2011, the Company entered into an operating lease with a third party for space for medical device assembly and warehousing at a building in Fishers, Indiana. The Company is required to make payments of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">5,083</font> each month from <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">December 1, 2011</font> through <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">November 13, 2013</font>, and $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">5,287</font> from <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">December 1, 2013</font> through <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">November 30, 2016</font>.&#160;The amount of leased space at this location is approximately <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">9,761 square feet</font>.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">On December 5, 2011, MIT entered into an operating lease with a third party for space for warehousing at a building in Lubbock, Texas. The Company will be required to make payments of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">1,475</font> each month from month to month.<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">Total rent expense for the years ended December 31, 2013 and 2012 was $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">84,011</font> and $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">69,512</font>, respectively.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font>Future minimum rental commitments under non-cancellable facilities operating leases as of December 31, 2013 are as follows:</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt" align="left"> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"> <table style="MARGIN: 0in; WIDTH: 100%; BORDER-COLLAPSE: collapse; FONT-SIZE: 10pt; OVERFLOW: visible" cellspacing="0" cellpadding="0" align="left"> <tr style="HEIGHT: 12px"> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="85%"> <div>Year&#160;Ending&#160;December&#160;31,</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="12%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="85%"> <div>2014</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>72,444</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="85%"> <div>2015</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>63,444</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="85%"> <div>2016</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>58,157</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> </table> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"></div> </div> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"> &#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> <i>Litigation</i></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">On June 8, 2012, the owner of the radiopharmaceutical manufacturing facility the Company formerly leased in Crown Point, Indiana commenced an action to recover the use of the premises and the remaining rent due under the lease. On November 14, 2012, the owner was awarded a judgment against the Company in the amount of $85,525.98 plus interest at the rate of 8%. The Company and the owner agreed to monthly payments in the minimum amount of $5,000 until the judgment is paid in its entirety.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">In May, 2013, the Company was served with a First Amended Complaint in an action commenced against related its CEO and principal shareholder. The plaintiff in the action is seeking to enforce a judgment against the CEO and principal shareholder and is seeking to have the&#160;Company&#8217;s Westmont, Illinois offices, which it purchased from the CEO, reconveyed. The CEO and the principal shareholder have disputed the basis of the judgment and the Company has denied the allegations in the Complaint and i<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">s</font> defending the action. The action is currently in the discovery stage.</div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table> 85,525.98 plus interest at the rate of 8% 5000 two hundred (200) votes 0.10 0.7 1120000 821000 <div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <table style="MARGIN-TOP: 0pt; FONT: 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0pt" cellspacing="0" cellpadding="0" width="100%"> <tr style="VERTICAL-ALIGN: top"> <td style="WIDTH: 0px"></td> <td style="WIDTH: 0.25in"> <div><strong>1.</strong></div> </td> <td> <div><strong>DESCRIPTION OF BUSINESS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</strong></div> </td> </tr> </table> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: -0.25in; MARGIN: 0pt 0px 0pt 0.25in; FONT: 10pt Times New Roman, Times, Serif"> <strong><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font>&#160;</strong></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> <strong>Description of Business</strong></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> <strong>&#160;</strong></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">Positron Corporation (the &#8220;Company&#8221;) was incorporated on December 20, 1983 in the state of Texas and commenced commercial operations in 1986. Positron Corporation is a nuclear medicine healthcare company. The Company offers positron emission tomography molecular imaging systems, clinical and support services, automated radiopharmaceutical systems, radiopharmaceuticals and radioisotope processing and production.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">The molecular imaging systems portion of the business provides Positron Emission Tomography (PET) scanners. The automated radiopharmaceutical system portion of the business offers the world&#8217;s first robotic system for the preparation and dispensing of radiopharmaceuticals that provides unit dose radiopharmaceutical agents used in molecular imaging. The radioisotope manufacturing portion of the business enables the Company to process and produce radioisotope(s) that are critical components required in nuclear imaging.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">The Company&#8217;s objective is to generate revenue by offering inexpensive molecular imaging systems and support services, disease specific software, automated radiopharmaceutical dose preparation and dispensing system, radiopharmaceutical(s) and radioisotope(s) for nuclear medicine primarily in the field of cardiac nuclear medicine.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">On January 17, 2012, the Company acquired all of the issued and outstanding membership interest of Manhattan Isotope Technology LLC (&#8220;MIT&#8221;). See Note 3.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">MIT possesses the unique and specialized expertise in all stages of strontium-82 (Sr-82) production and spent generator lifecycle management. Currently, MIT produces&#160;API grade strontium-82 from target material received from its foreign collaborators.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">Positron Isotopes Corporation (PIC) was formed to investigate the possibility of building a cyclotron.<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font></font></div> &#160; <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"><strong><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font>Principles of Consolidation</strong></div> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"><strong>&#160;</strong></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">For the years ended December 31, 2013 and 2012, the financial statements include the transactions of Positron Corporation and its wholly-owned subsidiaries, MIT, Positron Pharmaceuticals Company and PIC. All intercompany transactions have been eliminated.</div> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"><strong><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font>Basis of Presentation and Use of Estimates</strong></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"><strong>&#160;</strong></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">These financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America (GAAP). Such principles require management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font></div> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"><strong><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font>Affiliated Entities</strong></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"><strong>&#160;</strong></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">Affiliated entities and their affiliation, as defined by FASB Codification Topic 850 are as follows:</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">Solaris Opportunity Fund owns or controls common and preferred shares of the Company and its managing member is the CEO of the Company.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">The Company has a <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">1</font>% ownership interest in the joint venture Neusoft Positron Medical Systems ("Neusoft"). Both the Company and the joint venture's other partner, Neusoft Medical Systems purchase PET systems at a wholesale transfer price from Neusoft. The Company maintains one of five board seats on Neusoft's board. The Company currently accounts for its investment in Neusoft on the cost method and has no recorded value as of December 31, 2013 and 2012 based on prior losses of Neusoft.<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> &#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"><strong><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font>Concentrations of Credit Risk</strong></div> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"><strong>&#160;</strong></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">The Company maintains its cash in institutions insured by the Federal Deposit Insurance Corporation (FDIC) and at times, balances may exceed government insured limits. The Company has never experienced any losses related to these balances.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">During the twelve months ended December 31, 2013, no one customer accounted for more than <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 10</font>% of sales and a separate customer accounted for <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 80</font>% of accounts receivable. During the twelve months ended December 31, 2012, one customer accounted for <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 26</font>% of sales and a separate customer accounted for <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 70</font>% of accounts receivable.</div> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"><strong><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font>Cash Equivalents and Short-term Investments</strong></div> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"><strong>&#160;</strong></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">For the purposes of reporting cash flows, the Company considers highly liquid, temporary cash investments with an original maturity period of three months or less to be cash equivalents.</div> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"><strong><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font>Accounts Receivable</strong></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"><strong>&#160;</strong></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">Accounts receivable consist of amounts due from customers. The Company records a provision for doubtful accounts to allow for any amounts which may be unrecoverable, which is based upon an analysis of the Company&#8217;s prior collection experience, customer creditworthiness and current economic trends.<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font></div> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"><strong><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font>Goodwill and Other Intangible Assets</strong></div> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"><strong>&#160;</strong></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">Accounting Standard Codification (&#8220;ASC&#8221;) 350 &#8220;Goodwill and Other Intangible Assets&#8221; requires that assets with indefinite lives no longer be amortized, but instead be subject to annual impairment tests. The Company follows this guidance.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">The Company tests goodwill that is not subject to amortization for impairment annually or more frequently if events or circumstances indicate that impairment is possible. Goodwill was tested as of December 31, 2013&#160;at which time the&#160;Company determined that the carrying value of goodwill was impaired. Impairment loss of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">346,000</font> was recognized during the year ended December 31, 2013.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">The impairment tests performed at December 31, 2013 and 2012 were based on a discounted cash flow model using management&#8217;s business plan projection for expected cash flows. As noted above, it was determined goodwill was fully impaired at December 31, 2013. As of December 31, 2012, no impairment was indicated. Goodwill as of December 31, 2013 and 2012 was $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">0</font> and $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">346,000</font>, respectively.</div> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">Definite lived intangible assets are being amortized over their useful lives.</div> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"><strong><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font>Inventory</strong></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"><strong>&#160;</strong></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">Inventories are stated at the lower of cost or market. Cost is determined using the first-in, first-out (FIFO) method of inventory valuation. Management assesses the recoverability and establishes reserves of the various inventory components on a quarterly basis and is based on the estimated net realizable values of respective finished, in process and raw material inventories.<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"><strong><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font>Property and Equipment</strong></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"><strong>&#160;</strong></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font>Property and equipment are recorded at cost and depreciated for financial statement purposes using the straight-line over estimated useful lives below:</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:center; TEXT-INDENT: 0in; WIDTH: 100%" align="center"> <table style="MARGIN: 0px:auto; WIDTH: 80%; BORDER-COLLAPSE: collapse; FONT-SIZE: 10pt; OVERFLOW: visible" cellspacing="0" cellpadding="0" align="center"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="66%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>Estimated&#160;life,<br/> years</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="66%"> <div>Buildings</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"> <div>39</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="66%"> <div>Furniture and fixtures</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>5-7</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="66%"> <div>Leasehold improvements</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>1-3</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="66%"> <div>Computer equipment</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>3-5</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="66%"> <div>Research equipment</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>7</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="66%"> <div>Machinery and equipment</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>3-5</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160; <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font></div> </td> </tr> </table> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">Gains or losses on dispositions are included in the statement of operations in the period incurred. Maintenance and repairs are charged to expense as incurred.<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"><strong><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font>Impairment of Long-Lived Assets</strong></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"><strong>&#160;</strong></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">Periodically, the Company evaluates the carrying value of its long-lived assets, by comparing the anticipated future net cash flows associated with those assets to the related net book value. If impairment is indicated as a result of such reviews, the Company would record the impairment based on the fair market value of the assets, using techniques such as projected future discounted cash flows or third party valuations.<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"><strong><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font>Fair Value of Financial Instruments</strong></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"><strong>&#160;</strong></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">The carrying value of cash and cash equivalents, accounts receivable, accounts payable and accrued liabilities and unearned revenue, approximate their fair values because of the short-term nature of these instruments. Management believes the Company is not exposed to significant interest or credit risks arising from these financial instruments.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">Valuation techniques used to measure fair value maximize the use of observable inputs and minimize the use of unobservable inputs. The Company utilizes a fair value hierarchy based on three levels of inputs, of which the first two are considered observable and the last unobservable.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">&#160;</div> <table style="MARGIN-TOP: 0pt; FONT: 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0pt" cellspacing="0" cellpadding="0" width="100%"> <tr style="VERTICAL-ALIGN: top"> <td style="WIDTH: 0.25in"></td> <td style="WIDTH: 0.25in"> <div><font style="FONT-FAMILY:Symbol">&#8901;</font></div> </td> <td style="TEXT-ALIGN: justify"> <div>Level 1 &#151; Quoted prices in active markets for identical assets or liabilities. These are typically obtained from real-time quotes for transactions in active exchange markets involving identical assets.</div> </td> </tr> </table> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: -0.25in; MARGIN: 0pt 0px 0pt 0.5in; FONT: 10pt Times New Roman, Times, Serif" align="justify">&#160;</div> <table style="MARGIN-TOP: 0pt; FONT: 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0pt" cellspacing="0" cellpadding="0" width="100%"> <tr style="VERTICAL-ALIGN: top"> <td style="WIDTH: 0.25in"></td> <td style="WIDTH: 0.25in"> <div><font style="FONT-FAMILY:Symbol">&#8901;</font></div> </td> <td style="TEXT-ALIGN: justify"> <div>Level 2 &#151; Quoted prices for similar assets and liabilities in active markets; quoted prices included for identical or similar assets and liabilities that are not active; and model-derived valuations in which all significant inputs and significant value drivers are observable in active markets. These are typically obtained from readily-available pricing sources for comparable instruments.</div> </td> </tr> </table> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: -0.25in; MARGIN: 0pt 0px 0pt 0.5in; FONT: 10pt Times New Roman, Times, Serif" align="justify">&#160;</div> <table style="MARGIN-TOP: 0pt; FONT: 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0pt" cellspacing="0" cellpadding="0" width="100%"> <tr style="VERTICAL-ALIGN: top"> <td style="WIDTH: 0.25in"></td> <td style="WIDTH: 0.25in"> <div><font style="FONT-FAMILY:Symbol">&#8901;</font></div> </td> <td style="TEXT-ALIGN: justify"> <div>Level 3 &#151; Unobservable inputs, where there is little or no market activity for the asset or liability. These inputs reflect the reporting entity&#8217;s own beliefs about the assumptions that market participants would use in pricing the asset or liability, based on the best information available in the circumstances.</div> </td> </tr> </table> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: -0.25in; MARGIN: 0pt 0px 0pt 0.5in; FONT: 10pt Times New Roman, Times, Serif" align="justify">&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font>The following table presents the embedded conversion derivative liabilities, the Company&#8217;s only financial liabilities measured and recorded at fair value on the Company&#8217;s consolidated balance sheets on a recurring basis and their level within the fair value hierarchy as of December 31, 2013 and 2013 and 2012 (in thousands):</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"> <table style="BORDER-BOTTOM: #9eb6ce 0px solid; BORDER-LEFT: #9eb6ce 0px solid; MARGIN: 0in 0in 0in 0.5in; WIDTH: 80%; BORDER-COLLAPSE: collapse; FONT-SIZE: 10pt; OVERFLOW: visible; BORDER-TOP: #9eb6ce 0px solid; BORDER-RIGHT: #9eb6ce 0px solid" cellspacing="0" cellpadding="0" align="left"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="37%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="13%" colspan="2"> <div>Level&#160;1</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="13%" colspan="2"> <div>Level&#160;2</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="13%" colspan="2"> <div>Level&#160;3</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="37%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="12%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="12%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="12%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="37%"> <div>Embedded conversion derivative liability:</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 26px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="37%"> <div>December 31, 2013</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>6,968</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 26px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="37%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 26px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="37%"> <div>December 31, 2012</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>3,981</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> </table> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"></div> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font>The following table reconciles, for the year ended December 31, 2013 and 2012, the beginning and ending balances for financial instruments that are recognized at fair value in the consolidated financial statements (in thousands):</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"> <table style="BORDER-BOTTOM: #9eb6ce 0px solid; BORDER-LEFT: #9eb6ce 0px solid; MARGIN: 0in; WIDTH: 95%; BORDER-COLLAPSE: collapse; FONT-SIZE: 10pt; OVERFLOW: visible; BORDER-TOP: #9eb6ce 0px solid; BORDER-RIGHT: #9eb6ce 0px solid" cellspacing="0" cellpadding="0" align="left"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="80%"> <div>Balance of embedded conversion derivative liability as of December 31, 2011</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>1,238</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="80%"> <div>Fair value of embedded conversion derivative liabilities at issuance</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>2,129</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="80%"> <div>Reductions in fair value due to conversion of Convertible Debentures into common stock</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>(544)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="80%"> <div>Debt modification expense</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>432</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="80%"> <div>Loss on fair value adjustments to embedded conversion derivative liabilities</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>726</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="80%"> <div>Balance of embedded conversion derivative liability as of December 31, 2012</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"> <div>3,981</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="80%"> <div>Fair value of embedded conversion derivative liabilities at issuance</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"> <div>1,501</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="80%"> <div>Debt modification expense</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>821</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="80%"> <div>Loss on fair value adjustments to embedded conversion derivative liabilities</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>665</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="80%"> <div>Balance of embedded conversion derivative liabilities at December 31, 2013</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"> <div>6,968</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font>&#160;</div> </td> </tr> </table> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"></div> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> &#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">The fair value of the conversion features are calculated at the time of issuance and the Company records a derivative liability for the calculated value using a Black-Scholes option-pricing model. Changes in the fair value of the derivative liability are recorded in other income (expense) in the consolidated statement of operations. Upon conversion of the convertible debt to stock, the Company reclassifies the related embedded conversion derivative liability to paid-in capital. Since the fair value of the embedded conversion derivative liability exceeded the carrying value of the convertible debentures on the issuance date, the convertible debentures were recorded at a full discount. The Company recognizes expense for accretion of the convertible debentures discount over the term of the notes. The Company has considered the provisions of ASC 480, <i>Distinguishing Liabilities from Equity</i>, as the conversion feature embedded in each debenture could result in the note principal being converted to a variable number of the Company&#8217;s common shares.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font>The derivatives were valued using the Black-Scholes option pricing model with the following assumptions:</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> &#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"> <table style="MARGIN: 0in; WIDTH: 85%; BORDER-COLLAPSE: collapse; FONT-SIZE: 10pt; OVERFLOW: visible" cellspacing="0" cellpadding="0" align="left"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="55%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="13%" colspan="2"> <div>December&#160;31,<br/> 2013</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="13%" colspan="2"> <div>December&#160;31,<br/> 2012</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="55%"> <div>Market value of stock on measurement date</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 3px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"> <div>0.0048</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"> <div>0.0085</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="55%"> <div>Risk-free interest rate</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 3px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>0.11</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>%</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>0.15</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>%</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="55%"> <div>Dividend yield</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 3px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>0</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>%</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>0</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>%</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="55%"> <div>Volatility factor</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 3px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>200</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>%</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>141</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>%</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="55%"> <div>Term</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 3px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>1 year</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>1 year</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> </table> </div> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> &#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"><strong><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font>Debt discount</strong></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"><strong>&#160;</strong></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">Costs incurred with parties who are providing long-term financing, which generally include the value of warrants or the fair value of an embedded derivative conversion feature, are reflected as a debt discount and are amortized over the life of the related debt. When the debt is repaid, the related debt discount is recorded as additional interest expenses and the related derivative liability is relieved into additional paid in capital.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">The Company valued the embedded derivative conversion using Black-Scholes method. The debt discount attributable to the warrants issued with convertible debentures during the years December 31, 2013 and 2012 was $0 and $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">331,000</font>, respectively. The debt discount attributable to the embedded conversion derivative liability at issuance during the years ended December 31, 2013 and 2012 was $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">1,500,000</font> and $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">2,129,000</font>, respectively.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">At December 31, 2013, convertible notes totaled $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">5,780,000</font> of which $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">1,328,000</font> was attributable to the discount on debt. These notes originally were set to mature on <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">December 31, 2013&#160;</font> but were extended under existing terms through December 31, 2014&#160;or were presented for conversion subsequent to year end.</div> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"><strong><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font>Income Taxes</strong></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"><strong>&#160;</strong></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">Income taxes are accounted for under the liability method. Deferred income taxes are provided for temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and amounts used for income tax purposes. Deferred taxes are reduced by a valuation allowance when, in the opinion of management, it is more likely than not that some portion or the entire deferred tax asset will not be realized. Deferred tax assets and liabilities are adjusted for the effects of changes in tax laws and rates on the date of the enactment. We recognize tax benefits when we believe the benefit is more likely than not to be sustained upon review from the relevant authorities. We recognize penalties and interest expense related to unrecognized tax benefits in income tax expense.<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> &#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"><strong><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font></strong> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font>The Company&#8217;s federal and state tax forms for the years ending December 31, 2010, 2011 and 2012 are subject to examination by the IRS or other taxing authorities, generally for three years after they are filed.</div> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"> &#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"><strong><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font>Accumulated Other Comprehensive Income</strong></div> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">Accumulated other comprehensive income relates to foreign currency translation adjustments associated with transactions denominated in foreign currency. The balance of accumulated other comprehensive income as of December 31, 2012 was $143,000. During the year ended December 31, 2013 the entire balance was reclassified to net income.<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font></div> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> &#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"><strong><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font>Revenue Recognition</strong></div> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"><strong>&#160;</strong></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">The Company&#8217;s revenues are currently derived from the sale of medical equipment products, maintenance contracts, service revenues and radioisotope sales. Revenues from maintenance contracts are recognized over the term of the contract. Service revenues are recognized upon performance of the services. The Company recognizes revenues from the sale of medical equipment and radioisotope products when earned. Specifically, revenue is recognized when persuasive evidence of an arrangement exists, delivery has occurred (or services have been rendered), the price is fixed or determinable, and collectability is reasonably assured. The Company obtains a signed customer acceptance after installation is complete for the sale of its Attrius&#174; PET systems.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">For multiple-element arrangements, revenue is allocated to each element based on their relative selling prices. Relative selling prices are based first on vendor specific objective evidence (VSOE), then on third-party evidence of selling price (TPE) when VSOE does not exist, and then on estimated selling price (ESP) when VSOE and TPE do not exist.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">Because the Company has neither VSOE nor TPE for its products, the allocation of revenue has been based on the Company&#8217;s ESPs. The objective of ESP is to determine the price at which the Company would transact a sale if the product was sold on a stand-alone basis. The Company determines ESP by considering the facts and circumstances of the product being sold.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"><strong><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font></strong> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"> &#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font>The Company typically provides a one-year parts and labor warranty to purchasers of equipment. A portion of revenue recorded upon the sale of a new machine is allocated to the warranty provided. At the time of sale, the Company records deferred revenue in the amount of revenue allocated to the warranty which is amortized over a one-year period.</div> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"><strong>Research and Development Expenses</strong></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"><strong>&#160;</strong></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">All costs related to research and development costs are charged to expense as incurred and include salaries and benefits, supplies and consulting expenses.</div> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"><strong><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font>Stock Based Compensation</strong></div> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font>&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">We recognize compensation expense for share-based awards using the fair value of the option at the time of the grant and amortizing the fair value over the estimated service period on the straight-line attribute method.<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"><strong><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font>Loss Per Common Share</strong></div> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"><strong><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font>&#160;</strong></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">Basic loss per common share is calculated by dividing net loss by the weighted average common shares outstanding during the period. Stock options, warrants and other dilutive securities are not included in the computation of the weighted average number of shares outstanding for dilutive net loss per common share during each of the periods presented in the Statement of Operations and Comprehensive Income, as the effect would be antidilutive.<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font></font></div> &#160; <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"><strong><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font>Recent Accounting Pronouncements</strong></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"><strong>&#160;</strong></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">The Company has implemented all new accounting pronouncements that are in effect and that may impact its financial statements and does not believe that there are any other new accounting pronouncements that have been issued that might have a material impact on its financial position or results of operations.</div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table> <div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"><strong>Accumulated Other Comprehensive Income</strong></div> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">Accumulated other comprehensive income relates to foreign currency translation adjustments associated with transactions denominated in foreign currency. The balance of accumulated other comprehensive income as of December 31, 2012 was $143,000. During the year ended December 31, 2013 the entire balance was reclassified to net income.<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font></div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table> 35000 0 1328000 12084000 <div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <table style="MARGIN-TOP: 0pt; FONT: 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0pt" cellspacing="0" cellpadding="0" width="100%"> <tr style="VERTICAL-ALIGN: top"> <td style="WIDTH: 0.25in"> <div><b>21.</b></div> </td> <td style="TEXT-ALIGN: justify"> <div><b>SUBSEQUENT EVENTS</b><b><br/> &#160;</b></div> </td> </tr> </table> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0in; MARGIN: 0pt 0px 0pt 0in; FONT: 10pt Times New Roman, Times, Serif" align="justify">Management has evaluated all events that occurred after the balance sheet date through the date when these financial statements were issued to determine if they must be reported. The management of the Company has determined&#160;the following:<br/> <br/> The Company issued an aggregate of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">320,000</font> of convertible notes to unrelated parties in February and March 2014. As with the Company&#8217;s other, recent sales of convertible notes, the notes are convertible into shares of the Company&#8217;s Common Stock at a rate equal to the daily volume weighted average price of the three trading days prior to a conversion, mulitiplied by 0.55.</div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table> <div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <table style="clear:both;MARGIN-TOP: 0pt; FONT: 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0pt" cellspacing="0" cellpadding="0" width="100%"> <tr style="VERTICAL-ALIGN: top"> <td style="WIDTH: 0.25in"> <div><strong>9.</strong></div> </td> <td style="TEXT-ALIGN: justify"> <div><strong>CONVERTIBLE DEBENTURES</strong></div> </td> </tr> </table> &#160; <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"><em>Convertible Debentures 2012</em></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">On January 12, 2012, the Company acquired a building in Westmont, Illinois, which the Company previously leased from a related party for corporate and administrative offices (see Note 17). As a part of the price consideration, the Company issued the related party a convertible debenture in the principal amount of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">250,000</font>, which shall be due on December 31, 2013 and bears interest at <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 8</font>% per year payable quarterly in cash. In addition, the Company issued warrants (&#8220;Warrants&#8221;) to the related party to purchase <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 25,000,000</font> shares of the Company&#8217;s common stock, par value $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">0.01</font> per share (the &#8220;Common Stock&#8221;), at an exercise price of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">0.01</font> per share and expiring on <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">December 31, 2013</font>. The related party is entitled to convert the accrued interest and principal of the convertible debentures into common stock of the Company at a conversion price equal to <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 55</font>% of the lowest daily volume weighted average price for the three trading days preceding conversion. During the period ended December 31, 2012, the Company has converted $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">100,000</font> of the principal amount of the debt into <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 18,181,818</font> shares of common stock and recorded loss on debt settlement of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">44,661</font>.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">During the twelve months ended December 31, 2012, the Company issued additional of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">2,210,000</font> of convertible debt with maturity date December 31, 2013, of which $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">460,000</font> bears <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">8</font>% interest and $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">1,750,000</font> is non-interest bearing. $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">510,000</font> of the convertible debt was issued to unrelated parties, and $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">1,700,000</font> to related parties. In connection with the issuances the Company issued warrants (&#8220;Warrants&#8221;) to purchase <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 68,500,000</font> shares of the Company&#8217;s Common Stock, at an exercise price of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">0.01</font> per share and expiring on December 31, 2013. The lender is entitled to convert the accrued interest and principal of the Convertible Debentures into common stock of the Company at a conversion price equal to <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 55</font>% of the lowest daily volume weighted average price for the three trading days preceding conversion.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"><em>Initial Accounting</em></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">Under the initial accounting, the Company separated the Convertible Debentures instrument into component parts of the Convertible Debt, the $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">0.01</font> Warrants and the embedded conversion derivative liability. The Company estimated the fair value of each component as of the date of the issuance. The fair value of the embedded conversion derivative liability exceeded the value of the Convertible Debt less the allocation of the liability to the $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">0.01</font> Warrants, which resulted in a debt discount of $2,460,000. The discount is accreted to interest expense over the life of the Convertible Debt.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px 0pt 0.25in; FONT: 10pt Times New Roman, Times, Serif" align="justify"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font>The following is a summary of Convertible Debt and the initial accounting of the issuances (in thousands):</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px 0pt 0.25in; FONT: 10pt Times New Roman, Times, Serif" align="justify">&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"> <table style="clear:both;MARGIN: 0in; WIDTH: 95%; BORDER-COLLAPSE: collapse; FONT-SIZE: 10pt; OVERFLOW: visible" cellspacing="0" cellpadding="0" align="left"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="82%"> <div>Convertible debt issuance</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>2,460</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="82%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="82%"> <div>Allocation of debt to warrants</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>(331)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="82%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="82%"> <div>Allocation of debt to embedded conversion derivative liability</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>(2,129)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> </table> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font></div> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px 0pt 0.25in; FONT: 10pt Times New Roman, Times, Serif" align="justify">&#160;<em>&#160;</em></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"><em>Convertible Debentures 2013</em></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">In December 2013, the Company issued $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">2,520,000</font> of convertible debentures &#8220;(Convertible Debentures&#8221;) to certain investors (&#8220;Investors&#8221;). The Convertible Debentures do not accrue interest. The debentures mature on December 31, 2014. The Investors are entitled to convert the accrued interest and principal of the Convertible Debentures into common stock of the Company at a conversion price equal to 55% of the lowest daily volume weighted average price for the three trading days preceding conversion.&#160;<font style="FONT-SIZE: 10pt">On December 9, 2013, one of the Investors agreed to convert $1,000,000 of his outstanding debt, pending authorization and/or issuance of additional shares of common stock. As of December 9, 2013, there were not enough shares available to convert.</font>&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> &#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> <em>Initial Accounting</em></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> &#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">Under the initial accounting, the Company separated the Convertible Debentures instrument into debt and the embedded conversion derivative liability. The Company allocated the proceeds to the embedded conversion derivative liability. The fair value of the embedded conversion derivative liability exceeded the proceeds from the Convertible Debentures, which resulted in a debt discount of $1,500,000. The debt is accreted to interest expense over the life of the Convertible Debentures.</div> &#160; <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font>The following is a summary of the proceeds from the issuance of the Convertible Debentures and the initial accounting of the issuance (in thousands):</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> &#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt; TEXT-INDENT: 0in; WIDTH: 100%"> <table style="clear:both;BORDER-BOTTOM: #9eb6ce 0px solid; BORDER-LEFT: #9eb6ce 0px solid; WIDTH: 100%; BORDER-COLLAPSE: collapse; FONT-SIZE: 10pt; OVERFLOW: visible; BORDER-TOP: #9eb6ce 0px solid; BORDER-RIGHT: #9eb6ce 0px solid" cellspacing="0" cellpadding="0"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="85%"> <div>Proceeds from convertible debt issuance</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>2,520</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="85%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="85%"> <div>Allocation of proceeds to embedded conversion derivative liability</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>(1,500)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> </table> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"></div> </div> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"><em>&#160;</em></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"><em>Convertible debentures as of December 31, 2013</em></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">As of December 31, 2013, the holders of the convertible debentures issued in 2012 agreed to extend those issuances through December 31, 2014. The related Warrants were also extended through December 31, 2014. Approximately $821,000 in expense was recorded for the year ended December 31, 2013 related to modification of the Warrants.</font></div> &#160; <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">As of December 31, 2013, convertible debt totaled&#160;$<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">5,780,000</font>, of which $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">1,328,000</font> was attributable to the discount on debt. These notes originally were set to&#160;mature on December 31, 2013 but were extended under existing terms through December 31, 2014 or were presented for conversion subsequent to year end.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">During the years ended December 31, 2013 and 2012, the Company recognized interest expense related to Convertible Debentures of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">1,970,000</font> and $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">1,628,000</font>, respectively. As of December 31, 2013 and December 31, 2012, accrued interest on Convertible Debentures was $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">277,542</font> and $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">148,741</font> respectively. <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font>Convertible Debentures outstanding as of December 31, 2013 and 2012 were as follows (in thousands):</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"><em>&#160;</em></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"> <table style="clear:both;MARGIN: 0in; WIDTH: 100%; BORDER-COLLAPSE: collapse; OVERFLOW: visible" cellspacing="0" cellpadding="0" align="left"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="55%"> <div>December&#160;31,&#160;2013</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="14%" colspan="2"> <div>Unrelated<br/> parties</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="14%" colspan="2"> <div>Related&#160;parties</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="13%" colspan="2"> <div>Total</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="55%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="13%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="13%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="12%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="55%"> <div>Convertible debentures- face value</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 3px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="13%"> <div>4,030</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="13%"> <div>1,750</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>5,780</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="55%"> <div>Debt discount</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 1px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="13%"> <div>(1,328)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="13%"> <div>0</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>(1,328)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="55%"> <div>Total convertible debentures</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 3px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="13%"> <div>2,702</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="13%"> <div>1,750</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"> <div>4,452</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 13px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="55%"> <div>Less current portion</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 1px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="13%"> <div>(2,702)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="13%"> <div>(1,750)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>(4,452)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 13px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="55%"> <div>Long term portion</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="13%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="13%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> </table> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"></div> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"> <table style="clear:both;MARGIN: 0in; WIDTH: 100%; BORDER-COLLAPSE: collapse; FONT-SIZE: 10pt; OVERFLOW: visible" cellspacing="0" cellpadding="0" align="left"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="55%"> <div>December&#160;31,&#160;2012</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="14%" colspan="2"> <div>Unrelated<br/> parties</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="14%" colspan="2"> <div>Related&#160;parties</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="13%" colspan="2"> <div>Total</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="55%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="13%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="13%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="55%"> <div>Convertible debentures- face value</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="13%"> <div>1,510</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="13%"> <div>1,850</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>3,360</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="55%"> <div>Debt discount</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="13%"> <div>(350)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="13%"> <div>(1,448)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>(1,798)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="55%"> <div>Total current convertible debentures</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="13%"> <div>1,160</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="13%"> <div>402</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"> <div>1,562</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> </table> </div> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> <strong>&#160;</strong></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> <font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt"> Subsequent to year end, various holders of debt issued in 2012 and 2013 agreed to convert their convertible debt pending authorization of additional common stock at a specific price based on the weighted average close price of the three days prior to the conversion. A total of $2,220,000 have been presented for conversion&#160;effective January 2014. Of the $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">2,220,000</font>, $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">1,120,000</font> was debt held by unrelated parties and&#160;$<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">1,100,000</font> was debt held by related parties</font>.</div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table> 1328000 Warrants were originally set to expire on December 31, 2013, but were extended by the Company through December 31, 2014. Warrants expire six months after the date on which a registration statement is filed and accepted by the Securities Exchange Commission permitting a sale of the shares issuable upon exercise of the warrant. EX-101.SCH 9 posc-20131231.xsd XBRL TAXONOMY EXTENSION SCHEMA 101 - Document - Document And Entity Information link:presentationLink link:definitionLink link:calculationLink 102 - Statement - CONSOLIDATED BALANCE SHEETS link:presentationLink link:definitionLink link:calculationLink 103 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical) link:presentationLink link:definitionLink link:calculationLink 104 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME link:presentationLink link:definitionLink link:calculationLink 105 - Statement - CONSOLIDATED STATEMENT OF STOCKHOLDERS' EQUITY (DEFICIT) link:presentationLink link:definitionLink link:calculationLink 106 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS link:presentationLink link:definitionLink link:calculationLink 107 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS (Parenthetical) link:presentationLink link:definitionLink link:calculationLink 108 - Disclosure - DESCRIPTION OF BUSINESS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES link:presentationLink link:definitionLink link:calculationLink 109 - Disclosure - GOING CONCERN link:presentationLink link:definitionLink link:calculationLink 110 - Disclosure - ACQUISITION OF MIT link:presentationLink link:definitionLink link:calculationLink 111 - Disclosure - OTHER ASSETS link:presentationLink link:definitionLink link:calculationLink 112 - Disclosure - INVENTORIES link:presentationLink link:definitionLink link:calculationLink 113 - Disclosure - PROPERTY AND EQUIPMENT link:presentationLink link:definitionLink link:calculationLink 114 - Disclosure - ACCOUNTS PAYABLE AND ACCRUED LIABILITIES link:presentationLink link:definitionLink link:calculationLink 115 - Disclosure - CUSTOMER DEPOSITS link:presentationLink link:definitionLink link:calculationLink 116 - Disclosure - CONVERTIBLE DEBENTURES link:presentationLink link:definitionLink link:calculationLink 117 - Disclosure - NOTES PAYABLE AND ADVANCES FROM RELATED PARTIES link:presentationLink link:definitionLink link:calculationLink 118 - Disclosure - NOTES PAYABLE - CAPITAL LEASE link:presentationLink link:definitionLink link:calculationLink 119 - Disclosure - STOCKHOLDERS' EQUITY link:presentationLink link:definitionLink link:calculationLink 120 - Disclosure - PREFERRED STOCK link:presentationLink link:definitionLink link:calculationLink 121 - Disclosure - OTHER EXPENSES link:presentationLink link:definitionLink link:calculationLink 122 - Disclosure - LOSS PER SHARE link:presentationLink link:definitionLink link:calculationLink 123 - Disclosure - INCOME TAXES link:presentationLink link:definitionLink link:calculationLink 124 - Disclosure - 401(K) PLAN link:presentationLink link:definitionLink link:calculationLink 125 - Disclosure - RELATED PARTY TRANSACTIONS link:presentationLink link:definitionLink link:calculationLink 126 - Disclosure - COMMITMENTS AND CONTINGENCIES link:presentationLink link:definitionLink link:calculationLink 127 - Disclosure - SELECTED QUARTERLY FINANCIAL DATA link:presentationLink link:definitionLink link:calculationLink 128 - Disclosure - SEGMENTS link:presentationLink link:definitionLink link:calculationLink 129 - Disclosure - SUBSEQUENT EVENTS link:presentationLink link:definitionLink link:calculationLink 130 - Disclosure - DESCRIPTION OF BUSINESS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies) link:presentationLink link:definitionLink link:calculationLink 131 - Disclosure - DESCRIPTION OF BUSINESS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables) link:presentationLink link:definitionLink link:calculationLink 132 - Disclosure - ACQUISITION OF MIT (Tables) link:presentationLink link:definitionLink link:calculationLink 133 - Disclosure - INVENTORIES (Tables) link:presentationLink link:definitionLink link:calculationLink 134 - Disclosure - PROPERTY AND EQUIPMENT (Tables) link:presentationLink link:definitionLink link:calculationLink 135 - Disclosure - ACCOUNTS PAYABLE AND ACCRUED LIABILITIES (Tables) link:presentationLink link:definitionLink link:calculationLink 136 - Disclosure - CONVERTIBLE DEBENTURES (Tables) link:presentationLink link:definitionLink link:calculationLink 137 - Disclosure - NOTES PAYABLE AND ADVANCES FROM RELATED PARTIES (Tables) link:presentationLink link:definitionLink link:calculationLink 138 - Disclosure - Notes Payable - Capital Lease (Tables) link:presentationLink link:definitionLink link:calculationLink 139 - Disclosure - STOCKHOLDERS' EQUITY (Tables) link:presentationLink link:definitionLink link:calculationLink 140 - Disclosure - LOSS PER SHARE (Tables) link:presentationLink link:definitionLink link:calculationLink 141 - Disclosure - INCOME TAXES (Tables) link:presentationLink link:definitionLink link:calculationLink 142 - Disclosure - COMMITMENTS AND CONTINGENCIES (Tables) link:presentationLink link:definitionLink link:calculationLink 143 - Disclosure - SELECTED QUARTERLY FINANCIAL DATA (Tables) link:presentationLink link:definitionLink link:calculationLink 144 - Disclosure - SEGMENTS (Tables) link:presentationLink link:definitionLink link:calculationLink 145 - Disclosure - Description of Business and Summary of Significant Accounting Policies - Additional Information (Detail) link:presentationLink link:definitionLink link:calculationLink 146 - Disclosure - Straight-line over estimated useful (Detail) link:presentationLink link:definitionLink link:calculationLink 147 - Disclosure - Embedded Conversion Derivative Liabilities Measured and Recorded at Fair Value on Recurring Basis (Detail) link:presentationLink link:definitionLink link:calculationLink 148 - Disclosure - Reconciliation of Financial Instruments Recognized at Fair Value (Detail) link:presentationLink link:definitionLink link:calculationLink 149 - Disclosure - Derivatives valued using the Black-Scholes option pricing model (Detail) link:presentationLink link:definitionLink link:calculationLink 150 - Disclosure - Going Concern - Additional Information (Detail) link:presentationLink link:definitionLink link:calculationLink 151 - Disclosure - Acquisition of MIT - Additional Information (Detail) link:presentationLink link:definitionLink link:calculationLink 152 - Disclosure - Summary of Consideration Transferred (Detail) link:presentationLink link:definitionLink link:calculationLink 153 - Disclosure - Summary of Fair Values of Assets and Liabilities Assumed (Detail) link:presentationLink link:definitionLink link:calculationLink 154 - Disclosure - Summary of Fair Values of Assets and Liabilities Assumed (Parenthetical) (Detail) link:presentationLink link:definitionLink link:calculationLink 155 - Disclosure - Other Assets - Additional Information (Detail) link:presentationLink link:definitionLink link:calculationLink 156 - Disclosure - Inventories (Detail) link:presentationLink link:definitionLink link:calculationLink 157 - Disclosure - Property and Equipment (Detail) link:presentationLink link:definitionLink link:calculationLink 158 - Disclosure - Accounts Payable and Accrued Liabilities (Detail) link:presentationLink link:definitionLink link:calculationLink 159 - Disclosure - Customer Deposits - Additional Information (Detail) link:presentationLink link:definitionLink link:calculationLink 160 - Disclosure - Convertible Debentures - Additional Information (Detail) link:presentationLink link:definitionLink link:calculationLink 161 - Disclosure - Summary of Convertible Debt and Initial Accounting of Issuances (Detail) link:presentationLink link:definitionLink link:calculationLink 162 - Disclosure - Convertible Debentures Outstanding (Detail) link:presentationLink link:definitionLink link:calculationLink 163 - Disclosure - Notes Payable and Advances from Related Parties - Additional Information (Detail) link:presentationLink link:definitionLink link:calculationLink 164 - Disclosure - Future Maturities of Notes Payable (Detail) link:presentationLink link:definitionLink link:calculationLink 165 - Disclosure - Notes Payable - Capital Lease - Additional Information (Detail) link:presentationLink link:definitionLink link:calculationLink 166 - Disclosure - Future Minimum Lease Payments and Present Value Of Payments (Detail) link:presentationLink link:definitionLink link:calculationLink 167 - Disclosure - Stockholders' Equity - Additional Information (Detail) link:presentationLink link:definitionLink link:calculationLink 168 - Disclosure - Summary of Series B Preferred Stock Option Activity (Detail) link:presentationLink link:definitionLink link:calculationLink 169 - Disclosure - Determination Of Fair Market Value Using Black-Scholes Option Pricing Model (Detail) link:presentationLink link:definitionLink link:calculationLink 170 - Disclosure - Summary of Common Stock Option Activity (Detail) link:presentationLink link:definitionLink link:calculationLink 171 - Disclosure - Summary of Warrant Activity Based on Common Stock Equivalents (Detail) link:presentationLink link:definitionLink link:calculationLink 172 - Disclosure - Summary Of Outstanding Common Stock Warrants (Detail) link:presentationLink link:definitionLink link:calculationLink 173 - Disclosure - Preferred Stock - Additional Information (Detail) link:presentationLink link:definitionLink link:calculationLink 174 - Disclosure - Other Expenses - Additional Information (Detail) link:presentationLink link:definitionLink link:calculationLink 175 - Disclosure - Computation of Basic and Diluted Loss Per Share (Detail) link:presentationLink link:definitionLink link:calculationLink 176 - Disclosure - Antidilutive Securities Not Included in Computation of Net Loss Per Share (Detail) link:presentationLink link:definitionLink link:calculationLink 177 - Disclosure - Income Taxes - Additional Information (Detail) link:presentationLink link:definitionLink link:calculationLink 178 - Disclosure - Composition Of Deferred Tax Assets (Detail) link:presentationLink link:definitionLink link:calculationLink 179 - Disclosure - Components Of Income Tax Expense Benefit (Detail) link:presentationLink link:definitionLink link:calculationLink 180 - Disclosure - 401(k) Plan - Additional Information (Detail) link:presentationLink link:definitionLink link:calculationLink 181 - Disclosure - Related Party Transactions - Additional Information (Detail) link:presentationLink link:definitionLink link:calculationLink 182 - Disclosure - Commitments and Contingencies - Additional Information (Detail) link:presentationLink link:definitionLink link:calculationLink 183 - Disclosure - Future Minimum Rental Payments for Operating Leases (Detail) link:presentationLink link:definitionLink link:calculationLink 184 - Disclosure - Selected Quarterly Financial Data (Detail) link:presentationLink link:definitionLink link:calculationLink 185 - Disclosure - Sales, Operating Loss and Total Assets Attributable to Business Segments (Detail) link:presentationLink link:definitionLink link:calculationLink 186 - Disclosure - Subsequent Events - Additional Information (Detail) link:presentationLink link:definitionLink link:calculationLink 187 - Disclosure - Stock Options link:presentationLink link:definitionLink link:calculationLink 188 - Disclosure - Stock Options - Additional Information (Detail) link:presentationLink link:definitionLink link:calculationLink 189 - Disclosure - Disclosure - Debt link:presentationLink link:definitionLink link:calculationLink EX-101.CAL 10 posc-20131231_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE EX-101.DEF 11 posc-20131231_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE EX-101.LAB 12 posc-20131231_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE EX-101.PRE 13 posc-20131231_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE XML 14 R39.htm IDEA: XBRL DOCUMENT v2.4.0.8
STOCKHOLDERS' EQUITY (Tables)
 12 Months Ended
Dec. 31, 2013
Black Scholes Option Pricing Model One
Fair market value using the Black-Scholes option-pricing model was determined using the following assumptions:
 
Expected life (years)
 
1
 
Risk free rate of return
 
11
%
Dividend yield
 
0
 
Expected volatility
 
200
%
Summary of Common Stock Options Activity
A summary of common stock option activity is as follows:
 
 
 
Shares Issuable
Under
Outstanding
Options
 
Weighted
Average
Exercise
Price
 
Issued in 2012
 
 
197,600,000
 
$
0.01
 
Forfeited
 
 
(7,000,000)
 
 
0.01
 
Balance at December 31, 2012
 
 
190,600,000
 
$
0.01
 
Forfeited
 
 
(2,500,000)
 
$
0.01
 
Exercised
 
 
-
 
 
-
 
Balance at December 31, 2013
 
 
188,100,000
 
$
0.01
 
Exercisable, December 31, 2013
 
 
188,100,000
 
$
0.01
 
Black Scholes Option Pricing Model Two
Fair market value using the Black-Scholes option-pricing model was determined using the following assumptions:
 
Expected life (years)
 
1.75
 
Risk free rate of return
 
0.75
%
Dividend yield
 
0
 
Expected volatility
 
218
%
Black Scholes Option Pricing Model Three
Fair market value using the Black-Scholes option-pricing model was determined using the following assumptions:
 
Expected life (years)
 
2.25
 
Risk free rate of return
 
0.27
%
Dividend yield
 
0
 
Expected volatility
 
125
%
Summary of Stock Warrants Outstanding
A summary of warrant activity based on common stock equivalents is as follows:
 
 
 
Number of Shares
 
Exercise
Price
 
Weighted
Average
Exercise
Price
 
Balance at December 31, 2011
 
183,583,338
 
$
0.01-0.15
 
$
0.05
 
Warrants exercised
 
-
 
 
-
 
 
-
 
Warrants expired
 
(134,583,338)
 
$
0.01-0.03
 
$
0.03
 
Warrants issued with common and Series B Preferred stock in private placement
 
114,850,000
 
$
0.01
 
$
0.01
 
Warrants issued with convertible debentures and notes payable
 
103,500,000
 
$
0.01
 
$
0.01
 
Balance at December 31, 2012
 
267,350,000
 
$
0.01-0.15
 
$
0.03
 
Warrants exercised
 
-
 
 
-
 
 
-
 
Warrants expired
 
(144,850,000)
 
$
0.01-0.15
 
$
0.02
 
Warrants issued with convertible debentures and notes payable
 
-
 
$
-
 
$
-
 
Balance at December 31, 2013
 
122,500,000
 
$
0.01-0.02
 
$
0.01
 
Series B Preferred Stock
  
Summary of Common Stock Options Activity
A summary of Series B Preferred stock option activity is as follows:
 
 
 
Shares Issuable
Under
Outstanding
Options
 
Weighted
Average
Exercise
Price
 
 
 
 
 
 
 
 
 
Balance at December 31, 2012
 
 
2,500,000
 
$
1.00
 
Issued
 
 
-
 
 
-
 
Expired/forfeited
 
 
(430,000)
 
 
1.00
 
Exercised
 
 
-
 
 
-
 
Balance at December 31, 2013
 
 
2,070,000
 
$
1.00
 
Exercisable, December 31, 2013
 
 
2,070,000
 
$
1.00
 
Summary of Outstanding Common Stock Warrants
 A summary of outstanding common stock warrants at December 31, 2013 follows:
 
Number of
Common Stock
Equivalents
 
Expiration Date
 
Remaining
Contractual Life
(Years)
 
Exercise
Price
 
 
 
4,000,000
 
(a)
 
 
-
 
$
0.02
 
 
 
118,500,000
 
(b)
 
 
1.00
 
$
0.01
 
   
(a) Warrants expire six months after the date on which a registration statement is filed and accepted by the Securities Exchange Commission permitting a sale of the shares issuable upon exercise of the warrant.
 
(b) Warrants were originally set to expire on December 31, 2013, but were extended by the Company through December 31, 2014.
XML 15 R54.htm IDEA: XBRL DOCUMENT v2.4.0.8
Other Assets - Additional Information (Detail) (USD $)
Dec. 31, 2013
Dec. 31, 2012
Other Assets [Line Items]    
Deposits $ 54,000 $ 53,000
Corporate Joint Venture [Member]
    
Other Assets [Line Items]    
Deposits $ 201,000  
XML 16 R48.htm IDEA: XBRL DOCUMENT v2.4.0.8
Reconciliation of Financial Instruments Recognized at Fair Value (Detail) (USD $)
In Thousands, unless otherwise specified
 12 Months Ended
Dec. 31, 2013
Dec. 31, 2012
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Balance of embedded conversion derivative liability as of December 31, 2011 $ 3,981 $ 1,238
Fair value of embedded conversion derivative liabilities at issuance 1,501 2,129
Reductions in fair value due to conversion of Convertible Debentures into common stock   (544)
Debt modification expense (821) (432)
Loss on fair value adjustments to embedded conversion derivative liabilities 665 726
Balance of embedded conversion derivative liability $ 6,968 $ 3,981
EXCEL 17 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx M4$L#!!0`!@`(````(0!0JJSS?@(``'PQ```3``@"6T-O;G1E;G1?5'EP97-= M+GAM;""B!`(HH``"```````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M``````````````````````````````````````#,V\V.VC`4!>!]I;Y#Y&U% MC)W$22M@%OU9MB-U^@!NODZ8&54CR@@5J6=#1!+?>[#0M_)= MW.S[+GD@YUMKEDRDZLH24[D&' M@7P25QN_9-L0A@^<^WI+O?:I'AWB5[?A@ZYW>D-*U]8$,F$6 MQAILM?A$:WW?A>3S/MX^)G'4>99\/+XX]EHR/0Q=6^L0D_('T[SH,GOLD,:5 MTSM^VP[^78S!^,D.XY._-WA<]RUNC6L;2FZU"U]U'V/P?<=_6;?[:>TN/5_D M1$J[7KM>8H05!$%2BD"A13!0JJ`D55@<*J M0'%5H,`J4&25*+)*%%DEBJP215:)(JM$D56BR"I19)4HLDH463,463,463,4 M63,463,463,463,463,463,463,467,467,467,467,467,467,467,467,4 M67,467,460L460L460L460L460L460L460L460L460L460L4616*K`I%5H4B MJT*15:'(JE!D52BR*A19%8JL"D76$D76$D76$D76$D76$D76$D76$D76$D76 M$D76$D76"D76"D76"D76"D76"D76ZG_)&N+9=N+3Y[__3:>!@%,'ZY\[QDF#RQN^.-E/XRQ#0\V)WGR:G5C]!@``__\#`%!+`P04``8` M"````"$`M54P(_4```!,`@``"P`(`E]R96QS+RYR96QS(*($`BB@``(````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M`````````````````(R2ST[#,`S&[TB\0^3[ZFY("*&ENTQ(NR%4'L`D[A^U MC:,D0/?VA`."2F/;T?;GSS];WN[F:50?'&(O3L.Z*$&Q,V)[UVIXK9]6#Z!B M(F=I%,<:CAQA5]W>;%]XI)2;8M?[J+*+BQJZE/PC8C0=3Q0+\>QRI9$P4P>J/OH\^;*W-$UO>"_F?6*73HQ`GA,[ MRW;E0V8+J<_;J)I"RTF#%?.L0""@,``)DQ```:``@!>&PO7W)E;',O=V]R:V)O;VLN>&UL+G)E;',@ MH@0!**```0`````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M``````````````````````````````````````````````````"\F\MNVD`8 MA?>5^@[6[(/YYYXJ)INH4K9M^@`6#!<%;.1Q+[Q]1R@U16I/-NALD&S$\`N? M<[YC&S\\_CKLJQ]IR+N^:Y3,YJI*W;)?[;I-H[Z]?+Z+JLICVZW:?=^E1IU2 M5H^+CQ\>OJ1].Y8/Y>WNF*NR2I<;M1W'XZ>ZSLMM.K1YUA]35]Y9]\.A'^'OY>0RVNUJR>5XT:GE?:J^KE="Q?_?[B_7J]6Z:G?OG] MD+KQ']]1_^R'U[Q-:2R+ML,FC8V:=N7Z_([VLS*SJO\SCK#'$32.U>1QK(;C M!/8X`8WC#7D<;^`XQ4M4*?N(QHF6/$ZT:!QA&UV@T85M=(%&-VRC&VATPS:Z M@49W;*,[:'3'-KJ#1@]LHP=H]'!/SIUPCW+'D:=Q:!AA_S8"?QMA*T>@G3L> MYHYGI[*'J1S8N1-@[K"5C(7,KNT.UO;`)E:`Q(IL1$2(B,A&1(2(8!,"`D+8 MRA&H'&%GCL#,T6SE:*PFN8,T]VQG>>PL-B(T M1(1E\]Q"GCMV,76XF+(AX2$D`EL[`6HGL"$1("0B&Q(10B+>%!)YVPYI]74< MRHW#7*Y#O-U\$7!TZX_ MMX=AU3%LZ1BH'N.@Y6'6'C2B"N##L##0Q!RZXZ%E8=QZXZ#E8= MS]:.A]KQ;$AX"(G`AD2`D`AL2`0(B<@V>H1&CS=EUEC^^I4N^#QOUN=7.`0] M;%`995,30E/87A+H)6%[2:"7#/M8&7BP#%O'!D.332D'*>78E'*84C<-ONE$ MX1)^TZZW9$V\:.GD\[K?^=MU+0\.V8\C)G(SIDX!4U]]4#%XC<` M``#__P,`4$L#!!0`!@`(````(0!/0#XRE0<``&X8```/````>&PO=V]R:V)O M;VLN>&ULE)E;<]LV$(7?.]/_H-%[*U%W9^)T*`I..)5)EJ2$F3P0]1E#+/KH?&[^/A0&3[/);9 M]^OA+KSY;34/-WG^=,``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`8EYB[ M0PJV>OJ&K1'^SN^6@%)B:+0Y;LAZ\6_N5$,'_,9W:0H4?4/#K:MCF9X=FEN^ M969`N_"*LF9HL*EN^_.+N]TP/^!J/<)O)`)8'ZVB!IWGLQOF^RA]H].929&# MP_8,[8@<^]MC3M`IGC&FU$TTZK8N.@H(P?U,GR9J8&,XK_A$(\]V+"PX#\V_ M>\^CP$TTX&9CXT_NP7`[R5&X)AI1C=)Z+L:%`.IQ<,-+$5%,I__3%;L144ZG&J=.7HD2)YI7M3+< MB@ZRBA*^%5$I$%9GI2B]4YU>W1LOY*5.C^U&,]4P[OK5I?D4WID&+[6M2[,I ML#,-6%C>?YL(I[6`\YW3F&G4ON\BG>6!'Q(E#>&3C5Q*AD([TZ#UQ3['A4C$ M/%"'9OK066>F!FE0%9$ZMRBD#]PS?DA.N7L"&F,JE2RO4QDO$0G9M(%OQ.U:A4LF99T@6;4_PQZ.FXJ&?1S*E*FM'Q)D?SHO#/-81M M8)-5>2$1Q$94D<3EMUUK`WONN7/F&L5>@;M[@?LC+OV+083FG1`T;H_]4TGET!MQCS3J`B5Y M`X_H&-C.24TT<,D"]S0KE(D(+:@.!KT%[DT^!>36E7K'0G4HN`L-W%YM0=6Y MMCA/G%-9:*S>U*H(_#;"!SKHB&F[F1&A!645@UXJ[90+^Y\94QW*ZD)C]12/ MS&1:IV\;*+95!5U)]XX%-5\,>O$$5;Y_>LP3]'#98`N"SPY#XC%P6"(%TK@E M:QW`=%&@-?<*\2`*M2<0H07M(PQZ`:'Q1)'";Y7'<1?>JZSA-BJ>1,7OJ`Z% M>*%!3.*Q\C2%5I,J=P]*F.K0IEJ\Q_#7J(#!5=S<8T-1KXK6$=%94H8QZ.5U MB@<9O7&K7A;"0)O8J`X%<:DQ?*[I,9_S8JDW5T3'P`'UO&!+C>BC:[(7O'$L MS]U]VE:(T+*CHQ&-#`YUU6Z5ZZB4^\8$-S*I*ZI#B5YJ1)MX_1:K*=BL>2#V MISY#QW1WW24E&H->H>UL#Q/$`>9%SZI(:3ST%+#4@%9Y*1=]PW!S0AG"V&N( MCH$3/"FT1G0CE#5]B<4_A\>;VA.A)24:@UYBN.P^<2^)]",`SDJ2ZE"BEQK1 MOGKQBY[T(K5=-7MV!**QDZO.)SJ&>MO:GIY7&M(].T45B)W2XJXTBGOVY:,Z M.,^<_(L(K:CK8-"K22\$Q-N&L*+88M";&42X&<(-FK,+&G&;EV6#;9@C%*I# M5W>E81O4]Z7XIT8"G*GC0[M/-IU$=3K%;+`=-<'BG?0^2O9X6:X^U-OFIM*C MTW\5?/H7``#__P,`4$L#!!0`!@`(````(0#RC.F;`@4``+L3```8````>&PO M=V]R:W-H965T&ULE%A-CZ,X$+VOM/\!<4_`)D"(DHP&6KT[ MTHZT6NW'F29.@AIP!'2GY]]OF7(P-IT,7-)-ZE$\OZIZ)MY^^2@+ZYW53-XS39F95IL^075D'DR.LR;>&R/CG-I6;IH;NI+!SJNH%3IGEE M8X9-/24'/Q[SC#WQ[*UD58M):E:D+?!OSOFEN64KLRGIRK1^?;LL,EY>(,5+ M7N3MCRZI;979YMNIXG7Z4L"Z/\@JS6ZYNXM1^C+/:M[P8[N$=`X2':\YRWG4#_YNS:#/ZWFC.__E;GAS_RBH':4"=1 M@1?.7P7TVT%\!3<[H[N?NPK\65L'=DS?BO8O?OV=Y:=S"^7V845B89O#CR?6 M9*`HI%E27V3*>`$$X-,J<]$:H$CZT?V]YH?VO+.]8.F'KD<`;KVPIGW.14K; MRMZ:EI?_(8C(5)B$RB0>L)=QNJ1KG_C!S[,XR*A;X%/:IOMMS:\6=`T\L[FD MH@?)!C+?5H8\^K7>6RJL423Y*K)TN6`5#=3G?1^1K?,.DF82$B,$)J*'&(CD MAA"5`'8]15BX2=&#$GXN_HV1N$EG%*X,1F,(U1')&.'Y/43C"-(-.3[F)L`[ M&Y+W4D3&DV.$1)V4)/#<_JF=WLDP3->N4E(CM9I#2H`-4I[^U!@A`9*B;J"' M$RT&*@)P^II<=_W[]@",3S_Z?S0 MIX=.3URU(JS++"4#0S=G"0.V)LM%T`/64 ML!HW.FL[Z-#F=)K[@01);N%H2!(#$/FJ5W5NLW8$BB_JVA00H]%C"?J\FG>" M.B=AVY/=C`JTH1LW8!BOX-G_W[("%J\+'/)`C\M`>9 MG?80HFLG;'F@W;0II6CF>EU5-TN>0\5':F'(/R] MM`BBP"A](K-(0'B_LL9^,%&Y3_8%8NY8%$%(P1B71`;#[F?,PET.WF)T[8R- M82*_3S8(HKQ`5A9!V/QDY5-O]"H.9RRB%A)"`Y^&:B'($\]0\(BA9/6)):PH M&BOC;^)\A,#Z^F_Q[":&LYONH,/I`W!T'7`25,`( M.TW[[_=>+F$Q81W:ES;`\?&Y]]CWVLNO;WGFO(I*I;)8N6PR=1U1Q#))B\/* M_>O/Y[L'UU&:%PG/9"%6[KM0[M?U;U^69UF]J*,0V@&&0JWSM/")89%-89#[O=I+)YD?,I% MH8FD$AG7H%\=TU)=V/)X#%W.JY=3>1?+O`2*79JE^KTF=9T\7GP[%++BNPSB M?F/W/+YPUP]7]'D:5U+)O9X`G4="KV..O,@#IO4R22$"3+M3B?W*?62++8M< M;[VL$_1W*LZJ\]M11WG^O4J3[VDA(-O@$SJPD_(%H=\2?`6#O:O1S[4#/RLG M$7M^RO0O>?Y#I(>C!KMG$!$&MDC>GX2*(:-`,_%GR!3+#`3`7R=/<6E`1OA; M_?^<)OJX4?DZ1TG7BD](R_X=`K*$B$K\A"4!]\]V?^`\S M-IO?9O%(41W@$]=\O:SDV8%5`W.JDN,:9`M@OD1&.MI8_R]4B!%)'I%EY<)R MAR@4^/.Z#J/9TGN%G,8-9G.-829B>T&@%2"OU0B1=S4.9_TB!<$H!5U`;1MZ M`=RM-K\W[S4B^$^\H00R-%X)@L'ISL3S^U[(&\+<=S$]<3:$H0U(NMK0R0!6 MNCU;.&CE0@+:Y`0/@:E@0YBHMM6?0>F93DW$UD#XS$`8&F&U=S7:M2'8U!:& MWMPT MH.')R6(KQ-2'97R\/BKZ]NK,"&359X.8^K"2=_2-])GJ/\S25K@!GPE$/M\% M`59@0SVP<:A0W#"<0G<'NV`S[]-4.O]UQZ()#Y_]<5`>Q M%5FFG%B>\/+BPRF@?=M>K!Y]/$KWWF_PPH7OO?8#W'=*?A`_>'5("^5D8@^4 MTTD(^Z6B&Q,]:%G6MXZ=U'#3J7\>X68KX*@^G0!X+Z6^/.`$[5UY_2\```#_ M_P,`4$L#!!0`!@`(````(0`!?/R49@0``#@3```9````>&PO=V]R:W-H965T M'IFO>M:JJ`Q;?WZN2\T8:7K%ZZ9.*[#JT+ MMBOKP]+]Y^_GI]1U>)O7N_S$:KIT/RAWOZU^_65Q8?QXDBKG$_8F=9P9L^:*F_AL#EX_-S0?"<752^35:5=B$J_+FY?7\5+#J#"&VY:EL/V10UZF* M^8]#S9I\>P+?[R3*BVML>:"%K\JB89SMVPF$\U"H[GGFS3R(M%KL2G`@TNXT M=+]TOY-Y%A#76RUD@OXMZ87W?CO\R"Z_->7NC[*FD&VHDZC`EK$7@?[8B3_! M8D];_2PK\&?C[.@^?SVU?['+[[0\'%LH=PR.A+'Y[B.CO(",0IA)$(M(!3N! M`/ATJE)L#*5MZSZ#R'IZ!8D MZ(*$H+X['TR"-"9Q\D"4J(L"W]$+)OS`XD1:[Z+17(IT!R*^K::SF8+[PT*473,6F<"E=CH M1!BK2*8CTR2Y,1YXN!F!)/>-C!L0,!AUG9N!)"*WN-+D&AG(R2>C$IN[1#9& M*.I!BKUZ`2]=B'U3EOJ^JFV-S$P6)Y["^2&QZ1-AF.A$AH0Y`XIZ0.S5"UA5 M#Y?"0#TRB53_1,)`Z%>1C8I,9SJ2(0*?MSQ]L7?@\K'7+V!5?^H/]PXRJ#^* M8FCZ0_E]0O0!CP*KZ<#;,/C)CZON$63T2%NJGCZ@7\%#]9TWQ MND4FDGMGF/7K.=..D*NS,4+9\^(.H=);(Q0U!.84/;)E_0P^X.=L>Z@;M/[H=X.-PI"8J(C M68>8TZ!:$*/->O\0'(3]EJ\WS0X:[9HJ$\8F#_B_;#R(\6;O`8=AWX/>.`E" MZ"&8^GI?W"@((:;!U2$V%L2,L[>`$[%O0>^>!*&N#%]X&!NMV(BZ,#8>@'G` M@Z#5JR&<#7LH08:ZE:$+//W@).RKX%0T.]CE/QA#/PMR%X\MIMH\AP M`]HQ-NK%[+-7CY.RK][02A$:+4`?B0S--B-](E`KI*0_>&@D2WK8A(:WH1UT MS;!Q"W6,.2#L(G\.&6Z@[.2K^_C#&=Q_X4'_.#_1G MWAS*FCLGNH<.XT_$RX$&WWS@0W\"\)ZQ]GH@ MWJW&ULE)K;;JLX%(;O1YIW0-PW`9(`B9IN M;OVU\X/';K_JD_"S; MKFK.6U6?::I2GHMF5YT/6_6?OX,'6U6Z/C_O\E-S+K?J6]FIWYY^_^WQM6E_ M=,>R[!50.'=;]=CWE\U\WA7'LLZ[67,IS_#+OFGKO(>O[6'>7=HRWUTOJD]S M0]/,>9U79Y4J;-I[-)K]OBI*KRE>ZO+<4Y&V/.4]E+\[5I=N5*N+>^3JO/WQ MK?KJ*J4A>;^'!NVOSY!/7^I2_S8M2^?A'DZZIHFZ[9]S.0 MF]."BG5>S]=S4'IZW%50`Y)VI2WW6_6[OLET2YT_/5X3]&]5OG8?_E>Z8_,: MMM4NJ\XE9!M\(@X\-\T/@L8[$H*+Y\+5P=6!/UME5^[SEU/_5_,:E=7AV(/= M*Z@1J=AF]^:570$9!9F9L2)*17."`L!?I:Y(TX",Y+^NGZ_5KC]NU84Y6UG: M0@=<>2Z[/JB(I*H4+UW?U/]12!^DJ(@QB,`5@XANS`Q[I:_,"2KFH`*?HXHU M7<4:5*"!CRKFS-*U]<*ZOT+K000^!Q'#G%X4'=RDR26V#HG39_9JM33M":71 M;R9!HD>=NRLUIXY?&Y"7]_G38]N\*M`K0;6[Y*2/ZQL=E,>F0XV^-::OVA(T M(J+RGC1`VQD)^'P@ M&"]YOS$G&H[$*!KQ@9@73?A`.@:^O$LV$J2;0FIO^864,OG]O$N.:20T2>-8 M5F<,O-_8X'(F$HL5BW@B8FL!%8A'A1!*1 ML(P%6^=49#B53"0^%(7Q<#')0T(S'O(!EP]X?,"G@8]NV)K)UC#XC+%8)OR, ML5DFNH.)1<:TUJQ.(C+6@F/2.YA,SC#&+"<90VC&&#[@\@&/#_@T\#X@!7P@ MY`,1'XCY0,('TC'PWAEMC;,MDS-,FN"1QXQ!9(Q?P--(/A:1JX#[,"+8&N>G M0QDHRFW4X%JIBQ(>2O@H$:!$B!(12L0HD:!$BA*9C&!LA2D28ZO<3D)O51CT M;E8M#&ZX<"@CLQ,E/)3P*;&^SA(,F"!JFL8.)0&J$:)$A!(Q2B24H"6UH)A\ M05-4(I,1C)LP967M=2@C-(@",ACD0X$@_(T,<,\FCG:IW@*BF.9%*$=9>L MS#\.P?+>2K99A.[*+2Z=`:+57'U22Y%84D*7?)+AFT$`GBX8B/ M(P&.A#@2X4B,(PF.I`-"6\A":/#9U[^SKI+U_P17Z78!ZZHP&@]["O1IHK6'(SZ.!#@2#LC0JT7G(PR(\9LD.)+B2"9%6%/) M!L8$4^E^!VLJOQ<,!]RDO]+=,F[6[S(_+L5E@3<`$LM]'`EP),21"$=B'$EP M),41\MK`UZ,@]92^%D!/=>NR/91N>3IU2M&\D"-_TG!OT=OK"-^7Y(R1BSOZ M!HY@Q7B@;^#05(P[QL;Y3,L8$3%8C/;S>&MQ`N^:'\(V\/U;E3 M3N4>BJS-R+EX2]]CH%_ZYG(]JWYN>GC_X/KO$=XW*>%,6)L!O&^:?OQ";G![ M@^7I?P```/__`P!02P,$%``&``@````A`+].+QP]`@``#04``!D```!X;"]W M;W)K&ULC)3+CILP%(;WE?H.EO>#@81,$@&CB:*T M([525?6R=HP!*Q@CV[F]?8_M!&64J@V+@/'O[S^WD+^<9(<.7!NA^@(G48P1 M[YFJ1-\4^.>/S=,<(V-I7]%.];S`9V[P2_GQ0WY4>F=:SBT"0F\*W%H[+`DQ MK.62FD@-O(>=6FE)+2QU0\R@.:W\(=F1-(YG1%+1XT!8ZD<8JJX%XVO%]I+W M-D`T[ZB%^$TK!G.E2?8(3E*]VP]/3,D!$%O1"7OV4(PD6[XUO=)TVT'>IV1* MV97M%W=X*9A61M4V`AP)@=[GO"`+`J0RKP1DX,J.-*\+_)HL5U-,RMS7YY?@ M1W/SC$RKCI^TJ+Z(GD.QH4VN`5NE=D[Z5KE7<)CS*+L M.9XD($=;;NQ&."1&;&^LDK^#*+F@`B2]0.!^@21IE,ZS))O]GT)"1#[!-;6T MS+4Z(A@:\#0#=2.8+('L,IM`??Z>&:3DSKRZ0_XHJ`UTXU#.TS@G!R@ANVA6 M]YIT5!`P'R,`U]L(_NWLQ!`A1J/S;)J,7!_=*FBFMYI1\-W7B&]-L1`;3L!U,IUEV[QDF.C1\H`W_ M2G4C>H,Z7D,!X^@9QD^'>0X+JP;?V*VR,(?^L87/#H>NQQ&(:Z7L=>'^,>.' MK/P#``#__P,`4$L#!!0`!@`(````(0#Q\W&@[0(``/`'```9````>&PO=V]R M:W-H965TB9"LEX'6'7;]N_6!BR=94*H0,-0RPH52SY[L M*UHK0R)H213HEP5K9,=6)=?0540\[9N;A%<-4.Q8R=1K2XI1E:P>\YH+LBNA M[A=W1I*.NUV MK%M_?C)ZD(/_2!;\\%&P]#.K*9@-;=(-V''^I*&/J7X$R?99]D/;@*\"I30C M^U)]XX=/E.6%@FX'4)"N:Y6^WE.9@*%`8WF!9DIX"0+@BBJF=P880E[:^X&E MJHBP'UK!W/%=@*,=E>J!:4J,DKU4O/IE0.Z1RI!X1Q*X'TG8O`#<*_:[%-7:U-]T21S5KP`X*M!\IE0_1&=E?`W/ECJND=>\LP M<$J3W&F6",.9`2\D-/EYL_#ND:+"6HGNIM6W-@^%[O;&R^!SA!SUDI`0W\N-+B)$V(!EJTYWTX;Q<=DLG11@,Z)NR\/RQ@JW!N$[;U[GES9;#7_#A M9E)4;!+@VI.>BAI)AB,TE'Q9J@9/IJJZ4$[_M!_X=UX[L_L`#-R&Y/0+$3FK)2II M!JF.-0?;A1G99J%XTPZL'5&PO=V]R:W-H965T MVE_>O16Z]4"$9+R/;=SS;HF7,$U;N M(OO/[Z>[F6U)1>#B66:4*@L<2AG9F5+5PG5EG-&" M2(=7M(1(RD5!%#R*G2LK04EB!A6Y&WC>Q"T(*VUT6(@A'CQ-64P?>;PO:*G0 M1-"<*."7&:ODT:V(A]@51#SOJ[N8%Q58;%G.U)LQM:TB7GS;E5R0;0YYO_HA MB8_>YJ%G7[!8<,E3Y8"=BZ#]G.?NW`6GU3)AD($NNR5H&MD/_F+C![:[6IH" M_67T(!N_+9GQPQ?!DN^LI%!M6">]`EO.G[7T6Z+_@L%N;_2368&?PDIH2O:Y M^L4/7RG;90J6>PP9Z<06R=LCE3%4%&R<8*R=8IX#`'Q:!=.M`14AK^;[P!*5 M1?9HXHRGWL@'N;6E4CTQ;6E;\5XJ7OQ#D5];H4E0FXR`OHX'3C`;^^/)^RXN M$ID$'XDBJZ7@!PNZ!N:4%=$]Z"_`66<67LT,4M)C'O0@,Q34$I;C934+IDOW M!4H8UYIU7Q.T%9N^8C0^25S@.T%"ZDW(RV4_PFDQ%-BV&G"=J=>H"1N:R6EF MD^+FEJ+%!A,-9]/BR`Y,R0+/#]N3KC$\-^'0\[QV>(/AR]0M)I`,9]+B!M-Y M"4PAUAB>7&/",'R>JGVN9(L)FFHXDQ8WF,Z6R(3AJTP8'L`T^0B3%C>8NOV. MX:M,&![`-/T(DQ9KIG/UPUY3H0;!_'Y387@`F#[,.CO%"';2VR^C'M0&G`6S M=ENO45,#3ON$&!]`.&\3WB;3XC99Z'=['S5(=C?JDV%\`)D/A6H6[S::47?9 MNN]`+:K+=F&WJ`5#Z#J'P#MTN&^WFZ[[-O@H0KH+E:OCH=E6SOM<:\>`$[U5 M-'TVO=]Q9E2[>+-@WFFY6H0[K7_AK6@)NGQX3\!CM"([^H.('2NEE=,4$#UG M"AN0P%L"/BA>F>-RRQ6<[N9G!KIYX`XY5P='_0]Y'0_7/T'``#__P,` M4$L#!!0`!@`(````(0"F,S5XQ3(``$3E`0`9````>&PO=V]R:W-H965TA[\@L'&8/P"?,ND MZ>[4[H2N)#,]\^_/,I(O'CY_>/SUX^???WZ]7HW_,7C]ZNNW]Y]_??_GX^>'GU__ M]^'KZ__YY?_^GY_^?OSROU__>'CX]DH)G[_^_/J/;]_^.GG[]NN'/QX^O?_Z MYO&OA\_ZE]\>OWQZ_TW_\\OO;[_^]>7A_:]//_3IS[?=@X/CMY_>?_S\.DLX M^>)D//[VV\'/]]^T_5__^/C7UR+MTP'QTU^*^.?'/S]^^^]3Z.M7GSZ<3'___/CE_3__U._]G\[A^P]%]M/_ MJ,5_^OCAR^/7Q]^^O5'PO_KR\-O/KT/G M)*X/CU^__>6GIT=H\_'A[Z^EO[_Z^L?CWY,O'W^=??S\H(=;.VJW"_[Y^/B_ M.W3ZZVZ1?OAM[:?'3[O@ZLNK7Q]^>_^O/[\M'_\^>_CX^Q_?M+^/]"OM?K.3 M7_\[?/CZ00^I8MYTCW9)'Q[_U`;HOU]]^K@[-O20O/_/TY]_?_SUVQ\_O^X= MOSGJ'_0ZPE_]\^'KM_''7>3K5Q_^]?7;XZ=M!G7RJ"RDFX?HSSRD<_1F<'1T M>#SH^RF]/$5_%BG=-]W!4>?H^`7;4@[.BJS@V1W M>.8'P,'+=W!G?["5#I3.#^041TJG=*CH^'[IH=(ICI7=7XK?Z^6/3G&L=$H' M2_?%#G6*@Z53VN$_\N`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`4#L$0^T8#/N# M+^L-IOX_X8^OYXU'[9F!]6E:,Q/5_% M_+"J0.G.C_LCK;2Z6M+^X"M!M:3:\1CWQV/;C^6'Z/>#-N;'8_MVYX=H&4IW M9'[,EI+S8[;\0_7'-C^,RU":7#Z;OM73[_XY6+6I\ASY9UIG^<,#=U)CDJ5G6BE^RH=1T9'":[85-G M^OV$V38QR8%\FS%E$=/-N:LC_6YR'-\;3`AU:'"8!(58A](-"KFAY8VN_?(A M5[0,U=>6.UJ&:FO+'2TS@UZRWT,N:1FJ!>62EIG^<7)`A]S2,C0X3-P)>TT/ M\Y/802IRR#WM]`JD=IX+N:;E5=5.&F'OZ?,YN:CM.;FI9:AV4(=U`M4>ZUS6[[]^[406[Z+A;.EUVCUI,+:$E1/:O"VGE3S M]N`HW26-WJ90@[OG25B(6X)JJ^M0=W:VIK, M+3W15EJGACV5UKF;_/0THVIOG[N?JK3/;,&N7Q6%]#1EANF"4;I@G"Z8I`O. MT@73=,%YMJ"\)16SZ^`P>7*Y,YC[)B8]3P<'B@Z4'Q_5S4Y>(H3\F&F'\N.H'FEOEIT=L4:O"VWT^A!F_K4(.W=:C)VZ/D]55L M]#:%&KP='"4OYV*#N'6HP=PZU*#NH%;I&MRM0PWREJ%*[=$[12JUI[WN[.A* MWMTP29=L$T7W&8+OD]F[](%]^F"$&I+8FU)O@._YX9\ M#Y:6Y+NPM"3?AZ4E^4XL+S[6]GRL[?E8V_.QMN=C;<_'VIZ/^SU?&KG7GBOW M!T/QRBGN]_Q^R7XW?P^J%=.XW_-MT/Y@:(-JQT>L'1^Q=GS$VO$1:\='K!T? ML79\Z!W13Z?;IWU?.6GK#2$O.&GO:+V6+>MSE!39F#%:W_[Z(K$$(D1 M$F,D)DB<(3%%XAR)"R1F2,R1N$1B@<05$M=(+)&X06*%Q!J)#1);)&Z1N$/B M'HD0&&'K`FL7V+O`X@4V+[!Z@=T++%]@^P+K%]B_P`(&-C"P@H$=#"QA8`L# M:QC8P\`B!C8QL(J!70PL8V`;(]L8V<;(-D:V,;*-D6V,;&-D&R/;&-G&R#9& MMC&RC9%MC&QC9!LCVQC9QL@V1K8QMMI8Z85Z@V^E%WK7,'8_]?-K79;?=[_! M<3);BQG3U@^1&&;$\=,5[<[!TW^J%^-&2(R1F)2)WKO^07^0--FS,G'8L!G3 M,G#GG3!Y*T7,F);3 MUBD20R1&2(R1F"!QAL0T(_K9A[G>9$UI_]_=T3^2*YKGF'B!Q`R).1*72"R0 MN$+B&HDE$C=(K)!8([%!8HO$+1)W2-PC$0(C[&!@"0-;&%C#P!X&%C&PB2%7 ML>7$$]B^P/H%]B^P@($-#*Q@8`<#2QC8PL`:!O8PL(B!30RL8F`7`\L8V,;( M-D:V,;*-D6V,;&-D&R/;&-G&R#9&MC&RC9%MC&QC9!LCVQC9QL@V1K8QLHV1 M;8RM-E9:HCX>^H*6N*/3EIB\439F3,O)^A2)(1(C),9(3)`X0V*:$>^>6F)] M+GB.`1=(S)"8(W&)Q`*)*R2ND5@B<8/$"HDU$ALDMDC<(G&'Q#T2(3#"R@5V M+K!T@:T+K%U@[P*+%W+S6LXS@>T+K%]@_P(+&-C`P`H&=C"PA($M#*QA8`\# MBQC8Q,`J!G8QL(R!;8QL8V0;(]L8V<;(-D:V,;*-D6V,;&-D&R/;&-G&R#9& MMC&RC9%MC&QC9!LCVQC9QMAJ8Z44ZF9:+RB%.SHMAKN(GE[XW M&+%%XA:).R3ND0B!$98NL'6!M0OL76#Q`IL76+W`[@66+[!]@?4+[%]@`0,; M&%C!P`X&EC"PA8$U#+F'+<\&@4T,K&)@%P/+&-C&R#9&MC&RC9%MC&QC9!LC MVQC9QL@V1K8QLHV1;8QL8V0;(]L8V<;(-L;_54KA[F[G+VB%3WA2"Y,/;\><:3D1G#(R9&3$R)B1"2-GC$P9.6?D M@I$9(W-&+AE9,'+%R#4C2T9N&%DQLF9DP\B6D5M&[ABY9T0W%-WI^_/K%M=T M/U%F#"%U/U'.,90,AI.ZPRBOR[!2MQSE',-+W8.4[ARNLR/-4=7#G'\#0:GNJ.KKRNPM.6\[-N\U%-&AHR,&!DS,F'D M+$>R"\[)&S2G_//GC%PP,F-DSL@E(PM&KABY9F3)R`TC*T;6C&P8V3)RR\@= M(_>,J%JB9:J6S!@JJEIRCB&CJB7G&#J&PL>6,XRJ):_+\%+5DG,,,U4M.<=P M4]4RR\G>(GWPYB`Y':E7\HH,-]4K.<>P4[V2B6ORU!4O9)S#$G5 M*S%'O9(90U+U2LXQ)%6OY!Q#4O5*SC$DU5<#<(XA:30D5:_D=1F2QD+2EA.4 M>B6OR_!4O9)S#$_5*SFGW=-JK]S=@#S]CI^^[M;1_HF83G;?\NK'I-,[^>50 MRZ-[RLB0D1$C8T8FC)PQ,F7DG)$+1F:,S!FY9&3!R!4CUXPL&;EA9,7(FI$- M(UM&;AFY8^2>$=7,3,@6UU0SF3&$5,WD'$-)U4S.,:14S>0<0TM]9Q+G&&(& MPTS53%Z7X:9J9CUGD'X5BKIFG4KN`Q$,0=4U.<=05%V3*JNR3GMGE:[YNX&\.6N"1TSNU^\-J%T*Y[DM!4[ M&=3RO'?*R)"1$2-C1B:,G#$R9>27"=/OVXE=C*HW#$'Z9>Y MG39`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`PS@Z%F M,-P,A9R95OWC[G'R"C44;E;$JQXZH2IG[]WQH'O4>Y=`AIVAT+/EJ`B&GL'P M,QB"AL+0MNTI%&UC#$=#(6E;SM(X?`I+VW(*1]L8P]!@*!H,1X,A:3`L#86F MV<':>!*+AJ;1T#0:FD9#TVAH&@M-6_97K(J:O^NMZF`L1&W+,3R-AJ?1\#06 MGF;[*_NJP_19)Q:BYF>@0>?I_Y+?S#`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`P9&3$R M9F3"R%D#TG^7C'&G#5!R9>F\`:GE7#1`2R`:GE+!SHJ@%* M5G;-R+(!J6W/30.4K&K%R)J1#2-;1FX9N6/DGA$U3O1.C9,90TY=.^<<0T]= M.^<<0U!=.^><)D%K1Y<&F_6D.F5(JM993TH.5+U)DYDF2].<)DE3QG!4U\]Y M>YHL3==E2*K6R>LR-%7KY!Q#5+5.SC%45>O$'+5.9@Q7U3KK.;6C5;W3H9I\ MK6E!S=FG,R8UBK.2?G&-:J?W*.8:WZ M)^<8UJI_MN54^^?NONXOF'-FMX$OSSF/!^EK$5U_WY54;<-^&)KLP5-&AHR, M&!DS,F'DC)$I(^>,7#`R8V3.R"4C"T:N&+EF9,G(#2,K1M:,;!C9,G++R!TC M]XRHJ;S!B>JF]RCN&IKJ1S MCN&IAIR<8WBJ*^F<8WBJ*^E9SNX=@/_^Y;!SG'Y,4/V2",-133=Y>PU'-=WD MG,+1YW\GPU!U2UY38>CS:VKWL]HL=W=H?T&SS&[H7FZ6^OA4]4TKL=MVU_?\ M"CHB0TX9,3)F9,+(&2-31LX9N6!DEB.=@R=Y#MX<).^HFG/&)2,+1JX8N69D MR<@-(RM&UHQL&-GFR+,/_RUGW#%RSXA:)4JD5LG,J<$8-NK:.:_+\%'7SCG' M,%+7SCG'<%(?->>Z=LXYAJ>:7G*.X:DFEYQ3 M>/KLJ5FM,DMYGC`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`R&$H&P\E@2!D,*X.A93"\#(:8P3`S&&H&P\U@R!D,.X.A9S#\#(:@ MP3`T&(H&P]%02-KR!!,,28-A:3`T#8:GT?`T&IY&P]-H>!H-3Z/A:30\C8:G MT?`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`R&&(&P\Q@J!D,-X,A9S#L#(:>P?`S&((&P]!@*!H, M1X,A:3`L#8:FP?`T&I[&PM.6Y\UH>!H-3Z/A:30\C8:GT?`T&IY&P]-H>!H- M3Z/A:30\C8:GT?`T&IY&P]-H>!H-3V.[I]6&N;N_>WF."0TSNQU\=7Z9?HOD M(=XS_I21(2,C1L:,3!@Y8V3*R#DC%XS,&)DS6R>LR3%7+Q!RU3&8,3]4R.4D2$C(T;&C$P8.6-DRL@Y(Q>,S!B9,W+)R(*1*T:N&5DRAGL[K:9/-D:/JI@\JH*([-5I6LQ M9-0`D]=BZ*@!)N<80FJ`R3F&DAI@<4AK8\.:M:JEIR MCN&IJB7G&)ZJ6G*.X:FJ)><8GJI:8WALQ#[.[ MP6M3]A\,'+Q+GDIB#K4,#!D9,3)F9,+(&2-31LX9N6!DQLB26D3M&[AE1Q<2O9U#%S)CL'IN=-P?OJO\9_2.Y M]YA&FIQJ^*D+Y^4U#]X4'VW*_^R._I%\5Y@&G+QF0U@-.#G'4%8#3LXQI-6` MDW,,;37@Y!Q#7`TX.<=05P-.SC'DU8"3#D'$-@74;G'$-A74;''+50 M9@J'6YY3=1F=<:L[).8:GFG-RCN&IYIR<8WBJ.2?G&)YJ MSLDYAJ>:!H-3]4PV]95;9B[F[FG<\YC?3X(FF9V#_CJG#,9 MD\3#MAO%9Q\X9V3(R(B1,2,31LX8F3)RSL@%(S-&YHQ<,K)@Y(J1:T:6C-PP MLF)DS+9G)5 M+![B7>1/&1DR,F)DS,B$D3-&IHR<,W+!R(R1.2.7C"P8N6+DFI$E(S>,K!A9 M,[)A9,O(;8[`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`P;\]/GXK_H>$>OOWXY?_??+QE_\G`````/__ M`P!02P,$%``&``@````A`!EAE?-4`P``5@L``!D```!X;"]W;W)K&ULG%;;;IM`$'VOU']`O,>`[UC&4=(H;:56JJI>GM>PF%6` M1;OK./G[SNQ@C/&EMOU@&_O,F7-FAV'F]V]%[KQRI84L(S?H^:[#RU@FHEQ% M[N]?SW=3U]&&E0G+9P43I4L,,W4)ATQ3$?,G&:\+7AHB M43QG!O3K3%1ZRU;$E]`53+VLJ[M8%A50+$4NS+LE=9TBGGU=E5*Q90Z^WX(A MB[?<]N*`OA"QDEJFI@=T'@D]]!QZH0=,BWDBP`&6W5$\C=R'8/88C%UO,;<% M^B/X1K>^.SJ3F\]*)-]$R:':<$YX`DLI7Q#Z-<&?(-@[B'ZV)_!#.0E/V3HW M/^7F"Q>KS,!QC\`1&ILE[T])U]K(XB^!@IJ*2/HU"7S6),&X-^R/)M,+6#Q2 M9`T^,<,6#UE%3PBR0.R1"ZT.X1K.)_7 MQ30"AGZ\T!NV78!KN')("PHQM!_1'/KX:C7LU&-^B`(.Z"B8-/RD@ MS-`J.)%[^_AC451!V%!#FK/OPEMP8 MM)\[;)TL59XP]=G[D]/N`VBUZ^W;J*Z&W00A#37H$A$XCJX^@X"&6'L.A/YN MOM0B"!3:'MPIW.O_`,?4]>EIN.VG'W1ZP%)'+J4_<0L$G>&W'?OG.]!&=8_@ M8,S3'#SO_L@(_/\`"FB^[;OOSL`:=-[]3?,/'_@'-T%W`-:@\^YO&GZPWQRF M[TZ_&G0\/:TW]/0ON%KQ3SS/M1/+-:XN`;1K\VNS5CWT[6+4_`%;3<56_#M3 M*U%J)^&PO=V]R M:W-H965T?W[55D&D+B.L,EJTEL/A%A7F\^?UJ?&+\7!2'2`(9:Q&8A9;.R M;9$6I,+"8@VI829GO,(2;OG!%@TG.&L75:7M.DY@5YC6IF98\?=PL#RG*4E8 M>JQ(+34))R66H%\4M!$]6Y6^AZ["_/[87*6L:H!B3TLJGUI2TZC2U=VA9ASO M2_#]B#R<]MSMS1E]15/.!,NE!72V%GKN>6DO;6#:K#,*#E3L!B=Y;-Z@51*: M]F;=YO.7DI,8_39$P4Y?.I>I(5ALGZV^;0OPDQL9 MR?&QE+_8Z1NAAT)"M7TPI'RMLJ>$B!0"!1K+]153RDH0`-]&1=7.@$#P8WL] MT4P6L;D(+#]T%@C@QIX(>4L5I6FD1R%9]4^#4$>E2=R.!*X="0HL-_*1'WR` M9=&QP+5G\2W/],N MIICD'!/Y[H"9"(;:CP6KG+V+N[D7KA9!/48ZHZ4_\+<);34&2C=X"::(W9N( MY#7$Q`4\9NSB]=@5.#8AHT&9-TI'J]>8L?JELYSI?P M5*SC&A@P:>B0=( M_?T>%'CN8;8+MAJ#G';?NU;H3#[HR]5LP6ZR(+2\Y>03GBU()@L<"UUP%GS$ MF0)/G;G1,Z^NCL9TSF:1[UZ;3"Y,3@H1?D2N`D_E>O[L]-AJ3"<705L8-D!K M9S>9=RT430KU_.*V:.AMZHE]60WWLF MH7^U/POXNT+@W'0L`.>,R?X&'FP/?X`V_P$``/__`P!02P,$%``&``@````A M`,'2VE&ULG-S9 M;N+*%@;@^R.==T#<-V`SF*`D6PV>\,!@!L,E39P$[1!'0$]O?ZI<=J"6'?]P M]I8ZZ<7'LEVNY;&Z[O_YLW^K_(H.QUW\_E!5:HUJ)7K?QD^[]Y>'ZF)N?NM6 M*\?3YOUI\Q:_1P_5O]&Q^L_C?_]S_SL^_'M\C:)3A65X/SY47T^GCUZ]?MR^ M1OO-L19_1._LD^?XL-^MN/_!4OS8 MO>U.?Y.DU'S8\WMMU_E-9FF^5._I)+O]]M#_$Q?C[56+JZ6-'\ M-M_5[^HLT^/]TXYM`6_VRB%Z?JA^5WIKM5FM/]XG#;3<1;^/%[]7CJ_Q;^NP M>_)V[Q%K;;:?^![X$WD] ML=W=9EO$-ZSW]%>/CEO6HBQ-36WS3-OXC:T`^[.RW_&NP5ID\R?Y^7OW='I] MJ#8[M;;6:"J,5WY$QY.YXRFKE>W/XRG>AP(I:2J11$V3M-C:IY^W:RVUK75O MR<*6EZP*^YEE46M*J]&Y84TZ:0[V\YSCULW1TB3L9Y9$J77;[5:GJUW?**S" MDLVY.V=1:VJWK;1OV2"%]0BQ@WC72!N7[]>4\KV:[FOYS3 MW+XZS6RS+OI,IZ8IC;OF#6W,>[IHG8M.T[I]J[)NHYX;1]5N;V0U:QW^2]HZ MS>M[##M.B*WAOV2-V_D_5H.U:=(JO'#2/&KCZAY<%X>(Y(BC;TZ;Q_M#_+O" M#N.L<8X?&WY24'H\=7:L$4>&SZ//5P5__Q8YRV]3TA6%_GHVJR&908#HMV>@%AN8QA)'7A^0Q,\,/H'PC+!JPL\!Y MC5*7!CP:\+,<7RYEE(EL*6,:F-#`5`3.ZQ%DXLNES#*1 M+65.`PL:6-)`*`+LS_,^IOMOE7WI;$BKKC/!UJ3.^NEG9V45*'76XA-BUB>Y MYGTRVYY^%C@O6.NTY1:X.#'3>EH4&5(KR\QDQY"0!E8TL+X( M2/V`70K?T`^X9G?9%P>$3HN<^/K"L.5]7AJ1;CJ`0H?"@,*$PH+"AF((A0.% M"X4'A0_%"(HQ%!,HIE`$4,R@F$.Q@&()10C%"HIUF9`*D=W&WU"(7#]4V67, MN<@T MG-Y0AUS+=:CEZE"8LCJ$0A>"/5#E=^N-6H/4N@$SF%!84-A0#*%PH'"A\(3X MLC5\F&$$Q1B*"113*`(AOMR2&?PUS#[[ M<@T<*-Q,%&^DEWW\Y2)\*$90C*&80#&%(H!BEHGBQIAG'W_9&`LHEE"$4*PR M4;R:Z^SCHM64RHZ=,.6ZXR\FFRQ8?MI+OD8+D%1'/T5E%8B)CHF!B8F)A8F- MR1`3!Q,7$P\3'Y,1)F-,)IA,4\)^B"[;3NX)^5V?^(]S&E'.</KW1NN3$TD]1:?&*/"5$QUD,3$Q,+$SL M3Y)T0/D\/4P_[%P\X9&%\_GUHF-J,K#!Q<3#Q,=DA,D8DTE*Q#8K21G*VSS% M20),9IC,,5E@LL0DQ&2%R;J4R*7)7_5>EN:5YU?QAOBR1-4&>8_1Y^/(V%5P M2?T-,-$Q,3`Q,;$PL5.2]DA-G!GD/CF\PCAX42XF'B8^)J.4I$>6I,SD+1KC M)!,IB=(5_\MIICA-@,D,DSDF"TR6F(28K#!9EQ*Y6/D+[,MB!1?!XGWW99%J M7?*NM*\(5%JDD.@XBX&)B8F%B8W)$!,'$Q<3#Q,?DQ$F8TPF*1&%WFIU.KS6 M:8W"71W@) M2'29LFN+8L>UAAX228F M%B8V)D-,'$Q<3#Q,?$Q&F(PQF6`RQ23`9)82T1LZ7?%VAQ8I[%0+O*0E)B$F M*TS6I40N4C[,X88B%:,BY"(E0^KZ2MG0B;1((=%Q%@,3$Q,+$SLEV0&C\&94 M;%%*U(+;)0T:YF0IQMR@?(!$9<%>N53(S&. M0BY4.KQ/*1MLD18J)#K.8F!B8F)A8J=$5*'25/EX=_E0/I2)=I;![ M1WIK/T5E#W8QT3$Q,#$QL3"Q4Y)V(O:XC]0G3N%@XF+B8>)C,L)DC,D$DRDF M04K2IKTK.&//9-(I.$#.\8(6F"PQ"3%98;(N)7)]WC;8B$\+0U^\W-&1@BDJ MK4\\V`AG,3`Q,;$PL3$98N)@XF+B8>)C,L)DC,D$DRDF04I$B:J:UFZ1X6LS M22BMKD;_G?`<+V:!R1*3$),5)NM2(A@(ES=GGDS*1]R[: M'1GJ,+@&Z=<@XQID7H.L:Y!=@,A3[2$F#B8N)AXF/B8C3,:83#"98A)@,L-D MCLD"DR4F(28K3-:E1"Y7/B3D]EM3/L]9KFSI@(84E9Y7X8@4'64!$KWSA!CEX.2XF'B8^)B-,QIA,,)EB$F`RPV2.R0*3)28A)BM, M^`RC]-1V/OB+2A4SB(KY_/;1X24:1&]OQ\HV_LEG!V6/B1_O/\-BZE)/[;%9 M7]C\*"1NJCTVZTP^;JD]-OE,/FZK/38'33X^5'ML*II\W%%[;$::?-Q5>VQ: MFGR<3;'ZO2AN*#TV35_>VTJ/S<67C_M*C\V-EX\'2H]-7I>/K]C4KD7QOMKK M%ZW/0.VQ*7[R>72UQ^;YR<<-M<>F^V'Q^N<.8#.W?FQ>(G]S>-F]'RMOT3/; M=XT:GS'S(.9^%7\YQ1_)=(T_XA.;LS7Y]97-T1NQ208;-8:?X_B4_84OX'/6 MW\?_`0``__\#`%!+`P04``8`"````"$`!DAJ+&\#``"5#```&0```'AL+W=O M69/7$^5J6GDT?)Y M7U"&=AG,^\V=H>CD7;WT[',2,V&#TV85$YB!3+O!<+(V M']SEUO5,>[.J$O2'X"-O?3=X2H]?&(F_D0)#MJ%.L@([2E^D]#F6?X)@NQ?] M5%7@!S-BG*!#)G[2XU=,]JF`#8I7ILP\89M-N^@*`<:ZH/;]4P(#:S^P^@_Q%`&=0%[*0G5)H&\/SSU4[:JN$1@,%' M`&50%W"AIRA4F@:PNTG5\`A`>6*V&LGPCI#B#ICO=,"49E95]KP+5=I.8U?K MNKB%2HJ[5)U\A$IS.1^*;4BA;0K(^0TIJ]37ND@M&L(;E.A\G;-AN*2N:N># MG:36J)KV6XD^[)]7JHXEN_3HE>:JGM[&"OQ.WP]KT6#:E,]EBCA5` M,%/72O4B:%E=0W94P'6P^IK"]1_#M&ULE)9=;YLP%(;O)^T_(.X+&$)(HI"JH>I6:9.F:1_7#ABP"AC9 M3M/^^QW;"0%GZYJ;-OB\?O.<,\$RXHZU(7>8'KD"YG!>VJU/WY MX^%FX3I"XJ[`#>M(ZKX2X=YN/GY8'QA_$C4AT@&'3J1N+66_\GV1UZ3%PF,] MZ2!2,MYB"8^\\D7/"2[TIK;QPR"8^RVFG6L<5OP]'JPL:4[N6;YO22>-"2<- MEL`O:MJ+DUN;O\>NQ?QIW]_DK.W!8D<;*E^UJ>NT^>JQZAC'NP;R?D$SG)^\ M]<.%?4MSS@0KI0=VO@&]S'GI+WUPVJP+"AFHLCN-_([^SP MF="JEM#N&#)2B:V*UWLB/Y_%]\0Z03O ML<2;-6<'!TX-?*?HL3J#:`7.*K,(ZO/WS"`EM>=.;=);02V@'<^;)([6_C.4 M,#]JMD8#;\"@":>*[%(1Q8/$![X!$E*_'E)MFD)&L\%>Y[$UDH4NLTHL&RU, M`*`RUP.H35#-4062V"8PFME(,Y\R9F\I)HQ@,F9\NX-*G+J0[M"=Z(+-:):Z MOXO9TN(:1Q$*DR$\@8+C_7XH);:ASB?"M,QH9@;J_*4ZF/TC."&:7T.DQ#:1 MU:"MT1BB,%D,=3!(XR@:E7C"E%S#I,0VDU6(K=$1>>G0+$!6I:;Q^>A&,V1FA)D;OB6\(AEI&N'D;*_&4PBO MS;!J1N<6K>`:A)%EK6&PO=V]R:W-H965T7>U1(Y4I,U) MS5L:HVX/L+KR&L1<9A+=[BP8N"9?269_N&MLJ8"%H3!?RR8IT\N379 M6^P:(A[VW57&FPXL=JQFZKDW14Z3K>_+E@NRJR'N)SPGV)TND;?=]/GYS>A!CKX[LN*'SX+E M7UE+(=E0)EV`'>*M[\,2)\M#(FP=%D!O3']<`-EB$.%_]W\0Q1'^`M462[$?S@0-/` M,V5'=`OB-3CKR&:0'\,QQ/I:J!"C-KG1+C&";H?M$LKSN(WP;.,]0DZSHR8Y MUV!;D9X4NA2`-S!"Y&/&?V?]A*+%&D570;,EY@9X#VS!Y+GGBEDX2"P2R-#; M2;08LCEZ<(3G@Z^!,YKY2+.P%>DEA<4&)F.V4R4O9TMOBA$DX"4YT=(F2(PF MZLLZ=Z.5]5E\NIH4.AWKEV[H6Q]+;_'#FS#FO\RMQ5/NU83;:+#?@V,76QP^ M/@>?;`C'"@MU\1Y4+9Z@+B>=GQC-$=6WXTA?6;2(HO<0:?&4:/).)$9S))HL MIM8B=NH@'T###W>%\N0GT2)G<3^#T-RS`W.](2;\14;)6 M.C4MP-)W(V@N84X.&PO=V]R:W-H M965T[F6T)B.J#C!6?U0D3N>ZX9.@6EI:X4%OT:#[78T)0E+ MCP4II1;A),<2_(L#K42K5J37R!68/Q^KNY05%4AL:4[E6RUJ6T6Z>-J7C.-M M#KE?48#35KN^&,@7-.5,L)V<@)RCC0XSSYVY`TKK948A@2J[Q0D+GY;XL!.7SC-OM&20+5AG-0(;!E[5NA3IF[!P\[@Z<=Z!'YP M*R,[?,SE3W;Z2NC^(&&XIY!(!5MD;PD1*5049";>5"FE+`<#<+0*JJ8&5`2_ MUN<3S>1A9?OA9!JY/@+--H M=HN*WZC`N57Q;K82-")P/HMXLRF:AA\'5"E"H6EOHQD8K:Z2/2+^D$C&",,]O.9Z]PI>V5";L[.@9UXC M\WJ2(,\/?-A679.)#0:%OC<;,(EFX'A^5:=B!(#%?GT`!?<"]&J[T4A8![A# MR`O0P%QL,"&:`]'+F&CD"O_A+?X5;/KWHZXL]:+::$3[1U$0#*S%EX07^`,@ MN02,]$;A(].XVEI\^`J,KU;UD!D@Z`?02!,@<`T#=<38($)_&#'1Q!755]W$ MQ?XX;E[!IOD(]=UKIG'ON;.AN5@C[YO3&^,888S!_!;["N[;G_5FCV:T?0^^ M/H/)$6MBS/T88;B']N*&ZM=TW_^\Y[^!]/[C3=7FTUN9<8.,)1A%=`3=U^AO M;4'XGL0DSX65LJ/J61!L']W=KI]Z\.J.J/L#VID*[\EWS/>T%%9.=O"H.XE@ M[^"Z(=(7DE7UEWS+)#0R]<\#-*X$OJ'N!.`=8[*]4"U7UPJO_P$``/__`P!0 M2P,$%``&``@````A`+9+P`+-!```SA0``!D```!X;"]W;W)K&ULE)A=;ZLX$(;O5]K_@+@_`4,2FBC)40ET]TAGI=5J/ZX)<1)4 MP!'0IOWW.\,0BDUJI^W(K=>>55GHES;;.+:%B]3L<_* MX]K^Y^^G;P^V53=)N4]R4?*U_>$L'%#:K/89.,"P6Q4_ MK.U'MHS9PG8VJS9`_V;\4@_^MNJ3N/Q69?N?6VO\OV;XYK6U_/ID%KL\`MW:\;IXRE+2M]*5N1/$?0:R3(A&O M$_%A]-W]V63JS8*'KZA,.Q5X[U7%FW@/,S:;F\?BD*\V3%'2))M5)2X6U!Z, MO#XG6,EL"TMQI.9:/PN126^$E@88+/W"GD8>KU=`U=+"*,EK`GT&-(%>?R^/+;M MF)G*1#0F%'_QF/!GO8CD!^KI?C\(0_5*X5<&%Q(#A=:G:-Z_N0W"UDA$1B+6 M$9(_&,C0']:F#RN`/F_XT-J&(/8>`N\C?I1*8N9MH<[<]I_BDPCX[%642$1& M(M81DD^8=U_WB0^I/I4QAL0PMS4**YQBDF[K3!J)6$=()N>R27T2$5;-!?+H M0V(TH]\:B1 MD8AUA.0.NZ'!)J'/'<*RN\![4')'S'#T@;>0F>V84E\V&;4-TL[A*TMFV$$T+_V;6T>':%(> MF9%8B\ANL6%0W)JW249MANQ6:6?"#B*WGHM;I9I:DM&:-2)Q]Y[;*K)9;!X4 ML^:)RJCED,VJS4\'#0<1##HO6G9O0,I\CLQ(K$5DOS`\=R<6GU"FKC#-D M!`W]*LC6C$0=[UR#J0V1"UC=5!E!L];JU)_.1UX)T!B).@T- M$FL1V2LV&`.OAGQ2.R)[5)J"D.EZEFZ*&I'(K!)K$=DE-AGWNZ26!!:D_I=% MX(V6(EW?TKDT(A$S(K$6D5UBEW&_2^I)AKD1;GN>UE8H7/!KR8$+U5_MCJT9^%U MI[\!ITGGY,C_2*IC5M96S@\@Z4X"6'&ULE%7;;J,P$'U?:?_! M\GLQEQ":**1JMNINI:VT6NWEV3$&K&",;.?2O]\Q3DC29JN4!\!P?,ZUD@S9<&Z':'$=!B!%OF2I$6^7X]Z_'FUN,C*5M01O5\AR_<(/OYI\_S;9* MKTS-N47`T)HA3X1[! M9O)F]V-?@!\:%;RDZ\;^5-MO7%2UA6JG8,CYFA8O#]PP2"C0!''JF)AJ(``X M(RE<9T!"Z*Z_;D5AZQPGXR#-PB0".%IR8Q^%H\2(K8U5\J\'17LJ3Q+O2>"Z M)XG28!2GV>T5+,1'U!M\H);.9UIM$30-:)J.NA:,IL!\<.;C&+S^SRIX="3W MCB7'T.W@PD!Y-O-L%,[(!G+*]IB%Q\#YB(FC`4,@GB$H".0TJ,MI/F@[L--V M:7?!+/R#AV!QUP1`73>:03O*SOPN?`%SI*,5?Z:Z$JU!#2]A:QADD&WM)Y%?6-7U7_-2 M69@@_6T-/PP.7T08`+A4RAX6;M8-OZ#Y/P```/__`P!02P,$%``&``@````A M``@JY`3Q`@``\`@``!D```!X;"]W;W)K&ULE%9= M;YLP%'V?M/^`_%Z^(21*4K6JNE7:I&G:Q[,#)E@%C&RW:?_]KGTI";1+Z4L" MX?B<>XXOUUE?/C6U\\BDXJ+=D,#UBLHJ1>V)I]#UU!Y M_]!=Y*+I@&+':ZZ?+2EQFGQUMV^%I+L:?#\%,-NU#>@/9P=UK;^T._)!.P4KZ4.N?XO"5\7VE8;L3<&2,K8KG M&Z9R2!1HW#`Q3+FHH0#X=!IN6@,2H4_V^\`+76U(E+K)PH\"@#L[IO0M-Y3$ MR1^4%LU?!`4]%9*$/0E\]R1!X&9)$J?9XET6#RNR!F^HIMNU%`<'N@8T54=- M#P8K8#;.(LCG;6=@R:RY,HOL4D`KV(['[2(.UMXC1)CWF.LW,&$T8#R0'VH` MW=,:SFL;,-1(G*-V&`^\MKYKQ,0GF'1`C)2!9KZR`6\(<`_*49@,O*B,F*7- M)(A]WQ^>CW2AM/FZ!CS6743+@1=U$3/#,73*?&4#?B]KQ,Q03C^B;,!CS]%) M]Z!GQ,0VZRP\)C)*>C%6G=??9M%4?=ICB$FM>II$2;H8MF14@#D#3EZP\\UM MP%/A:8LA!H7/M-CR([H&/-4]OC(8-V)0]R)9AEGXMN$`QL=\QQ8]E3Y&B=(] MJ-=>P&OUOQO&EGV7'9$8[#2?01XSCD!J/DV,3 M]]H(PGD2Q6F034*-%9T?W3F@X M:>QE!?\L&,QUWP5P*81^N3%GXO!?9?L/``#__P,`4$L#!!0`!@`(````(0#@ M[QK]?0(``-0&```9````>&PO=V]R:W-H965T[MH$E4%'V`G%\ M[O$YY]K.[/95-NB%:R-46^`DBC'B+5.E:%<%_O7S\>H&(V-I6])&M;S`;]S@ MV_GG3[.MTFM3E+Y(- M2>-X3"05+0X,4WT)AZHJP?B#8AO)6QM(-&^H!?VF%IW9LTEV"9VD>KWIKIB2 M'5`L12/LFR?%2++ITZI5FBX;\/V:C"C;<_O!";T43"NC*AL!'0E"3SU/R(0` MTWQ6"G#@8D>:5P6^2Z:+,2;SF<_GM^!;TWM&IE;;+UJ4WT3+(6QHDVO`4JFU M@SZ5[A44DY/J1]^`[QJ5O**;QOY0VZ]N&$0*-!$:>Z8 MF&I``/PB*=S.@$#HJ__?BM+6!<[&47X=9PG`T9(;^R@<)49L8ZR2?P(HV5$% MDG1'DH'ZW7P:I3=YDH\_9B%!D3?X0"V=S[3:(M@TL*;IJ-N"R128G;,,\GG? M&5AR-7>NR)<"VD`W7N;7HW1&7B!"ML/8NU^7`Q[K^]2)D%C#G,CN'&&B#37^Y-@?^J)\!5(WA'PQM'`*Z4LON!N_@.WZ/Y7P```/__ M`P!02P,$%``&``@````A`..]O4T)`P``K`@``!D```!X;"]W;W)K&ULE%;+;MLP$+P7Z#\(ND?OAV78#F(%:0.T0%'T<:8E2B(B MB0))Q\G?=TG:LD2WJ7.Q3>YP-#N[YFIU^]*UUC-FG-!^;?N.9UNX+VA)^GIM M__SQ<+.P+2Y07Z*6]GAMOV)NWVX^?E@=*'OB#<;"`H:>K^U&B&'INKQH<(>X M0P?<0Z2BK$,"EJQV^<`P*M6AKG4#STO<#I'>U@Q+=@T'K2I2X'M:[#O<"TW" M<(L$Z.<-&?B)K2NNH>L0>]H/-P7M!J#8D9:(5T5J6UVQ?*Q[RM"NA;Q?_`@5 M)VZUN*#O2,$HIY5P@,[50B]SSMS,!:;-JB20@;3=8KA:VW?^,L]L=[-2_OPB M^,`GORW>T,,G1LHOI,=@-I1)%F!'Z9.$/I9R"PZ[%Z\P(,!1HGB"5305L0`)]61V1G@"'H17T?2"F:M1TF M3IQZH0]P:X>Y>""2TK:*/1>T^ZU!_I%*DP1'DA#4'^.!$RQB/T[^S^)J12K! M>R309L7HP8*F@6?R`,(!6)O9-@=03$(2[H&L5!RE-QTO80BO>V2'EH+C*,1GJ5QU9#%LI>F5@^ MV9@)`$>F`MY^L`2#P$GF:90:3]:8:((Q_,O?0LRT`P1)\%Q0&IT3U=VL,4>3,L/"7$<39:'O>>?# M,Y?DH+KZ&I#@N:@P"D?WM2B-T:)NHLALIWDX/E=VIBI[CRH)GJM*H\Q0I3&Z MQ6/SSPD31#(7:8U3C';.N'DI;?PDW#4P# M8S^'8:7VW3$`PV)`-?Z*6$UZ;K6X`DK/2:'#F1XW>B'HH*ZV'14P)M3/!MX* M,-QAG@/@BE)Q6LB!-KYG;/X```#__P,`4$L#!!0`!@`(````(0"1[HU(5`0` M`#82```9````>&PO=V]R:W-H965TV:)FR758>5O;??[V]S&R+UTFY2W)6TI7]1;G] M;?WS3\L+J][YD=+:`H:2K^QC79\6CL/3(RT2/F$G6H)ESZHBJ>&R.CC\5-%D M)Q<5N>.Y;N@425;:R+"HQG"P_3Y+Z2M+SP4M:R2I:)[4H)\?LQ._LA7I&+HB MJ=[/IY>4%2>@V&9Y5G])4MLJTL6/0\FJ9)N#WY_$3](KM[SHT1=96C'.]O4$ MZ!P4VO=Y[LP=8%HO=QEX(,)N572_LK^31>SYMK->R@#]D]$+[_RV^)%=?JFR MW6]922':D">1@2UC[P+Z8R=NP6*GM_I-9N"/RMK1?7+.ZS_9Y5>:'8XUI#L` MCX1CB]W7*^4I1!1H)EX@F%*6@P#X:Q69V!H0D>13_K]DN_JXLJ?A)(C<*0&X MM:6\?LL$I6VE9UZSXE\$D88*2;R&9`KJ&[LW\68!"<)A%@<520=?DSI9+RMV ML6#7P#/Y*1%[D"R`67@VA?C<]PQ<$FN^BT5R*:`YI.-C'07NTOF`$*8-9H,8 MJ(`6XZF(N(^8!BW$`7VM2'#]>9%BD2IRZK?TTH\-0F8RS,*QN'-#$0"1>5Z` M6`31[$0@G,TT!8CQNQ@5$9L0BD8@Z6HT9U"`5S:XVV8G"HCZY`UBYC*_)/`C MU1RK9A*V9D45[._QJ@18537UYRTOY@PQOE3U$KA:2F/%//4?J`J?427`JJHH MT/;R!C$AQLKU=56*F42W6E%B%3VC2H!559X_U6*%&$A4F^5;/&0T8Q-"T29& MV=-]0BP:J@#$F#2:$(K&N:K17`$"K,:O7P&(P;T6N+>L8>P>615-!)II-W!F M41*MJO+TS;1I0*:0&2&JOO\W`+!WFWL;09!1IPFBZA2MN;,!!^*(C=SKPE[>5>7Y-V;L;Y)R91NC-GHF$*#IZALYWL6JH;J5 MU`,ZD>>^*VIVGQH3XM5KL'8;$&8WTOIU_,BJJGIJ3)#^G/`Z\Z?)+H+NAP3; M2L-S'Z+JTP;&R.QBSQ^H7=-@:'2:(*I.;7@,U"[V^VZ5]#LSN0X%\?(9]K*K M6&]]6U7UU+@@_7GAZ:]$FP9T/W5-U*Y3X]Y,5O1YVN08EUVY:JAV&Y!)IQ&B MZM0FB#F['G9\;ZY>#T'W1>`^-$)4G4#S1!P%6HUCOWKAK"Y`UZ.%%F9QE.^8_5MU MHRX\IN,IMJ#5@<8TS[F5LK,X@GOP#M[>Q<\#&[+8>.*0I]V/Q6<#<=]I#7!J M/R4'^GM2';*26SG=`Z4[B6#B5'CNQXN:G>39B`>T7WS6_P$``/__`P!02P,$%``&``@````A`)/$Q8>:`P``4PP``!D` M``!X;"]W;W)K&ULG)==;ZLX$(;O5]K_@+@O8/)) ME.2H2=7=(^V15JO=^5Z>3[II**KPJ(^XWU>7KP;B[.[,L\55++M0G`+B30\YB3,`G! M:3[-)M9\5YA_Y/Y/D6^V!LH]@(@PL$GV_B1T"AD% MFR`>H%,J"P"`3Z_,<6E`1OA;\W^?9V8[\WO#8#"*>@SDWDIH\YRCI>^E.VUD M^8M$K+4BD[@UZ0%].QX'\7C`!L./74(B:@)\XH;/ITKN/5@U\$Q='5MLDRW/%;U!)[%(($.?)T'QS`?S[L$)D('`)\U3"DI$3BH4Y^@HF3K(QQ\G8P21-OTFGFT8::T,8-1$< M)18>OOZD=X1-Z&YN1J+DXK9I!S_$P_/^?CQZ2]AXQW74 M)I!$%PB:\26[.FXG$$_[^PEQEKL.1\ZQ`ST4X97SB:51.\@O/8.20%VE4PE)Z=ICKSITT2C(;(ZR* M,3'RPR&)^5,>OZ4\JS!(P<]1!?SE*;F4MVAI/"9<&A6O;Y>'.$\O$.(E.2?5 MCSJH;:7QZOLQRXOHY0SK_O"F47R+77_HA4^3N,C+_%!-()R#H/TU!T[@0*3M M>I_`"D3:K8(?-O:CM]KY"]O9KNL$_9OP:]GYW2I/^?77(MG_GF0>'Z.U<_95??^/)\51!N6>P(K&PU?['$R]C MR"B$F;"9B!3G9P"`?ZTT$5L#,A)]U/]?DWUUVMC^?#);N+X' M(K$'O15$%BOS(3_(T:SUWE)AC2+(HXBRL6&[P_02ZO.^#;S9VGF'G,92$_8U MGJK8W12B%(#7,,+*NXSZK-]0A%B@B"H(MA"_@-@-&R/7[2O\%EXA@0QU242V MIG?WP8U(3(*L=@"601L?(5$S[6CF!-*D4!@A2)?1G"TAWMB0@"8Y@4>N'*+& MQ(:*15UX=^*V=57`(%'CP828@BW4E(2H,8&9%`K;7&4;5U@Q::BPJ#$QFA0* MXT)E-!=6B&G^:&%1HRE;O2=W.*Q'5\"$S75ZB!E,B"G8DA06-?HK(YM)H;`% M*MNXPHI)0X5%C8G1I%`8/6BXXQ-8JVD&:6FEZ%9;VHQW/)45UM-E'6`4:K(A M&;E\Z*%HBAY!V?2#*M.G[$/5/S5F[DM& MXJ$'=*L<,'*7$DH1I*KQ:K(1=E(B:^S1]:CY)'8R\MQH?(7Y:CE#[^8L$J1:3=*R0CKT!M;GT`Y.(@G.ORG^S83LT@.77JBI:@A(.=H1\?;&JA5_I*SL+ZS M!(S>84O1G01B!#JHLHG._OGLH1^HIZ/U*NS>#$5-]DAV=W2\S:Y*2'Q%;+_Y MH"^+O[AI?1F]SY$BXQG!.,TB6HM2(;]D*TQC*S[I<:$4T2IB`Y2#@W@:+QGN MTTSC)6[O"*-(0R`)R?B]*A,G,7=GIG$0ORV-W'\H,E;7)%$+3-QC9!-$#X!S MV-P2]!\M,!09.4T2A5-4M7N>S7FLU:0+^N2@CR+-E?%LW!]7TT;\8X!,XQL^O7/Q461, MFTFB\D&8[IX;=S9\,6OHCW@I,G)B'+U$Y21.,I!'C8/TSP:*]!>7158=I/.7 MO@I''&0`3N,<_;.!(B,<2IH=VNY@%8[XQP" M'XC]/#/X!Z]^;9Y*?'(Q&-H\GT(+ROJ M)_M.,P#O"B[1D?\1%<77[(!ZB-^^9MO\#``#__P,`4$L#!!0`!@`(````(0"I!?`' M`@0``/4-```9````>&PO=V]R:W-H965TK^K$5*^'*GM<%E7!8'SQ1 MU8RF*JC(O:GO+[R"9J6K&9;U+1Q\O\\2]LB34\%*J4EJEE,)^L4QJT3+5B2W MT!6T?CE57Q)>5$"QR_),OBM2URF2Y?.AY#7=Y?#<;R2@2@F!O%/VD,O"]=E*VIZ=<_L//7UEV.$I(]QR> M"!]LF;X_,I&`HT`SF$Y"(#_3I%A:8`C]$U]GK-4'M?N;#&9A_Z,`-S9 M,2&?,J1TG>0D)"_^TR#24&F2:4,"GQ=(K@3.FD#X;`*)W]]]'.AI]R1+(6A#._Z`165`CIA)%;]L3O>BI):A%V(+`*%/0Y9)I MO4'PV@4JPYO%\$9;C0D,C(6(6X0M!6),*9B_X,,J;B5A$-2K<;N[R$Z7QER3 MU")L27![4])U=Q!LNQ-:[FC,0M55X*N_(2+6B$`UO%DYBZ$45=TA]O,';=X: MA'&VJKOA/;<:8QH4D=D0$VL,F<&GD?VH0PW*/!R*O>X;@BV%@=_QZ@+7F('" MP.ZY%F,G$5]SQERX+@;!MABKE[8:$ZHD^A/?NASKR^,,1I_1@6!;AY62K<:8 MIMBMUB)L2PB\8TQ/;NLU%?6[9FM`UU1UD)$L:X1?3Q710W8XCNR&:T"ZXPBY MFU_JN08T3AG!L6G4SLU=IP*M_,WLMFM`IE51$`PK/VY`5N,%_8P;-![!X6H( M_HV#>A0/'!RUGJ*$46ST?>C;O=>!1BF%N$\(0K1E6V#UUY9H4-=_(RWZ^H5L MXFR]W9QF$ANO65RJ0%[0GXH'IX:IP(EIW`UK9P%]]]E]1`_>08YF_=C5XY%H M4`#]W@_GP)X&/6J4)6M@M_/@LUHOC?*^4ANMS9P>:K7Z%O=E9774OPCU_JM7 MOH+5!Q:S/!=.PD^XVV*'=V>[O?MABO'6^2WNXY?.3Y?Q)?P#F4.`VIQ'3`NX MLKC$1<)VZ?>Z(%BZ*WI@WVA]R$KAY&P/POU)"&55Z[5='TA>J75VQR6LV^KK M$7Y>,5CU8#5VG3WGLCW`5'8_V#:_````__\#`%!+`P04``8`"````"$`0&3Y M;),$``"($0``&0```'AL+W=OY/8N2-@-%S";5=:K?;RG`X&HDYBE*2;Z;^?<@S!KNQ"\]+I^!P? MRG6JC,WHVX\B-SY856>\')MD8)L&*U.^R\K#V/S[K_@E-(VZ2A9=7ID15)/>`G5@*RYU61-/!:':SZ M5+%DUTXJ4EZ<0.(UR[/FLQ4UC2(=K@\EKY+7'-;]@[A)>M5N7WKR1996 MO.;[9@!RE@RTO^;(BBQ0FHQV&:Q`I-VHV'YL?B?#;6A:DU&;GW\R=JZ5_XWZ MR,_+*MO]EI4,D@TV"0->.7\3U/5.#,%DJS<[;@WXHS)V;)^\Y\V?_+QBV>'8 M@-L>+$BL:[C[G+,ZA82"S(!Z0BGE.00`?XTB$Y4!"4E^M,]SMFN.8]/Q!UY@ M.P3HQBNKFS@3DJ:1OM<-+_Z5)'*1DB+T(N)`]!><#FCH$<]_0L6]J,"S4_ER M"!!LNPYX=I.?7H=_$0E4D:?7`9W5A@+/+I0OKR.Z3(9G-_GI=1`H(^DJ^':3 M^>I*+%DC;/EK23$/I+2CY):&A:.I"`RGZV%A%';3M+540 M^ARYH**.@V)::ZB'35!1%QNX55'50,T".-H\88%@ZQ80@D*>2HYLA1?'Q;F: M:3AQ(E0Z1CQIV MH^(!P3O%5H,CY8M+LP5.FD_8(MBZ+3ZNLZGD2%M0RF=WL/D=;'$'B^]@RSO8 MZ@ZVOH-M[F!;B07MKO!B#Y22T9(NKK[X&/OX%"9FX>0'>I-/)<>7VY+K4<]% M53=[R)AC1J^S%HA!(HKBB#&#N*@4EAK#\6UB(XV5QJ">'Q&T&ZY51A1`!R.) MC4H@D`X'[]1P,Q9)O22,^AX-;H%*S^3-5UY#"E8=V(SE>6VD_%W<:BFDNAN5 M%^XI&<*1'4[>:'P#%_%VW.H`N`B?D@/[/:D.65D;.=N#I#T(8$>MY%5:OC3\ MU)Z_7WD#5^#VWR/\XL'@RF$/@+SGO+F^B"-_]QO*Y"<```#__P,`4$L#!!0` M!@`(````(0!&A)FWHP<``$$R```9````>&PO=V]R:W-H965TI-GY>6B,)L-!,P_XR/; M[]-M8F?;]U-R+J63/#G&);6_.*27XNKMM/V,NU.SQ<0R"!^\)D7I MIL+E<+!]+\KL])^$C-J5=&+63BQJ?6TW1^9R9LSF/;Q,:R_TVGCY=!.HL54_ MZ+6YN7<_YK631=M)[WY0:%5-H=>F*9_NQZJ^F5Z;FWOWPZ!I)%4EW6YN/MN3 ML9PCU92SXS)^>Y'ZW6\Q%U\O*PI_\!U%U'' MJDNLEHH7N\LHA-,EEE.+M\7M,M:,(UX762R4,?2[S'*F^`FZS&JI,&&7488F MZA*M!C/]:(%C^NEU$S2MIZTI/#>4`5U+AI:\9IK/^5AM(&%#PH&$"PD/$CXD M`DB$D(AT!!.+!K6'6()^'M)4:(2@14F9DVL)K:HU:[I0E6I;K9ERK]VV3BUE M#CIMJZ5^KLNM2SY#/&Y5%E*_;35,4YF`0=N\-%?<==BV&G-+\1VUS>9RR3V$$+0:-4J/UY*A3V_$4K6`A`T)!Q(N)#Q(^)`((!%"(M(13"S*@7J( M)6@U:I1)LI:,3BQ(V)!P(.%"PH.$#XD`$J$DYM4B\F!9EC*Y(V:?MK,>)A0E MJ3V$$C2/*EK>E$5H+2&=4I"P(>%`PH6$!PD?$@$D0DA$.H*I)>KM=NJLSQP$ MS<-JJJ0U:XG(660MEXJ4&VG62&E#PH&$VVZ$.5=3+P\Z\"$10")L-Z([$E'; MS-K(]*%ZJX<^@N;ZS`U5(,EH%-A`PH:$`PD7$AXD?$@$D`@A$>D()I:H;WNH M5>%\\>LFXC6DTPLC-D8F=U<+&^Y/]=,E,<]-)/5-%5I MM]S<4%*WP8B-$0U14,>]A%SY&`HR$K"%69T0B9F<- MY5J)&KN'5K(D;VLU-Y0(7QL2THBQP8B-$0)AQ,=(@)&P0<1WJ[=$HYK+$3,:MWTC+I>HQ7O( M)4MW'F>=I%]7W]=Q!A';@(B#$1":]=L5 M,>5F1CO8[N3\-:45#>^*8"\.1ER,>!CQ,1)@),1(I$6XV5_AWMC9&'(RX#2(F]TIMIM>8?]H.'R,!1L(&$>WH MC$?$S.UFFP+E.+NY"$2T@H'$;O^*(T7!R,N1CR,^!@),!(VR+UTGQD??I:!]-L/,>56 M!\I`\(9([4BCA8T1!R,N1CR,^!@),!)B)-(B/,[Z;8C0470USM1'^[IFY"DW MI1;8U$:M8G"SQ,%>7-:*V\&R*K/V\/T^1@*,A*P5REB(<_UB,.5`W9HH]9$G M]N7QZ5.2OR6;Y'@L!MOL79S&-RF]:Z[*7PJLC4BX&QV1/+B>C!2U^N?P)@'Q39I?JW/!K5M+1_>K?`_U4(Z&C MTI,1P?LL*Z]OQ%'EYL&PO=V]R:W-H965TKAUCP`K&R'9"\O8=VPG-;EHIO0&<_//-_#,# MZ=-1-NC`M1&JS7`2Q1CQEJE"M%6&?WS?/#QB9"QM"]JHEF?XQ`U^RC]^2'NE M=Z;FW"(@M";#M;7=DA##:BZIB53'6_BG5%I2"T==$=-I3@L?)!LRBN,9D52T M.!"6^AZ&*DO!^%JQO>2M#1#-&VJA?E.+SEQHDMV#DU3O]MT#4[(#Q%8TPIX\ M%"/)EB]5JS3=-N#[F$PHN[#]X08O!=/*J-)&@".AT%O/"[(@0,K30H`#UW:D M>9GAYV2YFF"2I[X_/P7OS=4S,K7J/VE1?!$MAV;#F-P`MDKMG/2E<#]!,+F) MWO@!O&I4\)+N&_M-]9^YJ&H+TYZ"(>=K69S6W#!H*&"BT=21F&J@`+@B*=QF M0$/HT=][4=@ZP^-9-)W'XP3D:,N-W0B'Q(CMC57R5Q`E9U2`C,X0N)\AR>A> M"`D%>7]K:FF>:M4CV!E(:3KJ-C!9`M@9F_S3&#AR,<\NR(>"VL`P#GD2S\0C/C:`YSUV&WP\&JSD]YJRSLI'^LX1/$807B",2E4O9R M<&_/\%'+?P,``/__`P!02P,$%``&``@````A`/MBI6V4!@``IQL``!,```!X M;"]T:&5M92]T:&5M93$N>&UL[%E/;]LV%+\/V'<@=&]M)[8;!W6*V+&;K4T; MQ&Z''FF9EEA3HD#227T;VN.``<.Z89UC1"SF67"72(6=L#/F-^-"0/E(<8E@HFVE[5_+S*UM4* MWDP7,;5B;6%=W_S2=>F"\73-\!3!*&=:Z]=;5W9R^@;`U#*NU^MU>[66\/7.=K?;=/`&9/'-)7S_2JM9=_$&%#(:3Y?0VJ']?DH] MATPXVRV%;P!\HYK"%RB(ACRZ-(L)C]6J6(OP?2[Z`-!`AA6-D9HG9()]B.(N MCD:"8LT`;Q)__/QY M.1`R:"'1BR^?_/;LR8NO/OW]N\*1R5D1SBB!4-?A.KL$S( MP5SX15Q/*O!T0!A'O3&1LFS-;0'Z%IQ^`T.]*G7['IM'+E(H.BVC>1-S7D3N M\&DWQ%%2AAW0."QB/Y!3"%&,]KDJ@^]Q-T/T._@!QRO=?9<2Q]VG%X([-'!$ M6@2(GIF)$E]>)]R)W\&<33`Q509*NE.I(QK_7=EF%.JVY?"N;+>];=C$RI)G M]T2Q7H7[#Y;H'3R+]PEDQ?(6]:Y"OZO0WEM?H5?E\L77Y44IABJM&Q+;:YO. M.UK9>$\H8P,U9^2F-+VWA`UHW(=!O-29#`P<7""P68,$5Q]1 M%0Y"G$#?7O,TD4"FI`.)$B[AO&B&2VEK//3^RIXV&_H<8BN'Q&J/C^WPNA[. MCALY&2-58,ZT&:-U3>"LS-:OI$1!M]=A5M-"G9E;S8AFBJ+#+5=9F]B(K5"MQ:FNP;<#N+DXKLZBO89=Y[$R]E$;SP$E`[F8XL M+B8GB]%1VVLUUAH>\G'2]B9P5(;'*`&O2]U,8A;`?9.OA`W[4Y/99/G"FZU, M,3<):G#[8>V^I+!3!Q(AU0Z6H0T-,Y6&`(LU)RO_6@/,>E$*E%2CLTFQO@'! M\*])`79T74LF$^*KHK,+(]IV]C4MI7RFB!B$XR,T8C-Q@,'].E1!GS&5<.-A M*H)^@>LY;6TSY1;G-.F*EV(&9\F_W4`BA;JI)6@8,[F3\N>]I!HT"W>04 M\\VI9/G>:W/@G^Y\;#*#4FX=-@U-9O]2!=(.SB"QLD.VF#2I*QIT]9)6RW;K"^XT\WY MGC"VENPL_CZGL?/FS&7GY.)%&CNUL&-K.[;2U.#9DRD*0Y/L(&,<8[Z4%3]F M\=%]T].#8/``#(H```#0```'AL+W-T>6QE M4E>\6@WS/=E;>VW,=Y_Z^? M]8N;?B\(#7=MV)YKSOLO9M#_]O[7O[H+PA?;_/1DFF$/1+C!O/\4AMM;30M6 M3Z9C!)?>UG3A-QO/=XP07OJ/6K#U36,=X$F.K8T&@RO-,2RW'TNX=58B0AS# M_[+;7JP\9VN$UM*RK?`EDM7O.:O;]X^NYQM+&Z`^#R?&*I4=O2B(=ZR5[P7> M)KP$<9JWV5@KLXARILTTD'1_Y^X&\/\H.]>+?O%_/^U?]7JSR MPEL#B-_]>^>%W_PF_N>K/WSUU>!?7W_SC^_-]3]_^'WQ=S]\W=?298A,\$&U MS,M!I5CX=2Q92S2XO]MX+E$$0$<&NOWB>C^[.OX.@@'4P[?=WP6_]'XR;#@R M1'@KS_;\7@A>!OVB(Z[AF/$[%H9M+7T+W[8Q',M^B0^/\$`4&,G['`OU M>(5NUUDBFE2G&X3!=!KC$:J3`RH9>+!:)^/'`SJQM:;U:QUC/[96I$6U7M+6 M*L9%P8;'K)7YBJSC/R[G?5T'#AD.!FA6ZK`3+39;#&"]SA:[FG:FV5@?Z]=2 M-6.Q6/0;+CC699JR9D']S?7;SLPI?[$R[1(:[BH#,.'D6M&"U*W([VL=_W01 M)QT7M--X+)+*2#]*O9P;/UN.&?0^FC_WOO<B M,VHOQEIC^"R\R!J'O=U8/%IG1R/X-$N%B6#E6]L0 M`^30ZI+L)[@PJ1^'%V[;=T:A'D`.6+:=]?7C*7:^<.3^#D:,T/1='5[TDI\_ MOVRA[W5A&D+;:/'[:M[]Z!LOPU'4_8F=$'BVM484CXNHVTY28G'U3E^\B]8E MR$11E`C5]<7U"82^>Y@MY"-=S&:RA8YT^"-9Z)LI_I$L5(?_%M)LFB321!;( M3%XOM'`Z'EQ>SV:SF^'5S3B:1D9=)1%ONVGPV<6"69J8B@BD@F(UO M9EC;85)>8J[`$K MSE6"0)%7"0)%7I76?"8,/%/N58)`D5<)@JZ]FHY5B[2Q+G9FTOKC9"ULXO5H M0ZO)6M'4"'/JTO/7,)JG5Z"&US`CQL?N[VQS$\)$ZEN/3_AOZ&WA[Z47AG!I MZ_YN;1F/GFO8\*.6GI'^6W$F7/R#ZWSS?OADK;[`8FQO*;9-O,2I5LA8;X+3 MQ.1Z,KB>3$=7\<`F:6G'7%L[IZA=MO;!N`0SHFWK%2I%DB`'XB8PR#(.45[UIYRP**UYS35%?BED!L/(_P3 M=<<'-*TYHZAGS0D'M*PY0U1''C>I=YGP;.L"Z?D`DCU[L[>W@P$+Q2>F>/9( M,.$GW(*/+_@(T]UA=6O%$ZU!0K-R):P#643XG';V%19_`-*>MV6YHN#R$ZV3 MJEXKOCO5VT`JB<*D>X)F;&7:]B=LC_Z^R3HRV.2\OWO>D)MWX(XJO+L%[PW" M'^%*0O)CW'W%+V"MLI-&I2?UC.W6?OFXW645+1$?QBD7^ZB%J&_/7 MT;4>QXRV:?NQF.]\+S17870;6'01JPS/N`3/,!$D@N>8]2M#<`FO+S,>8`,MM0>X@`9U%1Z9"&"S)T4`3E"!`&_02Q(;PE,% M`ABB4P00H#D"@%,1%FYF>%$!X*@ERRA6%<40MT.FY2:`%Q4FT*'JRBEYPS+.5V800KJ` M(;<(T$"51>1%)>%<6#,'4&V1!XE]"`D*I"+5$`".$@C$$4-%]1=V(3-:'BJJ MP#0:%)5@"H'5X`YS@GJ"54A%&`"/DJP@`D(515(,JC@R=\58%442 M"*H8DGAB?&**U.BV:;R)2O9/AV.\I%VV]P@>2N?_?6<];VIW4H=E4Q/(2D^/ MQZ=X=`1G1,,4F:7Q,Y$&WBB/FZ>])\^W?H$I$S\;N8(#IM_'S]*&UHH>^=DW MMI_-9YA%X\N`SYNC%*S!E*\/N^O]7I/%I=OG""P"GJXQ1*WFT51?NS._%QE\ M=[LV0FI!X.Z.:@Q`_\HQH+\3.T@/0TEIBNRAVE71IJMJ$-17&#O)SC<<9IU, M*TH]@C*&T$*<#1;9=CD4P[7D(N(HC*@J3STD6W:U5"<3X7A_1JI"&.^U-\*' MMY,TK(W$H=V@RS,A;2W:^IOCA2]QJ'0X-Z<:]^^/I^?E_D[0M7!_5#C3(DKC MM1KPX99&!T'8L28-<73E('W5J"&NC=I2V-4DH!IV";GR9*LA5YYK?@D6>C>]RK=H9:`"_,_.2X16O+Z3-]UA)O1&-B1)>/#5O-W<^ ML6X#YY^H++:Q;BEE@0NJ.KK34E:96:LIZXS,2GF,@:X;Y7BWT)*>?5@5CFAB=%;L: MN.=K=*8%"YT:?N:!+C2UM(@)!H\963X\P1`@K4,YN@Y8N(4URSL(O&/K[&B- MF9?%9A'N^688,SH+X;JIC:>8"AJ&6%]&6[]X6;4NIEL!;+.MB1DH=+FAE)5J MMZ-(DA^_6KZ+=UY;$$7":S**EC7V8*\J)I'B$YI3L%X>HZ]R<;HM5.&3^.N< M*MMLV3ZAR*3LJ)7WU36>D\"%1=,>'%N`HM,KO#3,^'Y&D0M?90$ZQZK/C,[K M90'N^1J]O'=I%.BE;$DS\\C`YC8NP#M?&[-(X?WA.0Z,3>"^#J-#K!Q?>JLC MN4E'0HI+!\@.%@]8-RT>C`%XCIT^.EL,APQOU]G4`F]%.A7J1-7%D%9C2QN\ M9JIM*3@I'N+"5^!,.+_/+#3534BLB:H-P M!$#$KC=P(BJEGMH2*F(>>$]5L)+,J!$_8682-R\O& M:[IF6%["Y5M9:A`4]\5Y3O`H:)7"<;%NT4V79!6_YZ\8)6>I0'F`=*"`W(B! M;P"H(C*5$2/&*P4%7DF7QYIJO$FZ$S.YL_$V2C/D;CI-FL`#WE219C18\#B1PW?]#U%:$04L M!:]>$ZF>'FZ+\#SIQ"JCF42^%2+]D]%\&8)B-]ZJXQ:>PTHJ#QS.F1Q>5*6$ MD(UD>*T\:VL0$JTX1GI*=ZU`4ME:N`"0 M;I(/[%>XH,!*K[(!+FC!R>L<`XEW=*?/A#8M$J6>KO'*R%SI/5Z>AN=UR[V, MFZBEUU]Z22`#2*M@DPF(%>5B`\KSO56I:-5-`:RTF]K;\#U]<98+N!&%"G6# M;?"59FS=AYHZ7F'<7JXHN85:Z0+'=R9-=+LZVKPZR:%]I9$E!!BBK08Y!U4>J0V M'5\O/C^,/CLJ]'[KF&`T_>'0U^ MV[OHO5FA+[*&!2O<XH/)=PU7RFLC(_3KCMIX*VOSKH1QZK^!WJ(KBHK-R//%;'@K%*9>5^ MY+&**C?%E?L1I%+;PR^:RLK]R'EB(L@35,?PKD$8TF\`MQC3(?C;EU M)X+6?3#6:37@`8-U1@3&PK!7.]O`QYJF@G!*)0KAEHJ0I"=S]:6W@$>^9H)X M/F`9%1'T[GEK&ZX1>OY+#Q\+D(GC3I\*BONCYV4VXA)&\%($T)],8VVYCSVP M2UQX>0SCS-=$3)8+W#SXD+`F8N#L&`V//QSVFHB!LV,QG%2Q?Q(1\][=[C(/ M<2[%TBTBXH/E?C'7/'*XA4<`4D321W,7^D86?SRE1H*&^8@/"LYD<(J(GON[ MWS-^A.<"IT;$-I_D#N[QB0#_RRXD9L2SB!"\QUI$R&IQT-@^`H=;F MQMC9X>?LE_-^_O.?S;6U3__^8/U^!1"%L.V#]#-AR", M_NWM?&O>_\^[A^O9VW?ZZ.)F\'!S,1F;TXO9].'MQ72R>'C[5I\-1H/%?\%D MCNT&M\_#R;S_%(;;6TT+5D^F8P27CK7RO<#;A)#'?T=*:`$^ M>_L3+G+_/P```/__`P!02P,$%``&``@````A`)81?[,>A```(L8!`!0```!X M;"]S:&%R9613=')I;F=S+GAM;,R=W6XKZ/J0FKZ:B]VKO=V;`78!81]@'T*/XB?9W_^< MB,C(R"R*&MO`#,:V6!D9<>)\?T7D]__TR]6D^E#/%^/9]+?WMAX]OE?5T^%L M-)Z^_^V]=V>O-U_>JQ;+P70TF,RF]6_OW=2+>__TPW_]+]\O%LN*=Z>+W]Z[ M7"ZO?_WMMXOA97TU6#R:7==3GES,YE>#)7_.WW^[N)[7@]'BLJZ75Y-OMQ\_ M?O[MU6`\O5<-9ZOI\K?W7KYX]OQ>M9J._[RJ=_VGK<7"]X9U:/R\5X]?%0]V=JHMA]O/2D?OAW,T\.GY<-_7DUY^+C_S01L#N&_ MOAE/Z^I@65\M_ELYVS?E#VF&LYOKNGSXS=;CS=^5/^Z`G9%AZ/5D\+Y\^LW% M8++H3)16.:[GXYGP.JKV!LOUXUZ/%\/!I/IC/9A7KZ'(HK-.'R+3,N'UL%K_ M!*__6,YY-A^(&:O3FZOSV:1\^LWQT>EN^6-@D-W9U16\<;J<#7_>J$XO!_-Z M41VMEL;.3+GFM9/Z_7BQG`_@ML/!50<;6O'@[.3HL-H].CE>,\P MW2_5[^J;;FUO;FT^VRCD"!OY0 M3R:;/T]G'\%"/5@@P*/J8+%8U?/RA6\.9^5/88[?SR:KZ7(POP&@"7IBS;`( M]4E]/9LOC6#+P;*'1?Y8KYO"YJ]VX<#WLWD78Z=7@PD`5,T*$/AZ,.V,#(`? MK\XGXV'U>C(;+$N@=X\.3X_>'.SMG.WO5:]VWNP<[NY7IS_M[Y^=KM,E!]/J M['*V6J`*%QNHJDF]6%2SY64]_SA>U-7BNAZ.+\:W*YGM#AR!UH/%HEXN?MUY M/%A<5BQ8#?6/^L^K\8?!I)XN.QC<&9HB753S>E@SZ'Q2;U0&(3B;?1Q,AW6% MMJQ&L]7Y\F(UJ0;QA=E%=7_KZ9:ME&\>S^OKP7A4U;]@#A9=HI_-E@C(L(6`[AS8DCFZ7CC0]J^E MXN+.AMB$U01V&56C&@,S'`^6,@:"[-GC`-F3I\_+60]@Y^G[,3BJ'.\]$PZN MQ,5_:28,TW4H>"0."/.4"_D6?8WR6927R7AP/IZ,ER"X0_Y$U>O!C9,4I3(" M:K`!`>@)DN/0]G2T8&2*O-1%E3![-I![C!]5@,,$$OU7<8/H,165=$&]7G M<,$*1@R$XX=E-<(XR7,P\F]M/-E^Z:RYM?'BNY?EZOM7Y_4(CP#_0_/*^6': M.9*S',/;MR"US;:W#"SQ,9U-([/?$25W>`/G!E4+-BI1MC>^V7]@OX96Q;!0\ M#I^SIW7V>F5NW&/KV?.TVR4\M>@8',>_O5$BN3._*<:,5(:'.[UZ M"@LCA#O5\;R^J'$C1N[]E$LTCVU:)U\Y*$SVZDN3A7&G=QSWTY?&W6J;CW'B M<.CKY1A/].'=;'7]R["^7KH#6(T&R\'7F.^D@W/+^@6C6F*R942#_2S'',_[ M31UZ/F-(^#=8N?+]'J.6OYK;L_+5W3[=NB$UVVC5[COF6QO[;#0JX/9A'85P MI^&N#.XT]!9ET9;:C2"NY:R%8-RRL\[(T?C#>$005LU[0JC.Z"^B8MT;_=A8 M-_H6A`2Q_?&KQ/'T#(_Y[?XA;O+1Z^KH>/]DY^P`7[K:.=PC'GI[?++_T_[A MZ<'O]ZN#0_[>7R>AI_BQ78=G%\V)4WU1+7H?_SB?X7-?SV<7XXZ"/<)1Q'@3 M*$:'LV.\?JRGC,'WE?LTNAI/+=$E]I M2D@#!_[@"OF<<@QG,B=EE.:LL^0#O4CORPY`N6 MT_L>OC`EWAP^*\1B0@C>$P64TP8TFSO^)009X.N3WM@/D+_ ML\-Z64UZL-?G:_2->\WBX_>X+!8!#6\JI1P6N-CR10>C/ZT62V&T0YU7@P51 MK3AN-)ZL%/Q,`R056,+Y<,4LWZM$4??5CX!PJ3D&>,&#]X2Q[K/=HC=:YCGI M`ZF#T[.CW=_]=/1F;__D])MJ_U_>'9S]L7JPM__Z8/?@;*VM-KJ5D"J=]Z"; MSSN5WUD=>S14_>O;&C=^WDFG'5HD$D9M5$Z0\.=B[5MN!2T2.+H@76*>U"OW MG[[NI1^_\%*8N^.E?=TJ.W=;I>.6W;)*DRY;.RCSN8^#S[T;(KEUY,"#2AZ, MTX(HXKIQQ(.0/9!0/ER[<++?S@-W66S/@YBU4[X:3"PQ,EA6>2:XDTR+XQX0 M8+A\/*R^]$[&3:;!HCON_O9REN14'%UROU)T!AFO1GDVSE<*9T'V9:R@/`/G M/S1!^=(N6HJTCBE05LTHY.JT''\KE):P^H]"J)>_:K4Q0;RKR_\P5IHIRI6= MX__4L^'2@U"Q8^#N1+*MQ*M;WP)RP[9 MO&"3C3=ZDB(5S'4Q&(>8/%^\G*S-H\.^*$"3)55X"SF_3E\+\\X6T2198S+P0?4*<;SZ""/B_QS.5J,6;7FE^(*9,;2"Q@.KZL>1+E_+N7)/8QC6V26VW%/.8LJ=:)#H'-PY8FT5-. M'X'JR7X?%]4.6\YM:7_^7QKHJWFTE!@W6A:!KI>8XQ61+-;K[J%4_L;;@[,- M$RBI5@GL8$@=ALQBB9S.AOJ`*U\J-W0QGN+X?&%#KV;S^>PC@Q:4X-.YQ-D4L/F\\)_@V&4/\HH0YS"J'DZ+_V-9/MD*CV\DA0TIUO`5!WIR%V.A"^-370D[%9&:U2=WU1]="E!THMXBLJ. MU]6#4>W_>BAA=,8A9+5_W%+'-'Z0-BT';E3GE.6G(/N]\3'AV:S#@K>\K<0< MY")"[GGO='5][?D+$@ZVLJP2@.-OT\*"ONIHBY1B4>6AQ$2>-K#21#D`9MNT M=52TPNU6+:LK\60D$G<*CIV5?6/1Z>O= MIG:9`U5BN#U%0@$:I:P#FL,I2E.H-';NK3(ADSUY*G(Y7J9BNZ;=NB3;CY7M MH,]N50[PCK$.*%T@GDHJHMH4&:*J73M3Z]5O#Q9U71U*-S[MI`C;>Q_$0B\8 MP]JJAO1%U_2.KE^[8%.2`);$#*8:[$;XMS)2XRE-.-;T%9/UE3LHG3GV3W=/ M#HZ5AU86ZM6[TX/#_5-/29^^>_MVY^2/EITZ^/'P@%34SN%9M;.[>_3N\.S@ MD.PW;2"[!_NGY:S!'1`S'L_H(Q%._G7G7(U!PV4GY72'"??JQ7`^ME!1FNC5 M:D%#6#<".5:E?@[U=F=SZL1.W0<$Y=5?_^U_8QBN:7CYZ[_]GX<(F/R<81@% MPGB'-(:EQ&AHVZBVOGOY1-RJ=RFAP@8L>U;_PGNF85$D=/KQHF1$H:JRK3"P M+6D^%#,\?\3V>R`:,TDU70TIW\^KJWH$@FAONZP'D^7ED-2C)A6HCVB:J=F+ M_0$`.()[40]HZYM7X:H#*?U\M;A9JFX,Y M2+:K[F?P+U#:]&BD?`B*9L4TU@ZBEK'9-:G,J\&P7EFML)FEYZ%CQ!Z,%[,E M6%#2F20+-/+L/G^.5OA8L^FCDE.TP;5`LU>T+SL$]R+$>2"[YI=U733HW8_( M.&N0\>!XG\PI77=32A<+1^9=MKEVV4`!@?)Q-I^,_OIO_RZ]-*=8,)^=ST!5 M0)1I%`TC0J7"[WPHOE%F7B5T$,.>>I&YO"363!NDJY,ZHG)+/8,KDL[*B\1( MK8-(WW.+-%>#Z>H"*5R9D[8.P?54+3,+PWKD/]0;8(FNQD+\&Z(&N`+A'Y"# M-/B-B>=H4C&8TH0"1SPT)7&D2=72RQ^'2%WY M1]/JG^$$=2;B'ZF'=WNC1>T8J524ZZ/\N0DQ.+,:!QI,E83%Y?@:>$(4`'>_ M'4QA9;K%Z)ITM7!6#R^GL\GL_4WUYLUN]0"EC-F50GY$HBR8VR<=6&6:T7H+ M."^PI/)^.+>GB#EJ8\.64BA4*/JEUONIO<;)C/$,1@\?D3.;4* M-3R2P<@6,V^,%M#W>/A2L'.9"@^3`=F>TETF0GM%:S:9#,YENV;HK%)=)G,2 M4+IH6SJR>F[;Y'LS.U(2`LGW$A332"!R;$USDA94:G`:!Y6V.A/DW571%<,Q M7KZA$N]G@5&G%P357`+X&KQIF1M,VZ(B<`"*9%ACM[AANV&Y$!^!%K.T'G&R MXF0%+C69%?>4?&)E`9VPD)MY28\0^9$6H/GC1$6];M9.)Y> M/FZ9.&'2[:PF`I&/*H(!9V@I,,QQ&XY+JG[$5?6TJB=CZN&RG1W,J6CH("L3 M0^K*S)E6>`>7LI7]Q1)9IOFO1.39)2_$T+&-FF9EUS7L4W[US"(N-?=_'"^5 M:K"4C)0A^B+2S[D;!.DYC3W^KI#\#DO#7Z=R=@QDNN+GZ._JP8\[.\>2T!4U M_6RJH,LSX1"_70U^KBOJ";XKHS0YG-65I_DA)]9M@"-:EQV8E M"P%./.=CKV8Y)_N["?DTD"W'A-JZ=WP5>-6PK7WVX M+B^?/:YDMQE]@0B16>X$[JW`M#[B$$KTA+YK!$ ME%>M2;\!&0`\5V_7$C`VTBKEY"F`QU=MW!)$Q/1831-'4']B'81O"`.KGSB` MU(X0="IHR7]8G7@"I%W(_3F?X13@Z7.<2&%.>!,0[4%[!N^G6+IZ<(&4!R+R MN"&1-&I#.=LTJ!*>[.<`+M2V#Q>$O/( MT/`'>183&6WQ=:U\P03P\458X4"/K="<6Z$'K_=D@X4#%!U:4';GW&OE8O$; MG!3E'JOWLP_U?!K0Z0O)C'#DJQ7T&2+Q;^?NW(P]Z)0Q"LB)C>6H7J!$J<3% M.E*RUVBLY<=Z8HZQ'>]:8Z7)7,^,D3BKY*WPP:0`O9B"DHW,,_[=UF/$+?2= M^=9A-XM[X(S^EU_Z*V'&_.C%H^HK`<5Q%;NO66C[^5?#]F(];!W^4U)?&:AP MM,1V?TK']G(33^\*)HFU]8Z!CYX2&@"&@KSX*ES$*L]9FGG#F/MQ.(/E>AP?J;$4QK2U(=D*W".EEH]&O_1 M*JBW2,Q"&GA[-A])P>-V?QA;]D.LV#V9`^@$`.2A]5CB$I?X>#G&C9$@LK75 M5#,B77Y`Q)]AWUP/67T<]L;YG]P$/RZCA06EKJB&V$O%IF@N.0AXFZ@E4BZ1 M]\GFHY3(&2PO+6]E;!)T;:4J[.P*`[RDZC?J^OP_SF:CCV-\42D5J]S!5ND0 MSHX5Z-;@6YR$0\?Y4RQ`R^0K]MHYW;5DV!,,/W_>91W&XR-9#*_D@'PY+Q": MRSG&W$_*1`.OKY'>X'LT$5=PZSG*QD1$E,#U"OQTLI">_$;N1IY M3F,<[E#SQ1LME6)P3P``6KV'_:6&.VQYEHF-38+.#9@TR'EW.B,%EBV>5:&- M<3(P'#`$+FJ^"^$!V\-/XXM**0C95UR@\9R6+2(98)(1D3,!0GS)9ENLCM@3 MBDWJ1U5"O?*2@A45N\98?OX$TIU195V8M_[\*6J'42VM8XZ>K2=N)24POQ$C MN`U&VA(:+`MJ(!&Z5%F=7;9%4%(%:ZRLUN<@X_U7-9-70G(V2"=6>+OI"W18*-Z0D+,_,@4M9NH-ME# M.M>D0"R=Q%12$1+;H=">ID+U[!B'"+!SE,0&;I`A(L-R"Y4<#10S!(3V[L;F M!+'E-K%AR$J&&D]0.^]`F\0@:[C"=(,B:@/P/HX\NB)2CX13K5R63FPY1 MU.F79%:A9-(M,:@2WFMA-(EP):4IWB/46"UJ'8HTB>],+@.H(Y"=$E1\H-*` MH@X+_8T%Q+1H;N8'4>982N2L09SLBQQ-9">C@1-;;UDJEI-,&^%?)*FJ!Z\/ M7A\]C+XI,\J/-8A,("P@?Z1<54CPF$)+B:9D'G3*$","5I%.K,68X_CR6JR] MPF1%`'P@.N*4:[;&L,E]&M/^F90;,@J?P,GL0S/R/XFM-0LK6/3LST M-"FM43(!-LIHYV99 MGK'BFHETM<2O%]>4;WY[C^C;>/3>#Y\_5>6"/WJPV$1:'.2TLP-6`W7!#(DX M*08)?$8]A*E=\M+CX%+REO*DJ*ZWK+&DGH`Y-*!5$:%D8HQ#:PUY45(O,U/` MG'26V4OOEN`>-.:3M=_@66R^0:>-4-0Z`5X./X;U27,0RRM9*^"BG:QE"Q$- M^3!]%E(QH1P7F%#3NQ[$;<&Y5BK02B=ZDZY4:G?7EJ>Y6!F?3$GS-C9$K\YT MZ(Q9S$7RQ$]0K&Q;L\003J^>SV8_NYQCD%%6S8[1$M&9$$080"A+>DE: M(.(.1>T.J<]ZR6BK2U#L'Q(J5D6U@:.>P#/[\3H+'X+P21)DD+#L98,[!E:E`XV!-S3#TS0O[N9TD?T1,6W:L31:XY M!Z`4*B..B&=EN)A6A`W$*^0VK(D0GE"FRGQ0Y\!SL;FB0[$)K*"P2HPEP*PW M1+*@,SP7*,@!SH0?[+^I'C"R_@7/RZ:TABBMQ%]*:6--F.#*;([:,%3OD0$. MC*R5-#HMU^!<["IE>\ M"6?A(K1GR$AH@@9B@:JQ=*8O";.;)QU4_?5__H^2Q]YH_6J+H/1_5?^RH@=' M260[MB&JF1\;J&-ULTI'1Z$1S!`4*V2/E);#HXR:3`O0+F](=ZQ#'\&V MV-K0X1P!,H$[5SF)5_.?766,-$\P_@U/=#=V1Y)QB.]F<_!A`-+D'XM)1(7% MC+:X0$,WV$&*&KW:SW)/C"[O,G9-$O"1=+Z))_^-SB4% M">O53MQ7$&@J(\H;F:0TN3\Q\Y(^I7]'!+E\R-3^!;)[KG@FJ+-V0:U/5;G> ME2Z!@,#+H54PV4^'+:B]-S`86L.^F*,VQ"XC)5FJT*\81_5F&_$\, M3-WY%?]!8X)-$^Y)>MB);4QY?/[4.6,7?N\BL MN=O?!$U0=WN#\!O+(9)=:W:0'D9FOGSI@NR/?;:#G MW,38'Y>;R#1(`N42D(P(%Y1N\3:A*[^?$*)+9S,YP'O$-JE>3P?#GS=,A&0Z`\`.;F]&B6,*5O)SY_<906CHC M>MA/OQ`$Z;0:,=+H17,\>RX7:FYHD`$+*&D4=9).Z=8F#?&H>G>-R&78:^&S M.>4A!K236RT3(UT1#E.R52T:@_,["S;S*J`A#0FMK-6=UAFV9,Y##V+N/+$7 MCJ&[X:*3U0\80NFD36)PC6^"T4L,HI#%M^UXZKQ@J79G&^(B7GU>[!;J8+D@Y92H@E$X#W:;RQMOKJ28.X%8'#>A0ULW* M@:95*6Q53U_2Q>TBB.CI_X_YK_&WW&[Z%RE4KFM]?(^_*-VY2;HB6;:E7^:O MJ8+ZD#/5[VD^^%B=T!P]U=.+`2ZZI2_"\&]M8FY9I9:)95J1C)6!>M-<3><1 MQC[IAV5(@V<0_8.@(1OA_)M)0M`CC8V"16L2BJB%<"<<:%6G4D@L!;$3!;)X MVRL!@7&$?L)`L$6667[>=*5>T$B\H(&"F^5G;^R.C.`S@H=OFPMGSQ"W1DW0 MR2>/VU31*&:?&-&GC9)_Z^6?D&G+O5`BJN@R=[R:J+D_?Z)!L:VUES^\M<*# M@Z%M^6E/)*K,`90OJ@-EDR*A_&\86CZUNI7+8;\J?]B+5R'=J*FW?,J%HG@2 M5HQ0%_=L7@XX0W;*W[;,W2I_M>,C4?C*AZJS2)M[%M=SE]?*A"`/=%B:*3*A M,V_,76+KN#RZRB!G5K6'AE%S']EO0],K%\5/V!"^],W^I/Q7V6O5:[ M168:[%E$I`]2FT(`H[EG+_%!T)+`&+(DTVP\15O5,G_*P4O7.7*^+VANGQGH^IZ)O\`YX62&0-+>,FD6N, MS6B5\NG>-1SE,=TNG0*"=G43:=6-B5)73773NJ>^#&#"0*8?>[&?^=%YSZ=# MNJ9SJH!W:^.97^QHO]_?WMC:_JX'\I)V.SW5\'3&R^[RG%JF:JDK#V&V^\\V M7F#T5*Y'3[GTW;>[/%,)OX]4B7$M4A'3PS1D#7SRV#.$R3-UK)0M-+8.(F0F M.S45F[LI,ZF]PT;7OU#YD2"L[*@Q>5RSD6;@99[FL]7[RTYD_/3S)[2!37`- M;?%BF$%>:D8K-7:3T.>9P(G19"<5<>"NY-F7[J6P^5E>[(?U%7#RX! M_<)31;9`:UV[E@FW_@B4E?4%3L8_TVL`B5'A<)+^0:N-<'4=SW1Y(@`*/9<7KB*XRHDY[.M096K>KKJ(A)#.LZ9S\P^]2.'!"LM- M!ERB83DC[#,#@L;GC^C'4+X0#FG!#VT;=HZ>?$>B4`[1HIA;=Q':8H4_B\D,*3#K5^+[Z7D+_EH*$;4&#M.W,# M+=!^W#04S_S8D:+UM]B)S]M59%7*E&XF"D)TU#YHYT\DG^6D;K)C7E/Z)=O= M+7#V)ZA"@]'64[NMN-6K&Y4P?%;2^(F1+8AZ!$4M3EFX;=RI$K@S88?Q3M1B M1X+JQ+-YVGM)@9(WFY,;D-H\66O7,SLOS:!&>O'30EWVTF6A\S^U7Q!7V`DQ M$I?6,![:&+!#E(:&JB.K1*=29[,4$&M+0%J:[P8!C_5,>:Y.9EK3*G'A#E>KCAB= MK;BJ)YJT;@?U9QG*FXH^+_JM``.XI]XT>R3N\;7L5&T,3/$C2-.&RU.H1X.\ MI/3IT6V<5`[I![LC!6E!O>E5[2.:#>YR($/(;0EJS1,!6H*ED2$<00D^.#NZ@OR^&#]LDYW0>8=[M)WZ$W(W2#*FN4Z MF#XA_DJ7.>^!BG"9<[7OF=Y.:68'IUT]H#(C*`=7+HKBTBS9E=!AI#RQVUL! M31OC&%@""5R1;D3*):;1_<84ZR*B^#-F4LUQ8KF8;>GL[=2N!7UE'>62AW@W M9>E6M%Q^:>DX,$YMTKU08G/3178`P4>ZEZ%A^;R,)\)[&:6LX>@)9\CEZ[.W M0*V^240]#Z')#B5+YYQ@9(NP(6X?@)S3EP6W$+NK8%)V.N0&`?W,7#@\Z MXGT&:K1Z-':TD[J;@:"C?TP3XNG$R=!WV60@%B-D;$)BUP^!B\_M9QW)4G,J M[3`RE$VJPZ)*`\:HF^S[N;=#^MN0#-IJ:D'F'""M_`58&N\P)"H=%#6@N^B,U1[&.=6M8Q"WJQ MP_$FI(O+B>1&-WF*?$H)M1(2>]X](.&QDZRLW,@,C.!A@?D1)@"RS\D?#8[Z MQ83809W90-WTE"F.5]1D%AW#;?\KQC%W"WFV23E:P1XM"9+X;+'B'#S73WF: M$&%(5(%9S1R3NI&_W_9A+CF7II`CBY0QPTRTE+V]O[7]9./IDVU+JYJ>]JI0 M^#8-'AK^5S9Z:V/[J:6JI>T[H7%[94]ZZ8`P^Q0WD3'3$M#9[P:4HV#^BN(` M/;%@\QKEVW==4PR#P'/W5B?7)=U@U::EF1D$B9CKN(0ZA'WARD43<.4`X2'( MR3&L>IDJJ#/O#;?-(J3S;+K0!$NB?'OC&7=\*5$.J-E-D*E`#I%9%QN;*N/+#;VV M_?)9SVM<8TFU'RVA&M\Y7"T!CK?">0#27H?K7=IW<+;NK+/,$-GGR*N:C%2/ M7^F;VT(3`P6U/0F7-E>)G].9Q_RC[E_1K:8([`_"SMQPRY-&WS,44N3U"R>A[.FSF(RLN*/U37V6K,8 M`HQ+D`WJV.?US4QX6^&46$IMZ;L.&:<0,D7VNJ:#S(*EG,4X?$3MXP+T(QWR M8:G:$^2SKM08P+=Z+"0C62,`"W8"CG(9--Q9]W/]5LM:1KV3=M8JL7OL,I=2/G&R92"5$ M3/XU-.U[P-?%Y+`-#:(U-,^FR?5*DOU+1A5 MSD?"UA,=0,3_35R)RSSV+Y38;.(W8^U`W>2)MG">@(INJTZ@Q$,W@N;IP\!7 M687863FRK_$L0[\%PL#*B8.[!W%V=O_EW0'?:PV70W)]4NFLO%*(HP.'.[K8 MF&LQY`>MO^GQZ,ZWCG'L!5\1K^4.EX>EB^RQEK"BN6*D#"O_P@GM.-?5053/ MQ_'"U)WW%`6D5ZIX/V3ZQ6^(U!U*NGE,B)76B1I^,YAY>0)VH12IIWD=@IJH M6_ZVV]-"DEBKQL4P=NG8`7KPU[0*/S2P9#_]%B9V33K@NI.T:+[,?$^RX5".C]U\(!76'M.1*"& M!ZZVF,P,.FX\#&0CP1PH9&K$A]3XH26+'I@?1RK%RYAZ25B**:^.ZYQ(IU%@ M5VW@62H#DMN"2;9!"&W\J_EY:/PBPPE3$7?+<;'[YKZ=K\Z)P/SN.;&3AR&6$C?"#?B`=_V8. MW_NV\%BLZ2T<`S1.XX(\6!=94!AU/IC^[+9,"49)VI6F\V2_+F&A/B^_F0-I MTD?,'U*`,3^EJS*N.%JLO]FL>"W)#'^%,#GD-FW/;%/7I8BYY`@-<@YVT<=& M+G2&3)OG!.9U]UC:&)X*:FHPU=LF2VX5.,FHJ;(UP[0G?8%),'42@?J]U%)'K/.ML`VO_&3K!5LM M(*[A8C^6B9-"\&9ZB-55;>Z=MSR\8G9%'V'%3P"#1@E*26YJ3)%&F8VGC0]2FB[U7)A:]2TQ4VI`)E1F M1YS3`KT<)Y1:,U'*C"/_=N-8<+Q%P7PSJN!VDL[*?F&WPR>B8454>/K3U:DG M26,>G6D^EF]1[`^"IS4S^RCRY^ZHO$_H+-($U/Z`?!40150 M09>'LG-JT(LZPZ?[`NES0,.285H)7:YIHO9!D@58CC;Q0(?O=M&3)4'V\:FN MS4>QV7L59_G.L:G1\E>X"/6D6=R"1+U7CCO,U%[G&3CLV6$Y+%Y54OXN[HJZ MQX\FZH/O/=P!YEK-#FX8@F+&K%E953AMB"'R\R%VCR&UT"K>27)A-KQW/C'" M9_)3=+#A:K8"8^V)TA MX19=F4H,#$^W'_]*^_H:;XL9^UOJ7CIW&V115H@YFH/ZL7%,($4J>3,X-[&$ M]CV[;BG?'MH\-K.E*V=$@X8.;1)I\K5XP[3K>8[U9$;:&GS[L6=A1,"F_N%* M)-N M]+^)NM.461Z3">UL[)249?OTJW;NASACW[3.,+S3H-%:S MN/OOT(19VY_7]3P^&?:@Y"ROUE%81V<_[9]4.Z>G^V>GI>;=B[V5UM2_4>WZ ML23U4V[H`\9J(LGLCVL!>VIK/85>:@8?["%'T MOTCH*/:C]J6/@Z#QE+AKW:/*D^+^5+F^32],^+B!P7[_F:'9WT?!M#V&-]HD1S MW#Z%!1(]^#9<6!]E:R/BO\:W^<(YX]?A2JEX(6VYPY/L9BG7$2'R,WIU:H9* MZ@J#2##1>_>K'6_X[=?5">$2GRJSX`;ER%E#%%>\MNKO='W8YT^Z*T^GV__> M-XAIYC-P'&UG6XDI%-3>T+C(0*<$9#0K?^V&)L!C?4R\ M),YQN,T+T2;!C=N+7#>.Y'J6B^_9"S@A7W<+V#^($YTU=EIU.&R[;E3"TI9; M#Q^2X:N].W_<>?5FWQ#%CR?O]O>J-P<[KP[>D,Q<^[D:/B>2W?O#HG;OSYOL M(-]Z[#%:->\O3M$!.;X7/'+#ON4BBLP%AJODD"<:[-]N:&NMKQ+V$!H4[VEO7-DZ6(5+_``[7_>?/7IKEET*Z_\(O%BT/;QUXBY?"P@1H M@\5U,F"9'%\E@<3>B\1/:_WGS^T(EO<5$,U%BIF'J'(IU4&=A\%!5J:`YDWE MBQZ_,++8M>J'X?M-QRJ];^X0F"Z6?_WO_S?:3$/O3DI,Q%#&8B@_O&,=&R#F MEEHX9BI!9G5.ZMX<6:#VK>R.$]99]\C*L"Y:W@5OP9^E:A$(+`S3>ZW6!UF4 M@VXP9SG*Q)/'O_+ZCL51\*,$)C+C1O4\/I[R^25Z+D).CEHL0N!.K5[@KBYR MRF+G+5[P0R`)LVB3T)G=V0,].K_'Y![(F.SMO\+D<9FY=#C[*2&J+F`I4(\,'WN!F?]`Y$SRD(3[ M@7JZZ=^/D6?^,EK+LA,D3LV5#H:V]YKB_;1#,GU??R5PJMO1LA MFG&2..&>5VDR8EBN3?50WM7X4V67!0;2)&^2 M>%1%$!2.$PO*E3.(`3#-8VN$Z4-DR$:U"(BN@V1C;M6R6!`>$#6->-'<-TAG M`5:/-P#Z7L,;=C)V%&\T,$JU+ZJ)O!8UC'8EC<)R=EV/;RNEX9X]LS26!;IHF;1UD$JF(E[ M2\%&7V/@[?Y6.&CKFQ]7)KX^762S0F M^MX,5LXI)LVI]]T:>*&H34`^'FI%3^,^[4//GV]U5.@>S;=!;=_ELQ/%_H*\ M1\$A,RI^HQ-K*YUT+NC.*0?5>.V$LEIUS/)V1#F[TO#^T^<^ETLVTMSB,W5& MN9Y0U-C7Z_6(H]<-.,)O%R3(%%77S#X[T.@N(GDW5%HIT`_*Y-+.$-,?S#OE MOCCY>K9)K16;UKPV%9DZ+':K3DGJX_G+=$*]88*,RTQ]Y.K@[ZX*N)75G*R_ M50?L]AM.8_465PCZ3Z$#2M-^H/HP'$]<%/JIRQ'O#&O&!6$LJC*,;>N) M^#T6Y4`5<#3-C3@LP0N![ZFSH]0(4R+&KCD@PI^RTM&"FX1(#]1L.*BE.=I966OU@Y@!-"0K$+/QL1NI\&G;$WP-6-@Q-8C* M)@%(NK9$?Y1HP$.B$*DGH28J,0V@Q;J9G3O2D#:VH@>"_J7PSF(X#9AI"M`;-04>ZH/^A:/#&MMXE,$EO,-EEENK!+C]I6%1Y'MUT^;P`Q,]_KK3_UL6G%2M$L\/\-'F;_CI.N3-YUY/>HS?Y36)?/ MGXXR\G]GH2(BX>D5)1]O9YY+N$$FS-+<4XL2 M")"3ARG%X!]L-4T+*022GK^KKLJ8:YJ!NXH<4V-77S_GWLGT)BM3E MU2\.=[5EZ5:D)--X'7\'.Q94U%=:,^&UN\.<:36B?\=?8?F^=,,O19CL/$I@ MX1C1"C]W,8-I'_#+7?FOE)%\IYG>=V1W2B$(^H)J1(C\KO[.EV`&8C25_%-3(?1[ZLLC-%6Z MA[=VBIUKD-KT$+[<3D7LZ&*UVLIB]'_;"9T4X$$EKBULDIP$>J>$0*=+"8I24T1H&G>*##LR;RK!>9*0YS1CE,<37[Q1 M.\YD5W)^_M3GS+[CVXT3Y:!+Y:-8E81)^?.)C_[\:-QMO4B:T0^)4S MGNGBO>AG1"4=]%NK`TSQ]%NO M]UZN>]HK,1LJ!%IG8J:PS;84T-=C+,G2PLG[+/,]0:XZG8D(+5YX613_WNX$EWZ.:/I1%5 M`DJ2,9P2;4Z)K],Z_Y^]<\^-X]CR]%8*!@W+`"7S(4I43]\+E/B0V4V1O"1E MM]$8-/B4:%,DP6)9TD7_T7OH#6@%LP@M958RW^^=*#)Q7@FNP>J5XH>)T.[N'&T5*Q/H/0VK/#P:;^[LO!_L;V\-# M$B3VA@2ZZN#6CC69W`N9$?V1K<4%"WG6ZG;K^Y\^*GEE^#D;P&R)(%U\VAGA M4@:D!(%JQ"U'O:-\8_N:(K5+@C_T,@#ZF1@3W!][>$&G3YTC1M-()MF!>6:UFRS0A"G'7FC,+-5!YK[*D M:U_!YMN^A(V?P<.'N0I8U\ MD_#K$,E=1TOQC="@0\_,IA58'NGP:D-=> M+A3<%A84UVL#"XKK_H(4RGK@%,MV4ICGV6":!'S\YZ)#Y:88I'6<8AOZOVZ0 M(6IOU#4E@!N<"S6BSE$KD60`1+JFQUI09)@0^G2C?[)30FH"+50%N/4P?1]2 M(SCE'P?^0^MR;NN1<9M5$8_Y*QQ%C1 M$8:Z<-P.Y<(Q)HP+?AR8>^N$%0[YF,L@<:2@!!:<]NI4)+J,R1"Z?;BD2@X>#M>'>UN%P>["],3S8*!\.2>Z43%!N M:IN4"DXLOE^#::__?__KOR=_070:!93UVS%1:)8798`D?=S06H:YR+X!6:DI MJU8",MV])*=M\.FCI96OE9GQP5NIEV4G4>8)P#&@I`L8IRA@\4W!/8DV/BD< MN.%V98.T0EETT[AX.W[K>XWZ@-0%M!;6($V,97R*:2RI@]E1(N3 M*YK"(TF5$H#@36U]TY%"Z$@*]I.5SK?A2/'\>CBJ%+YAE*+F5N,9IJL.?6?H MWT2)WYN!#OMOKO>V`[_E>B;3):QDU2#"2I0(J6EIN0O/SXZL)F6Y*@H0\;M\ M92]'P/)'7V^*G;R3Z\LM.J=8[K\EP:H MJ+IP,I2IP*-87?31E3*0E*(4CJ+/&(S0TQ#"J,7$/A7(7UAMTN><_46YD+@O M&F#R1K-W;>O_D6Z_/;%8SQA&81KR[UQZ=Y:-R4X#%)J0V/PP<)+F?L48\J6BID+B`F0CA'2G#2&#)IL@V!U)["E0 MD;;L3*'WJ"P78&X^4B2G\M>1SITG8VOB3(9-[ADUWPMJ".3'F]I^TWBQ6:?W M\^5$K]!!7-7YP0^S>WOQ&@J_I!F3!R`I&U5C"-W_PJ-%U[K\M/;.2&VQ\M9! M3T/K(.>Y2I]-'MN01TM_R5N&=W,Q><>)SO39X+MUD+G?=B(F`0+/Z\[O2S4, M;]!$Y5*BL]'"MR3TFLT"51G,=+A>D`%_K8D5A%*D7O<7M)_+_.3M.T+-RC^M M#U4,':I^2>F#"-IN\/DU+82UAW7*)$Z40*,.Q]8T/5ZR>6<01'I*@+5M9YO0 MWP(>P[O'1$S5PP1)QN;ADJ?1Z9<]]PVB0-U_K)+"[I>*G)#8+^J!_+WL!#R+ M#5P'JA:_%3>]82Y9W$SX,`N>9(D=6H#B`9&B'EPT)HYGVY/.O]H/*QUHI:_( M..=V&$O3B])MRC3_+RXQ]ZU;K1';#*T>[9]\TJ\J,"W[8Z`0JZ\Y5CB@R4,Q M8L^6*QZ%B41/CE@#;8[4A9#X4K"N3#?(<^N=#[3NR4+0?I-L"EL:[ M,$8NU5Y:SWG!!?=BZW(#ZA-I#0GX^4KI,=9CEZ!$A6Z[C5/]// M+K&':6`;C`\JBN&,3L@G`9Z+;Y4QV$TT%O7<8N8)#C)LL4L`YT>/RE"910[N MY(\U>15MIMS5"EF9D%OP4B2\E:!2Z MH,&\Y)CA!3,6P-B[P9SWJ"F-S8P:/=.M.�G-_NG0'V?"MQ<[ M/QY4$\Y!R@*=CY>6EB--#-:;"-W!+)[0<6H$CZQ>S_"P2/B0B";5 ME4\BRHG;[:R!:WU3+#]6>J7&SBAF8WA^7\E?=! M>/7DL:<2FK256B^&1%U29@GBI:BP;,<^I]<->K#'D#XB;&2P0>OT+6=Y!5:& MD';7".Z,1YMT/\EUH?OQ\$GW">N6PELPNYD90"W_*I2MR'^K$X?O(?Z:3T6@ M?VG&X/Z6:>*O<5"D?=R?+S#L&`76/4K%K312X,G"\OS3Q9RR9Y4FA$9`TFF+?%<_)*V<]I-SVY/<6UN>'9JCN!+\ZM3OO;%N.UREOZF M_HIX8+^P&H9F&'!PPC5%VGLV_V25(1++S_HXDZDT*;$!#`T7G'(@G9[">NC$ MI';AK^Y;KF9T>>4U`M-[#X7(AXQZV+@),-Q&]#HF% M"?9R?'GAVA^VRRE"^*GLL"<9OLS.)9Z:%?9D.7^[+9<.P0S^2`]:Q/<@1 M$W;X>\,]M\54E^?`VE;W42D#Y3LTZ4:J+.%267R6\Y?9\063?Q'+2P9Q(Y3R M<[7Y301%5V.)_"T[<4K)DJNS;4.5'+/KZ(3;SOX(#A7:$WQID=/!H>Q$W79N MOD.:B.H,\S@7<[!BSJ(8B MC^=7G^:.GO:'I.9G!UJ54E?FL%^MD*N18!(SZZ8R;<-YA_>&&Y5NQDXR-)]'3[NFPT88ZP&(B(&?$A6[R[@TQ3?6N M"T-N2/_P*/)IUH/'&A*%!#LI7J=*6C@;(+A-@ICH=K/-(BX$@C1TE9@WB=<6 M`(_YB3BY8-JME[MX]($242Q9`928**2NCR\O-"=,$2Q+@%;*CG+KGRRL!.[5 M>$&[\3?6V^#0\0?H$`>O;#$].U;[$,T>VV!0-"B@),??)0P;DBZ6>HQW(OEZ M7CI+ZP*3$GZ4U.]&]188U;UX^=E*!4`TCCS9HT#1L+=<5XUWCZ&7^?IRA,0ZN9/6.[W5E\57=$^PA3*I<=E\HYY>U)DDY!PK[=[QS6,L@!OQ M4/F:$W`!F2+X7=GZ4:Y$6\L]O"V46G5S'_(Q*&SN_CYP7VZ<]R^A(W.2T@X5?N)`_+W>?3!(($Z"Y@&YY28)C\Q M6UZQW#N*H2"R+F0[M:X6V7VU''`!>;*%6O&B1(>IST%DQD+=QL#ZO6BOPNA= MSP$L=G8E;'[,-'Z!',PC;VVR8DNH=K=)2S_P>=7JW:I21`/89,8 ML_5'FO'8SVFV^LO#@Q.25Y3S9#M]J*").`O%\6>7:!FM9\(P3Y+!X!<^_ZPU MIHNL(B0)620??)^W%Z-?'IZK%U\*Y2B&XS_&/*W!APN583YP\0W-%(-L1W8I=G'<02M]?.U"1]Q-;,_[<12PM+8XI";C#H(69+9H\61 M1M8DLLD88YXA+PE/_"EM@O*8>$T.HD=YURECA.&*!NX,"4M%PBU9+:'D4_O4W3S$#7:#''KU MZ.`1PQC8X96E.!FC"//BU+DTMH(U@+;2YMH[#DAK!5.0AR%M15;PCIC.`8M: MR$G;WV"7)V&D6?1)1Q1O>RAP*%;NU*1E-L:D!?@@#K?09=IEP3R1D]0TX3/$[WJKCSR5$!JKU MPB%I/RTN(F"K70*@5<^I<'896-ISN6$'YHBO=M26S@\>!\>3LS&M&E*>^8H- M<-5AT)]#RP63>(.0QQN.^TZ*]!]C4M*]6&OGG M,$(K=LE&FC3O>GF5.&;&$ZMBJPUC.B"E$>4#N\IO2Z&P#[LN- M;Z_*Y])BB?U4@QJ&9"VFGG&]Z.RW9?EKS#EF[*-X+S"EO=N[476&`[-J/GW< MDJK-\.YR6Z^4=U/^<;7CJ%O6`+?\N^7$EG]\ M?L04!JP!"#;I,M'>+)_5>>I=`&1A\'=@V/G91<F.1)SF>=O9K:"MM/GH)WRK6#B2)WJ7>QRH:44R4N MT$I!$RP&#[ZR'_7?2@F-B:Q"='%V@RYD'Z*";AZ;H1I9@`1LL(@GZ&"280@/ M8Z\5E^\\K_8=&84)AYE9_2)-5^J88[Z#K*A/VM;,]IB:[,6;,?(`EIZ$N'EQ M#F$]6"'3&:DM"+>5"1<`'"$7`0!$IW1]S729)-T;.7I>KRQ9H@OB_;B;X/Q: M[F&PT5R%7T>IT*H^5_WKTQ!DCXYB5\$S9I_Y.<38R+H^Y4`5W9ED2ZS]Z(J" MT\9%-K<<)@.X(&)UE[@1FX).=7YQB[@,;;X%29"4LZTWGI9).Z`-4Y!/.7)V M9:_YQTU>)09@^X\`X].+2+6(3G'=U*4MPC_1BJV5-PB`T[)(!:5.41L<$,WE MISS^F,"/)66#(JP:(:D-JK6.6Y-IL/0(GXX)'\<'M'+:1(\N3EJ%J=E+'9C( M,G.+JT9)42M7VQ?AG4/-TZYZWE37\\5'@S]7&J,]3G#O1*:286>$88XV(9.A M':#I82:)EOA'AW;[QY),+&]ZLT][_C%,VBA? M:.TZ^*B;G:;N8ZWSX$RX(/"$;J4XP"039F=L(1'8IALSY=47^U9O.D3C6O7UL2NOW/.^&>5B\0A5JSPA>XMN`R*8HRSWTAGL M9!BI^0H-S'*+-E^@A0KOTFJUX;?<:]DZ6G0U/UDS\^33QP.9-N49-QJ\JWX2 MG5I0C6E?0+W\?3^ZP\H?UAH][M/'[8OSZLT'/Z%BCRK?P8.C^D_'Q9^L_T'D MQG]2^X,_M.U!=M:LQ0&@&B1<#PQU=/$^MC_Q,57BQ^XW9^B'U9G*A_E:]<]> M"#6ZXUJ#HW/`=#!XH(@BI=&'>H(#-;FR_CIXC4_>,)+=:[X@8%5V8A.^O;@S MH^W(IG5%Z]`GE-NCD,2_D9C M2@!\4=UNN1^AEI@]C`\TTQ@D.#FK>.EI+!@WI`FER#$`@XMMI&^J9O8,MX3] M@Z+^R[/7`$?K4O"NUA2>`1`LBH!^_"O;6!QGISW'<,L`Q+(OL"/]/?Y3KFO3 M\O"A8>KX#>DJZ$#X*W5+RC9@=9TE>HE4=WR'=F-$Q=DP*7_1DN(1!9:&@3`!%3, M00%F:"M6?*^7\,J.K^YL7H<:LC7_S!HBS.M33-LEH`87X##O+KR+__@F?C=] M24=PR#4[]GN[!//QU_FQ%',%6A8,[$6D7H150.WT3-/^8&O^/?<#ZP9ZERNI M^1`XA'U;2LS3^6=]P95A%FLPZ9H33*ZK/QH<-`7X1\TP[Z0+YL0=\`&W+R%- MT3[&H05+<\]_J!BW9R.T#XR>Z42[ESB![TINDS!;!>:)FP7OM)>Q67FE>$): MZ"1W9@XV5):^#_HCZ\7"\U\'>]$U&B21%-?`WNUA3J!VI+'=`XZ;O.89+,M7 M(R(I*DP>Q@>K7W^;*!0Z=@#VQ;5>S\)N`^RR*:FV84Z'[5%'@U^?`/#M"-W?-$11>OE M9B+,V3C*KQ>G.$1-#MV>\44W$K'N!.]YM.C656;7EE\+UW%Z1H6\ZIK;HG@* MI,,BXL(P5KM?\M4XBU^P4C&0EGZ;P2YLWZ3]JI.8%%1U/&"2&QN.'.J&GCVC M85D;7QR.B6T3,VU38A1$]%E5ZQ7X@]J:&ELNQ@]FV.[;J=2V;K?(LIU` M'D03Z>@>IM$]?HP+=F4IDX"]F)FA9=&UMN3?W3LHTM\$$W/6YSF1W%3X_O.* MA6::4)NQ&X=,W+/W_3F/KJ<&'U!:Q8?5S<162JPA9RG\=^I#T2*8>K,LWL^: M\G7L6G[V1DEP*7@UZ1R@0,#?_/-#>_9%!9C9F%N]1_4A`=W23"4=7LR.WI^) MY,3;,+5CKYSIS*T7_`5C@V&UP!`UP9&15Y0C,S*L^FQ?F&%5?"F7H_>@0(I? M5BCH6NVH`ZC/4L9\IE!?6WMJZ6--S4V#Y#=)4W&1!UF&.ZPQK2`A%`8I)R7I MU>]-)[63ELZC(_1NHH^TRFY%XMC]A+4?K/"K.]X+WQK.#]:(G\\/-HS2-J=2 M&K8X"=)2"\)(;!.KM/BQ]Z%+B2`4(1-!<2)#ZO/C_7U0C/54T+Z#U.P[_'S> MITJO]3UH?C`$1(O`HR8S.S5/_$1!T=#J'Z^JU+CV^U+^2EMN?QF-9#;Y64MP M,7!UXT[=YGJQ(9/=,W*K#FGM52'UYYA/D7B(*[&?)ZH/D`2-/52LI2[M!O,D MMY-PPGKN%.&%0B$S4BN)-?@"(MDIK!$&WR8";.G`];IJ`AHE M,.ILH^%),N<^LDYE.SC,/K<'J.VSW<,NR-1`;BZ:;7!+2SB2":!Y%?@K<#HJ MFU:Z9VQ;.N6D77RHP<'L=CI8A"Q>2]3$(#XB@OL_/4`K!`6\N9WRC];]LX%7)E/BR-23!J!E=A[$1(3^@T='T9`7! M31BF6-VLF\O88H,W?CL"0X$O3WR$BZ[PT\>YI[1#43%T"UG(RPQN>JL?QH7W M\]A;BENMQJS35*N3:Z.YI\A.3\HET&K-_HRW)#C/Q2FC=K^/EZWZ][=A3:D. M%:3:@X2%'F\=01*5DH%IR"VH1_\^"'!S/4(2<0<$RA#V>*-T"OFU;Q150R5? MHH..J"*^F-7#ZM&:^N?H'VD>J^;%R0!\"@%ZH# MB$782,43O&KH)",H0*&&@&HL?@FNTS59;(O`J'`O&S;BWSPA=GQ[]H;L9M<1 M^'?=EW=[]P"M \\/UP?Z.\KXVC6^:CO!X-]F#%![+9)O#AYT063AR\4K?X MG.6WVUN(PQ2U$FY66;Q-Q]_\/6XX"RQ@55B,C]4OKG%+ZX+C!IUP`(?X#<2@M4FT;((_?(GR(IJ'S6%!#@4OX=4Y< MV>>"69MMFA=UX&-\-U>"I>XJ/X7)S+`:>[''-4I2*1BCT`TRYHY&YAJCVE-. M:!#*`=@&;0(9J!/KJJA-Y:!J3-4Z>O\BMOVF>3,1FJ!$6FRR)W]#Y_.;28]WAJ_Z:T@#RBJS*9HAY%A&D'Q, M3X0NG,,^X(ISSP5;H8?QB^R.)YS%X'.%4ROO:^#<^>W-F$R:$$$\G8J+@HI> MG&FNG5V]*W*Y&%=F`=$@NJ:_:T#$`XPK`?>@+P4,<:_;;DPM,8=?)3/&U+X2#?#'%*6HPWQ+5D9F6X45U%X6O[@;$M7FN^L?&K][(KIE*0(S+)` MBZ'X\1[6+"^@;$9;Y4>[MV:ACIR4R]>&W.##=(4V;-#SL!XD'NS8[L5B5/%=5&]>S(.4NF!>8VOQR.`.*KO:"WSE`7385BRZ/(('>\\ MO\<[+^[QSL$]WOE^VCON8XP<;M)II:G5OS>E8C$+NWPF0+:"4M_S6SMKNR\W M!H?#?ZM-KRUF,)``=GCT'ADY4MZ]6A;/E*EFOAR8C+27:+@DKJ-\$D4?Q//` ME1#5E<9#D``-]`J\.SXC.)T-GC@G?G^+:L>;VM/=T7LEG_78KZ5;267PR&]" MX%2>H";!3N"X"&'#9M6N[>QN6VW@">FS']@)5X2($:]M/J@\+?1+](!:QU]9 MF5_V.89!9*%1*T\=DH#]2B?T=,&EA>7E1X-7*?F^G0Q&KJ0!97EU2=\0_S3C M3B-0-*/B:BQ_\*D*XS0`2((`3KVR\/7@^MT522%O+FX&)Y;I%725:[1!NP$C MS>1,MD"E4IULX,;5'0D!EQ>D8=H7U[)GQ/90\;LV=">>S)5W+;+D[KEKW):W!9QF([&\5_$8SJ7 MZ7[.4!+NYN.76_Y1M_`#QI#,Y4PHQ[3V("2U;KIZ_1!R?\L!^3^Z6W>[DH)- M[ZK1&PZ`C65#M`#W!4G*)W>!4R25MN:X@/[(O%IWD5DXCM2<0%<-O^>.T5R@ M8J!V&FTZ<1&L$ZF;8BZZM)S!^`P:?NNJ@]`+4HLMUHS$<25VU-8^:Q5FO?YV MI8JN]TN:LU'%Z;*"<3LH5KH!KGSP^?7U+]_IQ*<7J.*>QRPF<7[QGLMW,)3O M#/&0J3(I8[4&*2X19*@W\\/1Y=AOS9BNTL7+)74?S0X0TE@AR&G!/I.3%,DP MFEZZH_TBN]+2UX4W3=4`=QD$L8T."E<8*,9PRHT3Q[F8J&9-5C:#,J#%QJCB MS)`._&3Y\=<>$\,'=RFW"'))A&\B1ZXBB8KLOOUS4DC8:J_J.C0R+H'Q/!RS MK24(N<'KSAV6*TBK\OGLL/:[B[\'Z`,*<]V4CZ]Y$C=[U7$=[:<\*&8SY4X? M+RP^^-=O!WO;PYWR@_&$J@ZPM0?")+6-X<^NCTFH<5+53-69BK&$6)/0<%4@,5Y=J5,%0^H,0"=PC;]# M4I;"Z4F22XO!R\MRDIWB!.8A$(Y>GNEEKL^?E>3.*NU%-4JB-)^R-AK8Z"/E M,JN\`OW)?=/:/K9K:`7O>6%GEZ'I4E"36(!^+.[>NVO1OH053L"P5L1Q#:\# MDS55\UB;O*(-!E.>36U+A]"N`@5Q/I/Q]CECGAA[/KO0R4+/:J,N$NR*C>Y= M[;>T$K60>'U$95'#+VZ`ED44G9US MDM9R\P$`ED*;]XR(,(V)JC>187+%RA<[9XRS>3#BZ;AD-!'Y?MNBSURMEGH< M@!)/8>IZE`_^3D=Y2QL93=E(F2-Y,;9B$AZFJ$#VOTB(>J?!H3!)BE8*TO[$]/*3>:&^X?_C3X'!_N',P7#OHW\W:;YAJAHTS;YPV_]R&PU/E?7SU,.LLQVJ!$P%P< MJQH2E7U&J+45I!F?!LU#2""G--&V)2=G(M>;)0[A(8P%CT`%^!6M&V'WYCCW M4U60XBB;9\>W8UT.0YRBK99(NZEF^_RST-WQCSZ+IZ,SD>@>!XD)*'_^I83H MD'5X-3S/>=%4Y%I<]5[H?_XY0*XAONG+P>-[W4<<,^39_!F1_`F(Y>>@O[8A M5ILH(3J8F`3G"?^'8'4L0$"0W%YCLZ"@KVWLFJ1=V]Q-6J'I5.9+F<.%X4TY MQ7?G!H$_E"%2&,EUS!IM>=H\VI*-=E[YMHO27U+\0"SO/K3QCW073A?A*HQ1 M1KDPG38BF/\A<,I[3M-4_AXWTB]"_@SJ")W%O_!)_@1AV#0%NL^E_..($%AO M.DH0Z_=C6G`S29]&ITZ\2CZZ>_,CR\L,/:3A^94Z M7OWEJ]$8WXN,BIN[K[[[ZS^/_NY_7ES0OTZN+UD)`+P]^\M7B_K+[29&A#]R MB'HVXIOO&.K^EAYY_'I^]%9FBBULCW]WN^AO]2^PBZX:0J[.&]8_MRJ,O2="E+EHI,\E3*I/" M7`M!]B7)%_X=6X#C`FDUAPDFB`O#3Q\E#70A2#R?RP[>'9T79)#@@5)EH:$W=I?MJF45U\%@AXZ%)E MB;&W;04`2L)LA#MHH5F7,38[2):#_AK0NE=+T`[FXH@Q.YT+Y/)P2E]*C5!C MR*7\Y&.*6:/-@..LE2E&5VU9D6%4%"<$T#*Q@D])"1$SK!]3H$<7$!3__^ZO M&8ZIBE%+MDG>AIEBJN,Z/QY?7-H5\>T?\?7*LSL_V+J\O+BZOAC%$9NY3@RB M%[,\&\7KC3K@;[R/)9F[YXQ8)TSP(`R_XII;-N"WQCNB,]K=(T>G1+Q#WP_" M%SY&E")!/'[60)/4J$-X9-1"`LK;!GN^WCDS]22KHXJGM+0)^;`$F;LRL2XI M`6B-?>W8A3E)G_2T$+`6=](Q_@Q0#S(K$639"$C6JEB\^]OY^.K7\F68]TB- MLRVX%;Q#(#>7I;+Q&<:^=$SP5`0RXJ3<7O'X,'B5.!H_:EV3*"9VC0A4&!TL MX1JB@\1RK^1E)EDH)L27R?"APKG(J#&B4Q0)-9-+%SD*R*)8:[6252LEW4E3FEDLJC"_3`(*R(P`VGZI(K_B2LB=# M;\43PGSZD.068?"N&/P3)H9I.U%R!ZF2Z(2W_T M[9*43D%I*3%G$*M#(O3.ZD@*0UN4;N8S"4&2GE"K;U'G^1*C@0BM$F>(?(0F96TMASGE<3"OS$B M1``]&!K4V4[L#/Q15DA"5/Z6^.6?-;[I?W2(J+@8))#?\*ZH^RC(250EZ4TA MJ-*7"E<(U"R..K<%U]5"T_!*O5L!S[<"""A]I>9O MVO*Y=9^5]D/G)AVAJY]X2=PD/+[<.GRYL7-X,!CNK`_6=G<.MW9>;.RL;=4Y MD`@LC>0T\6:FM,AMNO.<#88Q#EDE@>S&.$&8OTEMD`1P M%)5\&EC(%(4XE0>'%8*=CK*I*#6J=%S8`]/*O4HSIDPYA+A)\O*!'>)C;L`- MS$LBNV7G@FRB`RX<4+_Y\)RPC?>[ZQ%U&_'>[ZNT919*+@Y$,9%)"S\Y*H\!\(FD['K'D M0!"F;,:)"#_UOB;>R?;X^-C,X<.S]T<@I4X9D<_ZJN,8F'PMB_./GZY4U^(W MI'L4EE<8>GA]!P89Y@?[R:A%>&K4P:FQO1H=(_G'=(7BML;OYE:9?;ZXZ/?Z MY-G\BOQ(**T:Z`7SO?Q0?7?3LW'EP7D[?FL;8!\G&5<;F_ZG2/V)4KXN+\VS MP40LI?Z*R14,AYON9+2X3;AJ,>6>\3D_P06L2`/>-:5*8YLO^TC.DGD;I9.7 M$Z;`.J6'#%)/$))A?GU#3/`MF$K6LB@7__18,[[&EH`0SN:)GO'N(70J0Z#J M@.@PQK5;%B9]",9P9>A7=WM#E=F%9)9I%+\1N&V'K!Y7D.P+)A3!'M"DX?2V>@2!0 MI;`HL\%H3J%_-F0\1WA\96GE$1WKK`-,4B2,I-E?2*1;_;I-&G'_OH/&:VW8 M#M02XPI?C`B7?=G%_QCY>6F;2AN'><36B[+X.`N)V@Q(+.]^ZXJ&>^@*SMOR M8PHB9M9ZDUB@LFES4H8`1E#2)5\"'<0.XHG_\01SD4&XRP"[J)7D0>O&+65. M,(\".'1\45(RM:X!VA?F1*.S,VO>"FZ<78%S=#4^ M1@#!\RK-UU>[BH.@'T7E"L,BZO;41RHT;R#I3D^56X=+"QO;&F)*F_O2)+:F-_ M^Z?!YM;.$!UPN#U8'QX.2^3[&Y(,N02J-W;9.L5H$_(BIWYC\.#5SO#5^A;[ M^+;(/>[Y_*>/AM#EKY;XTUGOIFP!?EB8+U])ZGSGKSMDA!\P4:!25E_<*HN6 MLA4E^#Y0(GW18_WNKWK7?\D\QP\-/TX,G4.!7;FC.`YM$$?Z"*-:;P17=_GB MP<8+T^:KOY\Y8]PG?$I$#9[;G]3V(P,I^2Y,%'4:C`2IK\=$WES9]@Q'2%D- M/#`W6,ZDY,B_$*N:K>,+L*$.AAQ24A&AO;;HL>)2%1_HA]M?SFQ7PG,>`TV- MCR,Z].EC:>ST\#T;_5/20%4A887L!L<.23=";_OT<3=['49D4(ARW&J21$A7 MXQ/D3=!N^1(L[)0"B7+37`&J5[C23,CWM2<,#NME&%0KK[\1DOJ$;! M,YN;!AX5PXG)SWS3BQ;@N#!,>'+Z!&"QUL-J/F_%UWQ$0]`_?43.2,"#)\T5 ME+%+XT-#1Z$M[_]]-$7-L`0U;3DL[0+#_:YOT0)UD#[U.R* M*.,Y$W,-U5TF',O;_NL-Z5&`,G\K5#?- M+-6(Q(R$@!]'2N``%8S1./RYG<@5XIZ;;&V6H\Y*8E36JBYM2D&NFR3&Y:LJ MEI?!Y$WH5O+6_5K+KF2%?\".6[Z^VSI\]?D,N\HW?=$V\+J?&1J=56L?O'I^ ML/&W5QL[AX.-'_C?!^7;=%N/+9XWE&,SJ>G0RX9M2[.)?`6]7/S-W[9:EE2) MV4S7.`XC.O$1J/Y*["B:X^*&]H=W].T0;^3F`T$<74JC\]CR^B@0I5Z`,3CA\RLH6682T9EQ/YN8LZR^, M=1MK,$66&W,2Z_RB&XS^<5%ZOB7X5=Z2,@.+?0(08>U06X+[P$/,9BQ!(MR) M$RB7-CV0#""TM+O&BCARZ)$=LQGD[$)3&,L2]WHF2@$6'JW4PZ[6-P[6]K?V ME.4_V-T6OU,%2R7)?*FO'XK9U=]F0CNUQ2#-[CD= MUD3[I&2I8N5N,`0_-I)6M(&*0!P/WO=J=(9S>+"-5Z3B2QMTAS@]Y:&U)D5@ M'>X9>G!M-Z7)@Y>X6,>6E\-W]F.+,&QEFRGW@S)3%##D%^JLI6$^EQ54@D:?*-?+X9%M!(8WCC/I@51SI&I#P[6_ MO=HZV(K8(J_;@S[8-V.4`9?)4#^%58N<6W^=:G_-.\WVS#9TGFS"+@>S[;P> M02SVDI@/-?_B&S[6F;(NUQEMMH5E""7;\\CU*W&.5NFCH,.E!T>'95R%LE*Q MVDIAV]J1=-C=-[+H`<[>_BY-DRBR$9DA5+;V9(CTPC)0')V6AC\-GV]OV&O\ M7=]XSK=>[4]XW&BV0;#!OV]+S]^2 M0OB_RSMS6G#>S'O@(W@_&NPV_6UF?",+(_5["KD;=VI*?B$X@\]PFLJR17F? M`J)#2DIA0R*X74[T[R^MX4MUIH,&#XOCN3+=L1S,>0M$D0E044W'XX?8@WU? MW]D]Y&Y:5[W^`QX&_KBYO_MRD)=I3;KTX,)]J?R$X)$])[U9%:![W;/G6C\. M'@[6CFZH7X<;6L"H#[D25P$&\9O!;>PO\C7G4]@\[34K4-FHJ^]WM]4L>%\KULEZZV_!@S7R?0=?92]I0TQ$;]B>N4'_Q] MQQ2VN]3UXI-TV:RGED2RNY'60W>M;1E<>QA^!RH=*L\PA+&8BTK-.FCO$*EN MA[8T6VZ1XYDQ?.>^WT;CZGPO78;^"0RO]NT5EN/G]=&Z2&69J% MV%K3S6B'9=P2_X$OO7=NL]V[R0:3Y>CV489E;[\^#%`Y'<#5=^ M<-U*NIWGL=WTO-27C!(/FFX]N?2+ZCI,?MA$W;/S#1ZLG^$7N<2__.I@?3!7 M774F2M-B4_0$%60K!4&*[\6(S&)(*;3$*4_7_"+=/7S+%%V21:3/E2_PR!A[ MQW3X77%]?6I8KA$ZV@X<4%`#PM!3Y9?,<5(3A[7 MO*F8L:AV9YN'2G/HD_?Y@Z=1@Y*?U^0V]0\E#GF?3F"%Z>T*9C(%] M13Z&U2C]P`U(CRSW?@`":6+;0WG)O7,1CL)@NXW==HN86[[[/!9(]%U$-!%! MS.0W;6S$2<@]\.YBF6*5AA):;$'7%U]>UN>>6\N M%\'I&4Z\,O.J+YG7`Z[(O0]GG+XT^/E;@5:O\+E`\V8C)4IT;.TS8-;Q]N?" M)G$.9UE6(Y$QD=PROY\#9*K4(?/G42POJ`:+FV;_@U3Z)%9UYYW;:CE?]-3. M-?[$EC=FHMF;0''2^().&U]0="!4>ORVPD^#:NO^YVKFM_]YN42$W^H7F@KF M.,X=Q4(6LCF]/O.@#5Z,W,S*;:4N.TL!K5H M"I4[=7B"1[-I>2;WW+WUNP4L:!+21H,-9<*4^UJ>^.N_J#O0XE//0"I?39IJ MOMM)`(U^%??+>RM3;]V`,:79"V1/D>&JLR/7.'3YQ0VZ?#_$O?0P)!O)<60- M'H/RJ875;<,I1E3F)?UY\A$2R$^NWQZK"[%4<#XW](&!3$]+TSF&[3K88$27[YGP\BU<7.&&`/26BS0& M,Q0O*I__//!'S%?>8)<]T4$UF1$)DF:8F3GP,T'""BBZG:9BME(CHF=PZV>K M=R_LL`X.CGMSNM8JDQC1.K%0N&M%VTV*1LMXZ=6)MZC3(&1XJYCE-#&7^V7B M>Q\F:B;IJ?F!)5W-#PZ5'E#B3_885%'^&@V:0FF>MMO6:VC18\#*(ZD?R'U##)BU+H6OGLI2$8&;U_$@&:/^/KU)6QIYG990[WL]:!\(` MRY][`+\ZP5=8O%+QLJW.X%_YX8ZG.@(J^;:\5LRDH M_NET9UJ(@B5E=Y!$=D=_";E).Q?//:0X7JTY.29YXV@^OKZE1@*]M[I_S/`( MS(>Q\6-H8Y1'Y-;7.W1%*:K+ M#Q>7'BY7CH?P_58^9VO$%VCU+@3_RJ]G>ET))-,;.DB*U:(Y-X/N8QE3Z;+^ M$Y=Q5QB_W-:LKAGV<:M`Q>SRZLSVUDQ-D,(-^M>P(+R')5Y$>?&_)2L8?0JY'5&6=H4K0E-F: MY>\P`2JP1LH+M[.4OUN`-^6".7CMP9A<,5%)]R>#=J;T0\_29#W+4J2GMB:Q MX)"PMC;2=M&>6IUOROV8MZ8IJ))]:ZMPKS?-4:ZXEO+-Q&0DO*3U37G>]QXX M4H]U$?7:Z`?EBA$`4XY0;20HM&).7B1>;GWH&J_JP"S%1+MOBLB[#DM-1\Q& M@1>]2@7GXN+EZFD_9Q[W[F'2\N0=7K/6[62I$T/;_?DX4ZF^!7IHIIV@6)<)/LD/C&I64&*:\G67M20,C.0OWN5(9"2I&]"%;;IWH,Q-9'Y(I2 M58L*QHC.G6C*!_G/J"N^6Q);;(`49/F((+?`X:P==<6+8,U(NXT(S<>R18=E2D5$*YG8X&W M)3"$7Z(EL[%;RX!LE/HJ/J(]*2>\*PE"`CMT.R1["_N?..^]L=+LC#[./AR_ M?C18\E+VRO"AIK_?_^P_ACK@$@"4O?'FLVZKR(RMT(=ON7I3/N^%GC?-$EOH ML>'>>VF4E>!V61C#<]C+H/?G`X)PZ!/?T]CA M2EGQN:($27GBL2?CE[LUG`I0J7%*]QM^7"C?W'B/TU^9X8TB7CXB?QOFV&WY M=\.X/E.;-(C3^A5O\U,U9RQ7[ND&5#YF"7Z!:"/-3F+]]GRL'3DER8U8%U8J M-43SHZ>(44C%T'@]+Y4 MU_KJ(`C'X2Z!,!/-`[6?35YL:#)OS1`K:;OF$KV#P':US31KOTQ^6F=IQFZ< M29A'!`K\IL"!(6Z5!E`ZKO?@!5J<9O<-T"A8,TPC2^YZGIT M!T?D+_>S,\8JK&U.)NL-RN/^5/4.G>/"AX\H/!$55B2V.4).,F9J)/(I%V)# MI@BPP6QOC#>P@4O4/+2:]]C36TK36?E$R8&SA_"KL(O9Z4C4B6HZU!6$3<@W MVI8,A]%LC7JD)9RS77[.YR92%1VQ;[&E"6)Z896:1$TN%$)IZU\66=##@EA? M/,NJO0E27SZ_M\>PFE[1]Q"\IHY,Y0'ND9PLX0*W. MMO5^/66HOMR,,.E8(]LEF7X[BG$["USI=E'*"BHYF`8MA*1RL%G2X@S%7&Q8:'4LCX/TK8TVU5;< M`+R3.*'^NXY7`XUQ2&]"+IL0&.W+)_NB9[E^I1(=G0D](GQ1]:ZB*0[/#'&W MW33"OL/@S`Y2=H=062HW:D62J(\%BE"VP(-#OVPQE?HJX&L0&V]N_5AHH204 MI$%7$;\CAZ)H_Q2';M":;R#0POR2"DMQWX64?*Z+OY,N_O16S.1\=9B)*2UG M+'!+,^-Y>U:+]+FU_U7$D[OKA%H^;-S'E MN'D#92O11LD8T_6&0DO*886@C!#5D`BXM2I5(S*/[BKKWJN/R2;;K-F1D&>? M`60?!>\H6:JPCYD[L3#)>$Z?WH(\&>=G+W$*>4#X-J_2&%@1@`FMUH@BJ=A1 M^`'#X2T;K]).8RT4_I+<*'YD(##*%+8])V\`RRTHH"U?=MQ6;*6S>RBW& M'5RU);>-JS:G"VI[N>QZ(\)`XL75'^D`P1]TYS$:+D8R>$Z3=^VZ"RKYE#WD M1PWT"CH13Z3B6[JE`&O90S127]OF=>5[Q\B1&/)L%`7*!FH<[7TU:I:6R8;\ M+Z!8_(_V5*QVB9.YF%4%.EF--V,`,AH'3Y@.3>1!O+1XTX;--=8DT`PDAS7( MSAD_&4AG>HYK8> M#DLA,+DE5YVFJ48W$NQ')IR&OIXEL_^GC2RRO154H3P(3S53,MTM"# M`<=9-&C`_,)+2/F=]>:M6D@$1E$,!2H2"CVHYT2FI(NS$QR>X'\#ZRUSSE-E M(2\HIQ:A;H.V7L&FI)[@&E,PMZE@V#<,OPMH0+[N=C8.+ZX]V583#0H;KU]G M+M'V)OK.:@X&A2=4K^I`A;>9]#E0X;>%*T2EEPVD!P_#S]+DMFE5B^DJ(/@0 M+F*07HYX?L_,_`=50#GH/(XL7#G4/*2J=^RD'1[)>.Q"H8P;S@:S"S0"X&X" MQ`:CZ8W8[4K^],$Z@^9-0@U4RJC.(>LTJ?J!GJV>O(R2`A8;`=U-2+^]-1&M M67"'9=Y?H/EJQ*/]^Q4I/:]GN&\GY\UGA.O/0IIXNT)`)TQTRT!XQ`_0F9*$ MG"#D$9CT+Y`P!K1!R4"KLW\`IRPIK@ED#\X:,3Y$)X288@E_3(%/"J)C\7/+ M%L,.4/+T^"H@Y=%9-:LN"\C-UU(D:K[^:`\QDC83%*S>OV<;,NN8#HH@CDG7 MT,U=PQ-G$DBC$17G+-=. MGUD1CI\M.%^(UK<1K%>\C*)UQ,I5BM'O"(BI>$WQKG)&?KIB$U%H`'ES`4_, M0`_6P([#$PPW/2*'D1\3^-!2*Y"2Z2@++#(V!+,PKGX$J$1;M'#X>F+U@!;C M$BGVE)D+"Y^7#&!CB.V@'4<8A/";+\T3OP2<2:*;+4?;_#X#P"OR08"+@BGE M_/$4?%2+AD*U^O$8WE?TTFFN<>5N'Z!T!/`_/&\N@-OLAY>ZD6_YCY&?*#J] M_RB@E3AEWWT-R@4<(H%5#0;;+3###+'="4),K\J9?3R/>#%\+P"+0-<%K&S2 M"2A?NHM@TK63]O&IF,-@/$!C-95\1H#LR@$Q9I4+W[8BKL]X,V'\Z5T&!XBR M`X[Y.]3>X)S/LC'VE1TCA@:(=P8$R,C(+,C"6@<+JGO5\S+=P=/XH<`9]/`'N(J!+\"?&IS_?=_*S^ M4-\']3.AW`-#TP.B$&66X+TJ2"M[%Q>:!`)V9^F9F$%D]L#`X5&.Z(-P;0.T M('@ZAC62-[T7S&17*7*(?NG[MB[QFFEVT7.V[_!?W\I(!&]?H-('I*QF>.+X MS8-Q2!@OU&$VF[L>O.]BE;XX.S'>P]5(]%OT(R'T5=PG22=;77``:Y M&=R$[R+1JJD8VJJXR7U/;F@0AQ*&5=E\#`^5L-,7MM.4HG6G(59#`.!?/_)= MD!K#P*1C`5U]B\4,!)0!)@R/T+>.,KF\%N-2G1T5R'$=^14C6[`TK>;V;@`-%Q%QRTHK;+%H'UNKS M2IH")ACL1$*CA/Y$5P>H1!`2#]+[$2$3:%V$2;#K>&'^`0Y^K:I2[KR5`R-4-]CC;@6XEU M5B:-?HO=Q5#:Y5=XL%$!Z4W6M-Q,&HCPO?D`&_X;E3X-+FVA>K[E[_G5/L#4UHAI!2T+]Y MXKH,OR/U<_:]01)(`L/"\WS#3'02%^?+J[;(M/I%5\EE:I"F9;1W)Q'`HRFH M$M?Y$NWM7-Z>WG_% M8\_`"C-$H#WL1E1DA;9W"QYIHRW1;_D./\;P&@O4:?:9/JAS:7V==]>SS\]Q M+K^*K&P8!KX0>*6>[(I/UF)+:("YJV>1DE-2PI!JT0\H(.'M:JH_'@.F^O/% MH(`-*17])Z'"DTI8PGMH8*E$K.0T(%"X912ZP/F`L`S5(N\3,';W)K>0QPT1:N1BATY%8$6TC2LG"U]N61 M81',-[H-^Y$Q;G;;_RA1-9;0T'\;9>D+LQ(+YU'S-5W$$+<#\X_1/%SR=FXR MR&&7C8$V]TMM]DD41^=7"K130D^%:'<\*+Q4*_9V6\16)2>KTI>)@X,8JX.C MLU<@HZS3HZ.]#T=^QWR(Z4(K'=6-P6OUK8WB?@EV:F]^MYL@OO]3%[K>B8I!MV">Q`R^3NV?_/(K*P['%K8[@A6)A2UW/YY8DT-&(US;P7P6Q6[@@=QZ84W[7(B0MI6_-2TO M_T61)T-A$%\&"8!>CONSV',70?PPB(-`W?J>LC;;K&I^L:!HX".;Z*EXZ>UHY/:#"EFHDHUOFQ`3HGD?%HE0$G9$84@2EBJC4=S/59"@%LV3 M)281M&MX1$,)HD4N1;L=#<+KLA2T^?]!$Y,(6M*O'-%0(K.FCJ6W8]<64+!B M%6M\$X68X"S4C]RB1)95X!/:5!F.%]=A!4I8U\W!,`XEQ"I4U+<'63(X[5'S")*HQB'%83RY M`#T\NA5($)&8K-8@7 MAO$\&APF&$6K4.&,3,+3N`2U+JG1?K1L4HRB5:AP1F;A#=TBIA8F-:-=BF'T M$@7/-W**3DV<@G:IU.B[],Z@BF3D"[[&%V@K2`UN%G8"26HZ*E'QC!S!US@" M;06I0;S`C>8A;>9T5*+B&;F"/W2%A#:#U(SB81B]1,439_AD5_#QQ+]UA079 MN:W4Z&L=FW54HN(9.83XUDR?[0;M@)H[[8"#>G85S,@?_`G^(#6?>Z;S!RF9 M@F?D#[[&'P95AQK\-D/V/)4!Z*":,2-7\(>N$-/'=*G1IT-6&H;12U0\(U_P MA[Z0#"H--7(R9/95FKT52[I,(Q>HN*! MQJ#JA)I4'6V$`#5WO^3+\2EL1G80:.Q@T!&HD?L:X7=]\E@NXTSA,W*%0.,* M@Z9`C>3S$9#RH68*GY$MP-7Y8&\'?8&:<3Z]=6#5X>4Z7CZ7K#ZPE)U.C97S M-W%Q[L/WN/Y=O-3?>LNM+RYGR?LI7/9W[SO]`-RUG[,#^SVK#T756">VAY#N M3-R+UWA;CR]:?N[NA%]X"[?LW:]'^*L*@\M?=P;B/>?MYPOQ]X#^[S2;_P`` M`/__`P!02P,$%``&``@````A`/[0]\>U!@``,1\``!@```!X;"]W;W)K*)`E-V5=J75:B_/ M#,9C%&,L8#+)WV\UU::["IN!O$QBU^GJTW4Y!>['#]_*D_,UKYNB.N]ILVBNN1GL!RJNDQ;^%B_>,VESM-]MZ@\>7*YC+PR+MC64WQ4AT.1Y9^J[+7,SRTZJ?-3V@+_YEAN4V?:WEW-5I\\G./"^++*Z:JI#NP!W'A(=GGGC M;3SP]/2X+^`$*NQ.G1]V[D>Q38+(]9X>NP#]6^1OC?5_ISE6;[_4Q?[WXIQ# MM"%/*@//5?5%07_;JZ]@L3=8_;G+P)^UL\\/Z>NI_:MZ^S4O7HXMI#N$$ZF# M;???/^5-!A$%-PL9*D]9=0("\-=-^+I1+U\E>F[8J_T.0T*[0B=1.?&"O[7(AUZ$(H_>]>,BH.^"GM$V?'NOJ MS8&J@3V;2ZIJ4&S!LSJ9#_&Y?3(XDEKS42WJE@*Z@71\??+]1^\K1##3D!@A MT``]1%)$,D3X80_Q@%[/$4X^GZ-:Q#@&O?ON&#%"UEV4U;D2ZPM"``)C$Q@/ MC@)#$*V3^Q';&"&!!6&(9`Q!J(&3Z=04>.?"*?ND^"M&;+JEB%;"0);99 M!B;IA!/4M,UI6DVI18S;FG%#2-!QDP%CGA#KZ@ZUZ$>HJ46,VH910PA2"P?4 MB#44_5H2M16E-EYD"DPI!+58W0I"2U5F=,2%&$TE"2$TO2QK&"2DP(V3. MB800$F'Z0BM#2,DV"[$TE4=(;2@I55L!9'Z] M0@DJ09X>/Y1ODEA3Q[H);(F/K#+7L;/-*ROZE!8;`>]TP5#[`Z[]PI;WP%23 M9F5;+.*X$SJER)-E3*)^VS(6\C&@,5AN`2>>$',8 MW:/%Y'^\"^10]GD\8HU!6L+D24<+/:#U'J=9BJ]>6ME3F26/NKIL23>[:DJV M42Z-FM#*FJ7W;:FG(Y$`UT8@`FPI3B MK%$@AZ/`TDL=0<3@SIL@M'*GXT<`*1>?TJOOW54Z[N2V$-'ZS MQH./TC\JPAIS>V_=$>CF-H32FS4C?!1W^^DCXM-+8[#D@X`%-[EKIK38;'A' M1X8SP?H%12<5,;=#HJ,V!J'T9LT%'R5]/*F(&:4W!B'T@EFSH4.SEN!)U1CL M5;GB;X/)?3LE-FL\!*CK=K6MF(S%&C,6MU$(I:?$?/*C>(#2/YI6C1FEAVYN M0R@])?S3Z2GT>VE%#/:J6)H1@`T1W#-36D!]!BV%IK16;*#'`6)NAT13&X-0 M>K/F@_JM%^C!P&PO=V]R:W-H965TX!=N\&/Y_MULK_3&-)Q; M!`R=*7!C;3\EQ+"&2VHBU?,.(K72DEHXZC4QO>:T\DFR)6D'`,-7W M<*BZ%HPO%-M*WME`HGE++?@WC>C-B4VR>^@DU9MM_\"4[(%B)5IA7SPI1I)- MG]>=TG350MV'9$C9B=L?;NBE8%H95=L(Z$@P>EOSA$P(,)6S2D`%KNU(\[K` M3\ETGF%2SGQ_?@B^-U?OR#1J_T&+ZI/H.#0;QN0&L%)JXZ#/E?L+DLE-]M(/ MX(M&%:_IMK5?U?XC%^O&PK0S*,C5-:U>%MPP:"C01*FWP50+!N`72>$V`QI" M#_ZY%Y5M"CS(HVP4#Q*`HQ4W=BD<)49L:ZR2/P,H<:;.).F1!)Y'DB2-TG&6 M9/F_64APY`M<4$O+F59[!$L#FJ:G;@63*3"[R@;0G]]7!FY3XC.^@A.X+FMZ#TC""@?K8`LO]OP26!58RN+8S.`M[G/("&5Z"+R5<6 M@.?:PM^K=^`"I[[N-$Z&;T1#>.+#HW0XO,1?28*K^R4=^$HR>R,9PKF7S`=_ ME(1=NU_2@:\D+XT+K0WA4&4V3K)+ZT.5X2Z%5>OIFG^F>BTZ@UI>P\3B:`0$ M.MRD<+"J]RNU4A9N@']MX(/'8=_B","U4O9T<'?U_`DM?P$``/__`P!02P,$ M%``&``@````A`.Z-4KNE!```5!,``!D```!X;"]W;W)K&ULG)C;CJLV%(;O*_4=$/<['!(.04FV)N$HM5)5[=U>$^(D:`!'P$QF MWK[+&`@V;)SI30CF\V_[]_(">_/](\^D=U16*2ZVLK9090D5"3ZEQ64K__SA M?[-EJ:KCXA1GN$!;^1-5\O?=[[]M[KA\K:X(U1(H%-56OM;US5&4*KFB/*X6 M^(8*>'+&91[7<%M>E.I6HOC45,HS15=54\GCM)"I@E,^HX'/YS1!+D[>JLZM3QY1BZ/R]>WV[<$YS>0.*996G\VHK*4)TYT*7`9'S,8 M]X>VBI-.N[D9R>=I4N(*G^L%R"FTH^,QKY6U`DJ[S2F%$1#;I1*=M_*+YD2: M*BN[36/0/RFZ5X/_4G7%]Z!,3W^D!0*W89[(#!PQ?B5H=")%4%D9U?:;&?BK ME$[H'+]E]=_X'J+TD]/]74K+\V%8:E+#7#IB*K:3XFD+"5O58WS?RFDM5)41&]%X-J*:.;" MTM3UTGI>9-F*P+43,18KW;#LKW1EU:I`NYV*OM!M0S/,+PS(;%7@VJKH(/RD M&U9;&:Z/+MB&L3+M+]@!"[29&+BV*O]C8M:M"%P?77G6#86&2A-Y;ES'NTV) M[Q(L9PB&ZA:3Y*`YH-R%'`V0/@A_%8,0?$3DA:AL91@>A%<%"^=]IZDK>Z.\ M0[0G+;2G$/SVD*5K+'.88,P5R[@3C;&$UQ%DB9#^^5W!3--!QW250KX@H@7- M7:V<5@8E573/[KN#1-_!NS8[H,`49*@NY8TAG"6],+`T6 M\2D"0^UG:=R=X!DHG(*,)=M<-`D]^L3X#-GD>9\)S/C,%QSX`I3$#<3X23$17HTAJSE(S(8;R"E#;TAZW@)+Z#Y6"25@&/FVC#9&=I3 M"'[[@."(@Y!PA80G)'PA$0B)4$A$8WO"YN38T+B9]80<"(1$*B6B.8!R&%_;0 MX>="FE0:.PK-F2TD7"'A"0F?$JW9FK'F4E#` M/-P*V;,?BY7-[5&KG-9<-]20]O!5"YP#A,4YZHK1CPQXHN1 M0(R$$P@,ZI&CFQ1*#AM(6`Z'_A@4G0!ZF$"W=#DJ+^B`LJR2$OQ&#@HLR'I] M:7^(\;(DNP^NW-4-RWW-@9W0N'RO._LIG8/NP)?UF'=U!SZPQ^6>[L!W M-I0K?8?@3.,67]"?<7E)BTK*T!F&HB[(AKNDIR+TIL:W9@-[Q#6<9C1_KW!Z MA6#'IRX`/F-<=S>D@?X\;/`4=B8S__YL62U9:@E][T??UT[EUOWTZGTWK?]R=G^WV M#Z]?'IZWKYM/Y_]N=N?_^_S?_WS\M7W[:_=]L]F?J<+K[M/Y]_W^Q_WEY>[Q M^^;E87>Q_;%YU6>^;M]>'O;ZZ]NWR]V/M\W#E\,?O3Q?%JZN;B]?'IY>SP.% M^S<7C>W7KT^/F^KV\>?+YG4?B+QMGA_V6O_=]Z1,_/7A[O6]]>MV\/?S[K>?_C%1\>0^W#+RGYEZ?'M^UN M^W5_H7*70473Y_SA\L.E*GW^^.5)S\!O]K.WS==/Y^+=R[1P.AA>9/ MFU^[V..SW??MK\;;TY?NT^M&FUL[RN^"/[?;OWRT]<4OTC^^3/UU_=`%P[>S M+YNO#S^?]^/MK^;FZ=OWO?;WC9Z2?V;W7_ZM;G:/VJ0J MGORQH4WR\,_AYZ^G+_OOG\ZO;R]N2E?7GN)G?VYV^_J3+WE^]OASM]^^+`+( M\RL5B12,2%%K;YZ_N2@6;DIWIZCH\0Y5T9^A2N'"*U[=GE"36Z.A/X\:IYY. MR8CHSU#$N[B[N2G>WI7<&T4M=CB=#T>5PD7A[L:[.>6$/!T100?Y0\,TKO;E MR3I11^N#4*=P!_!LG50@' M\G7LI*Y.]\-U>%;^@]_O\NNPJ_P'X0B\/7VVN0Y;YUK/+]3YC5GK6OU]Z"S_ M0:CS&_4IAD;W'X0ZQ9,-6@Q][C\(97[CM(JAT?T'H<[OG%9H].)Q]'B_X=!B M.'K\!Z8^!:V:8T(5PU'C/XC^W-69ET%H'C*X^K!_^/SQ;?OK3%_9:!OO?CSX MKY.\>U\Y3-\@*Z,\?B^.-4)]%?%E/IWK.-2DW>F+B+\_>U=>Z>/EWQK\CP8J M!Y#^&T&E@I=D*AG,;3')5#,86Z<6,/$*E6R=>LCX+P3\LVC8!JJ=.03,22KC!.B"6?3L2275`)"OS).(RNJLW4[(*Z7="P"YIV0#`#-/,W8T5JR,'9NS`3!R8J0,S MGY6(GI^KCM4RIU>0J")10Z*.1`.))A(M)-I(=)#H(M%#HH_$`(DA$B,D MQDA,D)@B,4-BCL0"B242*R362(@PPJX3MIVP[X2-)^P\8>L)>T_8?,+N$[:? ML/^$#2CL0&$+"GM0V(3"+A2VH>3Z,)$S^B[>"3GCTY_.]0I;%"&>WCJ3O"A6 M#J"\G$&BBD0-B3H2#22:2+20:"/10:*+1`^)/A(#)(9(C)`8!\0'\\;OE?Z7 M'$"3.%"X20/3..#=^412898`?`$+F,>!K$,L`B!G$"^16"&QCE?C<*)6/450 M0]AO4HD?)^MTQ1CN_4X18SA#9/2*&,/E$,9P`9%9#S:8NR7C23"1>\Y.B%@@T46BAT0?B0$2PX"X#8+A6F^MMJ?M$6J,D9@@ M,45BAL0\ M8)& M``7]YP6+8VL6JB29Z\-$93%5P^2,IUI"YMH[R"0[L,XJC81*9GV;K-)BI,U( MAY$N(SU&^HP,&!DR,F)DS,B$D2DC,T;FC"P863*R8F3-B&92X+892?Y&U!,R*=BWJO+Q MVZJMS3EE+Z!RC%)AI&H07?GY'T5P=7%E;52LL4:=D08C349:C+09Z3#2-[X[EV@@!2KO M$P[FU#C*JTLRCC0S3HDC'T]>O+NSKKF5_4\B5:84IHBU!ZABGL\)JRI(U%BB MSDB#D294I`7/MQ//>[4_K#L\.ER%+B,]1OJ,#`SR7K\-X?D1'V+,R(21*2,S M1N:,+!A9,K)B9,V(9D^^K31X`B#'5_J^$3.A^?)T'`RHP-O MD#YA(13LIXXOA$KIZ,%-UQ7_$^$UG7(:K!HA9AED!5@M>OZX)K,69'5&&HPT M(\2OB+7;J14]^6XMVHQT(B3[7+O1\^\>I<=(GY$!(T-&1HR,&9DP,F5DQLB< MD46$9'?0,GK^W0Y:,;)F1`,(G:,9Q(R#`W7QPSH.-M0,8AT'(VH&L8Z#(77Q MPSID2DP4C3(.9NC(P[)%J1R&&62MX^T8Z>?'>* MZC#29:3'2)^1`2-#1D:,C!F9,#)E9,;(G)$%(TM&5HRL&=$P0GMH&#'CX$0- M(]9Q\**&$>LXN%'#B'6.AGS7U#AB'0=W M:ARQCH,_-8[R=))QY.^WCL>1_R4:MWHC'MRW$&S3MF+)>O.F['\C3W[F5!BI M,E)CI,Y(@Y$F(RU&VHQT&.DRTF.DS\B`D6$&HB]3CI\G>O@LC%$&9:UBQXQ, M&)DR,F-DSLB"D24C*T;6C&A`I>V6[@3-J#1F]8)>M&/&P9=Z6QWK.#A3;ZMC M'0=OZFUUK./@3KW9FW4<_*EW>[..@T/U=F_6R?*HW>\.#M60XF,Y>%1#*D\G M&5+^;NUX2$$X!9N[D^%D?WU#V<,MX!5&JHS4&*DSTF"DR4B+D38C'4:ZC/08 MZ3,R8&3(R(B1,2,31J:,S!B9,[)@9,G(BI$U(YI,Z#6-)68<#*E+)]9QL*0N MG5C'P92Z=&(=!UOJTBG0"98SMP5_\TGRHH>F$A_*P9B:2JSC8$U-)=9Q,*[)/2*5@"[>52M8;/64/-WI7&*DR4F.DSDB#D28C M+4;:C'08Z3+28Z3/R("1(2,C1L:,3!B9,C)C9,[(@I$E(RM&UHQH*J'7-)68 M<3"DIA+K.%A24XEU'$RIJ<0Z#K;45&(=!V/J!3W6<;"F7M%C'0=SZA4]UG&P MI\82ZS@85&,IT`G2OW#E[QF-TC^12@5_$ZU[*AWPY-UUWE71>N._;*B<.Q@J MC%09J3%29Z3!2).1%B-M1CJ,=!GI,=)G9,#(T"#A-X#>IJ[AL<:8D0DC4T9F MC,P963"R9&3%R)H1_;K(8`_\N^VO7Q:9MTO^<)U5',RHWQ7).@YVU*^*9!T' M0XJ#(\7!DOHMD5P?!U.*@ROU.R+Y6`Z^U"^)9)W0F3ESL(R,SONC)_3F^X2# M-27?F\DX\G?7GA!'P6;<^"*I]"&51ND=NZ4/UH>F5@H.4-4%JKE`=1>HX0(U M,R#K,FV+D38C'4:ZC/08Z3,R8&3(R(B1,2,31J:,S!B9,[)@9,G(BI$U(YI- M:4M9(U/3B9DL:]HZ6%0<3*HIE7>L9$IIX"12RK\+XEI#.?^- MIH+_9ZG%DY5$94/E!'>%D2HC-4;JC#08:3+28J3-2(>1+B,]1OJ,#!@9,C)B M9,S(A)$I(S-&YHPL&%DRLF)DS8A&5.#('*]I1#'C8$A=0+&.@R5U`<4Z#J;4 M!13K.-A2%U"L$QHSVC-Z8SY9Z'"CKOYC;3K4M&)1!Y]J5K&.@U/%P:J:57PL M![-J5K%.OEV36>5OM(VOJ/RL*NK]YY!5P?Y(,O-&*D MRDB-D3HC#4::C+08:3/28:3+2(^1/B,#1H:,C!@9,S)A9,K(C)$Y(PM&EHRL M&%DSHEF%7M.L8J;BP#@X4APLJ5G%]7$PI685ZSC84K.*=;*,J6]Q6!](K0G% M4@[NU(1B'0=_:D*QCH-#Q<&BFE!\K'R3)A-*7WXE$@J2R<=3JRAK=5DN!%3. M*[L*(U5&:HS4&6DPTF2DQ4B;D0XC78.8MQ?]%W/1NXN'U.^Q1I^1`2-#1D:, MC!F9,#)E9,;(G)$%(TM&5HRL&=%<0J=I+C'C8$==0[&.@R$UEUC'P9*:2ZSC M8$K-)=9QL*6&$NLX6%-#B74DP4B3D18C;48ZC'09Z3'29V3`R-`@ M\6^DMB)RQ"IC1B:,3!F9,3)G9,'(DI$5(VM&-);02!I+S%0<&`='ZG*)C^7@ M27$PI<82'\O!EAI+K.-@3(TEUG&PIL82ZSB84V.)=1SLJ;'$.J%!@YD@^`J( MY&ME3:4\F2"5+G??-YM]]6'_\/GCR^;MVZ:R>7[>G3UN?[[J]3G]2*-8\=G; MYNNG\U;AOE4\OTR5MPOW[:SR3N&^DU7>+=QWL\K%NY>L\IIWW_`RCMOT[EM9 MY>7"?3E+IU*XKV255POWU:SR6N&^EE5>+]S7L\H;A?M&5GFS<-\\E%\>V_GS MQQ\/WS:]A[=O3Z^[L^?-5VWSJXN2=MO;TS?_>FKPRW[[0_OB_.S/[7Z_?3D\ M_+YY^+)Y\P&%OVZW^_`7[9C+7]NWOP[]^OG_`@```/__`P!02P,$%``&``@` M```A`+#G*+1V!P``1"L``!D```!X;"]W;W)K&UL MG)K;DJ(Z%(;O=]5^!\O[44%$L=K>-%/R.GEKU_'0^UG$"=A=!K4E4:K7@M.FV@;GMX']7_^MK_UZK4D M]4];_Q"=@D']=Y#4_WK]\X^7SRC^D>R#(*V!PBD9U/=I>NXWF\EF'QS]I!&= M@Q/$[*+XZ*?P-7YO)NO/HAZ:XE^^C3BFVV@K@M;<@2>V02=9KFX\DC8[_ M<4C)I;A(.Q>!SUQ$41MJKZ-T]`=4M%P%/H4*9/I1%#S MJO)HM71S$>AK0D1I]#H=3>]U[Z]<(U=1F#?R)FH]+J.(EF8/0N?QIE;`*%G] ML@LQ_!276WS1#]0 MA&W8@RB4^G!W4H1QV(.0>:)NP'>\4%<#MN_O"TT^4F0#C^FG_NM+''W68#0' M_R1GG[T;E+X"TN5##8PQ#/[.Z$$=,!A%$A@??[X:6N^E^1/&M$W.##D#_R], M5]=D9B08-H0Q81,'6#C`Q@$.#G!Q@"<"*G(R%HS(R40$7!,I9R! M.KWX&!5I7"1PAB=%!(E,BP06F141)#(O$EAD4420R+)(8)%5$4$BZR)Q(R*Y M$EX5#[B2T9(K<<`(!Y@\@#E.6-G"C(T#'!S@X@"/!]SZPN@@#X[O8"9E#!YJ M[F!F90QJE?D=S**,:1B1ADH1%$C9)."3ADH1'$F.2F)#$E"1F)#$GB05)+$EB11+K M*D*R)DPO'[`FH[.EV<5V1@?UBR%G(`,7!EN3)$Q.Z-EK%M;OV9_<_2Q2Q"8) MAR1<.B/>+=(U2K(Z)HG)+<$ET&@\)8G9+=$NJ[(Y)RI:9G&KH73*1):DR$H2 M*:F/=04@>1/6+)(WV59"&Q:=U?-[E@I[%#EPR)F*FAB1A$D2%DG8).&0A,L) M(^LKZ-WK5<2-*^(F%7'3BKA91=R)N#,U6V)`F3 M)"R2L$G"(0F7)#Q.P*YEW@=0;8Q)A0E)3$EB1A)SDEAPXE(2--HL28$52:RK M",F=L!O\A#M9*NQ.M!\SY$R5.TG")`F+)&R2<$C")0F/$_SEIS0T-&,9DP(3 MDIB2Q(P3?"Z!YO5S,O6"))8DL2*)=14A.9.=3Q2L:9#SQRP9\J:.IN/#'+HU MIZ&C"AH"CED9VPPX-[Z%5EQ1",FC5@T8M.(0R,NC7@Y MPK<1-*VK=U"UC$EB(A'M5D?7>NAU.Z6168YH?.HA+P[F59$+21PV(4O6T\LJ M@94L4))\747(QF0;X[?&9`MR#5;SU0MR=C"+7_8ZVI4=YE"E0;E.!6+2*A:- MV#3BT(A+(QZ-C&ED4H(8^+1R6@*A`6!6@A@ZG@640$AG48(8^/1J60(AG54) M8NBH\ZU+H*N.[%ZV87_K7L*U?']?'E;1DF'([@I0PRJ)F+2*12,VC3@TXM*( M1R-C&IF4((:.E@#3$NC:NMFI^XQ&YC2R*$$,?"J[+(%0;E8EB-%%\\)U"735 MD3T+@]TCGF4XFKIVT3MOR"ZF4)[E"%^,:(VN(?WIUCINTII4C7+/7R#>7 M^18SW-`K:-JTID,C+HUX-#*FD0F-3&ED1B-S&EGDB-A)1?Y;T@HK&F&7"+_V M$7U#'5/ARU%\,MM0_G[<5P6^W#L3N$-R\9A3N, M9_\]F/GQ>WA*:H=@!T5L-=B=KYC?@N1?TNB&ULE)9=;YLP%(;O)^T_(.[+ M9\)'%%(UJ;I5VJ1IVL>U`R98!8QLIVG__8YQH-AITNPF`?SZ]7/.,3XL;U^: MVGK&C!/:9K;O>+:%VYP6I-UE]N]?#S>);7&!V@+5M,69_8JY?;OZ_&EYH.R) M5Q@+"QQ:GMF5$-W"=7E>X09QAW:XA9&2L@8)N&4[EW<,HZ*?U-1NX'F1VR#2 MVLIAP:[QH&5)D8X/;DU^C5V#V-.^N\EITX'%EM1$ MO/:FMM7DB\==2QG:UA#WBS]#^>#=WYS8-R1GE--2.&#G*M#3F%,W=<%IM2P( M1"#3;C%<9O:=O]CXONVNEGV"_A!\X)-KBU?T\(61XAMI,60;ZB0KL*7T24H? M"_D()KLGLQ_Z"OQ@5H%+M*_%3WKXBLFN$E#N.40D`UL4K_>8YY!1L'&"N73* M:0T`\&LU1&X-R`AZZ?\/I!!59H>1,X^]T`>YM<5(X%62T8/%NP:6)-W2.Y!?P'.0V2*8XSU M7*@0HS2YDRZ9#=L=HN!0G^=5&H=+]QERFA\UZU.-KRLV@T*6`O!&1HA\ROA^ MU@<4*98HL@J2;:T>@/?(%ACKGBK"^2C12"!#UY-(,51ZLG`:ST9?!:"4YGTX-7:$"Q)HAF_X6NI2G>YRRJ38H$K>?-4KH31JY23PIPNK/3<5 MS,+S9#Y4<)JXRVB]6F?S/?.%.(J&FLVT_:[H=$EP`4\>Q9.Z?H"G#F[M-$F, MPWT-_5GF5QTG430_S9VFB`/MN%%E50U:]:\&LQW>X+KF5D[WLOD&L)/'I^.' MP5T@6X'Q?"T_&/J6/PY`O^[0#G]';$=:;M6X!$O/B>$48:KCJQM!N[YK;JF` M3MU?5O!EAJ'5>`Z(2TK%<",;V?BMM_H'``#__P,`4$L#!!0`!@`(````(0!D M%C,\,00``"H0```9````>&PO=V]R:W-H965TFWX'A_0H!`7'4.U<1G]J9SIW;]C5B5&:!.(1==[]]3XBRY-""]LVR MY/SR-SE/))-O'UFJO=.")RR?ZF1@ZAK-8W9(\M-4__-G^#+2-5Y&^2%*64ZG M^B?E^K?9K[],KJQXY6=*2PT4 M7@(LMMH'/.O)3^_#O8EX39&G]P&552T%GO52'MZ'?YL,SWKRT_L@D$8RJA"W M+YE'=V+('*E2+HC*:#8IV%6#,@8U?HE$4R!C`B_W9).I4:???V4?I)U0^2YD M*C%(+`X5\S[S1];$>(9K"SVH0_ M&JHJ09M!Q+)-C(9H+6&;L1WUAU9MQ/.0$]=M9N0@G4V;\4>(V;89Y)I=FV@L M6`D@-#@E@-V!$S3TTT8..Y:G>F(N&6AY=9Z[*K'H)8)>8ME+A+W$JI=8]Q*; M7F+;2^RZ""58X-0G@B7HJ0ZI4`?"L49J*.:2\:N690\ME&F+IIG8OJG.#A2S M.4+B2\5LF:@)KQ6SU4COJG%NFF;+=U&!;)OF%X^8J"OL M5+O?*%,E(/!M?B(@@L;5XZLNG4L&?KX.&JZ>7B+H)9:]1-A+K'J)=2^QZ26V MO<2NBU""!6H*6R:A.]!V2.);1,0[K!=7%X*8;GP M$?E:J!(S.+?^CYB)63AFJ/O,)2,[W]>/5\UCT6$+.FS+#EO885MUV-8=MDV' M;=MA@]N;\(]7Y>N+.6AT9NE\>3>3!^6,%B>ZH&G*M9B]B7N7!?/J47DEG),Q MG"KA<(C&MW!5K,:-V@!7M4MTHK]'Q2G)N9;2(TB:`P_*N)"7/?E2LDMU1-RS M$BYIU;]GN)-3.!6;`X"/C)7W%W$JK6_YLW\```#__P,`4$L#!!0`!@`(```` M(0!BJ&#ZQP0``-<5```9````>&PO=V]R:W-H965TYHN8,. MUGYHJYPYG+EG[AR8V??W(K?>>%5GHIS;WLBU+5ZF8I.5N[G]S]\OWR:V53=) MN4ER4?*Y_<%K^_OBUU]F)U&]UGO.&PL8RGIN[YOF,'6<.MWS(JE'XL!+N+(5 M59$T\+':.?6AXLFF'53D#G/=T"F2K+2185K=PR&VVRSESR(]%KQLD*3B>=*` M_GJ?'>HS6Y'>0UOQ\"T5Q0$HUEF>-1\MJ6T5Z?3'KA15LLYAWN_>.$G/ MW.V''GV1I96HQ;89`9V#0OMSCIW8`:;%;)/!#&39K8IOY_:3-UVQV'86L[9` M_V;\5'?^M^J]./U699L_LI)#M<$GZIU!1H!FQ0#*E(@_OW ME&V:_=SVPU$0N;X'<&O-Z^8EDY2VE1[K1A3_(%)CES'RH#^JXS/765&&.DN1)LLQM M6.XPO`9_WA;Q))PY;U#35&&6?8Q'$:LS0EH!\BX:8>9=C=>K?I8BP5**=$%J M6^(7P'W1QK3[]A%^<($0)5"A^Y5(\-P&\LN-P\F%%K4A9-R%4,3*A"#2@*0K M31HYOKE$S\62@\#PSOWC2405+!%CTFA"$(V@Y^L:Y2!:QGBBUQ$QXW;ECM'#1D+6),&DT(HE%&G;:/ M#"\_.8B6L6\M8L+66M\-PIZ[!@!1&%.%9H,E6%.F&XP04_%,""+-@QWWZ]5K M1PU9K$`FF48(U2EWZ"^[[.&^WMT(^S8K$+:P5NH5N>BYGY>I.KF/=]29'?9P MU^^JBK1`6BJ,L7A(8!G7*4 MUC&];=I#$#8S^"A_Z+:Y,D*H3BU-!NSNQTBD/0AI!:/=XPN`Y57?[G"_RD?%S*5"!6K0, M^'PE4[R8WG;I( MG38,[O6`3CF*UK/?UBWUW$:W61C[0>#3!EL12,18[-VR&V;;E3E@MT13><'X MDQG?J1B"C&4T0:C=6LCZXT-X)4<[M1_PE-T2@$;/4]M_$<#8^9"E[M^(KG M>6VEXBC/R!B\REV^O9S?/3%Y8J-]OX1SO?80S+E<@&.U0[+C/Y-JEY6UE?,M M4+JC")JIPH,Y_-"(0WNXM18-'*BU_^[A`)7#B9`[`O!6B.;\09XW78YD%_\# M``#__P,`4$L#!!0`!@`(````(0#Y]YTA_@(``'`(```9````>&PO=V]R:W-H M965T MT;J(T>]?3W=+9$F%ZPQ7O"8Q>B<2W6\^?UH?N'B1)2'*`H=:QJA4JEDYCDQ+ MPK"T>4-J6,FY8%C!HR@<.P[1&QF$E;O'@>4Y3\LC3/2.U M,B:"5%@!ORQI(T]N++W%CF'QLF_N4LX:L-C1BJKWUA19+%T]%S47>%=!W&_> M#*%^I MG_SPE="B5%#M$`+2<:VR]T=`N,8)NAR@DE.=U M$T7NVGF%G*9'33+5>$/%]J30I0"\CA'2UF?\?]9/*%JL4705-%MB7H!WQ^:/ MSITJ@K"3#$@@0[>3:#%4NG=P%(U"3HQFUM/,NY-;_.TUQ8`-3&YGT^*V'[ND M1-$H+8G11&TYPS"8N?`S@C,2^.QLSO@#.&CS/IQNLPC^#*^74F\:0P9#@L1H M^@11-!MJME/-!V\?TH-%X;IM+UW9'ZUNSWH_B`N%B2CB# M\*[G46\:$Y[]#:'1=(3!.(>7UP=UUA?>:)Q\G$&]:OM0GNYM=[$\^'J6C-XG<.&TX]GI M%F#@-[@@W[$H:"VMBN1@Z=H+*(\P5X9Y4+QIQ^Z.*QCU[=<2;G8"L\JU09QS MKDX/>A)V_RML_@$``/__`P!02P,$%``&``@````A`"Y^_WXB`P``60D``!D` M``!X;"]W;W)K&ULE%9;;]HP%'Z?M/\0Y;VY$B`( MJ$JJ;I56:9IV>3:)DUA-XL@VI?WW.[9IB$W'X`5BG^]\^<[%/EG>OK:-\X(9 M)[1;N:$7N`[NO[.UN:7T+6(/>_ZFYRV/5!L24/$FR)U MG39?/%8=96C;0-ROX03E[]QJ<4+?DIQ13DOA`9VOA9[&G/JI#TSK94$@`IEV MA^%RY=Z%BRP,7'^]5`GZ3?">CYX=7M/]%T:*;Z3#D&VHDZS`EM)G"7TLY!8X M^R?>#ZH"WYE3X!+M&O&#[K]B4M4"RIU`1#*P1?%VCWD.&04:+THD4TX;$`"_ M3DMD:T!&T*OZWY-"U"LWGGK)+(A#@#M;S,4#D92ND^^XH.T?#0H/5)HD.I#$ MH/Y@C[QHGH3)]/\LOE:D`KQ'`JV7C.X=Z!IX)^^1[,%P`!D%@O5J#)B/0U$1DYQ"& M.""Y7)P$KUR(V,L.>)M'1W]`%K7VY+@FV="5VSC1F MHG1%46SE:VR=!D?-AJ;I-9HDV-84FF_=:,Q!T\PT9F-C?&Q_0]'L&D42;"LZ M\NJFUABM*(YL26-K-#OZ&IKDW!I="N?;78)-3=#N=IHT:*I;*HU3NWAC>Q1, MXG^T5'J-,`DVA26)]=Z-QFA=-^$'P@S`&64P?J[(F4*;VB!IQVKH2AY0^B!: MAT'..QF>;=1UU)-,7_0M9A7.<--P)Z<[.:4B*,.PJR?H)ES`;0B3R]K/8+*J M?7\PP&#K486?$*M(QYT&ET`9>#,X?TR/1KT0M%?7[Y8*&&GJL89/&`SW;.`! MN*14O"_D\!T^BM9_`0``__\#`%!+`P04``8`"````"$`5J&X3\D#``"S#``` M&0```'AL+W=OQ M`X$%`43UY9L:>#.LO M[W45O%$A&6\V(8Y0&-"FX"5K#IOP[[]>)D]A(!5I2E+QAF["#RK#+]N??UJ? MN7B51TI5`!X:N0F/2K6K.);%D=9$1KRE#5CV7-1$P:4XQ+(5E)1F45W%"4+S MN":L":V'E;C'!]_O64&?>7&J::.L$T$KHH!?'EDK+][JXAYW-1&OIW92\+H% M%SM6,?5AG(9!7:R^'1HNR*Z"N-_QC!07W^;BRGW-"L$EWZL(W,46]#KF9;R, MP=-V73*(0*<]$'2_";_B58[3,-ZN38+^8?0L1]\#>>3G7P4KO[.&0K:A3KH" M.\Y?M?1;J7^"Q?'5ZA=3@3]$4-(].57J3W[^C;+#44&Y4XA(![8J/YZI+""C MX"9*#$;!*P"`]Z!F>FM`1LB[^3RS4ATWX70>I0LTQ2`/=E2J%Z9=AD%QDHK7 M_UH1UE"]DZ1S,@7ZSIY$R5.*T_GG7F)+9`)\)HILUX*?`]@U<$_9$KT'\0H\ M7R*S''VL_Q.[O-*N9&:I)DGC0N6-.EX/9H9H_0J7%+E6: M+MQJ95;342UG2]><.^9T/J32H5H\0J7%/M63>]O,:N:77#T-V;`EM'9+G>!^ ML0.EGW.C)G*[@%KL0WFYR*S&0F$T\YG&Y@GTO^'D.%C+1["TV,7"V*^@U=C= MCOI4V#S]V.;P8.A9XSS==PS-*H\,H6%[F-MGG0H^=/=%D=_K\AL"%])[(MPN M)K8M>]PDH/-[]Y M4PV\V.LPN:=XA%/TSC*UJX)T.R;*[TU4,>]=-I?>8^*3TU\\' M*+U_DK%5=6@HPC.WL$-'Z4`=/6R5(1*7]:&'AA[6_-.-\)"&[@Q9U875.^"= MCRNKQ;*SHQVM:BH.-*=5)8."G_1&ULG%3;CML@$'VOU']`O*]M5-$J[4BM5 M52_/!(]M%&,L(+>_[V`:Q]MDJVU?+`.',V?.S#![/*J*[,%8J>N4LBBA!&JA M,UD7*?W^;7WWCA+K>)WQ2M>0TA-8^CA_^V9VT&9K2P!'D*&V*2V=:Z9Q;$4) MBMM(-U#C2:Z-X@Z7IHAM8X!G[255Q8,DF<2*RYH&AJEY#8?.T" MB8&*.]1O2]G8,YL2KZ%3W&QWS9W0JD&*C:RD.[6DE"@Q?2IJ;?BFPKR/;,3% MF;M=7-$K*8RV.G<1TL5!Z'7.#_%#C$SS628Q`V\[,9"G=,&FRPF-Y[/6GQ\2 M#K;W3VRI#Q^,S#[)&M!L+),OP$;KK8<^97X++\=7M]=M`;X8DD'.=Y7[J@\? M01:EPVJ/,2&?US0[K<`*-!1IHL'8,PE=H0#\$B5]9Z`A_)C2`0:6F2M3.IQ$ MX_MDR!!.-F#=6GI*2L3..JU^!A!K106N5MJ*.SZ?&7T@6&Y$VX;[YF%3)#YK M"@R=RI=$HCI/LO`L*<4^Q?@6C=W/6<+8+-ZC'>(W:!E`^+V`.D2,[$-[O[R69=CHAQG<#C/\ES`>C(;WQ2?L0AQ"!]"H!YK<#HV0?H;> M]?L7.^&,^*>*(7;UW_WVEZY4C+L` M044`L:1M!=_.W?DS`9/_$>`O70FX^!P$!%`G(+FJLD3H MG1]`AKJ[W>YM6`S:2>H.<#8;7L!G;@I96U)!CE>3R!?2A.D."Z>;=LXVVN%4 MMK\E/L*`S9I$",ZU=N>%?S^Z9WW^"P``__\#`%!+`P04``8`"````"$`X(^= MDF<$``"2$0``&````'AL+W=O%S`)^:_%0+"=9L7)C$\>S+5JF;)^5QXW]_=_G3PO;XB(I]TG.2KJQ MWRFW/V]__VU]9=4+/U$J+%`H^<8^"7%>N2Y/3[1(N,/.M(1O#JPJ$@$?JZ/+ MSQ5-]O5-1>[ZGC=SBR0K;:FPJL9HL,,A2VG,TDM!2R%%*IHG`OSS4W;FK5J1 MCI$KDNKEQRR/U&IDG::M0`,MN5?2PL9_(*B8+V]VNZP+]R.B5]]Y;_,2N M?U39_J^LI%!MF">1[/ZA.4T%W`S@(_Z\=YLG' M4=QNF/[[=LCG>MJ^5M:>'I)++KZQZY\T.YX$C!1`&;`:J_U[3'D*TP!C.7Z` MJBG+00+^6D6&SQ.4,7F3[K*].&WLRI7?^X^+3!H1>&U$B._,B;>5]:F M+GNTO-S@DN(K$"YK;&L2%?U7Q4=JHTB3ZBRL6&U0CTYS/SK MUEN[KS"W:4.$DH"_'4%4(FH)G$@4C7L77'#;68:IZ%N^_SBTSA!&9ZUJ*"_T MC?B:$9.8J$1L$M..4*S"A(^WBC`\H[T2!9UJ79%0$C!-71%G*A%]2,1#A.(= MAAGO'>&-#77IG,U59Z$D^MX7*A&9A)8N'B(4[["JQGM'6/6^5)V%DNA[)]KS M'9F(;GZ(4,S/'C&/L&J>:`LKE$A0+\LIF4VT=)'\OI].MSY$*-;GCUA'6+.N M+<50(GUK1%N+D8GH[H<(Q3W^VNCMA<,;"\*:^]LF()>K1!3WVHJ.3$1W/T0H M[I>/N$=8A/HN+8>VK80- MTP^BN8P:9%8O$3(-_&"Z\&?:PQ@/"JEAL'6-?I*(;'3]S9-H:S1LF'X(7]^" M[C!:T'@042-@CQL?07;$?@1?WX:(9)0(6HFC.XP1P92Y(6H$;'7C(\C&J$30 M]IJ0F,W3UQ9]=(>Y^6M^V)@R-T2-`-5Z(`+2ZFKPM0TG)))19N$V>.TONL-H M2#R(J!&P[XV?!=DEE5G0=IT0SP`0A6T.M*( MYCFW4G;!$RR!F[NKW9&\.2MW7\#A]IP`_"!,=%^P,-X]]^4[?\```#__P,`4$L#!!0` M!@`(````(0`-^B_<(0,``/P(```9````>&PO=V]R:W-H965T.V^8.[>;#Y^6!TI>^0UQL(!AXZOW5J(?NG[O*AQB[A'>]S!2D59 MBP0\LKW/>X91J8+:QH^"(/5;1#I7.RS9>SQH59$"W]/BT.).:!.&&R2`G]>D MYX-;6[S'KD7L\=#/"MKV8+$C#1$ORM1UVF+Y9=]1AG8-Y/T*N'"_N6 M%(QR6@D/['P->IES[N<^.&U6)8$,9-D=AJNU>QLNM[GK;U:J/K\)/O*SSPZO MZ?$3(^57TF$H-K1)-F!'Z:.4?BGE5Q#L7T0_J`9\9TZ)*W1HQ`]Z_(S)OA;0 M[002DGDMRY=[S`LH*-AX42*="MH``+PZ+9$[`PJ"GM7[D92B7KMQZB59$(<@ M=W:8BP>=$B"9/TNHNOB52"]TB@S8K1 MHP.;!GZ3]TANP7`)SD-FFF/,];54(4=I",C9&XSQM##?U=_0))!)E(\MX@N)9&IV%XJXF24&(Q0 M.YMQ_NH.&1AE$.R%LY)D03KZJ]+>:-C_.%W=?SY3"*%V.T00?5LNFN=UD&6719,/KK"FI-JNC")+#ISI>C M,)IR,^C22[KK_95!-IWU\W=:`R4:ZVOW=U#(8S5+YM,N-@`S$_#MPR'%)E@8 M3+ZZ;%HS5V6;+2*+>VLLS^/IY!A4<@!:U\OULLD@DR[*)G]-IS6:+DVG0ZE6 MM^>K6305U&#++]FN;S@99+)EH0OJ1;S/9X MBYN&.P4]R`D30C_&;_7PNX/AIT:%/R[`\.G1'G]#;$\Z[C2X@M#`RV"O,SV^ M](.@O;HC=U3`V%$?:_B7@>%.#SP05Y2*X4'>RN/_ELU?````__\#`%!+`P04 M``8`"````"$`&RBW<"`O*CHJ>I3=9K36.MO[WEFO;%2I+P(;6_BVA8K8IZDQ3ZT__WG MY>O2MH2,BB3*>,%"^X,)^]OFMR_K,R]?Q8$Q:4&&0H3V0X=<2Q9E*B@/'-\UYT[>906-F58E4-R\-TNC=DSCT\Y*R0E M*5D62>`O#NE17++E\9!T>52^GHY?8YX?(<4VS5+YH9+:5AZO?NP+7D;;#.I^ M]QZB^));7332YVE<A= MO9_31!Y">SJ?S!;NU`.XM65"OJ28TK;BDY`\_Y]`7I6*DOA5$GBODGCSR8,_ M6RP'9'&(D2KP.9+19EWRLP6[!M84QPCWH+>"S)?*B$==:U>I4",F><0LH0W; M':H0H,_;9KZ>EE0GS<(NI$5J!`+DM$'L^A3WY>:$8!+C; M[,MEG9\8$&8``]AU]S/`(+,'@<&`,!J#P*TQ6A?F.H?/JT>PL79PW3Y4/6&T MM=M77N@K#^L_!O7UGS`#&.#!8-QU_3L`@XP>+,W^$T9C$'3L_V`,!PPR.`33 MNLND`V$T#C5"VP$>;/K[VZ"B^I2H0$-(H"_=K85';J8;@BE&!=)(=*GAH6_= M3X/<3J,1/-3=)CU4ZM#6:-0071##$X?=&1X9W^?65(&&D`#,B$Y@E+$S&W>' M1R"-1##KZ,4HC\2G`I-&T#@)6URR@X1AD@,%(2?L$62P77JC_%)%]0K2XIC! M]5S5-^'N$J0%N?L$&24;_KDFSV"$&B((*-\TR=+[!&DQ3>[ M#G5\R+[_#E%1IB#F4V\%&M"+Z2C?5%%]=T@%&D)BE&_"D,7TBGGC#JE`&HF& M(#1KH5%$SLH]^YUEF;!B?L(YB@L;SJ$8\3OT#C%B.T9[]&97[M!!6 MQG80ZDX6X"4E#6GH0O*C&G1LN83ABOIX@&$:@W&!.P'PCG-YN<`Q4#V>V_P" M``#__P,`4$L#!!0`!@`(````(0`UE=Z3=0\``#U5```9````>&PO=V]R:W-H M965TG)P^'(ZHER-JAI+U\1]_O#Q?_;X] M''?[U[M1='T[NMJ^;O8/N]>O=Z/__*8^S$=7Q]/Z]6']O'_=WHW^W!Y'__CT M][]]_+$_?#L^;;>G*_+P>KP;/9U.;\N;F^/F:?NR/E[OW[:OU/*X/[RL3_3/ MP]>;X]MANWYH.[T\WXQO;Z7S27N7M:';]_?/FSV+V_DXLON>7?ZLW4ZNGK9+,NOK_O# M^LLSG?.-_M/\#]RVYSV!_WCZ=KD-LV3GH$O^_TW M;5H^:$2=;Z"W:F?@7X>KA^WC^OOSZ=_['\5V]_7I1-,]H3/2)[9\^#/='C>D M*+FY'D^TI\W^F09`_[UZV>G0($76?[1_?^P>3D]WH_'D>CZ9)-/YC-Q\V1Y/ M:J=]CJXVWX^G_&NGZM/[T\;#_<47K#1WZ^+;6JU>TU-[<16'FM+M,_NHJH_FL MW=R-2'2*_R-=VK]_BJ?3CS>_T^6XL3;W:!-QBY6ST->>=IM*D$F@),@E*"0H M):@DJ"5H`G!#PG7JD6"_0CWM1JOGSOO>`2_G6$CE+%R75(),`B5!+D$A02E! M)4$M01,`)A4M5;]"*NWF;D3_#0)MQK6Y-S9)&(TB%E>=2:$5DV]WBVX="O3.*&#!_KZ,&0#H;OC M@(%H:SX00R;C;@%9`4F!9$`4D!Q(`:0$4@&I@30A86+0'7^`&-J:BV'(G/0/ MA)>STQFYR4R!9$`4D!Q(`:0$4@&I@30A8?K0Q3A`'VW-]3$D#!8@*9`,B`*2 M`RF`E$`J(#60)B1,#%J^F!@Z?9E2ADFS/S"#T9ZX4(:04$$@S6[%9=X9=8$$ M)`.B@.1`"B`ED`I(#:0)"=-.9ZY,O//K7VO.%;(HC"5$*:(,D4*4(RH0E8@J M1#6BAB&NC,[W9%8\(3@PIG2&+X+*(A%5D`B;CH&PJ>_H(BU#I!#EB`I$):(* M48VH88BKJ%/!4,6?Q)?)'"DC<2=XKPL2TB^0884H190A4HAR1`6B$E&%J$;4 M,,25TZ]VKP2N5 M=B46=X/$2A6+^Y_>0..7:(HH0Z00Y8@*1"6B"E&-J&&("ZF3T5#(GZQ4)G=E M*U68SK9[%ZL(4(HH0Z00Y8@*1"6B"E&-J&&(*Z/3T`'*F*R5*6/0E)8BGX_/ M$AE&G95?J0!E$2"%*$=4("H158AJ1`U#7"R=I@X0RV2U3"R#2"PGPRH"E"+* M$"E$.:("48FH0E0C:ACBRN@D=(`R)F=ERABDK^$@C"8RC*S5M-,OC7HZCN7> M9&:MXJ2MY:JB=W8SB\:S5O`/<2Q28.7Z]`@^+*\< M8UYI$<6K%]Q8!7.0HE5FT=C/E')6+>*"Z^PK#'I]>QY/V]OS3[0W>5L8_V.# MA/9BYW/EK$+MNX[N7#-K98/]PS@:B^T1Q?SPD])94GA2/SD3DU2Q,S%(W!#$ MSN-JW%FY8:>(,D0*48ZH0%0BJA#5B!J&N%@Z.1H@ELFEF%@&B3Q?3-=*)WR4 MA)&5%PM0AE8*48ZH0%0BJA#5B!J&N%C#DK`Q)F$6A7D^HA11AD@ARA$5B$I$ M%:(:4<,05T:G/6$8O3_/I_56YOD6\3Q_+NY_*V_E0\SX"N3.T$HARA$5B$I$ M%:(:4<,0%W)8@C;&!,VBX)Q7B%)$&2*%*$=4("H158AJ1`U#7!F=)84A]I-E MW215;*4R2*Q4"[IRP4@'*T$HARA$5B$I$%:(:4<,0$RL>EO&UYCSCLR@, M(T0IH@R10I0C*A"5B"I$-:*&(:Z,S#';E&=R33>C@5NG,::?%HF%2N2-*V_5 M+52(,D0*48ZH0%0BJA#5B!J&N([#4MP84UR+6(09JP"E:)4A4HAR1`6B$E&% MJ$;4,,25D4GU^84JQDS:(A%&[RSB M!=E<;H\ZJZ`@@,],L%X\E8)&3*N<'Z.!Z62+?FXO9DX!Q9^7G&%"&5@I1CJA`5"*J$-6(&H:8 M6,FP%+,UYQ>$1>'*C2A%E"%2B')$!:(2486H1M0PQ)7Y92EF@BFF12(WD#N< MWJJ+,$09(H4H1U0@*A%5B&I$#4-BL?89A]HI5"E",J$)6(*D0UHH8AKN.P M[#/![-,B%F'&*D`I6F6(%*(<48&H1%0AJA$U#'%E9/;Y_@C#Q#0Q2$28W%_W M5C["NHX.96BE$.6("D0EH@I1C:AAB.LX+---<,O8HC#90I0BRA`I1#FB`E&) MJ$)4(VH8XLK(W/I\F9R8?#9,MBR:TXK>E2GQ7#YY<%;^"63J4=!Q(3+HS%NY M8%.(Q3.RH\S=8CN"%UD MX1Z%M;)[%,EM+"YRY=QXS[E#9ST7ULI6X-%L(CR7SHWW7#ETUG/-/4]F\D%7 MX]RTGOE\]%4>@Z]V_1JQN-HMTJ_/>+6AKG56?F\EM6CB@RZSB%Z`U_M&'Z)X M+.[\"OWDZ*=P?J:M'Y#?G$2P&U2AC]KY^,NQ--;"^.%BR_+D74NK3H*DV`:) M:T)N%-F.X4:1152SNV4FLVAF7F(9SV[%G4FAFQS=%!91S:OGK"_:[9C#:#=( M[R#XF)&O-=7<U%B6'7<>>NX!U3TM"8"7R*H7N6_JD0_5&$H3;^6$ M5XARCT)?8GTMO)7S52*J//*^L#3Q5LY78Q&]KD>(JRP+0!F7%Y4F^MJ4]T^# MPM+$6LU#I8W53TH3VS$L3=!7CE8%HA([5FA5(VHLZM-0UU?AM7V^B)Z8C<_]Q;1CUL<6B%*+9JWWSYI:\(,D<*..5H5B$KL6*%5C:AA'7ET#2O:)EBT M6232,"A-3$=V4[+H;)J?6?>V-(DFDVM%UY!6O23TL19^&" MT3K6>TA!,A7+@:VU"*]F`59F$CR,F?<]3GKN;!6\ZCU MG,A*J$3'U46.:V=EASR9BEMLPSSS6=(UTKE9NBPWFYI2BTV3052^NNA>6:L` MI8@R1`I1CJA`5"*J$-6(&H:X8KHZD8K15ZXH'`>^OZ=?[Q>9@T6ZY.Q"-%[( M'65OY:1-$66(%*(<48&H1%0AJA$U#'$==4T4ZG@^MH>OV]7V^?EXM=E_U]\LH[7JT\<.FP^JW2?3I7Y&0"YDRV2RU"EZ3\MT M3%]A:VL.V6<:4TN;RBI8E]+ M0BUME@3'H?.AYT0]?6(:`;UHV=="(Z`7#?M::`0F*97'B6D$E%3T]9E32_LJ M%/194$M[:Y0M8QJUV:.&%IHY^D%`SW'&,VJ9];;0".@-[[X^-`+S3I8\3DPS M1Z_S]O2)Z$SII\=]+31JND'UM="H3:XFCQ/1J.F'DWU]:-3F13/99TPCH-_6 M]/2A+KWG2:?9JW-$9TE?>^CQ%%%TT!<,^EHH.N@7_'TM%!TFHQA@_1XNJ=A]=KKD.VQ_YPL/YN/*HK!WNMKJ:?#/8VT M-_!H!OM.@!ZU+?5S(3QI>N*VU,^"L(4>J='!^UKN2:C[7J&HGE^N>ENHK%]F M5`GC<=+)C%KZ1DT5_5+UME!AO]3U)7JCRGVIRTQLN:?SN>\]GQ6UZ$=WV(>> MDR[U4]"^ECFU]/6A1Z1+_?`.^]"3TJ5^8$L2@XY^'XG?I)VW/R'05]D:<5J=FHF0.<(H:;GI;-T M@&FS.F;@`--N5?2TMKLI)!MJ!-6 MX,#8*X9^.R($@QUC=,PK\%ME'>DIN>7-[^S^,\W.EP;*/0-':"PX?H2T3B&C M0#/Q9LB4LAP$P/]6D>'4@(PD[_QZSX[-96U/YY/9PIT2"+<.M&[B#"EM*[W5 M#2O^%D&DI1(D7DL"UY;$FS\=,&T'P/7[G^JW)'#MGCI9$'/]6.R@:DFR196W#^H6RU##AWC:^ZZZ<-Y@D:1NS,V.(&K'O(G!& M(&VH`Y$.Q!+@@*/>%E3]$VPA"]KJ!.TZX.'3TSQT$=V04`'].8,)#*06$84<[!D=7/>;`+H\`;8+2(_HCJ M!H8F%)E0K$"J*VQBDJO_2+YH>8IR`2G)-Z`0MT*8:E)49$*Q`JDRL2&-E]FV M+SG!`M(2O-!F-NFC'@DVH,B,BA5(58[=9KSRMC?)R@4DI6Y/#"@THB)[B/>B180"_06_J!WD*K3-320U0W,'X\$2#5 M#/:I\69$5U,FM8`\C[\2>R[1VPT1`7#IY(0=!'8>/N;:$H[:J(7/F0F9NO!/ M35+<,7%RU1@VK/'&1'M3C`EH,>UU[XF`Q+FR?7TWH*B-D@;&RD!5)O:M\3)% MEU-D"NB1?[T%$1&@Y+^%Q,$4CR%1&]4FVY_-!G(M$ZDFL&&--R':FV*BA3#5 M@EDYIGM=6RFYXJ`8SFU4/BQ/_;AE`XP0"'2.:W*FOR;5 M.2MK*Z8'O611FHXL'B1-C3?<#']!_ M(=O\`P``__\#`%!+`P04``8`"````"$`TX]-J9T%``#^%0``&0```'AL+W=O M69PVT9CW!8PZYF_3Q75#7UA';3:EV%\J#K4Z=/=U;#^^%9>G&^LJ@M^ MW;C!Q'<==LWYH;B>-N[?7],/*]>IF^QZR"[\RC;N.ZO=C]M??UG?>?52GQEK M'&"XUAOWW#2WR//J_,S*K)[P&[O"G2.ORJR!G]7)JV\5RPYM4GGQ0M]?>&56 M7%UBB*HQ'/QX+'(6\_RU9->&2"IVR1JHOSX7MUJRE?D8NC*K7EYO'W)>WH#B MN;@4S7M+ZCIE'GT^77F5/5]`]ULPRW+)W?ZPZ,LBKWC-C\T$Z#PJU-;\Y#UY MP+1='PI0@,/N5.RX<3\%41J&KK==MP/T3\'NM?*_4Y_Y_;>J.'PIK@Q&&WQ" M!YXY?\'0SP>$(-FSLM/6@3\KY\".V>NE^8O??V?%Z=R`W7-0A,*BPWO,ZAQ& M%&@FX1R9B\.S7GC3D/7>69UDQ9(Y3KY:]WP\E^Z M&0@*2H;(-AFN,GDQF2_]:0#/&DLR%21P'2!Y\/292(2K2`S[AS_(@]+:JN$J M\E:3<#4/Y@NL^D'B0B3"520&,*H/,CT:[-:[.&NR[;KB=P<6!`QK?041 ML$G3Z-F=C=]S$>Q#DD_(LG%A)8-1-4R];]N9_[3VOL%TR47,SHX)](B]C,"Y M@;2Q"20FD"J`!XHZ63`/?H(L9$%9LJ"=!'J=H:%!1LB4V`02$T@50-,`T_`G M:$`66$JJ-8&O%[VCF)GJWT(/V7?@S,E M2"L$%O3X0C!8+X20>=LSV@6YMY#80A(+255$JV^IUX>;SQ*V;;GUC=Y^D$QA:\/)%2RZ`8@E!&N_U[$PFE`B MHJ8S<<3PC4:62IJ665>%K6B\*M&X5(L(6BVEJKFIB@*"/B=&/U%H?X)(!`1' M6SHEV1)4&ET"-ISQ$D1[ZLO9!03UQACCNQN*#2Z"Y@-U,DT(EYLH2$YESD M+SL.$QA6^,#V/P7/Q7F96J*FC"`PIU\!,WOI4)3F$$%3U2&"%GX[R0+?GF0J MC2X/VYLB;T`&O)MT.J@9:CH(`H?DA-D'!&F>$+2@MS@\[" MO6IL>DK5/V8*=4Y-#$&&*=;*IRC-%((T4P@2IGR8#NA3>71]V"$5??_C"O53 M30A!X(HZNZSU3U&:401I1@E($*+R:$)"HZ'_D%$MB=[G!60896X.(DHU M2D"J40)Z8)3&H^LS3@*H+\1!'[TUA/;I0$"&>>;I0$2IYDDNV(\?=%5)OZ+= M8F"[T*AUO=C*E8EI^OF5W[ZW&RK;"-IFG#8EA+L(/9$^/-''BY)5)[9GETOM MY/P5/RI!Y]^N.YB^>.V>(CA:`H&)!WZ$ISG[#IRG(CPMV7?@Z]FG]D7(X@*J M@?A="%_;AO!I!&_%`_PSX!],F$7PIFDG[!81O%@-X,L(7E$&\%4$KP:`>YT" M^/IVRT[LCZPZ%=?:N;`C#*3?MK**OM_1CT:8^,P;^/[6^GF&[ZP,=FT?W]:. MG#?R!SZ@^W*[_0\``/__`P!02P,$%``&``@````A`&N2;)^W(@``S\P``!D` M``!X;"]W;W)K&ULK)U;TQ)M*2R)#I(SGOGW^Z(!5"'Q0"1+X[D0QP\26=4O MLE"9=<*/__6O+Y]?_?/V_N'3W=>?7F_>G+Q^=?OU_=V'3U]__^GU__GO^H>+ MUZ\>'F^^?KCY?/?U]J?7_[Y]>/U?/__/__'C7W?W?SQ\O+U]?"4/7Q]^>OWQ M\?'/J[=O']Y_O/UR\_#F[L_;KVKY[>[^R\VC_O/^][WV MY.3L[9>;3U]?>P]7]R_QWQ[NWO_CR^W71^_D_O;SS:/V_^'CIS\? MHK[GY[?"-W;_V.\C=?OKU\*T\___CADWZ!D_W5 M_>UO/[W^97,U;?;;UV]__O&HT/_]=/O70_+_7SU\O/NKN?_T8?ST]59R:Z#< M$/QZ=_>',^T^.*3.;]&[/@[!_[I_]>'VMYM_?'[\WW=_M;>??O_XJ/'>ZR>Y M7W;UX=^'VX?WDE1NWFSWSM/[N\_:`?W[ZLLG%QN2Y.9?Q[]_??KP^/&GUZ>G M;R[V^]W9Q;G<_'K[\%A__IFLSLYV/@N]-/?PL:?Z"BWQ]^NOW&#NY=L\"ST MT]^XP=,WVXO]9O_FXN7[)%':['/=7?V._I`;D,'?0W=-B]V6WW MYQ?'`7E"DXTBT`>$"\4PUD]O:S/'D/[/RJW%P-DLD>/;QYNJ5I2=MY^//&37*;*^1\_*+<_/3 M:XV,CI('S0#__'FWN?SQ[3]UT+X/-N]HL[$6U]'"':'.[2$'50[J'#0Y:'/0 MY:#/P9"#,0=3`MY*R5E.C>#?(:=SX^2,0KR+8-%WFVD7+6*70PZJ'-0Y:'+0 MYJ#+09^#(0=C#J8$&.T4?7^'=LZ-)O`T%+369!02J0 M&J0!:4$ZD!YD`!E!II08:756^#ND=6Y^>KW3?+H#Q/7(,<0"J0&J0! M:4$ZD!YD`!E!II08>907K9#'65MY/-DHB7'GX>W)YC2;VA:#.9J(*J*:J"%J MB3JBGF@@&HDF@XQPFG)6".>LK7">G)W.I]UKD`-(!5*#-"`M2`?2@PP@(\B4 M$B./INT5\CAK*X\GJN/2B2J/K=EH#BV0"J0&:4!:D`ZD!QE`1I`I)48Q5P>L MD.QH;C4+R!>_?JXB.A!51#510]02=40]T4`T$DT&6;%<3IR7$F>G;UP%O;:: M\.FU$HT81>]<0:1XS*)OE\ULBU7L>""JB&JBAJ@EZHAZHH%H))H,LMJZG#G5 M]NDDPQ62V<$;D`E$;Y6@`ZTJHIJH(6J).J*>:"`:B2:#K%@N#4[%$^C\/9:HE#H,K5VSZFHU5-U!"U1!U13S00C423059:EP6G MTCX3AR%I3O7S*`FZZPW0@:@BJHD:HI:H(^J)!J*1:#+(BN42X!5B^7S93'H> M;30QA%0NKPO<54Z%D+.(,70HL*K`Z@)K"JPML*[`^@(;"FPL,%T>3G^'E=$E MRBMD]'FUD3&DVL_5)V"?:1DB/LLDOOW*RF:V6D`2J:%43-40M44?4$PU$(]%DD-769=:I MML],?CX1-_IY9"8_H,,&J"*JB1JBEJ@CZHD&HI%H,LB*Y9+J%6+Y'-R(-:?E M:;UQGI]I9ZLEV("J#5!-U!"U1!U13S00C42304:_[;K2XVAN2X^`TF`C.A!5 M1#510]02=40]T4`T$DT&6;'RTN/I(W/+\B*@;&:[R()ML9J#C:@BJHD:HI:H M(^J)!J*1:#+(ZK>NO-BRO`C(!!O+"UI51#510]02=40]T4`T$DT&6;%@%E<9C=2;M>K)8X1"U1T:HF:HA:HHZH)QJ(1J+)("OMNO)B MR_(B(!.'+"]H51'51`U12]01]40#T4@T&63%J(>J*!:"2:#++ZN7Q_A7Z^/##ZH6*XW@(=B"JB MFJ@A:HDZHIYH(!J))H.L6"Z!3\7Z_DG/EP)&Q[DZ2#*]T^R^XO5VMEHF/:"* M5C510]02=40]T4`T$DT&66E=NI]*^\QQ[*L#HQ\*ANLMT(&H(JJ)&J*6J"/J MB0:BD6@RR(KE$OE4K.^/0U\2&!WG*B&-P_R2RW:V6N(0J*)53=00M40=44\T M$(U$DT%&VM-U%J(>J*!:"2:#++ZK:LX3EEQ!&2"C14'K2JB MFJ@A:HDZHIYH(!J))H.L6'];Q7'*BB.@+`[S&VN+U1*'K#AH51,U1"U11]03 M#40CT620E79=Q7'*BB,@$X>L.&A5$=5$#5%+U!'U1`/12#099,7**X[OO[A\ MRFHDH"P0\SMKB]42B"A0*EK51`U12]01]40#T4@T&62U75>-G+(:"<@$(JL1 M6E5$-5%#U!)U1#W10#023099L5S>GV:!3Z?,I[Y,2%.]@+)@R^]D+%9+L+'D MH%5-U!"U1!U13S00C42305:_=27'*4N.@$RPL>2@5454$S5$+5%'U!,-1"/1 M9)`5RR7W*X+-UP(FV.;R(*TK\CL9I[/5$FQ`%:UJHH:H)>J(>J*!:"2:##+Z M[=;5%4=S6U<$E`8;T8&H(JJ)&J*6J"/JB0:BD6@RR(J5UQ7?7=_N6'($E$UZ M^4V.Q6J.0Z**J"9JB%JBCJ@G&HA&HLD@*^VZDF/'DB,@$X:"`: MB2:#K'[KZHH=ZXJ`3+"QKJ!51503-40M44?4$PU$(]%DD!4KKRN>"3;6#KNY M!$C.L+O\3L9BM03;W#&BBE8U44/4$G5$/=%`-!)-!EG]UM4..]8.`9E@8^U` MJXJH)FJ(6J*.J"<:B$:BR2`K5EX[?/\9EF7%;JX.TCC,[V0L5C'H#D0544W4 M$+5$'5%/-!"-1)-!5MIU985[_2Y[2CD@$X:"`:B2:#K%AY6?'T&=:]C)@=F0%) MK#38\ML5B]4\LQ%51#510]02=40]T4`T$DT&6?W6U0Y.I5P_%`K7P2J)OP-1 M1503-40M44?4$PU$(]%DD!4KKQV^^PR[9UD1D-OZ\KKL+K]=L5@M<Y85`4F_J,PUT8&H(JJ)&J*6J"/JB0:BD6@R MR(JUKJS8LZP(*`NV_);$8A4E/1!51#510]02=40]T4`T$DT&6?W6E15[EA4! MF6!C64&KBJ@F:HA:HHZH)QJ(1J+)("O6WU96[%E6!)3%87ZW8K%:XG"N1R*J M:%43-40M44?4$PU$(]%DD)5V75FQ9UD1D(E#EA6TJHAJHH:H)>J(>J*!:"2: M#+)BY67%]Y]\67'LBQ5'?B-CL8I!=R"JB&JBAJ@EZHAZHH%H))H,,M*>K:LX MCN:VX@@HC4.B`U%%5!,U1"U11]03#40CT620%2NO.+X[#L]8C`24S8?YC8S% M:HY#HHJH)FJ(6J*.J"<:B$:BR2`K[;IBY(S%2$`F#E&?'&A5$=5$#5%+U!'U M1`/12#099,7*BY&G*U]]_".OW`)RQ6%2<>0W,A:K)=A"Q;&\FEO1JB9JB%JB MCJ@G&HA&HLD@JU]><;CC^/M>*#UC-1*0/9#W^77[Q6K1UOM*(KBB54W4$+5$ M'5%/-!"-1)-!5MMU!:"`:B2:#K+9Y\?+,),D* MY0R%QC71@:@BJHD:HI:H(^J)!J*1:#+(BI67(_]!(+)4.9OKDC00\SM(BU4, ML0-11503-40M44?4$PU$(]%DD-4VKUZ>"426*&=SB1*5N28Z$%5$-5%#U!)U M1#W10#023089L<[7U2-'?SGN,O;9;\KXW5XL MF8C]&>LR\'-FX`$9Y;<7V4Y=1ZM4>>\K*+_LW_&S)E7L4%!^71Y\SCPX(*/0 M;I]?>8]6J?+>5U!>WT:W;]57L4LZI-^6/L]'GXD@YISG2!VOB0Y$%5%-U!"U M1!U13S00C423039.UR68[DMMV6VK@+($/;\"OEC%2?=`5!'51`U12]01]40# MT4@T&63U<\G=R^_1G_M<4/>LHPSO`DH3=*(#4454$S5$+5%'U!,-1"/19)`5 M:UT2>`[&)XM5C%L:B)F@6EOK+:OEVLHJ_.("N#2^!6 MQ(S/]TS,>&1D`#JQ:;+58Q5VOB9H%);[.LGFZ7:RBK\X@*\.Z3.Z< MF5Q`1@9OE:##8I7L^CZ[%%@M5G'7:Z)F08FOL^RDW"Y6T5=GD)'A8EV.=C2W M.5I`R6^^)CHL*-GU71;(U6(5=[TF:A:4^#K+LL)VL8J^.H.L#.ORO@OF?0'I M'N+$]L%ZLHPR&B)4FL`M*; M?,?/!NY/W/]LUE6S6Q-16@YLS[*9M0U6%R&1MFZ[Z..X-U:B=1FH`CY/1@*R M&>A9GH$N5HM$WI>^MA51%:SEX/$V^@YA]-1$3\L! MV@;TK4A)?5@]\K3576'9[(]?$G[\^.G]'^_N'"BN27*JD#_60K]<,)L-*`N@ M+,"O%ZOXXPX!72Z?G*\"]CK[2`/+[I>IWR<8 MT]<+C[*XRHZ2Z\4J_J)#0)?)O8^`=.O:?\OTO!1787MI7'GD'@](=,[&K(W; MV_KJ/I^44K=6N3QI/2JG99NT-1=I_WWWYS'25H0=\]H+C[*PRW*4Z\5J4=%W MO%P2XBI878:I_:2H8MA>&G3!D_M=<86>PM0>K,[**J9NK8HN%TUSWCS^HHQ/ M%^L7/J5-<^&`TOJ)Z$!4$=5$#5%+U!'U1`/12#099$5TR6TJXC-B^5S8B.61 M+=;/LB3P6M.Q.[$FDAZ(*J*:J"%JB3JBGF@@&HDF@XQ^FIS7Z')>^:5^3?!YEA:0C<+S+/V\ M7JSFV8ZH(JJ)&J*6J"/JB0:BD6@RR`J[KA"X9"$0D(E";Y6@`ZTJHIJH(6J) M.J*>:"`:B2:#K%CK2@*=!Q%L(;-/SVL[W,$('9-T]1!0O(.AW-+F#%7LPTOI M.O>NFFA\GIM.U$QU2*I3S]^\EG[I M,M&7GW&.YMF,Z3RXW#SY(;R-$3H:^7W';]S&B!T*VKM,;L4N^\3/:!]RP50A MWL:X#%:I]A[%VQB;+'^K8I?4\;>E=[G4BM_A4R_S.SQ*YH3K2Z`#4454$S5$ M+5%'U!,-1"/19)"=)B2I$\Z=$SD/A!51#51 M0]02=40]T4`T$DT&66W799V7S#H#2I2Y)CH0540U44/4$G5$/=%`-!)-!AFQ M-B?K=*J[)]SU.^ MI^N+S0E3N\B>.7'-9LGL&=E\ZMIF5Q&TXI7?H''^S0ET<[(NT?+V^5#XO,H, M!4]?L6MZ_HKL&R>PV%PQ&8S,P[>71@'K82,$`HIU8O. M8YN3=(SK#1EV`26"9WGG8E9%%5" M>W>)^!(:3$*#26@P"0TFH<$D-)B$!I/08!(Z99G0+IE[>?ZU.?')GU73LT02 MQ2B8I`.3=&"2#DS2@4DZ,$D')NG`)!V8I`.3="G+I%N7NFY.F+M&E@5B?BVSYW5F8"NSF9,]@H MDP(13($()NG`)!V8I`.3=&"2#DS2@4DZ,$D')NE2EDFW+G7=G#!WC4SWYA+I MO)WN9$8FZ3P[YBA+R8Z+!JE=["P]@\-E(])S9NDE@.Q:K22>S:([29PR*\EQ M=?9G4H%SFP6]TQK MU()ID5K/PGWXS>7YF;MAFEU'5]B@JS3RS'W>;]X3WNV+9KJEXN[(GKPYR0)+ M090ZSX+(9;%KIAJ?]5K%/+-ES'DV@TBQV2Q1#$R*>:8/J;O?\\/QUFA!,/24 M8&`ZJ#S34QW?5"?ME:GC4L\UZOA4U:KCF:E.^430QK7[:[").F!2Q[,YGDZ^ M$4_H*GEF]G0\>;-8$Y?B:7;$(]!EG&L4\QFJ52QDK3I!SG&_*\23-U/8)8J! M23'/M`K$,9ZVQ>>HHE7B38+-WI8=*1V`WFR^)E(X`&='%,PEE:E@^4WW%STE MLPGK75H=?;YJYH]=_B"8CDMOINA(=/1,'SJ/3#H&IM\R#PN?M8IFB3L)"79G=+RY\HDW6P69=))(+C;I=(% MMC^&X.;B0E?X2BF>(QL/`$XS=%A3N).KM;]J1T8(>N MNF#[355G[XFG)"^R0A_7OH30R2-Q+WO"9A/6T#3JFG4UP_+(9%H;WB?9R?4. M+0X/IM7AP;0\/)C6AP?3`O%@6B$>3$O$@VF->#`M$I^R3%*7(*>2/E-YA^4S MK70^R;;?!CA'8,:5-Y=T7VK.79?`)).:L).:8%(33&J"24TPJ0DF-<&D9LHR M-5UNO49-GXM;-3U+`NQZ8];A/`:GI(.=`A%,TH%).C!)!R;IP"0=F*0#DW1@ MDBYEF70NR5XC7S>7L,>Z:/7L1I3=*!23K/=/T@"=CD?5O_ M/FLTJ;OZSV%4*>Y;ZD\2S8;(O^^S@D>JS6?0GU:._8WZ1 MR>ER]S5R^ES?RNF9E1-,5^C7:@)S%'LF=4.3-IY9K7S+-,NPN6>O)0B ME%01+F$KJ3RT(9^'K:2:S1*IHK^25"X]3Z7ZOCHPK+EIHR_4!N9@!I."GFF9 MM;C+BC[/,@4C/)\MI2"A%(S0*.BA6\XMJ0.R&\52<#:+NZ-@B_Y*"KI4/%7P MN4S0I^Y6JD(ZO\,+_1N5^KA8$YB^FN!JA+-`0I-[M5'E< M:'/%"(2%.0WXN;V8A:#X[`)S.W@W!47**IHIAHP=JUG=@RKXTFK MB>QI=VTT2]QU,UO<]9$][6Z(9MY=)J_+V]?(Z_-\*Z]GM@:_P"W;L.1GFN'.&Q;QKA@9E+484`#V;N[8!Y!'<760A*\O`CEBU(\L(/PQ8T M"MY,LW.([RRR-`"I\VP`7/:?#L#QN8XS/,:Y1B%UGHV"JQHP"CJUOOSMKDU82M0.AZ]&LD,#MS%"5WMH M^*[ZCN9Q[C\Y+5UCULP3MK#$K8:CL-72<'BS)6ZSFSP:#CC7<+S$N8;C&><: MCM1Y-ARN$LF'8_5KGII-Y"9[HBPP>X#@9>K8U1X@WIW6`W0CHK.`'Q(<(-[, M'B">N2_(SI-0:43"#FNZF,T*)^/X&\Q1\I(M:%B\V7((7R59>4/E9%,=GHMGLT1>SY3QN/#^8;/[ MU@D@]%VB3S/.["_5,COM2')O9EZ'+\4WMB#)7[(%C<*\A7"*R3)9#4#J/!L` M5TNE`W`\%Z\\"S@?^9SCV;-G@=DL&13/W$Y_.TAU%@A=3!=;8A*[F>`G,/<&=C"L')]II4I[M=A=9!:A)"MO0Z'CFOFXW=\4Y M1Z.S;"(<,ED:H)%)O6?PB*Q=FB<;_,ZLLX+8$ISJ`FL*K"VPKL#Z`AL*;"RPR;),35=ZK5'3EVI63<]T+R_*).G` M#@4FZ6`GZ<`D'9BD`Y-T8)(.3-*!23HP29>R3#I7+ZV1SM=75CK/[)7-R^PB ML-2#:+FY#`,TN[9MF2-)_-8E=I#B;-9Y:X MRR_C:AAFL^A.PY"R;!APS";Q3W3,(!I&,`T# M'$R:SRP1Z3*['B/-9[.X*](<3)K/+'&7W[60YK-9="?-4Y9I[HJ@-9K[HLEJ M[EFF>9:/2O/9+.Z9-`>3YF#2'$R:@TGSF24B76;9AC2?S>*N2',P:>Z9>Q4D M&DIA0DF<]LXD=H70&HE]X60E#L74J8%5G@L(#`5OR[%V1T?E,KF(`F, MCA+8,W>+?LZA=I=9=BC-T56:@TG@X$Z9[NP.F;`T1U=I'IC^)%VS(=0HS%LH MUS\:DM1Y-B2N-%HS)*'86C+;=YNPO&YRX41#DI9<<4@\"]6FGC4K7]YB5PU* M<.?>=IBUV%UF2;%&!9O5J(!I5#P+UT2R25&C@2X:C<"4&,][@-Q:HV$\\S%J MC4;J/!L-5P^M&0U?/]D#Q#/[%-(E\\#9+![/FH/`=(B`:33`I#R8E`>3\F"2 M&TQR@TE;,*F9LDQ-5\.L4=/7/%;-4`>Y%PWF85?`\KW1KO M9O7;X_QSO2$[%%A58'6!-076%EA78'V!#04V%MAD62:=2^W72.=+`2M=*`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`V=SP4MZ>5DJ[,_'\\ MAO4$?KU[?+S[V<@X]_N[A[C?[@-_'5W_\?QXL'/_U\````` M__\#`%!+`P04``8`"````"$`Q+BHD@,&``#+&@``&0```'AL+W=OA]#"K/N.# M;;=Y1N]9]ES0LI%.*GI(&\1?[_-C??969)]Q5Z35T_/Q6\:*(UP\YH>\>1-. MPZ#(9C]V):O2QP/6_4H&:7;V+?XX[HL\JUC-MDT/[B(9J+OF:32-X&DYW^18 M`8<]J.AV$=Z1V3J9A-%R+@#Z-Z>G6OL=U'MV^JW*-W_D)07:R!//P"-C3]ST MQX:+,#AR1C^(#/Q9!1NZ39\/S5_L]#O-=_L&Z1YB17QAL\W;/:TS(`HWO7C( M/67L@`#P&10Y+PT@DKZ*[U.^:?;X->[%DR$9CF`?/-*Z>HF5%WPK+[J3*P,3-1#?:F`RZ@W'_83PV=V!D0Q?H'&?-NER7K%3@!)# M?/4QY05+9G!VAD%Z:(%Y#Q<`PIW<<2^+$+V!%==(YLMRV(_GT0L2D"F;E6M# M3(OUV8+G#>&U,0*=+XB1>^$Q\ESRH%=GP25H*^3UV<(."$!]04#PH!U\2)?>R"`=3(TP+J)4RNA9F:V*'B7K5P?0WX+G0 MN+&(ILVBE)!85!VQ\%NW6AWD2_1&F8VZ!,*-S4"D9!BW!;;6)<9,8W,FWG0Q M&?7&B+9CXW%/9AA2@C#T%0^LFFF-[&3PQYM&!]>3P8W-R:5$QT"7&!B@H#X_ M$S*]:=MO*R6RH+#Y\F+EE(7%F!]`T3)CRT5$B@PH=)$)/.@BO(^41E_.4 MR$K\V(;B7=8CG6A/6%M-J-.Y3(B/Q[W(?YWN= M^VYN`>'(J@G%>$8+$*+RH1*A+"]/AK$#@!SG>3(DG>A06%L`*.[3 M-D?*RC>;CPYO.Q`FDM?T#E4B*Q?VD?!BY;1%)T),7$)4(IEF57KO$F)B$>+M M)P3AR_D"EKMZ)H>#G60 ML6=^^PC[Y;P5RZO153+`W>B`NW`T0VC$=:6C&4$S\HX90S/V:>+);`UZ]\P3 M3Z$11Q%GGCZ\B:M71\-O=$4[.)H8&G%OXF@2:!)O!!B#K98O-HS!/L>G`6[8 MIO@TP`U;"9\&N.&![M,`-SQ7/1J",3@)^308@\.*3P.L<63P:8`U-NP>30RL ML;GV:8`UMKT>#<$87%7X-!B#:P*?!ECCE._3`&N<'ARUCS?D/$(W:UU#+_P$``/__`P!02P,$%``&``@````A`+(V?&VW`P`` M2`P``!D```!X;"]W;W)K&ULK%?;CJ,X$'T?:?\! M\3[A$G)#(:.&5N^.-"NM1C.SSPXXB=6`$78ZW7^_53;0V&1[.E*_)*%J])YHJU@O$[<8.:[#JUS7K#ZF+@_?SQ\7KN.D*0N2,EKFK@O5+A? M=G]\VEYX^RA.E$H'$&J1N"Y^>*UE*#M+0D$OB+$VM$CU;E[X&K2/MX M;C[GO&H`8L]*)E\4J.M4>?SU6/.6[$LX]W,0D;S'5@\3^(KE+1?\(&<`YVFB MTS-OO(T'2+MMP>`$*+O3TD/BW@5Q%D2NM]LJ@7XQ>A&CWXXX\\T=T_5J@"39[D]T/*@/_M$Y!#^15;?%U;(4^*&T2P*%ZMU`/[.G@KYP!#3 M=?*SD+SZ5WL%'99&"3L4^.Y0H+[>\)]W_O#=^<^7L\7*GZN@TXV>9JU$N">2 M[+8MOSA064!+-`3K-(@!K#^]1ACT^#\Y0`<$N4.4Q`7*<%`!.7S:+8+EUGL" MW?/.)YWZ!*9'UGM@NH#>P!%$^0".B((<,85(.NT-KZ1#BU#O81,"H3Z`$*(D M+GR.1%N9#%+M$XV5M73-!A>;9?0A+!$E<:.-0=/BD'9.;]$<7&R:<$G&8EZ_ M=WVAH;-B,V116X)055T0F?IEP^I8Y%?V1IDM;R&"SB81;5FH;J,*+!M;C$@K M,Q)>NN5\M@*R-]X[!#)9:,L"*G=456M+E<')S@4D\/VY0&A, M*(T^M!Y'])NXHNV19K0LA9/S,XX:,._LMH-9ST%IX,,@I+K+9`5')#5/3%9" M6%'7<;(RAY4Y$K)68-ZZN[X#-ESQ3R'$57\(;5_& MT$FG1--5G*VNV=J$EISR4,<.KG"29V"E.$CSWKP+GL'S#%PW^`W7\```#__P,`4$L#!!0` M!@`(````(0":(?RJ(@D```@H```9````>&PO=V]R:W-H965TGAUP@C6`$78F,]]^ MJV_N2WF(HS/GX3#YN>I/5W5UNQK[\8\?Y]/L>WWKFO:R=;RYZ\SJR[X]-)>W MK?.??VOG7'NNYGH'#IMLZQ[Z_1 M8M'MC_6YZN;MM;[`E=?V=JYZ^//VMNBNM[HZ,*?S:4%<-UR[Z"Q$MS:OJ? M3-29G?=1^79I;]7+">+^X2VKO=1F?R#Y<[._M5W[VL]!;L$'BF/>+#8+4'IZ M/#00`4W[[%:_;IUG+RK]I;-X>F0)^F]3?W3:OV?=L?W(;\WAS^920[9AGN@, MO+3M-VI:'B@"YP7RSM@,_/,V.]2OU?NI_U?[4=3-V[&'Z0X@(AI8=/B9U-T> M,@HRZJ[/&BKES/;O7=^> M_\D*".Q/A#)_"V0_GP$5.7.UR^%)WP*3_C7 M'7M08['"I[#W5O,E"59K-MX[GJ'PA$_A22"?4\8(R63?"9^3Q@CKDMG#YQ?' MN!&>\#EMC`M>"JRRDJJOGAYO[<<,EBM,>G>MZ.+W(E"3)<7S,Q39KVH,BHN* M/%.5K0-Q0!EUL#"^/P6$/"Z^0S'OAO`_[4"\,WIW7&;I5XEH6D2#R9#+A!)$Z MZV521TGG$MV5+H25S_N9A]4FL';D4NHP:3-MM-N9GC;>&QFKA".H%%F7,:T: M6!*>FO!$(F65"@1'?NF822OEF$ND'`OL6$HKYFC&1YN="25].82*2L4H&, M^4>..78LL&,IK4;FG_9$T^/C'90QZ1S11:5-.OIU1%CIDS[B.+(3D>FK0"`MF!BC!*,4HPRC'*,"H])`9GRT]]+BX[^4?K'_)[R! M,\+FB#>5_#<)8:6A1*!/^G]E)3?*#*,SO5K=Y!.)H%&7XTP%"^F)X_O3CE]^[.:EY@,5C+T1"+5%Z0"B8.`[P8A3@@2RK%0\;E0:7B9 MBX8V6M-3PMLR(R5#@Z>GQ#IXQ/2!'NV+U-0F$JGB3P5:PZU_:#A(:)TV,^FH MM'*)E%:AM%B7Z5K]16FXF"FAK=CTE/#&S4B)Z.7@8P@C\*V#8$P&*U4E`NE5 MPI&H$L]E_YEM=X:5"#53PA@5WTF?129Y%<(B54F$*P`/W`7CV&EYF2 M+[68/N\G]4(1R+KEV`=M9:52PK6TTV-/)%*3FPHD MR\1=P2YKIX2/0+N!Y5BHL(1@`=I"I>%EIH1V@Y.W6/CY!*5$(#K77)F_LL-? MK#C7M[Y$7W:`!+V%0)7P&7L"KQ@!">P ML2L$KK!G7Y8:O)/T/,9W(#6N!$)CW^##NTTC_'D9/?-WGJPOWBTC>)X\,M0P M@@>A(WP5P;/!$;Z.X.G:"-]$\#`*VA[>Q&+_/,(;=S4\%W+G<$]_;=M>_@%?O1C>X7OZ/P```/__ M`P!02P,$%``&``@````A`.:O(]&W"P``6S@``!D```!X;"]W;W)K&ULK)M=<]I*$H;OMVK_`\5]#!*(K[)]*D:?(*&MK;.[UP3+ M-A5C7$#BY-]OCV9:\_$JQ/B;[G_^C#]-NIWC:?UROW[>OU0WW9_5L?O'[3__;[M/I]#KK]8Z;IVJW/E[M7ZL7NO*P/^S6)_KOX;%W?#U4Z_NZ MT>ZYY_?[H]YNO7WI2H79X3T:^X>'[:8*]YMON^KE)$4.U?/Z1/T_/FU?CZRV MV[Q';K<^?/WV^FFSW[V2Q)?M\_;TLQ;M=G:;6?;XLC^LOSS3N']XP_6&M>O_ M@/QNNSGLC_N'TQ7)]61'<[-R,.KV;J]K M!_UW6[T=C;\[QZ?]6W+8WN?;EXJ\3?,D9N#+?O]5F&;W`E'C'K2.ZQGXUZ%S M7SVLOSV?_KU_2ZOMX].)ICN@$8F!S>Y_AM5Q0QXEF2L_$$J;_3-U@/[M[+8B M-,@CZQ_UY]OV_O1TTQWTKX9^,)YX9-_Y4AU/\59H=CN;;\?3?O<_:>4I+:GB M*Q7Z9)7153#N#RX1&2@1^FP1.7/WH6I(GZKAZ&KL]:>#,8W@3#NZ6H^=/E4[ MWW]7PY%J2)_09(?`NQWH<`N(/OJEW M-0F"X6CRFR@0JT4.52_UY!JJEV2X/JUOKP_[MP[M3,CR M8I1C;I;GKU8G+4NA\EG(W'1ILFG='6E+^7X;#/WKWG?:!C;*Y@YM/-MBSA9B MS0O9T`61"V(7)"Y(79"Y8.&"I0MR%Q0N6+F@-$"/?-TXG`+F[W"XD!$.9U?= M,=`SX/A_SA;<)'1!Y(+8!8D+4A=D+EBX8.F"W`6%"U8N*`U@>9=6X=_A72%# MCQ4KG`=VL-Y)FZ$9\R/;9-Z8-"X'$@&)@21`4B`9D`60)9`<2`%D!:0TB>5^ MVLK^#O<+F9OND!X!9[83973._XU)XW\@$9`82`(D!9(!60!9`LF!%$!60$J3 M6/ZG#=SR?WM*Q9NVL*[=S.ZYDX0>:F(']]QP;JZV3XO5$\HS+NB)L+9[(DE0 M9Y+ULV`.)`02`8F!)$!2(!F0!9`ED!Q(`60%I#2)Y4)*N2P7BD>S'US1+%SX MBR/GP_:VMSVJT)FV"(*$46(8D0)HA11AFB!:(DH1U0@6B$J+62[5*3N;DWT MH8U7%)9.%"ODA+'[I-5631PCBA#%B!)$*:(,T0+1$E&.J$"T0E1:R)X`D=V; M$_";F);%`*6+[*P[49:3XZV8!A2B580H1I0@2A%EB!:(EHAR1`6B%:+20K9+ M1MINO=WM*86F?;=DC!E3&J.,I6;I86X1$ZH19G#;-Q?D7 MN=5`H4(#(?7]UN][SBE`I`UX\XE1)M%62L8YFTFU`6T5*T0?/)I$(:-AB@TS MJZ$]9I&U7S!FF>1;8Y;(TV=FT M!RARZ@L&*%-P:X`232@C-"9UZDZJM#+F)B27B+BWHL$?.3E)I*S&0WDX,)FX MYP,QZYC3_A[IU)&>!K[3Z\R2MOTF4N,+_"8S:D7EF94<1(?F4G-M2(M:;2&TZR$',+(UX8:9'4%ADX.V?&+6H1*S+\MCS> M"RY\=-0JCHMD6N\$C-.QN6I(<\6;8*A0H$<7*30>U2X:^.`C>2]#)4&5U%;Q MQTY?,G5=JMA.NBS7]C'75H@"ALX.,S5JV)9%EGO/CG_O77V6T1E9'?XJ'C^5( MB3][5D0 M^?U?GP59)5BS()$QY#E5E^[9@T(CFI_F@1<$SC<>D;9B5\2L9>;54M[2\B=. MC9.B5L9:.F`6VNI,OY;:BON5LY;N5Z&MM!;T:Z6M6*MDK;I?UJP-W!)(K!U_ M)'Y+V'9(1)@/2NJ6]B-5(:LT#@*G'INSE1Y8J!#EJ<;`H*;F.\H4V!]ZSNS& MK*S=GS"B8TCV1JK82"9V`^?YE/%M*`=O(@F\O%!6Y[N\5%9CU>5QW[E9K@S( M9=R]@I'1Y95B0U7X."HE-Z%):^VR/>5NI7?^.3^0-96Y(A42QPS-[;R1FZZS ME4X00D:Z>H]87IX!?/)])UQB;),PTLJI(^/T)>,6^L8+1$N%:+74I4,P=?J2 M8YN"D>[+RI%QLNF26]1]L6?FLO)R@.6E0LX*='HP9RMS!4HM(PXC9351WI@. MG4(Q9AD=NPDCK9PZ,NZ9<,9-M,H"T5(A2@+DU(R#@NXB;ZU@M$2UO%=TZ_H4C.ALGGNX8FW9 MFT^^DRF5W*9E68DB_*_/FE!Q4A&)Z!'%O9S31,#24@W)Z.Z?X7 MC(S^KQIVMO\EFUE61O_MW=4]>G`7[_M.>>@]'(@#A408R%O*-VWDS_IWU>&Q MFE?/S\?.9O]-O$5#A?OM=8/E*SYW7G\F?@%#$G"%WOZAGV:T7?'I2OWC-F@S MH"MU.@I7AG1EV*;F!S-Q//K??A:1:[.^H6ZWVU*FV/GT>SC[+UYO< MSE)?6[LZFM&/-+&C=^,9_9:PA4]F]`.Y%CZ=T>^XD-.7S#/Q/3)>H>^-9^*K M8;Q")?I,%--XA8KGF2AS\4KH3V>B7,0K"5T1Q1]>H6)O)DHYO$*E&]VG[0H= MFM&,M'K,)Y=1PD-JO<;Y]&K7Z_JQ*M:'Q^W+L?-"[S]/P```/__`P!02P,$ M%``&``@````A`'C(!*-R`P``_PH``!D```!X;"]W;W)K&ULK%;;CILP$'VOU']`O&\(!')!258)JVU7:J6JZN79`9-8"QC9SF;W M[SMC!PH.C3927T(8CH^/SXP]7MZ_EH7S0H5DO%JY_FCL.K1*><:J_/Q M;NXZ4I$J(P6OZ,I]H]*]7W_\L#QQ\2P/E"H'&"JY<@]*U;'GR?1`2R)'O*85 M?,FY*(F"5['W9"THR?2@LO""\7CJE815KF&(Q7LX>)ZSE#[P]%C22AD200NB M0+\\L%HV;&7Z'KJ2B.=C?9?RL@:*'2N8>M.DKE.F\=.^XH+L"ECWJQ^2M.'6 M+Q?T)4L%ESQ7(Z#SC-#+-2^\A0=,ZV7&8`5HNR-HOG(W?ISX@>NME]J@7XR> M9.>_(P_\]$FP[`NK*+@-><(,[#A_1NA3AB$8[%V,?M09^":'JA,P5&@&041,J6\``'PZY0,2P,<(:_Z>6*9.JS)Y)PE$81+.Y)KDR<'(>",^! MV2\'>D:]-N.!*+)>"GYRH,)`GZP)UJL?`UGC@F%H??F7+>`'DFR09>7"UH`5 M2\CERWHR'2^]%_`_/6.VEQB_CT@:!*8-Y+4:P9W_H!%94".F$D5OF\!?T8$E MJ$'8@L`H6]`$"G"X=!J/6IA9BBPHO16$]WYA)9%FY MX:(GT_)E>P9=D]E";)D@J>O==<\0K-6T23,1.!BPR.:6-^9C!',/UF&OJ*:W MZ$!P7X>)1/J`TN64=".]F6;]F?06FT:C&:B],3G(U)=A(B"CN^*)94L+LG.! MO:RS^:_G`L']R4VDZT$WTO,`ZJD[$WH01*/;'4">O@@3L1P(+0=:D.V`#]NV M*^RZ!1K=G_XW&PO=V]R:W-H965T:[.\"+:#:VL%4J`HTO995Y9MX5J6(>DN^?L.-XGDN(Z3 M]B6*CV:..&>&Y)!W]?FC/AMO9=M5S65M.A/;-,I+T>RKRW%M_ODU_K0PC:[/ M+_O\W%S*M?FM[,S/FU]_6;TW[4MW*LO>`(9+MS9/?7\-+*LK3F6==Y/F6E[@ MS:%IZ[R'G^W1ZJYMF>^I4WVV7-N>675>74S&$+2/<#2'0U6485.\UN6E9R1M M>J_45+3J(L@.UZ:-G\^0]P? MSC0O!#?]@>CKJFB;KCGT$Z"SV$!QS$MK:0'39K6O(`(BN]&6A[7YY`29LS2M MS8H*]%=5OG?2_XWNU+PG;;7_4EU*4!OR1#+PW#0OQ#3;$PB<+>0=TPS\WAK[ M\I"_GOL_FO>TK(ZG'M+M0T0DL&#_+2R[`A0%FHGK$Z:B.<,`X%^CKDAI@"+Y M!WV^5_O^M#:]V<2?VYX#YL9SV?5Q12A-HWCM^J;^FQDYG(J1N)P$GIS$M2?. MU)X1CCM^'O>#Y\]_?,I)X,E)G,G"]Z>SQ?S^U^$M#1V>W/&^_8S;PY/;+R?N MPG?\[X4YYX[P_+$1PB2E(X3G0R-<#9BPD.[N MFI/I[P1`)HJ*I7(HLW^K,B@O0O)$6-8F#!X*J(.I\;;Q?'MEO4$Y%]QFBVT< MU6(G+$CM$MI0!R(=B'4@T8%4!S()L$"$00DHZ?]!"<)"E!`Q;`4P2N-J80L+ MX1+J0*0#L0XD.I#J0"8!2M@P(_6P/5B;;J\J(M_$"=8/)=]:-K?,9BH7Q4R+ M?#`90D=(A)`8(0E"4H1D,J((`*N)+@!95G]P!A"6M3F%*21-`2W36VYT3Y+! M9)`$(1%"8H0D"$D1DLF((@F$KTOB^A-`[U<%<:,:B+%O&>*X=$F8:]D?7LJ2 MC:N&,B)8B>41W1\',5;'P1"?;K!T:=DA)$1(A)`8(0E"4H1D,J)$!=O$XU$1 M8S4JAO@PLZ6:\S25!R.1E!`A$4)BA"0(21&2R8@2*%3\XX$28S50AD"@(H8= M0D*$1`B)$9(@)$5()B-*5##9Y:C8WCDAO4A_JHJ7;"0+`&&0@[-%G1Q<6U'J_QH-!@$$#2SH9*2T8JT+4"C+=KI:"!H,D%#VVQ5 M$M)=2/W4C=Q#6"+Y#NM%8-<0U%L.D1UH2*WG3[5)+:S&.$(.>9"MP=&=:3MN M)+XXHZ(MIDN5.,;$R4/$*;>:VY38<5RM&C.%6=6,M":/:\8:&44S!CDP48?0 M/=]70]O!+D2F&CNB\?YRE(%W* MXU+PGD8N'P9IY:-5P<[A5G+Y#(ZC%`QRYU0*=[Y0!8TQ2R(@=OXDBU?*(<[B MZ*6<"1"2NY6'A[-P87<:L9 M6T1<3>88DR0<\D>25"5Q;(TE4UC4B4/Z,$FB[VQ"K&M3JH5!D`21])W#(;DT M&`0[CK"*N-5TM(JQ8\(AR3'%CIGBJ,9'.C(IOI\K`=;6*6$S2"D!QT'K!;<: MPPZ)!\R;.6SGPP9T8^_E5NPT!)=FVHDYYC32#I4\Q)P**\X\\[1^(5.852U) M=W='RZ_-E5X2?:>&6(^HB,DA4ASLB^QFD]T^U65[+'?E^=P91?-*;BUA4]RL M!IA=J6[G`9PI@$#'%P%TY1@/EP'TKS=PQPY(.XC?0/L7D`X/OX'KW"=ZX-"_ M3:YY;]AOW0#N6##/U@O@[@'C3]/@B65:_\`T@),Y=MC.`CA)`FX-#G"]>\V/ MY6]Y>ZPNG7$N#R"D34\@+;L@9C]ZGL3GIH>+79K/$USDE[`_V^18?VB:7OP@ M'QC^-+#Y!P``__\#`%!+`P04``8`"````"$`DX>$D$\&``!8&0``&0```'AL M+W=O_`%VS`6$`5\ ME7:EU2J[^^PQ!JS!&-F>3/+W6WVSN[M8PB3[$H=#U7'7J:KNHF?U\6MS-KY4 M75^WE[7IS&S3J"YENZ\OQ[7YU^?DP](T^J&X[(MS>ZG6YK>J-S]N?OUE]=9V M+_VIJ@8#&"[]VCP-PS6TK+X\54W1S]IK=8%O#FW7%`-\[(Y6?^VJ8D^=FK/E MVG9@-45],1E#V#W"T1X.=5E%;?G:5)>!D735N1A@_?VIOO:"K2D?H6N*[N7U M^J%LFRM0/-?G>OA&24VC*&F[XOD,<7]UO*(4W/0#HF_JLFO[]C#,@,YB M"\4Q/UE/%C!M5OL:(B"R&UUU6)N?G#!W;=/:K*A`?]?56R_]W^A/[5O:U?O? MZDL%:D.>2`:>V_:%F.9[`H&SA;P3FH$_.F-?'8K7\_!G^Y95]?$T0+I]B(@$ M%NZ_155?@J)`,W-]PE2V9U@`_<-2D-4*3X2I]O]7XXKD)I2F4;[V0]O\PXP<3L5(7$X"3T[B!@\[S[DS/$?GF>/9P3L6X'$.>'(. M9[;T?2]8+AZ/`BRI%/#D)-[[21:+Y[)19+,*V7J!B*S:IK MWPQH0DAA?RU(2SOADVF(0F%I'4OGORH'2H:0?"(L:Q,6!D710[E_V2BT$QVH\D8.D)BA"0(21&2(227$44`V!UT`Y),IJ,DB`D1DB"D!0A&4)R&5$D@?!E2>[7`C&FD8L5;QGBN'0CT'/. MOO3AW9)0TUZAK`..B\?708S5=3#$=\=FW"$D0DB,D`0A*4(RA.0RHD0%A\#C M41%C-2J&0%2R@$NUTG:CD4A*A)`8(0E"4H1D",EE1`D4ZOSQ0(FQ&BA#Y/0A M)$)(C)`$(2E",H3D,J)$!2TN1\5.S!F9*(937;YL6S88W6B:.30$.R\)AQHL M0_@P1@Z_'4.<^5B]$4/FL).-K>,NM#TF'HU$YA.$I`C)$)(SA+U>B=^!T^&G M!:`DJ@(%MI.6`6C8\2A.61K<@RT/3<6 M;PRH:+YMJYHEF#A]B#C[#G&N$*N2D7GD<)ZK/4-M-$>$PDJ8`FDDPE64Q'&FWY7'A0$E4*,IH\+@4? M9*;%;*$_:)!J]6@+V`DKN7I&1U&),;=R%U2*A=86"29)!<1^1Y*M*[M/D@L/ MNA)5"C*2/"X%'V!D*1BD5876#SN'6TV.D8"FA,8-RH"C(H/2X%L=;V4P9I>XIV7.S(UZ1!Y*H8':>J8!"OBB#06!+,D@I(+HO[ M++EPN5$79)B2Q/BA0Q=B1!HQ2"L7K?]WW%'91/AT-T471:#*=QM':-E=6H\9.IC4I]A^K#S;R*9(P2*F/N?>D'S+< M:I(D(A[05E)F8P[Q^OC@V]KQGG`#J%3A5FR^P@7-#7X/^&^]>.N%<'V!';9!"#^\`;?&-\.] M]K4X5K\7W;&^],:Y.H"0-OW!UK&;XT:;Y/,%?,"H8:.P9G%R' MMAW$!_*"\6\BFW\!``#__P,`4$L#!!0`!@`(````(0!?_@%Q21```(""```8 M````>&PO=V]R:W-H965T&ULG-W9[?WUU>;]9P)2*\[Q^N?QX.'U_N[O://S=OZ_WM]F/S+I8\ M;W=OZX/XY^['W?YCMUD_'5=Z>[WS[^^S=V_KE_=K%>'++DF,[?/SR^.FLGW\ M];9Y/Z@@N\WK^B#V?__SY6,?1'M[3!+N;;W[Z]?'S>/V[4.$^/[R^G+X]QCT M^NKM\4OSQ_MVM_[^*H[['R^]?@QB'_\1"?_V\KC;[K?/AUL1[D[M:/28"W>% M.Q'IV]>G%W$$LMFO=IOGA^NB]Z583/G7=]^^'EMH]K+YO3_Y_6K_<_N[OGMY MZKR\;T1SBQ,E3\'W[?8O29M/\B6Q\EUD[=KQ%`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`SEOG()A@&YEAP&Y)6,'!=*Z@5CBYZUZ^4$II+`5!.86@)33V`:46./4\TH ML<>I5I1X=NNT'<9/FR>_XS!VG&X"TW,9JQ/U'<8>%`Q3\7<9:S#6KB,=5A+A[$/:Y7`%(OQR,AY<J]@LU^X6Z_4(C>.%D#+,;IIG`M`(3#%7M MX(68P)W`!"MU[1=ZP0LQ4?H)S"`PP9:&P0LQ@4<)S#@P0>!)\$),X&D",TM@ MY@G,(H%9!B8XB)7]@KBM/W;/8V\T.KFX[K^@DTO]<"URZ&3&M-*YI$SA>-5[ MX^>S^?O[/Y/J<1HLGY)?5TN16]II:)_X<[:5W-U5$T4#11 MM)10#9$63RGL9FACB,YI"-E*=HCN*^0K66U8-G9 M[==1-%`T4;244$(QF)'!\M$3WV+* MM>Q,MAZ4E)2)RV04%115%#44=10-)50VWJ1SXG&A/:@T#>*X>&CA5MI&B.@\ MU,$(710]%'T4`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`R9C)B,F4R83)G,F,R9+)@LF:R8B'H,F<@/U^YD,U->UG MMBG)DMZSHXUZGYI)A4F528U)G4F#29-)BTF;28=)5Q.=\/+^5?QG#KD]PWCR M[>V(Z1LFD\MGTZF,=1TWX-T9,ADQ&3.9,)DRF3&9,UDP63)9,1%)'Y=N9M++ M6I5/)+TJ<3&2WGY06Y*%^"+I3_N/*6K@')SW)JR`QI,I1:L:N^-GHFQYU M0V1R4='@S329M)BTF728=#4YW_H]0ZA\-\]/WQ"N1AGPC@R9C)B,F4R83#51 MC>(H>IEQC#F3!9,EDQ43D>EQZ6%FNDBASV2Z7,VZDSZ3`9,ADQ&3,::J$QU=JD) M1YDRF3&9,UDP63)9,1$9KW+-G4AFQLMRF-.Y/?Y=-/D7;Y%,MTIL2AJYMZXO MY(,J'$>A625P%BYT%?<,HVN'"LSO:"8EC_6ZX M\.SZ/29])@,F0R8C)F,F$R93)C,F>W8M.2!SK=\.%9]?O,>DS&3`9,ADQ&3.9,)DRF3&9,UDP63)9,1&Y'-=A MS5R693"GN9SP09NJGC%SVJY9\Q32=WVI:/5>68N8&;S"I,JDQJ3.I,&DR:3% MI,VDPZ3+I,>DSV3`9,ADQ&2LR?D>->$@4R8S)G,F"R9+)BLF(M\3%[-YLECF M$_FN:FS,?+?+VHZQS[V-I^?PN%J=(ZEPE"J3&I,ZDP:3)I,6DS:33DB<>\[-6L_=X4WTF`R9#)B,F8R83)E,F M,R9S)@LF2R:KD,BN[?ALEW"YJW>;J2VNE"]);Z#OFY;(F ML9?I*DH,J3HV9(XA-=Y.G4F#29-)BTF;28=)ETF/29_)@,F0R8C)F,E$$]WI MQ.?N1R;Z*4>9,9DS63!9,EDQ$=-X7)*8B2[+9T[G\&1OI,O/4K<3/F6_D:Y1 M3*J6F5285#4Q1A;KPJ+&8>I,&DR:3%I,VDPZ3+J:J(;)^M%2AAX'Z3,9,!DR M&3$9,YDPF3*9,9DS63!9,EDQ$1F?N`Q.?G^!D?%PU:YJBKL]1YB`BT^,RP+Q^EV4UG[A^5]4XQJQN/VDK^7$E.\=4+3.I M,*DRJ3&I,VDP:3)I,6DSZ3#IAL3QJ+(7+G0]S#F>G3Z3`9,ADQ&3,9,)DRF3 M&9,YDP63)9-52!PG4&1Y7'Z962X+:CZ1Y:H.Q\CRR!^>^@KI>T371\%I$3NK MQU7\Z%D=28TW5&?28-)DTF+29M)AT@V)HX_TPH4Q28[M.N`H0R8C)F--SO>E M"0>9,IDQF3-9,%F&Q'%R5G$+178'Y\5%V)JG,G+ZLQ"WE M*''+V']FJE'P]2R>GW;=58Z'JGI*9%S+!19])@TF32TD1_ M79&K^(6#=(P@SC?'32&*7XQR")W26#G8YWT9,!DR&3$9:Z):KB"_(B;RGMB$ MPTR9S)C,F2R8+#51AV3UZY6Q\$:4G-CE8"*]U1D,\LM/I5/&)VV;"2ZNIR^9 MM"6W)NV,_5:9^!9SB6(RJZR)&H+<=2]A%,<`5S765^EM-T0M#'!V0*\S:3!I M,FEIHHXWG8Y6`K4Y2,<(XDYPU?)J,Z+ZQ<^D\]'J%]Y4G\F`R9#)B,F8R83) ME,F,R9S)@LF2R2HDCMXO4CPNPU1^WYU\O_;;9O=C4]Z\ONZO'K>_WD7%FB>* M1<-7KW:;9_F]V5^**?EMN7?A@OVWKQ_K'YON>O?CY7U_];IY%JO>W\JOMM^] M_)!OKJM_'+8?QV_O_KX]'+9OQU]_;M9/&_'%F_>W`C]OMX?@'W(#O[>[OXZ[ M]^W_`@```/__`P!02P,$%``&``@````A`(8Q\W"H"```3BP``!@```!X;"]W M;W)K=S4V^KXLIS_\_?GNVP^:[OBN"WV];%:U/!3M?7TJC^K*KFX.1:=^;5X6[:DIBZVY MZ;!?R"!(%H>B.LXAPD,S)D:]VU6;\E.]>3N4QPZ"-.6^Z)3_]K4ZM>=HA\V8 M<(>B^?)VNMO4AY,*\5SMJ^Z["3J?'38/O[T+IT23HWZI\ M;ZV?9^UK_?Y+4VU_KXZERK:JDZ[`\ M[;N_ZO=?R^KEM5/ECM6(],`>MM\_E>U&952%N9>QCK2I]\J`^G=VJ/344!DI MOIG_WZMM][JYG%(DYN1UF`(S/`3T57/#TV]?M,S1KUS/94Z#DH'E3D\\C`1S_6H:&J,>H@ M'W64Y5Q-=S6*5M7GZY.(X\?%5Y73#6I6#@U5K,\*70IEK_>H1FY[=&?];$6+ MM15=!>UM!7]0L7MODCWW6A%>S!,G*D/CG6BQJK3U8%4J^N@5:")+PQ1KGX)X M4T'&>]/BY5P-O$^*$()Y`TUNRGF7BB`*@H!*UE22Q[$M(>[4/+?=Z7D6JG7H MKZ6^B6?&3,TU7(_, M]4MJB:=TBB<>O-74HN9I^0R9F@BH('GAA%)"A@#`3=-$B;4?+Z@G1-W0<3= M@0C<9=+1.,Q#EW-01*&GM+I#CW<'_9RX2Z[<@0AS9T\JS)Q]/8H\WA@3;DP[ M:./4VP736%<0@;<[&;@*>\:!WJ4,+8A))!`.%"0,0BL4#:Q4&Q1I:N>4KH1) M-!`.'"2\V:((,B9R_>Q+4K"@-A%$(H?;KF!,N%%1!PP2CE`3\CS3[T3HL.?F M!4W<)"`(%Q$X1U&$B8MUFKOC`$,1EIWI=FWE;N0,A"9O=^.(MQ9I@^!. MAL0#NB0203=6U.8D6.@78E;BB'<6U&`2,]+5T!VA"=O%4'>3@"&O@1'Q]H(: M=.?J>U0A=7:'9N`D;$@'-E*^"4`1V@L#6CE,G\V-.RGU#F_(X21P2.CX:H;W MG4VD?"N`(C7!>A%C\MHKH?6=Q`_IX$?*'KY"T;G`CATR5:1D^1!W^K7+7L)^ M[!HU;W]\[:+(O5W!BV"=[$ZIK4G,"!VO%2E?LRCR)(TJTN'=9SB)&4;-B% M0Q(736*$43-&9)P1*,*RFF=?'@[^4,)S2YTQ3(Q;$9$#%QG'!8K`810GI'SH M$.*<(NS1'/!X_1)(P8 M-5LE.<<(BG@S05\`(GZ1YFL2/")H_;2>'!XH\M83XK@EU!]CR,AEX6!)SB;5 M*@(13P_FCE`D&?Z<)680T0;U=/5//',7+RZ'"8IPXB4YV:"`32*1YHWSTJ%( M(F,'4D;X="`EYT@QH=6HV7=VZ-"&B1[!$(WC'V*)N8LGDK,$10,&;8K$*?G, M@V;PAR@27U-$[5KHGF6%H@&#$`&F04PWVM2@;N+66\BXM1+KNV@&9<`1@J(! M@Q`!#7HJ/(D=,;!#5:?'@@PX.U`$CS9?W=+,KE'`C=.\,6:,S-LU.V3`V1&# MB#\>EX;-#>D[*,#`,=+@]7N(O/I>+081)E"=O;'7)]H<@9%X$D:,FDZYJR\Y M4.-&!!H;39&84>1&[Z><":F;WF5Z,L"LO1(R`Q,'1/0G2GZ?YBZ:1A'R M&8@B]PS$BZ[E0_TQ>-SP=0V-JV]B$M#XTN>54'L,'3?L0?3T+] MZ0X^N3$GT/?54_H&Z"@OB`;*"Q>AO%&JSBM9Y*$.U4!MAS5#XI:M/YDSE<]VIR7>U75W_D4?<^Q/`C_]#P``__\#`%!+`P04``8`"````"$` M8N<6NV4"``!/!0``&````'AL+W=O(TIR[22&Y<`+W`9H@*+HS#QI]+13-=F`L5(W&4VBF!)HA,YE4V;TYX_%W0,EUO$FY[5N(*-[L/1I M_/'#:*O-RE8`CB"AL1FMG&N'C%E1@>(VTBTT>*701G&'2U,RVQK@>7=(U2R- MXP%37#8T$(;F/0Q=%%+`7(NU@L8%B(&:._1O*]G:(TV)]^`4-ZMU>R>T:A&Q ME+5T^PY*B1+#Y[+1AB]KK'N7?.+BR.X6-W@EA=%6%RY"'`M&;VM^9(\,2>-1 M+K$"WW9BH,CH)!G.>I2-1UU_?DG8VHO_Q%9Z^]G(_*ML`)N-8_(#6&J]\M+G MW&_A879S>M$-X)LA.11\7;OO>OL%9%DYG'8?"_)U#?/]'*S`AB(F2ON>)'2- M!O";*.F3@0WAN^YW*W-79;0WB/KW<2]!.5F"=0OID92(M75:_0ZBY(`*D/0` MZ:'[P_4T2A_Z27_P?PH+CKH"Y]SQ\%'@?9.'K'R2X]_[_K1 MBA=[*WX*WMLT;"#[[.W5?6\5O;/Y*R?8H4LGOEL]3-._'?E#&<6;G`W$@VL+ MTZ`9=*U+[N/N!*6$&=6V)T&L?SA3II]W3 M[4_Q>>K2QTX7,,\M+^&%FU(VEM10(#*.[C'`)CP18>%TVZ5JJ1TFN?M;X8L+ M[^Z_?SQ9O3\]>7?[_>;^T]WWWSZ>_-__ MKOYV?O+N\>GZ^Z?KK_??;S^>_//V\>0_?O[W?_OIS_N'WQ^_W-X^O=,6OC]^ M//GR]/3C\L.'QYLOM]^N']_?_[C]KI+/]P_?KI_TGP^_?7C\\7![_>G8Z-O7 M#^O3T_V';]=WWT_\%BX?7K.-^\^?[VYNB_N;/[[=?G_R&WFX_7K]I,__^.7N MQ^.XM6\WK]G;^V\_M(E?[[[>/?WSN-&3=]]N+MO?OM\_7/_Z M5:W,?_`?E,5]\N/B@+?W\TZ<['8'3 M_N[A]O/'DU]6E\/J;'?RX>>?CH;^W]WMGX_1_W_W^.7^S_KA[M-P]_U6NG6B MW"GX]?[^=U>U_>20&G]`Z^IX"O[KX=VGV\_7?WQ]^C_W?S:W=[]]>=+YWNF0 MW)%=?OIGAI?X=6EX\6_\L MU->U$^I'IIXY3&WU^`GU[X6?<*7N<&SJ_L^K/N-J/)_N_X06J[/WZ_/=:O?2 MZ5BI#_B]19UA/7<&'N('WYF.?;.X?KK^^:>'^S_?Z8K7SA]_7+OQ8W7I-NMZ MY4;'X#NZ87VW&:_UAJC2> MS`*D!*E`:I`&I`7I0'J0(2;&CZ[4!7Y<;>O'$_D9#_T`4H"4(!5(#=*`M"`= M2`\RQ,3(T-AF9+ALL]Z]U\6W<'YV&[*>/-EILHOZ47*5'Z9*H\P"I`2I0&J0 M!J0%Z4!ZD"$F1IV+L<;=\Z/.L;HU%)`4C4=_("J(2J**J"9JB%JBCJ@G&@RR M9EP61&+VL\;";N62?]*O`DHZUCH9H.9:H]N"J"2JB&JBAJ@EZHAZHL$@*](E MQ5CD"UW,!TL%EO&8K]S]BOR9+@94L%9)5!'51`U12]01]42#0=:,RWZQF3% MH!C+\B@ZYL,*J"`JB2JBFJ@A:HDZHIYH,,B:<0%T@1F?5\VUYU'2C;9I-YIJ MS=T(J'1WS/8ZKHAJHH:H)>J(>J+!("O+I=$%LGQX-;)"GHWG0J!B!502540U M44/4$G5$/=%@D#7C#\S/9?SCD[G6U(V( M2J**J"9JB%JBCJ@G&@RRLEQ0?OTUM_:Y.K[F`HJ?%1`51"511503-40M44?4 M$PT&63-I^GZA&S%BKZ?P'(]&R5/JPUQK[D93PQ&5K%41U40-44O4$?5$@T%6 MUK*(O6;$#LB,1HS8K%42540U44/4$G5$/=%@D#7C0NV""\QG8'.!A5BL<2K* M1LDC^H-[6NW"\_S(KB`JB2JBFJ@A:HDZHIYH,,C*A2<>SQA5'=AV@C"[GZL`8JB$JBBJ@F:HA:HHZH M)QH,LF9NIUCBY%40E4454$S5$+5%'U!,-!AE9 M[JL1"V0=J]OT'5`T7A^("J*2J"*JB1JBEJ@CZHD&@ZR99>E[P_0=D'VDM$Z? M?<^UIFY$5!)51#510]02=40]T6"0E;4L?6^8O@.*!N4#44%4$E5$-5%#U!)U M1#W18)`ULRQ];YB^`TJZ4?J`>ZXU=R.F;]:JB&JBAJ@EZHAZHL$@*VM9^MXP M?0=DNA'3-VN51!513=00M40=44\T&&3-I.G[S;%IPV`>4-+#TF??-12L51)51#510]02=40]T6"0-;,L?6^8O@-*1J/T MV?=<:^Y&(9#/EV')6A513=00M40=44\T&&1D;9>E[V-UF[X#BD:>AA12501U40-44O4$?5$ M@T'6X[)@OF4P#\CT,%\K0@5KE40544W4$+5$'5%/-!ADS2P+YEL&\X"2^2Y] M+#[7FKM1".;S0%^R5D54$S5$+5%'U!,-!EE9RX+YEL$\H'B^(RJ(2J**J"9J MB%JBCJ@G&@RR9M)@_GQLVC)]!Y2,1NEC\;G6W(V8OEFK(JJ)&J*6J"/JB0:# MK*QEZ7O+]!U0-/0\OT'9`=C3;IL^^Y MUMR-F+Y9JR*JB1JBEJ@CZHD&@ZRL9>G;_7`F^5IJ0&8T8OIFK9*H(JJ)&J*6 MJ"/JB0:#K)DT?;\]-C&8ZQ%Y^%I;]->53?I8?*XU]["IX8A*UJJ(:J*&J"7J MB'JBP2#C4;\N6?)8_%C=!O.`XH&*J"`JB2JBFJ@A:HDZHIYH,,B:28/Y\_.= M&XZ2:R^@9*!*'XO/M<8^4Q"51!513=00M40=44\T&&1E+4O?+@*DLD+4GJ/B M(=327F+^=L$F_2Q^%QKEA72 M=_28@+4JHIJH(6J).J*>:##(REJ6OG=,WP%)UJCA0%00E40544W4$+5$'5%/ M-!ADS:3I^\WSW8[!/*"DAZ6/Q>=:H]J"J"2JB&JBAJ@EZHAZHL$@ZW%9,-\Q MF`=D>IBO%:&"M4JBBJ@F:HA:HHZH)QH,LF;28/[V'L;,O@O1VXYAZ1/SN=;< MPZ:&(RI9JR*JB1JBEJ@CZHD&@ZS'99E]Q\P>4-2=#D0%44E4$=5$#5%+U!'U M1(-!UDR:V5](5`SFNRE?QU-A^L1\KC7VF8*H)*J(:J*&J"7JB'JBP2`C:[\L MF!^KVV`>4-R-B`JBDJ@BJHD:HI:H(^J)!H.LF67!?,]@'I"+LU&B2A^+S[6F M;D14$E5$-5%#U!)U1#W18)"5Y0+SZ[\CMO?Y6O>+XS%?!12E\`-10502540U M44/4$G5$/=%@D#63!O,WSW=[9O:`=.W%/2Q]8C[7&FT71"511503-40M44?4 M$PT&68_+,ON>F3T@,U#Y6A$J6*LDJHAJHH:H)>J(>J+!(&LFS>S/SW=[!O.` MDH$J?6(^UYJ[D=]6=-&6K%41U40-44O4$?5$@T%6UK)@OF=`5!"51!513=00M40=44\T&&3-+$O?>Z;O M@/2;HK$W'(B*@-R/^^=PM4T>GI>FH?F<9VGP=?/R:O?>O6GPZ]7]PYD MW_2TT3N;_&OMCENQ>3B@^.,3%0&Y7^!''S]Y:%N:AO;C+TNG9TRG`;F?M4>? M('W>-];:3R>C&-'9\%Q#.&Q(#<+X6CSYP^01IKS>FR M"$B_#76O'MRNSO;)W5QI&MF/G2:XYP?&,\:T@!+5Z6.)L5:LVF]+O]+T'WN_ M10_Q-?03?%TL]F,O"TQG#$P!);83<8>Q5FS;;VNV?9ITJ](TLA_;18K7WTFX MRS5YQ!]08CN][1IKQ;;]MO3+3V<[:5":!O8C+\L49\P4`26FTQP_UHI-^VT] M9]K7<+\7CRZ9^:*U1[(L`YPQ`P043VM$!5%)5!'51`U12]01]42#0=;,L@G_ MC!-^0#(3G8A=FH[F6N/D5Q"51!513=00M40=44\T&&1E+T" MBH[Y0%00E40544W4$+5$'5%/-!ADS2Q+C^=,CP$E`U42!`]SK;D;^6U%%VW) M6A513=00M40=44\T&&1E+4!1GSD0%40E4454$S5$+5%'U!,-!ADS%VDP M?_-`==R2S>P!)3TL?9`RUYIZ&%%)5!'51`U12]01]42#0=;CLLQ^P

4-S# MB`JBDJ@BJHD:HI:H(^J)!H.LF5QFWV^.#YR?OPN\8$8/2"]/'OO*84;Q\X7D M*581:KG74LV/@W;SDR;[D9?%XPO&XX#T5_'JRVKSF;C,H7'IFS.:'X/.%L^EK)V?P7#_H\ MNNAP,GTM>S+W\P-"^Y&7!<(+!L*`HC-W("J(2J**J"9JB%JBCJ@G&@RR9M)` M^/:9G%GQPB,[D^_3IV]SK7'4*XA*HHJH)FJ(6J*.J"<:#+(>EV7%"V;%@,Q, M[FM%J&"MDJ@BJHD:HI:H(^J)!H.,F=5I+BPN_MNQWXP=84>F-R&.74>K8KC= MN95))J9E,3QSK_Z9AY1]\I!.2V5,U<;-::T,;$Z+94SUXLTE#VNT@,94;=R< M5M#`YK2$QE0OWEQR9ZYE-:9JX^:TKD:\N43[LFRY.F6X'%GD4GY]O8C);V#S MGPEX4F7.,[U]<60R%^K-;64.;64.;64.;64.;64.;64N;IN86Y9W M5Z<,O"/3ZQ3#G^S3+TBHO_EF^I/L:$/6`M/\$EW/R2VB1/IJ[OV#4;4D2<@M M]B"WK]F#=+]F#SH#V(/.P&OVH)/BJ^E-@<[0_F(_WWTNTE4>T ME32TE::X;:)I6=9?G?*1],BFGKP^2P9P6?/-;$\.[*6>[*N]V).Q![E]S1ZD M^S5[T!G`'G0&7K,'G11?32\K=#UY!$&=HGCCR2E*;SI>&J9YJ[$Z]2R* M4SHG8.K)8!I*P#1N@,DVF-2"R2.8/())&I@TQ2S1M.Q&9W7*.YV1):D]&79D MSC>-;,HQ0Z5FD1)K` MI`E,FL"D"4R:P*0)3)K`I`E,FL"D*6:)IO0^YWB_N'_%S?_JE/<\(TN2T_Q( MQB\1,54S\XW?7-*4&*UQ]M6/+. M](_`[!?7SN9G%N%HQVIQXAG9O*JQ%J0+-P1^0%VOUHDWK4_G:_@9)SDT%XG? M>&@^3=M#\\R>C;-DA#^LW$,=W9SY+V`>#U=+[4U-QX"A0_-,P<&=M;_MMLED MJD.+MY0$I>/L\83'X_)=?#C'3JB1[/5?O%Z%5=WL(8;0073;[JX?H\YT]Q)#YXK.X/DMN MU'6(H9JYX#QS+^&<[>![T&-3O9$R'VITV/'&D\-V>0>'_:K!U%UHR3=Y5X$E MUR"'EY"RS`GU3.^*C$YHV(6_\UCM3I.K68<6;RDY-)=1XD-[Z1KTF<:>/<_, M<)F[!D.U^;-K3)F:1L<3=N&_'GZ>OE%?AQ-O*#D<%QSBPWG+->C#ASW$P'3U MS[TL@V%S[B<7NEE,'T'H$.,-)8?H)OV_>H@^.-A#],RX\;2A[O!B97T?D_PW.UN=IXL6N56I]\(LU:IA9, MZ]2"::%:,*U4"Z:E:L&T5BV8%JL%TVJU,4N4NF03*WUAZ`RKDIF+;ERI+'KC MSHI,FGR*LIK`I`E,FL"D"4R:P*0)3)K`I"EFB2:7F)9H\@G+:O(LZ6!)Q9W8AF5.U<1>2&;-$DHN`L207C.+I\U4_ M#%UI)L7L&9AUY^M%3.Y"6W^ON#Y=)?E>VJ8:XS%)&[8D;6#2-K5UD4I;3VZ0 M9&RJ,6Y=QN(M)<9EJH%B?]P-Q; MX>>FS%2AFEX9ZPY;W]2Y,/_;EW]++,OH]*%&#S**3R"CGCW_":355PN?X/S] M[M3\CY]`UN-/D%AWP7>)]9"DC?40GA4F9W5GR4,760_5YJ;JHU/3T8UZI6=Z MIN\4G[Y?X?YJ;A7M\#RYH9-D[%"2L4,937>8)"D)G%KE=Y@X=:EZB=.0TVG/YE0$Y#-=.3IZ:14\]T'$>G]G&-NNC4)']\QR=2$HJ]2>C4=-R; MA#ZW-]F83H1XZ-1V/3SW4L]!# MUZ=)SY//J5'^"$>?V)]\3DW'_V+R+9F)SO79DS^^B M&ZOIP.0_\>9"]Q)O/J1;;W%P#\^US0)NX>$O6;DBDQ%L3T;`9`1,1L!T^&!] MA@V6)9I8LZ'=&LN!/?X:PGCTFXSDR;4DR8P:0*3)C!I`I,F,&D" MDR8P:8I9HLG%[EC3\:'C[KWFRJ5/5\+2;M:@3_7VYO<<-[]F5;CQJIV:COU1 M4L$D%4Q2P2053%+!)!5,4L$D-6:)5)?,8ZDOQ.^PF)LUY[:A1:+GYP&Z1,'4 M]\"D"4R:P*0)3)K`I`E,FL"D"4R:8I9H M$\S5QLY4K,C*#*LRK,ZP)L/:#.LRK,^PP;+$G$O42\SY!&[->1;_L%]W@=JN M)MLXU)%)$^I)$Y@T@4D3F#2!21.8-(%)4\P232X6QYKE"JB.3U6ES8R>553!9!9-5,%D%DU4P6063U9@E M5EV*CJV^,+J%M>:LN9#$YP%?FL!TC8))$Y@T@4D3F#2!21.8-(%)$Y@TQ2S1 MY'+Q$DT^1UM-4[:..UCR[%+FIFICQY$Y,)D#DSDPF0.3.3"9`Y,Y,)D#D[F8 M)>9<5%YBSD=K:RZ.V^&9B%FM;KP.44^:P*0)3)K`I`E,FL"D"4R:P*0I9HDF M%WZ7:/)AV6H*`5IC:#2"X2'FN)J=F1>FIF.GDSDPF0.3.3"9`Y,Y,)D#DSDP MF8M98L[EX27F?'ZVYN),/78P,%V'8-($)DU@T@0F36#2!"9-8-($)DTQ2S2Y MA!MK>ON]05C'SAJ<`G3<]_"X=UP";YXJ)'5J&O4],$D%DU0P20635#!)!9-4 M,$F-62+5Y>%8ZC]6V^N;RT__+&X?;VZ_ZRH\=?ED^JZ3E.&OM8&9>P,R:8JS M][&/JN^!21.8-(%)$Y@T@4D3F#2!25/,K*;CLG0+-(5E[+3%L4=`051N;%AE69EB5876&-1G69EB787VbEYEP>7F+.YV=KSK/H M/D":P*0)3)K`I`E,FL"D"4R:P*0)3)K`I"EFB287<&--?^'>P#W>2+\@')C[ M5]3Y\->&N5K4^>+L'2Y;UI-5U)-5,%D%DU4P606353!9C5EBU>7AV.H+HYO> M\4!S<:8.,VNHISU'FE!/G0],FL"D"4R:P*0)3)K`I`E,FF*6:'+A-];T]IDU MK)AG+]\I6\=]#W]M,(OM'47KBIZ:CJ(E%4Q2P2053%+!)!5,4L$D%4Q28Y9( M=5$YEOI2W_/1VIJ+X_;8]\"D"4R:P*0)3)K`I`E,FL"D"4R:P*0I9HDFEXMC M37^A[_F(;0V&V*TQ(AKW\-<&LPS?V/>FIE'?`Y-4,$D%DU0P20635#!)!9/4 MF"5278J.I;[4]WSJMN;B)#[V/3#U/3#U/3!I`I,F,&D"DR8P:0*3)C!IBEFB MR>7B6--?Z'L^8EN#4^R.^Q[^VF`6Z!O[WM0TZGM@D@HFJ6"2"B:I8)(*)JE@ MDAJS1*I+T;'4E_J>3]W67)S$Q[X'IKX'IKX')DU@T@0F36#2!"9-8-($)DTQ MLYJ.Z^DMT!36WS.:QC7Y%"NCP0U_;9BKC9VI6)&5&59E6)UA38:U&=9E6)]A M@V6).9>BEYCSJ=N:BY-XZ&!FT;YP'9))$]I*$Y@T@4D3F#2!21.8-(%)4\P2 M32X6+]'D8[35-$7KN8-MTN\"'E;CHGYQ'":3N6ES8T>4.3"9`Y,Y,)D#DSDP MF0.3N9@EYEQ27F+.)VMK+D[;8P<#TW4()DU@T@0F36#2!"9-8-($)DU@TA2S M1)/+ODLT^:QL-87\K&X\C6";]->FZF!3M;'CR!R8S(')')C,@9@T>R)ORC,U<8^5:S(R@RK,JS.L";#V@SK,JS/L,&R M1*K+O+'4%VXPPSJ+UES(S?-X?UB%>N:A+IDTH:TT@4D3F#2!21.8-(%)$Y@T MQ2S1Y`+N$DT^$%M-(21K+U$'PU\-PI*0^O-&U,&FIB.3.3"9`Y,Y,)D#DSDP MF0.3.3"9BUEBSF7>)>9\1K;F0FZ>E:B#@>DZ!),F,&D"DR8P:0*3)C!I`I,F M,&F*6:+)!=Q8TU\8W'Q6M@9#?M9YBOH>_FH0%LBT5^W4-.I[8)(*)JE@D@HF MJ6"2"B:I8)(:LT2JB\.QU)<&-Q^?K;G`YI]W?7C\U=V_/T;VYVYLN,;V&3+G$\]DLB6.9^Z#\^6.9^Z MT\R5[5P[_=4O6^;:Z8]7V3)W'O07FVR9.P_J+MDR=Q[TM#U;YLZ#'AKGRK:N MG;[WDRUS[?3UE6R9.P^^X^/\[=QYT!]-W#;)D[#_K"7;;,G0=]I2Q7MG'M]/N>;)EK MIY^I9,O<>=!O,[)E[CSH)P;9,G<>]+WZ7-G6G0=]LSU7MG;.]*Z2;)ESYE_U M@/.P<>=!/^+,M=NX;>KGA]DRMTW]YBY;YLZ#?CJ6*SMUSO3BU6R9B`]/2$;D2'9860\B5Z*"T&$"FY%S[T=IWN1+)U6INN1)]`JUFEBO1)]#2 M7;D2?0(M794IN9!4+<:4*=EK/_G98Z_]Y.>.,[71$LB9K9VIC=;[S97HLVF] MVTS)N3Z;%G?-E.QU3O,SQEX=/3]?['6V\[/%7IT\/U>XJ3<_\^YU?O+S[DYM M\K/$3FWR<\1.WO(SQ$[>\O.#FV[SLZV;;/-S[59M\C.#FQCR\X*;%O*SPDZN M\W."FV+S,^Q.KO/SZU9M\K/!5FWR<\%6KO,SP5:N\_.`FU;SL^I6KO-SZD9M M\C/`1FWRX_]&KO.COQO\\V._FTKS,ZF;2//SJ!OV\Z.^&_3S8_Y&KO,C_D:N M\^.]FS[SL^=&KO-SYUIM]"W9S!6\5AN]FR97(M=Z4T.N1*[U`I%K7-]E+_R)6YEZQ='E^A1J/N)6*N+-=.;[G97NH?N3*]*FA[J7_DRJ[V%Y=7 MV;O'@TH.V9)2)66V1"^-/]4GU'H__/1Z*?SII=X"GRO32]]/+_66]US9U;E. MKI9-YQ:OSG5ZM1!XKD0G6`MAYTIT(K7JLTH^3)?>X\\__;C^[?8_KQ]^N_O^ M^.[K[6<]:C@]KOOW;>U;D_^,IO&3UU_NGI_MOQ_>M?KF]_G3[X"KH2<;G M^_NG\3_<#OZ\?_C]^#CCY_\1````__\#`%!+`P04``8`"````"$`5..$1'`# M```*"P``&````'AL+W=O<`E)&A12)53=K;0KK59[>7;`!*N`D>TT[=_OC!THEVR42GT)87PX/CXS M]GAU]U(6UC,5DO$JLKV):UNT2GC*JGUD__[U<'-K6U*1*B4%KVADOU)IWZT_ M?UH=N7B2.:7*`H9*1G:N5!TZCDQR6A(YX36M8"3CHB0*7L7>D;6@)-4?E87C MN^[<*0FK;,,0BFLX>):QA-[SY%#22AD200NB0+_,62T;MC*YAJXDXNE0WR2\ MK(%BQPJF7C6I;95)^+BON""[`M;]X@4D:;CURXB^9(G@DF=J`G2.$3I>\])9 M.L"T7J4,5H"V6X)FD;WQPMCS;6>]T@;]8?0H._\MF?/C%\'2;ZRBX#;D"3.P MX_P)H8\IAN!C9_3U@\[`#V&E-".'0OWDQZ^4[7,%Z9[!BG!A8?IZ3V4"C@+- MQ)\A4\(+$`"_5LFP-,`1\J*?1Y:J/++]Z62V<*<>P*T=E>J!(:5M)0>I>/G7 M@+P3E2'Q3R3P/)',+^*G)SP\3_CI_&W2\42.$:T]N">*K%>"'RTH+)`E:X)E MZH5`UBS>,+1V_,\-L`%)-L@2V;`C8*$24OB\GKJ+E?,,MBJQ%,^0"-R((:,8,H>ML$WD3[`T$-8B@(C/H`0<@2V?#;,>VVKV!K,$'7 MV7D?$K>0H\YW0>,[ M-QW2]#68R`S*MK/6M`P$=C0.D?!Y40@N#^YB<#D36KB;J1G`!13=R9] MZ"P]/%[?ZP$R]6682-\#SQUXT(*&'GC0/KK2+IN@T?WI3Z&N#;U0SP?OW.D; MZ#[S7B,TU4"*.4\'5HP.W18U\@*/OZL+`G;@,!5-""O"K-LT8=.`2BKV-*9% M(:V$'[#!ZDW#'0;70P`C>&C2[#07R+'Z"88=P/X[/X M:0BGZQB_"<(-:!T/;(,P#L[%YR&G(O?AK!YSN"78;S$N-.N`&XB M-=G3[T3L626M@F9@I#M9P%82YBYC7A2O=;/?<05W$/TWASLGA4;H3@"<<:Z: M%YR@O<6N_P$``/__`P!02P,$%``&``@````A`$MU278H"```^",``!D```!X M;"]W;W)K&ULK%K?;Z-&$'ZOU/_!XCVV`>-?BG.* M@6U/:J6JNK;/Q,8QBFTL()>[_[XSS`([.UQ"HKN'Y/+M[/#-S.Y\N]BWG[Z= M3Z.O:5%F^67CN..I,THONWR?71XWSC]?U,W2&955E\NOOU ME]N7O'@JCVE:C<##I=PXQZJZKB>37%.*OBS>)R4UR)- M]O6D\VGB3:?SR3G)+@YY6!=#?.2'0[9+HWSW?$XO%3DITE-2`?_RF%W+QMMY M-\3=.2F>GJ\WN_Q\!1,F+Y.$$<7]S9\FN\5W_(=R? MLUV1E_FA&H.["1&5,:\FJPEXNKO=9Q`!IGU4I(>-<^^NE;]R)G>W=8+^S=*7 MTOC_J#SF+[\5V?Z/[))"MJ%.6(&'/']"T\][A&#R1,Q6=07^*D;[])`\GZJ_ M\Y??T^SQ6$&Y`X@(`UOOOT=IN8.,@INQ%Z"G77X"`O!S=,YP:4!&DF_U[Y=L M7QTWCK<<+X-@-E\NP,U#6E8J0Y_.:/=<5OGY/[)RM2_RXFDO/M"G<7\^#A93 MWX6'OC9QIB?"[V;B>.8%B^5;$\%MS1M^ZXFN/UZXTY6/M%^A.M<3X?>@)TXH M877^HZ1*[FZ+_&4$BQHR4EX3W"+N&IPUB:='MZ7X426@!.CD'KUL'-B-D.,2 MEL_7.\C9[>0KE'RG;;;2QN4686.!]46WD0W$-J`,8`(1M6%!*7]"6.@%PVH( M;1N@B].*,FPLFBF1#<0VH`R`Q0#+\"?$@%XV#OPT2N/SQ&_)9F;6;\Y-PM:D M#4P@L4"4B;#88*?\A-C0R\:9K5AP5D6VVNBUX%J3-CB!Q`)1)L*"@ZUK!M?? MQ)JM@\9U#,VSMX2X'NTCJPXT&,"SC7IV(3,>L)^'\T!CSH.0P&N7?RB02""Q M0)2),'X+S@][SP(:;M/X!G[`2G=K MU*9;(+%`E(FP<%PX9)CQO)[OVIJ3UI"9<0E%$HHEI!C$::)"&Z`HHD%$M(,8C31'T93I/4B-$D"%=:=R#SIG:" MM=6\#29R>R9Z#QAA0:RFKFOQ"ALKHZ8:"F"CM)F1-6VLEA1ST!>S9@`= MI7,TZ[8M3P/*I+&&[3I_R:\_JC.<_MI"D]B::]LCR-R"$HHD%$M(,8C31ZVT MZ/O+CQQ,/5)=%D(KQ%TB?:^[+U'GUA,-M8PD%$M(,8A']2X%]Z2":V@^:UM& M**%(0K&$%(,X311-(_D]O]8+AA!O&:#-('2MP#00C'1+ M7/0_;>4MZKVR]+HM4%=.-5YZNA^J\?#(2+M99%K.H4^W!'W/OD1Z9`5=N(M, M0]U[HUA;^72GGP=^,+?:B6*.>(U0=X='0BK-(M$0;&#9P3X\ M,$\L0M\Z/+S>&&IK?DK0D%4K^VC?6!FUTM`<)+!=K5)$&RO:43>KZ7)IK0/% M?//@4%Z-\KT1'(FQ62=?ZW.7[K"!C*(T4&<5:PCV2+,056,E6QBLS??0E`)> M.X"V"ZN_3:5O]]"PL3)K0+[8Q)X:D)7>0OYL[BZMQJ^8;UX#2_;?J(&4=I\@ M\W0BH4A"L804@SA-2\<__/X&.B:V5[:*".*W7]_:HZ&>:!Y.)!1+2#&(!X5R M/'S]DW@SY@09G$)H/=;U.Y)0+"'%($X3A=2@67?9*2RZ=WXZY9,@LP`(LE)O MWV'T1"/,2$*QA!2#>$RHGT9,;RQ[4EO&G""#4^@+*))0+"'%($X3!=.@B:G_ MV*'<)^EE(1!D)=]2WU!/-`*-)!1+2#&(1X62:$3U1O))0!ES#6'W)L_TD39] MI'I.B\4W^/0#"`KR?`V^J^.<``7A#WC0`#>`';-P(, MX)UGWPA4`6XZ<@2^'W'?_Q28T&._Q<3TX;@T>O#[V?J>OG]AAPY<>ZE"'7L7 M!52QMXA0P]X2KM;P$0P$/&D?#-^[N":/Z9])\9A=RM$I/G7#@]Y!5^XJ-]`'.$;-BF\]IGBYQ^'/*^:/_`![7=V[OX'``#__P,`4$L# M!!0`!@`(````(0#R^S]*`@,``(D(```9````>&PO=V]R:W-H965T"($D#0JI`E6W29LT3?MX=L"`58R1[33M MO]^U#320+&JEO01\.3X^]]QK.YN[9U8[3T1(RIL8^>X,.:3)>$Z;,D:_?C[< MW")'*MSDN.8-B=$+D>AN^_'#YLC%HZP(40XP-#)&E5)MY'DRJPC#TN4M:>!+ MP07#"H:B]&0K",[-)%9[\]ELZ3%,&V09(O$6#EX4-"/W/#LPTBA+(DB-%>B7 M%6UES\:RM]`Q+!X/[4W&60L4>UI3]6)(D<.RZ$O9<('W->3][( MT4QPR0OE`IUGA9[GO/;6'C!M-SF%#+3MCB!%C'9^E-XB;[LQ_ORFY"A/WAU9 M\>,G0?.OM"%@-I1)%V#/^:.&?LEU""9[9[,?3`&^"RP$)Z;RB_.6>R`P,!1IWOM!,&:]!`/PZC.K.`$/PLWD>::ZJ&`5+=[&:!3[` MG3V1ZH%J2N1D!ZDX^V-!?D=E2>8="3P[DJ6[\F?K8`4<5^8%W3QX7EC\?*)G MQ1LO[K'"VXW@1P?Z"^3)%NMN]2,@ZTVP#(,M_W(%[-`D.\T2(]@8D+"$2CYM M@R#8>$]@?]9ADG.,/T:D/4)7#>0-&L&<_Z!1LVB-NI):=-('7D7/)X)ZQ%00 M-%$#_7>Z1D8KK<8KZ2VV#-S7#?[F7::)QBIL!%2<)KR8=,P`FI9"7V0G M>_]Z*31XO'@7T0[8?.U1:X\71D1)4E+7TLGX01^CMU"R(3J<\#OCX"2>P,EO MSLEI?!ZE%_%!!/L"=$SPNS#:F0T_B2=AE(87\,DR@C*>\R2K*%V9/`&PO M=V]R:W-H965TR M[:KFO#;);&X:Y;EH]M7Y>6W^\RG^\&`:79^?]_FI.9=K\TO9F1\WO_^V>F_: ME^Y8EKT!"N=N;1[[_A)85E<0\_VV>KN[1EOA^^5>?5V60*07N/1G,X5$49-L5K79Y[)M*6I[R'\7?'ZM()M;JX1Z[.VY?7 MRX>BJ2\@\52=JO[+(&H:=1%DS^>FS9].$/=GXN:%T!Y^(/FZ*MJF:P[]#.0L M-E`<\]):6J"T6>TKB("FW6C+P]I\)$%&EJ:U60T)^KQ`1 M#2S8?PG+KH",@LS,]JA2T9Q@`/"O45>T-"`C^>?A^E[M^^/:M)V9:WN+!P+V MQE/9]7%%-4VC>.WZIOZ/61&NQ51LK@)7KN+X,V\Q=P:1&XX.=X2K<"0SXLY] M^O`;?B[W@ROW\;SF"[!`O7+GC$ MZ_>-%%;H,%*XL6)KV[Y'07 M(`&(B=IBCQZK[6O%!E5&11ZIRMJ$,*",.E@A;QO'\5?6&U1UP6VVV(:H%CMA M04N8RH8ZB'00ZR#10:J#3`(6)&',!!3V+\@$5:&9$#%L!9A28VMA"POA$NH@ MTD&L@T0'J0XR"2AAP[+\!6%3E;4)_TH%L%#CW#(;5ZX2K49VH\F8"T0B1&)$ M$D121#*9*!F!#><79(2JK$T7UI24D@/V`RH\1"Y&/&6$6(/.X.GYF#';GKP;"E14V$HXX"M^?YQ4&-U M'(QXPW$[[#`[1$)$(D1B1!)$4D0RF2A1P;EQ?U346(V*$0\6N)3`I9;ET4A, M2HA(A$B,2()(BD@F$R50J//[`Z7&:J",0*`BAATB(2(1(C$B"2(I(IE,E*A@ MB7NA;;O1:"2R%B.2()(BDC'"!J3$3Z"C_>D$#")J!CB24X!1R)'_,&PN]IPX M:N5'D\&8`"'CCY643%:T>P$9[91.)P,ADPF9H>E64T*;#*FMNC+W$):8?,): M$C@KA/26(]KFCU/KN',UM)VPFN((.7)@MD9'VY^VTZ'<(F[ETS%`M*ZJ&V/= MY"[=E%NY_J#K$&W`F2*L9HSV)_=GC'4S2L88(K!,Q\`=%[68W&I*=0C'$EU[ MX"BR'W'DDB&,I:TMJ5BX3"J)0)-*RI&]'%3\I7;X9\)E4%&307L3*1D_M*40 MWN!,@]QRI%655ND[8257%=-RV.LEW8TB(4_WL+>-7IHQ%DDXDD12@>!H'"?- M]K5T9XJ6FBC:L4B)^L8ZX_V-G!&&I,G?$8XFJY`CG[T1L_"9E<\J?;G4"BW& M*@E6205BG1&9SU&-R(-10Z=]DQ3ZC]4(:[Z4=<205B/:IKJCM^FBD6N$(6EZ M(V[EL"1]<%VTT2"91/A,I98*)&0\5""RC)HEVG3]=)98YZ9DB2&E;CB2ZX8[ MPB1*Y8TV8V;E+X:5Y+E:=#$D>5K/8U\KK%&4,F;W!NR%IP@%&(4811CE&"48I0I2(V;-GE:W+8W@_+ZW@\B MK%M40A\;R*D8''U%[.CY!0M+:G)#C"*,8HP2C%*,,@6IV:`MGY2-;^RNK$%4 M0N:(GJQ,F7WD9%^@ZK)]+G?EZ=091?-*/V#"=KA9C9A]7=TN`GBA``&=/P30 MDE_A!!Q@AJ_=`1>(%M\)EP$TO%T?\1WH%\,:$N([\#7X,?A#44?+_U* M?,5^:P?P;0;K;)T`/E%@_N@&C^QKL_X`-X`7>.RP]0-X]01NC0[P=?B2/Y=_ MYNUS=>Z,4WF`Y,^'5Y:6?5]F/WJ^S)^:'CX+#RO^"'\'*.'\G]-%<6B:7OR@ M#QC_LK#Y'P``__\#`%!+`P04``8`"````"$`H7+D9(T#``!�``&0```'AL M+W=O1[Y$J91FM]DO_]Z_'NZGO"8FK#!>L(DO_C0C_?O7YT^+(^+/("9$>1*C$ MTL^EK.=A*-*C*4$L/92DDB8()P66D+_(:2W.TK_$0I^?8^N(B?$E3S@3;R0#"A2;12\ZSP2,%+%Y]H:(2*&B$"88C%2DE!60`'QZ M)572@(K@5_U]I)G,EWXR#D:3*(D![FV)D(]4A?2]]"`D*_\:4'P*98(,3D&& MD/W)/@@&TU$\&O='"4U&FB#"$J\6G!T]4`W<4]18:3">0V3%;`SUNH-:!E5%RF='P0]&<2ZN<0!ZMLDVBL5V5 MM<%`MYK2=A";7@1R(2P6<)O_KZMR6OI0F";#233IL#"8F9;/>#:>VN9-VYS, MIK%M1FUS/$C>O:WDH=SMY-VJ5N!NTN]QM?+7!@,W;XAU2]^+0"Z$E?W8SEX] MF_T"4DY]`C(8%XM>!'(A+!:32Q;]#Z9RZO:B*R"#&6H!1;8\-@X;.MNN]=#* M7(WOUKO1K1X%[F8\L[-:&XRK[KT(Y$)8V<_L[&]3CW+J4X_!N%CT(I`+8;&( MX1W>;H*BT2\?[=7M1E<_)]!U`;F,J#'V2BA6$^QF#6ET)^VX(^WU">2J?S\$ M.2%V!]1\:U&X34BQF8KN078".:F8.`X(MXOAZHQ:5S MOHGGL,59"LEKO45LF M87_5/W/XOT)@88H"`.\8D^<+M6DW_X!6_P```/__`P!02P,$%``&``@````A M``L"&ULK%;; M;J,P$'U?:?\!^;W<`KF@D"JAZFZEK;1:[>79`1.L`D:VT[1_OV,;*)!LU)7Z MPF4X?/ZU/C#^)@A!I`4,M8E1(V42.(]*"5%C8K"$U?,D9K["$5WYP1,,) MSG1253J^Z\Z="M,:&8:(OX>#Y3E-R1U+CQ6II2'AI,02](N"-J)CJ]+WT%68 M/QV;FY15#5#L:4GEJR9%5I5&#X>:<;PO8=XO7H#3CEN_G-%7-.5,L%S:0.<8 MH>=S7CDK!Y@VZXS"#)3M%B=YC+9>E"R1LUEK?WY34O=X1 MD8*A0&/[H6)*60D"X&I55*T,,`2_Z/N)9K*(D>_9@1\NEA[@K3T1\IXJ3F2E M1R%9]<>@O);+L/@M"]Q;%L^SPX4[TR17$F=M(MS;Q-G\6J)CY&LW[K#$FS5G M)PM6&.@3#5;KU8N`K+/!#-T;\R]?P!!%LE4L,8*M`3,64,OG33AWU\XS%"!M M,;MSC#=&)!U"U0WD]1K!G0_0J%B41E5+)7K7!=Y$^Q-!'6(J"(SZ`$&*)49P M'9@VL61G,,'0V?E$9`^9J@P^1*5BB5&P&LFJ\Q<0<\S6$P0X!4YX@2H(+^-T\@CI>T+.(DH6*.ST1'`\-/I!'S`^T%E9)8O````__\# M`%!+`P04``8`"````"$`)@=FUH0&``""&P``&0```'AL+W=O;8+='.I6JJI=GEI`$ M;0@1L+OG_/O.8$,\'II-VKXLF\_C\5QLCPW+S]_RD_.6EE56G%>N/QBZ3GI. MBEUV/JS1>?BG.Z,/R_>B?*F.:5H[H.%;U\2HK\`BJ>LU-6 M?V^4NDZ>++X,I3[//?F'FA: M+W<9>(!A=\ITOW*?_(4,YJZW7C8!^C-+WROC?ZLLG`KZ6S2_?QZZG^K7C_.5.YH,PNEPY(.X\YQ6MLD MKU5=Y'\I(5^K4DH"K02>K1+X]T:'D>X`S[:#,>J-CF/=$9ZZ8S"8^L/Y:`K6 MWN@'K8V;\-3]9E)EM17,?K95F\.[`$((#5)<8% MY2]`69LF-727N'_*&R0,E3RAEI4+:Q=24L%D>UN'LW#IO<$$2;3,ALOX5&+; M2N!L0+61#80-I`$\\*AS"]+\/[B%6M"MUJ!-"ZY^!I8/K43;);*!L($T`/$! M)J'MPPC68?\*:C.!G6"MD$Q,J(T;)3,VTV6);#N1S@]&!"/2),056!:V*[@9 M/#C+4,O*'<^)<_8TTT*WG.M$.N<8$8Q(DQ#GP!'3N=OY0>'&AW;LC2)^T"P; M?TYSM56M(0S>N[2((;!^[S<$A:DABH3-OMZLORTC$2."$6D28M_T$?M0F-JG MR`PB8H1B:L6K$VKC&S$B&)$F(2;C<<38'F_G%H6IR8J$0;>#;!F)&!&,2),0 M^V`MF/;A]CV:845]=&VA(FJ[(F"[&>Z9%>Y.J`LW(X(1:1+BC@_[F^G/[7@W MTM1HCP8TP+#'@)[<#_S5?6"#:V-WD8C*^KVIG"5:CM& M'`F.)$'4):Q"ADL?1%[5+&*Y0B3R#$6PS>$\,Z0$1Y(@:B:6&,-,C'P0#AZ? M[[ZN56;L%:*QGP^M&:\[&AY$'`F.)$'4*2PMAE,?Q%X7(M-RA0R;MCY#$4>" M(TD0-1-KT?UFHK2U.!6R`LQ.@9W4=7(S)/#X0">2)(A:CB7I?LM5`2.36]W^I@E+YL"0>_I>P0G M-WT-4H6-6*^0'\#F`AKTY6@^LG<5)::OPNKRH]!\VE4'X3,D-5(=B4?!0[6T MD:;+52,_&#='TV#HCRVK6XE)9V+4ZH%]OG,WF%C7"Z&EIDKS-!B/+=62J*9^ M6<7W]H0*>(W5"&[GK5_6'6+;2ERWV$BC\(J$1G`GPPOO9-3CA!H<<@3+B3J! M=="8;A\XH:JF.:\"A?!M"(X.R;%BO&TES.1H/==M3&@IG8EPYH?6B5H2/=0) MJQA_X`2ON+@HZ":^Y2CB2'`D":)F/E1>8;;;=4LC>O.86S-V>Y7J]DZ.!$>2 M(&HY%KG[9XDJB626L"JYQ;L!C7G$D>!($D3-M,HK[IT3>!T%(SUX(@YXZ=7( M*EQLQ?)J?.W8YD-P)`FB7F'ANS_XJDR2X+/*N0T8BC@2'$F"J)E6??T/P>>U M-^@*[74W#^=LI^FDVDA'UXXM$AQ)@JA76.GN#[ZJBR3X&EUW7O6J6KW\S-/R MD&[3TZERDN(57T/#[%XO.ZS>D6^"";PD;_9/UC*%EJ8RLY89M#2O#.T6'[3! MX0\"PEI`&YR@^EI`&QQ:>EJ"$8PSZFT90\NXMR6$EN9M.[-@".,T;WY8"WPH M@&MCCP5^`"U-*6%]P#:X[O3U`=O@AM'7`K;!"9ZWP)>*I_Y1H$./_`;,ZI4' MH_IL>AJ#_J9"VVZ`K;VF0AY[TPA9[$TBY+`WA?,%O`D!A[UN8/@"&ULK%A=CZLV$'VOU/^`>-^`"1""DEQM M/FBOU$I5==L^L\1)T`*.@/VX_[YCQB8>R*;IU;XLR\G,88Z/[3$LOKR7A?7* MZR87U=)F$]>V>)6)?5X=E_9?WY*'R+::-JWV:2$JOK2_\\;^LOKYI\6;J)^; M$^>M!0Q5L[1/;7N.':?)3KQ,FXDX\PI^.8BZ3%NXK8].25RV2U+Q(6ZB_.>7G1K.5V3UT95H_OYP?,E&> M@>(I+_+V>T=J6V46?SU6HDZ?"M#]SOPTT]S=S8B^S+-:-.+03H#.P4+'FN?. MW`&FU6*?@P(Y[%;-#TO[D<4)BVQGM>@&Z.^?`'[6UYX?TI6C_%&^_\OQX:L'N`!1)8?'^^Y8W M&8PHT$R\0#)EHH`"X*]5YG)JP(BD[TO;@P?G^_:TM*?A))BY4P;AUA-OVB27 ME+:5O32M*/_!(*:HD&2J2."J2.:3*`C\,)H!R8U$7R7"525ZEX??R`/6KFJX MJKQHXD4!"T)9]8W$4"7"]:Y*'1RN;O2W:9NN%K5XLV!*PX`TYU0N$!8#F1YV M?'1OQ$<^@`&2Y%&R+&U8BS#$#4R>UU7HSQ?.*QB>J9CU.(;1B(V.D.Y*VNT0 MV`V!Q``<4-3+@FGP";(DBY2E"UIKX*+3&VC0$3IE.P1V0R`Q`*(!9N$G:)`L ML!@,:WSFTJ+7&.,3_VC(I@_IA8V0W0A)3(1H@X7R"=HDR]+VYX:X,!B*4T&W MQ/4AO;@1LALAB8D0<;!T37'7MS"]=&1PIT$_>XU(`-.B7TT^FP[\Z(-TVG:$ M[$9(8B*D9%CZ]YT4]/'HZYS.52I!-K^[IQ/#5@F;I9ZG:P5='!A,[8T*,"W0D.&!@CXV M0>=TCZ829.\S).#Q8R)/6^TISY[7`N8M%'YEI4QAVJC#!S90H@PA,.F$811Q":&HZA%#H=O.4C=<'H:'R9/\SY%V1`>>\7H?JEJ9#"(%#VK2-W,1@ M(1%/$`KQ,(O32D&X,-CL2M4F#ZU:-C:CZA\S175'4PQ"`U.&JYYA%#$%(6(* M0LJ4A^D5?28/U2>[H*'O/US!GDEF%T+@BCF[1NL?HXA1"!&C%*2,NK*%R;>@ MWG`J1+9+0\B/&84]E^A#::'/`*&(40L0HA&X99?)0?;*1#O1YV"Y.:ZI6==J"7!9?=\)LX?[0; MFML(]FNB64%R%\$GXGLXO@F6O#[R#2^*QLK$BWS'GD/Q/8KO_]M9#"<=R!_@ M\%W@L3OV#?"U_%YP)7[MQ?#",^993V-X6QCCCW[\B-\=A@_P8SB!CQ/600S' MW"MX&,/Q$G"G)X+O!^?TR']/ZV->-5;!#Z#=[<:[QB\0>-.J<7\2+7PYZ"PX MP9<```&0```'AL+W=O_>//QX>+/P[/I_OCT_O+Y&IR>7%XNCM^NG_Z\O[R M?_Y=_K:ZO#B]W#Y]NGTX/AW>7_YU.%W^X\/?__;NQ_'Y]]/7P^'E@CP\G=Y? M?GUY^;:YOC[=?3T\WIZNCM\.3U3R^?C\>/M"_WS^GRXGDXF MB^O'V_NG2^MA\_P6'\?/G^_O#OGQ[OOCX>G%.GD^/-R^4/M/7^^_G=C;X]U; MW#W>/O_^_=MO=\?';^3BX_W#_[3?/EZ?A\^_&!SOO/)+V]8]_] M/\#]X_W=\_%T_/QR1>ZN;4/QG-?7ZVOR].'=IWLZ`R/[Q?/A\_O+FV2S7ZTN MKS^\ZP7ZW_O#CU/PWQ>GK\/S=F#:?#*+*UU"[ M['O@G\\7GPZ?;[\_O/SK^*,^W'_Y^D+=/:V^?17?CC=D:+DYFHZ-Y[N MC@_4`/K_B\=[$QJDR.V?[R^G=.#[3R]?WU_.%E?SY626D/G%Q\/II;PW+B\O M[KZ?7HZ/_V>-$N?*.IDY)_37.4EF5^ETOESU7L[43%U-^NMJ3J=OJTFMZQM. M?_F8Y.3,H1:N`OWE"NNKZ6J>S!?F5,_47+J:])=K)E=).GFM'EUC?1/IKZNW MOEHFD_5L>?YX:U>/_KIZY\\LH:CI#V3^P]58O$W%A/O?_(>K.GU3(Q.*&'M0 M'SIO/2C'2_+F@+FV8=M?!?GMR^V'=\_''QT]HVU9+JVC=6MC3B=KB;# M)25.@(X\X@2,M3P!2X3:TY5J4.:,`K4M<6K[IO5SL)DC20(4.4(RH0E8@J1#6B!E&+J$.T0[072(IE\H@1 M8MFT@ZY>CIEM8M%J-J",D<\A2"5W^PQ6=+N?RFBX",SY`R=[\`2J/`F?S MM716>ROVU0@DA3`9PP@A;((AA+!(".%0*(1%2HCY4K:],%,>A:`QX\:7C@4' MJ#P*A%BH*:3V5NRK$4@*8;*1$4+8Y$4(85'0SBQQ*!3"(BW$2@OAS;CQ)7L+ M(V(X9BB$RA1JK-@()(4PB)(2P2`CA4"B$14J(5$5SD7@S+P0+B?F?#)L2*U8.I>%:<+I0C:B=U:X?2I'<5TR1T(S29 MCLM(>W.9D3ID!BP_<2ST(L9;#9H@*AP:8F<2C1VL6'GD&X&QXZQXW8&QX]U0 M*Z5..KT^G_1-ARR:3W?KT)RZPNL$L>.L*(BY8HZH<&@VL;$SG<>3; M$)')-MZM>"+AY-V`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`H:K4`^\GJ;0=N68&.K-U7G8-*7?J9`2Z73B%^=*LQ=M MX]:?ST+?"]JR57C6>J[T-CS(Y8@*1"6B"E&-J$'4(NH0[1#M!9)*CTMXS#Z9 M&@@<$NO*=*GNKF3>RNMG?0631(%6):(*48VH0=0BZA#M$.T%DOKIK.[\7)FZ M_,I?DUN'`ADR1#FB`E&)J$)4(VH0M8@Z1#M$>X&D6.,2,]JOA&"S:.$W-S-G M%:#<(7F/+EAMV>>4G%4R\=O!9;3F0MVBJKP5!W,=<=9X,S_ZI/HN>NNMV%DW M..O3<"GAN-PLQ=S,H4"O#%'N4'!KM7!(ZF7]2Z47ZFYHA<[JB+/&FP5ZZ9OM MK;?R>ME6)).(7N/2LQ33,X>$7M8J0+FS$GI9*ZD7,Y_&5:YJ,O&L'IB/S<8? M(I1'Q6;KK;P\?-"(/";7"O/`7[I]81XCT[."18%$F;,*4.X0K9FYL85#4C7K M+)DL![MJL/.L'EBHFJUKEN5#2I/J"&VQ(=W@+*+:N*33;&MK>8;L,&@5/'CI M*M+*@.7)'5K:^P/):C9?S68SO>?!%7U$E8PFE!(-0L`-B,J9+6B<':S2E;J@ M:W;F_3>,SOMOG1E=Q&9_C^YOJ!2T8S^]:S'TSJX8N]+2CHNA9^[ M?-TW:NN07+RN]%+$6WE)K2_:Q3&!\%LR2Z.1S#5]I)7E* M15N-[AM&X14`UTGKK'CQ=S514=2QFT@O)77W_JBW=%^HSTA;&T:O!/\KGCMV$PE^O5[ZI81CCLLHA^2% M`(\Q>2O?"]87[3J9"X%&==L-^D*P5O2D%E<4+E= MWGWS)O>ML_+7&8Q#8@V"Y$PG7Y%4KMN MH92'E=G.W5(F'`-3G$\'*ZZ8NXITH]'.I^E/!G17TQ^RC!TR$L>NK:_$,;AO MWN2^=5;^$4B5X11,%W!"BZ0I&]<'*=X1% MYH[!4!'BL9B[BF%L#[["BFHJKUS%U\(=W#=\Q/"$H)M;9R72)FA]Q[XB5X!9 M;NG.2.8C'R"<&R]JK+%(C>_0'X.5[P_GRSW\-HT^;%FX(XKQW?F:T&P7]"1T M")O10#N8I2NU)*OQ`(U#R_"2BO2(]V^N;'PDK!.NY:5AEIGG>N-MCX29*4YW MAT-FY!*'I&PF=LC1CX3U?OK/9PRB+E5VNG4V9J4^&*GNR;S-$!&("D0EH@I1 MC:A!U"+J$.T0[062.IOU$W;M>)V-G_Y2"S2$UN5 MB"I$-:(&48NH0[1#M!=(*JW7:^&/FK5B9'%&!J$14 M(:H1-8A:1!VB':*]0%(_LUH((_45_>SB(IR+%Q:1?JQ,ABA'5"`J$56(:D0- MHA91AVB':"^0%,NDZR/$!;>BH4O$54> MA;[4'<#:6[&O1B`I@\GS1\A@EP4B9BP2,@#*S3ZG%2MLNLHJ"F_%32\151X% MOO3MB]I;L:]&("F#2:='R.!R]#`:+!(R`,H7`PJ:/E^ MA59[*_;5""1E,-GL"!EL\BNBP2(A`Z"H$Y77YDI,"U= M6"1W)&`7R%NQ##DCOQXK''([U-%E0XG5*D8TL@R3/63UM;-RKT&JG;F&?>#Z MBF[\C(F!WEPNI!Q2"RF5\&7>:I"(D1]="H?.WQ7"ECLU45/.J60>8JDI57QE4,@L=9\>V-=(:;ZR5[\M4J M1MYY[=!/(H4K1")%IZV_M-.ZQ&S6(15`*G7(O)67R?I:]Q]>M,]@."L3[S_O M]))]^I\]1?$PS3U]YQ_Y*U/TE\E<];\1GE#JW] M-PH*AVC)W^]63_K7CN5>=PKAR&31-<('.JL]J/IZ[)R3=-L*M5$XGK;UR M_Y^W^):8USJDPD[E*)FW\BI:7^O@(0-GM;8W'Z=Q%6VU8$>HXFKGAW:VLK>X M]=#.#8P,8"87#:=W'7]OVZPQK^JJS1I&YEJ1'6?R/CSDZ$V$I.6K2CC&()0A6#F;7S_.>=^KBC0JD14(:H1-8A:1!VB':*]0%)IDUJ&2I]/ M;98V$PUS-X?$)L)"/TV6>2NOG_45K)X+M"H158AJ1`VB%E&':(=H+Y#4SZ2I M(_2S6:W0SR*Z+\_*9$M`.:("48FH0E0C:A"UB#I$.T1[@:18)@L>(99-FH58 M%M%ZR5^JZ5KMOV;+P8HES1$5B$J/0O?JUF7EK=A][5%8426OC;?BBBVBSJ/` MEUZH[KP5^]H+)(1?CW.9@SJDA%>32.:MN%$YH@)1B:A"5'L4*+-6B7#C MK;@1+:+.H\"7?OYNYZW8UUX@J?*X3']EL_,PO!U2*JO%>>:MN%$YH@)1B:A" M5'L4*+-6$V+CK;@1+:+.H?`9TEV$[455*:I>+IR?H%:X+G`H6!AEC'PFFCOD M%D9I_R$*-:X46*UTR'R(8\@=TK5:'598L4;4L"^9#"M?+5;L&)W-_W;>O;M? MI^)JSVYPS68"W*HB#QSQ#EB`I$):(*48VH0=0BZA#M$.T%DF*- M6UZM<'GED%A>S?53JYFW8I5S1`6B$E&%J$;4(&H1=8AVB/8"2?W,2NCM*P;Z MX16]Q\#([S'8GU:Q/RKQ>'C^JTR\159WM M8DHE_1UH*)E12;^[I$INEHO-C?V1&E5">R$;LUL0:<&2SH?6P;&2%97T$[OV MMDI)@_Z=.%5R,TLW-[2E'O%&)>8;"K$2Z@7Z.D"LA%I-#[9AR4TZW=S08T)8 M0F_7;LS[I[$2THW>K(R54-OH-<)(24+>:&Z(E9`W^@XOEMQ,J1?L*T9*'?JB MU,9\H$^G8,EM"ZD7HAI3;]5=!-O,S4YXFE+)QFSOYEM M;N@#XGCH+9U[[-2W1L>8/?5PK(-O$M/26`E],9S:&FLLK-MF81TG0 M&SU_026Q5M,C"502:S7=I:>26-OH)=R->0<0CT.OXF[,B[:QD@65Q(Y#[UM2 M2>PX3;JBDMAQZ,W=C7EQ$(^SI9)MM(1>8-Z8=R.Q#KW'O#&O2&))027F34DL MH3>8-^;]Y%C)@DIB9UK2F9JW4&-U5E02/4Y",4J?-,8Z]/'P34W?`8^54/_8 M[0$U$%<)Q:A]-A]**$:CQZ%OC6_,1Y7Q./3)],TV6D)?3M]DT1+Z@/K&?!T= MO>4):1UM=4ZM+J*MSA.*47NQOG[_''?O/QX?*'?A>L_?_F5?@?P0!]GGI@/8WX^'E_X']3&PO=V]R M:W-H965T=]>6S.U6;ZO6JGOS_^Z[>' MM^;ZI3U4536ZNI[*#7Z\O\_9RK]'IY+0+BY=S_[L^5Y!MF"<^`Y^;Y@LW+?8<@?.<>*?]#/QQG>RKY_+UV/W9 MO.55_7+H8+I]B(@'%NZ_QU6[@XR"S(SY7&G7'&$`\/_D5//2@(R4WS93!E]< M[[O#9NH%,W_I>"Z83SY7;9?67'(ZV;VV77/ZGS#J(QI$/"D"GU+$=6`3_>XU]L1DN#Z$+C6"H82RP8;?5T'# MNG_DPW74**1&W]09B8#=2$_$R(1#.#CCW-B,6!#>0VJSN31G,Y)&*H!8$&\] MA)1(:663$J^,>.7$J]"]C$!=Z);OC[2W-D.5:`FIU&)=6;%**U>%%B/2'5E@ ME[RT\IR^,#XM76=A2J>HHZ0S1#>E#M`G%% M*P7W.*R\K410(H@B1&JR8T3**I&(+0?'%*V48X9(.>;4L4"KWM&,CW=!]\B8C/H%T0R9]SE: MR'SS9P$_\?W@((C+WY4-DAK+5J(5+"ZU*#RKT8^DE:OF+4:DYBV1R%OT9>HN MH%\,R!H00]"4,JJ46THL\-G2&E.!;B,EP9L>+3_OE+QLD?2D"`0EH4I>(F45 MN\0JD<.A9H-3+_O->Y/SYN;>V$`IF[OF=ULA&_#([:5,6(X,I0 M+2,[H7"$A<]O;]:\I:BA:BE#=%,VEU92]I,SMT6G`U^I,AL$5E^P=:65OE=9]Z%(V6#QQA0E%*44913E M%!4&,I,#`[63P_P9S/-'_QK!A:PB%B@P&E'/REC$MW5P!"N5#8(2:I52E%&4 M4U08R,P&[VVT4GEG7Y*]D=IQMM"46,%$%,44)12E%&44Y105!C+B8U:']E.' MDE[$G&F)]+:@Q(K6O)!+)HXOG^`%-R/!U*)11H?Q]H<+P,A<-[Y3N MWAZ9Z*OT>[1$5H581Z5(66$D,2)5_(E$*_U^S`+K8)RBHUXFLM]36KG2XL7F M.E9'5*#*2)7P3NK^E'!KJTH$XOQ8O!( MRLZ)]-*+A`CE4NAVP14XJ)%2L?K0=S:4H=W$X+;05\LBT$O%VA@C986.,2(U MP8E$.,&,^;12AJ]#H8P*Y:80+$#/MTJN,+S,0N&-WOVK1[2%QH8BD%4H]I\& MV&"%D<2(U":02"0+A05KS_>MFU>*;GJE2'&EE)M*2\;6+LF)[F7FY$,]*!QD MR8XBD+FC+*P!1-+1V%&DHUXF`F&9K%9D;TRI4(9(">42H=#:">QZ*PPO(R7@ M]8$RZ:W-358BLTP6UN$T4E9#F2!2DYM(A&7B+.D>BUY:E2!20KDE!`N0I,3P M,E/"N\&[5PZ\\6!7"2)U7!;O-(@'U:?J^E)%U?'83G;-*W]?`0KE\6'`^#+% M,GP2;U-85^`<'/)3)R227%G!E;[;(5?6<*6O&>L*O+3QQ$:UP&&,LQ`>O8Y\ MMP"%$>+T-X=#+"5R$\C:`\ M6X7PA(%R.$*%_)PS=L4-$^CMZ96,N>#37YD/X<$K)Y?RI?I/>7VIS^WD6#W# M%#O]TZFK>&E%_-(U%YAZ>/&DZ>!ED_['`[Q<5,&#)X?_D>"Y:3K\!;YZ/KRN M]/@/````__\#`%!+`P04``8`"````"$`V_G0(4X*``#4+0``&0```'AL+W=O MWVNS;4B$\?$:C?'K:K(NH7+_MBOU1BAR*[>H(_:]>-J\5 MJNW6GY';K0[?WEZOUN7N%20>-MO-\6'2';6[M]=U M@/ZW*=XKX^]6]5*^IX?-XVRS+R#:,$]B!A[*\ILPS1\%`NLV#R_'&&Z?1B1&%CX^#,JJC5$%&0ZKB^4UN46.@#_MG8;D1H0 MD=6/F[8+#6\>CR\W[7[0\0>]O@/FK8>B.B8;(=ENK=^J8[G[OS1RE)04Z2L1 M^%4BCM\9.+U1?P`B9QP]Y0B_V'K'\7J!:/N,&URM.PV_V%ZO,_1]+QA^T&"@ M/.$7/3_7TX%RA-]+>@K+K.XI_&)[G^SI2'G"K_+T.I[K#X;UQ)P)C@,Y5+G`(.YH#X0[7JZPP\-U!,`Y'OGXI1 M5R9_O9:BU7%U>WTHWUNP0<&`J]>5V.Z<4*CA*I*M-^OJ5\L*UI-0N1,R-VV8 M:U@Q%>P%WV^#H'_=_0[K=ZUL[KF-8UN,T4(L5B$;41!3D%"04I!1D%,PH6!* MP8R".04+"I8&Z$*LFX!#OOR.@`L9$7`,U3T"/0,NB2Y:H$M$04Q!0D%*049! M3L&$@BD%,PKF%"PH6!K`BBXLPM\172$#]P,CG7V/IK.T\:R<)Q%O3)J0,Q(S MDC"2,I(QDC,R863*R(R1.2,+1I8FL<(/&]GO"+^0N6E[<`,PMA//#NZ],CH7 M_\:DB3\C,2,)(RDC&2,Y(Q-&IHS,&)DSLF!D:1(K_K"!6_$_70OAIBVLZS!C M>.XE\6%U-8'WO8$=^'%CA&X1(S$C"2,I(QDC.2,31J:,S!B9,[)@9&D2*ZI0 M,ET056%M1U42B"H&;,Q(Q$C,2,)(RDC&2,[(A)$I(S-&YHPL&%F:Q`HA%(]6 M"&69T1$UZ_%EL_YV7\I2^T3"]J&N2[I- M-T$T9,$+)1'N,/?BY`D!LK/(9TG^T>IHX] M?-B8K.%_+4>$"MF,)2(Y0@8X%O=;$2@=SD@A8W9CA:"J$77"E7,J4DPHY4(9 M$3H9*E/(#I6HPLQ,^5JH9"UG[3@2&=DRAK]9`BDD9KO9ID_W]7R(C?F*.(HYBC MA*.4HXRCG*,)1U..9AS-.5IPM+20'5):AW_I]N#R\EPA\S3.4:30K\_CV@!W MG(2CE*.,HUPAHTL3;77Z+#_5!MC^C*,Y1PN.E@K)]NU9$$4XW5G$NT-QM_KT M$Q%7EO+FKJ*0,>0Q1Y%"@;GU^SZY0<3:"D.1H)9Q=-16^F;C#LFQ+--6J)6C MEJZR)]I*:[%^3;45:LU02_=KKJVT%NO70ENAUA*UZG[9LR:*?#IK;B!>,/_B MO3,^R''E\<":*75B,.L3WZ]$AC,V4`Y3%V M;X[(Z/)",4^=U8C*$EW,P)M=MJ=<'$G,*3]?[;GR!&/-LSK4F&O-H6]'Q\H1 M;H4XM`B1?N`0H[Q\;''ENB1=$NZ3(M+*&9$AIYT=5_LF8'YNV1FA#FI#202IZTF=WV?]&`L%KV,VXQQR1[LI"B^C,=0,V M04T0(4WM"?KH;/NI%S*07VQ)2426%%D+8^5H+2GIV->)':,5F(D=QNEY;-Z: MUG`=IHW3H-E(,\7Z2H?<#W)TT4U/T$.CJ4*!RB+X-(CHS+C.')&C>[-`;=F; M*Y=42DOT.;&L8#58R^IKI;M0(1NA1'`0QCB.785TTD4*>>F#7LK%JNS'RK)*(UZ$19G1_`5%D%D%N_[O\,.Z;[/T=D]'_1 ML+/]7Z*9967TWUZ\XI&`N;O2-/C<@RG8QU@>*"320#8I/[^4GXSMBL-S,2ZV MVZJU+M_$IY5PRKR];C!^]SD,[^3[-W(%'CB%XF$+B+,K([A2IQJ]XO;@,]+Z MD36Y`M^7WM6OU`F_A^].ZX\T*7=!Z%3;_1`^:.%]NO/".[ELJ9`7PA<8W.'> M#^$;@A,\".'%..?1((27SYRG@Q!>*',.1^=0''+Y%3C4AN+XR:_`02\4QSA^ M)84KXE#&K\`A+!1'+'X%CE303GVEVP0%OJE]73T7\]7A>;.O6MOB"1*C5Q]D M#_*K7/F?HWI:^E`>X6O:^L'I"WP]7<#[IYYXH/94ED?\#S3=;;['OOT7``#_ M_P,`4$L#!!0`!@`(````(0"5K*39_P,``/\,```9````>&PO=V]R:W-H965T M^TS` M"=8"1MC9[/[[.[8QBTT:I=)]">%DYGB.9SR>K)[?JM)Z12W%I%[;[F1J6ZC. M2([K\]K^]3-Y6M@696F=IR6IT=I^1]1^WOS]U^I*VA=:(,0L8*CIVBX8:R+' MH5F!JI1.2(-J^.5$VBIE\-J>'=JT*,V%4U4ZWG0:.E6*:ULR1.TC'.1TPADZ MD.Q2H9I)DA:5*8/X:8$;JMBJ[!&Z*FU?+LU31JH&*(ZXQ.Q=D-I6E45?SC5I MTV,)NM]UGT4 M\*'3,S0H"^5R,('8!)(!H&F`NC,US.`(WCX\*A/<"8[)(!/!PLR$M/&U=!DR M>I->QPB)1T@R1#0I<"),*;P/_&&5<9:U[4.!#\ILKD>^ZXSNB>M->G$C)!XA MR1#1Q($04YP73/Y<'N<1\E18.XD$4""]X&!I5EQOI-P.(R0>((*;Z_')AC7A#985.'O9$7DAW(A[!HU) MMBO.H8#"AYL]4ROK;VTZJXJT:$DLISWT<\_W#=YDR*L)@I/Y MN"!NK`N2B#M=*D&!(:@S6'X(DDCP@<02@48I;J'9./HAB1:]"\WU\?"%M1Y_ M!_'AA"\.&3$Z[UY9#%*B>#Y.3-Q!70:"A1L832[1>'01_$9\N*A@^#.3H""^ MQY)9CG=R:JA0>T9[5);4RLB%CVX+T-JC_5BY%7(,?,?'31'T*;'#KL@@H9W`P\C:#2`.ST1C)]->D;?TO:,:VJ5Z`0: MIZ*_M'*`E2^,-&)X.A(&@Z?X6L`?#01CRY3W_A,A3+WP!?J_+IO_````__\# M`%!+`P04``8`"````"$`3C>])R4*```)+P``&0```'AL+W=O7-XW+PVA_J^_[T^]?]X^/>_[MZ;X^?32UV? M>Z!P.-WW7\[GM\5@<-J^U/O-Z:9YJP_PY*DY[C=G^//X/#B]'>O-8^NT?QWX MP^%TL-_L#GVIL#C^C$;S]+3;UD&S_;*O#VFO?HN'O,=X<:H@UY$AGXU#2?A6GR*!`X#YAWV&;@/\?>8_VT^?)Z M_F_S'M>[YY;/'X/:A/6X@HR-S(9FR;5V@`_.SM=Z)K0$0VW]K/ M]]WC^>6^/YK>3&;#D0?FO4_UZ1SNA&2_M_UR.C?[_TLC3S2J$_&5"'RBR/AF MY@WGH]G/BXR5"'PJ$>_F=C(93V^O$(&O:U\'/I7(['J1F1*!SU]O"0RPMB7P M^>LM\:`_R/2(CB%#[]_XMQ-O,A7YN9`3K\LL_*)R-[:=.]B<-P]WQ^:]!S,&M/GTMA'SC[<0W1F[M6QVU]'_ MJ9]#WQ0J'X7,?1]2`%WX!(/SZ\-T>GLW^`H#:JMLEMS&,RU6:"&ZO)`-;+"V M06B#R`:Q#1(;I#;(;)#;H+!!:8-*`P.(=1=P&+J_(^!"1@0<0[5$0!GPK>BB M!;H$-EC;(+1!9(/8!HD-4AMD-LAM4-B@M$&E`2.Z,)!^1W2%#$S06G>>S.WN M+&W&1I^W(MZ9="%G9,U(R$C$2,Q(PDC*2,9(SDC!2,E(I1,C_#`=_8[P"YG[ M_GBNQ7\ZG9O!72JC2_'O3+KX,[)F)&0D8B1F)&$D921C)&>D8*1DI-*)$7^8 MP(WXNS'0[/;KS@B3%C(2,1(SDC"2,I(QDC-2,%(R4DDB7]X(-FS\KNBOPMJ, MJB2WHVX97#$22.+YT`@MK-;68TU675PYB@CI6M9"&Y,5:B4E9(UMUS?(M0$L^?=?T@ZHS<(G'W'$42+I)V1FZ1K'N.(CD7*3HCMTC9/4>1 M2A)'4F!!-)+BF(-@D.$D)*S-Z$NB3T*,!(I,NU"N&0F95\1L8D82YI4RFXR1 MG'D5S*9DI-*]C'XM"KTK8MB:FT%42!1+VGPR-L?:"JTHC@$BW=&?3DW'M;*" MOBSZRVAF350AJI!PA.BB<&P*CT?6K)6@"@FGB"X*9Z;P:&*U.$<5$BX0710N M3>'QS`I5A2JML)EE47WI9>WED2)*>&NH*.3!6-2R/#&3M4*K>3=:`D14FJT5 M\N=M2N&\QU0)T854(D2D$ELJ5H=+T(-$4D0DDEDB/LN5C(1'*@57*2V5J=66 M"EU:%3,QHG"[(C&RSH-*`"?'I2>1,?P\SWJ/%5I1GPL0M6>$[39MK=!HW";F M@P>+C9T:]6VD$W&=V-89WEK%8H).I),BHO9DMLYH;NW^EJ`2!]SC@E2.JK1 M9`4H1`UJ3X3HHFRLK-RR"6J0;(KHHFQV439'#9(M$%V4+2_*5JC1RIK9%:7C M%=E5E2:U;RF.'&&N-,;?=&AM-5=H1?TT0$3]=*V0&G_>>.+-?4LI1#=2BA"1 M4LR4?-;G$W0CI101*65<:3*V1G..;J14("*E\B>4*G1KE^7^IJ/%D M-6NL27J!VRXM*V6E[;4#A7Y0WY,5+GDA1Q%',4<)1RE'&450HY2 MWQ.EIA[\'VS)9&5J1%DO5E64&0K:[X'YZ0?UOF9&<99JPA59I-GIJYFU>8XU M,W1-'"S5F"YGE;B99H9RN8,5&B,Y7OAK9BA7*>:H,L6>U\C4KPT3H6)-2!+I MU7_[7?!_##K!"12B^M^*]9H,\&5"A8P3`#)3A;>E$Y,!ZB0.G93,W#H9&:!. M[M`IR,RM4Y(!ZE0*N9(D*MPKAI,LB(WAI-?(:C@Q%,#^3*11&Q)KCD)$M/I% MB&@LQ1PEB,@Q142.&4;KS@9\?C:@D!B<6IJMJGZ%5K1W M#A!10;Y62)4=HPG+*2O((ZX26RHCJXQ-T(7:DB*BMF2FBC>T2K8<74BE0$0J MI:DRLI:V"CU:$3,QUYT-^/QL0"%C_/&S`;2B/A<@HMEDK1">#?CSJ;5^A.A$ M.A$BTHDM'<\?61TE02?221&13F;K3.S[%3DZD4Z!B'1*2\?W[#.&"IU:'3-# MHO3^^47'EY6ZON@H](.S`64%4S6NA`$B?RB;(X:)%L@NBA;7I2M4*.5-;-[W=F`S\\&%#+&'S\;0"OJIP$B MZJ=KA=3XF\_@3,T^&D`O$HH0D5!L"L'IZW3NL2&H#C5(*>5*F:4TF@X]^^`C M1S=2*A!1FTI+"0X^X-:7>?18H5NK9"8*EL9KAJ$PMS8J"HGQ):7EO4=Y-6Q? M'Y_K5?WZ>NIMFR_B3N/H%DY(.RPO7$(%L1`;5)"PGL!5S(^^@R_ABF9[M<"R M7_IP==-E/UK`51.'_ACTVVC:0N,%W(W@#LO)`O[A[^`>/(#>RI]`\;80U0!_ M`B7<0M1GKB>W\,3E`[7;0M0$W`E](*@NOB`836U=(``NNR#R&L+AY!4%TZ M$83499]`%W7Q%#IHJS/H7A@N(K]MGNMB'4Z]U_H)!O6PO=1RE%>9Y1_G MYJV]$OJI.<,5Y/;7%[AR7L--H.$-S!E/37/&/R#Y@^X2^\/?````__\#`%!+ M`P04``8`"````"$`[-U(7-X'```"(0``&0```'AL+W=OW9 MV?W[5%_*W5WM,.SE9;T=Z5Q^9?\]O3K+X]O3?NI.U15/P&&<[=V#GU_ M64VGW?90G/[-*I^/4F\V"Z:FLSXY@6+6W M<#3[?;VMXF;[>JK.O2!IJV/9P_J[0WWID.VTO87N5+:?7B]WV^9T`8KG^ECW M7SFI,SEM5\7+N6G+YR/8_<6=EUODYA\L^E.];9NNV??W0#<5"[5M?I@^3('I MZ7%7@P7,[9.VVJ^=#^ZJ\`)G^O3('?1/7;UUVO\GW:%YR]IZ]WM]KL#;$"<6 M@>>F^<1$BQV#0'EJ::<\`G^VDUVU+U^/_5_-6U[5+X<>PKT`BYAAJ]W7N.JV MX%&@N?<6C&G;'&$!\._D5+/4`(^47_CSK=[UA[7C!_>+Y57P16;C`\\1=G-RD&4A&>J'CC4I=2$Y[?M%38HWRI\,1?O&VI M#U(1GJAX?:E3D14\R>*R+Y\>V^9M`CL7XMY=2E8'W!6P878)_P[Y]G_I!GG& M2#XPEK4#9D`F=;!'/C\%R]GC]#/D]5;*;&P9UY2(4((E,:.-*9!0(*5`1H&< M`H4&3,$)@R<@MW^")Q@+\P3:L$%`N<8C9J,$JL042"B04B"C0$Z!0@,,LV%C M_@2S&0M4%CT!9@^FG1LA,S>RQ!2)!I'!%Q:26$AJ(9F%Y!92Z(CA$2@X/\$C MC&7MS&%/:7N"9/Q&"EUSR2`RN,1"$@M)+22SD-Q""ATQ7`*U5'?)>._!8L"$ MN>6XXHU`%I""RA>N3V(_"*%:;"&)A:06DEE(;B&%CAB&0NV_W5`F;!HJD&`^ M;/_(0F(+22PDM9#,0G(+*73$L`KZDFZ5*/+WK/_VAWK[:=.(`6`DK#X48$8^&80P\JF%9!:26T@A$+$@PW[87S]L M/^,P[1>(;K^%Q`()0MX3O1E-^F3X?C!=)ZP#^$,W#G9C@C*:4LB`7B/PS;(I'<2B:U MM#)+*[>T"EW+L-2%0?MV4[FT::N$7-/6!;$5I91I,4*ZHA?0G)=2OL+%AM68!"$H=@.7%RS-N*0V5X:*BBM'*!!!(!NK,$A,1[%I MZH<=)48RPU$"(DE'C(M<*:4\'$MH#AU<\PKQ<"*E0E&.QI+.8LYN8LY-9B^< MD4FGD`+N2-*Q0>R*+S\V%_Z:DHS03&? MOYKS*IPBIE0SA#35'#%-M4",JYIYQ"8NS?9W;)3SF5KIQA40)(RR44)**K:E M$@EI2T]12BEF""GZW%8L4(HKFO:Q0>MV^\189FP(`=&6$YK;/6*5!7J5JX(3 M(Z2BGTC(6P[.2E%**68(*<7<5BQ0:B2F;`R[W68QM!DV"X@4`:OS2"D5K1C, MYUZXVA\2*24[SYTW#TF92)%'46<(7:7.";4?/)"N5B#/2*JPZ>UVMXE9SW"; M@%A@AA(8N,2VR)52*N`Q0BK@B80@4]C,=1<&I#6DJ*-H,H0432XA?RYHW!D= M?0M4&DDC<+7NC^\:VED.D1E.0B2[R(P0H91*@5A""V5?(J$`IK#!Y2.]6"Q" ME'XQTMI+B+B=Q*^378_V#S8!:XGR?H^1HJ>S=P$_QW63DDT<2.D(IE0BQ MA!:0:9I7B$$)2HE>?.?[/BEJJ4V=H=)5ZARE)/5\Z9'T+0QJHV)[9&ZFWKRM M&W,6\ M8[.8#_6RRPF@]>J=(7!IMT(I%:\8(5W1?D^24C!.L;+@^TMR;)0BC6+.$+K* MG".S?`-;^J0&%D@SDBAD9'W':?9HZLFATZ@M5J]"*17N&"$5[D1"LE0FR\.Z9O^&PO=V]R:W-H965TZ35:O><:TJK`35KPR_#,C#UCO/SVD6?.NRBK5!8KEXU\UQ%%(K=IL5^Y M__W[_#!SG:J.BVVIX5+%A9E'QMRMTL3\223 MMUP4-1DI11;7P%\=TF-UMI8G?9J4LI*[>@3F/`*]]7GNS3VPM%YN4_``P^Z48K=R M']DBXC/76R^;`/U,Q:FZ^M^I#O+T1YEN_TH+`=&&/&$&7J1\1>GW+=Z"A[V; MIY^;#/Q=.ENQB]^R^A]Y^E.D^T,-Z9Z`1^C88OOY)*H$(@IF1GR"EA*9`0#\ M.GF*4P,B$G\T?T_IMCZLW"`<3:9^P$#NO(BJ?D[1I.LD;U4M\U\D8LH4&>'* M2`#T:IR/^&S")N%]*QX1-0X^Q76\7I;RY,"L@7=6QQCG(%N`9?0L@/@01^OK M5ZZ"CVCD$:VL7)CN\'@%^7E?AU.^]-XAIHG2;&XU3%=$9P6F`O!:1O#\FK$[ MZF<4%",*9@'9-G0#;+=L!EETJP@F+9I&`A'J3X)BB.;5B\-IT-HE.-*,KS6Z M(K(I-#8PTI\-Q2L7'+\$97;QF=A(,V_2R0(^\WW?8-,4T[FFT-A@EO=G0['. M%O"Y_N8-:<8-FTE%8V$S%HS#:VP-*AP"A6(=*IR.#2C20%#:H(:Z(B(%\XE[ MQ"_C&MET"!F*33(SE:2QD9&B)9NVX!H8-K2.:F%?D?B0"7AQG.8::;KS26.4 MSP$U4I.F<28T@(D%W7+7`06"UR-G9&K4)-VM30G!* M1'23*2X^Z\R>X>/*O5U^0BGYA)E).H.#H7/*M'YL$;W MYZ.*;B^]C$16/IM$Y\,RW9^/BCI8;RL%-'(SOR2B_';77T:2;A=T/M`,X$/U MW?E'(NO\(PG\MGY>%K[.-ZA#X-[+Y)M=9K9:'R2:-+5VS,+`F*"1LM*';E"K M8!V]8F;L=39*U/URM3IL_42/WJ"&P:C6P]RY9.5F8Z)$5CY;5]'YC+YQI[IT M-0RSUS(2087#W:8_,N(;J?%N?AUN4-M@77WC9NF2J(4S2G>DC/2`XX/Z1J,V MUNW,V.UNE*C[Y33SK!(M>'Q0WVC4][;$2F3EL[46G0\K>.^ZS*G>V^NR$G7O M5=2@VC($[,N&R[%T7X&=/[SL2Z-YRDRP^4VA1-8`]FX<',Q<<][A0_7=!)/( MRF>3Z`D>U#CP0]EH'+>-5XG4A\\$-TU&;XDT"6=\?BW1^8S6T3//72W$+('< MUA_40K9)=,Y!+83W:2%*9,US[Q8"QSO:/.P9QXY6YE?AF+U&" M;D_$C+O=I43F9V(%)?S2%N5S2611=U/+8G.>\R!K.D)I_#W!F*.`0Q!^! M>"=E?;[`(Y;V%'+]/P```/__`P!02P,$%``&``@````A`&/:/$CD!@``3R$` M`!D```!X;"]W;W)K&ULK%K9CMI(%'T?:?[!\GN` M\@(T`J*&*#.1)M)H-,NSVQBP@C&RW>GD[^?48N.Z=;L3(UZ:YFYUZ]2M4QO+ M]]^*D_W63G'?)J3QG*_][5OOO MU[_^LGPIJR_U,G/A"N2ZLOSY5U:%A>$>,I/>?-=!?6](EU\.IS+*GDZH=_?1)2D;6SUQ0E? MY&E5UN6^&2'<6"?J]OEA_#!&I/5REZ,'$G:ORO8K_U$LMM'<'Z^7"J!_\^RE M[OWOU=%,%Y['A_5"/P9^7MLGWR?&K^ M*E]^S_+#L<%PQ^B1[-AB]_U#5J=`%&%&02PCI>4)">"O5^2R-(!(\DU]ON2[ MYKCRPV@4S&,13V'O/65U\S&7,7TO?:Z;LOA/6PD32T<)3!1\ME%&41#/YD(& M><,Q-([X;!WC43R;A*\XCG7Z"HT/29.LEU7YXJ'$D%]]263!B@6"M3#HICM@ M7L,%@,@@CS+*RL?<0(]K#.;7=3R-EN.O&(#4V&Q<&V%;;%L+.6Y(K\L1Z-PA M1QE%YBC'4B:]:077I`.24&M!$P)0=TA(1D'96*#%=@8;;8.)<$UR:IML.Q.: M9727+&64E1\]]#)PQ]88O95F9T+31*'WP>0G8%MHTEAETXVBEHA@HLI.S`DZ MK1JUQ=:F56C3(:E(8SL5+9&IM-EM6Y&:]E9;LR%M26.[+2T10:"Z'4Q$2#I^ M-:"`RR6L-^7?!EP:VRUK2=SK9%]B]1%%TV])DDN,@1A(+C**G8*6Q)B>O3&E M\Z(SHOT76"SZ:;T-@+*VFS"L.+C4*+;)QF$TH#IV5@\,@@A0N0QJ1A8/A2$49-@[W(4GA MLJ01$1R<3=>K/(EUS)JQ;\\+96T3E!'U<;!$%@[!?7A2A2%I<#PY<_9ZG16M M!ZRQ0W!P>5(%4!.SI8RM);)QN`]/!BY/&A&I![ION%HY.`SBR<#E22.RZN%5 MGI0'H#NL%RH,J8>.`7O;AQDYKFR-HT[6'J%!/!FX/&E$%@ZO\F1P'YY480@. M'0/V<2`GD*UQY'`8Q).!RY-&9.'P*D\&]^%)%8;@T#%@'P>ZG32.#`[A()Y4 MUG8"1M3'P1)9U1?>AR=5&))&QX!]'.A^TCAR.`SBR=#E22.R<-!67&L,3T9" M7M8,/5^$+E4:$9KM0T&WE%G8;0\BQ-`E1".R>FH(T;U`"!E"#&-D/_!XK>*0ZN,8<4YWT,:1 M*12"8<*<[I)MHXKU9T^D4,3XJ'FXA2A2+P:.ZTLHOG=,H81PZ>0409:5;L3U M6C[+5QZ4U'K9B?43U":*\0:E'G\`#PXAC$\`'YPA.`VPQH:=T83`&IMK3@.LL;GE-,`: M>U-&$\`'-PZ-!KB695EP&PO=V]R:W-H965TR;@)*@!(^QTNO]^ MRQC3&/=F,U+WH0DOKQ[UJFQ3V7QYJ2OC&7>T),W61)9C&KC)25$VYZWY\T?Z M>64:E&5-D56DP5OS%5/SR^[3;YL;Z9[H!6-F@$)#M^:%L3:T;9I?<)U1B[2X M@6].I*LS!K?=V:9MA[.B#ZHKVW6?CTWI,N.%?A^05Z6 M2^W^1I.OR[PCE)R8!7*V2%3WO+;7-BCM-D4)#GC9C0Z?MN8>A2E"IKW;]`7Z MN\0W.OELT`NY_=Z5Q9]E@Z':T"?>@2,A3YSZM>`0!-M:=-IWX%MG%/B472OV MG=S^P.7YPJ#=/CCBQL+B-<8TAXJ"C.7Z7"DG%20`_XVZY$L#*I*]]-=;6;#+ MUEP$EK]T%@CHQA%3EI90>D>CB#N(P'40<<'(G8#%$`#7(0`Y MULKWO6"UA,?>B?2&2+C*1UG([9TP^+:W"=,B>ZZR-6'W0E,H M++?G7>`M-_8S+)%\X$0Z!ZF,@V3P](!E^`$>N`ILGTEK/&=6^$AP/*5_,U\C932F M(8F&I%-$\08;Y0.\<96MZ:TGY@)OI68>#:1[YD;*:$Y#$@U)IXAB#K;SU-S[ MAY[<.IS<>Y#/C@3BP[(8=Y/GS';3823)L%A#$@U)IXB2,FS]QU/F9#5E@4#* M,IN#AL0:DFA(.D64_):_DA\GJ_D)!,%RG)1TME`.(TF:B`6R@JS&,'LZR!/7>D'\3T*QB[$`P)M?S,0!&I8 M(DA+KY=%:.'`GTI)I\J*(]AZCSOB9-610):+,>.#0-!Z1&(-2;2H=,I1\D/P MQG\\P9ZM9CA`;T7WU=(R-2R%$1438[P,8:5#_`R'27+? M;_L9'O$)\QU^Y(;PPM-UHD4(;PL=WWOA7DRJ\P=X(9S`>D#DAW#,O8,'(1PO M@-NC$$R<;7;&?V7=N6RH4>$3>'&PO=V]R:W-H965TW+>CF9.7C.C.W! MJZ_OU4E[PTU;UN>UCF:FKN%S4>_*\V&M__D]_K+0M;;+S[O\5)_Q6O^!6_WK MYM=?5M>Z>6F/&'<:,)S;M7[LNHMO&&UQQ%7>SNH+/L,O^[JI\@X>FX/17AJ< M[WJGZF18IND:55Z>="P+EXK?.XH28-/>0?S;X_EI>5L5?$( M794W+Z^7+T5=78#BN3R5W8^>5->JPL\.Y[K)GT\0]SN:YP7G[A\4^JHLFKJM M]]T,Z`PZ437FI;$T@&FSVI40`9%=:_!^K3\A/T.>;FQ6O4!_E?C:3O[7VF-] M39IR]ZT\8U`;\D0R\%S7+\0TVQ$(G`W%.^XS\'NC[?`^?SUU?]37%)>'8P?I M=B`B$IB_^Q'BM@!%@69F.82IJ$\P`?BK524I#5`D?^_':[GKCFO==F>.9]H( MS+5GW'9Q22AUK7AMN[KZFQHA1D5)+$8"(R.QEC-KX2#')2QW/&WF"2/S1/;X M^CN.<^8((W_ES$/FTO;NOQ!^[>.%D?EY,S0W/YJGR]Q@_-P\/>8(XZ?F">NS MGR>,GYGGDKG!^-`\#5H.?76%>9=O5DU]U6#)0L+;2TXV`.0#&2\KFI&AT/ZM MSJ#`",D385GK$`.44`N+XVWCVLN5\08%73";0+5!HL666Y#J);2A#$0R$,M` M(@.I#&03P``1!B6@J/\')0@+48+'$'!@E,:2PN86W"64@4@&8AE(9""5@6P" M"&'#BI3#MF%WNKVO\'P3)]A!)OFV'2F;`;69"T4A13Z8#*$K2*0@L8(D"I(J M2#9%!`%@9Y$%(!OK)U<`85GK)V8^&HRX:K&" M)`J2*DA&$3HA(7Y87_\Y?L(AQD^1:?P*$E+$7?1'H&4BJ>BCX?`05+=2`6PY5:3PN$0_7XA6TS$(,OK MI;"\A2AHS%U&EH1#(TLJLB"YAC/NTK.(8I"VZ7$Q:),EB$$AJ2ZDE&X1LQI5 M##DTIC1B$*\+>EP*UF^-DPD0A:2ZD#*Z MY59C1D,.C1F-&,3JPI,:K9A[C"0)AT:25"192"09][A1%:1SFDCQ4R$32&A!!!2]@MF-88=@BI$'`_VX^$`4H]=;F71$W)N2E]M M,3.8%%?"?>XRI]R*,;NVU"AD`K.H)>GDN):P$\I:?J\O_47%!S5$^T%!3`:1 M2J!OI/=K]`:DPLT!;_'IU&I%_4KNSN`MJ?7A[Z__G3 M_W#7[UVNV]/3]E"=RH?^]_+2_^/QG_^X?Z_.GR^O97GM@<+I\M!_O5[?EL/A M9?=:'K>70?56GN#*'D[E]NGVNEX&+JCT6QXW.Y/?:FP//^, M1O7\O-^57K7[RW:[QUWR^CE5)VWGPYPW]^H5T3^&. MQ(TMG[Y[Y64'$069@3L52KOJ``.`?WO'O9@:$)'MM_KS??]T?7WHCV<#]V[J M3&=@W_M47J[^7FCV>[LOEVMU_)^T,!,96(Z'9U/=^!,1O6\ZG+$ M%#HZAXO.T0[EG*Y+Q-M>MX_WY^J]!^L.C/GRMA6KF+,418'%(;^]*9>_JQ8H M$Z'R4<@\]"$%4`<7*/&OC]/%_'[X%MXXL(YXD8ZCX)M.S$9D.F\8(IX_/2,!(R$C$ M2,Q(PDC*2,9(SD@AB;QY(]BPH!C!M@05O#"JPMJ,JB1WX^;1O&;$D\2!KJ<= M5K(=VFBK)JX>!D1FY5[VQ#(2(F3!)V@ECQ),$RD!L;=V10T*R::[C7?B2 M..Z\F0=!8V07"9OK*!)QD;@QLHLDS7442;E(UAC91?+F.HH4DEB2(CHG(RO= M]5*;F_%7J+T.<>0AJ@\*ZGFXXF\'A*1IRB MBA;.$'4*YZ;P9$Y"5:!*+6QF6?0P[=;[!X4C6QXCRQ(YL&"VLCRE6596>GIX ML*T3BR`XXHS9*.0NZI3"<9*IXJ.+5@D0:960J)`)%Z&'%HD1:9&$B+@L5^R& M,JZ2$Y49&4N!+O58S,2(]N:&Q*AN2-_42ISGB/BVIX[CD/M8HY6>CP)U1DOR&XP12>MDR'2 M.KE"%6F&/.7X@WY?6^'^P>3M2@L#`4^A'_7_+3,=9_D%PA59T+)K M/\W(YCELF:%K9&%QB[7E2,N;M,Q0+K6PK,6T'#\(:)FA7*&8K>L4_>C_7R:R MJS7*I-WHJC)AR(,=@PZ MB39`G=2BDVDSNTZN#5"G4,B2)/>VHX':W"PGA=I'`QQYB'1);#CR$>FG7X!( M.X8<18BT8XQ(.R8F_O(=(-^48AU7:,IRRGK"$/N$I(5,:DC8W018\E1J3'DI@J MSHBT;"FZ:)4,D5;)394Q>;05Z,%[$_>VLX':G-3?3YT-*$>C_AI'+,F-LL*S M`7!LP)56\/3#='B(VC5G62&EH[V)]U%#RP:( M.F5#9667C5!#R\:(.F633MD4-;1LAJA3-N^4+5"CEC471EAQ;\FN,"?U)Q%Y M_I&.?@T[#N%HU%_CB`G?*"M5?XLYG*D1(9\+!8CTA`]-(3A]G2T<5H)L2#%7 M2HC2>#9RZ,%'BF[M(F0WEQ,E./B`-]/,H\?"4#(3==O1@/@EE"9*(5%?4EJ^ MX2E?7SN6YY=R71X.E]ZN^B+>WAS?P0EI@^6KI=!!+,4&%23(%7CI]*-KX2MX M&;5^U8#8KUQX2=5F/U["ZS`6_0GHUP&F0I,EO+_!'5:S);P`8.$.7)#SD"A! M\[84W0#W@19N*?HSVY4%7+'Y0.^V%#T!]X$.;IE;U:!?@"LVGQ7XK*Q7UG!E M;;T";?%R8_T>Z+?@BNU[?/`1G14?-73%2]'RVJXLX(K-)X;@V'@*H;'Q#`)C M^X8,PF*S+V`VVC@W[9GRZ]0_D,13VJ?]T_ MRY>VY1_7Z@T69GCONKK"N];U?U_AY?H2?NL=B3>=GJOJBG]`\H?-Z_J/?P$` M`/__`P!02P,$%``&``@````A`$2=5U`9"0``I2@``!D```!X;"]W;W)K&ULK)IM;^(X$,??GW3?`?&^0!(2*"H]E3Q+=]+I=`^O M*:1MM$!0DFYWO_V-8T]LS^0H[>V;9?MCYA_/>&Q/0NY^^78\C+X6=5-6I_78 MFB M:$>@<&K6XY>V/:^FTV;W4ARWS:0Z%R?XYJFJC]L6_JR?I\VY+K;[SNEXF+JS M63`];LO36"JLZFLTJJ>G[U6)Q:*5(7AVT+XV]>RG.#:L?=-7+';?WE M]7RSJXYGD'@L#V7[O1,=CXZ[5?Y\JNKMXP'B_N;,MSO4[OY@\L=R5U=-]=1. M0&XJ!\ICOIW>3D'I_FY?0@0B[:.Z>%J/'YQ5[LW'T_N[+D%_E\5;8_Q_U+Q4 M;VE=[G\M3P5D&^9)S,!C57T1IOE>('">,N^DFX'?Z]&^>-J^'MH_JK>L*)]? M6IAN'R(2@:WVWZ.BV4%&06;B^D)I5QU@`/#OZ%B*TH",;+]UGV_EOGU9C]W% M9.',;KT%J#P639N40G(\VKTV;77\1QHY2DJ*N$K$@]'+[[U@XB]FG@/7O.0X M5X[PJ1R#R=+WY\%27/W"%>';;MCPB<.&`)>^XP?O7#)0GO")8YU?Y[E0GO#Y ML<'"6NL&"Y\?'.RM\H3/ZP8[E=/;54NT;;?W=W7U-H(E"!/8G+=B03LK4,,R MD2GN"^>_Z@8*1H@\")7U&.*`DFB@V+_>![/EW?0K%.A.V6RXC6-;A&@AJE'( M1A3$%"04I!1D%.0&F$(2^DQ`L?Z`3`@5D0F,88-`I\8E8:,%ND04Q!0D%*04 M9!3D!K#"AK7Y`\(6*NLQ_&L4P*T=YT;:S*TJL4W"WJ3/!2,Q(PDC*2,9([E) MK(S`IO,#,B)4UN,YK"DC)71-**-+*>E-^I0P$C.2,)(RDC&2F\1*"6RG9DJ& M#Q'<#(1Q%SF.>".)XW8[@TN7O?S6AXL/9LH:".S.UP]$&-L#D<3OCLYNBPD9 MB1B)&4D821G)&,E-8D4%)X<9E=B$77\">?G@-BQT[(`E\6'QZ]PZ,[+J>B.< ML(B1F)&$D921C)'<)%8.8`V8.;A<8L+8#E02"!1C"!F)&(D921A)&0'9]H,XSXY)W.1-Q/MB_E[LNF@A,2UN9`*7O0 MMZC['-FK6(M7(G43+6Y;0G&?#1NY@2*%/)C=_B#VW<"NAUA;83TD'*4<91SE M"LE!V)D0?&B(P20^3J;,;(/'TKG2#3KBDBPS5#9KCFR#I7._8/=9HN[S05@H+1,4HK M*%Y$$;>*%3*&GJ"5=DP1:?F,.^9HU3G:\8E^S]A0+I\\KNP.S9U#(7KRD"=- M(9KIR8D0Z=F/%7(7?682M-*.*2+MF''''*T&YE2TA=?'+)M(*V:)R"9`3QY7 M6>G9BA"9N\?`)B`=U?EPX\Z79"-.4$=+IX@N2F?*"J6]X):<:CGJ#)2*:"NO M3YML0JVT2?3.(0-;1GP M3L:9T9XX1Z>!,A)=H9&/SQTQLK6TTB01J2[2(X2NLM(E$"GDZ_ABA0(XN(U3 MAQQ7"==*N5:FM;I<2Q9M>F/RN4J!@^N`"EQ1TB%:Z$"*% M?/#O'0>6H93WY5E\XWD>V=02+IU>)9VAE9*>+UQ2OKDE;6<35OBELKOR-!8J MI+61R#JI%#*+3"%/_M3:=7SBKD,TU+"MX(F6(-.N*2+#->N9=LV1#6Q!H@$U MEMP[IY5L5ZVUI3I8<8E^Z@/VDP`%R'Y"3RNTTO,5(3)SQ9>)LH(/L2UXWH+<4"5 M,U16=V`+C^R!.&O:"4!)6WN+0_:\$*V,O061GNY8(9AND2%_ M1L)(T$6KI(BT2F:KW,[)!.;H,E!!I(?]U/X+:YMN&`J1PB+1A6BEIS]2R#RH M%'KGH.):*=?*M);(-[W/L32LG54\'3-WE\_EB;?(G2ZI)3I](1KI(H@4>N>8 M0D?X[!;@#A0=;L`/:N10]K+%3TUQ>=TI! M7\:*3B%]1?D.DGRKY%C4ST58'`[-:%>]BO>+H#KO[WHL7W[:.-Y*/(J&0;-O MYO!-]PB9?K-8P8^'`Q[+%?S\-L!O5_!KU0!W9G"%[K:57L&!=[+@-X\A'Q>^ MZ4Y(X@,/=E?BZ2OW@0>=*_$LDW\#SR[!9^@;>"GL8>@J&S&P`:4-#&O0'M([ ME-V'^>I!OG1&PMA`U@>3'JS@5VL(8=H[P$MBY^US\=NV?BY/S>A0/,$DS[J' M$;5\S4S^T:J'$H]5"Z^'01W`RT7P.F`!3ZAFXJ?MIZIJ\0]Q@?X%P_M_`0`` M__\#`%!+`P04``8`"````"$`1VLA_T4#``#Q"0``&0```'AL+W=OFE)3:-*PX=]S079E;#N M9\Y<6S(0M^_")8]HW5%-R&/&$&=IP_(O0APQ`,MB>C[]L,_!!&1G-R M*-5/?OQ*V;Y0D&X?5H0+"[.7.RI3CRQ3 M162Z"\M?S.8.P(T=E>J>(:5II`>I>/57@YP3E29Q3R1P/Y$$EKOT'3]`DE<& MSD\#X7X:.`_.LT\'VEI]:\8=462S%OQH0(6!/MD0K%2D0XP%@5$?(`A9(A.N%Z;-AY;$&N,-G!U"DAXR5NE]B$IDB4QO M-9`Y,BH^@5Z3V4/&,J'0+\V\OO^Z0D-PJZ;/HHXX[JPM.W=<4]UGJ*T+F\_Z M!X46O$<*@H=2=`2E=.J2+M1N^\%_<>T@TU*$C/E3OQ9*] M4=GTH'$^L,%=G`BOYP/!P\E/D?,^2RXC`PN@IBYG0@N6*SQMWVL!$@U5Z,C( M`G]D00\:6P!]9Z#L=0]:]'#Z+H2%H)>L^Y`^>BLJ]C2A92F-E!^PQS@.5&\? MU@TP7H7)"@G&<3^,@ROQQ`^AW*9X:*1;]TH\Q@9[+>Z&>)Y"&?--+[U MPJUNU&.A7IAX5P;$BS!97(LO0Z@5F,#NB:#A-F1/OQ.Q9[4T2IJ#6;-VEPC= MLO6+XDW;RG9<0:MM'POXM:)PS,\LJ*><<]6]X`3]S]KF'P```/__`P!02P,$ M%``&``@````A`!?TTD^L"P``'CD``!D```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`V:WOC!>>?_X+9V(R8(1S\4VM:/5:?5P=VB^#6B]H.\^OJW8ZN,$3%&?81[3(:Y)^>]E$#9Z5I6R0@Y)+)!;(/$!JD- M,AOD-BAL4-J@TH!A%2U8'V$5DZ&%TT@T*XV6/&9B9*-E7Q?2^0=LE:6+470.2>[D,Y)(#&0!$@*)`.2 M`RF`E$`JG1A.TN7+<++_0BZ7.!;=&B8GNN1D2AFO6>A9F=8%R6$1D!A(`B0% MD@')@11`2B"53@Q_Z,)]A3\LVO2'DSFOA=AZ'@*)@,1`$B`ID`Q(#J0`4@*I M=&*80;7(%6:P:-,,3N9ZLGCSA94L(LCKK@111U2.>0OKRAIW03+'$B!I1W0A MZWS/NB`IE`,I.J*$',7I=;/^O&QX4=QS M=GI4:?#Z@XF8?G-"?LL]"`71S.7$HZ6V.X&]A74UB;L@*92`4`HQ&9`<1A40 M4P*I]%&&;;1P&[;UV$,-@?2'19O^<$(A58J/LUW0YEU*)+W$B@JEPY.O9[BT@VWF4HP9&8J"1[4)KP;.] M[PB`3HHZF=PGF:D]"P[H%*A36CI]ANLZ9L:SDO[W#1>-@?)MZ7`TI\M)M[QX M"VLQ#T44SP3Q0P4?.*4JIQO8?E,[OU9^1SEBXOD MRXOD*T/>/&ITN3E[U/YJWMH?I,Z7,FPYLJ\*'%$G)M>N4$1I*$(4(TH0I8@R M1#FB`E&)J#*0Z1CK1O0\?\<9WKP82[CH9VA5[#+.6U@9%U(F,TOG6FFLD#[0 MNKC%*DH:GR!*%=*UK/4U4U%2*T=4**2TL/U045*K$LAMYVBZS%H3W>5?ZD`< MWN`8YHN>1T]+@72G.7JG"Q'R%"5GE`BD';44HS)$.0XL,*I$5`G4YR'K4W0/ MW\E4WM889G%$EP4YP9!5>:S^4"@2:#[IHF)$"0Y,,2I#E./``J-*1)4QT,PN MUK12!FEG$JD M[Q(H9R)**L^Q-8%]+BY2+DUESYM9^UQ)&2S67+M5_*6SO54Q.TB!6"9TAPE; M$QFEBHY((+U8$V@FBC7/=BY!F11E,HEX9W+C3"96AY.C3B$'J4ZIE$CJ^`M+ MIS)TC/QW/Z05;%4LOWEW:)T6UHZ%8B"M_G)9B00Z7TS%,FK..PW'3K$$E5,Y MAE9TE0)VIY&)J+G3*D_L3BA'X>(BX5)&B5VF.\)FJU89RN918FV3ODK99\5E MM9G+NR]]]9*(^6]^)2OO\2OE/>R+;SW2U8BMI2!)V])Z1B5*IP M;1HF48Q1":(4488H1U0@*A%5!C)=92W&1[C*6Q6:?Y?)LXGUT^C2Y4'G7>UB MI(61&B91C"A!E"+*$.6("D0EHLI`IJNLP?@(5WFC0N>';JO5T"_9@QRLP]&O M)'8/JF*DAQ&B&%&"*$64(;YU]H9HINKI4$1I*$(4 M(TH0I8@R1#FB`E&)J#*0Z0SK$ZYPAK<5AC,ANN&M M`K6MJF@()5+'())(1<4"DM+%V*H+-7JBCE(]?2*U&,2A"EB#)$.:("48FH,I#I(ZM6+J]) M/%[<&)=(CK0YAR)*0Q&B&%&"*$64(NJ];H!GE[L=*O7Z(T MHYSL3D9O;O_8*P;JOVI)I`_$2E1$T8+."B-WZEH_G"92!@LCNN=^S5%OP\T* M3R"],))(.1!)I!5&`NF%D8S"PFAB%W#M67Y)8=2.M':Y[T?&N=U?BH'ZX9!( M*XP$$D_JW#C3L6V^'-1COEWMG2^,Z#48.[$D4H41?]&%OPVPJP\O=5AOM\?! MNOG"7F*A1'BXZS!_PX;JFH`5`[1VP98I;6DG:VUY]&;!(W\MQ]JRI"ULM>Y3 M\VF+W[ME3EO:U+#5'-H#7H?:6UPO8+^8]7R/2_.A7WUPRZ,[#1[YS390H^^A M(AO'+%V:#_7O?5MH/M2,X!:ZGQFP.VVXA6Y8TGSZMM![3H_M+45[S^C]I_9E M(9N[].4]W[`D6_I<>9R0?N\`C85]1,_H"=4D:=^0$^E$A]U^4%O MI[VM7NK_K`XOF_UQL*V?Z<0?MT_I'?C[;?R/DW@PXU-SHO?2VF MZ1ZSZNFY:4[R#_8%W9N-#_\```#__P,`4$L#!!0`!@`(````(0#2&.Q&PO=V]R:W-H965T1*9">2;)TT*5/>% MW3Y(H(#S9B4>`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`!E38F1H0#`R7&K8*DRN/O.Y#5E/GISJ-)+THSPHS(VBS`-( M!5*#-"`M2`?2@PP@8TJ,.@VX1MWS@XYK;?UX(C_QT/<@!Y`*I`9I0%J0#J0' M&4#&E!@9+BP;&U/\O'#70&LSU+0IJRJ@K"_E26II%8T>B"JBFJ@A:HDZHIYH M(!H-LB)=0DUS_//=REUK9/TJH+1C$1V(*J*:J"%JB3JBGF@@&@VR9EP@3JQRET>Y-(^R'G9L4]0^K)BH/1!51#510]02=40]T4`T&F0]ND":>GRAAX7\ M>CF/4[N-1XF&/=&!J"*JB1JBEJ@CZHD&HM$@:\8%S!5F0AY-S7B4=:.3O!O- MK9:!"JC:`-5$#5%+U!'U1`/1:)"5Y0+H"ED^K^HR)1[SSEU?ZVMHNA'0@:TJ MHIJH(6J).J*>:"`:#;)F7/1<8<8G56,FA%>;G4[S;C2WBDH/&Z"*J"9JB%JB MCJ@G&HA&@ZPL%TU7R/))UL@*X38)4AN@`U%%5!,U1"U11]03#42C0=:,2YXK MS/B@:LS,V36-X-G=O/UF;K5T(Z"*K6JBAJ@EZHAZHH%H-,C*V_0;6?*M6DUSNV7>C=]FEJI`O-E4UZQIJ(>J*! M:#3(RLJS[_.9;7EF4Q,U1"U11]03 M#42C0;9B+M"E6E_XXOO\9RH6(J'&O/F$`J'[[=QJD054L55-U!"U1!U13S00 MC0996>NRY)99,B`S2H8LN=SO/;!51503-40M44?4$PU$HT'6C`MT:3=Z];V3 MK8^&IH=Y9`?0;?8$:A]63*[V#D0544W4$+5$'5%/-!"-!EF/ZV+FEC$S(@R@ M[ED]2O2*`73:3AXSM]E]]UUL]=P`NK29QP2BBJ@F:HA:HHZH)QJ(1H-,Q8[7 MQ M39/)<8BPR:U!H@-11503-40M44?4$PU$HT'63!YT7QWGCIF!`\IZ6/X,8VFU M]+"0E!?;%5O51`U12]01]40#T6B0]9C'XA>^CLR^QP$QSN5)\977P\=SA$PN MW[;9HX!=;/5LG`M;6JYT#\MJL8@544W4$+5$'5%/-!"-!IF*G>0I^?F*3\*@&U`V2N9WZI=62S?RVTK/PVQ5$S5$+5%' MU!,-1*-!5M:Z['O"[!M0/F$& M#BCK8?GCC:75TL/\MA+;%5O51`U12]01]40#T6B0];@N%I\P%D>$\_!)'B)? M>1Z>MH/;*ME3@EUL]=QY>&FS5"Q$U^747+%53=00M40=44\T$(T&V8KE"?2% M\S!CYDE(B^:^]#83NE]:+;+F%2.JV*HF:HA:HHZH)QJ(1H.L+!<2O_]"QCW[ MS7Z>%I`Y#_M6"3JP5454$S5$+5%'U!,-1*-!UDR>DE_H1G,8CJ7?*:V$'Q&E M^3A[7K1?6L45#T0544W4$+5$'5%/-!"-!AE9^ON$-=UH:FZS;T08)5T:-CWT ME:/DM)U\E#S.'@7L8JOG1LFES5PQHHJH)FJ(6J*.J"<:B$:#;,76Q4QWJL^^ M^`&YCUB>WN5"]TNK15:(FJ(>J*!:#3(5FQ=S#QES`PH&T`SH?NE531S(*J(:J*&J"7J MB'JB@6@TR,IRB?#[8^:I#Y#*&_&8=P&9`=2W2M"!K2JBFJ@A:HDZHIYH(!H- MLF;6QP8J+V M0%01U40-44O4$?5$`]%HD/6X+A:?,18'E&C8$QV(*J*:J"%JB3JBGF@@&@VR M9O(,_.H;BF>,QP%E/2Q_\K&TBE_>`U%%5!,U1"U11]03#42C0=9CGIB?OZ]P MQE@J(>J*!:#3(RLI3_0O=:`[O\9AW9P'A@N$L3[:OO.,R;0=W M7+*G!+O8ZKD+AJ5-W/L#4454$S5$+5%'U!,-1*-!MF+K,O`9,W!`V05#)G2_ MM%ID(2E7;%43-40M44?4$PU$HT%6UKI8?,98'%!R=;`G.A!51#510]02=40] MT4`T&F3,G.<9^-7GX6E+-ND%E`V@^9./I=7:"`:#;(> M\\3\_`!ZSE@<$0;0\SQ$OG(`G;:#`31[@+"+K9X;0)[+%53=00 MM40=44\T$(T&V8KE"?2%BC%FGGN4#:"9T/W2:I$UKQA1Q58U44/4$G5$/=%` M-!ID9:V+F>>,F0&E`RC1@:@BJHD:HI:H(^J)!J+1(&MF7`W*M!EMON)]E#D,JL:/@06KF7=22[G]WD MKLRV[.ZO"X+G#((!N;]72O8@OS\:6YW-Q3A$=#Z]:_0X.TU4`]+?M[OVH)YOSL^SJMS(KV=U> MEX@NF(@"RE3GMW%BJT1U0/HK<[_;9R=Y#S$KV=W.T]8+MGG+[L*CS'8F;A]; MI;;]BHOMHZQ;568EN]LN4GS_(Y$+GT#21R(!9;;SR\'8*K7MMZ6_7'>VLQ4J MLX+=Y769XH*9(J#,='Y]$5NEIOVVGC/M6VPT`"1?F>5+:X]D70:X8`8(*#VM M$1V(*J*:J"%JB3JBGF@@&@VR9M:=\"]XP@_(IJ/3/!TMK>+)[T!4$=5$#5%+ MU!'U1`/1:)"5M2X#7#`#1(1KR(OR:7OUJUVF[>37D*=9?-C%5NGY!N.?/[GK M%W-+Q8"J94NQ54W4$+5$'5%/-!"-!MF*K8L3%XP3`=EKR%SH?FD5-1R(*J*: MJ"%JB3JBGF@@&@TRLB[7Y9BIN,J15;U40-44O4$?5$`]%HD*W8 MN@QXR0P84#:`9D+W2ZM%EM]6,IA4;%43-40M44?4$PU$HT%6UKJ8>J(>J*!:#3(FG'9 M]/NOKS4Q4_ZSIX"R;I3?S5A:Q3YS(*J(:J*&J"7JB'JB@6@TR,I:%XLO&8L# M,MW(MTK0@:TJHIJH(6J).J*>:"`:#3)F-D=Y"'[U2.4W90-R9%DGRZ^]DF9S M+RLPO4'>[:UY<;%>(0^F=\B#Z27R8'J+/)A>(P^F]\B#Z47R*N[YT= M3_?N7S+&J+PY\DSOL8^=2,9FEMPV.\WN"4JB;^;>L;C<73M=;MQE^YUG[Y=V M-L3@Y8;?;G/DF?[T)-E9,.T9F,H+IO*"J;Q@*B^8R@NF\H*IO&`J;\HR37F6 MGBY1-B??55\&Z\V19[:^,TL+Q_KZ9EE]_^+NZ>9H7:[U[?.!SX==6U\PU1=, M]053?<%47S#5%TSU!5-]P51?,-4W95E]2R'WXG*:>>2E;P13[>;(,UO>F3U? M7M_,EO=LN2>;[?>Z4+DY8JJ,S);7MTN8R@NF\H*IO&`J+YC*"Z;R@JF\8"HO MF,J;LDQ3GC!_(!DP?6Z./+/)X"R[DUZ5[YU?;0A:X%I;$Z$9U>B$AFVKK$I:98%2KG%)\CM]WR"='_/ M)Z@"^`15X'L^047QS?1J7F?H[/)LN9"9?NZD$J4;STKDHO*:$OEH;4ODF5YW M&_VK)I[9GAS8,A:K`)[9GHQU91OK2BW6E4>L*X]85]*PKC2EZV::7"Y>H\GG M:*O)L[DG;\^S`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`-S;[Q=[!2^ M@^%3W9^IE"Z1==AA'Z8NDAVV._OGA[U)[D[^U_T??_4W1^K_\0]C=/(M'+IG M)@^&=@E3;T4[G3'`=!A@FO\:3!-@@VD&;#!-@0VF.;#!-`EVRJR^:ZAY5NL";)]?)&KI/[G6:?6I-ESL_AEUZS98)HV&TSS9H-IXFPP MS9P-IJFSP31W-I@FSP;3[-DIRY2Z9),J?6'H#!,1F7$E3DZ4O#MJ0R9-/D4E MO5&:P*0)3)K`I`E,FL"D"4R:P*0I99DFEYC6:/()RVKR+.M@67)1!YN;)1T, M3.;`9`Y,YL!D#DSFP&0.3.;`9"YEF3D7Q-:8\\'-FO,LZ3C2!*8.!B9-8-($ M)DU@T@0F36#2!"9-8-*4LDR3"VYK-/F@9S5YIN@;>XXT@4G3S-*1+KM3+7-S ML[@YF0.3.3"9F]DS'R&9<[/X$9*9LDR2BX"II-<]W`O3%UEW/EU:=V!RYYE> M'.Y._]NC39;OI6UN$8])VK`E:0.3MGG=L/4LG,G8W")N7<;2+67&7,I,C;TT MO(?8:DZ,(:GJ4Y9@=)[=V5!/"\W2I!^8FQMF6969*C33J^O=8>MG/I?F?V?5 MWS++,CKO5/0@H]@#&?7L^3V05M\L[,'%N],C\S_N@:RG>Y!9=\%WC?60I(WU M$)X5)A=UY]E-%UD/S995U4?G5:,;]4K/%*ZJ_R!F5.7JM=5RL/QJ8=Z%GKH]H@^YY7*1QA]XO/DF*2"22J8I())*IBD@DDJF*2"26K*,JDNOJ927_K6 MAH1LS'EFKLO#_%,)4]]#.VD"DR8P:0*3)C!I`I,F,&D"DZ:499I<2$TU_4#? M\WG7?GL]L_>$+K+3BL:]N5G2]\`D%4Q2P2053%+!)!5,4L$D%4Q24Y9)=5DU ME?I2W_/9UIKS+.EGT@2FO@_FQGSIGL8@9*Y/+_V1#5M:'JXE9Z4LLM_[4E(ONI$/Z<,#!G9O:V MO+'4U6P6053%;!9!5,5L%D%4Q6 MP6053%93EEEU632U^M+7UF=7:RZPPL#K(MR:K?O(9[>>QL#8M<%4!#`5`4Q% M`%,1P%0$,!4!3$4`4Q'`5(24945PH6R-)A_BK*8YV*7=-[N?K.X[-TNZ+YC, M@M,>=SG3476*'[NL"2;MT-.:_*#3[Y MZ&/3XF0W994;0K/G<\/<**D@F"H(I@J"J8)@JB"8*@BF"H*I@F"J8,IL!:=) MHE+'+PQ`85(I4\$XT93)#9>9WOUF:;:8(ZL*[>H":PJL+;"NP/H"&PILM"PS MEZ?:E\R%5)IF9C.U5!A\T@[V^NNU,-V4[7LAV-G8@*<#9J:J2;2DSJM&@9(*)JE@D@HFJ6"2"B:I M8)(*)JDIRZ2ZG)9*?:GO^5QGS07&<7>:="G=^FO'W3![4S;N9L]:=IO8[-EQ M=VD4JZ4*^F"ENP61J8)@JB"8*@BF"H*I@F"J()@J"*8*IBRKX,K@%^9VLA7T MP<]>KUUF>C7NSLVB)9D#DSDPF0.3.3"9`Y,Y,)D#DSDPF4M99LX%N;1WOM3W M??"SYD(87*[-I`E,FL"D"4R:P*0)3)K`I`E,FL"D"4R:4I9IB9NZF3W"O`+;XX+=:2D"1U7C7I>V"2"B:I8)(*)JE@D@HFJ6"2 MFC(K=9J=*I7Z0M\+LUF9@<_,C8>?<6YLA;1 MDCJO&GN[I())*IBD@DDJF*2"22J8I()):LHRJ2YIIE)?ZMD^F=J>'5BA9[N` MEF[=E>PUM[#"U%+ZV/24ESV;V6D&'WV>GI#IU#R?&7%>7!K%:JF"\XJ1J8)@ MJB"8*@BF"H*I@F"J()@J"*8*IBRKH(MKJ>.7*NCCG:U@B'SI!4&8)2MYIB5- M:"=-8-($)DU@T@0F36#2!"9-8-*4LDR3BVNIIA\8/7SRLP9#&M0Y9.YYVTN. M'G.SV,\D%4Q2P2053%+!)!5,4L$D%4Q2P20U99E4%]=2J2_U/1_OK+DT\L5, M!B9-8-($)DU@T@0F36#2!"9-8-($)DTILYJF:<16:`K3CAE-@65W.[(1<+]9 MFBT=C*PJM*L+K"FPML"Z`NL+;"BPT;+,G,MD:\SY#&?-A5R7#FYAAC0SN)%) M$]:5)C!I`I,F,&D"DR8P:0*3II1EFE;FTS#3FM7D\ZG)/\?Y+^[5P>9F20<# MDSDPF0.3.3"9`Y,Y,)D#DSDPF4M99L[ES34=S.=3:RXPYI]IE":P0X%)$]I)$Y@T@4D3F#2!21.8-(%) M4\HR32Y4KM'D0ZC5%(*I!J+YBWE\A&?$88:[Q*;,S:O&3B=S8#(')G-@,@!*M_[JP=4G-WUL6ISL(:H&U]#L M^<%U;A2KI0J"J8)@JB"8*@BF"H*I@F"J()@J"*8*ILQ6<)K5+77\PA`19H$S M%5QFAGM&[WZS-%O,D56%=G6!-076%EA78'V!#04V6I:9H%EH1;/B)=F2=]+0V.X7-N]@QUMXG-GAUWET9)!=/0&"L(I@J"J8)@JB"8 M*@BF"H*I@F"J8,JR"KK4ECI^:=SU*<^.'G/R2\?=3*_&W;E98@Y,`PJ8S(') M')C,@"W!IS/OA9/_W;[J6<+=G$_[FX?;7#V^O-;938./_'+9J5LV_4T^EYVY9=.?_W/9N5LV31B0+;O6Q;OV1=-,ESY/RQ1`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`[\;]\K#O1OWRH._&_.*0?WVJ5%4^V6G)6#X5G*KOE$\$I^H[ MY5.92P;ZR[+"-\N-R<4A^?I$^U8^`6C)6!Z.3[1OY<'8G9_+IV=W=BZ>G'?' MVC>]3;.PU\>JJ=X:65JB?=.;#4M+M&]Z91^77!\K4Y5//5HRZC5J7&=WHGZM M]Y.5EJCOE$=S=]XLGS;=6;-XTKS>GEY=ET\I6C+JG=J%/=C*@5[/7EHB!WK7 M66F)ZJ,7?W/)M$K;N412#B3':4[&TMW*L:02Y1*\R/+G2NPM+1Z]EIVY9Z?CU-L.3*_VCM.Q:PWBY`MJ) MPC[L7)E+W'7``K^>;D\4%NSZ.O6U9:S[WN^&IZ>2_7TWL[3Z[TC])Z.UVT[XK7Y7LMV1>75%I2 M%9=H\J$C[6&QHVB&IJ,K3GH2E,NE9;M-/NVZWNE MM9:Y;XOF_BTN<^.,IK#5LO?S]_SQYY_^N/GM]O_"7^Z>G^Z_3)`B?;V\^W3ZX!KH%_.O]_5/\#_&PO=V]R:W-H965TR]3-MF![ M$5$=!\T^K.*CF4,>#F>&XO+;6WUR M7G';5:19N6@R=1W5^]>/_&'N.EU?-+OB1!J\\`0].MW&/?GQ//Z\HCKHMN0LZX@3=[TM9%#S_;@]>=6USLF%-]\OSI M-/;JHFID[2XE/1P_R[8W7N)%M=WD-7%^WSR_FA M)/49*)ZJ4]6_,U+7JGZBM M>>$M/&!:+W<5**#+[K1XOW(?49+[ONNMEVR!_J[PI5/^=KHCN?S25KO?J@;# M:D.<:`2>"'FFIM]W%`)GS_+.603^:)T=WA MM[@K846!9N)'E*DD)Y@`_._4%=T:L"+%&WM>JEU_7+E!/(EFTP"!N?.$NSZO M**7KE"]=3^I_N!$25)S$%R3P'"&YX1@(1W@*1^1/YE$4QO,9#'_#,Q2>\!2> M_G7:-_R`E>F%IQP1UOR&0RPS.!XC=?X4.8D9)'BG+RH7TA:ATL-]>UW$0++U7V".EL-G8-DBW2*4% MW1"4=FL"F0GD"N"!HD$6!/T+9%$6*DM.:".!JT[?T"`MI,O6!#(3R!5`TP#[ M[PLT4!;('R4T`3)#PVU"+7Z&KL%D$&8AF87D*J)I@PSY`FV49>6&"T5<'(3Z MS#?"Z):XP6009R&9A>0JHHF#-%;%C5<]F3K4F&F08V\X$L&V&+(I0`M=53H8 M2;>MA606DJN(-F5(_?NG3(WU*7,D#H9,22UD:R&9A>0JHLUO]IGY46-]?ARA M+>BZI/[46%)A%`\BMB-N?ASK;ADW"D)6]J(I_-,-TQ^K M\GE#>(\;V3\!#,8K+^70M7($J?L]\,U2*XP65ZTC*(SF7&PT(E8EUL0B MZ-6WU/X@9]9G1^((QQD92,:BZY40#9(^(FU[ULZ1)X;[NS;OGD;]C/0@;Y"P M@F`/ZV?D0'JU&6 MJ,%*.FZOCA+*;"C7(%T4;8B*J`^VA&B?ZLPY%(>#F!19T-:&,AO*-4B?)FUM M]T]3-$)UFAS24C7PC6-'BH25DJL24BNUG:S"RI^Q;)W[1G/,)0LCUI4!\2>4 M46LC)SD40348LB'PC3-'2H6#([HNR59"U]-D)J#`9S+B*(ABHYKETHL1Z4IH MK[P_1KRS:DD@(-CEBA(C^U/$K>`A=_Q60DJK$)!H@BBTFZ!T&@D)[8_W"^'= M5!,B&JQ:H`+?RF9AI89D<)3:,L0A$9*':.'/C1-^+DQX;/60T'ZH*.$?4Y]L MZ+1QFWN.0W0O*)$RMDHJ'+5(<<=`C12'XBG;EXQ#RP:DZZ0-D%%X0?U MB[=,+5:BB\(L%"ESO>6DL+96^G`HAF8T.(X4!F'%,^IA,9W/C7V0:]R:.-_H MX[?%,6N]-@@(XB3W4RHA)7TD=+7*!`3U3#KFTLK.%]]H_A],<^CQDGK#"*`X MZ3$P:F@JK91\D9#J:,=`6(D4"L(8S8W"GTLBNZK!K=0G-ABS-F+`FS;KCSRZ M_):*7WK4N#W@%)].G5.2%WH#!;UZO1Q@>3V&DD=^/V:\@<-00L\LL);6&Q_> ML#LUZTT`;]BGD?$&KN$>QSW`86P,&&+4'@88Y0^31SA#CDPV3.#K=02/$OA$ M','C!#[-`/<&!7!==RX.^/>B/51-YYSP'A9SRFI=RR_\^(]>''Z?2`\7=>P< M?(2+60P?&%-ZF-L3TLL?=(#AJG?]+P```/__`P!02P,$%``&``@````A`('/ MQ:HB!@``\A<``!D```!X;"]W;W)K&ULK%C;CJLV M%'VOU']`O$^`<$F"DAP-=Z16JJK3]IDA3H(FA`B8V]]W&]O@2YK)G-.78;*R M]XK7\K:]\?K;>WW27E';5RJ2]`\52=JOYC(-6UNO3SP[EIBZ<3Z'ZWG*)DW,,' MA;ZNRK;IFGT_`SJ##%35O#)6!C!MU[L*%&#;M1;M-_JCY>?64C>VZ\&@OROT MUG'_:]VQ>4O;:O=;=4;@-LP3GH&GIGG&H?D.0Y!L*-G),`-_M-H.[8N74_]G M\Y:AZG#L8;I=4(2%^;N/"'4E.`HTL[F+F]F;LP;0O"M2?4]4F%*76M?.GZIOZ'!%F4BI#,*0D\&0D(N9%@TP1XT@3+ MG#ES=[$,M9R_7QBN4$0R`O44V`&^I7UP!F&6C.["$QB5@.ZZH-Z!!MRP90T9+%"16 MD$1!4@7)%"3G$<$2D,];#*?9="1) M(0WRIB(@B`V/*8!#G>X)1KFJ)1B<*:WL.:W6;->5;!*`M.O/N=&J)% MJR@$O3\GVG%$52&+6DUF,6CJ&&(*S5>#-TMIXTQ8QD22,F@BR422A702Y2QC M(!&MP/T1UQ'>+AJ+=%-P[K%J#"@DE8TT@)!%<77#(/+B@G>8F$+SQ6#%0EH* M"R2>'N1JD(Z&D(6-4UHQ*!I M0F,*T:KP/(DE82D32\J@B27[A"5G*5?J`C=.G!D_=,!:M/OB/2*05"[2^@]I MHC4E1A1R)W4QA3RRB5BNQ)*H+*G*DDDLCE1UN<`BKAW<?;*-D`Y-6#L$ M@H)A.TN(BP?7T#2O$87@L&%1,846YK!G6*ZCE(="DZHTF4QC2#>.^-Y?A7N>3)4>Z1L$Y"F$M MY!?)122Y,*I1>T`A.ITZK6Q>\"4CG)S;]0B3&]#`\^'%!`@D/%KXT,)?P9=^ M/)QR4GRZ]*'35>/AAO5Q>-^2X@-\\WHE/IC['%^8KN.O#^R7@QC@BN'&]%`?T>]$>JG.GG=`>S#*'%["6W-F2#SV=J*>F MA[O68.H/,Q9[!)[9NF9Q_P#XRW]=M_`0``__\#`%!+`P04``8`"``` M`"$`V9FPD78%``!^%```&0```'AL+W=O\9S82YL M1';S$H>?S_P]YS(SQYY_>VN.UBMJNQJ?%K8[&ML6.E5X6Y_V"_N?[^G#S+:Z MOCQMRR,^H87]CCK[V_+WW^87W#YW!X1Z"Q1.W<(^]/TY=IRN.J"F[$;XC$YP M9X?;INSA9[MWNG.+RNTPJ#DZWG@<.DU9GVRJ$+?W:.#=KJY0@JN7!IUZ*M*B M8]G#_+M#?>ZX6E/=(]>4[?/+^:'"S1DDGNICW;\/HK;55'&Q/^&V?#J"WV]N M4%9<>_AAR#=UU>(.[_H1R#ETHJ;/D1,YH+2<;VOP@(3=:M%N83^Z<>%.;&F0@;]::XMV MYP(>$>D)=G]9$T[:JEZ['S7_4RB6S$BH>4X$K5XE&4W<< M^=/[10(F`E?G`>MKF`=< MQ3SN=<:A.1I2GI1]N9RW^&+!.H(D=.>2K$HWCFR+YYHF1F3_1\F'?!&11Z*R ML&%BD-8.*O9U&?K3N?,*558QFY5IXZH6:VY!RH#()CK8Z"#50::#7`>%!!P( M@H@$%-H71(*HD$AP'U8<7$/C:6YS"SXDT<%&!ZD.,AWD.B@DH+CM?XG;1&5A MPU]1`+Y1`-0F4*I$"X4P$;$PR,8@J4$R@^0&*62B1`0VBR\H!**RL`-84U)( M9JJ_*V;T44B$B0B)038&20V2&20W2"$3)22P]\QFO*)E` M"4JQB-18K(41'Y889&.0U""907*#%#)1'`T_XR@Q5AVE!!SE/JP-DAAD8Y#4 M()E!1)ZV?%(^Y*J2<73M0W*&O&A0"2/M*"KXD$%%#0;IF(P>\9/; MATO;+C@/N5\KAK1RTJI[S:VD>F+(IR\?9.?9<'FR7[TN]9I,39',%,DY@GU4 M),T+M7`7BI8:*-)C28'Z>'FYM"-3(D(15`T/TII9*25"K4+ZOD3=9X@6>A1I MA9::*AE#DDK.D3<$T1V/C1IA\[M1(Z2;DES_J2/&92V97",4:36B[:)K-M"5 M:X0.5&J$(1JDAR#0-QE3)F-(DLDYXC(3HT#8G(?9J`5"&JQ?CA+KTN0H4:34 M#4-7J\1E`^$BE;>^#S.K<#H4P230O$O9?:D@L[N$_1GV>[K4V<=T0Z" M-1Y.B)9^/Z(_>I:H)]S#9Y\A9P?XSH=@!Q^/(#T[C'O^@SQ`?#E<_@\``/__ M`P!02P,$%``&``@````A`#!G<"YJ#```Z#H``!D```!X;"]W;W)K&ULK)MM<^(X$L??7]5]!XKW`_@!3%Q)MH*?#5=U=;5W]YHA M3D)-P"E@'O;;;\M2(W6WEX2=V1<[,S]WMZ162_K;V+>__=B]#KXUA^.VW=\- MO=%D.&CVF_9QNW^^&_[W]_S3?#@XGM;[Q_5KNV_NAG\TQ^%O]__\Q^WW]O#E M^-(TIP%$V!_OAB^GTUL\'A\W+\UN?1RU;\T>KCRUA]WZ!/\\/(^/;X=F_=@Y M[5['_F0R&^_6V_U01X@/'XG1/CUM-TW:;K[NFOU)!SDTK^L3]/_XLGT[8K3= MYB/A=NO#EZ]OGS;M[@U"?-Z^;D]_=$&'@]TFKI[W[6']^17&_<,+UQN,W?U# MA-]M-X?VV#Z=1A!NK#LJQWPSOAE#I/O;QRV,0*5]<&B>[H8/7KR:3H;C^]LN M0?_;-M^/SM\'QY?V>W'8/JZV^P:R#?.D9N!SVWY1IM6C0N`\%MYY-P/_/@P> MFZ?UU]?3?]KO9;-]?CG!=$]A1&I@\>,?:7/<0$8AS,B?JDB;]A4Z`/\?[+:J M-"`CZQ]W0Q\:WCZ>7NZ&P6PTC2:!!^:#S\WQE&]5R.%@\_5X:G?_UT:>":6# M!"8(_&F"^)$-9=?R]XSHPG_&D\ MHU'D36Z"Z'*+D?&#!6/\IB-_/O6F,Y6@"PW>&$?X\\JN>E`%W2C57Z[JK(?3 MJ?Z"K88?2Y`'):!;M;5P>1K'NI:ZTDS7I_7][:']/H#U#HT?W]9J]_!B%585 M90!CT=DZE^E?52F4IXKRH,+<#2'QX'Z$I?7M?N;/;\??8#ELC,U"VGC4(D$+ M5?LJ;,I!QD'.0<%!R4'%0VI)7YD]%49E#\>]0 MZ;-4H06ZI!QD'.0<%!R4'%0LV1O:)H6 MQNA2)L\FYTP*D@F2"U((4@I2"5(+LA1DY1*225BH))/]!S%N<+'VG MH-@AF;ENI(>P2DD/M;X<*=%T>MENOBQ:B`HG64^9!W!DZX-N*+;6G[`L89[ MSD*I6A@)RS9+7()6UC$UR&9[PFHJ(TZTV^KXOJ+;YK2WK2_4+J"Z3:LZXMDV M5FZV-?+]+MO,(<.PG0/MLCHGK^BR.5;=+FO$,LW46:)V"34PZY@:="G3KA/M MMCJ^KNBV,F?+T2!5,C2T.@S%K]Z0BFX=K$ZK.0K':-J"B;L3,T M\;F;^EA2"'4IL%1J!&L&Z28R5@U*# M`MB([?D^$V>>C@56&"N7L8K^6.P@*JT5QJIDK-I:N?UBNF-IK3#6BL0BF88M MFV;Z<@UVYG3W-:!M1+(T\N>H,;F@3XP3U#+6=8H(]CQGH;)#-S-6/JQ7QXH) MJQQCV?`%HHOARP^%KS"6#5\CNAA^::S@F6[W5/9FQO38"L-TD>FL*"7I;J/O M+&XM/-T#!NX:U40%^C<(]4@W,0CD@9T&;06%CB@S5J1>C95U+#"6=2RE8X56 MUK%&9!V7TG&%5CWUJN3H%9G1ZI5D1J-SO?H1VX<3WY6\^G$XHHLSGAFK]^I5 MA"\^%+[\4/@*8[GU:EJ\V/NE<0ST[4MP,V?:;44BTWJ][E8`CARQB_S5K8#_ MBVX%NCC=`6CWDEG`AKA`*S=3;%=*K`TNFE2B3*)SQ8&(<54=K&HU M7#)O?L3NUA.T5=@Q4.@;[)D=HH)Y'I>+DV^O`6"?D64Z@1 MFT*Q=Q@K=PHU"NS(,PRO[T^\Z80MU]P8Z)V6CHF+LG?6V?DQ+!YUBT`C,E\] MZ\Q8V5ZGUA%C90:%^E>.N2_&X4:AXU!2Y"=K4:L94HL&P?*W)277F;9RSS%5 MA%#$9)V96.IW0GBUAS^$R(U+WQPI??&38],2A8Q-(S)O\@X*UDFW&MUY,[%@ MN=FDR'5FK)1.@.&*>^:<1*9SV2=%O*G]%?;W]@TVB/=T":P0L>@,4C?)I,FP M3Q:HM7GET_0NCK@W81OS`JT@1><,LFTWL3:X.E*),HERB0J)2HDJB6J)EA*M M"*)IY^4D11,H4;P M-`JK(9$HMVAE#3!R3<+0 M-"G-Y*;IG0+2$HOD0R,FU]A]9Q(:*T>N&:0.H_->+U6IL0JU"`]'T0WY;Y9] M8IG-L2FKY`M$MO7R0ZU7M/7Y:#HA_\G6:VRJ:YVF6DFT*U*M%1U)M1%Y[NGH M1^QV.(%4<6&"R+EQ,PB>!Z@RFHP\KBBMCS,]AOB:90:=`K4F@DJYM"C:A(GK.]*%&O2:M;5NN8(K+E MD1ED:A$^'*+O(>76I7]H)HFBK=(ZXE98T;:\D)5];5WZVZ)I)'H359G3A]<(;(W*?IS*/W-R:XY/#=)\_IZ'&S:K^I3)[C)O+\] M8_,=5CB)'_2'6.P*W'S$2K%#J8@K\/$6R-.^*SY06T6ZR46=^5$*Z$/5=`ML5*DT@?^$KNH3>;,`&]^8?T]]H' M,7SCT!,_C!]@UY<7%B',8Q^?PF=[?1R&L.@=`LCG..F]`BHZ5AI9M@YR$:[T MM0\".E;"4/J`CHZ5/I17%E&\Z)NJ)(J3/IY%,;P^+>/`JT9QIK=N5D+PXE"L M7@N2/O`:4*Q>\H$KX[,3?&?XMGYN_K4^/&_WQ\%K\P2+<](]M3CH+Q7U/T[F MZ<7G]@1?&'8/,E[@B](&?MF?J!?XGMKVA/]0#9R_4;W_$P``__\#`%!+`P04 M``8`"````"$`.1G,*#(!``!``@``$0`(`61O8U!R;W!S+V-O&UL(*($ M`2B@``$````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M````````````````````````````````````````````````G)%!3\,@&(;O M)OZ'AGM+:3=C2,L2-3NYQ,09C3>$;QVQ4`)HMW\OZ[HZHR>/Y'UY>+Z/:K'3 M;?()SJO.U(AD.4K`B$XJT]3H:;U,KU'B`S>2MYV!&NW!HP6[O*B$I:)S\.`Z M"RXH\$DD&4^%K=$V!$LQ]F(+FOLL-DP,-YW3/,2C:[#EXITW@(L\O\(:`I<\ M<'P`IG8BHA$IQ82T'ZX=`%)@:$&#"1Z3C.#O;@"G_9\7AN2LJ578VSC3J'O. MEN(83NV=5U.Q[_NL+P>-Z$_PR^K^<1@U5>:P*P&('?;37NW7B)6Y&26YF5:DG5!Z+R@\]EK MA4^M\3Z;@'H4^#?Q!&"#]\\_9U\```#__P,`4$L#!!0`!@`(````(0!I>AUH MU@4``%\2```0``@!9&]C4')O<',O87!P+GAM;""B!`$HH``!```````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M`````````````````````````````)Q8VV[;.!!]7V#_(?![:Z=-%T6@N)`E M.A%J2ZHHN\T3P4AT3$075Z2,>+]^AY(OLC-VMWV*(\Z9.7/54-:7USR[6HM* MR;*XZUV_'_2N1)&4J2R>[WJS>/SN<^]*:5ZD/"L+<=?;"-7[,OS[+RNLRI6H MM!3J"E04ZJZWU'IUV^^K9"ERKM[#<0$GB[+*N89_J^=^N5C(1+AE4N>BT/T/ M@\$_??&J19&*]-UJK[#7:KQ=ZS]5FI:)X:?F\68%A(>6O5IE,N$:O!Q.95*5 MJESH*_*:B,SJ=P\M8$=%4E=2;X8#J]_]UZ()SX0#BH<+GBEA]0\/K`?!3=!" M+BLUM-;Z=BT275972OX+8?O0NWKB2A@Z=[TUKR0O--`R8NT_S>]LI70U_%Y6 M+VHIA%96'P3:A\W/KFSWM[P9?O[42,"O8TFCH64"!\<<8ZDSH8)%R"N-4/[\ MJX%OZ(QFU/,)I91;Z=TZL6H6!`_ MD(C9E)Y+CN?/(;)!Y!'S0A#00> M1C.HDPD*<6:0G"DP=$D8@#1' M2'QZQJ-)`*4"*8`.LR.<[$$06VS_.Z+@97']E(30J2B(BDZ:50]OD.8YL MG]J.*:QSV9A"M;7]:$H8LA-#M1+?.5=#E$R(8X;%MQF8(-'DD8T]'[+B0:!= ME!,E]XT%_'`VHA!XJ`-&3/7B/"^WW9^TZ@>4S=M.9#%_@I&,2G?Z[9(8WG:7 M$)>[#W<7;ZQ+5HZ;Q:3?[O07;L4OM5`PZ3$)Y-,K4,A!HV)KGM4-'UBPF%X*-D(A]Z4Y!U:)J`IFIZDT^UYC`O82 M%&(G/VNI&CG#"E+7Q:$06N(%'K`,9PW[(YL8?9338 MRJR1^PW)+(3M>A6`FU5SK%674KMBH1`/LE'`R@DK.>1#0[ MKZ#!-+,3&#/FMC$Z\PK8]B=0VN;8W,N@5QN+J)6#JRVA0[3,E0:%M/U)7N&2 MJPXUNQLV*`08K&J]GX`CKF32-*$KLUJC$!ON5:DYA<'*MM=2DQTHI'-STRL2 M:$-X+[R^I57EJ!5#S+3L-I'N+N^@`R;0>4C1U"#$^6"3-1%!(;!+OK`PXV\G M,[QM)`J)1-:\B,P-=<.:^$OLN@J%G(R$ M3Z@0A<\#"LJY>2-`S4U*I9H,QR48P"'UDQ(_:V#`B!G?^_'7E%(77!E M&UL4$L!`BT`%``&``@````A`+55,"/U````3`(```L````````````` M````MP0``%]R96QS+RYR96QS4$L!`BT`%``&``@````A`,5ZQ`(*`P``F3$` M`!H`````````````````W0<``'AL+U]R96QS+W=O&PO M=V]R:W-H965T&UL4$L!`BT`%``&``@````A`(6&VLQ'!@``!B,``!D````````````````` MSB$``'AL+W=O&PO=V]R:W-H965T&UL4$L!`BT`%``& M``@````A`,*A.38=`P``9`H``!D`````````````````Y"T``'AL+W=O&PO=V]R:W-H965T&UL4$L!`BT`%``&``@````A`*JO]J`8`P``4@D``!D````` M````````````"WL``'AL+W=O%.RH0(#``!W"```&0````````````````!:?@``>&PO=V]R M:W-H965T&UL M4$L!`BT`%``&``@````A`+9+P`+-!```SA0``!D`````````````````/84` M`'AL+W=O&PO=V]R:W-H965T&UL4$L!`BT`%``&``@` M```A`.#O&OU]`@``U`8``!D`````````````````0I```'AL+W=O&PO=V]R:W-H965T&UL4$L!`BT`%``&``@````A`$!D^6R3!```B!$``!D````````` M````````KZ@``'AL+W=O&PO=V]R:W-H M965T&UL4$L! M`BT`%``&``@````A`/MBI6V4!@``IQL``!,`````````````````O[<``'AL M+W1H96UE+W1H96UE,2YX;6Q02P$"+0`4``8`"````"$`'>T].#8/``#(H``` M#0````````````````"$O@``>&PO&PO=V]R:W-H965T M&UL4$L!`BT`%``&``@````A`$L!%P)3`@``AP4``!D````` M````````````Q%X!`'AL+W=O&PO=V]R M:W-H965T&UL M4$L!`BT`%``&``@````A`+#G*+1V!P``1"L``!D`````````````````Q7H! M`'AL+W=O" M0U<#```P"@``&0````````````````!R@@$`>&PO=V]R:W-H965T&UL4$L!`BT`%``&``@` M```A`&*H8/K'!```UQ4``!D`````````````````:(H!`'AL+W=O&PO=V]R:W-H965T&PO=V]R:W-H965T&UL4$L!`BT`%``&``@````A`#65WI-U#P``/54``!D` M````````````````$*D!`'AL+W=O&PO M=V]R:W-H965T&UL4$L!`BT`%``&``@````A`&N2;)^W(@``S\P``!D````````````````` MT\,!`'AL+W=O&PO=V]R:W-H965T&UL4$L!`BT`%``& M``@````A`)HA_*HB"0``""@``!D`````````````````Z?`!`'AL+W=O$D$\&``!8&0``&0`````````````` M``!&$`(`>&PO=V]R:W-H965T&PO=V]R:W-H965T&UL4$L!`BT`%``& M``@````A`&+G%KME`@``3P4``!@`````````````````*3`"`'AL+W=O&PO M=V]R:W-H965T&UL4$L!`BT`%``&``@````A`$MU278H"``` M^",``!D`````````````````HEH"`'AL+W=O&PO=V]R:W-H965T&UL4$L!`BT`%``&``@````A`*%RY&2-`P``1@T``!D````````` M````````O&P"`'AL+W=O"```&0````````````````"`<`(`>&PO=V]R:W-H M965T&UL4$L! M`BT`%``&``@````A`!SC0%8=!0``P!(``!D`````````````````<```&0````````````````#'?P(`>&PO=V]R:W-H965T&UL4$L!`BT`%``&``@````A M`-OYT"%."@``U"T``!D`````````````````I9X"`'AL+W=O&PO=V]R:W-H965T&UL4$L!`BT`%``&``@````A`.S=2%S>!P```B$` M`!D`````````````````O+<"`'AL+W=O&PO=V]R:W-H965T&UL4$L!`BT`%``&``@````A`(.;O4KO`P``\@P``!D````````````` M````[\L"`'AL+W=O&PO=V]R:W-H965T M&UL4$L!`BT` M%``&``@````A`$2=5U`9"0``I2@``!D`````````````````Y>`"`'AL+W=O M&PO=V]R:W-H965T&UL4$L!`BT`%``&``@````A`-(8 M[%RG)P``RNT``!D`````````````````E/D"`'AL+W=O&PO=V]R:W-H965T&UL4$L!`BT`%``&``@````A`-F9L)%V!0``?A0``!D` M````````````````TRT#`'AL+W=O&PO M=V]R:W-H965TAUHU@4``%\2```0`````````````````(I"`P!D;V-0 B&UL4$L%!@````!>`%X`Q!D``)9)`P`````` ` end XML 18 R70.htm IDEA: XBRL DOCUMENT v2.4.0.8
Summary of Warrant Activity Based on Common Stock Equivalents (Detail) (USD $)
 12 Months Ended
Dec. 31, 2013
Dec. 31, 2012
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]    
Warrants expired (Exercise Price)   $ 0.01
Minimum
    
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]    
Warrants expired (Exercise Price) $ 0.01  
Maximum
    
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]    
Warrants expired (Exercise Price) $ 0.15  
Stock Warrants
    
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]    
Beginning Balance (Shares Issuable Under Outstanding Options) 267,350,000 183,583,338
Warrants exercised (Number of Shares) 0 0
Warrants expired (Number of Shares) (144,850,000) (134,583,338)
Warrants issued with common and Series B Preferred stock in private placement (Number of Shares)   114,850,000
Warrants issued with convertible debentures and notes payable (Number of Shares) 0 103,500,000
Ending Balance (Shares Issuable Under Outstanding Options) 122,500,000 267,350,000
Warrants exercised (Exercise Price) $ 0 $ 0
Warrants issued with common and Series B Preferred stock in private placement (Exercise Price)   $ 0.01
Warrants issued with convertible debentures and notes payable (Exercise Price) $ 0 $ 0.01
Beginning Balance (Price Range or Weighted Average Exercise Price) $ 0.03 $ 0.05
Warrants exercised (Weighted Average Exercise Price) $ 0 $ 0
Warrant expired (Weighted Average Exercise Price) $ 0.02 $ 0.03
Warrants issued with common and Series B Preferred stock in private placement (Weighted Average Exercise Price)   $ 0.01
Warrants issued with convertible debentures and notes payable (Weighted Average Exercise Price) $ 0 $ 0.01
Ending Balance (Price Range or Weighted Average Exercise Price) $ 0.01 $ 0.03
Stock Warrants | Minimum
    
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]    
Beginning Balance (Exercise Price)   $ 0.01
Warrants expired (Exercise Price)   $ 0.01
Ending Balance (Exercise Price) $ 0.01 $ 0.01
Stock Warrants | Maximum
    
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]    
Beginning Balance (Exercise Price)   $ 0.15
Warrants expired (Exercise Price)   $ 0.03
Ending Balance (Exercise Price) $ 0.015 $ 0.15

XML 19 R55.htm IDEA: XBRL DOCUMENT v2.4.0.8
Inventories (Detail) (USD $)
In Thousands, unless otherwise specified
Dec. 31, 2013
Dec. 31, 2012
Schedule of Inventory [Line Items]    
Finished systems $ 24 $ 310
Raw materials and service parts 927 698
Work in progress 40 0
Inventory, Gross, Total 991 1,008
Less: Reserve for obsolete inventory (444) (457)
Inventory, net $ 547 $ 551
XML 20 R78.htm IDEA: XBRL DOCUMENT v2.4.0.8
Components Of Income Tax Expense Benefit (Detail) (USD $)
In Thousands, unless otherwise specified
 12 Months Ended
Dec. 31, 2013
Dec. 31, 2012
Income Taxes [Line Items]    
Benefit for income taxes at federal statutory rate $ 2,415 $ 2,704
Derivative losses (226) (596)
Discount amortization and other (949) (565)
Change in rates and other (2,286) 21
Change in valuation allowance 1,046 (1,564)
Total $ 0 $ 0
Benefit for income taxes at federal statutory rate, rate 34.00% 34.00%
Derivative losses, rate (3.00%) (7.00%)
Discount amortization and other,rate (13.00%) (7.00%)
Change in rates and other,rate (32.00%) 0.00%
Change in valuation allowance, rate 14.00% (20.00%)
Total, rate 0.00% 0.00%
XML 21 R46.htm IDEA: XBRL DOCUMENT v2.4.0.8
Straight-line over estimated useful (Detail)
 12 Months Ended
Dec. 31, 2013
Building [Member]
  
Property, Plant and Equipment [Line Items]  
Property, Plant and Equipment, Useful Life 39 years
Research Equipment [Member]
  
Property, Plant and Equipment [Line Items]  
Property, Plant and Equipment, Useful Life 7 years
Maximum [Member] | Furniture and Fixtures [Member]
  
Property, Plant and Equipment [Line Items]  
Property, Plant and Equipment, Useful Life 7 years
Maximum [Member] | Leasehold Improvements [Member]
  
Property, Plant and Equipment [Line Items]  
Property, Plant and Equipment, Useful Life 3 years
Maximum [Member] | Computer Equipment [Member]
  
Property, Plant and Equipment [Line Items]  
Property, Plant and Equipment, Useful Life 5 years
Maximum [Member] | Machinery and Equipment [Member]
  
Property, Plant and Equipment [Line Items]  
Property, Plant and Equipment, Useful Life 5 years
Minimum [Member] | Furniture and Fixtures [Member]
  
Property, Plant and Equipment [Line Items]  
Property, Plant and Equipment, Useful Life 5 years
Minimum [Member] | Leasehold Improvements [Member]
  
Property, Plant and Equipment [Line Items]  
Property, Plant and Equipment, Useful Life 1 year
Minimum [Member] | Computer Equipment [Member]
  
Property, Plant and Equipment [Line Items]  
Property, Plant and Equipment, Useful Life 3 years
Minimum [Member] | Machinery and Equipment [Member]
  
Property, Plant and Equipment [Line Items]  
Property, Plant and Equipment, Useful Life 3 years
XML 22 R33.htm IDEA: XBRL DOCUMENT v2.4.0.8
INVENTORIES (Tables)
 12 Months Ended
Dec. 31, 2013
Inventory, Net [Abstract]  
INVETORIES
Inventories at December 31, 2013 and 2012 consisted of the following (in thousands):
 
 
 
December 31,
 
 
 
2013
 
2012
 
Finished systems
 
$
24
 
$
310
 
Raw materials and service parts
 
 
927
 
 
698
 
Work in progress
 
 
40
 
 
-
 
 
 
 
991
 
 
1,008
 
Less: Reserve for obsolete inventory
 
 
(444)
 
 
(457)
 
 
 
$
547
 
$
551
 
ZIP 23 0001144204-14-019623-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001144204-14-019623-xbrl.zip M4$L#!!0````(`+F+?T18FQA7+'8!`.F<&``1`!P`<&]S8RTR,#$S,3(S,2YX M;6Q55`D``TW>.5--WCE3=7@+``$$)0X```0Y`0``['UYDZ-(DN__8S;?@=6^ MGNXV2U4)T)G556O*JSIW\MJ4NFMZGSU+(R$D,8U`PY&5VF?ON[\(T`$(<8DC M0O*QFAFE!(2[QR_\"@_GE_]XGVO<&S(MU=`_-_@/K0:'=-E05'WZN?';^*;9 M;W#_\>6O?_GEWYI-[BO2D2G92.%>E]R59$MC4Y+_M-;W<_P'_D.'PQ]$OGDO MF4VAQ;>Y_]UJGPNMC]N+MUY]'?1O98?#`8?W5\WEUIJU(7XH?S'?]S?C>09FDM-5;=L29<# MM*@QM(>O5RVC+?"]N#N\*]8W*&AA(IG,[=Y[!A\E4S8-#7V<2++=1.\+3=(E MVS"7-_CO]8-DP]%M/J1W=FFBV^N9T;V3%-#+Q]]ZU^)3<* MP1L5I$;?@W^(&`>]R[/HZ\DO$3>H^ANR[.A;O-\B;M(E5;:B[W%_(K?PP5LL M58Z^`?\0=;F],/=/CK7XJ3#%L.:%@R6T^R M0,D0J71\GF2/)0GMF@^^D]5\D)MZY2U&M@2Z`[E>B8N1J:!E1S*#\B3#5M01 MELPV?"A230DOV`?;A`\MIA1Y6$V18"!'^-`J(Y/@0DYXX1F&'`X!2H+I@/8JC&`U8L6K.GLJH%U.'MNU/JSIUJ#U M\2O)HEW!==:IS9YDVD$M5Z1=;OOVE]NK,(+5_>5VGOWE=DE['VU?BK[[(C+E M$H;-1W;!XINZ3;&4O8^V+Y.\%BRKYB.[8,72!.LJ2=8V= ML);KY@L?2HG+7,BQ%C8$(>?W_XN$7&\%.1Y##G]V]UIY1B04@!S?;/4R0\Z[ MJ8S-ZXU@!5>P;&UBA]=R=L&Z-Y52%1`6;/\4!=LO6[`#QI-7N00[*"EYU?/Y MV`/&K%#8Q\XN6+$\P?9]B.TSYFN'$=O/@]A^2>%V?Y7W\E0!6Z4-NX+-NEOG MJ@*^M'0K:P(-1H6#DP8G,=J.'+VZUC3J`!)1F03)%*4GCAN^L\!FLUXZ$\ M!A%3]L*M$HOPF;,Z0<@)Y61K`Y)AQ6P$DHJ52(:59*)/,GP!DB$=/Z[4.=+= M1D/)/3^":'H9X:\+3955VV."4]:R^=Q8-70YCV%I<\E^ ML7C4[0RTY?QC%(5LK"$!\,`&'JJR-BL\7``>HO`0*993T`^`!\KQ4+%^&`$> M/)9(8[;S&)F<@G(`,-`,AHHUPZ\`ABA+$2F64U`.@`?*\5">?HAN)O1RCQ15 MEK0K]*;*R(H$Q(5CJ3JRK)''J'4DH(AFR[4:44*I#@XT=TZ*;J(&**(<1;1V MC`NBZ%E25&,QD\RY)"/')L(#+'E8VB\:0%2,=0-$L8,H-BS=;[JD:8;[1@(` MD@ND'8F`1HK12(`?6O%#F?X)Y7/`PZ;.PZXCC0,PH!D&%65W(5*BW*^M(^$/ MD&`%$A49"_`UJ?(UZ_`6``!T`J#479Z(+O4O]Y(^DVP\R*UEV,8"C9$\TPW- MF"[O--D/C;7HAO*_'-52234KVZ#8RY#G.2;+INL1@7KM)>CI<+Q#8X4C&W&[(&Y50+ M0$(=4LH#R#?)1#.#+*(IP&('%CO2.4(P8//A]2'%VF+-CP>"9Z01Q^P)F[KE MV)1T2W*/TU@72_\O;&,A"X^>IE@_K28HN"WBRO!4(UM2@0%AR8`PT9DKB"^P M/Y3:'YJQ%,JK73@J%@D`*,C<-D+R2^>8$VSBRXUCZJKMF`@+Y49])Y\L0$44 M*O9+ZK@1S7\=CD`LDM"=JDZ,P".HJOO_+I2?\.6 M17W5T!5Z#5A4\OZP_8)01=4>S"=W7 MCPBP=3K8JJ2/`V"*&4Q5'M(&LZD0TE*#+`AI:]:90]LV5<=Z0O9H:6&Q0E\# M#\1[Y')D.C+[T5,%J7=H*FG7+BMLX@#S<+[#Q(F>,=W7NC@/$EZ>3&.N6I9A M+A\,.[C]%!5B`VX*S5BXE$1.04V6C_*N;P!Q@/AA:KFZUG2`5<`JS4ZD_\3% M3$63ZWW)R(^?50O]R2$KG+52,%/J) M_0*DO0SMN0!R5XG!:N*;78>8?T757&4[PDK7=(O]KM]ES5&0B M,@OIKP!I6B$=.34`Z41(Q[P5%B!=-:3I>3,MLWB.>9$IX+E>%5WSRU09A/0W MR32E8$H!0%P7B`.3`;"-@6TH&;@5*`"9!B`G3`]`.P;:U_.%9BP1.0)4C#QB&UD*9IXY`E2,/&(460IG3CD"4\P\8A17BF M=^.0#4C#QB%%(*9AXY`-V,+&(=5`IG/CD`UHP\8AI:"F;>.05CAG/+6R:5-R MJ4F6]3AQ+V`;CC$LT;NM<20[=0`G.N#$DG:*V4.6T"G#";9C"C^:"'"B`TZT&KL@G&YU'"1+VE"6#0=SJD\?=71*'4W*Z?38V0@!L%.#6CUB"+*O5F%I MQ/63?#!T>&='AG=V1,JK.F35T7(4\,'>VX(J:[@-^H-5_<'&"Z6\.C#++;I9 M%9UO'T`DZBL4Y)4Y5:_E!:J+6G@)Q6Q*&*%"S[3 MB:X/\)]86"#@2]6W0L"O8F&%@(]58K1Q],"&EW]7J62/'DXY]21`*U\NQ+W\ M25I*V%X<:P5"O9F/Q'J#W2D`F)?II@+DJW1*`?X4:'GWC<@K&3_:,V2N/@D4W`(PPAFQ0FK5,%@P M/"):?F$F'1-9Y)>3`TR")&JJ1\/8X84RZ]'B7AT%<*``#C07SN\+:&79F3MN M1><5FA#I7#FFJD^OT!O2C`41"/9EIRBUN\\NOM*&K9DD!I8L=1/+[<(5084% M)0$HRFH(K]7IS'Y"IHS_#JFOTP54I%#`/$8<&@+-1)UFJN-X$,"`9AA4<`0H M;&F@!(/:$@S*#,H>"(U-)%F.N000!4`4(1:`40R,H)*'P4H>1J"US6^XNSA$ MPB::D7EX0[>Z;,PA&125#(H7%D`N'>0@"7D\24@VP`#^P-Q=<+#F2U,@10"D9$-*O750-2)% M!*1D0\IQ;M^$-G/!^C!N?2KK%0K6AW'K4RM2P/HP9'TJJR&!K3HVMNKJ\&%A MKXWMO;::,0.;94QOEM6!'J@_HJ_^J(Z8&/:MJ-VWJBR&`<^4.<^T.FR`9WHL MGFD=F`'/]%@\T\K0`YXIU9YI13C@P3.EUS/EJ\(`Z`*J=4%E.(`(A;D(I3IL M0(1R+!%*'9B!".58(I3*T+-ZFT&*\NR3A$J,>$X!%Q>G6;:?5"0?*993P,,( M]$20+:_7YW[9G`(HOH*2B%(2D6(Y,CS$]L#+]>9#<$A*<$BRT`.O3:RB/V2^ MMQZ"5U:@5U;%HH!7)>9>%>G?=`AN2(%N2!6K`EZ/F')50-!%>=#%+*;`OZ8Y MX<#?,Y%FK!@/X,+0[,+4("YKR(BXRZ.D.N:=_:GK; MPEX^:=C*#G6%>(YN M0?3%DOUWO:=B;GUQ4#H`I!@@/2,+D19I&WD"HOS,N39OCXP`5S&XNG%,724O M;,"2O5'?W5:;JR%SZ MA0OZG'(_/6;6`.VEHQWT.J"=*K2'RIZ^2::)Q?JH0S\H;V,F+)`CJW**GO[Q M=P.FWS_]&X$O`X98=Y!?T3HCVLL`D4A+5M-]4VRU3=T MH^J2+JN2=HOA:3H[&VM7Z-7>_L0V>*)X6?^613)'IDU")T,!(\QBI*)3HOS: M>SU%$`18KV66*V]%";-=JTM!=[<1`,=1*OSXM`7,-D07>Q/C`(XCC@_XV&($ M@,"1UYG5T2$_KAX``%<9X-(5*S`)N#UQ#V@Z*H!'044M92'8/KR"HJ0!K_4H M2IKQ&DH9@%ZE`J>U>Y"5-;L$Q4@%X&KW("OKH@D:C@K`U:[A*JM)!0U'!>!J MUW#E`J[5?N'7M48S%4VNWY'LD'WPQ\E$E9$9@!]R7P[\A#W/Y1C/@27)Y(7D MUL72_PO;R,O"X^80W7[!U8285KO)5X683<$$("8;8J(%=]R(634E_$]'5PW3 M]XXL:$*]MPEU.F$=&6Q:X@O?6NU5`WR."3[AS6_LWK2R;GX'4%=P4JO5V78" M11/#1$/,L$*8]D1"1+OYBDT0N>@(\>!^%\EP79JE4Z+3NYWCX<1&Y@E-<12_ MQSC#_`LV&VZF$%9QC2$:ZA$=E<]YWO+P@.RX$]@F"K>W)`'I*VD[''_B!AYY;[`1;M@$YBA0Y MBJ"LF(,5/Z@.5CF4$D"Q!"B"CJUR,:Q\L/4BN)?TF61C\W]K&;:Q0&,DSW1# M,Z;+.TWVH_S"L50=6=90_I>C6BH1*]N0WLN0"Z(4-"5\ZDNSUQN]CO_@M`]C+_3RN7JD2%E:Q!C-N;SYR6H\,R7M\0$`T(/JT M_+\]"P&@71*T3QA;0@NR?\<9F0JM,M`CO+3$-7K$%_RGBQYO0_P"B@6";`5? M&!HIGOI@A?^)F6$EXOO*@17?V<**;T-2F=6DLM#D.SE@Q9>R5Q$-*[!UU-HZ M!M#S.QX"5%*B_^T7$^!I57G9ZJ[QU'YI=K` MUW#*E"UC%ST49Y:"N5+_K!=?_;^>=3!*%!NE2@!!P-!?6Y?.2ZN7)WE^1]Q! M,]"O]L[0IS8RY^3J[=MP6$5,@6HCS_#1PG2A&1!]?98-H[.?V;)UFJU>&0Y3 MQY>J[&Q2E9`58"\KT,F3P^R4E,,,P8H'/YQ5/SPOK$KI,Q6"U0!@=6JP*JT6 M<`LG*(8H+3@XX6*(8(3B1W*1$4K'%Z%T(4*!""6OH71+BE"Z/IO?W13J M>$9M"#8_SN9'BJ<^6'7SV/QN234Z<;`"5Y(E5Y(96'T%6,7!*E(\`*N([GJ7 MAKDP3/SL_S14W?X=<^F8J]<,'NU+-K<.VE[>:W'F2WRK9M^G2_J;YK%@HM@S M4?T\NJ1?7O-K;)I$2/4SD^H/Y@ZZ3;%5@KKA_4W\^0T^H$TBRVT20XJ(S]6% MG_(/42U(//#6N:G ME0=6[DWEPBKX#FV`%6.PHONMVP`G^N%4W1MZ^!=^580T_F[\-S*-1QWA3T^: M%#@13/Y^D.:,%Q8%N7"]FSU[G?+_E'1',I>WEN7@ M,`"=Q(1'\ERG6YOC=*X?)>6_)AA00@%**`Q^1+NI'3QVE+)`RQ*]-P5.^Q$Y[71N8Y4&.*S%YW-#/Y7"W\I0 M>I#3$5^5O#-CL%:2U@H<"F3T4.!I`PZ45<]5J)Z@8!2IE1I5Q)$FJ/ M=OU--[?"48-%-P":B%1"M,!`*T54>]SJJHU7U5"6#4=WNZWH@>KT8\]QNWC9 M+X33*/<`!<.R@J&L+F0/QIX!83FSX8"O["5KR&V[:Y%?TN_1`"Z+QF6A5CIA MAF%U1+AW#XZL(*E\^1N7^AC`2`@SUPE%L!LVGF!:THV=[@#:B30+^NHA$CO`@]:$5Y5`E. MC!BA*931A\=%C/@B=$#'')N.$9M":2^Y7[\-`A!S3(@IZ3T1+F+:+_@?6*4C MLTIM_*^,K+CXPK?6C1/:+WSQ'O!)UI.S47=&>;%[.-"C'YJ%TFH)0ED_;?1'@I1]'AYAN4R@M M-]=_X;N`F&-#3+_)=\M#C-"%3,NQ95KZ3:$LQ)">'@(@YL@00[IXE.7'$,3T M(,/"%-B..5+<`7Y)+Z"(*EI[,HVY:EF&N7PP[&#UV4D47D?R#X5]RLXG/(2J3^]46YU* MQ"7T@V/[+7'1',8+.:.YV31UCA9$3>`12+HO1VL??%._+!<#0$,?:(+OQ/// M?M6MGU'JCZ5Q_G M*67X33*QZK<9EZ"[RE>L5"G!A;,#ON"DD@M2(?R7?VLVKS4W^\R-D&N(FTWO M4@6IYU>&["HUDEGB5JOZ&4WV.D4-E[P;8M&5%[[QA6\U__[+Q_"3UER1[X?X M2X7\<*-)T\Q#"(TO$TFSD#=&X%G^0=:#/[FJZMI38YD'$QL!*[KWP5$CWZB6 M+&E_(,F\P=]8F<=N>V,'1PT]=/^X'GGY1NXTOMS\$36N[Z'^D;%+1V*"T7+^ M:FB91^LVOCP]CBZ]\0*/\H]Q[5I!7S66-JB$S^]KCA?#0H2=&S+8GGV>T,$S2H,<+V[./C)7='\0M M2'KR+@4N99=X2J;8\NWVAT'+3XAOI#49FRUDR9H-=87\ M'VD,^"9IB!R(Q;7BA_O(QT_!%TRP$ M:>[%TRRTQ<-)7K6CLIZ1C/`M.%1_0/8*KNFEVT^BM!>@-&[0@@@,B7*00&!/ MS$W@K4ZV!TF@BM)+3&C%$]0)2ZJ3K[53D_#DVDLD(DUOX:=+JRMB*9:$,(7-UN:'+&1>MF*#;A4Y0HT6.=BA)0:&)2=I>S$Z1]WMZ MJ22I^7Y?B%`CF4<-,9Z@RH5NOY-FU)4_\"0MB3.`UR?^QG20NUN'K*N5I6NSPC[;$YFATQ,L`CMX(J)'NU@FD*22M#Z MH?E+1Y.[L[1"8U8AM1.4_"`HI(BA#J,F*)YV@G[GA4%6,=3%5( M6DEJO]/-0]45,G&@34X+'&!2VTEJ?M`-ZXG]HQ9$84AZ"1I?'/3YW!0>(KFD M**#=[02CWH+)"8DI0=WW^5!8DH(:0Y^25[#[55]J\702M'T[Y-)'#78@04$! M=9(<^FXK,T%[E%N."*B3H/1Y/HW6WQ]Z'$)I2(X'Z_Z$D,T'S#R"3#`!X9@M M.-IN:5;67&<_P>CP(2AFHJ(L M%H*2[R>E_UK%<;"I_"):P5EU+\>?-40^D!WP.:G2_1_W^[TE0.GEG&!_.N%*K8((K('Q MT!PF&#LQM)%>%N,W*B8"W6%/3@G7'?F&]#\Z_=PFV-#@S&8GI%160K.55-A< M$"ON$;/@"=/?=,F[$$^\:KD:,+/Y2-HJ6[N@F88OFN:0Q!,L-=\;'$!S1-S] M))F/IIOQ4%QG\@F9[DF?U%(>A(RT[^1H\&1!ZP,YF9N!A&*I#LIYP-=`M7>$ M:NC8,\,DLY1>QGZSO.<`E]A:_R>2W/#8Q9`9$JI8/9GNJ:0,DFPGD^@_"I

/Q!ZA9`7>YAPGPB[!8DPXBSA@82&A)GNV&.R,&,(#43CWM7I M!=E/IJ_;XCO=/<&_-]QA%(4D-BB#HF#Z.X_!*6K'$8>+*=4^_V'_+D1:S7\P MWX7MM/*MM.;N$+Y7[4#\MUQZ7A]V":_J.`Y3>!7M=J_;$>(9C'9\%)P6&I)K0`-M/L%!7)Y@$6].!:>S[< M1RCE=FU-EJ0`?M-L775J#%8*8#%%QL@[#5*7+BJ`QQ3IHG0\QBS35>N,/.TO MD^HKNV*0LO50&4D0_`WS0R0D'3?KAWKK["/ATK#LQPGI$^56K"+S396QGC4T M)8=]@Q],9ISLDDZ%#7KA!@]IR?QJ&I;U9!J3<-%_*O$EM<,0 M@B5POL&RTQ$GGX1:PWZHUTH<'4A'IJ21:D-EKNIN*V*R2;9J)9A#1@E%@D*O M%R(NGH)B"(X39D(I8%L4NH<03$IS)5,F?5&O\!+7#+=L,[]\$VK_.MUV2*W$ M#%\$K7&B33H,U@YKX0RTCI"F8:.!K[V7S#\1:32<6ZA)K93:?!"S^\<^F,H8 M<2:U6!)"9QW24_FX("]3V/Z>P^0F=EGJA9KR[(R9EZ@XB248DDZXQVQZHK;G MY'+(*L&.-$51[$?3M1TV/V5Q`DNP+,UV3]@SC?LIN\5$8$\OO\Y+:JHD\&+X M@$1@Q'P$Q8DIZ4!P+]3.,H&@KY*J$\D]ZMMF2]OR9W(2$[O.=OA,:"K1)9B+ M9K<;5!II22F8A3AA)UB19B]LH#.RL*DXOS<4=:+*;@5_?DV8U*FI+_#!0O>H M80^A+4:624V;UH=MT]/F"7J$;-M[#\WCQ-=D?5"KY)5B2-7E)(Q=!9IPH MDXX""WV?+-,2NU&KY&#V@Z$;0?6:6X4FM7':.20>3T`AY,8)-\D.A:U0)FJW M"F(D:>AQ$CA?H5RHA)]BI2!T51T*AA,>).^DT,M_?HV&S4%\DG)/,&G8W M@T8A-3B*1'&2Y1(%49I^=I*Y1S5ZX87^%[-`GR1@$ M)36M:O8&H;Z/M4L2/W*%V0NDHUQYMJ3^5COL[HQY&&EQ$Y*^6V,":=[;!Y$Z MG9&SHV]X=J;HP2&9^`O)4N4K57/P#PGI_5323'DR3.RV5\Y*=JK*82IN'M+L M$@K=CM!K'D+7#5S6VVONS217Y=V?8V;2;OXU6X$ZD@1"BJ$[3OB]#'3S MN>G&@=HA69:D'EF[5B@P8!YJXF26&,6&-7DL-=D[2*4165(SK&9WT.5W'>^, M#:0.H#U&P(EML'8$G(=V[.F^J>0%TA%]3'+(.\'0#8+"CAN\`$+CA)O>[&4A MTM_Y(M3P(H3O\?J'%G<`_K./1MS23_SOCCC2.G!A&O\;6I_XLCC;+?;>."!S?'CD_O0 M]`_\Q*UNO7@:TZY%T8D(]\0-Y/>$"=-IR::DO(NSG!,SMB$F>#E[9C$^<8_RLBRO!]6&X4< M=H')9=A3=E-*QL0=^M6QR!/PM>?<'"FJ+&D MVA?XWB[O47SZ1\*SB.]:L:%L=[,](:$I.8Q,WK`K+;#XWS"]^%D6^D`_*$/K MB6I:\0)";VZ/-+R(UK,30`N&V\3`%B:VQ::*(>*NG$TZ#L\E<0ZY M5S=]@LVHB5<<>?`:&3!WA=)ZN1&PM'GAGJ5:MF^"\-*4)6N&U0A>5IIED"G2 M'`5MV5R0A+2[Y'Q:RK(,XD[AN?ZNVC-7K\V0I/S+D4P;F9:K6BRL:FPTM[B? MR,VKJ7>?L]8#)G*[?G%$`6^O_YDCE<-881BR[]>-?OO`_:9O?_0>^W'SR!7Y M1*N[B;C5!6?;+U:7GF&-\DK^(L!T5&OFTRP35<=H]I(JENTI-(-$.MQ/J[M_ MWLK'QYB,3-*G=LO@]YDJSUQV=,/VI*]@*A0_YTAUG[QB[\R;"9-P8-E8I/Z[ M/(6KP<(IG59,U,0@=L^CRD\)]V/H>3^>_6B1)_VXHGA+U>99'\G#R!_$XDX, MTLB3H,MS-DP2G%BNZ;8DC1"V59@:292X]M0@+<17RUBR;5/%.'%OWRR>74\` M:UEWZ>#'J89"%@>QZP1W/[E6U7`L_&SKY_/R9J2P>&0U2QJ:V!7`R1/=W?!IA,F6,:JDA84^<8\X]KJY>_QVSI$D`J9G<[4[%_O) M>+[]^FL4'DWEA\1X5!?H#-!D11;U>2N,_[C!O.G$OM.`, MAC&TL_@^<>$8%,/`-N:K"[^M:.JUML%LC_]A-S#?2AVMN6YL M=JXOAI=___K\^-O#%9X^69Y,9+DLM3UV8QQ2#F?M1B3),ULMAW-548AK'>"P M7?!BKG\"LZS>,KDW2>4)0^P+3,\^@!O`#>!FUDQ/W/_D-=/M!#-]']X=K&O& M4[/)ICHK;A8CV/M?Q:JII^'5U>W#UW4*L;/.P%?/:H1NXL^Z8HOZ6020GC1( MA;->?T#]+!Z_[3PLQ$VRG<\1)2^G[##ES5M1-M75"Z`\-5>@5"+47!/0#F@_ M&;3GRE`?#=PIL>CE1L->TMHMW#EE[RUQ98MX92N&XY:CU#_%!6;^T@8I&>5" M41Q39)X08G%8*+!04N4#^BW^E!<*)=Y#N?F`^A-X-#B*-+`7MX;]JN<4-P73 M\0^[@A2S!_`&>!^WH2XWS*]_JFGPR6A@KY+T9/&:JMS=0X;F#^`)\*1X_H[? M4)9;Q/T8.+L*==PTSB']ZJC<;3F&Y@_@"?"D>/Z.WUI"+?4Q*"26RE2I\=I_ M$L[:_>[/U,\90/)T("F>=0>MDX8D)781ZJ2/1`^!KWZ00NIWA=K4$2`3D+D? MF?Q92ZC/>Z,!FY28RG)#2%\WS%-VBVH]6T'7[A`M9RO*#05J.TD$:#].M%.# M[)]..^="B=4N-\#UC@T%&_V>LJM6[[&(.CL'57\L@DK!1"?[1+%_TA$,+`M8 M%CO+HGW6$TX[Z42)BP`EQTSG%PLYW\?PX8D*^:>RR@7@#?`&>)^"H:ZB;_70 M?3GS>>>UFZ M2CP3>WE>.P2@!=!6V/&\)T(SZ?IM*11)'XEF8M*_I[HU;J=5FX("K`)6,V%U MT.Y0/YG';TRAC)J&@A,H+(4R:D`[H)U-M$-'Y?KM>!6%U9*[&7O*3AM4CE97 M.5I0\)([@5UD=:EXUN^?]%MK8.$PMW!J62C"6;O:/9S]:R%0G/^[(:SL*>=C. M,.XD$L8P@$P%F9\;6&ZK$5WQG?.MU@^?./>:IB8M#<<^GZCO2/G4X&2D:=9" MDE5]ZMY'_EY(BK+Z>_-\<_-)V5#C_VAN/ZYE_,M'QVI.)6EQ/D)3LHG^C!:& M2KK'S6,X&4L(__&,)I\;3RW^!?\36KPX-GCA1?0^-SA5P7,AR;:JO/"] M7N-+"`SWP^>OMQB56/3XOZO%[DU%&/!GWA=GW(A,'=J? M&_]T+%N=+%VJQC/$30Q-,[Z3@WP>7DRT,)&%Y6=YKP8["QWUXR1=X6R?J\I) MMFVJKXYWNVUP]@S?S[TZEJHC?+WE38>%1S+);QQ^G&HH%J?JI*#"1@KWDZKC M7PS'PL^V?MXM1"Q,<)[^=-5-6L%]XE:WKHT&67QK81*-V$A0/`40[U/"=ZX. M=K^X?;BZ)CRT5*QCO]U>C7\EE[=\6M&;DCVV;X!>NS(B*%H;D=45=]NKD5NC]T"!K`*,4`[&S MP_H?2#*W[%_K"E*V?UXA&\"D3\[F>D^/-4#:[;V2:1XS68)I`+"$/U+ M6M@-JK`72>?\YN88IC_3].?)/;&YO(\B'9_N;-2(Q$!P-(J2"2PP9ZX,]='`G1*+7FXT["6MW<*= M4_;>ZJV$+:1]WZE4PE8G+(C%8:'`0LE;,MYOP0FT^KV'C@3V:.E%1LWO(T/P!/`&>%,_? M\1O*0-('2?&L.VB=-"0IL8M0)WTD>@A\]8,44K][VJ]7IX$]0&84 M,OFSEE"?]T8#-BDQE>6&D/`RBA![T)Z?DK,5Y88"\#(*0'NA:*<&V3^==LZ% M$JM=Q:LG@HU^3]E5@T[ZU1V+H%(PTR?=`0#RP*6Q*)"_JFL<@%X`[P!WJ=@J*OH6SUTW\T#!<\TSB#]R@HJ M2@&>`$_ZY^_X;244/!^#0F*INK2@;>;?S&%,JH:2@X@<)2 M**,&M`/:V40[=%2NWXY745@MN9NQI^RT0>5H=96C!04ON1/815:7BF?]_DF_ MM086#G,+IY:%(IQU^Y`6V'R6\+S['[1F_?+N>OA\CB=@%F0PS%^($Y>HW>&C M_G!%38;'TVPJR/S9/.=;K1\^<>XU34U:&HY]/E'?D?*IP/CM6<2M+B?"3/D.)HZ'$R M0E.RZ?V,%H9)SGW=ZA,R^;9JZ!?+U8]C]&Y?:(;\YY>__N6O?^&X7]:/>49O M2'>PU&1#M_%%SVCRN?'4XE_P/Z'%BV.#%UY$[_/+:J/]"KVI,K+NT?P5F8Y% MGC.R)1N1@2X<2]619:W&M8;OJM7@5.5SXT:2;55YX7O]!N?HJC?2;Z.K!J<@ M6<5@M3XWFF+C"]\5R1K:F;5K*WNFS,T9UA50C]OA!/?U-H][N!&8@@-S]'):R( MOIC`D=@=M*KBJ$BDM1/XXEM"93/E2R/G9:>3P$Z)O`3740&\=%,K@1+Y*!)K MO83)Z7>%K-/C%8X'.1E:CWKA&BW!F(MB3PS0[A&6F=RBU%6"`>=[XJ`8<@O$ MQR#!:`_:G2)H+A33@P1+W6D5(N%A:/0,^^+ M,VZ$3'7"^=+%;OP5>*`79;M!:=H'?N)6MZY3"R003`K1-H$L#O)\!&WRV^&( MV#8646GN;[=7XU_QB!^$CJKOAL3XHV6;ACYU0__6!S?4VWZ3(P_P3\>RU4DO;\^JLB)4NR95MVI)BV"0RF[5@BJXH/BRRR^-"/J.7UZK;GS:[,=4FO91,T M>;+$%3]Q>W7]7/C[M*5F*IR^>7E_>WOQ\`1BV[[K6F-*SI5[Z&/7M_=_?E9> M'>JP!<#<2MM",>)UO[D'5G?Z&!:XF%;4Z=?9U++!BY-@DR6YS7:PLL<)S:I3 MK+:IS,=O0V]3VV;[IR/L`X!2`**FS>D>#^&I"8C7WRBY:#?;]/V[S;)C;KT1 M!>Z8Z^SEY(RA9?NM/G]"S0KL86H>0VO@C[W@9_8@SJC%;/V-[2'!41X<_XX\ MDL&&*K$AL9%8YHF,0[9@(`$B`5($D*_$GL7'K@PN5!1CW)%0>;)<(L\VB=YZ MPE,05:AJ@0,RVEL[:RDA*B%:!J)-0QYTDQ`5&J*&*;VHA*C0$&VV6\*WX?Z3 M*E1'FU$4=?P:X%F+<>`/G%`YQKOJ#OJ&0A'4VR/RM@IU+O!/FKZU4]H2JQ*K MZV&U*7Q;2JA*J'*W>M!<6B*H)[%:%JNM@_:K@H0H]6^,R$NTMZ^>2$Y)F#62 M8ZVAJ]I!7]DK@GH2F\785#OREO5MJR>Q68Q-HZM*;$ILOD>_&BX&*\*JT6CJ MYD%C59!`H[X+X18%'GQ+1!D34'IH!40Y57H6=6S%\OI*WW$C>:O$UM438!]7 MF`618_5,W=ZP*A$I$2D1*:)Z$I$2D6*I)Q$I$2E<@%'O3L:?!+%(^HKU2@+K MATMJ[V6.8C.7)QGBEN@B M',_C0FTEM;>D;MS[1A2X8VZ-VGL3/@B1[2'!41VUM\3&X6*C%+6W!,CA`J0, MM;>@^)#S0SD_%$H7R?@I&3\%UT5"5$)4<%TD1"5$!==%0E1"5.9]2FIOT=03 M(.=Z+?V@B3]%4$]BQ68Q-LR6) MY[>MGL1F\9BN'3CQO""!A23S%BWB%$$]`?9MA5G_D+2@(J@G$2D1*99Z$I$2 MD6*I)Q$I$2E<@"')O+<>:HJ@GDC+($*GA';;:J/3D53>$J^[@5>MH9NM1E>3 M5-X2L;N"6*.E-C15^EB)V%U!+%[PH34/^CS3%JB\1,]VFF[$^- M3Q1YLC_-V2NM!0M+OM12<$Y^A@[&=MWS@SX)&`]T7"-KE\^EI^,/W4GTJ3_1BD'Y/&^\?/$3U]L:SQYYCQUYU<.Y[EV8[E MWG@#Q&GH^-XS^1'^XOKV]R]__]O?_Z8H_QC[U/[\JP\27/J>30+OJT-MUZ=1 M0*;/*C98`KX\DL$_CQY4[1O\IZN:\>QK^C>#?SY2G#[8W+)#I_]-ZYI'7V;0 MM#%'NK*`9IP7R(DJ6`Z:;CS7=?^-C##_H9:]U><5=:Z:BR;/*%Y?]Z#PY:N;R_N[QZO"M95:U. MXSQ'-'_*[9,A@N>@X?_&OY5M[H4<^[T"CUELA@KTJ_:*@"<'^JJ"_QMCKVXH MX9`HE_YH;'D396A1A?P8,Z)OA48]&EI>"&Y`"0CUH\"&NGP/OQ`D&>8+/.25 MN/YX1+SP#,KQ*/E/!)_=24-Y(U#@*_0ZJ-YRO)DB<0.:T#/E:T0`\DP,UQDY MN%CD14@SJ?@#/+#7C^R0(H=,7R$65#J!NAL@PROQ(I"'U3!PX:'(8@M-H+$S M<&P+95`&@3]B;V`5[%^4&=7T_)`7^I\(!0H=*"L<6J&"F^$T&D`1#NB![_6( MXH])P+R@Y4*I_!@AXOA,>+T"184HB[_5>4PH^E&HVGH M#555\R,.ZF=!#>!\AZ`>"2C':4?7VN?UB0,!:%,KD"94$M90Q=`:R!!JY&WV MYKBNXA$P%5@:D!6-"-,!$!H0BT);(%L,"OQP]'-<))R`Y*V40A3`2,F4!48!'Q)$'+U$8(;$8#K=PUA8X8CH>[Q0] MA*(-ZM!!Y&+!%(86&%:F_>),?(>S9&(IG*Q98`)D7.(HJ$8PE`L>.P7S&'SP6B%%T'/:UN4=UGV`88AYQ4Z-W95?Y""L%JWUV@WF^6\7@.' M!3]"<<;6A,U&F=>Q[2`"_5R'NP^'^[J*I6RJ1;Z9C10>>8$F`"?VY@??T?!) M4U4_8C74SKRQSI0_9RH.L.F"V,M"^,&@$(UM?X1/,4PP1QFPZ4"/3'R$4@0@ MBX(`W31K_Y[E,GCF<3*&/S+7G?6R@>50PA`)(P%-ZH1&&*0VDZ5>!58\F`;C^@<3W9.5#?CZ`\JP>17G8@R(S8 M(%$\K&2%!BDMY<5G5N.QEQP(JAX(UAJTYP9J9S1V&82QC1P`\A0?"$&&I<@- M'0BM"_E%)SS2'EU$K#,`P0&%4`OF]I#%X%9 M/`J5P99V,IW.6'U`/`@V,Z^9NM:!Z[_%CCX%>[8O8-'I+^#_3AAT`Q]G-S3D M\RV(,]AL+)G(L_+(#X_1DDC!W#U!\4 M3,?$7_PILXR3+/DD"T6/2:,M7-Y1C07+.ZTCF!(X_(W?G[X>@4%MZ`8N_>?1 MJ7'TQ6B#'=1T22JIJ:0$S8P$K6^&6B1!>[D$$%6]1X)V1H+N`@DZ*VQ@OL<& MFEIBD:V[P@;M5BD)&*O.`R?561<*.JY'+Q-"T\V<$)G*RLNQ&A#PAQ5R--\O MQFI4Z*J^RAS:N^4H@0U=-5;(T2IMCSL2WGC@J9/DZEM' MF#(H,5<(HW8ZU0A3!BLKO*AF=-5*A"D%F!4.U6C.=.2EPEQ9@8=#Z0,)GC!G M[!=,);OP^E_C1++U433C;;_!'.`;*SHKJ'[TY123%5,I5PCR/KG+`*XKH-PE ML*FIXLE=!L::]B%R)[F2%SQ5\HXM==\/V*OW48BA(<[KW@U[+3N<\.S+^8'- MU+IZ.],9L51-&89BD2.9Y8!3N1X9@DV#9'CF24P-G8PGED">V-U/--MJYV. M\.',DBYBE`AG=+/5U80/9Y;UIQ+AC-%2-574EBS5^4J%,QI;6JY\J_+2^R@HFBM5GFC9Y/<;7L.+OC-\L; M6B'T*.4FS@5\)O;0\UW_9:+H_&2;]KYB1*-?0\[$(U&H^E6 MLZ7\QG)^Z-`9*S=)OM1#%-A#S'JZ>`D(2PE0CE&@3.G37W)UO#GA$%N-;4SC M&TD*UFFR&8E?-9.79.V`.8&S$:)T;@>;RY9":0\1R>AL=YBE:<.,;^ M!G\D,.$XQ0R8L37A&_J8?N"RI.`W^#Y!EBJ;V:W2S+=\'M)/)RAJIE&0)8M/ MZS.M@HD5F$.+R:B$RG(,MEE/!'"9'II=7*>L-RP_V@SS*) MF.D106%@>13'V-ET_&D?CKL9"3$[C2>60XO.-EN:YC*`QP91T'.@4T,'IV/" M\!A@;DPT.NWH/P=1S^GSS]P?0!5!/C7ZA7B8+>,'F$Q-[(G-,H^SI2QX,W8> MV?=9>BBE++-G4*H,]LZKPQP4'DD(0DS+@3X7IS['[B9?[VQZ-\WD@SN>[49] MGFA(APV6O,/2NAL\*Q7]'*9M0:V\;X`$8&G\W8;:,:^)1BQ'G/-:@!).+V)R MI"J\$J_O!SS;"5H4RGCQ_3Y+$6/IEN@J9[(]4[G@E3Y)LD-I@^>&)EGK%IY8 MF/[*P6,Q1P#.$7,)>Y;WG2>)C:V`E3S"XFS`'\`3O$!`QIC9[H5)6M:;%028 MB!@;SO'Z9.0E0N5]6WHT(IR,6<8]RP:#8L`.^#OF:5I9)/.QP($68KW[%0%0(&3<-GSYP%"W;WS^);89=:K-*P(-?%KBTG4/ZPW(AYZ,M< MLS^GS?X1[5GA*=M:FS:SF'++F!ER9XA5E#Y>TYE9&9I?JLH_WC5_.E=^N7_\ M>O5X>GE_>WOQ\`1UVM!3K3$EY\K]'U>/U[?W?WY67J&O06&KEZABXR"#1-$2 MU0Y3R;7;\S04EW%DBV$LAS,_\'#`E!LBJ"<`J:4XW##FO*YFND@CCB!Y`RX^RV&EX$AM-4O7C<2S9@XEL,%`WF!2S.C(=9,9O[XPVP M$U<1%O@Z734;>G=KO&TB8%X09U?O5.S9#RWWD(>TE1W;@(Z-1[BQ_NTW;BPD MVSHO<#UU3-W6M(M`L[N-C57D$,VM.L0/ZBK5;FSF5C`V2D20JQGU+2V&Z/J5 M<9*Y,`XE($3]Q>W7]7/C[I@N#,T/4PHKC`7/N M@5*L$?L]@;VTZ'#/!V7AU9,+A\OGCAV]*WP;[G\@7=_]FT5^Z2K)/.*#>F'R MT2&OKHB@WAZQXM>[&M@RC8;9DJN!VW=BB3__&"?VP'(C#WGL$D&]/7)3]I= MB+K+G-PXY"%HJZDB8LVI*DL5$6:&==SF)Q6WYLY$0+@@[JS>21:>C"W8BCKD M84P$];:8!R+`S*O*A([C+M[^W)(3L^U[LGHG9MOOW2(,6B*HMZ,!8KU3JAUJ MO_WW1/7.J7Z-\X\.><@10;W=SU>H=\W*:+8:6L<0OAWWZPKLNLJM_VKMBL27 MJ;EL=R-+\H#W>#D#AQ2EUL(_ONVP?%Q&%,.);&C"00,%)Q0ATWS3ZN_[*[KK M#S6(*,%+TEQG0!8*BNFY50K3RH,2+Q&4Y%;5@S.;A3SEFF'L,)21%16?GE08 M#]%+AF@HOH*1*JA(PR2Q#W7GZXZ15R54HY M>\]HIZ##,>,FZ>21UWW,A*G;`O!UQX) MWPCQJG48!=>35EJ^482[FNFUL%#EW/<.N@E"?3` M$7.@_#Q%+%Y,]97J!)+]'['QN6EW>ALZ]E!YPYLNI^^FC^%A"8?A>PI<<[N?HQO`,8W^?=LD9D;V:'`<13RR]?]'G*SL63[N*>,K.`["1NQ M7!=/ETI'5Y')#OLXDM90Y19OXU:,N)PSY;_)),,_.>6B`F>3H!S0SQNGTM8P M\PV1$%2"A&\$N=[0),D5YGC8PV5R,UZ^^(Z+^`I,XE%"<^;O)?=M)M?&?OP) MCT,3\\V/<>'H,A@`")/3QCUT1");\]7 MSDD<8_;"/DB+O(?\PN@I>JN?.<[?5KV+-ZNNQ\<]R^+]9`])/W+)_2!Y_R+U M`/272>;;>SB]V[5P>@O7O25)EB3)VIMM*TF2):1ZN[]V+$FRY%:6),FJU3U) MDBQ)DG48F!?$V4F2+$F2)4FR)$G6]KM*62:KW5G9VF2-*EGG&OO4SA207)-% M'Y"SZ8+S2>%[6.M[%K@ZA['`)2Y%)RP4TNN$ER*9$"4$DN)=*J MA`CJB7381>A5-$DN)8H3D^12>^.F=O),GM#S+$DN)8B7DN12>^2G=G(Z).5)+F4$!N1DEQ*DDOM-,(%<6>27.J`YUB27$J22^V-)Y/D4COMO,2: M=.W:E&J'VF__/9$DE]IA/R3)I22YE"27FE=KMW):-\I'S26S7EF!=Q^%#YQ? MXX%S0E@O4!@$M9PJ9BY_53,Q9U5_]O%SFWV>R5_M'BF1Y_`WQE%`CO!\O@/8 MIH"SHR_JF1[+7J+ZV3/F!5F[F#\23FY`RH#0D-Y`^$WZ]P'^BYK?11QUOPQ^O<)N\@$FB8N,#Y<^ ME+X@]UC/Y![/JJEEU/S]Z6M61_7HBZ87ZK=:DASJBC*O$_#.8/=BY`>A\Q>: MYF;*&7;!4X!SREW0>V]AV^G+E6HRI2H4;;;%KAVHG=PZKZ0_\^COC%GL%HG% MUH>DY387L#[M M_P7SN374;RU5WUCD5ZN1!^;J@?^F.8>=A#SW?]E\FM:__&Z(HBBI(5 MJ'?QPZ$S]NHLM9=9!A@;Z?H.,]ZFFP'@92+\TS8LUUV%-+W;WLAT!?J]PUK: M%FQCJLMM8VYL&VV5-UDT2[]$.WHAGT#@N`58Q'\0IZ^6R^COEGB9J@VT?![8 MT;N+?=0[--S4>`\!:!R$DP?7@@J\?II2_H$F6S[+;)F&V6JO;[6%JGWPE+IJ M:QE;FI-OB-J,S[NP&4TC?>`9+!]IM.;RP;"K=Y;,E3?6<%/389Y/4@8@]];W M7IY),/I*>A_:+Y?/K=OQW+)"Y3:U%PS`_RE[PC`),-/A`NRV?E)]VU4ZG MM;[=2BBYJ?V238,+QA'\D:9:/JDWFBVM8ZQOJKP^LU.L&^\5>JT?3`J8&=<_ M=&[6<^B\@%FOLO/2JQCVDI7M_''FZ8[9[!(YP*!HXRP^L,S9#^?7R.$C#0/H M_/C-Y,?,TS]LL"^0/2&_N*:;NS^N[I[O'V^NGM:ILM:U^O/*9NPD&;^`B6EE9`%\R.!J!#Y+QG%*F"8YZ%E)GA MF#'Z^A&%A^G)1_"-KF%/+L5'L8KB`B()5G$G)&W,GZZ-2B$UVH_/5A3Z4R$Z MPI$K++3(1OD+22NLOWFZV29P.[-/:G8JWL_?IC(?G[F]36UU$[HF]`+`*4#1 MG%,]\8ZI"BP-URG83DG#'T;*_5"V@KM4W2;T366#;_ M6LVOB]G\0OIHP;*8B]PV9C'0(00B=`+QR&AK9Y5%R/4503WQS]%4Q+2P,5'( MQI8I,(W>%!X0$N_[@?>MX-O0).O(]D?PZI+BBT;P1^M-P0O^`L=R.5,KWIOG MV'CH/Y!<;MM63Z2S914=[JB>XZO(=W7U@^9U$T&]/<1N/5AM=3O"-^;^C[/U M1LI_^L%WO/%R'/@O`:$R4I9<.B)=5U0?`6>1PVL>=%PAX2\L_.N!^^DAHUV0 MT;W>*'J'9N4'$G14N"(H>$PBQ%)XMZL)#PV)_#U#_E:0KC5458;KVQ_0ZPW7 M;R%$_ZP\$EP,Q_S:0/%[@!82$@CBXUS^0Y[5R1AF7^AP"TQPW&PV#YH*5Z)[ MK]%MM@\:W8(,X#(B%\"1U7I]]B[0/PMS??96@QJS*7?+93>1W615-S$/>I5K M7]E#JSK/RPI.CO-6)+[8QVVK/5N=.P$=X.E;Y*1,KHEW_3<2X(EGVZ>AX@?* MR`J^D_`LH^'T$_)8*@Y5^B0DPZ0*OE_\X=_9;[6PE4J5_49+:=AN2BRPAQH() M-SXKI+9),^"^@ASCO!1R#+47"]$%$%T`T070<\E'_F#J2FV)+J#?SHZ/CC;L M_^XX(Y%^%KLO!O:J9[`[H)!OF\&1W^XOW[$1-TS`L/CUW8?FN]\T`%@]Y\'Q MU'!["Z5EA&JL%ZK9J.\CU9W^_#7>&+G]3&GKA3K7NOE")8?;5Z;L1#77R]0Y M[^TA$^YLN;9O7):JT7JK7">*GA]A8J.U/M]4*]7J#?76>GV>EL@-%Y M(W]ZY#BOEB(['=WU4H`,*Y"S7HS^"(D/IO#'+E/2VP"8U@HGE!AM3XFRTW.^ M0:+VBK6^1J(O7!>\;X_NX$?=NGJ9<5OP#&E&*R3-J`\=^-PXEY_3HG77..PZ M&*Z7E"MWS$BPF2.,\(A'EW,4^BM(,['FM_H<_UJ>KWKW._P/0C6^?^4CT]"M M2XY;ROM"\.F#-?\J']WV!0X.ZV;&76]^:^FV!S)<_>.;,[SLI_EP/N/]%U-D M-%OC]4&S=KW7_*^?-PI=C'9_Z"Y'L@V(\?OIM"9HH$Y:KUNN3H#P>CNTF.DE M=;GC%A+@W.J@S]#5;8$B.[;X-$_^DJ/2FIB#`&QUVZ]2*?SAWH-A+V'\S-+H MADNC`4NC5!2V(.F!2W]H:!_JC:0F60%3*D#FH5O)PZI4H2U5:'Y`+:(UDRM@ M058H;+5T(L'?:.X+$[PK!>_@C#?KV\QXY*$ON3!<Y.%+"U"`VO&C@K_,F'_BS@E6I!L9>*)*'0F*[GF MAX_"T>=(DEFM'NGV;G`+\O_)^C>7[.I_OEW??KVZ&>XR M^JHV1-S$**AS4#"_%PI5%#%AH'O$3!BM+_GX'H\6%Y&(J44B5AP%&%%X'0Y7 M4+7WXXG"2U6+$H77$1A1X65Y>A1>9-\3XNA2Q0DKMN,OSR]_\DT+$T-ZY%@1 MZQ%942E[,^KT4#$!G`!^K`!7)%:7NVOYL^_:IN>[7/;IQN8+?B82+M5-><2/ M3N[DHGHG_6"D"NH15+>$:K>MO"V//YB6_0RO+OC$L4;,G,Y3`8 MX\^IMR>DSBF*(U!>.*((3`TC)UOI]QSLPABZ-=OH'ARCO7HI'*,CU3@JB4FR M6.&(29(HZ]2BO%*8TFREZ8A)LMRF!"W+RHVH\+(D)DFR+S%)4F>8F"2548^( M]LKL5)TXT9X*ZA'`">#'?A>7F"2/QJ^IM?'D&![S(";)JM4CJ!*3Y.$$4V*2 M/!H/15P(1,]'4"6HJFK+XP^FQ"1Y%-Z)4GUBDB2HGBI4B4FR^D!*3))'X9TH MS2=V/L(J855=8QY_*"4F2=6>ZZ,G^8^,68^8)`GOIX1W8I)4(*X3E\5IE1O$ MKD=,DH1UPCHQ21Y-""U1TR2A.[C13 M$>0]$I,D+11:*,0D6223Y!'P/>[.\OB[ZPB19GCLBX&]8';\'M&8?)6D8;[` MZZV\W*?Y<#[C_1=39!@A&^^8;YO!"-_N+]^Q$3=,0)/X]=V'YKO?VA+C6V@H MY2U0N_C!;SCM<_C8]WZ::NLU[?6J431^*.\Z\4S>?IHVUVO:U:K1-'IB(CYE M/RU;Z[7L5*1EM)TU/@4!#'[',CUS7PBW-ZCR M7+6"O&Y72:^KE>!U>QM\4;L:14OPNNEVM8*][7M_@@BH";HE>]WQ#BE21 MU]5*\+KG&W*D1JN:H)J1CL(>8=E[<1;W4X8^CJ MML!A'5OD4,OO3A1_WBZ%*#Y%_VU8L&(#,O+@VD%9+:O0;:_]D86G1KT$?&O` M1C+PJ')%IO*<]G6V!/:<65X7.R0KKY]I;=->KH'AXX,L\WMGLEQ\B`O'WSR$97\AV`^ M(\/&>`O^#7_;%AZY+P"Q.7W\$),/^[&5 M\^W]D&/MEDP!Z,5$N);@KA@^"VP\1$!Z&9X[)GW05O#ATPH?95/O2LM:O&&:1!Y-*.%6>7 MO@3,?WR;5PVS7IM@=JPP`W?6G[FFQ5J5>S.*FL&KWEAV*@"I$9\Y`B$&9D8)_G+`XNR)V_*=6C/=]6SNUF`87SACK\;& MX#[ZGN>:OGPOB/!GB178;06S''[+[N?"XU-!N"CN!K?T("UI*C?8X".--`=# M/G@,-RQR5S#]T>7P"]@T]"ZQ;PG_-G&?C3PEC`_P$^Y0.F-#A&'0$EO,$?;& MEJ^ILYGCRL@!W@@D,EWF^)[PX%2$=7#Y):]5:*A$3"_A>K<1TE?6PBL7*64& M:TDQ,TW`(D=MYOKS=`MPQ@-3N1P,*C@3,\L$N_K>Q''-?R7S!`KV,RQZ?8;[ M8'4+;8A;I?`W^"LZ-@X)9^R.3P%I>-DEL,&1CR:<9@%>?$S&T$51X6BU3XOWC MFZXL\1["1SAP]?P!9=X4EFN-75N6:3LFC/(\,8U).E\#!VHZO@"_9N&#`Z-$ MZCXQ^9A=O7##QV7.!N.Q"<&8O?^"R]#%7%G(+.,(MOT+K!>"8 MFNIB.O&A]_BJP(P#$]4`@% M3BUGS&9FOFM,=$ROX@614"RZ7*/[4606"F3VP0HI%H[ULWHCK2\:1@I7DTO1 MABR!NX8)(L]<\!>%+X@U$@3,Y"\S4Y;&;[H@`B\:^F5(I$*CIFH>F88:AALD M5]&R`9%AHFS#G`4)A6NYC%R+"!HJ23-GX"`-$`XG,/\.+,!AJ5@H2+$] MGW9FA8:R6,XSZC7235B:3X[E3SGX:Z190&<-DNF/$30P6LG.XP3*0VPFI5D3:>5[@4:OUN@U:KU&;U7\ MN@CL=2_MA1J['%P8/GI3?$F;YX\"LXA5H$I-JG2PISG7.L\.94&%YO"=VNYFRHWY]K)H*Y`WIO,>9>,%6#'4CLU;;??(H%4W^,= MH'>^Q^T-$G$(F!A^*_-O[]G)]V"Y#16\N^C!X$7OE&CV,]N^W_V M/WVY8OV;2P9?WGV[NF1?KON?KK]<#Z^O[G<9\V`I:F(Q$XJF8\6:&5!COT9A M*6[*KT8>(KZ;*&_IAMF9M?`2Z-V7=QK!P6'C"3R&,`4&B3!'&3L6)%>8$[V7 M?2+'%W"T^.D7%:>WU+0A06%D<`R6>01&H9^0WB;*%H*CUWI#5/GE%]WWG/@2 MO?:/,87VQ>#+E_[M/4AB@#GTF>`?V0`\U^TF`+P M4B=CT?U?$4/+LG(C*KPL=WDE0VHRM.2JU99F)FX@*6??5VM,YM_)_*]YK_9A M+N^3>(W7T-5'LKV;JBI>8>.C>0&+"NI5^!JB$WC'4*]UKCP"".`$\'U>HJ6= M](OB%0G=Y;X\.[PUP%QGKEO8\ZO*XBJ\[_L(K;R2KD#RIH-X1^:>2\_S*6L($58+J3E"M+NM3`:J*1-*W M*4D-9XHD!9*3[I33)Q74.R+_5&ZJWZTK;TN"*D%59GTG#55%0FFY1>G`F^"# M:&%`#4E_Z%;I*_8M*F;LMY^`0RT8M),N&`CN)P;W1OVD\:Y(5"^W0#Z@9/Q$ M:HT"=W*658HHJ?YA6Y_`3>`F[E4@/H:4J74.86]20TO'%.\)8>1 MDZTT%]HK"A%$0>1>11 MQ%*C`DW)2FV)/*K15`]4:@2>90"H93(HZKR4,2F17`_(;@3>90*49W(HTZKUB!^ M'>+7(7`3N`G>/M+Y:6$:M1 MAEC7X:;]<&)WGRQMO51:MY<2*W^\O:7*SE5S`[[:K5=()?=GPI*^>C%,P8?Z MRZLGK;7!E.G5N6'!'%IX:I>%(P;F1,"_*"9'-+Z6UYX)"?WJ9UK;M)>S2_CX(#>=G,D\["'.R';+H__RA6>.YZNO?_'M M'C2_NF.75[>#^^OA_9;#KY@S(SQ5L+&#YS^9!@QNVDP?/>FVP9$; M$X3PQX!\WT5N3-R0:7'H";<1G,RQ@\O`&G5!B,1EEM5>Q?@I"3]K[!DR!/9#I]VK856* MW__0;77PCQK,F)AQ6-U/W)J?L6O;L/R1?"(R5F#+88)1XF-A3O39S'5>P*EY M<.W,^)W.N?QC[#I3IB_&\B8PR$0?L9FE&R"';C-9.:%`6KW>E>8:@[3LQC53W92GX]P4Q?<-G^2\1Y3?/S)]#!7:0FO= M,/C,0W>R#*;#Z1MMEV$NU7<>?'D-[I2/+F54O869=$;WX,*Y@!F6/XD5>:DV M=.`#I*;X^3M@8>K8\H)?Y1+W!0YQ[X%'QZ!\!5CRYH@8QX8_1?_%%-_#6N16 M=[UY\JSD]T-P]0+S7<<6G^;)7_`2F7PXV=@04HMD(G]]\QG*C7;0#4Y4FUO- MPI9S][^ZY?-#G+HUW9=Z-&L;YRRM?7;*+AS[B;L>,F=?\H>R?CEPH)T;3#^0W=!,F_@WN&]E@`XUW8` MFJT62>'*MS>[BF;L*K9591GQ\=(&.09N,%5RE<`)TL.\[2K(M+>^S[C[78JQ M;/M&,;D2%GVKXB=B37^NCIVOM&=<(WY6TUNHX*#]+AQ;&-S M6ZYX]=9T]D"];OI>QRJ1B\Z<$@HK$?ZU^F9WV.@%_[TVJ8#\'T1':* M,1/\&_ZV7^$?S4.F`Y`_#E"L7[AN#/'#0KWR*RP@F7M/@37 MX['W6,('FO8TK?X1?X[_;'S\"=;W$[8/=,N*FGUA^R`ZJM']*!@/[U()]CQQ M&*9'W\`K\1&3[A`<*M2V_X)KKF$WR>(ZC*PUV)SK;M#B?`Q>PS31GWC4(<:N M970L>%#VCP\N$`I_.%QP5[:(GTUODA3IC-WZKO`ABD?=8U2GEI`.&\3%6D,Y)-K2PLB;"E+.AW0/,)(2@":%/,!>VMK\))7$7`8VO4A,#9X0 MWF)W+Y,3G#HH!-#NN8ZVJ537VJ$">\JVO'\&$(U;,')>+/@*/9J4L[TR9Q,8 MB!]EXM8)5M?BFPW9V_K+7=]<#+Y>L6'__Z[N=[GNP29KL9@)1=,IVIH94#)/ MBYSP1,=P(3.0$8/%*N!:PL0[I7@S#3_,HAOFX6U52`QX39YG.QY[X-P&K__P M5YC8C#DX:(@8IG0"`9_@&0MNUR[=>:ZEX@'>,Q[!22"HP6P.01.B)T1%^U$* MQMXGX80%^0N"P$8>#_PG4=3>!"6CHR&"G`@+SA996*UR8$9/70>4#*XUE>K>TJ/U M8[$0!F6#T(#5YA"X4%C#S.2Y#YCU@8R")[93=$Y@1;4Y\3(S-+A`<##8-/7< M*@P+H8$HH\ELP[/0F5.IH:HO6P+=T*$_WX&+YZ9%&%L6NHMC9[_>YE!"[JQ_ M_+P(CFQ6*"1BXG"#H"#E'=]N[0HAF1_GY._A&QC%` M(D(#F`(>'2ET:U,N:G9MX69`$"<`#>F<,XF^TITHUU%^O^`*36U0R2\T_N!? MY]D+L.)4IF.+)AF8B2ZVY^R=A67#/5Y%-P4PSR\^DS`K(/DZ*BG60PIXPQN> M)?G[#3B7&0GAC3=W=4=;Z!KCN&\,+8%"*L$W4/\='X`0`\&1X?$)F--$U9*-L*%E$Z"Z M(K<&3P5KBJD_3X9,$RPB(+W\*FL&X.%I0+;#&O56,*Q%VF@1]?(\8S%'#)IZ MR\Q"59[)(L,B>RS#\IT":X9,IT3)S.C$<*AL>_/A;;ZGPQ^>34)G$_>TP#%] M5'QR\"!>.3HB+WVP2=M!BP7OBON;V^?$WU9?]YKYUWJ.TF<.Q])C17,]!UPW"YAW`9L1U?7M]98@6:_7 MS9EUL^.$>@?Q@%[3&&L_]-NU7OV&N1OF;IB[MNJZP*YO13M"1],DB`?T>!H# M40U^7$JBACT;]FS8LS)%Z3?78[%4L5/90)I$7W=S\DIU0TMX,)UX0*_,YI&' MG:9T-;F?/*ZL^K)DF3AL#<4^]\O:<&W#M6&N';5Z4F738'G@6HZU;[FNZQ-+ M:UIX92[5S][DP1;C`3V>7(6"FC,?1IA)TBZGF0WO-KQ;/>_VVY79CCSP+L=: MN%P?^-(T__P)SWI5;3HE%C&\IHRT',\[`#YE\XP'](Y(J!W6NY`&W*]MP[H- MZR:Q;F>7O*JC85V.U7&Y3K'7;SQ<^^87(!#KK1FEW/Q%WI@;)JE5[.T4FM(JC5F=466R]8?Z& M^2MD?JG=ZG::(W(^%7^YT0!LO^VU,,%Z<)Q@<\`<>OL?&!*_V/# M\`W#GP;#,T5_T@S/2F4WSWJ'LH]VIMX"6+SO-E$S2;B8!/M&C)N-E'5FZC4+M>KAG0%]T)+?F[D MCZ):X-$'K[HC%P-^K=K.[3F!MT(@[Q-X84X[]C>&UL/AMIIO[!Y M!ZO.M(K"VF!BK:/MCZ#"5H9>"21VG/8[&'J-/&FKRW?3U?U6F(+&^GC^=O%T M(=QZ/<3]J2=+UJ83GE@T&Q;UK$XW0L?('S^P"1CR@G4BQ6&X%CFG#:FQ82DV M.`TU:/3'B?/EGT53Z8O8K??]$7<(T14);92)]Q6K]?T M13S"!6SZ(C9BM$:+R/$NW,;1W:9YZ9B:;GRN\,XX-PR0GP%^X'/MF\5M=G?# M`,WN/MI3T\SC\22;S)O:&9L51^A`C6EB`.J48]H\H%="OFBYK9(.=H132IIH MJROV:L,31\KR)1QL'BA%^F`Y`&7POA?.KY`S2D@16T=S%XNF$?FEB/R*1/R@ M73FG-R*^KB)>JA.O5R_2*Q#AG#ARQ65^)SERU\32WF0'Y^E6VVF9AX1G'M#C MN$>/R'4]_@=)ZO.?KE]/?Z1TK=D*36^6YZ;E:/_U2NT-53"=&;&X=T#KZ9?P&T@J M=O3C@2R[4;>ZDF%^E_+(-V(M.56LS@EI&/4H1&I93DB_UW!F(T(YY,SJG!`> M^)(3)Z3V$H=BJ]VM;,)JG1G@Y$4`1\4, MVW'\<69P'Q6[XIP?_I;:)\W+0=M+=>X6/JF'WP89M'T3&;AUA6338-#Z6ZS>[A@<`N^- M=)4_X5B$SP*]YER7EZ;K?)IJWXGZ.7.>P>KYUNJ3NH(F_-$*/OH\\<^?7/O\ M5987G^YH2\5G^3L6Q>FF[5KDF7QW+G53^?/GO__M[W\3A'_ZUSXI,Z*Z.IE, MK\F46!91X;ZQ;1/''AOJO2:_:+KF:,1^QO>L'B,H0!KXXY%,_W7VT!:_P?^P MT_VS*4K?.NSSF:"IL`BRXFCJMX[4/?LYQ@4[3\$0S@IDJH+'U^`<%QS*8MH: M/3(WIX+J499.<)$I;5=#62RBRX[W$YE.B>+0+IC71"'S%V()';$E(#'I#=B* M7I!QH$EH:@G/TTH./]^GD.$E%X M^?@45.76%M5H_1KV;-B3X_6KJ:*,E@.*U14^)/JZ)KS;T13!((X_4]UXK;C9 M.0^F$P_H[2*PRAU!LFTRRH'KUH:MH+=ZWNVW M*[,=>>!=CK5PN3[PI6G^^1.>]:K:=$HL8B@`BF8(-*?1.P`^9?.,!_2.2*@= MUKN0!MRO;<.Z#>LFCM7<):_J:%B78W5\'_#_Y7SOS2HS"C@@?\Y-@K*]=%K9.^?B#M3 M@V35JKV=(A-:Q5&K,ZHLMMXP?\/\%3*_U&YU.\T1.9^*O]QHP._\]&;GP0!L M'*!*6YD>UMGYP)0^_X.!&H9O&+Z@7KZHZ$^:X3FIV2K.Z&G<^9VW=JD-XW:V M\$MH(%=YE\7NH=RCO8G'4]^X9A,UFZB*J4;-)BK1Z*AY%\;$/^@2]HZOY2&%`GLTVWQ"!>PZ;;8B-$: M+2+'NW`;]WF;EJAC:KKQN<([X]PP0'X&R#M,J-G=-5S<9G>?.`.]<'Z%G,'5\-/JM_?1B_R*1/R@73FG-R*^KB)>JA.O5R_2*Q#A MG#ARQ>63)SERU\32WF1'>R,5]V_F(8V:!_0X[OPCI&PU^"7Q96_42-"JT:NY!"V),P<>"+E'BE=:[9" M\YOEN6DYVG^]`GY#%4QG1BSN'=!Z^B7\!I**'2AY(,MNU*VN$)G?I3SRC5A+ M3A6K1'`43'#=AQ_G!G<1\7N'!*@%G%YL=7K M=T\Z-E\/_JZ7..>'OZ7V23,W)[Y:N0=/-8HB'FU?[JU7^)CZA,UFN>0Q.)QKS2:YK0US:Z3-AM-4]KNR=]& MHN9C4LIZ;NW'KVP]-\4?P;(P;>735],A]H.\Q"NP"DXW;=?::\9*OY09*PGC M(9A8H#LI[P,_"]ZMOFQ$ML@<$[$2*I%Y%:MH4'P;.^8B*2CDC;%H7T@]S5@7 M\O#1=BS3>*4G)NV+D-1/^H1L$5R?(=K27_9U\GSS!*+^W^/+^YO@%>.OU\+X M^O?QUROX]?9Q\D5XO+D?/]]8C>)/`_F/:SO: M=$E7:&((_R,;KFPM!7'0$K"9?XN.N[EBDW,$V;;=.5&%J67.A2]WSX(,&L(A MPH+M*&`=9R;%2-OX4/C#\AY+4_GP__GJY^E/\_'$U MI8<-WC&G`C66BQI\,VBW6Z!-Z7KX\VXN!,#WEKQ8#.&VCS#B98$<,3!W0_5P M`G`I?`M+,Q1M`2AAOKJL*)8+UVC8/9?8%&YGIMD)5)'A5G.NV39V::4_%X_C M<`W'EO=R0P"I1@P58)W+CFMISA+?/P9T=$2[=R%L!THR"#B8B>)F@21^QYQ^ MX"9=7\;HCI?-X:^9OD0BT3E,CLF(;!H>G:/$`IH62BQQG1\\6K$I4MYZEC'0 M2>A=]"(O_@%;^5X3A07&E0%26-27972?PJTV M44"UT9]@"7#K$L=F#+JZ$!YM.L#+*WP)4Z2P?CI@3H=`):V&110T%%1!!58R M7NDU2R);ML!X;#,RPKM<\$H6^:Q.;XTK$E@7K!_;`800\Y`\8)(K42S(E/!K M5&E1:L@+(.]W#?8ET9>M0O9AH03N]=;W"D6ST+=T$O8CT&Y!%.R8IB]329^? MYM(ZR:/+O5+1A6+7[XYXH&$);D;!)DBYT]KV'"5W'4@[YYWH;YX6VRCUHL83 M"$T"RU#PFF,=TKK40G/*GID6Z%5BS:G0MIG5!A!IEG!U,Z'L=W4[01D_(_I" MF+I8@;>:A<@V'+M3MHC@&KY&P1L-TSA?;;47$/U`F`MAO$G.%:N[6U*22/)4 M&X7X)UE]0_/-9C,-P:U[(Y:SFFK()G@"A0`Q6_A@$\]L$0J6L`L92P!3A;=*BVR*DCYQ"K%W"R@V->FF@+H MK&QLD`4`]99B3-H@Q@*T#?0J5!*\R;,U*$"#4<>QF<:% MA_!"!S#^%*;T&<+^ZK*K-\2,XX=B(_+25PA2T#]-\JY@A64)OP>$__Y)=AUS M!42_O>5DXMC!UD90O&.WM0MR3S9>HT@MAG)&\A4[27W#7YR`[0).#KZ30Y_- MZ0X'?U6BS$V%?@&H]-(GL_GJ,\`/].C)+%>5XW++*@5-V*Y@#/%?`%3/%C:E MILB7.V]GV\RK$HLTNTE%FF(GL'%Y7MD2&7=_^73@YC"9M$@23]7O8KZJ'TX( M/=[8,TD2->MW6J82_Y,[ZRF%>*@F/&Z;J=OK-1;3T>3;'B@@RG_&;9XT63^E M=CT[]\LJ.C69WIO&ZS.QYAB_BJ;D[I!F.R@ES;;Z^#0?4#11\B9*WD3)CS/L MVD3):[5V+.)DC>F4A,EKZ&IU$3) MFRCY,4?):]]*(E^P.A[L#E\9/.%Q5?HPF3[XA8EWQE=XRC.ML?C"2BPBD>^Q M/3$V1KR'9X)K:.S*WYZNSP25*!KPOXVD^%D$5P3^$Z"U%UA[X?AO(EO/[^86 MJ(U240.1L3MF'C#1IA\NAI,FTZ>E[9"Y?6M:?\PT939!_K0?=!FK_',#WVF' M@%^X%HE!W_./4+)?6B"0TK>QXUB::S\0QWO"%QI$),T$NG2+^=P=2'H,B#A67#SA*VO>'`(V_^,SETQ@\[M;B=#_>6#ZW=_8M?8']BU!?&RK(YLXJV_OEB(XV3-L"IRD#4/ MQ);V)F-M["^R9J#Q,3&"[[X29_L,H&Z&:7`N=<5>#.X,((J"6@I!':=VAOH^ M!['9W0_J6P(6-[H^B;T0KP!BS7#!!)RL.GOL0/P,[7PN25$S9'N@2D,K;74R M]/9Y;U0T6JM;'PF`JX!X9V86G1]X9VR]U7.M7H;N%MO=*)K[`WDPM--6-T-1 MGXN]?K=TO$%C.VC*L6>/YZ;E:/^E-TVFF%I)FX9MO:2]#*4]ZHYBF.6!HU#H M4U:FEZ':>_U>(="GKN:-`=#0Q7S$)G_;+T&&Z@>9.-QJ6T4!*@.;M"7),@O$ M$E#)%I]T;>G71`V^O?GN6+)IJ9HA6\L[##_ML'P9]D02LL7!6QU)TG@@PU@Y M+$ENIE/67B7@->"E*+^-'4\C8X#3=4QX5/CB';BBGQ+]E(`$%YUN0(4"0#P< MUFD+/Z@(:^HCYWE>U"JVT2R.^^RY$!VF(WK>OF@//-=]9[!*12Z-=T?9R'7* M1,Y)?(JGG<,Z>VRH$^Q5MOT"]M-.7](7<&OH#H%JRG+VTPYB&*KBAN7<&=5M MMGA1ED=?2C]P:F\G>?*9((4CF+:0G&%#ZZES&2;/%B:0O`N!7OL/9OA MRCW8W>&S\_48(:`K#MCQ\1?9F,F.(QMWMNF8"_),E)EAZN;K\EY7V%&R2K1[ M\BKK-V#,.P7L!%]%V+!>=Q0=08*:J*0]> M^\L38@.$Z68`#-2=\NL+.6_S[4_,L#D^2]&R9^.E" M!F[Y%&$Q4>-!1JI,IF;/$U#=&X$4G3;(R(4I!('-.1KYCZ$&*;$HS$GJ=;I1 M.;+YI6OT!?GL++\09V:J01QN\FX0RYYI"]AEF$0MOVYQ:#;(,(APDX` M@ZC,D'"\FFED>O.=*"ZN^V0ZA<=:\`#Z_2T='Z/)NO=]>,<_:PZF']X9JO:F MJ:ZLKV_Z04ITJLUBB[VRE>D5:YJ.MNXU\&Z1$G1!54>I%>3?VKCC8 M80Q+@SG=U!';G6@`.PQ3_OU_K\TUAPF-B?&;O8.Y.AB<_>R`C2GTVC\(IK]E M!(6:G;8`/SF"J2@N[8;O->CV.U+/Y:5@:Z\&]A"7#4=?"CK"$[[&'^`D#C[; M`M,X2^S[#!M"U_Y+!,VQA:^3>T%!K(256(,KX'TNV-]3UG<`_%6Z6AJ5G;37 MP*KKM?P=WKO29GDD6)QL:]TJ<"Z"S_2!^+AD0PQN,13DN>39_\QM^/WC]OK<&:IAR MN,6T[N:W[0Q/BADP3#FNPGSED%N3#=.8==3P3';,F_W-GQBP+F63H?OVY+[8 MY"\7[K]Y@_^+9/I&?WI>+LBZ^!JFFPN==DBW9,`;9\MP6G8%B*6<8F'N;@10_8 M'"E\GQT9%`1F%)&5&3Y=,]FP).*)#T%6$10@VL@:V&PJIV?.H>FFXBW@D_ASC]#$71][%`9:9G;="WG5#'P+ MHAC&(C9%B5YN@D6J@IJSO<&)OLGF3S!IY<.04B@,2Y2T*Y+)BD+/BU]QQLH= M(*K;9A3US0^AX(-U:1&ZO"]+_P<-[J>2TUV8.",3S##-)JS[%>+'X#87+("` MD(*)B4,7;;J$[UCR`I:R]2=Q0R8QJ)HF;R(E(E]WRTU?"8Z#05<#LP.`^^QGM`(KC`U1E[X3A3`%M;L3FA MP9=Z#V'A#U:]P)&G%%V_$R(R+FL;1^_.-9&][=PVW;X.5N8X?UX75K8C<(%93WBFX94"4R1>`2;\;(&A,(8M`! MD1=LI4&X@UUO#74L0@[0OT'E%_Q9U_9VQ2QWE3U;FCU[_'LVTD-U'9K-Q.BD M-Z5$(!D6J? MT..@E?@.:)70`C-!8'T8M,1V]R/W:]BP*(/-A* M/*#'4P/I:O!K3'F.T6O8LV%/OA5EN5[E-3',N694&0_FP2CB`;V:BJ)R#?8: MK5_#G@U[\9DRW4SUV.RD01AEH)YOIY.OYZ(?LJ&%@_H\23="IIS M5([$$UO=GM3J])LAI@W'UH5CI7ZO)0V:65S'[LQ6OWMYL,9X0(\GX=0X"PU[ M-NS9L&>M%.6A_=;$NO!3-IAX0*]>F1OE6O$?VA?M=F6)&PU'-AR9Q)'B27/D ML0YX+JKZGS[8+_XO"/P-=?=;=KIA`!V@*4-!O9A6W[%C`*]7TF&[-Y3&&6/# MTZU^=4*LX=^&?T^"?X]?"1_<^_Z%%R7<^"!')\3V=C*V$F+GW"]MP[D-YR96 M#+6;6J'J5>_!_=\G7E1OXS\;@XU?$!_>! M?^5%$3>>Q-&)L<-Z$MVAU.I+/>X7N.'?AG_K&<,Y?O5;KA_\1(?C^@-QN;>V MZBFH>#`FC]Q?D*16KP;>0L._#?\F\:_4'[0Z/?[Y]_C5[>&\796\.-S;5_44 M6#R8C\?M&8!?.^JT>KU=RH$:#FXXN'H.'H#).!*;D][J56[9)[VL60)U=,T% MMD!H_-SC-2./VT\0A\-6A>DI#?\V_+L?_X[:K7X-^/?XE6ZY?NZFDJ*J%7#C M-1R=`#NPW]L>5)F6TO!OP[_[\6^OTK0J'A;X6-M6^G_0):0-ZEY,2R46;1?G MO9T2[Q,VL_LLT&O.=7EINLZGJ?:=J)\SV\ZMGF^M/JDKR,(?K>"C3^%__N3: MYZ^RO/ATXTU)>B#6$[8G?";?G4L=S(.?__ZWO_]-$/[I7_BDS(CJZF0RC=]" M6UB/#?6:-;!^QI>L'H/]$AWXXY%,_W7VT!:_P?^P==&S*4K?.NSSF:"I_SJ[ ME15'4[]UAKVSGV,+%>MAR%8K3^-"X:S`=8^W4LP/1F)[S.<9$::FKIOO0$S! M:V-('!N^M)R9X,#/BCE?N`YK%6E.A9?-O<)9:\E(.\F60+XK!$`+?E=E1SYD ME\G>=ETF$YN('D73R6'3=#*D.\)-H0H?'E//#E<<=S#;B&W3=/)$FTXV>Y;W M/=LTG6R:3C9-)ZN6T9R%F9+$]E=W3JPJ1\[S$(7@`;V]F\=Q.2;M<.AS.46M M8>Z&N1OFKND![I[C[HO+S\@_-K`J5N#A+)\'].HUD^VPZ28?!BVQW:UL2%O# MHG5FT=)8I77Q##GFE%E/)@'HX@']&HJBLHUV&NT?@U[-NS)\?K55%/N&9,MU\U M#7O62E$>VF]=E14J7L,F]%!/V6#B`;UZ96Z4:\5_:%^TVY4E;C0* M)\V132^'JGLY[-BB(=[IX:OI$/M!7M*+S$O9B#5Q&-L3HRU]$]O8O$&*-6_H MGPFNH;$K?WNZ/A-4HFC`SC:B^?.@/6RWVP'$ZZ^*`_.'%RT?LV#Y5Q>+AB=3 MBM4DB)C'$-S0=4(*=9V(`SX(`DWA'Q>FADR35Y<8*75;,`O>P% MD/JC3J_7.9H5N)DO='-)")4R$]I`MQK:]W,P_W`H'A'S)]J6;`DJXO]TEY'Q M?WM0;V4;<9DY\JQ&Z:[L$7A6293GB?MSN+:H?(^.^SGP;FG`]NB]VR3B<^#= M=MLYO-MZ*]XDRG/@WW;;)^'?)E&?`_^VV\[AWQX/W2MT;;OM'*ZMU!]T>L=# M;JY#P+P(EGVVWG\6Q'[7[I(O[:$[A7INW85_)"!WX6 MO%O]-J=X>I[9I=S/*HAV3U]ETL73$QQSD910YW519TW5U_,3X.,+S>WO7M"C M\9?D0_U(*L;&ATR>?[UY%&[^W\/-UZ>;IYS/*S7WX7.D*?VYWUH^N>6^M%W+ M_168+PF9'LEX%X!0L8,4KF&_XP2%&1&61+9L@6"K<<'O,"YTQ):`FXVF.**L M:]%K423(QE*PB(+Y'*I@XG86R/<%,6RLQYL*\F)AF=]!\CA$7PHT=6D*F]I' M/Y*@\V,,\!];/]H(\H]K63D4Z$YKT.^OQK_@4RF!$<2"WR-U.FOO:0'6]H(H M*##UY84PB:*N&51RPK\=`AQOS"`E]@7_ MS%/N?(EB8;V++8?P+MO%F6SQPN%]7;+I4W49$SZEJS!^OU>XOX(J%WHZP;2 MNKJ,&8R.?(PE5E:7-`0?;R.TA=:9K\HNF:\YR MC>/9)*88UPOHI0IS4]6FFD+]BO*D\E`2#R")NAVI8(G,_VZKDV2(F;D;%B,F M$L!G-@.Y4*SF2E!;M'#(-"@(H$$6I@WJ"\00"*$%;)\EY13REZLM<%NV"C9> MA@D,[$,$3KJC$WQKR%X-V_K%@K(.R860^(+8C?D6N9/7@2EVP;M)CL3[3%-F M@F8+!KP6I08!_!<6U+&(H2\&Q9,/6F9CTE!-`K8.D!?&)D+L.U5:* MXLY=9IDP9'`"GD5F@!#*:/!+S#FYB$!0XWS]?2-,:R,:O51_?.(^;[<[Y;H9 M.VX4JXJ)OW)'D-*HU.Q`[0VV=BX,,D$.O M+P+6-/IF*+%S<=0N$EC/I/`M#F\31"V,[2DN92@UJ9V%1!ZX2L4N98VD#$5W MWF]W#H*>OY.\0DFX':692]1[+V:QTW:1,O3AN=3)0B\/8*6BE[9Z6?I4[/8/ M@MX5^/"@G:VQ^H9FD(T5D@0\8VVG'9>ABL^'PPRD4L`I`Y>T%=Q/Z-@ M9/Q=^4A`D+H[:'=T9DP4.F@3_>8SAP5UE5I:*[[1CNSH_-(7CD;8*6>I?DKKM@O`` MZ45CX,_F6/G+U2SRX`7C'G1PPF#'W/CQN.W7HY-A`(C1Q<@/2N%(I"Q&)T// M#SIE(7'IVII!,!P&RSN9X@)[OVQ?W-_MY/=OMP&D!"32UB)3:Z>OQ1:(;-A1 M:%;;^\JI3I::%G-)J018"L+;BP(WC;(9"K4S M[&RD[-8PQW*5MR=N-\MO[DGMC>#&WKX_H"ED[6:H1DD2=P9T@[2XU0Q8C#WE M;S=#%W9[_4X>T94`3.%HI)$_0QM*O5ZW(#2HIC14_!?:+V^RCGKU@5B:J<9= M@!W6(RN"W&M'%?LVX)2`2MJ:9"A%*7;\43PF8UACRUK"9&T'$[:;I1_C,>?@93L`DK;(&=JO(VT!")[-/,O? M47OO1)0,U1;UU6H"Y93M6"[:\Y2U MZ+&MCH]V=IN MB02]#/WEPYSRTCV!2R-HADX"Y1HP2%X(O0/99\QWP??`;:MPP&\&/,!+\[C? M38_V,H\]`Y"W`J5P)-((G^VB[8[`RA)B-T^L!]ERO#]"BW:+>3[L_,6/#X@[ M+$>&OHITNMP:GO)02EN<#,T7Z^BP!UITC0/?"Y?66?JI(7[^?7]G#IZ M9Y!*12QMA3(4><\[Z"\0N]`"3VGLZ]EDG,G"B;N=5_0S='ZG/XHJ_2P0"@(Y MC?29_F:_O1/(R;LIP6!,W]=IU,X?B\T+1,'`I]$]0[=+_5&*4,J/07C%6((D MO8[MF%Q$S^[*]>3`/D,8KC#EVG_/6NE]/W_,-QWJ0G#C!S,' MP'/+#LHY\1SD=]4K6LL"<,S*1!X,Q$.OYI9-J_)BFF%8B",>N+8`/+,#!KOA MZ!\43Z8HIQ\)"F7%H<4VM/IB>^4VR,S$DI+/JC>!4!#(*2IMD'6>VXW%-;<% M^1>L_[^G]3T3X^8[GOF")SC#9[!'[$#F_#9$YMN+`C>-Q)GI5<,HB;<&.ACR M@;\&YH6]1^.9P;"4QC/HYL8F;PLRK9O;7.(JO!.+X%534]?- M=UOXH&&YH^G:<(7]\5,9=:21_B_MBZ3N+_O6P0*@6D)!K%96!YC0!*1[.@`I MBB-BZ#7]B;4.6N]EM'[Y9^%R\GA]\WA^-;F_'S\\P4L56"UY89//PN3WF\?; M^\D?GX0WS49.R&YBY!$,)S4E-3$ZQ#C`W896#<*3_WKKDYU\-@]6'?@]^`,9 M?X>)5@K!X[!JL"QBH)K'/'Z?J__%&DH*XN*[8)NZIGK,R@.VW1_.D+6!>8$_ MI374?S.\/A^TPY/U$_U](5N8`-`L;(T7UHNZLYR)6AHNWZVD;RX0MWZ#*Q$W=<&W6[;10;5BTGNMV0J@F MS'KF'5"U-9(:RGX`[K?33SO7E`CX.)\P_CZ^N[ MK[^W5:[T^9^%1LF/3"3]G9DTJO)_>1QI2_+8EIL!MTP M;<.T_#)M@@W8:PV&)\VTG%B$4_J?LBS"ZW`K]*I6.S>*!Q%1V\7;.5OCPQ,@ MO[P3MY1W/E4.HZ0_B*V.-/S8[(%F#Y2X![I<[X'*]'W#_H)UVTA[ M7NS;-.4@/MS$BWN>LG/#`WJ[G%QP*^D*BIKN+/UV)F*"&2"U!FV)>_9I M=D?IN^,P-BY7O-_$:CE`KP3>/[)0[LZ42;"%NZUN[Z3%?9F6L,\H]S>W^*QM M[8)RH[_WQ+:]&5:.L#`M[%MPRBY1$P(XOB!PD<;!!VH9GW34H-DBQQHE2SX3 M`6NXX?>&WX^0WY.BPM04/FE^Y]@6+C=2?&_B6%IBS:LVA'GPB#(W/:R=H)KN M"[[_).,$6]*E_%!")0;Q>;-)FDW2;))FDS2;I-DD>P6A3WJ3A(WNGV@'H/"# M]FQ%M.I_5'"+H\,^MX8MIS:O?5'P,\X\<'^IM8W2-)P*-GQVPZE=3MKJ65); MRQ8V3<.ITUS8IN%4'1?U2!I.\1*ZK1+OVC><*C/]BK/^(:>*:MV[^9SJNIT0 MJ@V+UG/=3@C5NC>I]7IGS23YI-\=I^/M8^#NY^=-@=-K\S8DM>I#F3UY]>],$:NL]WN1FGUYN=F)X23QM MS[W9*,U&R36=HFF;UFR39IMDV=]BJ]<_Z8V24N^36/1"24(+-UY,2R46K:'P M"$2!^<2J-N@UY[J\-%WGTU3[3M3/F;48J^=;JT^J_^FG\$ M:&">WQ/9)O:=<:L9LJ%HLO[DR`ZAMTZFV)^*D&O-5G33!FM]]3`TYAWXXY%, M_W7VT!:_P?]PF/>S*4K?.NSSF:"I_SJ[E15'4[]U!Z.SG[V%6JM^V;;<1XBL M^[Z5/+M7'07;)5S4D[X7GL>7]S?G]^-_3WZ#ES`>6=\+J@,\Q=CI5]EX!5;) MKNGQ=T6TW&CE6\:WEV,NDEQ,KPJI?2'1DJP_0.R<__$X!JGS8A'YS_-WV`#K MVPX^`L>9QBL5+^(%9=/@FYRRQGNW[#KFAC>O2XD(&HG@?)T\WSR!O/XW4E[P M)$2O_5FX&C_";IYMM(,XK/@HODXL4R6G&UJQ::D5,D"L$'<:-(6XH-?SC5#F[MS=A\"0.4V?1$^0R5P%\AT!QYCOK%W:4`HH/*< M?NG:9.K":[4W8C-07RW3A@?,\?00W^*!/B.ZZL&;0'D$Q=`,@`>H,;,%OPA/ MZ(@M)$.'0A3_5A+>85W_4>2ZB/U6I]V.+`Q]=:$OB3Z_!2ME+P@HN3>B+UL@ MA9V9("N*.W=I05.P")II($6+1;@E]GL5XGL!JQI"CWQ?$`,XD3&%9H?VI,\G M2R);N)N1M:OCDZK)QK_\K9.N*%2T1Y;MUL4@=9J`H>!:U%X)OI-#G\WI#H&$>E8,;)T.6#HJO?3RV^1F"*>R7%66XY9TR)JT M7<%"ZIYR+(\'])K4XVBCA[5SF5:[?=('F-S(HN(2>S;(HEY5R\Q#5@\/Z/%D M`.TIE`K$F3>AQ`.W0^J>L>WA`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`AHK.'9$Y-9TK6WQ MZ!:/QPJ,7='0WK9>CEXJ&N).:/A@;(_&G1?^OS,4W56)>F?XOVR!4C\5I@%0A,'NGOW!I;=';K#(QU?MW1%NVF35HCQK8Y^SVJ[ MK;U%VW;9TU7TGLN>#]KJB1)GBW2%OP];;$<1*FH#]^'*--Z(Y6!G`RSMUPS; ML5RJ(;;O`O+M#A#49!T@P!0#<'@F!OE"B\Q=&W'#-]RMWC#^KMDQ(O4+;QSR M/"->W0&":"O$+%[]RAV;:+BV$+'S0# MOC%=&VZR/WX28I#OU1%CU?[BHH<-,&)48/^^D.AO>0E2P1CY4##AGL82TEM[ M!.&(Q%X>HT&NZ!X10 M;:_C*K6Z_28MNWKQ5%R<-TD\5;]A>8ACGR1ZQ1Q4%XA?@A!JUH\C252NH30& M7\*+"8!'0$TEQQ3>9UR8R)]Z'3$)HFF>L%47`I-8R+Q MC%Y-A5"!^#4F$M^2J`H3">/`JDI4C"2_$><9C3LI2T ME?/.V<]2M]^.9(6D`%P];M_^8"YT^*I[TWAUB#7'JY^7"Y)`@Y2T&*3!.;@^ M5='@QE-XURLEMQKE$*!N9^&[/YN,,D@D@63CAD^>W\TMD.NU4[)WZ![H297M M@;+6?UL2I202T?47>^V=:11].;R2C&E[@=S9(KUV2I(0@M<;#*/0;7IE$:!] M^VH:CX3F3CS(EK,,TSG\_3-(*AL1,`W[4"Y M<'PS;*%],$V5_:E\EV&<=+M4.X52O]*%[1:`E,)3&8:$-&B7AD[1N(@9=L.: MV-H.EQQU,F6LD)BEZK.6:%-QS?;8%8Y:AIEPGK5B^5#[&E28YM[F8H:"WPQ3 M\+9"P"J%I3+T^^&0*QRS#*M@%\QV,,FD&%09BKO3Z1_,6I1*8:@,32WVQ`,B M6#AV&2I?'%9@#L=9+$./BX-1A;9A*4PG9:C[3NJJE(YQX>AFV`%BM[OG"N>W MW6+,)V7H<;'7+\F(+(>Q,G2_*/;WL2,/RS49JKZ[G7G_Y)C*GW>V[0(7N99F MO#X02S/5IYEL$9M]?VM:3\1ZT[":(CFB)H4B:M*W*W,^-PWZX##"J\&X6`/C M+.&JA6E@;(W&SZY6QXV3*19"$#OT`#P*".%!?V$7)=`G;##8%(TPB>Z^WJ(9 MVN_W!Z$Z_:V(4!\27NY*PWX.&G8'`ZD#(ED\?CK^LBL=!SGH*+5CP>]2J/@[ M]ED,8_8;P%4/9LR*SP`?YJ%?,@5J0[Z=>3`K'I2+^:HBWEA5-52+LOX@:^J= MX95=5J!7.AG&Z>C$R+CK=NYD'G2=&"%WW=B=S%A;Z82,J:0KV9Z5)A)CR'>R M-6MGV&GOHED1C6TX:6O\8ZAD&/0,C7P+>3@V8@?VK",89_+QL8V M#%+W(,;A3H2(X901->QV\UMJA\>EB$7-LE5%K@FPKW:+$2/#\NSDMSSW\QTG M.`OM0!S0;>=03*Q59-Y=3<'?9O%SXQL#/<,RRZE-`Q!*@;F(-(B5[[`Z+E1'2C&=4;@W207`J6.)TLTRI*H@2`WLMDWF'M<\P MG.""K=',@K(JS(OFD(R#VT.0KD)=]8U>_L`Z>&^3GMK-$]32(U?YXD*V)Q?"A:P%(49[;`M28 M9?9M0:QO]!GKU!7#Z0V9,*R!G83AS7=8!LTF#Y:FD-6/MO=K0D?@C7C$8F!^ MQ5PZ%CN`%.$6[\>;[PO-HC7=UYL[0UY? M\.YO44,9[H.]9.,O6XF0%/NB[;-W_E0^BG+THN!XA"[%V`ZV[&3Z;,E8[TI_ M26638K#MM[-D3\_OU+TK$DE+&SHALK17#:Q(_)913LQ59U<,]NGMML7V^EJG M0IZ.J@&?B`)^(X.C5W#HAN M5C%>M]\7`Y65!.PV9@XEPR7V94=;CA@VE7()G>#S!&?ZF:5VPVYNDR8%L@,B M6'`,II]5Z%<2A;X2'%-AS@GRR]AQ+.W%I?T&GLU'HA(RQ\]8-0`4L4Q=AQ?Y MUMH.;)`1:#H?C'K14-,>X!T8TV^1YN533=$?>:]JD)1FH M1?/N(,-$BQ<`YH%Z'=,@QA+*EH,$2J#=ASG;>#?/2Q0 M.)XYLJ[ZP]ZNX81"_/+"<>Y6X<\7YX`63H]>)0[HUBTTBD$V?5K:6M^:O'6" MA62DQ57SOFD1@SS5"GTI5UKI`?/1-@\VZPTRCN9ZN=V,PV-2Q()FG+R5CSYC M@^W=SZ(I,2)+CO&*E($0-I86-P!_5[^ M/<`'?D5LAOR=,&I`CV)C4VF#:VO*,*%@#3TAQ:=89`8/TMX(BYKL2JS\O3GJ M1:5_G?WWQ'G9::BI?O!'ZK MP%?6=.A1+*DY"=H],"KA3"UCM+/8C[5:W08C+Y2_Y>%#44N5$:,<#'I=:1VO M%)B+1;.H]4NQ%G']NL-!5]P+32HC9J:N$LMF4@'VLN[2N#0VVC*-Z(Y.WL>L M8H2HWC1P,8,R^YI16:WUQ:[43BBC+AS-;9R/K^2=_G(8!_\;:Z#PZX-%I@06 M7MU,;N_8AEZ00.JLCGRBE#\XL*)!:82+`-_/:L$OQO,D=P)^DSV'ZO#6M(CV M:K"=J(1[GL&NI'_IU',+2JY`FTZFS_+W';#-;*T7W1/EP%TI=3;G)O6SFOD? MG#"7KJT9Q+:OB:U8VL)[!/CT&NQ&V+@-8W7A#E"H1_B(X(*0&UG"B=!'N(. MG%CF,TW=T*C)`@BR#IO[7V>X=[7IDF+R@'DY`*YP95H+DQ4#"!]`1`@,J:$D MM3^CM)"-Y>H;\?-'X5VV!0T$![N+J`+<=TT4JH,%J=T2Q-&P`U<(^"P;U3&N M,.QVN$\V,+-E#O)#(=XG"Z>S".:",!#PV?B$_H60"*$&#Q$,5]&);`ESHH(+ M;1!A1F3=F2FL2(6"?"$\P^L]^`$`,!=L8>$_DLWI*PH^,(O0'S38=H(*PP+PX``[>C[_!GZI+!?$%_SR5,M>, M.UB1/38NN;!@UC-R+K+QBR>?<#G>-!5>M6+.&Y^5G@-6^O!P\_Q1L!79,(#M M&"OF89*-K_7X%[][-RU=]3>D./AL"U/-LAW!,H&BFN(_:6I:]')0]@O9VSO( M3ZIFHP^,N,)+$EG2F= M@B*GANA&C(E!"RWIE_XN=DQ_=X2V1O3I'^R/#'XJ"BR-0:FLG`C!(N!66`Q: M7XSXL/+/M'7;8#']0=G5?/D/4>@`4I#EL*3`02C[81W)&S%OGFW)HME8'4B`]\"PRO:%+>&.77>@3&R)#;E]I2-PUZ;*-"1_^(B';_# M[;BFM186(&)I^M+7EE.-Z"IN!=!DJB8K:[BS`Q3-U^7POW]E?`A9&Y]N7L.FUH7`#H1,,%8Z#0K7RBL0&FT!FV" M_Z/+"GKN+Q`^5)2@P(";_@O+C.('-!0(!-BCR`4V'L^@1A:HM>]H[OQ\*`D? MGBSXU\>0O>8_RG!\$0F1%G"ID8U"`]"3_I"\"*:^K(E4,"88K,#@HX? M[@2P+502?>G4,N>"(UNOQ!%0G%EH2EM@BX.X5-FOV`QURIQ[4(.Z+K^8%!*[ M82@?5EA8^L_"288"7C<%FOOOBSTGZDQYF]R.>E4/=U?,;X*5`%&.6D\SWD!" M:*^H^*B=!LRHL7'9%%PZRSCJ=[Q!CGQ+9&%A?8VF-P>'0! M;6Q.EGTP!;>A'H"'330%;:K.]3%\[S( M"V'"7#/5BV/Z'@`>E#(,(H^9R>`9"%-9`Y]-MOX$N^P-#]GPSG\4B5O[HMT> M1A$#.Y4A%PU]@CF(9H`:QFX*;@7SJXN'K+=.XF@$OPYNI-W,UT\A4N/E. M%)<&<";3*6P2J\5^!"]C"?]O&/Z=>/%J`+M_L7<&X/4O`0/3PEN`\Q1!7F5V!/L MY,C>I6SLK2QE=ZHGZ%_!TFXB3,QC64ECU'.;[A$LV?C3%O[#6`)`!4D-W&VH MMA_.98E15/QY"BDI7"W;-L$3C@401M?`UU39_H`G8CAH89$WS71M?7GN[88` MG4V/5%C6DVXE)O"AT'[AX\^?509 MP_+O!*OYX?(W4W?GP,J`"+896=`'^V:-,[-`93FLZAWN7.(QH<=TRJI0/LK# MZ>L'M`76>B$1ABB25LZ[* M4;[/-&4F>*$9O#'*5584)WQK8_\5"BN(_"_RDDI[RIV7IFS1,Z5K#40*1GY; M*.WQ#,[?U/("3WME/6*7AY8P)##HT=G,M&AL'%4!F"@J-5.\9WG7_0CB!,4/ MF'R>XW2W2AFA:1Q@8&!P$F\CTRD"(],#0(L>V.F:$WOQCW;4T4*3L=`M00'# MEXIT8XMQ`X0J\;-'#\0G!/'L8PM@IF?0FV1C5-13Q5JHM=1IM:6VKTFC`!IA<1]UYB(C'`%BOA"H=B$GLY5*L=2Y\+C.]--J:2 MG)HL=/."H=*(\;3P_!Z13XF3R"<-G00?9 ME"L,/=]:5CVXJ0N]!GA&FL@!S8)=U>VQ6@DE[(INND*7A3?@7W!GT:7USS3! M9P6>1O:A`ES%6%^ATJV[?K[0\&3E/#DZ%$^*+2ZY4FS8DD>V%!/Y,C@T*)@U M1U*G)4F=1-8,PMR7:6>([#RE6+A&4JLC22VI-]P$V5J1F"1!IL M9[B&[?X#B+DL,1!B\4RE[*.#?X;5CXE5I:V"J,P%1U)PU#]?DF" MZE*I7B1X:W(V`F2+;:Y5+@G8U@ZMRRTAC!&U8'YH,8O?8J,Q,&[H+#&@2(M> M?(T83:@P:::@@'4H))1@(^@LQN[ECESYA?YWQBK]J'PNZ&2$H7P%[F4Y,#)' M<`];`CERA<)F7RY;X7!H,Q-9:(EN*O5J*P;25 MU5Q9=+BW7BK6;.+*-S$_)_:=A+JV\K9,1@E,3N/FT/;,!KC+"(@>MW&39$ES M8]H(8^0?,WV/EG.N*&VI2;#1WT(WEX1$E4E).D1:AZY5?.2R7P=U*B;4&#;J MM#)URBJ">X>TB3OKQ^T;E=@>TO"`9ZZM8?T#*YU6XCEU M[0(K@:Y-V<"E$'#4Z@^E5J\SRJ5FZ*D86.=5$;W)M28-YPG%+O M&.N!(NG29V6*(YVBZ>5 MLK.'+7$HMH;BQC**]+A%-%,O'L5H-EQU&^Y_7(/4VP77&Q>\8?8MF/VPA7'] M5K\_R-`NXT-7Q:4"%=X\K=+H@AJENS$*7E6Y(*JX;FLXR*7F6K&6NT5K7"GS MF.^70YLE?NN9W([=`0L(6J-!NS48YO++MSVPJ*G(JRG85%+KFV9'E9,"LV4R M)6,=.]E53;3':=U2T,VW6O`SDE=,?P&&;`$NA$M@"%:PUR2VG,+^&[NO<%,0 MDN%N`YY0^E7#D2&.[!SR`$)LB<-A:[@YUE^9G0I0#3NMOI0KCR24[A(0L:(# MR%"WFM#QX_O,I)FWO@>_ZM^HLFFV03MP0,J9X1A;S!BA_ES'.U.E&M9S[FEE MN:'HKLHFTOJ]]:@UAU6R0*'(S$G)MJTY6\T'H!:V"$S7!\]_L_=-]$]TEP8)% M]UFH=P-PQ41Q3&\6AK3A0$^S0W&[I/0O>96?%77&BBU'ZK8ZH]Z!%7AC9B:" M'1NBDNSF)>:6RDPB%%X@`GLUHT(HSXR/%AWR80CD.[$4;=6%H81191N[W]+` M-IU%G]#CB':.2)DDQ=S7H"XFNM63&LM$!I"]FX)A&N>KGA@O1+9"\TJB+3M* MD^W#Y,[]=/UN)\V>;_:\'S?,'(Q5DST?V=1KL^1BFSJE!=HQ;'^QU4D*5/L" MX*81`/L*@-7S<^SX%8MMW/&;&CH=OK$*#2V!M6IYR0J;TM.\\HM-93<>IX4> ME"S5"@Y7E"O)4/KD-3*J<:ASQH0T1G/^0J,_"OQ.#)O5@B]TV1^020<`KR;_TF%`K[BI8'.!3H/7S6F: MD=>&S2\B9Y>XMA])NM1E>-.3,C-UW!>4I.?(YGC!W%2)?A&[!E2IKOV7T*F% M[MQ+V?63FNB\-?@(ESA>?U1+L_\\GV*\:J4'L2<<^]&?-B@L-:*KP@<6L]*\ MA[,'OA#AO\0R6WY'-U_&@-"@XX$6L@94DNU9:/PBSF)$C.D\/I.P"Q77LD"8 MZDLZF)C-)@,//W8O&X7AU>##50@$L>;^$T*"A"ZH);#^)R2)(!LJ!2-C(\,9@D-7%1[JQ?'+B":2@P=95-=A7(!E0]LSD-QIQ\J1.H62F MYYA11)9$QOT^5O`H!'8EMMG74IAD=682T4RX<0V[>,)OX`N_JW";R^>3R_FMS?CQ^>`!(%UD)> MV&2-'SX+D]]O'F_O)W]\$MXT&^-_9Z#\=!V[E,/:_>NLS?Y>8/*D]__?;W^)/PO19E.%24!.T#N^>YJ?.^_#=;/,>?>A7]X8';;@-2[ICJS?YWU M^S^$K_4]8&?@0O3J!> MG#\:PB*.:QE5+7QN;(]H#Q>WPHE[N+)-7"!>ZVC]4(>]6Z[RO8X$R+@7U4>T M8\O5NFWNE[+1N@69S4%HEWLA?43;MUR%ZU?'\KR8Y6KH2$TT M6E1YN*1VH?[RHF:EK?)8L-WY'./.:2%___!*<<`\^0A!WP39U35V%V>YO;I\3?P^E2$5> MF!J@6XO'K:Y^GCRD@>&IB;4+OF*I$Y M*EPZ/YPAAP,/`IM):X@]T2/.`+T[3&A&W0J7O%@_TK40S!ILEK=6&_`>7C'HUN9\\PM]M^I^R&'>58\SSHI;(LYRHV.(.6))4 M[!TMT3W*PZ/J15-ST%FT3#IOEO+$-F+YG'H8;7K2G,N)*BW76[UAE34_34UK M2C2G.JW:N*C\:55NW-$/7IE84S)Q:INO\4N/@WDY4:;E^J7^@7/CFB:F/[$= M)HA!WM%1VHV[$J!Q;T]HL4]^NS?<7D-NYT2+5W:`V^'>A*MRIW=@IZNF2Q.. MJS=B(RG/Z[*()P)Q=$J\,]42#Y'#S55XWC55&@A\[)J]UW_W8VCN-LO.$8$B M-T\3,.#"U#A(P``K%5K\&!NU<"M*%9M;V]I).S\,(4\4XLCSVIUL/)H;/'AH M-=DW^S/`$=@;>Y_E%[I]JC0X>-@Y*87Y^]<3!T7:D=>'_V@*_KF$=1)T<0VF M63^8MH:S&WZTA4M3ME0LM+_6+$+;/J_ULJ67A/K7?A1DU5S0IMAP(9W(=_.7 MBS7X=P86=N#0GP==-H0/9_1'_'SVL27(KC,S+>V_V!`S/+&G2.X!<#:-.PQU M#8CV,,X>3Z*P\23T$4WOZ?+YDY-^U.)@T.JG=Z0.^J*'YAM$ MNSN'1@1C8U1O-/!:\13M_AR@9`2[%!M1X*,`PV)G$(XV-LU&L1<1B-ZP@JEF MV8[P%RR*`Z`#G=FJ7.=#L57^GAQD#;-E:-$.V*ND0$KZTF9V@M>6*"5\6JS& M(_CI(?BTW3M"CG*2S?M"BO;/N4UWKXE]RD7A]PO9M.G MO/8AE&)AO3.$K^8;BW=N/A,*!<[+'TZZZ5PQZRQH=0:*L,F"`2_TS[`J/R+B MY^1G[>#GU:!#E&7C0*<^W83#DD*.?-XU70\P0H1";%O6K,TD;$)`;SCF.>)3 MAD.>,43IWMKA>*'@[=\>1B""7=^<+C2G"\WI0G.Z4!L?J>1^H1=2<[I0_1YN M3A>.?1N7?;H@#;A?S>9TH3E=J-6>;4X7&KW;G"[4=ON6JW+%Z@QG3C1NVND" MSX&.&IT&C)/3HJ.'`C.YQ!SO44:.=SB)F\;""WW]J-5->[G\)FLZ#0UA=O\J MNSSA""(UWA]"816YI6GTKJXO:2@[5X`_N:YCK.N1,*Q&>^`G'I,0VM,WX3&] MIO:*GV'`$5:,C.R-G(/5:4PO@Z*9R[MSW+@9U)MB<)0Z&G)7@VI_5/B9ZA:]_$5NIO76*YA1;G=--KL)RV6;@8@GB%Y=HZSB*-K*H%G4 MLM`K81Y#,R(Q>LCGI3.>*`]SHF;+[2QY6\H\IT0$CD/\\-7TY(W%ULO%A MU6JDLD0O?A?UR-'+S[-=K@<@5JDK>5A=3G1E90,?BG50$W&J?*]RMD*-Q^E[ MG.W&XZPO>GQZF,>G)7G@44ZT9'FFT>$\S)K91R>)7GXQ)7)MW'^06KW&0:TM M>GQIV+(+,QH_E`,-6UZ@GLMQPCS85I4.6*TS`>KJ3%0V8+7.BWWR!,C/[7VN M#V=/FOLYT?+EGLSR.%Z8!Q/O"":7G=QXX;W]]4(GI@Z'+;':@'FSCZK<1[4= M`%C)=FE""EP8&^4>;?,Y8)@'6_,(YK*?WH#A4B:T[SXQM7J#H]E)E>ZDVED< M!Z069R;'@78*_;:X;MN_A6Y#_NK\)Z0TZR1;BV6S<<-55:7)Y@57UUJ5,/`H6U4^!I^1+;P!7= M"*%&RY?1*J'('@C-FO*QIA6TOSCLTC?AV-PZ-N7L]]@=XQW0XSP,LOLY9:?5 M@W\ZG7H\MM]O^%4+EOP-)S:<&HC4[GG M5$XLHG)C7R&+",<3-$6-V^S=:O!+JID7.UT_>M7,[^34;^?',3]X?&J7`%2; M_T3H>C-R#1F7KYKH4^=13@RD`X6,O-%.=`R6EPF&PZ,PRPJ`NQ0>+#(E%IA0 M7H*89@@+2WO#F;P+75;(G!@.]^8T3]85UYZ1*'9;PUX]RAKKJ:9JW*6(KW!3 M+4H*&Q[EW)1J>/0$3*D#Q9JBII3Q1BP',[L%E;R`D>3B\#$TK0S3@4\+>>E/ M(>/:T.8P)[JNCI78[O@](+E?]GHJKAK'`'8-7AV?XFIXE%<>Y4N,')=&)F[8!?_ M/46/WQX[6&)5TR^>?X>J2!N+_V[1]51(Q\#(?$6O&DYM.+4>,:R3YE1.#*:# MU>95FHG.5]"J^$STPSKI'\3N*E&*_WEN]=0V-/6DG$//I-C6\;E M_]#G^`VF)IV*<\^(ER/!QG>JH_JJ<8)*$X9J&)1K!CWX#)*&86MF7%663L7_ MV2V/8V4X=JT*;2,J256GKO/@@/$Q[I"KS)72]DLM8FBG'8_@8SL<)_MS'XEK M"AM7GP\R`:N4$4&E0GQ2TX+V!&ZLZX+I.K8C&SCPQQ_79`NR103%M2QB./K2 MS[I#AKN(XE.SV50!\)$I56$21.92!?1(\%RXGE&EAX>QQ7BPW'%L(DEV[(',*UT82[10QJ'243#<\2J:S8=)3P+#F M%'_TI\5RL6:;#C'5Z)'-9,T`$1;>@X5BRXKBR'B!^KTTC4YT^_)O(EKU+BE*SMO4; MPU;/->,D\L[7&?Y1GK$<5_)V%\/A33>78@512>N79`A]D)NFTJ>&7EUES4D? MS?.`WO'DDI1V(E#961@//,J)$EGF?Z59[]QS"D_^Z.+GH+ M9UMD/\@?A5@3`\'6O@MSTW!FMB!/P2(2G!D15)P)8QK"^TQ39H(L6.15`R3I M22.@`[_BK!A!LX6IIA.5%N_)BD(6#OSQLJ3/>"**:VD.CIZY^:[,9..5T*-F MS;;Q*0MBS37'P>P06;!EG6#."-YGSV2L!\2209JKX"[@:K]%E7^1ET-R@20N M)ZEE$]]2J4`!>S$ME5@TD\![.]V/GS#_XK-`KSG7Y:7I.I^FVG>B?L[,2%@] MWUI]4E?`A#]:P4=_T\:8;>=M(9QMEA_%OJ/0W)A5(LS%`%-A5J!I!OLGG!*U MQC`Q1@`K.]@F[P0VB0D*3C-D75\*-G$$Q_1W#[#F6@I32WAQ'78?^>X00PWV M!/#_0C;PLV6ZK[.U>[L7]6;"?_[DVN>OLKSX1)-(9J8.P-F8/^(LOYH.N=9L M13=MUR+/0)I+':[Y^>]_^_O?!.&?"]-6/HVG($\T$"_JC>%0V?%@ZIJR7%V- MU<,._/%(IO\Z>VB+W^!_2/-G4Y2^==CG,T%386%EQ='4;_UV[^QG/OEV=\WE M9R[]Q[4=;;I<+5F@AP)""CXE#Z^I"L6H2I6[)R*AQ2#>8E"-"1)!LT#KLE]! M*;8$V194,M4,)C)NQT^7(#-4;:HI3/<^FPM-$8:]-DTFA:OY3)=,7$Y.JTJ,^AM9C!UI&3C8$=K4E[(#M'D'Y4VH70YVOV%/\6F8RB1,+7/N/^]""!,5$]L<^`?>;E!+ M?:J]H84B6[`EB.S@]_Z=`"+](?J$(#L>O`G31?MK"KL-=XUFO`$-F=NQ>@H^ M$+%73"#OG#@SD_DBN+R&"6Z+@N:1*KS)NDO%)0"UGG*.=^`0`N$%**'B,P%3 M>"U8*C;;QCZZ-33(\ME5OA7FFV]W!K*2:2WWM[_ZIVA_K>A7.V/E:*PN?PFH MM86!#H=:8"#<4&*`T00B`+8V%1VPV>>R]2W4X^^M('GJCY:T_%#K7;+H0OJ/19U$1&J8*"!9^( M(NJ-6/(+[$^'B7,0<[!]-7L&EX#>(-9;8$N\@5EBNG;H'6"`+$#<&DRZRL)? M+LA\8H$(!6FF,4,3_K42;?@4>(,VI]0PP)NU"%#OOU1X43E)7P8O7A#8P6^( MM('`J"TV,-A4`'KZ6$M^%_`QE@8:10O(74!8*2IWK&AJC(&-#8L^U MR=35!5U#T?I"0!FWQ<^X.OWN4E^X2,9;;NNB)5B MFW#J?./+H0!O79N2%E[BEPTML=;K9%:6DXS+XM)JDW;LI:OI*)MV6=:CR:WE MJ\:DR+Y:G=$IKRLG.[BX=*&D'7SK6H9&H[9HF()?2EL75[7L/"00'22WMAPM MW#L?G/+*<;)ARU6Y]T2V"68A"-I\88$3.-^QB<71R&F^].]6&U8\KZRO*0\K MQ\F&+5?#XD&@BUF()!("/%$976/MVCD_Z9$TG&S6_R,I,,X@5.W4Y91'=*%>.5Z[0U+SH^6-N81`KB#KE MP\%B8?V%Y0@&"7:&H&KV`A,@-=-@V3J:H>@N'@5[29/!62^VEET05HMD^S_# M%YJ)%],,0A7S;3#MTF`3,C!7A2QDS?)Z\,YDZQ4>SL,4IOL ME;Q9*6OI?G.D#EXXL:[I4LCZ9'IO&J_WVAM1Q[!,CGU'EP3@O3,E*URUQY"@R8!ZH2,%L:7W9BN1<$Y;7 MYV7P*;)E+3'KA"498P*@8X-H@X74Z4+*="%;6-"!R7JRY:>HP![5%&W!,EM< M>JZ`^7B*;,^$*59UX*VFE_I"9R3/-/!L>%<#?% MH*?/6QH*.,2&YD#:M*;3=G7*=+8+/IQ%WC3R;D+H(>\EYA!E9FA_88XA?2D`LK#,_Q`E1`)0!33U&[X)4<+$PE0- MH,"4]E!F9;V3#8L7NW')_DA>7>`/TUK"<\PY>9:_^\G?.TCHT4E*:$HX@5*N M=E+L:,2QMPH.K@(K?E-\,8%9@:ZA>K7KNN8G4[.4[`OAVJ_+TN+/P#,A3?4> M`?;EPK1P>H&J3>$.`K8C9@F_&3/.HYF*8'V: M%JUU7V4JTI)Y[S&N[8$0`+BZ,`1^`#?\Y2JL1E`.9"&0#60E-7G?9\1H^<:Q MN=`,_!F@G:_2T.%7JA7FIH4T^Y/H6)8L&SB$%S^`YX6@4+CQ7D9GZ/*[GW[N M,.84X7@A_L*325P/`H7>_$(-,44$CA81W@MF?&GDC]$;OQ\UD M,1$[&R"566$`MB9@BI.517GZ&`P$S&AU@?U8!X08(.!SR/JJ#'15'^8[([Y& MA]>YQNHN-0H_4"/$+=ZM]5.&Q:J3.K4M**VXD1%A*(F#SR"'""PV2"!D-.I# M4W:!73:W5WN-YAK"KJ&C6N+E<6WZ_V)0)$=K:=P7--J8!RW/0%U.;A[ M?$)YP4H0X7548@:;H26\`A-;M)L"`\$B/A"K%B1+^A[:7:1^3!U8>"GF5Z3Q MP9,R`Y&ND\GT"6N'+]&V?I"7*,3&[[*ETG8*DP6U>'_WY3V8@>Z)VS3<)J@0N=5GY\QRHC\6NH"B1F.=8YTKKLTV5Z,*[O*D8 MC);>4^8.%H*S.@(&15,X4&'A0`T.WFY&C03OQ^()V2>'M4X[A-;U`FI!>$]*K MFW52L>I>INX7O4[MXGK M'?'V+3FN)PZY7\PFKE=R7&\M\E9L7`\3&O>.[$E-9*^)[#61O2:RUT3V^+)/ MRG4OI`NIB>Q5OX>;R-ZQ;^.R(WL2_^U%F\A>$]FKU9YM(GN-WFTB>[7=OB6G MR%=G.'.B<9O(7E+L+=X2Y4:V#!S#\4`L^HZ]&U?!WR<1JD.@@I8A]Z9M"T!# M+#O'$"Z@J;6N$8 MS5<2>8XM@/2R'9FU-E#=5>LMUB_P0J#BQ(LLPVJ"A+%DP^M1POH7J)KNTC&8 M-E%<*^A88IC.6I-"A78O9[T0O%XD:^`9+NVN@&VWUB'$=@BK%ZXP7:..APB1 ME9G_'H80MM,B-J%=<3R8GL*-$R=!XT3$$!M&6&1&#!O?QSH4T!GT00<6KP78 M"^M6YL-V$>7`^NF:G+H@KCI@8XQ9VR&XZ0$V&GQ4V%")@IH@BMU3U"6/!,/W M0D!;(4K<0TJVINW6AKXR=*JZ-E_H=$U0I&'')WB6'"S;(K)LK(\4:^?JRQ,V ML!Z^GLM+VDX0OL-^1@EC/9F04DUB>XVE_$Y-;(8SMHVBHYB6GJC.`!ZT[#B6]N(ZQ&\266/) MNH-DW)#NA+DX&%0AX1+(Z370\4W&)]A[)S7U>96OT2R8BQ[FP>S9=@M-)S6@ M';B"8*U0KE4SXPL>$RVEQJW0R*\S)*7YQ"0U)>N9+;,Z$S8+X!MCRLNU:+-J-#<&K.@[F M-S6GFM7UI,WSY"%1U&R#_3]V0#I_0D.G['RDG2F1F&+8;G)!_2: M+L&JV8%5;<%M#HO0M>.K9S4<;SVCJB7A"CV.15'IX8CN1=)1+ M69E)T.P_[O=?Z;&%9O_5PQXH-USP^ZHX49C*BF-:W!M^]11)Q^"E\!4H.,VA M"3Q@U>S`NA@%)1=!=T\Q4L>)65!NF."96'/N3;YZRJ%C<$[X"@Z(=*!WLY[- M;CRFU:MKJ*#9C7G;I)17T\9_0=%^U4`;:HH>+"R,=998?>2,#?7F+U=;8(;F MC5^P]9M-IJY^7TA]T8#7^J)B"_%\HM+B..)3E)9#8X&>A3TI9`?H9[/Z.94L MX'N-EL=AB5Y"L;6P<"U8.A(NUHO6S-%2NZ#,SJ7+)NBTMNF%Z.8[9Y5(37?E MN+RMNKMRE3GU2>W@FA*0>I2`)%@T*^T1X(W]L".5'[0U]LFL[-'%0))V[*6K MZ2B;=EG6(W>]=N=:?O*A.Z-37E=.=G"Y+5AO7 MKQ2TGB=\]_D_/@W;+DJ]Y[(-IF9NHH-L2QP`H..;"W@FN(;&WOC;T_69H!(%4-'M?YV==\Y^;@>M M0!,A+@F\48L M6S.-:Z)8&-R],X([[PS;L5PV,2$Y_4H*I5_%R3A(A[C7[5*`MXHG(02DF-DS+4K=AKBT4@M.I*CDT9\=@` MUA=M,&=Y1ZR`KJ\[$SK#1CH715B,X6G0^MFB#727]-6[ M$C3#OCL73T)HQK1O)\/`!#:3NN))$.8;FQ>Z%X]E6,9B5VJ?Q);M%&WS9!CP MHVYO=PK4+46K9S@[YZ+4Z7:DT^#D(K1Z-\,9JDBKTPFZD]`` MW90P5`%ZIQMV?=CXWC`A[K[>GOT\&`X[TJ`[&L0&=(7!W`^/0M93RL:DWY:V MP>'0C%W(@F98_X->?W`*0B(6H^UFV?#2L'\2]I58L'W5S7`#AB/XSXD0MC3[ MJIOA'9Q*[$0LV\KJ9G@+YV)[V!F<"*T+T9=LF8K#INW79K5CCT) MB#U^L,B46!91]\*DDXT)1FI&HY+1N=!*G(@4+H:QS[ M6],"$KQI2KX4J&]!/A:0@C%D0#%,#&(7.-@[B/[B"5<@6*%RMI_#ZAR-NH,8 MR7,3HQ)27FY+R_W%:S^'R=L=#*1.IU'E!&F:EQ!54+&*C9V53P*[.L%PXIF*5>SIS$AQ`9S(ZI/RW6G= M?%=FLO%*)M,P^D2!>_+F,1?'8QG.CI\K7!!N>>C%1&.J!R.$OMOKT&&3U$'*A2S9P;9 M567<4V)_933(+D+CG@J_[D^%C(R,2Y543H\"A&6.L'H] M:%&0R,P1FZ\'/0H0G(-CH44!XK,H\S.=%CN=J,<@S7'*W^T.^KWR3OB+$D[# M'*?\G7:OWQV6E11:K'`9YCGS+_,,LSC9,*SPS+^X73W,$7OD^A2V6,-HF!$_ M['9/(CFU0`&6$4V4:-'/Z5"T(#&:5:5V&J>P!0KS[(#DB="R`)7"71':5OF` MA9$A3ZZIU"O3V.D4JAM'.6S14LWJ3F%::93##"W7K.X4J@]&.6S14LWJ3F&2 M>%1W@[3@3=<8I`5O_<8@+4,`-09IP6*0-X/4`]>+VTVL1YS>Z$?O'BQ-(:L? M;>_7+1K2C6(VXS?O46&T)=B<%V$FV@6D.%K1A;K6WC25&.HCK-$#/`>627XE M430`A82.:%L(_8R%#YN-"]Q[F\%$Q#7PHO1'C5WH@A:%,Z)A1ECFPL$2PL-Q)L!%F8R?"%;F($ M7'XQWXCP#V0,84$L@5H,=!`IWNZ\`PF6B)--%!?;R@F.)5-;AH*TL#2\TJ07 M,U@VT39&I[Q$I6P(:T'ME(*LAE0&&K1C1][?@"S?Z.MCG"1>=/O9V$806!,* M0[)P*:R>+=![A7^(E'-D M2WC#\UU!HSO`1TK0#&`.4%[L238^*L*6K`J./2LDF'*3)9V-?@>.-%Z39&G9 M!&0J6W@S'4!ZM:\V<4L8SG2,'F1K8E$@V'GZ%CMC;YTZ:'=S[XRPFLF'P4&V M1@$TZ)W]G,'@85%;!$^70HD\9FL&)?J)E&BU#[?;2Z',WI&K07N01)G>16]8 MC1C<79L6L%_BANDFF=%+D1DYM6GTIDK.`P?M'%'+C7AF!F,*46_[;WVQC>J- M[O3"-5PE4;.!F".@6=2R57+>#[XDLF4+Q%#! MY[HF"MWY0D=L";@O:!``Y42+7CO5#!EX1-8!%4\JV&!^8#2+,(?>D@T;=Q%P M#W+1@VEK2!-@)VMA6I29Z#.Q6.A]9NKZ\MQ\-^#5MOMB:ZHFHS1J"5_NGEO! MS0\@'N:R0EP']KIN^W8-?=##W=6%,-9UM(*(I7B_1."8R6]$>"'$$(BNS0$% M\`TN:CCNJ`AAF'B(!`\D*A*5`-'HXS`H]TK7]W(97/(@+_&K\;MLJ:NA`&/; M=IGQ9#]J]I^W%B%^S!+C7!ND;_O9A`],^K9CTK>;%6$3Q=@!4YD(E$JQF^\+ MHF"/KE!D<`>*]5(HUEX_CRL3^H.0ZW=3A\?HFK/2`.*1E&7RHC MQ.%D="YZI)V"=.DI2'O0.QTIG8=FD?%PIRZE!*"6@Q7CH"@ M;B<1"PCR(/V[]*!**DL) MIDLH6N65["?^9I/)],:;B&M3!W&Y1ZQ,ZI]BK(R2E@8X0L2E\0@@+WZ_(G#M MXD)'$^!ZGL'2)(>L@HC0PB(+&=,--'J&-S6M.6PEX5US9H*\"J-@(HH?&WTE M!K%D75_B[V3AL'LQ^(6]7VCB`JX[,L%X#L`ILO#AE_'XX>.%\.0JL_"CO%P< M`?"1F03`7)>Y_"<1B,\_E*GD8-_#FV1'D*=3V/WTK8"`:>%[Y3E"2U\,UQ.' MW:J')D?BWZIF8VJ.R_(N<+L#?OCF3?>PMZ@H'[UCQ422XGV;P+'(&S%<#P#R M'44?_*'2RM/03930M!#U0A@KC@LO@-WEZO3TR=41=D#;$J:6.8?;3#M$IHO2 MPM`U#!3N*OT3SK\Q1XV%;=&FN8*=`MH./NV@*`:GJ"@B)&0'*Y2&`A*Q.58Y M2JVS.I^8RQKL/`W6G?9&D^T9J@KXV]$MUH!*==Z*#D3*'73O;>#S7$@Q3,`WP7.`A)E@;OLT"%V..[=RT\%Q.-@H5 M)_`I(E%^0+%FR[IOK`@VVE34H4H&JU!@A@G`>*]#QE6(]H::\4+8DKA2*XVR MA:(@]3FBYR`G/6MH%^6P:]9,(!#:8#;AO[!VXPU6!>BPO]<\/$EC"#5@B(R4 MO9]F8/J?.\2:@[9[`X.>^A.-:71\II&?<;)PL%L.>1@$]K+>OR"+!(V-#+'K$?5[)^?W$W.D5Q MYQ-2""A9NSU[-,)GO&[",-%B.]3"\:)5JDM8?,DWM6*N$MP-&QTTE["PS#>- MYOZC":::[HLS=?7`5`)1(NL@SNC/-%O->\7[3%-FU$L#4>,:^$1PO1"@EO>; M9@OT3$YP%S2J#/^3]:47<0[)1K8<0TDPOYF&2CQ4`4KKF6ACPB0&.9<4P0'_E2;F-I:3"U3-,;-QU],4WW7=!TD\)WA MR,8K%EN,::1U;Z'::9^B4/4I2AF7C@\5`LH*C+2-\7BT\ALMQ265#,EX92^_/XZ6KUE_CYH]#IM870S[EX*+@_J)EF9R_LH(3:F)JADJF& MYSY@EH+]B?$8'6@*3P3A#A(?;-O_$C!67UP:@G.(K.(OMOOR'WJ``TK",/"D M0P.)KEGL#`CLV)C:F9JH2A``4`*O8/YB]*T)OI46N:5+(+SZ?$+77=8^(+!6V`H9&CB MO3)X'KP=5)"MT5#6BH'?99O"BN%::AVLA0B#%8#G,?,"`\9H1@0_^6BK!/UP M#?/QZ?O1UE!DRUKBMF,%V/".U_#;&8A$O1#N`F`Q;(Q7_J-(:=OI]K$D+"IT M$02TH%X-W&?A,T6L:]@4-VUV3N$[)RZ_T-/&TW1"SR@V%Y8([\0BGKF+QBX] MH/9BFZN0`.P@E>B":^/B!J?E$?OW!7]%BW:ARWBN;_['LX-Q8Q(O6R849;@` M08\;VF]2T1(TA[)3:!-$.!VL>]R['K\G8D6?F;`+)1JH#Y&([AQOJZNA_;QA M$X>H!5<4NJMB^PE?5/JN;>&Y/BX(J$Q]N;X93\D^J]$VOPZ;.ICULC*9_-P1 MW,D$]^C*\A'0MT5YK%FP?0EZR-10JG-(+;]3%W<'5XE\D^FMGT1S!U:AY4E%`CT/513+)>N9;:X!%A]J;2_=#&Y?@!GPG:8Z>2)HBCQ#P0&#@2BR:Z^R MVNS@',K`TP+_!YM0Q\WCJ`OA2Y"L]T)TC;Q1OS!P'3PW`2P.V@`+W`0[J,QD M5:H$8XY^+$ZP-/M/E)T:M6Z\Y+9HZF(8`/[7ODXZ[7;%$+APU)EGOA0N*?&& MKV%L5?%:B?A"/#[U3N`Q1HL*`)<5C#R6*8,UR)BO**]8=2E\D#$P"ZM. M'_G13QWUDD)AJ:F["/Q!N[%A>SC3Q90>ZT]XN-\V;?6JX+F:PZQMJUT5B2B^4" M_T6A&7[I3".6;"FS9>"+L1-2'22<3MT2]K`6?O0""309V`)N==Y-P6OY0P]K M\0$!%'YNL([M!L/PU9O1F)4:,;C.GRHB:PU%;S#H02H3A^>;_/?LHA1O%>L2=^%OZO2]U\*G)M*BJIZ^F)1)N%[E20?MA>PG=F0N(5+`RZA6"#(9,[ MRP5>B+&]%TSO1!V`6MLBLGY.@VM_N;1M$977X4X4P:M7JL6'03/>3/T-+8`X M)`FN4H@XGJ\B1)V5HO82)?C=U^L;Y.5SMO8^PZYV&/OW!?VIV6NGM]>DS7L- M=X`-*DJ7K4T%)FO;\3/;/J']2OO+J+%MFOUD=EICT*S[%8^".B>V.(Y90AJJ8OS^4W&5##QR`5 M4"S8IFOY)*5M;BSO+2FN02,H&D'!D:#HA`7%;^MV*N:_$)JQCO\/_AAL9`=^ M!8XW3-^!H7L*79[-WI"_T;Q=:Y&I'JV6P_V$XH M;!H?Q+'"VMES?%6J5%E:'3M5"SFEWA9)>K*RZD^(U5.L'$FP9X2PL(:,CW0M M>AK\0HNU/2=4LYA'2_,WO`V6Z`9G',6%SN0^T,>8K@W?V!\_U8!;2]U9(7UP M3Z;PW(C8:*-<\-163%&&-??EY/'ZYG&E?O_7B+ST88%1OM!E_RQX5]S?W#XG M_KXB&:S.ZA\FEKS7#_$8R7O,U>3^?OSP!#A@!J6\L,G:%OHL3$"#W]Y/_O@D M8.8G0+NZG5H8FX%\O/OEUR0HLTT*;_5T(&222?'K#7NR*"V^)]D28=V,)2_$ M\M%Z_O<]X&6@UM&CZQMGJ`1"Q"T98!+'G'L7_N'!A),G?).H,_AAW3K9S(79 MAD:5R(@%X!+G;SI_IRV(`>MP@VWGAS/<%,"E!C8U233M`OS%9C&/9S&E9C&/ M9S$[)[.882^HT94U7<3*<(F8=.N[OT$54)7JAVNS;J>%:L.B]5RW$T*U8=%B MK#6=AIFVQ_IR?/5_?GF<_/;U&A9.4:931=F5%-T,`^XF7S!UN1X]S%[VPZ(_ MUU15)RGH%[V#.5O=HM&S<&@53_@5+94:]FS8LV'/ACT;]N1__4IDSS+-O(?Q M]?7=UU^\PT"I[Y^0YB3/E/ZG+--OO22[(B[(C68]A51QJYB`WC^*E4T^PWH' MP[W* )7IUSOX(-@S8,RO4*-@Q:$P:]FMQ/'E=AN[(8MM\:]8?XIHUKRC%Z#7LV[,DQ>@U[-NQ9/]ONL(&]7;)EC\;"YP&] MXW%+F[A)PZ`-@W*X@@V#GC2#=EJCX2X53D?#I*46F`=%RN'7'V8"Q?[0UZI( M=W=8"U\786UA#E;OCF7GAJ+IB)W?3B*M;_BJYKOEM6YXU0R#]KO%P<:&RJK- MO3F<^,#$%HY!8YI0Y_)HX;O?^2%J%H]Y)59MS%IX: MMM=5WJ77-<*,K.#0_H\730PK4K+K5$:<3]3D./&1OO0ZW8_%_-QO!BZ'4[ M)YWHP(F4*M?LNJ<#/",&EZQB&-<+8)M;>)>GK-)V;2O'&8L M]"X/Z)4@*3GUKWV2[%P\7*2`%%N]]DGG'W`B()NPX3%)O5,.&QZF)\)0:LRZ MZJ76WJJL"2N>FNM\&F'%[J%MPJV$9[_?.V7^YT1X\A9F]!SBIN'@-I*B`Y)" M-5V:7U\]A_`39MQ$%X[MSR+=ZB-NV:675KO%;0TA/S51#`I.:_N2"K:>HP-2 M01MYE6F^(IH2F:598D6;(NN*J]-Z-9F-3W;@!7B7'Z;U!['Z4UV]V:]P>_+) MF5^7%WHR@\2U:>6=<*G+RI_G3\K,U`$(DTYJ/O=',--1[Q?"U4PV7FDF:'S@ MJX=/\J&=5Z)')]/"K28.IL9Y]":@],$+P'Q,+-9;E>CA"\P%L6C0QKX0?EL` MR:)9JP$]6>:JBK$>\(5HJFHK3BM=MFUMRN;;(WB,)+D/(N&Y"UE3SP%H15YH MC@S4>=)P79()D_O!Y+M""%[(%LNREDC_!*99(>FGYWI3?E<,@A1LI=WP3L(+ M@[64PM35=4'5;,5T#8?._X[P%RVRM/V8&>4I65$LXFQ>`O]E_D,%$WYE'$VL MN7^383K$CKYO)K/IQ!J0R2/'PC*QA@^SF.&^\=.5T!VV6W2_:S2ZI]DXD]S5 M[!D2[3YDSTTM2PSR[*>P=Y)F%7. MG70[0#GJJOKT(FE<^M:JHS3M_1P1@]XNH_M7]60M+GJ2M!4BTI9.UF;29%5N M#3++G=-K;AUS,GL@UV.743T>DYY9`^#^A5&(3=+<+:*3OWO[RWX3BX+JY MV<(\,>ZAM_"NY\R5;>$A_R?/QV^P%'?RG&2P/&KVG^=3BV`?.C`JB>T(5H7F M"5_'R!RO976IAML:(N56*+V$TE'N925F03-_N-^_Y4> M6VCV7SWL@7+#!;^;NNQXR7JRXI@6]X9?/472,7@I?`4*I'9E0JF)$S0[L!9& M0;D[4.R>8J2.$[.@W##!,['FW)M\]91#Q^"<\!4<$.G6FZSJ>I]IVHGS-K M`%;/MU:?5/_33^&/5O#1A_B?/[GV^:LL+SYAB[??,05R,KWU)]G=!4/Q'DQ= M4Y8___UO?_^;(/S3O^F1O!'#)8^LA`OK1]AUS^2[:[45VU:/")'EY:RR M"8`"ZIK&*_[E$5((49(N5'#%&FN5,H6Q#K2*;=$4$G&'R/.&LCR++;]7H^M: M%FPY?LT17E.5$V1=8'\Y6H+FI^\L$R-,4$GJ5H0J6K&JF9IN.N6`/MR^$1_\"^M;$I\6'8R:67OI7 M7R`]8J^.WNYBS>V"6%/4!5Y+#8HMN\_>6"]J14!-)]`:NC[%A/<9P5),RR`J MP+H@"FWBINO+EO\"0;/#\-(;`%[;E6TLLB7TO)7!+1N`G875S/2MY+MF(_55 MHL.5%JL^-16ZQ*KPP;162,(O;SBR%!YMX7A3^/UCRZM.1>(!"%0?"'"/2I#0 M(*5!BKVE*1EPD?GA]N/K(MB/<+J@D`&*:WU5I^ M^P+Z1`*DFK-Z_^@S;IX>PL_`>^"Q\*S@20VK%@KK)5%DUR:1;@DH"PVBT:X- M=!W`&:#K@'(%94F@U/`VCW^]E@`^8^-#J-0,,W&BDH5%]U1)P(SP(/@:=P?L M"5^LDI#8E1W@$TV910!_IX7ZH-T,&Q0E/6:I;ASVV%CK,WH6UF#`'SO M.@/S[HP4:_8G[XY3<"W"C.4L%\R884TN5)36P)'DG,Y11V'+F$J7@1>`9U%Y M>&U(7$N!S05F#FUQYAM2%\)86)A6?!NNVGU08RYL%,BPQ]_!CE1FN+/B>@BO M7+W5`Q$LE7&T.0T^:ZW3"NU*HY(IH;;42M&QM\MSUA0D@'#S:]D&1\CFB-C* MH@T3"HAMUG!+!?Y]IJN^[MO;@+DR&QOJ-=RKFW3Y;UB+%G;O#MY]YS2\^X*@ M2O!^X\TPZN3^QOSX`H,80B2*T0C`4@7@H8-2-6#L&EGB\<`CD_)T#X3DO.`) M>KON0J:^TG*LZZ!@;<=>=9&#?6N%UTL-K1>[DL8/9[+UZGGY7D,U&5OK>4$G MO!'^T%V5BBC9TKQ@X`LQR%2CL4)WL=#]K]$1P1@#N!7>XQ+".'6R@S+-FK@E M](3=TB[1O43A"]=1)W0&"M[2?J&#$'LRP?+$^Q/V([B"VU*XMH(SY/?N_`*>PU.IO2"\7?-CIE: MW3/!!4N/OH0U?#L#CE&TN:S;_SJ[^WI[]K/4HP7'`74*1[5H6OZ"&LN^,QZH M/OK%PH[U.:S0XJC:RZ9J@?1,0+=HBMZ:UI1HM)DB[`G8")K7#--_ZV'IV\^F M;[=3+--F4F"-Y`C[G6V[1+UV,4+#+J,OL>F/WI-OOA-+T6QR8!H.MN/1K;&I M4D`62*9A#@'9'M1%0'XU#?8.UHTT=':_D;\/RY6C0Y)[!VJ4R-5_$,ST(>H8 MO"KYE?@;Z8&&F`]A#'3;(>+_]G3]#?RY;Q3Z\!I(9S^+%R5Q>QH)MJ:\O97: MS$_]DK=`5\RS"NWM+(CB:'%PRX*?A9$JV1Y[$:CP33/!@SAZQ9VA8/H`N2;L MW_RM5Z>"C;0???C3+@4N1[=VVN4E_EIF[HY=9V9:&`']#7-P0M;O@RX'%C!] M[B."Z7V#<08/JC10Q,,L1V_WY:B(+O$U>K!P*(.SQ*<[*!O]Z/MO-IFZ^KTV MS2=P+EU-1_X(4W'CLR^7S\L%2:!G_^SGA\[HWP&I^UL"@_:!=-W^Z#50:/8!5!5S,.W[:+Y M-C-`4Y0@OW4M@ZX?/.-6^TY7.B_\,(1C$5@X@7,<-IV*\"N$GCF.F<3A4*S-\5U9T>D"2)WCQ*E( M4A])9+H`P@]RNJGMB[;(1]2`HYAT`?0?ED/_4PY(%[`JHQ)"FUS%H0\0V-Q_ M&?IY#\SX$4X\AC0+6(A<9V;)"W%DPTZ/L2_M'QHL"O-[/&69F;IZ M-\<4::9FRG.6^QU`73PFU/.O>A=CW7R@CCO7=8BU:ZA[FQ7O'1/:^5>[OW]4 MJ"BTO[`""6L9?D:)*S[@9\6+03W_J@\KC`6N>;WT6/UY)GM>L?T5AUO;H%MS M!%K^8!4L$X/L:EWD.!SI%A:ZWQ9WKHG^_&[N2/1!CO,241P6%H[EE^R;S?U' M@IU7X/LKKXV**^O8L3%?5&SO?3$0042T_WT(XN]`@Z-9H#WVD!0S4;FB06$+ MM.I*-@XFU.[!OWHRQ@L(KN0F[,&UEPVLF MN7;3*GBVQ?G;_N0$]^7#R\=__E0T^#R098_MV]^^]Y1&1(J MT>[)JZS?&`Z\.`'F\*G(PMVP(;:#/BXU0%SCA6Q!<)ID<*>8ST7U>H7%EN:+ M_!_3\G]+6H]A"FXBXA;:ZVE`1A8Q^'XR'2L*EKW;CT0AVALM1"T3GU$6/D-O MJ=)A+&!](CE-42B'[2R.DOJ'(GL:F&(6,0<[$?.:O#B!=?.;L>IQ<*W9]-[4 MO7T#W*"J<#&V8J3-SY*ZHX:9)OJ^=:89QFH-8LMKO#F`FRV1;+/#B/@9$K5=L#8]C+`T:2J8/[ M^-8BQ-<4CZ!"MV_>,^RG[%`/1C$DP?-"D@<#+-!7'.0!-MQP1PS2E&OT3#4O M$-L`'TQBVA'\-/V)6RD?^%$P"N:?-`F?IBY]_NE5SC\I&(S25"DG_),&?IJ* MI?4@W8SMNSL+^7=B?&![SA_%PQU9KR@(I#1BQ@\)MP7IL'43GC.UC>(>Y4CJ M%(>=WK#3Z<0U9*E)B$6U7X@6`NQ"H2V[@53>:6'7(HE=:),GK[+3+9I[#IL, MS%X0KP=G)2R(9/QS9>.M/["EPTO9-M^,F4;X\`TSM$51&QW M$@^G2D:YVHJ>76B9I^5'?]`ICU]+5B")\0K`NH5+ MN[P*I!KYMC]5I>TX[LCEVFXTS%%.)DJ':ZZ7OA"A,Z;#8EXHT8$J]"NXHMA7F=2B&W'\9MJCVZAQ_`62RS*MD8?)V2"RM'G)[6M2C0^+^ M2[-%DFJ1==S'U@]Q-^)ODVP@5<_FQC:XN>QFV<&V+2(X_U::Y MNRS-%LXP)Z3@3Q_L1OF2FJH4JP]*"H#D<(?3"G1WHO<6OG(),4W>J)M2`[P+ M=:7\75`P<:^FU%UID.W-]:+96=JNV\FA:,$G[8MF]BU`5,WHJEO3H"XY7ISQZ])3N1-.8=Q+S?'J5EPIO6 M"S)MX&-GAO%G[!1"W>%D(B54+PP[[50P!K$,ML2W[0W2MZN91J;`X8J+57V3 MZ118PHIL739F]D&VG.4S[!X;P0>Z7"[#OZSOVHZ82>5#H;>J52P2O?2"36F7 MU8O.>`EOUU0FQ4;>SRP"_V_)J)#A MSJ6-%^"/)E+&(]M%I&)](RW3F?!W$P7^(T*5H%P.3O7^V<_.NRG,7$/%0=T? MI';[(]#*`&%4$@T7;"$)5&)@/!*D&&%[=J%KL9+P=B\(1,/G MI(J\86=P]C-U5W&-1;IZXIIEDO[2]4VQL@*8(`D:M2:(A4UPY:C?8$(L)K4W MOCN/[-X)TEP#4>.`IK\]A:1;2-P-`.<;(NH5\K;%1.)F"4AFC,D+S9'UK>G[ M[9(`'Y(Q[#<5]QS;B/C(U5?KVZZ;H\R@TPX6(A/"8E`93QUB;8E)CM3^W@Z( M^,MX-U^`X8[OGDSO#'"97E'VC6V;.#887II#=#`L<]6#Q`!/Z1!Q#KY#I]N/ M[(&<@!0+_^92X&%\_F$<_MU!9_U.+/--0_T&KAS:E(9C6DN<`V>]K3E%>:C= M2X?V7.P$_)'Z[KVA3*-I/Y.F^0%<47_M8)(>6DY`D,FH/]DZ[$#2019)NYTH M!^<"I%#PTV@]S,^_.P'^2!8L[F)/IA@#&ANJ)WAH>^O)BZZ]YA_Z$@,^Q<=' MX*4(X?-#LI]U`H!W$RB=9U1;*;RM\$[V[=][=0^#M;59L@SJ$$][6J M=G9E-\&<]T`D.K!U.]=S%W-D!>].EE6>H6#>7*72#:L`DQT,JSS3N'8R$3=N M[R?W9>7#)H6]-C%2BM)<]19+D2J1UV8"N3%@M0FZ/.T+>IFB+QI>8K1F\Y#] MAI$6]8/9==EM+C:"FZ<30"^ZYMEPE`'WMYOO#C`O"67#)<8@GA1BR/#0!`[? MRA?=%M="3E!RK%@_AW;MQHMR=SI!R;B;"N`B$$J/K'?S8)(,2YE+,TK")(=: M%KE=FT2,TML:B@4NSEJ$DU'`"T`2-:4I*'P0$Z'/T]MI)'4DJ9,2:8W#D1-P MAO`N4.<9BTFAEGK#3+@],`I0QLG`9BCC+#U7F#).ABZ',I;6IE8?0AE[X'YC MQV=F(6=X_5Q=?2K5Y3[:.^CR8DF5PQ3H[&T*[,"_W[[(QDQV'-FXLTW'7)!G MHLP,4S=?E_>Z$D;]TK4U@]CV6/G+U6R-IH.LX9EG"LFVQN@^V#V:2UEW-'^D M&Q*6/F`MLP5["AHVN5Q>P2J^FE;"&@YRQ+0'?:F?[+(7C5GHH`Q#+ND)0=_" MW%D$/P_R!`1V7>@H_%]DQ\6&[->IW3GYH0R-CHF=B'>[*R M0$30J9MG!@F;0LD=]X>;B).&Q2.;#_*\)O! M*\`FE-H)5M<@Y:#`3Y4ZA$F8#%S^H_/#6H3)T.:P4P[-N(F`#MO;7#($57HQ"5(=5&>/!BE'):CP,Z5CEU.E"<1>B]%[;*0C+1ACA;. MC"7WB!']8IKJNZ;K06;$O6GO<`X\3%>M\1R2Y-=N`B[W8)'A,.4L/5IP[3][ MAW?&F30]S7T3ZGL;.9UO8E+4>I2>[M[I'<3(V015ML[\-I3N.]H&"4"7VB8+\_H@LZN M-E*A6.]M#N:91.#7X)3F*!Q@10?\2(YOO\.2%816#J^TS[?4*9(:Z:I>+$!D M[>3@@`':]_'N?FOWUJ7M*$^O^WXG?@9<\MG=)EC3#]ZEX4%,F$W`Y8EH#P\2 MI\FS[#G,AHZXCZ+)(W[S`-HM6'[F$AAY`$OW0:5^M]>OR`=-A+Y('W34SN.# M=KIY9$9:GL+66W*[0XL83CG.WCNC_E#J=48EGM`%N!2FGT;M'-I:DMI#L+>V MQHQFFB.O6&1&#%M[PT9CYIR@X_Z5.)/IL_P]5T>UL:*XBL>F9NW)K1C)Z MO`X@#TJ)9/B%&,22];&ACM6Y9F@VG=C[1KS#X:W#)Z-X`^2U="9Q'?`,(/8R M*'JAT#!P:4+88R3F.>7N2%*_TS^8/;$)U(RAOYW#'/QL@BZ/9W^@DY\\ZYXG M=VT59B[-I,@#::\2ERP/9'FF\PUZG'A5>1!*#_]*^_M%.S(T:-EA`'M[L$O* MPST&0*S(U.U[TWAUB#7'JY^7"[*NB\0,[2H>5=&7AN?>Z\J]^2*%`*]5ND/&?0:)SLX;90(XQ57%YKMJ*;MFN19\#R M4E]KXI3'!I3`0OW?NO-9U=X$VUGJY%]G7\:/O]Q]_22T%P[\\_VS<#OY^OQ) M$/'O9VT.DOHK>1<>S;ELM-@7+0').!7._O>K\UG`QSDX&"?ZP//GR0-]:/X' M?A:\6R\GS\^3+_3N,T$ANFXO9`5D.,IY^O="5E7_[W=-=6;_.@/C]8<00)8/ MS>\WC\]W5^/[\_']W2^`IF,N0I>I_F5_W%T__PIOO)!ZFA%<`'3"S_CQ!3]T M+_#C3R_^ES]Y%]"+?W+4A"<_W_R_9__E_W%M1YLN-S]_\OSKS:,P?GJZ>7[* M^::?'"OT&1>"_2G/%Y__E]AOKU[D`W1U?S-^_/1B.C.V-.>WXR]W]__^%%N; MS_2WI[O_[X:MW>>=&>5,D'7MU?C761A]RMF"S.J994>X)@K=AD)';`G(N"WD M;AL\#K!SL24-8C$%?O?1"(,N_!@#X,?6CS:^^D;:@T]F2/B870A:AI3()W>ML!^TZ MIX=V"),R+Z8%I@+=^AZ`5`)\0@'P6:#7G.ORTG2=3U/M.U$_9XJ0U?.MU2=U MM>W"'ZW@H[_/8O[R1E%=I*><4.PQDG)X3%)'%$=[A-[W\ECZ(1SZB04K(RG/ M@>5HT!X,LX.A.5V6/:V*40E610ZWC2WD0:*A`9*5IG"/\K3.%(?LOP<(8`P# M5CZ@PR-QX>]5A_[6_MZNVSQ16'G;?%S(-N_D!;S%K?0OQ6"=)V(]E/8\ MPRQHH0M".8>Y)K6E^)'"-NM\[?MC>9-S1YWTDNQ>]!C9?_X.[XW9KIV,LI]. M4>_M@*:U%B;H.O(_Z)C^SOQ2MH8JT>[)JZS?&(Z69$5UTE.7X?&YP-S+$1B$ M&'/P31PD$3-'X8]XD"*#G5`:)J#4S:/O^:F;R+%(W?0$JB+SU/9:G&$(E6'R MR5*>MIH<+4X>C#):EQ2X.-=P[1M-"OA%UHR)$?R]=9O"45J;36RC+_5C\FG3 MJ_M#-T^A$'`Z'.5(;"C(9#H!TGC-IAK24;1+GS>C8&-SH?^N4 M<,;5S=-W9>>V$S%*C.>F:S@I?"RNEG3D-3R/[[ETFZ#3ZX='T&<"L/_.RX8X MOWEP,',[!]AY.H/VZ7^V]H!I)`1E(&:538PGXC@Z82V(0P]8=3Y-V`J;8,X8 M_-'MC/PA/?E?OT;HI"#55Q=W(B!-%&Q.`2+H2M9UHEXNO>ML[\(D8UGT-W8, MFUQZ?JTT;#_P1KUT`Z,S;,<,C'Q(;?+CV''0E0MZTW#*1;8.1#6C:;$'0((?NJ6XY_V4'/?8%($*2$8MXSVF1/Y"[1O_6/07:W./ MBC9M9L-(U"[40>[G.#R1X@9J"8AO35M[JW>D3;`_/,WSCH6+]N8_($GRK<;A M"9=A>.;CTT3D7K*Y^64#67\GF,DV-K";`%'@X[.)7X5FP,9(_4CFX+K"]RAM M+,#-E?5G8LTW"<@2"=H_^_FA\^\8Q;B@1='"]M:TID1#)\=FX/F3T3/ZB$7+ M_`HE?HZP7;=3K.3-I$+19`^M/(M@I-K*A9(W3]EH>U`L?=?0W4N2ELA[&;Y# M?]`+!P6W$*2[$&\5VZ*KE#%TQ3L;_/;\;OY_Q#(G!H%/#[H<:>&"?W^5YPDY M77EZ-/MC*8I@C$VX56%,!GU$`C+^CVRXLK7$^"Z.9,U)Q#R958/!6@^5X[8; MBR.OE--`C$95ZV(@1N,(NU$HX[AY$.L(ER[`Z''"!NJI*FWV+NM>!;K]2!0L M"%#_T)R99GP%])[?B?Y&O@"NLY0F@^W.2I+OAG)&)'D4).$6@TJ)%EAV[]:] M&23':??:*(H2,*S2GMJ5=+GJN-M%"_=\IA,7ODF);#L`ATSZMSB\/@6?+`3" M';Q),VQ-H3E`)3!U>OQ?'**Q4@HS1S&+J)POLO4G<>CWWF$[5:YCARKB].;< M>Q-DE,?&Z#`;PZ]]R`8X_:3K-T.>FY:#]B^6K&4<=W7\L^1M&B$-T\\2-IYA M)8!6)"[23KBD)T-T.O&#UBT1*MWGV'#:'F/8P#"A629V/@;.TY%]?2IKB2Y( M^59DZK;?D8KIAG2W(JMR%S-Z1P*DF]7=T3%&E,M@I%YCN6QIN>Q(Z/2\E",Q M8G:DS2"_48,3F'8T:@[KQ.T8Z!SFF4\XJLB-*R"2^B9K.C9%`*>;+E0I-,R1 M^#M:&S%;$H+IYBB`3#(3R#II5=-/,S`7GU,+HC/&,/0&">F,22#N/?,N>C*R M)U+BOC/K2LPG+B\C;I3#?NX,:I:;7"*YCB?/N13RI)O18D=:EPR[)#H_6*9" MB&K?6N8\-0L3D$TR,U)$198W/LJ8VQ1%,`70G>N'"L(C3WQWRW$U"90-`J>#@1JL!62G*^F]?B9/'`(XADQ*N MQ,3'>&'BUB"5A5-*$FS:G`G$J=_O%8M3-%-B]R:&&&4KOXNAHA/98EWRCKFA MH=C)W]%PXT,>'F]N;QX?;ZZ%I^?)U?_9LW$AC]T*@VZ*:RAQ!^OSC`CHZLC& MDH$]E,3!9UNX0DD.%@::\>94`#]F3EVAEB#;`OA;.($)/OLI,;;@P(,T+P"` M=Q39&%"0VM@9<+T[(-.`^+J%+R_@?2@GIJ"Z!0?>@HT9Z;^QDZ`!H%G"W`1- M9M.,K`L!"7!I@@>'3[G6+*(XIF4#*@%RM+FC2K#?E&:0%KQ+@Z?`=X@O]B4$ MX@FVJ\R\AR;!@ZT=WS5XH.O0R]],A\+"3#3A94D)2/&9F3JVNVK1;RQJ5[:\ MYQ$@+OU#>]-T\DI8RT@@@0/V*.M!#^]>/8G^%0*L!410=!>%AP" M`!#A]_Z?B"V]'W`@\P5;>WSRPC+?--M_%^*R<"UE!@YQ"ZYU@(*HXQ$W6S/^ MQ$=.78.2\,6[&5B'-L*,PDF)Z(&IK*Q+BB#YKM!<_P`X"L>*(H*[H%J1PNMFZ?WE,7N8%,`9^`O6I#AXV9NI@_DJ6TM$0C."/W7M+U=3O7T` MK[+A%_8F"Q:7QDT`E+4W(0IQB-FZZ:SU`4,+MI4)#R!R&B-M9%A8`.!1&S8X MVD#T?5-3U\UW!&KCX_@74+P*TQ445'>Q_$YA+*SL%N%I1=]D[<8!])R2-D-/ M`:NKA:J70E7520`F#%JC!'V\RQ\A#;!I$X4U,>H-W\RX$)[\1[C>P(.K'17)$-82IK8`W0(P3A#;W&EB=]J:_KB?&-4+V# MQ-7`)])D75]Z*HMZO_`M=H,V2/`@A7JJO@B_P9<\@EXE<^I%A'\5'CQM*GC! M)31%"`L[T8L!`QDM`(96L9VN+^(&%OCA&Y%`I847*$CS#T7",8P`\O<&-V(QH[:(AK4Y_OX")@>\T6/$,(K'6P MX,#$@/=8U`0(3$OZD`OACQG8D.G4Q.<%9T+47J5&EK\:V,6:P!LM>G8KN`;2 MO2489A3AX(;P\L#35*+H,K[.LW_S4=Q[B$4W$*'K_`Z8$6^AL>EZRU]53#"6_X%2*D0NWY-PWF$%J1RV MO1"YX%@R\W40NI77AAV,2$&^%-?-CQ7+*PQ=^RR+NY8*C*Q%:@)^,G[ MGVW[D"=G\[OW3P.P46)DM1A/;FW_;?;DBL3I)N+#;83E'R(U)&2+^7YH[*XY M<2)<$:"UR6!AYY`A$;.R*<*&[#H$N5R'\,.I]OR/2V]!2Q=-&@V,GI3;Q_2> M7];?G2ZF.R<800&.L'-A`YE9G=%KM7K_5'0[V4P;4]&]LXVIL MXS6-4"?CLN:V\7/,!`Z=VW&[YT\",*%3AC6\E@M@"YLV8>G*W+=VO4.(N)6< M8"<6[*%EF-CAV-]F4SH1S$13^L=8.#'=@'XDKYA`(!O.CZLU&K>$JY9PW1)N MZ,VWF9;TS7>%@%B0??N4&8NZ_$[O]Y(-%#SAP5P#&4#`>*^7OB%/IZ@`P20- MLC]B-OD:\BUAEFB\KU,)%]LPG8@![Y\HY#>J4U_!PY'!.E3U,BE'!UX@H4&J[F7S_4R:ZH<2A7S`IW)`GN%,&[%M2M':O5V*:* MV[>_-O8M;S*AL6\Y`TSLE9@`L;8!-]FX`8_+3F!;!M\6'67".NI-Q[S):Q5[ M0,A>7$?2DHT_??,/2^=6U@DJQ'")5JH-Z]5MT=JND/U'#5>PJA86>"BM&7L7"LO180M6#/8O8H6-P$2^NH'>6C$(DSKF.> ME$.RG;7.8HLXW$T`"%J)06KXW-4=;:%K@2$XL;17 MS8#'^TV;A(=2PIGM"S'F.3$>8%6`+UCR]T;S=DLI)!A$W_W#1W\55%G3EV"K ML`YDM.(/P[JL$YD7V5TE%L\LLBF7."A4S&:,,(\Y[Z8P@,(,I/,2^(^AOK0HQK9TFUT/BZ0G?N MUKIMVWP._P_\S-HIO&#S28LV-O`PH/T-/F%[@\\"O>9>5`0*+- MN89^D&#M\8WSB-9L,6V)].OJ`AA[;W* MR*W;O:1T>L).-6*L.=*F5^\)XN;^0`!`2A=0!+$C=7<",=RV:H*GCNN=M?*1 M,&6>+)UX*75[&_MEK5Z\#W2IU,MHK]3?`;8PA?>B7$:;I`V+6@A<:3034WH_ M(ES#WD:&VPA;9A>X<*^Q[>>N`M"Y!A4EC7+.#U8I2*6N1)ZI\@4A1<6S5T4> MR-[TKKYEZD.Q$VW6N1F^M;ZS:'9Y#@X;D';G=V]YP#[YIC%V6%`!Y>*S^=4T M$$/+U'76`)DZ\F-ZW$742UE'CU=[]N=--8NO-$MQY\@9"O$;V%X%A=^>B7R-H9IJ)-T09[-> M9QCW^;%(LZ7"H.0U#TKK)0NHIT^G7&LFFX9*$7OA($A+[7W;4%-9P/3WM8LY M`FQ("9,.7\D[ZZ1_:#2_A3JL[C:M%&B3PXQ;[U6=CQZ%M[`MCT-V&PNY0X?; M)&E#Y3]V4K>IA/'DSRU!AJQ\[X`-%,#DQ=Y71Q^]W@]^S%XWW_$TAH7NO8C] M*H*_1>B>*$0-CD=H['[3CLU!O8B^FBQHJ,-XQ4ZW5V#9+@$2'`]@1^W;KZ:^ M@T,DT5H[^N-4,4%V:K!?*#NF=NCO#W=5'T3*V&/P+D;%YVH*W M.9*QY;#.P;J(%V&(E$."X;Z&2/$1D&^_&58`M1:=![0[ICG&N_3$HF-#P:6^ MMXT'+(QC@B!]JO-YQUH&CA5Z/@.[;F*0+7KEB^U..^58H.R+[V,)V&9-9!GLC&V)[D$I M&JW3.PKWH"AF*TB,I,\AE*24($W)NVE'!$O9A2GGH#O*'.JX_49#?!91QZQA M9MQW2W7"BF]P0;0#\M M9"4NO`8>RXG/)GZFZ0UB#,0NT&W4&O1%P08I@PU&"7$\&H:>O.MQVS&(77[6[+`WM"?_/=H>-<@EL3PQ!/L-6P6065 MML5BW-N5ZSP,]4,'!5JK#+:<1[IS7RAFTM" M(M][ZZGI;^3CSX,)/9 MI/G*OP&^-*U4QJ1H!=R4_Q+#;@4MIR516((_PP;'O+)6TS,P\K")R$(GU.3S MK\5&_"C)'2]]GEAO:`3B-)Y(360Z$4-46'.37=@*<\R2H:Y5'HGV[:M+9X8] MS&1K/K9MS7:>EC9L-#MQ[_DY=D_D=;XA!-C-FM#6&T:'`B8#O3]N4O&X]3+2 ME_K]T:%PHPD8KOU`]L9)3,=I,-@%):KJ//?+QE!FD%"R$3O8PROCN[13GEZ6 M2=%>5]FI>!2"N?1-&H0P+\6![658*]5@WODF]4I?\XPH1CS)[3"8]SW7I%3, MTP^QQ"0#M7S,NY[742JWIYM6XM[P'(&/7;.,=ME;($RETO=61FI5-9JD_TTJGE%BF/=3#,#J M-,GPF]@O'?,4,[$ZZV'X3>J7K4/[/%J,(!/;4NF89YQU5<+MB/F`8PW:3SZ+YX>>;[PMBV(36Q>0ZT0#=,\=9L=:2!I*V.JCI9V1#1>W()!#7DJ"4 M&5%='9;M_[*8B+Y<":X[8^K/>7ZF%09[C%WO]TL9N\Y?:3H`!0MH&J\)A>JA M'TJH6W^^^7_/WF#W>S*%Y](O[KY>WR`^;36YOQ\_/`'8BJGK\L(F MGX7)[S>/M_>3/SX).$P:X%E=_3QY2`/C\>Z77Y/@R*P$]Q=/!U*%:&'YA/CU MACU9E!;?0[^K_N\A:@L8.B667S?__.][P,W`K:-'5S#.3VN5]I\%H,/SW=7X MWG\TL(%CSKT+__!@&K0!?EH*_Z^SGOA#9#MD]$?PBMPY1:8(7.(F2.%:L.B M]5RW$T*U8=%ZKML)H=JP:#$.A4X/WK;'^G)\]7]^>9S\]O4:%DY1IE-%V944 MW0P?XRMQA"=9)_8.RWI8].::JN))X$;TBMZAG*U>`GK_V`$K.C4V&:V'\?7U MW==?_%/4GG_\?7A4$P109R!ROX8-BYXTBW8[$O=KV+#H2;-HI]=(T89%N6;1 M[J#/_1J6R**<>!U3^I^RO(Y?+-/&=BKF5'.$#SK\\;&J-<^-:#W%4G'K6#1Z MY;7B5\FJ7^[5L6+5A5296*_-,&EYM>'4[7NV?M%SE MQ$4I_V`$'9-3]D5Y0(\GH<1-C.2#V)+:8F4^<\.;#6^F\69[.&QXL^%-+GFS M,VHWO-GPYC[X74WN)X^KE*K2>+73ZDJ]D^953AP-W^4"/@W-<;@(B'W"L3'.$UW!DPY$-1S8< MV7`DM^@U'-EP)'<.1KDG&7_$YURMN1+,R6B..GA?W?JTX=B&8WV.E3">Q_V2-AS;<&S`L;WND/LE;3BVX=B&8Q,\FI]H+^?P@_9L M*KWJ:5UPL^KDYQ;=$;MI[=VT]M[3VV\ZQ%7>E8/C/H\;L6U:>S>M&X]^$3G> MF)6U]MZE'P3/]&B8H[C6W@UOG"YOY&KMW3#(Z3)(GM;>G/)'8Q\V]B%7N#0= M/YN.GYSCTK!HPZ*9]/:FS?T.,@YYSIQ8RB-N%_# MAD5/FD7%EB15UO.I8=*&2?.-2&ASOX8-BYXXBS;9F=7['4US[^,02TUGS^+G M8U3FBC2\VO#J=KS::3HF-[Q:#UX5VY4-=6EXM>'5+>4J]VMY_"Y*T]R[QC*I MEK6MW,1(/DBM45\ZZ<:?/*#7\.:&QO.=TVY*RP-Z#6\F\V:OWS2>KQJ]AC>3 M=;IXXHWG.7$LFF;>O'F3!_1X"H-PG1(Z&K1;PV'3RKOAUWKPJ]B2>OW62&Q:>3<< M6Q>.[?3;+;'=R-B&8^O"L3C@0^R>=#U3!:V\$_^@I*:MHU],2R46;:KLO9TB M^8EU?:;7G.ORTG2=3U/M.U$_9S9G7CW?6GU25Y"%/UK!1Y\2__S)M<]?97GQ MZ4F9$=75R63J-=+5E[>:(1N*)NMWQA27W]%,XQGO?";?G4O=5/[\^>]_^_O? M!.&?"]-6/M$Z^2O3<"Q9<1[DY9P8SC.QYO:5:P/[$FNL*&3AP"/)`[&PZ0'X M7G`=)8L"]\%3'\GT7VWBE&3(#D%,KG39MB=3>L'XNV;'R#1H MA\CTV]-UF$KGG;.?1:G7;K=#V[847!,I>F?;+E&O70N?#?B:ZN^R[A(0C_07 M.P]3%$@H<0="9:&0$^\G&AUBW]^:%N#TIBD')X`4(@"+5X5I)[37[1=,T!VG\AL@WR1P7)2!370AIV/$\(\(49(?Y#E1CUHJP`,8!=K4%!WY$1E95HB(-O66"Y;2T-[`> MWHB@!\O0HM=?F?.%;"R9.3>4Q,%G6S`-?2E,?>,C?(\P]]:.!FLMHJ`Q!7\X MPA066GC#E8;;-SX9@*+=G62,\;XP82?8,T(A@D#HSC3T_],:91BQL8[X49'C.5/`[SPH=L85=9COT.>$/DO"!/L9T;?C& M_OAIS7+D;NE3+.X"8.5O'DOPST4O]/IAQG"6-6^GF=:R:V^RSJ!IM!;!A;O6 MW9NQ[:3WYKY':1K@OTL1;K.8G"[FZ?14/X'%W*6.LYZ+6>\&^8VNK!:7IF]N M-JI2_7!MUNVT4&U8M)[K=D*H-BQ:C+7&6=I"D@%WDR^8NER/'I[0$3\/Z/&4 ME%(-?D5+I88]&_9LV+-ASX8]^5^_FM8C^=F;[#!0ZE?60"_)]%L[0JZ*"WBH M2N,!/0[J)/GI^)@@K\ZY7\&&01L&Y7H%&P:M"8,6W_#7MRC%[#G@U[UL^V.VQ@;Y=LV:.Q M\'E`[WCC]SEBX MCAUZU/]U97\BK9ACX./P>[F'5YK06W:8/#$K?-<-V+'?N5=?+CH"C#_#] MKX;VW[7"=Z\P/5+D'CS+]OM*V$WM>116_FK/5R\<]4ZJVIRS\-0PH:V:UR(' MVSSD['6QJ2M$928!#_$?'M"KO]U:;J02Y]15=@#-`Y-R4F12G'>2)-!N0YUS M#%JY=<:DE2B/NE_/X15JY-MHC45T%'5L; M?:*0AZ3"/XX9EFT@\EA#.0>-9;#17L!#`F\;[Z17SN=PE8U-\TY9$_*`'D]" MCAL;[4.OVVU&8E8OT,JUT;##I3`W56VJ*31B)Y#O"V+8C>'%^VHVAA=#K]LY MZ40'3J14N6;7O6G3-JHA@TNFC:6]`+:YA7=YRBIMU[9RG+'(X0E0UT#;0.J? M,K]S(AS+->&*.S_R@%X)DI)3_]HGR<[%PT4*2+'5:Y]T_@$G`K()&QZ3U#OEL.%A>B(,I<:L MJUYJ[:W*FK#BJ;G.IQ%6[![:)MQ*>/;[)SUOG1/AR5N8T7.(FX:#VTB*#D@* MU71I?GWU',)/F'$373BV/XMTJX^K95>:`(V5\=6]W&ZW2KFU<<&K&>JW+B81 M?M$,;>[.'W%:M>Y-LK9O36NR(!8\SGB])[)-[/W+[_K'5WZ75`;&J`K\2\DJ M6)2N-$=3\YP!UP`^@\UCG"NH!G6=LM\4V,C3=*9/>MAS2/O-$UOA1;+M%?_9 MIUXCMZ'*BY?BNZ32.29;]JJ=*[WV[5!C`TMPU'OKVN_?1+8"+KRAE:W!W_X6 M"\T6%%L[Z,IZSJLI&I=B5O1D<&N&)A7C`>^.-Q]G84EB"]1]]Y3C(K4,%->F M-/E05U^8K4E8;>0817<[J+X;-.E5*,!W;F M1HJ5>,2;+,5..@/^6$PP3J7886VQWK`E]@95KSEW=D1F!TO%]/>FT(E*;^U7D.O3! M6WIF@K"J?L/R$.7B`3V>PAO5X,?E;"H>V),3252NV30&'\8K"@3O8N6TY*^F M69ZRLN(!O9I*L,,&8S]@I7.[Z9#(0326WP#LCD&L>$"/!L_&ALH"MC>LU'I# MI$L*1;JD>-A*3(]$CGJB%,3N$M^Z#VAIF>9#*16T8;2<+_/U!EPW[Q@G=0S M`9D_7+H)R("BTBRJ>T+5"R#\:X;:,2V3V`GO12FAX_]VU*PA=]H,>9NS@(S=H>9FU]RRZ\:M3*JQN>34#J.`(O!X\KU?5,J]MJ MM]OX3[.D):?I[K]^28;0!_FD`V"+ M[:3/12-VJD:O_I9NN3P*EF[3I7OU^?`)-[4YTZ_R[#^&(?UW=W316SC;(OM! M_BC\X6=<$#P[)(*M?1?FIN',;$&>@D5$R[=4V2'8R/Q]IBDS018L\JH!DBP) MT_;32["H;*KI1*4%8;*BD(4#?[PLZ3.>B.):K)7AS7=EAGDN]*A9LVF>YH)8 M<\VA-6.R8,OZJN;,IEDTK!H&/:I@M8%1_F_U':@XMN>=@\MWENYG/S<_-F+EY[1B:G^W\4F@@5 M%'X.(H6?FL'^681:7&X'9LBZOA1L MXM#L>Z9`0#JO9>ZUA!?78?>1[PXQU$`M8,*D;.!GRW1?9VOW=LN5Z9OE,/_) MOX?+0XUGOEY[J:;/\O>Q#'F$?;0I%)&TXDBIL4A(*LD="VM&`UZ[7#(KR ME0GS$'?O1EU@`G"Q_:P/EOR[:S]L7E*U!KP$J/9'A9\(?PEMG3,R!YG*%NX\ MIQ=_\1,(J?8.?S$)BBDB7S,5Y6S%6H\ M3M_C;#<>9WW1X]/#/#XMR0./-+PS85&R>@8*,1QHNSN9.33X&AV4J4[J786QP&IQ9G) MP<-.2>D[=:P]&3*[`&SN*S`V'$W5=!>'6@9=E6Z^*[JK$O76,N?X)M>A+YI, M;V0+YXO8#\2BL.S59V#`=Y\!MA_;V[3"\FO65T*(WNU]Q^K+_ M<6U'FRXI^+@6Y_YB"';0X^K#"RXY=D,)AI'2(:5^$P-:X?L1=JPC:`9;.BS^ M,X@CZ*9M8T,L=I&@R+KBZJS9U@>XQ)F9KBT;JOWQ$&T.V+\I!?(3]30['@3_ M>.3RWC_(&'[6M#O8M::XVS^F>O&#'PY5B:TT"%?']]90Q^E6`?HWV#,J--3, M\]B#;\!U/YGEWC]"T^S9RA>1XSV[331UFX87.X;6>,:X6?ZMEG^7LJ%Z;N^C MBZ(GB>W0O'&!C:$6QL+"'T3-&K6=D@PJ<:==J_5KTZ(-?S;\.])\._Q M*^&#>]^_\**$&Q_DZ(184^_3<&[#N3FR'VN0]7C\JO?@_N\3+ZJW\1^.3H`= MUG\0_?:DW"]QP\$-!]>;@X]?$1_!)')\8.ZTETAU*K+_6X7^"& M?QO^K6<,Y_C5;[E^,"UC\J>O[S)KCC,SAO5R4O#O?V53T%%@_FXW%[!N#7CCJM7J_IM--P<#TY M>``FXTAL3GJK5[EEG_2R=@W4T35WGJG.&:9<"BT>S,CC]A.\QES<+W##OPW_ MIHQ^.^4%YD3IENOG;BHIJEH!-U[#T0FP`_N][4'3%;-Z]!K^W95_>_7HZGH@ M!7QLO2J+ZBP9[UUY#?K\3<:G_B)KQL0(_MZE!^7P3'`-C=WRV]/UF:`210-6 MLI$D/_?[/>#0`+O-[UZ#TB6(XB/198>H#[)%&SE&`!S;$V,S8*/-@)UWSGX^ M%]N=&&Q);]P7+"D&UJB=#E9>>!:FK7P:*XKI`I<8K[>F=4U>G%O-D`WDSRO3 M=NP'4]>4Y3X=1DX MQ.1HG1"A/(SM6%WJ<[QKSDQ8>!ON?68*V(UU89EO&@I@00>\SAUBS86IOPE: M<)FFS(178A!+UO6EW]M5<&9$>)-UEPCF=)4P(Y@6_6$J:U;PJVP(V-Q0Q8ZP M:D12>GUDA2F1'=!W>MB2R M9:^/\*!TU!*E41:M^=]8=1("XX0A?*W(;C1,AV!#M)]C$P1OG5%WC M+45"OCZV*,I@*UP`!08.F.),2KCP_Q;\J=D.%2)@Q,!:SBS3?9VM+7PW>"[8 M*_1!"]AZV)93%:;P54ALV>Z+3?YRX3?$&P43RJ7USD93NQXDT\A,XZ\H7RLPJT>[)JZS?P&HZRS%P_K<'<'5!G9K6DD+&KG-MA`>)=&>`Z^(B M`?'J..K=5-0[L1!$!G*;9WWL.CTD#W]]8\&"7]S.B(O;"9SE-(Y.VGHXDEW^><&EXPN[53CV`%Z=^APHE4$E[Q8/]'+ M?T/S,?S%Q'5L4+_(Q)&O=SZN;U;[,*O]!\&32:*&5VT,IJ+\&EEP;UQJY+L' M2U-(WJ,?F^4[L\/M->1V3K1X90>X3>?/M)W>@9VNFBY-.*[> MB(VD/*_+(IX(Q-$I\Y_E%[I]JC0X>-@Y*2T2]Z\G7K5U2.PG$?F#DIK+YA+%%?JGM`[`>V>F M#HC;-W^Y<.=7TR%_>%V6)M8C[D9[KUY]_5,H^_?Z4@7E_2^X2MC,10G/AB!` MXC=9)ZR#%;\-`!@4I5;\[U3AOW-)?JZM6H'SL[_-WQMRDN'`M?NRX52$MR*U MKR[U2+&/"*NPYVCY$FV!HBL(:[1\&47S15;#-VO*QYI6T`CAL$M_5+'$X@[Q MDG1LRK&ER'T@^0CS"JLY-1AV6CWXI],9?M"[%7-)\TVJ/DVJ)7\![8_:8[GQ-(K[@0UR=+SHZ$":?+-FUKA(SJ"X0$] MCCEU6X.LX=2&4QN9>N*G]HE`-7FOV2HWHQ<0\;EJ]7CJ?,H)P;2@4)&T3&%-!,,)]]M MG!*C&<*"SO0CPD*7%3I7AWMSFB?KBFO/2!2[K6&UT]%Y\)%X0(\_-<57N`GM M*>X7L>%1SDVIAD=/P)0Z4*PIQ\1G-*T,.F-UP29(>90O<7KJ/,J)<55NG(K'X4E\A9UXL9T**?7?N;-4 M?]#J-'&K`Z!W@N>$):+.8Z)ZP\AU863N@EW\=Z@Z?GOL8(E5%:>:\Q7!XM2A M*M+&JBQKD@=GBP?T.&9DOJ)7#:R;Q23,L)\959>E4_)_=\CA=B&/7JM`V MHI)4=>HZ#PX8'\-TN,I<*6V_U"*&=MKQ"#ZVPW&R/_>1N*:PWI^MN"6-\H#F>"2A0-=H:-4QY^QNT6(NGA*+'U(F2\^=:T MID2CP=NQH=[@D3A]`E_+,BQG6W!>;_.4B>[W!_T48+_K3 M\W)!UEE.1*44IDV8(NVSGSL2*O.`U3;`R`D31(;M??NB&=K(_/_V`-9T(4:I7D?^%GP;O5="30$LTRTE2$;'4BXBE[&+6+'7"0% M,;VAA>T+J:<9ZR8Q?+0=RS1>:21H=$%-O>";'?R`_[BVHTV7&:^ZFGSY;K\Y,P_GH-KLW79_"0;KY>W=T\;0-$J=;ZY\B8R'-&1'\U5YS%_NW]EI6I@OBB`;QVRW!F1$!9;9L+`4ZJ8ZH@F8XIB`;@@F27T:Q"IXX M+H'L+P'+LI#A9LU2A85L.4MA:EHX-9;,3-?&6S#9PIQ.44&A2"+8"O"K)K_* MEMRB4/[;M/Z\$)[A_>SI+./5QNN^R$M*L2D(;9]D$9?_QQBR/[9^M!'-']?\ M?(8XFEUT/?")^$W+0P&11%T#LDZPB`'/0SS@:Y2:^(.L`Y:`MK`DLF5?"%_@ M`3-]B1<[./+V'T7"*;:&7L3)_B6OAJ@,`@KZ:CL?4!@$&Y@=X% MB"\X9#Q>=T62Q(1-\C\NT'?`9M]MMT4V;`RV`_#3G*B:`DREDC?<&K)M@TD& M;\/M$MD^#CSFQ=5T5-ZX)VXU>T8L@/P.S"39D-ZWVL!-A4X'(RDR8X]X0II8Y+W3WKHX>P],(5V^&W6FZK[-"W_C5 M?//>V`D==@:R`Q>K8(I*PT$4K[+)V#D@&3MM^LI^5+0%0@$Y69Z;+KP6>)7N M)-7;,[`/8#/9`ACQU"F@8\87"\L$?T9VB%ZLHABU!GU1L/]R82<*4T*<&,3< M"Z^:"=H53_9\80LF_/Y"-E60WKLO+^`1`H#DNVQ'Q>B[INO""SF@+!5;W4$O M79:RCP@)?K@H\NV1%_//,77B[F?3`35/S42P;,$T8ZR)Q@0U)8'+56"PM;P: MJEPP'@I<7+!Y.>RVUM1GX:JL/VKUO&9+@<($NWY!%$=[`X'=2-%B82W23XHL MVZV+IPO"G$5D*2L#1RM!W$UP@84MP3"-)HNLWH@GX&=%$B$45KNGI^N1<%0;PTU>>"\6 M)%R/6JY?ODHBNYKWD_^^"2\:3:>363' M+Q.IDC_[<>_!NT2,"%-S1X'OSM;['@&]AK.\1> M=Z?";E@/2DPGKWI%3P:WA!2@BI"K:X6SU MKWP92*UN]Z2YF!O95EXBZP;AU;1!.()&FYQVCSIL5G:_4Z44XX&=N9%BY:FO M#5*L?\K*ZUA,,$ZEV&%ML=ZP)?8&5:\W+U*LBNJ2T@ZCZO?@HN/`93Z7VZ2< M%10L^T]SM%=Z]$^AY##OK^XG2#3AR2#"D,U)80E/YKM!+#RKP3\L6=7,Q4P& M\:@0UZ$)3/!L=RHKCFOA\8YWYK.,)$M-09X22U_Z&1V:(5Q9\&#AP=0,9Y7) M1(^4B*'`%9AXIP3Y>(KY1MB1J6L3'YB%1>::[;5SHM"1N:P9"`4];55=XAU, M.7YNX05F/@9)/=UU1/&L5<:$=`1"^(^KOM(\1_D5GFP[$:P`"R>2K_*/8:_5 MDWH7HZ&PT%U,8,3T!;A+=CSJ.13XX0_19`,??@8!3:Y45\?\0+55SH'W1O\@ M+O3F'I;8`[:.IM-+5H!KV.-*HR37L)LH7&$1ISE[+1;6.YJJRHXPHWF"R$^@ M.=[\CF2R<*M9P!+C.3OVQ^MTX"T'5RC@^M!.\#C/(CJPCTI7\>IF0IEF`5M. MT1:P">T9S73!(DG&6^RAVG2Z8E/%SYJR"?D3-PEP&#%@:V)RU09.3WL/_27Z MN)G\1O#&8.D\,K`OAI(X^&P+?\"60-:&?:_KFF%JMI'/!"90$@"DP*E:O;"1?+A=2^R3=\9W2G^4_R5 M@[<+*C$T[R99UPE3/ZM]&*P=)461!H4=L2@`CBFAYWJAI63X!\L:)`1[X`'. M5&XN`2#YE:QO^?I4`V]7XQ,IO*)%`^H330F+UO[T@^)#_#QDA:`/C-"!M1$N ME0J^Q<)0-Z$*5&QWSW[.K0>\JJD0C.NPK^H=O(QSKVHJH;"P0"1ZJ76%/5I5 MF`EBO%+KP0(V!B95:9GM[R8N(JO>SE6ZAN*7V+]&GY)8K'NER[;M58XG8=<_ M^]EY!W$%U@'F]GV0VNV/PAM61`8LMQG8Q.+FA`H\7)-2P,]?_BVV8W7&B15T M49"NM3<-Y)[Z"-`\$`L#6R`]#KQ"X5)J4`41S$3$;+!II9+!7T?95,#*LF]! MN82J8J_)BY,+T^@]7E]1_"6,+3[M#G2IY=(R1T#SVV^&I\K*,;*@%.0C]/I5M:LWV7=)6,5[1W$8S)=M5K= MOI923"]8!@LA`FGJZ]?V(9AE&M@1\-M84=`TABW[8.H:JHE]"D!%L2D`32T` M]<+CF\-M6U6*;EDHFOZTZYNGJ\>[A^>[R5=A)U07$MNN&1DT6(,G;?C!M#<$%!\Q:F*Q'@/`!+6O?SY36/$])_/R1 M.N/@(GIW@>5GABI/I'9+$$?#CN\^V8YGIM/R$.KB!5XY_60I&OB:7FJSYQ?" M$_H70B*$6+`D&*ZB$]DK_P/&$69$UIV9@GG/"@,Y&AP"UYA8MK#PGX@Q+YL% MQN;FJR4O9DMA;NI$<75X+*C25W03[:4-AA9040$/FX;I$'[;70`T#@U(,']; M=N$QE!1)H;W54Q)^9!2A/VBV"0H"_6^P*^Q5T2_\J;K,5>6?I^H4;4+VV+CD M`JZP)YMHL,.33[@<:!G;`7/>^*ST'+#2AX>;YX^"#4:402RO*"H/DVQ\K<>_ M^-V[:>EJ)!0TI;$PRP2*:HK_)+\Z9F&1A>SM'>0GC.%@93/@"B])9$EG!B[V M"E$T-`75M)/CUN`5T-(%+R"]1E"&>X3!HZ'N31@3`Y6^'0DF.::_.T);(_KT M#_9'!C\5!9;&H%16':>"6C2`UA;WKZ^6L6`#N"AYPSQ?^NN3L.0C^\F3E?OGQT M=@QQZ[>S:U/4VH6A<^?W$,[&H-WY2L>*B=$@#<8<_R]]HH'X"Y@/L1)D&/#2 MW[#-R'[@AHH)<06I@-P`Y/@@:3\1Z:1[W'=VKB+XSVM#7M--@>*G6!SP`%^, MN#N#0XW7()-H7KO.1^UUD!G;ZF*+\P4]N3AS0+;P>+%3Z=5AT0U/'&1GD:`D M69>+6^WS04\7,!\.*R#3QX8AC21N"2K/NY/_&)F"CZ:$SJGEF32H#GE>'+#!^ZDG>D1A^#J2B4L,)>=?AQ;LQW`*S+H;)H-`\C`5(FNAQHKNG MD[]\,:<6FH$VP-!VG1.X#4G4<;5^9HZ#(@:&G`<.]\4$I@#2]N*=LTTTW"#Q MJ/%L]8..3KD`01R]E]D9^"ICWTYALB@RV6URWFA>>#WF\1+NEC,/J89+>XT; M8J35!$4D&0:6.2AUU!)>HU+8]A$%SG7Y-)'O(I_\&@C\B_SG1!PG$QB'HRPO\B&% MKQ,[GK30Y2_10A,:.C!_-TE)V8A3GYS8J8]C1[N-#C9#*TJV3"L$6FKO%#O' MNJ([Y60T@K-!QKU3.#QX2!K'&C>&QQN;P=5F:$XD(N22]"OPS8Y#D:+`NN#1 MXB#.A`[YV1.1^\/;$:*QLX[ MU"XBNI*BT(_)?:N$JJF.'I-!PUEIEO7`?'.Q>GU[DG"?$M447F,?.5 M9HTBS90B4TFP4>T5`PPP9R;!F'\G#$@.&Z'':ABR"(X$9RAF!?I-&"+]4&PA MCSQ78BU9"^G42%NAS$3)6L$&,0AI0F$*'`+M%.3;1S?T=-=G?QF09!/@XYVXU7UCV&`\<4Z_`>MH'"1B,2Y M%/'WU@:Z>3)A.=]$1N>R>$Q)=@$\G:0Z'@R581(*D=]]YAZJ]\#+*)K+.<.? MJ:YRP>7R^1/Z7$@W!P59#FDH"S"C&#(#-1?#MYT;3.X)%&^5':&Y,IF#,B:N MRC%_DAR"0B=8SC2GU)EE28BCC'G662O)5#K63[E1(KGC/H6%!,EXJ2V]@Y>;B]CL/K6RE4^@?6K2>1T]".U`K$HZ:P;2+131&HM%,9-%J0B;@RZ6N+/0E5([24 M%6/;7!"N!-8#=L;B!A$2?`$4Y,%#?()R5#33\EA&/'F9ITC&7YTL MRDJ2&\F06>V81.@9LKAIF6Y.)Y,F+C1F4K(")6&@K.>%Z3`9I7XNDV'A&_05 MJ')TLZP+B92!ZN`0(T`51@X.*$/1B)5I+)V&$EL$V-[,@+XH"W&7-C0,M^0R M%#17&CNYA.J2F>,.V/18YCQ0=I0T`SJ(T!%.A.LD\*?7ND];%MQT%EQ;P_\* M0X]*3>'Y.2?C_UF0L.`&\_&=$PJ;:,7>C;U&4,:]PBP,]+44/,9F:L7)U<=" M%NO@8,],='T2#>7OZ\@@'>TC0W-(.A8!>;%%PD&@!LD9[4\^K"FT."2<,Y#* M_^8@9@]3,CDFG'GX2YQ27A3=54&`L34"+A81R:@CD,#G;C_E_9;U_&Y`<$=K M8VMLK,U235O@W&@ZH7T7N+M)8>OD_DKZ(_]=OHER6T'1TF;'$5*10IL:.1B# ME4@/NXC<=(*916BL!H)"@N:JR[P]$:NL`33=902,:08X5C1/ESO]\AV`]J24 M@P;R4LPQQ^-H0:"H#.J?7(XLBF9X[*1O$?JX,7N70T1LL;-\L&@FK[S,\_RH MY[[RPH9SYZGRFH9EI_:QHH;;))\UZ)A_,D4=*C&K128=K8PGF5,BFY9\'`U# M*R+$#4!%G02E=M,;LNFKTD31:Q$D831KG&:R,2J6W@(*VXT4G(^GUD^BPE,<0(&B;B,85F$'9P9K&[99$(T]CHP\`' M(8$#*Y8GA+4M46X52&\FDF`K.K/!LJT;4WYL)841G[Q_+RU577:J!V^W>5\M.<%/KA/ZHA/\.8T" M0:E]*)B.Q#TA^J]KVVVHB;J2:LWUW,('W;75@;1AYRPYL/5>N51X!DL\H2PS3MGR8&M]X;%L(PT05M-P02XI3RZP;?KH'NP MS3MGR6&M]W:]Y#%GD3M>_V&U@3\W^&9M"Z*O_ZC6>Z_^QEQ,PHCFO"[;S*+; MR]7BG:LT/FHQ`>0E==FVV3E8[5C_)8&D<2\ MP\(B9NH_ET%U*GQN,9T#L9@P9ZDKPWIE+&\'$9@(ZCU+J&!!(K!6/(6>I&3X MQV"X/*(>7PU5;`IE1TE48!4<++&2,N@D?'48AM_E.':=L]%$2RSC9F3UGKS%0CC?"+Y5\8OY.M`15Y`P6[\%" M,;'LE,4ZKR!?@K)T!6+GR5C`*!"8T`AK;"/]6GZZL&NUD`/6@7;^T+3].0L3 MRZMKM\QZ;1.Y+F7$Q#\(%F`..:53!CAE?#EE,PHS(W0LUXU2OH@TGP:<11B; MK>#?X?4I,+-[BKU1"1K$%E5$\Y"[+(TSQACG^$(!2Q1>O<2^$SE%%:*VA]P7 M_)87JSJJ)$J0-,-8"IUQ7H/DSLD@#5@[&9%H,A?5N@5Z`TC"T7UWDN@AJUE7>K@@D MCI%'8?Y&Y1H8:G*'E2=4&WA=DY"CL@.PO0EG"!5)-(V%%UH:JW2L?VC9R!2W M4L459JW37YSD+I2JM@+AP@;R M46AD:Y_!H^;XFDUH)9'/,K2,#&1/[?6]HU[5T:TH[#P:ZZR-:AB976+.GK?. M)>&TS*JM@K/W=OL'(L@EK%+3XN*S!5/>`U+>U6PR#'UC-8_?[O4>$>T?-V^: MFU2,`0%Z=7H:]/J@]][YOY22H(GED@F)R2PFR1(5,+F'!1VH!K34Y@SVBOE+ MCBSO@T2>S*92"P4:1[!?79L2DZ:Z"6RM\Q=V*-LM%!'+N\ZN%CT&$=R&_BW5 M")X;R>(A>:(%LZHL`9T2T)5[KPDV.V'RO[OT4WO6MN^L]9>?-3P!,5Q16.5Z M2<&GA>/X7AX?X[PJTW#QF#[>5QV8=,_R>LA2Y<4R2_Y:8+'(N\V:@R M;D%LS^Y<\VMY=7K8CK(U%^[>N8D]D8=XPI]UV2V#J6$SN`I4I3M,([VDTFRE M>GE`-6@91Y M-J0/FCJU$1_YQ>IU>)ZH?E,1YS"\"Z1./XH1,25-=/O%8GAEFI14"U-95UL? MV?+1=8J6VJ&L)X-(,E))R(^^4@X+^$GM(;=22VB>^1150@FZ1J2J[AJJ+JJL M'Y,A]_#>!:4.[S>D3;HS&5UJQDU;\%$43U0`-UQNQS)O9Z7X>LI=FV<"&TJI M.B)E+;M9:6FLI2&+4SCQF',->@!-IA&Y=G+0`VD$)(V6_#?"<);,J\&/`!49 MB$4[U$R8QO!-_+K-+,[O@R\4@O)P7G'YS3V?\?F6#P]A@_?R9"WUQ)?3S]>E MOV=+!KN3_2/94F4YR7,994L'>2G#818>>').,\;R-"VC^<@(_AD<61.W]>.3 MV?R,YL)L!S^_PD,!5`J$V"\7[?+Y]]K-W)S-[+>;N3F;^9)LJF9NYH^'>+=W MY=HW<6US>0Y(P+9.M21(W?:YMONV75-M2;29^[9%4VU)M!IIS;+2O#LS.E%B%IIT_RJYDHM>;;DV9)G2YXM>=J_?PW%7;@X M^?3I[/=_*6=@_U![2%>>O5\F^BT6K%H3%=B+PF`9HD;)]'ZJEC=I@E6.X8.U M$6P9O^I:OX,M@;8$:O4.M@3:$`+]>/[E_#(SV]5%L(>=MX?'UN_J=@I_]=K] MUG^H;9#];9A>JYJVJJG%TVO)LR5/BZ?7DF=+GLV3[59KV'M)M.S&2/@V3&]S MU-+6;M(2:$N@%NY@2Z!;3:"#SMOCEV0X;0R1UII@GBZ8=AZXPL?9:3@)K,3J\`!C-9UX&Z35?;JVYEF*G/UB;`]H&(K4DR:0Z M[:2,H1E@QD_G:02?C?4(XA2YX38K-S9,SR9'B]6J>+_3ZZ^M!+L-U&H)2ZM7 M1KOD7IJ#YQH:D@?_)*')VX#E?:2_$A26048;@H:$!=L1=!^?G$S@J3@)W>_; M?!/:,#V;F)PU,MK.P?[^:^NW;O,96KTR&K"E!`&("4*8\#Y53;IMOLILF)Y- M/,EJP6M_L-6!#I9PJ7K%KB]A3#"JAL#%/#3C*@-V^`SMYV#O:V./["$0;9FPTWB>MML M-EP-)L)QOQ7KUL^U?O@J:\V*VZ8Z;X=9<7_5,N&SF.?AX<$VT[\ES-,V,Z-2 MB%O`P>=PB@%P"B],*;Y^_11BCYEQV;I8+']6J59O,&277UONEK4YA/;D1,E1 M6)K;5Y:P=5TLD`JWD,YV79[0L1Y+&E'GG?/"9^[U[Y8Y#'P814J7FKB[!3*7>=YV/ M8Q;<4"3H?,%7-9]RIYU*T:/*M/!JB(6IL1Y]"%/:40:8UZ7)>EF*'G803GE$ M1IMXU_DZA24K1JWFZRDC5SVT]8`N1*&JG?FU\EDJ*K\9@>`* M=AYZX8Z;&X.YE,XH]7W'$[$;ID%"];\+]$5)EK&VF1%-,=>->+)\"W1GNE$G MA%\E1?-HHE\*PH3'Q?[&3%8G%K!,:CFF48@Y?!C%#.^=7'UT]H_W.G3>!5GW M1(PUR5,1CW'1OACRW"@*)\[I7RG6*D=>0<]WT)]8"5SWQER'(!:"AQ]"(M[RR)!"9)!2G*EFGMY668993V& MLU-2J]PZ[K:"=-0L^W2WK%SZLZ^.VF[OZP(;5*>,SJ^G>"UN>AFW=0KW; M#T*Q\KNY/<(V$>ZJC_!+_-U]@J<[S7":P7(KX>W<4<<2A`Z&2 MQXD3K5$\LKB_4\+F"2+T9RGN[ZT-DJW4W?[9^5NT17-<1?*X@4?L1 M7)NLQ-PDCZP6_9K*D3=!2[#(4]/?6QI1: M.T%[`ALA%-1[`GO[VVBILT0LJ-=,<,VCB?4B7S/YT"8H)W89!WI4]ZG=S_8T M;M+N-=54T)[&!W(D5U,8!RJ3>(B8E/`SYMEV%A[-^Z&'=!(K#,/S!&;(4;%0%7:E$E;C+&DZ;ZDD M!9<:]`6_I>Q/3-W,F\3!.$;2K_V$U20N;>;_JI3)0O)T.4G*K,IB1N6$)^/0 MDQG%4*(%SG MWL(:5+_25![ML;6V_V`UB0F%C*SFH.H1"HVQ+.>*R7(P0M%60!O/@IY3SFA'XQD7`&\$J5 M(U_$QBH26#87F((<#K]/))=(X=\1_"FQ&@@%`D$8HC"]&2]L_'[>+L@KU-`4 MCAXFZ7D$/V&PK3@=QORO%+/`8-ZZ_OCBX=Q0E:SIQWY5&MJ9Q)VY9O<*_+)) M6L+&J#MJ%Q+H()!X@-*DT+E`#025"E M@3>G:30-M6*AFTEC-81\@-F#QO#S<4=8G1.^&6`'^`@X5!HW/BN7%QX M440H)N9#DBL`$K#OT[M#'!YL(.AOQ;$O6RK:3$*CU1N!'<$.N'*%70-#"EKQ MV9UL`U-C,A`C3./-H),"YA*R+6B'/(DN-&+ZL?E MRQ+B[&(8*1,!WDR(*17Q6P%T3'A!2E/DMPREYQ3(+Z(YS@T$=$OFR[D'WH+2 MF>F:T%T:9&]YQ?'#:AC4HE[=K=6:9`^#:*V)#U@3#;9N[V+4!Z54AHXUXAZ: MN.BX$4(<'1K@-9,XXSB98HIL>EZLW*-_]W+]%)D6R(__`29%\-GW;`+(=>4V'70'=T;.4OH&'8W.03,^Y.#8*-$7F82"F\D0&MIEEC:GM!E M)'KBNNE$X2F>$VT@P48N'#:(Q;$OA+!#%A]D'="$/\2;1^DYYBJJN[Q("26(1$#YQN5 MYKAA#D7-GC;.)?7NI#VMMS]`XP&(945[W%)SG"'RZ:%@0P8:)DDI`4]4_RL4 M0&QF?ZUHTR!'Z26(_T'*G4LI:>/Q?(S];BCM;;0!89EL&,GM5S#*Q'X3D,G( MIX$*J=;K8N83(YYP3[@@2_*_4C$E"*EI%((ZGD#O$X;*7$",TH5MC1A]#21P M*UQN=$7JJR="$8=).)6-@Y9XJ1^@7DM;R\"1E5)8BHZKG][%]9CKNO@ZJ;!3 M'J$LK*\:FJU\+UX*Z1L5AOKP`BU,5Z^8U,+A!@K06'`UY2[5V0*9N*,[T-Y: M-5YZ`<8;IXRN/4XIL:[V19-;3AHXI,485M\##1\620($AZ[RE^^`S*TG";_< MHO;/49L/"#[X=4)><1G#(1H0T`$>`YFB+PWH%&Y/`D?FTT3"=9,2`(\EL!Y2N!"$\SOU M80B9VJ)7'6T")^@#2&-U2(_VWSL7I]=./(L3/FE!@:L=ZV=8?Y#'$@';T>6^ M)#F#_.("!:-ESM5&'4*'UJ\,&1K_I!5+1%+.1,*.N>^3P3"2Q_"R_`79AMX#O0++25M]22:J5C M_ MLK#IZBK)B1$:@J_Q=,"9T&R5&VR7)C3D!A:?`*OR_PPH*,BYBZUK&L:)IIO-(J\UI%&\N)%7B\B4,-BXM"QOBMU MKQ+#'?MM`@$WVB+93#6I=J.GD\RF4G[2KBT4,H#NNZ3F(W]7_AXC&*2 MQ2G2R(7S#)(5%;[2LMNN,,S86"Q0]797)M M`.TV[)SE[.:2Q["?L-U(])^`-/Q0JB2G*L"S<6KLQNCC)[X/%RW&,!O^SLC< M+\_8+_DDJ>AC%MTH05HY3)D1!RT]JC*.&?@(B[2;57M.01U/IU-??XUW/8KQ M<'/KH-]FN5K:L]Y+P\TW$=#Z&E)'*&M&&1U/3E\9&*3YI?1#H MF&$^9-='B5#'J7(=GE6K7-4*;/:/M>E,G(JK7TA'/M9@N\)3V'+PU6_P6F1A M4$#I'QC2DZ^ON6G`_2]0'.(<:FJHP^=+K3.RK>Z(XC MDT7.#XR9W?!B24`G3!.R@^&K1CJ.TG0=*8G(&P%V,\MOPCM`AAMXPD^5`1I$ M[3QT$ZVV2N#V\I*FQ-O;W*K[+L`&TW([GD M6-3).9$!YDA@%]`I?':E9Z=QJO;&V`SFR[T*=(9.Y#%G&'\.;;%\VZ:%;9-1 M[<14`WVHI<<*OIZP&;:&+@7T?N2A^UE!89 M+S9$8VY$=2?5?A.0QCNLB_G>H6>Z/IL!AWY'CO#WC]:OS-J/LD]>1F/FQRC_ MJ-$V?GF3QMT;QJ;OKH`"*"(@2/+3>!'ZPH7;YYK?)Q]\N+9^_><__OD/Q_D% MEL)]9\3S47AE@;5+SDX-S++7*5H"_KCDH_]]=;'7^P;_Q^BWZ[#7_S:0GU\Y MP@,6@\%[WK=>K]=_]>O<`7DQH3NO[#UO=HZJR,[:@%J[QMH&U#8TH-;^:^&% M#%[?#_I6.5,)5\H'=*XVO^P2Z!N70/\;B($3N*G#:/8[9E#_1IN;QM@H@N*< M!D@9`=?+WZ]`H(UA43YL>X+K\.#H".\HNO;(CST[CD M4S:C@W$^^I@GNQ,\SQ-F,S^^_>7CZPY>_6H,[H&.Y\=87):O0>9R_:13TPLC M/8G/@_S2_3;7N+G>5V-H")$N\8?KV927+?G!@TO>&_2/"XO^Z&`+@L:?8?0= MJ/JCQ'7YH$[S"V2)PX='V=\[WJ=A+N]U?M6OLL3VTUO.>E47*"8SS&.EU35(7+'H>P8'.X\VEX33,E1850M^;[=_(()% MN#GX.,0/_9X4P(?E//=19+TR<:S0P=77#U>G__?U]/=KY_0/^/=5L;O\@ZIS M/"=+/#ZN!R#Q*A`^:*YGOW\ZQ1W?$X'>THR\Y']%\(-BR6]9YC-ICEQF32N] MD=_F2ED6(9QEX657=3SF7%8,SO`GLMSC.X5#A:Z8,N61H"BTFF?&N\G0M9DS M@<'*Y&F,M]$APWG"MC9PF?IOUHJ7[RJY:4+,!`=Z?U?8>>.SJ4FK46'X],U- MQ&]4*G6U`$3]QZYS$BMI M<$GL(0EW&(U+5AV*M"_M648S'V*8_0_=<\?UWW.N#[J!Y)$;>N7E&O;; MW4=5[A^Z^_*&/Y[_3N/_\.74^73Z`2Z2KY>G5\_I?=D-UP![.)_0$ABLZE.. M/(=B/LU)/F6_[:!)=H[SP/DW"^A&ZO6E4:`8L\K0Q[$)J+Q3X3J:7XFPR"S6?&P)S M2G$/M=L-&@99:(K@"UF,;K6`>P>+DH5>4;BQ0;H;HJ.0$,W*`0>'!+J0P;#` MO5VI;^FX,+2?R8NIPK%G=#N`=``"7T0`K([+XO&NT_-'? M>_^G^C+[JO?^M98ZBGMFQ'M7.]?^`>[%HJ3WN.BD_;HH.G5PF"K,J%):V=O= MZQ4'AILA?8@ MI%)2)"81DTDS\:5FH[B!#,MWW2CE!L01CCSG"'FV:AEN*LG<)EG,:T`D8!MX M?G(C,F&[4L(^.)@[Q6HLH&;AO)XBU.N,S5*I'E:=_LRG4S`JJXBZVM4:JVH:Z]<,'EFH1<]#$XLR4F9>%E/G5RX]B;GEEA MRX6&KTT'.=&7$Z>3"1KR@7P6SI1F(XN,<_ZD@\A+1N\PC>&E^/6[.G:R&"^Q M>[`T8J*2W:V5*`U7WQ>J'[D8"Z(\CG-^RP=]JL4WWQ[\_-[Y<'[YZ?2R^_'\ MRY>3BROH'B';V#3F"]3RWCG_X_3R\Y?S/]\YMR)&*GC M^KBD1NC'>0U6D_\+'+QME=M5[F;)]'YZP:R>7MSV8'W%;?<6YTH2AO6[6".1 MFF$.:V1/(_I?%4M1QI[6?V"KFY^5_,C>Z3W`F-8SOQ(FU.Z?19RH7D'II*"# MDZ@$"JPVCV_S163#]&JL(5\G=ZI71-H9#'JOK=^ZS6=,3^;1+V),ZS^E-MQ! M-DROH4RHPOFU(I+=G&@=(M)3/2/;?%'9,+V&D!]LY`88 MH84[Y20R'VGHPB.,BB;?\C@)HV)\XIG^UGQ-!X244J"J5R,#Z[*P!!6\D#]& M`;VEN4?[\MFL9\HYMC)^[^!@)5%VA1/R&&;FN;&@;[/@Z""+`#&6]0;Z+RSH M3SV=I(1/C\4<."8%*DU5(6!5L?=O!484>&^P/H[R>!*,4!X\7IYZ0,EV)H10 M-ER)&D?``$A*/"!$`=4*NX4U)D=W/O+=XK5G*4N1H[!Z<'X#0Q"M7M8UQ!QZ M9G#.RV+\C!HQLHP3!MK%.D#N>6U6%>"7C2*KJUB^'D^-J^OI4/CL:JHFIDX- M8RZRSJ*,^^\+((N"^GGZ]+?S>Z^\%PN>QU@C99/A05(K3PP),09C;( M*GJP:&:Y*!S#A8RQ-M[.CNFU\7;&5$N,^Z346[^+F^_"J="97,*LUG]@;?#6 MV3"]AKIC*IQ?&^M@-R>J5VPJ.I--;;YU*&^N1&4!!]/S`X7I_!+^WJ/_U<71 M=LBBTSJ8RQW,/ZZ-YX:30O>U^Y>;YKBNS,6[43YJP_577CFB=5O74T3OI'RU MI:-A'/J>JFS_$."<]&S#0*C"1^XXY/<))PMG&!?!;R0&^!+/KD;3R0`)R-/' M_%@W2!;_I4V<3$&$N2<,`G_F_'3<)Z\EU:Y29GI5.41BFFEWZX/E1XQ*VY/0 MH\I*)D:`'NGN`F.RTL)?6GUF&1DLF-&2,&&^"9Q>+094Y^BX#)>T'ORN7F?0 M/UZ,GT`"T?5VM2LY,<$5%`8>T6NLL<]#D(I$P'R@.J+8F.-BY>NT/*1AX$!' M\J6,PE/R`O)[$9,[`/'J'S@Y6,6,WL_+-TJ(VTQNCS-H<)R-IO86X*$N6+T9 MH<`M8RCH^%G$U(H( M:K?`QQ>"00HK60)7N!#X`T=@R;I11:I*H[*.CCH'^_VZEVW_N'.T/X<>4URS M^KRXRTC0B`=:(L9EI*^N]5CY5FT!`6F>>+X*.)!''9S-A/]XF:7AR%#&#TH, M:IKF[__`I)&X@7 MZ+._,/6O&FP4O].%@13V9[NQ#=[82[6MV0JTF]J`31T\O*G7J*]NS0[^N,=J MG?,NNTU_R%'1S$U;O.B+D*E_L%^[TQ,1DV3,^^B.S!^B*R2R[/_<[>8*LCLFV8 MGGU$^M*T@1KBW4J(EDHY6;^K+=%N+]&6R(`4_F']KFY^Q'EUR07E#C(CVWI= MNVU#?L%+[>V6[?'J%^#I_*[W3'ZG5V4UE_0.1:"M+2B]/0-;<0;VK3X#:[OO M6^K?3.JW@]++4Y"VG=M;(M_6:_&DD(,EV1+;K-S8,+V7>"ZLY70564U?S/U> MO(@E8D"_<[37MYY\VM-1^^E8C8QK%>VWMEH+IE<#[6^8*??%*U,B"^]W]@^V MFMW7*0EK0I&X=;WGR@7U6G^_8+%M-XTBJGL>1IA)N\TJ46L"V#PC<)7"P0Y) MQEMM-6B/R*9:RTOL&TGN959A$X:VF=XMEX7HMQ5]"A>VQ;D'8 M!HWHT4,/>^=X84IHV5MI)WCFNEB$@%RE0-QM#TE[2-I#TAZ2]I"TA^2'C-!; M?4C6@`;;M'8;B#]5*UJ>%5!3"V>FQ9[*S_[CV%,O<;HU,[NVD6@V+?;4=FYL MBSW5Q$W=$.PI6ZRXZYQWX[&GZHS$L@Q*9%NGVG1@GVW=MRV::DNBS=RW+9IJ MT[&G;)'6&I")U6)/V3Z]S4%(J6"JI:DA![TV-:0E4LN)]+C-7UKW]%HB?5C& M&W0&AUM-I)9(?"VVE!TQ,&T,^2IBR.NY<'<&;89$2]T;2]V]SO[^=N/DM/2] M*?1=C@-U]':[Z=L2670E.%`JU;W%@WKV&6_#M+4S^[G4.#K?ZH#R0^E-XIZKB\=1P5J1>C?='DU%>GCB3C2). MHC"X*5DXXX?Y-;%CY$_?F?(=<:[28TW+P,T'F3B;P99R$[G>')0YSXBEWQ4BXSC02+G>& M+(;.X!'HQ+GCR)[@;P8]L1ONN'X8<_4D-(S/)&,8GN.Q68S?AQ$.%+^7PXNA MVUWG!+Y$10U>^:G?Z??W.LADH M.@<%"2-?EZK'M/>4,<__OD/Q_G%?.PL``:63H!HOP9L@L@B?W/ODW**(04G\/8E M'_WOJXN3^#SH];\->M_P.'\S`J8^938*_.4W2BM+8^RCV,7)O8A?.<*#W65P M"+QOO5[O[2L@#2&[^'KUZ17LD"O@IHQQ.7[M#?K'L(_%J3TX9IKD+__5[7X. MP^3W,.'`#UUB(-!%MZO7P!?!]W"2`1[[`'\X]?16%N(WC))F^>_/F[NYN M]WX8^;MA=/.FO[(,_O\$'7ZGGD]D4GH_8N.Z>5AS]12P%IC> M?ZM9'QT=%%^'!UD21OI+GPVY3]]^Z[URWJ@ASP_Z&0/6KT`'$Q^:1UKC0??K M57$8L']A&KE\;AR??X=A_/HGBR(6)#'PT@AX)LA[`OBP/W-B3O<"OY\*_"%P M=&*A,^AUB/-WG&&:R/?T0N'I0W[W,9Q,68"?HS"]&2^\N[_[RYO"K)5HTYG+YMEJ":C_AY%X21;9OD5O/?(@JHGWHQ@+[OYPL[OTO*]/WSJ MW@_LV/N!L?=JDV-Q[\#MFXR!B8\2V"W<2@]8*6[_W5BX8[B/(WXCX)S*RSM. MX%<\L2`=."/AXU4,<@%S73Y-1ZZ(LX?NY"QJH*C!(D4-*J$H&%1QL,BI MX/M?WF`3XAW^F\;__U!+`P04````"`"YBW]$KL(2H&40``!A_```%0`<`'!O M.5-U>`L``00E#@``!#D! M``#M76USV[@1_MZ9_@?5]UFQG=SU+IFD-XY?;CQC1Q[;Z;73Z=S`)&2AH4@5 M(&VKG?[W`B!ID2)>)%E@L?SX\],\&CU@RD@2?]H[?'.P M-\)QD(0DOO^T]_7V;/S3WNCGO_SQ#Q__-!Z/?L$QIBC%X>AN.3I!*;JE*/C& M2OK1X9O#-S^,^(]WA^-+1,=O#PZ_'_WCX/L/;P\^'+[_Y^B_5Y?_&YW>W([& MH\?'QS0#D_0728!2:2JK7"-M"_&_<=EL+!Z-#]^.WQV^>6+A'K?!:/21 M)A&^QM.1%.!#NES@3WN,S!>1$%P^FU$\_;2W2%@@S/SN\&U._]UY_(#C-*$$ ML[V18//U^KPF+2/KOC"SFG+NK M+&K:%H0Z"H(DBU-VA9;H+L*$'1'(I)Z&,R-5PM"'V:8GF`I MA+.`3;HVA$FXG]"4<(U/\!W'):/N)M,0MR#639H$WV9)%/)!2+A,NG252479 MCIU8$I%0#)2?421&FYL9QA[HZ1FT+-X-'X"QZ&)L,ITLQ-C.QS;&_?DXF2\H MGN&8D0=\SB>$.=Y$>C_^;3A#-I\CNIQ,A10D+-[(IZF833&E.#S!*2*1LX>X MLFM3]#-$Z%]1E&%NM"/&..[<8)61A3_+YAMKXLF]!<4JTXN?S`K"'X'S,Y^SS@=/7,5QXM25TG/>49X.8YD9Q%;!&\BQ"@*(@B^2,?<%?6!,%/Z4X#G%8"B/8;+PJDR$;?V&4 M!+671")83&A=X>(=,B*<(G8GP\*,C>\16NP+0^SC*&7E$VF:\<%A$1U^5SS^ MK50VYQRA.QS)]_VVWJ"T1A?B'6?=/*%\A?MH[/-@; M/6)R/TOY[ZX0$%.D6&?S?\0:Y0%%?$%IPX]S$C6%_C,6JA1>PL!M3*$67)Y#2C5F_4%E;K4 M:A3>04"!+U47B(3%DL7>:33M^X*+1GPU0-_#`"B/J*_XLBJMAM7F;F,F`P.7 M'B>3^*!'-1[,WHL0-U>0RWOZ%$29B&]_29+PD421<;1S(0*(W2EC$[LK7 M76%9[P6JEH#CG=I1JHNC]1J\%SC!QQG#IL..H)>(:53`G`4 M=)+A,Z[Q-8[$JOL*4F\EZ!9I9%35T/T&`[B*)[V\QG5<'=U,`K6P. M"RIM"*V4'?""73-T.^V,.]#V`S4'10`OY>5&?T5+]U,-#5$_0#-I`/R0P^N" M0`=G(-*T"EDN$B;.^R;36_1D\RTK>4\V/Z0`+,;I(H-"!A(NH'-B8-[*%]=X<'SSV_R(EUFJ96;0&` MXS%V*12`C$U>5"02A_+AG,2$I51N[172F^87&R4DW-8]KS'CV)0!/!I>8X:Y M8<0-FQ,^>D>)S&*V`VBAZQ-\%E4`[WO>X(CSO.>"7R+Z#5>4->5&&HCZ!)M) M#\`;G5^2.*E/"';(##0`$`,0A!D,!+C[EMK;':#1$@#L5D=67+JH*V&?%CM< MVB`2"V>(&IVDD3XU&RR6+$1]@E&5YT`)_>MQND;%(EJ/]6;JY4ZC0[3F)E!'W%UU0UP M[I^FJH_U7%!!`0%!]S,\A0*0]\I,)]]G/#HB]W&>!A,^:Y'&2>S<\8R'(J]$?[#DF_:ZEL`=/%-'&2]J[=J$\![ M^!YZ5E(-S_-,0].IY[:,7Y\?*6KPJRGL-5-H-@A*:QX%O,_E136O,AK, M$,/LBI(`'T514:J_$$@TK-NVD$I=8F@G;VEI=\1#K.)21%$V2ED$KP7EG=[2 M83_>H8)3/>II?)>E@ZVO;NL)=B"KSBUV$ M+1H""/Q59M9602[$!KS'\RSJF4@PG>%09G*[0+)&``F:FEMIP5E3H`\@7:/' M2Y1B2E#DA%&]??\@JLL/.N6ND/C7A'X[%Y%8@-U&MC6"_F&TI@#@%-EGD5?G M;$X0U9I#`LAE"JH)[WZ0_7*+)\.GTSI81>VZ[#P$56RK+ALA@"[@`I-S;7WX MJS0>0V?S3%;F.\$+B@,BC<1_1[A((RAW<'QW8]M_14_=HST#0!QE/;[WV,&H MVVVUXNX4O:4H="A=::0"T-TV@,]2C[FN(NR162AZG2Q1Y.RE:HK!`*E6#W3T MEN?G.->2U1$,`T*==H!#.Y%F+3),3I\"PD0*KS.45LIA8&I5$_"5D=/Y(DJ6 M&!>UJ;W6!`ZTPP#805'`MTGR[S%ML.:S$0X#7)N6SO=(NB_IN/I0>P=QACJK MZ@I3(JZ#!U34.#W!^;\&I_-CTUDM1R$?#U,?"$?N\_(KPURX_-*[J&\0I.3! M]BTE'R8`>MHF\"JJ03JK##@NX8.-['"W27%4O\F>D`\3`/#[NWQCB]!#8#LH*=]([*[;GTS M0SR4F$-7GC8&2E700.-O55./['@2^ZSLSYW$9Z%WC`'.W-9>H<2,?!,YN MJNKV.X""7;D]YX5RC6Z@\-9TU.`*X\BA*3N?6GA<$);??R^*ZO'0/S_-UMWR MWY;A0#W!37F-B\`XD="/7J;4B(U&?C/#@;J(F_(:%P&QU];4Z3AC:3+G#AX^ MH#B0*6PG6&:;^#F&D<]`_<&HL\8-0"3\-54IA[WB2V!>T#=H!PIW0T\-Q"#V MVV0!1.Z4D^E-F@3?N&O^BBA%?/0Z2VCY%;$)/8X0F1M[NA^?84#OI[/!4 MF5:70!1FX,O>6C'$(Z'A?9Y%>#P3/\]%U:),[#WJ2,2BR+_,:\MO'X3+O8BE M-([Z(XC%:UFJ/^"&]/UD@8)F$%YAT$^#)8P-1;$LEG M;S=+:*IR59,[5L4^,.-SE_Z;.A:B7N/BHJ`NYP7"/-Y@7N/%\]FA(XQZDD'`J%E=;L\?)?)[$/ M*;9!-3A4&QH"3B2MCCSN>!JI!H&G44/W#-$7+3)1$9(+GE',)EG*4A2'7.7N M*MJYNY7)E5Y08/'N56KP&0IP?FICD%Q/`J`W:`!HWDK3Z0`X:*\+_35&^5TZ M')X0%GB!IJ3M*WI*92`6XSS+Q$!U26(RS^9RL5LFKBPNH!I4*SOT-IKPOFQ`0:TU:4W@KT/I72=%#F/;Q^3OV-$7<=J)TZOP@>J M"@.NG^&J"W\G;LL1*KQ>BRM45`9\,.*HS5F2T99\H<+JE;A"16/`18!=E2$/ M;8T*%5:OQ1-6&@,NU6%7IBQ@?AX'41:*3=#R+UMYA8DM,`]I)5PPZ0LY%T)C M"+_`044(%^2-0WW_SS.\Y.[^7#[D[,0)<7Z[Z18]Y>F1W>V(-40Q?QM,W;RK MG>,U66S?`M,1`.@*)AB:&\5J-0"'PPV1G].#14678T3IBF4%U>XFH5>\S0:=F^W%S7F-LB MX&O8/*HMBKN:_.Y:OQ9P/ M@]7QS,=](=D=8EA:_O]02P,$%`````@`N8M_1#+E0DBW=0``<)H'`!4`'`!P M;W-C+3(P,3,Q,C,Q7V1E9BYX;6Q55`D``TW>.5--WCE3=7@+``$$)0X```0Y M`0``[;U;<^/&LB[X/A'S'SP^S[:;NFO%7ON$KKVTMEK4D61[]DQ,(""P2&(9 M!&1#O^U] M^MO@]/_YX?^]__+__7#U^/3#3S]\_?KUYQ&T4-8M_!QELQ]^^HE_)XG3/Y[# M@OT`@J7%WW^]3Y_V?UD4_+$I^;=O1;Q2^NO^ MHNS@E__SR^UC-&6S\*_U'^%HD7\MZ*N?YM%85FK M2BG7#V@)_G\_+8K]Q'_UTV#OI_W!S]^*T5(N*#,JEY]I-W#X2_/''T%=/_SP M'WF6L`\ZG_<9&E M19;$(\[H>9APM3Q.&2N+'W_@C?[Z<+,"$QJ(RSQ+.5F_\`*_2!KX!81S)=Y] MF+.TG+(RCL*DMZQKK=D1'$9$&3\G[)(]0^-5SHJG$/[71+-X$Q9$O&1%E,L*,[2T6,UFX7YVW#\&$_2>`PJ2V:C$1LU-!1UXWG\"I]Y9;=Q^!PG M\'E6?&%A`<2,0.X'%F4YU#@KK\,X_RU,*C9,X9=5GH/S94&VZJT&+,2` M][.B@"45.&]-4?`[&*==D1BV[@'8R@;"+4KAIRQ`OH$U)BVS'+YD!D!0T8(X M]WD&\T?Y!CJX@O'XPB<5,[ED+5B9>>H=">P=W_B>#+X"O\DKUJ;,=.+1;]'& MNE`5)4S#^26K1;&QHS-JTLK2-GNIROFV@.]N(E#:99Q4L!3=9D5QS_+'*8P7 M0Q2&K=KH3+"U'?$OP.KXR+=K-=EW60E+95+!ANXF79'JCI7=\5GZF,.MR458 M3*^3[&NG4RC2D*M#G8UA8]RN*S##JN2V$6[ZL0!!T)H%P:&CLO8<.7KE!_GB M.L]F#RSA/0"6R-+.$=7.MRR`OJZX1K^$Y7RTPJALB68&2J\MRTQ=A"]Q&2:W M<%9EEHG1;MH>#W$:SZI9_440HIYLH'O<0Y^''YMC]WCQAT[D=/F`C7UOF45_ M3+,$C@T%WS3![JD_5X:-VH(Q?&D.GY8`Z#1GQ::RG%;>ZD-;&-F"T:EI.[NT M65PN^C"L%-R,QU)+5L2NK6]C^]+;2JW3JHWQ$B:P##3VFG3"-WN@RJ<,)M7Y M0;0L\_@9-H0PVSYE"U/M(YMTF.#L?,NRW:6U=RE!G)L4^@T(M#0Z#\I!8F`]-FK1Q4Y%%M967G^1!4^5;ZS/:EPW2 M-FSHF24L@B'[ORJ87UF>O"W-U/R6U%#!6FU9$/J_[I/0ACU;W8ZETWZV,,Q> MLL::^11^:^8-\S.^NBU;0J?-#-[8O>$K5]]>6%JP'TK M9N;YV*^_8J&?HY0X?EH<9+`[SF]$PSK^$^1^L.2+^6O!+WX1[UT2@0+[M MXN7N<^`VG7S)1LSPKL+:YVQNWQX9OWHX7U5\\^DS.."\UMVYTY[-H&6[^]'9 M+$OMP5"V9V60YV$\F990B`UAHWM5E/&,3S._%FQT'P>5BPT3!M?9Q/H*]P`NL.JLLGK,QT"\^7HIYL1@XF MM^Y?L+5AF1^!+6U7-%JS;1)]`-K#9&&9O,[R]Y,^MV7V,8;J-KV$%.;1`M7\ MQ_87E^Z4<5K^,HIGO\S+_!(FR8]*-2".G0N_3.[1>5AKIVZMKTCP,_>5<_L MIZ4*+`HK;+VOR&E6GED=2XL&EX)!CXW3>G*[A>96/L2^E2P=L='B4URBSJ[, MM9?2GSX- MYK[?_V/^ZV!Y/`-D[`9^+!9?2<)GEM3?#O#"P>'INYX\25X?TW2DK@L&AY]6 M)'[G]BQ?E1WZUZ+5>53;34M_\FYE2ZJH`";*79I']\0?N@9O__<P[UC2W2[\K&=+BIZ0VIQ6K>IZKF8&/KXU+=JULX"_I^%U^L M]P/O2\%%$A;%W-"(3#C*.L'A_LY,/WI@Q&P=^F*K+2,Z>O#"P>&!U^E*3^=B MGA`T8H*.=I<@&A.==:94$^"QMPFPMB"?K5J0OZP<-453(%XK.#QTR9WH++S) M&S):D"E0`4;,V(E?QLX[,2:L%1P>[21C.!@Q8QW.FYNV1/Z;^?#(I6%&DQF!LF6LB"`@Y/0T M&_38;X?%E/L4PS^M2\VS\B+,\[$/!$GR"Y<&QG" MJ3>3Q.*1Y0.+&,@-Q_<[5LZ!R\:=I%IPY-(PX8A!)2"$.&_6B<4SXS>04T)4 MNUAPY-0BX8:8#0`($=ZL$+#/>0GCT=P74CUTA.6#(P+G6%-J<"0(1][L#BO( M=+<3P1&!DZKQ/+:!`.'"FT5A$8>`N\B7[6`$\HE,5BTX(G"FU=[P*9$@C'F[ MP;Y)RS"=\*;06U$R/6J M-^M$RPWN+DLCY7PH+!\X05S@$A!S/=@CEZA0<$[`[&)YN:YD1?7NS-;1C M":4CP:MLM?E!MXG@F(!%PLA69(0,8=:;H:(EO+XI":\4'!,P21@1HN14A!!A MT;MI0A;_2=]2H=%*<$S`<*$@26Z]T`6)4.W/U6(M4)::5J1&<$S`Q-&)0AD@ MA"YO)H_%`^$']LK22L/F(:X0'!,P>G0B2X('X.R8IOAF614B:,#`(1=Z,(>WH6L/G))XT,7TU5BQI MQ>"8@`FKV\*EQH6X/WLS@ZP%G]'@3E@A."9@M.K&&8X'X[NK/7@X:0Z/-F]&A)JK>&!2>[:HM:!X%0X>\929>[&HG)_(26':JK?5^!$&'1 MHR-(VT%,]BM%]&/,,%2'81)JX1G!`P8G3B208(H^OF.E#D`1VKV9/QYX#*Z4C:["/(W32='" MM`PIBC*MKAR<$C"/=")7$QO"IS=SR5->YY9\TUH1-PL'IP1,)9WX0K`@_'@, ML+&.S>A`$)P2,(5TX@?!@O#CS?:A.N3T<+4+3FG902PX:>$X$5[GQR%`_\MJ M*+@M!XA;S-JK2,F5`3/!PL@!YAHS'@.R/J.8L@-]@F8P+$A M@\R%*C@?/HS<8)^`8;L+:1(XUB+)V23MQ'HMA/_ M;W!`P`BMQX$>%FKQY.R'`!P<$+!+=QDV$CCD(L\E2?:5FS"OL_PRJY[+<95L M!H72>&]JT@ZH@H"/F)G]K@-`:H'LEC&E^$U6[33ZP`J6OTH]^_!*`)*$(Y() MBRHT!./4O5\0O^0LBN=YNUX25BLZ'9W-LKR,_UW_'HVQH^=9T>L3H$`2KD]& M@]HJ=FJQ\JZY^MEM_,I&ZZ%[6L#;`"7=Q+PQ4`H!!U.S#M$5I;WH?,ANF+]7 MNTF+,J_3E_^:AHT(T&_CHEZ$\"7:J#[`(6`5T".M`S!J$?I6-XKW83[,:^RC MVMGDGN6/TS#7]P_&&@#P!,P&9D/1!)F]8'_(\%L5YJ*9"&"6N(Q?XQ%+1P\@ M&(ATEJ;5#!N")FT$`Z=YT.P/0W-PU,+]K2*H.U=Q5I73+.>SB?807*\(8`D8 M'OH,/3$B:C'^1#+?%$5E3%U3"4`2,#[TIZV-AEKD/Y&\K639AKRU:@)<`EYQ M_V!#=8_B2U`.;.G0"5<*C%"]P0 M6+GJ(34`WL[9\Z10R(7[6Q=6;[&350.@.V=T4^.A%OAOY1E(([.$+T%I@+4S M5A4E#'FHORUZX;=B.0&H"@2LG>F\)&I?-4/=:OC?(S6"TT\6[]"C*1M5"1N. MUT)?Q4_T*MUXY:"$PIQPJ1:%EV[=\2)NO)[NHQ?PEA50"$C M6K\R8"9@GC+@UA2:$U]_6[.+ZHF,H'1PXC1HA/2=3`>:4`3HRX"MOYBAXM-^ MXC3@A)%/.\H:,A;EF(B]1.CK-'WB-N"$!'P"F77%L-R9+ MY=CN,:IZ>]90S(.;A0&;RZM-EQ,@!H;8RX-5,>_"&5..+:P*K/E.+\.T9T%, M]3I$K<,A]N;`,EVT)D1[O*GF0WN)[&^XIL*%LVB<3H8ID_NQXS5`<@+7DO+Q M(#A5JP`Y?TRP(<#3U\R0@V4-$)G`[6)_#M8`V7M/H,T!%#<=":TZ(#:!NT$+ M/*Q#DK\1V):!]9(541[74@S'YU4!Y_:BCLU2S69A_@8;S'B2QN,XXKZP2S#W M61)'_(W>,DK=33K.\MGBG;@-YMXMVLG)QD@1 MR[U;T4Y.]FB<"'JHW$&T$V0EN&-5D8W+^_GB^H6->&BPQ[>"3Z8\LF>8OMV6 M(_D>R*B18#`X\GA"$/=PP7K1!10Q:^-R3Q3]6<5%HV&Y]0JI`4IR>:!PLFYH M02)F:13)RG^$[;?21**L"XB=GD:T35M21O1)%(`C9I=T3B>-AGBAZ&Q9\ZD=R4P<)O@HL\-SD#WJFT=#K50*I;YHK6.V2-.M7+Y MBZKR>YCG85HJH]^LE`-(Y!PFUT>*F"0!#&JQ3ZY`M-&(AWE8I!*]CM,PC6)N MH%YZ`2H),VD&%$'@T747/LU14HN;\B7\5Y9?5$69S5A>*#8EFX6#@=,4(TXW M)1@::M%)>%<D5:YR:)U@,#BFE@ M.4%.UHNO*SU+-@IR20F\^E.-`\%Y&8-B+Q:()7?O:9:7/-\R7XF?X&LJ5V]1 M>8[-I5G?Z8HD0T0M"LB&K,KI#:G!K\K]7DKJJ%^3L!5(U")_V*6,UGIDESO5 MBN0O%,C:8SOE.4Q8GF,DX)DG'SUBUF1XJ`7]4$9H&>Y\\OBSLY/]D MB,U>U`_LFB5.LSPNWV[2DN6L*.]A90>!P@F[2?^9@49^F[^61B];=!O@]_(> M@UMU]U8S14@MYL?G+!M]C=\]^`0C;5$$$)QZ-"OV&E%K&.C%\TAYK\F;.,)Q M\<=[-QK(URZT&JCCD\=;S%YL:>"R%]@#B].X_.1PO!F=&YOPY+5`]H'3G;RK M64X+ECR:A]>(UUM.&3[8._1HK^\U]+I!1:CW9BE93/WJ'E**".&+B.?'=1BQLYG1_O^]"B!TZU>PM7W_!B;$O9N(,\B7$/:Y MW%T7Y@YMWMJ5.,I=G3:5J!#N!MM]B;6XCFV,!$7]D&IQ,=O*F_VECM?%1F?I M"%9Y+NOH#+ICG->A)X5C$19>W6);2$BQ$FL?53T<"$"UQH!PM`5#&#K'TCV'/Z*E,::<@!X^*)P[*VOI?W<6[/ MMD:A.BPSN-I-4.P[]:AN[Y/3B^%.C^IJ+6XJ>U/NG7I4!Q+3N';JH7*R*<27 M(_W\;3ZNZVUZSOZL6!IATY=!;4!/)@2;TVG-6"?$'NPMY19)K;PTUJ@-J&D$ M>=-F2$&P"BJQ!WY;(9C&3+U=ILEF11?)7RQG-Z4;@4YUP$_`C5M[2.KS+`9* M+)I9JW\O?_Q'S')0W_3MEKVR1'\!ES0`ASWO#M^^UG"E6H@].!3VY4T0G>9[ MM!W0!(W(A2;$&04GME*;R&E-XB"\H#-`(/D+9V=231@?R%YK9NF_G=<1J!8&$3^E/T M])>7F:31.\)PYB9T,_ MW\W=[YYW`XLUSC1N>_=<)9%R=@>YY]>^@6I1=?6XA]HGJ-[V[A$Q(_10.=G; M7DM;TCU*!T57:YB&#JS=X*(Y`2*>9A3VCLV_-^F[P^)8E\N.+06#3WL?[^2! M;%4ZJ\?:%2_2`[@/;MNQ=2'>NTRMA1DCWZ@1#NQ[&-Z=-4/LCO<^?*NE:W)V M/C`N;L1=M=/)158(.X5N50Z80-#0K\&8[L,VB5/XP9IIM_NV.R M!RC&;8$Z*=D87?>0COJ17A%ORW+U.:O[<1JQ/'6=?Z;]+9GI""\<[.W;2SG3 M_H+4I+-1$/ASZ;.&IYF1*$6PCB%R?S_6$^])+F4TZ!A$\`>G1(_I^TX?D78T MB`BM3YMR[Y9!9/\398.(ELK)&D0>^)J7LM%5F*.IMQM3&`IB?N<783&% M'3?_ATOY&B;\D'567H1Y_@:0ZYV[A"RM^H#OL?9CKC2"\4G#B,_UOMP&C0D/- MS_H^SR+&1L4UX+XIBHKWK<9V*#.ZHI6"D\'.S7$J-'(WZ&V9O@!1D27QB'>L MQQ+^.S?S#N%@7YN^N,E0$!7*A[?64CZ9W0PO'.P=>'-)7DJC"J>Q6A#ZES=/ M*$R!V(9[4^[OQL9VX-U#24:#AHWM8.>6O<<2*QRP92=C` M*P%&`M>]9ORHT!"SEGW.LZ*`;?58:GINE0(4!)PTS#C9$)^8?6M^,$@G5]]> M8,IFQ=ES4>9A)*,$K0,("3C2F1&D`$/,!>8S2T'$]!ZC+NJ208RQ'20$;.!/;""\=>`(/0E?]Z7O?`.JV916@^0$D@_^EF.\!ZW4(>B\-L#QFH^FY#5F'0>WQ_EV69JNRSGN3QL9161<@ M$PBU8<:<)BAJ;_87*8_4:]9:28!#P'*AJ74Q94)$U/(BO_M;"]]HW+'R/F>E M-/.);A.@``+&CEZ4FD&UETY9\IKI2S:*QW%47[M)=AK2\L'Q(0&31R=F-'`Y MSX?<](A'5I;-I=1[_J/[\$WB':^J!WAWFA8]?-0R*-3_9Q6_S.0N07H-`'@"ABU+:YL: M*+6DS%V&JZPC$S!P]>)2@8U:/N;WTRCW>[K(>'*E"D1_]R4_4L':VVTCAP?V'E-(._O$(1[$VW!RD"K\G_+)UNMJPM:HFIE\#F2CMG M*9-?,B(U`J\)!"UV!@29O134EA8+5FK9_%;*`10"UKY^B\(F'FJ9IG72B=[S M/.>@];+,X^>JY"YK3]E]R-V:=6Z5[7P!3I8?8C=O2Q/4DF7+P%W#JA1/TL85 M/GI[RL.T`"`<9SJJ_R^I%["ST;^J9@722/_KYH.@7`+'"JL]Q;PS]E6?O33@ MVYOD>LY@`)S`$<9SOUE5!K7,XXOGP/*."7%2E4SF3JBH"2O[ MSMUN:4&RET`<>\\'T\P4/G?V"FOJA-U5'&(MRER.6K9B6)5%&:8C$!BS[)JW M!!`)W'?IL=8+HCRM^+9>,)U%<-0LXB8HZY>XM!;`Q\[D<%X50$!1M,2\U7B^ M)*L6[!UW,,\A(V5=?=(@0,+"T!E<;J"ECY34:A+T=PD*.D^6K/8X1:HKI`:H MQ'M^2A5AXD5("LC)0R>[=/$?<\:4:8B4=0$QC<224D;T212`<_*:BC"=-%YC MN>;5P9,M9`'\$J;3L(2-S4V1E=D+>V+1-,V2;/)VFT1HDAG=JH"%P/6`YE`2 MK)7:$(F][A(@;JXD%C<6!7^3ST;#O'Z;#^M)L^T=CIO-;O-7L[':X0.P1R%@ MBS;=1;G0@>MPT?Q<"B>8>2!;.)U&\`^<=H;CI3$=&^8:50$#@9-ZI]VP-CIB M#]$68"^RV7.RUR%=*H#;@+.FEV'NCY">P_D]$=YXUTR@26& M1QZ*1W,/DP=6[T;K@'^+6/-&:[2#3X&2"%P,VQK_=K1![66>8%U#@)[E.8R% M>?YZ_M-P#+L>CJRH@TG>9E_-]@G=OP.J)'`5;'$KT5<5U!X4VH/XCW@RW4JW MXA\"91*X*O;?K]YU8>\MI,$^%I/Z/2.@R;Y5W1I`I6EBZK9/U05L[WUD[]W+ MU;>7N/FI__;DO:U@[X2`,ZGC_< M43K)*W\9%_6;MH>PE!XA\5J`\W0';0;ZR)P_P-2?.>:GEQ[N# M1@`;F.6O.+?EUO-8S69A_C8#:&]9<7T,I5_HG+)4W?"\B$07W/@R7"[\LMZ,3IXM;?+8@S MTME]Y`1=Q3ZJ6]#)X8ZX!?7D]>.X!9W0O%L0#27!:JH-T74>>.%>MZCCDS07 M&TTL\,7E9]'?L)N6YMK5\#;LU'.R=>K0CD^E2J&:( M1>PV@#2PTV<&H`>/7JAD>LA<#R12TB\/NTN;;`&ZJ-VR8!IL]67X737[<-:P M4WNNAJ::U#..F306N+T4Z&$K.Q4[_?=`^9?I;.6XZ_0.H8/IS)Q00TL:?H'P M42UIITX/\OTM::<;)WA#<-^7)>WT:$;!428^Y_MU!`=^:46R7GV[M?R+_K%:_(W16@(=7?(HYK'W4>`\@+SMQ MV_P&:(7\*UUKRX5*#=;>]?7O''=9R1;"\?-HEDZ>6#[CN2`L=`M)ZZ`)\IZW M_3N$4@$^'@)BPLZM$G.K[Z9IXH[9Z!,:7P'5D'?E[=\WM!5A[^5?_S[",Q9_ MC9,$%L#*RHYRM4$`3-[UMS_S(LSRAWA4[SZ:&*-35L91F'RLBY!]BZ[U!"Y" M]C^Y=(WI?A%2J]G:14B-DLY%2,&BGR?9*PS=N.G,\,-Z'X9?!;=L$B;--2MR MW2$H!6!=6F!<7W'45*T2CX)T6.0^5&XN MM?*&3Z,VH'9J!=*^LM5FR)#@=:C$?'*W0C"-*7F[3*MF<7M'B:4`?&IB<+B< M9LGH9O:29Z]-6`[YM:YF=4LJ&A@5Z#T^X1=0NNN?T^KR;!7IO(S:(6.[=LD#O'=#8 M%O50.5D+]'*X\LU!`8.8WYO+<\^+*@!&CQN<3JN(#B!BMN.EJ`_AUR^P`\OC M,-'BJET>D'E\46"'JDT\Q(S`2TE_S_(_;KA/<\2D*=S%%0";QV`;=K@2`"(6 MV&`IZN<\TR.I+@A8?,>RZ$U."P@Q^^Q2Q/=DV5K4M(H'^_N^(T/T)F@##C'; MZ5)0L>.JJ!C@\!V.H3-N! MO7<<_-Y,$4U)MPGH7]["*NB2(!XE9@B_&U/-OO=@"=T(TK#>[+L*B^#,IK#O M-ZP!JD65*6'?5<0"AYHF;+W14SE9Z\T6_`?WO>=(MS%K&4,F9OG9@E/9/HU, MZMH,&1*\#I68P6@K!-.8B+?+M`.O05OOJ>)D%*<3I2?!:D'`1"`FB/8P$W,G M@D3,_G1=Y:#5*N=/BJ_C;_PGM=,'7@G.2P1B=_2D306/F&W*S'57HQ:@)!!W MHR>)2GS4'/(NLME+5;)\B5-)(5(#X!&(C]&3/BDVYZ_8'UC!`.^T[?E]'49S MAV&Y6[Q.78"Q*S[QFQ09HJ26%O9+&$WCE.4K5F3E6)/4`I@$0DST'&]*?/:2 ML#H^2:AN-^45`2P!%]9^AFD=A/;RKMJA\RR*JEF5A"4/@OV2LRBNPUO`SPFK ME9^.%H&RZG`8!H'I;'\"%$@@5F6_+F)7%]32O:+BRF]O9=4`*(%\,([FA24^ M>6K7;5WSK@4ZXWTQBO)J);"11:]WG<_)KG3-&PGV#^T%YM7YLM117KL!$-OE MN1#WG.^@7,&6U1#G=W-A>^CRM*CO6V](C\9U[2%Z5*1Z77OH]%38[;KV4/BR M85/NW;JN/=RG<4O00^5DKVO71O)3'H[8/)RI?'N.U0*T'D/YV5F"M&$2NY*= MPWS(WL*$@]0B4E0#T/E^.V&31!PBL2O71?J].6@U?^(*@,WW>PIK],D0$KL^ M?0P3QN-57'V+XH(]A=^T:534!+2^WUQ8XU,+*K&+UZO92Y*],?;`:BM,"[*: M6F5=0.S[S88U<"*GWT5\H!$AK/+33TC1"U"8>8?:\S,32F._L,;2^` M\ET5)2S,[Z=A/CLKBK@H']\*OIN4>X@JJ@$&`D\?!!U?L#O6@N(Z@>%96>9Q M5=PS/?4CQ>$$0.#I@I[:I1"(6<+6C\]J\PA2`]!Y]&OO1OS*HW8*9OFL.!N]AFG$[F&;`[\*)TR1Q-.XH>#XU/>57Y3,MA^I"%H_YTRIL#L+XO`JV2JH/6WAL&4VH74\=9%+&7TLYPU6@3 M8/N^';1*LC9D>\\ M@Q+1W-A7%]_-9<>QRTUKEV#C'0G3N!`Y1O>M5"]$CIUN/KM=B'`MJJSSQ^@V MDNJ%R/$Q#0MA#Y4[N!#!S:Y(Z5-REL'-FM_%7R2KE@_\2WEUMFD-G63T=FL0 M=./;H-V54/%`[Z,&8N[9M6SQ*WMD494W:2+QB4)="3`2"/C2AQ\QXRK$Q.ZB M%-U=0JVB)J#U&`/&U9QO!)Y&B/@S.`&,-CKE7<9W($DUXBD!5ZQWL#?I:[&S MY%DN%/SJ6R/U-7"](O?O.6E?._E/='HQZ^W\2$8(B[M%M(H M]W9I%\\0+K3UW=@;3UQ>M76,/6V/1@TKY`EZ\4;5"GGBU.C2S0IYLK%^B^7> M+2ODR2EA*Z2>RLFZ9?<F4&(V562/KY.K M7E45\#JUW6D[K#OGU*0KK>N'F`>\X_Y`8_W9@8Y!-@?!(\LYQ'MHDN4Y&SV6 M6?2',N2OI!:@)1!B6V^P(@[M[(6U87TM.-M/[Q*BRR)1SP0Y#)@1#$<7X3%]#K)OA8^/#>6@MQJ M^&!L%@X.!OZL*@MIE-X0*P6A2VS];91*@?NJ&:ENO M`TCI^#,+JQ)X)"[-EZLW(\12\,\SG3W]NWR`,VE]X7K??TF%&H7PPL)?TV+ M%Q;%XYB-U$%^L3H`T:EGAOD6?Y,`A#$Y)&J7QM99([KIMT*?:M_O[ZZX>2*K MMYQME`5H!+QH%`,'.9^)L=#+\&ZTX4"69@(N-)U(PN%0NQ"^8R6_F[O/L]=X MQ)^>_UKP)]C#%QX])DXG9U$9O^J&5S!O#)1"P$G#[,JJ*TKY#>VN1#XZV"-@ M'NE*`4KH.D"$*V\6D[/1OZJBK"_3G[('%F5I%"=L1?"GS-Y`=O$Y4"P!&XW= MGN-.3T@']&;]J0'P'>AUEE]FU7,YKI)%ND#INHY7"XY]YD!U3R&V-5!I!+E0 M]V9"NF0O.>Q\:A\DGA)REN5E_._Z?R7,2VJ!>@@8_K9-O%(A"._>C%"?08M< M"\.41VT?CD$/@+Q\NT_"M+SZLXI?9O(T(7H-`'@"!L5M]P83W2`=PYO=ZV;V M$L8YEV\XODG+,)UP-_.SHF!E<C'WOB]DER^/7D+NSWZ2`L:KU!4JZ MSUD9?M/:*\B;``5\ARN"F7:0[N'-QCC/\U,T<]4#XW)'996#&BZR0GY^5%2% MB>\[[`YZ6D&Z@3=[XTU15#RQT\(1+1W-GYCR=$*/+'^-(UC?\HLDC*4O-(S: M`342N.G9^@[27$5(;_%F\5QDF875[YD'N`:Y>-XP4`5W:,S2`M24-X=ICFS2 MO#2ZF/(?;]+F9=1PC%7A>^F!I(]MX>NP??<9DMA7U]R>9I$>[?>,;.]FS+K0.J)C`Y>BV.X]"'<@#&6^6T[,H@FT92*,F>KTH`*(0 M@6#+_(JU@-!J+V]KVR9_D[X"W"Q_@VT5+)0,S-Z9$Z=*- MX46(]F;BW)1\L<3%PBV"5CV`2L`EQA6U&T`13KW9)3=%OL_92QB/+N?>F_-= MZ%DZJM>M#IL!G09!.03V!JYZ@;X&D.[ASUZ)3E;SA/3_]4:0+J'-P/E)I8+V#K!)BD_&[URXVO!$W"Q.D:26:^0M`.J M('#?X:HS*($C?<";26\3PF*>>V"P^%5F>[^UN@"9@(G/%=="L$B8%6\&/'UO M82NO(D`)!(Q&UIWKC=`C7<";%R0B/]_<%K8>R$@:`Z40,`M8>2"C1(E0[\TX MN+AF?\K.HC^K.&HW$AP<$#CH=R5/[JF@BQ[I`MZ,@!OR+ZXO M&7>Z:>):SO\B\WG\>C'D6,38J>$3FNZQD"W.% M;,I'J@!``EX_78E!IGK.BM7N<#H?"\@"-@+7,W5!<`XK$M_5F M*6N+RJ6$H]WU"Z:LOVQ?B/\[=N'IEL+/M()O-G*VG/.NPMZ M*V*1YL0LK`N:HVLSDDY@T@PH@H`9V\Q<98X/(=I?#@,A@C/H MO7G^!AWUMS"1.B5HU0?H!(S3-J@5`D,X]9?BH'IY:5)=AYL)$L$("\ M(H`E8).R0QG2'33P(V1[,T_QL_B[W/-#.C^O+0+F-!ADM.LV`0H@8+ARV0', M-(%TA0XV+>2I=KL_UK>33QG?SY=O#6C$&4^W:G!P1,!VX8).,PT@-'8P86&I MY5N;DWEHFF9*N>%=+&41__3O<3E]8`G/)7T?YN4;8HGLUR``)F"G<$9Y3[T@ M'<&;(6MU-AKF\02TD]27989SNJ`N0"9@U]C>9(ZJ`&&]@U4+&?[O=UW-_+.( M3K7>*9N_#L=CQF.;H:$X.C8'8`E<3S@;^KVT@G0!?\DJ&NT,6MKB?9T6-5 M0&@"-CB7.WDY)L6C>$D#\H&:77@I!.)\? M;T!-O[SKZ1:^.M???ZS^=D5][%O)8#Y8BP*]?O_Y_'5617I2 MN+`+2@<'QRZ/OF&2X(-'JD_\\")$@.1*@G9`M%'YMRA+2^C(5\TY^.\_%FPR MMQ/-_P[CDHW^_B.TS&B0J4CWNUD8%.'RZ&J4ZQ?E28?6=S!(^%8:!-V%,Z;, M&HM5`7Q.SYW:J7XQU>L0M0X'"BBE>/7'F^J_+[V++[";0$4VT-SP^I4 M`PP$SFGRD8$:XA6H$'\(YXSL=V-D7BTX=;JIV#8C*ZB0,["3RRVA0$_9(^/Q M],Z;S;\.4::M@88(')P[\M<-+')NU;#&ZZ@<)%!-4XGPU0Q MEO`:P6#O=!?G/B4BY(!LSQBX(<'3U\R0A64-+O,N3F%*1`@+WGSBVC?^[9N` M\[?V7Q2F"/U&0'$N7:5[-=K/AVJ([!FX6#@Q.G7E':]@I3'M1L MM@$BK'E\C]F;-5IF"Y?TJ0P9`WN6C%_3_%V$6'4*$Y<&D0F9MIWUO4IPZO0.H].^ MK\/%U#H@A#%OGE2KTBZ>83U`?ZL?BHS>#]S:',H:`240<++KS:H:(L*S1YO$ M,HH(S"/#O)&Z=AT`T6LKF-1"H:P-L`EXQ'5@5AL;0JFW%XD725@4P_'[SF/MZ+KP\YW^5G=VZ-`>*(7?AHD=Z9[#(1;1=5ZIW-.^6 M[%JJL^)]HAF.8=L\BM-)_1?4';IK>P"7G/E+RJT%M`BYWHPR;A\XG-*['-!> MBS60(632?8C8]N'K]1QQI2%0!KF+A`XTZ\%$.+?WXI#G/!RF7+1'5I:-#QDV M\XK*@I@$GHB:SJHX$D3AWL);B6/H&<2B6ZT4G%*PS'08/"I("&_^PJEG:3P_ M5)VSD#\]FN=ZTDNFIE,=@._FV5,?',*J-WM0.V+TJA7KHLIS5N?\X`[SS?]( M^35I")2QFV?1+C`1SBTZK(C.2O)'')(J(/1N'1GU`"$LD(B$;B7:;; M.FZ[A#]1<0"V6T<&-1B$)6]VEO?P<_72:[@YT:@=G)X2""73@T,E-H32#M86 M9!LR7WNA,\7-0]=+V!YA&Q!A81!TMPYS*BB(SKWYJ%R'<5Y?G)R-_E4U$83> MS>B2`22MQ^-H[^;.0P<60N$!@5>ZPZHLRC`=U>?-W7^;>^HOLJN%M[E.=VV= MWN;6^M39J[40T'F;6[#HYTGV"J,K;GB$'];I@U\%MVP2)E=I&:.^KX)2`-:E MR;V_<^O)1J@!%(63A[>ZVF^$0=T=UXN`Q$YWRDK75%2+F\K>E-O)FUF'FJ;A M3MI#Y0Z>N^ZH+[[3PXF+Z:HK2&NO:&DX=9^ZC3?KQ!7_=,/)5070VD-;,J31 MF#JWP9YJCK5W37&7I6T1Y'[APL+!*87@K]@H$)@&)"BL/8E5.^$K5"V4D,#U MG(&>,0C6GK/2\[X_H&PJTSYZK@.R]_1U%ZYZ#DX)OZ#0YA!%1NT%K?XUZT8" MR%/"CBD2HH0XJ#UW71/R0GF=(ZX0G.X3=J/4)VD%#K5'KFNR:MV^H74`(N%[ M4WW&UA')G[1NZ\J@[:ITEH[.1J_7,B-&X M4\!CGU"]4SAUNNYWNU,X%5[@;,J]6W<*IR-T_BSBQ8,K21$#/\]PWP?/C)^XU-GY5! MA8R8Q=]F^.##3TX-:WVB/=>JUR%J'8XUTSY)NFBL2?9Y4RU5]LX[]X`B+HHL M?ZMG!_GB)"P,\I*S9:Z/`L'R),%"[.[`3LS2PT_D#)EREC3@4+LS>*R>"_9G M!="N7KF+!'Q/L7]`:@`\E]=P6]M$2.%1NR00"*MK$P[5#W% M9<*&XYMT%+_&HRI,%.NQ$W'?&VS"C-ON6=UGJZC0Z@7&,MAH"8QFQ\]0UFL#)^!3''<<3R MLW14_WZ>WC),YK]7)"\Q;RHX.22PVG8:H@*;0&<%V`LIBK!\7A5QRHJBE3[V MOLJC:3@/B7B6U*VQT5.V=OM_FZ63)Y;/$+\GBZW#&/+HAF/EFMNF(JC%)%W9 MTF3G8?J'9);?+`R@/-XZ]657AZ%`7=O)[EL?9*(Y`<"2HG5:]X'#@T7/8 M%H4:$"G&"A5'J#Z;`[A*10&;C.H#=(]V>#?L2J%2"R+:WVXTY1 MU&HM(ELR@?#?R\NGPP&9[,`B&E8)0P'LU#NGPSV_:7U1+6XJ>U/NG7KG!!+3 MN*WNH7*RL=/:=V3ORV][GWT/)]HH?N'OD>]@KGSZRI)7]@4FSJEL&>S5+FB, MG/NZUAID`36QEU=&B/Z;A?G3U\Q6MY@W!WHAYR9OOS>L@)4^Z/(1LN`B?(G+ M,+EE8<&L12BP=,73$FUT5A2L+'3VZ;)JP>&^/\-L-&6CBKO.K$O(153NX-6U M`9S+R56ZK5`?=R(1W1ONN_4.M?M%+"_ M$6)?+/=NG0+V#PB?`O14OKUH!^VA>)WE5W]6\6=15,VJVE!_R5YR%M7[:TV2>WP!M$<@8I^-/M%;"<0"-!AC MNTYXOL7ES+8!-;;>I?2^"-HE$&)P:UW,1"G2F!);OH6#%F?5K,:Y\)@X2T?W ML#C"CW6&IN%X\8VBHAG0!WG+`;X@ MF2,E;$1``=RD3U\S?B&ENY'2:`FT0=[DT)/W=;"4+1$2#/!-9HO\95N@$?+6 MA?[TK\&E;$?`45QG56Z)_V53H`_R)__>]*^AM18F#PD$`Z M=]?LKZ*E%K!2!T1?R@$Y@3183GEN(%(+C2Q>CV46_3'-$OAXP>_U MRC?GZ;HVOBB[Y%)5"09[-O-R;7Q(GHM+7!SXW?HS,TT]K?98-8COYA;*:1YU M@QBQ,C(TKIWP;.E4KYV."#XZV\P"+99[MZZ=CB@_.M-3.=EKIW:"\*<\3(LP MJA?]\[?V7Q3AJ_4;`5VX-$LXF:^ZHB1VW;29-5Z3T64O=FI$T(Y0;4J#FLPV M0&(7119(HS%W;H,]U23K[;;G)GUE!;2M3-FP6A`P$3#O8"-%S(P(@>LD76T) MY2&\-TN"A`0,,'HZED*P=LF!*/DW.*!+>O!&&9"*@"G$0+&;PI.[6A#%7U?G M.\-K`4P"#D!F$XP2#CEKOU&F`8U:`).`^TX'UF1PJ-G[E[%S'B.6AGFG'0D@:B;]A82_IL4+B^)QS$;J#&=8'8!((Q./A`"$,3DD:CFR MK+-&ZZ!CESYEQIP.9@5DHW!HI!H5@'RC' M8R]S%:+^E="0BN.,J"R(2<#QQUSM.!9[.:)L)3*8S;*T7E(UD@VOE05(!'QQ MC.A18+&7W,D./8(D18J]&U(#X'E_X=5U]R:%1"WUDDA8_F/.U)EJE74!LM_W M85J4Z+,H`$;I-(O@?1J`I@")@"-0>38&NB#9%:RJ7E&:19-6`!?\G2.H:`IC%#5`^@ MNC0:;L>H@0.CEI)I35+E!"HL#]":I&K4"@9[>P2NA[5YU(=$+<-2(_%9)^J$M3A.`KO.CM3)(%%+K=1( M_+D3=<):'">!>^F.U,D@.4^Q=`8+]*B.<";>X6\6`D`[YT&.H9`G4+*I7G13 M)RH6')[X]17']"73:EMT1*_V[`_=]4ICC]Q/P:I]\'X'`P*BZ',VSG*VE$&^ MX146!H%]IXH5]E&!JB7R(XKN<,K'>O2X9+FFGD5E04R/]T1&:L;%1[3L,8=R M.W&(P@BV61A`[>R%$(8&H_"F?K*`*O"]UQ^UUV5\G6HVL"#,.;M MT&V;,1HKN@/JE,N\1X^&I;&G3I"D]FH0E.<8"?BE*D:/F#<9((0LRV^WS_E; M?7[6A(Y9.QW-\_.>OUV$)9MD.?8&S[0)0.4_0V6G`Y\Y2(0Z>\=M39'DIQJC M1@"9TWQ#FH=)3VZ53Z3MF1L>LKO?FOL"3-I;SI(U/\#'%@4U4G"-S>8YV>F:3`$*H M\N:EL"ZJ\@@@KL"#O3BU_&L?V22ZUR-K!1!"E]=4P[;HHK%RN>!-N2+9\T^X MY4\.M]:(/+\KUP9ZAX>EK M]G^Q/!NF#'[BHLA7"J0X2$TA^K>PBPO6"CD*)+R2/4O`/\.T"O.WFZ*H>&8Y MN<:%A;FD!![CZ>I;A@'1MKTS^=K'6\$\X3>JD[I698Z$P-N[CFQ(,2'L>'QX M`)N06L[1997'Z>2>Y7$V>IR&.2N:WU]G^2/+7^.(R5\BF#04')YX]-;L%,FT M#U"$=7M.#-=AG'\)\S_8(M5DZPDH-A1E=4!L$@8TTTBS:DP(%1:SB&=I`5L- MZ!C73#AB!*5`-(]NE-W5+4*!*-A?\JZL*+^P,1OM=\ M)<.7O.+_BC]N>464'%[02@/3XM*,7:2I0"'/^3OTK\MZ'^3"O7R&-ZFD8 M5L@:@C:+6`,`WF-&+(N,R@$B[/K+@E4[7?!C^G!162>CJ6U5I]5L.'*XW\+ M=R[*.B"VQW#"/8X#2DP(%=[,'ZWCH09Q&K4`YJX:-I2H$/*\N3*(-LE:_,DK M`MA=LWV8`$-8])=._;W;=3@W:-0&V+MF7#%&AY#JT>BR-I<\5L_+3;+<^B*K M&`P&/H/`VYU>1<@0'OVE/U\76FF.06IP?+LZJ\HA(91Y?B+2.IXV,L\?3K#1 M0$J>HB['O+N3J1XXA%`ZUI=V)^S`YKPB1[NKQC0M9`B/]EP]+I*P*(;CW\,\ M#]-RF->&A$:&F[2Y%41/?^JJ@,)I5%-WIT!M;$CR'WN.(7,9W@-$7\+^">-$ M6)A+NFOKEA(-HG=OB3=67P)^"PK)`6*D.[1/K.VUSJ;955:=CM/K-?EF'=MDV,*#B'4WI.4SP#Q-H,]5_K( MRK+)D\T]GY;B+3/$8UL?_18XIET[`':#B-#FSQ0CVE;?55Q/T/]8Q#<*,1QG MPR1AH_.W>;EB7E!J<^O7,M?7KOK9V(&.=!5_)B`1JJMOL+V("W:?PV*S_&/G M_J%H#C2SNPX>W?$B/<&;[8AO.=_GN.72U(J34Z]9LC5@C;4`.=);4+06Q[FK]RQJ6$B68W]./MQXN1$JXHQ/,)-ZGW+^ M]E[D/GRK.^37,!\-F[NCS_5,M+"M?K&Q* MI(41U-\97_C8Z`Q&6#AA*^MCG^YG3PK.PZ[:`;>O)J2[^GN9QM$]JP?F,Z*` MWUC!`:<\/22+X,>GC/]J6)5%&::C.)VL*>6!<3KA][!JE'D8E568/+%\)ML< MT1$2>M.G7=UPD],B,A;\&5Z%LX'Q+,O1[>H678H(XSF/9(+/CR*?D\<%SQP"+^\='O<3F-TSOVK7SZRI)7]@4F MLBD>==1*ZUP7.VG[M0H?Z0K^4BGU/,!<9_F8Q67%_6=PKQ6'7^-ZW57[L3MU M(-W,7]JGGDA;F[%FKG78R3:^Q76ZJUX#KI2!=#!_R:GLX;R!37V<%G%47[1O MIZ.M?I.'V]U9IP7'2D$ZGCV_S)4`(,WC"6[G."MKFXC,!5!=DV/8M[9QU?V]*_AG'"XRO"DEM#WL*1:OV37,.[>JWB6"=(KZ-K+-??V#5VJ;D7 M[I;WV.)O@\YW+KS3MI6#=,BY^0Q4]LN[SD#R/^:Z_(_5WZZH$LZ3/*;NDOH5 M97[]^O5G4$Q9*\P/N-FOH;)-*#ZD=L[M6[A[6L%RXEHBX^\J-U!*FC,8_TY M44UG':X+W,58/_KDT?@AZ]>"/;`$`6*_]#4*FNGV!@Z6W[CC2_VL;)E0Y$V9 MBTNG.N!V:2[PLM#HXT8L`53Y5LZ&>@T`=AKYO?2)ZD9T&RYRB/5F^]XBU[16 MQ.V1KEI!!]Y,T%>SER1[8^VY3IGO&:T#4`GD(#,9BV)B%0`1#K=LM7U@2?V> M/\P!5AZF11C9M>#:Z6"(F#+CKF[5X-BCXW@T9:,J8<,QQL/YV\I?$`-PK_:" MHX'++9/0$FQ&#G*]TAWL=V,!'KC<&&EMABVPI6$*'J`[(JJFX('3-:Z;*7BP ML9:)Y=XM4_#@F,:&L8?*R9J"+[+\)LG$:P5' M>P3R[V)C"%D[57"(6;)K>:_C-$RC.$R,2!/7`I0$DOAV($T&QYY-&KG9NV-5 MD8U+^8W>2B$0S.,S8C,]8]+;L_8B:FV+)]?M9DD0T>,C@PX*QB#([;$VWGK$ MBHZ[+``"$;A^-M#IFN2(*KW%)*@GKB$<%T*>1,UH]A;7XN<[`G<4':9O*1Z$ M-V_6A=4HQ(J#Z69AZ(S>?0&<'4`QN`B'WHP.JW)J^4!A50`@C7M^3/M`Z<]XI1W\9Z3ZBP#"6H88P7E`2*!]4T^ M2I\CFT=Q;2)SRUM:;PYH%DF@M;A;94JUN>_X>.[,\9L4_5K.'*MR6*\&0(E=IIF2J4:'T.C1"B-,?-?$@+IC7^L_=4@1N-8`@"=V MIV?L;V^`$R'9FT5&EMVP!\>K]0&ZQU!5#BD6P41\P/V9<[23":UGVCG:]^AP M;(,U(2"$'WM.(XY3BA_M$[B`Z,**&4*$)F^6FON%:L" M`#W&RK:SF9$A0ZCS9G_9=GKK8VHN,,8'#T.L".$>']\L3\"`GY^`0#KW9BU:7FY;(/)U7T4[P?YG6:`M40NR] M0;_56ALRT@O\/?_)BI+?$KZR5)KO8:4<-VWO^EPLP(-PX\U*=,GJ`"G%65&P M4L(];+$ID("W-)=]10R/12LG7Q2:+2O%^K!V.`11/ M?E/_!8^0W[$]CG='#>(V<",\=[`/&?)\$>=1->.)C2*V2&D"?RWFKVWGLEZ& M;\:,Z[?,=;"CYB&[&D!Z00>C$=(+?JT_GK/1V>B52[5^\XIQK*K'Y=]1ZX\) M/H0?(N^E+F`=>8,.=3;+*L56%*\&2`<[?MC7@(<0>;3=>(K?;6#_]MRL\JQ2BRW8IQ>.`WCP2JQ4UE;\J]6S$.#XBD MB>BA-N_`I>5C6U-85^"$8R9VBKEVX-0"XB10WL'&ED,%\*-%-SPX MI#&=;H.][>7E,0F`=$#,)[/=VP7;\37)B84KC)O=_J52O+D7%`9=+ M<]ZV5R4<(K'`@^N"*JT]O8.%HSRC:?(*WER]#^K^*5) MJ;[(N21C3ET[.#JDD3S9SGJGC9A:Z$94\/<<3%V(;F=P.O2;E-F8(D.&UZ%2 M"_*X%89IK:?;H5JYUG8PJF`G.S:*HS"Y9*^U9T0!*T>BB"0LJ0+"$W"@TQY0 MHN.@"IR]J(^X"Q:;9E4!BX6,O"@@&T!^Y$E,P? MF@70#%-WNZ;%P;8V)'5`;$] MFK!L7C6K4=J+OR@C9_Y).,_DIR$6$1YX\H>D+8", M!V%A$-2C4YE-'B3PJ`5-O&1%E,>U/,/Q+8/]"..";4399CAY?PD@^139%@J,CC[Z!UB?&-BAY@,3M M>02F19;$(WZ5M`Q+Q]^KA<7T.LF^%OI33*S,@K!4%DEV<<:$1$?DQXJ)^NRQY\+M-[L-&_%>>BEQ0N")FA=$Y!I(%DV MS!H"G1!X\V2VP'1!*/71V]:^ZC%,6&N'G15\\_B4E6'2/%L^*\L\?JY*/F$_ M9>?<'`C[],=F+2RZO+NP%<&^EN"!O60YE[SU&$1K_Z51/3@Z]A=.(R']R>ZFSEV M>F/7;=]X+'Q7LRGW;NT;C_<([QOU5$YVW[C<.JUO%W3SE(CJ`6*7Q@8?DY8! M;F+O.>8"*OU*5LH!$J?!2,QSDN#Z1HC:A$/LS49G8FC,AO89VN*[C+:W2F'@ MME,LW"N."81Y$71QP24!+K^U-QM8DO5P%&A1&K:F._0M=X#9"8P/L8 M/8VK4%A[<('&1X$C&R_/1G)U;Q0$^2B8<[2TC`A/[8G$//Y?\,6HJ#V&6$BI04]P1".0K$BM<@H:R:F];%A:-&_2*)NQVJZI M'BR26@"30.37ON-&"9#:PP6!P&;\`2P"7M!*O6O3U>"A]OI@?E>@'F&K!0$, M`2?IOH-*A,G>6P&;!"F)`>$)Q`L5*52F^D9J^6.`K=VG5;-9F+]M!%,_2T73/;(JFNPP2EH0NY M/*1(K[ND^A3W>Q3!=W.#=>+2_]G(&(QRH7%#=8*[.1.]-W$;0+_;#=7)QM(L MEGNW;JA.B"2#[J%RLC=4MUDZ*5D^XV-7XZ6[J'AP=.K]:;OA%*2&0^R::5U0 M=2@0807`1N-Q.JYX/:+:<(A=/%FDBL:T9Y\S!U=1=KB;IUE0AFI9*0>("!A6 M9"-$S(\`!+$X8U<@V0A.G9L1T"H`XN6GN,<;XD_AS'FWH(IOQ((5AH]CWR$_G M;^]EYN'!:ECOV-(1#VVI=2!U\3G0*PWC@X!M9)0[TX*3V_7OOG?1,I5X[V9D M/0H>RRSZHXV5RZZ\HY'4`K0$C#+NI@NDWZ@40LQ#8=M9[8Z=)I-VNB$Q14G, MP:%O-K3C3WX]Y[K2H":S#9"89X,%TF@MP"[94ZVM%A_QMKZO>+R[43(XII:% MO=W_!29!#`*Q%&D7TYB-K[ZQJ.)N%,/Q.(X8;K[5J`4H";R8TR-*&PXU5X=E MH`2>V:%\XSNG+#4)M2*J!U!=NG8YW65H`*/F#+$FJ7*=$I8':'[3A!L0(&9. M`HN:.X0UQFAM+NQ3MT6'B$>6QZSXQS^K-,[RUOW-/51B>AZEU./8< M,4CR16M)LT>< M(V!-UAQ,@A.=-D1[^=+<.-BI/;.0&@"/3C![4V.E#)(\[QH)QM1>,5@=@.@W MU+T6!=JLM4$AO)%Q9>W-&ZTESC:!RJ7-7]#U5;'5SD6B\@"1@'N^8@AIT=;& M@U#ES:;2.I/>924K[L,WA0$3AQ5=?5^1G(,N+R7"?A!%'Z2AF0 MV:.[7E>M"R`X\1LW[>KW+(\SV%..+L-2U>=7R@(&CV'5^G9^`10G'N&F=%S' M110F_\W"_!I^H]IL'@\&]LA9@.. M$[=P76J>\G`4IY/'M]ESEB!TK)0!F3TF+>M*@0""&\=NL_WI13:;96GM@]>D M"Q]695&&*9=5NFN5501X'I.<=65(%Y<;7VXSVA[8).:I*AJ'%2E1JT4!@D>? MFW[4B)"X<=,V'$.`)N>Q4$;LVW^Q-_FP62T+(#R&X.HY4D10W"1STN7CHLKS ME?V'?#>,%0/]!(H;ERG#1>89F0O MLX7Q1S/HT456!2#MX$E?C[09276GN8#Y=I+E\CW`2DD`L(,G?12(&_=G M,R;NJ^?*V#),/ MFY*P2[1`Q%M3_(%;R:VV3K7@^-C;Z]SEHTAE#,"5@L'QT=;OMO55N=I]90CH MW&Q;H/`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`6&FQZD3/'[YSAZG3J@%+A=K77N'?H)'+-_9 MX]0)V5#E_UF[L1&X8^79,W]T$,)[MA*3KUT-#_P%.*D>Q=9833L+7P.].KQ193UCF1-(\3NRC>`WN<9 MC)GRC9^`Z]A6?U;QRTQL'S!O!'3@\466]5ZAP.DZ%YI&+WU@!WOKW,ZWL;(1(UX7PT\_J> MTWM<&^9U20QI!,]',Z_O'>Z,>=V4+,+F]3Q^#7F>Y\\@*K)B9BQ_9K!][D[N7"SQMT^XK2*T\G> MNX(D9EZ_25]94391&CB2LQD/1?+O<.Y$$Q=15DD-GGH-`':/9H].!)L`(V;) M7D)]8+"9CN(D;BSOTS"=L)OT*@UY%`O^=W$@L4[M!"?['LTA'2DVQD?L49@" M03\;6/_&06<>[2PN^H0V:&+F:X-UJI[:ZE^ST?MOK[Z5>0@H8N[+JW)B=/`U MT*KOA_2=NY)M+5`SM5^-QRSBV]OWP0,3YNH`.BOG.Z8ZR!D(\K926-*9++0. M:O/]2L*T\UA#;<]^C]A?=21=/145_%B$7[!V;A``^WX^H4NS#:#V`@7K,5L* MY9MOA-O;X[-T-"RG>$;9ONT"?-^O*OKPW!&OFSC$;F=]XR-']T9!2;X#$[B8 MXV5@[05`[C&U+P34.EI8:!6@[XI-T!I:-Q&4;0]]0S.A?B.@A%TS#YJ"D\=D MWM;%?0NEZQ@CRT_QA2_)BBIGM]JW]X(ZP;C MB7:^Z]M\I[E\>MWF'ZC?08KA?+3;?+?)?&S"WZVS+$DQ5A16`RHQE$2S&5R%,XCBJQ^&.WR>&&0T^DEJ7): MDBM0K>PV#.=1/:RHF\8,8T_OJHFEPY6T0O_#6H(O*V_K8DGO ME>A\$P2Q.V'\H:=D`<8K@4+(7+P9GE=4H(C=T>+BWL:SN&S,!@\A:$II-XCRZ]!M63J^:PNYTZ0?O:Q*QUW>N^&)/W;70NXVO8<-"_FQT1,J/*/'[EK(CW?G MO9LI663?N]UE:;;8JC0;G?D"(>$.K0-(??NRF*]Q"C3$7K;=P.*:P\%1S=): M24#C^\F2.3="#,2>G/'8/W50<#4EZT6#DQ/?1F-S3L0@B#T9>W^L^A@F;#A> M">>E$_A,KP'`[MN8;$Z@"31B=P$MG_$A]#\^95=Q,:VM:.-+]JQB5%H7$/LV M('!7G\^T0S%(N,,K!8,][WDOS8E3XJ$2-BPMLB0>P2%R MM#Q*SD^&TRP!F8KF0HAG*8GB9SN>]OB=;6^GGYR>48US>51*U#+^%K+ M3NNA6MQ4]J;<3DRA#C5-P]#90^5D#9K+X=JL MK>^Q.W6O=T3U@M,!5<=AP7QD`(F8=7--4.4M@K`\(".6BA77OY@X"2QBQD]K MA-&8$-TQY\"3V=)\"8'&(.SH!KEJ5Z`V:C+"#R:.GL/$P0'-3LG.^N:_=A M/+I)+\*7N`P3)4W2>@#5H[&L,V4:F*B9.7\/\SQ,2R5=*^4`"H$T=L;T"##8 M\^&U=L5=S:J$&S)K:RU'E[,IWTTM');5(TNW#5`!@3QUYJ/,#!^UZ$70A M"V>QBRQ]97D9/R>L[F[SPZ$DV@!>(SAUF@S/LNU0"PRB?WNOL<4"R!_%R^J` MV'Y-@EIJU6:B#0KAPIY=P@47-*Q]KDA1V?H&]ORN&E$XS.%X;CY1FXVDE0"` M;Y=&=:='29&"0JYC.Q@IM-DX[T3'^:KHOKT2+?&QB0HAQ%XLYTTA/G%QFN7E$\MGW,OR";ZFNL05E0=H5"/8R2YO<2@(2]YL M!QNB*J\!D1H`CT@@.USYFFRU`2%\^7.1L,D7C:V<"^)4V[@];Q:&NZQDQ7WX MQN>0VM@X_UEMM5/4!-@$;*_2P22F40L70J,WYPD.[R8MRKSB*X)B:=LL')PZ MS5#E:%W#<"#D>/.+6)7S+IRI9TFL"@"DX9"$Z5Z'J74X"%_>GH99YHO6LF:/ M..6B9L\V49\NYO.PPH]EHR2(2L")2#X"!&&C2,H^?JY+O MNIZRNRSE#U%!@TG]K+X)XG,V^E=5E&QT'B8\%=A`NM=T\<'@]("`AXSI(V!W MFD"ZF;^G*-,0A!U695&&*4/.8#@SYX4Q05&S6^ M6?WK3((-RQK_5?NG*\ MK`^K'(''2?:X70.&O(CV:.T1BM[,/LWOK[,<=B6O<=2%7*0AZ.`$-M166)8B M1.CV9BJ2]50+;(O;`550N#FT-J01@`C7WBQ.V%,3'A'NCI7#\5/X34*Q3O5@ ML'>T6DOUGZ'1U"L<<8)1H33S>& M-]L`%>S<\#4$A_#KS\HEZY_UU-1UZ-:5`?1'V3YOH$*H]&OZ0GIB1R;?ZP)D M`C$`[`W-%BB$1X_1`B7]K_[O>5BP$=\RP'ZACN3Z.8?-0M>!*FD2%/11+!N: M6)'.0-*@9;4OJ%H$]7R4([(>5*0G6'8Z0CLJ_^,\WD)Q]8WE45R\AW05>B69 M-04@=^84W`\C$CC.WELJ:3>SP:.DI>#49S)?>S0J(2(L>C-=-?=4''/QE"%Q M:^90&K22*=FX+5#)SAV4.H)$>.]@QNHR#;>N0O*K;]$T3"=L.&X_:F,15"IC M/'^`K?9!'3MSE'(`'.D''6Q?'69Q=]W`M'E0QL[LR.WC1CJ!-^N8SIRV%F9D M!9\B#XR-YD%Q.[=OMX<;Z3#^GL.Q\MVZO^H.\\!&C,WXSV+'&$D_Z=%J<'JP M3:PP^'5D\3T53-JIXOJ_W0_I]^%:_)^)Y MJ6O%#6OZ"KZ.-!G'88F9-;\;IJS6Y!.0<@X?_@-=DVU_"/3PB>9P:@@2K<^. M=("F__!D1Q/`;!M^VC#/>';[Q7"4=2)[C8/2W$:"M]IQK..VEGW$T8SR]#7; MSHRR\2$^FFCNWYS-*)@.K"5.<=5)H/4M+3R"3W$E$8B5N=6.@FJ!6J*7=Z`; M>SX>#F)A\ASF#_%D"H<>LS7'K$T^Y=(T'FHN-9W@$LL>HUPY:R/9655.LSS^ M-QO]"F>+O#4>>`+G5\*F^0FEU(HD1]/;;#U#(97P"*`7EY?"?>(C-)0IV$4`$4L-WO?M/8!R M&KG>0H2$1N]BME!$U'+F6*!I5V(D=.!+&3K8WR,BZU$2`"^!LQ4Z<)!940E( MGDMG6W;P50'?KWMNTG&6S^J=UR5/>I'X,(RW=:YC&Q>6!W5[].!?/3F=O]4B M*K=Z>"U`XS3BE73?)].OULE1@(1.IFHZ^T!"<;*4_)EO"O&P63L;D`E`.74, ML;(I-(K$U"!RDB[;+TV[LRDTYHMNKFWKN6,!+H&+&73G56\R0#M6(YM."$1 M>">BR8(F&F+VPN5&:LTU%4O&IU6/Z\?E3=IVCV(2A-2,B,+LD!(6Q=DDH:,Z MO6LW/Y5)*!"3)P-&+1FW/=*(GM$LLJ>TW_LSA62SV=QY4+GSV"C+L1%X)R4; M-`F'<6O\:@*$\7R)BS/L;GT=]W*LB9#1BX5][JLO\?E M]($E]?5*,8U?GK*KM(0NJYPS#5OB^J!AF)31I4FP%E1J2;[]4D]K(=U.'U`N MK=[,,N=9F(^&X\LX9Q%\HKB8AG$^"U/E.BNOR%$3,(9V&Z]BWK4`V\LN;H?> MU[_^;-]/W+*]Q:).)-<#1 M$S.H=B%5`<]>6G.K]X=S=_6YM_J*Q_#RCTM?=O4-HU%S7#/$++)ZQ/<`:R^? MNHLQ?LF7*Y:.'J`70_^-X,`83O1'N+@Z]_$B9O+M,KZEX.QE97=!*W^,WCQ5 MJCNG\!,7M93PK3@OJP#JSK>(`].V^`G-QKJ-<"T0>,K68;=D M"I%:ZOA5J7_+2NB3R@TQ7HFC)!`ZJ^\P%4"BEBR^GDGJ15UVZ[TL%`SV!SM) MS`8$>6+X;;VGN&0EC/`XK:U>P_%U&.=?POP/5M;GXU\+Z#[G21C]4413*%X, MEWLP^,.7;,02?Z\MQ.]NS_B1;E+??YZ_B4,%W.J$+>K=.']BZF]4*5XGMX`4 M&!*#5Q_]OL$UY7)/)'\;;(MH9-A;5A*=YR<%BWZ>9*\P2\5-OX0?UKLC_"JX M99,P:2SIR.6OH!1'2]&3R0J'JST%1^_DT8DN;8I;OO4B7&2_-[>X'C?U+9#< MR=,1E\JF<5?:2^MT'X#P,?RL7A2>UXQR;LQ4AMW_ULJ^>*OLU53N#&=)=ZKD2-U%X\N8#]6\:=CA+8&_GH MNZM?![4?$[@(WL7>*U2D].77UH*'5[-9F+_!^57T,K2QZ2U"[OYES\,[U(F_ M*$4[9L\[=FD+<&_/.^D<]M%4273L>73"R1R[]`[V9OD[QM\/*W3QX8+/'#LU M1E@)/G.,[AU01!\N^,SQ,0T;HQ.^Z-H>'00Q.29@2D''#3(I*@%]%'/;-D=H^BGEM#O-S[11_DS;)]Y0IHNU_C:N5@),D M\=Z(*^ZC&,WF0*^S?,SBLN+OL=+1U;>7.&\>Z2VP.^R=RF]SE1-P^23>5W75 M2"SX>KWID*81'RYL@'BR[NZ-<:40<'9TW;>ZZH5:2*>N:KK+T@9A$P?D)BW* MO*IM"NBP<3'C=1"#$_%1'`L<3'[=-4HMP)7%G?/OC+NCL]'9*\O#"5MYDKF= M(X],`M#_*8'@!%1[="=E4@O\U=V6*]QYN^K0]J3@//PU3=M7*+58:,YWZ9[F M[EYR<:X(F#]]=_XMJ)A:\+G>$\*PG,X?FM^D43+!@,2.0) M)KX>6%$RM=A^8B_IYK"MR%:YF:MR_AM^PSW7F4PCYL[OVQ&+,_6=7'[XU;`\ MV.'6O>%:053_\H'3[&`#?^$(=\P';N`T<;9S'[B::.<^<`,\W?:.^L#9C><_ M&%!,K6:%=84OG$0?Q/SA+,61'[A-@FXK^'_-@)@[&3!BSG'V."/J(F>1/+*> M9.^>M]_$8AEQ7*LR%(>U64\8RG]_JU8./*8W#R M^SQ[87GYQG5>\@D'SD5/:*L5AT$C'O*Y9B?Y7 M1"?F=M"-`5HN!MVH(.M$\"7\%L^JF9*4E7(<$@$'^LW^+B9#)#LQ=X$OH#TM M&MKE.!0"QGEM&@2R$[LK1Q>_\[HS4_2+N/+;G_1UP=-[!X:QPQ? M5GK$:=3FL)V>Q;6W#_H<&7*\`9;8C>UV.*:U0=D6V:HMC;>[S/,J3OC-E7(Q M72W(01&(NJ4_UL3T"4%1NZ&[KO*T-D8#P.OX6VV65M*%5^(H"02AZDN=$B"U M^ZA;_AATFB6CF]E+GKTVEW!*'B6U.$X"!XN^1*H14KM*X7;TJF3Y$JF.1[FH M!C<)?H!95(Z.VDO_+V$TC5.6O[61:ASIT5H84-4([3U/?\F*J.8'SDH- M._PWP0,K&*">JFF1%>?2$GBMT94/#6CRM]&$3@[-S=IM/);=[VC4YK@)&&]Z M7O+H`T4(/O+T^+WEX=9Z4?1[F-<^0G^]@,>OY0\)7+SNQ@OX0Y?6'_FV*F[7UB#V,6RK=?4ATX/3M9>P!^BT0MD MP(A=1=OCC);UUP5Y#BZOD=/2?/\U3'$O`6$Y+B:!\ZJL_PM.1`@*:U?3GM51^YZFX?QA6G&7I:^L*-G(71@! M4QDX!02.OJXWR5M6I[7K=63:$.,9:B%:/C=`7VC;_@17RD=Y$K79QQQIB]CM MO;L1A+]O?&"7$W"`ZJTB< MY-OQ2T#E1T')1Q\D,[N+?JVK/[DGR-;-\//=^2+R;`UKF+8L\GR\OH8)^\LH M+^U1)_["^>R84?[(Y:[0O5'^!,\8:UE)'\$H?\F>R_>U7F&)WRP,FC@FZ*UM MAU]Q+T*50,SFOBKG73A3N_-B53A`&G[:J/)UN-H`1,SB;ILQ6G9WF]21?2PV MWZTI/1//TI$*HGQQ9':J+WX,D]6+W5]-&V,:X7`ZR+7G:FK7JB] M*NL[*K8;W%T03V&DPJCQ, MG'X/]/6)@.W`4<_;ANKDSSM)=C5N.O;4ZS8^S;7X45RBM]8!,2TB?=&U*W1' M*,N]\_;[HOC3H,7!1_&TVT9?E&H1Z8L=3.ON^Z)X+['M;JDA!=D^A9B0(L/%ALJCUZ-HN=(KT\)V]F/J@B=3V/DR> M;7=3NPT5(\/AXUZ+^=_3F,L%7%&(N4A\.-A0,3(<_%ZU]5DBZS?%=8EU;?C> M$/63C!^^_O+EVHZ2D4%QN-V'NI<@[BO@?V5%_;IX]&L!(_T\":,_BF@*)8IY M;D60G`>=ST:L4]9!Q%[4^ORMY"DM6I9O/^V9_5M?P%ZL"LMQ*;8>"E*E$X$A M!Y'[(SP$73Z//W];_OB/&`9?'DW?;MDK2Q1/:/0:X!KSGM-/QJ5XQC,"1^PA MZ%+@+S#!PJZ\GJ`W42C?&AJUPU7AU"]0^Q&.$74*]@V0$WM;ZJ\3T'H'Y*4W MD'VN6F_!M+;42UN5QZL:LP4;%9_8\U117)J'N/CC.F>P&RY9SHKR(2QE#.DV MP4^3'OT6NO%G"([8ZU5QU*$7%L'9YC)^C4=PWNC`KJ@)K@"/9T][[$K`$7L9 M*Y/^MRP!121Q^=:#W]5&N!*-L-">,2>VLKDY\'M.C++JW+`'MVY[?/9 M`B5]J;LMXTQM9P(Y65F`V0[,CEK@\WSDCT)/*R42&@8Z8I6/3S)'N%,1`W$Q'\L#[_ MP*^"6S8)DZNTA`D2L;X(2G$->0]AHL?(*HLX%B<6%5T2&FG0D_%Z$2ZRWS05 MN!XW]2V0W(GEPJ6R:5@8>FF=K(7@(LM?LAPV9__,0">_-6Z(&JDOT5H' M1$B?%V]UU#"(V1(N6;T'DL=P;(IP`+Y/B]KK.R*\]*R_K3WF=57WBB98S0/T MD3"9WWAR3Y@AK)6PU4PG=<;;3A%ZD2V>T7>56])NK06#_4\6'[`MMPM&TFAN M:\W;Y.A;YWVG[UR[;)X[UWK4;71JR7?K>TUB$QX>ZVK=;+;Z[7!NS+2%V/\LF(WZ=/7[+]9F,MV M=L9M<=5X?*EB>Z7KJP=B>WE]&/!59J]S+%OC:O'H[>Z_>ZQK@MC5HC:0ZZS* MK?6/96-<*;Z=`7QVCW5%2*\FA8?1__B%2\"CV-0Z_/\!4$L#!!0````(`+F+ M?T1HW-PZK*(``&1@"0`5`!P`<&]S8RTR,#$S,3(S,5]L86(N>&UL550)``-- MWCE33=XY4W5X"P`!!"4.```$.0$``.V]>W/D.)(G^/^9W7?`]:RM59F%JBJK MNF>F>V9V+?3*UHQ2H9&45=M7MK9&D0B)70PRFF0H%7UVW_WPXA/$BP\`D7M_ M=)=2@COAP,\=#L#A_J___7V7@#>8%W&6_MOO/GSWP^\`3,,LBM.7?_O=YZ?K MLW_^'?CO_^W__#_^]?\Z.P,?80KSH(01>#Z"RZ`,GO(@_*VHZ,&'[SY\]P>` M?OCIP]FG(#_[\8__O#[/_WXPY\^_/%_@O_G_M/_"ZX>G\`9^/+ERW<1 MXE`2#M^%V0Z'O)''ZVW-00(`ZEA;_]KO7LMS_Z?OO6GJNV'[__'I]O'\!7N@K,X+G`G\KC'O[;[XIXMT]PQ\GO7G.X'>Y%DN??8_KO4_B")PM_ MX8_X"Q_^$7_A']BO;X-GF/P.X):?'VZ$`OVQPXL1?8]Z::N?]S"/L^@J'=?A M/K7]GC^605Y.Z'N;WF;OG[(R2$;UNTUIL\=W<-PX-W16QQ<933AN?%N4<_>X MY'MK/*C<:";XW[>H#YW>P?<2IA&,JOYA:HE=)#U&Z9GGQ]_]]^JUJ#5'/Q: M$?S/?Z7?Z@FPSKN#&^1AU1OTHT("UN+[,$-+[;X\ZPBSS;.=[K"R'F2ZLK>G M00<=3`+2^VU0/!,1#L792Q#LO\>H^1XF95']AN#H[(XY M3HF#;S1W87(-/-T_N]&@<#BNMF@)">SIVD[[!%/$^HM5: M8JGES:WKCZ#7?3#5S58`-?3"-NN,>Q]!ZD%W@!;JT2,E,#"G^DBRIQ3W>;:'>7F\1R-=KM/H"KE0^QWJIH9%U:"U MKAXZ\O1Q5=&L`*$"01J!FLXKTZL]6WWH&4Z5!_@S,])F;/Q!I9[ADP/40\,^ MD[Q$4%C1>JQ^!HO`>*3:4\IU&&:'M"SN@V/PG$#42_2;_`"CVSAXCA.TPX;% MQ2'/(9'@#@T>^X=ZS9C.VKKRSC`:W%:1L02,)P$ZXPI:;+U:?.9"15\CYH6$ M7UIBMHJ-YNBE3FB>FNBJ@H?+G/U1.`TK8+`SI_"?=9$9?%^?'B4)39 M#N;K!$$%GXV]08WE3Y/>NC[KRM7';46W`N='4)&N0(O8JR7,:/KZ4!TQ=]:! M.:@UA<[:H\O`%335D@FP*5A$"F]6D=$"5C`$%3*]43!-&`HTS`B#]E3L*LC3 M.'TI[F'^^!KD.N9>3&)=C22][^.J:@I06T`:>V7$5?/01Y7>)+C#D8YUEM`X M1Y+,1`U!:7FS^P;SYTQM>$T$N=T\/H+[JP?P^.?UPY5_2J"TK9H(LJ<&MUGZ M@M;'W466HODJ8^3]7\+G,*U]R$Z>4YON M][/AC860PH&#+>H[[U$_V[YNT#3E^C+TE`=A!SN7[O5&@2#>5=:`CSW\WV4E MK,]PU-9ZN+EUY`MZW8<,:5:?S/ED;&7#WD>,>LPG!,^VF>O903TRNT&T:BGD MT/#*-(Z5:/-TA3S=]5_6Y[=78'UW"=:7/Z_O+M`OKQ\VG\##U>WZZ>H2M7AX M$D;B3)8MRL(#OA0E,8?+3Y?C@&=-[>D$/1NICKV%X"+8Q_BM!PP*6&RVM[`H MH,Z*H*"SOC2HY.#<"MH>4`*0;0$E\6JYT)J<_KIA,#..8':37L=ID(9QD#PB MBP&QX:A[:N:53^3K%J8CQD$!XS@%-4O0\&S!VZLE;ZE1Z:Z)9^!B?7_SM+X% MMU?K1P_.@F91!JG:3],$>V;AL40??\V2".8%#JPJCWB9U%A^5(36%5LI21^C M;8+_^@\__?%?`"4#F$ZY"MG23,MBV=1"/>SUU*[UR&PI->#AB7;I+09M MV@X8O5P*)TGZM+GXCS]O;B^O'A[_ZS_\\X\?_@EIWW]^OGGZBZ_:9K"^C82G M31UD"^UF6R^^]YGR8;(9N0/-TY**5SI&!C;;EDM:47JV$.A/'(]*TUES`,@G M?.:@`SW6T!W(JIZ*X?0K:>(3:CJC*\3'P-":(J&`X7OK.O=)E8GNM<[+MZ$S2]MX'B&AT:R/;WB871@U"^2H$!; M>N(6"=1<@\:=J1_HO]CJD\;8E2#-G9L#[BZ200"M3(CBHM]XU-18-8G=Z"UY M[P7@>/1*5V>4PV5@EID$FT.),S#C!-,@S5+4'L(="=`J*MGVM6P%F:,L!UF+ M2M3N.[K1B[ M0_N9:?H]Y5*MD`9.T\8HN_CX>/6T5&B]IHF>U$FK"6D&HAG M2QMN[TBI^'X/ZQ9@#9>/.C10-W7GJUX'I/V??$&V`"W#`)="Q69X?O&Z3B/\ M'QQ;]18D.&!X75X$>7Y$.[:?@^0@BR#1I'<0;J\G%Q]67[R2E%[DAQ;I"F\H M*VI`R%>`5$MQJ3&3Q0SQ#[`A74B8/5<.QYY(*_`,7^(4YU3`^W7:E47E;$H6 MV902HM\JY+/[UL'`LO!O&HS-BOUTD@\PA*AKSPF\@U6N`YF+("5SEAA2((4P M[V'3GA0\6%4^Q++64-<7'BE4WA(JP:5/@B3)ON!BFV'84^A!%O(A+,OJKKA+[0_W M01Q=O>]A6D#U2B9H[R!9_W"_^2SUI!U@#2TM69KY]\U$@+2A!VEPI*#A<^DK M$>/H;$?W3,?U68[P#,<6FG7LLZK'I(,@[!S?N$?R(!ZDIS;>U6"1.TMR,G]J MK`ROZM*:*OXX6".EZE9.J78?87C8'1)2KCN">[0[B8,JC`'M-I@S]M/O_]&E MLH\5>-V=/R\\-1W%TJX/X]"3NTE+-.8X91ZU5Z@K5^]A^LJ M)^HW%Q*(VS'U`DU+EULJLZ[[XH1*@=)'O`9*;&^GE/LH9QLHR<[)DPV3<*U(_7Q7;2_B9/OWIPE4&_*9"`_D<]GHI,U79N%_53I^M)Q3_U;!5^P)S*4 ML<>/T)0I0MZLSV]N;W`.5I*EM9VL!UQ>7=]<^%!_WA2C7`KX40!UHH/Z45TR M(I=ZI@Z1:FN67T%>1F)474\:(@_"O=18DFB')X%?!K4\-6(:M+AX6?M2(SA` M4>G1I^NDF23>4_(50!"-J.`!$SQ1E;BTY#A/$E0R3RYB-@QT<$))7F6^*NL@M/P4//N1]Y4*%3@A@L9U`&-S3I#]-78`WR# MZ4$CJ$)$X*#*D*#G?)$A]L:/M?0!\=J=_YS"($]1YW/:TCW>Y8CARPJIX6(1 M[0=XC01Z@.2BX3[(\;HC`_MP>_M8%_2;@SI"-YXQP%H"UG1NJ/^1=CN%+_@K M2K!K]GX=O>%+IX**D#,1]C(1K`)?!AX.]VKDN"FFI;;P@ZV=EM(2F\=._1U+ M.YP]#CEE"2LT+DI-!&$;&G!6!Q_M\55HEKI'OP1#LL)@KIWZ5M&)S7,2OY!9 MT_'M%81."[,,2B*MO`):)*N%':`1-56,!$J(0)HJ8FD#8RH++G3R)_^47$]= M9)5=5+IB4?4'B[S*5%Y`8%_513U7U>WU1;/']#^J2Z>RB*`(UX:-XH(<'-&' M3*N??OQG&@KT8?5/?_QGIQJO*R/6=`\57:H:[]LY3 MAO'!YO91/MQKQ1E'$TGIQ7L2(R&:\XVTEL(?ITB&(@[[2@@Y/^30"N36H/7E MJ$,:)2TY[?`CW'N*4-6)AZ[2V%GHQDA$ZAI65J`[9W[:!&W=TCP4<1\'3X+R M6TNW_GL/`9&;1Q\B"8:?3W1\Q<4-@N;2:20'VH.7'LM(C]TJB MAM3@RQ`-/+FL4#NJRK-7%9XURR#[%<(^6@R:?!T_8@SCTH/P6_/@=/_"T;M9 MI559%@=;NTBW,M#G@4PE[=3?JRI7X@W.D;]4WCWM-_IF$M`:!F^XG7O82R`S MD&Y%CA>;MT6[799JH9QOZN"&B.LM[R_@)BQ)_\]B:-BZ+M'M,,'RG\!_^>&[ M'S[@V!\*ZW\!/ZU^^.&'ZG^@>`UR_!CK4+YF>?QW&/T+^+#Z_1]^7/WA]_^\ M^O$??R2W1/@W'U9__/&?R&\8":F!$9&_MRI^N%<;$0#YNQ@9^BP^S(@BDBH@ M2.Z#.+I)V7Y'HC=""OL/+H1]YT/2JI8`-P5Q6NU:?7A%,48,G-_J#(D1TL;N M@:\`$O>20`=%5M\G57DKR)X&J><^AZ\P+>(W>).&V0[>9@7.];#9/@7O,O4P MY>3BG9*AK`,O=^HL'W1CWN$!*!/P#6;S+4V#DFT!XN6#MDV6GDH<=B2.":'S M;+0VY]4#DS-.:0<>-8W76'LFZ@&609S"Z"K(<7+QHM7M2[I9EE@E'6+KADA+ MHCY&*R)048%OVK!EA`NG6-*R-*/$6W=RL9%6;J/^EY7"IKG05Z"^A3#5'GM& MX2F'07'(CUH[WJ'&UI5^L,=<7`5KM.2^UTP-S+K-=K__^,/JPQ_^L=[EELAI M*#Q0!#%H^L!7(<;EN;[1>;X7Y_B:Y_?KLLSCYT-)+E?+##_^\B5*1$LF&A3% MUU-=:#F;=BDQ5__=WDCHWT1X$+PXF+!'HLUJ4N^24`V@JI]\BC;T*]!15Q:J M(4E/(H\U1A=]IFFFYJNPCEEO2/%G635-25O+-=6'^SNXO`'63GDQ;0,1RM'N MUJQ6#K7-_7_]!OGXE`=I@?JB@(L^J8.]OU(:?N??/(8_@C:1%\@RG2=^DVDR M2>YQ=QD789*AW0%\@N_E.>K!;R,@.,C%&S0.RV@`S(8!^!6S`(2'T\" MW:Z?KB[!_?KAZ2_@Z6%]][B^>+K9W'E0\7<$4G654`E3NR$.<8DS_V.?I(XG M#)&/TO128U$PY.,D.,)$SJ%`!$9/2ZRV.704TZ/%8]3D#L46C)Q9SV"LL[*8 M,O(3R#*;JX]D3Y:8Z1)O/GVZ>?IT=?=$DQA?;.Z>;NX^7MU=W%QYL-",P^XH M-76^W#S"%]S%!TC>K__R,K"NX^MD3&ZN"D4H/G-M3EM`<&?G[+(FQZZUA465$KJH.#$L@ M2+F/G8ZJM5=V53T=@HSTRKFP!ZGS0Q&GL"@N81'F,;D[0MN[\Z"(B\WVOI5T M5,?HCF%F'8*C).Y#LV("6ES(:0?A@^/'VYP\LN&S2-\6&HE:\72OD>/1W-?4 MJ5"VJ,%\G_#M?_R2QMLXQ.5W.:.CIIV&\3R`9EXLL+1!1%/B1,64.)>!,P&P:,"'49K@3GPNXV5X59;P+ M<"8H_/6C3*G'L[(;J#-.6GWE19SP[VM>X%?*#3A76B?B.PYLFH#M3MS39&!/ MT,_U=ALG,;Z%OT*6`(?>:6JC!J%=W=.1A-NAU32@(@),HUS?[LTITT+]C[+P ML*L0:V=:OG.L\MKJTE%P0UV9$MD:OL+HD$!L3;(]S,OC?8)7^C3"(;1[/%N5 M2<$&9GM(;N,WM.[CUP]*E9^)N>78V9E&A#L@9'S!!B]4E#,@K,&:!9P3YO5J M198OQ!X0_LB^D!UXO4_D9=K M,-JD#Q#GI$-["N+5Z.S41_*SOD4?*W=?*3"?*G%6^YU*Q0ML4E!S8P=ROEB+ MN<>BSFQ_T62V'\C:WQD>O!-`7\AR3!>4H!E/D'$CYWYK/TE=^GOZ&73%XKUG M;>6JT\AUB,Q;05+1%.?'UK^TKD1'L;-_6SI.:MG269_6MSFMP/FQ_0OO;,1< M`W'8[8+\6!W:Q1',Z8D`B1BGJ?#<:_D4K'/WMI.!/L\.`N'B-2C09B6/0[A. M"!?\3=/-@B8?9_L"73FEWFW%!!`NH&'CC5[.)G:CD,W22P[LUD4!6=1T>^5& MOS[L7"KI)&"+'/<1J':Q]-ZD./8CRX^LVHA2>\U9.%QBE=+)=+8FK@KA`*JI MKH_^9A#SYN[GJZ?-@Q?Q^Z98%"^')D"TF>Y9L(77T3(=8@?)H#4DXN]7*=&* M'?`$G0,>:XN@EF:-$_!ACG7P*R5QNQ+-(HKK)Q;+ MR6#WJ852-?@G%IIZ83$4&#G,7W`1^.LLO\P.S^7VD+!XE.(!AC!^&ZB9/J#R MAGSL!PP;RLE=A5;T`#$`%8\Y/M[@,L8/X&"XF*RHBLZZ-4`FX756\0Z]:@ M:NY2S48)0:IXY;2=>YU1(ZFO(+HPZ&W+5O>9ON$R\3W4T='EO"XS7L%:NYD^]GFOP*]#>JJNT/U)IO\W(-5QUU@ M<6'5<(77SU;6Z.:;GI0+^-\1,V9)DA<U,2[2V"++XG!',[`?GC)&8B\PA3,X(%]"P M8?=:JXY"M%DYCL690_26M`&3MKU`!$IIK8;4C(8W%T\S$=L3+MHOX7-YDQ9E M3F*H/Z=LB)'%B0NR[1,??AC2V[U8-Y"+?Y?Y7(*&%K2(046]\#&'SAWZ!`EI MF%M)]"R"SZC1(8D]K0QJMMP=3H1@W4#RTH%B) M!ECU9=>/$DPM22>B89P9<55,]S[(-_ECB8TR"3NYA_DCKO#VGG6RB`45L2YJZM[[,$.DO'RO'APG>!G=SUU0 MCP:Y.Y?Q6QS!-'I`GT8?7:?I82?R-,QXV/4V#.53J!)H&("*`\`LB#H1)LY6 MY]DD91H55?+EB-#E*NW)%%I;KL>H9&?)'J^/KI9M8M.*=5UX6GNYY@D=+],# MDJ@`24E`0^//BFPD#;,;7!5QMZR*(,T MBM,70SWO4'JA[%U9=#6^1>6;VNL*U%693"60:[T9P)R.\@@!9[<^1Y:./>+2 MHG92B4,MTU#YC2SU_F1KDG!Z9UJVEM/I\T2F25(VVG:U$$U-&BH18J1&3NR# MP5Y:2N72'FALTSKX\FH+/4H./S?/%D1QI/NZ>V9M%7&HZ\K=LI#"O8X+]V7= M=9XV7GFP2S:6P+_]\8(B.-5F^;982PD<:K'>AEA.YEZ?Y3O'H47;DVWP.$D\ MW@#K`$RI(QYL?9]RDK_JV.J51#\&6UM7B^$^]S%4M>KH@TL=,.QV!_SN`2\! M2A_G2I2XR,12O>:[#X[X*1^.(0_#'"U1K5PY([*SC&'K,&/+J%&097&IWXPR MCO05!^7924/D:W*7649D?7&Q^8P+N-ZO_[(^O[TB22K0+Q\^7UV"VYOU^AR+#>`HD&[R_#3'C9P<0IZYNH. MEAX;J+E55.*_+**?+LS:IZ!DO=]L;[/TY0GF._S89(0[H\O*H4G2EE9FXQX]-TY>;%,WA MCO@TYT?V1S-[8LC1H1$QE5WF,+#FH&8&6MQP?8BJ@7];D,G#$"0X8&"S)^4@ MD.1D]["JD7FV_I]U2&EC->3)"+QM95I+["YI;+P@I[+4@^VZN& MCAL[U:H%!;!7-E4.G6ZQ5!WZ#"&+*D MJ+%#Z&A.`5?W7F?\W0((_YA#>)GM@EB6>D^#U@M0]>71@=<*5&3@5TKH*=0& M)TL'=)*9FK`,?PK2UZ`L@_2FR,ILC[;UX6N:)=G+\38)A24R]$GM+L]ZTO3Q M5%,!1@8:.H`(G1;-F"+7C:">C!U7P\ED6'-"#!2GXY`8:XV]M:6;O$WAEPPU MMKYZ#/98E0?2%T=$/-S]Y4`UUJX@NVL0Z;?SSY.V-^7=A$TK\XT>^ORS%[51?JZ@;7R MX%Q]$*A][9*@U)Y*7:&/1Q'.,5]5O+^.TR`-8WR05VE^H=0X,S;6%=)0RCZ\ M*G+0T(.:0AU4=`.L2X"ZP+&L;7.J2]8(\ M)BN\BS)Q.-AGTX<[Z`QW9C[<#@)9K!@-0=B+18MAL5!;U3%6J]S^+<#3,.C8H^K1>U.':0R28!^?FQC'=24WFR0#69-B%C=*7.` MQ:&.*>_CM*C=85$JDY[1;0/1FPL[@TD30E%WQMQ"L:BMN/*N08_<"S`.2*7I M`K0\`)>!1+,)MQ(Y.'XJF0B..EHFQZ(3[Z/^\<\QS-'PO!YOX1L:96T'1,K` MI0\BETSNAK3^55,#0NZC+Z(QAQ)W1'L"'2\#?#]'^282/GXL#!(Y):!M8.JW MCZ*<1BT[JC>'#@![D^X/94$4Z(.^NS)$Y0Z,@S+(UF]*L&(&\H,GH0YF\K"^ M>Z0T8B@)542%([<*\>,HA?C1*X7X<81"_.BQ0HCE87WW4R%^-%>(01RY58B? M1BG$3UXIQ$\C%.(GOS:N6M*PGONI#C^9J\,@BD[K:NDV3N%-"7=:&]5YOG.2 M5TSM<9(I*4M.@J^5!B^(.Y?NW.43NQ;&'P/D:WXHMP?CEODQ;J9>PEE*LW!A$A4')R5AH@KRV0\]"8"MWE)<2!L*X1+%6,Z`V.[ MT:-SC$0?G5V>.%7@\).IAF\O_-.;X,/9<-()*YP9)"[T0)I\:RK7$]$`46C? M=/B[CO.;$1OS`']D+)\`]3=IB$MT0;3\D__>I$V([E;7;QW-R2ZZ1\G:1W3% M!%1<$(X[X?I;0?2YLPPXLXA-)'RC$?+:CA;>X`8EJ6.*7327CQ7"WOV*RI*C[+>ZF/&=K77V"A\W1B.EL#5J[>,9E(*WDF0]@`QN=4DM?.)/M9 M3_I32EAK#';!FYV12)^@L.TO2CWD@89VE6VHIWTX=1'D03+:F3MM#=I"6'2` MJ\#$3+"47:K)&KN#I^RRH3?;RU^R&./T_^^]4W43WK7H8GV"VOV2Y;]A_K06 M"CNR%:F=H+%=M1/UF,L+1MO5=6]82S<7FZ-Z'K*>/R_:8XKX/[.Y12U`W]6(_H#D%_2LCK?&W!Z`'^`;3@_3.NVEB'2*MWO'GU_1/ M*_"4(3UPLMC3YXNL*#?;CUD6X8B<1YB_Q2$L'K,DDFBXC,BZSDLEX"NZ%R4^ M]B;-27!610`PQ;+&01/8Q@*1J(]"8C%L`EX-J+X*Z*+)GE)\S+.BN,^S;2SS MC#JMK,.^VT=N&YN3PM_DS\N"NL2\59#6Z>R>_-GEDJ??2_!-@O[QK7MM&T!J M7[V$,+6G3W5%R:OW/4P+*$MJIT%C7==D_>_#I*F>635>_C9&MK'^RU49%:7\%4LK"F5!*0?RN M+DVE+%XX8-,$"SHT[I5&$W+:;1@QN_EM3%FL4(\3!+ZFN93D/\&6XNA M1%MD1/;KO,LDX`[.:&."J+JY5THR6IQ=U=R]>JA!Q952UT24PTV)R6;$ATV( MUN;#@\V_3L=))T'&;3K<0UT($^5>PSFPZ=71+=K^ZT"[W=H=N#M]%L.;W?!] M@QM^ZQ/&I?W'OP888A72L]1IS:&Y>^U$+WF4"S53!'%[NGF7I5FW-\Q::)R( M:=!:UUL=>;C;N19-K8@9@*Q%P?(^AV7P+CL3UF9A_W!87SKN,!61,L\.="O`M!BL`&*Q M`I2)%_OZ"1*W1,3WBFXU?SXY?-B^F6H9=PP^2L6F/(^#S^6G+(JW<4A<;.N]]ANAOX[U%?Q&D! M?X(F4K5_A&69D-#;S78=DM*!Q7UPE#R#4]/9U4P-.0:W_)L4-$3X171%!BB= MLV?P8P5"0"\:@;(M""J!]L$Q6$XB+?T=(51<@@BF60D+4+X&)5ESQPII3<=U MM:JCZV8J9?&H%6_YA=MDV:FK@M#^`:Q*DN'3#NE9SL+GLEHGG./$\F9+JP

3Z"+7?%!A`^H&;D-$9VK*C5"AP1&?%EWQ8'TU(!\?4V7$J\L=M?RP*ZV17K MJ*)X3ZROAQY`^^8:T%J[6M>SAC M&;S23B%NAC5)`1I[J+\*\A3I<7$/\\?7((>X7$.(`^'CY(!V71+T*RFM:X%: M%J[\`*,`B`00FA4I]!'2YQJ4SHM;:G/9&CDBV@:DD)TU(Z,-$`IW^,P9,W-Y M,#&'8#:%,LH48BX<3H%!'RD3@8@DX`P\]V5V;_;0UF4:%Q1ET3W@F,X6L>PV7Z*92G@%.WMVB9)O_N8;#7%80NHL1<)X+2&OP,3O;&?$0S2],Z" MQFYA(,J8/(0!+](F2X=<.OLCTR?/L[\[/R`C#(NBU:E;C4JFP$=E/4W`OH0[!CWC[=*$"<@BR/T`"4&0CP9Y$O_NGFR4MC,$&)-,S&9`V:X(GAXPSD[M\' M1[QONX<(7&C[]@(WVSM8TK->D5^F16K72].39N@4%6\7`:,##2'63GRD16D= M'A6,E^P,;?O/]DPRLJW=-^(AK<2GJO&2XFD="BP\QP5W997L9_Q\X! M\AK07,3H)UK>7K18S\7=[GH^VYCH>.T%J%@#PALTS$&+.VC8`\K?H5NPV`#= M(X"[B?@^8;FT/)W%1,,E;8(=?IU$GU]UK3+Y'7BNZ]GQP98PG?;>)"#+D'\7,F"M9W,\VU:UX'DP;"OJ"!1#\5R.[38-@'2([C MHHN@>&5;S\+H:&B13SEW/6<8+:V[D>8[H/,A4'T)X$]59QZ%C\=5=D:O-5!A M9Z""/$?MZ%/TO!JT$`\:.P@K5EZ>@GVUH'/I!\YEY%1.X;P6SNE!GD"4=:-6 MQ0/^:;/='$K<]^+G(#G`V^R+V5G?E._XMG^R`J0SV!#5GUH M!$$!X> MN_'J/_)<3:3[$XS8XV&W"_+C9MOYT!-:2(HMS',8J1ZM&3"P:ZY,).-JP5%: M?,S;15^+W)^';L9SV('?R`E<$G/2MW&ZU)ZA3?1Z3@]J7KRG,YLW,Y"-?'%G MXIH5))N#]`'3='@VR2<"HT]3C(^/1_Y M%4^.SL>.D?:Y^;#><`\*B^I%(3[+J+[CXXGY7`-VP=X.EEGX&S4QNWV0'GT] M_YZD2WJ'WS,HDI<6YS8.GN,$65)8W*3A`?]J'B,SR-AGNS(\$I--28LMJ/B> MC.G0&Q-18-A)F0N)(DRP$$HM\-(H?)C'!'SP6^$_S*'>SM,@3Q18TG]/%?7# M#&KY8?X#I?J2IT"[$?(&!3D"+?5'OSOL#,XTC?DY.G0REUMR#-5L;`NRN2?\ MB-?=7D892P]/04>"8/B\:A("+$):[\C4C)G?8-8X4#5$LE^'K&,F?A*&%S^" M[9T(U4\(+[!+EI:T:SAF''4/_P?O[-Z"I)WD7N-,=M)7G!_23ALCK5/;_NEL MZ\TW^TJE*>3Y`_H0_:'U*;^.<><=,]S"LUOU>07L/IJNPX/(#["AK#)413AM MU?`S:@]CB6:P,:K#[MD,C!WKVBD9AKHD*_\W(V]O+:EL/*;:SUX906PZERXE M.+/--!F=^F_$?B00L7O-$F0O=OL\>Z/QR"=B24W$GB?I1%6O<`7V!"N=LH6X MP3,$AX):WRQ]R7`H9U:7[CDARZNT/V/MK:;QL>K#MKWJIFRR;&\V[S>\M;HZ MXS.7]]K9W+4*J2]Q8:A7\=3&:#WE040S^M/"CJP&^:E8X%$BSY/^IU>UO1.9 MC_U?2.(93LCD:ANCB:ZNKB6R8X+OLA)6W\<''&C5?(+Y[A(^S^'J2KE[:W;E M8S+5X!+NE64EWB[^`,!?`/@3IV%LS<8(MZXLQ8F85C,!YS&J*8%&M0;1#0+Z M[AE^W0`B]&6<6HT`SZZ@7DA8+7JO4>C)IR=62`V M!0P/.9V(F(9I-I]0<<9L2AP7$(3U.E/4_2Q?XSQ"_\H)<_0+'-Z$K[9*V']` M>T)+AH$A';MT&%M1.TO(QRR+<"[5-?$Q9E@M^@R]71@XR:>N`15#0#F>Q@FS M8!%W[#+;!?%04@LC:G^PV)%I%!8IM<]HY.=-&XVB29M2C*OBC0\WJAOD MF]8%\B>(2X&)W$1M0N7],N*Z'KTE5FH.R6 MKQJ#2!]J(Q3GQT_!7[/\(D%.H,+%,.+B4:6$(1F-*@H4X/D("`M`>'CC?(R8 M5_W,_(I)]0*]30?O@IW:,3'FY!.*!;*:(7G5P3%FY)'W,G*B#2"MGF6+/C8M M["%T=03M[/O-O7X.5YI2^2=6O>"AD>7\7?&P3O!L+^,B3++BD,.;]`WQSW)\ M]*IX>:8@LNO%JB3H3W_3'K0(EL_^HG6B-T&8,R-QK'FI6@#K^*8&Z)KR="U\ MA=$A@9MM]96C_'6:L+WE!VCB?G-OS%A3_*JL;BQ_0&8'Y6-DR+1EL/<(3@&A M[CLW+?S,"^C;.(4W)=P)'Z;):9P#N]U_37!C$D!HED*XND;F6$DRRY*,U=4E MA'&IM)R:J!17H"/V7/&Z)WCK4*#^X1LAV5&(B,"Z1](=<,5J)J2FV2T M(_R89\52`>-:A1*UA:A[7AP+C!?W6PTYM01U4Y\0KQ`!]WM7_9WF\X?Y&PX(P:%1/N%_"$-"^(L!Y`#] MOV3Y;S?X71F.M="!?X_`'?[[/9@AL'L"<`T($[:^@.YE5/)?`F33Q("39OGYU@NH,+(98'0.$`P^OHKX>B MW+7S.,B0W&GN#L_=7@L1`EKM%H*VWM,J0P%ND77[$WB`V%.!8)OE('LNT&=* MB*PXX^`1W@C171P5V##C0%EP[ZN+2W@#1G4.*H-T72=WT6UA<:`^F,HAW=7Q.,G;^^ M01\W>383!L<)+N.GC`WH-W20]+?74_YU"VVP=/BBUIY3N[<>;#*',Z1!U_$[_DD=UR(CLA]W)9.`.X:N&A/[6#7W`N$3Y-BRYNZA MKX83%_*EB25[*F$6UJY%95TIS$*\W82M:VG%6$'4.>ULJH5!4+HQGNPI!BYH MT+T"**#3![\6;B:U\B=,>K1V3VTTY>'N*!E9"^K$+:HIG2)_%LD4.F#GS&F^ MZ5F;3(^UTR83=>J<-9GKDKW5[E,0OL8IS#O'7\H53TIE?=63R]#'6]VZ?WCD MP?(W11*/UD$-4/770FU$>?#&_%829FM"[,\+\UM)A*?BR/76;0"N4]&\>#G/ MH5'[X;P`BAYHF"KV0T7HCV:)XBP4:1MLQ(M,4BN57-TE:05>Q.%<7FB1-*K$ M!&ZSW+3W\A:C3Z+?Y(=NOC3MFWS+98$]LK("#>R4S76WH:V MUTE2_(95)9'L9J54UK>R(#:Z;>J(&AMW/JZ9>H%^&FP'DJT%C M\QD0+6+`%%$->A&!@Z=`@I[SCX%8G8;*_'N`>.W.5X"OBDVXQ[L<,?RS'S5< M++Y9"!*(2[A?O8=Q`9^"=VW8*RGMOU!0RL+E00FJ@E*4!B`BGY1BK$1E\`X] MC5AH-6NMJHR,/EWB9T0!&U-G! M>J`X8V2J%I8PV^UA6I#3`/>ZHXVVOO880LV>_FQP25G^&$"M/"I"ZYJCE*0/ M,4(P>.KC@W1C/.`9G`Z-P M-G8<'%P:CU("P:WQ!`V8HM#T:[J7Q,+FEA52V&L.;+2E;W>]"PI@3PWDT.G" M7`@2FJ?2CH[)\9*.3@]M?LS]X4Z]":"&YGK3\+ M%B%%^Z`LM]%K9Q\RO7Z*(>)-"8S!H>5`(1[7"EWZ`U9FQYAEH:DW'0S!2 MF2FA7&69QX?B'NIILK"YY?`L8:^Y!]UOWFK2IN4DKB>M]Y*PF:&]RZW7H0_G@28HS<1\\OB<,--:<;BDVU M0#'F.?`EF2/(;&RVYT$1A^LTNHR3`[Z>R0ID,O)'M'A#@S-?8X[.CGW-99>= M_#;<<&49PH]I!FS M%'BZ"O(4)_VK/M7KQ?D1]7&7I:1NI&91LQ$L796'&B.]K'I4Q:^%8A[FYT=` MV585==V?4R\T(MG0B*SX(5GA(L/Z8V)-\6=0$T']IXDZ8EWUE=[[9+:G8`)D M3N=T,^##EF'!<9E@##S9A9SHX'AN+N6;GUGMR@2SJ?CZ'4)/CIFIMD7F?.P: MQA%R\GIS2P!+0!^`8W^1:0D^EGM"O&KQO*#-P' M.O'*5A64>Y2BU6RSM+ZBWB+(*W6GGL+DVV[3+S!^>45=6J/U,WB!R)U[AOEF2WJ].91%B?0.2=(3 M0.)?C65HW1$;+3E7DI8Q`HP3H*SPL1=A5H`6NX$3#)S06 M!3$"9^!+-58!&ZN"CE#6?&LIZP>W<4K>%7P\Q%&0AMR]S:+8J.1]YL:)CH![ M+VF:)>B[4W.8`7M6D'P^?H./,#SDJH2?.D36K9E4`OX2FC8&3>L5N-IN85B" M3,B8F;[D+.$NK.-E"S7;NLC+=T%Z#.@^@[ZH1]G@W?BGD?6 M6!F^,[T!C--^8,Z(`721R'=>917E^%U"4UT4^QT6Y.J=2G&-1KDC1W]+IU\2 M>)X/.2P(#1(I9?03@K_3MVI"'XCI*9EFG&L.T]ZD!5-DLWZLND;S,L8K6Z7\+ELNJ919U9!Z:#>K$H6 MOFQK30$P2<>^>E"!;YI$$2)QKS&:"./+T1K`RWZ2Q,E]>^C=Z[(2_:)DC0KH3WF< M`'-D%,[O41N8YS!J?4GQ@%^'TO(3`QU9^+0LF`B<@YJLHZ\>O/%?1"RG4?T. MYLE>2+ZV0G6C[@VUR?762GNW>*M17W>^3WBR51LU.DL=@KA^YN3#4&W[0S7X M_,>3ISU+:=[,YT`"M3L9R[3>XH2T[F+L_I ML!3\=IHUQYJ-"0"A\"):P61BA(E/E;/B`&"/(4R#/,YT4^AVV[N#5*_?8BQ5 M#;VYDY,.O1`[XG&W&7Y"^_`Y+?8PC+XLCG$?FC=[G.D![?#6(=H1ZKZ2&W848X)+]F!1I>SA.]S"H^$7U+MIOD$"6K)0YJ\C^Y5\KQX![(&#`)V18/ M8J._'HJ25+=XRAX@'JDX@9V,!T_9?"J_S.?L'],N,VK7:'D:<(R>O1S%E:4CP;_'/(1["0T'?^0S9*/TC688A/H64'ZV7-P3;+044` M*@JWCH6A+.L$N0_X:3Z1):ID":2RV/7HU0CC/7M=>%E\[P[WR$+&M+)B&JUW M65[&?Q\,"FH_5I91V7_Q+I5AH`)"W7J%:VXFD%SOX4P,;=(5N,O2?9Y%AY#^ MTWF6M?%R$N&"5GOW"J0!/.[!NR[J[*G/S6X?Q#F]C[I)2S3^.(Y[712P+*YQ MEA&8Q&_2+#G:'*RKE;YL?>@UE/C2O*$%E'@%*/D9H7>[+LTE9-P(&6!B]PIF M",V^LHW"I3W%^QC$:8%]4EALTJMW['X>XN*5]A>_HY"HG`:M=673D:>/0$)# M@=F!8JMT]$8/_R6=1S[N89-SQ[QBU!NZD'WIR^#.3ZAW-&!FHZ/#- M2$4)&E*WAF&D<+4E_AA\!&NE3A\X#1>K* M(=2@;RJ*;_$U68MH(1=ZJ@JIQ*K_ZJ/.#&!+K2Q"8+G4DOL<[H,XNF2Q3%=T MV5^GT:9\A3D]1C)2'SV&'NB5IN2:"L>X`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`&E*,T63 MQE5L@O-$`KHRG&=YGGTA^9H/:01SD*+V5:R!>_U186D@?8`&D.SIP@/]W'4-"4UM)?4!;-]G($,S3.9U#,U4,&HKP9Z&'*S))`8/<7K M8T%[IXM!N]_RE8#&GB[QJGC\,B#K_5V6QBERW=!^`#S#@+P)"UC>B"5Z9P)0MUX84TT2RM3N*9')J!UZIV)Y)%[:G6T%BX` MLWQ:>LW\W>92#81@N5;@-4VGE_S#&78R@/_NQ4LTO>[B=]+N`3X$`?[IBVC^K3X1RW;P*7C' M)^8*M/9:NGC^U>OKP&,O7`Z!-"&X=?XD6J_#)>FP+\@=1,3`NRTQ'.QN4+#U MOT/"H1^;&)\T&@@4N(R+,,F*0PXU_)_IK)UL9":.QN#FACA)C&DK-@Y[^(-A M-PUG3]RI!08&L3HCXQ'5K3W9WLRA#T-;GOF4P68-3-33O"`%J.DK-E)U^H:< M&'V0:;^"T$%U3(4D_!%915`_S5RQVNW@1G)B9FMUG"C0OB[G1P\!RPPGDJT/ M!3U012WH\64L]7%GLR#(<]GTC/Y4XF@\G.@2[\-H+V4*I<_"0:D0;>D&S!M MMV556R;Z:CYL6;"HL6`XN\N^]<#U^1`G$3[T($]Q]P!ET;K!)!CS<9- MMA\=RS>3\7"U8]OD\4NAF# M3I?><8B+G9G!U+6W9%DU=1&9.C_W8A(UDV_"E#HVP9%J`LJHKU8E\>I;+OK7 MS78+<2#X4&CR-'9VG:CQ4@M=![1O8]NU.KO=P$+(FM0<'3I0\XU!U^+4^[>A M31NV/"1=^QF-!",!P2Z=H@60@,>`3G.]K\6R-DCX@I'`FF1R)%ASB";:@8X[ M-(L1L)AO@=Y:;7+LEK%_D`0M18Q[>AV_PX@FT:_2MLC3J',:.X*RPSSTA:U($Q(P4==JSS_BY?ON%B2P[\PAE\G[GV(48I9T=QV&":DZ[ M@"IBQ)Q,Z'66MZR9Y.))3&+]PDG2^P%7O6D-4//V6NW0$)A)4?D984<:?`S[ MZ>:)IA.DM.";`D)RGP9^_ZWC"Z-E9\GF[9!*6_JW0GJJ,D&#E7?6/P?)`9(J MS`4]F!4I]AA.=O5]E*R*L\_!N!1`&`'*:=F8,/7]\RQ2=\\IJEP&^$BB@+@4 M(OAS/V[,I7)4"SEW;V(=UFQK&"1ZC^U&]M@:R?7@WR?N3OM\!5& MAX04AIK:H(GPM`/^?QL'_)[_@_],(M/SD M,_Q'">0^U'2NF:%$KD\*-75&2Y\'%6:F$[W#3IJ;L[-7="Z MDJ%L)A!5+X4:^+29X[2)UMKO0"_O,%WO/ M6W,?^^%+C^^]XX59#I7.(JR#DPF@?3"`['!;NX`5]%=FJ#P!Z[B>.P:J#!X= MF*JQX>KJZ#9.X4T)=S(74$CA^`JIW??!*_?6[?JON#$@K1T71_=:!NW'8DM) MX.[JCM,$^?6=0`VFQ$_5&;D&MY:;0UF408J?-*N"%<9PLAP_-496#EU-"CO! M:4.+S_)9[O3BB686_&P.T>U%%(V&>#>B:"*^72VVUT$(Z=-1[=6V3>)XN>WT M7F'I5P"W7O;U]HBU2BI"6Y&:O!(^.0OJ&6CGPMKB&?#I$;9,$>2+K4@+;">I MK`R--"=MOZ6C-)3MOBH.YQ?34*T2%\K>DJKH5I33K.R4/^.LE5_7J+?U&'M3 MN4>@@W.C&'Y5+(WR,#Z[=>1^J`,S5 M:X=[AF'=-$"XS=J`SP7\VP'MP:[>\&,A]#U%H):0PD'M/U'?^02F54M`F@+< MUIM0+,4<\!7O-";`*8*4L582&A]0)(R\$N#(FP@LY5QH8&EL/-8B:%*Z"X+V MKE$D7+LX!+EUB*=VWSO(RY=>#;38@_I37"9PL[U)H_@MC@Y!HEAX!>VM0UW4 M[SY62#N<>Z-IZ(.:.7ZWU3W20A\@ MR0)`G2S`SH:X)Z:YITC@/% M>#F4T6(5"6`T/D5=J<7YE*7E:W+$"D3"G,N,J@Q:O?;-904N->9>3;0@)X_& MDN+-E?+<,$/T@-:\->OB53J48M*0WK$RB>52*E5%"C`M6)=,RP`B]TF_]"6L M!S">I,>#&+9X?\O2ZFZV M[>H=N$80+A*D2B"L16W_;E=+)F&"85R7LUV!IRZ/Y3Q`=L2D<3>JIC-F,?*P MUR'4GUN-+`1R,OMQB'(IN-BX8:3=^O0>7F=BN*`Y[5F9DDRP]9'K+*^K$;6W MR**+5CU:RPD$]>218H@4I&DJ;W7.>ESF#)PF&BFA16H(-46VXO:IC],DP'-, MV[8S;1JRV%X4+#2'Q89*K>:RTP*T":.PUY-Q,."/M5Y0X^'P'Y M!"#?0+]NO@+H9^+`78E`>X.5L,%*Z&`]L\$JZ&`%]6#MR&"%=+""UF!%RL%R M93EFT#R9H9E-[3RV2]<)3K)<>QF<-/'L=DKWB_[;+>VQF]6.T:\V;N]78]DF M#^EPPF;X?R*;)^9=D^VA6-4VY%MO#[@?"R?XC3>'78L]J:X/$!)OI&1 M?-S:,0TY5=:)L@",1Q545@#$!?TQ+D+4EERNL&/[HQ=9.";-NE03S*;<,WQ? M'/)<'@YIQL9/=#=23@*WM:"`,4NJN>Q^1`&,@>DH?1S$J&?J>),^? M:F=;WJGZB7F=DH;*9$I2NJK9DX]#)*\;YH>_*&5VWT6 M*65"GHA&3E)#?W6OBO"Z2+:IR*>ZI(H&W(/%MI1R`CDP[A+B9I:+'8YF%O[UF M203SXA)NXS`NFV(--V,J>YAS=%7A8X3LDH(7;6Z`L1M;^&+R"!@6Y)MW),XZ M8_%?_^&G/_Y+/2!G)U0+9*QN"&J"3%.,*;5!6A_&X3[E45X/1-3<<@T08:^Y M9XUMS:--Y0\9[:C7.`&HNNA(8:]>B1P_W1HE.N"QY[+=I&_(A2P&E0.'4Q-<*&NWDNT','HZGT?YV01EKM3XO9V M72M)O_N0J)J"IJU[GVM:_QV[."K0=-P=/<1,@/#G--?>4P^WM0M=07_[TUXW M\V5G/:[?CJ$J`T<'IFID6,Q/B+9#$.^*Z'GI1;;;9RF^YU95O933V<])J)"# MLW3TC+MIYTTI+JT9X=(.ZD^'/6SU^J*L@BEH;QU+HGZK,.11X4OIT/?!HS'N M4RX`81[#XL__?DCC+&_5^KU'1##/841N;>1KJ1D/RU>%9O)QUV^$'/P94`:@ M7XO9TMQ,Y]T;%R_76K8(B-M;^V2X+J[@"E!;?-\";FY-T5Q@-'E M(8_3%UI0[?$U0+-,?W^=Y>@KSBYO$V>2>:82A51F?=,YH+)S/Z*$[@7"\EL]@QKLM2X#=WM/.QJO-6X\IDJ.$BRM20L8EW?`%3(%.S MV9+5Z1(681[O504+I&0.T"^58L`XLN;8T2`$*]`B<:T-$X0IJ#"12AB[VJ'& M&*\DN@"SIRO=&\J?,[Q6/>!D_;(%0D9D74^D$@SD:FC?.Z\`;0\H@5L=&2D( MTXXW*D@N$<2F?JAQU=<.75!9/LWL/#!^@%B!Z?/ZQWT2R]+E:U&[.;=4RJ3Q M[!V7U":$+%J%D+I5H!ED@TRVG,E&#^H*L6S63^7T\#AX%&<"QNEU9"EG)-16$+2CT,!H$2TMB4A16 M5Y2[`[X%P[YCTWT0MN5CXCD_0]#0E:$JL!J*,C%G4Y-'9D,XN'W8/ZGOCIWJ01?(?14T:">NIL?.CCBN5,C]RZ MC=.4J@\I2@88'2@SP"CK(S-,[,W::#)W?5-I/G'^8%*YQNHR\`Z7PC59%YG> M+-AF7=D>XS9.X4T)=\+(IG&\G*:UUI57E=!:N2?%S`#AYM+! M\%9Z5VFKC?`N2U@]`NRS:&T[D>13'J1%$$X[\9S$UI4NCQT%";"[V47;3$\E M6_T"@W(F&Y93RED_26T$=F`&G;$8'Q"^PNB0P,U6U.WS8^6=\\(,%B4Z<'WM_=7XX/0L`N"OZZ;,_836\@XS_8:V5VI^CWD M[GSIW]V_E-7LJ&,[/CCA':LLF>T)0/L4*T#6:F`78.V>]><,_(Y=0LC+K$%M?AK4DXAS1`P1/ M696]M@";O%-!:048J=M(OM&BE1G(*M'PZ]J.:*%,-)M^@SX6^TZ"*1!M!I)G M(811<8VD;;LIE_!9IEER,@?!Y%(I^"ALVAS@]CTO%9.X#B@?)PP&+*ARK>Z) M,)%0&+M!Y6J,\6'EN@#S)$W&'?Q"_C0Z/4:+@5]I,=J2C4F'@>AI"W^S8*A% ME&6_<*]A9L@T2O@@@*5SK2./V2%YWCY#)1.4)L0>-,7G:,%G%8Y23E M>IT:$J50[7PR=8[5??<]F+>69%C;-`V)3-6F/%A)@J+8;'\)\CQ(RTU.7IW1 MK]^D],NBPPHM4LO/5[2DX1Y_8"I\$,OH\,:04%8&XB9EQL'9\<(<&07G6)29Q\;1;U/N!]]"X*6!MD>M2MUZ!IZP,$M=[<6U1+JN5W(_#*A6$ M!MYQ:^!GEL`-G(`JIKE&UFETD:7XS3A,0^0238S=&,_95?C&A+&0!"NTN((@ MC4"'[ZD$<2P_-.NYAL9!&,=4)1)$1,`=O+-3<.K?:^`KP1, M"9B#41P&R27$6=+718&X)XIBM%(2RT%UTMYS46RT-:#-0=7>AW?%LPCB.D1/ M#:5NT)XNCB;`^Y<@AZ_9H4`J)`?U0$.[4![JZ')P*WFWJ+^IOEW\N:;&G>'7).Y\)R:6)/;KZ(337//C M$X':6MP3PZ"`J'\/&`8)NV.1;8F'V]O?$0OZS2!E>N#V\&BP35E?*_26'I'+])Z1@K\GQ/CCNAJ^C-6CL MKIR*_G-'.[@YJ-L#1@`8A;,5T5",JMM[VH+4+,MJ)4V(D$'%S>6Z-]/T[&73 M8VT]T]&5SNJEKRA3-9@Q?2R#O+P,2N'EF:"Q`YT=Z/$P&EA#0%H"W-3AUDVW MZ[2S$?HCCK'R5S4GS(+K),U2W/-J*`?]E,*&<1HD[4_(]$_0V'(I0T&/N6)Y MN!WHSO^"^J=>)U?3;;6U@4$.*N(7"L M<9CH"\%%4>]WZ'9'LI,;R<_^J^21MP'H=Q;K9HX\%'KW@WZ1!$@?W:[9U1UL5BPB_INIM9`NE[2!@#)NY%# M:+2Y?#V73;TZ^E.)WS,494ZFHEW%^X-TW3)CY&#!,I24C]=_+D'#805J'J!A M4KUB9F]>7*]@VD$9%E9L6,R2U8 MRQU%O$&;.'Z2U-9)8EMV1-0U M'#GI<\5.%@9!DX4'T9*%9G1AX4%F0K-^XRJK>]?GHHN,M9M0SD(WAG,0UA/T MZR&(XFR/_-T=VJH>2OPAA9;)*.SJFK3O7%3'0&/W:C=9!)?ZM_3X6U-%M1)T M%%)7`R:HY>$.Q;.ZO[-`)7:XJ;6M6B@MWRX,&VR_'FAEFIH])@D4Z)G?G]R#W01(/J@EJ/!9G%" M=O9WDX;9#I(30#66I50.RA#*9!"'.=#F]&C8#[B/E21!#3T`OP:8^-*(FDB: MYZKJL-L%^7&S9==D\7,"\?W9.HUNTKB,@V0=AMF!O+79;*O$IB;755,_X.S* M:O+(R*ZM*'-\]-QB3S+2DVL:]@70?`(WK3_BW]W5DH-U5@]7IC]KBY_:=SP[WFXIM8,PI;W-"?!$22 M<>?>H"D'W1U>U`F(!`3.,2-.0#2`&G\R$$G'7X6M.]$#-O82UN1B^P9H#D1S6`@3- M"FO4W-1>=VA<0[O3?QU48`(_X3U*%.\@S@-*`7(1FN:$^36:0D.4MTD<@[S3 M>PU@X/9>0GR,(+X!G(>2'-\B'%F\Y3\\%_!O!YB65V\Z@W?X@_WFKO8 MKIL!TLZC,&3)L'/7ULHQMP>7]9<@CS2.&'OMK`.DW\\^,LC?_3I,'!S:/A8D MXVK19N!W8.?X)>=%ML.YM&B=B]:#Y_-CTX:E+"`];[J?1O=H0NZ"G?KP<9G/ MV;=9RXQ:']E7?SO$Y1%0@/MSY+DD9CB#N3A@+-=V;8N!NZ5,^BZEZ@2E"DE M5+=^\:)2./3(.30IO'(!E"QJ0_R2QMLX#-!25N\O[[,DQHE^G^![>8X^_IM, M-S09V-<47[ES&<\XW M%1[IIT0SA*JJ5(LIL==L)M#._`HM"N71I/RQ%JWEB&D]>;CX7D9&*O-20D_K M\!K,5S<:UWBR3)WL`H;?O61OWT)\&+8&I[;:S.;;]_W.ZP^CO`#=S.[N!8MJ=7,I!+:^X]S.,,K361 M(.N\I*T37>[W5ZC4M"'R$B))SGG;^CTXVD.*+AGJI1%QC?S8(/D+#/)K])NA M`V5I:R>HX/LLQ`5M"G!;0!K[@0S!J`]A0SKD=M!!X:F/CTY[APCI]EN%$69" MO$/)P.B+<2(<^J60\I0'N'+RXW'WG'&SPN3IM;&*B'[_N/*!Y8,A&>6%C@U:S/$ANT@B^_P<\RNU+OZT+D\+U5V1%:$-`6@+4U`<\ M"$9[P%+(AGHI1%P<\KSC!,OWKN+F5G$AZ357J9DV[6Q4_-C%JH:^C1"]<5_6 M;/P"D^0_TNQ+^@B#(DMA1*HW#(4.:M`X,"/B_@O,"28X^PU3@(J$5B9Q^%9$ M>SIX^Z(U%\M"Z.#9(17A8$]X?G)`ZODRP8 MBM@0M',`@&X_!=-/&P'2RH?)'QA>XY18M8N,O+!#5@W]5,012:+?399P\8I_O$G7._P< MC^3&'B0I"EC*"J9;^;IULV5G3/LZ5!<<;GV6U&=G7$"'#6A_&C4C'T?:!NCG M67[X0=(5('V8V\S\D0YN"E]PH2N5H7$SQJTA@4&>9@>'YSL.-+AOV*RKKSV[ M^)^'($0H=:EV>3_)$:9.KI1Q M_.RG3ADI-P=?Q@=[BFIM);<$WNBL@S%PK\R3`,_E9)F.=D_6UR9!P2CG3L') MKQ5W4%;3I;>=)<1KAU!KDHT6+=4,3\AE,>R9WDH2V.F1VZ80%XRZ21%V67H$U$58E`]!"7'@%XSN(8)#6@8OLHS?)DRL M&T`C";FWCK@R6$.]`A4]P`Q6@+(`#8^E<@S!;8P3PV?IQT,)]A9Z.;WNJ_0#W-`%\P57]E6BPE,JZHLIEZ&.Q:3U4&-JMNHV4!`L29KNV M&^#XRM),D/MZ0E(D1ZHAATW3H*$B?0N@K1^N=D.M3CW!?%=WLT!N^#4,L`NI MO2G2XN5X;Z0GK]+W;+%9`<*HL2&8%6"\W(-V]'3+O5/CN;:YDB7$6P[RLAW% M*#M6TB=UL*8II>&7@X3NV#%-)U;80L$$K7VN9:'L+A)ZZ.-7"A/H33AT/8IP;[DP,-J*%-=*=8U/E,,\SV[__X<-ORNSN MXO;.YKW?;^GDX\8>!$J8RH#^_LU_?`ON;]>"#.XN0#L(&!%R)6B9![[*:Z'A MMLY@*UO,NO;*B_5+.=RBB9]_A;K$%P&X:%U*']2Q*EN7L`CS>#]4@:!.MJY! M:3F]O8XL_':#$($V%<5*B\ZA89LD5-@6:H^%BA872JM\Q7)3]9WK&@3:"M6M M0&"H3?.K_-5NGV1'F.,8A!SBWP;YL=.(7HD8V@-]MEX8"X-1T(=GQ11TN/8: M4K[^69H91H0W0[`:D:@S(MV&BX[(%#/E&B2>VCA3"Z)C`,>9C\6L(YS-(`YS M\LD&"F0U1C0\+4-G*+;0ML$3LV;+RNVWR9*IM8&54NOT!,/T&"2P(!\(PI)= MWI'K@'7TA@.XFH@5]$=!R:BQC.R:I3&2HF`#&A5T?,3ZM,#O`.#FT M2O-)'5925S?5)9$Z8%+O&ZGWBTJM992\$]N:21JMT!V+-%&;ES!(USBYR6NY M21^R()INEE3L/#%.2JF-3!3C!C8IP/Q.Q%2-'`.!YF[9&"`O(L=C<"*&RX]! M<&_&],R`GC$SL0%+F+2+0U%F.YBO0SP>\[A;6CP],6YZ\AM9N(HE:'B>B)6; M,A@"+0^KP0B:P3@1<^?9:+BW>P:V0L_X&1N*"1;P[K![AOEF^W@L\#WC=9;_ M\AJ'KYL\@GF!MKHAC$2&3HO4KCW3DZ:/34H%-EO`Z'!22$`H`24%E-:A<9HD M6;8%!:5;@8P*M%]2("T#,Y-$8(OFZ@N9*PW1K%D+`[WJ&`5CI;(7^TESS#T% M[T8OW*54UB,^Y3+TP<9R/*+FOCY2UYB3?C"D]H0X199.AA0YF0_8DH6E"<#E M/+QNK#AW%YM/5^!I_3^N'KW4"V4*$GTX67Q0(RVP(M$+&9'] M)R(R";C+I@-)_=^.1T?M5U6!',\50`XI[FZ*))A>9MB[A M%J*N1$AI27;'8IU&MW'P'"(7%N&'!UFVS*5799KJN)%5B/*C>2^;_'S M..>6Y9%PK\03%4"<>VL"^EVH/TZ!G:7T!6B]>E^][V%:0!9%/<($C.#JT`R, M&0.9`C3\\+]:3BKC";YA7+_UV"*X&Q2?C,-H]1`;B(FZ8<](W.=9"&%47*/Q MP?5,\2DJMF_2C`LR(NLJ+I6`>]S/&@.,!U`UIPN:ZWP+$P2)6X(LD6_!Y%VM MD1B]+%@XH5*8PZ"`*[".(I*(*TC`51)JH7&Q95\V$].0+52:4TA[5"7\=$O^QUS:;&[B_Y+RX>D$?-PBT><3NT< MK>91N\%%5ABM,K-\SKTUF&?4M,P%N2NI_L`^M@)M;N2LIOK@"I!/GCWC;W:; MX:]Z95:6&<7'$FW!D,$A,H>M]A[:G!FU3VF49E<]AU8+N>'(Q)9'_"ZE1%V_ M^MLAWN\4-T0&3-Q;&)F$6G:C8K`B[]1*8B1J)EZ9`1-1S[/LM^]+)&84;Q$; MB-2NP`77MO$[DC\@_#S4E=JK"=9ICT)5!N,!%C!_@_B$?!V&^2%("O)? MV#XP1W^LVHFBZ!;YE/5GI0N,EH9F#SH$H.(!$#]0?0VPSW6NM'"#JK7;]ZD6 MQJ\:@*0U`-@0YLL.@.Y+51LC0"M1/D.T`X$@2(A%P)Y1M@5O07)@'B3Z_9>` M&%-RZLC0A0TML:D@:-6BQW?\$8P.(N_J%W6WDTP^_6-!BQN51FQAMO:-;R"_HHCS?`U_JTW&;%DP]W!C'JL;?K? M>?R&+,4;_!C$*3[4V*3-[^Z@W.U6TCKPMM7R\$MQ]?<5P%2L"CI^L];^$R)> MJ!BZ69[L,2)66>1P=#DM&8Y7`&RST>\@+BF;@`(M:@<$LZ.D_(==5UL3FKR' M;81+>\IV34=:<--\0>K\'N+TA1TR9JDL`?$89M;5<93$??`R)M)`A:J2-V8& M&FX+*:S)IGB6(6C@Z\TI^W@P]_5U*I)M1O8C_ZRD)7=P9Y$+GI?QWTFG-EL< M:(U=CGRH,W(D&OFP&UOX MI:@CP"Q\UV..9&_4ECLU^;DZKUI7QU7C=5F+N6\*KC_5>YD&61S%.P*JJ M[;/(U]Q9G%G'3/+N5W]3WOY>YP^=3])CW:7V[OA<0-O\+#J$DB,*)W9G?AT3 M&J*E%,R>9:J7X,:XHO6W:V#7)3OB>*R.6#N-)99H%N[6+<\\8S+>V0E*4)T9 MUMS[1*N%,SEKG0TN,U#FA_TK3X[\9U2FOLF979,F7,SJ]*5[B5'WM M!(9VKWBG2#[6'K0N\#KU)*-&0<5U(5(KRXD.A69W&CF\D!)H3+"(ER+L0"/V\S)O1.!AO`'4M@VO_QS#@ MU82))_Z-9G2GOC_#?)9EPUHU[^8GB4SZ[_>QLTD(ZUAL.GQH_3'/"IFZB0C< M/Z"N>J[U6)HT7C@,7.6DIG#Z"[F!)^>!Y`$@.]<`H],S/V+)Q85"#0+/@ M1YN^=AHCV\\^^8(CH*?4(7]\NTN('-.X;+]EI:];;](2(F#(7Q`J:1THDUH> M7I4(3?LU_JI^HE_1.4[W/D&L9$BL6"J67;W21""O54;PFU*9#X:'G!1>1M-% M'M??924L6/FK6]7K;&URR_7VM*7B,CE12M`B!82V*IRG\;#;RDV]6Q'M58,S MPV>W\-L8<-I;GY[B$J=ZODFC^"V.#D'R2UR^D@(0>#OV&N^?LBNT32N/E]DN MB+D3KI:=,>9D?>TRE[6/VG9CG`V$-@>_4@(/4J^.G,Z^Z9\TEU-2,;$LD1?X MBC(_KM]C<2JEH::64R$-]E:8#I0U`[_BAJY-FF2DNQE<5,-LSU2)DXM*K)*, MR+H!DDK0QXTL7:Y[0Z.>C+Y-T9T)'P!U&^]B>J53;-+/A>S,PX2)1X`;D-`$ M@"O08H!3P2`6/H-2-*'Z()7/IL7+HK\=T+K["9:O6=0\3M]\26&.%^:F>+#L MKDB?A_VK(@/YN)LB0@LH,6BH5Z"F;U4A=X]7X[GD+E;&3>0$#^WB-8;;JW>T MJ<'W.9OM-@YAODXC\OOK.`W2,`X2]OM/$->W%7EPHUC9]?#&29RVX(<[G;/-S6S;SW^BN<]FK6W3NUICVO`$M;>@+7(9@,HE6, MD0E@75/WX#XXXLUF<9WEG]."WG()2F[JD=F%L%H*+J,\I0`5"4`TH"9R6'MS MFCP%V%,:[/H=:G'2S&W,_/CYV5?S@S,\-`*)2XI:TU]-S>FHLI':V-M9/L!J MF#=;E?IKT%C?+$90%^);\C&]=OI#L[Y#C;[;32DF1@R?$TP%ERG;CP-\RCZG M.0[P@-%]D.-@/^'^8[BQY0V(H,><'W^`X"D#=4O`FCJM?V30]S)#'DS5][VL M[_8V(3*P='MZO,<^%5/7#IT',W M\.IQM_\1]Q5"7.H(\.FJ/!)_A>GJ-N_2;!UW36 MSA[23!@-X2L;PG,%6EQQ)4_"=T7N#RF^64;F]JGR$XD6QA\!Y"M+G2X9U?B< M<8@V3W^^>@!7_^/^ZN[QZM&]-L^E$Z)'//,HQ)37".$KC`XX_K45M(UW%G&* MK!%9WPL".IF:C^9D^8W"&%FY>U/&!&RVG7A^S.>FX6-/5;6>+LPB^6&WPZF8 M,UYP8K1NTKC$41WKD"1=PA?(J.E-41S(R9M++W3>F4=2A:T!B+HS[_KYQFB% M[K[DF*C-%MT6WCIJ>+Q2*OO.AE2&H4QXS"%HS(M73K#&G'`KHNZ$3%CL.N[V MK2HF0=3:[J(E[+-J3W3K30""?-@[9D=GS"U&E-5&L+>ZZ^QY=(CMQXWI2"1; M^&ZS]*6)&@,^>CR39.UY-J@YLD@%V!S*HD1.#G)JW%M7?5AR(6&&F+2G:OBU M-<0N'%-^B6+Q3:VKT4!OAXK2DR:527:;.\.HQW"9'IN<+1CUEU2S1]8HDE:7 MM*FB(CCW%5*.97OJ=Y]G(811<8TDZ3G\$DV44EE72KD,??14K0&>/&Y#ZQ+Z M4^3H[TO=KL!S2@)B=I#@7KDUE*6OY]J:8OF.Z`Y)'!2O-.)7O?1*:-S<%0GZ M/[PW8HVKS(K?L/;?+I02SFR!-A&GODC(A4FKK5]YR9`T>.VEAI'%C5Z)IHB\ M)MP^EL@+?LV2")EJ^N)0XS1)D][^=D]3+F['5]%AUZI-"=BK4Y\.FXPFC]L1 MF<^DL[]=4LC!![=6[0$F.(O3ZJY4$55O MU<77F1S.W]>?&:M[[\/N0.)6B&6^R';['+XB@UQGL55#3I^'B]VZMGP#F\R* MEMW*=ZAK7P*G4/C6)W2:SNG`SG3,A-H,RBZ#.(7159"GHU&87E_!RROLON,2@6:',_$K*I MIZ&;A$)S#F8'AOQ5LIS&!W`(WRB+X>''6V6=Z="`R,POE^E'"N2_H]TB^8!\ M!=$A<@$3L03#.,'M<;P;P\C:F]5%?U8&P*(U);.BY7P47,Z]PLOY","<^PZ8 MH8E1($8\*[-"YN,HR'ST"C(?1T#FH^^0&9H8!63$L^(H2=83^IK`]U6T=YOP MJM5O95HKW-:YTZLU^M+\3<-#[Q`WRA3I0@KWV!&ZQ0+T./>)-6=!B:"Q_O`\ M&&K7`B!GBNQG]=&=DM(ZIM2R]+'5*?C`GF57__3I8$]SEOI8,YJB*0^6\!K* M>,O=HJ&6EA\<#?65OVO%?DY=",0Y#A2CW'TEHAAB>[:E%U2#@PL..0Z/D%@5 M"8UU>R+KOR)&&2U33?.%`K[VB*AZ9/7Q$$=#M?%&2H,CR@%95U6>;Q\Z$D;[@RW.,L+=$@H:Z\5/DW MUM%?#T4)H_,@P1/^01H!L\P''83,+#1R@W:_&U:S`O6W`/L8:'\-9\CH?J]. MSKL"U2%DGWTEQ;![MHOK_\_AFW6;6?2ZW`.7R)4WSK[Y%ETI"%=19\$Z>@ M(.V_=6Y@YNRVW7,+`=;Y$PLIT"T[4#AW`8PN#SA?^CV9)%QK%[9/=C^G<2D] M/S7CX\;=,9!S>/=*&0#*`5`6M(`T7('6^3[)Q1B+A$F;L"H:T1 MB\8OR%@@'RW,=COT1_)O#Y1O#)0'U]YQ./9#:>FOK[/\$>9O<3B8\F\D'Z^4 M=DC.$4K+_HBS"E>,_%5:'9FK/#0T>TNCGT3$0BJB+\HJA+")LBKPZUQ9J0=0 M]_(B*%[--760B2]J.BPA_\;K#2;9GCS">215>4@16E)WO:V_Z%_,Z6ZI+.;I MI;KJR2[55?*$SR_OUAC)F@JKA+%S;>V:E''*.L3#%UT=E&^\JO*+J[>:JB6Y M4E&]54XQ<$]U&R2?4LKFNAGM"R M*,W_;@I*Y[I&C,%(56O3^J)I'7E&[![]U3.I9)IJYJUJ\3`T6X401-`XASXH1IS@:+'U10QWIQRR#Y+]GSY@E:/-<`<+52\4=/Q94 MSK#5'IPQO<[VI,;]":V;&JI@M)IJZX%S4T!LU*R60,W1%T.@(?N(5?H4S<#H MD5!;`6\U7Q?Y)HO]K'HO"]45&A[\QU^"/`_2LKAZAWD8H\X,*/%X5@Z"?8VE MU5=;MGJS$Z6*%ZB9N2PO,(OHU=^P]_VE$F_YZ`N]`@*S2'AWP"'26#XJ$LEI MB*MUTGE&_C>@L2`@*$``4(M#0E)PX;_`@>'YSH13U'O"5;J+DL? MFJ)=BGK4@L9V+8VHQ_R+DQ0\M$K!+5Z36DN5QO>>-G6->2E>.JC6`,O\JRM= MW>=87*6ZC&JHLLXJJJW' M-A-;XAAL6GD@$^1$9)VE\D@V]R-X.4B`:2XOGQ2SYH%C#'LY,D&3(W-5F3!F MZ]SNXV<1/2%89`&7OO:.JZ=<,><<'R6%9G>3[^7C@F8\;%_"2@G3@%5WZB7^@7)FP^XI\? M,\-] MX>G;V1E&R=#,>FA:3PR/N;"W!`WV`&6VJ^3V.CK*MS8_;.9@IG,7$:+&G%!5QEHIOC MX`%&$.[PS\/9#B0F:!)7^PG7)HT!=[D$RU[ICGZ>E8:I*.6*6RLS_WC<"F-^ MK*:?FXYU+C7=7$"?L*GKUMMM_)_[/`[AND"^48C=6NP&/>4!26F2"UXI3^1G M=]LV06[^F56GX'3;UR8T8%V`AA_VN1E'^F>7V[(91Z$E]9Y(716_C5.MS`-V MMF`>3;OKR[VIFM_95,VC]A/L&#:AFQ1WXQ&694)*YXELU'!;N_9'T%\^"6%1 M@$U*B]HW+1V:#)..(U4@)J!8NN-:NC^MYZ[550;PCBJJT>VD@M\E1!O$N*1' M+JV7R>1ALDD9/RU&+FOYZ4DJ*^C'.%2!(_P[[H7CY70/%):0V7VBX6G@E=0K M-$:NS13H:SX1(R9BTE"Z5T(38/*IWTU1Z:;F0"L8%_7H@F9H7J>15K)P4T9. M*Q)H2:HH4-".O?8$HF.F4E:GP'0>IU1VPF?WFRV+SMKD#_'+JSBV44UBN::3 MM/?<$05NC3?B51SB)@>$PFE`X@A!ZE#P>,E^:VVJYIT!UYLL#6WHUM+2505[ M"TMU0LQ,B>%JHD5M?0G1DXG+FL&HJJ7#_4IA,#?]Y<%X8B:L"0S.5^_[."?* M?XE6(]%J(&AL=QT0]5A@.$'3$."6#@V_;L];/8Y0"U^>S$P<>-?V7HKTCJ77 M@/D$C=OL(>::ON##NPOTJ>,VR]'\1D7W@W<9!Z1*%",6=K733+H^=&IJ:]4445L41.Q6I=Z;.C&C!X>41CCE],X_Y,W?6U%^5 M&B.->RU1(8B_+]"!CST-N,^S/['$ MU^SO3!89,VX;4'\%9#FHOH-5%'_IC'RJ/DFHOW9*QPSVQW%@[-Q[@`NJ(+<_ M6UK_[!FN:R0(+=2TO8[3(`WC(&G>@K*^2DR1)KUUXZ(K5Q_FF(ZE74*N8$W: M>BM<,$.PD-*7,%>K_`S290+IW"NR$23[JCD"CQ:+$`VX.^U**6UW9QV6\5M< M'I6;O#F9VR]--,>(R/QP<3FBSF9N!2KNWFS>EAVBPVX7Y$>:YXID=^CN;2M& M[JW!?#K#53*:66&FWYHC9^$ZR_'K;V:[TI>+K-"Y!!S%Q/_&O>0#"Q!_G?!Z1B8S(PR1L_+AS-\3HT`7\*(`Z/&I]^I+9.6H=^-!I M';4.C=1R1ZWH:]ZLUM:&3^.H%;$YY:-6(Q!-/FHM18-U,D>M0O,TZU&KPC:Y M-,^(NZ6[L,%/G9B)'ARM!8TT_MY79J:UAE#'4&-&)VVJS<`TW5B+!^QTS+78 M7,UKL%6VRMZYUP-\P4F4LOQ(4Z8^!>]0?;0LI;)^4B67@<^K7;6N,@*3]OY> M(IF)UY;)_1&1!KSZ9S_:V')R.(PU&RT;$I\H:P1!6%X9FP*4^7 M1\'&\DM/@%OK.*VI;3`;=<*`YE)//=KOC;N>#_>"'0V-:F`:!#P MR^M6LN"K=WR[##6VOAK4#K1)1R8><)2*O!AI9\-FA#[OB9>0UXL-LS8X>84S M1*;%#?1@%`<](2.O2W'Z$;3BXB<^ZM.G4=SL;YI'RT=8]+4J;P M)MUF^8Y(H1TU.9FSN\CFT6,AB0JF/%?=3/EMOJ#%V+O3LOF'!CN6:8B8U-4Q MAT/"F0/Z=V0O@A(T`^K>8,RD.L(XZSGT9I;@@;I'[?=AV\NZB&EA&B)@S-!5 M(("YY++K_I8UZ+QKW8(61V]4W_U0>',=/5(!!)?.D]`_L:9E4X+N$H8Y1"[* M3=I\N65W14ILR,1^]4H3"0>#@EL%"RL.:$%JX5+]IF>\E'^D4J;P!9]I2E5S MJK`/"(XA5;LX!5NLD&]$(:,#J:C;+4'=J]D-20GJPK\JEC-._ZJ9_U@T_Z[/ MT4?I-%>B813A4F%5ISX&<4I+^O%_NX.R6@XC>%G?B8R1ETN- MS]JUD+L"F$U50ANI[&`;Q,Z+&EYS#$)5M;)EWH*FLCPV<[`:@I:]BQI=]ZKJ MUV@UZ.\Q)NJ`1<4GL03K9V2!@E"JU;V&]E6VWU-.'VF`S*]5$P]*.0Z/+@<6 MR=#:S)0&MS#/(8W.U$N,)J!PD`=-U'<^"1AKR0*)?G6^#1PAP\/5]=7#P]4E M>'S:7/R'>Y@KH,,G+-/`C;/HQ?,CJ:Y%]HCZ\8E=*M<1B#T9E#&&X/D(:(TT M>CCB@>G4F!5%M)QX2BRFZ:>%VDA_;N,4WI1P)RMH*VAO/PV_H-_#A?5J&/V* MVP+2V`,(20>?RS6O'GE[L#G/@CS:;"_C'(;H$\7%*T[:$Z3*>N4J0NM`4DK" MO3W"!!A1-0FH:#RJT:TW07V,F@H@28=`4:8O<@-)DXN0^F,VNN`/D`(T@/\?$+1-P]OJ&R@5DR='I=;,N8?E$\RE/IV"SAL85G*8P(_0 M^`NZSM3H@FU@7JQ6Q:NN@?K;9-2KS;:Y29#M(@R8N*B9IR_A0&VY^I:,PR5A MT-RE%5Y$O9E/Z$#UN5&SZ5%R0/S;8GTH7[,W)',QAJ;RQ=(^GI^',X^8W"S,_4;WOD-)N,SQCT`[0_@ MY7]`NU@&+A]OFN;!E.D"-A)0KI^GM;HMZK7.E=<";(PSRXEM/C-6BBCEHQ"QHY0GX"4,2 M/<3%;]PY9-'/[V:=M$P7BZ M\`([<49?D4G4'.):_&,,D^@K,X0RM5W4$*IU]L0-X<]9@M@D<7ET80K[7_\Z MC"$WIB[,8=.)K]4@*H>Y'HNWNN57:A>'M=B*992IL,57F$&>QNE+484XZJIE(4#.J-HPEC]3:QH+AUY(7U/LR&3P`X_XG0U(<>]537!VPDX%ZP* M22L`Y^Z@>&.SP+=.QW&0C-<";D)=XK;UO16@7UR!<_@2IQB-X#Q`7PZ7\A+V M,(^SZ+$,\G(Q3\%@7#FQP3WY@V/V9*K'OTB3HY%OXE_@[YZVE9*;QBQL48CX]YV1W6DQQ<&+%=1I=O>_CG'"HI5MP#=3X]LFMB#KCN>3ZV/H^R?/?ZD%[ MT5PDU9Y>(E&7(TU:P>C[K0_+17>XGFRL&IZ,V2DM*]H&U0W M3L?E'C?*"]AEU)$S]LJ?9=QM]47JDWN1]-KQ!#`UQW9^];^);SG!/LSF9DXV M#C8S`!7E9LNJ@TH,9:^=@SP^W7[RJ7J*$B_JK(54^>TFY!D87S[GCG!P+::' M@/NLB,MB712P+"X.>8X`*T&$H+W]9`Z"?O/E0&@[0!NN`&OJ'B/2D>XR-X30,1-ZTLUIEN6H\OZ;P&\.QZP?ES#)P)^'_CK.L"X:NZ)M5C]8M86:4 MP6O*I=:N.7OAW_HUZQB/6);G M9R"NXVM:#2V/)KO%16L@&57PS=>_>YO%<%N/FCG))53E)6S*5_;X\":EQ92; MHLIN=W]3>^;?,KKX7"RZ2R2]HRU!U3_P3=7#;[^>U=3Z-+6BE[ZF==3Z.-;Q M4#'=HW^)RU=6*)L6.8G@,^I#[0NF68E^V@='$B[P-:R[=JS][%O5.4V]S1OE MY[*)??@4(&#%Y?%2GCI'1N3@;EDB`7_!_%RVHI-6H&H/+I?+*:-EB8S$N!BR M!RNPJX2)G"?(L22.W1``E:KP<0!Z>N(ZV30-.E/42^&KI;0BUY@-E%DX\W34 MMKKE2<)J:[.@ZV&;578:*NM4_Y8X)[47[K]K[<_D=,-#3\2]Q2]X<]>HP%@-;SN@[P\ MBLR`FLZNDFO(T<=I30(8#1N;X5(23@D])F;Z[PX[YQS#"6H* M4)&XP>PH49K.Y[21RXWT^'G8#LZ#ZQVTEF9TML\&:C%!8S%#),8 MHE5#WMRNEHI[S;FZK"6HFRJ6$VN(4(Q\!PM:PV[/P4#0W,.\/.(+E!*'H5;= M^ES`[2&YC;>RX!(M:NO.B)Y,`V:'4*W()6E)@_(\M:&?7!@WT4Q0TC]HX=F)']-BQ>13!H&,7Y1B8#L*G+YD6 M"%OMG("PW4_1E*(V'H%0L\=^@)"#P1`(!1CPZ)6%*+Z52Y!%(EV?7@.60*NX MP[>=10FCY0HEF??!OY<3,X[O`H\-^DXHXN9F:_!CQ4GQ'J`^"H<_?XB M2\L\",M#D#S!?+=(VNIE^OD5^IX)'!PX M?-8(OOD+#/*3SI"]I*VRYX]/-E0GL*H,EY)?.$>3QD=/Q][KC.`"QAM_%I#O M@M:'^^_83M0$CQE3'<%/PGAJJ^1LEM!0'R<<17R*TRPG5K>$"'@E\L5#O!%[ M@3?IOV=Q6OY,7T\+PVD,&-@]1C"1;""XBM""BA@TU.AW@-"#BH'+3;%K*:WM M9(V!VMFGCD3I!,6Z@XT@<<*4VJP0@V\;R&4#?=7\ M>'@NPCRF*Y'$`U41.J@AHY"$SQW27+2LJ#^W`ATBMR[<6($**E"AEL1NJ1P= MH/&U<_119E-IJD>ZFVVK;RP9#8QD"4LT:!VHCEJ>XW+7UA9ZCY`$<_Q`G3;U5L-Z>-14KT$PVM.MNV`'-]M/ MP5^S_.*`?((=S.F[3(E:26BL:Y2L_YPRL08>/3U5#G\?19IC/V&C6K%51D`/ M-+2[X1SJJ7#.U4'0UC:-PA'N;`P5P^MP^:6Y#L;YL3RM^T5X0!ZM=9C2>>O' M&HO%MH0!%H65B4"RO6"QO\',ON4%)P:E$I_>GS8#X#H4SEQC.\OS6'6U MN&XG`>K>MGJDE#_@"(DJ1]PCSHT5ES':WP=)`J/S8Y48GC64GNI.Y6Q_S9\\ M%MS2B3EBD%?/A;('Z!'FYL?G2C$W>'YNB&9NP M'ILOK;'))6-CU?N81X\XWV1.)3J!0*9-%;;`U0Q:(H))]K73"5V2CMF2%>$& M*\#-;:;^2$,&>!8+]3)Y.T[*A,$0_ M/F7X5^:/.,PK_;CII"=U?QS-T))VG7:TJE5-N@K*C/QZ_',X#U8!7^>N&;0O MU7@&;#S#UBB2!.]H$R#CW??'/ MG]R2H#FJ2QK[OG/IN2=O?[`GEO3UU7FW9`OFML3FAN`$SD>Z0C4U[98X#Q%_ MZW3./R3CM8"I[&MPJZ"F!P9QX?'C8O$#A?`G<0JA4KC93AWTM,UJM"%^B4GO M#![BXK?F::8BT%!"YB+&4";%0!Q>TQS@]JO6VUOW,-:9E('8.\T9F3USWCJ* M8OS?(,&[H;2`Q0,,LSR"T2_(-8K3._A>/GV!R1O\A#8_K\*W['-Q]R%?WH@Q MT4Z5U_`&%7-0<0>4/<#\`?T`H%_P+D?>#$/4&@E8C41>C<07.A(I'HF2CL1N MR9&8D$7//[2X#A>.<=/7+=V,I>R; M[<-R.YF):![,QS+(RS$F>HG1Y!),@V^TRM[/-!97J3#VR?9(7%$@6!Z&*>O4 MSA3^!8S0FSW66;V%,#F0M MQ,`.?NUTCM*D8[;DO4/KB\O%P-H-%=(;Q,HWV&9YR5J[/X)84.?FCN!1*IQ7 MSCF^!'+DIP]\^M1=]J'1M.J]DSL]'W*,.AS@5A`_;1A]Y:ZL/NH6\FH)ZKYV M#U=H*1=V=A5F\G3\WI9H-VF9QVD1AR2CGIVP^OXW3\X'EHV?M3#Z^LLT&>)I M.\0F([H9,']Q/1AOXL$X)3=9J:(+AKO+]'-*5?CZWG&S784T'HD.. M=;*DC3VHMJ2'O&[9=0/834GS'N2_P9+H&.0A*&I(/(L>E MVY:=,M=JKZ]?!U,M.U&??^1X%B#H#,&+>`A.PM/75,JE(DSE&NG+T7B=M<+^T;CHTR=\ M-"X<35M'XTTVFZ_S:%Q[@/G\-E_KP;@AYN8_&&\P]Q4?C,OMY'('XSI&TH^U M9/@%F.UE1:L7)[O"Z(VQG<6F_SBUZHV=E:>$N;UU9]RPSYQ[YNMNZE MC!ZFHN%G0(XJ1'^UZYJ!S5YJB3,VV`Y7N\OZ?;G#QUUIF.\')+7=,3 MQRN=C3W6U&&?F)GA*UK:Y@'P'"M;:\C_-UG81IGG6=>U";9YRK*&O4:NU^PU MW?GQ`CF2+UE^7+_'XA?`)BPL+RE&TG'Z1#SJ@06!,<"+0<4"_(J9N*Z:-&(V MNQ@>.Y4>W;,5RFS+5(_JN/->TB^5(^:J(_[=R>!X\R$]^ MZL;<\@S-?,#\%2P+-DR5]3SH/BX:UT&0&)SX#19/LN<(?#N[ MIPT#_>S#H-4$_$H:N3XR$`UNYUQ`/K++'S\)RZV/8>+E$92P(+O9(93SHNWC M9W7,0=3,9=T?LF.0X(*"\J+N7#.[B.)[R94BJ%HHJKE;N5\RZ*YCV`JFOP-, MZ=S/L\;=QBF\*>%.>.`^W-;96M?NKW2]PPT!:>G:0,E&6[3P"8;:\F&+ULF' MTV,(^>VD+UMQ42^'GX:AY7:'ME/(NR7;7?'3,.L[6O7VTH^]WKHH#CNZ:<5Y MCJ]S"&_2$J)I+A^&7U*:LW"W!U1+)]D/MHA7)*\UP/2@8@`>G+VPG$%.W.QL MB^6)*WER+[3'%)G"G:\1+-UJ7E7WZ#)^BR.81B,T;YB%%YHGD$Y7\^HB:16] MIXJG*68MQ3&&B0=5'DSQJ*-O:C#ZH6\_9PGR(9.X/$[0N#X3KW2.D]!8ZQH. MGNN=4M26)-L@1'#S6_F&P6FB?C)D^J&`N&C?2+6CI%XI&Y/&6,7<%_`<(96X MT[XH4!M<)FK#(VO"^=$M6OY@KCBX[#6R>V+4[V%_HMG??3BRU.RJXT.LP2GO MG%Y)YGOJG9D"31>*)Z" M&'JO)BQ(8O?F2ZX;_#V7CF),T->G+]G_#?-LDT+TTST:3?DB(6QN5T_%O>8\ MA"\9P$T!:@OP/W!K'Y81?1'0I/U(NNT8O@JH=*"KA9,)L/WW(#T$^?$&.4ZX MT$I3Z@G_1G5%JTEL%]*Z$O71P>A`1=BN#D9)?4#[\G>OH]@3+?*Z(?^#AG]ZG]=LJ7X)MUF^8XLR#*O34UB374T>L^=?;+F MH-7>$R]!=RXJ')E-A+W3EGZ@Z4VZ*5]AOME#G',F?4'[75@.(;^5,8,A/VS MF3$(=*I@5< M\6,`\FPQJ^4+"#;)2XTD#I[QX7L,BS]YJ9(*V&JHI19F[:GF'?S"TH[C=Q=Y MEJ(?Z4.8XCY+XO!(__\)OI?GJ!N_2134G)5U-1TA;1_"B`5H>(`NDQ6@#,"O M[+^8$R"L'&UG9I0[IVR1Y-7V1%63"W-?X[C.YSB$Q!A+I+>D^WF,W;28TMW63. MUC5T^ECPKTK8DW3"<@5:3%>`L5T1W%--H*Q;#V^]>G<[$U;ZZC$K4"RO4OU. MZ6RE5(1N5B:9),-F>P"LWNR(S$5Z^O/5`U@_/EX]/;K7-#UL#:XSFL":$E83 MOL+HD,#-MO5!Z7MW&87EH!I9W[D0#M88UZ?J0-Z/!_'J>>A&<&A.@DW?`W4L MEEZ^-$T<>`-U[_AEG?YIH;L1,U.GT4_W!JT_U;P/,#3/$XQ4"^.RZV-)6[N& M2=!?Z_!,7K?9[AE\[1 M^?%S`:-69,0Z1*I+8D"DP0;Z3!R$&1A(R`<8E`!3@XH<)Y?]!G,`3$$/KA9L-2:P=26CH1N=D0ELQ'&0*N$GW!WJH MC[NHFYMCB,I=?H!!&22I`6C[%:@H?,JVH2\+S<\6,UFB2A;/4DN)\27,$Z`" MUX15[?Q0(,TKBG7XMT-MB<9TU M[X!N\2L$>J6K$X16P^#AME.-T/3!.[MV>616+2V4[OU;-$JMCWAMU-,\8GJ[B?4;)/\%$#$'? MN\"A\:`0A!9-1<0$J!M]6GE,-I:;77B/EIG;JXX!LS]G/=/FOH/E.2;>8A!R MMS^=SE?=OL2;]:+H:J!^15WY17C%9D'Q2G)%<3 MX>8XJ'D&X1&.?N_>`QL-6R[D>1IF?514]%4XGZJVN'FLK&V99U!7S.ZT%%8V M``A1?S@EE>4`/%YI!>CU4&VO$89FT]H6,W^5MBWQ=)W%W$Y*967B(S#]XPEI M+(?=T0HK`*[]YZQ/P3L-,K^#.F]4N\V=/3SM]5KXFA2UJ[-SX?":;$ON3.D9 M_CI)LB\XBY\'@4.:@I%^@J@2KT3BT;Q![I5(!BC10U8QFNPIPFV3;$F"_TXK MZ[#O]I'+7=[\U0,DR_M*`=Q*<.4>N`,`Z.-5./O.PT6OXQ19L(GAHH-,?`D7 M'9;0,%RT9G(2X:+Z(I-PT7U+Y&TMZ`F$C$K`JQDRJD2NS3=R*?**>P MV?X2Y'F02M]]*^@<5CD:ED-6XJBFP'YZ1>-)(*.F."Q)40%RF.!\O:#,P"Z+ MXFTT)2;"_G]02P,$ M%`````@`N8M_1#3)N4C>A0``\_<(`!4`'`!P;W-C+3(P,3,Q,C,Q7W!R92YX M;6Q55`D``TW>.5--WCE3=7@+``$$)0X```0Y`0``[;U9<^/(DB[X/F;S'VKJ M/E>5J%UMW7U-:QZ=5HIJ254U=\;&8!`9I'`*!'2P**4S-O]]/``N(!D>"Q!@ M.)#Y4JF2(@+QN7MLOO[[__R8A3^]LR0-XN@_?A[\NO?S3RP:Q>,@FO['S[\_ MW_QR^O-/__,___?_[=__CU]^^>D+BUCB9VS\T\OG3U=^YC\G_NBO=-'_I\&O M@U^/?H(?#@:_?/637_;W!H<__=][A_^VO_=O@[/_YZ?_]^'K__?3]=/S3[_\ M].W;MU_',$)6C/#K*)[]],LO_#MA$/WUXJ?L)YA8E/['SZ]9]O9OO_W&VW^\ M).&O<3+];7]O[^"W1<.?RY;_]I$&:ZV_'2S:#G[[/[_>/8U>VPMY!,O?O>:L,E__/P6 MIR-.YH/!?MG_?US%HWS&HNP\&E]'69!]WD:3.)D5L_[Y)S[N[X^W:].',8(L MB2/.A-]X@]_D8_P&4VPXR?/1/_,`O@KC#2=?@TQW8MO]+$QFF+VRY#Q-69;J MSF.MBX4IW$;O0.XX"9CV%-:Z6)C"0Q*_L23[Y#P'(K]Q_NO.1=S7BIR,XCS* MT@?_TW\)&8P/OTER-KX+_)<@!$'0)YC>6!8F?9FG63QCR14K)J$]P>U^-B83 M@YPD60"(K]@+\"5/]$F&=+8PK?LX8U5.C-_YIIS>)/'LD87\B'GP$Q/N&@QH M>?J7_EN0^>$=*\XB\]FN][PBX+ZS*#AP(\&`QV:ND0-K8_%K(1$."_BTH(+^E!;M;7P\?TG9/W,8[_K=:!);_=H\ M($"(X2.O+`M&?MCXM-@8S<+$KU@Z2H*W\CURD:=!Q%(NU4_Y;.8GG\/)4S"- M@@E\#QY3Y?T3A/T!9L?%??&O]K/,TM><`W_F]YX=P5Y\JX57JQD,K+?=YZ/9 MG`0=6WI*FLU+-L*.GI6FS-4?L:U7G=F,I4/L\H5G-FWC85M\[=6?N6B45EY^ M9E/$^UL^Y)\R^&]QF1E.AF]#Z;:E'*CU-X3AHM(:R^)[PG1ZZ[V<7P[/Q^/BDN2' M%:O#%`?JO+/*+>"7HK=,INCH&-+ZBVS>-OM6S?R$!M*11MD-UX7,OG;>7KW)WM-H(O^^'JT3><8='+G_I@5."4;;I6K8@@#:^98%T#8++X0RWFU/E`*R8`"[PR M'-3F%O[$^.WM8MW;JGSXGX^RX+UX*-?:MPU&MJ(OR5@R"Z*%R@:>`E_]Y"]6 MBD(+RA-+G]O%5:BQEX?.J';O%;-9'-D31>5X-B?_IY\DA=Z[_,0%;%#C8529 M`E_A[WYHOO,U^H1-B)5K2^6C\UG5!:4WJ'5_5`O;M\&`MKU8;2D:M,:S8Z=\ MR[/YKLG-`R,XM*^",(==IFJI-;U;FXUJ0P<`#X\Q_T+PSIZXO:.X*,*EZS8: MA?F8P2-E;5;W+*N/S]+'[)J]+8B>[FB6!"]>Z*2OYNL5OEQJV,S%33V6K4E' MY;F[I-5\J5ZPB$T"0\68P8#.[=2[,4;;\V2WL![4X[3H_VYA_K6&;M?[Q8J. MK=[HMA_3CS`#/UR\:6_B9.YY%4V+5W"39[3NT*V[_AC>';7&LC%IOWC$+6@2 M%QO,EEVL*CC15&9Q%NI(BQ(=0?? M7)L-^\A8!!?JQ7SX0$V"^8ML`_#1,!ZM?2?D>0[B1`6;_\:3?>#\)>49'K+% M0*'_PL)B>$^[KW=R<+*BC^YDYS0I,B^D;/3K-'[_;.F+?X[:W0 M;?TR>@W"I2A,DGA6B[+SV<2ZP/(4IAB_E>OZYY^X?UWR'S\/?O[I;:%GN"OI MA,(H,!3$W`U?[]C4#TLJG'\$*<+.C5;>8/_HP"4;U9S8YIP8@YAC^X0Y5D*X MBF=^$"'LJC;A.`]=\TI,^VT>"28N9M`!808)!!,.*W:;L1FVOF1=0)[/7/// M=*VI\8C9>M@!MC[#L`HV\B;>R>$>0;9ML`%GW0J#F%5'A%EU#@#&',1-Z$\1 M7JVU`:"#+C)+`$+,K6/"W%H`?V!)$,.-;'SE9ZH5MM86@.]WD7L2,&(NGG2` MBS?P@O3#_\7\Y`9^HSKP-EH#>(KW2FU."N&(>7G:&5Z6XJG/S4I[((#SNV=S M?FX!$G/TC#!'GQ.?6^>?/F3S)@A9@CU2A&T!>2<5/Q(P"!LI:X#F9TBY^3RR MMSCA_A/<=1U]FSNQI(-SIJ)],1/7PIJY^DO4]]_*^6:A5FZ^,VF@,]_O9S5 M93Q[F8>&K5RAGH'<%V&1RGP+D]D`WK[3RZ,6`]871`U\EIQ@,KC1L#LWBZ5: MQ,1HG=B1QD5@PF6<9ND\`ICGJWI(V)L?\.1=E0FNV"!9>I9&]@;[Q\>NUJAP M9CIK4]Z18W*J/[/+&_'RU2*!I87[SI*7V-G2K1;_<;!T%Y__O&>9QGH4-??V M]UTML>5TS!:8K)NW[_0&KR2T>+TH$?7@D!.6IG*P9!;SX!%4674R&NM'V=?; M/W*UF-"YF2TNDV&\?:>V/3.NB%>>,=P>K$2M^FL.5J;.O.;J*OC;?1R-YO^C M7KA-A_;V3UVM:ZV,;T9+O.:(WKY3(Y-55HHW@R:$Z<&^L%7VT,E;M/SVQ>=B M-NK>3X_H4"E.HM7;P#OP*E)PIP;X@5I`+8/ZT]8 MY-/!(KR+HRG/6K614+'FV5MC-*]IG&&3!?IB>&-&>GAN0P^;4A];D#C67NAS M]*O7.EB7:Y-3+SQ1I8JY;L M8#%4OY\.)WBV4KJ";N8,%NSX)O)QHK5M[1.W1F(A1/S&QY:H_AN76[-V"&>"V:`>W% MND/K'[M9?LL21\M]\"%6>M&8=/<.G7G4+*>'I8D1-_3VPY97$3D:8!D_&"C!T1>*-/;<.TWI\0AYV8C!TWE')'QR:G`;AV,I/4T3 M;B,J\'+F3YKL4W7QCD@\\;5XIX7%4BX:*LOT;[66J;"7=T3".EACF>)P+.6I MV=;9.+PXWTE2*>*-O2,2KE+F5^5U!(12V33PGRMSH6OX"*XU](YI:8;6.2-F MHP"!K?PT[K?@$MREOLNGJ+UW3$)?)&"4C*,B$+:2UKAG+*\3Q\MEP#^5:F3G MV:6?))]!-"T*Y4D-G!K]O6,2#G$X/S$#IBXV6]EOW,O#P@OWD8T8((:3ZYXM M_)4TO)I%W;QC$JHK4^XK(=E*D4/ARE4-F9*PN=K,.R:AP#)EZQ8$6ZEP*+!Q M'CXZ+Q6F7K;"]MXQ"965*6-Q++:RY!#8G:LTT;U^>< MI(9LTD0%4X=7_)@S-V!""2W6/G_2]@O M;.\=D]!R:?,;!X&X81@KNJ@!7: M+?](G=@JS2&\$Q)Z+R-MIA$V1"HZJ`X3A#$;R<'F]?:$A.++B)E*>1!A1"2@ MPPHPC0AW#7V8QBC>"0GUF(+!I&K[9&]LRC7T*J).W@G)-1JM1@M083PN8/*M:N<"2*-)6P6 MM?>XDU)W^2R!A#!:7_MV5C(Z8E,^N%-6KX72*M>SH+5W0D*G6HO)&!R$P<8* MMRHM7*M:JC&HPYFN1<5?0W#LEH7^MQU\,#\)A8XT; MA9T;N9)H&<>4?;W3[K['],`AHM!!K5IA)*Q02M\\*NSDG797M:I`A?"\DUYK MUV=]I=G>DF#(21YOHSYR=U+1NJQ!AU2DU?6M=VIL"(2,!.(RRMN9]6 M@M-4H0."UMXI";6:@F%B+F-P$/9VTH^M4I);&1BRT=0[):$RJ\5:(1:$K\9* M,O?+]GP\#DH8#WXPOHWFMTZ9>5O690&[^PV&L4S=A>GW!ES.'GV/^0>#B8C>:V29'T1L?.TG41!-TPHUKM@D&`6RZYVZLW=&0OE62S`TT2&RT$'WN.>$^6F> M?&K=`+8;>V(V@07BKKX8C9!479*HU>;AY9R04;;6XBZ!!N-O)$$_5 M0[:!H[-W1DW/9L'-%4>*2(6Y:]N&RF:W!0&KKU47*7&U540;S!OLN2L'MDXU MO8I^PAXZ?'SE9(S<+& M>J5^F@T-9"&QY"0\PSPY;`#O08TN_LI^8,G3*]#9R9$U?^"%=O(-# M5TMT57)(O3C.2MW4L__AJC[Z_//;!>PEHB;IY9WN M.2R7OC4MO7+I>#>`0^+=I*2X>`&IH?5B$?T7SU!AMGR0?+47+&*3(./C2=8! MUM0[.:U1WEP]E<.]@?0E(VT/DW)JL943:UUN-8#T0F`KT3N?SXD?I4`/[C7F MX@C`YJ)Q#JBZ>F?.'CG8U,R.!H-1O#,2+QB<:2E7?T3HZ=K='MF=U&DSB9 M%5S469MZ`P!$$FM2AQ'B16B"LQ>WV"*OLTY&=9&5?<&<"2T?W+B(Q9_77C]6$WY2\K^F<.0U^_.5M7&''16%=(% M.'/B;%5MS$EK+6%]``@-EUDIH9$5)`?5BW6#%A%^*,CZRK)@!.A M'#A3M]AT<$`F[4ZTX32@_R@MS42<2;R?E%*)Q1.#\J#`LJOXX."#Q MA,"8ACV_%8!^%!E&J_(.#DA8`^LP7`*(0)UAFPS_4HOAPE[>X)!$C%P=ADL` M$:A/O)O"TH-#$F%O>NS30V.IVC"5Q6JSMO3@D(2IJJ,_#,/[&%;,W<7(5YR_9)`^W:W=JE&PP&0?H1TM) MM<%9L1S4@-B?2L?+PI\\>+O@TR.P+'F7)AW#.P%Y:"E-M"1`A:=7A8Q7N1A@ M\J.@@`L_AZQ@430^GW'3[[^*WZ/E"&4[AJ5/`.EIZ6KT-A.KZ/M43/F&UQED M=\$[&V]6.:P0K4H&5821.=7'2*-^,/"1YNO7;*,V2G-/A]\@O MIP\K)DB+8Q>_EACU!U*0T`'JL;P&-%LEG"EL#^N/K`<_&28%W<9%5IEE?"N^ M)>@-`(0CH28TVP9,L%FK!VU?@[0.X[+@S&+QH\`"<"<1U$^PQ:_ MR1C>X(B$BM!@`S"'9ZLBM/O+Z3KV0J33\SQ[C1.^`VHO_@&!.OC*5P+J M3R'I+:C*4Q[I`83IH*99"J9'=:`W8>H=[K)N0*(.JH/5B/I3$7HM%W")5L)K M06L@2(?T=4H@;=6`WF6DSQ5+1TE08!A.+O(4")(6.6#SV3IV`:!9-@ MQ,T7I"+_XUT4DT/9L-.)_\$[>8+#G:F$MZ%YA!K#@PD^#=#AY MJ'!<)^C.?##O[(S$G4K%'/'RK(NWM4`]!_*S#98O8=G*U9*D!L,"C4G'17&Z/M]$H MS+D]1+QO&NPI]K_&$\"2\""LN1VU1A%;,7(4I/0&:%1X652R4JU\L.=DD,4B MZ/0'-I%P2:DG2`80*83&R9\V@)U'^K&7;(XEFA8UI,S>.9JC`%%(.*35?_,8 M`;45*4=A7WAD4^Y\#;>Y2L4@Y6X@Z<7WS@X*@SXR&N%J^.I7U2O7WP$,1_(& M^S1<&^IM`_70THA!L[47P,,N9X]L%$^C(E^E_KU4V9>OG@ZK/G3QV8I6(&J-QFG98>58?<7]"X#;+;^J?,HJ>G%(=O(&8 MH;,5#T=A-[EGWRJD2N((?ARQRG-;7S1,A^+4)!$D74]6:L*U%5WG-C5_,X?= M(F=63]QU:]1!Q!(?CE[9.`\9]^Q"=/D+]R[N[#7)0ZY>+8FI?$Q:&9R7%Z-O M6M\J@VB=`#URVEVJ7.\"_R4("Q>SKT6D`;S#(WALY4D"9"Y<#G4.@5KC`=/H M'P1H=Y[V*17Z):-TVU;UD:V1OLT[>MJ86K M"7C*;K^K?7D)]3Q-\UDQVW0XN6))\%Z`-#[I#`?DFSM]5U'5Z58/M"4'8K>7 MTO,1G.1EF9_AY&N0U;EF8L$*BRONZA/**O)X%UB5[FH[+25%,,'TXK/R?UK% MU6H,!_"=VJ?TV(-HCVKC)7%I5#\]\F3TZJ,Y:T=ZIW6M<8`R3MT5 MZDA"`Z"M7?=VN;#`CDHZ0X:LE5U)->E3P\VC,L8KB-)QOW7 MK]@+C)PG+G<([F4/Y)BM3RNKN2G4&`T8ZZP:_'H:DO!#4G!*S%X,3A^*9Z]+ MNF+=;C<&0I`P%1LN6`Q('XIEKV.[]V=,N5ZQ+MX9C60M&+MTF+N)QFW=;$3A M?\L]Z/UP96D<1DQ>8Q7O`3!).`7)V2!0XJL@6Z M\FR@L92BQ.X"7>FW-M[AP2H&W=0.KCN2=WI"XKTBY9K4$&Z&M$_Y1U8T6*>> MEL.LNC,0C.#ZEXJ&*;CV\GSL4C5\'_/$JRN5^/B=EWM.;X"2CZR(;'[P$[<& MI;4IJO7!HN;>X(2`X>>KG^5)86:'=\Q/F;OE5YT%YP)+4Z:S#J7]@&,'[A?D3_QB',/>4N*=FG MNY6\/1>^VV@L97E'GIW/W>FZL%6H+*GK#6'.5&ID:9!685"K(OIA+=VT60%= M2)A+A>PR-9668'[82B-."1+*!Q6OM*VE):`^F$N?&'>TOWA8*]V*ZHPU>G': MD+"@HFQ#UK$24FLQ;`YW;1VUL:B.W-XQ"951G7UZ$P5)^^GJ7KY*)S2_CY]_ M\Y-2.LN<0BF/QBP)7XG(C)BI)MG2A_@UB,2;"&6X5,MLEPHD*F38?HF+$UQ5 M270^RH+WQ?/)["5>=W">_8:$_DQ3[*PC)U&RHZ7=[/E;O)O=;.M#?!T3>7ON M;C?#J$"BUD=;(L9=!'8D9-N?X@0F<6G>J9BA=.A1@9$*D83:HS_])/&C+!TF MC\'TU=2D:S@F/RI(N-+5/R1K`>ZG,P!R82A*=Y_GV6N>UOCCG&-=>C[LG#+]<&6XA/T_#H,Q=UI84CH= M3H9OK*Q%R9,]"E*TN\D%P;^\G*56.@AA#V__H$8V1[>VE_T#$O<2*46U3"X% M$#H6EY2-?IW&[[^-65`R$7[8Y!W\RKMC4S^\YHG8/A&KBJ"5MW](43U7L&"= M6>CDZ9A-=#E5(D#-(YM-`*93?05*^6T&;4^[%Y:/ACKP_4-:5VETC:DP]"%& M;%Z\0\;"11,`32(H!6.'F'GKL[=DLQBS25"6.OF2PUTL&C%W==G3;#CAU6>+ M+-\L>8?[;_H4KP@HLC2CG8!*5!\1$AZK\/3(FO`EB=/T(8DG@>P>76D%%"!1 M6\B,HUL`+&GILYA[X[EDX/RA%DWGY7!T\MRC?8`V5)7L$N8JX)#0EEM:K2P" MJ&$1$RA%PM]+P4ID<>M@ZY$J6UH.2WKQDO0#*I%P M#:LE`1K(>J5Z9B&,.06T7_WD+U:AEM15#.L$!"*A6ZK%>A6L/E66WB*0R1GO M[1^1T$75XC*"QEIQ:#K7N%+!>@?751WFKEH#0:BZW>AN8;0JOU*)@;]GV4/",O]#]C[3'`*(1T*A MUD@@S,#:JO/9JH>P/_62A]DK2U!RR6[DTHY`)A)ZU4:[ MM@Y$6Q63W4O"ZHQZ\K>*B2[K)&B=Z+(!@&PD%*^6SG,U5%MED=U+2)UM0K9\ M2*A?&\F!`AW">O.J`,[?]"MM!<_Y=!GSY(8YSRNZ])J\8),XF?M*/OL?+/T: M1'$29)^+Q]!Y-%X?I?2B_LJRUWC,*R&E67$95GHW[F06P$`2*N*&[]`=TPL1 M^`ZJ)YPHVT:$,-9<'>E\-18%3/\<*P(<3$.V'."GXE65)\))G1718_.!KUI>Q M]`7OI"_O)ENT0(30V..0PNXB(\P-G,/!-"H+XXP^GQ,_2H$(G$;1N/B_L!2" M\3_R\LQ=D+*F5-;_(#"&Q!/.JIR9BW)3`B*2W4FO2AU6--P]@6@D'HR.I6Z= M'(@,=="M\]I/(CALT@>6+.(8@Q%W;PK"/&,R9VQ%3[C+=-!BK`4*X3Z-O`A_ M,AX1S<;G,+H_9?=QKT?Z^(-C@FD+E;L(C6R)!F-"$0@8;N7,TF\ M`3>"W%(U6*?UB*,L&'/$5BBOZ:G>'Q7(25T$Z"N,TUSHO)+V\TXV$7T[6^=5< M"&"*YVG*,AX0V*SDN-&(0`02N@4EGU2+M@;JUE+9NY0GOC7%49EC!3$CU)`I MXU&!PB2T!XWEJB9R2[N^Z]P]LUE0VAN+)#U%B3T6C9P6'I),RNAD,!K'&^R? MG;E?W&NE.QXYJ\-*[8YEK(.=ZBAFXWN#`QK%!>OP5;4)-*=+/\JFL)"-X`GV MW[F?P'TT_+P)(A\HZX=7?N:[VQ+$\]'8`^0=O9.-Y[23-;\]Q]MH$B>S@JLU MUKC!>$``$L\Y'3:IEK`Q[)ZLV.FJ<*:;\D;E#![9&[?11%.=PD9(%V]P0N#! MMCF[BAA=?,[_:)AATV1$(`*)!YN<2:K56`-R2SJ^7:[&*Y:.DN"M5!M=Y&D0 ML;1(`)3/9G[R"60)IE$1WQ)EJYK6#W$8\-O+^7@G3MT) MU8Q89QP*H?^9-`>G3ET+4,IO,VA[VFXS:2*;XSW+TWB2/==-D;+A)D/X@T&;OU#Q-P1[(UU8/4AP^;R8C+Z9QZDQ:&B*/.( M]`#*.O4*,=U8M>"X+2+6'H?YCPECRJ*/RKY`)A)."%(NZC->@,U2=DZ[._E7 M/WKUL\R/;M,XB]_8,QN]1G$83S_OPI%\_];H"L!):((T.238S;5!VDK)B"H&B&5& M(B6[388!(I*(I:XC#>8X^Y1_\ZO_CSBYS-,LGL'U07%D;S?V!F?NE90UCFP, MB:WLFTXW="[WP\D:1.6AC?;Q!H,3$J\KC&5B!JOPV$K&:?=)M9CJ,&+R!]16 M0PZ+1ERQ@O""AQ(&QE:R3*>+\>DU3K)GELSXV?0,7U/LL<+VG"!.59AU]UD9 MFL;I,DFR5[G3(CVX7QB-*$8)RS29O(;(5JY+IVR^C".XK64!B'N1%%)U>1:V MYP2A$;0H99B8R3)$C3-AMG*8;F]7=Y)J;*HN'&JGC+::@/J3Z'+]\?=[Y,^X MI\^_X&47I`45M'56@K[>OEM?8TUNZNBP4'2V,EVV$FR^F;;L@24C3O\INXW^ M'@=1]@?\7Y[@:8JU!^"&58HK7<[K6AAM9:YT>C;SHG;?@C"4+.]%$X!]YE1M MV6@9;Z"PE7O2]<6*2VB9K/`Q2/]:B>Q`?K]"NP$-]YR:#ALQ60.9K1R,=J]; MJWFN,FH_LA$+WF7.C_)>`'A`\=VKL15K`;.56-'I$@9T^2P/>0[[ADFB#$<" M(KI-X=IHH=<#:RMC(P7;P^(\NYV]^4%2)-&1Y^04=P#*N$W`:N50%V+J4VK$ M]4?(C3]BYS.C5]FJ"U#'K2N!Q=?8%JH^)0U43?*P3OB0'6%<*^%P'HV7 M51PT`@25?>%-MK_OS`BQC')#YXE%()D.P7&2T&'K<@0Q69C!I1.7U*#$LA]- M5<;'91N.FX35WY!18FYOPJ(3MM20G4H[5*45QT["HWJ3&Q*>KK M#Y[00\FWM78B'DGFGT?XI3FZ5C4W*NVX_A)^#UKG%8D:LCH\]50+K:P6HIK MTOB=Z87$2/IQ6E#XHK>E/UJC+9"I1R[ M'?!TVBQ9DD?#HU/8`XARV(N-7H[/5LB3X\5/!I/<;07)TXO-GTU M1L>!48C/R2-0&RCUJN:FK#F'2$(S5I>-&N`!*VF1 MN7(1X5TIT_`5+KSPQAD#*1[9B(,KGO?T]9U6REI,3E>=8P*E,'!K[_5*N M+S[G4ESX;B;LGSFO#*VP'6KT!E*1N%VVNH"-Z=$'IX$E6!%4I651HS>0BD0J M+FVN*H1"A;0/O@@BL.ER4:GM4!K=@5@D.DB1]\%L0+IMMY+7.'W0<(!\)%Q<3 M9AOL.G+8O7"*6""\C=[R+"U(-=`_C;9[>8[C=QOP4R$8&%9+[A$4HK=$6/=K M2?(7&#(D8"ML#44BX"[3`:;%(2:A@R[_$9;%$;L&* M1@"K&'$X$>4!YVVF$<^=5K%S6;0*UYZ#RM[;>&#@\ZGY)H9PFPUMI_N.U5,H917V4_W4<52 M1^VGW7HN[#M57K6T#;1(*TOV6@K:#DLO!!K)4EI@M=$+`<^A8FRV?8,OQ..G MS$\RNPF&;Z-1PH.?KECY[VVT\F.;Z$I#S9&\P1Z-#`^M"THS`A$P\6+>O.PE MJ_I*+H"MT%3V:]0GUV003I+O8W.I39NFAMRS4EPBN+EE\[;.XAO\SP(97Q\O MV2/C4$<\@UPTO8Q3H4CI=N7$ZHU:5.N4TJ2()8NN>VWG=HF[+_"ZX'E&A]'V MW^Z9+!.>\5C`"%I6GK:EJR:%>F0XMG5W_KYV)0D5;)F1R\OS=31VI&%?04P+ MDHY_3SF)0G_T5SIZA1;IL`#YD`0C[MT7CYG#A*$K_?XR+$865J73S8-;XY[% M2^>2G%*]^&8[/@M:CEHXJ81702$<.LII^JZ?0#$"T69B/BJT53K`Z"BTN^;! M"?2CI8C08;="8@R`N]6UJ[=YF0X<;K;`F!)_TOA?5-]$N2S`E+*2S7=)(PM2J\]RHLE+B&\8'--N>!=.;&H)ABR?+$Y.EJ0\75/V><4FP2C(7"C% MI//2T(YI]??.-O)=N`"H+)FSUA"F3"*!@P%]D8N[`!8=U5J[?I]G-#(IB%BP MSBQT\G0T7VVYR`'"7.3!L\0DSZ.J@_9:)[@4L[2\X?%C(N+@S*R M5](+2$,B[%_"-V15JS"1T%0A=H)R\D^:;%1U`;PDW`NU>:@'J`_)78`8LSC2 M6Z5;;8$,)/RQC-5?.Q^.@!/#@!^/;Z-)_"S(_5#)7V@_(0\*!RIC1 M&JCZ4(3F3S])?(T"%&OM`#X)^[PQ4P4H>E%)YGPTRF=YR%5VP^R5)9PD"7ME M45JXI(_BF;I*J_880#<22B;S)6V&L!?E9AZYXV+$QM=^$@715%U?2MP!*$)" M*67,.-2I6:'.OB@GAWZZ*-4OYEQ8) M#N8:'+7N2MH)T+IW?5&S`^6A%!;"Q%TIL;29>%&+BQ?K>-W[K%ABXS8NA(^[ MTEUI\_%++3Y^6Z$%" MYVA@Q\5A(+X4W=)/;>%3FG"1'D`3$II'"<,T.5S%@_"X6YJF^SACZ8/_R66] M4*_-?U:KG!0]@48D](U2%HJYKH4,X7ZWU%"<)JO<)XI=>[NQ=W;0D0>J"@/" MS6XIG];!W?LS]8:-=0&JD'"[P?BEP]U--`B/=^54A7E>\!OA?(-1.%QLM01< M)'QEY'07N5H@4!`6=-5>WU')G%/8"VI!XU6)<0]:P M"A#"[$X&SLU5,[5X+NP%)"+QW*W#=3#-6@OU;+9X+>WEG9R2N8G5X M+@&$1)UTL@C5\K2[T\@&OMT8Z$A#H6%^$]O`@#"U6XJK[0C%VV@4YN,@FC[$ M2<&3+$N"ESSC9'J.[^-H%$<93!RF,ETDDC@?_R-/,S:^\$,_&K&!5"+:^*!W MYC9'ATI6,,EJCQ:(=!HKUIIG^[:8LR<=YEF:^1&GD%1_OM$62$+B6#$4#S$, MA+/&2C8RG.6KX#9-BHD5*0>JMK_?HT":9=EH'"`EB0=%C0W##"(B M+9VL""&#?\^^%7^I*R'+_G!CHZ4J:BP9&]`0B3#6#KK/JHV`+O?-\O0OV?9[-]@_[N"-U``:(A`=K-V@MW%>^NEKXQ.& M#^*='9&P&;=QNJSP(>+132VHSG993SZVQP#R=7#C,(2'Y&WIJ+Y4LC**#;7N MME%T!H+UY[FRA0L1!&,=*V%!*(NNU9.#55\@%RU;>.-MH0(+D0)C729A*2@E MO_COA9^R,;]DP0VK8-^7!*Y7=3<)R9!`W/[HP#31(J)DK#PE+$K%ZK$J2:H1 M@;3]48CH@47DB$;TK'R)\#_.NT%O2;"@@4(=T'LU0(F*P MXYH*9F)0"K@-*9",Y)T==\@@VP@D(@.=K)U0VI*+.CW/,9(%:DZ&DE*2P\1X M+"!G!Y^V-6$B4K-CA6F=`Z1B:$RN/T:O?C1EPTDUM)-77I36Y[8U/I"R0X_? M%J`C4K1C!](:YT][0F0Z/!"R0Z\@^\@1$>JD)E9G+]Y(KK-&&QZ!T_!$4PT/ M1._@6\D>RT)Y&R!J-Z9X<=U`(V!HS( M5'>UQ'UPR#TFD5B/AD/N,5Y]L:9#[GH%\J$OXTF<3(K/E*G##Q63W=9;%SY54E!J[I#>?L;.36:0*E^55H" M?JLA3,-I6MEFY!,\2Q"$WTOIJOU]]T6"$1:L,PN=?/]+5^V[S;2"4GZ;0=O3 M)ED9O2IP=Y*`0+RQM^\V1XK^NE%AL%1M:AR/B@0@!0&HI$[?SC`LN?"I.P/! MW"<'E;!2?`/4Q=6T(A4UK_FU%Y'14Q+HX3Y[J#&?,1R62D^Y=VGFGI;GT9C_ MP_&]^R'7[)UGEWZ2?`*Q"DVRA-%:_8%F[C..&O/>`)JE0E;NQ0'VL3@'E/-4 M4@`??I/D,/_`?^&UO@.67N8))[9,.ZX_"M#/JVL4[>:=[ M'=S%57AL%;ZBP/"')!XQ-DYO@&;<*,RE>CA1F#+Q3MZIVZ)U]1BNPF.KGM4V MPW>IHST?P94D+51SP\G7(&M;3[OU/84R%FOO[6_X6-B0H+/4TK,!79/I$>0!*G_L==.)*G M8=;H"L!)^!!H;MN_46L+:?;R!JJB4F]`01 M@%VXSY0N,?,4`,.DN)MS=ZZ<"_]P4DT08"8?-3X`=">16D$M&]HR59L*!'39 MR*'"K2O#/'OP/[D5[($E(\XB[L6\=!3$#A6-KH">1)")J0R8X;.DFJ:TMUS& MLY<@\I>G;TFSN8[G,DZEN0'U!P'ZD0@I:;I'Z"*UI*-N)8!$0(/T(4]&KW[* M'I)@Q,[#8CB.<<;],__%]SS8#/UHRKW.S].4"<7"XNA`11(NU[7V$YLDZ)$* M_2:(@HS=!>]LO('U]Y1-\O`NF,BLHSK=@68DHH[J;C/Z&&VIVENX:0C`7\91 M%D13H!S\E`8P5[_<-XOW7F$6GI^^J='-I(5/`7E)1!+9VGGLT*,]13^)JP]" MI',>7SPM?-G3QS+D#^Z)G"IIX;!P%W\SNQW5_PZP@43Z!XL7J*;$0&2RD_F+ M[)'G;\%4EA'/[H>`$505Q#N6RA4U$+'<<2XD@[L_ACB[\8,$\UEK,!J0B:H" MNM[=7AY M!;^P"*"&W(UO/(/G##>_9_"@`>`L2F4//)WN/`URIQ5)!B`1T>AD!J3E3G@; MO>59RN/CN-/GHY])G_QX+Z#162)Q6 MG53YV$"-2(@%-?,NW>^>\MG,3SZ+S"8KP,]PWTY+#!9=[Y3?4OGB:0\`Q_N^ MM=6F_*K46T^O-TS8?5"1(7D%2\H$[`\'OS5OJE/W+NDFW--W_%JB^^'QI_2Y M.J5ZFJZXJ,]X`;;OTN/OE*I)0\0AP::N#?*'QY_L%GKJWH.[E0U^`R()%T"3 M=U.:#2?SE3`N,U0LW`72TE]`<2EM-"C0K`,Z_%-Q64?PNWS6CC93\]/:RDW#\8"7!_9UG9J3T%-]F@SF.38M6>"% M3#%J3HH?>M(U'91;@U-39AJJ37$[TP^U:45Q=496P[;D8FVUZ1E>L[[?:M,S MJBZW(@[559N>X077?JA-"]W3F?N$TKO8[S<0=TR+NO%:6498S1-4E;02IR$T M4*LV^`I0M0-NKV?BE`MMD(*$XK6Y@#TDL+,F\%P.?4`=%:J\-^ZK8T<+&] M@[T.>,LV%R8%`4@H1+L<9GNPUX'4#?IB5)L$='.*FN^\U=O`>FY5>P<=_@V@ M9P.]:8S9K7Q]B>/Q MMR`,X&59,/+#/AKO#O;LU6TC M8+P[V.N>NFZ=%]:,=P4IZ!COVBT4=[#GWI6L`9O6F8X"I&.*:ZN8W,&`7#&Y M@O+;#-J>MELKF;7"!V*5V\7G,WQ;8337Z`VD";QXV^WL+8G?RT0XF_,PP&`4HV#W7/.7984P` M2W8OIV>(!/0*\KT_4Y\GAB,!"4FH<(RY;BP\.'I+]BZWEQ`_DQY"PG8`GX2G M7BVN(9>,;7R6W.JI.6PN-9QU7;D.!H0B8&V='FK$MI(%AVXTMD7.K#F%;)5F MLR.C5W/J%9G?YQ4P@W^Q\4/"WOR`!_!5YLY3/(5QFB>R>%Y+(_,48J?VM+JC M5S;.0Y[SH6[<%G1L(/S@Z%1;I:%?;O12,[H%!B2,D-M>)U("DLU"?- MZ\!QD0Z<]@K=ZT!26#3AJ-V; M-23\$*^XC>FWIIO($WE`6_3565\#*^"JG#&DG[V!_T,(=??&E M3\T;^GI[F)3[K4B#;-*+MPC2]W+K/M@GD,93R@D-5X=]]#[7IPOWP;[SJYF0 M\BI7AWWT(N8X(%@@=\H+F:P/0"40ZV^PF#01]2;>=PF0Z]-3@,W]5F77-7$' MH(I3JX`FV\17.!DD2Y=P0HQ^]+]]A0=B$OBA%I^K[8$F!/3_3=F\C8A`U6'+ M7/XS3OZZY=&?(Y9JL7FM`U"%@`]P4SX+(%FR^Q-B])C)1!_25YC)>@,S:B0XPJ M,BCK#@$PW7L[FG!$O(S,X'XW>KH#$EZ(9LS14-T=D$H8V)KJ[L"IP@"EO$IU M=^`\EU]GHI0.2&3_:[(^C>'^B$W2B@(Y(%$P0YNKAD*QB;0/AOR+'$@91%.E M*\UZ0R``"5]%;5Z)62T"U1N=X4V>1`'W$P*ZW`0?_"=U3`#>R3LX))%9KR'+ M50![HTDT"TS4Z`7T(9$3KZ$`*!$22'EGRV=R]I;#-)8$TO"7%/8`NM`..M;C MO!2=K8(;]A,=/@*M@4ZOU5C:&W\T#X:1AQKK]`7\W8DSWN:N(4YKBDKGR_NK M#P2-6+*F=E(N<4DO(!")Q&\-E[D2H;5\;LY%`*74G49`H+HSD*OSJCA3M+9R MN1$6#I5I6=X1R$0B4%B7H8;B4,&(B(*Q/M"]*)R/1ODL#[F=](K!Y$?!/#[T M+60%VZ+Q(A-TD?O0('.[[4\`Z4FH%YN)EUUJ((*HKWXD9"I'HL=F.](2(2(&YDZ+#FWL&[G`^3H8C9)\+?]N*S9WG0_KV^!-1O,.CO:L/09U M/BP-;]$>`*;MWD&E"<4%ST1#\-^-Q?W(?623(6LT[.U'J%:G5_;V(W*AZ07E M5?;V(^>!Z0UV6-GSVGP0((9[;Z9&ZZ\NYMZ$VVQ@?T[\,9L70I&_F;!>0!_W M`58U.(H^A^1`>Q..,R?08_SIAYP\6D(@Z@%T<1]Y95,`<)"]L;C?1C`'EF9S M_0]M$5#T!#JYC]BR)@M: M8'MC?[^>O87Q)V./K%`$5HBE%@ME7Z"5^X@O:X*A"9>`D=Z.:)3I:+9HI98+ M>4?OX-A]I)@UH=#!VA]SO@[9C)\4LE&`@.X5?&T],=3`VZKJMDMM^F6>9O&, M)8MD5=:RP"K5Z5I?UM>G&PT'_*L1Y(9!*K^HJSY'FL.4W*MP&I%3H-"18OUN M=./'[O4P4D9H:,*/OX_(LV-ZD6?'&I%GQSV)/'L"4A?>U(N\ZT]L6CA7*V+. MI/V`/.YU(0;KSP!4'V+*YJB4T6-K[0`^"7\-#1XAS-U&0[).U7T^"IF?/+SZ MR>P\38,T>_I,^45:[C2NZ`:`2<1^";@@N,1H@2&@@<:LD5F6!'GZP/18AS3W M#MPFG#=CF10$`96Q]DM":2:6=`&T[E_G!@>?'I[>Z'8W7UAJS0S2`^CBWOE& MR3?Q.2B%1$!7BR5#Y5:(RS@J7K\/_F<1/\"2&3R3W_UHQ!Y8,N(2=G[HVZALQN@M26=K9924=3,;A)6#!]S8;18^R/FPN#?#@@%,4'3@.1 MT,%K2_FZ6\%8['?GHQ%[R^QL%1IC`LGA,G?[X&H]X=^ANM66S#Y"%EE8>77&:4/I@7ZDB4QI9MAL#(6BHZN6<0K1+")P^I-U[ M8D7AKH?%C`N0RMPMDE[>X8"$AA]C&F9(4P`B8)BQR?"+6@P7]@+ZD,C&5H?A M$D`$S#LV&?ZE%L.%O8`^))*PU6&X!%!O+$(ETK_58KBP%]"'1%ZV.@R7`+)D M%VJFT;-\_WX:LCOU5EN@`PT5E9Q1R.-*C*9/ MV>^,SF'DO"*1BJP6@W%`_4EKM]S3[C3276XW!G)T5>.U@:%Q@C@*F_$]R[AU MY"&)WX,Q&U]\_IZR\6TT?&,)<"2:GH^RX%V5IZO^8$!)6KJR#1Z+):(N3ENY MY"A5[3M7;>X3X)A5E=!J+BL`D1X;2Q#HT"IRLU))_C1S:* MHU$0LC70S[&]3:2-SP%32.CM[,I=>Y1"Q+>#&L$">@HX;N+D*LY?LDD>+J*6 MI3=3O)MWXC8)1/OLQRZW*IH@8F.L5Z2PZU4S"&\D#I;(C:07D):$*GG78J,D M"2(U'4PP\@6>AYQ^PX@[86XDSM?)YZTW`)"-A(YZUY)D0AW$#TA?)THH>_?M M[,T/DM*5[1;8'$T#GFPC35F6W@11D+$P>!>ZO1J.X`WVW29`="599O1!9&O' M?O3VMJR4TY/!LKK^X*3+@_2U),45>U'M5M*^WJE;;VJ7&Y4&81`YTM?[$MJC MGEZ!$Q<^4(T7_&)1JKHIB3L`54G8Y78M,3)J(&+20=7QZ@"_8DGP#AC?V6T$ MU,D+2@-Y'Q*6^1]:-R3Y$$"Z[_(D,Z,/(EK=K'%2ACJEY0[[R#CF498G0,++ M.)6_]A5=8;O^+H5)CRZ($.EKM0D)T6V:YCPR;N$M&XW_]),$GA<\HNJ))>_! M",[TY#+T`ZG=RV@<8`$)F_;.;]WF1$)DK9-Z]44"'#CQ7X*H8#8/VP0RGDG:$)GJ2= MO,'@^^*]-DF0X,P=YXVQ=(^/0-#]E%VQ\E^@&M\85Z0K5+NR"[S6`$"YP^_2 MJ&=$'D2P]/7EA`X=`?`%YDO_+H"3$7Y$?,P5RAM5WLB(#W](I+;"(R6#`3E)J'^L MA$35>C7``_4&\PT,2*IVZK)?['^GB M1P2HDXKF+>P+IP+&G?C*G+;SO\@\_TV&`2*24/^T+$1*"B!BU$F_;'U:6CFX M@(`DM#]V1<@4/R)`YA[;5.\_-T$$CTI+]Q_)8$!.$OH>*_1]G+,4+=:BZ`&E(^!#692IR*$G1(H+0R3PAC^QMZ46N*0I8 M%R`."96=75&0HT5$05_/2^@N4A7ZPEJBB"\4M@>RD'"6;V\_V("*2("QGI;: M9J`C`<+V0!82&MGVMH$-J(@$=-)IMPJ3(X1'_%Q]?6FJ'<_ MY`OG@25!/-YTM9`(D,DP0$(21AHSE:@Y0D1(S)6A1(7D'-9,DGS"\OC##Z4N M2EK]@6@D#"\VQ$((#9$'8YWH6R%S,,TD^RZD@L05I1VIP.\BQFZPI51<1XZ3 M:.5O;V%!)S]69@]^ M(,WQ6&D&)"!A*3'BF)CIV[`0SG;0.;4,GGSV/[C11\'F4+NBR3Z$@HOE.>8O[VR MSY)@B*.Z;E?O\)B$WK,-83"C`2($.TWFBXA`]3(W3\18;H2W7+0C-N*3_C/( M7A]9R!7W#WZ2?2+VDV8#`JE(Z#A;$Y>&E$&$R%@W2N](&B;!%"@;%DX-AF>1 MH"^0BX16='>'$$H$1&9V[%.*;#TKGX1RUUSD@=U<#N5?AQ.8+U`,30!78>&D?K%BTF44XN\1S+3JB(=M4$:#`%%( M*'-;VY9J4`,1D1U7FL/?4JMTS3=Q4A%ZR1L*ZP*`2>AZVWP[R;$CS-ZQ-AAA MME('4%@KB_HN:7G'QV3`?"0@3V]5=(U((I:8D\;*72#Q;U4:W\&,Y]3_]\W? MKQ&??60,=K(E#;?(7V3F2>+HUU$\*[^][GP'(P/!TO/Q."A15R%)49GRZH;`";Q8)(S!+4B*'`AH5PD+L,8 M@(-Z_)QW\\[3OFBO(/KL-ET-*`NB?=O M3>[7@XL\>0D)Q0:6ZV#ZFCVP9,0Y,V4UUKMP!*`&"0\E.TM?`A%YL791N;X1 M-8:*@K0]4(6$:L.$\1J`Q&S>J>LJ9H*+X)7HA_,,U$$T'4:*58SW\`;[9]W< MLY68Q`RDH8K'&XW=UXE)D1]T%>D-_ M$"`Z":<^0[6'*4!$0KJEX5IS'5)I0K8;>X>G)%SV3'FGEH`J/H33N])\(1OY M[U&RFF^@>E:)6P,^$H]FC/*"G5L&!&&4L?ZJE8/WT8!;HK8`D80VV8!7.`R$ M4YUU3ER=,W>+Z!1ME?+=*I[EE*!&V=!>L($&870GLU2N`[WQ1ZQTGM3F]*J+ M=T;1-+3!.QUV;T)"^-U)!\!UI(L8TT?8THI8M/%*2:,M`;)!@(`$EW\-F5"# M1*2D@W'7E?1H<,P-DQ)OX7$"H`N=K52KI>P-!"/A!%I#*K31(>*P8T<]2P(1 M^FDZG,R]IH?)(U?G7G_``@A2]I`$W+%ZX5(]_ZOLJE!G."`J0=.FGLC4AHO( M$`VEVSHE5C:?`M%YNMH>AQ-XOHZ#:%K\!8U=J#L>D(J@RE4J&1;P(HXKG=3E MM1L)=4;1D*9]`]'`AHA"!U-5*KU>JPZOC6*UUP8",A(TN=40$3V@B+S0",>^ MB^&LC#BL)Y9E9:@H=F*(V@)$@HIZ]6F`8T'8M6,%8)L9K`V2$Z]W\LYHJ'IK M+%P5*(3K'2R)K5R];ISN0K*M:!GUXB$1T4NM8+?>R MKE"_S!-.Z?-HS&-JRO^12H?)0$#(KNH=Z@!%),98;VG9]5GT')8'B$FZ`-*N MZ07T("',ZZ1CG/VB!&>G77OS:Z-"&&^L."04D_)[Y,]BP/DO-N8QD$;V)4%? MH%.7G_0:V!`9,%;\.96!A<*SBP]YE;1 M6$JNX)2]\XNX,HYZK1W`)^&%+F..F)T"&):R(;@W`E\#IC&\6*Y8$KP#*][9 M/#\>3\ZUV,WP`*(ZPP`%21B%S07!'*6E)`HM1-<_\RJ4\L"P2A-`0\)`J\\S M,0)+V0XHV.Z:YHL[/B-HGU7>FS`@EK(@$++--@1I!P4,UV)JKW,!LX+!@SS+,W\:%QXU+=@Q%9]5-]: MK3N2=]AEL_0A*;.T&S/AWVQ M/^\\625=6[5@8=8%V`<+=M-#G$ZGSEZ@-A8^^, M1K%GC.P"E8$$AR53M5TFZ7-("(N$+=*`/1@(2^9A0E:K)@J4A#:\N*>-T>+T)R9(-FAJS;0>)'M+P`VO,?A1;8T/U62D($3S-LGE; M(J53)(S?U&,>TO#RJL%F(1);)NR,NR118NFE,BA4W,$[.R!X7-=A\!H@6X9N M][OX!DJM^%^T#Q"'Q(.V.;4!(`=I&B>?A1C+ M=U]A8P!'4(>W27S!_BM!\Z/>\49YX*,]@@H\.8\U`%FRR#C==)_REY3],P=R M7+]S$Y4ZDC"8B-AL*9$Z."T9<6Q M^]*Z?`W8Y/H#5@A/%C*<3((12\ZCZ0^>_E[[`:0WFG1R3.@5H,%3S> M:I.`1KQD+?O2G<2?SJ0[$-6I1KO)46&.DT;<),+PBSR%V:;I^>B?>9`6-K:' M/!F]^O.BD^=A,1H;/\<;UER>_>9YGOT&DP<[H\/^3%U<-E@N$!F;I&@4<#IXIZ6P*@`;)/Q:+7X5;KII_/P5]'HDI/1OV!;$XM`^W(AA0LC6+0KMU] MCP;4-CAKWGL`Q&V=L`;!/I9YM5($\=1N);XOK.#9;E9I;VD)'I+UAS>7R?.+L;`(::3+F^](4R91,`K3D[D&BM`\;U$7QT-2/A` MB%BPSBQT\OV/M3K:=QKA@5)^FT';T^Y#$CQ["7R.]DD$<*A7FQ802R%8%.[Z M57OVZCI1?>P\)$$T"MYX-/@]W%2>O['PG7V-H^Q559"O]KA`98)!)!M"()8; M"[@M!7^Y#_`SHL7_8G[R_"VV)5+SX8"B!$-5[$O2&EQ+H65N,X17[[*7_EO` M<^,P/V76LE-8,HM6I@8LN6-IRG1>/M)^WM'!P-D3:/3*QCGWRJQ.<7R>P@2S M5/DN4O<&<"0V=PT.(*\F78S?S5/J@,0>J\T7C??5`:[2)HM1'Z+;5.)85$=EVC=Q'R+KH`;4C4@#1EOAZN MWM3-7KM7EK?*"S_D'@1/KXQE)?"+SZ_^/^+D,O1Y$,(HG^6%B>J*`=I1P5#= MMT/]+P#=25@M;,A38S+T*<>'*5UNPF#ZFBWWXRTR!=8%4N^+P!D2-IJ=":@) M65JK5^[`C!U$P2R?%71:>%F=1^.'\F-_^&$.U\C%'XBH>M9FOIQ;;JSZ48WC M'1WV615T2$\5I,>1!JJAP^])-42C$* M=D9VF@H,4(V$VW*K4E*"M)4CET`1.R7HA<'Y-AJ%^9B':B_^TDA@\&&!Q.3T MG';E2(6]<8)>0GE2JM08OH3!M,Q6J2D[E1Y`&A+:41MBL07+6K5$4AM*!::9 M\F6[(Y")1+%RR]Q?0V1N\LA;&5M:'6&P(!2*@A,-:(&2G"0""&`+GK5K') MJ[ELMP1L)!0%>OR1@K!D^&R!07_`0U"R2[3-[T M-&*1GP2QJK*MJ#V0Q;VZJ,;#10+&5O%+IW?7!:S?H_2-C8))P,;J4K98'Z`+ M"<\@"=,0+LL1.2Y[B5R=KN=:].N/MR`I2"R_1F'MO:,3$CXY"B8(;E9R1!2, M8`CKUG+C*AXFHK8`D(2#C#G+<#36K%3N+TGQ;!9'Q6&COAIMM@5BD%#[&+%6 M@<96\4?WK!44,%30!@"Z?G-[T-2.(U+,E*X$8D0\A\3QI0W(V5?H!,) MG9*4C?J<%V"S5:O1[EWIJQ^]^EGF1[=IG,5O[)F-7J,XC*>?=^%(?OYJ=`7D M))12FBP2',O:(&V57W2_E2\?">7.!T?76QP5*1`TG[>B?D`DI_JKQL]<')2M MHHI.-_<->,H-7=@>Z$%"9Z7!-#&W):@:%U9L9?M^8DG`TK_]/8^".*F4)7E8 MS$E^V38>`VA!(CY.PBC!)FZ.T%:U10*[>8']0E,@-'IY@_U]$E-4:B#MAL#.3JIVL>0((SMEN)G'=R]/U,K\[$N_%)% MPF".,4R'O5MPD&",72E^;%E>ETJ/HGR3VOHJ:,\)0D*_I^`89H+%(2$\-E;W MM/(.*':L"QX!R]\^+$H+6N->)P2%R(I=06;*XB%`A3.ID$ M]"'T(_XL4&RIU6:<"D[-FG6W4@$(A)7&&B>G6^@"EW+K7&_(24`BUD+`%SD# MU^:/L'!7NB5DBWS^%O]?+(F'$8.?^+SEFR72'"#22'8JI+Q@NY3C0%(R[#BD M#>'8W_TH]Y//VS3->9TG.;^$C3E*$C$5NMR2H4!X14/1LS'Q2IHF^(WJ+:C5 MF5.!1!!%35Y*42&\W;'SCG9NL3M)]115%TZP3D6-:@)"6-A%-QR.M1#2\56> M!-'T@25!/'YZ!;*FY>]OXN2))>_!B,F]JDT&\HY.*5YB-_DLO@C5@8I(S$Z# MXY`E?^,'R5<_^8LM*@96@L"P-2_K`X"):/<,>*N)"F'CCBO?8$6TXRC-PPP$ M\H8)UZJ@%<"B&.^@P2P1#H0]W:PO$Z?95Y:]QN,R8Y,RS[JH/9#%J>*GT3XK M080PNIM*H#6_S^HI(E,FH)V`0!2O7'HL5\%"^-Y!'Z5UI`]^,DR*<*!Q(2$874S05#B`I`!E."N!7+!TE00%-Z0HC[N8= MG;EW[JU_#*B`(3DH.YFL:5WF_XCY!>>15S>7&@C03D`@]^[#=M;_-BR$[SO6 MDEE\B*_1Z)%QL2\3HS^]A8&L4H)&;R`911.\P9-;!Q\B$C24:_-R#Y6[S7D. MU]LD^)?PKJ?L`Y")N$09/]Z4J!!&&JO8**SMBAI!@^T:O8!$W56?*7$AK.^D M\Y3H0:/%?7E'(%3W=&PFT!`9Z&:)Z97`UWCG:?0&DG5/B6>,#Q&)G68I;^D\ M>,I?ED\:N8Y/UM$;#-PF/+=[+(BP(3+02;W?%F"ET@_IP6G3W=-`#@IA>#?+ M-F\J,DJ\\X`?-AY(6:_HR^G5Y4-`#QXB#MVLQ"S&7(I_#5F8=^24ZJ[*5PL; M4JZ$AB?;9>BGZ7#RIY\D?I0-DT)A5<[_-BH]!="WOKHK4(!DWE&=-[\V.H2_ M-+S?YO-?I:R^@OLJQE%A8XZR>^>U$@_"M4XFI5J/W/WJ9WG":]^).:WNQ"G4 M73N\$A?"^4[JZM;!+LJS/P+8\F$*&]6(,VZJ+PFR03@%NWM:&^-$)*63JCW$ M#;#07%CPG!2/`W0DD`_(LN>D%"HB,AW5!&[<;L]G<1YE]5Z`FWTYO;IW-32% MAXC#CEW\D+OA%S^([F*XY49/+,O"(K,EKK,5T;\]\2.(18^/T!NBXD;Y,ZN&`]N(4 MZJXE4PT,87TW'1>Y@GXKC](YWQ:GQ*/LMP/GUDRDUT'Z4P2Y'"ONP\44Z>Z31HH)X78G-?.UKU%+%9.^:[?U;W%^=%?SWQ8Y$/&D82E` M0"_S!LWST*:/;,0G/OXSR%Z#Z)Y]9,_?6/C.OL(&_(JGY+$R.J=C1RT,5@F` M"%(GK0]-GXLW<3)A099SGSS=-=*T1Y!$"'MI.6B*94J%]CRC&A1 M1+>^Q?G178^>MLB!B&$ MBT9!KAT\8S<_R;G37>-?RU1!9+:33O86+\.E#G,>D[#CEXGXV\"O#J;!W#5Y M$''>55DC&G+L^KG203?2MLF!R*6Q(:,BET#9WZJD!8!_S8G^[YN_7Z,Y^\AX M&90EZ;:H#A0,LB2.?AW%L_*S3_ELYB>?W/&1EQ:_6,^X46(_'V7!.X_C81D< M-3__IP/'LB`=A7$*FT21:7?)OD<6\N`1GOXSW;)?I>&&;JCW]]Q6,.N(I.L2$E&X:LO]62GW$9MR MA0_%O##SI*8K!6RZB$21"K+Q8)R@))1R;4MF7U[]T1R<_FEH?BCO85B MA$,TR<:^2>7M]SIRO&O6]IN(HY)0I=UP%6V/GSVM.+683X/SD8:>D^@"J$]3 M9&U\7ZY=V_M'6Y'+=F8`O'-;QX#Z>JA%3F0I&%N4.J,DZ5\P_Y[;8'XJR\(Z M29&ETNGL@,C(8NJGO5.U%0VSUWGMHMMHE#!H M=<7*?UV?.\UFY@T&;D."J2RHG9`965+?5X*%[KUB!FY3RE!9(E;)B2R%FJ9> M$LJNETW:S2-_EGDL?H\`9$63_1#Z*VUV09Q'3NOY;[C;R)RT,GJ:YV7:S;0X MG[\;5PBW-$;6D@4C\RYC'*Y8QI)9$!4##B7=LZH?7419DGTAP@Z`51TO#,<0R_]:E!$=.)X!! ME\\E!#108;,)Q^G4P0*G_3:/!!/O11@">8=TM\58=[,)6">8I9`)]Z*Y=<'7 M2,K*;[#%W?4\3?/9PG=IGIBUK8RZRH]RSO3'^G2,1FVU3D%+P1:=UN6):/48 MI'_=)(Q5JP>VL3GK?INSJS\V(X7`[X"0EF(T>B?WBSWB*G@/QBP:[U+N1=_F M['*:M["+R+R1ETW@.$BKF M2T`9A\&8J]*6N0#2X>323U]OPOA;^E`P]95EPSJHR*0T]L:R;=^Q0 M";R8EU*3N]80IDQ"&ZLF*[(L!6B^%W7I,1%MJ8`%:HWG\?>A\#RFI^\\UE!W M'O=&V[D03BWMY59C(`0-9:1RC:DP]$$_J*P26OH"E)&-C8JJK@T$!*2AQD-8 M*Q:$.AA;4[0YR>`(%_59'/W(VZACS1YL9++_X;Z`&7,&`ZMYYV$:V)^RW#UX6U1N5\HTSANM>5T()%K1,8E,5\Q+#^R-N[.268PH/$N MWN/QTJ(\XZ2S9.L? M+Y_#7_)@[$<\G+&;,DT\=^-@T!M/EQ;E79>0=G,W/K.DJ_=F*I<3$D\RXL*- M$1).0N'(= MXAG`C"VSA%[F6^'&I3?C]YL![+`W&/=#?MW]X3:[[46YX1G^PVT6=>^@D1G`"L/;=YO%H_^[Y3;+@Q!6 M:E*%K^QV8Z`$D>!BR[P52Q!*@#YXQ:Z#N_=G3.D8BW7A5"%QW4$9IL/?+3Q] M\(F=WR>4_K!K[3A^&J>#G$%BKHJ@6'*%S9P;](N;LF+?7K8!\+TK)B[9KC=Q M]\&[M,"D7+V55AP["8_.36Y(>+8V-VXKA0_.*,1N=VR.-:EC"TO M+_X#,=9*?K_(B22JY.P]"J( MAPAJS9P1)`(8OX]HWOU!GU^2;LB)+`;C:!`RKARU'<`V?`^P1!!>3ZF`?9J\L*5IL4M+U1:[9S+AVY8>KPJ[(C"PI8VMQ MKTXG]^>0BG,D8D9=+Q"KY$06@K&A6:0D8X(E<:M.A#NB);13R/:#CD M:W!-S&\9+K<)BQ"[\?Q^,(SP-";"=AP3"<]=&<4%IE<$!XEBG'(6/7^+M5BT M;,>AD=!4U6/1)@Y+^8(ZH0MRGO;BB(8/QF[.:%L$ZT-NI-K$V"KR4ZBKGE_] M:!%&%D?O+(5[>GO14*9SX'SKC\?%D?W\Z34)2B+-E)&CW%"+&DM[()J8P/8G M.$'[8[C=EM"6Z/4C19;&VL7UI8^,W]`*16)4Z$YR/WQF23O7CC;FR<6@/S[0 M+C;V^D2WE/RKTVOOQ@^2/_PP9^=IFL_6';-:LRHI/\J3O_4GP*N%5:%+P?;J M4^[2KY^'RL32DEZ<-B04J"C; MD'6LA&3)3D*`W1>UV"WLQ6E#0HU8B]TR2'VHT5"B_%*+W<)>G#8D='*UV"V# MU`L#1H'R;[78+>S%:4-"EU2+W3)(EM3T=AT2RFD_:?)/U060TJB0J\D\33R6 M]-LTGE!VW^ MZ,I3>*LM)P0)S8B,3C',_5.S9PO:<("3\ MRNONU3)4C9/@DV3SGT'V6GC;<\O(:_#V'%]'&2P,Y?9M.!(G(@EMF8S%FD*A MA=16ZGBGXG(1\V"LR560L!%\(KU\]8-DYD?*?5_>D9.(A#:M'FO%8J(%V58Z M=3**\SL-_U5A>TZ03M_K9:AL)1MWRN;UUVIA7T_/\^PU3H)_27` MIK#M+^)MDD?N1+;F3+/\8SK_J\:I8#0<)RO#2`:ROO-*$=Y8K?MU@T M?H05`VMEQ%DXU=]/Q-V!7$?D5,-U=A,I/%NIF0E)PR,;L](YKU@(QL<+TI\3 MC(0ZHJD\R/'9RF),4B!43NK2?IQ`)+3)]@2@BLM65F!"C"_OU!57=<-G1J4G M)Q()3;.==\8V,EMY"SK."\+^G@%%J9=`=A)..A-:A MQ@72%*2M'+"$MH<_X@SD7_FTP#MQTI!00S?=%`2@;*4I=1^MK!50,P_?.*!1 M`<:/SF$IL=B359ZI9T!V$7(':9-T9%N]O-.3 M?6=+9.&:H(Q#66L(4R9Q'5)25>%&4P'S(^YDT^/_](3$[4;$+`5;Q5!^Q)E$ M0`@2)YR"4VHC614.R8S+`I:0WP2%BVU2M0":(/D2'W<12_,9Y/(IK> M1G!787.PDB6(]@&R.#5<*CDF7H,*/'V("+F-,@:\R-3,W6@))'!J3ZK)4B&* M/L1ZG(]&">,(U)S<;.J=GCHU_M1DI1A&TT".LY*7$9MRD[33E!M?X-"_B^$6 M$#WYW,OF(>&[4?;Y$/JE=_4;/Z8DC-8;`.CF5-5?D_TFX/H0(\+QIAPP`\C7 M'_Q,RH/TE8,<3J[8BTH0I'V!3$Z?N`UD0`.7VR`1Y,[,I_38.17=C'T MUHRU!XA.7ZZ&K-/`THM8CX(B=2[1\HY`(:=OVIH+50>4K6@0]^58KE@2O`/, M=\8WJ&&T^G^9SA3MY`WVW2HR:C)=BIO.=Q4'DYW'!RX:?!Z#P: M7P5ASF^/<#(M7$[JJ/"QDV.I!];]N$1EWW!$[V!#;]H$V,JA_-I/>%J]Y> M-DFE?SW15%H'&@X+!',:%]'&JK5'%TN6B297;$2:%*#N\QE_.<2)ZBIC.@[0 MQ;T>VPIO!3)3CQ@]JBYRS[+RI" M*Q;%LR"RL!4(1@+:.`U[<+D9H.2PE!K+O5IF(WE[6:9C7D^GXB2^01?)KE%O M0*"J>WM+76$0;S!-"&')-N->O`I4P3M[8J,\"3*>/53'4Q+K!-0AX778A+>( M7E"!V9*YQKU$*!:91"P4/8%.[FT^+9Q31O!MF8E<:H_/X:D_WEH.]S&_KX4Y MC'4;K>G]X";7NE*YX9ST=)Y`:6SAJ630G7KXQ@ MXT-`,O?^>"T)@GA':8-^WXT>_)1$II$V6*BA'3]%U6:]THZ?.M6"H917:<=/ M47U5MZ(U&XKTQ:=X`$4X3(M?]0[.2&04:7_7V!DQ^Q!6@!SU_HPI`WQ478%( M)'*6M"X')N*W29X^Q"S8KU%S<$8BV8D>"Y$+K@H>`8V_3?;;K%ES<$9"T]:< M_1)XO='BVZ]AK[4#,I!(@MR$RP)`_8E^J*3;XG$^*]IHU#R1 M]@1"D5!$-N&\%L2VXB(<6$!G;V'\R5BQC0T+1$HI0/L`<4BD,&["?P4X6[4O M6KNG;;PP2@3XRM;LZ1WND5`6-KRUJ2':JF+A?F4WU'+=:52_L/4)(#T)Q6!G M5-$;E+-5DZ/S0GL^BW-IP@4KXP/1"6LCZPI1*X):)9BMZB$NW8%*+^UG_X-< M'LAE5JSAY":(_&@4^.$#GS^72;6;HTYW[W2COJ$+>*:9(8E48M(F+Z)U$*"B MX]U")D4DC3I\(F8IV"J&0L>KQ6&*2!KE]!2<0G0)"!R2T:(P099FP>B2G]@) MYGZ&-?5.:=2G4:\].0*W+AQZK$&7$=X8P+D/HD2)KF90%85;#PD%BX;%=.7J M%E%;[_38?4BCA.@2%FW#L.3)T,P"@C!J>8-?>3?+5!W*/D`>$CIOS8U/#<62 M'X+;W%Z++%;<"_W23Y)/>*%]\Y.Q[%Z)=P+"N`\(5'-.?`E1P>I#ZD4-^U!@'#NDS':EPY&2U9N?Z9!QD<4=EK/+Z-WN'8*M[B MWR*6\%+86F4:M<<`LKF/_:LK'88H>Y$)\GHR82.NX%P2C5>G?&2C.!H%85#R M+;MA@,T/^3F;PT0^UQK+Y*;YZ$!K]XG.:DN4+?RV'##L7OSQ[?3ZXRU(2JTP M8+B/0^QZ:3"$=^;6%;*6)-0#:OLDW,]+T]X7,X;2'>>IBQ+W9D+ M!#S4L!)(>GFG@SWG6F13X\"`A-E9254]F\``MP1WZCBV;!,8D+#5BIAE;!,8 MX)5Q.\7AQC:!`8EP$`6G]&T"`_29U:T8V25!9!HUO#$0@I:Q5G^M;F#H0R#H MUF7EGF4Z^9(DW8`XM(QY&VP3,UF-J`\QFULH\0O[0O%O(@7JT8"4),(&U.S6 M%!-=R+V)^]RB`+_2SG\WKTO`GT/P;\G3:'S!(C8)LG210XJ-JPTNX]1HI['P M.>`("6N.-2&T1I/>A*=ND6BM+A501*=PE_X@0#T2,1'6)$J!E&X`36 M).\L!5B\>%WNAVGQ+TPZ\%^"L,SS$(T7[5`+O_U/>:?[)!QL3.6H77I8,DY1 MB+7B24VM88OP)E+>IV8_GOW!X4P8CI<++4 M^\^/P/E5O%=&H?U]Y\I(4Z/0/@GELI*J>D:A?52U_%T;A?9)*IKWU?$_8B@_ MC$(1$()6\(^84_I&H7W4Y<5QH$@E!E)FYT';`C1:5@!T]2D@],/*4RT!6Y9K M7_U.=?]4]`4RN<]BCO,/NX!JH6IJ\R'T[)C[WB'7T!:Z;" M80*MJ5V%T#ZR\ME=<^Z]?/6C*;N-KB-XNQ0/>X7'M-$XWNF!^\`Y6`+11),!6"NXZA)EI_$*!@]S30IO!LI5]U&T]]Q=)1$KR5FM2+/`5* MI=PM]"F?S>"].)P\!=,HF`0C[IP\*HYIH,5#'`:C`*[!#IQJMF>AX5.#=_). M-K13NW3"D-'V&;AY`1__2^:1H34`0"01LZMB`N*J88#1DF>.RXS(_\7C`(CE M0BYWQ*5]7]N';:N'=[)16;D#_FLG;@L%:U%4X>14`?+#=VW3C>B$2-E>`;,4 M;!5#^>&[%@$A2/AL*S@E9B\&AZ3OVMP:P<^L.Y7OFJ@M0"-Q-5&O/@4$FGF. M8;(1#T"-LB1XR?GD^-0K=WZ,5^J>`-N]30/GAX!YNI@L91]H13&-8)@7V4JX M)C5AQO3QK#>\4;2 MI%T^;);UTK"I7WRN_47UDJTS'A#`_>JUPD3D^52?*'0>SRD;_3J-WW\;LZ`4 M+_AA4ZK@5]X=F_KA=90%&5:`1-`*P-((**G/J776HQCIO)5U&5HB0-_$FTT` MIE/;'4KY;09M3[L/*?PNX^0M3D!$_QX'4?8'D`KV-(VZT&@O;[!_XG1UBGF% MZ#*4."R]FRGXQ^IM4@H]I?X@0'<2J;6L[=)U2="';(%59$J%YW9C(`0)(X4I MZ]0"4,5GZ;WM]CQX#=CD^H.-B@JPP\DD&+%$?1[@O;QC&GFL,*8A!X,*4&_2 MXQ5(ES5*C1@N[@7T(6'Y6D\R>15Z-8:`282=@T])F'S MMQ2\U(*?9!67G"W;+0$;B8PT!KS!0%B+X;'/H:^!8KTL&P`4$MEC#/BQ,7<* M$2X63ZMEHF6CTTKJJ8*[]V=,^?#$N@!52"B,,7[I<'<3C:T@$=H-?2.@O9`#Q([N)Q?F`(2!60KP,/]H6W7'_+8;?:@UC9S!6);X1R= M]IL\=IL<2)-5R%)'X"",[58![B>6!"S]V\-BQ@5*Y78NZ>4=NTWSH^(:LH95 M@!!F=S*MSW(5E#6$5YF.=;=V43\@$PGM87O;.XX:$8XNEMY>PE/N\L+VWF#O MA-9.CW--S&X9+,2KHUM%M`':+([T]OFMMD"(4Q+Z9QF;L!N[&`O"5&,=&X6= M'=GR[C2J/*JZ>B-++ M/$G$#MOZG6%O)2$G>FQ%%#B:*!&A,%;74=@Z'I)XQ-@XO0%*KJFTV8M,(&3= M@$CD[&&FHJ#&APA!)SW-"DF_3=.?`-!LF#P&T]>LE-G;J)17S,="HRO` M)V'=J<-1,XP(BW=:2M76)9"]^<&BTN=]'(V4+P*L"Y"&A+FGV>5/A@UA>R=3 M<*^;0&\C$$669CQ/6:%(&\^#4_VIO-JE[B#>"3W?'>-'HB%:).C(6'DXYB'% M183BESP8E]D9G6L2@8+\G@A2]I`$([;\8SK_J^S-4&BD9G+]H*W`?6;);$F`%*#>,)_'@6I?433&`G*2 M,&O;NZEH@T9DJ&N.BFG&347O+,KEMY%*.VX9[/[Q(4"$L+1;(:U7K$@UDY;U MD31L5J+V0!`:">*:+6P<&<+J;KD=KN]<7_GFQ-,#R(L6X)V\P6"O\Q8I)3R$ M\[OR2T24C?.;ZO7'6U!F.T>XB#?F\#IK-E+"0KAFK$2TG>AQ^^K`+PK%\^,\ M7>DXAA.@Q)C;.?A?T%2==ET$RRF=IQK53]SEW MMBINF>D\+'\.\,K_-!84_9$YX3JK9+1+`R07SJ[\%A'A^;V8,7S[?/S.H6RZ M6&"BH>K'07=6;6B"$&%KMW*N;P@YG)"?(+SG,T51:EDW(,^@\RH>#8`(_YMD MF=ME>E"N&0^*XMN\+DQ9#V?*HJ)\Q\XRA)I.0C]):-V1O>/#/7LF?GP2JYEB MV3X-1X")NR_';(O^(G\`0TI\-TD]#]T7/S;ES3I[453?01K/0Z<*$93RVPS: MGG8?TGCN/+?CH?N$^LT6:UW0;@MI$,GF>$A9B8*R3BT`57QNTW9:R%IU2,X3 MMDI>P%1\M:@X4<5_CULZ&B\.SE%/3Z=:Z MB4ZYO8H[`$%(Z)YP9NDQMXK&4@9-I^Q]8!%7BJY@*F.?D1Y`$A*N`3*&B5DL M!60I(R<%?Z&')'YC<&CQ0CL9['<\5/R-;WX7G\_P;<4FKM';.SYRJEZTN*=K MH[65$-3M)H"AY5B5&[Y&;Z`5"6\Q;;8:2L4F4EOY22W?M=DX&/GA%7LO3*LI M;'.A(IFOI`L@)>$HI,T4T05=!8]&TE'<=82]QKR$_%3.Q:V&`(Z$OT\3WB&@ M;*4*;85C6H?3G20K28U1@"Q=5VW51FTKIRB!)S?S4P:X'SGGPGGDG>P5)FH/ M1'%?::X.'Y&W&8Z10JY19`\H9SU-6)&&ZRO@?PT_'\JP!6S%R_H`8*=Z,4M, MU<1I*VMH6XR=3Q;>GDDF\^04-@:('5&*:;)2#-!6@M!6CFA>,B6L3E[&16%C M`.E4U663BQ*`MC)_NC];*P7)AY,[!L\`QB%SMR+NESQE9439HCA!00YYPOX: MXP%1G>K/+)_-#6A@*VMH*]M#,='QTYL_DF_M91/O^+@C&C'-#;T*RU;6S\T- M8)>^=C=Y42`SB()9/BOOD?.-+KV)DPWQK.-H9R^C@)*%$A>\6N-X@X.]?6L+ M9Y6?THCF4A^\)F-R="1T('5X(EB>%FCQO3CF`5KW&A$+_%J7`AQI_[WU`*=3 MQ09.^VT>"2;NUF$/>PB9B*529UEO-$X?]\H-ZTNU.47ZX+2W`7&-'@M*7.7L M-GK^%O\OYB>R)Y?Q6)R.[G4MC61`_/"J2PE+WH$4'!WT20!?9?9$:SD:)ZE[ M%9!3X=JDA27?QTZ)UTV<)]:D:SD8)ZA[39%+X=HDA24WRVW9VJ4FXHF%;)2Q M\7_G?I*Q)/QIA>S[5T$,3Y8/A2-[)\8FK);ZLDH.I'\0-8@)J)1P/#DFX?LJ8I:"K6(H=#0&[DHSGIR0B)57<$K,7@P. M246#^,13:A04W0`P"9=3]9K41].'5_\\\9X\;+-L`J#=1U!K,4:\"M=Q].B! M_26)T_0AB2>![+Y7:044<&IK:6[9]EM!(\0=@<()I,*F*SH M"91R[S[:@.U:\"P%]=&I1O`GXQG0V?@<3@Y_NDR,5E!@F&<\71H/?].7DGH# M`G7=6W(:"$\3U):""#&9VJF:R@]9Q6T+]D\`^QQG?E@FVSW/LB1XR3-^V7V. M+WAX!DO3)S8MU7=MI*HJI@2S6)^5=![ZV:H:#.X=;V@%=JG>6)HLY[-Z9&]Q MPN=?T01=?,[_J-1RF8_F';M]/MMF(Z)&J4L8.BJTEG-@$7F$U^63VL7F&'^8 M]\G#YMCM4QREO,*_YAA_>7\?DK^(3W`*PDDI/I<4N%PY)#10L\^QTF5+1G8SFKMAH" M,A)9[_4XA$S?DG+*O=I9&-M?DIL1U7+:23]%AL8Y5^)A*G4H12Q26X&.\"*5Y=BCW;%NJTU;F M-(U%*ND%!**A,&JX7I40;266(BD#9KP'@I!()*;DF3:K2T2V,E&Y9_' MV>L-@0PTU$L-%[,(E:W,4A3<>4I\2K8"%32'Z9-8+'+R(D],%`\= MLV6#W>Z;GXPU$AZOM0/X-+2Q*&N0'7`;!!U;98,%.G??8N/+>,;3_LWYL,HL M=/&Y:C,/'BMHL2)(-.991^_]F3K#<1N?`V:0T!@+)`39%5HC0C_LL_'HKRIA M.%!E+GU)+R`-#7UU:VS'C+<*DE@RW;I_5>VZQ-4)C>JOID>8*4*WUF#[HE&G MGM6)VPCQNJQ3"T`5GR7+LEVS?W6R"F/R5DOOA%YYWBK!199D!`0!"[*E*-+7 M@$VN/^8EQ(>323!BB?)FT<+U_WP$!UI:V#$56S32`PC3 M2=66%(XM@[73A2Q"R'],F'K75O8%.I%0V>@UBL-X^GD7CA21+NJNWLD^"2V8)HL$-VYMD+8*(;G?RC=W/K5Y M'>D!A"&A'C/6E,C@V"J5Y-;"N8U0;3C'^@!=2"K$UMBFS>DJ)EO5BRCQ6FW' M%K4'>M!0B,D9IL7E*B);=8\HN'YNP+S3B;U"N@!Q2&C'&N[<&W@09AOKPB@P MN_*HO(\SEC[XGPK/1J2'!S="BKS>X)WR:2W`A/"[B8ILI_[!7)<[+*:?6DFS M5!U0E35)U-8[.W)+!6L>TI(\5&6*(=5'=9).F8WD'9V=6GO5Z7]>6I/-#3<:MN.1O4'HV<8,8,6FU,9NF.4^T*M=J"QL#.!)O)!')!1<7"89>U>[B*&[A/?'!QL\Q1\N2 MM'2HT5!:ZW0'FKG/DFUQO]7';,GIU^D^K$*KW)_U!@""D?`\T6=N/>&HHK7D M(NS64W3V%L:?K+JLE,IQM`^0A82#B@D3Q6*@@&C)1[C9`:+.(Z[:*F7:\=IC M`87REJ MZYT<'%I;J-4/K.C\#'2Z@&'^TIF7H!M,T?UM#:>=8(UI`;*D4=QT+$&D^=]_ MX]-\\5-6T/'_!U!+`P04````"`"YBW]$QZ=N$R,?``!<=P$`$0`<`'!O'-D550)``--WCE33=XY4W5X"P`!!"4.```$.0$``.Q=X7/; MMI+__F;>_X#SS=RT,Z?8LI.VSC7OC6S1B5YE297DM)F;FS_WP(D)5`D0)"24[3'+XE%`HO=_2V`Q6()_/CWY[6/GC")O#!X=]9]=7&& M<."$KA!YC8%+OH<8OZ-K7GQ'8^1UE] MU'W5??4&P1]7W&TC:I,EIB-[C:.-[>!W9RM*-V_/SUF]31AYE(0! MJW4.;5QU+Z^ZP+>/USB@=R%9]_'"CGWZ[NRWV/:]A8?=,P2"!M%;J.OH$..E M\(0C6EXE>5=2*;`])RJOPU^Q*MU\E2<<7P.A3I0"A//V=6KKI16@#$$H1_M M(`AA<(%!B?]F3S8;+UB$Z4]XP.S[+6-X#M41^^-A.I`/#5RT?NC$;(SI!:X5 M4(]N!T"2K'E#9\@#[2A+[!K/FG?QP@L\SF;WH@O#8E9=_!-(H806$HC]>'Y( MX:]_.20?1]@=!W_C?P.`$5#C==FHD=9/BZCK[ANI6].Q?2?VI8VFU4]X`#[E&A=QK55;C?1K%=*S.?QW;XT` MY?$=&D^L:6\^@`*H-^I#R?O)U/I@C6:#CQ8:C."WU8)?"_SQ8D9#Y_,J]%U8 M"UB_Q3!;@1/N.1Y5@*ZJI0;[C1;8#.O9?'S[TX?QL&]-9__VKU?7_X&LGQ\& M\T_HF[YU-[@=S-M^7KN?W]K1ZLX/OY3,J.7%U&!^I]]S;WNS#^AN./ZEG6.; MHU8QUVK44>/Y?1,\V]E7>Q&"(X=X&];F>'$31UZ`(S9ESN+UVB9;&%2]9>#! M*&K#,L3A2VTO6$X`7L?#:9<]DH8:_Q_8ZL6+'#^,8H+9#VMV.QU,V(S+0+]Y MF`U&UBR9?&]Z2<^5`_>CP8P)O=@Y.[=WHX?1O/!Z#V:@.W<#JRVQTLM MXGT(X$`7=C!)EZ&Y)VJTK@_1>C]F6H=.>VM-1ZW294KO.>"O1%[2A>XS/Z?P M5*G\[L6A\GNWX)W,!EE7N1_,6P1D"(QALB"]*-HM[<4':KUW#_4^GG^PIJ@W MF[7+=X7&!\$3"!J2W3PB/E!K_/)0XX/11_`"QM-V9%#W)D_4*KI!JMU\6I@;M$,S3I?>K=#"V.&CR8]#%_ERU?#Y^J<7ESB,OMPVP^OH?9HV]-QC!UMP"HEJ9/,&AY MT"7Z^!%D!@WN@P@EK]10?%>`8@R3RG0^8+VC;]W`8/8P;3N$'(]12+$X1KE/ M+,H>W9%P/<4^"P;`HGP_JND75^/V_2%NH_'<.AC7^A]9:'Z&[J;C>S2UACQX M,.E-VQ%.%]!;>^-1VQ]BGGAPB%_NK1JNPGH^#Q=TN]YD,.\-T=#JS=K(N12< M8K`[@:7DN1J0PI)=%N1NL9`[UGB!"6'13E!^YE+GGBDQN"RLW"=3Z\Z:3GF( M$]!H5:] MJ+5>6+X/QS.8`D#QLP^]:3OH*T(F;.]Z;C_O0R;[!VJ=%];KR=8TFO=^;>U< MKO&?)KZ=AL&3/]5:+JRS7U]TO_GI6S09]MKHMU3)@K^_G1,[B&R'IVXD>I>^ M54-16%J+?O\G-)_V1K/>+4_<:)&1K['7:X_R_5N>1\-W[G"PW_M3%5#C4[+> MOK\?S)/=W"23AF_96:-VOTZY$,`^=J!__!Q#!\'$W]YY`:RD/=MG2?7IHD!= M1@U488$]LX;6+>M)/S]`5[*FPT_H;C""%?8`EFW]WKS7@B4':\G[2@9+^DL- M0&')/+/>\V[2ZEFJY_@QPK_%(*SU).C[\*E:[\65\"OLG:;Y.07LA8YBP">1)322FI#:40,CB5H22MMV:B MG20C`B]YIX:R$(FZ;0HMPX7T$&:DD9-8;%W`5&#:7D6`=-*").LD6L01*#B)7TK1HE[82& M%J!:V[PB-"7/E:"\+H17\EN^+11U]G[SRZS#QVH@"N$+<1^XA>&8';&\UU=5 M3`U3(32AW!UK<3MRFRPW[>B45*-7B&54;IFU"&KOG>6QRCU3HU*(9&3[:*WR M7SA$WW-=+JGM"X<.]3&U/?\4<7L5>;5)%"(C`B,H7*",%60'+DJ98<\%=M"> M'Y0QQ$(L.Y[$@Y;0-PE;K:4IU@3$]I8K"G7Q^`D3*Z+>FJVV'R*\B'W1:O2* MJBV@$&3)B'88510"680SNBCFA%L4*U&TUH_8=;&;1+\BWA^)]P1,/&$A?'D/ M"V50NPM=?8J=D$"-'KVS/?+1]F,\#N!A3`ATK1L[\B(1^Y=L0&TQA4A.Q@K: M\X+VS""!&Y2QP\>3C"%D4\180IPG=N3ECBO$V6KM32.%T`G!1_,].YE#=C[; M((@HX6??1:P,#-O_G3,!T::.):*VFT+T*-\AB_V\7]*XOMH8"D$JH27TQ)M" MS/=8(KK"B#?8F24MHC!Q3S9)FVC-&FUMH=;!)I4.J6YA)E8#6J:`&M1!!$TBS09QEC;3(-D9VM^1CQXAY;GJ,(T_\3SZHRZT` M-`NK$2T$VX257HXP$BBW4.I#N7.4HO$B.5('_''!+X9GX.N4(UNOKAKH8EQN M#_3>KXK8SZ0I[J>+#GS:6@O^R<'/G=AWC"64$5*;13$PV-@L\N<.MF92Y]RM MRCE_M:#6/0ZLUV6CL"V++\W6ITZ]920OQ=(9`DT$?[!EJWO-WK'BP$X_#P=6!:-J$]";0&%J%,^1B$:`^7#>-JBN#T-17>-MA;1K.>/ M8\IN/F-WVE7V]V)9-<;%I*_R7B[0;6$\7?)_Y:!^$DIJ$RA$J/(IYMP_2YM% M"V@7I0VCM.5V!FAN*'GK55&C73PE22"> M?G7$FVA[^A$8[]*!,0L'W^0/64U2<7H.]9[XW6\E"S/]>FJTBT%P[E^LTQ-2649+8)33+ MQG2^HYBTG`[TO.V#)*_46-+VT7V;Y%4WBK->AX'NN%!56HGY]X7H7"XVPRBW M(\"Q>/YB$\(__DA4=V/S9@7FJ?H5SKO^L75L!8O MLCIPVUI_O3&DN:/X]=)[=$JK`2U$UI($GXQPBV=S/-E%ZC%-'6CV:9+3"]R^ MY\<4N^*1$/F=D5IUU-@6[\O:4^??:S+Z/)22MH!8$PC:0+R1%N/J[)2`>BY3 MGO>$9^P[-!Z,'H5T$#A^[&)W$.0@'6$J@_XTI-0648BRB8VB?:LL_(JR=I$7 M'%H.M-W:RA%GDE2.[IIEU6@7HFP)5<3)MB/[<2-[F'T>TT\=(-!JDA9[.)Y7 MEE2C6(B>"329-YU19;!FB;DMA%H0!FPM.5[L.EOJ]=S@`&2A!1RUBJO!+&:? M[0@S+/<=-//`4$J]A53O]IG*D;6RE!+`'PK1*W9GS>=O$:/:#JG-P9/=6U.) M9Y.*:H@+H2HQ:V2+Q$9:Q(\:@66'?FDDC#:JJ\:])*%LUPI?)>7:::%O#GTN MB6#*9/:SO?N[D(PW_`/28,GW_.79!YH5U:`7`EH'>0=)(_O4`H`9[=I)LA): M=^O8`^5R06B=DFI,BU\HIC31CJAP>`@CVR)8C:#-MWFS'A;R$\?F(72.]!M# M2HGW&%.6KS4/LZ/`LB/G<@B?@I+:`@J1+][FOXL]-TS/*>,-9^LFL6E$P_V) M9EGKK:'4ODVJ.K&H1@4U[,7CR7:D44*[G;6/`':_X2^>.9T]44-3GO&5[O%' MK=)UE*Z7HJ=16`U5,5U+A*KM09+Y9.G'NG_(^6S M?Q[!_Y[B!7KF3R@4>W<6>>N-C\_29RN"%^_.``NGI>7G7_"4*_>E[[ M61'60@ZYYT?BOPK)\OSRXN(J@>Y03VG#&0F;.`4J7ZXXC>[U]?4Y+P5$^$?@ ML'H\SY@_0^[/Q M8$#GO^%7$(2)P:>"_PABA82BP%[C:&,[*I:]@*7X.$`^G#,CZUQT@6EIP[S1THKGV*=1]J2S)U5+_@@[KY;A$QC!$XZH M-D,EU=*_CV6$?]1+MK4Y$>ME/X[F)28$!PXG>EF+&;'B[E=G3Z81._C96=76 MRZX2_^M8C02VYT2,7+<.#_M:R9^=/8%&7$2>4YN'K`[[X^CVZ8;49R"KQ/]J MP,+A$'2=3#8!7K(M#[V1RRQ5[O+9G78'PTZ;$XTEY)SYNF($FZFB3?*FO3>PC,O6`XH7K/%U!FRTU+OSBB)F:_*2X%WZ(7NG-=S MX^0+[/0J)9V2B&RAZ-V=OW)(PW62,>D$^6M2.8E`N6_#=ZO; M.7ZF-W[H?,Z$`N0`\KUXFV,+VHQ>2K))+B73)YVZS?#KV/5X_8G(@F1NN M;2_XNG@IN9-)),:3(0E?B]@UV*,%]DE&1&_K&1KFADV MXERBA=YBP4_7QZX54)X%:J;,&GS*3!6&9#?VV:?IZ6E\+&N'BH?['5R*,F0G MS//KCDS3PHEDJ=943)P5V^1FWU;BGN^G$YKI2M%D6R(_BZ3N+Y5X@(?@`K`[ M)=A8SY:!MWSU=3#0K4/P/FVRK25U$O"@1:&3HH^VS\(AH!W\Z%%]5>A+(%%! M?A*XC=<\]O0$L]V3Y^+`G8)E33#I, MFF7.='<$Z[+9H$"'=YVO+JI+WZZVS*;B1SPXF`AD+$I$NK>#E4W!T`912&', MG&-G%81^N-P.?<<8'TR+RTH+?I$+GTRT]Q<65*+HQG9[`C]#KI<#1P-XR,LK9%]]?4\(&:YIREB4RLB3/<3##E":/QPOA=/A"[S(+S6K>97:+ MV86L,!V!/V0O\2AF+B/_U#O]RIM_KRL>MWO0,_GKK[QR;\*T=.5R<'>9,3.% MG#--48R;$B0,2L2Q;!(`@NFW%),D4`!H\V_9DT\?CXTD'`^2%I/ZFS%1%HDZ M"$3UDG@,XW``](,E.[8ZR4(W-ZAT*OGTU;?[Y(KFKI:;8B@!`^JM':VR3W,, MM:<7$:J&_4D:$Q8K7]'>ZDZ"304ZVL#`M?`RY$7M+#]AFQAK02+7LLA^U1V0 MYDR7-5AM*JQQ$ZHNQW4,/.*^8S*V\"VS[<'NB#&('\E^E15H7HEHCCZ:F]/*/2[AJEYS7,X*]BKSQ;):6_-<1RF/^D(9M)FEYJ[2^,IN-C;1"M5\ M2C,0(FS#>"3VU3O;V>6"&#*4Z+&IFZVFO/'81&CK\:W.4U,2,6XHJL'T$6(; M-%C59+?2Y+6N@S;1YFLR+MV[Y[5--G$IB[+/?F+'A\%PLK+)&IQJ+Z*S;<2L MP9C1NI)#65=E9TK%T00;)Y&4,VVS,VB(43)7/:!HGKMOY)A2F_=*AY=M@H-$ MNZH'5&^VR;4MM[X=F3?T'"7&255C4/"&O^ZEGWS;$['J<]Q,]'[ M.`CY379_(.%+>:Y>@!QWK6F.?Z##I$2^_><8Z6W?\S"Y MT'7`SW,YT4[/2R6::G$OW6+=;)('MI_>9S:(HCBQF"#`_.#P7SRZ$@\N/]&& MPXLEHQXAE.P;"*C.>('YB&LVN_KMD&#R=KP`"V3CEL%&TU@BZ4$(@6-'*_&X M^5V@Z"%P,1%O7C?9>&H*(A]1]@DQ=S`_[?<>3!9>R;8B-7\_!"5_4=;7LH^. M>.)#DA&==$.3-=!$&N6L0EDJ*5"%YS!3FQ[[:<)S'?'9\5_&>`R5'-:4[,IX MR:YJ.$*E-.9AZF8E/<`P@>LS7@=ABWWTL4]Q-DQV/68E\CX$9.\*F;3I)&-, MNI5FI!3E;&F$^4J`%3XJ,F?::,)SI?AL+9-MP60ST-`S<=9LPK-TJ>VP+_\% M-8I)4>9%+W78E9[9$JZ]*`K)EM>(Y'#5\0',.[Z@R^ ME%`27C!O6).Q6.UW;(T9Q\J8DO#_$0=N2(SA/,^.;$/CF4(Q[.X_(S.&?SEK M.OZW.194SI9RD^##/^+`"XG@$!A]>J@NN[)L"?C;Y;EPS][7WS:%`%X;Y!N]*&V-5$KZDAYB"]V">$.5L261@G[;= MV^0SINDA2LF&/.\]!WX;#[V,JEUL+G02 M_NK%=!42=@S8T:>I'`V1FCN%2[WW2E67B)GE2M?E^6CQC7.M:[,N4<$_["!F M_3#=QS1F\)3PI;AF]>NC!)!MJ>,X"A?FN`4'_,C. MK?7,X5C@138ULKS!\2+-?AB3*=LVR9)%)IP9`\X;T^)2)VNXUC7T)O:PYC)( M?3TI0>&F#-,FT3IPH0>B9JY!%JY?& MR%'"TS&&:)`/4)=?V:&7+*+>6Q+,']X#F96_3<\3,WA31,VV2M:TT`Q$H7UA M;R-IQH4G7WERD7`E6^Y[0;H-DE8Q0@8)5RH)9>L&2)W/S3J,>8\CW7,-NPF^%ETCT-G,>/$D-G1C-G.[F<+=E&DNUZ MX89]M`?F`*2AHCF2J)B3;FS8V?:P,6*4\%3=[823[H3\%O8-_(#=1VW[^_L] MQHML\6]FUSM6%(FRYB&U?6-`SG$CO=G@4-S`G#B2BCE=>>9?0G/E$9C3EF<% M#I?!$HGLZ10[Q-PLCOOBK68;*>?-9Z MXX=;3-C023"/%)-MKE"26?K[)YO^7WE7U*,V#(-_TO[`7@YN=[II6T\WMDE[ M8Q`@4FFFM,#UWR].4E*@;I+2@F%O"-KRV742Q[$_GRU`)\6P&]1%,V8L00UB M#OH&!=K&B2`].7^8;V&+XZIECJAIKR=]!\BQPC])WW+!?2&^6(!=`=;MK\+BCD.FVFZQI#/:D^>0[#:6<`5NS]U MAQZFC*+QB;8G=]4T2>_0LGE2K&HQ#"HZZ2#!&78R7DVSI;H`DDW-4]-4[.JM M&,DH)AI_IX)%0I-",%`TC+)FZH]F8[`<65++^&^$A^4:K#A;?'I7"@%[2!8+ M/H-V\W/]_3Y"8;\G$YSLA-JW;I',K6A'%V:?9$HZ$%P>*1)],1G;:X:%E778 MS9GMBJ<\U1_*Y]*S#W7J+"]T[+5MV$0-S"KF9(!4VRG?ZS8'Y5W M+6<\[Z$LL"`_.T)0]T1#AW30!7TBI\!ZIG\Y.V!\]A%* M=^!8)KW(\R2#QWYG16%^(EPOWPPWOC200-%\&SB\/@HN=J0TS:4;$[4EN?"D MAR##-J+UFH&QNK5<"+F;RGE^^(!O(B60R!*%UM,_ZXW-&-\"BE>1\EE)+=H0 M@-,;8*D:/8!+I(-0#Z"L>IVY.YR`=J;FNR1CQ.,OO_WJ<,FR?`QN%EO]'Y.1R6AZ8ID*XCP M5<>N9,=A-'"O)0'WDO:YZ_/9PN4C4(^81^,/:I#PR-1V1AGA2RTSP_GDE-FF M(N6(W#R-N50VF.O4M2K5"_BM['&OW8\\3LLC%5727CPO]7PQT)I)>^)F#^.> MI%C7HT1T,\_\R'$JZ"T']2DW8-\@NL=,NZ&&A`X#[E_K*4=GL[[A=9R.]T36VR+U* M@])294+JJC)#V.UB72_99\&SXB9S/@*4U BP$E2%S80G76BRBDOK:/6?E"\MFHLM_[&! M]Q@AHF8VQ^U5)7I`WJJA+P#C]^6=2NP6N MM6JISMWT&<#UJ7R'D^QBJ@2Q^]7J4(MOSU)B;G_MP.DT=GS]E'D?/LS7J!-. MFSP-?)[#P%YB8%1^6_Y70\,3,KA-6S\XI?,1&NJJ,T=*SM( MX('T[EJ>_1]JCY2W+27E!(5UA$;E6,U%2T&OXB8*-AH-/8PF4R*9/<5VWOLC MDXH+XHERFM)J,WF,R&]TA/+XFU&A%)[0BIN.ZH_P!'<^(Z3_5G`8Y]]. M_&920);"3@`O!YD7@B(+:R=1(Q.'I"HZAA:(TWLXJX]Y*WH`8@M/&\JVXB1S M(:$AU8S*F\"CC]HYJ(+:2U6DN7*PC.,^6!V44.C%$\YE&$AD17W*"&CQ]RI`Q0````(`+F+?T18FQA7+'8!`.F<&``1`!@```````$```"D@0`` M``!P;W-C+3(P,3,Q,C,Q+GAM;%54!0`#3=XY4W5X"P`!!"4.```$.0$``%!+ M`0(>`Q0````(`+F+?T2NPA*@91```&'\```5`!@```````$```"D@7=V`0!P M;W-C+3(P,3,Q,C,Q7V-A;"YX;6Q55`4``TW>.5-U>`L``00E#@``!#D!``!0 M2P$"'@,4````"`"YBW]$,N5"2+=U``!PF@<`%0`8```````!````I($KAP$` M<&]S8RTR,#$S,3(S,5]D968N>&UL550%``--WCE3=7@+``$$)0X```0Y`0`` M4$L!`AX#%`````@`N8M_1&C`Q0````(`+F+?T0TR;E(WH4``//W"``5`!@```````$```"D@2R@ M`@!P;W-C+3(P,3,Q,C,Q7W!R92YX;6Q55`4``TW>.5-U>`L``00E#@``!#D! M``!02P$"'@,4````"`"YBW]$QZ=N$R,?``!<=P$`$0`8```````!````I(%9 M)@,`<&]S8RTR,#$S,3(S,2YX.5-U>`L``00E#@``!#D!``!0 52P4&``````8`!@`:`@``QT4#```` ` end XML 24 R79.htm IDEA: XBRL DOCUMENT v2.4.0.8
401(k) Plan - Additional Information (Detail)
 12 Months Ended
Dec. 31, 2013
Benefit Plan [Line Items]  
Defined contribution plan description All of the Company’s employees who are United States citizens, at least 21 years of age and have completed at least one quarter of service with the Company.
Defined contribution plan employer discretionary contribution percent 25.00%
Defined contribution plan employee contribution percent 6.00%

XML 25 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; word-wrap: break-word; } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 26 R73.htm IDEA: XBRL DOCUMENT v2.4.0.8
Other Expenses - Additional Information (Detail) (USD $)
 12 Months Ended
Dec. 31, 2013
Dec. 31, 2012
Other Expenses [Line Items]    
Nonoperating Income (Expense), Total $ (3,766,000) $ (3,233,000)
Interest Expense, Total 2,137,000 1,753,000
Accretion expense (1,970,000) (1,628,000)
Gain (Loss) on Disposition of Property Plant Equipment 0 (18,000)
Gains (Losses) on Extinguishment of Debt 0 (282,000)
Debt Modification Expenses 821,000 432,000
Other expense (143,000) (22,000)
Derivative, Gain on Derivative $ 665,000 $ 726,000
XML 27 R57.htm IDEA: XBRL DOCUMENT v2.4.0.8
Accounts Payable and Accrued Liabilities (Detail) (USD $)
In Thousands, unless otherwise specified
Dec. 31, 2013
Dec. 31, 2012
Accounts Payable and Accrued Liabilities [Line Items]    
Trade accounts payable $ 849 $ 1,127
Accrued royalties 87 87
Accrued interest 278 154
Sales taxes payable 89 78
Accrued compensation 70 80
Other accrued expenses 28 108
Total $ 1,401 $ 1,634
XML 28 R76.htm IDEA: XBRL DOCUMENT v2.4.0.8
Income Taxes - Additional Information (Detail) (USD $)
 12 Months Ended
Dec. 31, 2013
Dec. 31, 2012
Income Tax Disclosure [Line Items]    
Operating Loss Carryforwards $ 55,340,000  
Operating Loss Carryforwards, Limitations on Use than 50% ownership changes that occurred in the Company may significantly limit the Company’s ability to utilize its NOL carry forwards to reduce future taxable income and related tax liabilities  
Equity Method Investment, Ownership Percentage 5.00%  
Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent 34.00% 34.00%
Operating Loss Carryforwards Expiration Dates 2033  
XML 29 R81.htm IDEA: XBRL DOCUMENT v2.4.0.8
Commitments and Contingencies - Additional Information (Detail) (USD $)
 0 Months Ended 1 Months Ended 12 Months Ended 0 Months Ended
Jul. 07, 2011
Apr. 19, 2010
Dec. 31, 2013
Dec. 31, 2012
Jul. 07, 2011
Medical Device Assembly
Jul. 07, 2011
Warehousing
Jun. 08, 2012
Pending Litigation
Dec. 05, 2011
MIT
Commitments and Contingencies Disclosure [Line Items]                
Rent expense   $ 1,800 $ 84,011 $ 69,512        
Monthly payment for operating lease agreement         $ 5,083 $ 5,287 $ 5,000 $ 1,475
Start date of operating lease agreement         Dec. 01, 2011 Dec. 01, 2013    
Final date of operating lease agreement         Nov. 13, 2013 Nov. 30, 2016    
Operating leases description   2014            
Leased space 9,761 square feet           85,525.98 plus interest at the rate of 8%  
XML 30 R77.htm IDEA: XBRL DOCUMENT v2.4.0.8
Composition Of Deferred Tax Assets (Detail) (USD $)
In Thousands, unless otherwise specified
Dec. 31, 2013
Dec. 31, 2012
Deferred Tax Assets, Net [Abstract]    
Domestic net operating losses $ 18,816 $ 19,529
Stock option compensation 223 606
Book/tax differences in fixed assets 27 32
Accrued liabilities and reserves 327 272
Deferred Tax Assets, Gross, Total 19,393 20,439
Valuation allowance (19,393) (20,439)
Total deferred tax assets $ 0 $ 0
XML 31 R71.htm IDEA: XBRL DOCUMENT v2.4.0.8
Summary Of Outstanding Common Stock Warrants (Detail) (USD $)
 12 Months Ended
Dec. 31, 2013
Warrant One
  
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]  
Number of Common Stock Equivalents 4,000,000
Expiration Date    [1]
Remaining ContractualLife (Years) 0 years
Exercise Price $ 0.02
Warrant Two
  
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]  
Number of Common Stock Equivalents 118,500,000
Expiration Date (b) [2]
Remaining ContractualLife (Years) 1 year
Exercise Price $ 0.01
[1] Warrants expire six months after the date on which a registration statement is filed and accepted by the Securities Exchange Commission permitting a sale of the shares issuable upon exercise of the warrant.
[2] Warrants were originally set to expire on December 31, 2013, but were extended by the Company through December 31, 2014.
XML 32 R25.htm IDEA: XBRL DOCUMENT v2.4.0.8
RELATED PARTY TRANSACTIONS
 12 Months Ended
Dec. 31, 2013
Related Party Transactions [Abstract]  
RELATED PARTY TRANSACTIONS
18.
RELATED PARTY TRANSACTIONS
 
2013
 
On January 31, 2013 the Company accepted a non-interest bearing $250,000 advance from its CEO.  At the time, the Company issued no shares or warrants in connection with this transaction.
 
On February 27, 2013 the Company accepted a non-interest bearing $250,000 advance from its CFO.  At the time, the Company issued no shares or warrants in connection with this transaction.
 
On March 25, 2013 the Company accepted a non-interest bearing $100,000 advance from its CEO.  At the time, the Company issued no shares or warrants in connection with this transaction.
 
During June 2013 the Company accepted a non-interest bearing $185,000 advance from its CEO.  At the time, the Company issued no shares or warrants in connection with this transaction.
 
On April 4, 2013 the Company accepted a non-interest bearing $150,000 advance from its CFO.  At the time, the Company issued no shares or warrants in connection with this transaction.
 
On April 11, 2013, the Company converted certain advances from its CEO and CFO in the amounts of $ 500,000 and $ 250,000, respectively, into Series H preferred shares (see note 15).
 
On May 22, 2013 the Company accepted a non-interest bearing $150,000 advance from its CFO.  At the time, the Company issued no shares or warrants in connection with this transaction.
 
On June 21, 2013 the Company accepted a non-interest bearing $100,000 advance from its CFO.  At the time, the Company issued no shares or warrants in connection with this transaction.
 
On August 16, 2013 the Company accepted a non-interest bearing $250,000 advance from its CFO.  At the time, the Company issued no shares or warrants in connection with this transaction.
 
On August 26, 2013 the Company accepted a non-interest bearing $250,000 advance from its CEO.  At the time, the Company issued no shares or warrants in connection with this transaction.
 
On November 2, 2013 the Company accepted a non-interest bearing $100,000 advance from its CEO.  At the time, the Company issued no shares or warrants in connection with this transaction.
 
On November 7, 2013, the Company converted certain advances from its CEO in the amount of $ 500,000, into Series H preferred shares (see note 15).
 
During 2013, the Company paid $201,000 in deposits to the joint venture partner, Neusoft, for Attrius® Systems.
 
On January 3, 2014 the related party debt holders agreed to convert certain convertible debt issued in 2012. The CEO and CFO agreed to convert a portion of their outstanding debt in the amount of $1,000,000  and $300,000, respectively, pending reverse split authorization and/or approval of additional authorized shares. Remaining convertible debt originally due December 31, 2013 due to the CEO and CFO in the amount of $400,000 and $50,000, respectively, was extended through December 31, 2014. Warrants associated with this debt issued in 2012 were also extended through December 31, 2014. 
 
2012
 
On January 12, 2012, the Company acquired a building in Westmont, Illinois, which the Company previously leased from its Chief Executive Officer (Lender or Related Party) for corporate and administrative offices since 2010. The Company issued the Chief Executive Officer 25,000,000 shares of common stock, which were valued at approximately $250,000 and a convertible debenture of $250,000, which shall be due on December 31, 2013 and bear interest at 8% per year payable quarterly in cash. In addition, the Company issued 35,000,000 warrants (“Warrants”), which entitle the Related Party to purchase shares of the Company’s common stock, par value $0.01 per share, at an exercise price of $0.01 per share and expiring on December 31, 2013. The Lender is entitled to convert the accrued interest and principal of the Convertible Debentures into common stock of the Company at a conversion price equal to 55% of the lowest daily volume weighted average price for the three trading days preceding conversion. During the twelve months ended December 31, 2012, the Company issued 18,181,818 shares of Common Stock for repayment of $100,000 of these Convertible Debentures. During the year ended December 31, 2012, the Company expensed $77,000 of deferred rent.
 
During the year ended December 31, 2012, the Company recognized cost of revenues of approximately $623,000 related to the purchase of Attrius® PET Systems from Neusoft, the joint venture partner.
  
During the year ended December 31, 2012 the Company issued additional convertible debt to its Chief Executive Officer (“Lender”) in the amount of $1,320,000. The debt is non-interest bearing and matures on December 31, 2013. In connection with the this debt, the Company issued warrants (“Warrants”) to purchase 37,500,000 shares of the Company’s Common Stock, at an exercise price of $0.01 per share expiring on December 31, 2013. The lender is entitled to convert the accrued interest and principal of the Convertible Debentures into common stock of the Company at a conversion price equal to 55% of the lowest daily volume weighted average price for the three trading days preceding conversion.
 
During September and December 2012, the Company issued two non-interest bearing convertible debentures totaling $380,000 to it Chief Financial Officer (“Lender” or “CFO”). In connection with this debt, the Company issued to the CFO warrants to purchase 10,500,000 shares of the Company’s Common Stock, at an exercise price of $0.01 per share expiring on December 31, 2013. The Lender is entitled to convert the accrued interest and principal of the Convertible Debentures into common stock of the Company at a conversion price equal to 55% of the lowest daily volume weighted average price for the three trading days preceding conversion. These debentures are noninterest bearing. As of December 31, 2012, the Company all of the $380,000 debt was outstanding.
 
In September of 2012, the Company received an unsecured advance of $25,000 from a related party, which accrues interest at 8% per annum. This note was fully repaid as of December 31, 2012.
XML 33 R50.htm IDEA: XBRL DOCUMENT v2.4.0.8
Going Concern - Additional Information (Detail) (USD $)
 12 Months Ended
Dec. 31, 2013
Dec. 31, 2012
Dec. 31, 2011
Going Concern [Line Items]      
Accumulated deficit $ 123,432,000 $ 116,328,000  
Total stockholders' deficit (11,241,000) (6,190,000)  
Cash and cash equivalents 1,744,000 243,000 1,000
Accounts payable, trade and accrued liabilities 1,401,000 1,634,000  
Working capital balance 12,084,000    
Due to related parties 2,285,000    
Proceeds from issuance of debt $ 2,520,000    
XML 34 R42.htm IDEA: XBRL DOCUMENT v2.4.0.8
COMMITMENTS AND CONTINGENCIES (Tables)
 12 Months Ended
Dec. 31, 2013
Commitments and Contingencies Disclosure [Abstract]  
Schedule Of Future Minimum Rental Payments For Operating Leases
Future minimum rental commitments under non-cancellable facilities operating leases as of December 31, 2013 are as follows:
 
Year Ending December 31,
 
 
 
 
2014
 
$
72,444
 
2015
 
 
63,444
 
2016
 
 
58,157
 
XML 35 R75.htm IDEA: XBRL DOCUMENT v2.4.0.8
Antidilutive Securities Not Included in Computation of Net Loss Per Share (Detail)
 12 Months Ended
Dec. 31, 2013
Dec. 31, 2012
Series A Preferred Stock
    
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]    
Anti-dilutive securities excluded from computation of earnings per share amount 448 448
Series B Preferred Stock
    
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]    
Anti-dilutive securities excluded from computation of earnings per share amount 305,648 305,648
Series G Preferred Stock
    
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]    
Anti-dilutive securities excluded from computation of earnings per share amount 0 100
Series S Preferred Stock
    
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]    
Anti-dilutive securities excluded from computation of earnings per share amount 1,000,000 1,000,000
Series H Preferred Stock
    
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]    
Anti-dilutive securities excluded from computation of earnings per share amount 482,625 0
Stock Warrants
    
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]    
Anti-dilutive securities excluded from computation of earnings per share amount 122,500 267,350
Convertible debt
    
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]    
Anti-dilutive securities excluded from computation of earnings per share amount 2,693,553 722,910
Common stock options
    
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]    
Anti-dilutive securities excluded from computation of earnings per share amount 188,100 190,600
Series B Preferred Stock Options
    
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]    
Anti-dilutive securities excluded from computation of earnings per share amount 207,000 250,000
XML 36 R37.htm IDEA: XBRL DOCUMENT v2.4.0.8
NOTES PAYABLE AND ADVANCES FROM RELATED PARTIES (Tables)
 12 Months Ended
Dec. 31, 2013
Notes Payable [Abstract]  
Future Maturities of Notes Payable
Future maturities of the advances and notes payable are as follows:
 
Debt maturities as of
 
December 31,
 
2014
 
$
1,130,000
 
 
 
 
 
 
2015
 
 
455,000
 
XML 37 R52.htm IDEA: XBRL DOCUMENT v2.4.0.8
Summary of Consideration Transferred (Detail) (MIT, USD $)
 0 Months Ended
Jan. 17, 2012
MIT
  
Fair Value of Consideration Transferred:  
Common stock of Company $ 50,000
Contingent consideration 205,297
Total $ 255,297
XML 38 R67.htm IDEA: XBRL DOCUMENT v2.4.0.8
Summary of Series B Preferred Stock Option Activity (Detail) (Series B Preferred Stock, USD $)
 12 Months Ended
Dec. 31, 2013
Series B Preferred Stock
  
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]  
Beginning Balance (Shares Issuable Under Outstanding Options) 2,500,000
Issued (Shares Issuable Under Outstanding Options) 0
Expired/forfeited (Shares Issuable Under Outstanding Options) (430,000)
Exercised (Shares Issuable Under Outstanding Options) 0
Ending Balance (Shares Issuable Under Outstanding Options) 2,070,000
Exercisable, (Shares Issuable Under Outstanding Options) 2,070,000
Beginning Balance (Price Range or Weighted Average Exercise Price) $ 1.00
Issued (Price Range or Weighted Average Exercise Price) $ 0
Expired/forfeited (Price Range or Weighted Average Exercise Price) $ 1.00
Exercised (Price Range or Weighted Average Exercise Price) $ 0
Ending Balance (Price Range or Weighted Average Exercise Price) $ 1.00
Exercisable, (Weighted Average Exercise Price) $ 1.00
XML 39 R61.htm IDEA: XBRL DOCUMENT v2.4.0.8
Convertible Debentures Outstanding (Detail) (USD $)
Dec. 31, 2013
Dec. 31, 2012
Jan. 12, 2012
Debt Instrument [Line Items]      
Convertible debentures $ 5,780,000 $ 3,360,000  
Debt discount (1,328,000) (1,798,000)  
Net convertible debentures 4,452,000 1,562,000  
Less current portion 4,452,000 1,562,000  
Long term portion 0    
Non Related Party [Member]
      
Debt Instrument [Line Items]      
Convertible debentures 4,030,000 1,510,000  
Debt discount (1,328,000) (350,000)  
Net convertible debentures 2,702,000 1,160,000  
Less current portion (2,702,000)    
Long term portion 0    
Related Party [Member]
      
Debt Instrument [Line Items]      
Convertible debentures 1,750,000 1,850,000  
Debt discount 0 (1,448,000)  
Net convertible debentures 1,750,000 402,000 250,000
Less current portion (1,750,000)    
Long term portion $ 0    
XML 40 R47.htm IDEA: XBRL DOCUMENT v2.4.0.8
Embedded Conversion Derivative Liabilities Measured and Recorded at Fair Value on Recurring Basis (Detail) (USD $)
In Thousands, unless otherwise specified
Dec. 31, 2013
Dec. 31, 2012
Dec. 31, 2011
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]      
Embedded conversion derivative liability $ 6,968 $ 3,981 $ 1,238
Level 1
      
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]      
Embedded conversion derivative liability 0 0  
Level 2
      
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]      
Embedded conversion derivative liability 0 0  
Level 3
      
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]      
Embedded conversion derivative liability $ 6,968 $ 3,981  
XML 41 R9.htm IDEA: XBRL DOCUMENT v2.4.0.8
GOING CONCERN
 12 Months Ended
Dec. 31, 2013
Going Concern [Abstract]  
GOING CONCERN
2.
GOING CONCERN
 
Since inception, the Company has expended substantial resources on research and development. Consequently, we have sustained substantial losses. Due to the limited number of products sold each year, revenues have fluctuated significantly from year to year and has not sold quantities that are sufficient to be operationally profitable. The Company had an accumulated deficit of $123,432,000 and a stockholders’ deficit of $11,241,000 at December 31, 2013. The Company will need to resume and increase sales of PET and radiopharmaceutical systems, services, radiopharmaceuticals and radioisotope sales and apply the research and development advancements to achieve profitability in the future. There can be no assurance that the Company will continue to be successful in selling products.
 
The Company utilized $2,520,000 proceeds from issuance of convertible debt, $2,285,000 proceeds from non-interest bearing advances, and proceeds from borrowings under capital lease to fund operating activities during the year ended December 31, 2013. The Company had cash and cash equivalents of $1,744,000 at December 31, 2013, accounts payable and accrued liabilities of $1,401,000 and a negative working capital of $12,084,000. Working capital requirements for the upcoming year will reach beyond our current cash balances. The Company plans to continue to raise funds as required through equity and debt financing to sustain business operations. These factors raise substantial doubt about the Company’s ability to continue as a going concern.
 
There can be no assurance that the Company will be successful in implementing its business plan and ultimately achieving operational profitability. The Company’s long-term viability as a going concern is dependent on its ability to 1) achieve adequate profitability and cash flows from operations to sustain its operations, 2) control costs and expand revenues from existing or new business 3) meet current commitments and fund the continuation of its business operation in the near future and 4) raise additional funds through debt and/or equity financings.
XML 42 R62.htm IDEA: XBRL DOCUMENT v2.4.0.8
Notes Payable and Advances from Related Parties - Additional Information (Detail) (USD $)
 12 Months Ended 12 Months Ended 12 Months Ended
Dec. 31, 2013
Dec. 31, 2012
Feb. 10, 2012
Dec. 31, 2013
CEO and CFO
Dec. 31, 2012
Subsequent Event
Dec. 31, 2013
Promissory Notes
Dec. 31, 2012
Promissory Notes
Dec. 31, 2013
Convertible Debt [Member]
Jan. 17, 2012
MIT
Dec. 31, 2013
MIT
Promissory Notes
Dec. 31, 2012
MIT
Promissory Notes
Secured Convertible Notes Payable [Line Items]                      
Note payable       $ 2,285,000         $ 700,000    
Notes payable, refinanced with LANB principal and accrued interest     708,000                
Monthly payment to LANB on promissory note                   10,000  
Interest rate on promissory note                   5.50%  
Convertible Debt (4,452,000) (1,562,000)           1,250,000      
Notes Payable, Total 550,000 649,000           1,035,000      
Deposit liabilities, Accrued interest                   3,000 3,000
Interest rate on advances received 8.00%                    
Advances payment on unsecured note         305,000            
Repayments of Unsecured Debt         265,000            
Interest expense, Other 1,600         35,000 35,000        
Due To Unrelated Parties $ 0 $ 40,000                  
EXCEL 43 Financial_Report.xls IDEA: XBRL DOCUMENT begin 644 Financial_Report.xls M[[N_34E-12U697)S:6]N.B`Q+C`-"E@M1&]C=6UE;G0M5'EP93H@5V]R:V)O M;VL-"D-O;G1E;G0M5'EP93H@;75L=&EP87)T+W)E;&%T960[(&)O=6YD87)Y M/2(M+2TM/5].97AT4&%R=%]C8C(Q,68U,5\W,V$Q7S1C-#9?8C!B,U]B.#@Y M9#5D-C0W8F4B#0H-"E1H:7,@9&]C=6UE;G0@:7,@82!3:6YG;&4@1FEL92!7 M96(@4&%G92P@86QS;R!K;F]W;B!A'!L;W)E&UL;G,Z=CTS1")U&UL;G,Z;STS1")U&UL/@T*(#QX.D5X8V5L5V]R:V)O;VL^#0H@(#QX M.D5X8V5L5V]R:W-H965T5]);F9O#I%>&-E;%=O#I%>&-E;%=O#I%>&-E;%=O#I%>&-E;%=O#I%>&-E;%=O#I%>&-E;%=O#I.86UE/@T*("`@(#QX.E=O#I%>&-E;%=O#I.86UE/D=/24Y'7T-/3D-%4DX\+W@Z3F%M93X-"B`@ M("`\>#I7;W)K#I7;W)K#I7;W)K#I.86UE/@T*("`@(#QX.E=O#I%>&-E;%=O#I. M86UE/E!23U!%4E197T%.1%]%455)4$U%3E0\+W@Z3F%M93X-"B`@("`\>#I7 M;W)K#I7;W)K#I.86UE/@T*("`@(#QX.E=O#I%>&-E;%=O#I.86UE/D-/3E9%4E1)0DQ%7T1%0D5.5%5215,\+W@Z3F%M93X-"B`@ M("`\>#I7;W)K#I7;W)K#I7;W)K#I%>&-E;%=O#I%>&-E M;%=O#I7;W)K#I.86UE/@T*("`@(#QX.E=O M#I%>&-E;%=O#I.86UE/DE.0T]-15]405A%4SPO>#I.86UE/@T*("`@ M(#QX.E=O#I%>&-E M;%=O#I.86UE/C0P,4M?4$Q!3CPO>#I.86UE/@T* M("`@(#QX.E=O#I% M>&-E;%=O#I.86UE/E)%3$%4141?4$%25%E?5%)! M3E-!0U1)3TY3/"]X.DYA;64^#0H@("`@/'@Z5V]R:W-H965T4V]U#I%>&-E M;%=O#I7;W)K#I7;W)K#I.86UE/@T*("`@(#QX.E=O#I%>&-E;%=O#I.86UE/E-50E-%455%3E1?159%3E13/"]X.DYA;64^#0H@("`@/'@Z5V]R M:W-H965T4V]U#I%>&-E;%=O#I.86UE/@T*("`@(#QX.E=O#I%>&-E;%=O#I.86UE/D1% M4T-225!424].7T]&7T)54TE.15-37T%.1%]353(\+W@Z3F%M93X-"B`@("`\ M>#I7;W)K#I%>&-E;%=O#I%>&-E;%=O#I7;W)K#I%>&-E;%=O#I7;W)K#I%>&-E;%=O#I%>&-E;%=O#I7;W)K#I7;W)K#I%>&-E;%=O#I%>&-E;%=O#I.86UE/@T*("`@(#QX.E=O#I%>&-E;%=O#I.86UE M/E-%1TU%3E137U1A8FQE#I.86UE/@T*("`@(#QX.E=O#I%>&-E;%=O#I.86UE/D1E#I. M86UE/@T*("`@(#QX.E=O#I%>&-E;%=O#I.86UE/D5M8F5D9&5D7T-O;G9E#I.86UE/@T*("`@(#QX.E=O#I%>&-E;%=O#I.86UE/D1E#I.86UE/@T*("`@(#QX.E=O#I%>&-E;%=O#I.86UE/D%C<75I#I.86UE/@T*("`@(#QX.E=O#I%>&-E;%=O#I.86UE/E-U M;6UA#I.86UE/@T*("`@(#QX M.E=O#I%>&-E;%=O M#I.86UE/E-U;6UA#I.86UE/@T*("`@(#QX.E=O#I%>&-E;%=O#I.86UE M/D]T:&5R7T%S#I.86UE/@T*("`@ M(#QX.E=O#I%>&-E M;%=O#I.86UE/DEN=F5N=&]R:65S7T1E=&%I;#PO M>#I.86UE/@T*("`@(#QX.E=O#I%>&-E;%=O#I%>&-E;%=O#I%>&-E;%=O#I%>&-E;%=O5]O9E]#;VYV97)T:6)L95]$96)T7V%N/"]X.DYA;64^#0H@("`@/'@Z M5V]R:W-H965T4V]U#I%>&-E;%=O#I%>&-E;%=O M#I%>&-E;%=O#I%>&-E M;%=O#I%>&-E;%=O#I% M>&-E;%=O5]!9&1I=&EO;F%L/"]X.DYA;64^ M#0H@("`@/'@Z5V]R:W-H965T4V]U#I%>&-E;%=O5]O9E]397)I M97-?0E]0#I%>&-E;%=O#I%>&-E;%=O5]O9E]# M;VUM;VY?4W1O8VM?3W!T:6]N/"]X.DYA;64^#0H@("`@/'@Z5V]R:W-H965T M4V]U#I%>&-E;%=O5]O9E]787)R86YT7T%C=&EV:71Y7T)A/"]X M.DYA;64^#0H@("`@/'@Z5V]R:W-H965T4V]U#I%>&-E;%=O5]/ M9E]/=71S=&%N9&EN9U]#;VUM;VY?/"]X.DYA;64^#0H@("`@/'@Z5V]R:W-H M965T4V]U#I%>&-E;%=O#I%>&-E;%=O#I%>&-E;%=O#I%>&-E;%=O#I%>&-E;%=O&5S7T%D9&ET:6]N86Q? M26YF;W)M/"]X.DYA;64^#0H@("`@/'@Z5V]R:W-H965T4V]U#I%>&-E;%=O M#I%>&-E;%=O#I%>&-E M;%=O#I%>&-E;%=O5]4#I% M>&-E;%=O#I%>&-E;%=O6UE;G1S/"]X.DYA;64^#0H@("`@/'@Z5V]R:W-H965T4V]U M#I%>&-E;%=O#I%>&-E;%=O#I%>&-E;%=O#I%>&-E;%=O#I!8W1I=F53:&5E M=#XP/"]X.D%C=&EV95-H965T/@T*("`\>#I0#I%>&-E;%=O7!E.B!T97AT+VAT;6P[(&-H87)S970] M(G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T M<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@ M8VAA'0^)SQS<&%N/CPO'0^)SQS<&%N M/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO M'0^)SQS<&%N/CPO'0^)U!/4T,\ M'0^ M)SQS<&%N/CPO2!296=I'0^)SQS<&%N/CPO2!#96YT3PO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^)S`P,#`X M-#0Y.#4\'0^)SQS<&%N/CPO'0^)RTM,3(M,S$\'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO2!&:6QE'0^)SQS<&%N/CPO2!&:6QE3PO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^)U-M86QL97(@4F5P;W)T:6YG($-O M;7!A;GD\'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO7!E.B!T97AT+VAT;6P[ M(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@ M/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E M>'0O:'1M;#L@8VAA'0^)SQS<&%N/CPO'0^)SQS<&%N M/CPO6%B;&4@+2!C=7)R96YT('!O'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N M/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^ M)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0O:F%V87-C3X-"B`@ M("`\=&%B;&4@8VQA&-E M<'0@4VAAF5D/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XS+#`P M,"PP,#`L,#`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M2!S=&]C:RP@'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPOF5D/"]T M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XS+#`P,"PP,#`\'0^)SQS<&%N/CPO'0^)SQS M<&%N/CPOF5D/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ M-2PP,#`L,#`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^)SQS<&%N/CPO'0^)SQS<&%N M/CPO3X-"CPO M:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R=%]C8C(Q,68U,5\W,V$Q7S1C-#9? M8C!B,U]B.#@Y9#5D-C0W8F4-"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O M0SHO8V(R,3%F-3%?-S-A,5\T8S0V7V(P8C-?8C@X.60U9#8T-V)E+U=O'0O:'1M;#L@ M8VAA'!E;G-E'0^)SQS<&%N/CPO'!E;G-E/"]T9#X-"B`@("`@("`@/'1D M(&-L87-S/3-$;G5M/B@X,C$I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S6%B;&4\+W1D/@T*("`@("`@("`\=&0@8VQA'!E;G-E/"]T9#X-"B`@("`@("`@/'1D(&-L M87-S/3-$;G5M/B@Q-#,I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S&5S/"]T9#X-"B`@("`@ M("`@/'1D(&-L87-S/3-$;G5M<#XP/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^)SQS<&%N/CPO2!T7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M M;#X-"B`@/&AE860^#0H@("`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`@("`\=&%B;&4@8VQA'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'!E;G-E/"]T9#X-"B`@("`@("`@/'1D(&-L M87-S/3-$;G5M<#XX,C$L,#`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S2!R97-E'0^)SQS<&%N/CPO2!A;F0@97%U:7!M96YT/"]T9#X-"B`@("`@("`@/'1D M(&-L87-S/3-$;G5M/B@Q-BPP,#`I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^)SQS<&%N/CPO6UE;G0@;V8@;F]N:6YT97)E6UE;G1S(&]N(&-A<&ET86P@;&5A'0^)SQS<&%N/CPO&5S('!A:60\+W1D/@T*("`@("`@("`\=&0@8VQA'0^)SQS<&%N/CPO3PO=&0^#0H@("`@("`@(#QT M9"!C;&%S2!T;R!P86ED("T@:6X@8V%P:71A;#PO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R=%]C8C(Q,68U,5\W,V$Q M7S1C-#9?8C!B,U]B.#@Y9#5D-C0W8F4-"D-O;G1E;G0M3&]C871I;VXZ(&9I M;&4Z+R\O0SHO8V(R,3%F-3%?-S-A,5\T8S0V7V(P8C-?8C@X.60U9#8T-V)E M+U=O'0O M:'1M;#L@8VAA3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R=%]C8C(Q,68U,5\W,V$Q M7S1C-#9?8C!B,U]B.#@Y9#5D-C0W8F4-"D-O;G1E;G0M3&]C871I;VXZ(&9I M;&4Z+R\O0SHO8V(R,3%F-3%?-S-A,5\T8S0V7V(P8C-?8C@X.60U9#8T-V)E M+U=O'0O M:'1M;#L@8VAA6QE/3-$)TU!4D=)3BU4 M3U`Z(#!P=#L@1D].5#H@,3!P="!4:6UE6QE/3-$)U9%4E1) M0T%,+4%,24=..B!T;W`G/B`\=&0@"<^/"]T M9#X@/'1D('-T>6QE/3-$)U=)1%1(.B`P+C(U:6XG/B`\9&EV/CQS=')O;F<^ M,2X\+W-T6QE/3-$)T-,14%2.F)O=&@[($9/3E0M M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[5$585"U) M3D1%3E0Z("TP+C(U:6X[($U!4D=)3CH@,'!T(#!P>"`P<'0@,"XR-6EN.R!& M3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E6QE/3-$)T-,14%2.F)O=&@[($9/ M3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[34%2 M1TE..B`P<'0@,'!X.R!&3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM M97,L(%-E6QE/3-$)T-,14%2.F)O=&@[($9/3E0M M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[34%21TE. M.B`P<'0@,'!X.R!&3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L M(%-E#L@1D].5#H@,3!P M="!4:6UE2!O9F9E2!M M;VQE8W5L87(@:6UA9VEN9R!S>7-T96US+"!C;&EN:6-A;"!A;F0@6QE/3-$ M)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4 M+5-)6D4Z(#$P<'0[34%21TE..B`P<'0@,'!X.R!&3TY4.B`Q,'!T(%1I;65S M($YE=R!2;VUA;BP@5&EM97,L(%-E3Y4:&4@;6]L96-U;&%R(&EM86=I;F<@3Y4:&4@0V]M<&%N>28C.#(Q-SMS(&]B:F5C=&EV92!I3XF(S$V M,#L\+V1I=CX@/&1I=B!S='EL93TS1"=#3$5!4CIB;W1H.R!&3TY4+49!34E, M63I4:6UE#L@1D].5#H@,3!P="!4:6UE3XF(S$V,#L\+V1I=CX@/&1I=B!S='EL93TS M1"=#3$5!4CIB;W1H.R!&3TY4+49!34E,63I4:6UE#L@1D].5#H@,3!P="!4:6UE M6-L92!M86YA9V5M M96YT+B!#=7)R96YT;'DL($U)5"!P6QE M/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM& M3TY4+5-)6D4Z(#$P<'0[34%21TE..B`P<'0@,'!X.R!&3TY4.B`Q,'!T(%1I M;65S($YE=R!2;VUA;BP@5&EM97,L(%-E2!O9B!B=6EL9&EN9R!A(&-Y8VQO=')O;BX\9F]N="!S='EL93TS1"=& M3TY4+49!34E,63H@)U1I;65S($YE=R!2;VUA;B#L@1D].5#H@,3!P M="!4:6UE6QE M/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)RPG#L@1D].5#H@,3!P="!4:6UE3Y&;W(@=&AE('EE87)S(&5N M9&5D($1E8V5M8F5R(#,Q+"`R,#$S(&%N9"`R,#$R+"!T:&4@9FEN86YC:6%L M('-T871E;65N=',@:6YC;'5D92!T:&4@=')A;G-A8W1I;VYS(&]F(%!O2!A M;F0@4$E#+B!!;&P@:6YT97)C;VUP86YY('1R86YS86-T:6]N6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%- M24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[34%21TE..B`P M<'0@,'!X.R!&3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E M3X\ M6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W M(%)O;6%N)RPG6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE M=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[34%21TE..B`P<'0@,'!X.R!&3TY4 M.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E#L@1D].5#H@,3!P M="!4:6UE2!A8V-E<'1E9"!I;B!T:&4@56YI=&5D(%-T871E3XF M(S$V,#L\+V1I=CX@/&1I=B!S='EL93TS1"=#3$5!4CIB;W1H.R!&3TY4+49! M34E,63I4:6UE#L@1D].5#H@,3!P="!4:6UE3X\6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I M;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[34%21TE..B`P<'0@,'!X M.R!&3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E6QE/3-$ M)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4 M+5-)6D4Z(#$P<'0[34%21TE..B`P<'0@,'!X.R!&3TY4.B`Q,'!T(%1I;65S M($YE=R!2;VUA;BP@5&EM97,L(%-E3Y3;VQA2X\+V1I=CX@/&1I=B!S='EL93TS1"=#3$5! M4CIB;W1H.R!&3TY4+49!34E,63I4:6UE#L@1D].5#H@,3!P="!4:6UE6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I M;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[34%21TE..B`P<'0@,'!X M.R!&3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E2!A;F0@=&AE M(&IO:6YT('9E;G1U2!A8V-O=6YT#L@ M1D].5#H@,3!P="!4:6UE6QE M/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM& M3TY4+5-)6D4Z(#$P<'0[34%21TE..B`P<'0@,'!X.R!&3TY4.B`Q,'!T(%1I M;65S($YE=R!2;VUA;BP@5&EM97,L(%-E#L@1D].5#H@,3!P="!4:6UE'!E3XF(S$V,#L\+V1I=CX@/&1I=B!S M='EL93TS1"=#3$5!4CIB;W1H.R!&3TY4+49!34E,63I4:6UE#L@1D].5#H@,3!P M="!4:6UE6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O M;6%N)RPG6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N M)RPG6QE/3-$)T9/3E0M M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)RPG#L@1D].5#H@,3!P="!4:6UE6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA M;CM&3TY4+5-)6D4Z(#$P<'0[34%21TE..B`P<'0@,'!X.R!&3TY4.B`Q,'!T M(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N M)RPG6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O M;6%N)RPG#L@1D].5#H@,3!P M="!4:6UE3Y& M;W(@=&AE('!U2!C;VYS:61E6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S M($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[34%21TE..B`P<'0@,'!X.R!& M3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E3X\6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)RPG M#L@1D].5#H@,3!P="!4:6UE3Y!8V-O=6YT7-I28C.#(Q-SMS('!R:6]R(&-O;&QE8W1I;VX@97AP97)I96YC92P@8W5S M=&]M97(@8W)E9&ET=V]R=&AI;F5S3XF(S$V,#L\+V1I=CX@/&1I=B!S='EL93TS1"=#3$5!4CIB;W1H.R!&3TY4 M+49!34E,63I4:6UE#L@1D].5#H@,3!P="!4:6UE3X\6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA M;CM&3TY4+5-)6D4Z(#$P<'0[34%21TE..B`P<'0@,'!X.R!&3TY4.B`Q,'!T M(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E#L@1D]. M5#H@,3!P="!4:6UE6QE/3-$)T-,14%2.F)O M=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P M<'0[34%21TE..B`P<'0@,'!X.R!&3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA M;BP@5&EM97,L(%-E2!D971E3XF(S$V,#L\+V1I=CX@/&1I M=B!S='EL93TS1"=#3$5!4CIB;W1H.R!&3TY4+49!34E,63I4:6UE#L@1D].5#H@ M,3!P="!4:6UE2!I;7!A:7)E9"!A="!$96-E;6)E6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W M(%)O;6%N)RPG6QE/3-$)T9/3E0M M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)RPG#L@1D].5#H@,3!P="!4:6UE6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA M;CM&3TY4+5-)6D4Z(#$P<'0[34%21TE..B`P<'0@,'!X.R!&3TY4.B`Q,'!T M(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E6QE/3-$ M)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4 M+5-)6D4Z(#$P<'0[34%21TE..B`P<'0@,'!X.R!&3TY4.B`Q,'!T(%1I;65S M($YE=R!2;VUA;BP@5&EM97,L(%-E3X\6QE/3-$)T9/ M3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)RPG3X\6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA M;CM&3TY4+5-)6D4Z(#$P<'0[34%21TE..B`P<'0@,'!X.R!&3TY4.B`Q,'!T M(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E2!B87-I6QE/3-$)T9/3E0M1D%- M24Q9.B`G5&EM97,@3F5W(%)O;6%N)RPG#L@1D].5#H@,3!P="!4:6UE6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2 M;VUA;CM&3TY4+5-)6D4Z(#$P<'0[34%21TE..B`P<'0@,'!X.R!&3TY4.B`Q M,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E#L@1D].5#H@ M,3!P="!4:6UE3X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@)U1I;65S($YE=R!2;VUA M;B#L@1D].5#H@,3!P="!4:6UE6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA M;CM&3TY4+5-)6D4Z(#$P<'0[5$585"U!3$E'3CIC96YT97([(%1%6%0M24Y$ M14Y4.B`P:6X[(%=)1%1(.B`Q,#`E)R!A;&EG;CTS1&-E;G1E6QE/3-$)TU!4D=)3CH@,'!X.F%U=&\[(%=)1%1(.B`X,"4[($)/4D1% M4BU#3TQ,05!313H@8V]L;&%P6QE/3-$)U1%6%0M04Q)1TXZ M(&-E;G1E6QE/3-$)T)/4D1%4BU"3U143TTZ M(",P,#`P,#`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`G M5&EM97,@3F5W(%)O;6%N)RPG6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2 M;VUA;CM&3TY4+5-)6D4Z(#$P<'0[34%21TE..B`P<'0@,'!X.R!&3TY4.B`Q M,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E3Y'86EN3XF(S$V,#L\+V1I=CX@/&1I=B!S='EL93TS1"=#3$5! M4CIB;W1H.R!&3TY4+49!34E,63I4:6UE#L@1D].5#H@,3!P="!4:6UE3X\6QE/3-$ M)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4 M+5-)6D4Z(#$P<'0[34%21TE..B`P<'0@,'!X.R!&3TY4.B`Q,'!T(%1I;65S M($YE=R!2;VUA;BP@5&EM97,L(%-E2!E=F%L=6%T97,@=&AE(&-A2!W;W5L9"!R96-O2!V86QU871I;VYS+CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B`G M5&EM97,@3F5W(%)O;6%N)RPG#L@1D].5#H@,3!P="!4:6UE6QE M/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM& M3TY4+5-)6D4Z(#$P<'0[34%21TE..B`P<'0@,'!X.R!&3TY4.B`Q,'!T(%1I M;65S($YE=R!2;VUA;BP@5&EM97,L(%-E6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)RPG M6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA M;CM&3TY4+5-)6D4Z(#$P<'0[34%21TE..B`P<'0@,'!X.R!&3TY4.B`Q,'!T M(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E#L@1D].5#H@,3!P="!4:6UE M6EN9R!V86QU92!O9B!C87-H(&%N9"!C87-H(&5Q=6EV86QE;G1S M+"!A8V-O=6YT2!I#L@1D].5#H@,3!P="!4 M:6UE6QE/3-$)T-,14%2.F)O=&@[($9/3E0M M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[34%21TE. M.B`P<'0@,'!X.R!&3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L M(%-E&-H86YG92!P&ET('!R:6-E*2!I;B!T:&4@<')I;F-I<&%L(&]R(&UO2!I M;B!A;B!O#L@1D].5#H@,3!P M="!4:6UE6QE/3-$)T-,14%2.F)O=&@[($9/ M3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[34%2 M1TE..B`P<'0@,'!X.R!&3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM M97,L(%-EF4@=&AE('5S M92!O9B!O8G-EF4@=&AE('5S92!O M9B!U;F]B2!U=&EL:7IE6QE/3-$)U=)1%1(.B`P+C(U M:6XG/CPO=&0^(#QT9"!S='EL93TS1"=724142#H@,"XR-6EN)SX@/&1I=CX\ M9F]N=#XF(S@Y,#$[/"]F;VYT/CPO9&EV/B`\+W1D/B`\=&0@2<^(#QD:78^3&5V96P@,2`F(S$U,3L@475O M=&5D('!R:6-E2!O8G1A M:6YE9"!F6QE/3-$)U=)1%1(.B`P+C(U:6XG/CPO=&0^(#QT9"!S='EL93TS1"=7 M24142#H@,"XR-6EN)SX@/&1I=CX\9F]N=#XF(S@Y,#$[/"]F;VYT/CPO9&EV M/B`\+W1D/B`\=&0@2<^(#QD M:78^3&5V96P@,B`F(S$U,3L@475O=&5D('!R:6-E2!O8G1A:6YE9"!F6QE/3-$)U=)1%1( M.B`P+C(U:6XG/CPO=&0^(#QT9"!S='EL93TS1"=724142#H@,"XR-6EN)SX@ M/&1I=CX\9F]N=#XF(S@Y,#$[/"]F;VYT/CPO9&EV/B`\+W1D/B`\=&0@2<^(#QD:78^3&5V96P@,R`F(S$U M,3L@56YO8G-E3X\ M9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@)U1I;65S($YE=R!2;VUA;B6QE M/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)RPG2!F:6YA;F-I86P@ M;&EA8FEL:71I97,@;65A3XF(S$V,#L\+V1I=CX@/&1I=B!S='EL93TS1"=# M3$5!4CIB;W1H.R!&3TY4+49!34E,63I4:6UE"!S M;VQI9#L@34%21TE..B`P:6X@,&EN(#!I;B`P+C5I;CL@5TE$5$@Z(#@P)3L@ M0D]21$52+4-/3$Q!4%-%.B!C;VQL87!S93L@1D].5"U325I%.B`Q,'!T.R!/ M5D521DQ/5SH@=FES:6)L93L@0D]21$52+51/4#H@(SEE8C9C92`P<'@@6QE/3-$)U1%6%0M04Q)1TXZ(&-E;G1E6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`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`Q,'!T.R!615)4 M24-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS M1#$R)3X@/&1I=CXM/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%, M24=..B!L969T.R!&3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!4 M:6UE6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!&3TY4 M+5-464Q%.B!N;W)M86P[(%!!1$1)3D#L@1D].5"U&04U) M3%DZ(%1I;65S($YE=R!2;VUA;CL@0D%#2T=23U5.1#H@(V9F9F9F9CL@1D]. M5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=% M24=(5#H@-#`P)R!W:61T:#TS1#$R)3X@/&1I=CXM/"]D:78^(#PO=&0^(#QT M9"!S='EL93TS1"=415A4+4%,24=..B!L969T.R!&3TY4+5-464Q%.B!N;W)M M86P[($9/3E0M1D%-24Q9.B!4:6UE6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[ M($9/3E0M4U193$4Z(&YO6QE/3-$)U1%6%0M M04Q)1TXZ(')I9VAT.R!&3TY4+5-464Q%.B!N;W)M86P[(%!!1$1)3D#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@0D%#2T=2 M3U5.1#H@(V9F9F9F9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E' M3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$R)3X@/&1I M=CXS+#DX,3PO9&EV/B`\+W1D/B`\=&0@6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)RPG#L@1D].5#H@,3!P="!4 M:6UE6QE/3-$)T-,14%2.F)O=&@[($9/3E0M M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[34%21TE. M.B`P<'0@,'!X.R!&3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L M(%-E6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE M=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[34%21TE..B`P<'0@,'!X.R!&3TY4 M.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E6QE/3-$)T)/4D1%4BU"3U143TTZ(",Y96(V8V4@ M,'!X('-O;&ED.R!"3U)$15(M3$5&5#H@(SEE8C9C92`P<'@@"!S;VQI9#L@0D]21$52+5))1TA4.B`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`P,#`@,7!X('-O;&ED.R!415A4+4%, M24=..B!L969T.R!&3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!4 M:6UE6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,7!X('-O;&ED.R!4 M15A4+4%,24=..B!R:6=H=#L@1D].5"U35%E,13H@;F]R;6%L.R!0041$24Y' M+5))1TA4.B`U<'@[($9/3E0M1D%-24Q9.B!4:6UE2!A"!S;VQI9#L@5$585"U!3$E'3CH@;&5F=#L@1D].5"U3 M5%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!" M04-+1U)/54Y$.B`C9F9F9F9F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%, M+4%,24=..B!B;W1T;VT[($)/4D1%4BU43U`Z(",P,#`P,#`@,7!X('-O;&ED M.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$E/B`\9&EV/B0\+V1I=CX@ M/"]T9#X@/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,7!X M('-O;&ED.R!415A4+4%,24=..B!R:6=H=#L@1D].5"U35%E,13H@;F]R;6%L M.R!0041$24Y'+5))1TA4.B`U<'@[($9/3E0M1D%-24Q9.B!4:6UE6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M M4U193$4Z(&YO"!S;VQI M9#L@1D].5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q)3X@/&1I=CXF(S$V,#L\ M+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!& M3TY4+5-464Q%.B!N;W)M86P[(%!!1$1)3D#L@1D].5"U& M04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@0D%#2T=23U5.1#H@(V-C9F9C8SL@ M0T],3U(Z(",P,#`P,#`[($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q) M1TXZ(&)O='1O;3L@0D]21$52+51/4#H@(S`P,#`P,"`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`P<'0@,'!X.R!&3TY4.B`Q,'!T M(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E#L@1D].5#H@,3!P="!4 M:6UE6QE/3-$ M)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)RPG#L@1D].5#H@ M,3!P="!4:6UE6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I M;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[5$585"U!3$E'3CI,969T M.R!415A4+4E.1$5.5#H@,&EN.R!724142#H@,3`P)2<^(#QT86)L92!S='EL M93TS1"=-05)'24XZ(#!I;CL@5TE$5$@Z(#@U)3L@0D]21$52+4-/3$Q!4%-% M.B!C;VQL87!S93L@1D].5"U325I%.B`Q,'!T.R!/5D521DQ/5SH@=FES:6)L M92<@8V5L;'-P86-I;F<],T0P(&-E;&QP861D:6YG/3-$,"!A;&EG;CTS1&QE M9G0^(#QT6QE/3-$)U1%6%0M04Q)1TXZ(&-E;G1E6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,7!X M('-O;&ED.R!415A4+4%,24=..B!C96YT97([($9/3E0M4U193$4Z(&YO6QE/3-$)U1%6%0M M04Q)1TXZ(&-E;G1E6QE/3-$ M)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO"!S;VQI9#L@1D].5"U714E'2%0Z(#0P,"<@ M=VED=&@],T0Q)3X@/&1I=CXD/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=4 M15A4+4%,24=..B!R:6=H=#L@1D].5"U35%E,13H@;F]R;6%L.R!0041$24Y' M+5))1TA4.B`S<'@[($9/3E0M1D%-24Q9.B!4:6UE6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO M"!S;VQI9#L@1D].5"U7 M14E'2%0Z(#0P,"<@=VED=&@],T0Q)3X@/&1I=CXD/"]D:78^(#PO=&0^(#QT M9"!S='EL93TS1"=415A4+4%,24=..B!R:6=H=#L@1D].5"U35%E,13H@;F]R M;6%L.R!0041$24Y'+5))1TA4.B`T<'@[($9/3E0M1D%-24Q9.B!4:6UE6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U19 M3$4Z(&YO6QE/3-$)U1% M6%0M04Q)1TXZ(')I9VAT.R!&3TY4+5-464Q%.B!N;W)M86P[(%!!1$1)3D#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@0D%# M2T=23U5.1#H@(V9F9F9F9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U! M3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@-#`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`Q,'!T.R!6 M15)424-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T M:#TS1#$R)3X@/&1I=CXQ('EE87(\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$ M)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!&3TY4+5-464Q%.B!N;W)M86P[ M(%!!1$1)3D#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2 M;VUA;CL@0D%#2T=23U5.1#H@(V-C9F9C8SL@1D].5"U325I%.B`Q,'!T.R!6 M15)424-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T M:#TS1#$R)3X@/&1I=CXQ('EE87(\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$ M)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)T9/3E0M1D%-24Q9.B`G M5&EM97,@3F5W(%)O;6%N)RPG#L@1D].5#H@,3!P="!4:6UE6QE/3-$)T-,14%2.F)O=&@[($9/3E0M M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[34%21TE. M.B`P<'0@,'!X.R!&3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L M(%-E6QE/3-$)T9/3E0M1D%- M24Q9.B`G5&EM97,@3F5W(%)O;6%N)RPG#L@1D].5#H@,3!P="!4:6UEF5D(&]V97(@=&AE M(&QI9F4@;V8@=&AE(')E;&%T960@9&5B="X@5VAE;B!T:&4@9&5B="!I#L@1D].5#H@,3!P="!4:6UE6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9 M.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[34%21TE..B`P<'0@ M,'!X.R!&3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM M97,@3F5W(%)O;6%N)RPG6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)RPG2X\+V1I=CX@/&1I=B!S='EL93TS1"=#3$5!4CIB;W1H.R!&3TY4 M+49!34E,63I4:6UE#L@1D].5#H@,3!P="!4:6UE6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA M;CM&3TY4+5-)6D4Z(#$P<'0[34%21TE..B`P<'0@,'!X.R!&3TY4.B`Q,'!T M(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W M(%)O;6%N)RPG6QE/3-$)T9/3E0M1D%-24Q9.B`G M5&EM97,@3F5W(%)O;6%N)RPG3XF(S$V,#L\+V1I=CX@/&1I=B!S='EL M93TS1"=#3$5!4CIB;W1H.R!&3TY4+49!34E,63I4:6UE#L@1D].5#H@,3!P="!4 M:6UE#L@1D].5#H@,3!P="!4:6UE3Y);F-O;64@=&%X97,@ M87)E(&%C8V]U;G1E9"!F;W(@=6YD97(@=&AE(&QI86)I;&ET>2!M971H;V0N M($1E9F5R2!D:69F97)E;F-E6EN9R!A;6]U;G1S M(&]F(&%S"!P=7)P;W-EF5D+B!$969E"!E>'!E;G-E+CQF;VYT('-T>6QE/3-$)T9/ M3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)RPG#L@1D].5#H@,3!P="!4:6UE6QE/3-$ M)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4 M+5-)6D4Z(#$P<'0[34%21TE..B`P<'0@,'!X.R!&3TY4.B`Q,'!T(%1I;65S M($YE=R!2;VUA;BP@5&EM97,L(%-E6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I M;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[34%21TE..B`P<'0@,'!X M.R!&3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E28C.#(Q-SMS(&9E9&5R86P@86YD('-T871E('1A M>"!F;W)M6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA M;CM&3TY4+5-)6D4Z(#$P<'0G/B`F(S$V,#L\+V1I=CX@/&1I=B!S='EL93TS M1"=#3$5!4CIB;W1H.R!&3TY4+49!34E,63I4:6UE#L@1D].5#H@,3!P="!4:6UE M#L@1D].5#H@,3!P="!4:6UE6QE M/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM& M3TY4+5-)6D4Z(#$P<'0[34%21TE..B`P<'0@,'!X.R!&3TY4.B`Q,'!T(%1I M;65S($YE=R!2;VUA;BP@5&EM97,L(%-E2X@5&AE(&)A;&%N8V4@;V8@86-C=6UU;&%T960@ M;W1H97(@8V]M<')E:&5N6QE/3-$)T9/3E0M1D%-24Q9.B`G M5&EM97,@3F5W(%)O;6%N)RPG#L@1D].5#H@,3!P="!4:6UE6QE/3-$)T-,14%2.F)O=&@[($9/3E0M M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[34%21TE. M.B`P<'0@,'!X.R!&3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L M(%-E6QE/3-$)T9/3E0M1D%- M24Q9.B`G5&EM97,@3F5W(%)O;6%N)RPG6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N M)RPG#L@1D].5#H@,3!P="!4 M:6UE3Y4:&4@ M0V]M<&%N>28C.#(Q-SMS(')E=F5N=65S(&%R92!C=7)R96YT;'D@9&5R:79E M9"!F2!H87,@;V-C=7)R960@*&]R('-E2!I6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE M=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[34%21TE..B`P<'0@,'!X.R!&3TY4 M.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E3Y&;W(@;75L=&EP;&4M M96QE;65N="!A3XF(S$V,#L\ M+V1I=CX@/&1I=B!S='EL93TS1"=#3$5!4CIB;W1H.R!&3TY4+49!34E,63I4 M:6UE#L@1D].5#H@,3!P="!4:6UE2!D971E2!C;VYS:61E#L@1D].5#H@,3!P="!4:6UE3X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@)U1I;65S($YE M=R!2;VUA;B2!P2!T;R!P=7)C:&%S97)S(&]F(&5Q=6EP;65N M="X@02!P;W)T:6]N(&]F(')E=F5N=64@2!W:&EC:"!I6QE/3-$ M)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4 M+5-)6D4Z(#$P<'0[34%21TE..B`P<'0@,'!X.R!&3TY4.B`Q,'!T(%1I;65S M($YE=R!2;VUA;BP@5&EM97,L(%-E3X\#L@1D].5#H@,3!P="!4:6UE'!E;G-E(&%S(&EN8W5R6QE/3-$)T9/3E0M1D%-24Q9 M.B`G5&EM97,@3F5W(%)O;6%N)RPG#L@1D].5#H@,3!P="!4:6UE6QE/3-$ M)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4 M+5-)6D4Z(#$P<'0[34%21TE..B`P<'0@,'!X.R!&3TY4.B`Q,'!T(%1I;65S M($YE=R!2;VUA;BP@5&EM97,L(%-E6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)RPG6QE/3-$)T-,14%2.F)O=&@[($9/3E0M M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[34%21TE. M.B`P<'0@,'!X.R!&3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L M(%-E#L@1D].5#H@,3!P="!4:6UE6QE/3-$ M)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)RPG3XF(S$V,#L\+V1I=CX@/&1I=B!S M='EL93TS1"=#3$5!4CIB;W1H.R!&3TY4+49!34E,63I4:6UE#L@1D].5#H@,3!P M="!4:6UE6QE/3-$)T9/ M3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)RPG#L@1D].5#H@,3!P="!4:6UE3X\9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z M(#$P<'0G/D)A#L@1D]. M5#H@,3!P="!4:6UE6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%- M24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[34%21TE..B`P M<'0@,'!X.R!&3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E M#L@1D].5#H@,3!P="!4:6UE2!O=&AE3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R M=%]C8C(Q,68U,5\W,V$Q7S1C-#9?8C!B,U]B.#@Y9#5D-C0W8F4-"D-O;G1E M;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO8V(R,3%F-3%?-S-A,5\T8S0V7V(P M8C-?8C@X.60U9#8T-V)E+U=O'0O:'1M;#L@8VAA6QE/3-$)TU!4D=)3BU43U`Z(#!P=#L@ M1D].5#H@,3!P="!4:6UE6QE/3-$)U9%4E1)0T%,+4%,24=. M.B!T;W`G/B`\=&0@6QE/3-$)T-,14%2.F)O=&@[($9/ M3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[5$58 M5"U)3D1%3E0Z("TP+C(U:6X[($U!4D=)3CH@,'!T(#!P>"`P<'0@,"XR-6EN M.R!&3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E6QE M/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM& M3TY4+5-)6D4Z(#$P<'0[34%21TE..B`P<'0@,'!X.R!&3TY4.B`Q,'!T(%1I M;65S($YE=R!2;VUA;BP@5&EM97,L(%-E2!H87,@97AP96YD960@65A6QE/3-$)T9/3E0M1D%-24Q9 M.B`G5&EM97,@3F5W(%)O;6%N)RPG6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM M97,@3F5W(%)O;6%N)RPG2!W:6QL(&YE960@=&\@2!I;B!T:&4@9G5T=7)E M+B!4:&5R92!C86X@8F4@;F\@87-S=7)A;F-E('1H870@=&AE($-O;7!A;GD@ M=VEL;"!C;VYT:6YU92!T;R!B92!S=6-C97-S9G5L(&EN('-E;&QI;F<@<')O M9'5C=',N/"]D:78^(#QD:78@3XF(S$V,#L\+V1I=CX@/&1I=B!S='EL M93TS1"=#3$5!4CIB;W1H.R!&3TY4+49!34E,63I4:6UE#L@1D].5#H@,3!P="!4 M:6UEF5D("0\9F]N="!S='EL93TS1"=&3TY4+49! M34E,63H@)U1I;65S($YE=R!2;VUA;B6QE/3-$)T9/3E0M1D%- M24Q9.B`G5&EM97,@3F5W(%)O;6%N)RPG2!H860@8V%S:"!A;F0@8V%S:"!E<75I=F%L96YT M#L@1D].5#H@,3!P="!4 M:6UE6QE/3-$)T-,14%2.F)O=&@[($9/3E0M M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[34%21TE. M.B`P<'0@,'!X.R!&3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L M(%-E2!A2!A;F0@8V%S:"!F;&]W6QE/3-$)W=I M9'1H.C$P,"4[('1A8FQE+6QA>6]U=#IF:7AE9#LG(&-E;&QS<&%C:6YG/3-$ M,"!C96QL<&%D9&EN9STS1#`^/'1R/CQT9#X\+W1D/CPO='(^/"]T86)L93X\ M'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA'0^)SQD:78@6QE/3-$)U=)1%1(.B`P+C(U:6XG M/B`\9&EV/CQS=')O;F<^,RX\+W-T6QE/3-$)U1%6%0M04Q)1TXZ(&IU6QE/3-$)T-,14%2.F)O=&@[($9/3E0M M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[34%21TE. M.B`P<'0@,'!X.R!&3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L M(%-E2`Q-RP@,C`Q,BP@ M=&AE($-O;7!A;GD@86-Q=6ER960@36%N:&%T=&%N($ES;W1O<&4@5&5C:&YO M;&]G>2!,3$,@*"8C.#(R,#M-250F(S@R,C$[*2!U<&]N(&-O;G-U;6UA=&EO M;B!O9B!A($UE;6)E6QE/3-$)T-,14%2.F)O=&@[ M($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[ M34%21TE..B`P<'0@,'!X.R!&3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@ M5&EM97,L(%-E3Y);B!A8V-O2!A8W%U:7)E9"!T:&4@87-S971S(')E;&%T960@=&\@34E4 M)B,X,C$W.W,@8G5S:6YE6%B;&5S+"!A8V-R=6%L6%B;&4@=VET:"!A(&-O;6UE#L@1D].5#H@,3!P="!4:6UE6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2 M;VUA;CM&3TY4+5-)6D4Z(#$P<'0[34%21TE..B`P<'0@,'!X.R!&3TY4.B`Q M,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E6QE/3-$)T-,14%2.F)O=&@[ M($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[ M34%21TE..B`P<'0@,'!X.R!&3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@ M5&EM97,L(%-E3Y4:&4@0V]M<&%N>2!I;F-U3XF(S$V M,#L\+V1I=CX@/&1I=B!S='EL93TS1"=#3$5!4CIB;W1H.R!&3TY4+49!34E, M63I4:6UE#L@1D].5#H@,3!P="!4:6UE#L@1D].5#H@,3!P="!4 M:6UE6QE/3-$)T-,14%2.F)O=&@[($9/3E0M M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[34%21TE. M.B`P<'0@,'!X.R!&3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L M(%-E6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I M;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[5$585"U!3$E'3CI,969T M.R!415A4+4E.1$5.5#H@,&EN.R!724142#H@,3`P)2<^(#QT86)L92!S='EL M93TS1"=-05)'24XZ(#!I;CL@5TE$5$@Z(#DU)3L@0D]21$52+4-/3$Q!4%-% M.B!C;VQL87!S93L@3U9%4D9,3U6QE/3-$)U1%6%0M M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO6QE/3-$ M)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)U1%6%0M04Q) M1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA M;CL@0D%#2T=23U5.1#H@(V9F9F9F9CL@1D].5"U325I%.B`Q,'!T.R!615)4 M24-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS M1#$U)3X@/&1I=CXR,#4L,CDW/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=4 M15A4+4%,24=..B!L969T.R!&3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%- M24Q9.B!4:6UE6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,W!X(&1O M=6)L93L@5$585"U!3$E'3CH@;&5F=#L@1D].5"U35%E,13H@;F]R;6%L.R!& M3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!"04-+1U)/54Y$.B`C8V-F M9F-C.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[ M($)/4D1%4BU43U`Z(",P,#`P,#`@,7!X('-O;&ED.R!&3TY4+5=%24=(5#H@ M-#`P)R!W:61T:#TS1#$E/B`\9&EV/B0\+V1I=CX@/"]T9#X@/'1D('-T>6QE M/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,W!X(&1O=6)L93L@5$585"U! M3$E'3CH@6QE/3-$)T-,14%2 M.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z M(#$P<'0[34%21TE..B`P<'0@,'!X.R!&3TY4.B`Q,'!T(%1I;65S($YE=R!2 M;VUA;BP@5&EM97,L(%-E6QE/3-$)T9/3E0M1D%- M24Q9.B`G5&EM97,@3F5W(%)O;6%N)RPGF5S('1H M92!F86ER('9A;'5E6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA M;CM&3TY4+5-)6D4Z(#$P<'0[34%21TE.+51/4#H@,'!T.R!&3TY4.B`Q,'!T M(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E6QE/3-$)U1%6%0M04Q)1TXZ(&QE M9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U19 M3$4Z(&YO6QE/3-$)U1%6%0M04Q)1TXZ(')I M9VAT.R!&3TY4+5-464Q%.B!N;W)M86P[(%!!1$1)3D#L@ M1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@0D%#2T=23U5.1#H@(V-C M9F9C8SL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M M.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$U)3X@/&1I=CXX,CD\+V1I M=CX@/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M M4U193$4Z(&YO6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!&3TY4+5-464Q%.B!N M;W)M86P[(%!!1$1)3D#L@1D].5"U&04U)3%DZ(%1I;65S M($YE=R!2;VUA;CL@0D%#2T=23U5.1#H@(V9F9F9F9CL@1D].5"U325I%.B`Q M,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@-#`P M)R!W:61T:#TS1#$U)3X@/&1I=CXV-3,L-38W/"]D:78^(#PO=&0^(#QT9"!S M='EL93TS1"=415A4+4%,24=..B!L969T.R!&3TY4+5-464Q%.B!N;W)M86P[ M($9/3E0M1D%-24Q9.B!4:6UE6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/ M3E0M4U193$4Z(&YO6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!&3TY4+5-464Q% M.B!N;W)M86P[($9/3E0M1D%-24Q9.B!4:6UE6QE/3-$)U1%6%0M04Q) M1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,7!X('-O M;&ED.R!415A4+4%,24=..B!L969T.R!&3TY4+5-464Q%.B!N;W)M86P[($9/ M3E0M1D%-24Q9.B!4:6UE6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@ M,7!X('-O;&ED.R!415A4+4%,24=..B!R:6=H=#L@1D].5"U35%E,13H@;F]R M;6%L.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!"04-+1U)/54Y$ M.B`C8V-F9F-C.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B M;W1T;VT[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$,34E/B`\9&EV/B@W M,#`L,#`P*3PO9&EV/B`\+W1D/B`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`\9&EV('-T>6QE/3-$)T-,14%2 M.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z M(#$P<'0G/CPO9&EV/B`\+V1I=CX@/&9O;G0@6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%- M24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[34%21TE..B`P M<'0@,'!X(#!P="`P+C(U:6X[($9/3E0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N M+"!4:6UE3XF(S$V,#L\+V1I=CX@ M/&1I=B!S='EL93TS1"=#3$5!4CIB;W1H.R!&3TY4+49!34E,63I4:6UE#L@1D]. M5#H@,3!P="!4:6UE6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM M97,@3F5W(%)O;6%N)RPG6QE/3-$)T-,14%2.F)O=&@[($9/ M3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[34%2 M1TE..B`P<'0@,'!X.R!&3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM M97,L(%-E3Y4:&4@86-Q=6ES:71I;VX@;V8@34E4(&EN8VQU9&5S(&$@8V]N=&EN M9V5N="!C;VYS:61E6QE/3-$)T9/ M3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)RPG'!E;G-E2!F86-T;W)S M(&%T('1H92!A8W%U:7-I=&EO;B!D871E+CPO9&EV/B`\9&EV('-T>6QE/3-$ M)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4 M+5-)6D4Z(#$P<'0[34%21TE..B`P<'0@,'!X.R!&3TY4.B`Q,'!T(%1I;65S M($YE=R!2;VUA;BP@5&EM97,L(%-E3Y!="!$96-E;6)E6QE/3-$)W=I9'1H.C$P,"4[('1A8FQE+6QA>6]U=#IF:7AE M9#LG(&-E;&QS<&%C:6YG/3-$,"!C96QL<&%D9&EN9STS1#`^/'1R/CQT9#X\ M+W1D/CPO='(^/"]T86)L93X\'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA'0^)SQD M:78@6QE/3-$)U=)1%1(.B`P M+C(U:6XG/B`\9&EV/CQB/C0N/"]B/CPO9&EV/B`\+W1D/B`\=&0@2<^(#QD:78^/&(^3U1(15(@05-31513 M/"]B/CPO9&EV/B`\+W1D/B`\+W1R/B`\+W1A8FQE/B`F(S$V,#L@/&1I=B!S M='EL93TS1"=#3$5!4CIB;W1H.R!&3TY4+49!34E,63I4:6UE#L@1D].5#H@,3!P M="!4:6UE6QE M/3-$)W=I9'1H.C$P,"4[('1A8FQE+6QA>6]U=#IF:7AE9#LG(&-E;&QS<&%C M:6YG/3-$,"!C96QL<&%D9&EN9STS1#`^/'1R/CQT9#X\+W1D/CPO='(^/"]T M86)L93X\'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA'0^)SQS<&%N/CPO'0^)SQD:78@6QE/3-$)U=)1%1(.B`P+C(U:6XG/B`\9&EV/CQS=')O;F<^ M-2X\+W-T6QE/3-$)U1%6%0M04Q) M1TXZ(&IU3X\9F]N="!S='EL93TS1"=&3TY4+49! M34E,63H@)U1I;65S($YE=R!2;VUA;B6QE/3-$)T-,14%2.F)O=&@[($9/3E0M M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[34%21TE. M.B`P<'0@,'!X.R!&3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L M(%-E"!S;VQI9#L@34%21TE..B`P<'@Z875T;SL@5TE$5$@Z(#@U)3L@ M0D]21$52+4-/3$Q!4%-%.B!C;VQL87!S93L@3U9%4D9,3U6QE/3-$)U1%6%0M M04Q)1TXZ(&-E;G1E"!S;VQI9#L@5$585"U!3$E'3CH@8V5N=&5R M.R!&3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!4:6UE6QE M/3-$)U1%6%0M04Q)1TXZ(&-E;G1E6QE/3-$)U1%6%0M04Q)1TXZ(&-E;G1E6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`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`U<'@[($9/3E0M1D%-24Q9.B!4:6UE M6QE/3-$)U1% M6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!&3TY4+5-464Q%.B!N M;W)M86P[(%!!1$1)3D#L@1D].5"U&04U)3%DZ(%1I;65S M($YE=R!2;VUA;CL@0D%#2T=23U5.1#H@(V9F9F9F9CL@0T],3U(Z(",P,#`P M,#`[($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O='1O;3L@ M1D].5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q,24^(#QD:78^.3(W/"]D:78^ M(#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!L969T.R!&3TY4+5-4 M64Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!4:6UE6QE/3-$)U1%6%0M04Q) M1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[ M($9/3E0M4U193$4Z(&YO6QE/3-$)T)/4D1%4BU"3U143TTZ(",P M,#`P,#`@,7!X('-O;&ED.R!415A4+4%,24=..B!L969T.R!&3TY4+5-464Q% M.B!N;W)M86P[($9/3E0M1D%-24Q9.B!4:6UE6QE/3-$)T)/4D1%4BU"3U14 M3TTZ(",P,#`P,#`@,7!X('-O;&ED.R!415A4+4%,24=..B!R:6=H=#L@1D]. M5"U35%E,13H@;F]R;6%L.R!0041$24Y'+5))1TA4.B`U<'@[($9/3E0M1D%- M24Q9.B!4:6UE6QE/3-$ M)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,7!X('-O;&ED.R!415A4+4%,24=. M.B!L969T.R!&3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!4:6UE M6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,7!X('-O;&ED.R!415A4 M+4%,24=..B!R:6=H=#L@1D].5"U35%E,13H@;F]R;6%L.R!0041$24Y'+5)) M1TA4.B`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`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!"3U)$15(M5$]0 M.B`C,#`P,#`P(#%P>"!S;VQI9#L@1D].5"U714E'2%0Z(#0P,"<@=VED=&@] M,T0Q,24^(#QD:78^,2PP,#@\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)U1% M6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO6QE/3-$ M)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,7!X('-O;&ED.R!415A4+4%,24=. M.B!L969T.R!&3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!4:6UE M6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,7!X('-O;&ED.R!415A4 M+4%,24=..B!R:6=H=#L@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E, M63H@5&EM97,@3F5W(%)O;6%N.R!"04-+1U)/54Y$.B`C8V-F9F-C.R!&3TY4 M+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($9/3E0M5T5) M1TA4.B`T,#`G('=I9'1H/3-$,3$E/B`\9&EV/B@T-#0I/"]D:78^(#PO=&0^ M(#QT9"!S='EL93TS1"=415A4+4%,24=..B!L969T.R!&3TY4+5-464Q%.B!N M;W)M86P[($9/3E0M1D%-24Q9.B!4:6UE6QE/3-$)T)/4D1%4BU"3U143TTZ M(",P,#`P,#`@,7!X('-O;&ED.R!415A4+4%,24=..B!L969T.R!&3TY4+5-4 M64Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!4:6UE6QE/3-$)T)/4D1%4BU" M3U143TTZ(",P,#`P,#`@,7!X('-O;&ED.R!415A4+4%,24=..B!R:6=H=#L@ M1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O M;6%N.R!"04-+1U)/54Y$.B`C8V-F9F-C.R!&3TY4+5-)6D4Z(#$P<'0[(%9% M4E1)0T%,+4%,24=..B!B;W1T;VT[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H M/3-$,3$E/B`\9&EV/B@T-3"!D M;W5B;&4[(%1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO"!S;VQI9#L@1D].5"U714E'2%0Z M(#0P,"<@=VED=&@],T0Q)3X@/&1I=CXD/"]D:78^(#PO=&0^(#QT9"!S='EL M93TS1"="3U)$15(M0D]45$]-.B`C,#`P,#`P(#-P>"!D;W5B;&4[(%1%6%0M M04Q)1TXZ(')I9VAT.R!&3TY4+5-464Q%.B!N;W)M86P[(%!!1$1)3D#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@0D%#2T=2 M3U5.1#H@(V9F9F9F9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E' M3CH@8F]T=&]M.R!"3U)$15(M5$]0.B`C,#`P,#`P(#%P>"!S;VQI9#L@1D]. M5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q,24^(#QD:78^-30W/"]D:78^(#PO M=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!L969T.R!&3TY4+5-464Q% M.B!N;W)M86P[($9/3E0M1D%-24Q9.B!4:6UE6QE/3-$)T)/4D1%4BU"3U14 M3TTZ(",P,#`P,#`@,W!X(&1O=6)L93L@5$585"U!3$E'3CH@;&5F=#L@1D]. M5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N M.R!"04-+1U)/54Y$.B`C9F9F9F9F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1) M0T%,+4%,24=..B!B;W1T;VT[($)/4D1%4BU43U`Z(",P,#`P,#`@,7!X('-O M;&ED.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$E/B`\9&EV/B0\+V1I M=CX@/"]T9#X@/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@ M,W!X(&1O=6)L93L@5$585"U!3$E'3CH@6QE/3-$)U1%6%0M04Q)1TXZ M(&QE9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9 M.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0G/CPO9&EV/B`\9&EV M('-T>6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2 M;VUA;CM&3TY4+5-)6D4Z(#$P<'0G/CPO9&EV/B`\+V1I=CX@/&9O;G0@6QE/3-$)T-,14%2 M.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z M(#$P<'0[34%21TE..B`P<'0@,'!X.R!&3TY4.B`Q,'!T(%1I;65S($YE=R!2 M;VUA;BP@5&EM97,L(%-E3Y) M;G9E;G1O6QE/3-$)W=I9'1H.C$P,"4[('1A8FQE+6QA>6]U=#IF:7AE9#LG M(&-E;&QS<&%C:6YG/3-$,"!C96QL<&%D9&EN9STS1#`^/'1R/CQT9#X\+W1D M/CPO='(^/"]T86)L93X\'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA2P@4&QA;G0@86YD($5Q=6EP M;65N="!;06)S=')A8W1=/"]S=')O;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T* M("`@("`@/'1R(&-L87-S/3-$2!A;F0@97%U:7!M96YT/"]T9#X-"B`@ M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/&1I=B!S='EL93TS1"=-05)'24XZ M(#!P="`P<'@[($9/3E0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE6QE/3-$)TU!4D=)3BU43U`Z(#!P=#L@1D]. M5#H@,3!P="!4:6UE6QE/3-$)U9%4E1)0T%,+4%,24=..B!T M;W`G/B`\=&0@2<^(#QD:78^/'-T6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I M;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[34%21TE..B`P<'0@,'!X M.R!&3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E2!A;F0@97%U:7!M96YT(&%T($1E8V5M8F5R(#,Q+"`R M,#$S(&%N9"`R,#$R(&-O;G-I6QE/3-$)T-,14%2.F)O=&@[($9/ M3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[34%2 M1TE..B`P<'0@,'!X.R!&3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM M97,L(%-E6QE M/3-$)U1%6%0M04Q)1TXZ(&-E;G1E6QE/3-$ M)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,7!X('-O;&ED.R!415A4+4%,24=. M.B!C96YT97([($9/3E0M4U193$4Z(&YO6QE/3-$)U1%6%0M04Q)1TXZ(&QE M9G0[($9/3E0M4U193$4Z(&YO"!S;VQI9#L@1D].5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q)3X@/&1I M=CXD/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!R:6=H M=#L@1D].5"U35%E,13H@;F]R;6%L.R!0041$24Y'+5))1TA4.B`U<'@[($9/ M3E0M1D%-24Q9.B!4:6UE6QE/3-$)U1% M6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO6QE M/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!&3TY4+5-464Q%.B!N;W)M86P[(%!! M1$1)3D#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA M;CL@0D%#2T=23U5.1#H@(V9F9F9F9CL@1D].5"U325I%.B`Q,'!T.R!615)4 M24-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS M1#$Q)3X@/&1I=CXX.#PO9&EV/B`\+W1D/B`\=&0@6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT M.R!&3TY4+5-464Q%.B!N;W)M86P[(%!!1$1)3D#L@1D]. M5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@0D%#2T=23U5.1#H@(V9F9F9F M9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!& M3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$Q)3X@/&1I=CXW-3PO9&EV/B`\ M+W1D/B`\=&0@6QE/3-$ M)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)U1%6%0M04Q)1TXZ(&QE M9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)U1%6%0M M04Q)1TXZ(')I9VAT.R!&3TY4+5-464Q%.B!N;W)M86P[(%!!1$1)3D#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@0D%#2T=2 M3U5.1#H@(V9F9F9F9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E' M3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$Q)3X@/&1I M=CXV,CPO9&EV/B`\+W1D/B`\=&0@6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!&3TY4+5-4 M64Q%.B!N;W)M86P[(%!!1$1)3D#L@1D].5"U&04U)3%DZ M(%1I;65S($YE=R!2;VUA;CL@0D%#2T=23U5.1#H@(V9F9F9F9CL@1D].5"U3 M25I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=( M5#H@-#`P)R!W:61T:#TS1#$Q)3X@/&1I=CXV,#PO9&EV/B`\+W1D/B`\=&0@ M6QE/3-$)U1%6%0M04Q) M1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M M4U193$4Z(&YO6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U19 M3$4Z(&YO6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO"!S M;VQI9#L@5$585"U!3$E'3CH@;&5F=#L@1D].5"U35%E,13H@;F]R;6%L.R!& M3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!"04-+1U)/54Y$.B`C9F9F M9F9F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[ M($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$,24^(#QD:78^)B,Q-C`[/"]D M:78^(#PO=&0^(#QT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B`C,#`P,#`P M(#%P>"!S;VQI9#L@5$585"U!3$E'3CH@"!S;VQI9#L@5$585"U!3$E'3CH@;&5F=#L@1D].5"U35%E,13H@;F]R;6%L M.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!"04-+1U)/54Y$.B`C M9F9F9F9F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T M;VT[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$,24^(#QD:78^)B,Q-C`[ M/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B`C,#`P M,#`P(#%P>"!S;VQI9#L@5$585"U!3$E'3CH@6QE/3-$)U1%6%0M04Q)1TXZ M(&QE9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO"!S;VQI9#L@5$585"U!3$E'3CH@;&5F=#L@1D].5"U3 M5%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!" M04-+1U)/54Y$.B`C9F9F9F9F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%, M+4%,24=..B!B;W1T;VT[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$,24^ M(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"="3U)$15(M M0D]45$]-.B`C,#`P,#`P(#%P>"!S;VQI9#L@5$585"U!3$E'3CH@6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[ M($9/3E0M4U193$4Z(&YO6QE/3-$ M)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)T)/4D1%4BU" M3U143TTZ(",P,#`P,#`@,W!X(&1O=6)L93L@5$585"U!3$E'3CH@;&5F=#L@ M1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O M;6%N.R!"04-+1U)/54Y$.B`C8V-F9F-C.R!&3TY4+5-)6D4Z(#$P<'0[(%9% M4E1)0T%,+4%,24=..B!B;W1T;VT[($)/4D1%4BU43U`Z(",P,#`P,#`@,7!X M('-O;&ED.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$E/B`\9&EV/B0\ M+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P M,#`@,W!X(&1O=6)L93L@5$585"U!3$E'3CH@6QE/3-$)W=I M9'1H.C$P,"4[('1A8FQE+6QA>6]U=#IF:7AE9#LG(&-E;&QS<&%C:6YG/3-$ M,"!C96QL<&%D9&EN9STS1#`^/'1R/CQT9#X\+W1D/CPO='(^/"]T86)L93X\ M'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA6%B;&4@ M86YD($%C8W)U960@3&EA8FEL:71I97,\+W1D/@T*("`@("`@("`\=&0@8VQA M6QE/3-$)TU!4D=)3CH@,'!T(#!P>#L@1D]. M5#H@,3!P="!4:6UE6%B;&4@86YD(&%C8W)U960@ M;&EA8FEL:71I97,@870@1&5C96UB97(@,S$L(#(P,3,@86YD+"`R,#$R(&-O M;G-I6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S M($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[34%21TE..B`P<'0@,'!X.R!& M3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E6QE/3-$)U1%6%0M04Q)1TXZ M(&-E;G1E6QE/3-$)T)/4D1%4BU"3U143TTZ M(",P,#`P,#`@,7!X('-O;&ED.R!415A4+4%,24=..B!C96YT97([($9/3E0M M4U193$4Z(&YO"!S;VQI9#L@1D].5"U7 M14E'2%0Z(#6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,7!X('-O M;&ED.R!415A4+4%,24=..B!C96YT97([($9/3E0M4U193$4Z(&YO"!S;VQI9#L@1D].5"U714E'2%0Z(#6%B;&4\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)U1% M6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!&3TY4+5-464Q%.B!N M;W)M86P[(%!!1$1)3D#L@1D].5"U&04U)3%DZ(%1I;65S M($YE=R!2;VUA;CL@0D%#2T=23U5.1#H@(V-C9F9C8SL@1D].5"U325I%.B`Q M,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!"3U)$15(M5$]0.B`C,#`P M,#`P(#%P>"!S;VQI9#L@1D].5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q,24^ M(#QD:78^.#0Y/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=. M.B!L969T.R!&3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!4:6UE M6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO"!S;VQI9#L@1D].5"U714E'2%0Z M(#0P,"<@=VED=&@],T0Q)3X@/&1I=CXD/"]D:78^(#PO=&0^(#QT9"!S='EL M93TS1"=415A4+4%,24=..B!R:6=H=#L@1D].5"U35%E,13H@;F]R;6%L.R!0 M041$24Y'+5))1TA4.B`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`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T M=&]M.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$Q)3X@/&1I=CXR.#PO M9&EV/B`\+W1D/B`\=&0@"!S;VQI9#L@5$585"U!3$E'3CH@;&5F M=#L@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@5&EM97,@3F5W M(%)O;6%N.R!"04-+1U)/54Y$.B`C9F9F9F9F.R!&3TY4+5-)6D4Z(#$P<'0[ M(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($9/3E0M5T5)1TA4.B`T,#`G('=I M9'1H/3-$,24^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL93TS M1"="3U)$15(M0D]45$]-.B`C,#`P,#`P(#%P>"!S;VQI9#L@5$585"U!3$E' M3CH@6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[ M($9/3E0M4U193$4Z(&YO"!S;VQI9#L@1D].5"U714E'2%0Z(#0P M,"<@=VED=&@],T0Q,24^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S M='EL93TS1"=415A4+4%,24=..B!L969T.R!&3TY4+5-464Q%.B!N;W)M86P[ M($9/3E0M1D%-24Q9.B!4:6UE6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/ M3E0M4U193$4Z(&YO"!S M;VQI9#L@1D].5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q)3X@/&1I=CXF(S$V M,#L\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT M.R!&3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!4:6UE6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z M(&YO6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,W!X(&1O=6)L93L@5$58 M5"U!3$E'3CH@6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,W!X(&1O=6)L93L@5$58 M5"U!3$E'3CH@;&5F=#L@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E, M63H@5&EM97,@3F5W(%)O;6%N.R!"04-+1U)/54Y$.B`C9F9F9F9F.R!&3TY4 M+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($9/3E0M5T5) M1TA4.B`T,#`G('=I9'1H/3-$,24^(#QD:78^)#PO9&EV/B`\+W1D/B`\=&0@ M6QE/3-$)U1%6%0M04Q) M1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R=%]C8C(Q,68U M,5\W,V$Q7S1C-#9?8C!B,U]B.#@Y9#5D-C0W8F4-"D-O;G1E;G0M3&]C871I M;VXZ(&9I;&4Z+R\O0SHO8V(R,3%F-3%?-S-A,5\T8S0V7V(P8C-?8C@X.60U M9#8T-V)E+U=O'0O:'1M;#L@8VAA2!#=7-T;VUE'0^)SQS<&%N M/CPO6QE/3-$)TU!4D=)3CH@,'!T(#!P>#L@1D].5#H@,3!P="!4 M:6UE6QE/3-$)U1%6%0M04Q)1TXZ(&IU#L@ M1D].5#H@,3!P="!4:6UE2X@26YC;'5D960@:6X@8W5S=&]M97(@ M9&5P;W-I=',@870@1&5C96UB97(@,S$L(#(P,3,@86YD(#(P,3(@=V5R92!D M97!O#L@1D].5#H@,3!P="!4:6UE6QE/3-$)T-, M14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-) M6D4Z(#$P<'0[34%21TE..B`P<'0@,'!X.R!&3TY4.B`Q,'!T(%1I;65S($YE M=R!2;VUA;BP@5&EM97,L(%-E7-T96US+CPO9&EV/B`\9&EV('-T>6QE/3-$)T-,14%2.F)O M=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P M<'0[34%21TE..B`P<'0@,'!X.R!&3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA M;BP@5&EM97,L(%-E3X-"CPO:'1M M;#X-"@T*+2TM+2TM/5].97AT4&%R=%]C8C(Q,68U,5\W,V$Q7S1C-#9?8C!B M,U]B.#@Y9#5D-C0W8F4-"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO M8V(R,3%F-3%?-S-A,5\T8S0V7V(P8C-?8C@X.60U9#8T-V)E+U=O'0O:'1M;#L@8VAA M6QE/3-$)V-L96%R.F)O=&@[34%21TE.+51/ M4#H@,'!T.R!&3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E M3X\96T^0V]N=F5R=&EB;&4@1&5B M96YT=7)E#L@1D].5#H@,3!P="!4:6UE6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S M($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[34%21TE..B`P<'0@,'!X.R!& M3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E2`Q,BP@,C`Q,BP@=&AE($-O;7!A;GD@ M86-Q=6ER960@82!B=6EL9&EN9R!I;B!797-T;6]N="P@26QL:6YO:7,L('=H M:6-H('1H92!#;VUP86YY('!R979I;W5S;'D@;&5A2!I6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM M97,@3F5W(%)O;6%N)RPG6QE/3-$)T9/ M3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)RPG28C M.#(Q-SMS(&-O;6UO;B!S=&]C:RP@<&%R('9A;'5E("0\9F]N="!S='EL93TS M1"=&3TY4+49!34E,63H@)U1I;65S($YE=R!2;VUA;B6QE/3-$)T9/3E0M M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)RPG6QE/3-$)T9/3E0M1D%-24Q9 M.B`G5&EM97,@3F5W(%)O;6%N)RPG3XF(S$V,#L\+V1I=CX@ M/&1I=B!S='EL93TS1"=#3$5!4CIB;W1H.R!&3TY4+49!34E,63I4:6UE#L@1D]. M5#H@,3!P="!4:6UE6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O M;6%N)RPG'!I6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM M97,@3F5W(%)O;6%N)RPG7,@<')E8V5D M:6YG(&-O;G9E3XF(S$V,#L\+V1I=CX@ M/&1I=B!S='EL93TS1"=#3$5!4CIB;W1H.R!&3TY4+49!34E,63I4:6UE#L@1D]. M5#H@,3!P="!4:6UE6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE M=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[34%21TE..B`P<'0@,'!X.R!&3TY4 M.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E3Y5;F1E2!S97!A3XF(S$V,#L\+V1I=CX@ M/&1I=B!S='EL93TS1"=#3$5!4CIB;W1H.R!&3TY4+49!34E,63I4:6UE"`P<'0@ M,"XR-6EN.R!&3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E M6QE/3-$)T-,14%2.F)O M=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P M<'0[5$585"U)3D1%3E0Z(#`N-6EN.R!-05)'24XZ(#!P="`P<'@@,'!T(#`N M,C5I;CL@1D].5#H@,3!P="!4:6UE6QE/3-$ M)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4 M+5-)6D4Z(#$P<'0[5$585"U!3$E'3CI,969T.R!415A4+4E.1$5.5#H@,&EN M.R!724142#H@,3`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`G5&EM97,@3F5W(%)O;6%N)RPG"`P<'0@,"XR-6EN.R!&3TY4.B`Q,'!T(%1I;65S($YE=R!2 M;VUA;BP@5&EM97,L(%-E3X\96T^0V]N=F5R=&EB;&4@ M1&5B96YT=7)E#L@1D].5#H@,3!P="!4:6UE6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I M;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[34%21TE..B`P<'0@,'!X M.R!&3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E6QE/3-$)T9/3E0M4TE:13H@,3!P="<^3VX@1&5C96UB97(@.2P@,C`Q M,RP@;VYE(&]F('1H92!);G9E6QE/3-$)T-,14%2.F)O M=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P M<'0[34%21TE..B`P<'0@,'!X.R!&3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA M;BP@5&EM97,L(%-E#L@1D].5#H@,3!P="!4:6UE6QE/3-$)T-,14%2.F)O M=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P M<'0[34%21TE..B`P<'0@,'!X.R!&3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA M;BP@5&EM97,L(%-E2X@5&AE($-O;7!A;GD@86QL;V-A=&5D('1H92!P2X@5&AE M(&9A:7(@=F%L=64@;V8@=&AE(&5M8F5D9&5D(&-O;G9E6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA M;CM&3TY4+5-)6D4Z(#$P<'0[34%21TE..B`P<'0@,'!X.R!&3TY4.B`Q,'!T M(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E#L@1D].5#H@ M,3!P="!4:6UE6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I M;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[(%1%6%0M24Y$14Y4.B`P M:6X[(%=)1%1(.B`Q,#`E)SX@/'1A8FQE('-T>6QE/3-$)V-L96%R.F)O=&@[ M0D]21$52+4)/5%1/33H@(SEE8C9C92`P<'@@"!S;VQI9#L@5TE$5$@Z(#$P,"4[($)/4D1%4BU#3TQ, M05!313H@8V]L;&%P6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!&3TY4 M+5-464Q%.B!N;W)M86P[(%!!1$1)3D#L@1D].5"U&04U) M3%DZ(%1I;65S($YE=R!2;VUA;CL@0D%#2T=23U5.1#H@(V-C9F9C8SL@1D]. M5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=% M24=(5#H@-#`P)R!W:61T:#TS1#$R)3X@/&1I=CXR+#4R,#PO9&EV/B`\+W1D M/B`\=&0@6QE/3-$)U1% M6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z M(&YO6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)U1%6%0M M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO6QE M/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)RPG3X\96T^)B,Q-C`[/"]E;3X\+V1I=CX@ M/&1I=B!S='EL93TS1"=#3$5!4CIB;W1H.R!&3TY4+49!34E,63I4:6UE#L@1D]. M5#H@,3!P="!4:6UE#L@1D].5#H@,3!P="!4:6UE6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I M;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[34%21TE..B`P:6X@,&EN M(#!P="<@86QI9VX],T1J=7-T:69Y/CQF;VYT('-T>6QE/3-$)T9/3E0M4TE: M13H@,3!P="<^07,@;V8@1&5C96UB97(@,S$L(#(P,3,L('1H92!H;VQD97)S M(&]F('1H92!C;VYV97)T:6)L92!D96)E;G1U'1E;F0@=&AO'1E;F1E9"!T:')O=6=H($1E8V5M8F5R(#,Q+"`R,#$T+B!!<'!R;WAI M;6%T96QY("0X,C$L,#`P(&EN(&5X<&5N65A#L@ M1D].5#H@,3!P="!4:6UE6QE M/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)RPG&ES=&EN9R!T97)M M65A3XF(S$V,#L\+V1I=CX@/&1I=B!S='EL93TS1"=#3$5!4CIB M;W1H.R!&3TY4+49!34E,63I4:6UE#L@1D].5#H@,3!P="!4:6UE65A6QE/3-$)T9/ M3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)RPG6QE/3-$)T9/3E0M1D%-24Q9 M.B`G5&EM97,@3F5W(%)O;6%N)RPG#L@1D]. M5#H@,3!P="!4:6UE6QE/3-$ M)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4 M+5-)6D4Z(#$P<'0[5$585"U!3$E'3CI,969T.R!415A4+4E.1$5.5#H@,&EN M.R!724142#H@,3`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`P,#`[ M($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O='1O;3L@1D]. M5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q,R4^(#QD:78^,2PW-3`\+V1I=CX@ M/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U19 M3$4Z(&YO6QE/3-$)U1%6%0M M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)T)/4D1%4BU" M3U143TTZ(",P,#`P,#`@,7!X('-O;&ED.R!415A4+4%,24=..B!L969T.R!& M3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!4:6UE6QE/3-$)T)/ M4D1%4BU"3U143TTZ(",P,#`P,#`@,7!X('-O;&ED.R!415A4+4%,24=..B!R M:6=H=#L@1D].5"U35%E,13H@;F]R;6%L.R!0041$24Y'+5))1TA4.B`Q<'@[ M($9/3E0M1D%-24Q9.B!4:6UE6QE/3-$)U1% M6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO#L@1D].5"U&04U)3%DZ(%1I;65S($YE M=R!2;VUA;CL@0D%#2T=23U5.1#H@(V9F9F9F9CL@0T],3U(Z(",P,#`P,#`[ M($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O='1O;3L@1D]. M5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q,R4^(#QD:78^,#PO9&EV/B`\+W1D M/B`\=&0@"!S;VQI9#L@5$585"U!3$E'3CH@;&5F=#L@1D].5"U3 M5%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!" M04-+1U)/54Y$.B`C9F9F9F9F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%, M+4%,24=..B!B;W1T;VT[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$,24^ M(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"="3U)$15(M M0D]45$]-.B`C,#`P,#`P(#%P>"!S;VQI9#L@5$585"U!3$E'3CH@6QE/3-$ M)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO M"!S;VQI9#L@1D].5"U7 M14E'2%0Z(#0P,"<@=VED=&@],T0Q)3X@/&1I=CXF(S$V,#L\+V1I=CX@/"]T M9#X@/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,7!X('-O M;&ED.R!415A4+4%,24=..B!R:6=H=#L@1D].5"U35%E,13H@;F]R;6%L.R!0 M041$24Y'+5))1TA4.B`S<'@[($9/3E0M1D%-24Q9.B!4:6UE"!S;VQI M9#L@1D].5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q,B4^(#QD:78^-"PT-3(\ M+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/ M3E0M4U193$4Z(&YO#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2 M;VUA;CL@0D%#2T=23U5.1#H@(V9F9F9F9CL@1D].5"U325I%.B`Q,'!T.R!6 M15)424-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T M:#TS1#4U)3X@/&1I=CY,97-S(&-U"!S;VQI9#L@5$585"U!3$E'3CH@;&5F=#L@1D].5"U3 M5%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!" M04-+1U)/54Y$.B`C9F9F9F9F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%, M+4%,24=..B!B;W1T;VT[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$,24^ M(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"="3U)$15(M M0D]45$]-.B`C,#`P,#`P(#%P>"!S;VQI9#L@5$585"U!3$E'3CH@"!S;VQI9#L@ M1D].5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q,R4^(#QD:78^*#(L-S`R*3PO M9&EV/B`\+W1D/B`\=&0@"!S;VQI9#L@5$585"U!3$E'3CH@;&5F M=#L@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@5&EM97,@3F5W M(%)O;6%N.R!"04-+1U)/54Y$.B`C9F9F9F9F.R!&3TY4+5-)6D4Z(#$P<'0[ M(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($9/3E0M5T5)1TA4.B`T,#`G('=I M9'1H/3-$,24^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL93TS M1"="3U)$15(M0D]45$]-.B`C,#`P,#`P(#%P>"!S;VQI9#L@5$585"U!3$E' M3CH@"!S;VQI9#L@5$585"U!3$E'3CH@ M;&5F=#L@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@5&EM97,@ M3F5W(%)O;6%N.R!"04-+1U)/54Y$.B`C9F9F9F9F.R!&3TY4+5-)6D4Z(#$P M<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($9/3E0M5T5)1TA4.B`T,#`G M('=I9'1H/3-$,24^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL M93TS1"="3U)$15(M0D]45$]-.B`C,#`P,#`P(#%P>"!S;VQI9#L@5$585"U! M3$E'3CH@6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO M6QE/3-$)T)/4D1%4BU"3U14 M3TTZ(",P,#`P,#`@,W!X(&1O=6)L93L@5$585"U!3$E'3CH@;&5F=#L@1D]. M5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N M.R!"04-+1U)/54Y$.B`C8V-F9F-C.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1) M0T%,+4%,24=..B!B;W1T;VT[($)/4D1%4BU43U`Z(",P,#`P,#`@,7!X('-O M;&ED.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$E/B`\9&EV/B0\+V1I M=CX@/"]T9#X@/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@ M,W!X(&1O=6)L93L@5$585"U!3$E'3CH@6QE M/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,W!X(&1O=6)L93L@5$585"U! M3$E'3CH@;&5F=#L@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@ M5&EM97,@3F5W(%)O;6%N.R!"04-+1U)/54Y$.B`C8V-F9F-C.R!&3TY4+5-) M6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($)/4D1%4BU43U`Z M(",P,#`P,#`@,7!X('-O;&ED.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS M1#$E/B`\9&EV/B0\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)T)/4D1%4BU" M3U143TTZ(",P,#`P,#`@,W!X(&1O=6)L93L@5$585"U!3$E'3CH@6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,W!X M(&1O=6)L93L@5$585"U!3$E'3CH@;&5F=#L@1D].5"U35%E,13H@;F]R;6%L M.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!"04-+1U)/54Y$.B`C M8V-F9F-C.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T M;VT[($)/4D1%4BU43U`Z(",P,#`P,#`@,7!X('-O;&ED.R!&3TY4+5=%24=( M5#H@-#`P)R!W:61T:#TS1#$E/B`\9&EV/B0\+V1I=CX@/"]T9#X@/'1D('-T M>6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,W!X(&1O=6)L93L@5$58 M5"U!3$E'3CH@#L@1D].5#H@,3!P="!4:6UE6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I M;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[5$585"U!3$E'3CI,969T M.R!415A4+4E.1$5.5#H@,&EN.R!724142#H@,3`P)2<^(#QT86)L92!S='EL M93TS1"=C;&5A6QE/3-$)U1%6%0M04Q)1TXZ M(&QE9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)U1%6%0M04Q)1TXZ(&-E;G1E6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,7!X M('-O;&ED.R!415A4+4%,24=..B!C96YT97([($9/3E0M4U193$4Z(&YO6QE/3-$)T)/4D1%4BU"3U143TTZ M(",P,#`P,#`@,7!X('-O;&ED.R!415A4+4%,24=..B!C96YT97([($9/3E0M M4U193$4Z(&YO"!S;VQI9#L@1D].5"U714E'2%0Z(#0P,"<@ M=VED=&@],T0Q,R4^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL M93TS1"=415A4+4%,24=..B!C96YT97([($9/3E0M4U193$4Z(&YO"!S;VQI9#L@1D].5"U7 M14E'2%0Z(#0P,"<@=VED=&@],T0Q,R4^(#QD:78^)B,Q-C`[/"]D:78^(#PO M=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!C96YT97([($9/3E0M4U19 M3$4Z(&YO"!S M;VQI9#L@1D].5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q,B4^(#QD:78^)B,Q M-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!C96YT M97([($9/3E0M4U193$4Z(&YO6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z M(&YO6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!&3TY4 M+5-464Q%.B!N;W)M86P[(%!!1$1)3D#L@1D].5"U&04U) M3%DZ(%1I;65S($YE=R!2;VUA;CL@0D%#2T=23U5.1#H@(V-C9F9C8SL@1D]. M5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=% M24=(5#H@-#`P)R!W:61T:#TS1#$R)3X@/&1I=CXS+#,V,#PO9&EV/B`\+W1D M/B`\=&0@6QE/3-$)U1% M6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)T)/4D1% M4BU"3U143TTZ(",P,#`P,#`@,7!X('-O;&ED.R!415A4+4%,24=..B!L969T M.R!&3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!4:6UE6QE/3-$ M)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,7!X('-O;&ED.R!415A4+4%,24=. M.B!R:6=H=#L@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@5&EM M97,@3F5W(%)O;6%N.R!"04-+1U)/54Y$.B`C9F9F9F9F.R!&3TY4+5-)6D4Z M(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($9/3E0M5T5)1TA4.B`T M,#`G('=I9'1H/3-$,3,E/B`\9&EV/B@S-3`I/"]D:78^(#PO=&0^(#QT9"!S M='EL93TS1"=415A4+4%,24=..B!L969T.R!&3TY4+5-464Q%.B!N;W)M86P[ M($9/3E0M1D%-24Q9.B!4:6UE6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P M,#`@,7!X('-O;&ED.R!415A4+4%,24=..B!L969T.R!&3TY4+5-464Q%.B!N M;W)M86P[($9/3E0M1D%-24Q9.B!4:6UE6QE/3-$)T)/4D1%4BU"3U143TTZ M(",P,#`P,#`@,7!X('-O;&ED.R!415A4+4%,24=..B!R:6=H=#L@1D].5"U3 M5%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!" M04-+1U)/54Y$.B`C9F9F9F9F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%, M+4%,24=..B!B;W1T;VT[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$,3,E M/B`\9&EV/B@Q+#0T."D\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO M6QE M/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,W!X(&1O=6)L93L@5$585"U! M3$E'3CH@;&5F=#L@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@ M5&EM97,@3F5W(%)O;6%N.R!"04-+1U)/54Y$.B`C8V-F9F-C.R!&3TY4+5-) M6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($)/4D1%4BU43U`Z M(",P,#`P,#`@,7!X('-O;&ED.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS M1#$E/B`\9&EV/B0\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)T)/4D1%4BU" M3U143TTZ(",P,#`P,#`@,W!X(&1O=6)L93L@5$585"U!3$E'3CH@6QE M/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O M;6%N)RPG#L@1D].5#H@,3!P M="!4:6UE65AF%T:6]N(&]F(&%D9&ET:6]N M86P@8V]M;6]N('-T;V-K(&%T(&$@7,@<')I;W(@=&\@=&AE(&-O;G9E&5D.R<@8V5L;'-P86-I;F<],T0P(&-E;&QP861D:6YG/3-$,#X\ M='(^/'1D/CPO=&0^/"]T7!E.B!T97AT+VAT;6P[(&-H87)S M970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@ M:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M M;#L@8VAA6QE/3-$)TU!4D=)3BU43U`Z(#!P=#L@1D]. M5#H@,3!P="!4:6UE6QE/3-$)U9%4E1)0T%,+4%,24=..B!T M;W`G/B`\=&0@#L@1D].5#H@,3!P="!4:6UE6%B;&4@=VET:"!,;W,@06QA;6]S($YA=&EO;F%L($)A;FL@*"8C.#(R M,#M,04Y")B,X,C(Q.RD@:6X@=&AE(&%M;W5N="!O9B`D/&9O;G0@'1E;F1E9"!M871U M2!O9B!!<')I;"`R,#$U+B`\9F]N="!S='EL93TS1"=&3TY4+49!34E, M63H@)U1I;65S($YE=R!2;VUA;B<[($9/3E0M4TE:13H@,3!P="<^5&AE(&YO M=&4@6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)RPG2!N;W1E(&ES(&=U87)A;G1E960@8GD@=&AE($-O;7!A;GD@ M86YD('-E8W5R960@8GD@86QL(&%S2X@5&]T M86P@:6YT97)E6QE/3-$)T9/3E0M M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)RPG6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W M(%)O;6%N)RPG2X@5&AE(&]U='-T86YD:6YG('!R:6YC:7!A;"!A;F0@86-C2X\+V1I=CX@/&1I=B!S='EL M93TS1"=#3$5!4CIB;W1H.R!&3TY4+49!34E,63I4:6UE#L@1D].5#H@,3!P="!4 M:6UE6QE/3-$)T-,14%2.F)O=&@[($9/3E0M M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[34%21TE. M.B`P<'0@,'!X.R!&3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L M(%-E2!R96-E:79E9"`D/&9O;G0@6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I M;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[34%21TE..B`P<'0@,'!X M.R!&3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E3Y&6UE;G0@=&5R;7,N($1U M6QE/3-$ M)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)RPG3XF(S$V,#L\+V1I=CX@/&9O;G0@6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I M;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[34%21TE..B`P<'0@,'!X M.R!&3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E#IA=71O M.R!724142#H@-C`E.R!"3U)$15(M0T],3$%04T4Z(&-O;&QA<'-E.R!/5D52 M1DQ/5SH@=FES:6)L93L@0D]21$52+51/4#H@(SEE8C9C92`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`P,#`[($9/3E0M4TE:13H@,3!P=#L@ M5D525$E#04PM04Q)1TXZ(&)O='1O;3L@1D].5"U714E'2%0Z(#0P,"<@=VED M=&@],T0Q-"4^(#QD:78^-#4U+#`P,#PO9&EV/B`\+W1D/B`\=&0@6QE/3-$)W=I9'1H.C$P,"4[('1A8FQE M+6QA>6]U=#IF:7AE9#LG(&-E;&QS<&%C:6YG/3-$,"!C96QL<&%D9&EN9STS M1#`^/'1R/CQT9#X\+W1D/CPO='(^/"]T86)L93X\'0O:F%V M87-C3X-"B`@("`\=&%B M;&4@8VQA#L@1D].5#H@,3!P="!4:6UE M&5D.R!&3TY4+5-)6D4Z(#$P<'0[(&1T=&@Z('1A8FQE2&%N9VEN9R<@8V5L M;'-P86-I;F<],T0P(&-E;&QP861D:6YG/3-$,"!W:61T:#TS1#$P,"4^(#QT M6QE/3-$ M)U=)1%1(.B`P+C(U:6X[(%=/4D0M5U)!4#H@8G)E86LM=V]R9"<^(#QD:78^ M/'-T6QE/3-$ M)U=)1%1(.B!A=71O.R!73U)$+5=205`Z(&)R96%K+7=O3Y4:&4@0V]M<&%N>2!H87,@96YT97)E9"!I;G1O(&$@8V%P:71A;"!L96%S M97,@9F]R(&5Q=6EP;65N="!A="!I;G1E6QE/3-$ M)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)RPG2X\+V1I=CX@/&1I=B!S='EL93TS1"=#3$5!4CIB;W1H.R!&3TY4 M+49!34E,63I4:6UE#L@1D].5#H@,3!P="!4:6UE6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA M;CM&3TY4+5-)6D4Z(#$P<'0[34%21TE..B`P<'0@,'!X.R!&3TY4.B`Q,'!T M(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E6UE;G1S(&%R92!A6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA M;CM&3TY4+5-)6D4Z(#$P<'0[34%21TE..B`P<'0@,'!X.R!&3TY4.B`Q,'!T M(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E6QE M/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M M4U193$4Z(&YO6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!&3TY4 M+5-464Q%.B!N;W)M86P[(%!!1$1)3D#L@1D].5"U&04U) M3%DZ(%1I;65S($YE=R!2;VUA;CL@0D%#2T=23U5.1#H@(V-C9F9C8SL@1D]. M5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=% M24=(5#H@-#`P)R!W:61T:#TS1#$T)3X@/&1I=CXT+#`P,#PO9&EV/B`\+W1D M/B`\=&0@6QE/3-$)U1% M6%0M04Q)1TXZ(&-E;G1E6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z M(&YO6QE/3-$)U1% M6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)T)/4D1%4BU"3U143TTZ M(",P,#`P,#`@,7!X('-O;&ED.R!415A4+4%,24=..B!L969T.R!&3TY4+5-4 M64Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!4:6UE6QE/3-$)T)/4D1%4BU" M3U143TTZ(",P,#`P,#`@,7!X('-O;&ED.R!415A4+4%,24=..B!R:6=H=#L@ M1D].5"U35%E,13H@;F]R;6%L.R!0041$24Y'+5))1TA4.B`U<'@[($9/3E0M M1D%-24Q9.B!4:6UE6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U19 M3$4Z(&YO6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M M4U193$4Z(&YO6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M M4U193$4Z(&YO"!S;VQI9#L@5$585"U!3$E'3CH@;&5F=#L@1D].5"U35%E,13H@ M;F]R;6%L.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!"04-+1U)/ M54Y$.B`C8V-F9F-C.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=. M.B!B;W1T;VT[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$,24^(#QD:78^ M)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"="3U)$15(M0D]45$]- M.B`C,#`P,#`P(#%P>"!S;VQI9#L@5$585"U!3$E'3CH@6QE/3-$)U1%6%0M04Q)1TXZ M(&-E;G1E"!S;VQI9#L@5$585"U!3$E'3CH@;&5F M=#L@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@5&EM97,@3F5W M(%)O;6%N.R!"04-+1U)/54Y$.B`C8V-F9F-C.R!&3TY4+5-)6D4Z(#$P<'0[ M(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($9/3E0M5T5)1TA4.B`T,#`G('=I M9'1H/3-$,24^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL93TS M1"="3U)$15(M0D]45$]-.B`C,#`P,#`P(#%P>"!S;VQI9#L@5$585"U!3$E' M3CH@"!D;W5B;&4[(%1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M M4U193$4Z(&YO"!S;VQI M9#L@1D].5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q)3X@/&1I=CXD/"]D:78^ M(#PO=&0^(#QT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B`C,#`P,#`P(#-P M>"!D;W5B;&4[(%1%6%0M04Q)1TXZ(')I9VAT.R!&3TY4+5-464Q%.B!N;W)M M86P[(%!!1$1)3D#L@1D].5"U&04U)3%DZ(%1I;65S($YE M=R!2;VUA;CL@0D%#2T=23U5.1#H@(V9F9F9F9CL@1D].5"U325I%.B`Q,'!T M.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!"3U)$15(M5$]0.B`C,#`P,#`P M(#%P>"!S;VQI9#L@1D].5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q-"4^(#QD M:78^,3$L,#`P/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=. M.B!L969T.R!&3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!4:6UE M6QE/3-$)T9/3E0M1D%-24Q9.B`G M5&EM97,@3F5W(%)O;6%N)RPG&5D.R<@8V5L;'-P86-I;F<],T0P(&-E M;&QP861D:6YG/3-$,#X\='(^/'1D/CPO=&0^/"]T7!E.B!T M97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE M860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT M96YT/3-$)W1E>'0O:'1M;#L@8VAA2!.;W1E(%M!8G-T6QE/3-$)TU!4D=)3CH@,'!T(#!P>#L@1D].5#H@,3!P="!4:6UE M6QE/3-$)T-, M14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-) M6D4Z(#$P<'0[34%21TE..B`P:6X@,&EN(#!P="<^(#QB/CQF;VYT('-T>6QE M/3-$)T9/3E0M4TE:13H@,3!P="<^,3(N/"]F;VYT/CPO8CX\9F]N="!S='EL M93TS1"=&3TY4+5-)6D4Z(#$P<'0G/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%- M24Q9.B`G5&EM97,@3F5W(%)O;6%N)RPG6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9 M.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[34%21TE..B`P<'0@ M,'!X.R!&3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E2!R96-O'!E;G-E M(&]F("0\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@)U1I;65S($YE=R!2 M;VUA;B6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA M;CM&3TY4+5-)6D4Z(#$P<'0[34%21TE..B`P<'0@,'!X.R!&3TY4.B`Q,'!T M(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E3Y/;B!!<')I;"`Q,2P@,C`Q,RP@ M=&AE($-O;7!A;GD@86-C97!T960@6QE/3-$)T9/ M3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)RPG2!F;W(@86X@ M86=G6QE/3-$)T9/3E0M M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)RPG6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)SL@1D].5"U3 M25I%.B`Q,'!T)SY);B!.;W9E;6)E2!A8V-E M<'1E9"!A('-U8G-C2UI6QE/3-$ M)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)RPG7,@<')I;W(@=&\@8V]N=F5R3XF(S$V,#L\+V1I=CX@/&1I=B!S='EL93TS1"=#3$5!4CIB;W1H.R!& M3TY4+49!34E,63I4:6UE#L@1D].5#H@,3!P="!4:6UE2`R,#$S('1H92!" M;V%R9"!O9B!$:7)E8W1O6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)RPG6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)RPG3XF(S$V,#L\+V1I=CX@/&1I=B!S='EL93TS1"=#3$5!4CIB;W1H.R!& M3TY4+49!34E,63I4:6UE6QE/3-$ M)T9/3E0M4TE:13H@,3!P="<^(#(P,3(\+V9O;G0^/"]U/CPO6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I M;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[5$585"U)3D1%3E0Z(#`N M-6EN.R!-05)'24XZ(#!I;B`P:6X@,'!T)SX@/&9O;G0@6QE/3-$)T9/3E0M1D%-24Q9 M.B`G5&EM97,@3F5W(%)O;6%N)RPG6QE/3-$ M)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)RPG2!O;B!*86YU87)Y(#0L(#(P,3(L('1H92!#;VUP86YY M(&%C8V5P=&5D('-U8G-C6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM M97,@3F5W(%)O;6%N)RPG'1E;F1E9"!T:&4@97AP:7)A=&EO;B!D871E M(&]F(#QF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O M;6%N)RPG3X\9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0G M/B8C,38P.SPO9F]N=#X\+V1I=CX@/&1I=B!S='EL93TS1"=#3$5!4CIB;W1H M.R!&3TY4+49!34E,63I4:6UE3X\9F]N="!S M='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0G/D]N($IA;G5A6QE/3-$)T9/3E0M1D%-24Q9 M.B`G5&EM97,@3F5W(%)O;6%N)RPG6QE/3-$ M)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4 M+5-)6D4Z(#$P<'0[34%21TE..B`P:6X@,&EN(#!P="<@86QI9VX],T1J=7-T M:69Y/CQF;VYT('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P="<^3VX@2F%N=6%R M>2`Y+"`R,#$R+"!T:&4@0V]M<&%N>2!I6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)RPG6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S M($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[5$585"U)3D1%3E0Z(#`N-6EN M.R!-05)'24XZ(#!I;B`P:6X@,'!T)R!A;&EG;CTS1&IU2!C;VYV97)T M960@/&9O;G0@6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@ M3F5W(%)O;6%N)RPG6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)RPG M2P@=VAI8V@@=VEL;"!E>'!I M'!I M6QE/3-$)T9/3E0M1D%-24Q9.B`G M5&EM97,@3F5W(%)O;6%N)RPG3X\9F]N="!S='EL93TS1"=&3TY4 M+5-)6D4Z(#$P<'0G/B8C,38P.SPO9F]N=#X\+V1I=CX@/&1I=B!S='EL93TS M1"=#3$5!4CIB;W1H.R!&3TY4+49!34E,63I4:6UE3X\9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0G/D]N($IA;G5A M6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)RPG6%L=&EE3X\9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0G/B8C,38P.SPO9F]N M=#X\+V1I=CX@/&1I=B!S='EL93TS1"=#3$5!4CIB;W1H.R!&3TY4+49!34E, M63I4:6UE3X\9F]N="!S='EL93TS1"=&3TY4 M+5-)6D4Z(#$P<'0G/D]N($IA;G5A6QE/3-$)T9/3E0M1D%- M24Q9.B`G5&EM97,@3F5W(%)O;6%N)RPG6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N M)RPG2!T M;R!P=7)C:&%S92!S:&%R97,@;V8@=&AE($-O;7!A;GDF(S@R,3<[6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N M)RPG3X\9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0G M/B8C,38P.SPO9F]N=#X\+V1I=CX@/&1I=B!S='EL93TS1"=#3$5!4CIB;W1H M.R!&3TY4+49!34E,63I4:6UE3X\9F]N="!S M='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0G/D]N($IA;G5A6QE/3-$)T9/3E0M1D%-24Q9.B`G M5&EM97,@3F5W(%)O;6%N)RPG2!A;'-O(&ES6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O M;6%N)RPG'!I6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9 M.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[34%21TE..B`P:6X@ M,&EN(#!P="<@86QI9VX],T1J=7-T:69Y/CQF;VYT('-T>6QE/3-$)T9/3E0M M4TE:13H@,3!P="<^3VX@36%R8V@@,2P@,C`Q,BP@=&AE($-O;7!A;GD@8V]N M=F5R=&5D(#QF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W M(%)O;6%N)RPG6QE/3-$)T9/3E0M M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)RPG6QE M/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM& M3TY4+5-)6D4Z(#$P<'0[5$585"U)3D1%3E0Z(#`N-6EN.R!-05)'24XZ(#!I M;B`P:6X@,'!T)R!A;&EG;CTS1&IU'!I2!I3X\ M9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0G/B8C,38P.SPO9F]N=#X\ M+V1I=CX@/&1I=B!S='EL93TS1"=#3$5!4CIB;W1H.R!&3TY4+49!34E,63I4 M:6UE3X\9F]N="!S='EL93TS1"=&3TY4+5-) M6D4Z(#$P<'0G/D]N($%P6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@ M3F5W(%)O;6%N)RPG2!A;'-O(&%C8V5P=&5D('-U8G-C6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@ M3F5W(%)O;6%N)RPG2!A;'-O(&ES6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)RPG M2!I6QE/3-$)T9/ M3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)RPG6QE/3-$ M)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)RPG3X\9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0G/B8C M,38P.SPO9F]N=#X\+V1I=CX@/&1I=B!S='EL93TS1"=#3$5!4CIB;W1H.R!& M3TY4+49!34E,63I4:6UE3X\9F]N="!S='EL M93TS1"=&3TY4+5-)6D4Z(#$P<'0G/D]N($UA>2`W+"`R,#$R+"!T:&4@0V]M M<&%N>2!I6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W M(%)O;6%N)RPG3X\9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z M(#$P<'0G/B8C,38P.SPO9F]N=#X\+V1I=CX@/&1I=B!S='EL93TS1"=#3$5! M4CIB;W1H.R!&3TY4+49!34E,63I4:6UE3X\ M9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0G/D]N($UA>2`R,"P@,C`Q M,BP@=&AE($-O;7!A;GD@:7-S=65D(#QF;VYT('-T>6QE/3-$)T9/3E0M1D%- M24Q9.B`G5&EM97,@3F5W(%)O;6%N)RPG2P@=VAI M8V@@=VEL;"!E>'!I6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA M;CM&3TY4+5-)6D4Z(#$P<'0[34%21TE..B`P:6X@,&EN(#!P="<@86QI9VX] M,T1J=7-T:69Y/CQF;VYT('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P="<^3VX@ M36%Y(#(Q+"`R,#$R+"!T:&4@0V]M<&%N>2!C;VYV97)T960@/&9O;G0@6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)RPG6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)RPG2!I6QE/3-$)T9/3E0M M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)RPG6QE/3-$)T-,14%2.F)O=&@[ M($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[ M34%21TE..B`P:6X@,&EN(#!P="<@86QI9VX],T1J=7-T:69Y/CQF;VYT('-T M>6QE/3-$)T9/3E0M4TE:13H@,3!P="<^3VX@36%Y(#(Y+"`R,#$R+"!T:&4@ M0V]M<&%N>2!C;VYV97)T960@/&9O;G0@6QE/3-$)T9/3E0M1D%- M24Q9.B`G5&EM97,@3F5W(%)O;6%N)RPG6UE;G0@;V8@2!C;VYV97)T:6)L92!D M96)T+CPO9F]N=#X\+V1I=CX@/&1I=B!S='EL93TS1"=#3$5!4CIB;W1H.R!& M3TY4+49!34E,63I4:6UE6QE/3-$)T-,14%2.F)O=&@[($9/ M3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[34%2 M1TE..B`P:6X@,&EN(#!P="<@86QI9VX],T1J=7-T:69Y/CQF;VYT('-T>6QE M/3-$)T9/3E0M4TE:13H@,3!P="<^3VX@2G5N92`W+"`R,#$R+"!T:&4@0V]M M<&%N>2!I6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W M(%)O;6%N)RPG3X\9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z M(#$P<'0G/B8C,38P.SPO9F]N=#X\+V1I=CX@/&1I=B!S='EL93TS1"=#3$5! M4CIB;W1H.R!&3TY4+49!34E,63I4:6UE3X\ M9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0G/D]N($IU;F4@,3DL(#(P M,3(L('1H92!#;VUP86YY(&-O;G9E6QE/3-$)T9/3E0M1D%-24Q9 M.B`G5&EM97,@3F5W(%)O;6%N)RPG2!I3X\9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0G/B8C,38P.SPO9F]N M=#X\+V1I=CX@/&1I=B!S='EL93TS1"=#3$5!4CIB;W1H.R!&3TY4+49!34E, M63I4:6UE3X\9F]N="!S='EL93TS1"=&3TY4 M+5-)6D4Z(#$P<'0G/D]N($IU;'D@,32!I2`Q."P@,C`Q,BX@0F]T:"!W97)E M('9A;'5E9"!A="`D/&9O;G0@3X\9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0G M/B8C,38P.SPO9F]N=#X\+V1I=CX@/&1I=B!S='EL93TS1"=#3$5!4CIB;W1H M.R!&3TY4+49!34E,63I4:6UE3X\9F]N="!S M='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0G/D]N($%U9W5S="`R,2P@,C`Q,B!T M:&4@0V]M<&%N>2!I3X\9F]N="!S='EL93TS1"=&3TY4+5-) M6D4Z(#$P<'0G/B8C,38P.SPO9F]N=#X\+V1I=CX@/&1I=B!S='EL93TS1"=# M3$5!4CIB;W1H.R!&3TY4+49!34E,63I4:6UE3X\9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0G/D]N($%U9W5S="`S M,2P@,C`Q,BP@=&AE($-O;7!A;GD@8V]N=F5R=&5D(#QF;VYT('-T>6QE/3-$ M)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)RPG2!I6%B;&4@87,@;V8@2G5N92`S,"P@,C`Q,BX\+V9O;G0^/"]D:78^(#QD M:78@6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O M;6%N)RPG6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N M)RPG6%B;&4@87,@;V8@4V5P=&5M8F5R(#,P+"`R,#$R M(&%N9"!W97)E(&ES6QE/3-$ M)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4 M+5-)6D4Z(#$P<'0[34%21TE..B`P:6X@,&EN(#!P="<@86QI9VX],T1J=7-T M:69Y/CQF;VYT('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P="<^26X@3F]V96UB M97(@,C`Q,BP@=&AE($-O;7!A;GD@:7-S=65D('=A28C.#(Q-SMS M($-O;6UO;B!3=&]C:RP@870@86X@97AE6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)RPG'!I3X\9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0G M/B8C,38P.SPO9F]N=#X\+V1I=CX@/&1I=B!S='EL93TS1"=#3$5!4CIB;W1H M.R!&3TY4+49!34E,63I4:6UE3X\9F]N="!S M='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0G/DEN($YO=F5M8F5R(#(P,3(L('1H M92!#;VUP86YY(&ES6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O M;6%N)RPG6QE/3-$)T-,14%2.F)O M=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P M<'0[34%21TE..B`P:6X@,&EN(#!P="<^(#QF;VYT('-T>6QE/3-$)T9/3E0M M4TE:13H@,3!P="<^26X@1&5C96UB97(@,C`Q,BP@=&AE($-O;7!A;GD@:7-S M=65D(&$@8V]N=F5R=&EB;&4@9&5B96YT=7)E(&EN('1H92!A;6]U;G0@;V8@ M)#QF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N M)RPG2X@26X@8V]N;F5C=&EO;B!W:71H('1H92!D96)T+"!T M:&4@0V]M<&%N>2!A;'-O(&ES6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%- M24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[34%21TE..B`P M:6X@,&EN(#!P="<^(#QF;VYT('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P="<^ M/"]F;VYT/B8C,38P.SPO9&EV/B`\9&EV('-T>6QE/3-$)T-,14%2.F)O=&@[ M($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[ M34%21TE..B`P<'0@,'!X.R!&3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@ M5&EM97,L(%-E3Y&;W(@86QL(&]F('1H92!#;VUP86YY)B,X,C$W.W,@2!H87,@;F]T('!A:60@8V%S:"!D:79I9&5N M9',@=&\@9&%T92!A;F0@9&]E'!E8W1E9"!V;VQA=&EL:71I97,@=71I;&EZ960@:6X@ M=&AE(&UO9&5L(&%R92!B87-E9"!M86EN;'D@;VX@=&AE(&AI2!O9B!T:&4@0V]M<&%N>28C.#(Q-SMS('-T;V-K('!R:6-E M(&]V97(@82!P97)I;V0@8V]M;65N'!E8W1E9"!L M:69E(&%T('1H92!T:6UE(&]F(&=R86YT+CPO9&EV/B`\9&EV('-T>6QE/3-$ M)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4 M+5-)6D4Z(#$P<'0[34%21TE..B`P<'0@,'!X.R!&3TY4.B`Q,'!T(%1I;65S M($YE=R!2;VUA;BP@5&EM97,L(%-E3Y&;W(@86QL(&]F('1H92!#;VUP86YY)B,X M,C$W.W,@2!H87,@;F]T('!A:60@8V%S M:"!D:79I9&5N9',@=&\@9&%T92!A;F0@9&]E'!E8W1E9"!V;VQA=&EL:71I97,@=71I M;&EZ960@:6X@=&AE(&UO9&5L(&%R92!B87-E9"!M86EN;'D@;VX@=&AE(&AI M2!O9B!T:&4@0V]M<&%N>28C.#(Q-SMS('-T M;V-K('!R:6-E(&]V97(@82!P97)I;V0@8V]M;65N'!E8W1E9"!L:69E(&%T('1H92!T:6UE(&]F(&=R86YT+CPO9&EV/B`\9&EV M('-T>6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2 M;VUA;CM&3TY4+5-)6D4Z(#$P<'0[34%21TE..B`P<'0@,'!X.R!&3TY4.B`Q M,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E65E6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)RPG M6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM M97,@3F5W(%)O;6%N)RPG2P@:6X@2F%N=6%R>2`R,#$P M('1H92!#;VUP86YY(')E8V]R9&5D(&-O;7!E;G-A=&EO;B!E>'!E;G-E(&]F M("0\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@)U1I;65S($YE=R!2;VUA M;B'!I65A6QE/3-$)T9/3E0M1D%- M24Q9.B`G5&EM97,@3F5W(%)O;6%N)RPG6QE/3-$)T9/3E0M1D%-24Q9.B`G M5&EM97,@3F5W(%)O;6%N)RPG#L@1D].5#H@,3!P="!4:6UE M6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2 M;VUA;CM&3TY4+5-)6D4Z(#$P<'0[5$585"U!3$E'3CIC96YT97([(%1%6%0M M24Y$14Y4.B`P:6X[(%=)1%1(.B`Q,#`E)R!A;&EG;CTS1&-E;G1E6QE/3-$)TU!4D=)3CH@,'!X.F%U=&\[(%=)1%1(.B`X,"4[($)/ M4D1%4BU#3TQ,05!313H@8V]L;&%P6QE/3-$)U1%6%0M04Q) M1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO'!E8W1E9"!L:69E("AY96%R6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/ M3E0M4U193$4Z(&YO6QE/3-$)U1%6%0M04Q)1TXZ(&QE M9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!&3TY4 M+5-464Q%.B!N;W)M86P[(%!!1$1)3D#L@1D].5"U&04U) M3%DZ(%1I;65S($YE=R!2;VUA;CL@0D%#2T=23U5.1#H@(V9F9F9F9CL@1D]. M5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=% M24=(5#H@-#`P)R!W:61T:#TS1#$R)3X@/&1I=CXQ,3PO9&EV/B`\+W1D/B`\ M=&0@6EE;&0\+V1I=CX@/"]T M9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z M(&YO6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M M4U193$4Z(&YO3PO9&EV/B`\+W1D/B`\=&0@3XF(S$V,#L\+V1I=CX@/&1I=B!S='EL93TS M1"=#3$5!4CIB;W1H.R!&3TY4+49!34E,63I4:6UE#L@1D].5#H@,3!P="!4:6UE M6QE/3-$)T9/ M3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)RPG2!O9B!397)I97,@0B!03XF(S$V,#L\+V1I=CX@/&1I=B!S='EL93TS1"=#3$5!4CIB;W1H.R!&3TY4 M+49!34E,63I4:6UE"!S;VQI9#L@34%21TE..B`P M:6X[(%=)1%1(.B`Q,#`E.R!"3U)$15(M0T],3$%04T4Z(&-O;&QA<'-E.R!/ M5D521DQ/5SH@=FES:6)L93L@0D]21$52+51/4#H@(SEE8C9C92`P<'@@6QE/3-$)U1%6%0M04Q)1TXZ(&-E;G1E6QE/3-$)U1%6%0M04Q) M1TXZ(&-E;G1E6QE/3-$)U1%6%0M04Q)1TXZ M(&-E;G1E6QE/3-$)U1%6%0M04Q)1TXZ(&-E M;G1E6QE/3-$)U1%6%0M M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO M6QE/3-$)U1%6%0M04Q)1TXZ(&QE M9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)U1%6%0M04Q) M1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)U1%6%0M04Q)1TXZ(&QE M9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)U1% M6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)U1% M6%0M04Q)1TXZ(')I9VAT.R!&3TY4+5-464Q%.B!N;W)M86P[(%!!1$1)3D#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@0D%# M2T=23U5.1#H@(V-C9F9C8SL@0T],3U(Z(",P,#`P,#`[($9/3E0M4TE:13H@ M,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O='1O;3L@1D].5"U714E'2%0Z(#0P M,"<@=VED=&@],T0Q,B4^(#QD:78^,2XP,#PO9&EV/B`\+W1D/B`\=&0@6QE/3-$)U1%6%0M04Q)1TXZ M(&QE9G0[($9/3E0M4U193$4Z(&YO&5R8VES960\+V1I=CX@/"]T9#X@/'1D M('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO#L@1D].5"U&04U) M3%DZ(%1I;65S($YE=R!2;VUA;CL@0D%#2T=23U5.1#H@(V9F9F9F9CL@1D]. M5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=% M24=(5#H@-#`P)R!W:61T:#TS1#$R)3X@/&1I=CXM/"]D:78^(#PO=&0^(#QT M9"!S='EL93TS1"=415A4+4%,24=..B!L969T.R!&3TY4+5-464Q%.B!N;W)M M86P[($9/3E0M1D%-24Q9.B!4:6UE6QE/3-$)T)/4D1%4BU"3U143TTZ(",P M,#`P,#`@,7!X('-O;&ED.R!415A4+4%,24=..B!L969T.R!&3TY4+5-464Q% M.B!N;W)M86P[($9/3E0M1D%-24Q9.B!4:6UE6QE/3-$)T)/4D1%4BU"3U14 M3TTZ(",P,#`P,#`@,7!X('-O;&ED.R!415A4+4%,24=..B!R:6=H=#L@1D]. M5"U35%E,13H@;F]R;6%L.R!0041$24Y'+5))1TA4.B`U<'@[($9/3E0M1D%- M24Q9.B!4:6UE6QE/3-$)U1%6%0M M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,W!X(&1O=6)L93L@5$58 M5"U!3$E'3CH@;&5F=#L@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E, M63H@5&EM97,@3F5W(%)O;6%N.R!"04-+1U)/54Y$.B`C8V-F9F-C.R!&3TY4 M+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!M:61D;&4[($)/4D1%4BU4 M3U`Z(",P,#`P,#`@,7!X('-O;&ED.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T M:#TS1#$E/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@"!D;W5B;&4[(%1%6%0M04Q)1TXZ(&QE9G0[($9/ M3E0M4U193$4Z(&YO"!S M;VQI9#L@1D].5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q)3X@/&1I=CXD/"]D M:78^(#PO=&0^(#QT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B`C,#`P,#`P M(#-P>"!D;W5B;&4[(%1%6%0M04Q)1TXZ(')I9VAT.R!&3TY4+5-464Q%.B!N M;W)M86P[(%!!1$1)3D#L@1D].5"U&04U)3%DZ(%1I;65S M($YE=R!2;VUA;CL@0D%#2T=23U5.1#H@(V-C9F9C8SL@0T],3U(Z(",P,#`P M,#`[($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O='1O;3L@ M0D]21$52+51/4#H@(S`P,#`P,"`Q<'@@6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO6QE M/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,W!X(&1O=6)L93L@5$585"U! M3$E'3CH@;&5F=#L@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@ M5&EM97,@3F5W(%)O;6%N.R!"04-+1U)/54Y$.B`C9F9F9F9F.R!&3TY4+5-) M6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!M:61D;&4[($)/4D1%4BU43U`Z M(",P,#`P,#`@,W!X(&1O=6)L93L@1D].5"U714E'2%0Z(#0P,"<@=VED=&@] M,T0Q)3X@/&1I=CXF(S$V,#L\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)T)/ M4D1%4BU"3U143TTZ(",P,#`P,#`@,W!X(&1O=6)L93L@5$585"U!3$E'3CH@ M6QE/3-$)T)/4D1%4BU"3U14 M3TTZ(",P,#`P,#`@,W!X(&1O=6)L93L@5$585"U!3$E'3CH@;&5F=#L@1D]. M5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N M.R!"04-+1U)/54Y$.B`C9F9F9F9F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1) M0T%,+4%,24=..B!B;W1T;VT[($)/4D1%4BU43U`Z(",P,#`P,#`@,W!X(&1O M=6)L93L@1D].5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q)3X@/&1I=CXD/"]D M:78^(#PO=&0^(#QT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B`C,#`P,#`P M(#-P>"!D;W5B;&4[(%1%6%0M04Q)1TXZ(')I9VAT.R!&3TY4+5-464Q%.B!N M;W)M86P[(%!!1$1)3D#L@1D].5"U&04U)3%DZ(%1I;65S M($YE=R!2;VUA;CL@0D%#2T=23U5.1#H@(V9F9F9F9CL@0T],3U(Z(",P,#`P M,#`[($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O='1O;3L@ M0D]21$52+51/4#H@(S`P,#`P,"`S<'@@9&]U8FQE.R!&3TY4+5=%24=(5#H@ M-#`P)R!W:61T:#TS1#$R)3X@/&1I=CXQ+C`P/"]D:78^(#PO=&0^(#QT9"!S M='EL93TS1"=415A4+4%,24=..B!L969T.R!&3TY4+5-464Q%.B!N;W)M86P[ M($9/3E0M1D%-24Q9.B!4:6UE6QE/3-$)T9/3E0M1D%- M24Q9.B`G5&EM97,@3F5W(%)O;6%N)RPG#L@1D].5#H@,3!P="!4:6UE6QE M/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM& M3TY4+5-)6D4Z(#$P<'0[34%21TE..B`P<'0@,'!X.R!&3TY4.B`Q,'!T(%1I M;65S($YE=R!2;VUA;BP@5&EM97,L(%-E2`Q-RP@,C`Q,BP@4&]S:71R;VXG2!);F-E;G1I=F4@4&QA;B`H(C(P,3(@4&QA;B(I+"!A=71H M;W)I>FEN9R!I6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9 M.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[34%21TE..B`P<'0@ M,'!X.R!&3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E3Y/;B!* M86YU87)Y(#$W+"`R,#$R+"!T:&4@0V]M<&%N>2!G6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)RPG65A6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N M)RPG6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@ M3F5W(%)O;6%N)RPG#L@1D].5#H@,3!P="!4:6UE6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I M;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[5$585"U!3$E'3CIC96YT M97([(%1%6%0M24Y$14Y4.B`P:6X[(%=)1%1(.B`Q,#`E)R!A;&EG;CTS1&-E M;G1E6QE/3-$)TU!4D=)3CH@,'!X.F%U=&\[(%=)1%1( M.B`X,"4[($)/4D1%4BU#3TQ,05!313H@8V]L;&%P6QE/3-$ M)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO'!E8W1E9"!L:69E M("AY96%R6QE/3-$)U1%6%0M04Q)1TXZ M(&QE9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)U1% M6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)U1%6%0M04Q)1TXZ M(')I9VAT.R!&3TY4+5-464Q%.B!N;W)M86P[(%!!1$1)3D#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@0D%#2T=23U5.1#H@ M(V9F9F9F9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T M=&]M.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$R)3X@/&1I=CXP+C6QE M/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U19 M3$4Z(&YO'!E8W1E9"!V;VQA=&EL:71Y/"]D:78^(#PO=&0^(#QT9"!S='EL M93TS1"=415A4+4%,24=..B!L969T.R!&3TY4+5-464Q%.B!N;W)M86P[($9/ M3E0M1D%-24Q9.B!4:6UE6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!&3TY4 M+5-464Q%.B!N;W)M86P[(%!!1$1)3D#L@1D].5"U&04U) M3%DZ(%1I;65S($YE=R!2;VUA;CL@0D%#2T=23U5.1#H@(V9F9F9F9CL@1D]. M5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=% M24=(5#H@-#`P)R!W:61T:#TS1#$R)3X@/&1I=CXR,3@\+V1I=CX@/"]T9#X@ M/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO M6QE M/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)RPG#L@1D].5#H@,3!P="!4:6UE6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S M($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[34%21TE..B`P<'0@,'!X.R!& M3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E2`H M-3`I('!E6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O M;6%N)RPG6QE/3-$)T9/3E0M1D%-24Q9 M.B`G5&EM97,@3F5W(%)O;6%N)RPG6QE/3-$)T9/3E0M1D%-24Q9.B`G M5&EM97,@3F5W(%)O;6%N)RPG#L@1D].5#H@,3!P M="!4:6UE6QE/3-$)T-,14%2.F)O=&@[($9/ M3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[5$58 M5"U!3$E'3CIC96YT97([(%1%6%0M24Y$14Y4.B`P:6X[(%=)1%1(.B`Q,#`E M)R!A;&EG;CTS1&-E;G1E6QE/3-$)TU!4D=)3CH@,'!X M.F%U=&\[(%=)1%1(.B`X,"4[($)/4D1%4BU#3TQ,05!313H@8V]L;&%P6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO M'!E8W1E9"!L:69E("AY96%R6QE/3-$ M)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO6QE/3-$ M)U1%6%0M04Q)1TXZ(')I9VAT.R!&3TY4+5-464Q%.B!N;W)M86P[(%!!1$1) M3D#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@ M0D%#2T=23U5.1#H@(V9F9F9F9CL@1D].5"U325I%.B`Q,'!T.R!615)424-! M3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@-#`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`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T M=&]M.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$R)3X@/&1I=CXQ,C4\ M+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/ M3E0M4U193$4Z(&YO3XF(S$V,#LF(S$V,#L\+V1I=CX@/&1I=B!S='EL93TS1"=# M3$5!4CIB;W1H.R!&3TY4+49!34E,63I4:6UE#L@1D].5#H@,3!P="!4:6UE2!H860@82!T;W1A;"!O M9B`\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@)U1I;65S($YE=R!2;VUA M;B2`Q-RP@,C`Q,RX@06QL('1H92!O<'1I;VYS(&ES6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9 M.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[34%21TE..B`P<'0@ M,'!X.R!&3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E#L@1D].5#H@,3!P="!4:6UE M6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2 M;VUA;CM&3TY4+5-)6D4Z(#$P<'0[5$585"U!3$E'3CI,969T.R!415A4+4E. M1$5.5#H@,&EN.R!724142#H@,3`P)2<^(#QT86)L92!S='EL93TS1"="3U)$ M15(M0D]45$]-.B`C.65B-F-E(#!P>"!S;VQI9#L@0D]21$52+4Q%1E0Z(",Y M96(V8V4@,'!X('-O;&ED.R!-05)'24XZ(#!I;CL@5TE$5$@Z(#$P,"4[($)/ M4D1%4BU#3TQ,05!313H@8V]L;&%P6QE M/3-$)U1%6%0M04Q)1TXZ(&-E;G1E6QE/3-$)U1%6%0M04Q)1TXZ M(&-E;G1E6QE/3-$)U1%6%0M M04Q)1TXZ(&-E;G1E6QE M/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!&3TY4+5-4 M64Q%.B!N;W)M86P[(%!!1$1)3D#L@1D].5"U&04U)3%DZ M(%1I;65S($YE=R!2;VUA;CL@0D%#2T=23U5.1#H@(V-C9F9C8SL@1D].5"U3 M25I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=( M5#H@-#`P)R!W:61T:#TS1#$R)3X@/&1I=CXQ.36QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z M(&YO6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO M6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M M4U193$4Z(&YO6QE/3-$)U1% M6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!&3TY4+5-464Q%.B!N;W)M86P[ M(%!!1$1)3D#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2 M;VUA;CL@0D%#2T=23U5.1#H@(V9F9F9F9CL@0T],3U(Z(",P,#`P,#`[($9/ M3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O='1O;3L@1D].5"U7 M14E'2%0Z(#0P,"<@=VED=&@],T0Q,B4^(#QD:78^*#(L-3`P+#`P,"D\+V1I M=CX@/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M M4U193$4Z(&YO6QE/3-$)U1% M6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO"!S;VQI9#L@5$585"U!3$E'3CH@;&5F=#L@1D]. M5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N M.R!"04-+1U)/54Y$.B`C8V-F9F-C.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1) M0T%,+4%,24=..B!B;W1T;VT[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$ M,24^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"="3U)$ M15(M0D]45$]-.B`C,#`P,#`P(#%P>"!S;VQI9#L@5$585"U!3$E'3CH@6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U19 M3$4Z(&YO#L@ M1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@0D%#2T=23U5.1#H@(V-C M9F9C8SL@0T],3U(Z(",P,#`P,#`[($9/3E0M4TE:13H@,3!P=#L@5D525$E# M04PM04Q)1TXZ(&)O='1O;3L@1D].5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q M,B4^(#QD:78^+3PO9&EV/B`\+W1D/B`\=&0@6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U19 M3$4Z(&YO6QE/3-$)T)/4D1%4BU"3U143TTZ M(",P,#`P,#`@,W!X(&1O=6)L93L@5$585"U!3$E'3CH@;&5F=#L@1D].5"U3 M5%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!" M04-+1U)/54Y$.B`C9F9F9F9F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%, M+4%,24=..B!B;W1T;VT[($)/4D1%4BU43U`Z(",P,#`P,#`@,7!X('-O;&ED M.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$E/B`\9&EV/B8C,38P.SPO M9&EV/B`\+W1D/B`\=&0@"!D;W5B;&4[(%1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M M4U193$4Z(&YO"!S;VQI M9#L@1D].5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q)3X@/&1I=CXD/"]D:78^ M(#PO=&0^(#QT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B`C,#`P,#`P(#-P M>"!D;W5B;&4[(%1%6%0M04Q)1TXZ(')I9VAT.R!&3TY4+5-464Q%.B!N;W)M M86P[(%!!1$1)3D#L@1D].5"U&04U)3%DZ(%1I;65S($YE M=R!2;VUA;CL@0D%#2T=23U5.1#H@(V9F9F9F9CL@1D].5"U325I%.B`Q,'!T M.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!"3U)$15(M5$]0.B`C,#`P,#`P M(#%P>"!S;VQI9#L@1D].5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q,B4^(#QD M:78^,"XP,3PO9&EV/B`\+W1D/B`\=&0@6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z M(&YO&5R8VES86)L92P@1&5C96UB97(@,S$L(#(P,3,\+V1I=CX@/"]T9#X@ M/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO M6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z M(&YO6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@ M,W!X(&1O=6)L93L@5$585"U!3$E'3CH@6QE/3-$)T9/ M3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)RPG6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2 M;VUA;CM&3TY4+5-)6D4Z(#$P<'0[34%21TE..B`P<'0@,'!X.R!&3TY4.B`Q M,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E#L@1D].5#H@,3!P M="!4:6UE6QE M/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)RPG2!O9B!W87)R86YT(&%C=&EV:71Y(&)A M6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9 M.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[34%21TE..B`P<'0@ M,'!X.R!&3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,7!X('-O;&ED M.R!415A4+4%,24=..B!C96YT97([($9/3E0M4U193$4Z(&YO6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,7!X('-O;&ED.R!415A4 M+4%,24=..B!C96YT97([($9/3E0M4U193$4Z(&YO&5R8VES93QB6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,7!X('-O M;&ED.R!415A4+4%,24=..B!C96YT97([($9/3E0M4U193$4Z(&YO&5R8VES93QB6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO M6QE/3-$ M)U1%6%0M04Q)1TXZ(')I9VAT.R!&3TY4+5-464Q%.B!N;W)M86P[(%!!1$1) M3D#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@ M0D%#2T=23U5.1#H@(V-C9F9C8SL@0T],3U(Z(",P,#`P,#`[($9/3E0M4TE: M13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O='1O;3L@0D]21$52+51/4#H@ M(S`P,#`P,"`Q<'@@6QE/3-$)U1%6%0M04Q)1TXZ(')I M9VAT.R!&3TY4+5-464Q%.B!N;W)M86P[(%!!1$1)3D#L@ M1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@0D%#2T=23U5.1#H@(V-C M9F9C8SL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M M.R!"3U)$15(M5$]0.B`C,#`P,#`P(#%P>"!S;VQI9#L@1D].5"U714E'2%0Z M(#0P,"<@=VED=&@],T0Q,B4^(#QD:78^,"XP-3PO9&EV/B`\+W1D/B`\=&0@ M6QE/3-$)U1%6%0M04Q) M1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO&5R8VES960\+V1I M=CX@/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M M4U193$4Z(&YO6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[ M($9/3E0M4U193$4Z(&YO6QE/3-$)U1%6%0M M04Q)1TXZ(')I9VAT.R!&3TY4+5-464Q%.B!N;W)M86P[(%!!1$1)3D#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@0D%#2T=2 M3U5.1#H@(V9F9F9F9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E' M3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@-#`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`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=% M24=(5#H@-#`P)R!W:61T:#TS1#$R)3X@/&1I=CXP+C`Q/"]D:78^(#PO=&0^ M(#QT9"!S='EL93TS1"=415A4+4%,24=..B!L969T.R!&3TY4+5-464Q%.B!N M;W)M86P[($9/3E0M1D%-24Q9.B!4:6UE6QE/3-$)U1%6%0M04Q)1TXZ(&QE M9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)U1% M6%0M04Q)1TXZ(')I9VAT.R!&3TY4+5-464Q%.B!N;W)M86P[(%!!1$1)3D#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@0D%# M2T=23U5.1#H@(V-C9F9C8SL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U! M3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$R)3X@ M/&1I=CXP+C`Q/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=. M.B!L969T.R!&3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!4:6UE M6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO M#L@1D].5"U&04U)3%DZ M(%1I;65S($YE=R!2;VUA;CL@0D%#2T=23U5.1#H@(V9F9F9F9CL@1D].5"U3 M25I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!"3U)$15(M5$]0 M.B`C,#`P,#`P(#%P>"!S;VQI9#L@1D].5"U714E'2%0Z(#0P,"<@=VED=&@] M,T0Q,B4^(#QD:78^,C8W+#,U,"PP,#`\+V1I=CX@/"]T9#X@/'1D('-T>6QE M/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO6QE M/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!&3TY4+5-464Q%.B!N;W)M86P[(%!! M1$1)3D#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA M;CL@0D%#2T=23U5.1#H@(V9F9F9F9CL@0T],3U(Z(",P,#`P,#`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`Q,'!T.R!615)424-! M3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$R M)3X@/&1I=CXM/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=. M.B!L969T.R!&3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!4:6UE M6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!&3TY4+5-4 M64Q%.B!N;W)M86P[(%!!1$1)3D#L@1D].5"U&04U)3%DZ M(%1I;65S($YE=R!2;VUA;CL@0D%#2T=23U5.1#H@(V-C9F9C8SL@1D].5"U3 M25I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=( M5#H@-#`P)R!W:61T:#TS1#$R)3X@/&1I=CXM/"]D:78^(#PO=&0^(#QT9"!S M='EL93TS1"=415A4+4%,24=..B!L969T.R!&3TY4+5-464Q%.B!N;W)M86P[ M($9/3E0M1D%-24Q9.B!4:6UE6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/ M3E0M4U193$4Z(&YO6QE/3-$)U1%6%0M04Q) M1TXZ(')I9VAT.R!&3TY4+5-464Q%.B!N;W)M86P[(%!!1$1)3D#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@0D%#2T=23U5. M1#H@(V-C9F9C8SL@0T],3U(Z(",P,#`P,#`[($9/3E0M4TE:13H@,3!P=#L@ M5D525$E#04PM04Q)1TXZ(&)O='1O;3L@1D].5"U714E'2%0Z(#0P,"<@=VED M=&@],T0Q,B4^(#QD:78^+3PO9&EV/B`\+W1D/B`\=&0@6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/ M3E0M4U193$4Z(&YO6QE/3-$)T)/4D1%4BU" M3U143TTZ(",P,#`P,#`@,W!X(&1O=6)L93L@5$585"U!3$E'3CH@"!S;VQI9#L@ M1D].5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q,B4^(#QD:78^,3(R+#4P,"PP M,#`\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[ M($9/3E0M4U193$4Z(&YO"!D;W5B;&4[(%1%6%0M04Q)1TXZ(&QE9G0[ M($9/3E0M4U193$4Z(&YO6QE/3-$)T)/4D1% M4BU"3U143TTZ(",P,#`P,#`@,W!X(&1O=6)L93L@5$585"U!3$E'3CH@6QE M/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM& M3TY4+5-)6D4Z(#$P<'0G/CPO9&EV/B`\+V1I=CX@/&1I=B!S='EL93TS1"=# M3$5!4CIB;W1H.R!&3TY4+49!34E,63I4:6UE#L@1D].5#H@,3!P="!4:6UE6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA M;CM&3TY4+5-)6D4Z(#$P<'0[34%21TE..B`P<'0@,'!X.R!&3TY4.B`Q,'!T M(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E6QE/3-$)T-,14%2.F)O M=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P M<'0[34%21TE..B`P<'0@,'!X.R!&3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA M;BP@5&EM97,L(%-E#IA=71O.R!724142#H@.#4E.R!"3U)$15(M0T],3$%04T4Z(&-O M;&QA<'-E.R!&3TY4+5-)6D4Z(#$P<'0[($]615)&3$]7.B!V:7-I8FQE.R!" M3U)$15(M5$]0.B`C.65B-F-E(#!P>"!S;VQI9#L@0D]21$52+5))1TA4.B`C M.65B-F-E(#!P>"!S;VQI9"<@8V5L;'-P86-I;F<],T0P(&-E;&QP861D:6YG M/3-$,"!A;&EG;CTS1&-E;G1E6QE/3-$)U1%6%0M04Q)1TXZ(&-E;G1E6QE/3-$ M)U1%6%0M04Q)1TXZ(')I9VAT.R!&3TY4+5-464Q%.B!N;W)M86P[(%!!1$1) M3D#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@ M0D%#2T=23U5.1#H@(V-C9F9C8SL@1D].5"U325I%.B`Q,'!T.R!615)424-! M3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$R M)3X@/&1I=CXT+#`P,"PP,#`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`\+V1I=CX@/&1I=B!S M='EL93TS1"=#3$5!4CIB;W1H.R!&3TY4+49!34E,63I4:6UE#L@1D].5#H@,3!P M="!4:6UE'!I6QE M/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)RPG&5D.R<@8V5L;'-P86-I;F<],T0P(&-E;&QP861D:6YG/3-$,#X\='(^/'1D M/CPO=&0^/"]T2!S970@=&\@ M97AP:7)E(&]N($1E8V5M8F5R(#,Q+"`R,#$S+"!B=70@=V5R92!E>'1E;F1E M9"!B>2!T:&4@0V]M<&%N>2!T:')O=6=H($1E8V5M8F5R(#,Q+"`R,#$T+CPO M9F]N=#X\+V1I=CX@/"]D:78^/'1A8FQE(&)O&5D.R<@8V5L;'-P86-I;F<] M,T0P(&-E;&QP861D:6YG/3-$,#X\='(^/'1D/CPO=&0^/"]T7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X- M"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP M92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA'0^)SQD:78@6QE/3-$)U9%4E1)0T%,+4%, M24=..B!T;W`G/B`\=&0@6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA M;CM&3TY4+5-)6D4Z(#$P<'0[34%21TE..B`P<'0@,'!X.R!&3TY4.B`Q,'!T M(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E3Y4:&4@0V]M<&%N>28C.#(Q-SMS M($-E2!S=6-H('-E&-H86YG92!R:6=H=',L('1H92!P2!D:7-T2P@:6YC;'5D:6YG(&EN('1H92!E=F5N="!O9B!V;VQU;G1A3XF(S$V,#L\+V1I=CX@/&1I=B!S='EL93TS1"=# M3$5!4CIB;W1H.R!&3TY4+49!34E,63I4:6UE#L@1D].5#H@,3!P="!4:6UE#L@1D].5#H@,3!P="!4:6UE6QE/3-$)T-,14%2 M.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z M(#$P<'0[34%21TE..B`P<'0@,'!X.R!&3TY4.B`Q,'!T(%1I;65S($YE=R!2 M;VUA;BP@5&EM97,L(%-E6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W M(%)O;6%N)RPG6QE M/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)RPG2!C;VYV97)T:6)L92!I;G1O M(&]N92!S:&%R92!O9B!C;VUM;VX@2!B M92!P86ED(&EN(&-A28C M.#(Q-SMS(&-O;6UO;B!S=&]C:R!I;B!L:7%U:61A=&EO;BX@2&]L9&5R2!V;W1E(&]N(&%N M(&%S(&EF(&-O;G9E2!B92!P86ED(&]R(&1E8VQA2!B92!R961E96UE9"!I;B!W M:&]L92!O2!B92!G:79E;B!I9B!T:&4@0V]M<&%N>28C.#(Q-SMS(&-O;6UO;B!S M=&]C:R!H87,@8VQO2!C;VYS96-U=&EV92!T7,@<')I;W(@=&\@=&AE M(&YO=&EC93PO9F]N=#XN/"]D:78^(#QD:78@3XF(S$V,#L\+V1I=CX@ M/&1I=B!S='EL93TS1"=#3$5!4CIB;W1H.R!&3TY4+49!34E,63I4:6UE#L@1D]. M5#H@,3!P="!4:6UE6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@ M3F5W(%)O;6%N)RPG2X\+V1I=CX@/&1I=B!S='EL93TS1"=#3$5!4CIB;W1H M.R!&3TY4+49!34E,63I4:6UE#L@1D].5#H@,3!P="!4:6UE6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE M=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[34%21TE..B`P<'0@,'!X.R!&3TY4 M.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S M($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[34%21TE..B`P<'0@,'!X.R!& M3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E6QE/3-$ M)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4 M+5-)6D4Z(#$P<'0[34%21TE..B`P<'0@,'!X.R!&3TY4.B`Q,'!T(%1I;65S M($YE=R!2;VUA;BP@5&EM97,L(%-E6QE/3-$ M)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)RPG6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM M97,@3F5W(%)O;6%N)RPG2!T;R!T M:&4@0V]M<&%N>28C.#(Q-SMS($$@86YD($<@4')E9F5R6QE/3-$)T9/3E0M M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)RPG2!T:&4@ M0V]M<&%N>2X@5&AE(%-E2P@870@86YY('1I;64@870@82!P3Y!6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S M($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[34%21TE..B`P<'0@,'!X.R!& M3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E3X\8CY397)I97,@ M1R!03X\8CXF(S$V M,#L\+V(^/"]D:78^(#QD:78@3Y4:&4@0V]M<&%N>2!H87,@9&5S:6=N M871E9"`\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@)U1I;65S($YE=R!2 M;VUA;B2!L87<@86YD(&EN('1H92!C87-E(&]F('9A M2!T:6UE(&%T(&$@<')I8V4@;V8@ M)#QF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N M)RPG2!U;F1E8VQA3XF(S$V,#L\+V1I=CX@/&1I=B!S='EL93TS1"=#3$5!4CIB;W1H.R!&3TY4 M+49!34E,63I4:6UE#L@1D].5#H@,3!P="!4:6UE#L@1D].5#H@,3!P="!4 M:6UE6QE/3-$)T-,14%2.F)O=&@[($9/3E0M M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[34%21TE. M.B`P<'0@,'!X.R!&3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L M(%-E6QE/3-$)T-,14%2.F)O=&@[($9/ M3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[34%2 M1TE..B`P<'0@,'!X.R!&3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM M97,L(%-E6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S M($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[34%21TE..B`P<'0@,'!X.R!& M3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N M)RPG6QE/3-$)T9/ M3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)RPG6QE/3-$ M)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)RPG6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O M;6%N)RPG2!T;R!T:&4@0V]M<&%N>28C.#(Q-SMS($$L($(@86YD($<@4')E9F5R6QE M/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)RPG3XF(S$V,#L\ M+V1I=CX@/&1I=B!S='EL93TS1"=#3$5!4CIB;W1H.R!&3TY4+49!34E,63I4 M:6UE#L@1D].5#H@,3!P="!4:6UE#L@1D].5#H@,3!P="!4:6UE#L@1D].5#H@,3!P="!4:6UE#L@1D].5#H@,3!P="!4:6UE#L@1D].5#H@ M,3!P="!4:6UE2!H M87,@/&9O;G0@6QE/3-$ M)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)RPG6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM M97,@3F5W(%)O;6%N)RPG28C.#(Q-SMS M($-O;6UO;B!3=&]C:R!A="!A(')A=&4@97%U86P@=&\@=&AE(&YU;6)E2!P97)C96YT("@\9F]N="!S='EL M93TS1"=&3TY4+49!34E,63H@)U1I;65S($YE=R!2;VUA;B7,@<')I;W(@=&\@8V]N=F5R#L@1D].5#H@,3!P="!4 M:6UE6QE/3-$)T-,14%2.F)O=&@[($9/3E0M M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[34%21TE. M.B`P<'0@,'!X.R!&3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L M(%-E6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)RPG M6QE/3-$)W=I9'1H.C$P,"4[('1A8FQE+6QA>6]U=#IF:7AE9#LG(&-E M;&QS<&%C:6YG/3-$,"!C96QL<&%D9&EN9STS1#`^/'1R/CQT9#X\+W1D/CPO M='(^/"]T86)L93X\'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA'0^)SQS<&%N/CPO6QE M/3-$)TU!4D=)3CH@,'!T(#!P>#L@1D].5#H@,3!P="!4:6UE#L@1D]. M5#H@,3!P="!4:6UE65A&EM871E;'D@)#QF;VYT('-T>6QE/3-$)T9/3E0M M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)RPG'!E;G-E#L@ M1D].5#H@,3!P="!4:6UE6QE/3-$)T-,14%2 M.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z M(#$P<'0[34%21TE..B`P<'0@,'!X.R!&3TY4.B`Q,'!T(%1I;65S($YE=R!2 M;VUA;BP@5&EM97,L(%-E6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM M97,@3F5W(%)O;6%N)RPG65A2X@)#QF;VYT('-T>6QE M/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)RPG6QE M/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM& M3TY4+5-)6D4Z(#$P<'0[34%21TE..B`P<'0@,'!X.R!&3TY4.B`Q,'!T(%1I M;65S($YE=R!2;VUA;BP@5&EM97,L(%-E3Y&;W(@=&AE('EE87)S(&5N9&5D($1E M8V5M8F5R(#,Q+"`R,#$S(&%N9"`R,#$R+"!T:&4@0V]M<&%N>2!R96-O2`D/&9O;G0@2!A6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W M(%)O;6%N)RPG65A2X\+V1I=CX@/&1I=B!S='EL93TS1"=#3$5! M4CIB;W1H.R!&3TY4+49!34E,63I4:6UE#L@1D].5#H@,3!P="!4:6UE6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I M;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[34%21TE..B`P<'0@,'!X M.R!&3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E2!A;'-O(')E8V]R9&5D("0\9F]N="!S M='EL93TS1"=&3TY4+49!34E,63H@)U1I;65S($YE=R!2;VUA;B65A2!R96-O'!E;G-E M2!T6QE/3-$)W=I9'1H.C$P,"4[('1A M8FQE+6QA>6]U=#IF:7AE9#LG(&-E;&QS<&%C:6YG/3-$,"!C96QL<&%D9&EN M9STS1#`^/'1R/CQT9#X\+W1D/CPO='(^/"]T86)L93X\'0O M:F%V87-C3X-"B`@("`\ M=&%B;&4@8VQA6QE/3-$)TU!4D=)3BU43U`Z(#!P=#L@1D].5#H@,3!P="!4 M:6UE6QE/3-$)U9%4E1)0T%,+4%,24=..B!T;W`G/B`\=&0@ M6QE/3-$)U1%6%0M04Q)1TXZ(&IU M3Y"87-I8R!L;W-S('!E2!D:6QU=&EV92!C;VYV97)T:6)L92!P M2X@270@86QS;R!A2!S M:&%R97,@:7-S=6%B;&4@=7!O;B!E>&5R8VES92!O9B!T:&]S92!S=&]C:R!O M<'1I;VYS(&%N9"!W87)R86YT#L@1D].5#H@,3!P="!4:6UE6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S M($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[34%21TE..B`P<'0@,'!X.R!& M3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E6QE/3-$)T-, M14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-) M6D4Z(#$P<'0[5$585"U!3$E'3CI,969T.R!415A4+4E.1$5.5#H@,&EN.R!7 M24142#H@,3`P)2<^(#QT86)L92!S='EL93TS1"=-05)'24XZ(#!I;B`P:6X@ M,&EN(#`N,C5I;CL@5TE$5$@Z(#@P)3L@0D]21$52+4-/3$Q!4%-%.B!C;VQL M87!S93L@3U9%4D9,3U6QE/3-$)U1% M6%0M04Q)1TXZ(&-E;G1E"!S;VQI9#L@5$585"U!3$E'3CH@8V5N M=&5R.R!&3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!4:6UE6QE/3-$)U1%6%0M04Q)1TXZ(&-E;G1E M6QE/3-$)U1%6%0M04Q) M1TXZ(&-E;G1E6QE/3-$)T)/4D1%4BU"3U14 M3TTZ(",P,#`P,#`@,7!X('-O;&ED.R!415A4+4%,24=..B!C96YT97([($9/ M3E0M4U193$4Z(&YO"!S;VQI9#L@1D].5"U714E'2%0Z(#

6QE/3-$)U1%6%0M04Q)1TXZ(&-E M;G1E6QE/3-$)U1%6%0M M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z M(&YO"!S;VQI9#L@1D].5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q M,B4^(#QD:78^)B,Q-C`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`Q M,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@-#`P M)R!W:61T:#TS1#4Q)3X@/&1I=CY"87-I8R!A;F0@9&EL=71E9"!E87)N:6YG M6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!&3TY4+5-4 M64Q%.B!N;W)M86P[(%!!1$1)3D#L@1D].5"U&04U)3%DZ M(%1I;65S($YE=R!2;VUA;CL@0D%#2T=23U5.1#H@(V-C9F9C8SL@1D].5"U3 M25I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=( M5#H@-#`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`G M5&EM97,@3F5W(%)O;6%N)RPG"`P<'0@,"XR-6EN.R!&3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM M97,L(%-E6QE/3-$ M)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)RPG"`P<'0@,"XR-6EN.R!&3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@ M5&EM97,L(%-E6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P M:6X@,"XR-6EN.R!724142#H@-S`E.R!"3U)$15(M0T],3$%04T4Z(&-O;&QA M<'-E.R!/5D521DQ/5SH@=FES:6)L92<@8V5L;'-P86-I;F<],T0P(&-E;&QP M861D:6YG/3-$,"!A;&EG;CTS1&QE9G0^(#QT6QE/3-$)U1% M6%0M04Q)1TXZ(&-E;G1E6QE/3-$)T)/4D1% M4BU"3U143TTZ(",P,#`P,#`@,7!X('-O;&ED.R!415A4+4%,24=..B!C96YT M97([($9/3E0M4U193$4Z(&YO"!S;VQI9#L@1D].5"U714E'2%0Z(#6QE/3-$ M)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,7!X('-O;&ED.R!415A4+4%,24=. M.B!C96YT97([($9/3E0M4U193$4Z(&YO"!S;VQI9#L@1D]. M5"U714E'2%0Z(#6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO"!S;VQI M9#L@1D].5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q,B4^(#QD:78^-#0X/"]D M:78^(#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!L969T.R!&3TY4 M+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!4:6UE6QE/3-$)U1% M6%0M04Q)1TXZ(')I9VAT.R!&3TY4+5-464Q%.B!N;W)M86P[(%!!1$1)3D#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@0D%# M2T=23U5.1#H@(V9F9F9F9CL@0T],3U(Z(",P,#`P,#`[($9/3E0M4TE:13H@ M,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O='1O;3L@1D].5"U714E'2%0Z(#0P M,"<@=VED=&@],T0Q,B4^(#QD:78^,S`U+#8T.#PO9&EV/B`\+W1D/B`\=&0@ M6QE/3-$)U1% M6%0M04Q)1TXZ(')I9VAT.R!&3TY4+5-464Q%.B!N;W)M86P[(%!!1$1)3D#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@0D%# M2T=23U5.1#H@(V9F9F9F9CL@0T],3U(Z(",P,#`P,#`[($9/3E0M4TE:13H@ M,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O='1O;3L@1D].5"U714E'2%0Z(#0P M,"<@=VED=&@],T0Q,B4^(#QD:78^,S`U+#8T.#PO9&EV/B`\+W1D/B`\=&0@ M6QE/3-$)U1%6%0M04Q) M1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)U1%6%0M M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)U1%6%0M04Q)1TXZ M(&QE9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO M6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z M(&YO6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!&3TY4+5-464Q%.B!N;W)M86P[ M(%!!1$1)3D#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2 M;VUA;CL@0D%#2T=23U5.1#H@(V9F9F9F9CL@0T],3U(Z(",P,#`P,#`[($9/ M3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O='1O;3L@1D].5"U7 M14E'2%0Z(#0P,"<@=VED=&@],T0Q,B4^(#QD:78^,2PP,#`L,#`P/"]D:78^ M(#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!L969T.R!&3TY4+5-4 M64Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!4:6UE6QE/3-$)U1%6%0M M04Q)1TXZ(')I9VAT.R!&3TY4+5-464Q%.B!N;W)M86P[(%!!1$1)3D#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@0D%#2T=2 M3U5.1#H@(V-C9F9C8SL@0T],3U(Z(",P,#`P,#`[($9/3E0M4TE:13H@,3!P M=#L@5D525$E#04PM04Q)1TXZ(&)O='1O;3L@1D].5"U714E'2%0Z(#0P,"<@ M=VED=&@],T0Q,B4^(#QD:78^-#@R+#8R-3PO9&EV/B`\+W1D/B`\=&0@6QE/3-$)U1%6%0M M04Q)1TXZ(')I9VAT.R!&3TY4+5-464Q%.B!N;W)M86P[(%!!1$1)3D#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@0D%#2T=2 M3U5.1#H@(V-C9F9C8SL@0T],3U(Z(",P,#`P,#`[($9/3E0M4TE:13H@,3!P M=#L@5D525$E#04PM04Q)1TXZ(&)O='1O;3L@1D].5"U714E'2%0Z(#0P,"<@ M=VED=&@],T0Q,B4^(#QD:78^+3PO9&EV/B`\+W1D/B`\=&0@6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[ M($9/3E0M4U193$4Z(&YO6QE/3-$)U1% M6%0M04Q)1TXZ(')I9VAT.R!&3TY4+5-464Q%.B!N;W)M86P[(%!!1$1)3D#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@0D%# M2T=23U5.1#H@(V9F9F9F9CL@0T],3U(Z(",P,#`P,#`[($9/3E0M4TE:13H@ M,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O='1O;3L@1D].5"U714E'2%0Z(#0P M,"<@=VED=&@],T0Q,B4^(#QD:78^,3(R+#4P,#PO9&EV/B`\+W1D/B`\=&0@ M6QE/3-$)U1% M6%0M04Q)1TXZ(')I9VAT.R!&3TY4+5-464Q%.B!N;W)M86P[(%!!1$1)3D#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@0D%# M2T=23U5.1#H@(V9F9F9F9CL@0T],3U(Z(",P,#`P,#`[($9/3E0M4TE:13H@ M,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O='1O;3L@1D].5"U714E'2%0Z(#0P M,"<@=VED=&@],T0Q,B4^(#QD:78^,C8W+#,U,#PO9&EV/B`\+W1D/B`\=&0@ M6QE/3-$)U1%6%0M04Q) M1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)U1%6%0M04Q) M1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M M4U193$4Z(&YO6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M M4U193$4Z(&YO6QE/3-$)U1%6%0M04Q) M1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)U1%6%0M04Q) M1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)U1%6%0M04Q) M1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U19 M3$4Z(&YO6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U19 M3$4Z(&YO6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U19 M3$4Z(&YO6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA M;CM&3TY4+5-)6D4Z(#$P<'0G/CPO9&EV/B`\9&EV('-T>6QE/3-$)T-,14%2 M.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z M(#$P<'0G/CPO9&EV/B`\+V1I=CX@/"]D:78^/'1A8FQE(&)O&5D.R<@8V5L M;'-P86-I;F<],T0P(&-E;&QP861D:6YG/3-$,#X\='(^/'1D/CPO=&0^/"]T M7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T* M#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O M;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA'0^)SQD:78@6QE/3-$)U=)1%1(.B`P+C(U:6XG M/B`\9&EV/CQS=')O;F<^,38N/"]S=')O;F<^/"]D:78^(#PO=&0^(#QT9#X@ M/&1I=CX\6QE/3-$)T-,14%2.F)O=&@[($9/ M3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[5$58 M5"U)3D1%3E0Z("TP+C(U:6X[($U!4D=)3CH@,'!T(#!P>"`P<'0@,"XR-6EN M.R!&3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E#L@1D].5#H@,3!P="!4:6UE2!H860@9&]M97-T:6,@;F5T(&]P97)A=&EN9R!L;W-S("@F M(S@R,C`[3D],)B,X,C(Q.RD@8V%R"!P=7)P;W-E'!I6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM M97,@3F5W(%)O;6%N)RPGF4@:71S($Y/3"!C87)R>2!F;W)W87)D&%B;&4@:6YC;VUE(&%N9"!R96QA=&5D('1A M>"!L:6%B:6QI=&EE#L@1D].5#H@,3!P="!4:6UE6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE M=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[34%21TE..B`P<'0@,'!X.R!&3TY4 M.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E2!T:6UE('1H97)E(&ES(&$@=')A;G-F97(@;V8@2!M;W)E('1H86X@-3`@<&5R8V5N=&%G92!P;VEN=',@;W9E2!S=')U8W1U3XF(S$V,#L\+V1I=CX@/&1I=B!S='EL93TS1"=#3$5!4CIB;W1H.R!&3TY4 M+49!34E,63I4:6UE#L@1D].5#H@,3!P="!4:6UE65T(&1E=&5R;6EN960@=&AE('%U86QI9GEI;F<@979E;G1S(&%N9"!R M97-U;'1I;F<@;&EM:71A=&EO;B!T:&%T(&UA>2!I;7!A8W0@=71I;&EZ871I M;VX@;V8@;F5T(&]P97)A=&EN9R!L;W-S97,@86=A:6YS="!F=71U#L@1D].5#H@,3!P="!4:6UE6QE M/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM& M3TY4+5-)6D4Z(#$P<'0[34%21TE..B`P<'0@,'!X.R!&3TY4.B`Q,'!T(%1I M;65S($YE=R!2;VUA;BP@5&EM97,L(%-E3XF M(S$V,#L\+V1I=CX@/&1I=B!S='EL93TS1"=#3$5!4CIB;W1H.R!&3TY4+49! M34E,63I4:6UE"!S;VQI9#L@34%21TE..B`P:6X[ M(%=)1%1(.B`X,"4[($)/4D1%4BU#3TQ,05!313H@8V]L;&%P"!S;VQI9#L@ M0D]21$52+5))1TA4.B`C.65B-F-E(#!P>"!S;VQI9"<@8V5L;'-P86-I;F<] M,T0P(&-E;&QP861D:6YG/3-$,"!A;&EG;CTS1&QE9G0^(#QT6QE/3-$)U1%6%0M04Q)1TXZ(&-E;G1E6QE M/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,7!X('-O;&ED.R!415A4+4%, M24=..B!C96YT97([($9/3E0M4U193$4Z(&YO6QE/3-$)U1% M6%0M04Q)1TXZ(&-E;G1E6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U19 M3$4Z(&YO"!S;VQI9#L@1D].5"U714E'2%0Z(#0P,"<@=VED=&@] M,T0Q,"4^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=4 M15A4+4%,24=..B!L969T.R!&3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%- M24Q9.B!4:6UE6QE/3-$)U1%6%0M04Q)1TXZ M(')I9VAT.R!&3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!4:6UE M6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/ M3E0M4U193$4Z(&YO6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z M(&YO#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@0D%# M2T=23U5.1#H@(V-C9F9C8SL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U! M3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#4U)3X@ M/&1I=CY$;VUE6QE/3-$)U1%6%0M04Q)1TXZ(&QE M9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)U1% M6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT M.R!&3TY4+5-464Q%.B!N;W)M86P[(%!!1$1)3D#L@1D]. M5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@0D%#2T=23U5.1#H@(V9F9F9F M9CL@0T],3U(Z(",P,#`P,#`[($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM M04Q)1TXZ(&)O='1O;3L@1D].5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q,"4^ M(#QD:78^-C`V/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=. M.B!L969T.R!&3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!4:6UE M6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO M6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!& M3TY4+5-464Q%.B!N;W)M86P[(%!!1$1)3D#L@1D].5"U& M04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@0D%#2T=23U5.1#H@(V-C9F9C8SL@ M0T],3U(Z(",P,#`P,#`[($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q) M1TXZ(&)O='1O;3L@1D].5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q,"4^(#QD M:78^,S(\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE M9G0[($9/3E0M4U193$4Z(&YO#L@1D].5"U&04U)3%DZ(%1I;65S M($YE=R!2;VUA;CL@0D%#2T=23U5.1#H@(V9F9F9F9CL@1D].5"U325I%.B`Q M,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@-#`P M)R!W:61T:#TS1#4U)3X@/&1I=CY!8V-R=65D(&QI86)I;&ET:65S(&%N9"!R M97-E6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO#L@1D].5"U&04U)3%DZ M(%1I;65S($YE=R!2;VUA;CL@0D%#2T=23U5.1#H@(V9F9F9F9CL@0T],3U(Z M(",P,#`P,#`[($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O M='1O;3L@1D].5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q,"4^(#QD:78^,C6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U19 M3$4Z(&YO"!S;VQI9#L@ M1D].5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q)3X@/&1I=CXF(S$V,#L\+V1I M=CX@/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!&3TY4 M+5-464Q%.B!N;W)M86P[(%!!1$1)3D#L@1D].5"U&04U) M3%DZ(%1I;65S($YE=R!2;VUA;CL@0D%#2T=23U5.1#H@(V-C9F9C8SL@0T], M3U(Z(",P,#`P,#`[($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ M(&)O='1O;3L@0D]21$52+51/4#H@(S`P,#`P,"`Q<'@@6QE/3-$)U1%6%0M04Q)1TXZ M(&QE9G0[($9/3E0M4U193$4Z(&YO#L@1D].5"U&04U)3%DZ(%1I M;65S($YE=R!2;VUA;CL@0D%#2T=23U5.1#H@(V9F9F9F9CL@1D].5"U325I% M.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@ M-#`P)R!W:61T:#TS1#4U)3X@/&1I=CY686QU871I;VX@86QL;W=A;F-E/"]D M:78^(#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!L969T.R!&3TY4 M+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!4:6UE6QE/3-$)T)/4D1% M4BU"3U143TTZ(",P,#`P,#`@,7!X('-O;&ED.R!415A4+4%,24=..B!L969T M.R!&3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!4:6UE6QE/3-$ M)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,7!X('-O;&ED.R!415A4+4%,24=. M.B!R:6=H=#L@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@5&EM M97,@3F5W(%)O;6%N.R!"04-+1U)/54Y$.B`C9F9F9F9F.R!#3TQ/4CH@(S`P M,#`P,#L@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M M.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$P)3X@/&1I=CXH,3DL,SDS M*3PO9&EV/B`\+W1D/B`\=&0@"!S;VQI9#L@5$585"U!3$E'3CH@ M;&5F=#L@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@5&EM97,@ M3F5W(%)O;6%N.R!"04-+1U)/54Y$.B`C9F9F9F9F.R!&3TY4+5-)6D4Z(#$P M<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($9/3E0M5T5)1TA4.B`T,#`G M('=I9'1H/3-$,24^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL M93TS1"="3U)$15(M0D]45$]-.B`C,#`P,#`P(#%P>"!S;VQI9#L@5$585"U! M3$E'3CH@6QE/3-$)U1%6%0M04Q)1TXZ(&QE M9G0[($9/3E0M4U193$4Z(&YO6QE M/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,W!X(&1O=6)L93L@5$585"U! M3$E'3CH@;&5F=#L@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@ M5&EM97,@3F5W(%)O;6%N.R!"04-+1U)/54Y$.B`C8V-F9F-C.R!#3TQ/4CH@ M(S`P,#`P,#L@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@;6ED M9&QE.R!"3U)$15(M5$]0.B`C,#`P,#`P(#%P>"!S;VQI9#L@1D].5"U714E' M2%0Z(#0P,"<@=VED=&@],T0Q)3X@/&1I=CXD/"]D:78^(#PO=&0^(#QT9"!S M='EL93TS1"="3U)$15(M0D]45$]-.B`C,#`P,#`P(#-P>"!D;W5B;&4[(%1% M6%0M04Q)1TXZ(')I9VAT.R!&3TY4+5-464Q%.B!N;W)M86P[(%!!1$1)3D#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@0D%# M2T=23U5.1#H@(V-C9F9C8SL@0T],3U(Z(",P,#`P,#`[($9/3E0M4TE:13H@ M,3!P=#L@5D525$E#04PM04Q)1TXZ(&UI9&1L93L@0D]21$52+51/4#H@(S`P M,#`P,"`Q<'@@6QE/3-$)U1%6%0M04Q)1TXZ M(&QE9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,W!X(&1O=6)L93L@ M5$585"U!3$E'3CH@"!S;VQI9#L@1D].5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q M,"4^(#QD:78^+3PO9&EV/B`\+W1D/B`\=&0@3XF(S$V,#L\ M+V1I=CX@/&1I=B!S='EL93TS1"=#3$5!4CIB;W1H.R!&3TY4+49!34E,63I4 M:6UE#L@1D].5#H@,3!P="!4:6UE6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N M)RPG"!B96YE9FET(&EN('1H92!A M8V-O;7!A;GEI;F<@"!L;W-S(&ES(&%S(&9O;&QO=W,@*&%M M;W5N=',@:6X@=&AO=7-A;F1S*3H\+V1I=CX@/&1I=B!S='EL93TS1"=#3$5! M4CIB;W1H.R!&3TY4+49!34E,63I4:6UE#L@1D].5#H@,3!P="!4:6UE6QE M/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM& M3TY4+5-)6D4Z(#$P<'0[5$585"U!3$E'3CI,969T.R!415A4+4E.1$5.5#H@ M,&EN.R!724142#H@,3`P)2<^(#QT86)L92!S='EL93TS1"=-05)'24XZ(#!I M;CL@5TE$5$@Z(#DU)3L@0D]21$52+4-/3$Q!4%-%.B!C;VQL87!S93L@3U9% M4D9,3U6QE/3-$)U1%6%0M04Q)1TXZ M(&-E;G1E"!S;VQI9#L@5$585"U!3$E'3CH@8V5N=&5R.R!&3TY4 M+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!4:6UE6QE/3-$)T)/4D1%4BU"3U143TTZ(",P M,#`P,#`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`P,#`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`Q,'!T.R!6 M15)424-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T M:#TS1#$P)3X@/&1I=CXR,3PO9&EV/B`\+W1D/B`\=&0@#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@0D%#2T=2 M3U5.1#H@(V9F9F9F9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E' M3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$E/B`\9&EV M/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@#L@ M1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@0D%#2T=23U5.1#H@(V9F M9F9F9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@;6ED9&QE M.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$E/B`\9&EV/B8C,38P.SPO M9&EV/B`\+W1D/B`\=&0@6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO M6QE/3-$)T)/4D1%4BU"3U143TTZ(",P M,#`P,#`@,7!X('-O;&ED.R!415A4+4%,24=..B!L969T.R!&3TY4+5-464Q% M.B!N;W)M86P[($9/3E0M1D%-24Q9.B!4:6UE6QE/3-$)T)/4D1%4BU"3U14 M3TTZ(",P,#`P,#`@,7!X('-O;&ED.R!415A4+4%,24=..B!R:6=H=#L@1D]. M5"U35%E,13H@;F]R;6%L.R!0041$24Y'+5))1TA4.B`S<'@[($9/3E0M1D%- M24Q9.B!4:6UE6QE M/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,7!X('-O;&ED.R!415A4+4%, M24=..B!L969T.R!&3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!4 M:6UE6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,7!X('-O;&ED.R!4 M15A4+4%,24=..B!R:6=H=#L@1D].5"U35%E,13H@;F]R;6%L.R!0041$24Y' M+5))1TA4.B`S<'@[($9/3E0M1D%-24Q9.B!4:6UE6QE/3-$)U1%6%0M04Q)1TXZ M(&QE9G0[($9/3E0M4U193$4Z(&YO"!S;VQI9#L@5$585"U!3$E'3CH@;&5F=#L@ M1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O M;6%N.R!"04-+1U)/54Y$.B`C8V-F9F-C.R!&3TY4+5-)6D4Z(#$P<'0[(%9% M4E1)0T%,+4%,24=..B!M:61D;&4[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H M/3-$,24^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=" M3U)$15(M0D]45$]-.B`C,#`P,#`P(#%P>"!S;VQI9#L@5$585"U!3$E'3CH@ M"!D;W5B;&4[(%1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO M"!S;VQI9#L@1D].5"U7 M14E'2%0Z(#0P,"<@=VED=&@],T0Q)3X@/&1I=CXD/"]D:78^(#PO=&0^(#QT M9"!S='EL93TS1"="3U)$15(M0D]45$]-.B`C,#`P,#`P(#-P>"!D;W5B;&4[ M(%1%6%0M04Q)1TXZ(')I9VAT.R!&3TY4+5-464Q%.B!N;W)M86P[(%!!1$1) M3D#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@ M0D%#2T=23U5.1#H@(V9F9F9F9CL@0T],3U(Z(",P,#`P,#`[($9/3E0M4TE: M13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O='1O;3L@0D]21$52+51/4#H@ M(S`P,#`P,"`Q<'@@6QE/3-$)U1%6%0M04Q) M1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@0D%#2T=23U5. M1#H@(V9F9F9F9CL@0T],3U(Z(",P,#`P,#`[($9/3E0M4TE:13H@,3!P=#L@ M5D525$E#04PM04Q)1TXZ(&)O='1O;3L@0D]21$52+51/4#H@(S`P,#`P,"`Q M<'@@6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[ M($9/3E0M4U193$4Z(&YO"!S;VQI9#L@1D].5"U714E'2%0Z(#0P,"<@ M=VED=&@],T0Q)3X@/&1I=CXD/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=" M3U)$15(M0D]45$]-.B`C,#`P,#`P(#-P>"!D;W5B;&4[(%1%6%0M04Q)1TXZ M(')I9VAT.R!&3TY4+5-464Q%.B!N;W)M86P[(%!!1$1)3D#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@0D%#2T=23U5.1#H@ M(V9F9F9F9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T M=&]M.R!"3U)$15(M5$]0.B`C,#`P,#`P(#%P>"!S;VQI9#L@1D].5"U714E' M2%0Z(#0P,"<@=VED=&@],T0Q,"4^(#QD:78^+3PO9&EV/B`\+W1D/B`\=&0@ M"!D;W5B;&4[(%1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z M(&YO"!S;VQI9#L@1D]. M5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q)3X@/&1I=CXF(S$V,#L\+V1I=CX@ M/"]T9#X@/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,W!X M(&1O=6)L93L@5$585"U!3$E'3CH@"!S;VQI9#L@1D].5"U714E'2%0Z(#0P,"<@ M=VED=&@],T0Q,"4^(#QD:78^+3PO9&EV/B`\+W1D/B`\=&0@6QE/3-$)T-,14%2.F)O=&@[($9/3E0M M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0G/CPO9&EV M/B`\9&EV('-T>6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S M($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0G/CPO9&EV/B`\9&EV('-T>6QE M/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM& M3TY4+5-)6D4Z(#$P<'0G/CPO9&EV/B`\+V1I=CX@/&9O;G0@3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT M4&%R=%]C8C(Q,68U,5\W,V$Q7S1C-#9?8C!B,U]B.#@Y9#5D-C0W8F4-"D-O M;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO8V(R,3%F-3%?-S-A,5\T8S0V M7V(P8C-?8C@X.60U9#8T-V)E+U=O'0O:'1M;#L@8VAA7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R'0^)SQD:78@6QE/3-$)U=)1%1(.B`P+C(U:6XG/B`\9&EV/CQB/C$W M+CPO8CX\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&IU M6QE/3-$)T-,14%2.F)O=&@[($9/3E0M M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[5$585"U) M3D1%3E0Z("TP+C(U:6X[($U!4D=)3CH@,'!T(#!P>"`P<'0@,"XR-6EN.R!& M3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E6QE/3-$ M)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4 M+5-)6D4Z(#$P<'0[34%21TE..B`P<'0@,'!X.R!&3TY4.B`Q,'!T(%1I;65S M($YE=R!2;VUA;BP@5&EM97,L(%-E28C.#(Q-SMS(&5M<&QO>65E2!E;&5C="!T;R!R961U8V4@=&AE:7(@8W5R6QE/3-$)T9/3E0M M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)RPG2!T:&4@0V]M<&%N>2!I;B`R,#$S M(&]R(#(P,3(N/"]D:78^(#PO9&EV/CQT86)L92!B;W)D97(],T0P('-T>6QE M/3-$)W=I9'1H.C$P,"4[('1A8FQE+6QA>6]U=#IF:7AE9#LG(&-E;&QS<&%C M:6YG/3-$,"!C96QL<&%D9&EN9STS1#`^/'1R/CQT9#X\+W1D/CPO='(^/"]T M86)L93X\'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA2!4'0^)SQS<&%N/CPO6QE/3-$)TU!4D=)3CH@,'!T M(#!P>#L@1D].5#H@,3!P="!4:6UE6QE/3-$)U=)1%1(.B`P+C(U:6XG/B`\9&EV M/CQB/C$X+CPO8CX\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q) M1TXZ(&IU6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9 M.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[5$585"U)3D1%3E0Z M("TP+C(U:6X[($U!4D=)3CH@,'!T(#!P>"`P<'0@,"XR-6EN.R!&3TY4.B`Q M,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9 M.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[34%21TE..B`P<'0@ M,'!X.R!&3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E2`S,2P@,C`Q,R!T:&4@0V]M M<&%N>2!A8V-E<'1E9"!A(&YO;BUI;G1E3XF(S$V,#L\+V1I M=CX@/&1I=B!S='EL93TS1"=#3$5!4CIB;W1H.R!&3TY4+49!34E,63I4:6UE M#L@ M1D].5#H@,3!P="!4:6UE6QE M/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)RPG#L@1D].5#H@,3!P="!4:6UE6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE M=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[34%21TE..B`P<'0@,'!X.R!&3TY4 M.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E2!I6QE/3-$)T-,14%2.F)O=&@[($9/3E0M M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[34%21TE. M.B`P<'0@,'!X.R!&3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L M(%-E3Y$=7)I;F<@2G5N92`R,#$S('1H92!#;VUP86YY(&%C8V5P=&5D(&$@;F]N M+6EN=&5R97-T(&)E87)I;F<@)#QF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9 M.B`G5&EM97,@3F5W(%)O;6%N)RPG#L@1D].5#H@,3!P="!4:6UE6QE/3-$)T-, M14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-) M6D4Z(#$P<'0[34%21TE..B`P<'0@,'!X.R!&3TY4.B`Q,'!T(%1I;65S($YE M=R!2;VUA;BP@5&EM97,L(%-E2!A8V-E<'1E9"!A(&YO;BUI;G1E3XF(S$V,#L\+V1I=CX@/&1I=B!S='EL93TS1"=#3$5!4CIB;W1H M.R!&3TY4+49!34E,63I4:6UE#L@1D].5#H@,3!P="!4:6UE2!C;VYV97)T960@8V5R=&%I;B!A9'9A;F-E6QE/3-$)T9/3E0M M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)RPG2P@:6YT M;R!397)I97,@2"!P#L@1D].5#H@,3!P="!4:6UE2`R,BP@,C`Q,R!T:&4@0V]M M<&%N>2!A8V-E<'1E9"!A(&YO;BUI;G1E3XF(S$V,#L\+V1I M=CX@/&1I=B!S='EL93TS1"=#3$5!4CIB;W1H.R!&3TY4+49!34E,63I4:6UE M#L@ M1D].5#H@,3!P="!4:6UE2!I6QE/3-$)T-,14%2.F)O=&@[($9/ M3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[34%2 M1TE..B`P<'0@,'!X.R!&3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM M97,L(%-E3Y/;B!!=6=U2!I6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%- M24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[34%21TE..B`P M<'0@,'!X.R!&3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E M3Y/ M;B!!=6=U2!I6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I M;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[34%21TE..B`P<'0@,'!X M.R!&3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E3Y/;B!.;W9E M;6)E6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM M97,@3F5W(%)O;6%N)RPG#L@1D]. M5#H@,3!P="!4:6UE6QE/3-$)T-,14%2.F)O M=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P M<'0[34%21TE..B`P<'0@,'!X.R!&3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA M;BP@5&EM97,L(%-E6QE/3-$)T-,14%2 M.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z M(#$P<'0[34%21TE..B`P<'0@,'!X.R!&3TY4.B`Q,'!T(%1I;65S($YE=R!2 M;VUA;BP@5&EM97,L(%-E7-T96US+CPO9&EV/B`\9&EV('-T>6QE/3-$)T-,14%2.F)O=&@[($9/ M3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[34%2 M1TE..B`P<'0@,'!X.R!&3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM M97,L(%-E3Y/;B!*86YU87)Y M(#,L(#(P,30@=&AE(')E;&%T960@<&%R='D@9&5B="!H;VQD97)S(&%G6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@ M3F5W(%)O;6%N)SL@1D].5"U325I%.B`Q,G!T)SX\9F]N="!S='EL93TS1"=& M3TY4+49!34E,63H@)U1I;65S($YE=R!2;VUA;B6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)RPG6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@ M3F5W(%)O;6%N)RPG#L@1D].5#H@,3!P="!4 M:6UE#L@1D].5#H@,3!P="!4:6UE3X\ M8CXF(S$V,#L\+V(^/"]D:78^(#QD:78@3Y/;B!*86YU87)Y(#$R+"`R M,#$R+"!T:&4@0V]M<&%N>2!A8W%U:7)E9"!A(&)U:6QD:6YG(&EN(%=E2!L M96%S960@9G)O;2!I=',@0VAI968@17AE8W5T:79E($]F9FEC97(@*$QE;F1E M&EM871E;'D@ M)#QF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N M)RPG2!I2!T;R!P=7)C:&%S92!S:&%R97,@ M;V8@=&AE($-O;7!A;GDF(S@R,3<['!I M6QE/3-$ M)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)RPG#L@1D].5#H@,3!P="!4:6UE6QE/3-$)T-, M14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-) M6D4Z(#$P<'0[34%21TE..B`P<'0@,'!X.R!&3TY4.B`Q,'!T(%1I;65S($YE M=R!2;VUA;BP@5&EM97,L(%-E2!R96-O9VYI>F5D(&-O2`D/&9O;G0@7-T96US(&9R;VT@3F5U#L@1D].5#H@,3!P="!4:6UE6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I M;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[34%21TE..B`P<'0@,'!X M.R!&3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E2!A="!A(&-O;G9E7,@<')E8V5D:6YG(&-O;G9E3XF(S$V M,#L\+V1I=CX@/&1I=B!S='EL93TS1"=#3$5!4CIB;W1H.R!&3TY4+49!34E, M63I4:6UE#L@1D].5#H@,3!P="!4:6UE28C.#(Q-SMS M($-O;6UO;B!3=&]C:RP@870@86X@97AE6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)RPG'!I2!V;VQU;64@=V5I9VAT960@879E M6QE/3-$)T9/3E0M1D%-24Q9.B`G M5&EM97,@3F5W(%)O;6%N)RPG6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2 M;VUA;CM&3TY4+5-)6D4Z(#$P<'0[34%21TE..B`P<'0@,'!X.R!&3TY4.B`Q M,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E3Y);B!397!T96UB97(@;V8@ M,C`Q,BP@=&AE($-O;7!A;GD@6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W M(%)O;6%N)RPG2!R97!A:60@87,@;V8@1&5C M96UB97(@,S$L(#(P,3(N/"]D:78^(#PO9&EV/CQT86)L92!B;W)D97(],T0P M('-T>6QE/3-$)W=I9'1H.C$P,"4[('1A8FQE+6QA>6]U=#IF:7AE9#LG(&-E M;&QS<&%C:6YG/3-$,"!C96QL<&%D9&EN9STS1#`^/'1R/CQT9#X\+W1D/CPO M='(^/"]T86)L93X\'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA'0^ M)SQD:78@6QE/3-$)U=)1%1( M.B`P+C(U:6XG/B`\9&EV/CQS=')O;F<^,3DN/"]S=')O;F<^/"]D:78^(#PO M=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!J=7-T:69Y)SX@/&1I=CX\ M3X\6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%- M24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[34%21TE..B`P M<'0@,'!X.R!&3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E M#L@1D].5#H@,3!P="!4 M:6UE6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE M=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[34%21TE..B`P<'0@,'!X.R!&3TY4 M.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E2!F;W(@ M=V%R96AO=7-I;F<@86YD(&]F9FEC92!S<&%C92!I;B!.:6%G87)A+"!.97<@ M66]R:RX@5&AE(&QE87-E(&5X<&ER97,@:6X@36%Y(#QF;VYT('-T>6QE/3-$ M)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)RPG65A2!I6QE/3-$)T-,14%2.F)O=&@[($9/ M3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[34%2 M1TE..B`P<'0@,'!X.R!&3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM M97,L(%-E3Y/;B!*=6QY(#6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O M;6%N)RPG6QE/3-$ M)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)RPG&EM871E;'D@/&9O;G0@6QE/3-$)T-, M14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-) M6D4Z(#$P<'0[34%21TE..B`P<'0@,'!X.R!&3TY4.B`Q,'!T(%1I;65S($YE M=R!2;VUA;BP@5&EM97,L(%-E3Y/;B!$96-E;6)E6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE M=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[34%21TE..B`P<'0@,'!X.R!&3TY4 M.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E3Y4;W1A;"!R96YT(&5X M<&5N6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM M97,@3F5W(%)O;6%N)RPG3XF(S$V M,#L\+V1I=CX@/&1I=B!S='EL93TS1"=#3$5!4CIB;W1H.R!&3TY4+49!34E, M63I4:6UE#L@1D].5#H@,3!P="!4:6UE6QE/3-$)T9/3E0M1D%-24Q9 M.B`G5&EM97,@3F5W(%)O;6%N)RPG3XF(S$V,#L\+V1I=CX@/&1I=B!S='EL93TS1"=#3$5! M4CIB;W1H.R!&3TY4+49!34E,63I4:6UE6QE/3-$)TU!4D=)3CH@,&EN.R!724142#H@,3`P M)3L@0D]21$52+4-/3$Q!4%-%.B!C;VQL87!S93L@1D].5"U325I%.B`Q,'!T M.R!/5D521DQ/5SH@=FES:6)L92<@8V5L;'-P86-I;F<],T0P(&-E;&QP861D M:6YG/3-$,"!A;&EG;CTS1&QE9G0^(#QT6QE/3-$)T)/4D1% M4BU"3U143TTZ(",P,#`P,#`@,7!X('-O;&ED.R!415A4+4%,24=..B!C96YT M97([($9/3E0M4U193$4Z(&YO6QE/3-$)U1% M6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)U1% M6%0M04Q)1TXZ(')I9VAT.R!&3TY4+5-464Q%.B!N;W)M86P[(%!!1$1)3D#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@0D%# M2T=23U5.1#H@(V-C9F9C8SL@0T],3U(Z(",P,#`P,#`[($9/3E0M4TE:13H@ M,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O='1O;3L@1D].5"U714E'2%0Z(#0P M,"<@=VED=&@],T0Q,B4^(#QD:78^-S(L-#0T/"]D:78^(#PO=&0^(#QT9"!S M='EL93TS1"=415A4+4%,24=..B!L969T.R!&3TY4+5-464Q%.B!N;W)M86P[ M($9/3E0M1D%-24Q9.B!4:6UE6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/ M3E0M4U193$4Z(&YO6QE/3-$)U1%6%0M M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)T9/3E0M1D%-24Q9 M.B`G5&EM97,@3F5W(%)O;6%N)RPG6QE/3-$)T-,14%2.F)O=&@[($9/ M3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[34%2 M1TE..B`P<'0@,'!X.R!&3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM M97,L(%-E3Y/;B!*=6YE(#@L(#(P,3(L('1H92!O=VYE2!I;B!T:&4@ M86UO=6YT(&]F("0X-2PU,C4N.3@@<&QU2!P87EM96YT2X\+V1I=CX@/&1I=B!S='EL93TS1"=#3$5!4CIB;W1H.R!&3TY4+49!34E, M63I4:6UE#L@1D].5#H@,3!P="!4:6UE6QE/3-$ M)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4 M+5-)6D4Z(#$P<'0[34%21TE..B`P<'0@,'!X.R!&3TY4.B`Q,'!T(%1I;65S M($YE=R!2;VUA;BP@5&EM97,L(%-E2!W87,@2!S=&%G92X\+V1I=CX@/"]D:78^/'1A8FQE M(&)O&5D.R<@8V5L;'-P86-I;F<],T0P(&-E;&QP861D:6YG/3-$,#X\='(^ M/'1D/CPO=&0^/"]T7!E.B!T97AT+VAT;6P[(&-H87)S970] M(G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T M<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@ M8VAA'0^)SQD:78@6QE/3-$)U=) M1%1(.B`P+C(U:6XG/B`\9&EV/CQS=')O;F<^,C`N/"]S=')O;F<^/"]D:78^ M(#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!J=7-T:69Y)SX@/&1I M=CX\6QE/3-$)T-,14%2.F)O=&@[($9/ M3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[34%2 M1TE..B`P<'0@,'!X.R!&3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM M97,L(%-E6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S M($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[5$585"U!3$E'3CI,969T.R!4 M15A4+4E.1$5.5#H@,&EN.R!724142#H@,3`P)2<^(#QT86)L92!S='EL93TS M1"="3U)$15(M0D]45$]-.B`C.65B-F-E(#!P>"!S;VQI9#L@0D]21$52+4Q% M1E0Z(",Y96(V8V4@,'!X('-O;&ED.R!-05)'24XZ(#!I;CL@5TE$5$@Z(#$P M,"4[($)/4D1%4BU#3TQ,05!313H@8V]L;&%P"!S;VQI9#L@0D]21$52+5)) M1TA4.B`C.65B-F-E(#!P>"!S;VQI9"<@8V5L;'-P86-I;F<],T0P(&-E;&QP M861D:6YG/3-$,"!A;&EG;CTS1&QE9G0^(#QT6QE/3-$)U1% M6%0M04Q)1TXZ(&-E;G1E6QE/3-$)T)/4D1% M4BU"3U143TTZ(",P,#`P,#`@,7!X('-O;&ED.R!415A4+4%,24=..B!C96YT M97([($9/3E0M4U193$4Z(&YO6QE/3-$)U1%6%0M04Q)1TXZ(&-E;G1E"!S;VQI9#L@1D].5"U714E'2%0Z(#6QE/3-$)T)/4D1%4BU"3U14 M3TTZ(",P,#`P,#`@,7!X('-O;&ED.R!415A4+4%,24=..B!C96YT97([($9/ M3E0M4U193$4Z(&YO"!S;VQI9#L@1D].5"U714E'2%0Z(#

"!S;VQI9#L@5$585"U!3$E'3CH@8V5N=&5R.R!&3TY4+5-464Q% M.B!N;W)M86P[($9/3E0M1D%-24Q9.B!4:6UE"!S;VQI9#L@1D].5"U714E'2%0Z(#

"!S;VQI9#L@1D]. M5"U714E'2%0Z(#"!S;VQI9#L@1D].5"U714E'2%0Z(#"!S;VQI9#L@1D].5"U714E'2%0Z(#6QE/3-$ M)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!&3TY4+5-464Q%.B!N M;W)M86P[(%!!1$1)3D#L@1D].5"U&04U)3%DZ(%1I;65S M($YE=R!2;VUA;CL@0D%#2T=23U5.1#H@(V-C9F9C8SL@1D].5"U325I%.B`Q M,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@-#`P M)R!W:61T:#TS1#$P)3X@/&1I=CXS-S$\+V1I=CX@/"]T9#X@/'1D('-T>6QE M/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z M(&YO6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT M.R!&3TY4+5-464Q%.B!N;W)M86P[(%!!1$1)3D#L@1D]. M5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@0D%#2T=23U5.1#H@(V-C9F9C M8SL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!& M3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$P)3X@/&1I=CXT-S8\+V1I=CX@ M/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U19 M3$4Z(&YO6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!&3TY4 M+5-464Q%.B!N;W)M86P[(%!!1$1)3D#L@1D].5"U&04U) M3%DZ(%1I;65S($YE=R!2;VUA;CL@0D%#2T=23U5.1#H@(V9F9F9F9CL@1D]. M5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=% M24=(5#H@-#`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`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=% M24=(5#H@-#`P)R!W:61T:#TS1#$P)3X@/&1I=CXQ+#0U,BPU-#@\+V1I=CX@ M/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U19 M3$4Z(&YO3X\6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S M($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[5$585"U!3$E'3CI,969T.R!4 M15A4+4E.1$5.5#H@,&EN.R!724142#H@,3`P)2<^(#QT86)L92!S='EL93TS M1"="3U)$15(M0D]45$]-.B`C.65B-F-E(#!P>"!S;VQI9#L@0D]21$52+4Q% M1E0Z(",Y96(V8V4@,'!X('-O;&ED.R!-05)'24XZ(#!I;CL@5TE$5$@Z(#$P M,"4[($)/4D1%4BU#3TQ,05!313H@8V]L;&%P"!S;VQI9#L@0D]21$52+5)) M1TA4.B`C.65B-F-E(#!P>"!S;VQI9"<@8V5L;'-P86-I;F<],T0P(&-E;&QP M861D:6YG/3-$,"!A;&EG;CTS1&QE9G0^(#QT6QE/3-$)U1% M6%0M04Q)1TXZ(&-E;G1E6QE/3-$)T)/4D1% M4BU"3U143TTZ(",P,#`P,#`@,7!X('-O;&ED.R!415A4+4%,24=..B!C96YT M97([($9/3E0M4U193$4Z(&YO6QE/3-$)U1%6%0M04Q)1TXZ(&-E;G1E"!S;VQI9#L@1D].5"U714E'2%0Z(#6QE/3-$)T)/4D1%4BU"3U14 M3TTZ(",P,#`P,#`@,7!X('-O;&ED.R!415A4+4%,24=..B!C96YT97([($9/ M3E0M4U193$4Z(&YO"!S;VQI9#L@1D].5"U714E'2%0Z(#

"!S;VQI9#L@5$585"U!3$E'3CH@8V5N=&5R.R!&3TY4+5-464Q% M.B!N;W)M86P[($9/3E0M1D%-24Q9.B!4:6UE"!S;VQI9#L@1D].5"U714E'2%0Z(#

"!S;VQI9#L@1D]. M5"U714E'2%0Z(#"!S;VQI9#L@1D].5"U714E'2%0Z(#"!S;VQI9#L@1D].5"U714E'2%0Z(#6QE/3-$ M)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!&3TY4+5-464Q%.B!N M;W)M86P[(%!!1$1)3D#L@1D].5"U&04U)3%DZ(%1I;65S M($YE=R!2;VUA;CL@0D%#2T=23U5.1#H@(V-C9F9C8SL@1D].5"U325I%.B`Q M,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@-#`P M)R!W:61T:#TS1#$P)3X@/&1I=CXX,CD\+V1I=CX@/"]T9#X@/'1D('-T>6QE M/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)U1% M6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!&3TY4+5-464Q%.B!N;W)M M86P[(%!!1$1)3D#L@1D].5"U&04U)3%DZ(%1I;65S($YE M=R!2;VUA;CL@0D%#2T=23U5.1#H@(V-C9F9C8SL@1D].5"U325I%.B`Q,'!T M.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@-#`P)R!W M:61T:#TS1#$P)3X@/&1I=CXS-S`\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$ M)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO6QE M/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO6QE M/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!&3TY4+5-464Q%.B!N;W)M86P[(%!! M1$1)3D#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA M;CL@0D%#2T=23U5.1#H@(V9F9F9F9CL@1D].5"U325I%.B`Q,'!T.R!615)4 M24-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@-#`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`Q,'!T.R!615)424-!3"U!3$E'3CH@ M8F]T=&]M.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$P)3X@/&1I=CXQ M+#0U,2PQ-#`\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ M(&QE9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9 M.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0G/CPO9&EV/B`\+V1I M=CX@/&9O;G0@6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)RPG&5D M.R<@8V5L;'-P86-I;F<],T0P(&-E;&QP861D:6YG/3-$,#X\='(^/'1D/CPO M=&0^/"]T7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S M8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I M=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA7!E/3-$=&5X="]J879A'0^)SQD:78@6QE/3-$)U=)1%1(.B`P+C(U:6XG/B`\9&EV M/CQS=')O;F<^,C$N/"]S=')O;F<^/"]D:78^(#PO=&0^(#QT9"!S='EL93TS M1"=415A4+4%,24=..B!J=7-T:69Y)SX@/&1I=CX\3X\6QE/3-$)T-,14%2.F)O=&@[ M($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[ M34%21TE..B`P<'0@,'!X.R!&3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@ M5&EM97,L(%-E6QE/3-$)T-, M14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-) M6D4Z(#$P<'0[34%21TE..B`P<'0@,'!X.R!&3TY4.B`Q,'!T(%1I;65S($YE M=R!2;VUA;BP@5&EM97,L(%-E3Y792!E=F%L=6%T92!A('-E9VUE;G0F(S@R,3<[ M3XF(S$V,#L\+V1I=CX@/&1I=B!S='EL93TS1"=#3$5!4CIB;W1H.R!& M3TY4+49!34E,63I4:6UE#L@1D].5#H@,3!P="!4:6UE6QE/3-$)T-,14%2.F)O M=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P M<'0[34%21TE..B`P<'0@,'!X.R!&3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA M;BP@5&EM97,L(%-E3X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@)U1I;65S M($YE=R!2;VUA;B6QE/3-$)T-,14%2.F)O M=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P M<'0[34%21TE.+51/4#H@,'!T.R!&3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA M;BP@5&EM97,L(%-E"!S;VQI9#L@34%21TE. M.B`P:6X[(%=)1%1(.B`Q,#`E.R!"3U)$15(M0T],3$%04T4Z(&-O;&QA<'-E M.R!/5D521DQ/5SH@=FES:6)L93L@0D]21$52+51/4#H@(SEE8C9C92`P<'@@ M6QE/3-$)U1%6%0M04Q)1TXZ(&-E;G1E6QE/3-$)U1% M6%0M04Q)1TXZ(&-E;G1E6QE/3-$)U1%6%0M04Q)1TXZ(&-E;G1E6QE M/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,7!X('-O;&ED.R!415A4+4%, M24=..B!C96YT97([($9/3E0M4U193$4Z(&YO"!S;VQI9#L@ M1D].5"U714E'2%0Z(#"!S M;VQI9#L@5$585"U!3$E'3CH@8V5N=&5R.R!&3TY4+5-464Q%.B!N;W)M86P[ M($9/3E0M1D%-24Q9.B!4:6UE6QE/3-$ M)U1%6%0M04Q)1TXZ(&-E;G1E6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)U1%6%0M04Q)1TXZ M(&QE9G0[($9/3E0M4U193$4Z(&YO"!S;VQI9#L@1D].5"U714E' M2%0Z(#0P,"<@=VED=&@],T0Q,B4^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^ M(#QT9"!S='EL93TS1"=415A4+4%,24=..B!L969T.R!&3TY4+5-464Q%.B!N M;W)M86P[($9/3E0M1D%-24Q9.B!4:6UE6QE/3-$)U1%6%0M04Q)1TXZ(&QE M9G0[($9/3E0M4U193$4Z(&YO"!S;VQI9#L@1D].5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q)3X@/&1I M=CXF(S$V,#L\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ M(')I9VAT.R!&3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!4:6UE M6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M M4U193$4Z(&YO6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[ M($9/3E0M4U193$4Z(&YO6QE/3-$)T)/4D1%4BU" M3U143TTZ(",P,#`P,#`@,7!X('-O;&ED.R!415A4+4%,24=..B!L969T.R!& M3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!4:6UE6QE/3-$)T)/ M4D1%4BU"3U143TTZ(",P,#`P,#`@,7!X('-O;&ED.R!415A4+4%,24=..B!R M:6=H=#L@1D].5"U35%E,13H@;F]R;6%L.R!0041$24Y'+5))1TA4.B`U<'@[ M($9/3E0M1D%-24Q9.B!4:6UE"!S;VQI9#L@5$585"U!3$E'3CH@;&5F=#L@ M1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O M;6%N.R!"04-+1U)/54Y$.B`C8V-F9F-C.R!&3TY4+5-)6D4Z(#$P<'0[(%9% M4E1)0T%,+4%,24=..B!B;W1T;VT[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H M/3-$,24^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=" M3U)$15(M0D]45$]-.B`C,#`P,#`P(#%P>"!S;VQI9#L@5$585"U!3$E'3CH@ M6QE/3-$ M)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,W!X(&1O=6)L93L@5$585"U!3$E' M3CH@;&5F=#L@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@5&EM M97,@3F5W(%)O;6%N.R!"04-+1U)/54Y$.B`C9F9F9F9F.R!&3TY4+5-)6D4Z M(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($)/4D1%4BU43U`Z(",P M,#`P,#`@,7!X('-O;&ED.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$E M/B`\9&EV/B0\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)T)/4D1%4BU"3U14 M3TTZ(",P,#`P,#`@,W!X(&1O=6)L93L@5$585"U!3$E'3CH@"!D;W5B;&4[(%1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO"!S;VQI9#L@1D].5"U714E' M2%0Z(#0P,"<@=VED=&@],T0Q)3X@/&1I=CXD/"]D:78^(#PO=&0^(#QT9"!S M='EL93TS1"="3U)$15(M0D]45$]-.B`C,#`P,#`P(#-P>"!D;W5B;&4[(%1% M6%0M04Q)1TXZ(')I9VAT.R!&3TY4+5-464Q%.B!N;W)M86P[(%!!1$1)3D#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@0D%# M2T=23U5.1#H@(V9F9F9F9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U! M3$E'3CH@8F]T=&]M.R!"3U)$15(M5$]0.B`C,#`P,#`P(#%P>"!S;VQI9#L@ M1D].5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q,B4^(#QD:78^,BPX,#$\+V1I M=CX@/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M M4U193$4Z(&YO6QE/3-$)U1%6%0M M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO"!D;W5B;&4[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H M/3-$,24^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=4 M15A4+4%,24=..B!R:6=H=#L@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49! M34E,63H@5&EM97,@3F5W(%)O;6%N.R!"04-+1U)/54Y$.B`C8V-F9F-C.R!& M3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($)/4D1% M4BU43U`Z(",P,#`P,#`@,W!X(&1O=6)L93L@1D].5"U714E'2%0Z(#0P,"<@ M=VED=&@],T0Q,B4^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL M93TS1"=415A4+4%,24=..B!L969T.R!&3TY4+5-464Q%.B!N;W)M86P[($9/ M3E0M1D%-24Q9.B!4:6UE6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M M4U193$4Z(&YO"!D;W5B M;&4[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$,24^(#QD:78^)B,Q-C`[ M/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!R:6=H=#L@ M1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O M;6%N.R!"04-+1U)/54Y$.B`C8V-F9F-C.R!&3TY4+5-)6D4Z(#$P<'0[(%9% M4E1)0T%,+4%,24=..B!B;W1T;VT[($)/4D1%4BU43U`Z(",P,#`P,#`@,W!X M(&1O=6)L93L@1D].5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q,B4^(#QD:78^ M)B,Q-C`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`P,#`@,W!X(&1O=6)L M93L@5$585"U!3$E'3CH@;&5F=#L@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4 M+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!"04-+1U)/54Y$.B`C8V-F9F-C M.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($)/ M4D1%4BU43U`Z(",P,#`P,#`@,7!X('-O;&ED.R!&3TY4+5=%24=(5#H@-#`P M)R!W:61T:#TS1#$E/B`\9&EV/B0\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$ M)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,W!X(&1O=6)L93L@5$585"U!3$E' M3CH@"!S;VQI9#L@1D].5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q M,B4^(#QD:78^*#,L,S,X*3PO9&EV/B`\+W1D/B`\=&0@"!S;VQI9#L@1D].5"U714E'2%0Z(#0P M,"<@=VED=&@],T0Q)3X@/&1I=CXD/"]D:78^(#PO=&0^(#QT9"!S='EL93TS M1"="3U)$15(M0D]45$]-.B`C,#`P,#`P(#-P>"!D;W5B;&4[(%1%6%0M04Q) M1TXZ(')I9VAT.R!&3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!4 M:6UE6QE/3-$)U1% M6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z M(&YO"!D;W5B;&4[($9/ M3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$,24^(#QD:78^)B,Q-C`[/"]D:78^ M(#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!R:6=H=#L@1D].5"U3 M5%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!" M04-+1U)/54Y$.B`C9F9F9F9F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%, M+4%,24=..B!B;W1T;VT[($)/4D1%4BU43U`Z(",P,#`P,#`@,W!X(&1O=6)L M93L@1D].5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q,B4^(#QD:78^)B,Q-C`[ M/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!L969T.R!& M3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!4:6UE6QE/3-$)U1% M6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO"!D;W5B;&4[($9/3E0M5T5)1TA4.B`T,#`G('=I M9'1H/3-$,24^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL93TS M1"=415A4+4%,24=..B!R:6=H=#L@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4 M+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!"04-+1U)/54Y$.B`C9F9F9F9F M.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($)/ M4D1%4BU43U`Z(",P,#`P,#`@,W!X(&1O=6)L93L@1D].5"U714E'2%0Z(#0P M,"<@=VED=&@],T0Q,B4^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S M='EL93TS1"=415A4+4%,24=..B!L969T.R!&3TY4+5-464Q%.B!N;W)M86P[ M($9/3E0M1D%-24Q9.B!4:6UE6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z M(&YO6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!&3TY4+5-464Q%.B!N M;W)M86P[($9/3E0M1D%-24Q9.B!4:6UE6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z M(&YO6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT M.R!&3TY4+5-464Q%.B!N;W)M86P[(%!!1$1)3D#L@1D]. M5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@0D%#2T=23U5.1#H@(V9F9F9F M9CL@0T],3U(Z(",P,#`P,#`[($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM M04Q)1TXZ(&)O='1O;3L@1D].5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q,B4^ M(#QD:78^,RPS-S,\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q) M1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO6QE/3-$ M)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)U1% M6%0M04Q)1TXZ(')I9VAT.R!&3TY4+5-464Q%.B!N;W)M86P[(%!!1$1)3D#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@0D%# M2T=23U5.1#H@(V-C9F9C8SL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U! M3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$R)3X@ M/&1I=CXY-#4\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ M(&QE9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)U1%6%0M M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2 M;VUA;CL@0D%#2T=23U5.1#H@(V9F9F9F9CL@1D].5"U325I%.B`Q,'!T.R!6 M15)424-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T M:#TS1#$R)3X@/&1I=CXM/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=415A4 M+4%,24=..B!L969T.R!&3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9 M.B!4:6UE6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,7!X('-O;&ED M.R!415A4+4%,24=..B!L969T.R!&3TY4+5-464Q%.B!N;W)M86P[($9/3E0M M1D%-24Q9.B!4:6UE6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,7!X M('-O;&ED.R!415A4+4%,24=..B!R:6=H=#L@1D].5"U35%E,13H@;F]R;6%L M.R!0041$24Y'+5))1TA4.B`U<'@[($9/3E0M1D%-24Q9.B!4:6UE6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/ M3E0M4U193$4Z(&YO6QE M/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO"!S;VQI9#L@1D].5"U714E'2%0Z(#0P,"<@ M=VED=&@],T0Q)3X@/&1I=CXD/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=" M3U)$15(M0D]45$]-.B`C,#`P,#`P(#-P>"!D;W5B;&4[(%1%6%0M04Q)1TXZ M(')I9VAT.R!&3TY4+5-464Q%.B!N;W)M86P[(%!!1$1)3D#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@0D%#2T=23U5.1#H@ M(V-C9F9C8SL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T M=&]M.R!"3U)$15(M5$]0.B`C,#`P,#`P(#%P>"!S;VQI9#L@1D].5"U714E' M2%0Z(#0P,"<@=VED=&@],T0Q,B4^(#QD:78^,BPV.#4\+V1I=CX@/"]T9#X@ M/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO M6QE/3-$ M)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4 M+5-)6D4Z(#$P<'0G/CPO9&EV/B`\+V1I=CX@/&9O;G0@3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R M=%]C8C(Q,68U,5\W,V$Q7S1C-#9?8C!B,U]B.#@Y9#5D-C0W8F4-"D-O;G1E M;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO8V(R,3%F-3%?-S-A,5\T8S0V7V(P M8C-?8C@X.60U9#8T-V)E+U=O'0O:'1M;#L@8VAA6QE/3-$)TU!4D=) M3BU43U`Z(#!P=#L@1D].5#H@,3!P="!4:6UE6QE/3-$)U9% M4E1)0T%,+4%,24=..B!T;W`G/B`\=&0@2<^(#QD:78^/&(^4U5"4T51545.5"!%5D5. M5%,\+V(^/&(^/&)R+SX@)B,Q-C`[/"]B/CPO9&EV/B`\+W1D/B`\+W1R/B`\ M+W1A8FQE/B`\9&EV('-T>6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9 M.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[5$585"U)3D1%3E0Z M(#!I;CL@34%21TE..B`P<'0@,'!X(#!P="`P:6X[($9/3E0Z(#$P<'0@5&EM M97,@3F5W(%)O;6%N+"!4:6UE3Y- M86YA9V5M96YT(&AA2!I2!A;F0@36%R8V@@,C`Q-"X@07,@ M=VET:"!T:&4@0V]M<&%N>28C.#(Q-SMS(&]T:&5R+"!R96-E;G0@2!V;VQU;64@=V5I M9VAT960@879E&5D.R<@8V5L;'-P86-I;F<],T0P(&-E M;&QP861D:6YG/3-$,#X\='(^/'1D/CPO=&0^/"]T7!E.B!T M97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE M860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT M96YT/3-$)W1E>'0O:'1M;#L@8VAA6QE/3-$ M)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4 M+5-)6D4Z(#$P<'0[34%21TE..B`P<'0@,'!X.R!&3TY4.B`Q,'!T(%1I;65S M($YE=R!2;VUA;BP@5&EM97,L(%-E28C.#(R,3LI M('=A&%S(&%N9"!C;VUM96YC960@8V]M;65R8VEA;"!O<&5R M871I;VYS(&EN(#$Y.#8N(%!O7-T96US+"!R M861I;W!H87)M86-E=71I8V%L3XF(S$V,#L\+V1I M=CX@/&1I=B!S='EL93TS1"=#3$5!4CIB;W1H.R!&3TY4+49!34E,63I4:6UE M#L@ M1D].5#H@,3!P="!4:6UE7-T96US('!O M7-T96T@<&]R=&EO;B!O9B!T:&4@8G5S M:6YE3XF(S$V,#L\+V1I=CX@/&1I=B!S='EL93TS1"=# M3$5!4CIB;W1H.R!&3TY4+49!34E,63I4:6UE#L@1D].5#H@,3!P="!4:6UE'!E;G-I=F4@;6]L96-U;&%R(&EM86=I;F<@ M7-T96TL(')A9&EO<&AA M#L@1D].5#H@,3!P="!4:6UE6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S M($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[34%21TE..B`P<'0@,'!X.R!& M3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E2`Q-RP@,C`Q,BP@=&AE($-O;7!A;GD@ M86-Q=6ER960@86QL(&]F('1H92!I2!,3$,@*"8C.#(R,#M-250F(S@R,C$[*2X@4V5E($YO=&4@,RX\+V1I M=CX@/&1I=B!S='EL93TS1"=#3$5!4CIB;W1H.R!&3TY4+49!34E,63I4:6UE M#L@ M1D].5#H@,3!P="!4:6UE6QE/3-$)T-,14%2 M.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z M(#$P<'0[34%21TE..B`P<'0@,'!X.R!&3TY4.B`Q,'!T(%1I;65S($YE=R!2 M;VUA;BP@5&EM97,L(%-E'!E3XF(S$V,#L\ M+V1I=CX@/&1I=B!S='EL93TS1"=#3$5!4CIB;W1H.R!&3TY4+49!34E,63I4 M:6UE3X\9F]N="!S='EL93TS1"=&3TY4+5-) M6D4Z(#$P<'0G/E!O&5D.R<@8V5L;'-P86-I;F<],T0P(&-E;&QP861D:6YG/3-$,#X\ M='(^/'1D/CPO=&0^/"]T#L@1D].5#H@,3!P="!4:6UE6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)RPG M#L@1D].5#H@,3!P="!4:6UE M3Y&;W(@=&AE M('EE87)S(&5N9&5D($1E8V5M8F5R(#,Q+"`R,#$S(&%N9"`R,#$R+"!T:&4@ M9FEN86YC:6%L('-T871E;65N=',@:6YC;'5D92!T:&4@=')A;G-A8W1I;VYS M(&]F(%!O2!A;F0@4$E#+B!!;&P@:6YT97)C;VUP86YY('1R86YS86-T:6]N M&5D.R<@8V5L;'-P86-I;F<],T0P(&-E;&QP861D:6YG/3-$,#X\='(^/'1D M/CPO=&0^/"]T#L@1D].5#H@,3!P="!4 M:6UE3X\6QE/3-$)T-,14%2.F)O=&@[($9/ M3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[34%2 M1TE..B`P<'0@,'!X.R!&3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM M97,L(%-E'!E;G-E6QE/3-$)W=I9'1H.C$P,"4[('1A8FQE+6QA>6]U=#IF:7AE9#LG(&-E M;&QS<&%C:6YG/3-$,"!C96QL<&%D9&EN9STS1#`^/'1R/CQT9#X\+W1D/CPO M='(^/"]T86)L93X\6QE/3-$)TU!4D=)3CH@,'!T M(#!P>#L@1D].5#H@,3!P="!4:6UE6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I M;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[34%21TE..B`P<'0@,'!X M.R!&3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E3X\6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9 M.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[34%21TE..B`P<'0@ M,'!X.R!&3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E6QE M/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM& M3TY4+5-)6D4Z(#$P<'0[34%21TE..B`P<'0@,'!X.R!&3TY4.B`Q,'!T(%1I M;65S($YE=R!2;VUA;BP@5&EM97,L(%-E3Y3;VQA2X\+V1I=CX@/&1I=B!S='EL93TS1"=# M3$5!4CIB;W1H.R!&3TY4+49!34E,63I4:6UE#L@1D].5#H@,3!P="!4:6UE6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9 M.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[34%21TE..B`P<'0@ M,'!X.R!&3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E2!A;F0@ M=&AE(&IO:6YT('9E;G1U2!A8V-O=6YT&5D.R<@8V5L;'-P86-I;F<],T0P M(&-E;&QP861D:6YG/3-$,#X\='(^/'1D/CPO=&0^/"]T6QE/3-$)TU!4D=)3CH@,'!T(#!P M>#L@1D].5#H@,3!P="!4:6UE6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S M($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[34%21TE..B`P<'0@,'!X.R!& M3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E3X\6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I M;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[34%21TE..B`P<'0@,'!X M.R!&3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E2!E>&-E960@9V]V97)N;65N="!I;G-U2!L;W-S M97,@#L@1D].5#H@,3!P="!4 M:6UE6QE/3-$)T-,14%2.F)O=&@[($9/3E0M M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[34%21TE. M.B`P<'0@,'!X.R!&3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L M(%-E6QE/3-$)T9/3E0M M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)RPG&5D.R<@8V5L;'-P86-I;F<],T0P(&-E;&QP861D M:6YG/3-$,#X\='(^/'1D/CPO=&0^/"]T'0^)SQD:78@3X\6QE/3-$)T-, M14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-) M6D4Z(#$P<'0[34%21TE..B`P<'0@,'!X.R!&3TY4.B`Q,'!T(%1I;65S($YE M=R!2;VUA;BP@5&EM97,L(%-E#L@1D].5#H@,3!P="!4:6UE#L@1D].5#H@,3!P="!4:6UE6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA M;CM&3TY4+5-)6D4Z(#$P<'0[34%21TE..B`P<'0@,'!X.R!&3TY4.B`Q,'!T M(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E#L@1D].5#H@,3!P="!4:6UE M2!A;6]U;G1S M('=H:6-H(&UA>2!B92!U;G)E8V]V97)A8FQE+"!W:&EC:"!I'!E6QE/3-$)W=I9'1H.C$P,"4[('1A8FQE+6QA>6]U=#IF:7AE M9#LG(&-E;&QS<&%C:6YG/3-$,"!C96QL<&%D9&EN9STS1#`^/'1R/CQT9#X\ M+W1D/CPO='(^/"]T86)L93X\'0^)SQD M:78@3X\3X\6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA M;CM&3TY4+5-)6D4Z(#$P<'0[34%21TE..B`P<'0@,'!X.R!&3TY4.B`Q,'!T M(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E#L@1D]. M5#H@,3!P="!4:6UE6QE/3-$)T-,14%2.F)O M=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P M<'0[34%21TE..B`P<'0@,'!X.R!&3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA M;BP@5&EM97,L(%-E2!D971E3XF(S$V,#L\+V1I=CX@/&1I M=B!S='EL93TS1"=#3$5!4CIB;W1H.R!&3TY4+49!34E,63I4:6UE#L@1D].5#H@ M,3!P="!4:6UE2!I;7!A:7)E9"!A="!$96-E;6)E6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W M(%)O;6%N)RPG6QE/3-$)T9/3E0M M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)RPG#L@1D].5#H@,3!P="!4:6UE6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA M;CM&3TY4+5-)6D4Z(#$P<'0[34%21TE..B`P<'0@,'!X.R!&3TY4.B`Q,'!T M(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E&5D.R<@8V5L;'-P86-I;F<],T0P(&-E;&QP861D:6YG M/3-$,#X\='(^/'1D/CPO=&0^/"]T#L@1D].5#H@,3!P="!4:6UE3X\6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9 M.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[34%21TE..B`P<'0@ M,'!X.R!&3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E2!B87-I2!A M;F0@17%U:7!M96YT/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG M/&1I=B!S='EL93TS1"=-05)'24XZ(#!P="`P<'@[($9/3E0Z(#$P<'0@5&EM M97,@3F5W(%)O;6%N+"!4:6UE#L@1D].5#H@,3!P="!4:6UE6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2 M;VUA;CM&3TY4+5-)6D4Z(#$P<'0[34%21TE..B`P<'0@,'!X.R!&3TY4.B`Q M,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E#L@1D].5#H@,3!P="!4 M:6UE6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N M)RPG6QE/3-$)T-,14%2.F)O=&@[($9/3E0M M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[34%21TE. M.B`P<'0@,'!X.R!&3TY4.B`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`P<'0@,'!X.R!&3TY4.B`Q,'!T(%1I;65S($YE M=R!2;VUA;BP@5&EM97,L(%-E#L@1D].5#H@,3!P="!4:6UE2P@=&AE($-O;7!A;GD@979A;'5A=&5S('1H92!C87)R>6EN9R!V86QU92!O M9B!I=',@;&]N9RUL:79E9"!A&5D.R<@8V5L;'-P86-I M;F<],T0P(&-E;&QP861D:6YG/3-$,#X\='(^/'1D/CPO=&0^/"]T6QE/3-$)TU! M4D=)3CH@,'!T(#!P>#L@1D].5#H@,3!P="!4:6UE6QE/3-$)T-,14%2.F)O=&@[($9/3E0M M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[34%21TE. M.B`P<'0@,'!X.R!&3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L M(%-E6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA M;CM&3TY4+5-)6D4Z(#$P<'0[34%21TE..B`P<'0@,'!X.R!&3TY4.B`Q,'!T M(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E#L@1D].5#H@,3!P="!4:6UE M6EN9R!V86QU92!O9B!C87-H(&%N9"!C87-H(&5Q=6EV86QE;G1S M+"!A8V-O=6YT2!I#L@1D].5#H@,3!P="!4 M:6UE6QE/3-$)T-,14%2.F)O=&@[($9/3E0M M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[34%21TE. M.B`P<'0@,'!X.R!&3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L M(%-E&-H86YG92!P&ET('!R:6-E*2!I;B!T:&4@<')I;F-I<&%L(&]R(&UO2!I M;B!A;B!O#L@1D].5#H@,3!P M="!4:6UE6QE/3-$)T-,14%2.F)O=&@[($9/ M3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[34%2 M1TE..B`P<'0@,'!X.R!&3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM M97,L(%-EF4@=&AE('5S M92!O9B!O8G-EF4@=&AE('5S92!O M9B!U;F]B2!U=&EL:7IE6QE/3-$)U=)1%1(.B`P+C(U M:6XG/CPO=&0^(#QT9"!S='EL93TS1"=724142#H@,"XR-6EN)SX@/&1I=CX\ M9F]N=#XF(S@Y,#$[/"]F;VYT/CPO9&EV/B`\+W1D/B`\=&0@2<^(#QD:78^3&5V96P@,2`F(S$U,3L@475O M=&5D('!R:6-E2!O8G1A M:6YE9"!F6QE/3-$)U=)1%1(.B`P+C(U:6XG/CPO=&0^(#QT9"!S='EL93TS1"=7 M24142#H@,"XR-6EN)SX@/&1I=CX\9F]N=#XF(S@Y,#$[/"]F;VYT/CPO9&EV M/B`\+W1D/B`\=&0@2<^(#QD M:78^3&5V96P@,B`F(S$U,3L@475O=&5D('!R:6-E2!O8G1A:6YE9"!F6QE/3-$)U=)1%1( M.B`P+C(U:6XG/CPO=&0^(#QT9"!S='EL93TS1"=724142#H@,"XR-6EN)SX@ M/&1I=CX\9F]N=#XF(S@Y,#$[/"]F;VYT/CPO9&EV/B`\+W1D/B`\=&0@2<^(#QD:78^3&5V96P@,R`F(S$U M,3L@56YO8G-E3X\ M9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@)U1I;65S($YE=R!2;VUA;B6QE M/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)RPG2!F:6YA;F-I86P@ M;&EA8FEL:71I97,@;65A3XF(S$V,#L\+V1I=CX@/&1I=B!S='EL93TS1"=# M3$5!4CIB;W1H.R!&3TY4+49!34E,63I4:6UE"!S M;VQI9#L@34%21TE..B`P:6X@,&EN(#!I;B`P+C5I;CL@5TE$5$@Z(#@P)3L@ M0D]21$52+4-/3$Q!4%-%.B!C;VQL87!S93L@1D].5"U325I%.B`Q,'!T.R!/ M5D521DQ/5SH@=FES:6)L93L@0D]21$52+51/4#H@(SEE8C9C92`P<'@@6QE/3-$)U1%6%0M04Q)1TXZ(&-E;G1E6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`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`Q,'!T.R!615)4 M24-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS M1#$R)3X@/&1I=CXM/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%, M24=..B!L969T.R!&3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!4 M:6UE6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!&3TY4 M+5-464Q%.B!N;W)M86P[(%!!1$1)3D#L@1D].5"U&04U) M3%DZ(%1I;65S($YE=R!2;VUA;CL@0D%#2T=23U5.1#H@(V9F9F9F9CL@1D]. M5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=% M24=(5#H@-#`P)R!W:61T:#TS1#$R)3X@/&1I=CXM/"]D:78^(#PO=&0^(#QT M9"!S='EL93TS1"=415A4+4%,24=..B!L969T.R!&3TY4+5-464Q%.B!N;W)M M86P[($9/3E0M1D%-24Q9.B!4:6UE6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[ M($9/3E0M4U193$4Z(&YO6QE/3-$)U1%6%0M M04Q)1TXZ(')I9VAT.R!&3TY4+5-464Q%.B!N;W)M86P[(%!!1$1)3D#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@0D%#2T=2 M3U5.1#H@(V9F9F9F9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E' M3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$R)3X@/&1I M=CXS+#DX,3PO9&EV/B`\+W1D/B`\=&0@6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)RPG#L@1D].5#H@,3!P="!4 M:6UE6QE/3-$)T-,14%2.F)O=&@[($9/3E0M M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[34%21TE. M.B`P<'0@,'!X.R!&3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L M(%-E6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE M=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[34%21TE..B`P<'0@,'!X.R!&3TY4 M.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E6QE/3-$)T)/4D1%4BU"3U143TTZ(",Y96(V8V4@ M,'!X('-O;&ED.R!"3U)$15(M3$5&5#H@(SEE8C9C92`P<'@@"!S;VQI9#L@0D]21$52+5))1TA4.B`C.65B M-F-E(#!P>"!S;VQI9"<@8V5L;'-P86-I;F<],T0P(&-E;&QP861D:6YG/3-$ M,"!A;&EG;CTS1&QE9G0^(#QT6QE/3-$)U1%6%0M04Q)1TXZ M(&QE9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)U1%6%0M04Q)1TXZ(&QE M9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)U1% M6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z M(&YO6QE/3-$)U1%6%0M04Q)1TXZ M(&QE9G0[($9/3E0M4U193$4Z(&YO'!E;G-E M/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!L969T.R!& M3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!4:6UE6QE/3-$)U1% M6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)U1%6%0M04Q)1TXZ M(&QE9G0[($9/3E0M4U193$4Z(&YO6QE M/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,7!X('-O;&ED.R!415A4+4%, M24=..B!L969T.R!&3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!4 M:6UE6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,7!X('-O;&ED.R!4 M15A4+4%,24=..B!R:6=H=#L@1D].5"U35%E,13H@;F]R;6%L.R!0041$24Y' M+5))1TA4.B`U<'@[($9/3E0M1D%-24Q9.B!4:6UE2!A"!S;VQI9#L@5$585"U!3$E'3CH@;&5F=#L@1D].5"U3 M5%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!" M04-+1U)/54Y$.B`C9F9F9F9F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%, M+4%,24=..B!B;W1T;VT[($)/4D1%4BU43U`Z(",P,#`P,#`@,7!X('-O;&ED M.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$E/B`\9&EV/B0\+V1I=CX@ M/"]T9#X@/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,7!X M('-O;&ED.R!415A4+4%,24=..B!R:6=H=#L@1D].5"U35%E,13H@;F]R;6%L M.R!0041$24Y'+5))1TA4.B`U<'@[($9/3E0M1D%-24Q9.B!4:6UE6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M M4U193$4Z(&YO"!S;VQI M9#L@1D].5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q)3X@/&1I=CXF(S$V,#L\ M+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!& M3TY4+5-464Q%.B!N;W)M86P[(%!!1$1)3D#L@1D].5"U& M04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@0D%#2T=23U5.1#H@(V-C9F9C8SL@ M0T],3U(Z(",P,#`P,#`[($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q) M1TXZ(&)O='1O;3L@0D]21$52+51/4#H@(S`P,#`P,"`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`P<'0@,'!X.R!&3TY4.B`Q,'!T M(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E#L@1D].5#H@,3!P="!4 M:6UE6QE/3-$ M)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)RPG#L@1D].5#H@ M,3!P="!4:6UE6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I M;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[5$585"U!3$E'3CI,969T M.R!415A4+4E.1$5.5#H@,&EN.R!724142#H@,3`P)2<^(#QT86)L92!S='EL M93TS1"=-05)'24XZ(#!I;CL@5TE$5$@Z(#@U)3L@0D]21$52+4-/3$Q!4%-% M.B!C;VQL87!S93L@1D].5"U325I%.B`Q,'!T.R!/5D521DQ/5SH@=FES:6)L M92<@8V5L;'-P86-I;F<],T0P(&-E;&QP861D:6YG/3-$,"!A;&EG;CTS1&QE M9G0^(#QT6QE/3-$)U1%6%0M04Q)1TXZ(&-E;G1E6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,7!X M('-O;&ED.R!415A4+4%,24=..B!C96YT97([($9/3E0M4U193$4Z(&YO6QE/3-$)U1%6%0M M04Q)1TXZ(&-E;G1E6QE/3-$ M)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO"!S;VQI9#L@1D].5"U714E'2%0Z(#0P,"<@ M=VED=&@],T0Q)3X@/&1I=CXD/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=4 M15A4+4%,24=..B!R:6=H=#L@1D].5"U35%E,13H@;F]R;6%L.R!0041$24Y' M+5))1TA4.B`S<'@[($9/3E0M1D%-24Q9.B!4:6UE6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO M"!S;VQI9#L@1D].5"U7 M14E'2%0Z(#0P,"<@=VED=&@],T0Q)3X@/&1I=CXD/"]D:78^(#PO=&0^(#QT M9"!S='EL93TS1"=415A4+4%,24=..B!R:6=H=#L@1D].5"U35%E,13H@;F]R M;6%L.R!0041$24Y'+5))1TA4.B`T<'@[($9/3E0M1D%-24Q9.B!4:6UE6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U19 M3$4Z(&YO6QE/3-$)U1% M6%0M04Q)1TXZ(')I9VAT.R!&3TY4+5-464Q%.B!N;W)M86P[(%!!1$1)3D#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@0D%# M2T=23U5.1#H@(V9F9F9F9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U! M3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@-#`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`Q,'!T.R!6 M15)424-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T M:#TS1#$R)3X@/&1I=CXQ('EE87(\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$ M)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!&3TY4+5-464Q%.B!N;W)M86P[ M(%!!1$1)3D#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2 M;VUA;CL@0D%#2T=23U5.1#H@(V-C9F9C8SL@1D].5"U325I%.B`Q,'!T.R!6 M15)424-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T M:#TS1#$R)3X@/&1I=CXQ('EE87(\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$ M)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO&5D M.R<@8V5L;'-P86-I;F<],T0P(&-E;&QP861D:6YG/3-$,#X\='(^/'1D/CPO M=&0^/"]T'0^)SQD:78@3X\#L@1D].5#H@,3!P="!4:6UE3Y#;W-T3XF(S$V,#L\+V1I=CX@/&1I=B!S='EL93TS1"=# M3$5!4CIB;W1H.R!&3TY4+49!34E,63I4:6UE#L@1D].5#H@,3!P="!4:6UE6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM M97,@3F5W(%)O;6%N)RPG3XF(S$V,#L\+V1I=CX@/&1I=B!S='EL93TS1"=#3$5!4CIB;W1H.R!&3TY4 M+49!34E,63I4:6UE#L@1D].5#H@,3!P="!4:6UE6QE M/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)RPG'1E;F1E9"!U;F1E&ES=&EN9R!T97)M&5D.R<@8V5L;'-P86-I;F<],T0P(&-E;&QP861D M:6YG/3-$,#X\='(^/'1D/CPO=&0^/"]T&5S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/&1I=B!S='EL M93TS1"=-05)'24XZ(#!P="`P<'@[($9/3E0Z(#$P<'0@5&EM97,@3F5W(%)O M;6%N+"!4:6UE#L@1D].5#H@,3!P="!4:6UE&5S/"]S=')O;F<^/"]D:78^(#QD:78@3X\6QE/3-$)T-,14%2.F)O=&@[($9/ M3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[34%2 M1TE..B`P<'0@,'!X.R!&3TY4.B`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`P<'0@,'!X.R!&3TY4.B`Q,'!T(%1I M;65S($YE=R!2;VUA;BP@5&EM97,L(%-EF5D('5P;VX@<&5R9F]R;6%N8V4@;V8@=&AE('-E2!R96-O9VYI>F5S(')E=F5N=65S(&9R;VT@=&AE('-A;&4@;V8@;65D M:6-A;"!E<75I<&UE;G0@86YD(')A9&EO:7-O=&]P92!P2!A2!O8G1A:6YS(&$@#L@ M1D].5#H@,3!P="!4:6UE6QE/3-$)T-,14%2 M.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z M(#$P<'0[34%21TE..B`P<'0@,'!X.R!&3TY4.B`Q,'!T(%1I;65S($YE=R!2 M;VUA;BP@5&EM97,L(%-E2!E=FED96YC92!O9B!S96QL M:6YG('!R:6-E("A44$4I('=H96X@5E-/12!D;V5S(&YO="!E>&ES="P@86YD M('1H96X@;VX@97-T:6UA=&5D('-E;&QI;F<@<')I8V4@*$534"D@=VAE;B!6 M4T]%(&%N9"!44$4@9&\@;F]T(&5X:7-T+CPO9&EV/B`\9&EV('-T>6QE/3-$ M)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4 M+5-)6D4Z(#$P<'0[34%21TE..B`P<'0@,'!X.R!&3TY4.B`Q,'!T(%1I;65S M($YE=R!2;VUA;BP@5&EM97,L(%-E3Y"96-A=7-E('1H92!#;VUP86YY(&AA2!W;W5L M9"!T6QE/3-$)W=I9'1H.C$P,"4[('1A8FQE+6QA>6]U M=#IF:7AE9#LG(&-E;&QS<&%C:6YG/3-$,"!C96QL<&%D9&EN9STS1#`^/'1R M/CQT9#X\+W1D/CPO='(^/"]T86)L93X\9&EV('-T>6QE/3-$)TU!4D=)3CH@ M,'!T(#!P>#L@1D].5#H@,3!P="!4:6UE3Y4:&4@0V]M<&%N>2!T>7!I8V%L;'D@<')O=FED97,@ M82!O;F4M>65A2!R96-O6QE/3-$)W=I9'1H M.C$P,"4[('1A8FQE+6QA>6]U=#IF:7AE9#LG(&-E;&QS<&%C:6YG/3-$,"!C M96QL<&%D9&EN9STS1#`^/'1R/CQT9#X\+W1D/CPO='(^/"]T86)L93X\'0^)SQD:78@3X@/&1I=B!S='EL93TS1"=#3$5!4CIB;W1H.R!&3TY4 M+49!34E,63I4:6UE#L@1D].5#H@,3!P="!4:6UE2!T>7!I8V%L;'D@<')O=FED97,@82!O;F4M>65A2!R96-OF5D(&]V M97(@82!O;F4M>65A6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)RPG#L@1D].5#H@,3!P="!4:6UE M6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%- M24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[34%21TE..B`P M<'0@,'!X.R!&3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E M#L@1D].5#H@,3!P="!4:6UE M3Y!;&P@8V]S M=',@6QE/3-$)TU!4D=)3CH@ M,'!T(#!P>#L@1D].5#H@,3!P="!4:6UE6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9 M.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[34%21TE..B`P<'0@ M,'!X.R!&3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%- M24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[34%21TE..B`P M<'0@,'!X.R!&3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E M#L@1D].5#H@,3!P="!4:6UE6QE M/3-$)TU!4D=)3CH@,'!T(#!P>#L@1D].5#H@,3!P="!4:6UE6QE/3-$)T-,14%2.F)O=&@[ M($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[ M34%21TE..B`P<'0@,'!X.R!&3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@ M5&EM97,L(%-E6QE/3-$)T-,14%2.F)O=&@[ M($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[ M34%21TE..B`P<'0@,'!X.R!&3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@ M5&EM97,L(%-E6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I M;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[34%21TE..B`P:6X@,&EN M(#!P="<@86QI9VX],T1J=7-T:69Y/CQF;VYT('-T>6QE/3-$)T9/3E0M4TE: M13H@,3!P="<^0F%S:6,@;&]S'0^)SQD:78@3X\3X\ M6QE/3-$)T-, M14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-) M6D4Z(#$P<'0[34%21TE..B`P<'0@,'!X.R!&3TY4.B`Q,'!T(%1I;65S($YE M=R!2;VUA;BP@5&EM97,L(%-E3X-"CPO:'1M;#X-"@T*+2TM M+2TM/5].97AT4&%R=%]C8C(Q,68U,5\W,V$Q7S1C-#9?8C!B,U]B.#@Y9#5D M-C0W8F4-"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO8V(R,3%F-3%? M-S-A,5\T8S0V7V(P8C-?8C@X.60U9#8T-V)E+U=O'0O:'1M;#L@8VAA7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R M'0^)SQD:78@3Y02!A;F0@97%U:7!M96YT M(&%R92!R96-O3XF(S$V,#L\+V1I=CX@/&1I=B!S='EL93TS1"=#3$5!4CIB M;W1H.R!&3TY4+49!34E,63I4:6UE#IA=71O.R!724142#H@.#`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`P:6X@,&EN(#!I;B`P+C5I;CL@5TE$5$@Z(#@P)3L@0D]21$52 M+4-/3$Q!4%-%.B!C;VQL87!S93L@1D].5"U325I%.B`Q,'!T.R!/5D521DQ/ M5SH@=FES:6)L93L@0D]21$52+51/4#H@(SEE8C9C92`P<'@@6QE M/3-$)U1%6%0M04Q)1TXZ(&-E;G1E6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`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`Q,'!T.R!615)424-!3"U! M3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$R)3X@ M/&1I=CXM/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!L M969T.R!&3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!4:6UE6QE M/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!&3TY4+5-464Q% M.B!N;W)M86P[(%!!1$1)3D#L@1D].5"U&04U)3%DZ(%1I M;65S($YE=R!2;VUA;CL@0D%#2T=23U5.1#H@(V9F9F9F9CL@1D].5"U325I% M.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@ M-#`P)R!W:61T:#TS1#$R)3X@/&1I=CXM/"]D:78^(#PO=&0^(#QT9"!S='EL M93TS1"=415A4+4%,24=..B!L969T.R!&3TY4+5-464Q%.B!N;W)M86P[($9/ M3E0M1D%-24Q9.B!4:6UE6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M M4U193$4Z(&YO6QE/3-$)U1%6%0M04Q)1TXZ M(')I9VAT.R!&3TY4+5-464Q%.B!N;W)M86P[(%!!1$1)3D#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@0D%#2T=23U5.1#H@ M(V9F9F9F9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T M=&]M.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$R)3X@/&1I=CXS+#DX M,3PO9&EV/B`\+W1D/B`\=&0@#L@1D].5#H@,3!P="!4:6UEF5D(&%T M(&9A:7(@=F%L=64@:6X@=&AE(&-O;G-O;&ED871E9"!F:6YA;F-I86P@#L@1D].5#H@,3!P="!4:6UE6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9 M.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[5$585"U!3$E'3CI, M969T.R!415A4+4E.1$5.5#H@,&EN.R!724142#H@,3`P)2<^(#QT86)L92!S M='EL93TS1"="3U)$15(M0D]45$]-.B`C.65B-F-E(#!P>"!S;VQI9#L@0D]2 M1$52+4Q%1E0Z(",Y96(V8V4@,'!X('-O;&ED.R!-05)'24XZ(#!I;CL@5TE$ M5$@Z(#DU)3L@0D]21$52+4-/3$Q!4%-%.B!C;VQL87!S93L@1D].5"U325I% M.B`Q,'!T.R!/5D521DQ/5SH@=FES:6)L93L@0D]21$52+51/4#H@(SEE8C9C M92`P<'@@6QE/3-$)U1%6%0M04Q)1TXZ M(&QE9G0[($9/3E0M4U193$4Z(&YO6QE/3-$ M)U1%6%0M04Q)1TXZ(')I9VAT.R!&3TY4+5-464Q%.B!N;W)M86P[(%!!1$1) M3D#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@ M0D%#2T=23U5.1#H@(V-C9F9C8SL@1D].5"U325I%.B`Q,'!T.R!615)424-! M3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$R M)3X@/&1I=CXQ+#(S.#PO9&EV/B`\+W1D/B`\=&0@6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M M4U193$4Z(&YO6QE/3-$ M)U1%6%0M04Q)1TXZ(')I9VAT.R!&3TY4+5-464Q%.B!N;W)M86P[(%!!1$1) M3D#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@ M0D%#2T=23U5.1#H@(V9F9F9F9CL@1D].5"U325I%.B`Q,'!T.R!615)424-! M3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$R M)3X@/&1I=CXR+#$R.3PO9&EV/B`\+W1D/B`\=&0@6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M M4U193$4Z(&YO6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!&3TY4+5-4 M64Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!4:6UE6QE/3-$)U1%6%0M04Q) M1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO6QE/3-$ M)U1%6%0M04Q)1TXZ(')I9VAT.R!&3TY4+5-464Q%.B!N;W)M86P[(%!!1$1) M3D#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@ M0D%#2T=23U5.1#H@(V9F9F9F9CL@1D].5"U325I%.B`Q,'!T.R!615)424-! M3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$R M)3X@/&1I=CXT,S(\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q) M1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO"!S;VQI9#L@5$585"U!3$E'3CH@;&5F=#L@1D]. M5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N M.R!"04-+1U)/54Y$.B`C8V-F9F-C.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1) M0T%,+4%,24=..B!B;W1T;VT[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$ M,24^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"="3U)$ M15(M0D]45$]-.B`C,#`P,#`P(#%P>"!S;VQI9#L@5$585"U!3$E'3CH@6QE M/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO6QE/3-$ M)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO"!S;VQI9#L@1D].5"U714E'2%0Z M(#0P,"<@=VED=&@],T0Q)3X@/&1I=CXD/"]D:78^(#PO=&0^(#QT9"!S='EL M93TS1"="3U)$15(M0D]45$]-.B`C,#`P,#`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`P,#`[($9/3E0M4TE:13H@,3!P=#L@5D525$E# M04PM04Q)1TXZ(&)O='1O;3L@1D].5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q M,B4^(#QD:78^-C8U/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%, M24=..B!L969T.R!&3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!4 M:6UE6QE/3-$)T)/4D1%4BU"3U14 M3TTZ(",P,#`P,#`@,W!X(&1O=6)L93L@5$585"U!3$E'3CH@;&5F=#L@1D]. M5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N M.R!"04-+1U)/54Y$.B`C9F9F9F9F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1) M0T%,+4%,24=..B!B;W1T;VT[($)/4D1%4BU43U`Z(",P,#`P,#`@,7!X('-O M;&ED.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$E/B`\9&EV/B0\+V1I M=CX@/"]T9#X@/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@ M,W!X(&1O=6)L93L@5$585"U!3$E'3CH@"!S;VQI9#L@1D].5"U714E'2%0Z(#0P M,"<@=VED=&@],T0Q,B4^(#QD:78^-BPY-C@\+V1I=CX@/"]T9#X@/'1D('-T M>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO#L@1D].5#H@,3!P="!4:6UE6QE/3-$)T-,14%2 M.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z M(#$P<'0[5$585"U!3$E'3CI,969T.R!415A4+4E.1$5.5#H@,&EN.R!72414 M2#H@,3`P)2<^(#QT86)L92!S='EL93TS1"=-05)'24XZ(#!I;CL@5TE$5$@Z M(#@U)3L@0D]21$52+4-/3$Q!4%-%.B!C;VQL87!S93L@1D].5"U325I%.B`Q M,'!T.R!/5D521DQ/5SH@=FES:6)L92<@8V5L;'-P86-I;F<],T0P(&-E;&QP M861D:6YG/3-$,"!A;&EG;CTS1&QE9G0^(#QT6QE/3-$)U1% M6%0M04Q)1TXZ(&-E;G1E6QE/3-$)T)/4D1% M4BU"3U143TTZ(",P,#`P,#`@,7!X('-O;&ED.R!415A4+4%,24=..B!C96YT M97([($9/3E0M4U193$4Z(&YO6QE/3-$)U1%6%0M04Q)1TXZ(&-E;G1E6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M M4U193$4Z(&YO"!S;VQI M9#L@1D].5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q)3X@/&1I=CXD/"]D:78^ M(#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!R:6=H=#L@1D].5"U3 M5%E,13H@;F]R;6%L.R!0041$24Y'+5))1TA4.B`S<'@[($9/3E0M1D%-24Q9 M.B!4:6UE6QE/3-$)U1%6%0M04Q)1TXZ M(&QE9G0[($9/3E0M4U193$4Z(&YO"!S;VQI9#L@1D].5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q)3X@ M/&1I=CXD/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!R M:6=H=#L@1D].5"U35%E,13H@;F]R;6%L.R!0041$24Y'+5))1TA4.B`T<'@[ M($9/3E0M1D%-24Q9.B!4:6UE6QE/3-$)U1%6%0M M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!&3TY4+5-4 M64Q%.B!N;W)M86P[(%!!1$1)3D#L@1D].5"U&04U)3%DZ M(%1I;65S($YE=R!2;VUA;CL@0D%#2T=23U5.1#H@(V9F9F9F9CL@1D].5"U3 M25I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=( M5#H@-#`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`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!& M3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$R)3X@/&1I=CXQ('EE87(\+V1I M=CX@/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M M4U193$4Z(&YO6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT M.R!&3TY4+5-464Q%.B!N;W)M86P[(%!!1$1)3D#L@1D]. M5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@0D%#2T=23U5.1#H@(V-C9F9C M8SL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!& M3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$R)3X@/&1I=CXQ('EE87(\+V1I M=CX@/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M M4U193$4Z(&YO3X-"CPO:'1M M;#X-"@T*+2TM+2TM/5].97AT4&%R=%]C8C(Q,68U,5\W,V$Q7S1C-#9?8C!B M,U]B.#@Y9#5D-C0W8F4-"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO M8V(R,3%F-3%?-S-A,5\T8S0V7V(P8C-?8C@X.60U9#8T-V)E+U=O'0O:'1M;#L@8VAA M6QE/3-$)TU!4D=)3CH@,'!T(#!P>#L@1D].5#H@,3!P="!4 M:6UE6QE/3-$ M)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4 M+5-)6D4Z(#$P<'0[34%21TE..B`P<'0@,'!X.R!&3TY4.B`Q,'!T(%1I;65S M($YE=R!2;VUA;BP@5&EM97,L(%-E6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE M=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[34%21TE..B`P<'0@,'!X(#!P="`P M+C(U:6X[($9/3E0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE3XF(S$V,#L\+V1I=CX@/&1I=B!S='EL93TS M1"=#3$5!4CIB;W1H.R!&3TY4+49!34E,63I4:6UE6QE/3-$)U1%6%0M M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!&3TY4+5-464Q%.B!N;W)M86P[ M(%!!1$1)3D#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2 M;VUA;CL@0D%#2T=23U5.1#H@(V-C9F9C8SL@1D].5"U325I%.B`Q,'!T.R!6 M15)424-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T M:#TS1#$U)3X@/&1I=CXU,"PP,#`\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$ M)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)T)/4D1%4BU" M3U143TTZ(",P,#`P,#`@,7!X('-O;&ED.R!415A4+4%,24=..B!L969T.R!& M3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!4:6UE6QE/3-$)T)/ M4D1%4BU"3U143TTZ(",P,#`P,#`@,7!X('-O;&ED.R!415A4+4%,24=..B!R M:6=H=#L@1D].5"U35%E,13H@;F]R;6%L.R!0041$24Y'+5))1TA4.B`U<'@[ M($9/3E0M1D%-24Q9.B!4:6UE6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO"!D;W5B;&4[(%1%6%0M04Q)1TXZ M(&QE9G0[($9/3E0M4U193$4Z(&YO"!S;VQI9#L@1D].5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q)3X@ M/&1I=CXD/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"="3U)$15(M0D]45$]- M.B`C,#`P,#`P(#-P>"!D;W5B;&4[(%1%6%0M04Q)1TXZ(')I9VAT.R!&3TY4 M+5-464Q%.B!N;W)M86P[(%!!1$1)3D#L@1D].5"U&04U) M3%DZ(%1I;65S($YE=R!2;VUA;CL@0D%#2T=23U5.1#H@(V-C9F9C8SL@1D]. M5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!"3U)$15(M M5$]0.B`C,#`P,#`P(#%P>"!S;VQI9#L@1D].5"U714E'2%0Z(#0P,"<@=VED M=&@],T0Q-24^(#QD:78^,C4U+#(Y-SPO9&EV/B`\+W1D/B`\=&0@'0^)SQD:78@3Y4:&4@9F]L;&]W:6YG('1A8FQE('-U;6UA"!S;VQI9#L@0D]21$52 M+5))1TA4.B`C.65B-F-E(#!P>"!S;VQI9"<@8V5L;'-P86-I;F<],T0P(&-E M;&QP861D:6YG/3-$,#X@/'1R/B`\=&0@6QE M/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)U1% M6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!&3TY4+5-464Q% M.B!N;W)M86P[(%!!1$1)3D#L@1D].5"U&04U)3%DZ(%1I M;65S($YE=R!2;VUA;CL@0D%#2T=23U5.1#H@(V-C9F9C8SL@1D].5"U325I% M.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@ M-#`P)R!W:61T:#TS1#$U)3X@/&1I=CXQ-"PP,#`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`C9F9F9F9F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1) M0T%,+4%,24=..B!B;W1T;VT[($)/4D1%4BU43U`Z(",P,#`P,#`@,7!X('-O M;&ED.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$U)3X@/&1I=CXH.3`L M.#@V*3PO9&EV/B`\+W1D/B`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`P<'0@,'!X.R!&3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA M;BP@5&EM97,L(%-E#IA=71O.R!724142#H@.#4E.R!"3U)$15(M0T],3$%04T4Z(&-O;&QA<'-E M.R!/5D521DQ/5SH@=FES:6)L93L@0D]21$52+51/4#H@(SEE8C9C92`P<'@@ M6QE/3-$)U1%6%0M04Q)1TXZ(&-E;G1E6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,7!X('-O;&ED M.R!415A4+4%,24=..B!C96YT97([($9/3E0M4U193$4Z(&YO"!S;VQI9#L@1D].5"U714E'2%0Z(#6QE/3-$)T)/ M4D1%4BU"3U143TTZ(",P,#`P,#`@,7!X('-O;&ED.R!415A4+4%,24=..B!C M96YT97([($9/3E0M4U193$4Z(&YO"!S;VQI9#L@1D].5"U7 M14E'2%0Z(#6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U19 M3$4Z(&YO6QE/3-$)U1%6%0M04Q)1TXZ M(')I9VAT.R!&3TY4+5-464Q%.B!N;W)M86P[(%!!1$1)3D#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@0D%#2T=23U5.1#H@ M(V-C9F9C8SL@0T],3U(Z(",P,#`P,#`[($9/3E0M4TE:13H@,3!P=#L@5D52 M5$E#04PM04Q)1TXZ(&)O='1O;3L@0D]21$52+51/4#H@(S`P,#`P,"`Q<'@@ M6QE/3-$)U1% M6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO"!S;VQI9#L@1D].5"U714E'2%0Z(#0P,"<@=VED M=&@],T0Q)3X@/&1I=CXD/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=415A4 M+4%,24=..B!R:6=H=#L@1D].5"U35%E,13H@;F]R;6%L.R!0041$24Y'+5)) M1TA4.B`U<'@[($9/3E0M1D%-24Q9.B!4:6UE6QE/3-$ M)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z M(&YO6QE/3-$)U1%6%0M M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)U1%6%0M04Q)1TXZ(&QE M9G0[($9/3E0M4U193$4Z(&YO#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@0D%# M2T=23U5.1#H@(V-C9F9C8SL@0T],3U(Z(",P,#`P,#`[($9/3E0M4TE:13H@ M,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O='1O;3L@1D].5"U714E'2%0Z(#0P M,"<@=VED=&@],T0Q,24^(#QD:78^-#`\+V1I=CX@/"]T9#X@/'1D('-T>6QE M/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO#L@1D].5"U&04U)3%DZ(%1I M;65S($YE=R!2;VUA;CL@0D%#2T=23U5.1#H@(V-C9F9C8SL@1D].5"U325I% M.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@ M-#`P)R!W:61T:#TS1#$Q)3X@/&1I=CXM/"]D:78^(#PO=&0^(#QT9"!S='EL M93TS1"=415A4+4%,24=..B!L969T.R!&3TY4+5-464Q%.B!N;W)M86P[($9/ M3E0M1D%-24Q9.B!4:6UE6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U19 M3$4Z(&YO6QE/3-$ M)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO6QE M/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)U1%6%0M04Q)1TXZ M(&QE9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U19 M3$4Z(&YO6QE/3-$)T)/4D1%4BU" M3U143TTZ(",P,#`P,#`@,W!X(&1O=6)L93L@5$585"U!3$E'3CH@;&5F=#L@ M1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O M;6%N.R!"04-+1U)/54Y$.B`C9F9F9F9F.R!&3TY4+5-)6D4Z(#$P<'0[(%9% M4E1)0T%,+4%,24=..B!B;W1T;VT[($)/4D1%4BU43U`Z(",P,#`P,#`@,7!X M('-O;&ED.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$E/B`\9&EV/B0\ M+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P M,#`@,W!X(&1O=6)L93L@5$585"U!3$E'3CH@6QE/3-$)U1%6%0M04Q) M1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R=%]C8C(Q M,68U,5\W,V$Q7S1C-#9?8C!B,U]B.#@Y9#5D-C0W8F4-"D-O;G1E;G0M3&]C M871I;VXZ(&9I;&4Z+R\O0SHO8V(R,3%F-3%?-S-A,5\T8S0V7V(P8C-?8C@X M.60U9#8T-V)E+U=O'0O:'1M;#L@8VAA'0^)SQS<&%N/CPO'0^)SQD:78@3Y02!A;F0@97%U:7!M96YT(&%T($1E8V5M M8F5R(#,Q+"`R,#$S(&%N9"`R,#$R(&-O;G-I6QE/3-$)T-,14%2 M.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z M(#$P<'0[34%21TE..B`P<'0@,'!X.R!&3TY4.B`Q,'!T(%1I;65S($YE=R!2 M;VUA;BP@5&EM97,L(%-E6QE/3-$)U1%6%0M04Q)1TXZ(&-E;G1E6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,7!X('-O;&ED.R!4 M15A4+4%,24=..B!C96YT97([($9/3E0M4U193$4Z(&YO6QE/3-$)U1%6%0M M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO"!S;VQI9#L@1D].5"U714E'2%0Z(#0P,"<@=VED=&@] M,T0Q)3X@/&1I=CXD/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%, M24=..B!R:6=H=#L@1D].5"U35%E,13H@;F]R;6%L.R!0041$24Y'+5))1TA4 M.B`U<'@[($9/3E0M1D%-24Q9.B!4:6UE6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!&3TY4+5-464Q%.B!N M;W)M86P[(%!!1$1)3D#L@1D].5"U&04U)3%DZ(%1I;65S M($YE=R!2;VUA;CL@0D%#2T=23U5.1#H@(V9F9F9F9CL@1D].5"U325I%.B`Q M,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@-#`P M)R!W:61T:#TS1#$Q)3X@/&1I=CXX.#PO9&EV/B`\+W1D/B`\=&0@6QE/3-$)U1%6%0M04Q) M1TXZ(')I9VAT.R!&3TY4+5-464Q%.B!N;W)M86P[(%!!1$1)3D#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@0D%#2T=23U5. M1#H@(V9F9F9F9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@ M8F]T=&]M.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$Q)3X@/&1I=CXW M-3PO9&EV/B`\+W1D/B`\=&0@6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z M(&YO6QE/3-$)U1%6%0M M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO6QE M/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!&3TY4+5-464Q%.B!N;W)M86P[(%!! M1$1)3D#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA M;CL@0D%#2T=23U5.1#H@(V9F9F9F9CL@1D].5"U325I%.B`Q,'!T.R!615)4 M24-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS M1#$Q)3X@/&1I=CXV,CPO9&EV/B`\+W1D/B`\=&0@6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT M.R!&3TY4+5-464Q%.B!N;W)M86P[(%!!1$1)3D#L@1D]. M5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@0D%#2T=23U5.1#H@(V9F9F9F M9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!& M3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$Q)3X@/&1I=CXV,#PO9&EV/B`\ M+W1D/B`\=&0@6QE/3-$ M)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)U1%6%0M04Q)1TXZ(&QE M9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[ M($9/3E0M4U193$4Z(&YO6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U19 M3$4Z(&YO"!S;VQI9#L@5$585"U!3$E'3CH@;&5F=#L@1D].5"U35%E,13H@ M;F]R;6%L.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!"04-+1U)/ M54Y$.B`C9F9F9F9F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=. M.B!B;W1T;VT[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$,24^(#QD:78^ M)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"="3U)$15(M0D]45$]- M.B`C,#`P,#`P(#%P>"!S;VQI9#L@5$585"U!3$E'3CH@"!S;VQI9#L@5$585"U!3$E'3CH@;&5F=#L@1D].5"U35%E, M13H@;F]R;6%L.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!"04-+ M1U)/54Y$.B`C9F9F9F9F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%, M24=..B!B;W1T;VT[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$,24^(#QD M:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"="3U)$15(M0D]4 M5$]-.B`C,#`P,#`P(#%P>"!S;VQI9#L@5$585"U!3$E'3CH@6QE/3-$)U1% M6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z M(&YO"!S M;VQI9#L@5$585"U!3$E'3CH@"!S;VQI9#L@5$585"U!3$E'3CH@;&5F M=#L@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@5&EM97,@3F5W M(%)O;6%N.R!"04-+1U)/54Y$.B`C9F9F9F9F.R!&3TY4+5-)6D4Z(#$P<'0[ M(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($9/3E0M5T5)1TA4.B`T,#`G('=I M9'1H/3-$,24^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL93TS M1"="3U)$15(M0D]45$]-.B`C,#`P,#`P(#%P>"!S;VQI9#L@5$585"U!3$E' M3CH@6QE/3-$)U1%6%0M04Q) M1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO6QE/3-$ M)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,W!X(&1O=6)L93L@5$585"U!3$E' M3CH@;&5F=#L@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@5&EM M97,@3F5W(%)O;6%N.R!"04-+1U)/54Y$.B`C8V-F9F-C.R!&3TY4+5-)6D4Z M(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($)/4D1%4BU43U`Z(",P M,#`P,#`@,7!X('-O;&ED.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$E M/B`\9&EV/B0\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)T)/4D1%4BU"3U14 M3TTZ(",P,#`P,#`@,W!X(&1O=6)L93L@5$585"U!3$E'3CH@3X-"CPO:'1M;#X-"@T*+2TM M+2TM/5].97AT4&%R=%]C8C(Q,68U,5\W,V$Q7S1C-#9?8C!B,U]B.#@Y9#5D M-C0W8F4-"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO8V(R,3%F-3%? M-S-A,5\T8S0V7V(P8C-?8C@X.60U9#8T-V)E+U=O'0O:'1M;#L@8VAA7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R M#L@1D].5#H@,3!P="!4:6UE6%B;&4@86YD(&%C8W)U M960@;&EA8FEL:71I97,@870@1&5C96UB97(@,S$L(#(P,3,@86YD+"`R,#$R M(&-O;G-I6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I M;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[34%21TE..B`P<'0@,'!X M.R!&3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E6QE/3-$)U1%6%0M04Q) M1TXZ(&-E;G1E6QE/3-$)T)/4D1%4BU"3U14 M3TTZ(",P,#`P,#`@,7!X('-O;&ED.R!415A4+4%,24=..B!C96YT97([($9/ M3E0M4U193$4Z(&YO"!S;VQI9#L@1D]. M5"U714E'2%0Z(#6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,7!X M('-O;&ED.R!415A4+4%,24=..B!C96YT97([($9/3E0M4U193$4Z(&YO"!S;VQI9#L@1D].5"U714E'2%0Z(#6%B;&4\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$ M)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!&3TY4+5-464Q% M.B!N;W)M86P[(%!!1$1)3D#L@1D].5"U&04U)3%DZ(%1I M;65S($YE=R!2;VUA;CL@0D%#2T=23U5.1#H@(V-C9F9C8SL@1D].5"U325I% M.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!"3U)$15(M5$]0.B`C M,#`P,#`P(#%P>"!S;VQI9#L@1D].5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q M,24^(#QD:78^.#0Y/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%, M24=..B!L969T.R!&3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!4 M:6UE6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO"!S;VQI9#L@1D].5"U714E' M2%0Z(#0P,"<@=VED=&@],T0Q)3X@/&1I=CXD/"]D:78^(#PO=&0^(#QT9"!S M='EL93TS1"=415A4+4%,24=..B!R:6=H=#L@1D].5"U35%E,13H@;F]R;6%L M.R!0041$24Y'+5))1TA4.B`U<'@[($9/3E0M1D%-24Q9.B!4:6UE6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z M(&YO6QE/3-$)U1%6%0M M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO M6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO6QE/3-$ M)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO6QE M/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[ M($9/3E0M4U193$4Z(&YO6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M M4U193$4Z(&YO6QE/3-$ M)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/ M3E0M4U193$4Z(&YO#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@0D%#2T=23U5. M1#H@(V9F9F9F9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@ M8F]T=&]M.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$Q)3X@/&1I=CXR M.#PO9&EV/B`\+W1D/B`\=&0@"!S;VQI9#L@5$585"U!3$E'3CH@ M;&5F=#L@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@5&EM97,@ M3F5W(%)O;6%N.R!"04-+1U)/54Y$.B`C9F9F9F9F.R!&3TY4+5-)6D4Z(#$P M<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($9/3E0M5T5)1TA4.B`T,#`G M('=I9'1H/3-$,24^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL M93TS1"="3U)$15(M0D]45$]-.B`C,#`P,#`P(#%P>"!S;VQI9#L@5$585"U! M3$E'3CH@6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO M6QE/3-$)U1%6%0M04Q)1TXZ(&QE M9G0[($9/3E0M4U193$4Z(&YO"!S;VQI9#L@1D].5"U714E'2%0Z M(#0P,"<@=VED=&@],T0Q,24^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT M9"!S='EL93TS1"=415A4+4%,24=..B!L969T.R!&3TY4+5-464Q%.B!N;W)M M86P[($9/3E0M1D%-24Q9.B!4:6UE6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[ M($9/3E0M4U193$4Z(&YO"!S;VQI9#L@1D].5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q)3X@/&1I=CXF M(S$V,#L\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(')I M9VAT.R!&3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!4:6UE6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U19 M3$4Z(&YO6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,W!X(&1O=6)L93L@ M5$585"U!3$E'3CH@6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,W!X(&1O=6)L93L@ M5$585"U!3$E'3CH@;&5F=#L@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49! M34E,63H@5&EM97,@3F5W(%)O;6%N.R!"04-+1U)/54Y$.B`C9F9F9F9F.R!& M3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($9/3E0M M5T5)1TA4.B`T,#`G('=I9'1H/3-$,24^(#QD:78^)#PO9&EV/B`\+W1D/B`\ M=&0@6QE/3-$)U1%6%0M M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO&5D.R<@8V5L M;'-P86-I;F<],T0P(&-E;&QP861D:6YG/3-$,#X\='(^/'1D/CPO=&0^/"]T M7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T* M#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O M;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA'0^)SQS<&%N/CPO'0^)SQD:78@3Y#;VYV97)T:6)L92!$96)E;G1U M6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S M($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[5$585"U!3$E'3CI,969T.R!4 M15A4+4E.1$5.5#H@,&EN.R!724142#H@,3`P)2<^(#QT86)L92!S='EL93TS M1"=-05)'24XZ(#!I;CL@5TE$5$@Z(#$P,"4[($)/4D1%4BU#3TQ,05!313H@ M8V]L;&%P6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`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`Q,'!T.R!615)424-!3"U!3$E'3CH@ M8F]T=&]M.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$S)3X@/&1I=CXT M+#`S,#PO9&EV/B`\+W1D/B`\=&0@6QE/3-$)U1%6%0M M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!&3TY4+5-464Q%.B!N;W)M86P[ M(%!!1$1)3D#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2 M;VUA;CL@0D%#2T=23U5.1#H@(V-C9F9C8SL@0T],3U(Z(",P,#`P,#`[($9/ M3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O='1O;3L@1D].5"U7 M14E'2%0Z(#0P,"<@=VED=&@],T0Q,B4^(#QD:78^-2PW.#`\+V1I=CX@/"]T M9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z M(&YO"!S;VQI9#L@5$585"U!3$E'3CH@;&5F M=#L@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@5&EM97,@3F5W M(%)O;6%N.R!"04-+1U)/54Y$.B`C9F9F9F9F.R!&3TY4+5-)6D4Z(#$P<'0[ M(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($9/3E0M5T5)1TA4.B`T,#`G('=I M9'1H/3-$,24^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL93TS M1"="3U)$15(M0D]45$]-.B`C,#`P,#`P(#%P>"!S;VQI9#L@5$585"U!3$E' M3CH@6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,7!X M('-O;&ED.R!415A4+4%,24=..B!L969T.R!&3TY4+5-464Q%.B!N;W)M86P[ M($9/3E0M1D%-24Q9.B!4:6UE6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P M,#`@,7!X('-O;&ED.R!415A4+4%,24=..B!R:6=H=#L@1D].5"U35%E,13H@ M;F]R;6%L.R!0041$24Y'+5))1TA4.B`T<'@[($9/3E0M1D%-24Q9.B!4:6UE M6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U19 M3$4Z(&YO6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M M4U193$4Z(&YO"!S;VQI9#L@5$585"U!3$E'3CH@"!S;VQI9#L@1D].5"U714E'2%0Z(#0P,"<@ M=VED=&@],T0Q,R4^(#QD:78^,BPW,#(\+V1I=CX@/"]T9#X@/'1D('-T>6QE M/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO"!S;VQI9#L@1D]. M5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q,R4^(#QD:78^,2PW-3`\+V1I=CX@ M/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U19 M3$4Z(&YO6QE/3-$)U1%6%0M04Q)1TXZ M(')I9VAT.R!&3TY4+5-464Q%.B!N;W)M86P[(%!!1$1)3D#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@0D%#2T=23U5.1#H@ M(V-C9F9C8SL@0T],3U(Z(",P,#`P,#`[($9/3E0M4TE:13H@,3!P=#L@5D52 M5$E#04PM04Q)1TXZ(&)O='1O;3L@0D]21$52+51/4#H@(S`P,#`P,"`Q<'@@ M6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U19 M3$4Z(&YO#L@ M1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@0D%#2T=23U5.1#H@(V9F M9F9F9CL@0T],3U(Z(",P,#`P,#`[($9/3E0M4TE:13H@,3!P=#L@5D525$E# M04PM04Q)1TXZ(&)O='1O;3L@0D]21$52+51/4#H@(S`P,#`P,"`Q<'@@6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[ M($9/3E0M4U193$4Z(&YO6QE/3-$)U1%6%0M04Q)1TXZ(&QE M9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)U1%6%0M04Q)1TXZ M(&QE9G0[($9/3E0M4U193$4Z(&YO#L@1D].5"U&04U)3%DZ(%1I M;65S($YE=R!2;VUA;CL@0D%#2T=23U5.1#H@(V-C9F9C8SL@1D].5"U325I% M.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@ M-#`P)R!W:61T:#TS1#4U)3X@/&1I=CY,;VYG('1E"!D;W5B;&4[(%1%6%0M04Q)1TXZ(&QE9G0[ M($9/3E0M4U193$4Z(&YO"!S;VQI9#L@1D].5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q)3X@/&1I=CXD M/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B`C,#`P M,#`P(#-P>"!D;W5B;&4[(%1%6%0M04Q)1TXZ(')I9VAT.R!&3TY4+5-464Q% M.B!N;W)M86P[(%!!1$1)3D#L@1D].5"U&04U)3%DZ(%1I M;65S($YE=R!2;VUA;CL@0D%#2T=23U5.1#H@(V-C9F9C8SL@1D].5"U325I% M.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!"3U)$15(M5$]0.B`C M,#`P,#`P(#%P>"!S;VQI9#L@1D].5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q M,R4^(#QD:78^+3PO9&EV/B`\+W1D/B`\=&0@"!S;VQI9#L@1D].5"U714E'2%0Z(#0P,"<@=VED M=&@],T0Q)3X@/&1I=CXD/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"="3U)$ M15(M0D]45$]-.B`C,#`P,#`P(#-P>"!D;W5B;&4[(%1%6%0M04Q)1TXZ(')I M9VAT.R!&3TY4+5-464Q%.B!N;W)M86P[(%!!1$1)3D#L@ M1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@0D%#2T=23U5.1#H@(V-C M9F9C8SL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M M.R!"3U)$15(M5$]0.B`C,#`P,#`P(#%P>"!S;VQI9#L@1D].5"U714E'2%0Z M(#0P,"<@=VED=&@],T0Q,R4^(#QD:78^+3PO9&EV/B`\+W1D/B`\=&0@"!D;W5B;&4[(%1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO M"!S;VQI9#L@1D].5"U7 M14E'2%0Z(#0P,"<@=VED=&@],T0Q)3X@/&1I=CXD/"]D:78^(#PO=&0^(#QT M9"!S='EL93TS1"="3U)$15(M0D]45$]-.B`C,#`P,#`P(#-P>"!D;W5B;&4[ M(%1%6%0M04Q)1TXZ(')I9VAT.R!&3TY4+5-464Q%.B!N;W)M86P[(%!!1$1) M3D#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@ M0D%#2T=23U5.1#H@(V-C9F9C8SL@1D].5"U325I%.B`Q,'!T.R!615)424-! M3"U!3$E'3CH@8F]T=&]M.R!"3U)$15(M5$]0.B`C,#`P,#`P(#%P>"!S;VQI M9#L@1D].5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q,B4^(#QD:78^+3PO9&EV M/B`\+W1D/B`\=&0@6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%- M24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[5$585"U)3D1% M3E0Z(#`N-6EN.R!-05)'24XZ(#!P="`P<'@[($9/3E0Z(#$P<'0@5&EM97,@ M3F5W(%)O;6%N+"!4:6UE3XF(S$V M,#L\+V1I=CX@/&1I=B!S='EL93TS1"=#3$5!4CIB;W1H.R!&3TY4+49!34E, M63I4:6UE6QE/3-$)T)/ M4D1%4BU"3U143TTZ(",P,#`P,#`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`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@ M-#`P)R!W:61T:#TS1#$S)3X@/&1I=CXQ+#4Q,#PO9&EV/B`\+W1D/B`\=&0@ M6QE/3-$)U1%6%0M04Q)1TXZ(&QE M9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z M(&YO6QE/3-$ M)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO"!D;W5B;&4[(%1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO M"!S;VQI9#L@1D].5"U7 M14E'2%0Z(#0P,"<@=VED=&@],T0Q)3X@/&1I=CXD/"]D:78^(#PO=&0^(#QT M9"!S='EL93TS1"="3U)$15(M0D]45$]-.B`C,#`P,#`P(#-P>"!D;W5B;&4[ M(%1%6%0M04Q)1TXZ(')I9VAT.R!&3TY4+5-464Q%.B!N;W)M86P[(%!!1$1) M3D#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@ M0D%#2T=23U5.1#H@(V-C9F9C8SL@1D].5"U325I%.B`Q,'!T.R!615)424-! M3"U!3$E'3CH@8F]T=&]M.R!"3U)$15(M5$]0.B`C,#`P,#`P(#%P>"!S;VQI M9#L@1D].5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q,R4^(#QD:78^,2PQ-C`\ M+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/ M3E0M4U193$4Z(&YO"!S;VQI9#L@1D].5"U714E'2%0Z(#0P M,"<@=VED=&@],T0Q)3X@/&1I=CXD/"]D:78^(#PO=&0^(#QT9"!S='EL93TS M1"="3U)$15(M0D]45$]-.B`C,#`P,#`P(#-P>"!D;W5B;&4[(%1%6%0M04Q) M1TXZ(')I9VAT.R!&3TY4+5-464Q%.B!N;W)M86P[(%!!1$1)3D#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@0D%#2T=23U5. M1#H@(V-C9F9C8SL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@ M8F]T=&]M.R!"3U)$15(M5$]0.B`C,#`P,#`P(#%P>"!S;VQI9#L@1D].5"U7 M14E'2%0Z(#0P,"<@=VED=&@],T0Q,B4^(#QD:78^,2PU-C(\+V1I=CX@/"]T M9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z M(&YO&5D.R<@8V5L;'-P86-I;F<],T0P(&-E;&QP861D:6YG M/3-$,#X\='(^/'1D/CPO=&0^/"]T'0^)SQS<&%N/CPO6QE/3-$)TU!4D=)3CH@,'!T(#!P>#L@1D].5#H@,3!P M="!4:6UE2!O9B!#;VYV97)T:6)L92!$96)T(&%N9"!T:&4@ M:6YI=&EA;"!A8V-O=6YT:6YG(&]F('1H92!I"`P<'0@,"XR-6EN.R!&3TY4.B`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`N-6EN.R!-05)'24XZ(#!P="`P<'@[($9/3E0Z(#$P<'0@ M5&EM97,@3F5W(%)O;6%N+"!4:6UE6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z M(&YO6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M M4U193$4Z(&YO6QE/3-$)U1%6%0M04Q)1TXZ M(')I9VAT.R!&3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!4:6UE M3PO M9&EV/B`\+W1D/B`\=&0@6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!&3TY4+5-464Q%.B!N M;W)M86P[($9/3E0M1D%-24Q9.B!4:6UE6QE M/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)T-,14%2.F)O M=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P M<'0G/CPO9&EV/B`\+V1I=CX@/"]D:78^/'1A8FQE(&)O&5D.R<@8V5L;'-P M86-I;F<],T0P(&-E;&QP861D:6YG/3-$,#X\='(^/'1D/CPO=&0^/"]T7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\ M:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E M;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA6%B;&4\+W1D/@T*("`@("`@("`\=&0@8VQA6QE/3-$)TU!4D=)3CH@,'!T(#!P>#L@1D].5#H@,3!P="!4 M:6UE6QE/3-$ M)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4 M+5-)6D4Z(#$P<'0[34%21TE..B`P<'0@,'!X.R!&3TY4.B`Q,'!T(%1I;65S M($YE=R!2;VUA;BP@5&EM97,L(%-E#L@1D].5#H@,3!P="!4:6UE"!S M;VQI9#L@34%21TE..B`P<'@Z875T;SL@5TE$5$@Z(#8P)3L@0D]21$52+4-/ M3$Q!4%-%.B!C;VQL87!S93L@3U9%4D9,3U6QE/3-$)U1%6%0M04Q)1TXZ(&-E;G1E6QE/3-$)U1%6%0M04Q)1TXZ M(&QE9G0[($9/3E0M4U193$4Z(&YO6QE/3-$ M)U1%6%0M04Q)1TXZ(')I9VAT.R!&3TY4+5-464Q%.B!N;W)M86P[(%!!1$1) M3D#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@ M0D%#2T=23U5.1#H@(V-C9F9C8SL@0T],3U(Z(",P,#`P,#`[($9/3E0M4TE: M13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O='1O;3L@1D].5"U714E'2%0Z M(#0P,"<@=VED=&@],T0Q-"4^(#QD:78^,2PQ,S`L,#`P/"]D:78^(#PO=&0^ M(#QT9"!S='EL93TS1"=415A4+4%,24=..B!L969T.R!&3TY4+5-464Q%.B!N M;W)M86P[($9/3E0M1D%-24Q9.B!4:6UE6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z M(&YO6QE/3-$)U1%6%0M04Q)1TXZ(&-E;G1E6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/ M3E0M4U193$4Z(&YO6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/ M3E0M4U193$4Z(&YO6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE M=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0G/CPO9&EV/B`\9&EV('-T>6QE/3-$ M)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4 M+5-)6D4Z(#$P<'0G/CPO9&EV/B`\+V1I=CX@/"]D:78^(#PO9&EV/CQT86)L M92!B;W)D97(],T0P('-T>6QE/3-$)W=I9'1H.C$P,"4[('1A8FQE+6QA>6]U M=#IF:7AE9#LG(&-E;&QS<&%C:6YG/3-$,"!C96QL<&%D9&EN9STS1#`^/'1R M/CQT9#X\+W1D/CPO='(^/"]T86)L93X\'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA M'0^)SQD:78@3Y&=71U6UE;G1S(&%R92!A6QE/3-$ M)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4 M+5-)6D4Z(#$P<'0[34%21TE..B`P<'0@,'!X.R!&3TY4.B`Q,'!T(%1I;65S M($YE=R!2;VUA;BP@5&EM97,L(%-E6QE/3-$)U1% M6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z M(&YO6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!&3TY4+5-464Q% M.B!N;W)M86P[(%!!1$1)3D#L@1D].5"U&04U)3%DZ(%1I M;65S($YE=R!2;VUA;CL@0D%#2T=23U5.1#H@(V-C9F9C8SL@1D].5"U325I% M.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@ M-#`P)R!W:61T:#TS1#$T)3X@/&1I=CXT+#`P,#PO9&EV/B`\+W1D/B`\=&0@ M6QE/3-$)U1%6%0M04Q) M1TXZ(&-E;G1E6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)U1%6%0M04Q) M1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P M,#`@,7!X('-O;&ED.R!415A4+4%,24=..B!L969T.R!&3TY4+5-464Q%.B!N M;W)M86P[($9/3E0M1D%-24Q9.B!4:6UE6QE/3-$)T)/4D1%4BU"3U143TTZ M(",P,#`P,#`@,7!X('-O;&ED.R!415A4+4%,24=..B!R:6=H=#L@1D].5"U3 M5%E,13H@;F]R;6%L.R!0041$24Y'+5))1TA4.B`U<'@[($9/3E0M1D%-24Q9 M.B!4:6UE6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO M6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z M(&YO6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z M(&YO"!S;VQI9#L@5$585"U!3$E'3CH@;&5F=#L@1D].5"U35%E,13H@;F]R;6%L M.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!"04-+1U)/54Y$.B`C M8V-F9F-C.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T M;VT[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$,24^(#QD:78^)B,Q-C`[ M/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B`C,#`P M,#`P(#%P>"!S;VQI9#L@5$585"U!3$E'3CH@6QE/3-$)U1%6%0M04Q)1TXZ(&-E;G1E M"!S;VQI9#L@5$585"U!3$E'3CH@;&5F=#L@1D]. M5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N M.R!"04-+1U)/54Y$.B`C8V-F9F-C.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1) M0T%,+4%,24=..B!B;W1T;VT[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$ M,24^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"="3U)$ M15(M0D]45$]-.B`C,#`P,#`P(#%P>"!S;VQI9#L@5$585"U!3$E'3CH@"!D;W5B;&4[(%1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z M(&YO"!S;VQI9#L@1D]. M5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q)3X@/&1I=CXD/"]D:78^(#PO=&0^ M(#QT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B`C,#`P,#`P(#-P>"!D;W5B M;&4[(%1%6%0M04Q)1TXZ(')I9VAT.R!&3TY4+5-464Q%.B!N;W)M86P[(%!! M1$1)3D#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA M;CL@0D%#2T=23U5.1#H@(V9F9F9F9CL@1D].5"U325I%.B`Q,'!T.R!615)4 M24-!3"U!3$E'3CH@8F]T=&]M.R!"3U)$15(M5$]0.B`C,#`P,#`P(#%P>"!S M;VQI9#L@1D].5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q-"4^(#QD:78^,3$L M,#`P/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!L969T M.R!&3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!4:6UE6QE/3-$)W=I M9'1H.C$P,"4[('1A8FQE+6QA>6]U=#IF:7AE9#LG(&-E;&QS<&%C:6YG/3-$ M,"!C96QL<&%D9&EN9STS1#`^/'1R/CQT9#X\+W1D/CPO='(^/"]T86)L93X\ M'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA6QE/3-$ M)TU!4D=)3CH@,'!T(#!P>#L@1D].5#H@,3!P="!4:6UE6QE/3-$)T-,14%2.F)O=&@[($9/ M3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[34%2 M1TE..B`P<'0@,'!X.R!&3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM M97,L(%-E#L@1D].5#H@,3!P M="!4:6UE6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S M($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[5$585"U!3$E'3CIC96YT97([ M(%1%6%0M24Y$14Y4.B`P:6X[(%=)1%1(.B`Q,#`E)R!A;&EG;CTS1&-E;G1E M6QE/3-$)TU!4D=)3CH@,'!X.F%U=&\[(%=)1%1(.B`X M,"4[($)/4D1%4BU#3TQ,05!313H@8V]L;&%P6QE/3-$)U1% M6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO'!E8W1E9"!L:69E("AY M96%R6QE/3-$)U1%6%0M04Q)1TXZ(&QE M9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)U1%6%0M04Q) M1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT M.R!&3TY4+5-464Q%.B!N;W)M86P[(%!!1$1)3D#L@1D]. M5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@0D%#2T=23U5.1#H@(V9F9F9F M9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!& M3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$R)3X@/&1I=CXQ,3PO9&EV/B`\ M+W1D/B`\=&0@6EE;&0\+V1I M=CX@/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M M4U193$4Z(&YO6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[ M($9/3E0M4U193$4Z(&YO3PO9&EV/B`\+W1D/B`\=&0@#L@1D].5#H@,3!P="!4:6UE2!O9B!C;VUM;VX@ M"!S;VQI9#L@34%21TE..B`P:6X[(%=)1%1( M.B`Q,#`E.R!"3U)$15(M0T],3$%04T4Z(&-O;&QA<'-E.R!&3TY4+5-)6D4Z M(#$P<'0[($]615)&3$]7.B!V:7-I8FQE.R!"3U)$15(M5$]0.B`C.65B-F-E M(#!P>"!S;VQI9#L@0D]21$52+5))1TA4.B`C.65B-F-E(#!P>"!S;VQI9"<@ M8V5L;'-P86-I;F<],T0P(&-E;&QP861D:6YG/3-$,"!A;&EG;CTS1&QE9G0^ M(#QT6QE/3-$)U1%6%0M04Q)1TXZ(&-E;G1E6QE/3-$ M)U1%6%0M04Q)1TXZ(&-E;G1E&5R8VES93QB6QE/3-$)U1%6%0M M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[ M($9/3E0M4U193$4Z(&YO6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT M.R!&3TY4+5-464Q%.B!N;W)M86P[(%!!1$1)3D#L@1D]. M5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@0D%#2T=23U5.1#H@(V-C9F9C M8SL@0T],3U(Z(",P,#`P,#`[($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM M04Q)1TXZ(&)O='1O;3L@1D].5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q,B4^ M(#QD:78^,"XP,3PO9&EV/B`\+W1D/B`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`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@ M-#`P)R!W:61T:#TS1#$R)3X@/&1I=CXP+C`Q/"]D:78^(#PO=&0^(#QT9"!S M='EL93TS1"=415A4+4%,24=..B!L969T.R!&3TY4+5-464Q%.B!N;W)M86P[ M($9/3E0M1D%-24Q9.B!4:6UE6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[ M($9/3E0M4U193$4Z(&YO6QE M/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!&3TY4+5-464Q% M.B!N;W)M86P[(%!!1$1)3D#L@1D].5"U&04U)3%DZ(%1I M;65S($YE=R!2;VUA;CL@0D%#2T=23U5.1#H@(V9F9F9F9CL@1D].5"U325I% M.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@ M-#`P)R!W:61T:#TS1#$R)3X@/&1I=CXP+C`Q/"]D:78^(#PO=&0^(#QT9"!S M='EL93TS1"=415A4+4%,24=..B!L969T.R!&3TY4+5-464Q%.B!N;W)M86P[ M($9/3E0M1D%-24Q9.B!4:6UE&5R8VES M960\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[ M($9/3E0M4U193$4Z(&YO#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@0D%#2T=2 M3U5.1#H@(V-C9F9C8SL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E' M3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$R)3X@/&1I M=CXM/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!L969T M.R!&3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!4:6UE6QE/3-$ M)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,7!X('-O;&ED.R!415A4+4%,24=. M.B!L969T.R!&3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!4:6UE M6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,7!X('-O;&ED.R!415A4 M+4%,24=..B!R:6=H=#L@1D].5"U35%E,13H@;F]R;6%L.R!0041$24Y'+5)) M1TA4.B`V<'@[($9/3E0M1D%-24Q9.B!4:6UE6QE/3-$ M)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO"!D;W5B;&4[(%1%6%0M04Q)1TXZ(&QE M9G0[($9/3E0M4U193$4Z(&YO"!S;VQI9#L@1D].5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q)3X@/&1I M=CXF(S$V,#L\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)T)/4D1%4BU"3U14 M3TTZ(",P,#`P,#`@,W!X(&1O=6)L93L@5$585"U!3$E'3CH@"!S;VQI9#L@1D]. M5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q,B4^(#QD:78^,3@X+#$P,"PP,#`\ M+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/ M3E0M4U193$4Z(&YO6QE/3-$)U1% M6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)T)/4D1% M4BU"3U143TTZ(",P,#`P,#`@,W!X(&1O=6)L93L@5$585"U!3$E'3CH@;&5F M=#L@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@5&EM97,@3F5W M(%)O;6%N.R!"04-+1U)/54Y$.B`C8V-F9F-C.R!&3TY4+5-)6D4Z(#$P<'0[ M(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($)/4D1%4BU43U`Z(",P,#`P,#`@ M,W!X(&1O=6)L93L@1D].5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q)3X@/&1I M=CXF(S$V,#L\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)T)/4D1%4BU"3U14 M3TTZ(",P,#`P,#`@,W!X(&1O=6)L93L@5$585"U!3$E'3CH@"!D;W5B;&4[($9/ M3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$,3(E/B`\9&EV/C$X."PQ,#`L,#`P M/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!L969T.R!& M3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!4:6UE6QE/3-$)T)/ M4D1%4BU"3U143TTZ(",P,#`P,#`@,W!X(&1O=6)L93L@5$585"U!3$E'3CH@ M;&5F=#L@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@5&EM97,@ M3F5W(%)O;6%N.R!"04-+1U)/54Y$.B`C8V-F9F-C.R!&3TY4+5-)6D4Z(#$P M<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($)/4D1%4BU43U`Z(",P,#`P M,#`@,W!X(&1O=6)L93L@1D].5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q)3X@ M/&1I=CXD/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"="3U)$15(M0D]45$]- M.B`C,#`P,#`P(#-P>"!D;W5B;&4[(%1%6%0M04Q)1TXZ(')I9VAT.R!&3TY4 M+5-464Q%.B!N;W)M86P[(%!!1$1)3D#L@1D].5"U&04U) M3%DZ(%1I;65S($YE=R!2;VUA;CL@0D%#2T=23U5.1#H@(V-C9F9C8SL@1D]. M5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!"3U)$15(M M5$]0.B`C,#`P,#`P(#-P>"!D;W5B;&4[($9/3E0M5T5)1TA4.B`T,#`G('=I M9'1H/3-$,3(E/B`\9&EV/C`N,#$\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$ M)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO&5D M.R<@8V5L;'-P86-I;F<],T0P(&-E;&QP861D:6YG/3-$,#X\='(^/'1D/CPO M=&0^/"]T6QE/3-$)TU!4D=)3CH@,'!T(#!P>#L@1D].5#H@,3!P="!4:6UE M6QE/3-$)T-, M14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-) M6D4Z(#$P<'0[34%21TE..B`P<'0@,'!X.R!&3TY4.B`Q,'!T(%1I;65S($YE M=R!2;VUA;BP@5&EM97,L(%-E#L@1D].5#H@,3!P="!4:6UE6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE M=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[5$585"U!3$E'3CIC96YT97([(%1% M6%0M24Y$14Y4.B`P:6X[(%=)1%1(.B`Q,#`E)R!A;&EG;CTS1&-E;G1E6QE/3-$)TU!4D=)3CH@,'!X.F%U=&\[(%=)1%1(.B`X,"4[ M($)/4D1%4BU#3TQ,05!313H@8V]L;&%P6QE/3-$)U1%6%0M M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO'!E8W1E9"!L:69E("AY96%R M6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[ M($9/3E0M4U193$4Z(&YO6QE/3-$)U1%6%0M04Q) M1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT M.R!&3TY4+5-464Q%.B!N;W)M86P[(%!!1$1)3D#L@1D]. M5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@0D%#2T=23U5.1#H@(V9F9F9F M9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!& M3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$R)3X@/&1I=CXP+C6QE/3-$)U1% M6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO M'!E8W1E9"!V;VQA=&EL:71Y/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=4 M15A4+4%,24=..B!L969T.R!&3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%- M24Q9.B!4:6UE6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!&3TY4+5-464Q% M.B!N;W)M86P[(%!!1$1)3D#L@1D].5"U&04U)3%DZ(%1I M;65S($YE=R!2;VUA;CL@0D%#2T=23U5.1#H@(V9F9F9F9CL@1D].5"U325I% M.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@ M-#`P)R!W:61T:#TS1#$R)3X@/&1I=CXR,3@\+V1I=CX@/"]T9#X@/'1D('-T M>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)W=I9'1H.C$P,"4[('1A8FQE+6QA>6]U=#IF:7AE M9#LG(&-E;&QS<&%C:6YG/3-$,"!C96QL<&%D9&EN9STS1#`^/'1R/CQT9#X\ M+W1D/CPO='(^/"]T86)L93X\6QE/3-$)TU!4D=)3CH@,'!T(#!P>#L@1D].5#H@,3!P="!4 M:6UE6QE/3-$ M)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4 M+5-)6D4Z(#$P<'0[34%21TE..B`P<'0@,'!X.R!&3TY4.B`Q,'!T(%1I;65S M($YE=R!2;VUA;BP@5&EM97,L(%-E#L@1D].5#H@,3!P="!4:6UE6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S M($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[5$585"U!3$E'3CIC96YT97([ M(%1%6%0M24Y$14Y4.B`P:6X[(%=)1%1(.B`Q,#`E)R!A;&EG;CTS1&-E;G1E M6QE/3-$)TU!4D=)3CH@,'!X.F%U=&\[(%=)1%1(.B`X M,"4[($)/4D1%4BU#3TQ,05!313H@8V]L;&%P6QE/3-$)U1% M6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO'!E8W1E9"!L:69E("AY M96%R6QE/3-$)U1%6%0M04Q)1TXZ(&QE M9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)U1%6%0M M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)U1%6%0M04Q)1TXZ(')I M9VAT.R!&3TY4+5-464Q%.B!N;W)M86P[(%!!1$1)3D#L@ M1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@0D%#2T=23U5.1#H@(V9F M9F9F9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M M.R!&3TY4+5=%24=(5#H@-#`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`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=( M5#H@-#`P)R!W:61T:#TS1#$R)3X@/&1I=CXQ,C4\+V1I=CX@/"]T9#X@/'1D M('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)W=I9'1H.C$P,"4[('1A8FQE+6QA>6]U=#IF M:7AE9#LG(&-E;&QS<&%C:6YG/3-$,"!C96QL<&%D9&EN9STS1#`^/'1R/CQT M9#X\+W1D/CPO='(^/"]T86)L93X\6QE/3-$)TU!4D=)3CH@,'!T(#!P>#L@1D].5#H@,3!P="!4 M:6UE6QE/3-$ M)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4 M+5-)6D4Z(#$P<'0[34%21TE..B`P<'0@,'!X.R!&3TY4.B`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`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M M.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$R)3X@/&1I=CXM/"]D:78^ M(#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!L969T.R!&3TY4+5-4 M64Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!4:6UE6QE/3-$)U1%6%0M04Q) M1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)U1% M6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!&3TY4+5-464Q%.B!N;W)M86P[ M(%!!1$1)3D#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2 M;VUA;CL@0D%#2T=23U5.1#H@(V-C9F9C8SL@0T],3U(Z(",P,#`P,#`[($9/ M3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O='1O;3L@1D].5"U7 M14E'2%0Z(#0P,"<@=VED=&@],T0Q,B4^(#QD:78^,"XP,2TP+C`S/"]D:78^ M(#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!L969T.R!&3TY4+5-4 M64Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!4:6UE6QE/3-$)U1%6%0M04Q) M1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO6QE M/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!&3TY4+5-464Q%.B!N;W)M86P[(%!! M1$1)3D#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA M;CL@0D%#2T=23U5.1#H@(V-C9F9C8SL@1D].5"U325I%.B`Q,'!T.R!615)4 M24-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS M1#$R)3X@/&1I=CXP+C`S/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=415A4 M+4%,24=..B!L969T.R!&3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9 M.B!4:6UE6QE/3-$)U1%6%0M M04Q)1TXZ(')I9VAT.R!&3TY4+5-464Q%.B!N;W)M86P[(%!!1$1)3D#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@0D%#2T=2 M3U5.1#H@(V9F9F9F9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E' M3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$R)3X@/&1I M=CXQ,30L.#4P+#`P,#PO9&EV/B`\+W1D/B`\=&0@6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U19 M3$4Z(&YO6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,7!X M('-O;&ED.R!415A4+4%,24=..B!R:6=H=#L@1D].5"U35%E,13H@;F]R;6%L M.R!0041$24Y'+5))1TA4.B`U<'@[($9/3E0M1D%-24Q9.B!4:6UE6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[ M($9/3E0M4U193$4Z(&YO6QE M/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO"!S;VQI9#L@5$585"U!3$E'3CH@ M6QE/3-$)U1%6%0M04Q)1TXZ(&QE M9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)U1%6%0M04Q)1TXZ(')I M9VAT.R!&3TY4+5-464Q%.B!N;W)M86P[(%!!1$1)3D#L@ M1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@0D%#2T=23U5.1#H@(V9F M9F9F9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M M.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$R)3X@/&1I=CXP+C`S/"]D M:78^(#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!L969T.R!&3TY4 M+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!4:6UE6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[ M($9/3E0M4U193$4Z(&YO6QE/3-$)U1%6%0M M04Q)1TXZ(')I9VAT.R!&3TY4+5-464Q%.B!N;W)M86P[(%!!1$1)3D#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@0D%#2T=2 M3U5.1#H@(V-C9F9C8SL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E' M3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$R)3X@/&1I M=CXM/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!L969T M.R!&3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!4:6UE6QE/3-$)U1%6%0M M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)U1% M6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO"!S;VQI9#L@5$585"U!3$E'3CH@6QE M/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M M4U193$4Z(&YO6QE/3-$)U1%6%0M04Q)1TXZ M(&QE9G0[($9/3E0M4U193$4Z(&YO"!D;W5B;&4[(%1%6%0M04Q)1TXZ(')I9VAT.R!&3TY4 M+5-464Q%.B!N;W)M86P[(%!!1$1)3D#L@1D].5"U&04U) M3%DZ(%1I;65S($YE=R!2;VUA;CL@0D%#2T=23U5.1#H@(V9F9F9F9CL@0T], M3U(Z(",P,#`P,#`[($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ M(&)O='1O;3L@1D].5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q,B4^(#QD:78^ M,"XP,2TP+C`R/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=. M.B!L969T.R!&3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!4:6UE M6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,W!X(&1O=6)L93L@5$58 M5"U!3$E'3CH@;&5F=#L@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E, M63H@5&EM97,@3F5W(%)O;6%N.R!"04-+1U)/54Y$.B`C9F9F9F9F.R!&3TY4 M+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($9/3E0M5T5) M1TA4.B`T,#`G('=I9'1H/3-$,24^(#QD:78^)#PO9&EV/B`\+W1D/B`\=&0@ M6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)T-,14%2 M.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z M(#$P<'0G/CPO9&EV/B`\+V1I=CX@/"]D:78^/'1A8FQE(&)O&5D.R<@8V5L M;'-P86-I;F<],T0P(&-E;&QP861D:6YG/3-$,#X\='(^/'1D/CPO=&0^/"]T M#L@1D].5#H@,3!P M="!4:6UE2!O M9B!397)I97,@0B!03XF(S$V,#L\+V1I=CX@/&1I M=B!S='EL93TS1"=#3$5!4CIB;W1H.R!&3TY4+49!34E,63I4:6UE"!S;VQI9#L@34%21TE..B`P:6X[(%=)1%1(.B`Q,#`E.R!" M3U)$15(M0T],3$%04T4Z(&-O;&QA<'-E.R!/5D521DQ/5SH@=FES:6)L93L@ M0D]21$52+51/4#H@(SEE8C9C92`P<'@@6QE/3-$)U1%6%0M04Q) M1TXZ(&-E;G1E6QE/3-$)U1%6%0M04Q)1TXZ(&-E;G1E6QE/3-$)U1%6%0M04Q)1TXZ(&-E;G1E6QE/3-$)U1%6%0M04Q)1TXZ(&-E;G1E6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M M4U193$4Z(&YO6QE/3-$)U1%6%0M04Q)1TXZ M(&QE9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)U1%6%0M M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO M6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U19 M3$4Z(&YO6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO M6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/ M3E0M4U193$4Z(&YO6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!& M3TY4+5-464Q%.B!N;W)M86P[(%!!1$1)3D#L@1D].5"U& M04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@0D%#2T=23U5.1#H@(V-C9F9C8SL@ M0T],3U(Z(",P,#`P,#`[($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q) M1TXZ(&)O='1O;3L@1D].5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q,B4^(#QD M:78^,2XP,#PO9&EV/B`\+W1D/B`\=&0@6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z M(&YO&5R8VES960\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q) M1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA M;CL@0D%#2T=23U5.1#H@(V9F9F9F9CL@1D].5"U325I%.B`Q,'!T.R!615)4 M24-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS M1#$R)3X@/&1I=CXM/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%, M24=..B!L969T.R!&3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!4 M:6UE6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,7!X('-O;&ED.R!4 M15A4+4%,24=..B!L969T.R!&3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%- M24Q9.B!4:6UE6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,7!X('-O M;&ED.R!415A4+4%,24=..B!R:6=H=#L@1D].5"U35%E,13H@;F]R;6%L.R!0 M041$24Y'+5))1TA4.B`U<'@[($9/3E0M1D%-24Q9.B!4:6UE6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M M4U193$4Z(&YO6QE/3-$)T)/4D1%4BU"3U14 M3TTZ(",P,#`P,#`@,W!X(&1O=6)L93L@5$585"U!3$E'3CH@;&5F=#L@1D]. M5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N M.R!"04-+1U)/54Y$.B`C8V-F9F-C.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1) M0T%,+4%,24=..B!M:61D;&4[($)/4D1%4BU43U`Z(",P,#`P,#`@,7!X('-O M;&ED.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$E/B`\9&EV/B8C,38P M.SPO9&EV/B`\+W1D/B`\=&0@"!D M;W5B;&4[(%1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO"!S;VQI9#L@1D].5"U714E'2%0Z M(#0P,"<@=VED=&@],T0Q)3X@/&1I=CXD/"]D:78^(#PO=&0^(#QT9"!S='EL M93TS1"="3U)$15(M0D]45$]-.B`C,#`P,#`P(#-P>"!D;W5B;&4[(%1%6%0M M04Q)1TXZ(')I9VAT.R!&3TY4+5-464Q%.B!N;W)M86P[(%!!1$1)3D#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@0D%#2T=2 M3U5.1#H@(V-C9F9C8SL@0T],3U(Z(",P,#`P,#`[($9/3E0M4TE:13H@,3!P M=#L@5D525$E#04PM04Q)1TXZ(&)O='1O;3L@0D]21$52+51/4#H@(S`P,#`P M,"`Q<'@@6QE/3-$)U1%6%0M04Q)1TXZ M(&QE9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)T)/4D1%4BU"3U143TTZ M(",P,#`P,#`@,W!X(&1O=6)L93L@5$585"U!3$E'3CH@;&5F=#L@1D].5"U3 M5%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!" M04-+1U)/54Y$.B`C9F9F9F9F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%, M+4%,24=..B!M:61D;&4[($)/4D1%4BU43U`Z(",P,#`P,#`@,W!X(&1O=6)L M93L@1D].5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q)3X@/&1I=CXF(S$V,#L\ M+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P M,#`@,W!X(&1O=6)L93L@5$585"U!3$E'3CH@6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,W!X(&1O M=6)L93L@5$585"U!3$E'3CH@;&5F=#L@1D].5"U35%E,13H@;F]R;6%L.R!& M3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!"04-+1U)/54Y$.B`C9F9F M9F9F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[ M($)/4D1%4BU43U`Z(",P,#`P,#`@,W!X(&1O=6)L93L@1D].5"U714E'2%0Z M(#0P,"<@=VED=&@],T0Q)3X@/&1I=CXD/"]D:78^(#PO=&0^(#QT9"!S='EL M93TS1"="3U)$15(M0D]45$]-.B`C,#`P,#`P(#-P>"!D;W5B;&4[(%1%6%0M M04Q)1TXZ(')I9VAT.R!&3TY4+5-464Q%.B!N;W)M86P[(%!!1$1)3D#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@0D%#2T=2 M3U5.1#H@(V9F9F9F9CL@0T],3U(Z(",P,#`P,#`[($9/3E0M4TE:13H@,3!P M=#L@5D525$E#04PM04Q)1TXZ(&)O='1O;3L@0D]21$52+51/4#H@(S`P,#`P M,"`S<'@@9&]U8FQE.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$R)3X@ M/&1I=CXQ+C`P/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=. M.B!L969T.R!&3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!4:6UE M6QE/3-$)W=I9'1H.C$P M,"4[('1A8FQE+6QA>6]U=#IF:7AE9#LG(&-E;&QS<&%C:6YG/3-$,"!C96QL M<&%D9&EN9STS1#`^/'1R/CQT9#X\+W1D/CPO='(^/"]T86)L93X\6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I M;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[34%21TE..B`P<'0@,'!X M.R!&3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E#IA=71O.R!72414 M2#H@.#4E.R!"3U)$15(M0T],3$%04T4Z(&-O;&QA<'-E.R!&3TY4+5-)6D4Z M(#$P<'0[($]615)&3$]7.B!V:7-I8FQE.R!"3U)$15(M5$]0.B`C.65B-F-E M(#!P>"!S;VQI9#L@0D]21$52+5))1TA4.B`C.65B-F-E(#!P>"!S;VQI9"<@ M8V5L;'-P86-I;F<],T0P(&-E;&QP861D:6YG/3-$,"!A;&EG;CTS1&-E;G1E M6QE/3-$ M)U1%6%0M04Q)1TXZ(&-E;G1E6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT M.R!&3TY4+5-464Q%.B!N;W)M86P[(%!!1$1)3D#L@1D]. M5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@0D%#2T=23U5.1#H@(V-C9F9C M8SL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!& M3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$R)3X@/&1I=CXT+#`P,"PP,#`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`\+V1I=CX@/&1I=B!S='EL93TS1"=#3$5!4CIB;W1H M.R!&3TY4+49!34E,63I4:6UE#L@1D].5#H@,3!P="!4:6UE'!I6QE/3-$)T9/3E0M1D%-24Q9.B`G M5&EM97,@3F5W(%)O;6%N)RPG6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W M(%)O;6%N)SL@1D].5"U325I%.B`Q,'!T)SX\9F]N="!S='EL93TS1"=&3TY4 M+5-)6D4Z(#$P<'0G/CPO9F]N=#X\+V9O;G0^(#QD:78@6QE M/3-$)T9/3E0M4TE:13H@,3!P="<^/&9O;G0@'!I&5D.R<@8V5L;'-P86-I;F<],T0P(&-E;&QP M861D:6YG/3-$,#X\='(^/'1D/CPO=&0^/"]T7!E.B!T97AT M+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^ M#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT M/3-$)W1E>'0O:'1M;#L@8VAA'0^)SQS<&%N/CPO6QE/3-$)TU!4D=)3CH@,'!T(#!P M>#L@1D].5#H@,3!P="!4:6UE6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S M($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[34%21TE..B`P<'0@,'!X.R!& M3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E&-E<'0@<&5R('-H87)E(&1A=&$I.CPO M9&EV/B`\9&EV('-T>6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I M;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[34%21TE..B`P<'0@,'!X M(#!P="`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`Q M,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@-#`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`P<'0@,'!X(#!P="`P+C(U:6X[($9/3E0Z(#$P<'0@5&EM M97,@3F5W(%)O;6%N+"!4:6UE"!S;VQI9#L@34%21TE..B`P:6X@,&EN(#!I;B`P+C(U:6X[ M(%=)1%1(.B`W-24[($)/4D1%4BU#3TQ,05!313H@8V]L;&%P"!S;VQI9#L@ M0D]21$52+5))1TA4.B`C.65B-F-E(#!P>"!S;VQI9"<@8V5L;'-P86-I;F<] M,T0P(&-E;&QP861D:6YG/3-$,"!A;&EG;CTS1&QE9G0^(#QT6QE/3-$)U1%6%0M04Q)1TXZ(&-E;G1E6QE M/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,7!X('-O;&ED.R!415A4+4%, M24=..B!C96YT97([($9/3E0M4U193$4Z(&YO"!S;VQI9#L@1D].5"U714E'2%0Z M(#6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,7!X('-O;&ED.R!4 M15A4+4%,24=..B!C96YT97([($9/3E0M4U193$4Z(&YO"!S M;VQI9#L@1D].5"U714E'2%0Z(#6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U19 M3$4Z(&YO"!S;VQI9#L@1D].5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q,B4^(#QD M:78^-#0X/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!L M969T.R!&3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!4:6UE6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!&3TY4+5-464Q%.B!N;W)M86P[ M(%!!1$1)3D#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2 M;VUA;CL@0D%#2T=23U5.1#H@(V9F9F9F9CL@0T],3U(Z(",P,#`P,#`[($9/ M3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O='1O;3L@1D].5"U7 M14E'2%0Z(#0P,"<@=VED=&@],T0Q,B4^(#QD:78^,S`U+#8T.#PO9&EV/B`\ M+W1D/B`\=&0@6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!&3TY4+5-464Q%.B!N;W)M86P[ M(%!!1$1)3D#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2 M;VUA;CL@0D%#2T=23U5.1#H@(V9F9F9F9CL@0T],3U(Z(",P,#`P,#`[($9/ M3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O='1O;3L@1D].5"U7 M14E'2%0Z(#0P,"<@=VED=&@],T0Q,B4^(#QD:78^,S`U+#8T.#PO9&EV/B`\ M+W1D/B`\=&0@6QE/3-$ M)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO6QE M/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)U1% M6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M M4U193$4Z(&YO6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/ M3E0M4U193$4Z(&YO6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!&3TY4+5-464Q% M.B!N;W)M86P[(%!!1$1)3D#L@1D].5"U&04U)3%DZ(%1I M;65S($YE=R!2;VUA;CL@0D%#2T=23U5.1#H@(V9F9F9F9CL@0T],3U(Z(",P M,#`P,#`[($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O='1O M;3L@1D].5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q,B4^(#QD:78^,2PP,#`L M,#`P/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!L969T M.R!&3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!4:6UE6QE M/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!&3TY4+5-464Q%.B!N;W)M86P[(%!! M1$1)3D#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA M;CL@0D%#2T=23U5.1#H@(V-C9F9C8SL@0T],3U(Z(",P,#`P,#`[($9/3E0M M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O='1O;3L@1D].5"U714E' M2%0Z(#0P,"<@=VED=&@],T0Q,B4^(#QD:78^-#@R+#8R-3PO9&EV/B`\+W1D M/B`\=&0@6QE M/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!&3TY4+5-464Q%.B!N;W)M86P[(%!! M1$1)3D#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA M;CL@0D%#2T=23U5.1#H@(V-C9F9C8SL@0T],3U(Z(",P,#`P,#`[($9/3E0M M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O='1O;3L@1D].5"U714E' M2%0Z(#0P,"<@=VED=&@],T0Q,B4^(#QD:78^+3PO9&EV/B`\+W1D/B`\=&0@ M6QE/3-$)U1%6%0M04Q) M1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!&3TY4+5-464Q%.B!N;W)M86P[ M(%!!1$1)3D#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2 M;VUA;CL@0D%#2T=23U5.1#H@(V9F9F9F9CL@0T],3U(Z(",P,#`P,#`[($9/ M3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O='1O;3L@1D].5"U7 M14E'2%0Z(#0P,"<@=VED=&@],T0Q,B4^(#QD:78^,3(R+#4P,#PO9&EV/B`\ M+W1D/B`\=&0@6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!&3TY4+5-464Q%.B!N;W)M86P[ M(%!!1$1)3D#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2 M;VUA;CL@0D%#2T=23U5.1#H@(V9F9F9F9CL@0T],3U(Z(",P,#`P,#`[($9/ M3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O='1O;3L@1D].5"U7 M14E'2%0Z(#0P,"<@=VED=&@],T0Q,B4^(#QD:78^,C8W+#,U,#PO9&EV/B`\ M+W1D/B`\=&0@6QE/3-$ M)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO6QE/3-$ M)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)U1%6%0M04Q)1TXZ(&QE M9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)U1%6%0M04Q)1TXZ(&QE M9G0[($9/3E0M4U193$4Z(&YO6QE/3-$ M)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO6QE/3-$ M)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO6QE/3-$ M)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[ M($9/3E0M4U193$4Z(&YO6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[ M($9/3E0M4U193$4Z(&YO6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[ M($9/3E0M4U193$4Z(&YO&5D.R<@8V5L;'-P86-I;F<],T0P M(&-E;&QP861D:6YG/3-$,#X\='(^/'1D/CPO=&0^/"]T7!E M.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@ M/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C M;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA"!$:7-C;&]S=7)E(%M!8G-T"!!#L@1D].5#H@,3!P="!4:6UE#L@1D].5#H@,3!P="!4:6UE6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2 M;VUA;CM&3TY4+5-)6D4Z(#$P<'0[5$585"U!3$E'3CI,969T.R!415A4+4E. M1$5.5#H@,&EN.R!724142#H@,3`P)2<^(#QT86)L92!S='EL93TS1"="3U)$ M15(M0D]45$]-.B`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`P,#`[($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM M04Q)1TXZ(&)O='1O;3L@1D].5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q,"4^ M(#QD:78^,3@L.#$V/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%, M24=..B!L969T.R!&3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!4 M:6UE6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!&3TY4 M+5-464Q%.B!N;W)M86P[(%!!1$1)3D#L@1D].5"U&04U) M3%DZ(%1I;65S($YE=R!2;VUA;CL@0D%#2T=23U5.1#H@(V-C9F9C8SL@0T], M3U(Z(",P,#`P,#`[($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ M(&)O='1O;3L@1D].5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q,"4^(#QD:78^ M,3DL-3(Y/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!L M969T.R!&3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!4:6UE6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!&3TY4+5-464Q% M.B!N;W)M86P[(%!!1$1)3D#L@1D].5"U&04U)3%DZ(%1I M;65S($YE=R!2;VUA;CL@0D%#2T=23U5.1#H@(V9F9F9F9CL@0T],3U(Z(",P M,#`P,#`[($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O='1O M;3L@1D].5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q,"4^(#QD:78^,C(S/"]D M:78^(#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!L969T.R!&3TY4 M+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!4:6UE6QE/3-$)U1%6%0M M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U19 M3$4Z(&YO#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@ M0D%#2T=23U5.1#H@(V-C9F9C8SL@1D].5"U325I%.B`Q,'!T.R!615)424-! M3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#4U M)3X@/&1I=CY";V]K+W1A>"!D:69F97)E;F-E6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/ M3E0M4U193$4Z(&YO6QE/3-$)U1%6%0M04Q) M1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)U1% M6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)T)/4D1%4BU"3U14 M3TTZ(",P,#`P,#`@,7!X('-O;&ED.R!415A4+4%,24=..B!L969T.R!&3TY4 M+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!4:6UE6QE/3-$)T)/4D1% M4BU"3U143TTZ(",P,#`P,#`@,7!X('-O;&ED.R!415A4+4%,24=..B!R:6=H M=#L@1D].5"U35%E,13H@;F]R;6%L.R!0041$24Y'+5))1TA4.B`U<'@[($9/ M3E0M1D%-24Q9.B!4:6UE6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@0D%#2T=23U5. M1#H@(V-C9F9C8SL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@ M8F]T=&]M.R!&3TY4+5=%24=(5#H@-#`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`P,#`[($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ M(&)O='1O;3L@0D]21$52+51/4#H@(S`P,#`P,"`Q<'@@6QE/3-$ M)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)T)/4D1%4BU"3U143TTZ(",P M,#`P,#`@,7!X('-O;&ED.R!415A4+4%,24=..B!L969T.R!&3TY4+5-464Q% M.B!N;W)M86P[($9/3E0M1D%-24Q9.B!4:6UE6QE/3-$)T)/4D1%4BU"3U14 M3TTZ(",P,#`P,#`@,7!X('-O;&ED.R!415A4+4%,24=..B!R:6=H=#L@1D]. M5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N M.R!"04-+1U)/54Y$.B`C9F9F9F9F.R!#3TQ/4CH@(S`P,#`P,#L@1D].5"U3 M25I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=( M5#H@-#`P)R!W:61T:#TS1#$P)3X@/&1I=CXH,C`L-#,Y*3PO9&EV/B`\+W1D M/B`\=&0@6QE/3-$)U1% M6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z M(&YO6QE/3-$)T)/4D1%4BU" M3U143TTZ(",P,#`P,#`@,W!X(&1O=6)L93L@5$585"U!3$E'3CH@"!S;VQI9#L@ M1D].5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q,"4^(#QD:78^+3PO9&EV/B`\ M+W1D/B`\=&0@"!D;W5B;&4[(%1%6%0M04Q)1TXZ(&QE9G0[($9/ M3E0M4U193$4Z(&YO6QE/3-$)W=I9'1H.C$P,"4[('1A8FQE+6QA>6]U=#IF:7AE9#LG(&-E M;&QS<&%C:6YG/3-$,"!C96QL<&%D9&EN9STS1#`^/'1R/CQT9#X\+W1D/CPO M='(^/"]T86)L93X\"!%>'!E;G-E("A"96YE9FET*3PO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^)SQD:78@6EN9R!S=&%T96UE;G0@;V8@;W!E2!R871E(&]F(#QF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B`G M5&EM97,@3F5W(%)O;6%N)RPG6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)RPG M"!L;W-S(&ES(&%S(&9O;&QO=W,@*&%M M;W5N=',@:6X@=&AO=7-A;F1S*3H\+V1I=CX@/&1I=B!S='EL93TS1"=#3$5! M4CIB;W1H.R!&3TY4+49!34E,63I4:6UE#L@1D].5#H@,3!P="!4:6UE6QE M/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM& M3TY4+5-)6D4Z(#$P<'0[5$585"U!3$E'3CI,969T.R!415A4+4E.1$5.5#H@ M,&EN.R!724142#H@,3`P)2<^(#QT86)L92!S='EL93TS1"=-05)'24XZ(#!I M;CL@5TE$5$@Z(#DU)3L@0D]21$52+4-/3$Q!4%-%.B!C;VQL87!S93L@3U9% M4D9,3U6QE/3-$)U1%6%0M04Q)1TXZ M(&-E;G1E"!S;VQI9#L@5$585"U!3$E'3CH@8V5N=&5R.R!&3TY4 M+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!4:6UE6QE/3-$)T)/4D1%4BU"3U143TTZ(",P M,#`P,#`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`P,#`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`Q,'!T.R!6 M15)424-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T M:#TS1#$P)3X@/&1I=CXR,3PO9&EV/B`\+W1D/B`\=&0@#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@0D%#2T=2 M3U5.1#H@(V9F9F9F9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E' M3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$E/B`\9&EV M/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@#L@ M1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@0D%#2T=23U5.1#H@(V9F M9F9F9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@;6ED9&QE M.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$E/B`\9&EV/B8C,38P.SPO M9&EV/B`\+W1D/B`\=&0@6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO M6QE/3-$)T)/4D1%4BU"3U143TTZ(",P M,#`P,#`@,7!X('-O;&ED.R!415A4+4%,24=..B!L969T.R!&3TY4+5-464Q% M.B!N;W)M86P[($9/3E0M1D%-24Q9.B!4:6UE6QE/3-$)T)/4D1%4BU"3U14 M3TTZ(",P,#`P,#`@,7!X('-O;&ED.R!415A4+4%,24=..B!R:6=H=#L@1D]. M5"U35%E,13H@;F]R;6%L.R!0041$24Y'+5))1TA4.B`S<'@[($9/3E0M1D%- M24Q9.B!4:6UE6QE M/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,7!X('-O;&ED.R!415A4+4%, M24=..B!L969T.R!&3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!4 M:6UE6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,7!X('-O;&ED.R!4 M15A4+4%,24=..B!R:6=H=#L@1D].5"U35%E,13H@;F]R;6%L.R!0041$24Y' M+5))1TA4.B`S<'@[($9/3E0M1D%-24Q9.B!4:6UE6QE/3-$)U1%6%0M04Q)1TXZ M(&QE9G0[($9/3E0M4U193$4Z(&YO"!S;VQI9#L@5$585"U!3$E'3CH@;&5F=#L@ M1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O M;6%N.R!"04-+1U)/54Y$.B`C8V-F9F-C.R!&3TY4+5-)6D4Z(#$P<'0[(%9% M4E1)0T%,+4%,24=..B!M:61D;&4[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H M/3-$,24^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=" M3U)$15(M0D]45$]-.B`C,#`P,#`P(#%P>"!S;VQI9#L@5$585"U!3$E'3CH@ M"!D;W5B;&4[(%1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO M"!S;VQI9#L@1D].5"U7 M14E'2%0Z(#0P,"<@=VED=&@],T0Q)3X@/&1I=CXD/"]D:78^(#PO=&0^(#QT M9"!S='EL93TS1"="3U)$15(M0D]45$]-.B`C,#`P,#`P(#-P>"!D;W5B;&4[ M(%1%6%0M04Q)1TXZ(')I9VAT.R!&3TY4+5-464Q%.B!N;W)M86P[(%!!1$1) M3D#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@ M0D%#2T=23U5.1#H@(V9F9F9F9CL@0T],3U(Z(",P,#`P,#`[($9/3E0M4TE: M13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O='1O;3L@0D]21$52+51/4#H@ M(S`P,#`P,"`Q<'@@6QE/3-$)U1%6%0M04Q) M1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@0D%#2T=23U5. M1#H@(V9F9F9F9CL@0T],3U(Z(",P,#`P,#`[($9/3E0M4TE:13H@,3!P=#L@ M5D525$E#04PM04Q)1TXZ(&)O='1O;3L@0D]21$52+51/4#H@(S`P,#`P,"`Q M<'@@6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[ M($9/3E0M4U193$4Z(&YO"!S;VQI9#L@1D].5"U714E'2%0Z(#0P,"<@ M=VED=&@],T0Q)3X@/&1I=CXD/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=" M3U)$15(M0D]45$]-.B`C,#`P,#`P(#-P>"!D;W5B;&4[(%1%6%0M04Q)1TXZ M(')I9VAT.R!&3TY4+5-464Q%.B!N;W)M86P[(%!!1$1)3D#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@0D%#2T=23U5.1#H@ M(V9F9F9F9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T M=&]M.R!"3U)$15(M5$]0.B`C,#`P,#`P(#%P>"!S;VQI9#L@1D].5"U714E' M2%0Z(#0P,"<@=VED=&@],T0Q,"4^(#QD:78^+3PO9&EV/B`\+W1D/B`\=&0@ M"!D;W5B;&4[(%1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z M(&YO"!S;VQI9#L@1D]. M5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q)3X@/&1I=CXF(S$V,#L\+V1I=CX@ M/"]T9#X@/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,W!X M(&1O=6)L93L@5$585"U!3$E'3CH@"!S;VQI9#L@1D].5"U714E'2%0Z(#0P,"<@ M=VED=&@],T0Q,"4^(#QD:78^+3PO9&EV/B`\+W1D/B`\=&0@6QE/3-$)T-,14%2.F)O=&@[($9/3E0M M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0G/CPO9&EV M/B`\9&EV('-T>6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S M($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0G/CPO9&EV/B`\9&EV('-T>6QE M/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM& M3TY4+5-)6D4Z(#$P<'0G/CPO9&EV/B`\+V1I=CX@/"]D:78^/'1A8FQE(&)O M&5D.R<@8V5L;'-P86-I;F<],T0P(&-E;&QP861D:6YG/3-$,#X\='(^/'1D M/CPO=&0^/"]T7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S M+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE M<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA M'0^)SQD:78@3Y&=71U#L@1D].5#H@ M,3!P="!4:6UE6QE/3-$)T-,14%2.F)O=&@[ M($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0G M(&%L:6=N/3-$;&5F=#X@/&1I=B!S='EL93TS1"=#3$5!4CIB;W1H.R!&3TY4 M+49!34E,63I4:6UE6QE/3-$)U1%6%0M04Q)1TXZ(&-E;G1E6QE/3-$)U1%6%0M04Q) M1TXZ(&-E;G1E6QE/3-$)U1%6%0M04Q)1TXZ(&-E;G1E6QE/3-$)U1%6%0M04Q)1TXZ(&-E;G1E"!S;VQI9#L@1D].5"U714E'2%0Z(#0P,"<@=VED=&@],T0X-24^ M(#QD:78^,C`Q-#PO9&EV/B`\+W1D/B`\=&0@6QE/3-$ M)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)U1%6%0M04Q)1TXZ(&-E;G1E6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M M4U193$4Z(&YO6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!&3TY4+5-464Q%.B!N;W)M M86P[(%!!1$1)3D#L@1D].5"U&04U)3%DZ(%1I;65S($YE M=R!2;VUA;CL@0D%#2T=23U5.1#H@(V-C9F9C8SL@0T],3U(Z(",P,#`P,#`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`P)2<^(#QT86)L M92!S='EL93TS1"="3U)$15(M0D]45$]-.B`C.65B-F-E(#!P>"!S;VQI9#L@ M0D]21$52+4Q%1E0Z(",Y96(V8V4@,'!X('-O;&ED.R!-05)'24XZ(#!I;CL@ M5TE$5$@Z(#$P,"4[($)/4D1%4BU#3TQ,05!313H@8V]L;&%P"!S;VQI9#L@ M0D]21$52+5))1TA4.B`C.65B-F-E(#!P>"!S;VQI9"<@8V5L;'-P86-I;F<] M,T0P(&-E;&QP861D:6YG/3-$,"!A;&EG;CTS1&QE9G0^(#QT6QE/3-$)U1%6%0M04Q)1TXZ(&-E;G1E6QE M/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,7!X('-O;&ED.R!415A4+4%, M24=..B!C96YT97([($9/3E0M4U193$4Z(&YO6QE/3-$)U1%6%0M04Q)1TXZ(&-E;G1E"!S;VQI9#L@5$585"U!3$E'3CH@8V5N=&5R.R!&3TY4+5-464Q%.B!N M;W)M86P[($9/3E0M1D%-24Q9.B!4:6UE"!S;VQI9#L@1D].5"U714E'2%0Z(#6QE/3-$)T)/ M4D1%4BU"3U143TTZ(",P,#`P,#`@,7!X('-O;&ED.R!415A4+4%,24=..B!C M96YT97([($9/3E0M4U193$4Z(&YO"!S;VQI9#L@1D].5"U7 M14E'2%0Z(#"!S;VQI9#L@5$585"U!3$E'3CH@8V5N=&5R.R!& M3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!4:6UE"!S;VQI9#L@1D].5"U7 M14E'2%0Z(#"!S M;VQI9#L@1D].5"U714E'2%0Z(#"!S;VQI9#L@1D].5"U714E'2%0Z(#"!S;VQI9#L@1D].5"U714E'2%0Z(#

6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!&3TY4 M+5-464Q%.B!N;W)M86P[(%!!1$1)3D#L@1D].5"U&04U) M3%DZ(%1I;65S($YE=R!2;VUA;CL@0D%#2T=23U5.1#H@(V-C9F9C8SL@1D]. M5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=% M24=(5#H@-#`P)R!W:61T:#TS1#$P)3X@/&1I=CXS-S$\+V1I=CX@/"]T9#X@ M/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO M6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/ M3E0M4U193$4Z(&YO6QE/3-$)U1%6%0M04Q) M1TXZ(')I9VAT.R!&3TY4+5-464Q%.B!N;W)M86P[(%!!1$1)3D#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@0D%#2T=23U5. M1#H@(V-C9F9C8SL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@ M8F]T=&]M.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$P)3X@/&1I=CXT M-S8\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[ M($9/3E0M4U193$4Z(&YO6QE/3-$)U1%6%0M04Q)1TXZ(')I M9VAT.R!&3TY4+5-464Q%.B!N;W)M86P[(%!!1$1)3D#L@ M1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@0D%#2T=23U5.1#H@(V9F M9F9F9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M M.R!&3TY4+5=%24=(5#H@-#`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`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M M.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$P)3X@/&1I=CXQ+#0U,BPU M-#@\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[ M($9/3E0M4U193$4Z(&YO3X\6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%- M24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[5$585"U!3$E' M3CI,969T.R!415A4+4E.1$5.5#H@,&EN.R!724142#H@,3`P)2<^(#QT86)L M92!S='EL93TS1"="3U)$15(M0D]45$]-.B`C.65B-F-E(#!P>"!S;VQI9#L@ M0D]21$52+4Q%1E0Z(",Y96(V8V4@,'!X('-O;&ED.R!-05)'24XZ(#!I;CL@ M5TE$5$@Z(#$P,"4[($)/4D1%4BU#3TQ,05!313H@8V]L;&%P"!S;VQI9#L@ M0D]21$52+5))1TA4.B`C.65B-F-E(#!P>"!S;VQI9"<@8V5L;'-P86-I;F<] M,T0P(&-E;&QP861D:6YG/3-$,"!A;&EG;CTS1&QE9G0^(#QT6QE/3-$)U1%6%0M04Q)1TXZ(&-E;G1E6QE M/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,7!X('-O;&ED.R!415A4+4%, M24=..B!C96YT97([($9/3E0M4U193$4Z(&YO6QE/3-$)U1%6%0M04Q)1TXZ(&-E;G1E"!S;VQI9#L@5$585"U!3$E'3CH@8V5N=&5R.R!&3TY4+5-464Q%.B!N M;W)M86P[($9/3E0M1D%-24Q9.B!4:6UE"!S;VQI9#L@1D].5"U714E'2%0Z(#6QE/3-$)T)/ M4D1%4BU"3U143TTZ(",P,#`P,#`@,7!X('-O;&ED.R!415A4+4%,24=..B!C M96YT97([($9/3E0M4U193$4Z(&YO"!S;VQI9#L@1D].5"U7 M14E'2%0Z(#"!S;VQI9#L@5$585"U!3$E'3CH@8V5N=&5R.R!& M3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!4:6UE"!S;VQI9#L@1D].5"U7 M14E'2%0Z(#"!S M;VQI9#L@1D].5"U714E'2%0Z(#"!S;VQI9#L@1D].5"U714E'2%0Z(#"!S;VQI9#L@1D].5"U714E'2%0Z(#

6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!&3TY4 M+5-464Q%.B!N;W)M86P[(%!!1$1)3D#L@1D].5"U&04U) M3%DZ(%1I;65S($YE=R!2;VUA;CL@0D%#2T=23U5.1#H@(V-C9F9C8SL@1D]. M5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=% M24=(5#H@-#`P)R!W:61T:#TS1#$P)3X@/&1I=CXX,CD\+V1I=CX@/"]T9#X@ M/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO M6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!&3TY4+5-4 M64Q%.B!N;W)M86P[(%!!1$1)3D#L@1D].5"U&04U)3%DZ M(%1I;65S($YE=R!2;VUA;CL@0D%#2T=23U5.1#H@(V-C9F9C8SL@1D].5"U3 M25I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=( M5#H@-#`P)R!W:61T:#TS1#$P)3X@/&1I=CXS-S`\+V1I=CX@/"]T9#X@/'1D M('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO M6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z M(&YO6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!&3TY4+5-464Q%.B!N M;W)M86P[(%!!1$1)3D#L@1D].5"U&04U)3%DZ(%1I;65S M($YE=R!2;VUA;CL@0D%#2T=23U5.1#H@(V9F9F9F9CL@1D].5"U325I%.B`Q M,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@-#`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`Q,'!T.R!615)424-! M3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$P M)3X@/&1I=CXQ+#0U,2PQ-#`\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)U1% M6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)T-,14%2.F)O=&@[($9/ M3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0G/CPO M9&EV/B`\+V1I=CX@/"]D:78^/'1A8FQE(&)O&5D.R<@8V5L;'-P86-I;F<] M,T0P(&-E;&QP861D:6YG/3-$,#X\='(^/'1D/CPO=&0^/"]T7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X- M"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP M92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA#L@1D].5#H@,3!P="!4:6UE6QE M/3-$)T)/4D1%4BU"3U143TTZ(",Y96(V8V4@,'!X('-O;&ED.R!"3U)$15(M M3$5&5#H@(SEE8C9C92`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`Q,'!T.R!615)424-!3"U! M3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$R)3X@ M/&1I=CXR+#6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U19 M3$4Z(&YO"!S;VQI9#L@5$585"U!3$E'3CH@;&5F=#L@1D].5"U35%E,13H@;F]R M;6%L.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!"04-+1U)/54Y$ M.B`C8V-F9F-C.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B M;W1T;VT[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$,24^(#QD:78^)B,Q M-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B`C M,#`P,#`P(#%P>"!S;VQI9#L@5$585"U!3$E'3CH@6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO#L@1D].5"U&04U)3%DZ M(%1I;65S($YE=R!2;VUA;CL@0D%#2T=23U5.1#H@(V-C9F9C8SL@1D].5"U3 M25I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=( M5#H@-#`P)R!W:61T:#TS1#$R)3X@/&1I=CXQ,CPO9&EV/B`\+W1D/B`\=&0@ M6QE/3-$)U1%6%0M04Q) M1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO"!D;W5B;&4[(%1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M M4U193$4Z(&YO"!S;VQI M9#L@1D].5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q)3X@/&1I=CXD/"]D:78^ M(#PO=&0^(#QT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B`C,#`P,#`P(#-P M>"!D;W5B;&4[(%1%6%0M04Q)1TXZ(')I9VAT.R!&3TY4+5-464Q%.B!N;W)M M86P[(%!!1$1)3D#L@1D].5"U&04U)3%DZ(%1I;65S($YE M=R!2;VUA;CL@0D%#2T=23U5.1#H@(V9F9F9F9CL@1D].5"U325I%.B`Q,'!T M.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!"3U)$15(M5$]0.B`C,#`P,#`P M(#%P>"!S;VQI9#L@1D].5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q,B4^(#QD M:78^,2PV,S`\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ M(&QE9G0[($9/3E0M4U193$4Z(&YO"!D;W5B;&4[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$,3(E/B`\ M9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@"!D;W5B;&4[($9/3E0M M5T5)1TA4.B`T,#`G('=I9'1H/3-$,3(E/B`\9&EV/B8C,38P.SPO9&EV/B`\ M+W1D/B`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`Q,'!T.R!615)424-!3"U!3$E' M3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$R)3X@/&1I M=CXM/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!L969T M.R!&3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!4:6UE6QE/3-$ M)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,7!X('-O;&ED.R!415A4+4%,24=. M.B!L969T.R!&3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!4:6UE M6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,7!X('-O;&ED.R!415A4 M+4%,24=..B!R:6=H=#L@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E, M63H@5&EM97,@3F5W(%)O;6%N.R!"04-+1U)/54Y$.B`C9F9F9F9F.R!&3TY4 M+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($9/3E0M5T5) M1TA4.B`T,#`G('=I9'1H/3-$,3(E/B`\9&EV/B@V*3PO9&EV/B`\+W1D/B`\ M=&0@6QE/3-$)U1%6%0M M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO"!D;W5B;&4[(%1%6%0M04Q)1TXZ M(&QE9G0[($9/3E0M4U193$4Z(&YO"!S;VQI9#L@1D].5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q)3X@ M/&1I=CXD/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"="3U)$15(M0D]45$]- M.B`C,#`P,#`P(#-P>"!D;W5B;&4[(%1%6%0M04Q)1TXZ(')I9VAT.R!&3TY4 M+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!4:6UE6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[ M($9/3E0M4U193$4Z(&YO"!D;W5B;&4[($9/3E0M5T5)1TA4 M.B`T,#`G('=I9'1H/3-$,3(E/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\ M=&0@"!D;W5B;&4[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$,3(E M/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M M4U193$4Z(&YO6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U19 M3$4Z(&YO6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO6QE/3-$ M)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)U1%6%0M M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!&3TY4+5-464Q%.B!N;W)M86P[ M(%!!1$1)3D#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2 M;VUA;CL@0D%#2T=23U5.1#H@(V9F9F9F9CL@1D].5"U325I%.B`Q,'!T.R!6 M15)424-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T M:#TS1#$R)3X@/&1I=CXQ+#6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[ M($9/3E0M4U193$4Z(&YO6QE M/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!&3TY4+5-464Q%.B!N;W)M86P[(%!! M1$1)3D#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA M;CL@0D%#2T=23U5.1#H@(V-C9F9C8SL@1D].5"U325I%.B`Q,'!T.R!615)4 M24-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS M1#$R)3X@/&1I=CXU,#D\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)T)/ M4D1%4BU"3U143TTZ(",P,#`P,#`@,7!X('-O;&ED.R!415A4+4%,24=..B!L M969T.R!&3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!4:6UE6QE M/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,7!X('-O;&ED.R!415A4+4%, M24=..B!R:6=H=#L@1D].5"U35%E,13H@;F]R;6%L.R!0041$24Y'+5))1TA4 M.B`U<'@[($9/3E0M1D%-24Q9.B!4:6UE"!S;VQI9#L@5$585"U!3$E'3CH@ M;&5F=#L@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@5&EM97,@ M3F5W(%)O;6%N.R!"04-+1U)/54Y$.B`C9F9F9F9F.R!&3TY4+5-)6D4Z(#$P M<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($9/3E0M5T5)1TA4.B`T,#`G M('=I9'1H/3-$,24^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL M93TS1"="3U)$15(M0D]45$]-.B`C,#`P,#`P(#%P>"!S;VQI9#L@5$585"U! M3$E'3CH@6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[ M($9/3E0M4U193$4Z(&YO6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,W!X(&1O=6)L93L@5$58 M5"U!3$E'3CH@;&5F=#L@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E, M63H@5&EM97,@3F5W(%)O;6%N.R!"04-+1U)/54Y$.B`C8V-F9F-C.R!&3TY4 M+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($)/4D1%4BU4 M3U`Z(",P,#`P,#`@,7!X('-O;&ED.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T M:#TS1#$E/B`\9&EV/B0\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)T)/4D1% M4BU"3U143TTZ(",P,#`P,#`@,W!X(&1O=6)L93L@5$585"U!3$E'3CH@"!S;VQI M9#L@1D].5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q,B4^(#QD:78^,RPX.#(\ M+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/ M3E0M4U193$4Z(&YO6QE/3-$ M)W=I9'1H.C$P,"4[('1A8FQE+6QA>6]U=#IF:7AE9#LG(&-E;&QS<&%C:6YG M/3-$,"!C96QL<&%D9&EN9STS1#`^/'1R/CQT9#X\+W1D/CPO='(^/"]T86)L M93X\'0O:F%V87-C3X-"B`@("`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`@("`@("`\=&0@8VQA'0^)SQS<&%N M/CPO2!A;F0@17%U:7!M96YT(%M-96UB97)=/"]T M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^)SQS<&%N/CPO2P@4&QA;G0@ M86YD($5Q=6EP;65N="P@57-E9G5L($QI9F4\+W1D/@T*("`@("`@("`\=&0@ M8VQA'0^)SQS<&%N/CPO2P@4&QA;G0@86YD M($5Q=6EP;65N="!;3&EN92!)=&5M'0^)S$@>65A'0^)SQS<&%N/CPO2P@4&QA;G0@86YD($5Q=6EP;65N="!; M3&EN92!)=&5M'0^)S,@>65A M'0^)SQS M<&%N/CPO2P@4&QA;G0@86YD($5Q=6EP;65N="!;3&EN92!) M=&5M'0^)S,@>65A'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO7!E.B!T97AT+VAT;6P[(&-H87)S970] M(G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T M<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@ M8VAAF5D(&%T($9A:7(@5F%L=64@*$1E=&%I;"D@*%531"`D*3QB'0^)SQS<&%N M/CPO2!A'0^)SQS<&%N/CPO M3PO=&0^#0H@("`@("`@(#QT9"!C;&%S'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA'0^)SQS<&%N/CPO6EE M;&0\+W1D/@T*("`@("`@("`\=&0@8VQA'0^)S$@>65A'0O:F%V87-C M3X-"B`@("`\=&%B;&4@ M8VQA'0^)SQS M<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S M8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I M=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA7!E/3-$=&5X="]J879A'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO M6UE;G0@87,@82!P97)C96YT86=E(&]F(&YE="!I;F-O;64\+W1D M/@T*("`@("`@("`\=&0@8VQA'0^)SQS<&%N/CPO M'0^)SQS M<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS M<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)S(P,3@\'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0O:F%V M87-C3X-"B`@("`\=&%B M;&4@8VQA'0^)SQS<&%N/CPO3PO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R=%]C M8C(Q,68U,5\W,V$Q7S1C-#9?8C!B,U]B.#@Y9#5D-C0W8F4-"D-O;G1E;G0M M3&]C871I;VXZ(&9I;&4Z+R\O0SHO8V(R,3%F-3%?-S-A,5\T8S0V7V(P8C-? M8C@X.60U9#8T-V)E+U=O'0O:'1M;#L@8VAA'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'1087)T7V-B,C$Q9C4Q7S'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA'0^)SQS<&%N/CPO3PO=&0^ M#0H@("`@("`@(#QT9"!C;&%S7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M M;#X-"B`@/&AE860^#0H@("`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`@("`@("`\=&0@8VQA7!E M.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@ M/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C M;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA'0^)SQS<&%N/CPO6UE;G0@=&5R;7,@861V86YC92!P97)C96YT86=E('!A M>6%B;&4\+W1D/@T*("`@("`@("`\=&0@8VQA6UE;G0@=&5R;7,@9G)E:6=H="!O;B!R;V%D M('!E'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO7-T96US/"]T9#X- M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N M/CPO'0^)SQS<&%N/CPO'0O:F%V M87-C3X-"B`@("`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`@("`@("`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`@("`@("`@/'1H M(&-L87-S/3-$=&@@8V]L'0^ M)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO2!\($EN:71I86P@06-C;W5N=&EN9R!/;F4\+W1D/@T*("`@ M("`@("`\=&0@8VQA'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\ M:'1M;#X-"B`@/&AE860^#0H@("`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`@("`@("`@/'1D(&-L87-S/3-$ M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^ M)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO2!P87EM96YT M('1O($Q!3D(@;VX@<')O;6ES2!N;W1E/"]T9#X-"B`@("`@("`@/'1D M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS M<&%N/CPO'0^ M)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N M/CPO'0^)SQS M<&%N/CPO'0^ M)SQS<&%N/CPO'0^)SQS M<&%N/CPO'0^ M)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS M<&%N/CPO'0^ M)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO3X-"CPO:'1M;#X-"@T*+2TM+2TM M/5].97AT4&%R=%]C8C(Q,68U,5\W,V$Q7S1C-#9?8C!B,U]B.#@Y9#5D-C0W M8F4-"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO8V(R,3%F-3%?-S-A M,5\T8S0V7V(P8C-?8C@X.60U9#8T-V)E+U=O'0O:'1M;#L@8VAA7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R6%B;&4@*$1E=&%I;"D@*%531"`D M*3QB'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA2!M86IO3X-"CPO:'1M;#X-"@T*+2TM M+2TM/5].97AT4&%R=%]C8C(Q,68U,5\W,V$Q7S1C-#9?8C!B,U]B.#@Y9#5D M-C0W8F4-"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO8V(R,3%F-3%? M-S-A,5\T8S0V7V(P8C-?8C@X.60U9#8T-V)E+U=O'0O:'1M;#L@8VAA7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R M'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO6%B;&4@0V%P:71A;"!,96%S92`M(&YO;F-U'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA2`M($%D9&ET:6]N86P@26YF;W)M871I;VX@*$1E=&%I;"D@ M*%531"`D*3QB2`S,2P@,C`Q M,SQB2`R,2P@,C`Q,CQB2!)2!)2`S,2P@,C`Q,SQB2`R.2P@,C`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`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XU,#`L,#`P+#`P,#QS M<&%N/CPO'0^ M)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO M'0^)SQS<&%N M/CPO'0^)SQS M<&%N/CPO'0^ M)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPOF5D/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XR,"PP,#`L M,#`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO M'0^)SQS<&%N M/CPO'0^)SQS M<&%N/CPO'0^ M)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO M'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO M'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO M'0^)SQS<&%N M/CPO'0^)SQS M<&%N/CPO'0^ M)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO M'0^)SQS<&%N M/CPO'0^)SQS M<&%N/CPO'0^ M)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO M'0^)SQS<&%N M/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N M/CPO'0^)SQS M<&%N/CPO'0^ M)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO M'0^)SQS<&%N M/CPO'0^)SQS M<&%N/CPO'0^ M)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO M'0^)SQS<&%N M/CPO'0^)SQS M<&%N/CPO'0^ M)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO M'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO M'0^)SQS<&%N M/CPO'0^)SQS M<&%N/CPO'0^ M)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^ M)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO M'0^)SQS<&%N M/CPO'0^)SQS M<&%N/CPO'0^ M)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO M'0^)SQS<&%N M/CPO'0^)SQS<&%N/CPO M'0^)SQS<&%N M/CPO'0^)SQS M<&%N/CPO'0^ M)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO M'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS M<&%N/CPO'0^ M)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)S(P,3,M,3(M,S$\'0^)S(P,3,M,3(M,S$\'0^)S(P,3,M,3(M,S$\'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N M/CPO'0^)SQS M<&%N/CPO'0^ M)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO M'0^)SQS<&%N M/CPO'0^)SQS M<&%N/CPO'0^ M)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS M<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO M'0^)SQS<&%N M/CPO'0^)SQS M<&%N/CPO'0^ M)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS M<&%N/CPO'0^ M)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^ M)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N M/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO M'0^)SQS<&%N M/CPO'0^)SQS M<&%N/CPO'0^ M)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO M'0^)SQS<&%N M/CPO'0^)SQS M<&%N/CPO'0^ M)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO M'0^)SQS<&%N M/CPO'0^)SQS M<&%N/CPO'0^ M)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO M'0^)SQS<&%N M/CPO'0^)SQS M<&%N/CPO'0^ M)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO M'0^)SQS<&%N M/CPO'0^)SQS M<&%N/CPO'0^ M)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO M'0^)SQS<&%N M/CPO'0^)SQS M<&%N/CPO'0^ M)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO M'0^)SQS<&%N M/CPO'0^)SQS M<&%N/CPO'0^ M)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO M'0^)SQS M<&%N/CPO'0^ M)SQS<&%N/CPO'0^)SQS<&%N/CPO M'0^)SQS<&%N M/CPO'0^)SQS M<&%N/CPO'0^ M)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO M'0^)SQS<&%N M/CPO'0^)SQS M<&%N/CPO'0^ M)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO M'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO M'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO M'0^)SQS<&%N M/CPO'0^)SQS M<&%N/CPO'0^ M)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^ M)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N M/CPO'0^)SQS M<&%N/CPO'0^ M)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO65E'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO M'0^ M)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO M'0^)SQS<&%N M/CPO'0^)SQS M<&%N/CPO'0^ M)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO7,\'0^)SQS<&%N/CPO7,\'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO M'0^)S,@>65A M'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO M'0^)SQS<&%N M/CPO'0^)SQS M<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS M<&%N/CPO'0^ M)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO M'0^)SQS<&%N M/CPO'0^)SQS M<&%N/CPO'0^ M)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'!E;G-E'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO M'0^)SQS<&%N M/CPO'0^)SQS M<&%N/CPO'0^ M)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO M'0^)SQS<&%N M/CPO'0^)SQS M<&%N/CPO'0^ M)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO M'0^)SQS<&%N M/CPO'0^)SQS M<&%N/CPO'0^ M)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO M'0^)SQS<&%N M/CPO'0^)SQS M<&%N/CPO'0^ M)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO M'0^)SQS<&%N M/CPO'0^)SQS M<&%N/CPO'0^ M)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO M'0^)SQS<&%N M/CPO'0^)SQS M<&%N/CPO'0^ M)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO M'0^)SQS<&%N M/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO M'0^)SQS<&%N M/CPO'0^)SQS M<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO M'0^)SQS<&%N M/CPO'0^)SQS M<&%N/CPO'0^ M)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS M<&%N/CPO'0^ M)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N M/CPO'0^)SQS M<&%N/CPO'0^ M)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO M'0^)SQS<&%N M/CPO'0^)SQS M<&%N/CPO'0^ M)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO M'0^)SQS<&%N M/CPO6UE;G0@07=A'!I'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO M'0^)SQS<&%N M/CPO'0^)SQS M<&%N/CPO'0^ M)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO M'0^)SQS<&%N M/CPO'0^)SQS M<&%N/CPO'0^ M)SQS<&%N/CPO2!3 M:&%R92UB87-E9"!087EM96YT($%W87)D+"!/<'1I;VYS+"!/=71S=&%N9&EN M9RP@3G5M8F5R+"!"96=I;FYI;F<@0F%L86YC93PO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO M'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO M'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO7!E.B!T97AT+VAT;6P[(&-H87)S M970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@ M:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M M;#L@8VAA2`H1&5T86EL*2`H4V5R:65S($(@4')E9F5R'0^)SQS<&%N/CPO&5R8VES M960@*%-H87)E&5R8VES86)L92P@*%-H87)E&5R8VES92!0'!I&5R8VES92!0&5R8VES92!03X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R=%]C8C(Q M,68U,5\W,V$Q7S1C-#9?8C!B,U]B.#@Y9#5D-C0W8F4-"D-O;G1E;G0M3&]C M871I;VXZ(&9I;&4Z+R\O0SHO8V(R,3%F-3%?-S-A,5\T8S0V7V(P8C-?8C@X M.60U9#8T-V)E+U=O'0O:'1M;#L@8VAA2!3:&%R92UB87-E9"!087EM96YT($%W M87)D(%M,:6YE($ET96US73PO'0^)SQS<&%N/CPO'!E8W1E9"!L:69E("AY96%R'0^)S$@ M>65A6EE;&0\+W1D/@T*("`@("`@("`\=&0@8VQA3PO M=&0^#0H@("`@("`@(#QT9"!C;&%S3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R M=%]C8C(Q,68U,5\W,V$Q7S1C-#9?8C!B,U]B.#@Y9#5D-C0W8F4-"D-O;G1E M;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO8V(R,3%F-3%?-S-A,5\T8S0V7V(P M8C-?8C@X.60U9#8T-V)E+U=O'0O:'1M;#L@8VAA2!O9B!# M;VUM;VX@4W1O8VL@3W!T:6]N($%C=&EV:71Y("A$971A:6PI("A#;VUM;VX@ M4W1O8VLL(%531"`D*3QB2!3:&%R92UB87-E9"!087EM96YT($%W87)D(%M, M:6YE($ET96US73PO'0^)SQS<&%N/CPO'0^)R9N8G-P.R9N8G-P.SQS<&%N/CPO M'0^)SQS<&%N/CPO'!I&5R8VES92!0&5R8VES92!0'0O:F%V87-C3X-"B`@ M("`\=&%B;&4@8VQA'!I&5R8VES92!02!3:&%R92UB87-E9"!087EM M96YT($%W87)D(%M,:6YE($ET96US73PO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^ M)SQS<&%N/CPO6UE;G0@07=A'0^)SQS M<&%N/CPO'0^)SQS<&%N/CPO6UE;G0@07=A'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO M&5R8VES960@*$5X97)C M:7-E(%!R:6-E*3PO=&0^#0H@("`@("`@(#QT9"!C;&%S&5R8VES92!0&5R8VES92!06%B;&4@*%=E:6=H=&5D($%V97)A9V4@17AE2!3:&%R92UB87-E9"!0 M87EM96YT($%W87)D(%M,:6YE($ET96US73PO'0^)SQS<&%N/CPO&5R8VES92!0'0^)SQS<&%N/CPO&EM=6T\+W1D/@T*("`@("`@("`\=&0@8VQA2!3 M:&%R92UB87-E9"!087EM96YT($%W87)D(%M,:6YE($ET96US73PO'0^)SQS<&%N/CPO&5R8VES92!0'0^)SQS M<&%N/CPO7!E.B!T97AT M+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^ M#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT M/3-$)W1E>'0O:'1M;#L@8VAA2!3:&%R92UB87-E9"!0 M87EM96YT($%W87)D(%M,:6YE($ET96US73PO'0^)SQS<&%N/CPO'!I6UE;G0@07=A'0^)S$@>65A'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO M'0^)SQS<&%N M/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO M'0^)SQS<&%N M/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^ M)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO M2!O;FQY(&)E M(&=I=F5N(&EF('1H92!#;VUP86YY'0^)SQS<&%N M/CPO'0^)SQS M<&%N/CPO'0^ M)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO M'0^)SQS<&%N M/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)V-O;G9E'0^)V-O;G9E'0^)V-O;G9E7,@0V]M;6]N(%-T;V-K/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^)SQS<&%N/CPO'0^)SQS M<&%N/CPO'0^ M)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO7!E.B!T97AT+VAT;6P[(&-H87)S970] M(G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T M<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@ M8VAA'0^ M)SQS<&%N/CPO'!E;G-E/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B@Q+#DW M,"PP,#`I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'!E;G-E'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS M<&%N/CPO'0^ M)SQS<&%N/CPO'0^)SQS<&%N/CPO'0O:F%V87-C3X- M"B`@("`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`E(&]W;F5RF4@:71S($Y/3"!C87)R>2!F;W)W87)D&%B;&4@:6YC;VUE(&%N9"!R96QA=&5D('1A>"!L:6%B:6QI=&EE2!-971H;V0@26YV97-T;65N="P@3W=N97)S:&EP(%!E'0^)SQS<&%N/CPO M"!2871E+"!097)C96YT/"]T9#X-"B`@ M("`@("`@/'1D(&-L87-S/3-$;G5M<#XS-"XP,"4\'0^)S(P,S,\3X-"CPO M:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R=%]C8C(Q,68U,5\W,V$Q7S1C-#9? M8C!B,U]B.#@Y9#5D-C0W8F4-"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O M0SHO8V(R,3%F-3%?-S-A,5\T8S0V7V(P8C-?8C@X.60U9#8T-V)E+U=O'0O:'1M;#L@ M8VAA"!D:69F97)E;F-E M'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA M&5S(%M,:6YE($ET96US73PO M'0^)SQS<&%N M/CPO2!R871E+"!R871E/"]T9#X-"B`@("`@("`@/'1D(&-L87-S M/3-$;G5M<#XS-"XP,"4\7!E.B!T97AT+VAT;6P[(&-H87)S M970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@ M:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M M;#L@8VAA'0^)SQS<&%N/CPO'0^)T%L;"!O9B!T:&4@0V]M<&%N>28C.#(Q-SMS(&5M<&QO M>65E3X-"CPO:'1M;#X-"@T*+2TM M+2TM/5].97AT4&%R=%]C8C(Q,68U,5\W,V$Q7S1C-#9?8C!B,U]B.#@Y9#5D M-C0W8F4-"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO8V(R,3%F-3%? M-S-A,5\T8S0V7V(P8C-?8C@X.60U9#8T-V)E+U=O'0O:'1M;#L@8VAA7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R M2!42`R,2P@,C`Q,CQB M&5C=71I=F4@3V9F:6-E&5C=71I=F4@3V9F:6-E&5C=71I=F4@3V9F:6-E'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO M'0^)SQS<&%N M/CPO'0^)SQS M<&%N/CPO'0^ M)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO M'0^)SQS<&%N M/CPO'0^)SQS M<&%N/CPO'0^ M)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO2!D96)T/"]T9#X-"B`@("`@("`@/'1D(&-L87-S M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO M'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^ M)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^ M)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS M<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS M<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS M<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO M'0^)SQS<&%N M/CPO'0^)SQS M<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO M'0^)SQS<&%N M/CPO'0^)SQS M<&%N/CPO'0^ M)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO M'0^)SQS M<&%N/CPO'0^ M)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N M/CPO'0^)SQS M<&%N/CPO'0^ M)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N M/CPO'0^)SQS M<&%N/CPO'0^ M)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N M/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS M<&%N/CPO'0^ M)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO M'0^)SQS M<&%N/CPO'0^ M)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO M'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO M'0^)SQS<&%N M/CPO'0^)SQS M<&%N/CPO'0^ M)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO M'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO M'0^)SQS<&%N M/CPO2!V;VQU;64@=V5I9VAT960@879E'0^)SQS<&%N/CPO M'0^)SQS<&%N M/CPO'0^)SQS M<&%N/CPO'0^ M)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO M'0^)SQS<&%N M/CPO'0^)SQS M<&%N/CPO'0^ M)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N M/CPO'0^)SQS M<&%N/CPO'0^ M)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO M'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^1&5C(#,Q+`T*"0DR M,#$S/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO M'0^)SQS<&%N M/CPO'0^)SQS M<&%N/CPO'0^)S(P M,3,M,3(M,S$\'0^)S(P,3,M,3(M,S$\'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO M'0^)SQS<&%N M/CPO'0^)SQS M<&%N/CPO'0^ M)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS M<&%N/CPO'0^ M)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO M'0^)SQS<&%N M/CPO'0^)SQS M<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO M'0^)SQS<&%N M/CPO'0^)SQS M<&%N/CPO'0^ M)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO M'0^)SQS<&%N M/CPO'0^)SQS M<&%N/CPO'0^ M)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^ M)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO M7!E.B!T97AT M+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^ M#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT M/3-$)W1E>'0O:'1M;#L@8VAA'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO M'0^)SQS<&%N M/CPO'0^)SQS M<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO2!P87EM96YT(&9O M'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^1&5C(#$L#0H)"3(P M,3$\'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO M'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS M<&%N/CPO'0^ M)S@U+#4R-2XY."!P;'5S(&EN=&5R97-T(&%T('1H92!R871E(&]F(#@E/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^)SQS M<&%N/CPO7!E M.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@ M/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C M;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA3X-"CPO M:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R=%]C8C(Q,68U,5\W,V$Q7S1C-#9? M8C!B,U]B.#@Y9#5D-C0W8F4-"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O M0SHO8V(R,3%F-3%?-S-A,5\T8S0V7V(P8C-?8C@X.60U9#8T-V)E+U=O'0O:'1M;#L@ M8VAA'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\ M:'1M;#X-"B`@/&AE860^#0H@("`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`@ M("`\=&%B;&4@8VQA'1087)T7V-B,C$Q9C4Q7S XML 44 R43.htm IDEA: XBRL DOCUMENT v2.4.0.8
SELECTED QUARTERLY FINANCIAL DATA (Tables)
 12 Months Ended
Dec. 31, 2013
Quarterly Financial Data [Abstract]  
Schedule of Quarterly Financial Information
 
 
 
Quarter ended
 
 
 
March 31,
2013
 
June 30,
2013
 
September 30,
2013
 
December 31,
2013
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Net Sales
 
$
371
 
$
432
 
$
351
 
$
476
 
Gross profit (loss)
 
 
125
 
 
14
 
 
121
 
 
164
 
Net loss
 
 
(1,201)
 
 
(1,088)
 
 
(1,390)
 
 
(3,425)
 
Net (loss) per share - basic and diluted
 
$
(0.00)
 
$
(0.00)
 
$
(0.00)
 
$
(0.00)
 
Weighted average basic and diluted shares
 
 
1,451,927
 
 
1,452,425
 
 
1,452,548
 
 
1,452,548
 
 
 
 
Quarter ended
 
 
 
March 31,
2012
 
June 30,
2012
 
September 30,
2012
 
December 31,
2012
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Net Sales
 
$
829
 
$
1,224
 
$
370
 
$
378
 
Gross profit (loss)
 
 
359
 
 
331
 
 
106
 
 
33
 
Net loss
 
 
(2,962)
 
 
(1,235)
 
 
(1,568)
 
 
(2,190)
 
Net (loss) per share - basic and diluted
 
$
(0.00)
 
$
(0.00)
 
$
(0.00)
 
$
(0.00)
 
Weighted average basic and diluted shares
 
 
970,887
 
 
1,256,915
 
 
1,360,107
 
 
1,451,140
 

XML 45 R29.htm IDEA: XBRL DOCUMENT v2.4.0.8
SUBSEQUENT EVENTS
 12 Months Ended
Dec. 31, 2013
Subsequent Events [Abstract]  
SUBSEQUENT EVENTS
21.
SUBSEQUENT EVENTS
 
Management has evaluated all events that occurred after the balance sheet date through the date when these financial statements were issued to determine if they must be reported. The management of the Company has determined the following:

The Company issued an aggregate of $320,000 of convertible notes to unrelated parties in February and March 2014. As with the Company’s other, recent sales of convertible notes, the notes are convertible into shares of the Company’s Common Stock at a rate equal to the daily volume weighted average price of the three trading days prior to a conversion, mulitiplied by 0.55.
XML 46 R28.htm IDEA: XBRL DOCUMENT v2.4.0.8
SEGMENTS
 12 Months Ended
Dec. 31, 2013
Segment Reporting [Abstract]  
SEGMENTS
21.
SEGMENTS
 
We have aggregated our operations into two reportable segments based upon product lines, manufacturing processes, marketing and management of our businesses: medical equipment and radiopharmaceuticals.  Our business segments operate in the nuclear medicine industry. The Company’s medical equipment segment is currently generating all revenues and the majority of all expenses as the radiopharmaceuticals segment is still in the development and regulatory approval phase.
 
We evaluate a segment’s performance based primarily upon operating income before corporate expenses.
 
Corporate assets consist primarily of cash but also include plant and equipment associated with our headquarters. These items (and income and expenses related to these items) are allocated to the segments. Unallocated income/expenses include interest income, interest expense, debt extinguishment and refinancing costs and other (expense) income and certain expenses which are not considered related to either segment, but are instead considered general corporate expenses.
 
The following table represents sales, operating loss and total assets attributable to these business segments for the periods indicated (in thousands):
 
 
 
Year Ended December 31,
 
 
 
2013
 
2012
 
Total Sales:
 
 
 
 
 
 
 
Medical equipment
 
$
1,630
 
$
2,789
 
Radiopharmaceuticals
 
 
-
 
 
12
 
Total sales
 
$
1,630
 
$
2,801
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Operating loss:
 
 
 
 
 
 
 
Medical equipment
 
$
(2,486)
 
$
(3,690)
 
Radiopharmaceuticals
 
 
(862)
 
 
(1,026)
 
Unallocated
 
 
-
 
 
(6)
 
Total operating loss
 
$
(3,338)
 
$
(4,722)
 
 
 
 
 
 
 
 
 
Total Assets:
 
 
 
 
 
 
 
Medical equipment
 
$
3,373
 
$
1,739
 
Radiopharmaceuticals
 
 
509
 
 
945
 
Unallocated
 
 
-
 
 
1
 
Total assets
 
$
3,882
 
$
2,685
 
XML 47 R56.htm IDEA: XBRL DOCUMENT v2.4.0.8
Property and Equipment (Detail) (USD $)
In Thousands, unless otherwise specified
Dec. 31, 2013
Dec. 31, 2012
Property, Plant and Equipment [Line Items]    
Property and equipment, gross $ 1,547 $ 1,516
Less: Accumulated depreciation (504) (346)
Property And Equipment, net 1,044 1,170
Buildings
    
Property, Plant and Equipment [Line Items]    
Property and equipment, gross 500 500
Furniture and fixtures
    
Property, Plant and Equipment [Line Items]    
Property and equipment, gross 88 75
Leasehold improvements
    
Property, Plant and Equipment [Line Items]    
Property and equipment, gross 72 72
Computer equipment
    
Property, Plant and Equipment [Line Items]    
Property and equipment, gross 62 60
Research equipment
    
Property, Plant and Equipment [Line Items]    
Property and equipment, gross 667 667
Machinery and equipment
    
Property, Plant and Equipment [Line Items]    
Property and equipment, gross $ 158 $ 142
XML 48 R44.htm IDEA: XBRL DOCUMENT v2.4.0.8
SEGMENTS (Tables)
 12 Months Ended
Dec. 31, 2013
Segment Reporting [Abstract]  
Sales, Operating Loss , Assets Attributable to Business Segments
The following table represents sales, operating loss and total assets attributable to these business segments for the periods indicated (in thousands):
 
 
 
Year Ended December 31,
 
 
 
2013
 
2012
 
Total Sales:
 
 
 
 
 
 
 
Medical equipment
 
$
1,630
 
$
2,789
 
Radiopharmaceuticals
 
 
-
 
 
12
 
Total sales
 
$
1,630
 
$
2,801
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Operating loss:
 
 
 
 
 
 
 
Medical equipment
 
$
(2,486)
 
$
(3,690)
 
Radiopharmaceuticals
 
 
(862)
 
 
(1,026)
 
Unallocated
 
 
-
 
 
(6)
 
Total operating loss
 
$
(3,338)
 
$
(4,722)
 
 
 
 
 
 
 
 
 
Total Assets:
 
 
 
 
 
 
 
Medical equipment
 
$
3,373
 
$
1,739
 
Radiopharmaceuticals
 
 
509
 
 
945
 
Unallocated
 
 
-
 
 
1
 
Total assets
 
$
3,882
 
$
2,685
 
XML 49 R30.htm IDEA: XBRL DOCUMENT v2.4.0.8
DESCRIPTION OF BUSINESS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)
 12 Months Ended
Dec. 31, 2013
Accounting Policies [Abstract]  
Description of Business
 
Description of Business
 
Positron Corporation (the “Company”) was incorporated on December 20, 1983 in the state of Texas and commenced commercial operations in 1986. Positron Corporation is a nuclear medicine healthcare company. The Company offers positron emission tomography molecular imaging systems, clinical and support services, automated radiopharmaceutical systems, radiopharmaceuticals and radioisotope processing and production.
 
The molecular imaging systems portion of the business provides Positron Emission Tomography (PET) scanners. The automated radiopharmaceutical system portion of the business offers the world’s first robotic system for the preparation and dispensing of radiopharmaceuticals that provides unit dose radiopharmaceutical agents used in molecular imaging. The radioisotope manufacturing portion of the business enables the Company to process and produce radioisotope(s) that are critical components required in nuclear imaging.
 
The Company’s objective is to generate revenue by offering inexpensive molecular imaging systems and support services, disease specific software, automated radiopharmaceutical dose preparation and dispensing system, radiopharmaceutical(s) and radioisotope(s) for nuclear medicine primarily in the field of cardiac nuclear medicine.
 
On January 17, 2012, the Company acquired all of the issued and outstanding membership interest of Manhattan Isotope Technology LLC (“MIT”). See Note 3.
 
MIT possesses the unique and specialized expertise in all stages of strontium-82 (Sr-82) production and spent generator lifecycle management. Currently, MIT produces API grade strontium-82 from target material received from its foreign collaborators.
 
Positron Isotopes Corporation (PIC) was formed to investigate the possibility of building a cyclotron.
Principles of Consolidation
Principles of Consolidation
 
For the years ended December 31, 2013 and 2012, the financial statements include the transactions of Positron Corporation and its wholly-owned subsidiaries, MIT, Positron Pharmaceuticals Company and PIC. All intercompany transactions have been eliminated.
Basis of Presentation and Use of Estimates
Basis of Presentation and Use of Estimates
 
These financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America (GAAP). Such principles require management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.
Affiliated Entities
Affiliated Entities
 
Affiliated entities and their affiliation, as defined by FASB Codification Topic 850 are as follows:
 
Solaris Opportunity Fund owns or controls common and preferred shares of the Company and its managing member is the CEO of the Company.
 
The Company has a 1% ownership interest in the joint venture Neusoft Positron Medical Systems ("Neusoft"). Both the Company and the joint venture's other partner, Neusoft Medical Systems purchase PET systems at a wholesale transfer price from Neusoft. The Company maintains one of five board seats on Neusoft's board. The Company currently accounts for its investment in Neusoft on the cost method and has no recorded value as of December 31, 2013 and 2012 based on prior losses of Neusoft.
Concentrations of Credit Risk
Concentrations of Credit Risk
 
The Company maintains its cash in institutions insured by the Federal Deposit Insurance Corporation (FDIC) and at times, balances may exceed government insured limits. The Company has never experienced any losses related to these balances.
 
During the twelve months ended December 31, 2013, no one customer accounted for more than 10% of sales and a separate customer accounted for 80% of accounts receivable. During the twelve months ended December 31, 2012, one customer accounted for 26% of sales and a separate customer accounted for 70% of accounts receivable.
Cash Equivalents and Short-term Investments
Cash Equivalents and Short-term Investments
 
For the purposes of reporting cash flows, the Company considers highly liquid, temporary cash investments with an original maturity period of three months or less to be cash equivalents.
Accounts Receivable
Accounts Receivable
 
Accounts receivable consist of amounts due from customers. The Company records a provision for doubtful accounts to allow for any amounts which may be unrecoverable, which is based upon an analysis of the Company’s prior collection experience, customer creditworthiness and current economic trends.
Goodwill and Other Intangible Assets
Goodwill and Other Intangible Assets
 
Accounting Standard Codification (“ASC”) 350 “Goodwill and Other Intangible Assets” requires that assets with indefinite lives no longer be amortized, but instead be subject to annual impairment tests. The Company follows this guidance.
 
The Company tests goodwill that is not subject to amortization for impairment annually or more frequently if events or circumstances indicate that impairment is possible. Goodwill was tested as of December 31, 2013 at which time the Company determined that the carrying value of goodwill was impaired. Impairment loss of $346,000 was recognized during the year ended December 31, 2013.
 
The impairment tests performed at December 31, 2013 and 2012 were based on a discounted cash flow model using management’s business plan projection for expected cash flows. As noted above, it was determined goodwill was fully impaired at December 31, 2013. As of December 31, 2012, no impairment was indicated. Goodwill as of December 31, 2013 and 2012 was $0 and $346,000, respectively.
 
Definite lived intangible assets are being amortized over their useful lives.
Inventory
Inventory
 
Inventories are stated at the lower of cost or market. Cost is determined using the first-in, first-out (FIFO) method of inventory valuation. Management assesses the recoverability and establishes reserves of the various inventory components on a quarterly basis and is based on the estimated net realizable values of respective finished, in process and raw material inventories.
Property and Equipment
Property and Equipment
 
Property and equipment are recorded at cost and depreciated for financial statement purposes using the straight-line over estimated useful lives below:
 
 
 
Estimated life,
years
 
Buildings
 
39
 
Furniture and fixtures
 
5-7
 
Leasehold improvements
 
1-3
 
Computer equipment
 
3-5
 
Research equipment
 
7
 
Machinery and equipment
 
3-5
 
 
Gains or losses on dispositions are included in the statement of operations in the period incurred. Maintenance and repairs are charged to expense as incurred.
Impairment of Long-Lived Assets
Impairment of Long-Lived Assets
 
Periodically, the Company evaluates the carrying value of its long-lived assets, by comparing the anticipated future net cash flows associated with those assets to the related net book value. If impairment is indicated as a result of such reviews, the Company would record the impairment based on the fair market value of the assets, using techniques such as projected future discounted cash flows or third party valuations.
Fair Value of Financial Instruments
Fair Value of Financial Instruments
 
The carrying value of cash and cash equivalents, accounts receivable, accounts payable and accrued liabilities and unearned revenue, approximate their fair values because of the short-term nature of these instruments. Management believes the Company is not exposed to significant interest or credit risks arising from these financial instruments.
 
Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date.
 
Valuation techniques used to measure fair value maximize the use of observable inputs and minimize the use of unobservable inputs. The Company utilizes a fair value hierarchy based on three levels of inputs, of which the first two are considered observable and the last unobservable.
 
⋅
Level 1 — Quoted prices in active markets for identical assets or liabilities. These are typically obtained from real-time quotes for transactions in active exchange markets involving identical assets.
 
⋅
Level 2 — Quoted prices for similar assets and liabilities in active markets; quoted prices included for identical or similar assets and liabilities that are not active; and model-derived valuations in which all significant inputs and significant value drivers are observable in active markets. These are typically obtained from readily-available pricing sources for comparable instruments.
 
⋅
Level 3 — Unobservable inputs, where there is little or no market activity for the asset or liability. These inputs reflect the reporting entity’s own beliefs about the assumptions that market participants would use in pricing the asset or liability, based on the best information available in the circumstances.
 
The following table presents the embedded conversion derivative liabilities, the Company’s only financial liabilities measured and recorded at fair value on the Company’s consolidated balance sheets on a recurring basis and their level within the fair value hierarchy as of December 31, 2013 and 2013 and 2012 (in thousands):
 
 
 
Level 1
 
Level 2
 
Level 3
 
 
 
 
 
 
 
 
 
 
 
 
Embedded conversion derivative liability:
 
 
 
 
 
 
 
 
 
 
December 31, 2013
 
$
-
 
$
-
 
$
6,968
 
 
 
 
 
 
 
 
 
 
 
 
December 31, 2012
 
$
-
 
$
-
 
$
3,981
 
 
The following table reconciles, for the year ended December 31, 2013 and 2012, the beginning and ending balances for financial instruments that are recognized at fair value in the consolidated financial statements (in thousands):
 
Balance of embedded conversion derivative liability as of December 31, 2011
 
$
1,238
 
Fair value of embedded conversion derivative liabilities at issuance
 
 
2,129
 
Reductions in fair value due to conversion of Convertible Debentures into common stock
 
 
(544)
 
Debt modification expense
 
 
432
 
Loss on fair value adjustments to embedded conversion derivative liabilities
 
 
726
 
Balance of embedded conversion derivative liability as of December 31, 2012
 
$
3,981
 
Fair value of embedded conversion derivative liabilities at issuance
 
 
1,501
 
Debt modification expense
 
 
821
 
Loss on fair value adjustments to embedded conversion derivative liabilities
 
 
665
 
Balance of embedded conversion derivative liabilities at December 31, 2013
 
$
6,968
 
 
The fair value of the conversion features are calculated at the time of issuance and the Company records a derivative liability for the calculated value using a Black-Scholes option-pricing model. Changes in the fair value of the derivative liability are recorded in other income (expense) in the consolidated statement of operations. Upon conversion of the convertible debt to stock, the Company reclassifies the related embedded conversion derivative liability to paid-in capital. Since the fair value of the embedded conversion derivative liability exceeded the carrying value of the convertible debentures on the issuance date, the convertible debentures were recorded at a full discount. The Company recognizes expense for accretion of the convertible debentures discount over the term of the notes. The Company has considered the provisions of ASC 480, Distinguishing Liabilities from Equity, as the conversion feature embedded in each debenture could result in the note principal being converted to a variable number of the Company’s common shares.
 
The derivatives were valued using the Black-Scholes option pricing model with the following assumptions:
 
 
 
December 31,
2013
 
 
December 31,
2012
 
Market value of stock on measurement date
 
$
0.0048
 
 
$
0.0085
 
Risk-free interest rate
 
 
0.11
%
 
 
0.15
%
Dividend yield
 
 
0
%
 
 
0
%
Volatility factor
 
 
200
%
 
 
141
%
Term
 
 
1 year
 
 
 
1 year
 
Debt Discount
Debt discount
 
Costs incurred with parties who are providing long-term financing, which generally include the value of warrants or the fair value of an embedded derivative conversion feature, are reflected as a debt discount and are amortized over the life of the related debt. When the debt is repaid, the related debt discount is recorded as additional interest expenses and the related derivative liability is relieved into additional paid in capital.
 
The Company valued the embedded derivative conversion using Black-Scholes method. The debt discount attributable to the warrants issued with convertible debentures during the years December 31, 2013 and 2012 was $0 and $331,000, respectively. The debt discount attributable to the embedded conversion derivative liability at issuance during the years ended December 31, 2013 and 2012 was $1,500,000 and $2,129,000, respectively.
 
At December 31, 2013, convertible notes totaled $5,780,000 of which $1,328,000 was attributable to the discount on debt. These notes originally were set to mature on December 31, 2013  but were extended under existing terms through December 31, 2014 or were presented for conversion subsequent to year end.
Income Taxes
Income Taxes
 
Income taxes are accounted for under the liability method. Deferred income taxes are provided for temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and amounts used for income tax purposes. Deferred taxes are reduced by a valuation allowance when, in the opinion of management, it is more likely than not that some portion or the entire deferred tax asset will not be realized. Deferred tax assets and liabilities are adjusted for the effects of changes in tax laws and rates on the date of the enactment. We recognize tax benefits when we believe the benefit is more likely than not to be sustained upon review from the relevant authorities. We recognize penalties and interest expense related to unrecognized tax benefits in income tax expense.
 
The Company’s federal and state tax forms for the years ending December 31, 2010, 2011 and 2012 are subject to examination by the IRS or other taxing authorities, generally for three years after they are filed.
Accumulated Other Comprehensive Income
Accumulated Other Comprehensive Income
 
Accumulated other comprehensive income relates to foreign currency translation adjustments associated with transactions denominated in foreign currency. The balance of accumulated other comprehensive income as of December 31, 2012 was $143,000. During the year ended December 31, 2013 the entire balance was reclassified to net income.
Revenue Recognition
Revenue Recognition
 
The Company’s revenues are currently derived from the sale of medical equipment products, maintenance contracts, service revenues and radioisotope sales. Revenues from maintenance contracts are recognized over the term of the contract. Service revenues are recognized upon performance of the services. The Company recognizes revenues from the sale of medical equipment and radioisotope products when earned. Specifically, revenue is recognized when persuasive evidence of an arrangement exists, delivery has occurred (or services have been rendered), the price is fixed or determinable, and collectability is reasonably assured. The Company obtains a signed customer acceptance after installation is complete for the sale of its Attrius® PET systems.
 
For multiple-element arrangements, revenue is allocated to each element based on their relative selling prices. Relative selling prices are based first on vendor specific objective evidence (VSOE), then on third-party evidence of selling price (TPE) when VSOE does not exist, and then on estimated selling price (ESP) when VSOE and TPE do not exist.
 
Because the Company has neither VSOE nor TPE for its products, the allocation of revenue has been based on the Company’s ESPs. The objective of ESP is to determine the price at which the Company would transact a sale if the product was sold on a stand-alone basis. The Company determines ESP by considering the facts and circumstances of the product being sold.
 
The Company typically provides a one-year parts and labor warranty to purchasers of equipment. A portion of revenue recorded upon the sale of a new machine is allocated to the warranty provided. At the time of sale, the Company records deferred revenue in the amount of revenue allocated to the warranty which is amortized over a one-year period.
Research and Development Expenses
 
The Company typically provides a one-year parts and labor warranty to purchasers of equipment. A portion of revenue recorded upon the sale of a new machine is allocated to the warranty provided. At the time of sale, the Company records deferred revenue in the amount of revenue allocated to the warranty which is amortized over a one-year period.
 
Research and Development Expenses
 
All costs related to research and development costs are charged to expense as incurred and include salaries and benefits, supplies and consulting expenses.
Stock Based Compensation
Stock Based Compensation
 
We recognize compensation expense for share-based awards using the fair value of the option at the time of the grant and amortizing the fair value over the estimated service period on the straight-line attribute method.
Loss Per Common Share
Loss Per Common Share
 
Basic loss per common share is calculated by dividing net loss by the weighted average common shares outstanding during the period. Stock options, warrants and other dilutive securities are not included in the computation of the weighted average number of shares outstanding for dilutive net loss per common share during each of the periods presented in the Statement of Operations and Comprehensive Income, as the effect would be antidilutive.
Recent Accounting Pronouncements
Recent Accounting Pronouncements
 
The Company has implemented all new accounting pronouncements that are in effect and that may impact its financial statements and does not believe that there are any other new accounting pronouncements that have been issued that might have a material impact on its financial position or results of operations.
XML 50 R31.htm IDEA: XBRL DOCUMENT v2.4.0.8
DESCRIPTION OF BUSINESS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)
 12 Months Ended
Dec. 31, 2013
Accounting Policies [Abstract]  
Schedule Of Property Plant And Equipment Estimated Useful Lives
Property and equipment are recorded at cost and depreciated for financial statement purposes using the straight-line over estimated useful lives below:
 
 
 
Estimated life,
years
 
Buildings
 
39
 
Furniture and fixtures
 
5-7
 
Leasehold improvements
 
1-3
 
Computer equipment
 
3-5
 
Research equipment
 
7
 
Machinery and equipment
 
3-5
 
Embedded Conversion Derivative Liabilities Measured and Recorded at Fair Value on Recurring Basis
The following table presents the embedded conversion derivative liabilities, the Company’s only financial liabilities measured and recorded at fair value on the Company’s consolidated balance sheets on a recurring basis and their level within the fair value hierarchy as of December 31, 2013 and 2013 and 2012 (in thousands):
 
 
 
Level 1
 
Level 2
 
Level 3
 
 
 
 
 
 
 
 
 
 
 
 
Embedded conversion derivative liability:
 
 
 
 
 
 
 
 
 
 
December 31, 2013
 
$
-
 
$
-
 
$
6,968
 
 
 
 
 
 
 
 
 
 
 
 
December 31, 2012
 
$
-
 
$
-
 
$
3,981
 
Reconciliation of Financial Instruments Recognized at Fair Value
The following table reconciles, for the year ended December 31, 2013 and 2012, the beginning and ending balances for financial instruments that are recognized at fair value in the consolidated financial statements (in thousands):
 
Balance of embedded conversion derivative liability as of December 31, 2011
 
$
1,238
 
Fair value of embedded conversion derivative liabilities at issuance
 
 
2,129
 
Reductions in fair value due to conversion of Convertible Debentures into common stock
 
 
(544)
 
Debt modification expense
 
 
432
 
Loss on fair value adjustments to embedded conversion derivative liabilities
 
 
726
 
Balance of embedded conversion derivative liability as of December 31, 2012
 
$
3,981
 
Fair value of embedded conversion derivative liabilities at issuance
 
 
1,501
 
Debt modification expense
 
 
821
 
Loss on fair value adjustments to embedded conversion derivative liabilities
 
 
665
 
Balance of embedded conversion derivative liabilities at December 31, 2013
 
$
6,968
Schedule Of Fair Value Assumptions Of Derivatives
The derivatives were valued using the Black-Scholes option pricing model with the following assumptions:
 
 
 
December 31,
2013
 
 
December 31,
2012
 
Market value of stock on measurement date
 
$
0.0048
 
 
$
0.0085
 
Risk-free interest rate
 
 
0.11
%
 
 
0.15
%
Dividend yield
 
 
0
%
 
 
0
%
Volatility factor
 
 
200
%
 
 
141
%
Term
 
 
1 year
 
 
 
1 year
 
XML 51 R8.htm IDEA: XBRL DOCUMENT v2.4.0.8
DESCRIPTION OF BUSINESS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
 12 Months Ended
Dec. 31, 2013
Accounting Policies [Abstract]  
ACCOUNTING POLICIES
1.
DESCRIPTION OF BUSINESS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
 
Description of Business
 
Positron Corporation (the “Company”) was incorporated on December 20, 1983 in the state of Texas and commenced commercial operations in 1986. Positron Corporation is a nuclear medicine healthcare company. The Company offers positron emission tomography molecular imaging systems, clinical and support services, automated radiopharmaceutical systems, radiopharmaceuticals and radioisotope processing and production.
 
The molecular imaging systems portion of the business provides Positron Emission Tomography (PET) scanners. The automated radiopharmaceutical system portion of the business offers the world’s first robotic system for the preparation and dispensing of radiopharmaceuticals that provides unit dose radiopharmaceutical agents used in molecular imaging. The radioisotope manufacturing portion of the business enables the Company to process and produce radioisotope(s) that are critical components required in nuclear imaging.
 
The Company’s objective is to generate revenue by offering inexpensive molecular imaging systems and support services, disease specific software, automated radiopharmaceutical dose preparation and dispensing system, radiopharmaceutical(s) and radioisotope(s) for nuclear medicine primarily in the field of cardiac nuclear medicine.
 
On January 17, 2012, the Company acquired all of the issued and outstanding membership interest of Manhattan Isotope Technology LLC (“MIT”). See Note 3.
 
MIT possesses the unique and specialized expertise in all stages of strontium-82 (Sr-82) production and spent generator lifecycle management. Currently, MIT produces API grade strontium-82 from target material received from its foreign collaborators.
 
Positron Isotopes Corporation (PIC) was formed to investigate the possibility of building a cyclotron.
 
Principles of Consolidation
 
For the years ended December 31, 2013 and 2012, the financial statements include the transactions of Positron Corporation and its wholly-owned subsidiaries, MIT, Positron Pharmaceuticals Company and PIC. All intercompany transactions have been eliminated.
 
Basis of Presentation and Use of Estimates
 
These financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America (GAAP). Such principles require management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.
 
Affiliated Entities
 
Affiliated entities and their affiliation, as defined by FASB Codification Topic 850 are as follows:
 
Solaris Opportunity Fund owns or controls common and preferred shares of the Company and its managing member is the CEO of the Company.
 
The Company has a 1% ownership interest in the joint venture Neusoft Positron Medical Systems ("Neusoft"). Both the Company and the joint venture's other partner, Neusoft Medical Systems purchase PET systems at a wholesale transfer price from Neusoft. The Company maintains one of five board seats on Neusoft's board. The Company currently accounts for its investment in Neusoft on the cost method and has no recorded value as of December 31, 2013 and 2012 based on prior losses of Neusoft.
 
Concentrations of Credit Risk
 
The Company maintains its cash in institutions insured by the Federal Deposit Insurance Corporation (FDIC) and at times, balances may exceed government insured limits. The Company has never experienced any losses related to these balances.
 
During the twelve months ended December 31, 2013, no one customer accounted for more than 10% of sales and a separate customer accounted for 80% of accounts receivable. During the twelve months ended December 31, 2012, one customer accounted for 26% of sales and a separate customer accounted for 70% of accounts receivable.
 
Cash Equivalents and Short-term Investments
 
For the purposes of reporting cash flows, the Company considers highly liquid, temporary cash investments with an original maturity period of three months or less to be cash equivalents.
 
Accounts Receivable
 
Accounts receivable consist of amounts due from customers. The Company records a provision for doubtful accounts to allow for any amounts which may be unrecoverable, which is based upon an analysis of the Company’s prior collection experience, customer creditworthiness and current economic trends.
 
Goodwill and Other Intangible Assets
 
Accounting Standard Codification (“ASC”) 350 “Goodwill and Other Intangible Assets” requires that assets with indefinite lives no longer be amortized, but instead be subject to annual impairment tests. The Company follows this guidance.
 
The Company tests goodwill that is not subject to amortization for impairment annually or more frequently if events or circumstances indicate that impairment is possible. Goodwill was tested as of December 31, 2013 at which time the Company determined that the carrying value of goodwill was impaired. Impairment loss of $346,000 was recognized during the year ended December 31, 2013.
 
The impairment tests performed at December 31, 2013 and 2012 were based on a discounted cash flow model using management’s business plan projection for expected cash flows. As noted above, it was determined goodwill was fully impaired at December 31, 2013. As of December 31, 2012, no impairment was indicated. Goodwill as of December 31, 2013 and 2012 was $0 and $346,000, respectively.
 
Definite lived intangible assets are being amortized over their useful lives.
 
Inventory
 
Inventories are stated at the lower of cost or market. Cost is determined using the first-in, first-out (FIFO) method of inventory valuation. Management assesses the recoverability and establishes reserves of the various inventory components on a quarterly basis and is based on the estimated net realizable values of respective finished, in process and raw material inventories.
 
Property and Equipment
 
Property and equipment are recorded at cost and depreciated for financial statement purposes using the straight-line over estimated useful lives below:
 
 
 
Estimated life,
years
 
Buildings
 
39
 
Furniture and fixtures
 
5-7
 
Leasehold improvements
 
1-3
 
Computer equipment
 
3-5
 
Research equipment
 
7
 
Machinery and equipment
 
3-5
 
 
Gains or losses on dispositions are included in the statement of operations in the period incurred. Maintenance and repairs are charged to expense as incurred.
 
Impairment of Long-Lived Assets
 
Periodically, the Company evaluates the carrying value of its long-lived assets, by comparing the anticipated future net cash flows associated with those assets to the related net book value. If impairment is indicated as a result of such reviews, the Company would record the impairment based on the fair market value of the assets, using techniques such as projected future discounted cash flows or third party valuations.
 
Fair Value of Financial Instruments
 
The carrying value of cash and cash equivalents, accounts receivable, accounts payable and accrued liabilities and unearned revenue, approximate their fair values because of the short-term nature of these instruments. Management believes the Company is not exposed to significant interest or credit risks arising from these financial instruments.
 
Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date.
 
Valuation techniques used to measure fair value maximize the use of observable inputs and minimize the use of unobservable inputs. The Company utilizes a fair value hierarchy based on three levels of inputs, of which the first two are considered observable and the last unobservable.
 
⋅
Level 1 — Quoted prices in active markets for identical assets or liabilities. These are typically obtained from real-time quotes for transactions in active exchange markets involving identical assets.
 
⋅
Level 2 — Quoted prices for similar assets and liabilities in active markets; quoted prices included for identical or similar assets and liabilities that are not active; and model-derived valuations in which all significant inputs and significant value drivers are observable in active markets. These are typically obtained from readily-available pricing sources for comparable instruments.
 
⋅
Level 3 — Unobservable inputs, where there is little or no market activity for the asset or liability. These inputs reflect the reporting entity’s own beliefs about the assumptions that market participants would use in pricing the asset or liability, based on the best information available in the circumstances.
 
The following table presents the embedded conversion derivative liabilities, the Company’s only financial liabilities measured and recorded at fair value on the Company’s consolidated balance sheets on a recurring basis and their level within the fair value hierarchy as of December 31, 2013 and 2013 and 2012 (in thousands):
 
 
 
Level 1
 
Level 2
 
Level 3
 
 
 
 
 
 
 
 
 
 
 
 
Embedded conversion derivative liability:
 
 
 
 
 
 
 
 
 
 
December 31, 2013
 
$
-
 
$
-
 
$
6,968
 
 
 
 
 
 
 
 
 
 
 
 
December 31, 2012
 
$
-
 
$
-
 
$
3,981
 
 
The following table reconciles, for the year ended December 31, 2013 and 2012, the beginning and ending balances for financial instruments that are recognized at fair value in the consolidated financial statements (in thousands):
 
Balance of embedded conversion derivative liability as of December 31, 2011
 
$
1,238
 
Fair value of embedded conversion derivative liabilities at issuance
 
 
2,129
 
Reductions in fair value due to conversion of Convertible Debentures into common stock
 
 
(544)
 
Debt modification expense
 
 
432
 
Loss on fair value adjustments to embedded conversion derivative liabilities
 
 
726
 
Balance of embedded conversion derivative liability as of December 31, 2012
 
$
3,981
 
Fair value of embedded conversion derivative liabilities at issuance
 
 
1,501
 
Debt modification expense
 
 
821
 
Loss on fair value adjustments to embedded conversion derivative liabilities
 
 
665
 
Balance of embedded conversion derivative liabilities at December 31, 2013
 
$
6,968
 
 
The fair value of the conversion features are calculated at the time of issuance and the Company records a derivative liability for the calculated value using a Black-Scholes option-pricing model. Changes in the fair value of the derivative liability are recorded in other income (expense) in the consolidated statement of operations. Upon conversion of the convertible debt to stock, the Company reclassifies the related embedded conversion derivative liability to paid-in capital. Since the fair value of the embedded conversion derivative liability exceeded the carrying value of the convertible debentures on the issuance date, the convertible debentures were recorded at a full discount. The Company recognizes expense for accretion of the convertible debentures discount over the term of the notes. The Company has considered the provisions of ASC 480, Distinguishing Liabilities from Equity, as the conversion feature embedded in each debenture could result in the note principal being converted to a variable number of the Company’s common shares.
 
The derivatives were valued using the Black-Scholes option pricing model with the following assumptions:
 
 
 
December 31,
2013
 
 
December 31,
2012
 
Market value of stock on measurement date
 
$
0.0048
 
 
$
0.0085
 
Risk-free interest rate
 
 
0.11
%
 
 
0.15
%
Dividend yield
 
 
0
%
 
 
0
%
Volatility factor
 
 
200
%
 
 
141
%
Term
 
 
1 year
 
 
 
1 year
 
 
Debt discount
 
Costs incurred with parties who are providing long-term financing, which generally include the value of warrants or the fair value of an embedded derivative conversion feature, are reflected as a debt discount and are amortized over the life of the related debt. When the debt is repaid, the related debt discount is recorded as additional interest expenses and the related derivative liability is relieved into additional paid in capital.
 
The Company valued the embedded derivative conversion using Black-Scholes method. The debt discount attributable to the warrants issued with convertible debentures during the years December 31, 2013 and 2012 was $0 and $331,000, respectively. The debt discount attributable to the embedded conversion derivative liability at issuance during the years ended December 31, 2013 and 2012 was $1,500,000 and $2,129,000, respectively.
 
At December 31, 2013, convertible notes totaled $5,780,000 of which $1,328,000 was attributable to the discount on debt. These notes originally were set to mature on December 31, 2013  but were extended under existing terms through December 31, 2014 or were presented for conversion subsequent to year end.
 
Income Taxes
 
Income taxes are accounted for under the liability method. Deferred income taxes are provided for temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and amounts used for income tax purposes. Deferred taxes are reduced by a valuation allowance when, in the opinion of management, it is more likely than not that some portion or the entire deferred tax asset will not be realized. Deferred tax assets and liabilities are adjusted for the effects of changes in tax laws and rates on the date of the enactment. We recognize tax benefits when we believe the benefit is more likely than not to be sustained upon review from the relevant authorities. We recognize penalties and interest expense related to unrecognized tax benefits in income tax expense.
 
The Company’s federal and state tax forms for the years ending December 31, 2010, 2011 and 2012 are subject to examination by the IRS or other taxing authorities, generally for three years after they are filed.
 
Accumulated Other Comprehensive Income
 
Accumulated other comprehensive income relates to foreign currency translation adjustments associated with transactions denominated in foreign currency. The balance of accumulated other comprehensive income as of December 31, 2012 was $143,000. During the year ended December 31, 2013 the entire balance was reclassified to net income.
 
Revenue Recognition
 
The Company’s revenues are currently derived from the sale of medical equipment products, maintenance contracts, service revenues and radioisotope sales. Revenues from maintenance contracts are recognized over the term of the contract. Service revenues are recognized upon performance of the services. The Company recognizes revenues from the sale of medical equipment and radioisotope products when earned. Specifically, revenue is recognized when persuasive evidence of an arrangement exists, delivery has occurred (or services have been rendered), the price is fixed or determinable, and collectability is reasonably assured. The Company obtains a signed customer acceptance after installation is complete for the sale of its Attrius® PET systems.
 
For multiple-element arrangements, revenue is allocated to each element based on their relative selling prices. Relative selling prices are based first on vendor specific objective evidence (VSOE), then on third-party evidence of selling price (TPE) when VSOE does not exist, and then on estimated selling price (ESP) when VSOE and TPE do not exist.
 
Because the Company has neither VSOE nor TPE for its products, the allocation of revenue has been based on the Company’s ESPs. The objective of ESP is to determine the price at which the Company would transact a sale if the product was sold on a stand-alone basis. The Company determines ESP by considering the facts and circumstances of the product being sold.
 
The Company typically provides a one-year parts and labor warranty to purchasers of equipment. A portion of revenue recorded upon the sale of a new machine is allocated to the warranty provided. At the time of sale, the Company records deferred revenue in the amount of revenue allocated to the warranty which is amortized over a one-year period.
 
Research and Development Expenses
 
All costs related to research and development costs are charged to expense as incurred and include salaries and benefits, supplies and consulting expenses.
 
Stock Based Compensation
 
We recognize compensation expense for share-based awards using the fair value of the option at the time of the grant and amortizing the fair value over the estimated service period on the straight-line attribute method.
 
Loss Per Common Share
 
Basic loss per common share is calculated by dividing net loss by the weighted average common shares outstanding during the period. Stock options, warrants and other dilutive securities are not included in the computation of the weighted average number of shares outstanding for dilutive net loss per common share during each of the periods presented in the Statement of Operations and Comprehensive Income, as the effect would be antidilutive.
 
Recent Accounting Pronouncements
 
The Company has implemented all new accounting pronouncements that are in effect and that may impact its financial statements and does not believe that there are any other new accounting pronouncements that have been issued that might have a material impact on its financial position or results of operations.
XML 52 R32.htm IDEA: XBRL DOCUMENT v2.4.0.8
ACQUISITION OF MIT (Tables)
 12 Months Ended
Dec. 31, 2013
Business Acquisition [Abstract]  
Summary of Consideration Transferred
Fair Value of Consideration Transferred:
 
Common stock of Company
 
$
50,000
 
Contingent consideration
 
 
205,297
 
Total
 
$
255,297
 
Summary of Fair Values of Assets and Liabilities Assumed
The following table summarizes the fair values of the assets and liabilities assumed at the acquisition date.
 
Cash
 
$
829
 
Equipment and leasehold improvements
 
 
653,567
 
Patent
 
 
14,000
 
Trade and other payables
 
 
(59,282)
 
Note payable
 
 
(700,000)
 
Net liabilities assumed
 
$
(90,886)
 
 
 
 
 
 
Goodwill
 
$
346,183
 
XML 53 R83.htm IDEA: XBRL DOCUMENT v2.4.0.8
Selected Quarterly Financial Data (Detail) (USD $)
In Thousands, except Per Share data, unless otherwise specified
 3 Months Ended 12 Months Ended
Dec. 31, 2013
Sep. 30, 2013
Jun. 30, 2013
Mar. 31, 2013
Dec. 31, 2012
Sep. 30, 2012
Jun. 30, 2012
Mar. 31, 2012
Dec. 31, 2013
Dec. 31, 2012
Quarterly Financial Data [Line Items]                    
Net Sales $ 476 $ 351 $ 432 $ 371 $ 378 $ 370 $ 1,224 $ 829 $ 1,630 $ 2,801
Gross profit (loss) 164 121 14 125 33 106 331 359 424 829
Net loss $ (3,425) $ (1,390) $ (1,088) $ (1,201) $ (2,190) $ (1,568) $ (1,235) $ (2,962) $ 7,104 $ 7,955
Net (loss) per share - basic and diluted $ 0.00 $ 0.00 $ 0.00 $ 0.00 $ 0.00 $ 0.00 $ 0.00 $ 0.00 $ 0.00 $ (0.01)
Weighted average basic and diluted shares 1,452,548 1,452,548 1,452,425 1,451,927 1,451,140 1,360,107 1,256,915 970,887 1,452,364 1,265,270
XML 54 R40.htm IDEA: XBRL DOCUMENT v2.4.0.8
LOSS PER SHARE (Tables)
 12 Months Ended
Dec. 31, 2013
Earnings Per Share [Abstract]  
Computation of Basic and Diluted Loss Per Share
The following table sets forth the computation of basic and diluted loss per share (in thousands, except per share data):
 
 
 
Year Ended December 31,
 
 
 
2013
 
2012
 
Numerator
 
 
 
 
 
 
 
Basic and diluted loss
 
$
(7,104)
 
$
(7,955)
 
 
 
 
 
 
 
 
 
Denominator
 
 
 
 
 
 
 
Basic and diluted earnings per share - weighted average shares outstanding
 
 
1,452,364
 
 
1,265,270
 
 
 
 
 
 
 
 
 
Basic and diluted loss per common share
 
$
(0.00)
 
$
(0.01)
 
Antidilutive Securities Not Included in Computation of Net Loss Per Share
Anti-dilutive securities (based on conversions to common shares) not included in net loss per share calculation (in thousands):
 
 
 
Year Ended December 31,
 
 
 
2013
 
2012
 
Convertible Series A preferred stock
 
 
448
 
 
448
 
Convertible Series B preferred stock
 
 
305,648
 
 
305,648
 
Convertible Series G preferred stock
 
 
-
 
 
100
 
Convertible Series S preferred stock
 
 
1,000,000
 
 
1,000,000
 
Convertible Series H preferred stock
 
 
482,625
 
 
-
 
Stock warrants
 
 
122,500
 
 
267,350
 
Convertible debt
 
 
2,693,553
 
 
722,910
 
Common stock options
 
 
188,100
 
 
190,600
 
Series B preferred stock options
 
 
207,000
 
 
250,000
 
XML 55 R53.htm IDEA: XBRL DOCUMENT v2.4.0.8
Summary of Fair Values of Assets and Liabilities Assumed (Detail) (USD $)
Jan. 17, 2012
Business Acquisition [Line Items]  
Patent $ 14,000
MIT
  
Business Acquisition [Line Items]  
Cash 829
Equipment and leasehold improvements 653,567
Patent 14,000
Trade and other payables (59,282)
Note payable (700,000)
Net liabilities assumed (90,886)
Goodwill $ 346,183
XML 56 R72.htm IDEA: XBRL DOCUMENT v2.4.0.8
Preferred Stock - Additional Information (Detail) (USD $)
 1 Months Ended 1 Months Ended 12 Months Ended 12 Months Ended 12 Months Ended 12 Months Ended
Mar. 31, 1998
Dec. 31, 2013
May 31, 2013
Dec. 31, 2012
Nov. 30, 2012
Jan. 12, 2012
Jan. 04, 2012
Dec. 31, 2013
Series Preferred Stock [Member]
Dec. 31, 2012
Series Preferred Stock [Member]
Dec. 31, 2013
Series B Preferred Stock [Member]
Dec. 31, 2012
Series B Preferred Stock [Member]
Dec. 31, 2013
Series G Preferred Stock [Member]
Dec. 31, 2012
Series G Preferred Stock [Member]
Dec. 31, 2013
Series H Preferred Stock [Member]
Dec. 31, 2012
Series H Preferred Stock [Member]
Dec. 31, 2013
Series S Preferred Stock [Member]
Dec. 31, 2012
Series S Preferred Stock [Member]
Class of Stock [Line Items]                                  
Preferred Stock Shares Authorized     20,000,000       20,000,000 7,900,000 7,900,000 9,000,000 9,000,000 3,000,000   15,000,000   100,000 100,000
Preferred Stock, Par or Stated Value Per Share             $ 1.00 $ 1.00 $ 1.00 $ 1.00 $ 1.00 $ 1.00   $ 0.01   $ 1.00 $ 1.00
Class of Warrant or Right, Exercise Price of Warrants or Rights   2.00     0.01 0.01                      
Preferred Stock, Dividend Rate, Percentage               8.00%           70.00%      
Preferred Stock, Redemption Price Per Share               $ 1.46       $ 5.00          
Preferred Stock, Redemption Terms Redemption requires at least 30 days advanced notice and notice may only be given if the Companys common stock has closed above $2.00 per share for the twenty consecutive trading days prior to the notice                                
Preferred Stock, Shares Outstanding               447,652 447,652 3,056,487 3,056,487 0 0 12,500,000 0 100,000 100,000
Convertible Preferred Stock, Terms of Conversion                   Each share of Series B Preferred Stock $1.00 par value is convertible into 100 shares of the Companys Common Stock   convertible into 100 shares of common stock   convertible into 15.58 shares of the Companys Common Stock   convertible into 10,000 shares of the Companys Common Stock  
Preferred Stock, Voting Rights                   100 votes per share       two hundred (200) votes   10,000 votes per share  
Share Price   $ 0.0048   $ 0.0085                   $ 0.10      
XML 57 R2.htm IDEA: XBRL DOCUMENT v2.4.0.8
CONSOLIDATED BALANCE SHEETS (USD $)
In Thousands, unless otherwise specified
Dec. 31, 2013
Dec. 31, 2012
Current assets:    
Cash and cash equivalents $ 1,744 $ 243
Accounts receivable, less allowance for doubtful accounts of $141 and $50 247 273
Inventories, less reserve of $444 and $457 547 551
Prepaid expenses 35 37
Total current assets 2,573 1,104
Property and equipment, less accumulated depreciation of $504 and $346 1,044 1,170
Intangible assets, less accumulated amortization of $4 and $2 10 358
Other assets 255 53
Total assets 3,882 2,685
Current liabilities:    
Accounts payable, trade and accrued liabilities 1,401 1,634
Customer deposits 658 746
Unearned revenue 45 58
Advances from related parties 1,035 0
Notes payable - current portion 95 129
Capital lease - current portion 3 0
Convertible debentures, less debt discount of $1,328 and $1,798 4,452 1,562
Embedded conversion derivative liabilities 6,968 3,981
Total current liabilities 14,657 8,110
Notes payable - noncurrent portion 455 560
Capital lease - noncurrent portion 11 0
Contingent earnout payable 0 205
Total liabilities 15,123 8,875
Stockholders' deficit:    
Common stock: $0.01 par value; 3,000,000,000 shares authorized; 1,452,548,262 and 1,451,927,262 shares issued and outstanding 14,208 14,203
Additional paid-in capital 94,575 92,795
Other comprehensive income 0 (143)
Accumulated deficit (123,432) (116,328)
Treasury stock: 60,156 shares at cost (15) (15)
Total stockholders' deficit (11,241) (6,190)
Total liabilities and stockholders' deficit 3,882 2,685
Series A Preferred Stock
    
Stockholders' deficit:    
Preferred stock value 448 448
Series B Preferred Stock
    
Stockholders' deficit:    
Preferred stock value 2,750 2,750
Series S Preferred Stock
    
Stockholders' deficit:    
Preferred stock value 100 100
Series H Preferred Stock
    
Stockholders' deficit:    
Preferred stock value $ 125 $ 0
XML 58 R45.htm IDEA: XBRL DOCUMENT v2.4.0.8
Description of Business and Summary of Significant Accounting Policies - Additional Information (Detail) (USD $)
 12 Months Ended
Dec. 31, 2013
Dec. 31, 2012
Accounting Policies [Line Items]    
Debt discount $ 1,328,000 $ 1,798,000
Goodwill 0 346,000
Concentration Risk, Percentage   26.00%
Percentage Of Accounts Receivable   70.00%
Accumulated Other Comprehensive Income (Loss) 0 (143,000)
Goodwill, Impairment Loss 346,000  
Debt instrument, face amount 5,780,000 3,360,000
Convertible Debt [Member]
    
Accounting Policies [Line Items]    
Debt discount 1,328,000  
Debt instrument, face amount 5,780,000  
Convertible debenture, maturity date Dec. 31, 2013  
Customer One [Member]
    
Accounting Policies [Line Items]    
Concentration Risk, Percentage 10.00%  
Percentage Of Accounts Receivable 80.00%  
Warrant
    
Accounting Policies [Line Items]    
Debt discount 0 331,000
Embedded Derivative Financial Instruments
    
Accounting Policies [Line Items]    
Debt discount $ 1,500,000 $ 2,129,000
Neusoft Positron Medical Systems Company Ltd [Member]
    
Accounting Policies [Line Items]    
Minority Interest Percentage In Joint Ventures 1.00%  
XML 59 R6.htm IDEA: XBRL DOCUMENT v2.4.0.8
CONSOLIDATED STATEMENTS OF CASH FLOWS (USD $)
 12 Months Ended
Dec. 31, 2013
Dec. 31, 2012
Cash flows from operating activities:    
Net loss $ (7,104,000) $ (7,955,000)
Adjustment to reconcile net loss to net cash used in operating activities    
Allowance for doubtful accounts 91,000 0
Depreciation and amortization 160,000 226,000
Loss on disposal of property and equipment 0 18,000
Impairment of intangible asset 346,000 0
Loss on settlement 0 282,000
Stock based compensation 656,000 1,784,000
Derivative losses 665,000 726,000
Debt modification expense 821,000 432,000
Common stock issued for services 6,000 442,000
Contingent earnout (205,000) 0
Deferred rent 0 77,000
Accretion of debt discount 1,970,000 1,628,000
Inventory reserve (13,000) 0
Other 143,000 0
Changes in operating assets and liabilities:    
Accounts receivable (65,000) 339,000
Inventories 17,000 190,000
Prepaid expenses and other assets (200,000) 603,000
Accounts payable, trade and accrued liabilities (233,000) (146,000)
Customer deposits (88,000) (656,000)
Unearned revenue (13,000) (230,000)
Net cash used in operating activities (3,046,000) (2,240,000)
Cash flows from investing activities:    
Purchase of property and equipment (16,000) (73,000)
Purchase of MIT, net of cash acquired 0 1,000
Net cash used in investing activities (16,000) (72,000)
Cash flows from financing activities:    
Borrowings under note payable 0 305,000
Payments on note payable (100,000) (324,000)
Noninterest bearing advances 2,245,000 65,000
Payment of noninterest bearing advances 0 (85,000)
Payments on capital lease (2,000)  
Common stock issued 0 383,000
Proceeds from convertible debt 2,520,000 2,210,000
Payments on convertible debt (100,000) 0
Net cash provided by financing activities 4,563,000 2,554,000
Net increase (decrease) in cash and cash equivalents 1,501,000 242,000
Cash and cash equivalents, beginning of period 243,000 1,000
Cash and cash equivalents, end of period 1,744,000 243,000
Supplemental cash flow information:    
Interest paid 39,000 32,000
Income taxes paid 0 0
Non-cash disclosures    
Issuance of 17,000,000 common stock owed 0 269,000
Allocation of Convertible Debentures to warrants and embedded conversion derivative liability 3,695,000 2,460,000
Issuance of common stock, warrants, and convertible debentures for purchase of building from related party 0 500,000
Conversion of Convertible Debenture to common stock 0 578,000
Conversion of embedded derivative liability to paid - in capital 0 545,000
Property and equipment additions financed 0 50,000
Equipment under capital lease 16,000 0
Noncash consideration for MIT acquisition (see Note 4) 0 255,000
Conversion of advances to series H preferred stock 1,125,000 0
Series A Preferred Stock
    
Non-cash disclosures    
Conversion of preferred stock to common stock 0 16,000
Series B Preferred Stock
    
Non-cash disclosures    
Conversion of preferred stock to common stock 0 4,771,000
Series G Preferred Stock
    
Non-cash disclosures    
Conversion of preferred stock to common stock $ 0 $ 19,000
XML 60 R59.htm IDEA: XBRL DOCUMENT v2.4.0.8
Convertible Debentures - Additional Information (Detail) (USD $)
 0 Months Ended 1 Months Ended 0 Months Ended 1 Months Ended 12 Months Ended 12 Months Ended 12 Months Ended 1 Months Ended 12 Months Ended
Jan. 04, 2012
May 21, 2012
Jan. 12, 2012
Apr. 05, 2012
Mar. 14, 2012
Jan. 20, 2012
Dec. 31, 2013
Dec. 31, 2012
May 31, 2013
Nov. 30, 2012
Sep. 30, 2012
Dec. 31, 2013
Unrelated Parties
Dec. 31, 2012
Unrelated Parties
Dec. 31, 2013
Related Parties
Dec. 31, 2013
Convertible Debentures 2012
Jan. 12, 2012
Convertible Debentures 2012
Dec. 31, 2013
Convertible Debentures 2013
Dec. 31, 2012
Convertible Debentures 2013
Dec. 31, 2013
Convertible Debentures 2013
Unrelated Parties
Dec. 31, 2013
Convertible Debentures 2013
Related Parties
Dec. 31, 2013
Convertible Debentures 8 Percentage
Dec. 31, 2012
Convertible Debt
Dec. 31, 2013
Initial Accounting One
Dec. 31, 2013
Initial Accounting Two
Debt Instrument [Line Items]                                                
Debt instrument, face amount             $ 5,780,000 $ 3,360,000               $ 250,000 $ 2,520,000              
Convertible debenture, interest rate     8.00%               8.00%           8.00%           0.01%  
Common Stock Par Value $ 0.01   $ 0.01       $ 0.01 $ 0.01 $ 0.0001                         $ 0.01    
Warrant exercise price per share     0.01       2.00     0.01               0.01         0.01  
Conversion price of debt into common stock                               55.00%   55.00%            
Debt conversion, original debt, amount             0 578,000             100,000                  
Debt conversion, converted instrument, shares issued             17,000,000 17,000,000         510,000   18,181,818                  
Loss on debt settlement                             44,661,000                  
Debt instrument, Increase, Additional borrowings             2,520,000                     2,210,000     460,000      
Noninterest-bearing deposit liabilities                                 4,270,000 1,750,000            
Notes Payable, Related Parties                                   1,700,000            
Warrants issued     25,000,000                             68,500,000            
Proceeds from Convertible Debt             2,520,000 2,210,000       1,100,000   1,370,000     2,220,000   1,120,000 1,100,000   50,000 2,460,000 2,520,000
Debt Instrument, Unamortized Discount             1,328,000 1,798,000                 1,328,000              
Interest Expense, Other             1,600                   1,970,000 1,628,000            
Interest Payable                                 277,542 148,741            
Warrant Expiration Date 2013-12-31 2013-12-31 2013-12-31 2013-12-31 2013-12-31 2013-12-31                                    
Expenses related to modification of warrants             $ 821,000                                  
XML 61 R35.htm IDEA: XBRL DOCUMENT v2.4.0.8
ACCOUNTS PAYABLE AND ACCRUED LIABILITIES (Tables)
 12 Months Ended
Dec. 31, 2013
Accounts Payable and Accrued Liabilities [Abstract]  
ACCOUNTS PAYABLE AND ACCRUED LIABILITIES
Accounts payable and accrued liabilities at December 31, 2013 and, 2012 consisted of the following (in thousands):
 
 
 
December 31,
 
 
 
2013
 
2012
 
Trade accounts payable
 
$
849
 
$
1,127
 
Accrued royalties
 
 
87
 
 
87
 
Accrued interest
 
 
278
 
 
154
 
Sales taxes payable
 
 
89
 
 
78
 
Accrued compensation
 
 
70
 
 
80
 
Other accrued expenses
 
 
28
 
 
108
 
 
 
 
 
 
 
 
 
Total
 
$
1,401
 
$
1,634
 
XML 62 R65.htm IDEA: XBRL DOCUMENT v2.4.0.8
Future Minimum Lease Payments and Present Value Of Payments (Detail) (USD $)
Dec. 31, 2013
Dec. 31, 2012
Capital Leased Assets [Line Items]    
2014 $ 4,000  
2015 4,000  
2016 4,000  
2017 4,000  
2018 and thereafter 1,000  
Capital Leases Future Minimum Payments Due 17,000  
Less: amounts representing interest (3,000)  
Present value 14,000  
Less: current portion 3,000 0
Note payable Capital Lease - noncurrent portion $ 11,000 $ 0
XML 63 R22.htm IDEA: XBRL DOCUMENT v2.4.0.8
LOSS PER SHARE
 12 Months Ended
Dec. 31, 2013
Earnings Per Share [Abstract]  
LOSS PER SHARE
15.
LOSS PER SHARE
 
Basic loss per common share is based on the weighted average number of common shares outstanding in each period and earnings adjusted for preferred stock dividend requirements. Diluted earnings per common share assumes that any dilutive convertible preferred shares outstanding at the beginning of each period were converted at those dates, with related interest, preferred stock dividend requirements and outstanding common shares adjusted accordingly. It also assumes that outstanding common shares were increased by shares issuable upon exercise of those stock options and warrants for which market price exceeds exercise price, less shares which could have been purchased by the Company with related proceeds. The convertible preferred stock and outstanding stock options and warrants were not included in the computation of diluted earnings per common share for the twelve months ended December 31, 2013 and 2012, respectively since it would have resulted in an antidilutive effect.
 
The following table sets forth the computation of basic and diluted loss per share (in thousands, except per share data):
 
 
 
Year Ended December 31,
 
 
 
2013
 
2012
 
Numerator
 
 
 
 
 
 
 
Basic and diluted loss
 
$
(7,104)
 
$
(7,955)
 
 
 
 
 
 
 
 
 
Denominator
 
 
 
 
 
 
 
Basic and diluted earnings per share - weighted average shares outstanding
 
 
1,452,364
 
 
1,265,270
 
 
 
 
 
 
 
 
 
Basic and diluted loss per common share
 
$
(0.00)
 
$
(0.01)
 
 
Anti-dilutive securities (based on conversions to common shares) not included in net loss per share calculation (in thousands):
 
 
 
Year Ended December 31,
 
 
 
2013
 
2012
 
Convertible Series A preferred stock
 
 
448
 
 
448
 
Convertible Series B preferred stock
 
 
305,648
 
 
305,648
 
Convertible Series G preferred stock
 
 
-
 
 
100
 
Convertible Series S preferred stock
 
 
1,000,000
 
 
1,000,000
 
Convertible Series H preferred stock
 
 
482,625
 
 
-
 
Stock warrants
 
 
122,500
 
 
267,350
 
Convertible debt
 
 
2,693,553
 
 
722,910
 
Common stock options
 
 
188,100
 
 
190,600
 
Series B preferred stock options
 
 
207,000
 
 
250,000
 
XML 64 R36.htm IDEA: XBRL DOCUMENT v2.4.0.8
CONVERTIBLE DEBENTURES (Tables)
 12 Months Ended
Dec. 31, 2013
Debt Instrument [Line Items]  
Convertible Debentures Outstanding
Convertible Debentures outstanding as of December 31, 2013 and 2012 were as follows (in thousands):
 
December 31, 2013
 
Unrelated
parties
 
Related parties
 
Total
 
 
 
 
 
 
 
 
 
 
 
 
Convertible debentures- face value
 
$
4,030
 
$
1,750
 
$
5,780
 
Debt discount
 
 
(1,328)
 
 
0
 
 
(1,328)
 
Total convertible debentures
 
 
2,702
 
 
1,750
 
$
4,452
 
Less current portion
 
 
(2,702)
 
 
(1,750)
 
 
(4,452)
 
Long term portion
 
$
-
 
$
-
 
$
-
 
 
December 31, 2012
 
Unrelated
parties
 
Related parties
 
Total
 
 
 
 
 
 
 
 
 
 
 
 
Convertible debentures- face value
 
$
1,510
 
$
1,850
 
$
3,360
 
Debt discount
 
 
(350)
 
 
(1,448)
 
 
(1,798)
 
Total current convertible debentures
 
$
1,160
 
$
402
 
$
1,562
 
Initial Accounting One [Member]
  
Debt Instrument [Line Items]  
Summary of Convertible Debt and Initial Accounting of Issuances
The following is a summary of Convertible Debt and the initial accounting of the issuances (in thousands):
 
Convertible debt issuance
 
$
2,460
 
 
 
 
 
 
Allocation of debt to warrants
 
 
(331)
 
 
 
 
 
 
Allocation of debt to embedded conversion derivative liability
 
 
(2,129)
 
Initial Accounting Two [Member]
  
Debt Instrument [Line Items]  
Summary of Convertible Debt and Initial Accounting of Issuances
The following is a summary of the proceeds from the issuance of the Convertible Debentures and the initial accounting of the issuance (in thousands):
 
Proceeds from convertible debt issuance
 
$
2,520
 
 
 
 
 
 
Allocation of proceeds to embedded conversion derivative liability
 
 
(1,500)
 
XML 65 R24.htm IDEA: XBRL DOCUMENT v2.4.0.8
401(K) PLAN
 12 Months Ended
Dec. 31, 2013
Benefit Plan [Abstract]  
401(K) PLAN
17.
401(k) PLAN
 
The Positron Corporation 401(k) Plan and Trust (the “Plan”) covers all of the Company’s employees who are United States citizens, at least 21 years of age and have completed at least one quarter of service with the Company. Pursuant to the Plan, employees may elect to reduce their current compensation by up to the statutorily prescribed annual limit and have the amount of such reduction contributed to the Plan. The Plan allows for the Company to make discretionary contributions in an amount equal to 25 percent of the participant’s deferral contributions, up to 6 percent of the employee’s compensation, as defined in the Plan agreement. The Company made no contributions in 2013 and 2012. The Board of Directors of the Company may authorize additional discretionary contributions; however, no such contributions were made by the Company in 2013 or 2012.
XML 66 R68.htm IDEA: XBRL DOCUMENT v2.4.0.8
Determination Of Fair Market Value Using Black-Scholes Option Pricing Model (Detail)
 1 Months Ended
Nov. 30, 2012
Jan. 17, 2012
Jan. 31, 2010
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]      
Expected life (years) 2 years 3 months 1 year 9 months 1 year
Risk free rate of return 0.27% 0.75% 11.00%
Dividend yield 0.00% 0.00% 0.00%
Expected volatility 125.00% 218.00% 200.00%
XML 67 Show.js IDEA: XBRL DOCUMENT /** * Rivet Software Inc. * * @copyright Copyright (c) 2006-2011 Rivet Software, Inc. All rights reserved. * Version 2.4.0.3 * */ var Show = {}; Show.LastAR = null, Show.hideAR = function(){ Show.LastAR.style.display = 'none'; }; Show.showAR = function ( link, id, win ){ if( Show.LastAR ){ Show.hideAR(); } var ref = link; do { ref = ref.nextSibling; } while (ref && ref.nodeName != 'TABLE'); if (!ref || ref.nodeName != 'TABLE') { var tmp = win ? win.document.getElementById(id) : document.getElementById(id); if( tmp ){ ref = tmp.cloneNode(true); ref.id = ''; link.parentNode.appendChild(ref); } } if( ref ){ ref.style.display = 'block'; Show.LastAR = ref; } }; Show.toggleNext = function( link ){ var ref = link; do{ ref = ref.nextSibling; }while( ref.nodeName != 'DIV' ); if( ref.style && ref.style.display && ref.style.display == 'none' ){ ref.style.display = 'block'; if( link.textContent ){ link.textContent = link.textContent.replace( '+', '-' ); }else{ link.innerText = link.innerText.replace( '+', '-' ); } }else{ ref.style.display = 'none'; if( link.textContent ){ link.textContent = link.textContent.replace( '-', '+' ); }else{ link.innerText = link.innerText.replace( '-', '+' ); } } }; XML 68 R7.htm IDEA: XBRL DOCUMENT v2.4.0.8
CONSOLIDATED STATEMENTS OF CASH FLOWS (Parenthetical)
 12 Months Ended
Dec. 31, 2013
Dec. 31, 2012
Debt conversion, converted instrument, shares issued 17,000,000 17,000,000
XML 69 R3.htm IDEA: XBRL DOCUMENT v2.4.0.8
CONSOLIDATED BALANCE SHEETS (Parenthetical) (USD $)
In Thousands, except Share data, unless otherwise specified
Dec. 31, 2013
Dec. 31, 2012
Accounts receivable, allowance for doubtful accounts $ 141 $ 50
Inventories, reserve 444 457
Property and equipment, accumulated depreciation 504 346
Intangible assets, accumulated amortization 4 2
Convertible debenture, debt discount $ 1,328 $ 1,798
Common stock, par value $ 0.01 $ 0.01
Common stock, shares authorized 3,000,000,000 3,000,000,000
Common stock, shares issued 1,452,548,262 1,451,927,262
Common stock, shares outstanding 1,452,548,262 1,451,927,262
Treasury stock, shares 60,156 60,156
Series A Preferred Stock
    
Preferred stock, par value $ 1.00 $ 1.00
Preferred stock, dividend rate 8.00% 8.00%
Preferred stock, shares authorized 7,900,000 7,900,000
Preferred stock, shares issued 447,652 447,652
Preferred stock, shares outstanding 447,652 447,652
Series B Preferred Stock
    
Preferred stock, par value $ 1.00 $ 1.00
Preferred stock, shares authorized 9,000,000 9,000,000
Preferred stock, shares issued 3,056,487 3,056,487
Preferred stock, shares outstanding 3,056,487 3,056,487
Series G Preferred Stock
    
Preferred stock, par value $ 1.00  
Preferred stock, shares authorized 3,000,000  
Preferred stock, shares outstanding 0 0
Series S Preferred Stock
    
Preferred stock, par value $ 1.00 $ 1.00
Preferred stock, shares authorized 100,000 100,000
Preferred stock, shares issued 100,000 100,000
Preferred stock, shares outstanding 100,000 100,000
Series H Preferred Stock
    
Preferred stock, par value $ 0.01  
Preferred stock, shares authorized 15,000,000  
Preferred stock, shares issued 12,500,000  
Preferred stock, shares outstanding 12,500,000 0
XML 70 R17.htm IDEA: XBRL DOCUMENT v2.4.0.8
NOTES PAYABLE AND ADVANCES FROM RELATED PARTIES
 12 Months Ended
Dec. 31, 2013
Notes Payable [Abstract]  
NOTES PAYABLE AND ADVANCES FROM RELATED PARTIES
10.   
NOTES PAYABLE AND ADVANCES FROM RELATED PARTIES
 
On January 17, 2012, the Company assumed from MIT a note payable with Los Alamos National Bank (“LANB”) in the amount of $700,000. On February 10, 2012, MIT refinanced with LANB the principal and accrued interest of this note payable with a promissory note of $708,000, with an extended maturity of April 2015. The note renews annually. The monthly payment to LANB on the promissory note is $10,000, with the interest rate of 5.5% at December 31, 2013 and 2012. The promissory note is guaranteed by the Company and secured by all assets of the Company. Total interest expense related to the promissory note recorded during the years ended December 31, 2013 and 2012 was $35,000. The outstanding principal amount and accrued interest as of December 31, 2013, was approximately, $550,000 and $3,000, respectively. The outstanding principal and accrued interest as of December 31, 2012 was approximately $649,000 and $3,000, respectively.
 
During the twelve months ended December 31, 2013, the Company received $2,285,000 in short term notes from their CEO and CFO to help fund operations. The notes are unsecured and non-interest bearing. As of December 31, 2013, $1,250,000 of the notes/advances were converted to preferred shares (see note 17). The total outstanding notes/advances at December 31, 2013 were $1,035,000.
 
From time to time, the company receives advances from unrelated parties. These advances are unsecured, bear interest at 8% and there are no specific repayment terms. During the twelve months ended December 31, 2012, the Company received advances and made repayments of these advances in the amounts of $305,000 and $265,000, respectively. During the year ended December 31, 2012, the Company recorded interest expense related to the advances of $1,600.  As of December 31, 2013, and 2012 the amounts due to the unrelated parties were $0 and $40,000, respectively.
 
Future maturities of the advances and notes payable are as follows:
 
Debt maturities as of
 
December 31,
 
2014
 
$
1,130,000
 
 
 
 
 
 
2015
 
 
455,000
 
XML 71 R1.htm IDEA: XBRL DOCUMENT v2.4.0.8
Document And Entity Information (USD $)
 12 Months Ended
Dec. 31, 2013
Mar. 31, 2014
Jun. 30, 2013
Document Information [Line Items]      
Document Type 10-K    
Amendment Flag false    
Document Period End Date Dec. 31, 2013    
Document Fiscal Year Focus 2013    
Document Fiscal Period Focus FY    
Trading Symbol POSC    
Entity Common Stock, Shares Outstanding   1,452,548,262  
Entity Registrant Name POSITRON CORP    
Entity Central Index Key 0000844985    
Current Fiscal Year End Date --12-31    
Entity Well-known Seasoned Issuer No    
Entity Voluntary Filers No    
Entity Current Reporting Status Yes    
Entity Filer Category Smaller Reporting Company    
Entity Public Float     $ 10,995,744.90
XML 72 R18.htm IDEA: XBRL DOCUMENT v2.4.0.8
NOTES PAYABLE - CAPITAL LEASE
 12 Months Ended
Dec. 31, 2013
Capital Leases of Lessee [Abstract]  
NOTES PAYABLE - CAPITAL LEASE
11.
NOTES PAYABLE – CAPITAL LEASE
 
The Company has entered into a capital leases for equipment at interest rates of 7.25%, payable through 2018. The assets and liabilities under the capital leases are recorded at the present value of the minimum lease payments and are depreciated over their estimated useful lives. The gross amount of assets held under capital leases for the nine months December 31, 2013 and December 31, 2012 was $16,300 and $0, respectively, with accumulated depreciation of $1,165 and $0, respectively. Depreciation expense for this equipment for the years ended December 31, 2013 and December 31, 2012 was $1,165 and $0, respectively.
 
Future minimum lease payments and the present value of the payments are as follows:
 
Debt maturities as of
 
December 31,
 
2014
 
$
4,000
 
2015
 
 
4,000
 
2016
 
 
4,000
 
2017
 
 
4,000
 
2018 and thereafter
 
 
1,000
 
 
 
 
17,000
 
Less: amounts representing interest
 
 
(3,000)
 
Present value
 
 
14,000
 
Less: current portion
 
 
(3,000)
 
Note payable Capital Lease – noncurrent portion
 
$
11,000
 
XML 73 R80.htm IDEA: XBRL DOCUMENT v2.4.0.8
Related Party Transactions - Additional Information (Detail) (USD $)
 0 Months Ended 1 Months Ended 0 Months Ended 1 Months Ended 12 Months Ended 12 Months Ended 12 Months Ended 12 Months Ended 1 Months Ended 12 Months Ended 12 Months Ended 1 Months Ended 12 Months Ended 0 Months Ended 1 Months Ended 12 Months Ended 0 Months Ended 12 Months Ended 0 Months Ended 1 Months Ended
Jan. 04, 2012
May 21, 2012
Jan. 12, 2012
Apr. 05, 2012
Mar. 14, 2012
Jan. 20, 2012
Dec. 31, 2013
Dec. 31, 2012
May 31, 2013
Nov. 30, 2012
Sep. 30, 2012
Dec. 31, 2013
Series H Preferred Stock
Dec. 31, 2013
Convertible Debt
Dec. 31, 2012
Convertible Debt
Dec. 31, 2012
Chief Executive Officer
Dec. 31, 2013
Chief Executive Officer
Nov. 02, 2013
Chief Executive Officer
Aug. 26, 2013
Chief Executive Officer
Jun. 30, 2013
Chief Executive Officer
Mar. 25, 2013
Chief Executive Officer
Jan. 31, 2013
Chief Executive Officer
Nov. 30, 2012
Chief Executive Officer
Dec. 31, 2012
Chief Executive Officer
Common Stock
Apr. 11, 2013
Chief Executive Officer
Series H Preferred Stock
Nov. 07, 2013
Chief Executive Officer
Series H Preferred Stock
Dec. 31, 2012
Chief Financial Officer
Dec. 31, 2013
Chief Financial Officer
Aug. 16, 2013
Chief Financial Officer
Jun. 21, 2013
Chief Financial Officer
May 22, 2013
Chief Financial Officer
Apr. 04, 2013
Chief Financial Officer
Feb. 27, 2013
Chief Financial Officer
Dec. 31, 2012
Chief Financial Officer
Common Stock
Apr. 11, 2013
Chief Financial Officer
Series H Preferred Stock
Dec. 31, 2012
Neusoft
Jan. 12, 2012
Related Parties
Jan. 19, 2012
Related Parties
Dec. 31, 2012
Related Parties
Dec. 31, 2013
Related Parties
Jan. 12, 2012
Related Parties
Common Stock
Dec. 31, 2012
Related Parties
Common Stock
Jan. 12, 2012
Related Parties
Convertible Debt
Jan. 19, 2012
Related Parties
Convertible Debt
Dec. 31, 2012
Chief Operating Officer
Dec. 31, 2013
Corporate Joint Venture
Related Party Transaction [Line Items]                                                                                          
Due to officers or stockholders, current                                 $ 100,000 $ 250,000 $ 185,000 $ 100,000 $ 250,000       $ 500,000     $ 250,000 $ 100,000 $ 150,000 $ 150,000 $ 250,000                          
Proceeds from related party debt                             1,320,000                 500,000   380,000               250,000                      
Stock issued during period, shares                                             37,500,000                   10,500,000             25,000,000 18,181,818        
Stock issued during period, value             1,250,000         125,000                                                       250,000          
Convertible debenture issued             4,452,000 1,562,000         (1,250,000)     400,000                     50,000                 250,000   402,000 1,750,000            
Warrants issued 15,000,000 13,000,000   3,100,000   5,000,000                                                           35,000,000 35,000,000                
Deferred rent                                                                           77,000              
Debt instrument interest rate     8.00%               8.00%                                                             8.00% 8.00%    
Common stock, par value $ 0.01   $ 0.01       $ 0.01 $ 0.01 $ 0.0001         $ 0.01 $ 0.01                     $ 0.01                   $ 0.01                  
Warrant exercise price per share     0.01       2.00     0.01                       0.01                           0.01                  
Repayment of comvertible debt             100,000 0                                                           100,000              
Debt Instrument, Convertible, Terms of Conversion Feature                             Conversion price equal to 55% of the lowest daily volume weighted average price for the three trading days preceding conversion.                     Conversion price equal to 55% of the lowest daily volume weighted average price for the three trading days preceding conversion.                                      
Cost of Revenue, Total                                                                     623,000                    
Deposits Assets, Current                                                                                         201,000
Debt Instrument, Maturity Date                             Dec. 31, 2013                     Dec. 31, 2013                               Dec. 31, 2013 Dec. 31, 2013    
Warrant Expiration Date 2013-12-31 2013-12-31 2013-12-31 2013-12-31 2013-12-31 2013-12-31                                                           2013-12-31 2013-12-31                
Debt Instrument Conversion Price As Percentage Of Trading Prices                                                                       55.00%                  
Debt Instrument Conversion Circumstance Number Of Consecutive Trading Days                                                                       3 days                  
Unsecured Advance From Related Party                     25,000                                                                    
Long-term Debt, Gross                             $ 1,000,000                                                         $ 300,000  
XML 74 R4.htm IDEA: XBRL DOCUMENT v2.4.0.8
CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME (USD $)
In Thousands, except Share data, unless otherwise specified
 12 Months Ended
Dec. 31, 2013
Dec. 31, 2012
Sales: $ 1,630 $ 2,801
Costs of sales: 1,206 1,972
Gross profit 424 829
Operating expenses:    
General and administrative 2,779 4,326
Research and development 564 940
Selling and marketing 419 285
Total operating expenses 3,762 5,551
Loss from operations (3,338) (4,722)
Other income (expense)    
Interest expense (2,137) (1,753)
Derivative loss (665) (726)
Debt modification expense (821) (432)
Loss on settlement of accounts payable 0 (282)
Other expense (143) (22)
Loss on disposal of property and equipment 0 (18)
Total other income (expense) (3,766) (3,233)
Loss before income taxes (7,104) (7,955)
Income taxes 0 0
Net loss (7,104) (7,955)
Other comprehensive loss    
Foreign currency translation adjustments 143 0
Other comprehensive loss $ (6,961) $ (7,955)
Basic and diluted net loss per common share $ 0.00 $ (0.01)
Basic and diluted weighted average shares outstanding 1,452,364 1,265,270
XML 75 R12.htm IDEA: XBRL DOCUMENT v2.4.0.8
INVENTORIES
 12 Months Ended
Dec. 31, 2013
Inventory, Net [Abstract]  
INVETORIES
5.
INVENTORIES
 
Inventories at December 31, 2013 and 2012 consisted of the following (in thousands):
 
 
 
December 31,
 
 
 
2013
 
2012
 
Finished systems
 
$
24
 
$
310
 
Raw materials and service parts
 
 
927
 
 
698
 
Work in progress
 
 
40
 
 
-
 
 
 
 
991
 
 
1,008
 
Less: Reserve for obsolete inventory
 
 
(444)
 
 
(457)
 
 
 
$
547
 
$
551
 
 
Inventories are stated at the lower of cost or market.  Cost is determined using the first-in, first-out (FIFO) method of inventory valuation.  The Company evaluated the reserve as of December 31, 2013 and December 31, 2012.
XML 76 R11.htm IDEA: XBRL DOCUMENT v2.4.0.8
OTHER ASSETS
 12 Months Ended
Dec. 31, 2013
Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]  
OTHER ASSETS
4.
OTHER ASSETS
 
Other assets at December 31, 2013, consisted of $201,000 in deposits paid to our joint venture partner, Neusoft for Attrius® systems and $54,000 in operating lease deposits. Other assets at December 31, 2012, consisted of $53,000 in operating lease deposits.
XML 77 R23.htm IDEA: XBRL DOCUMENT v2.4.0.8
INCOME TAXES
 12 Months Ended
Dec. 31, 2013
Income Tax Disclosure [Abstract]  
INCOME TAXES
16.
INCOME TAXES
 
The Company has incurred losses since its inception and, therefore, has not been subject to federal income taxes. As of December 31, 2013, the Company had domestic net operating loss (“NOL”) carryforwards for income tax purposes of approximately $55,340,000 which expire in 2013 through 2033. Under the provisions of Section 382 of the Internal Revenue Code greater than 50% ownership changes that occurred in the Company may significantly limit the Company’s ability to utilize its NOL carry forwards to reduce future taxable income and related tax liabilities.
 
Section 382 allows an owner shift any time there is a transfer of stock by a person who directly, or indirectly, owns more than 5% of the corporation and the percentage of stock of the corporation owned by one or more five percent shareholders has increased, in the aggregate, by more than 50 percentage points over the lowest percentage of stock owned by such shareholders at any time during the "testing period." The "testing period" is generally a three-year period ending on the date of any owner or equity structure shift.
 
The amount of post-change income that may be offset by pre-change losses is limited each year by the "Section 382 Limitation." Generally, the Section 382 Limitation is an amount equal to the value of the old loss corporation multiplied by a long-term interest rate established monthly by the Internal Revenue Service. The Company has not yet determined the qualifying events and resulting limitation that may impact utilization of net operating losses against future periods.
 
The composition of deferred tax assets and the related tax effects at December 31, 2013 and 2012 are as follows (in thousands):
 
 
 
2013
 
2012
 
Deferred tax assets:
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Domestic net operating losses
 
$
18,816
 
$
19,529
 
Stock option compensation
 
 
223
 
 
606
 
Book/tax differences in fixed assets
 
 
27
 
 
32
 
Accrued liabilities and reserves
 
 
327
 
 
272
 
 
 
 
19,393
 
 
20,439
 
Valuation allowance
 
 
(19,393)
 
 
(20,439)
 
 
 
$
-
 
$
-
 
 
The difference between the income tax benefit in the accompanying statement of operations and the amount that would result if the U.S. Federal statutory rate of 34% were applied to pre-tax loss is as follows (amounts in thousands):
 
 
 
2013
 
2012
 
 
 
Amount
 
%
 
Amount
 
%
 
Benefit for income taxes at federal statutory rate
 
$
2,415
 
 
34
%
$
2,704
 
 
34
%
Derivative losses
 
 
(226)
 
 
(3)
 
 
(596)
 
 
(7)
 
Discount amortization and other
 
 
(949)
 
 
(13)
 
 
(565)
 
 
(7)
 
Change in rates and other
 
 
(2,286)
 
 
(32)
 
 
21
 
 
-
 
Change in valuation allowance
 
 
1,046
 
 
14
 
 
(1,564)
 
 
(20)
 
 
 
$
-
 
 
-
%
$
-
 
 
-
%
XML 78 R19.htm IDEA: XBRL DOCUMENT v2.4.0.8
STOCKHOLDERS' EQUITY
 12 Months Ended
Dec. 31, 2013
Stockholders' Equity Note [Abstract]  
STOCKHOLDERS’ EQUITY
12.     STOCKHOLDERS’ EQUITY
 
2013
 
On April 12, 2013, the Company issued 621,000 shares of common stock for consulting services. On the date of the issuance, the common stock had a fair market value of $0.008 per share. The Company recorded consulting fee expense of $5,000 for the issuance of the shares.
 
On April 11, 2013, the Company accepted subscriptions from Patrick Rooney, its Chairman and Chief Executive Officer, and Corey Conn, its Chief Financial Officer and converted certain advances (see note 17) in the amounts of $500,000 and $250,000 respectively for an aggregate investment of $750,000. In consideration of these subscriptions, the Company issued 7,500,000 shares of its newly created Series H Junior Convertible Preferred Stock, par value $0.01 per share (the “Series H Preferred Stock”). In November 2013, the Company accepted a subscription from Patrick G Rooney, Chairman and CEO to convert additional advances in the amount of $500,000 for 5,000,000 shares of Series H Preferred Stock. The Series H Preferred Stock ranks junior to dividends and distributions of the Company’s assets upon liquidation to all previously-issued shares of the Company’s capital stock and is not entitled to receive interest or dividends. The Series H Preferred Stock is convertible into shares of the Company’s Common Stock at a rate equal to the number of shares of Series H Preferred Stock being converted multiplied by the Original Issuance Price of $0.10 and divided by seventy percent (70%) of the daily weighted volume average price for the three trading days prior to conversion. The Series H Preferred Stock shall be entitled to two hundred (200) votes per share of Series H Preferred Stock on all matters which holders of Common Stock are entitled to vote.
 
In May 2013 the Board of Directors, subject to the approval of the shareholders of the Company, authorized an amendment to the Company's Certificate of Incorporation in order to effect a reverse split of the Company's common stock in a ratio of 1 for 100 (the "Reverse Split"), reduce the number of shares of capital stock from 3,020,000,000 to 520,000,000 of which 500,000,000 shares will be common stock and 20,000,000 shares will be preferred stock, each par value $0.0001 per share. The shareholders also approved the conversion of the Company to a Delaware corporation. These actions are not effective.
 
2012
 
On January 4, 2012, the Company increased the number of the Company’s authorized shares of capital stock from 810,000,000 shares to 3,020,000,000 of which 3,000,000,000 shares were classified as common stock par value $0.01 per share (“Common Stock”) and 20,000,000 shares were classified as preferred stock par value $1.00 per share (“Preferred Stock”). Additionally on January 4, 2012, the Company accepted subscriptions in the amount of $150,000 and issued 15,000,000 shares of Common Stock. In connection with these Common Stock issuances, the Company also issued 15,000,000 warrants to purchase Common Stock of the Company, which will expire on December 31, 2013 and extended the expiration date of 20,000,000 warrants which had expired to December 31, 2013.
 
On January 4, 2012, the Company issued 400,000 shares to a vendor for services rendered valued at $4,000.
 
On January 9, 2012, the Company issued 1,400,000 shares to a vendor for services rendered valued at $14,000.
 
On January 19, 2012, the Company converted 1,923,223 shares of Series B Convertible Preferred Stock into 192,322,258 shares of common stock and accepted subscriptions in the amount of $100,000 and issued 27,000,000 shares of Common Stock. Additionally, the Company issued 10,000,000 warrants to investors to purchase Common Stock of the Company, which will expire on December 31, 2013 and extended the expiration dates of 30,000,000 warrants which had expired to December 31, 2013.
 
On January 19, 2012, the Company issued 5,000,000 shares in connection with the acquisition of MIT and 76,261 shares of Common Stock were issued for royalties.
 
On January 19, 2012, the Company issued 25,000,000 shares of Common Stock and a convertible debenture due on December 31, 2013, with interest at the rate of 8%, to a related party as the purchase price for the office space previously leased by the Company. In addition, the Company issued 35,000,000 warrants, which entitle the related party to purchase shares of the Company’s common stock of the Company, which will expire on December 31, 2013.
 
On January 20, 2012, the Company accepted subscriptions in the amount of $50,000 and issued 5,000,000 shares of Common Stock. In connection with these Common Stock issuances, the Company also issued 5,000,000 warrants to purchase Common Stock of the Company, which will expire on December 31, 2013, and extended the expiration date of 7,500,000 warrants which had expired to December 31, 2013.
 
On March 1, 2012, the Company converted 603,711 shares of Series B Convertible Preferred Stock into 60,371,100 shares of Common Stock and issued 3,000,000 shares of Common Stock to a vendor for services rendered valued at $51,000.
 
On March 14, 2012, the Company accepted subscriptions in the amount of $35,000 and issued 3,500,000 shares of Common Stock. In connection with these issuances, the Company also issued 3,500,000 warrants to investors to purchase Common Stock of the Company, which will expire on December 31, 2013, and extended the expiration date of 750,000 warrants which had expired to December 31, 2013. Also on March 14, 2012, the Company issued 1,200,000 shares of Common Stock to an employee for services valued at $20,000, and 600,000 shares of Common Stock to a vendor for services rendered valued at $10,000.
 
On April 5, 2012, the Company converted 634,000 shares of Series B Convertible Preferred Stock into 63,400,000 shares of Common Stock. The Company also accepted subscriptions in the amount of $28,000 and issued 2,800,000 shares of Common Stock. In connection with these Common Stock issuances, the Company also issued 3,100,000 warrants to purchase Common Stock of the Company, which will expire on December 31, 2013. Also on April 5, 2012, the Company issued 39,682,539 shares of Common Stock for repayment of convertible debt, and issued 2,208,750 shares of Common Stock to a vendor for settlement of accounts payable. The Company recorded $26,456 loss on the settlement.
 
On May 7, 2012, the Company issued 4,000,000 warrants in connection with a Convertible Debt issuance to a Lender to purchase Common Stock of the Company, which will expire on December 31, 2013.
 
On May 20, 2012, the Company issued 2,000,000 warrants to an investor to purchase Common Stock of the Company, which will expire on December 31, 2013.
 
On May 21, 2012, the Company converted 73,226 shares of Series B Convertible Preferred Stock into 7,322,636 shares of Common Stock. The Company also accepted subscriptions in the amount of $130,000 and issued 15,000,000 shares of Common Stock. In connection with these issuances, the Company issued 13,000,000 warrants to investors to purchase Common Stock of the Company, which will expire on December 31, 2013. In addition, the Company issued 175,000 shares of Common Stock to a vendor on May 21, 2012 for services rendered valued at $2,000.
 
On May 29, 2012, the Company converted 231,190 shares of Series B Convertible Preferred Stock into 23,119,000 shares of Common Stock. The Company issued 18,181,818 shares of Common Stock for repayment of related party convertible debt.
 
On June 7, 2012, the Company issued 4,000,000 warrants in connection with a Convertible Debt issuance to a lender to purchase Common Stock of the Company, which will expire on December 31, 2013.
 
On June 19, 2012, the Company converted 16,667 shares of Series A Convertible Preferred Stock into 16,667 shares of Common Stock, converted 118,149 shares of Series B Convertible Preferred Stock into 11,814,878 shares of Common Stock, and converted 18,200 shares of Series G Convertible Preferred Stock into 2,020,000 shares of Common Stock. In addition, the Company issued 3,970,786 shares of Common Stock to a vendor for settlement of accounts payable. 
 
On July 17, 2012, the Company issued 1,000,000 shares of Common Stock to vendors for services rendered. The Company issued and additional 1,000,000 shares of Common Stock to a vendor for services rendered on July 18, 2012. Both were valued at $10,000.
 
On August 21, 2012 the Company issued 1,000,000 shares of Common Stock to a vendor for services rendered valued at $10,000.
 
On August 31, 2012, the Company converted 1,188,836 shares of Series B Convertible Preferred Stock into 118,883,629 shares of Common Stock. Also on August 31, the Company issued 2,000,000 shares to an investor who had purchased shares during the three months ended June 30, 2012 and which were included in stock payable as of June 30, 2012.
 
On September 10, 2012, the Company converted obligations totaling $35,605 into 10,000,000 shares of Common Stock. Of these shares, 6,666,667 shares were payable as of September 30, 2012 and were issued in October 2012. In connection with this issuance the Company recorded a loss on settlement of $54,395.
 
In November 2012, the Company issued warrants to purchase a total of 10,500,000 shares of the Company’s Common Stock, at an exercise price of $0.01 per share expiring on December 31, 2013, to its Chief Financial Officer. The warrants were issued in connection with the issuance of two non-interest bearing convertible debentures totaling $380,000 to the CFO.
 
In November 2012, the Company issued warrants to purchase a total of 37,500,000 shares of the Company’s Common Stock, at an exercise price of $0.01 per share to its Chief Executive Officer. The warrants expire on December 31, 2013. The warrants were issued in connection with the issuance of two non-interest bearing convertible debentures totaling $1,320,000 to the CEO.
 
In December 2012, the Company issued a convertible debenture in the amount of $50,000 to a third party. In connection with the debt, the Company also issued to the third party warrants to purchase 1,500,000 shares of the Company’s Common Stock, at an exercise price of $0.01 per share expiring on December 31, 2013.
 
Options
For all of the Company’s stock-based compensation plans, the fair value of each grant was estimated at the date of grant using the Black-Scholes option-pricing model. Black-Scholes utilizes assumptions related to volatility, the risk-free interest rate, the dividend yield (which is assumed to be zero, as the Company has not paid cash dividends to date and does not currently expect to pay cash dividends) and the expected term of the option. Expected volatilities utilized in the model are based mainly on the historical volatility of the Company’s stock price over a period commensurate with the expected life of the share option as well as other factors. The risk-free interest rate is derived from the zero-coupon U.S. government issues with a remaining term equal to the expected life at the time of grant.
 
For all of the Company’s stock-based compensation plans, the fair value of each grant was estimated at the date of grant using the Black-Scholes option-pricing model. Black-Scholes utilizes assumptions related to volatility, the risk-free interest rate, the dividend yield (which is assumed to be zero, as the Company has not paid cash dividends to date and does not currently expect to pay cash dividends) and the expected term of the option. Expected volatilities utilized in the model are based mainly on the historical volatility of the Company’s stock price over a period commensurate with the expected life of the share option as well as other factors. The risk-free interest rate is derived from the zero-coupon U.S. government issues with a remaining term equal to the expected life at the time of grant.
 
In January 2010 the Company granted certain employees options to purchase 2,500,000 shares of Series B Preferred stock at an exercise price of $1.00 per share (the “Preferred Options”.) The options vest immediately and have a term of three years. Accordingly, in January 2010 the Company recorded compensation expense of $2,500,000 for the Preferred Option grants. At December 31, 2013, 430,000 of these options expired and 2,070,000 were extended for one year. The Company recorded compensation expense of $567,567 for the extended Preferred Option grants. Fair market value using the Black-Scholes option-pricing model was determined using the following assumptions:
 
Expected life (years)
 
1
 
Risk free rate of return
 
11
%
Dividend yield
 
0
 
Expected volatility
 
200
%
 
A summary of Series B Preferred stock option activity is as follows:
 
 
 
Shares Issuable
Under
Outstanding
Options
 
Weighted
Average
Exercise
Price
 
 
 
 
 
 
 
 
 
Balance at December 31, 2012
 
 
2,500,000
 
$
1.00
 
Issued
 
 
-
 
 
-
 
Expired/forfeited
 
 
(430,000)
 
 
1.00
 
Exercised
 
 
-
 
 
-
 
Balance at December 31, 2013
 
 
2,070,000
 
$
1.00
 
Exercisable, December 31, 2013
 
 
2,070,000
 
$
1.00
 
 
On January 17, 2012, Positron's Board of Directors (the “Board”) adopted the 2012 Equity Incentive Plan ("2012 Plan"), authorizing issuance of 200,000,000 stock options to purchase shares of the Company’s common stock.
 
On January 17, 2012, the Company granted certain employees options to purchase 177,600,000 shares of common stock under the plan at an exercise price of $0.01 per share (“January Issuance”). Fifty (50) percent of the options vested immediately on the grant date with the remaining fifty (50) percent vesting on January 17, 2013. The Company recorded a total expense of approximately $1,735,000 related to these options during the year ended December 31, 2012 and recorded an additional $39,000 for these stock options in the first quarter of 2013. During the year ended December 31, 2012, options to purchase 7,000,000 shares of stock were forfeited and a total of 170,600,000 options from the January issuance were outstanding as of December 31, 2012. At December 31, 2012, the remaining weighted average contractual term of these options was 2.05 years. The intrinsic value of these options on the grant date was $187,600 as the closing stock price on the grant date was $0.011. Fair market value using the Black-Scholes option-pricing model was determined using the following assumptions:
 
Expected life (years)
 
1.75
 
Risk free rate of return
 
0.75
%
Dividend yield
 
0
 
Expected volatility
 
218
%
 
In November 2012, the Company granted additional options to purchase 20,000,000 shares of common stock under the 2012 Plan to a new employee at an exercise price of $0.01 per share. Fifty (50) percent of the options vested immediately on the grant date with the remaining fifty (50) percent vesting on January 17, 2013 The Company recognized an expense of approximately $49,000 related to these options during the year ended December 31, 2012 and will recognize an additional expense of $49,000 during the first quarter of 2013. At December 31, 2012, the remaining weighted average contractual term of these options was 2.05 years. The intrinsic value of the options on the grant date was $0, as the closing stock price on the grant date was $0.008. Fair market value using the Black-Scholes option-pricing model was determined using the following assumptions:
 
Expected life (years)
 
2.25
 
Risk free rate of return
 
0.27
%
Dividend yield
 
0
 
Expected volatility
 
125
%
  
As of December 31, 2012, the Company had a total of 190,600,000 options outstanding with 9,400,000 options available for issuance under the 2012 Plan. Fifty (50) percent of the outstanding options were fully and the remaining fifty (50) percent vest on January 17, 2013. All the options issued under the 2012 Plan expire on January 17, 2015.
 
A summary of common stock option activity is as follows:
 
 
 
Shares Issuable
Under
Outstanding
Options
 
Weighted
Average
Exercise
Price
 
Issued in 2012
 
 
197,600,000
 
$
0.01
 
Forfeited
 
 
(7,000,000)
 
 
0.01
 
Balance at December 31, 2012
 
 
190,600,000
 
$
0.01
 
Forfeited
 
 
(2,500,000)
 
$
0.01
 
Exercised
 
 
-
 
 
-
 
Balance at December 31, 2013
 
 
188,100,000
 
$
0.01
 
Exercisable, December 31, 2013
 
 
188,100,000
 
$
0.01
 
 
Warrants
 
A summary of warrant activity based on common stock equivalents is as follows:
 
 
 
Number of Shares
 
Exercise
Price
 
Weighted
Average
Exercise
Price
 
Balance at December 31, 2011
 
183,583,338
 
$
0.01-0.15
 
$
0.05
 
Warrants exercised
 
-
 
 
-
 
 
-
 
Warrants expired
 
(134,583,338)
 
$
0.01-0.03
 
$
0.03
 
Warrants issued with common and Series B Preferred stock in private placement
 
114,850,000
 
$
0.01
 
$
0.01
 
Warrants issued with convertible debentures and notes payable
 
103,500,000
 
$
0.01
 
$
0.01
 
Balance at December 31, 2012
 
267,350,000
 
$
0.01-0.15
 
$
0.03
 
Warrants exercised
 
-
 
 
-
 
 
-
 
Warrants expired
 
(144,850,000)
 
$
0.01-0.15
 
$
0.02
 
Warrants issued with convertible debentures and notes payable
 
-
 
$
-
 
$
-
 
Balance at December 31, 2013
 
122,500,000
 
$
0.01-0.02
 
$
0.01
 
 
All outstanding warrants are currently exercisable.   A summary of outstanding common stock warrants at December 31, 2013 follows:
 
Number of
Common Stock
Equivalents
 
Expiration Date
 
Remaining
Contractual Life
(Years)
 
Exercise
Price
 
 
 
4,000,000
 
(a)
 
 
-
 
$
0.02
 
 
 
118,500,000
 
(b)
 
 
1.00
 
$
0.01
 
   
(a) Warrants expire six months after the date on which a registration statement is filed and accepted by the Securities Exchange Commission permitting a sale of the shares issuable upon exercise of the warrant.
 
(b) Warrants were originally set to expire on December 31, 2013, but were extended by the Company through December 31, 2014.
XML 79 R84.htm IDEA: XBRL DOCUMENT v2.4.0.8
Sales, Operating Loss and Total Assets Attributable to Business Segments (Detail) (USD $)
In Thousands, unless otherwise specified
 3 Months Ended 12 Months Ended
Dec. 31, 2013
Sep. 30, 2013
Jun. 30, 2013
Mar. 31, 2013
Dec. 31, 2012
Sep. 30, 2012
Jun. 30, 2012
Mar. 31, 2012
Dec. 31, 2013
Dec. 31, 2012
Total Sales:                    
Revenues $ 476 $ 351 $ 432 $ 371 $ 378 $ 370 $ 1,224 $ 829 $ 1,630 $ 2,801
Operating loss:                    
Loss from operations                 (3,338) (4,722)
ASSETS                    
Total assets 3,882       2,685       3,882 2,685
Medical equipment
                    
Total Sales:                    
Revenues                 1,630 2,789
Operating loss:                    
Loss from operations                 (2,486) (3,690)
ASSETS                    
Total assets 3,373       1,739       3,373 1,739
Radiopharmaceuticals
                    
Total Sales:                    
Revenues                 0 12
Operating loss:                    
Loss from operations                 (862) (1,026)
ASSETS                    
Total assets 509       945       509 945
Unallocated
                    
Operating loss:                    
Loss from operations                 0 (6)
ASSETS                    
Total assets $ 0       $ 1       $ 0 $ 1
XML 80 R15.htm IDEA: XBRL DOCUMENT v2.4.0.8
CUSTOMER DEPOSITS
 12 Months Ended
Dec. 31, 2013
Deposits, By Customer, Alternative [Abstract]  
Customer Deposits
8.
CUSTOMER DEPOSITS
 
Customer deposits represent amounts paid to the Company by customers for devices in advance of manufacturing completion and/or shipment of the device to the customer.  Deposit amounts may vary depending on the contract. Customer deposits at December 31, 2013 and 2012, were $658,000 and $746,000, respectively. Included in customer deposits at December 31, 2013 and 2012 were deposits of approximately $658,000 and $669,000 from a customer that had placed an order in 2007 for five Nuclear Pharm-Assist™ systems.  As of the date of this report, there can be no assurance that this customer will fulfill its order for these devices.
 
Also, included in customer deposits at December 31, 2012 are $77,000 deposits on two Attrius® systems.
 
Our customer sales contracts require our customers to pay the Company 30% upon signing the contract, 60% upon notification to ship, and the remaining 10% after customer acceptance.
XML 81 R60.htm IDEA: XBRL DOCUMENT v2.4.0.8
Summary of Convertible Debt and Initial Accounting of Issuances (Detail) (USD $)
 12 Months Ended
Dec. 31, 2013
Dec. 31, 2012
Debt Instrument [Line Items]    
Proceeds from convertible debt issuance $ 2,520,000 $ 2,210,000
Initial Accounting One
    
Debt Instrument [Line Items]    
Proceeds from convertible debt issuance 2,460,000  
Initial Accounting Two
    
Debt Instrument [Line Items]    
Proceeds from convertible debt issuance 2,520,000  
Stock Warrants | Initial Accounting One
    
Debt Instrument [Line Items]    
Proceeds from convertible debt issuance (331,000)  
Embedded conversion derivative liability | Initial Accounting One
    
Debt Instrument [Line Items]    
Proceeds from convertible debt issuance (2,129,000)  
Embedded conversion derivative liability | Initial Accounting Two
    
Debt Instrument [Line Items]    
Proceeds from convertible debt issuance $ (1,500,000)  
XML 82 R13.htm IDEA: XBRL DOCUMENT v2.4.0.8
PROPERTY AND EQUIPMENT
 12 Months Ended
Dec. 31, 2013
Property, Plant and Equipment [Abstract]  
Property and equipment
6.
PROPERTY AND EQUIPMENT
 
Property and equipment at December 31, 2013 and 2012 consisted of the following (in thousands):
 
 
 
December 31,
 
 
 
2013
 
2012
 
Buildings
 
$
500
 
$
500
 
Furniture and fixtures
 
 
88
 
 
75
 
Leasehold improvements
 
 
72
 
 
72
 
Computer equipment
 
 
62
 
 
60
 
Research equipment
 
 
667
 
 
667
 
Machinery and equipment
 
 
158
 
 
142
 
 
 
 
1,547
 
 
1,516
 
Less: Accumulated depreciation
 
 
(503)
 
 
(346)
 
 
 
$
1,044
 
$
1,170
 
XML 83 R14.htm IDEA: XBRL DOCUMENT v2.4.0.8
ACCOUNTS PAYABLE AND ACCRUED LIABILITIES
 12 Months Ended
Dec. 31, 2013
Accounts Payable and Accrued Liabilities [Abstract]  
Accounts Payable and Accrued Liabilities
7.
ACCOUNTS PAYABLE AND ACCRUED LIABILITIES
 
Accounts payable and accrued liabilities at December 31, 2013 and, 2012 consisted of the following (in thousands):
 
 
 
December 31,
 
 
 
2013
 
2012
 
Trade accounts payable
 
$
849
 
$
1,127
 
Accrued royalties
 
 
87
 
 
87
 
Accrued interest
 
 
278
 
 
154
 
Sales taxes payable
 
 
89
 
 
78
 
Accrued compensation
 
 
70
 
 
80
 
Other accrued expenses
 
 
28
 
 
108
 
 
 
 
 
 
 
 
 
Total
 
$
1,401
 
$
1,634
 
XML 84 R16.htm IDEA: XBRL DOCUMENT v2.4.0.8
CONVERTIBLE DEBENTURES
 12 Months Ended
Dec. 31, 2013
Convertible Debt [Abstract]  
Convertible Debentures
9.
CONVERTIBLE DEBENTURES
 
Convertible Debentures 2012
 
On January 12, 2012, the Company acquired a building in Westmont, Illinois, which the Company previously leased from a related party for corporate and administrative offices (see Note 17). As a part of the price consideration, the Company issued the related party a convertible debenture in the principal amount of $250,000, which shall be due on December 31, 2013 and bears interest at 8% per year payable quarterly in cash. In addition, the Company issued warrants (“Warrants”) to the related party to purchase 25,000,000 shares of the Company’s common stock, par value $0.01 per share (the “Common Stock”), at an exercise price of $0.01 per share and expiring on December 31, 2013. The related party is entitled to convert the accrued interest and principal of the convertible debentures into common stock of the Company at a conversion price equal to 55% of the lowest daily volume weighted average price for the three trading days preceding conversion. During the period ended December 31, 2012, the Company has converted $100,000 of the principal amount of the debt into 18,181,818 shares of common stock and recorded loss on debt settlement of $44,661.
 
During the twelve months ended December 31, 2012, the Company issued additional of $2,210,000 of convertible debt with maturity date December 31, 2013, of which $460,000 bears 8% interest and $1,750,000 is non-interest bearing. $510,000 of the convertible debt was issued to unrelated parties, and $1,700,000 to related parties. In connection with the issuances the Company issued warrants (“Warrants”) to purchase 68,500,000 shares of the Company’s Common Stock, at an exercise price of $0.01 per share and expiring on December 31, 2013. The lender is entitled to convert the accrued interest and principal of the Convertible Debentures into common stock of the Company at a conversion price equal to 55% of the lowest daily volume weighted average price for the three trading days preceding conversion.
 
Initial Accounting
 
Under the initial accounting, the Company separated the Convertible Debentures instrument into component parts of the Convertible Debt, the $0.01 Warrants and the embedded conversion derivative liability. The Company estimated the fair value of each component as of the date of the issuance. The fair value of the embedded conversion derivative liability exceeded the value of the Convertible Debt less the allocation of the liability to the $0.01 Warrants, which resulted in a debt discount of $2,460,000. The discount is accreted to interest expense over the life of the Convertible Debt.
 
The following is a summary of Convertible Debt and the initial accounting of the issuances (in thousands):
 
Convertible debt issuance
 
$
2,460
 
 
 
 
 
 
Allocation of debt to warrants
 
 
(331)
 
 
 
 
 
 
Allocation of debt to embedded conversion derivative liability
 
 
(2,129)
 
  
Convertible Debentures 2013
 
In December 2013, the Company issued $2,520,000 of convertible debentures “(Convertible Debentures”) to certain investors (“Investors”). The Convertible Debentures do not accrue interest. The debentures mature on December 31, 2014. The Investors are entitled to convert the accrued interest and principal of the Convertible Debentures into common stock of the Company at a conversion price equal to 55% of the lowest daily volume weighted average price for the three trading days preceding conversion. On December 9, 2013, one of the Investors agreed to convert $1,000,000 of his outstanding debt, pending authorization and/or issuance of additional shares of common stock. As of December 9, 2013, there were not enough shares available to convert. 
 
Initial Accounting
 
Under the initial accounting, the Company separated the Convertible Debentures instrument into debt and the embedded conversion derivative liability. The Company allocated the proceeds to the embedded conversion derivative liability. The fair value of the embedded conversion derivative liability exceeded the proceeds from the Convertible Debentures, which resulted in a debt discount of $1,500,000. The debt is accreted to interest expense over the life of the Convertible Debentures.
 
The following is a summary of the proceeds from the issuance of the Convertible Debentures and the initial accounting of the issuance (in thousands):
 
Proceeds from convertible debt issuance
 
$
2,520
 
 
 
 
 
 
Allocation of proceeds to embedded conversion derivative liability
 
 
(1,500)
 
 
Convertible debentures as of December 31, 2013
 
As of December 31, 2013, the holders of the convertible debentures issued in 2012 agreed to extend those issuances through December 31, 2014. The related Warrants were also extended through December 31, 2014. Approximately $821,000 in expense was recorded for the year ended December 31, 2013 related to modification of the Warrants.
 
As of December 31, 2013, convertible debt totaled $5,780,000, of which $1,328,000 was attributable to the discount on debt. These notes originally were set to mature on December 31, 2013 but were extended under existing terms through December 31, 2014 or were presented for conversion subsequent to year end.
 
During the years ended December 31, 2013 and 2012, the Company recognized interest expense related to Convertible Debentures of $1,970,000 and $1,628,000, respectively. As of December 31, 2013 and December 31, 2012, accrued interest on Convertible Debentures was $277,542 and $148,741 respectively. Convertible Debentures outstanding as of December 31, 2013 and 2012 were as follows (in thousands):
 
December 31, 2013
 
Unrelated
parties
 
Related parties
 
Total
 
 
 
 
 
 
 
 
 
 
 
 
Convertible debentures- face value
 
$
4,030
 
$
1,750
 
$
5,780
 
Debt discount
 
 
(1,328)
 
 
0
 
 
(1,328)
 
Total convertible debentures
 
 
2,702
 
 
1,750
 
$
4,452
 
Less current portion
 
 
(2,702)
 
 
(1,750)
 
 
(4,452)
 
Long term portion
 
$
-
 
$
-
 
$
-
 
 
December 31, 2012
 
Unrelated
parties
 
Related parties
 
Total
 
 
 
 
 
 
 
 
 
 
 
 
Convertible debentures- face value
 
$
1,510
 
$
1,850
 
$
3,360
 
Debt discount
 
 
(350)
 
 
(1,448)
 
 
(1,798)
 
Total current convertible debentures
 
$
1,160
 
$
402
 
$
1,562
 
 
Subsequent to year end, various holders of debt issued in 2012 and 2013 agreed to convert their convertible debt pending authorization of additional common stock at a specific price based on the weighted average close price of the three days prior to the conversion. A total of $2,220,000 have been presented for conversion effective January 2014. Of the $2,220,000, $1,120,000 was debt held by unrelated parties and $1,100,000 was debt held by related parties.
XML 85 R64.htm IDEA: XBRL DOCUMENT v2.4.0.8
Notes Payable - Capital Lease - Additional Information (Detail) (USD $)
 12 Months Ended
Dec. 31, 2013
Dec. 31, 2012
Capital Leased Assets [Line Items]    
Capital lease for equipment interest rate 7.25%  
Capital leased assets, gross $ 16,300 $ 0
Capital leases, lessee balance sheet, assets by major class, accumulated depreciation 1,165 0
Capital leases, lessee balance sheet, assets by major class, flight equipment, accumulated depreciation $ 1,165 $ 0
XML 86 R85.htm IDEA: XBRL DOCUMENT v2.4.0.8
Subsequent Events - Additional Information (Detail) (Subsequent Event, USD $)
Mar. 31, 2014
Subsequent Event
  
Subsequent Event [Line Items]  
Convertible Notes Payable $ 320,000
XML 87 R66.htm IDEA: XBRL DOCUMENT v2.4.0.8
Stockholders' Equity - Additional Information (Detail) (USD $)
 1 Months Ended 0 Months Ended 1 Months Ended 0 Months Ended 1 Months Ended 12 Months Ended 0 Months Ended 3 Months Ended 12 Months Ended 1 Months Ended 3 Months Ended 12 Months Ended 1 Months Ended 1 Months Ended 1 Months Ended 12 Months Ended 1 Months Ended 0 Months Ended 1 Months Ended 1 Months Ended 0 Months Ended 1 Months Ended 0 Months Ended 1 Months Ended 1 Months Ended 1 Months Ended 12 Months Ended 1 Months Ended 12 Months Ended
May 31, 2013
Sep. 10, 2012
Aug. 21, 2012
Jul. 17, 2012
Jul. 18, 2012
Jun. 19, 2012
Jan. 04, 2012
Apr. 12, 2013
May 21, 2012
Jan. 09, 2012
Jan. 12, 2012
May 29, 2012
Apr. 05, 2012
Mar. 14, 2012
Mar. 02, 2012
Jan. 19, 2012
Jan. 20, 2012
Dec. 31, 2013
Dec. 31, 2012
Apr. 11, 2013
Nov. 30, 2012
Sep. 30, 2012
Dec. 31, 2012
2012 Plan
Jan. 17, 2012
2012 Plan
Jan. 17, 2012
January Issuance
Mar. 31, 2013
January Issuance
Dec. 31, 2012
January Issuance
Nov. 30, 2012
January Issuance Additional Issues
Mar. 31, 2013
January Issuance Additional Issues
Dec. 31, 2012
January Issuance Additional Issues
Jan. 19, 2012
Royalties
Dec. 31, 2012
Convertible Debt
Apr. 05, 2012
Convertible Debt
Jun. 07, 2012
Convertible Debt
Lenders
May 07, 2012
Convertible Debt
Lenders
May 31, 2013
Before Amendment
Jan. 04, 2012
Before Amendment
May 31, 2013
After Amendment
Jan. 04, 2012
After Amendment
Apr. 11, 2013
Series H Junior Convertible Preferred Stock
Aug. 31, 2012
Series B Preferred Stock
Jun. 19, 2012
Series B Preferred Stock
May 21, 2012
Series B Preferred Stock
May 29, 2012
Series B Preferred Stock
Apr. 05, 2012
Series B Preferred Stock
Mar. 02, 2012
Series B Preferred Stock
Jan. 31, 2010
Series B Preferred Stock
Dec. 31, 2013
Series B Preferred Stock
Jun. 19, 2012
Series A Preferred Stock
Jun. 19, 2012
Series G Preferred Stock
Jan. 19, 2012
MIT
Jan. 04, 2012
Extended Expiration
Mar. 14, 2012
Extended Expiration
Jan. 20, 2012
Extended Expiration
May 20, 2012
Investor
Mar. 14, 2012
Investor
Jan. 19, 2012
Investor
Jun. 30, 2012
Investor
Jan. 19, 2012
Investor
Extended Expiration
Jan. 12, 2012
Related Parties
Jan. 19, 2012
Related Parties
Jan. 12, 2012
Related Parties
Convertible Debt
Jan. 19, 2012
Related Parties
Convertible Debt
May 29, 2012
Related Parties
Convertible Debt
Mar. 14, 2012
Vendor
Apr. 05, 2012
Vendor
Nov. 30, 2012
Chief Executive Officer
Dec. 31, 2012
Chief Executive Officer
Apr. 11, 2013
Chief Executive Officer
Nov. 30, 2012
Chief Financial Officer
Dec. 31, 2012
Chief Financial Officer
Apr. 11, 2013
Chief Financial Officer
Stockholders Equity [Line Items]                                                                                                                                                
Stock issued during period, shares, issued for services     1,000,000 1,000,000 1,000,000 3,970,786 400,000 621,000 175,000 1,400,000       1,200,000 3,000,000                                                                                                   600,000              
Fair market value of common stock               $ 0.008                                                                                                                                
Consulting fees               $ 5,000                                                                                                                                
Cost method investments                                       750,000                                                                                                 500,000     250,000
Preferred stock, shares issued                                                                               7,500,000                                                                
Preferred stock, par value             $ 1.00                                                                 $ 0.01                                                                
Conversion of stock, description                                                                               Original Issuance Price of $0.10 and divided by seventy percent (70%) of the daily weighted volume average price for the three trading days prior to conversion.                                                                
Preferred stock, voting rights                                                                               two hundred (200) votes per share                                                                
Stockholders equity, reverse stock split ratio of 1 for 100                                                                                                                                              
Capital stock, shares authorized                                                                       3,020,000,000 810,000,000 520,000,000 3,020,000,000                                                                  
Common stock, shares authorized 500,000,000           3,000,000,000                     3,000,000,000 3,000,000,000                                                                                                          
Preferred stock, shares authorized 20,000,000           20,000,000                                                                                                                                  
Common stock, par value $ 0.0001           $ 0.01       $ 0.01             $ 0.01 $ 0.01                         $ 0.01                                                       $ 0.01               $ 0.01     $ 0.01  
Common stock, subscriptions             150,000   130,000       28,000 35,000   100,000 50,000                                                                                                              
Common stock, shares issued             15,000,000   15,000,000       2,800,000 3,500,000   27,000,000 5,000,000 1,452,548,262 1,451,927,262                       76,261 1,500,000 39,682,539                                   5,000,000             2,000,000         25,000,000 18,181,818   2,208,750            
Number of shares converted   10,000,000                           1,923,223                                                 1,188,836 118,149 73,226 231,190 634,000 603,711     16,667 18,200                                            
Number of common shares issued upon conversion of preferred shares   6,666,667             7,322,636     23,119,000 63,400,000   60,371,100 192,322,258                                                 118,883,629 11,814,878             16,667 2,020,000                                            
Warrants issued             15,000,000   13,000,000       3,100,000       5,000,000                                 4,000,000 4,000,000                                 20,000,000 750,000 7,500,000 2,000,000 3,500,000 10,000,000   30,000,000 35,000,000 35,000,000                      
Expiration date of warrants             2013-12-31   2013-12-31   2013-12-31   2013-12-31 2013-12-31     2013-12-31                                 2013-12-31 2013-12-31                                     2013-12-31 2013-12-31 2013-12-31 2013-12-31   2013-12-31 2013-12-31 2013-12-31                      
Convertible debenture, maturity date                                                                                                                           Dec. 31, 2013 Dec. 31, 2013         Dec. 31, 2013     Dec. 31, 2013  
Debt Instrument, Interest Rate                     8.00%                     8.00%                                                                               8.00% 8.00%                  
Issuance of common stock for services     10,000 10,000     4,000   2,000 14,000     26,456 20,000 51,000     5,000 442,000                                                                                           10,000              
Conversion of stock, amount converted   35,605                                                                                                                                            
Gain loss on settlement of conversion obligation   54,395                                                                                                                                            
Class of warrant or right, Number of securities called by warrants or rights                                         10,500,000                                                                                           37,500,000          
Warrant exercise price per share                     0.01             2.00     0.01                                                                             0.01             0.01          
Debt conversion, converted instrument, amount                                   0 269,000                                                                                               1,320,000     380,000    
Proceeds from convertible debt issuance                                   2,520,000 2,210,000                         50,000                                                                                
Stock options granted to employees, shares                                                 177,600,000     20,000,000                                     2,500,000                                                  
Stock options granted to employees, exercise price                                                 $ 0.01                                           $ 1.00                                                  
Remaining weighted average contractual term of options granted                                                     2 years 18 days     2 years 18 days                                 3 years                                                  
Stock based compensation expense                                   656,000 1,784,000               1,735,000   49,000                                   2,500,000 567,567                                                
Number of shares authorized                                               200,000,000                                                                                                
Additional expenses recorded within next twelve months                                                   39,000       49,000                                                                                    
Options forteitures                                                     7,000,000                                                                                          
Options outstanding                                             190,600,000       170,600,000                                         2,070,000                                                
Options outstanding intrinsic value                                                     $ 187,600     $ 0                                                                                    
Market value of stock price at grant date                                                     $ 0.011     $ 0.008                                                                                    
Shares available for grant                                             9,400,000                                                                                                  
Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period, Total                                                                                               430,000                                                
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number, Beginning Balance                                             190,600,000       170,600,000                                         2,070,000                                                
XML 88 R63.htm IDEA: XBRL DOCUMENT v2.4.0.8
Future Maturities of Notes Payable (Detail) (USD $)
Dec. 31, 2013
Debt Instrument [Line Items]  
2014 $ 1,130,000
2015 $ 455,000
XML 89 R34.htm IDEA: XBRL DOCUMENT v2.4.0.8
PROPERTY AND EQUIPMENT (Tables)
 12 Months Ended
Dec. 31, 2013
Property, Plant and Equipment [Abstract]  
PROPERTY AND EQUIPMENT
Property and equipment at December 31, 2013 and 2012 consisted of the following (in thousands):
 
 
 
December 31,
 
 
 
2013
 
2012
 
Buildings
 
$
500
 
$
500
 
Furniture and fixtures
 
 
88
 
 
75
 
Leasehold improvements
 
 
72
 
 
72
 
Computer equipment
 
 
62
 
 
60
 
Research equipment
 
 
667
 
 
667
 
Machinery and equipment
 
 
158
 
 
142
 
 
 
 
1,547
 
 
1,516
 
Less: Accumulated depreciation
 
 
(503)
 
 
(346)
 
 
 
$
1,044
 
$
1,170
 
XML 90 R51.htm IDEA: XBRL DOCUMENT v2.4.0.8
Acquisition of MIT - Additional Information (Detail) (USD $)
 0 Months Ended 3 Months Ended 12 Months Ended
Jan. 17, 2012
Jun. 30, 2013
Dec. 31, 2013
Dec. 31, 2012
Business Acquisition [Line Items]        
Issuance of common shares in order to acquire MIT 5,000,000      
Earn-out-payment as a percentage of net income 20.00%      
Acquisition cost       $ 12,000
Patent 14,000      
Useful life of patents 6 years      
Contingent consideration arrangement required cash payments, percentage of net income   20.00%    
Business combination contingent consideration arrangements, low range 0      
Business combination contingent consideration arrangements, high range 3,000,000      
Business combination contingent consideration fair value 205,000      
End year of projected net income to determine fair value of contingent consideration 2018      
Other General and Administrative Expense     141,000  
Fair value inputs, discount rate 25.00%      
Business combination contingent consideration payment due date Dec. 31, 2018      
MIT
        
Business Acquisition [Line Items]        
Patent $ 14,000      
XML 91 R21.htm IDEA: XBRL DOCUMENT v2.4.0.8
OTHER EXPENSES
 12 Months Ended
Dec. 31, 2013
Other Expenses [Abstract]  
OTHER EXPENSES
14.
OTHER EXPENSES
 
During the years ended December 31, 2013 and 2012, the Company recorded other expenses of approximately $3,766,000 and $3,233,000, respectively. Other expenses include interest expense, derivative expenses and other gains and losses.
 
Interest expense was $2,137,000 and $1,753,000 for the years ended December 31, 2013 and 2012, respectively. $1,910,000 and $1,628,000 of the total interest expense for the years ended December 31, 2013 and 2012, respectively, was related to the accretion of debt discount associated with convertible debt.
 
For the years ended December 31, 2013 and 2012, the Company recorded losses of approximately $665,000 and $726,000, respectively, on fair value adjustments to embedded conversion derivative liability associated with the convertible debt. Debt modification expense was $821,000 and $432,000 for the years ended December 31, 2013 and 2012, respectively.
 
During the year ended December 31, 2012, the Company also recorded $18,000 loss on the disposal of property and equipment, $282,000 loss on settlement and other expenses of $22,000. During the year ended December 31, 2013 the Company recorded other expenses of $143,000, which is made up of foreign currency translation losses reclassified out of accumulated other comprehensive income.
XML 92 R26.htm IDEA: XBRL DOCUMENT v2.4.0.8
COMMITMENTS AND CONTINGENCIES
 12 Months Ended
Dec. 31, 2013
Commitments and Contingencies Disclosure [Abstract]  
COMMITMENTS AND CONTINGENCIES
19.
COMMITMENTS AND CONTINGENCIES
 
Lease Agreements
 
On April 19, 2010, the Company entered into an operating lease agreement with a third party for warehousing and office space in Niagara, New York. The lease expires in May 2014, with an option to renew for an additional three years. Monthly rent is $1,800. The Company is currently negotiating an extension.
 
On July 7, 2011, the Company entered into an operating lease with a third party for space for medical device assembly and warehousing at a building in Fishers, Indiana. The Company is required to make payments of $5,083 each month from December 1, 2011 through November 13, 2013, and $5,287 from December 1, 2013 through November 30, 2016. The amount of leased space at this location is approximately 9,761 square feet.
 
On December 5, 2011, MIT entered into an operating lease with a third party for space for warehousing at a building in Lubbock, Texas. The Company will be required to make payments of $1,475 each month from month to month.
 
Total rent expense for the years ended December 31, 2013 and 2012 was $84,011 and $69,512, respectively.
 
Future minimum rental commitments under non-cancellable facilities operating leases as of December 31, 2013 are as follows:
 
Year Ending December 31,
 
 
 
 
2014
 
$
72,444
 
2015
 
 
63,444
 
2016
 
 
58,157
 
 
Litigation
 
On June 8, 2012, the owner of the radiopharmaceutical manufacturing facility the Company formerly leased in Crown Point, Indiana commenced an action to recover the use of the premises and the remaining rent due under the lease. On November 14, 2012, the owner was awarded a judgment against the Company in the amount of $85,525.98 plus interest at the rate of 8%. The Company and the owner agreed to monthly payments in the minimum amount of $5,000 until the judgment is paid in its entirety.
 
In May, 2013, the Company was served with a First Amended Complaint in an action commenced against related its CEO and principal shareholder. The plaintiff in the action is seeking to enforce a judgment against the CEO and principal shareholder and is seeking to have the Company’s Westmont, Illinois offices, which it purchased from the CEO, reconveyed. The CEO and the principal shareholder have disputed the basis of the judgment and the Company has denied the allegations in the Complaint and is defending the action. The action is currently in the discovery stage.
XML 93 R49.htm IDEA: XBRL DOCUMENT v2.4.0.8
Derivatives valued using the Black-Scholes option pricing model (Detail) (USD $)
 12 Months Ended
Dec. 31, 2013
Dec. 31, 2012
Derivatives [Line Items]    
Market value of stock on measurement date $ 0.0048 $ 0.0085
Risk-free interest rate 0.11% 0.15%
Dividend yield 0.00% 0.00%
Volatility factor 200.00% 141.00%
Term 1 year 1 year
XML 94 R41.htm IDEA: XBRL DOCUMENT v2.4.0.8
INCOME TAXES (Tables)
 12 Months Ended
Dec. 31, 2013
Income Tax Disclosure [Abstract]  
Schedule of Deferred Tax Assets and Liabilities
The composition of deferred tax assets and the related tax effects at December 31, 2013 and 2012 are as follows (in thousands):
 
 
 
2013
 
2012
 
Deferred tax assets:
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Domestic net operating losses
 
$
18,816
 
$
19,529
 
Stock option compensation
 
 
223
 
 
606
 
Book/tax differences in fixed assets
 
 
27
 
 
32
 
Accrued liabilities and reserves
 
 
327
 
 
272
 
 
 
 
19,393
 
 
20,439
 
Valuation allowance
 
 
(19,393)
 
 
(20,439)
 
 
 
$
-
 
$
-
 
Schedule of Components of Income Tax Expense (Benefit)
The difference between the income tax benefit in the accompanying statement of operations and the amount that would result if the U.S. Federal statutory rate of 34% were applied to pre-tax loss is as follows (amounts in thousands):
 
 
 
2013
 
2012
 
 
 
Amount
 
%
 
Amount
 
%
 
Benefit for income taxes at federal statutory rate
 
$
2,415
 
 
34
%
$
2,704
 
 
34
%
Derivative losses
 
 
(226)
 
 
(3)
 
 
(596)
 
 
(7)
 
Discount amortization and other
 
 
(949)
 
 
(13)
 
 
(565)
 
 
(7)
 
Change in rates and other
 
 
(2,286)
 
 
(32)
 
 
21
 
 
-
 
Change in valuation allowance
 
 
1,046
 
 
14
 
 
(1,564)
 
 
(20)
 
 
 
$
-
 
 
-
%
$
-
 
 
-
%
XML 95 R5.htm IDEA: XBRL DOCUMENT v2.4.0.8
CONSOLIDATED STATEMENT OF STOCKHOLDERS' EQUITY (DEFICIT) (USD $)
Total
USD ($)
Series B Preferred Stock
USD ($)
Series G Preferred Stock
USD ($)
Series H Preferred Stock
USD ($)
Stock Payable [Member]
USD ($)
Notes Payable, Other Payables [Member]
USD ($)
Conversion Of Series B Stock [Member]
Series B Preferred Stock
USD ($)
Conversion Of Series G Stock [Member]
Series G Preferred Stock
USD ($)
Series A Preferred Stock [Member]
USD ($)
Series A Preferred Stock [Member]
Conversion Of Series A Stock [Member]
USD ($)
Series S Preferred Stock [Member]
USD ($)
Common Stock [Member]
USD ($)
Common Stock [Member]
Stock Payable [Member]
USD ($)
Common Stock [Member]
Notes Payable, Other Payables [Member]
USD ($)
Common Stock [Member]
Conversion Of Series A Stock [Member]
Common Stock [Member]
Conversion Of Series B Stock [Member]
USD ($)
Common Stock [Member]
Conversion Of Series G Stock [Member]
USD ($)
Additional Paid-in Capital [Member]
USD ($)
Additional Paid-in Capital [Member]
Series H Preferred Stock
USD ($)
Additional Paid-in Capital [Member]
Stock Payable [Member]
USD ($)
Additional Paid-in Capital [Member]
Conversion Of Series A Stock [Member]
USD ($)
Additional Paid-in Capital [Member]
Conversion Of Series B Stock [Member]
USD ($)
Additional Paid-in Capital [Member]
Conversion Of Series G Stock [Member]
USD ($)
Accumulated Other Comprehensive Income (Loss) [Member]
USD ($)
Treasury Stock [Member]
USD ($)
Accumulated Deficit [Member]
USD ($)
Balance at Dec. 31, 2011 $ (2,868,000) $ 7,521,000 $ 19,000 $ 0         $ 457,000   $ 100,000 $ 7,567,000           $ 89,999,000           $ (143,000) $ (15,000) $ (108,373,000)
Balance (in shares) at Dec. 31, 2011   7,828,822 19,200 0         457,599   100,000 788,327,497                         602  
Conversion of preferred stock to common stock             (4,771,000) (19,000)   (9,000)           4,772,000 20,000       9,000 (1,000) (1,000)      
Issuance of common stock for services (in shares)             (4,772,335) (19,200)   (9,947)   41,165,240     16,667 477,233,501 2,020,000                  
Issuance of common stock for services 442,000                     412,000           30,000                
Close other comprehensive income (7,955,000)                                                  
Issuance of common stock for cash (in shares)                       38,300,000                            
Issuance of common stock for cash 383,000                     383,000                            
Issuance of common stock for investment (in shares)                       30,000,000 17,000,000 57,864,357                        
Issuance of common stock for investment 300,000       269,000 579,000           300,000 170,000 579,000           99,000            
Stock based compensation - stock options 1,784,000                                 1,784,000                
Exercise of warrants (in shares)   0 0 0         0   0                              
Exercise of warrants   0 0 0         0   0                              
Allocation of convertible debenture to fair value of warrants 331,000                                 331,000                
Conversion of convertible debenture to Series B (in shares)                     0                              
Conversion of convertible debenture to Series B   0                                                
Reclassification of warrant derivative liability to APIC upon conversion of convertible debenture 545,000                                 545,000                
Net Loss (7,955,000)                                                 (7,955,000)
Balance at Dec. 31, 2012 (6,190,000) 2,750,000 0 0         448,000   100,000 14,203,000           92,795,000           (143,000) (15,000) (116,328,000)
Balance (in shares) at Dec. 31, 2012 447,652 3,056,487 0 0             100,000 1,451,927,262                         602  
Issuance of Series H preferred stock 1,250,000     125,000                             1,125,000              
Issuance of common stock for services (in shares)       12,500,000               621,000                            
Issuance of common stock for services 5,000                     5,000                            
Close other comprehensive income (6,961,000)                                             143,000    
Stock based compensation - stock options (in shares)                       0                         0  
Stock based compensation - stock options 655,000                     0           655,000           0 0 0
Net Loss (7,104,000)                     0           0           0 0 (7,104,000)
Balance at Dec. 31, 2013 $ (11,241,000) $ 2,750,000 $ 0 $ 125,000         $ 448,000   $ 100,000 $ 14,208,000           $ 94,575,000           $ 0 $ (15,000) $ (123,432,000)
Balance (in shares) at Dec. 31, 2013   3,056,487 0 12,500,000         447,652   100,000 1,452,548,262                         0  
XML 96 R10.htm IDEA: XBRL DOCUMENT v2.4.0.8
ACQUISITION OF MIT
 12 Months Ended
Dec. 31, 2013
Business Acquisition [Abstract]  
ACQUISITION OF MIT
3.
ACQUISITION OF MIT
 
On January 17, 2012, the Company acquired Manhattan Isotope Technology LLC (“MIT”) upon consummation of a Membership Interest Purchase Agreement (the “Agreement”) with MIT and the interest-holders of MIT, whereby the Company acquired all of the issued and outstanding membership interests from the holders in exchange for: (i) the assumption of the liabilities of MIT; (ii) cash advances; (iii) earn-out payments equal to twenty percent (20%) of “Net Income” as defined in the Agreement; (iv) 5,000,000 common shares of Positron stock; and (v) entry into employment agreements with MIT’s employees.
 
In accordance with the transaction, the Company acquired the assets related to MIT’s business of refurbishing spent strontium-82/rubidium-82 and other radioisotope generators, recycling strontium-82 and other radioisotopes from generators, processing of strontium-82 and other radioisotopes, providing expertise in production of radioisotopes and radioisotopes services, including cash, equipment, leasehold improvements, patent, certain supply and distribution and other vendor contracts, goodwill and assumed liabilities including trade payables, accruals and a note payable with a commercial bank. The parties made customary representations, warranties and indemnities in the Agreement that are typical and consistent for a transaction of this size and scope.
 
The Company has included the financial results of MIT in the consolidated financial statements from the date of acquisition. MIT is included in the Radiopharmaceuticals operating segment.
 
The Company incurred acquisition costs of approximately $12,000 in 2012.
 
The following table summarizes the consideration transferred to acquire MIT at the acquisition date:
 
Fair Value of Consideration Transferred:
 
Common stock of Company
 
$
50,000
 
Contingent consideration
 
 
205,297
 
Total
 
$
255,297
 
 
The total purchase price for the MIT acquisition was allocated to the net tangible and intangible assets based upon their fair values as of January 17, 2012 as set forth below. The excess of the purchase price over the net assets was recorded as goodwill. The following table summarizes the fair values of the assets and liabilities assumed at the acquisition date.
 
Cash
 
$
829
 
Equipment and leasehold improvements
 
 
653,567
 
Patent
 
 
14,000
 
Trade and other payables
 
 
(59,282)
 
Note payable
 
 
(700,000)
 
Net liabilities assumed
 
$
(90,886)
 
 
 
 
 
 
Goodwill
 
$
346,183
 
 
The Company identified intangible assets associated with patents and assigned the fair value of $14,000. The useful life associated with patents was 6 years.
 
The acquisition of MIT includes a contingent consideration arrangement that requires cash payments to the previous members equal to 20% of “Net Income” as defined in the Agreement through December 31, 2018. The range of the undiscounted amounts the Company could owe under this arrangement is between $0 and $3,000,000. The fair value of the contingent consideration on the acquisition date of approximately $205,000 was estimated based on the present value of projected payments which were based on projected net income through 2018. These calculations and projections are based on significant inputs not observable in the market, which ASC 820 refers to as Level 3 inputs. Key assumptions include a discount rate of 25 percent as well as an increasing level of revenues and expenses based on probability factors at the acquisition date.
 
At December 31, 2013, the Company evaluated the cashflow projections included in the contingent consideration and determined that there was a decrease in the fair value of the contingent consideration and impairment of goodwill. The net effect of the adjustment is a decrease in general and administrative expenses of $141,000.
XML 97 R58.htm IDEA: XBRL DOCUMENT v2.4.0.8
Customer Deposits - Additional Information (Detail) (USD $)
In Thousands, unless otherwise specified
 12 Months Ended
Dec. 31, 2013
Dec. 31, 2012
Deposit Liabilities [Line Items]    
Customer deposits $ 658 $ 746
Sales contract payment terms advance percentage payable 30.00%  
Sales contract payment terms freight on road percentage payable 60.00%  
Sales contract payment terms customer acceptance percentage payable 10.00%  
Number of systems, orders placed 5  
Nuclear Pharm Assist Systems
    
Deposit Liabilities [Line Items]    
Customer deposits 658 669
Attrius Pet systems
    
Deposit Liabilities [Line Items]    
Customer deposits   $ 77
Number of systems, orders placed   2
XML 98 R82.htm IDEA: XBRL DOCUMENT v2.4.0.8
Future Minimum Rental Payments for Operating Leases (Detail) (USD $)
Dec. 31, 2013
Future Minimum Rental Payments For Operating Leases [Line Items]  
2014 $ 72,444
2015 63,444
2016 $ 58,157
XML 99 R69.htm IDEA: XBRL DOCUMENT v2.4.0.8
Summary of Common Stock Option Activity (Detail) (Common Stock, USD $)
 12 Months Ended
Dec. 31, 2013
Dec. 31, 2012
Common Stock
    
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]    
Beginning Balance (Shares Issuable Under Outstanding Options) 190,600,000   
Forfeited (Shares Issuable Under Outstanding Options) (2,500,000) 197,600,000
Expired/forfeited (Shares Issuable Under Outstanding Options) 0 (7,000,000)
Ending Balance (Shares Issuable Under Outstanding Options) 188,100,000 190,600,000
Exercisable, (Shares Issuable Under Outstanding Options) 188,100,000  
Beginning Balance (Price Range or Weighted Average Exercise Price) $ 0.01  
Issued (Price Range or Weighted Average Exercise Price) $ 0.01 $ 0.01
Expired/forfeited (Price Range or Weighted Average Exercise Price) $ 0 $ 0.01
Ending Balance (Price Range or Weighted Average Exercise Price) $ 0.01 $ 0.01
Exercisable, (Weighted Average Exercise Price) $ 0.01  
XML 100 R27.htm IDEA: XBRL DOCUMENT v2.4.0.8
SELECTED QUARTERLY FINANCIAL DATA
 12 Months Ended
Dec. 31, 2013
Quarterly Financial Data [Abstract]  
SELECTED QUARTERLY FINANCIAL DATA
20.
SELECTED QUARTERLY FINANCIAL DATA (UNAUDITED) (in thousands)
 
 
 
Quarter ended
 
 
 
March 31,
2013
 
June 30,
2013
 
September 30,
2013
 
December 31,
2013
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Net Sales
 
$
371
 
$
432
 
$
351
 
$
476
 
Gross profit (loss)
 
 
125
 
 
14
 
 
121
 
 
164
 
Net loss
 
 
(1,201)
 
 
(1,088)
 
 
(1,390)
 
 
(3,425)
 
Net (loss) per share - basic and diluted
 
$
(0.00)
 
$
(0.00)
 
$
(0.00)
 
$
(0.00)
 
Weighted average basic and diluted shares
 
 
1,451,927
 
 
1,452,425
 
 
1,452,548
 
 
1,452,548
 
 
 
 
Quarter ended
 
 
 
March 31,
2012
 
June 30,
2012
 
September 30,
2012
 
December 31,
2012
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Net Sales
 
$
829
 
$
1,224
 
$
370
 
$
378
 
Gross profit (loss)
 
 
359
 
 
331
 
 
106
 
 
33
 
Net loss
 
 
(2,962)
 
 
(1,235)
 
 
(1,568)
 
 
(2,190)
 
Net (loss) per share - basic and diluted
 
$
(0.00)
 
$
(0.00)
 
$
(0.00)
 
$
(0.00)
 
Weighted average basic and diluted shares
 
 
970,887
 
 
1,256,915
 
 
1,360,107
 
 
1,451,140
 
XML 101 FilingSummary.xml IDEA: XBRL DOCUMENT 2.4.0.8 Html 334 413 1 true 89 0 false 5 false false R1.htm 101 - Document - Document And Entity Information Sheet http://www.positron.com/role/DocumentAndEntityInformation Document And Entity Information true false R2.htm 102 - Statement - CONSOLIDATED BALANCE SHEETS Sheet http://www.positron.com/role/ConsolidatedBalanceSheets CONSOLIDATED BALANCE SHEETS false false R3.htm 103 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical) Sheet http://www.positron.com/role/ConsolidatedBalanceSheetsParenthetical CONSOLIDATED BALANCE SHEETS (Parenthetical) false false R4.htm 104 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME Sheet http://www.positron.com/role/ConsolidatedStatementsOfOperationsAndComprehensiveIncome CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME false false R5.htm 105 - Statement - CONSOLIDATED STATEMENT OF STOCKHOLDERS' EQUITY (DEFICIT) Sheet http://www.positron.com/role/ConsolidatedStatementOfStockholdersEquityDeficit CONSOLIDATED STATEMENT OF STOCKHOLDERS' EQUITY (DEFICIT) false false R6.htm 106 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS Sheet http://www.positron.com/role/ConsolidatedStatementsOfCashFlows CONSOLIDATED STATEMENTS OF CASH FLOWS false false R7.htm 107 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS (Parenthetical) Sheet http://www.positron.com/role/ConsolidatedStatementsOfCashFlowsParenthetical CONSOLIDATED STATEMENTS OF CASH FLOWS (Parenthetical) false false R8.htm 108 - Disclosure - DESCRIPTION OF BUSINESS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Sheet http://www.positron.com/role/DescriptionOfBusinessAndSummaryOfSignificantAccountingPolicies DESCRIPTION OF BUSINESS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES false false R9.htm 109 - Disclosure - GOING CONCERN Sheet http://www.positron.com/role/GoingConcern GOING CONCERN false false R10.htm 110 - Disclosure - ACQUISITION OF MIT Sheet http://www.positron.com/role/AcquisitionOfMit ACQUISITION OF MIT false false R11.htm 111 - Disclosure - OTHER ASSETS Sheet http://www.positron.com/role/OtherAssets OTHER ASSETS false false R12.htm 112 - Disclosure - INVENTORIES Sheet http://www.positron.com/role/Inventories INVENTORIES false false R13.htm 113 - Disclosure - PROPERTY AND EQUIPMENT Sheet http://www.positron.com/role/PropertyAndEquipment PROPERTY AND EQUIPMENT false false R14.htm 114 - Disclosure - ACCOUNTS PAYABLE AND ACCRUED LIABILITIES Sheet http://www.positron.com/role/AccountsPayableAndAccruedLiabilities ACCOUNTS PAYABLE AND ACCRUED LIABILITIES false false R15.htm 115 - Disclosure - CUSTOMER DEPOSITS Sheet http://www.positron.com/role/CustomerDeposits CUSTOMER DEPOSITS false false R16.htm 116 - Disclosure - CONVERTIBLE DEBENTURES Sheet http://www.positron.com/role/ConvertibleDebentures CONVERTIBLE DEBENTURES false false R17.htm 117 - Disclosure - NOTES PAYABLE AND ADVANCES FROM RELATED PARTIES Notes http://www.positron.com/role/NotesPayableAndAdvancesFromRelatedParties NOTES PAYABLE AND ADVANCES FROM RELATED PARTIES false false R18.htm 118 - Disclosure - NOTES PAYABLE - CAPITAL LEASE Notes http://www.positron.com/role/NotesPayableCapitalLease NOTES PAYABLE - CAPITAL LEASE false false R19.htm 119 - Disclosure - STOCKHOLDERS' EQUITY Sheet http://www.positron.com/role/StockholdersEquity STOCKHOLDERS' EQUITY false false R20.htm 120 - Disclosure - PREFERRED STOCK Sheet http://www.positron.com/role/PreferredStock PREFERRED STOCK false false R21.htm 121 - Disclosure - OTHER EXPENSES Sheet http://www.positron.com/role/OtherExpenses OTHER EXPENSES false false R22.htm 122 - Disclosure - LOSS PER SHARE Sheet http://www.positron.com/role/LossPerShare LOSS PER SHARE false false R23.htm 123 - Disclosure - INCOME TAXES Sheet http://www.positron.com/role/IncomeTaxes INCOME TAXES false false R24.htm 124 - Disclosure - 401(K) PLAN Sheet http://www.positron.com/role/KPlan 401(K) PLAN false false R25.htm 125 - Disclosure - RELATED PARTY TRANSACTIONS Sheet http://www.positron.com/role/RelatedPartyTransactions RELATED PARTY TRANSACTIONS false false R26.htm 126 - Disclosure - COMMITMENTS AND CONTINGENCIES Sheet http://www.positron.com/role/CommitmentsAndContingencies COMMITMENTS AND CONTINGENCIES false false R27.htm 127 - Disclosure - SELECTED QUARTERLY FINANCIAL DATA Sheet http://www.positron.com/role/SelectedQuarterlyFinancialData SELECTED QUARTERLY FINANCIAL DATA false false R28.htm 128 - Disclosure - SEGMENTS Sheet http://www.positron.com/role/Segments SEGMENTS false false R29.htm 129 - Disclosure - SUBSEQUENT EVENTS Sheet http://www.positron.com/role/SubsequentEvents SUBSEQUENT EVENTS false false R30.htm 130 - Disclosure - DESCRIPTION OF BUSINESS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies) Sheet http://www.positron.com/role/DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesPolicies DESCRIPTION OF BUSINESS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies) false false R31.htm 131 - Disclosure - DESCRIPTION OF BUSINESS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables) Sheet http://www.positron.com/role/DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesTables DESCRIPTION OF BUSINESS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables) false false R32.htm 132 - Disclosure - ACQUISITION OF MIT (Tables) Sheet http://www.positron.com/role/AcquisitionOfMitTables ACQUISITION OF MIT (Tables) false false R33.htm 133 - Disclosure - INVENTORIES (Tables) Sheet http://www.positron.com/role/InventoriesTables INVENTORIES (Tables) false false R34.htm 134 - Disclosure - PROPERTY AND EQUIPMENT (Tables) Sheet http://www.positron.com/role/PropertyAndEquipmentTables PROPERTY AND EQUIPMENT (Tables) false false R35.htm 135 - Disclosure - ACCOUNTS PAYABLE AND ACCRUED LIABILITIES (Tables) Sheet http://www.positron.com/role/AccountsPayableAndAccruedLiabilitiesTables ACCOUNTS PAYABLE AND ACCRUED LIABILITIES (Tables) false false R36.htm 136 - Disclosure - CONVERTIBLE DEBENTURES (Tables) Sheet http://www.positron.com/role/ConvertibleDebenturesTables CONVERTIBLE DEBENTURES (Tables) false false R37.htm 137 - Disclosure - NOTES PAYABLE AND ADVANCES FROM RELATED PARTIES (Tables) Notes http://www.positron.com/role/NotesPayableAndAdvancesFromRelatedPartiesTables NOTES PAYABLE AND ADVANCES FROM RELATED PARTIES (Tables) false false R38.htm 138 - Disclosure - Notes Payable - Capital Lease (Tables) Notes http://www.positron.com/role/NotesPayableCapitalLeaseTables Notes Payable - Capital Lease (Tables) false false R39.htm 139 - Disclosure - STOCKHOLDERS' EQUITY (Tables) Sheet http://www.positron.com/role/StockholdersEquityTables STOCKHOLDERS' EQUITY (Tables) false false R40.htm 140 - Disclosure - LOSS PER SHARE (Tables) Sheet http://www.positron.com/role/LossPerShareTables LOSS PER SHARE (Tables) false false R41.htm 141 - Disclosure - INCOME TAXES (Tables) Sheet http://www.positron.com/role/IncomeTaxesTables INCOME TAXES (Tables) false false R42.htm 142 - Disclosure - COMMITMENTS AND CONTINGENCIES (Tables) Sheet http://www.positron.com/role/CommitmentsAndContingenciesTables COMMITMENTS AND CONTINGENCIES (Tables) false false R43.htm 143 - Disclosure - SELECTED QUARTERLY FINANCIAL DATA (Tables) Sheet http://www.positron.com/role/SelectedQuarterlyFinancialDataTables SELECTED QUARTERLY FINANCIAL DATA (Tables) false false R44.htm 144 - Disclosure - SEGMENTS (Tables) Sheet http://www.positron.com/role/SegmentsTables SEGMENTS (Tables) false false R45.htm 145 - Disclosure - Description of Business and Summary of Significant Accounting Policies - Additional Information (Detail) Sheet http://www.positron.com/role/DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail Description of Business and Summary of Significant Accounting Policies - Additional Information (Detail) false false R46.htm 146 - Disclosure - Straight-line over estimated useful (Detail) Sheet http://www.positron.com/role/StraightlineOverEstimatedUsefulDetail Straight-line over estimated useful (Detail) false false R47.htm 147 - Disclosure - Embedded Conversion Derivative Liabilities Measured and Recorded at Fair Value on Recurring Basis (Detail) Sheet http://www.positron.com/role/EmbeddedConversionDerivativeLiabilitiesMeasuredAndRecordedAtFairValueOnRecurringBasisDetail Embedded Conversion Derivative Liabilities Measured and Recorded at Fair Value on Recurring Basis (Detail) false false R48.htm 148 - Disclosure - Reconciliation of Financial Instruments Recognized at Fair Value (Detail) Sheet http://www.positron.com/role/ReconciliationOfFinancialInstrumentsRecognizedAtFairValueDetail Reconciliation of Financial Instruments Recognized at Fair Value (Detail) false false R49.htm 149 - Disclosure - Derivatives valued using the Black-Scholes option pricing model (Detail) Sheet http://www.positron.com/role/DerivativesValuedUsingBlackscholesOptionPricingModelDetail Derivatives valued using the Black-Scholes option pricing model (Detail) false false R50.htm 150 - Disclosure - Going Concern - Additional Information (Detail) Sheet http://www.positron.com/role/GoingConcernAdditionalInformationDetail Going Concern - Additional Information (Detail) false false R51.htm 151 - Disclosure - Acquisition of MIT - Additional Information (Detail) Sheet http://www.positron.com/role/AcquisitionOfMitAdditionalInformationDetail Acquisition of MIT - Additional Information (Detail) false false R52.htm 152 - Disclosure - Summary of Consideration Transferred (Detail) Sheet http://www.positron.com/role/SummaryOfConsiderationTransferredDetail Summary of Consideration Transferred (Detail) false false R53.htm 153 - Disclosure - Summary of Fair Values of Assets and Liabilities Assumed (Detail) Sheet http://www.positron.com/role/SummaryOfFairValuesOfAssetsAndLiabilitiesAssumedDetail Summary of Fair Values of Assets and Liabilities Assumed (Detail) false false R54.htm 155 - Disclosure - Other Assets - Additional Information (Detail) Sheet http://www.positron.com/role/OtherAssetsAdditionalInformationDetail Other Assets - Additional Information (Detail) false false R55.htm 156 - Disclosure - Inventories (Detail) Sheet http://www.positron.com/role/InventoriesDetail Inventories (Detail) false false R56.htm 157 - Disclosure - Property and Equipment (Detail) Sheet http://www.positron.com/role/PropertyAndEquipmentDetail Property and Equipment (Detail) false false R57.htm 158 - Disclosure - Accounts Payable and Accrued Liabilities (Detail) Sheet http://www.positron.com/role/AccountsPayableAndAccruedLiabilitiesDetail Accounts Payable and Accrued Liabilities (Detail) false false R58.htm 159 - Disclosure - Customer Deposits - Additional Information (Detail) Sheet http://www.positron.com/role/CustomerDepositsAdditionalInformationDetail Customer Deposits - Additional Information (Detail) false false R59.htm 160 - Disclosure - Convertible Debentures - Additional Information (Detail) Sheet http://www.positron.com/role/ConvertibleDebenturesAdditionalInformationDetail Convertible Debentures - Additional Information (Detail) false false R60.htm 161 - Disclosure - Summary of Convertible Debt and Initial Accounting of Issuances (Detail) Sheet http://www.positron.com/role/SummaryOfConvertibleDebtAndInitialAccountingOfIssuancesDetail Summary of Convertible Debt and Initial Accounting of Issuances (Detail) false false R61.htm 162 - Disclosure - Convertible Debentures Outstanding (Detail) Sheet http://www.positron.com/role/ConvertibleDebenturesOutstandingDetail Convertible Debentures Outstanding (Detail) false false R62.htm 163 - Disclosure - Notes Payable and Advances from Related Parties - Additional Information (Detail) Notes http://www.positron.com/role/NotesPayableAndAdvancesFromRelatedPartiesAdditionalInformationDetail Notes Payable and Advances from Related Parties - Additional Information (Detail) false false R63.htm 164 - Disclosure - Future Maturities of Notes Payable (Detail) Notes http://www.positron.com/role/FutureMaturitiesOfNotesPayableDetail Future Maturities of Notes Payable (Detail) false false R64.htm 165 - Disclosure - Notes Payable - Capital Lease - Additional Information (Detail) Notes http://www.positron.com/role/NotesPayableCapitalLeaseAdditionalInformationDetail Notes Payable - Capital Lease - Additional Information (Detail) false false R65.htm 166 - Disclosure - Future Minimum Lease Payments and Present Value Of Payments (Detail) Sheet http://www.positron.com/role/FutureMinimumLeasePaymentsAndPresentValueOfPaymentsDetail Future Minimum Lease Payments and Present Value Of Payments (Detail) false false R66.htm 167 - Disclosure - Stockholders' Equity - Additional Information (Detail) Sheet http://www.positron.com/role/StockholdersEquityAdditionalInformationDetail Stockholders' Equity - Additional Information (Detail) false false R67.htm 168 - Disclosure - Summary of Series B Preferred Stock Option Activity (Detail) Sheet http://www.positron.com/role/SummaryOfSeriesBPreferredStockOptionActivityDetail Summary of Series B Preferred Stock Option Activity (Detail) false false R68.htm 169 - Disclosure - Determination Of Fair Market Value Using Black-Scholes Option Pricing Model (Detail) Sheet http://www.positron.com/role/DeterminationOfFairMarketValueUsingBlackscholesOptionPricingModelDetail Determination Of Fair Market Value Using Black-Scholes Option Pricing Model (Detail) false false R69.htm 170 - Disclosure - Summary of Common Stock Option Activity (Detail) Sheet http://www.positron.com/role/SummaryOfCommonStockOptionActivityDetail Summary of Common Stock Option Activity (Detail) false false R70.htm 171 - Disclosure - Summary of Warrant Activity Based on Common Stock Equivalents (Detail) Sheet http://www.positron.com/role/SummaryOfWarrantActivityBasedOnCommonStockEquivalentsDetail Summary of Warrant Activity Based on Common Stock Equivalents (Detail) false false R71.htm 172 - Disclosure - Summary Of Outstanding Common Stock Warrants (Detail) Sheet http://www.positron.com/role/SummaryOfOutstandingCommonStockWarrantsDetail Summary Of Outstanding Common Stock Warrants (Detail) false false R72.htm 173 - Disclosure - Preferred Stock - Additional Information (Detail) Sheet http://www.positron.com/role/PreferredStockAdditionalInformationDetail Preferred Stock - Additional Information (Detail) false false R73.htm 174 - Disclosure - Other Expenses - Additional Information (Detail) Sheet http://www.positron.com/role/OtherExpensesAdditionalInformationDetail Other Expenses - Additional Information (Detail) false false R74.htm 175 - Disclosure - Computation of Basic and Diluted Loss Per Share (Detail) Sheet http://www.positron.com/role/ComputationOfBasicAndDilutedLossPerShareDetail Computation of Basic and Diluted Loss Per Share (Detail) false false R75.htm 176 - Disclosure - Antidilutive Securities Not Included in Computation of Net Loss Per Share (Detail) Sheet http://www.positron.com/role/AntidilutiveSecuritiesNotIncludedInComputationOfNetLossPerShareDetail Antidilutive Securities Not Included in Computation of Net Loss Per Share (Detail) false false R76.htm 177 - Disclosure - Income Taxes - Additional Information (Detail) Sheet http://www.positron.com/role/IncomeTaxesAdditionalInformationDetail Income Taxes - Additional Information (Detail) false false R77.htm 178 - Disclosure - Composition Of Deferred Tax Assets (Detail) Sheet http://www.positron.com/role/CompositionOfDeferredTaxAssetsDetail Composition Of Deferred Tax Assets (Detail) false false R78.htm 179 - Disclosure - Components Of Income Tax Expense Benefit (Detail) Sheet http://www.positron.com/role/ComponentsOfIncomeTaxExpenseBenefitDetail Components Of Income Tax Expense Benefit (Detail) false false R79.htm 180 - Disclosure - 401(k) Plan - Additional Information (Detail) Sheet http://www.positron.com/role/KPlanAdditionalInformationDetail 401(k) Plan - Additional Information (Detail) false false R80.htm 181 - Disclosure - Related Party Transactions - Additional Information (Detail) Sheet http://www.positron.com/role/RelatedPartyTransactionsAdditionalInformationDetail Related Party Transactions - Additional Information (Detail) false false R81.htm 182 - Disclosure - Commitments and Contingencies - Additional Information (Detail) Sheet http://www.positron.com/role/CommitmentsAndContingenciesAdditionalInformationDetail Commitments and Contingencies - Additional Information (Detail) false false R82.htm 183 - Disclosure - Future Minimum Rental Payments for Operating Leases (Detail) Sheet http://www.positron.com/role/FutureMinimumRentalPaymentsForOperatingLeasesDetail Future Minimum Rental Payments for Operating Leases (Detail) false false R83.htm 184 - Disclosure - Selected Quarterly Financial Data (Detail) Sheet http://www.positron.com/role/SelectedQuarterlyFinancialDataDetail Selected Quarterly Financial Data (Detail) false false R84.htm 185 - Disclosure - Sales, Operating Loss and Total Assets Attributable to Business Segments (Detail) Sheet http://www.positron.com/role/SalesOperatingLossAndTotalAssetsAttributableToBusinessSegmentsDetail Sales, Operating Loss and Total Assets Attributable to Business Segments (Detail) false false R85.htm 186 - Disclosure - Subsequent Events - Additional Information (Detail) Sheet http://www.positron.com/role/SubsequentEventsAdditionalInformationDetail Subsequent Events - Additional Information (Detail) false false All Reports Book All Reports Element posc_EffectiveIncomeTaxRateReconciliationChangeInValuationAllowance had a mix of decimals attribute values: 1 2. Element posc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingExercisePrice had a mix of decimals attribute values: 2 3. Element us-gaap_CommonStockParOrStatedValuePerShare had a mix of decimals attribute values: 2 4. Element us-gaap_ConcentrationRiskPercentage1 had a mix of decimals attribute values: 1 2. Element us-gaap_ConvertibleDebt had a mix of decimals attribute values: -3 0. Element us-gaap_DebtConversionConvertedInstrumentAmount1 had a mix of decimals attribute values: -3 0. Element us-gaap_DebtConversionOriginalDebtAmount1 had a mix of decimals attribute values: -3 0. Element us-gaap_DebtInstrumentFaceAmount had a mix of decimals attribute values: -3 0. Element us-gaap_DebtInstrumentInterestRateStatedPercentage had a mix of decimals attribute values: 2 4. Element us-gaap_DebtInstrumentUnamortizedDiscount had a mix of decimals attribute values: -3 0. Element us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate had a mix of decimals attribute values: 0 2. Element us-gaap_PreferredStockDividendRatePercentage had a mix of decimals attribute values: 1 2. Element us-gaap_ProceedsFromConvertibleDebt had a mix of decimals attribute values: -3 0. Element us-gaap_RepaymentsOfConvertibleDebt had a mix of decimals attribute values: -3 0. Element us-gaap_ShareBasedCompensation had a mix of decimals attribute values: -3 0. Element us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate had a mix of decimals attribute values: 0 2. Element us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate had a mix of decimals attribute values: 2 4. Element us-gaap_SharePrice had a mix of decimals attribute values: 2 4. Element us-gaap_StockIssuedDuringPeriodValueIssuedForServices had a mix of decimals attribute values: -3 0. Element us-gaap_StockIssuedDuringPeriodValueNewIssues had a mix of decimals attribute values: -3 0. 'Monetary' elements on report '105 - Statement - CONSOLIDATED STATEMENT OF STOCKHOLDERS' EQUITY (DEFICIT)' had a mix of different decimal attribute values. 'Monetary' elements on report '106 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS' had a mix of different decimal attribute values. 'Monetary' elements on report '150 - Disclosure - Going Concern - Additional Information (Detail)' had a mix of different decimal attribute values. 'Monetary' elements on report '174 - Disclosure - Other Expenses - Additional Information (Detail)' had a mix of different decimal attribute values. Process Flow-Through: 102 - Statement - CONSOLIDATED BALANCE SHEETS Process Flow-Through: Removing column 'Dec. 31, 2011' Process Flow-Through: 103 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical) Process Flow-Through: Removing column 'May 31, 2013' Process Flow-Through: Removing column 'May 21, 2012' Process Flow-Through: Removing column 'Apr. 05, 2012' Process Flow-Through: Removing column 'Mar. 14, 2012' Process Flow-Through: Removing column 'Jan. 20, 2012' Process Flow-Through: Removing column 'Jan. 19, 2012' Process Flow-Through: Removing column 'Jan. 12, 2012' Process Flow-Through: Removing column 'Jan. 04, 2012' Process Flow-Through: 104 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME Process Flow-Through: Removing column '3 Months Ended Dec. 31, 2013' Process Flow-Through: Removing column '3 Months Ended Sep. 30, 2013' Process Flow-Through: Removing column '3 Months Ended Jun. 30, 2013' Process Flow-Through: Removing column '3 Months Ended Mar. 31, 2013' Process Flow-Through: Removing column '3 Months Ended Dec. 31, 2012' Process Flow-Through: Removing column '3 Months Ended Sep. 30, 2012' Process Flow-Through: Removing column '3 Months Ended Jun. 30, 2012' Process Flow-Through: Removing column '3 Months Ended Mar. 31, 2012' Process Flow-Through: 106 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS Process Flow-Through: 107 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS (Parenthetical) posc-20131231.xml posc-20131231.xsd posc-20131231_cal.xml posc-20131231_def.xml posc-20131231_lab.xml posc-20131231_pre.xml true true XML 102 R74.htm IDEA: XBRL DOCUMENT v2.4.0.8
Computation of Basic and Diluted Loss Per Share (Detail) (USD $)
In Thousands, except Per Share data, unless otherwise specified
 3 Months Ended 12 Months Ended
Dec. 31, 2013
Sep. 30, 2013
Jun. 30, 2013
Mar. 31, 2013
Dec. 31, 2012
Sep. 30, 2012
Jun. 30, 2012
Mar. 31, 2012
Dec. 31, 2013
Dec. 31, 2012
Numerator                    
Basic and diluted loss $ 3,425 $ 1,390 $ 1,088 $ 1,201 $ 2,190 $ 1,568 $ 1,235 $ 2,962 $ (7,104) $ (7,955)
Denominator                    
Basic and diluted earnings per share - weighted average shares outstanding 1,452,548 1,452,548 1,452,425 1,451,927 1,451,140 1,360,107 1,256,915 970,887 1,452,364 1,265,270
Basic and diluted loss per common share $ 0.00 $ 0.00 $ 0.00 $ 0.00 $ 0.00 $ 0.00 $ 0.00 $ 0.00 $ 0.00 $ (0.01)
XML 103 R38.htm IDEA: XBRL DOCUMENT v2.4.0.8
Notes Payable - Capital Lease (Tables)
 12 Months Ended
Dec. 31, 2013
Capital Leases of Lessee [Abstract]  
Schedule of Future Minimum Lease Payments for Capital Leases
Future minimum lease payments and the present value of the payments are as follows:
 
Debt maturities as of
 
December 31,
 
2014
 
$
4,000
 
2015
 
 
4,000
 
2016
 
 
4,000
 
2017
 
 
4,000
 
2018 and thereafter
 
 
1,000
 
 
 
 
17,000
 
Less: amounts representing interest
 
 
(3,000)
 
Present value
 
 
14,000
 
Less: current portion
 
 
(3,000)
 
Note payable Capital Lease – noncurrent portion
 
$
11,000
 
XML 104 R20.htm IDEA: XBRL DOCUMENT v2.4.0.8
PREFERRED STOCK
 12 Months Ended
Dec. 31, 2013
Equity [Abstract]  
PREFERRED STOCK
13.
PREFERRED STOCK
 
The Company’s Certificate of Formation, as amended, authorizes the issuance of 20,000,000 shares of preferred stock from time to time in one or more series. The Board of Directors is authorized to determine, prior to issuing any such series of preferred stock and without any vote or action by the shareholders, the rights, preferences, privileges and restrictions of the shares of such series, including dividend rights, voting rights, terms of redemption, the provisions of any purchase, retirement or sinking fund to be provided for the shares of any series, conversion and exchange rights, the preferences upon any distribution of the assets of the Company, including in the event of voluntary or involuntary liquidation, dissolution or winding up of the Company, and the preferences and relative rights among each series of preferred stock. The Board of Directors has designated the following series of preferred stock
 
Series A Preferred Stock
 
The Company had 7,900,000 shares of Series A Preferred Stock authorized for issuance. Subject to adjustment based on issuance of shares at less than fair market value, each share of the Series A Preferred Stock was initially convertible into one share of common stock. Each Redeemable common stock Purchase Warrant is exercisable at a price of $2.00 per share of common stock. Eight percent (8%) dividends on the Series A Preferred Stock may be paid in cash or in Series A Preferred Stock at the discretion of the Company. The Series A Preferred Stock is senior to the Company’s common stock in liquidation. Holders of the Series A Preferred stock may vote on an as if converted basis on any matter requiring shareholder vote. While the Series A Preferred Stock is outstanding or any dividends thereon remain unpaid, no common stock dividends may be paid or declared by the Company. The Series A Preferred Stock may be redeemed in whole or in part, at the option of the Company, at any time subsequent to March 1998 at a price of $1.46 per share plus any undeclared and/or unpaid dividends to the date of redemption. Redemption requires at least 30 days advanced notice and notice may only be given if the Company’s common stock has closed above $2.00 per share for the twenty consecutive trading days prior to the notice.
 
As of December 31, 2013 and 2012, there were 447,652 shares of Series A Preferred Stock outstanding, respectively.
 
Series B Preferred Stock
 
As of December 31, 2012, the Company has 9,000,000 shares of Series B Preferred Stock authorized for issuance. Each share of Series B Preferred Stock $1.00 par value is convertible into 100 shares of the Company’s Common Stock. The Series B Preferred Stock is senior to the Company’s Common Stock and junior in priority to the Company’s A and G Preferred Stock in liquidation. Holders of the Series B Preferred Stock are entitled to 100 votes per share on all matters requiring shareholder vote. While Series B Preferred Stock is outstanding no Common Stock dividends may be paid or declared by the Company. The Series B Preferred Stock may be redeemed in whole or in part, at the option of the Company, at any time at a price of $1.00 per share.
 
As of December 31, 2013 and 2012, 3,056,487 shares of Series B Preferred Stock were outstanding, respectively.
 
Series G Preferred Stock
 
The Company has designated 3,000,000 shares of preferred stock as Series G Preferred Stock $1.00 par value. Each share of Series G Preferred Stock is convertible into 100 shares of common stock. The Series G Preferred Stock is senior to the Company's common stock and junior in priority to the Registrant's Series A, C, D, E and F Preferred Stock in liquidation. Except as required by law and in the case of various actions affecting the rights of the Series G Preferred Stock, holders of the Series G Preferred Stock are not entitled to vote on matters requiring shareholder vote. While the Series G Preferred Stock is outstanding or any dividends thereon remain unpaid, no common stock dividends may be paid or declared by the Company. The Series G Preferred Stock may be redeemed in whole or in part, at the option of the Company, at any time at a price of $5.00 per share plus any undeclared and/or unpaid dividends to the date of redemption.
 
As of December 31, 2013 and 2012, there are no shares of Series G Preferred Stock outstanding.
 
Series S Preferred Stock
 
As of December 31, 2012, the Company has 10,000 shares of Series S Preferred Stock authorized for issuance. Each share of Series S Convertible Preferred Stock, $1.00 par value per share, is convertible into 10,000 shares of the Company’s Common Stock, subject to adjustment The Series S Preferred Stock is senior to the Company’s Common Stock and junior in priority to the Company’s A, B and G Preferred Stock in liquidation. Holders of the Series S Preferred Stock are entitled to 10,000 votes per share on all matters requiring shareholder vote. While Series S Preferred Stock is outstanding no Common Stock dividends may be paid or declared by the Company.
 
As of December 31, 2013 and 2012, 100,000 shares of Series S Convertible Preferred Stock were outstanding.
  
Series H Preferred Stock
 
As of December 31, 2013, the Company has 15,000,000 shares of Series H Preferred Stock authorized for issuance at par value of $0.01 per share. The Series H Preferred Stock rank junior to dividends and distributions of the Company’s assets upon liquidation to all previously-issued shares of capital stock of the Company and is not entitled to receive interest or dividends. The Series H Preferred Stock is convertible into shares of the Company’s Common Stock at a rate equal to the number of shares of Series H Preferred Stock being converted multiplied by the Original Issuance Price of $0.10 and divided by seventy percent (70%) of the daily weighted volume average price for the three trading days prior to conversion. The Series H Preferred Stock is entitled to two hundred (200) votes per share of Series H Preferred Stock on all matters which holders of Common Stock are entitled to vote.
 
As of December 31, 2013 and 2012, 12,500,000 and 0 shares of Series H Preferred Stock were outstanding, respectively.